Name	MOA	Target	Disease Area	Indication	Vendor	Purity	SMILES	Phase
(R)-(-)-apomorphine	dopamine receptor agonist	ADRA2A, ADRA2B, ADRA2C, CALY, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C, HTR5A	neurology/psychiatry	Parkinson's Disease	MedChemEx, Tocris, Tocris, Selleck	98.9	CN1CCc2cccc-3c2[C@H]1Cc1ccc(O)c(O)c-31, CN1CCc2cccc-3c2[C@H]1Cc1ccc(O)c(O)c-31, CN1CCc2cccc-3c2[C@H]1Cc1ccc(O)c(O)c-31, CN1CCc2cccc-3c2[C@H]1Cc1ccc(O)c(O)c-31	Launched
(R)-(-)-rolipram	phosphodiesterase inhibitor	PDE4A, PDE4B, PDE4C, PDE4D, PDE5A			Tocris, Tocris, Tocris, Tocris, Tocris	97.48	COc1ccc(cc1OC1CCCC1)[C@@H]1CNC(=O)C1, COc1ccc(cc1OC1CCCC1)[C@@H]1CNC(=O)C1, COc1ccc(cc1OC1CCCC1)[C@@H]1CNC(=O)C1, COc1ccc(cc1OC1CCCC1)[C@@H]1CNC(=O)C1, COc1ccc(cc1OC1CCCC1)[C@@H]1CNC(=O)C1	Phase 1
(R)-baclofen	benzodiazepine receptor agonist	GABBR1, GABBR2			Selleck, Selleck, Selleck	96.78	NC[C@H](CC(O)=O)c1ccc(Cl)cc1, NC[C@H](CC(O)=O)c1ccc(Cl)cc1, NC[C@H](CC(O)=O)c1ccc(Cl)cc1	Phase 3
(S)-(+)-rolipram	phosphodiesterase inhibitor	PDE4B, PDE4D			Tocris, Tocris, Selleck, Selleck, Selleck, Tocris	98.17	COc1ccc(cc1OC1CCCC1)[C@H]1CNC(=O)C1, COc1ccc(cc1OC1CCCC1)[C@H]1CNC(=O)C1, COc1ccc(cc1OC1CCCC1)[C@H]1CNC(=O)C1, COc1ccc(cc1OC1CCCC1)[C@H]1CNC(=O)C1, COc1ccc(cc1OC1CCCC1)[C@H]1CNC(=O)C1, COc1ccc(cc1OC1CCCC1)[C@H]1CNC(=O)C1	Phase 1
[sar9,met(o2)11]-substance-p	tachykinin antagonist	TACR1			Bachem	43.63	CC(C)C[C@H](NC(=O)CN(C)C(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CCS(C)(=O)=O)C(N)=O	Preclinical
A-1070722	glycogen synthase kinase inhibitor	GSK3A, GSK3B			Tocris, Tocris, Stanley, Stanley, Stanley, Stanley	98.53	COc1ccc2c(NC(=O)Nc3cccc(n3)C(F)(F)F)ccnc2c1, COc1ccc2c(NC(=O)Nc3cccc(n3)C(F)(F)F)ccnc2c1, COc1ccc2c(NC(=O)Nc3cccc(n3)C(F)(F)F)ccnc2c1, COc1ccc2c(NC(=O)Nc3cccc(n3)C(F)(F)F)ccnc2c1, COc1ccc2c(NC(=O)Nc3cccc(n3)C(F)(F)F)ccnc2c1, COc1ccc2c(NC(=O)Nc3cccc(n3)C(F)(F)F)ccnc2c1	Preclinical
A-1120	retinoid receptor ligand	RBP4			Tocris	83.72	OC(=O)c1ccccc1NC(=O)N1CCC(CC1)c1ccccc1C(F)(F)F	Preclinical
A-317491	purinergic receptor antagonist	P2RX3			MedChemEx, MedChemEx, MedChemEx	98.69	OC(=O)c1cc(C(O)=O)c(cc1C(O)=O)C(=O)N(Cc1cccc(Oc2ccccc2)c1)[C@H]1CCCc2ccccc12, OC(=O)c1cc(C(O)=O)c(cc1C(O)=O)C(=O)N(Cc1cccc(Oc2ccccc2)c1)[C@H]1CCCc2ccccc12, OC(=O)c1cc(C(O)=O)c(cc1C(O)=O)C(=O)N(Cc1cccc(Oc2ccccc2)c1)[C@H]1CCCc2ccccc12	Preclinical
A-33903					Maybridge	96.18	CC(=O)N[C@@H]1N=C(c2ccccc2)c2ccccc2NC1=O |&1:4,r,t:5|	Phase 2
A-366	histone lysine methyltransferase inhibitor	EHMT1, EHMT2			MedChemEx, MedChemEx, Tocris, MedChemEx, MedChemEx, Tocris	91.4	COc1cc2c(cc1OCCCN1CCCC1)N=C(N)C21CCC1 |t:19|, COc1cc2c(cc1OCCCN1CCCC1)N=C(N)C21CCC1 |t:19|, COc1cc2c(cc1OCCCN1CCCC1)N=C(N)C21CCC1 |t:19|, COc1cc2c(cc1OCCCN1CCCC1)N=C(N)C21CCC1 |t:19|, COc1cc2c(cc1OCCCN1CCCC1)N=C(N)C21CCC1 |t:19|, COc1cc2c(cc1OCCCN1CCCC1)N=C(N)C21CCC1 |t:19|	Preclinical
A-381393	dopamine receptor antagonist				MedChemEx	95.93	Cc1ccc(cc1C)N1CCN(Cc2nc3ccccc3[nH]2)CC1	Preclinical
A-412997	dopamine receptor agonist	DRD4			Tocris, Tocris, Tocris, Tocris	95.39	Cc1cccc(NC(=O)CN2CCC(CC2)c2ccccn2)c1, Cc1cccc(NC(=O)CN2CCC(CC2)c2ccccn2)c1, Cc1cccc(NC(=O)CN2CCC(CC2)c2ccccn2)c1, Cc1cccc(NC(=O)CN2CCC(CC2)c2ccccn2)c1	Preclinical
A-438079	purinergic receptor antagonist	P2RX7			Tocris, Tocris, Tocris	97.34	Clc1cccc(-c2nnnn2Cc2cccnc2)c1Cl, Clc1cccc(-c2nnnn2Cc2cccnc2)c1Cl, Clc1cccc(-c2nnnn2Cc2cccnc2)c1Cl	Preclinical
A-485	histone acetyltransferase inhibitor				MedChemEx, MedChemEx	98.69	CNC(=O)Nc1ccc2c(CC[C@@]22OC(=O)N(CC(=O)N(Cc3ccc(F)cc3)[C@@H](C)C(F)(F)F)C2=O)c1, CNC(=O)Nc1ccc2c(CC[C@@]22OC(=O)N(CC(=O)N(Cc3ccc(F)cc3)[C@@H](C)C(F)(F)F)C2=O)c1	Preclinical
A-582941	nicotinic receptor agonist	CHRNA7			Tocris, Tocris	91.53	CN1C[C@H]2CN(C[C@H]2C1)c1ccc(nn1)-c1ccccc1, CN1C[C@H]2CN(C[C@H]2C1)c1ccc(nn1)-c1ccccc1	Preclinical
A-61603	adrenergic receptor agonist	ADRA1A, ADRA1B, ADRA1D			Tocris, Tocris	100	CS(=O)(=O)Nc1c(O)ccc2[C@H](CCCc12)C1=NCCN1 |&1:11,r,t:18|, CS(=O)(=O)Nc1c(O)ccc2[C@H](CCCc12)C1=NCCN1 |&1:11,r,t:18|	Preclinical
A-674563	AKT inhibitor	AKT1, PKIA, PRKACA			MedChemEx, Selleck, Selleck	96.74	Cc1[nH]nc2ccc(cc12)-c1cncc(OC[C@@H](N)Cc2ccccc2)c1, Cc1[nH]nc2ccc(cc12)-c1cncc(OC[C@@H](N)Cc2ccccc2)c1, Cc1[nH]nc2ccc(cc12)-c1cncc(OC[C@@H](N)Cc2ccccc2)c1	Preclinical
A-7	calmodulin antagonist				Tocris, Tocris, Tocris, Tocris, Tocris, Tocris	95.2	NCCCCCCCCCCNS(=O)(=O)c1cccc2c(Cl)cccc12, NCCCCCCCCCCNS(=O)(=O)c1cccc2c(Cl)cccc12, NCCCCCCCCCCNS(=O)(=O)c1cccc2c(Cl)cccc12, NCCCCCCCCCCNS(=O)(=O)c1cccc2c(Cl)cccc12, NCCCCCCCCCCNS(=O)(=O)c1cccc2c(Cl)cccc12, NCCCCCCCCCCNS(=O)(=O)c1cccc2c(Cl)cccc12	Preclinical
A-769662	AMPK activator				Tocris, Selleck, Tocris	96.91	Oc1ccccc1-c1ccc(cc1)-c1csc2[nH]c(=O)c(C#N)c(O)c12, Oc1ccccc1-c1ccc(cc1)-c1csc2[nH]c(=O)c(C#N)c(O)c12, Oc1ccccc1-c1ccc(cc1)-c1csc2[nH]c(=O)c(C#N)c(O)c12	Preclinical
A-784168	transient receptor potential channel antagonist	TRPV1			Tocris, Tocris	95.13	FC(F)(F)c1cccnc1N1CCC(=CC1)C(=O)Nc1ccc(cc1)S(=O)(=O)C(F)(F)F |c:14|, FC(F)(F)c1cccnc1N1CCC(=CC1)C(=O)Nc1ccc(cc1)S(=O)(=O)C(F)(F)F |c:14|	Preclinical
A-803467	sodium channel blocker	SCN10A			Tocris, Selleck	97.96	COc1cc(NC(=O)c2ccc(o2)-c2ccc(Cl)cc2)cc(OC)c1, COc1cc(NC(=O)c2ccc(o2)-c2ccc(Cl)cc2)cc(OC)c1	Preclinical
A-804598	purinergic receptor antagonist	P2RX7			Tocris, Tocris, Tocris	98.54	C[C@H](N\C(NC#N)=N/c1cccc2ncccc12)c1ccccc1, C[C@H](\N=C(\NC#N)Nc1cccc2ncccc12)c1ccccc1, C[C@H](\N=C(\NC#N)Nc1cccc2ncccc12)c1ccccc1	Preclinical
A-839977	purinergic receptor antagonist	P2RX7			Tocris, Tocris	98.12	Clc1cccc(c1Cl)-n1nnnc1NCc1ccccc1Oc1ccccn1, Clc1cccc(c1Cl)-n1nnnc1NCc1ccccc1Oc1ccccn1	Preclinical
A-867744	acetylcholine receptor allosteric modulator	CHRNA3, CHRNA4, CHRNA7			Tocris, Tocris, Tocris, Tocris, Tocris	96.03	CCC(=O)c1cc(-c2ccc(Cl)cc2)n(c1C)-c1ccc(cc1)S(N)(=O)=O, CCC(=O)c1cc(-c2ccc(Cl)cc2)n(c1C)-c1ccc(cc1)S(N)(=O)=O, CCC(=O)c1cc(-c2ccc(Cl)cc2)n(c1C)-c1ccc(cc1)S(N)(=O)=O, CCC(=O)c1cc(-c2ccc(Cl)cc2)n(c1C)-c1ccc(cc1)S(N)(=O)=O, CCC(=O)c1cc(-c2ccc(Cl)cc2)n(c1C)-c1ccc(cc1)S(N)(=O)=O	Preclinical
A-887826	sodium channel blocker	SCN10A			Tocris, Tocris	97.78	CCCCOc1ccc(cc1Cl)-c1cncc(c1)C(=O)NCc1cccnc1N1CCOCC1, CCCCOc1ccc(cc1Cl)-c1cncc(c1)C(=O)NCc1cccnc1N1CCOCC1	Preclinical
A-922500	diacylglycerol O acyltransferase inhibitor	DGAT1			Tocris, Tocris, Selleck	96.89	OC(=O)[C@@H]1CCC[C@H]1C(=O)c1ccc(cc1)-c1ccc(NC(=O)Nc2ccccc2)cc1, OC(=O)[C@@H]1CCC[C@H]1C(=O)c1ccc(cc1)-c1ccc(NC(=O)Nc2ccccc2)cc1, OC(=O)[C@@H]1CCC[C@H]1C(=O)c1ccc(cc1)-c1ccc(NC(=O)Nc2ccccc2)cc1	Preclinical
A-939572	stearoyl-CoA desaturase inhibitor	SCD			Tocris, Tocris, Tocris	97.11	CNC(=O)c1cccc(NC(=O)N2CCC(CC2)Oc2ccccc2Cl)c1, CNC(=O)c1cccc(NC(=O)N2CCC(CC2)Oc2ccccc2Cl)c1, CNC(=O)c1cccc(NC(=O)N2CCC(CC2)Oc2ccccc2Cl)c1	Preclinical
A-967079	transient receptor potential channel antagonist	TRPA1			Tocris, Tocris	97.41	CC\C(=N/O)\C(\C)=C\c1ccc(F)cc1, CC\C(=N/O)\C(\C)=C\c1ccc(F)cc1	Preclinical
A-987306	histamine receptor antagonist	ADORA1, AVPR1A, CCR1, CHRM1, CHRM2, CHRM3, CHRM4, DRD3, HTR1A, HTR1B, HTR2A, HTR2B, HTR3A, TACR2			Tocris, Tocris	92.15	Nc1nc(N2CCNCC2)c2CCC3=C([C@@H]4CCCC[C@@H]4O3)c2n1 |t:14|, Nc1nc(N2CCNCC2)c2CCC3=C([C@@H]4CCCC[C@@H]4O3)c2n1 |t:14|	Preclinical
AA-29504	GABA receptor positive allosteric modulator	GABRA1, GABRA4, GABRB3			Tocris, Tocris, Tocris	81.4	CCOC(=O)Nc1ccc(NCc2c(C)cc(C)cc2C)cc1N, CCOC(=O)Nc1ccc(NCc2c(C)cc(C)cc2C)cc1N, CCOC(=O)Nc1ccc(NCc2c(C)cc(C)cc2C)cc1N	Preclinical
AAI101	lactamase inhibitor				MedChemEx	40.4	[H][C@@]12CC(=O)N1[C@@H](C(O)=O)[C@](C)(Cn1cc[n+](C)n1)S2(=O)=O	Phase 3
AB-423	HBV capsid assembly inhibitor				MedChemEx	97.73	CC[C@@H](C)NS(=O)(=O)c1ccc(F)c(c1)C(=O)Nc1ccc(F)c(F)c1	Preclinical
abacavir	nucleoside reverse transcriptase inhibitor		infectious disease	human immunodeficiency virus (HIV-1)	Tocris, MicroSource, MicroSource, MicroSource, MicroSource, Selleck	98.81	Nc1nc(NC2CC2)c2ncn([C@@H]3C[C@H](CO)C=C3)c2n1 |c:18|, Nc1nc(NC2CC2)c2ncn([C@@H]3C[C@H](CO)C=C3)c2n1 |c:18|, Nc1nc(NC2CC2)c2ncn([C@@H]3C[C@H](CO)C=C3)c2n1 |c:18|, Nc1nc(NC2CC2)c2ncn([C@@H]3C[C@H](CO)C=C3)c2n1 |c:18|, Nc1nc(NC2CC2)c2ncn([C@@H]3C[C@H](CO)C=C3)c2n1 |c:18|, Nc1nc(NC2CC2)c2ncn([C@@H]3C[C@H](CO)C=C3)c2n1 |c:18|	Launched
abafungin	sterol methyltransferase inhibitor				ChemImpex	92.48	Cc1ccc(Oc2ccccc2-c2csc(NC3=NCCCN3)n2)c(C)c1 |t:18|	Phase 3
abamectin	benzodiazepine receptor agonist	GABBR1, GABBR2	infectious disease	gastrointestinal parasites	MedChemEx	0	[H][C@@]12OC\C3=C/C=C/[C@H](C)[C@H](O[C@@]4([H])C[C@H](OC)[C@@H](O[C@@]5([H])C[C@H](OC)[C@@H](O)[C@H](C)O5)[C@H](C)O4)\C(C)=C\C[C@]4([H])C[C@@]([H])(C[C@@]5(O[C@H](C(C)C)[C@@H](C)C=C5)O4)OC(=O)[C@]([H])(C=C(C)[C@H]1O)[C@@]23O |c:4,54,t:6,37,64|	Launched
abametapir	metalloproteinase inhibitor	MMP9			Sigma, Sigma	92.8	Cc1ccc(nc1)-c1ccc(C)cn1, Cc1ccc(nc1)-c1ccc(C)cn1	Phase 3
abarelix	gonadotropin releasing factor hormone receptor antagonist	GNRHR			MedChemEx	80.78	CC(C)C[C@H](NC(=O)[C@@H](CC(N)=O)NC(=O)[C@H](Cc1ccc(O)cc1)N(C)C(=O)[C@H](CO)NC(=O)[C@@H](Cc1cccnc1)NC(=O)[C@@H](Cc1ccc(Cl)cc1)NC(=O)[C@@H](Cc1ccc2ccccc2c1)NC(C)=O)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O	Phase 3
ABBV-744	bromodomain inhibitor				MedChemEx	93.59	CCNC(=O)c1cc2c(cn(C)c(O)c2n1)-c1cc(ccc1Oc1c(C)cc(F)cc1C)C(C)(C)O	Phase 1
ABC-294640	sphingosine kinase inhibitor	SPHK2			Selleck	99.82	Clc1ccc(cc1)[C@]12C[C@H]3C[C@H](C[C@](C3)(C1)C(=O)NCc1ccncc1)C2 |&1:7,9,11,13|	Phase 2
abemaciclib	CDK inhibitor	CDK4, CDK6	oncology	breast cancer	Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, MedChemEx, MedChemEx	94.43	CCN1CCN(Cc2ccc(Nc3ncc(F)c(n3)-c3cc(F)c4nc(C)n(C(C)C)c4c3)nc2)CC1, CCN1CCN(Cc2ccc(Nc3ncc(F)c(n3)-c3cc(F)c4nc(C)n(C(C)C)c4c3)nc2)CC1, CCN1CCN(Cc2ccc(Nc3ncc(F)c(n3)-c3cc(F)c4nc(C)n(C(C)C)c4c3)nc2)CC1, CCN1CCN(Cc2ccc(Nc3ncc(F)c(n3)-c3cc(F)c4nc(C)n(C(C)C)c4c3)nc2)CC1, CCN1CCN(Cc2ccc(Nc3ncc(F)c(n3)-c3cc(F)c4nc(C)n(C(C)C)c4c3)nc2)CC1, CCN1CCN(Cc2ccc(Nc3ncc(F)c(n3)-c3cc(F)c4nc(C)n(C(C)C)c4c3)nc2)CC1, CCN1CCN(Cc2ccc(Nc3ncc(F)c(n3)-c3cc(F)c4nc(C)n(C(C)C)c4c3)nc2)CC1, CCN1CCN(Cc2ccc(Nc3ncc(F)c(n3)-c3cc(F)c4nc(C)n(C(C)C)c4c3)nc2)CC1	Launched
abiraterone	androgen biosynthesis inhibitor	CYP11B1, CYP17A1	oncology	prostate cancer	MedChemEx, Selleck, Selleck	92.23	C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@]34C)[C@@H]1CC=C2c1cccnc1 |c:21,t:7|, C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@]34C)[C@@H]1CC=C2c1cccnc1 |c:21,t:7|, C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@]34C)[C@@H]1CC=C2c1cccnc1 |c:21,t:7|	Launched
abiraterone-acetate	androgen biosynthesis inhibitor	CYP17A1	oncology	prostate cancer	MedChemEx, Selleck, Selleck, Selleck, Selleck	98.65	CC(=O)O[C@H]1CC[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](CC=C4c4cccnc4)[C@@H]3CC=C2C1 |c:16,29|, CC(=O)O[C@H]1CC[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](CC=C4c4cccnc4)[C@@H]3CC=C2C1 |c:16,29|, CC(=O)O[C@H]1CC[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](CC=C4c4cccnc4)[C@@H]3CC=C2C1 |c:16,29|, CC(=O)O[C@H]1CC[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](CC=C4c4cccnc4)[C@@H]3CC=C2C1 |c:16,29|, CC(=O)O[C@H]1CC[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](CC=C4c4cccnc4)[C@@H]3CC=C2C1 |c:16,29|	Launched
ABT-072	RNA polymerase inhibitor				MedChemEx	90.96	COc1c(\C=C\c2ccc(NS(C)(=O)=O)cc2)cc(cc1C(C)(C)C)-n1ccc(=O)[nH]c1=O	Phase 2
ABT-202	acetylcholine receptor agonist				Enamine	88.87	N[C@H]1CCN(C1)c1cccnc1 |&1:1|	Phase 1
ABT-239	histamine receptor antagonist	HRH1, HRH2, HRH3			Axon	99.38	C[C@@H]1CCCN1CCc1cc2cc(ccc2o1)-c1ccc(cc1)C#N	Phase 1
ABT-491	platelet activating factor receptor antagonist	PTAFR			EMDBio, EMDBio, SantaCruz	93.81	CN(C)C(=O)n1cc(C(=O)c2ccc(Cn3c(C)nc4cnccc34)c(F)c2)c2c(cccc12)C#C, CN(C)C(=O)n1cc(C(=O)c2ccc(Cn3c(C)nc4cnccc34)c(F)c2)c2c(cccc12)C#C, CN(C)C(=O)n1cc(C(=O)c2ccc(Cn3c(C)nc4cnccc34)c(F)c2)c2c(cccc12)C#C	Phase 1
ABT-639	calcium channel blocker	CACNA1G, CACNA1H, CACNA1I			MedChemEx, MedChemEx	96.74	Fc1ccccc1NS(=O)(=O)c1cc(C(=O)N2CCN3CCC[C@@H]3C2)c(Cl)cc1F, Fc1ccccc1NS(=O)(=O)c1cc(C(=O)N2CCN3CCC[C@@H]3C2)c(Cl)cc1F	Phase 2
ABT-702	adenosine kinase inhibitor	ADK			Tocris, Tocris	87.52	Nc1ncnc2nc(cc(-c3cccc(Br)c3)c12)-c1ccc(nc1)N1CCOCC1, Nc1ncnc2nc(cc(-c3cccc(Br)c3)c12)-c1ccc(nc1)N1CCOCC1	Preclinical
ABT-724	dopamine receptor agonist	DRD4			Tocris, Tocris, Tocris, Tocris	97.43	C(N1CCN(CC1)c1ccccn1)c1nc2ccccc2[nH]1, C(N1CCN(CC1)c1ccccn1)c1nc2ccccc2[nH]1, C(N1CCN(CC1)c1ccccn1)c1nc2ccccc2[nH]1, C(N1CCN(CC1)c1ccccn1)c1nc2ccccc2[nH]1	Phase 2
ABT-737	BCL inhibitor	BCL2, BCL2L1, BCL2L2			Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Toronto, Toronto, Toronto, Toronto, Toronto, Toronto, Toronto, Toronto, MedChemEx, MedChemEx	100	CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(cc1[N+]([O-])=O)S(=O)(=O)NC(=O)c1ccc(cc1)N1CCN(Cc2ccccc2-c2ccc(Cl)cc2)CC1, CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(cc1[N+]([O-])=O)S(=O)(=O)NC(=O)c1ccc(cc1)N1CCN(Cc2ccccc2-c2ccc(Cl)cc2)CC1, CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(cc1[N+]([O-])=O)S(=O)(=O)NC(=O)c1ccc(cc1)N1CCN(Cc2ccccc2-c2ccc(Cl)cc2)CC1, CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(cc1[N+]([O-])=O)S(=O)(=O)NC(=O)c1ccc(cc1)N1CCN(Cc2ccccc2-c2ccc(Cl)cc2)CC1, CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(cc1[N+]([O-])=O)S(=O)(=O)NC(=O)c1ccc(cc1)N1CCN(Cc2ccccc2-c2ccc(Cl)cc2)CC1, CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(cc1[N+]([O-])=O)S(=O)(=O)NC(=O)c1ccc(cc1)N1CCN(Cc2ccccc2-c2ccc(Cl)cc2)CC1, CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(cc1[N+]([O-])=O)S(=O)(=O)NC(=O)c1ccc(cc1)N1CCN(Cc2ccccc2-c2ccc(Cl)cc2)CC1, CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(cc1[N+]([O-])=O)S(=O)(=O)NC(=O)c1ccc(cc1)N1CCN(Cc2ccccc2-c2ccc(Cl)cc2)CC1, CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(cc1[N+]([O-])=O)S(=O)(=O)NC(=O)c1ccc(cc1)N1CCN(Cc2ccccc2-c2ccc(Cl)cc2)CC1, CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(cc1[N+]([O-])=O)S(=O)(=O)NC(=O)c1ccc(cc1)N1CCN(Cc2ccccc2-c2ccc(Cl)cc2)CC1, CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(cc1[N+]([O-])=O)S(=O)(=O)NC(=O)c1ccc(cc1)N1CCN(Cc2ccccc2-c2ccc(Cl)cc2)CC1, CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(cc1[N+]([O-])=O)S(=O)(=O)NC(=O)c1ccc(cc1)N1CCN(Cc2ccccc2-c2ccc(Cl)cc2)CC1, CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(cc1[N+]([O-])=O)S(=O)(=O)NC(=O)c1ccc(cc1)N1CCN(Cc2ccccc2-c2ccc(Cl)cc2)CC1, CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(cc1[N+]([O-])=O)S(=O)(=O)NC(=O)c1ccc(cc1)N1CCN(Cc2ccccc2-c2ccc(Cl)cc2)CC1, CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(cc1[N+]([O-])=O)S(=O)(=O)NC(=O)c1ccc(cc1)N1CCN(Cc2ccccc2-c2ccc(Cl)cc2)CC1, CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(cc1[N+]([O-])=O)S(=O)(=O)NC(=O)c1ccc(cc1)N1CCN(Cc2ccccc2-c2ccc(Cl)cc2)CC1, CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(cc1[N+]([O-])=O)S(=O)(=O)NC(=O)c1ccc(cc1)N1CCN(Cc2ccccc2-c2ccc(Cl)cc2)CC1	Phase 1/Phase 2
ABT-751	tubulin polymerization inhibitor	TUBB			Tocris, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Tocris, Selleck	96.81	COc1ccc(cc1)S(=O)(=O)Nc1cccnc1Nc1ccc(O)cc1, COc1ccc(cc1)S(=O)(=O)Nc1cccnc1Nc1ccc(O)cc1, COc1ccc(cc1)S(=O)(=O)Nc1cccnc1Nc1ccc(O)cc1, COc1ccc(cc1)S(=O)(=O)Nc1cccnc1Nc1ccc(O)cc1, COc1ccc(cc1)S(=O)(=O)Nc1cccnc1Nc1ccc(O)cc1, COc1ccc(cc1)S(=O)(=O)Nc1cccnc1Nc1ccc(O)cc1, COc1ccc(cc1)S(=O)(=O)Nc1cccnc1Nc1ccc(O)cc1, COc1ccc(cc1)S(=O)(=O)Nc1cccnc1Nc1ccc(O)cc1, COc1ccc(cc1)S(=O)(=O)Nc1cccnc1Nc1ccc(O)cc1	Phase 2
ABX-1431	monoacylglycerol lipase inhibitor				MedChemEx	92.26	FC(F)(F)C(OC(=O)N1CCN(Cc2ccc(cc2N2CCCC2)C(F)(F)F)CC1)C(F)(F)F	Phase 2
ABX464	antiviral				MedChemEx	98.68	FC(F)(F)Oc1ccc(Nc2ccc3cccc(Cl)c3n2)cc1	Phase 2
AC-186	estrogen receptor agonist	ESR2			Tocris, Tocris, Tocris	94.66	Oc1ccc(cc1)C1(CCC(F)(F)CC1)c1ccccc1F, Oc1ccc(cc1)C1(CCC(F)(F)CC1)c1ccccc1F, Oc1ccc(cc1)C1(CCC(F)(F)CC1)c1ccccc1F	Preclinical
AC-261066	retinoid receptor agonist	RARB			Tocris, Tocris	92.33	CCCCOCCOc1nc(sc1C)-c1ccc(C(O)=O)c(F)c1, CCCCOCCOc1nc(sc1C)-c1ccc(C(O)=O)c(F)c1	Preclinical
AC-264613	PAR agonist	F2RL1			Tocris, Tocris, Tocris, Tocris	95.07	C\C(=N/NC(=O)[C@H]1[C@@H](CNC1=O)c1ccccc1)c1cccc(Br)c1, C\C(=N/NC(=O)[C@H]1[C@@H](CNC1=O)c1ccccc1)c1cccc(Br)c1, C\C(=N/NC(=O)[C@H]1[C@@H](CNC1=O)c1ccccc1)c1cccc(Br)c1, C\C(=N/NC(=O)[C@H]1[C@@H](CNC1=O)c1ccccc1)c1cccc(Br)c1	Preclinical
AC-55541	PARP inhibitor	PARP2			MedChemEx, MedChemEx	97.34	C\C(=N/NC(=O)[C@@H](NC(=O)c1ccccc1)c1n[nH]c(=O)c2ccccc12)c1cccc(Br)c1 |&1:6,r|, C\C(=N/NC(=O)[C@@H](NC(=O)c1ccccc1)c1n[nH]c(=O)c2ccccc12)c1cccc(Br)c1 |&1:6,r|	Preclinical
AC-55649	retinoid receptor agonist	RARA, RARB			Tocris, Tocris, Tocris, Tocris	98.46	CCCCCCCCc1ccc(cc1)-c1ccc(cc1)C(O)=O, CCCCCCCCc1ccc(cc1)-c1ccc(cc1)C(O)=O, CCCCCCCCc1ccc(cc1)-c1ccc(cc1)C(O)=O, CCCCCCCCc1ccc(cc1)-c1ccc(cc1)C(O)=O	Preclinical
AC-710	PDGFR tyrosine kinase receptor inhibitor	CSF1R, FLT3, KIT, PDGFRA, PDGFRB			Tocris, Tocris, Tocris	98.87	CCN1C(C)(C)CC(CC1(C)C)Oc1ccc(nc1)C(=O)Nc1ccc(NC(=O)Nc2cc(on2)C(C)(C)C)cc1, CCN1C(C)(C)CC(CC1(C)C)Oc1ccc(nc1)C(=O)Nc1ccc(NC(=O)Nc2cc(on2)C(C)(C)C)cc1, CCN1C(C)(C)CC(CC1(C)C)Oc1ccc(nc1)C(=O)Nc1ccc(NC(=O)Nc2cc(on2)C(C)(C)C)cc1	Preclinical
AC-7954-(+/-)	urotensin receptor agonist	UTS2R			Tocris, Tocris, Tocris, Tocris	95.87	CN(C)CC[C@]1(Cc2ccccc2C(=O)O1)c1ccc(Cl)cc1 |&1:5|, CN(C)CC[C@]1(Cc2ccccc2C(=O)O1)c1ccc(Cl)cc1 |&1:5|, CN(C)CC[C@]1(Cc2ccccc2C(=O)O1)c1ccc(Cl)cc1 |&1:5|, CN(C)CC[C@]1(Cc2ccccc2C(=O)O1)c1ccc(Cl)cc1 |&1:5|	Preclinical
acadesine	AMPK activator				Tocris, Selleck, Selleck	100	NC(=O)c1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c1N, NC(=O)c1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c1N, NC(=O)c1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c1N	Phase 3
acalabrutinib	Bruton's tyrosine kinase (BTK) inhibitor	BTK	hematologic malignancy	mantle cell lymphoma (MCL)	MedChemEx, MedChemEx, MedChemEx, MedChemEx	88.47	CC#CC(=O)N1CCC[C@H]1c1nc(-c2ccc(cc2)C(=O)Nc2ccccn2)c2c(N)nccn12, CC#CC(=O)N1CCC[C@H]1c1nc(-c2ccc(cc2)C(=O)Nc2ccccn2)c2c(N)nccn12, CC#CC(=O)N1CCC[C@H]1c1nc(-c2ccc(cc2)C(=O)Nc2ccccn2)c2c(N)nccn12, CC#CC(=O)N1CCC[C@H]1c1nc(-c2ccc(cc2)C(=O)Nc2ccccn2)c2c(N)nccn12	Launched
acalisib	PI3K inhibitor	PIK3CB, PIK3CD			MedChemEx, MedChemEx	99.44	C[C@H](Nc1ncnc2nc[nH]c12)c1nc2ccc(F)cc2c(=O)n1-c1ccccc1, C[C@H](Nc1ncnc2nc[nH]c12)c1nc2ccc(F)cc2c(=O)n1-c1ccccc1	Phase 1
acamprosate	glutamate receptor antagonist	GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, GRIN3A, GRIN3B, GRM5	neurology/psychiatry	abstinence from alcohol	MicroSource, Sigma, Tocris	100	CC(=O)NCCCS(O)(=O)=O, CC(=O)NCCCS(O)(=O)=O, CC(=O)NCCCS(O)(=O)=O	Launched
acarbose	glucosidase inhibitor	AMY2A, MGAM	endocrinology	diabetes mellitus	Tocris, Tocris, MicroSource, MicroSource, MicroSource, Tocris, Selleck	100	C[C@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@H](O[C@@H]3[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]3O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1N[C@H]1C=C(CO)[C@@H](O)[C@H](O)[C@H]1O |t:37|, C[C@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@H](O[C@@H]3[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]3O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1N[C@H]1C=C(CO)[C@@H](O)[C@H](O)[C@H]1O |t:37|, C[C@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@H](O[C@@H]3[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]3O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1N[C@H]1C=C(CO)[C@@H](O)[C@H](O)[C@H]1O |t:37|, C[C@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@H](O[C@@H]3[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]3O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1N[C@H]1C=C(CO)[C@@H](O)[C@H](O)[C@H]1O |t:37|, C[C@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@H](O[C@@H]3[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]3O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1N[C@H]1C=C(CO)[C@@H](O)[C@H](O)[C@H]1O |t:37|, C[C@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@H](O[C@@H]3[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]3O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1N[C@H]1C=C(CO)[C@@H](O)[C@H](O)[C@H]1O |t:37|, C[C@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@H](O[C@@H]3[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]3O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1N[C@H]1C=C(CO)[C@@H](O)[C@H](O)[C@H]1O |t:37|	Launched
ACDPP	glutamate receptor antagonist	GRM5			Tocris, Tocris, Tocris	95.36	CN(C)c1nc(N)c(nc1Cl)C(=O)Nc1cccnc1, CN(C)c1nc(N)c(nc1Cl)C(=O)Nc1cccnc1, CN(C)c1nc(N)c(nc1Cl)C(=O)Nc1cccnc1	Preclinical
acebilustat	leukotriene inhibitor				MedChemEx	97.48	[H][C@]12CN(Cc3ccc(cc3)C(O)=O)[C@]([H])(CN1Cc1ccc(Oc3ccc(cc3)-c3ncco3)cc1)C2	Phase 2
acebutolol	adrenergic receptor antagonist	ADRB1	cardiology	hypertension, ventricular arrhythmias	MicroSource, MicroSource, MicroSource, Selleck	98.29	CCCC(=O)Nc1ccc(OCC(O)CNC(C)C)c(c1)C(C)=O, CCCC(=O)Nc1ccc(OCC(O)CNC(C)C)c(c1)C(C)=O, CCCC(=O)Nc1ccc(OCC(O)CNC(C)C)c(c1)C(C)=O, CCCC(=O)Nc1ccc(OCC(O)CNC(C)C)c(c1)C(C)=O	Launched
acecainide	polarization inhibitor	SCN5A			MicroSource, MicroSource, MicroSource	98.55	CCN(CC)CCNC(=O)c1ccc(NC(C)=O)cc1, CCN(CC)CCNC(=O)c1ccc(NC(C)=O)cc1, CCN(CC)CCNC(=O)c1ccc(NC(C)=O)cc1	Phase 3
aceclidine	acetylcholine receptor agonist	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5	ophthalmology	glaucoma	MicroSource	92.9	CC(=O)O[C@H]1CN2CCC1CC2 |&1:4,r|	Launched
aceclofenac	prostanoid receptor antagonist	PTGS2	rheumatology	rheumatoid arthritis, ankylosing spondylitis, osteoarthritis, periarthritis, lumbago, ischiadynia	MedChemEx, MicroSource, MicroSource, MicroSource	98.5	OC(=O)COC(=O)Cc1ccccc1Nc1c(Cl)cccc1Cl, OC(=O)COC(=O)Cc1ccccc1Nc1c(Cl)cccc1Cl, OC(=O)COC(=O)Cc1ccccc1Nc1c(Cl)cccc1Cl, OC(=O)COC(=O)Cc1ccccc1Nc1c(Cl)cccc1Cl	Launched
acedapsone			infectious disease	leprosy	MicroSource, Sigma	98.36	CC(=O)Nc1ccc(cc1)S(=O)(=O)c1ccc(NC(C)=O)cc1, CC(=O)Nc1ccc(cc1)S(=O)(=O)c1ccc(NC(C)=O)cc1	Launched
acedoben					MicroSource, Sigma	95.89	CC(=O)Nc1ccc(cc1)C(O)=O, CC(=O)Nc1ccc(cc1)C(O)=O	Phase 2
acefylline	adenosine receptor agonist	ADORA1	pulmonary	asthma	MedChemEx, Prestwick	97.34	Cn1c2ncn(CC(O)=O)c2c(=O)n(C)c1=O, Cn1c2ncn(CC(O)=O)c2c(=O)n(C)c1=O	Launched
aceglutamide			gastroenterology	peptic ulcer disease (PUD)	MedChemEx, MedChemEx, MicroSource	100	CC(=O)N[C@@H](CCC(N)=O)C(O)=O, CC(=O)N[C@@H](CCC(N)=O)C(O)=O, CC(=O)N[C@@H](CCC(N)=O)C(O)=O	Launched
acelarin	anticancer agent				MedChemEx	97.41	C[C@H](N[P@@](=O)(OC[C@H]1O[C@@H](n2ccc(N)nc2=O)C(F)(F)[C@@H]1O)Oc1ccccc1)C(=O)OCc1ccccc1 |a:1,7,9,21,&1:3|	Phase 2/Phase 3
acemetacin	cyclooxygenase inhibitor	PTGS1, PTGS2	rheumatology	osteoarthritis	MedChemEx, MedChemEx, MedChemEx, MicroSource, Selleck	98.86	COc1ccc2n(C(=O)c3ccc(Cl)cc3)c(C)c(CC(=O)OCC(O)=O)c2c1, COc1ccc2n(C(=O)c3ccc(Cl)cc3)c(C)c(CC(=O)OCC(O)=O)c2c1, COc1ccc2n(C(=O)c3ccc(Cl)cc3)c(C)c(CC(=O)OCC(O)=O)c2c1, COc1ccc2n(C(=O)c3ccc(Cl)cc3)c(C)c(CC(=O)OCC(O)=O)c2c1, COc1ccc2n(C(=O)c3ccc(Cl)cc3)c(C)c(CC(=O)OCC(O)=O)c2c1	Launched
aceneuramic-acid		CES1, SELE, SELP			OxChem	100	CC(=O)N[C@@H]1[C@@H](O)C[C@](O)(O[C@H]1[C@H](O)[C@H](O)CO)C(O)=O	Phase 3
acenocoumarol	vitamin K antagonist	VKORC1	hematology	deep vein thrombosis (DVT)	MicroSource, MedChemEx	99.56	CC(=O)C[C@@H](c1ccc(cc1)[N+]([O-])=O)c1c(O)c2ccccc2oc1=O |&1:4,r|, CC(=O)C[C@@H](c1ccc(cc1)[N+]([O-])=O)c1c(O)c2ccccc2oc1=O |&1:4,r|	Launched
acepromazine	dopamine receptor antagonist	ADRA1A, ADRA1B, DRD1, DRD2, HTR1A, HTR2A	neurology/psychiatry	sedative	MicroSource, MicroSource, MedChemEx	90.02	CN(C)CCCN1c2ccccc2Sc2ccc(cc12)C(C)=O, CN(C)CCCN1c2ccccc2Sc2ccc(cc12)C(C)=O, CN(C)CCCN1c2ccccc2Sc2ccc(cc12)C(C)=O	Launched
acesulfame-potassium					MicroSource, Selleck, Selleck	88.18	CC1=CC(=O)NS(=O)(=O)O1 |t:1|, CC1=CC(=O)NS(=O)(=O)O1 |t:1|, CC1=CC(=O)NS(=O)(=O)O1 |t:1|	Phase 3
acetanilide	hydrogen peroxide decomposition inhibitor				MedChemEx, MicroSource, Selleck	96.78	CC(=O)Nc1ccccc1, CC(=O)Nc1ccccc1, CC(=O)Nc1ccccc1	Preclinical
acetarsol			gastroenterology	diarrhea	MicroSource, Selleck, Selleck	100	CC(=O)Nc1cc(ccc1O)[As](O)(O)=O, CC(=O)Nc1cc(ccc1O)[As](O)(O)=O, CC(=O)Nc1cc(ccc1O)[As](O)(O)=O	Launched
acetazolamide	carbonic anhydrase inhibitor	AQP1, CA1, CA12, CA14, CA2, CA3, CA4, CA7	ophthalmology	glaucoma	MicroSource, MicroSource	97.61	CC(=O)Nc1nnc(s1)S(N)(=O)=O, CC(=O)Nc1nnc(s1)S(N)(=O)=O	Launched
acetohexamide	ATP channel blocker	ABCC8, KCNJ1, KCNJ10, KCNJ11	endocrinology	diabetes mellitus	MicroSource, MedChemEx	92.87	CC(=O)c1ccc(cc1)S(=O)(=O)NC(=O)NC1CCCCC1, CC(=O)c1ccc(cc1)S(=O)(=O)NC(=O)NC1CCCCC1	Launched
acetohydroxamic-acid	urease inhibitor	MMP12	infectious disease	urinary tract infections	MicroSource	0	CC(=O)NO	Launched
acetophenazine	dopamine receptor antagonist	DRD1, DRD2	neurology/psychiatry	psychosis	MicroSource, MedChemEx	91.12	CC(=O)c1ccc2Sc3ccccc3N(CCCN3CCN(CCO)CC3)c2c1, CC(=O)c1ccc2Sc3ccccc3N(CCCN3CCN(CCO)CC3)c2c1	Launched
acetriazoic-acid					MicroSource, MedChemEx, MedChemEx	96.57	CC(=O)Nc1c(I)cc(I)c(C(O)=O)c1I, CC(=O)Nc1c(I)cc(I)c(C(O)=O)c1I, CC(=O)Nc1c(I)cc(I)c(C(O)=O)c1I	Preclinical
acetyl-farnesyl-cysteine	methyltransferase inhibitor	PPARG	dermatology	acne vulgaris (AV)	Enzo, Enzo, Cayman, Cayman	91.9	CC(C)=CCC\C(C)=C\CC\C(C)=C\CSC[C@H](NC(C)=O)C(O)=O, CC(C)=CCC\C(C)=C\CC\C(C)=C\CSC[C@H](NC(C)=O)C(O)=O, CC(C)=CCC\C(C)=C\CC\C(C)=C\CSC[C@H](NC(C)=O)C(O)=O, CC(C)=CCC\C(C)=C\CC\C(C)=C\CSC[C@H](NC(C)=O)C(O)=O	Launched
acetyl-l-leucine			neurology/psychiatry	vertigo	MedChemEx, MicroSource	100	CC(C)C[C@H](NC(C)=O)C(O)=O, CC(C)C[C@H](NC(C)=O)C(O)=O	Launched
acetyl-11-keto-beta-boswellic-acid	lipoxygenase inhibitor	HSD11B1, HSD11B2			AnalytiCon	0	C[C@@H]1CC[C@]2(C)CC[C@]3(C)C(=CC(=O)[C@H]4[C@@]5(C)CC[C@@H](OC(C)=O)[C@@](C)([C@@H]5CC[C@@]34C)C(O)=O)[C@@H]2[C@H]1C |a:1,4,8,15,19,24,29,34,35,&1:14,&2:26,c:10|	Phase 2
acetylcholine	acetylcholine receptor agonist	ACHE, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, CHRNA2	neurology/psychiatry, gastroenterology, pulmonary	drowsiness, fatigue, headache, indigestion, chest congestion	MedChemEx, MicroSource, Selleck	100	CC(=O)OCC[N+](C)(C)C, CC(=O)OCC[N+](C)(C)C, CC(=O)OCC[N+](C)(C)C	Launched
acetylcysteine	mucolytic agent	ACY1, CHUK, GRIN1, GRIN2A, GRIN2B, GRIN2D, GRIN3A, GSS, IKBKB, RELA, SLC7A11	gastroenterology	acetaminophen overdose, hepatic injury	MicroSource, Selleck, Selleck	88.97	CC(=O)N[C@@H](CS)C(O)=O, CC(=O)N[C@@H](CS)C(O)=O, CC(=O)N[C@@H](CS)C(O)=O	Launched
acetylsalicylsalicylic-acid	cyclooxygenase inhibitor				CombiBlocks, Prestwick, Prestwick	93.66	CC(=O)Oc1ccccc1C(=O)Oc1ccccc1C(O)=O, CC(=O)Oc1ccccc1C(=O)Oc1ccccc1C(O)=O, CC(=O)Oc1ccccc1C(=O)Oc1ccccc1C(O)=O	Preclinical
acetylspiramycin	other antibiotic				MedChemEx	0.7	[H][C@@]1(C[C@@](C)(O)[C@@H](O)[C@H](C)O1)O[C@@H]1[C@@H](C)O[C@@]([H])(O[C@H]2[C@@H](CC=O)C[C@@H](C)[C@@H](O[C@@]3([H])CC[C@@H]([C@@H](C)O3)N(C)C)\C=C\C=C\C[C@@H](C)OC(=O)C[C@@]([H])(OC(C)=O)[C@@H]2OC)[C@H](O)[C@H]1N(C)C |t:42,44|	Preclinical
acexamic-acid	5 alpha reductase inhibitor	GAST	dermatology	wound healing	MedChemEx, MedChemEx, MicroSource, MicroSource, MicroSource, MicroSource, MicroSource	100	CC(=O)NCCCCCC(O)=O, CC(=O)NCCCCCC(O)=O, CC(=O)NCCCCCC(O)=O, CC(=O)NCCCCCC(O)=O, CC(=O)NCCCCCC(O)=O, CC(=O)NCCCCCC(O)=O, CC(=O)NCCCCCC(O)=O	Launched
acifran	cholesterol inhibitor	HCAR2, HCAR3			Tocris, Tocris, Tocris, Tocris	98.05	C[C@]1(OC(=CC1=O)C(O)=O)c1ccccc1 |&1:1,r,c:3|, C[C@]1(OC(=CC1=O)C(O)=O)c1ccccc1 |&1:1,r,c:3|, C[C@]1(OC(=CC1=O)C(O)=O)c1ccccc1 |&1:1,r,c:3|, C[C@]1(OC(=CC1=O)C(O)=O)c1ccccc1 |&1:1,r,c:3|	Phase 3
acipimox	cholesterol inhibitor	HCAR2	endocrinology	hyperlipidemia	Tocris, MicroSource, MicroSource, Tocris, Selleck, Selleck, Selleck	100	Cc1cnc(c[n+]1[O-])C(O)=O, Cc1cnc(c[n+]1[O-])C(O)=O, Cc1cnc(c[n+]1[O-])C(O)=O, Cc1cnc(c[n+]1[O-])C(O)=O, Cc1cnc(c[n+]1[O-])C(O)=O, Cc1cnc(c[n+]1[O-])C(O)=O, Cc1cnc(c[n+]1[O-])C(O)=O	Launched
acitazanolast	mediator release inhibitor		allergy	allergic rhinitis	LifeChem, LifeChem, LifeChem	96.68	OC(=O)C(=O)Nc1cccc(c1)-c1nn[nH]n1, OC(=O)C(=O)Nc1cccc(c1)-c1nn[nH]n1, OC(=O)C(=O)Nc1cccc(c1)-c1nn[nH]n1	Launched
acitretin	retinoid receptor agonist	RARA, RARB, RARG, RBP1, RXRA, RXRB, RXRG, STAT3	dermatology	psoriasis	Selleck, Selleck, Selleck, Selleck, Selleck	96.4	COc1cc(C)c(\C=C\C(\C)=C\C=C\C(\C)=C\C(O)=O)c(C)c1C, COc1cc(C)c(\C=C\C(\C)=C\C=C\C(\C)=C\C(O)=O)c(C)c1C, COc1cc(C)c(\C=C\C(\C)=C\C=C\C(\C)=C\C(O)=O)c(C)c1C, COc1cc(C)c(\C=C\C(\C)=C\C=C\C(\C)=C\C(O)=O)c(C)c1C, COc1cc(C)c(\C=C\C(\C)=C\C=C\C(\C)=C\C(O)=O)c(C)c1C	Launched
acivicin	gamma glutamyltransferase inhibitor	CTPS1			Enzo, Enzo	100	N[C@H]([C@@H]1CC(Cl)=NO1)C(O)=O |c:5|, N[C@H]([C@@H]1CC(Cl)=NO1)C(O)=O |c:5|	Phase 2
aclarubicin	topoisomerase inhibitor	TOP1, TOP2A	hematologic malignancy	acute myeloid leukemia (AML)	Vitas-M	48.88	CC[C@@]1(O)C[C@H](O[C@H]2C[C@@H]([C@H](O[C@H]3C[C@H](O)[C@H](O[C@H]4CCC(=O)[C@H](C)O4)[C@H](C)O3)[C@H](C)O2)N(C)C)c2c(O)c3C(=O)c4c(O)cccc4C(=O)c3cc2[C@H]1C(=O)OC	Launched
aclidinium	acetylcholine receptor antagonist	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5	pulmonary	bronchitis, emphysema, chronic obstructive pulmonary disease (COPD)	MedChemEx, Selleck	96.49	OC(C(=O)O[C@H]1C[N+]2(CCCOc3ccccc3)CCC1CC2)(c1cccs1)c1cccs1, OC(C(=O)O[C@H]1C[N+]2(CCCOc3ccccc3)CCC1CC2)(c1cccs1)c1cccs1	Launched
acolbifene	estrogen receptor antagonist				Cayman	92.23	CC1=C([C@@H](Oc2cc(O)ccc12)c1ccc(OCCN2CCCCC2)cc1)c1ccc(O)cc1 |t:1|	Phase 3
acoziborole	antitrypanosomal				MedChemEx	97.98	CC1(C)OB(O)c2cc(NC(=O)c3ccc(F)cc3C(F)(F)F)ccc12	Preclinical
ACPC	glutamate receptor antagonist				MedChemEx, Enzo	100	NC1(CC1)C(O)=O, NC1(CC1)C(O)=O	Phase 1
acriflavine	hypoxia inducible factor inhibitor	HIF1A	infectious disease	fungal infection	Sigma, Sigma	70.4	Nc1ccc2cc3ccc(N)cc3nc2c1.C[n+]1c2cc(N)ccc2cc2ccc(N)cc12, Nc1ccc2cc3ccc(N)cc3nc2c1.C[n+]1c2cc(N)ccc2cc2ccc(N)cc12	Launched
acriflavinium	hypoxia inducible factor inhibitor	HIF1A	infectious disease	fungal infection	TCI, MicroSource	53.49	C[n+]1c2cc(N)ccc2cc2ccc(N)cc12, C[n+]1c2cc(N)ccc2cc2ccc(N)cc12	Launched
acrisorcin	other antifungal		infectious disease	fungal infection	MicroSource	61.47	CCCCCCc1ccc(O)cc1O.Nc1c2ccccc2nc2ccccc12	Launched
acrivastine	histamine receptor antagonist	HRH1	allergy	allergic rhinitis	MedChemEx, MedChemEx, Enzo, Enzo, Enzo	100	Cc1ccc(cc1)C(=C/CN1CCCC1)\c1cccc(\C=C\C(O)=O)n1, Cc1ccc(cc1)C(=C/CN1CCCC1)\c1cccc(\C=C\C(O)=O)n1, Cc1ccc(cc1)C(=C/CN1CCCC1)\c1cccc(\C=C\C(O)=O)n1, Cc1ccc(cc1)C(=C/CN1CCCC1)\c1cccc(\C=C\C(O)=O)n1, Cc1ccc(cc1)C(=C/CN1CCCC1)\c1cccc(\C=C\C(O)=O)n1	Launched
acrylate	mucus protecting agent				Sigma	0	[Na].OC(=O)C=C	Phase 3
ACT-132577	endothelin receptor antagonist	EDNRA, EDNRB	pulmonary	pulmonary arterial hypertension (PAH)	MedChemEx, MedChemEx, MedChemEx	80.39	NS(=O)(=O)Nc1ncnc(OCCOc2ncc(Br)cn2)c1-c1ccc(Br)cc1, NS(=O)(=O)Nc1ncnc(OCCOc2ncc(Br)cn2)c1-c1ccc(Br)cc1, NS(=O)(=O)Nc1ncnc(OCCOc2ncc(Br)cn2)c1-c1ccc(Br)cc1	Launched
ACT-462206	orexin receptor antagonist	HCRTR1, HCRTR2			Tocris, Sigma	97.06	COc1ccc(cc1)S(=O)(=O)N1CCC[C@H]1C(=O)Nc1cc(C)cc(C)c1, COc1ccc(cc1)S(=O)(=O)N1CCC[C@H]1C(=O)Nc1cc(C)cc(C)c1	Phase 1
actarit	interleukin receptor agonist		rheumatology	rheumatoid arthritis	MedChemEx, MicroSource	96.94	CC(=O)Nc1ccc(CC(O)=O)cc1, CC(=O)Nc1ccc(CC(O)=O)cc1	Launched
ACTB-1003	FGFR inhibitor, VEGFR inhibitor	KDR, TEK			MedChemEx, MedChemEx, MedChemEx, MedChemEx	95.17	COCc1c(CN2CCOCC2)n2ncnc(N)c2c1-c1ccc(NC(=O)Nc2cc(ccc2F)C(F)(F)F)c(F)c1, COCc1c(CN2CCOCC2)n2ncnc(N)c2c1-c1ccc(NC(=O)Nc2cc(ccc2F)C(F)(F)F)c(F)c1, COCc1c(CN2CCOCC2)n2ncnc(N)c2c1-c1ccc(NC(=O)Nc2cc(ccc2F)C(F)(F)F)c(F)c1, COCc1c(CN2CCOCC2)n2ncnc(N)c2c1-c1ccc(NC(=O)Nc2cc(ccc2F)C(F)(F)F)c(F)c1	Phase 1
actinomycin-d	RNA polymerase inhibitor		oncology	Wilm's tumor, Ewing's sarcoma, rhabdomyosarcoma, testicular carcinoma	MedChemEx, MedChemEx, Tocris	88.46	CC(C)[C@@H]1NC(=O)[C@@H](NC(=O)c2ccc(C)c3oc4c(C)c(=O)c(N)c(C(=O)N[C@H]5[C@@H](C)OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]6CCCN6C(=O)[C@@H](NC5=O)C(C)C)c4nc23)[C@@H](C)OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C1=O, CC(C)[C@@H]1NC(=O)[C@@H](NC(=O)c2ccc(C)c3oc4c(C)c(=O)c(N)c(C(=O)N[C@H]5[C@@H](C)OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]6CCCN6C(=O)[C@@H](NC5=O)C(C)C)c4nc23)[C@@H](C)OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C1=O, CC(C)[C@@H]1NC(=O)[C@@H](NC(=O)c2ccc(C)c3oc4c(C)c(=O)c(N)c(C(=O)N[C@H]5[C@@H](C)OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]6CCCN6C(=O)[C@@H](NC5=O)C(C)C)c4nc23)[C@@H](C)OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C1=O	Launched
actinoquinol					MicroSource, Sigma	95.87	CCOc1ccc(c2cccnc12)S(O)(=O)=O, CCOc1ccc(c2cccnc12)S(O)(=O)=O	Preclinical
acumapimod	p38 MAPK inhibitor				MedChemEx	97.64	Cc1ccc(cc1-n1ncc(C(=O)c2cccc(c2)C#N)c1N)C(=O)NC1CC1	Phase 1
ACY-1215	HDAC inhibitor	HDAC1, HDAC2, HDAC3, HDAC6, HDAC8			Selleck, Selleck, MedChemEx, MedChemEx, MedChemEx, MedChemEx	95.76	ONC(=O)CCCCCCNC(=O)c1cnc(nc1)N(c1ccccc1)c1ccccc1, ONC(=O)CCCCCCNC(=O)c1cnc(nc1)N(c1ccccc1)c1ccccc1, ONC(=O)CCCCCCNC(=O)c1cnc(nc1)N(c1ccccc1)c1ccccc1, ONC(=O)CCCCCCNC(=O)c1cnc(nc1)N(c1ccccc1)c1ccccc1, ONC(=O)CCCCCCNC(=O)c1cnc(nc1)N(c1ccccc1)c1ccccc1, ONC(=O)CCCCCCNC(=O)c1cnc(nc1)N(c1ccccc1)c1ccccc1	Phase 1/Phase 2
acyclovir	DNA polymerase inhibitor	PNP	infectious disease	genitial herpes, shingles, chicken pox	Tocris, MicroSource, Tocris, Selleck, Selleck, Selleck, Selleck	100	Nc1nc(=O)c2ncn(COCCO)c2[nH]1, Nc1nc(=O)c2ncn(COCCO)c2[nH]1, Nc1nc(=O)c2ncn(COCCO)c2[nH]1, Nc1nc(=O)c2ncn(COCCO)c2[nH]1, Nc1nc(=O)c2ncn(COCCO)c2[nH]1, Nc1nc(=O)c2ncn(COCCO)c2[nH]1, Nc1nc(=O)c2ncn(COCCO)c2[nH]1	Launched
AC1NDSS5					Sigma, Sigma	75.43	CCCCCCCCCCCCCCCCCC[S+](CCC)c1ccccc1C(=O)OCC, CCCCCCCCCCCCCCCCCC[S+](CCC)c1ccccc1C(=O)OCC	Phase 1
AC260584	cholinergic receptor agonist				MedChemEx	93.47	CCCCC1CCN(CCCN2C(=O)COc3cc(F)ccc23)CC1	Preclinical
AD-5467	aldose reductase inhibitor	AKR1B1			Maybridge, Maybridge	88.22	CC(C)[C@H]1Oc2c(cccc2N(CC(O)=O)C1=S)C(C)C |&1:3,r|, CC(C)[C@H]1Oc2c(cccc2N(CC(O)=O)C1=S)C(C)C |&1:3,r|	Phase 2
adapalene	retinoid receptor agonist	RARA, RARB, RARG, RXRA, RXRB, RXRG	dermatology	acne vulgaris (AV)	Tocris, Tocris, MicroSource, MicroSource, MicroSource, Selleck, Selleck, Selleck	99.81	COc1ccc(cc1C12CC3CC(CC(C3)C1)C2)-c1ccc2cc(ccc2c1)C(O)=O, COc1ccc(cc1C12CC3CC(CC(C3)C1)C2)-c1ccc2cc(ccc2c1)C(O)=O, COc1ccc(cc1C12CC3CC(CC(C3)C1)C2)-c1ccc2cc(ccc2c1)C(O)=O, COc1ccc(cc1C12CC3CC(CC(C3)C1)C2)-c1ccc2cc(ccc2c1)C(O)=O, COc1ccc(cc1C12CC3CC(CC(C3)C1)C2)-c1ccc2cc(ccc2c1)C(O)=O, COc1ccc(cc1C12CC3CC(CC(C3)C1)C2)-c1ccc2cc(ccc2c1)C(O)=O, COc1ccc(cc1C12CC3CC(CC(C3)C1)C2)-c1ccc2cc(ccc2c1)C(O)=O, COc1ccc(cc1C12CC3CC(CC(C3)C1)C2)-c1ccc2cc(ccc2c1)C(O)=O	Launched
adaprev	TGF beta receptor inhibitor	AKR1B1, GPI, HK1, M6PR, PYGM			TCI, TCI	59.36	O[C@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@H]1O |a:3,10,12,14,&1:1|, O[C@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@H]1O |a:3,10,12,14,&1:1|	Phase 3
adaptavir	CC chemokine receptor antagonist	CCR5			Tocris, Tocris, Tocris, MedChemEx	89.21	C[C@@H](O)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@@H](C)N)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C(N)=O, C[C@@H](O)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@@H](C)N)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C(N)=O, C[C@@H](O)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@@H](C)N)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C(N)=O, C[C@@H](O)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@@H](C)N)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C(N)=O	Phase 2
adarotene	retinoid receptor agonist	RARB, RARG			MedChemEx, MedChemEx, MedChemEx, MedChemEx	95.05	OC(=O)\C=C\c1ccc(cc1)-c1ccc(O)c(c1)C12CC3CC(CC(C3)C1)C2, OC(=O)\C=C\c1ccc(cc1)-c1ccc(O)c(c1)C12CC3CC(CC(C3)C1)C2, OC(=O)\C=C\c1ccc(cc1)-c1ccc(O)c(c1)C12CC3CC(CC(C3)C1)C2, OC(=O)\C=C\c1ccc(cc1)-c1ccc(O)c(c1)C12CC3CC(CC(C3)C1)C2	Phase 1
adatanserin	serotonin receptor agonist, serotonin receptor antagonist	HTR1A, HTR2A			Enamine, Enamine, Enamine	87.69	O=C(NCCN1CCN(CC1)c1ncccn1)C12CC3CC(CC(C3)C1)C2, O=C(NCCN1CCN(CC1)c1ncccn1)C12CC3CC(CC(C3)C1)C2, O=C(NCCN1CCN(CC1)c1ncccn1)C12CC3CC(CC(C3)C1)C2	Phase 2
adavivint	WNT pathway inhibitor				MedChemEx	97.16	CC(C)CC(=O)Nc1cncc(c1)-c1ccc2[nH]nc(-c3nc4cncc(-c5cccc(F)c5)c4[nH]3)c2c1	Phase 1
ADD-233089	benzodiazepine receptor agonist				MedChemEx, MedChemEx, MedChemEx	98.89	Clc1ccc(cc1)-n1cc([nH]c1=O)N1CCOCC1, Clc1ccc(cc1)-n1cc([nH]c1=O)N1CCOCC1, Clc1ccc(cc1)-n1cc([nH]c1=O)N1CCOCC1	Phase 1
adefovir	DNA polymerase inhibitor		infectious disease	hepatitis B	Sigma, AKSci	99.1	Nc1ncnc2n(CCOCP(O)(O)=O)cnc12, Nc1ncnc2n(CCOCP(O)(O)=O)cnc12	Launched
adefovir-dipivoxil	DNA polymerase inhibitor		infectious disease	hepatitis B	MedChemEx, Selleck, Selleck	90.59	CC(C)(C)C(=O)OCOP(=O)(COCCn1cnc2c(N)ncnc12)OCOC(=O)C(C)(C)C, CC(C)(C)C(=O)OCOP(=O)(COCCn1cnc2c(N)ncnc12)OCOC(=O)C(C)(C)C, CC(C)(C)C(=O)OCOP(=O)(COCCn1cnc2c(N)ncnc12)OCOC(=O)C(C)(C)C	Launched
adelmidrol	anti-inflammatory agent		dermatology	dermatitis	MedChemEx, MicroSource	88.06	OCCNC(=O)CCCCCCCC(=O)NCCO, OCCNC(=O)CCCCCCCC(=O)NCCO	Launched
ademetionine	methyltransferase stimulant, phosphodiesterase inhibitor		neurology/psychiatry	depression, attention-deficit/hyperactivity disorder (ADHD)	MedChemEx, MedChemEx	0	C[S+](CC[C@H](N)C(O)=O)C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)ncnc12, C[S+](CC[C@H](N)C(O)=O)C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)ncnc12	Launched
adenine	protein synthesis stimulant	ACACB, ACP1, APRT, MTAP, PECR, SRPK2			Selleck, MicroSource, MicroSource, Selleck, Selleck	100000	Nc1ncnc2nc[nH]c12, Nc1ncnc2nc[nH]c12, Nc1ncnc2nc[nH]c12, Nc1ncnc2nc[nH]c12, Nc1ncnc2nc[nH]c12	Preclinical
adenosine	adenosine receptor agonist	ADORA1, ADORA2A, ADORA2B, ADORA3, PI4K2A, PI4K2B, TRPM4	cardiology	Wolff-Parkinson-White Syndrome (WPW)	MicroSource, MicroSource, Selleck, Selleck	97.44	Nc1ncnc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O, Nc1ncnc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O, Nc1ncnc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O, Nc1ncnc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O	Launched
adenosine-phosphate	adenosine receptor agonist	ACSL1, ACSS1, ACSS2, ADCY1, ADK, CREB1, FBP1, HINT1, PDE4B, PDE4D, PIM1, PRKAA1, PRKAB1, PRKAB2, PYGL, TRPM4			MedChemEx	100	Nc1ncnc2n(cnc12)[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O	Launched
adenosine-triphosphate	adenosine receptor agonist	ABCA1, ABCB1, ABCB11, ABCC2, ABCC8, ABCC9, ABCG1, ABL1, ABL2, ACSL1, ACSS1, ACSS2, ACVR1, ACVR1B, ACVRL1, ADCY1, ADRBK1, ADRBK2, AFG3L2, AKT1, ALK, AMHR2, APAF1, ARAF, ASNA1, ASNS, ASS1, CDK15, GPR17, ITPR1, NAE1, NT5C2, P2RY1, P2RY11, P2RY13, P2RY2, P2RY4, PRKAA1, RYR1, RYR2, RYR3, SLC25A4, TNK2, TRPM4, TRPM7			MedChemEx	79.1	Nc1ncnc2n(cnc12)[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O	Phase 2
adiphenine	acetylcholine receptor antagonist	CHRNA1	neurology/psychiatry	spasms	MedChemEx, MedChemEx, MicroSource, Selleck	95.9	CCN(CC)CCOC(=O)C(c1ccccc1)c1ccccc1, CCN(CC)CCOC(=O)C(c1ccccc1)c1ccccc1, CCN(CC)CCOC(=O)C(c1ccccc1)c1ccccc1, CCN(CC)CCOC(=O)C(c1ccccc1)c1ccccc1	Launched
adipic-acid	solute carrier family member inhibitor	SLC22A6			Enamine	100	OC(=O)CCCCC(O)=O	Preclinical
adiporon	adiponectin receptor agonist	ADIPOR1, ADIPOR2			Tocris, Selleck, Selleck, Tocris, Selleck	98.48	O=C(COc1ccc(cc1)C(=O)c1ccccc1)NC1CCN(Cc2ccccc2)CC1, O=C(COc1ccc(cc1)C(=O)c1ccccc1)NC1CCN(Cc2ccccc2)CC1, O=C(COc1ccc(cc1)C(=O)c1ccccc1)NC1CCN(Cc2ccccc2)CC1, O=C(COc1ccc(cc1)C(=O)c1ccccc1)NC1CCN(Cc2ccccc2)CC1, O=C(COc1ccc(cc1)C(=O)c1ccccc1)NC1CCN(Cc2ccccc2)CC1	Preclinical
ADL5859	opioid receptor agonist	OPRD1			Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck	96.95	CCN(CC)C(=O)c1ccc(cc1)C1=CC2(CCNCC2)Oc2cccc(O)c12 |t:14|, CCN(CC)C(=O)c1ccc(cc1)C1=CC2(CCNCC2)Oc2cccc(O)c12 |t:14|, CCN(CC)C(=O)c1ccc(cc1)C1=CC2(CCNCC2)Oc2cccc(O)c12 |t:14|, CCN(CC)C(=O)c1ccc(cc1)C1=CC2(CCNCC2)Oc2cccc(O)c12 |t:14|, CCN(CC)C(=O)c1ccc(cc1)C1=CC2(CCNCC2)Oc2cccc(O)c12 |t:14|, CCN(CC)C(=O)c1ccc(cc1)C1=CC2(CCNCC2)Oc2cccc(O)c12 |t:14|, CCN(CC)C(=O)c1ccc(cc1)C1=CC2(CCNCC2)Oc2cccc(O)c12 |t:14|	Phase 2
adomeglivant	glucagon receptor antagonist				MedChemEx	98.11	Cc1cc(O[C@@H](CCC(F)(F)F)c2ccc(cc2)C(=O)NCCC(O)=O)cc(C)c1-c1ccc(cc1)C(C)(C)C	Preclinical
adoprazine	dopamine receptor antagonist, serotonin receptor agonist	DRD2, HTR1A			MedChemEx, MedChemEx, MedChemEx	95.53	Fc1ccc(cc1)-c1cncc(CN2CCN(CC2)c2cccc3OCCOc23)c1, Fc1ccc(cc1)-c1cncc(CN2CCN(CC2)c2cccc3OCCOc23)c1, Fc1ccc(cc1)-c1cncc(CN2CCN(CC2)c2cccc3OCCOc23)c1	Phase 2
adrafinil	adrenergic receptor agonist		neurology/psychiatry	fatigue	MedChemEx, MedChemEx, MedChemEx	96.69	ONC(=O)C[S@@](=O)C(c1ccccc1)c1ccccc1 |r|, ONC(=O)C[S@@](=O)C(c1ccccc1)c1ccccc1 |r|, ONC(=O)C[S@@](=O)C(c1ccccc1)c1ccccc1 |r|	Launched
adrenalone	adrenergic receptor agonist	ADRA1A	hematology	hemorrhage	MedChemEx, MedChemEx, MicroSource, Selleck	97.2	CNCC(=O)c1ccc(O)c(O)c1, CNCC(=O)c1ccc(O)c(O)c1, CNCC(=O)c1ccc(O)c(O)c1, CNCC(=O)c1ccc(O)c(O)c1	Launched
adrenosterone	11-beta hydroxysteroid dehydrogenase inhibitor	HSD11B1, HSD11B2			MedChemEx, MedChemEx	98.71	C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CCC2=O |t:9|, C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CCC2=O |t:9|	Preclinical
ADX-10059	glutamate receptor negative allosteric modulator	GRM5			Tocris, Tocris, Tocris, Tocris, Tocris	96.26	Cc1cc(C)c(N)c(n1)C#Cc1cccc(F)c1, Cc1cc(C)c(N)c(n1)C#Cc1cccc(F)c1, Cc1cc(C)c(N)c(n1)C#Cc1cccc(F)c1, Cc1cc(C)c(N)c(n1)C#Cc1cccc(F)c1, Cc1cc(C)c(N)c(n1)C#Cc1cccc(F)c1	Phase 2
ADX-47273	glutamate receptor modulator	GRM5			MedChemEx, Selleck	96.63	Fc1ccc(cc1)C(=O)N1CCC[C@@H](C1)c1nc(no1)-c1ccc(F)cc1, Fc1ccc(cc1)C(=O)N1CCC[C@@H](C1)c1nc(no1)-c1ccc(F)cc1	Preclinical
AEE788	EGFR inhibitor, VEGFR inhibitor	EGFR, ERBB2, ERBB4, FGFR2, FGFR3, KDR			Tocris, Tocris, Tocris, Selleck, Selleck	97.1	CCN1CCN(Cc2ccc(cc2)-c2cc3c(N[C@H](C)c4ccccc4)ncnc3[nH]2)CC1, CCN1CCN(Cc2ccc(cc2)-c2cc3c(N[C@H](C)c4ccccc4)ncnc3[nH]2)CC1, CCN1CCN(Cc2ccc(cc2)-c2cc3c(N[C@H](C)c4ccccc4)ncnc3[nH]2)CC1, CCN1CCN(Cc2ccc(cc2)-c2cc3c(N[C@H](C)c4ccccc4)ncnc3[nH]2)CC1, CCN1CCN(Cc2ccc(cc2)-c2cc3c(N[C@H](C)c4ccccc4)ncnc3[nH]2)CC1	Phase 1/Phase 2
AEG3482	HSP inducer				Tocris, Tocris, Tocris	97.67	NS(=O)(=O)c1nn2cc(nc2s1)-c1ccccc1, NS(=O)(=O)c1nn2cc(nc2s1)-c1ccccc1, NS(=O)(=O)c1nn2cc(nc2s1)-c1ccccc1	Preclinical
afalanine	dopamine receptor agonist	DRD2			MicroSource, MedChemEx, MedChemEx	98.9	CC(=O)N[C@@H](Cc1ccccc1)C(O)=O, CC(=O)N[C@@H](Cc1ccccc1)C(O)=O, CC(=O)N[C@@H](Cc1ccccc1)C(O)=O	Phase 3
afamelanotide	melanocyte-stimulating hormone mimetic				MedChemEx	78.21	CCCC[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(C)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(N)=O	Launched
afatinib	EGFR inhibitor	EGFR, ERBB2, ERBB4	oncology	non-small cell lung cancer (NSCLC)	MedChemEx, MedChemEx, MedChemEx, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck	99.28	CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1, CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1, CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1, CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1, CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1, CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1, CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1, CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1, CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1, CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1	Launched
afimoxifene	estrogen receptor antagonist	ESR1, ESR2, ESRRG, PLD1, PRKCD, PRKCE, PRKCQ, PRKCZ			Sigma	47.39	CC\C(=C(/c1ccc(O)cc1)c1ccc(OCCN(C)C)cc1)c1ccccc1	Phase 2
afloqualone	acetylcholine receptor antagonist		neurology/psychiatry	sedative	AKSci, AKSci, AKSci	97.87	Cc1ccccc1-n1c(CF)nc2ccc(N)cc2c1=O, Cc1ccccc1-n1c(CF)nc2ccc(N)cc2c1=O, Cc1ccccc1-n1c(CF)nc2ccc(N)cc2c1=O	Launched
AFN-1252	FABI inhibitor				MedChemEx	95.38	CN(Cc1oc2ccccc2c1C)C(=O)\C=C\c1cnc2NC(=O)CCc2c1	Phase 2
afobazole	anxiolytic		neurology/psychiatry	anxiety	MedChemEx, MedChemEx	98.16	CCOc1ccc2nc(SCCN3CCOCC3)[nH]c2c1, CCOc1ccc2nc(SCCN3CCOCC3)[nH]c2c1	Launched
AF38469	sortilin inhibitor	SORT1			MedChemEx, MedChemEx, MedChemEx, MedChemEx	96.02	Cc1cccc(NC(=O)c2ccc(cc2C(O)=O)C(F)(F)F)n1, Cc1cccc(NC(=O)c2ccc(cc2C(O)=O)C(F)(F)F)n1, Cc1cccc(NC(=O)c2ccc(cc2C(O)=O)C(F)(F)F)n1, Cc1cccc(NC(=O)c2ccc(cc2C(O)=O)C(F)(F)F)n1	Preclinical
AG-1024	insulin growth factor receptor inhibitor	IGF1R			Selleck, Selleck	91.46	CC(C)(C)c1cc(C=C(C#N)C#N)cc(Br)c1O, CC(C)(C)c1cc(C=C(C#N)C#N)cc(Br)c1O	Preclinical
AG-14361	PARP inhibitor	PARP1			Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck	95.36	CN(C)Cc1ccc(cc1)-c1nc2cccc3C(=O)NCCn1c23, CN(C)Cc1ccc(cc1)-c1nc2cccc3C(=O)NCCn1c23, CN(C)Cc1ccc(cc1)-c1nc2cccc3C(=O)NCCn1c23, CN(C)Cc1ccc(cc1)-c1nc2cccc3C(=O)NCCn1c23, CN(C)Cc1ccc(cc1)-c1nc2cccc3C(=O)NCCn1c23, CN(C)Cc1ccc(cc1)-c1nc2cccc3C(=O)NCCn1c23, CN(C)Cc1ccc(cc1)-c1nc2cccc3C(=O)NCCn1c23, CN(C)Cc1ccc(cc1)-c1nc2cccc3C(=O)NCCn1c23, CN(C)Cc1ccc(cc1)-c1nc2cccc3C(=O)NCCn1c23, CN(C)Cc1ccc(cc1)-c1nc2cccc3C(=O)NCCn1c23, CN(C)Cc1ccc(cc1)-c1nc2cccc3C(=O)NCCn1c23	Preclinical
AG-490	EGFR inhibitor, JAK inhibitor	EGFR, JAK2, JAK3			Selleck, Tocris, Selleck, Tocris	92.57	Oc1ccc(\C=C(/C#N)C(=O)NCc2ccccc2)cc1O, Oc1ccc(\C=C(/C#N)C(=O)NCc2ccccc2)cc1O, Oc1ccc(\C=C(/C#N)C(=O)NCc2ccccc2)cc1O, Oc1ccc(\C=C(/C#N)C(=O)NCc2ccccc2)cc1O	Preclinical
AG-555	tyrosine kinase inhibitor	CDK2			Tocris	58.16	Oc1ccc(\C=C(/C#N)C(=O)NCCCc2ccccc2)cc1O	Preclinical
AG-556	tyrosine kinase inhibitor				Tocris, Tocris	93.77	Oc1ccc(\C=C(/C#N)C(=O)NCCCCc2ccccc2)cc1O, Oc1ccc(\C=C(/C#N)C(=O)NCCCCc2ccccc2)cc1O	Preclinical
AGI-5198	isocitrate dehydrogenase inhibitor	IDH1			Selleck, Selleck, Selleck	98.97	Cc1nccn1CC(=O)N([C@@H](C(=O)NC1CCCCC1)c1ccccc1C)c1cccc(F)c1 |&1:10,r|, Cc1nccn1CC(=O)N([C@@H](C(=O)NC1CCCCC1)c1ccccc1C)c1cccc(F)c1 |&1:10,r|, Cc1nccn1CC(=O)N([C@@H](C(=O)NC1CCCCC1)c1ccccc1C)c1cccc(F)c1 |&1:10,r|	Preclinical
AGI-6780	isocitrate dehydrogenase inhibitor	IDH2			Selleck, Selleck, MedChemEx	96.02	FC(F)(F)c1cccc(NC(=O)Nc2cc(ccc2-c2ccsc2)S(=O)(=O)NC2CC2)c1, FC(F)(F)c1cccc(NC(=O)Nc2cc(ccc2-c2ccsc2)S(=O)(=O)NC2CC2)c1, FC(F)(F)c1cccc(NC(=O)Nc2cc(ccc2-c2ccsc2)S(=O)(=O)NC2CC2)c1	Preclinical
AGM-1470	cell cycle inhibitor	METAP2			Enzo	58.76	CO[C@@H]1[C@@H](CC[C@]2(CO2)[C@@H]1[C@@]1(C)O[C@@H]1CC=C(C)C)OC(=O)NC(=O)CCl |a:2,3,6,10,13,&1:9|	Phase 2
agmatine	nitric oxide synthase inhibitor	ADRA2C, ASIC3, CACNA1B, CHRNA1, GRIN1, KCNJ1, NISCH			Enzo, Enzo	100	NCCCCNC(N)=N, NCCCCNC(N)=N	Phase 3
AGN-192403	imidazoline receptor ligand	NISCH			Tocris, Tocris, Tocris	100	CC(C)[C@@H]1[C@H]2CC[C@@H](C2)[C@H]1N |a:3,9,&1:4,&2:7|, CC(C)[C@@H]1[C@H]2CC[C@@H](C2)[C@H]1N |a:3,9,&1:4,&2:7|, CC(C)[C@@H]1[C@H]2CC[C@@H](C2)[C@H]1N |a:3,9,&1:4,&2:7|	Preclinical
AGN-194310	retinoid receptor antagonist	RXRA, RXRB, RXRG			MedChemEx, MedChemEx, MedChemEx	97.17	CCc1ccc(cc1)C1=CC(C)(C)Sc2ccc(cc12)C#Cc1ccc(cc1)C(O)=O |t:9|, CCc1ccc(cc1)C1=CC(C)(C)Sc2ccc(cc12)C#Cc1ccc(cc1)C(O)=O |t:9|, CCc1ccc(cc1)C1=CC(C)(C)Sc2ccc(cc12)C#Cc1ccc(cc1)C(O)=O |t:9|	Phase 3
AGN-195183	retinoid receptor agonist	RARA			MedChemEx, MedChemEx	94.51	CC1(C)CCC(C)(C)c2c(Cl)c(O)c(cc12)C(=O)Nc1cc(F)c(C(O)=O)c(F)c1, CC1(C)CCC(C)(C)c2c(Cl)c(O)c(cc12)C(=O)Nc1cc(F)c(C(O)=O)c(F)c1	Phase 1/Phase 2
agomelatine	melatonin receptor agonist, serotonin receptor antagonist	HTR2A, HTR2B, HTR2C, MTNR1A, MTNR1B	neurology/psychiatry	depression	Selleck, MedChemEx, MedChemEx	98.23	COc1ccc2cccc(CCNC(C)=O)c2c1, COc1ccc2cccc(CCNC(C)=O)c2c1, COc1ccc2cccc(CCNC(C)=O)c2c1	Launched
AGP-103	membrane permeability inhibitor				Sigma, Enzo, Enzo	100	CCCCCCCCCCCCCCCCCCCCCC(O)=O, CCCCCCCCCCCCCCCCCCCCCC(O)=O, CCCCCCCCCCCCCCCCCCCCCC(O)=O	Launched
AH-7614	free fatty acid receptor antagonist	FFAR4			Tocris, Tocris, Tocris	97.69	Cc1ccc(cc1)S(=O)(=O)NC1c2ccccc2Oc2ccccc12, Cc1ccc(cc1)S(=O)(=O)NC1c2ccccc2Oc2ccccc12, Cc1ccc(cc1)S(=O)(=O)NC1c2ccccc2Oc2ccccc12	Preclinical
AH11110	adrenergic receptor ligand	ADRA1B			Tocris, Tocris, Tocris	98.96	O[C@@H](COc1ccccc1-c1ccccc1)CC(=N)N1CCCCC1 |&1:1|, O[C@@H](COc1ccccc1-c1ccccc1)CC(=N)N1CCCCC1 |&1:1|, O[C@@H](COc1ccccc1-c1ccccc1)CC(=N)N1CCCCC1 |&1:1|	Preclinical
AH6809	prostanoid receptor antagonist	PTGDR, PTGER1, PTGER2, PTGER3			Tocris, Tocris, Tocris	96.06	CC(C)Oc1ccc2c(c1)oc1ccc(cc1c2=O)C(O)=O, CC(C)Oc1ccc2c(c1)oc1ccc(cc1c2=O)C(O)=O, CC(C)Oc1ccc2c(c1)oc1ccc(cc1c2=O)C(O)=O	Preclinical
AI-10-49	core binding factor inhibitor	CBFB			MedChemEx	92.82	FC(F)(F)Oc1ccc2nc([nH]c2c1)-c1ccc(OCCOCCOc2ccc(nc2)-c2nc3ccc(OC(F)(F)F)cc3[nH]2)cn1	Preclinical
AIM-100	tyrosine kinase inhibitor	TNK2			Tocris, Tocris	98.41	C(Nc1ncnc2oc(c(-c3ccccc3)c12)-c1ccccc1)[C@@H]1CCCO1, C(Nc1ncnc2oc(c(-c3ccccc3)c12)-c1ccccc1)[C@@H]1CCCO1	Preclinical
ajmaline	sodium channel blocker		cardiology	Wolff-Parkinson-White Syndrome (WPW)	Toronto, Toronto	93.74	[H][C@]12C[C@]34[C@H](O)[C@@]1([H])[C@]1([H])C[C@]([H])(N2[C@H](O)[C@@]1([H])CC)[C@]3([H])N(C)c1ccccc41, [H][C@]12C[C@]34[C@H](O)[C@@]1([H])[C@]1([H])C[C@]([H])(N2[C@H](O)[C@@]1([H])CC)[C@]3([H])N(C)c1ccccc41	Launched
AJ76-(+)	dopamine receptor antagonist	DRD2, DRD3, DRD4			Tocris, Tocris	94.73	CCCN[C@@H]1CCc2c(OC)cccc2[C@@H]1C, CCCN[C@@H]1CCc2c(OC)cccc2[C@@H]1C	Preclinical
AK-7	SIRT inhibitor	SIRT2			Tocris, Tocris	96.33	Brc1cccc(NC(=O)c2cccc(c2)S(=O)(=O)N2CCCCCC2)c1, Brc1cccc(NC(=O)c2cccc(c2)S(=O)(=O)N2CCCCCC2)c1	Preclinical
AKBA	lipoxygenase inhibitor	ALOX5			MedChemEx, MedChemEx, MedChemEx, Toronto	90.39	C[C@@H]1CC[C@]2(C)CC[C@]3(C)C(=CC(=O)[C@@H]4[C@@]5(C)CC[C@@H](OC(C)=O)[C@@](C)([C@@H]5CC[C@@]34C)C(O)=O)[C@@H]2[C@H]1C |c:10|, C[C@@H]1CC[C@]2(C)CC[C@]3(C)C(=CC(=O)[C@@H]4[C@@]5(C)CC[C@@H](OC(C)=O)[C@@](C)([C@@H]5CC[C@@]34C)C(O)=O)[C@@H]2[C@H]1C |c:10|, C[C@@H]1CC[C@]2(C)CC[C@]3(C)C(=CC(=O)[C@@H]4[C@@]5(C)CC[C@@H](OC(C)=O)[C@@](C)([C@@H]5CC[C@@]34C)C(O)=O)[C@@H]2[C@H]1C |c:10|, C[C@@H]1CC[C@]2(C)CC[C@]3(C)C(=CC(=O)[C@@H]4[C@@]5(C)CC[C@@H](OC(C)=O)[C@@](C)([C@@H]5CC[C@@]34C)C(O)=O)[C@@H]2[C@H]1C |c:10|	Phase 3
aklomide			infectious disease	coccidiosis	MicroSource	98.9	NC(=O)c1ccc(cc1Cl)[N+]([O-])=O	Launched
AL-8697	p38 MAPK inhibitor	MAPK14			Tocris, Tocris	99.77	Cc1c(F)cc(cc1-c1c(F)cn2c(nnc2c1F)C(C)(C)C)C(=O)NC1CC1, Cc1c(F)cc(cc1-c1c(F)cn2c(nnc2c1F)C(C)(C)C)C(=O)NC1CC1	Preclinical
alacepril	angiotensin converting enzyme inhibitor	ACE	cardiology	hypertension	Key, Key, Key, Key	98.51	C[C@H](CSC(C)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1ccccc1)C(O)=O, C[C@H](CSC(C)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1ccccc1)C(O)=O, C[C@H](CSC(C)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1ccccc1)C(O)=O, C[C@H](CSC(C)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1ccccc1)C(O)=O	Launched
alafosfalin	bacterial cell wall synthesis inhibitor				Sigma, Sigma	93.9	C[C@H](N)C(=O)N[C@@H](C)P(O)(O)=O, C[C@H](N)C(=O)N[C@@H](C)P(O)(O)=O	Phase 1
alagebrium	glycosylation inhibitor				OxChem	87.59	Cc1sc[n+](CC(=O)c2ccccc2)c1C	Phase 2/Phase 3
alanine					Sigma	69.19	C[C@@H](N)C(O)=O |&1:1,r|	Launched
alanosine	antimetabolite				Cayman	0	N[C@@H](CN(O)[N+][O-])C(O)=O	Phase 2
alantolactone	apoptosis stimulant, STAT inhibitor	STAT3			Tocris, Tocris	91.14	C[C@H]1CCC[C@]2(C)C[C@H]3OC(=O)C(=C)[C@H]3C=C12 |t:16|, C[C@H]1CCC[C@]2(C)C[C@H]3OC(=O)C(=C)[C@H]3C=C12 |t:16|	Preclinical
alaproclate	serotonin receptor antagonist	SLC6A4			AlfaAesar	95.15	C[C@@H](N)C(=O)OC(C)(C)Cc1ccc(Cl)cc1 |&1:1|	Phase 2
alarelin	gonadotropin releasing factor hormone receptor antagonist	GNRH1			MedChemEx, MedChemEx	96.08	CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H]1CCC(=O)N1, CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H]1CCC(=O)N1	Launched
albendazole	tubulin polymerization inhibitor	TUBA1A, TUBB, TUBB4B	infectious disease	cystic hydatid disease, parenchymal neurocysticercosis	MedChemEx, MicroSource, Selleck, Selleck, Selleck	94.73	CCCSc1ccc2nc(NC(=O)OC)[nH]c2c1, CCCSc1ccc2nc(NC(=O)OC)[nH]c2c1, CCCSc1ccc2nc(NC(=O)OC)[nH]c2c1, CCCSc1ccc2nc(NC(=O)OC)[nH]c2c1, CCCSc1ccc2nc(NC(=O)OC)[nH]c2c1	Launched
albendazole-oxide	anthelmintic agent		infectious disease	cystic hydatid disease, parenchymal neurocysticercosis	Selleck, Selleck	97.13	CCC[S@@](=O)c1ccc2nc(NC(=O)OC)[nH]c2c1 |r|, CCC[S@@](=O)c1ccc2nc(NC(=O)OC)[nH]c2c1 |r|	Launched
albuterol	adrenergic receptor agonist	ADRB2	pulmonary	asthma	Tocris, Selleck	90.96	CC(C)(C)NC[C@@H](O)c1ccc(O)c(CO)c1 |&1:6|, CC(C)(C)NC[C@@H](O)c1ccc(O)c(CO)c1 |&1:6|	Launched
alcaftadine	histamine receptor antagonist	HRH1	allergy	allergic conjunctivitis	MedChemEx	99.28	CN1CCC(CC1)=C1c2ncc(C=O)n2CCc2ccccc12	Launched
alclofenac	cyclooxygenase inhibitor	PTGS1	rheumatology	rheumatoid arthritis	Sigma, Sigma	96.73	OC(=O)Cc1ccc(OCC=C)c(Cl)c1, OC(=O)Cc1ccc(OCC=C)c(Cl)c1	Launched
alclometasone-dipropionate	glucocorticoid receptor agonist	CYP3A4, NR3C1, SERPINA6	dermatology	corticosteroid-responsive dermatoses	Prestwick	97.41	CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@H](C)C[C@H]2[C@H]3[C@H](Cl)CC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C |a:14,17,19,28,30,31,34,&1:8,&2:18,c:26,t:22|	Launched
alcuronium	muscle relaxant	CHRM1, CHRM2, CHRM3, CHRM4, CHRNA7	neurology/psychiatry	muscle relaxant	Prestwick	89.64	OC\C=C1/C[N@+]2(CC=C)CC[C@@]34[C@@H]2C[C@@H]1\C1=C\N2[C@@H]5\C(=C/N([C@@H]31)c1ccccc41)[C@H]1C[C@H]3[C@@]5(CC[N@@+]3(CC=C)C\C1=C/CO)c1ccccc21 |a:5,11,12,14,29,31,32,35,&1:18,&2:22,c:21,t:17,TLB:2:3:13:11.15.22,20:19:30:35.39.40,10:11:3.4.5:13,41:40:30:18.19.32,28:11:3.4.5:13,THB:34:35:30:18.19.32,16:15:3.4.5:13,33:32:30:35.39.40,36:35:30:18.19.32,6:5:13:11.15.22,9:5:13:11.15.22,44:32:30:35.39.40|	Launched
alda-1	aldehyde dehydrogenase activator	ALDH2			Tocris, Tocris	97.13	Clc1cccc(Cl)c1C(=O)NCc1ccc2OCOc2c1, Clc1cccc(Cl)c1C(=O)NCc1ccc2OCOc2c1	Preclinical
aldoxorubicin	topoisomerase inhibitor	TOP2A			MedChemEx, MedChemEx, MedChemEx	55.08	COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(\CO)=N\NC(=O)CCCCCN1C(=O)C=CC1=O |c:55|, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(\CO)=N\NC(=O)CCCCCN1C(=O)C=CC1=O |c:55|, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(\CO)=N\NC(=O)CCCCCN1C(=O)C=CC1=O |c:55|	Phase 3
alectinib	ALK tyrosine kinase receptor inhibitor	ALK, MET	oncology	non-small cell lung cancer (NSCLC)	Selleck, Selleck, Selleck	98.17	CCc1cc2C(=O)c3c([nH]c4cc(ccc34)C#N)C(C)(C)c2cc1N1CCC(CC1)N1CCOCC1, CCc1cc2C(=O)c3c([nH]c4cc(ccc34)C#N)C(C)(C)c2cc1N1CCC(CC1)N1CCOCC1, CCc1cc2C(=O)c3c([nH]c4cc(ccc34)C#N)C(C)(C)c2cc1N1CCC(CC1)N1CCOCC1	Launched
alendronate	bone resorption inhibitor	ATP6V1A, FDPS, PTPN4, PTPRE, PTPRS	orthopedics	osteoporosis	MicroSource, Selleck, Selleck, Selleck, Selleck	0	NCCCC(O)(P(O)(O)=O)P(O)(O)=O, NCCCC(O)(P(O)(O)=O)P(O)(O)=O, NCCCC(O)(P(O)(O)=O)P(O)(O)=O, NCCCC(O)(P(O)(O)=O)P(O)(O)=O, NCCCC(O)(P(O)(O)=O)P(O)(O)=O	Launched
alexidine	phosphatidylglycerophosphatase inhibitor	PTPMT1			Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck	91.99	CCCC[C@H](CC)CNC(=N)N=C(N)NCCCCCCNC(N)=NC(=N)NC[C@H](CC)CCCC |&1:29,&2:4,&3:11,&4:24,w:11.10,24.24|, CCCC[C@H](CC)CNC(=N)N=C(N)NCCCCCCNC(N)=NC(=N)NC[C@H](CC)CCCC |&1:29,&2:4,&3:11,&4:24,w:11.10,24.24|, CCCC[C@H](CC)CNC(=N)N=C(N)NCCCCCCNC(N)=NC(=N)NC[C@H](CC)CCCC |&1:29,&2:4,&3:11,&4:24,w:11.10,24.24|, CCCC[C@H](CC)CNC(=N)N=C(N)NCCCCCCNC(N)=NC(=N)NC[C@H](CC)CCCC |&1:29,&2:4,&3:11,&4:24,w:11.10,24.24|, CCCC[C@H](CC)CNC(=N)N=C(N)NCCCCCCNC(N)=NC(=N)NC[C@H](CC)CCCC |&1:29,&2:4,&3:11,&4:24,w:11.10,24.24|, CCCC[C@H](CC)CNC(=N)N=C(N)NCCCCCCNC(N)=NC(=N)NC[C@H](CC)CCCC |&1:29,&2:4,&3:11,&4:24,w:11.10,24.24|, CCCC[C@H](CC)CNC(=N)N=C(N)NCCCCCCNC(N)=NC(=N)NC[C@H](CC)CCCC |&1:29,&2:4,&3:11,&4:24,w:11.10,24.24|	Preclinical
alfacalcidol	vitamin D receptor agonist	CYP27B1, VDR	endocrinology	vitamin D deficiency	Selleck, Selleck, MedChemEx, MedChemEx, Selleck, Selleck	91.26	CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C	Launched
alfadolone-acetate	benzodiazepine receptor agonist				Prestwick	100	CC(=O)OCC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4C[C@H](O)CC[C@]4(C)[C@H]3C(=O)C[C@]12C	Phase 2
alfuzosin	adrenergic receptor antagonist	ADRA1A, ADRA1B, ADRA1D, SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A	urology	benign prostatic hyperplasia (BPH)	MicroSource, Selleck	93.3	COc1cc2nc(nc(N)c2cc1OC)N(C)CCCNC(=O)[C@H]1CCCO1 |&1:23|, COc1cc2nc(nc(N)c2cc1OC)N(C)CCCNC(=O)[C@H]1CCCO1 |&1:23|	Launched
algestone-acetophenide			endocrinology	contraceptive	Toronto	93.41	CC(=O)[C@@]12O[C@@](C)(O[C@@H]1C[C@H]1[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]21C)c1ccccc1 |t:15|	Launched
alibendol	antispasmodic		gastroenterology	bile stimulation	Selleck	97.28	COc1cc(CC=C)cc(C(=O)NCCO)c1O	Launched
alimemazine	histamine receptor agonist, histamine receptor antagonist	HRH1	neurology/psychiatry, allergy, pulmonary	sedative, urticaria, itching, cough suppressant	Sigma, MedChemEx, MicroSource	92.88	C[C@@H](CN(C)C)CN1c2ccccc2Sc2ccccc12 |&3:1|, C[C@@H](CN(C)C)CN1c2ccccc2Sc2ccccc12 |&3:1|, C[C@@H](CN(C)C)CN1c2ccccc2Sc2ccccc12 |&3:1|	Launched
alinidine	bradycardic effect 				AMS	86.45	Clc1cccc(Cl)c1N(CC=C)C1=NCCN1 |t:13|	Phase 3
alisertib	Aurora kinase inhibitor	AURKA			Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck	98.9	COc1cc(Nc2ncc3CN=C(c4cc(Cl)ccc4-c3n2)c2c(F)cccc2OC)ccc1C(O)=O |c:11|, COc1cc(Nc2ncc3CN=C(c4cc(Cl)ccc4-c3n2)c2c(F)cccc2OC)ccc1C(O)=O |c:11|, COc1cc(Nc2ncc3CN=C(c4cc(Cl)ccc4-c3n2)c2c(F)cccc2OC)ccc1C(O)=O |c:11|, COc1cc(Nc2ncc3CN=C(c4cc(Cl)ccc4-c3n2)c2c(F)cccc2OC)ccc1C(O)=O |c:11|, COc1cc(Nc2ncc3CN=C(c4cc(Cl)ccc4-c3n2)c2c(F)cccc2OC)ccc1C(O)=O |c:11|, COc1cc(Nc2ncc3CN=C(c4cc(Cl)ccc4-c3n2)c2c(F)cccc2OC)ccc1C(O)=O |c:11|, COc1cc(Nc2ncc3CN=C(c4cc(Cl)ccc4-c3n2)c2c(F)cccc2OC)ccc1C(O)=O |c:11|, COc1cc(Nc2ncc3CN=C(c4cc(Cl)ccc4-c3n2)c2c(F)cccc2OC)ccc1C(O)=O |c:11|, COc1cc(Nc2ncc3CN=C(c4cc(Cl)ccc4-c3n2)c2c(F)cccc2OC)ccc1C(O)=O |c:11|, COc1cc(Nc2ncc3CN=C(c4cc(Cl)ccc4-c3n2)c2c(F)cccc2OC)ccc1C(O)=O |c:11|, COc1cc(Nc2ncc3CN=C(c4cc(Cl)ccc4-c3n2)c2c(F)cccc2OC)ccc1C(O)=O |c:11|, COc1cc(Nc2ncc3CN=C(c4cc(Cl)ccc4-c3n2)c2c(F)cccc2OC)ccc1C(O)=O |c:11|, COc1cc(Nc2ncc3CN=C(c4cc(Cl)ccc4-c3n2)c2c(F)cccc2OC)ccc1C(O)=O |c:11|	Phase 3
aliskiren-hemifumarate	renin inhibitor	REN	cardiology	hypertension	Tocris, Tocris, Tocris, Tocris, MicroSource, Selleck	100	COCCCOc1cc(C[C@@H](C[C@H](N)[C@@H](O)C[C@@H](C(C)C)C(=O)NCC(C)(C)C(N)=O)C(C)C)ccc1OC, COCCCOc1cc(C[C@@H](C[C@H](N)[C@@H](O)C[C@@H](C(C)C)C(=O)NCC(C)(C)C(N)=O)C(C)C)ccc1OC, COCCCOc1cc(C[C@@H](C[C@H](N)[C@@H](O)C[C@@H](C(C)C)C(=O)NCC(C)(C)C(N)=O)C(C)C)ccc1OC, COCCCOc1cc(C[C@@H](C[C@H](N)[C@@H](O)C[C@@H](C(C)C)C(=O)NCC(C)(C)C(N)=O)C(C)C)ccc1OC, COCCCOc1cc(C[C@@H](C[C@H](N)[C@@H](O)C[C@@H](C(C)C)C(=O)NCC(C)(C)C(N)=O)C(C)C)ccc1OC, COCCCOc1cc(C[C@@H](C[C@H](N)[C@@H](O)C[C@@H](C(C)C)C(=O)NCC(C)(C)C(N)=O)C(C)C)ccc1OC	Launched
alisporivir	cyclophilin inhibitor				MedChemEx	91.48	[H][C@]1(C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(CC)C(=O)[C@@H](C)N(C)C(=O)[C@H](CC)NC(=O)[C@]([H])([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@]([H])(CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C1=O)C(C)C	Phase 3
alizapride	dopamine receptor antagonist		gastroenterology	nausea	MedChemEx	97.78	COc1cc2[nH]nnc2cc1C(=O)NC[C@H]1CCCN1CC=C |&1:15,r|	Launched
alizarin					Selleck, Selleck, Selleck	92.04	Oc1ccc2C(=O)c3ccccc3C(=O)c2c1O, Oc1ccc2C(=O)c3ccccc3C(=O)c2c1O, Oc1ccc2C(=O)c3ccccc3C(=O)c2c1O	Preclinical
allantoin	cosmetic		dermatology	skin protectant	MicroSource	97.81	NC(=O)N[C@H]1NC(=O)NC1=O |r|	Launched
allicin	cytokine production inhibitor	TRPA1, TRPV1			AKSci	0	C=CCS[S@@](=O)CC=C |&1:4,r|	Phase 2
allopurinol	xanthine oxidase inhibitor	XDH	rheumatology, urology	gout, kidney stones	MicroSource, Selleck, Selleck, Selleck	100	O=c1nc[nH]c2n[nH]cc12, O=c1nc[nH]c2n[nH]cc12, O=c1nc[nH]c2n[nH]cc12, O=c1nc[nH]c2n[nH]cc12	Launched
allopurinol-riboside	anti-leishmanial agent, phosphorylase inhibitor				MedChemEx, Berry	100	OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1ncc2c(O)ncnc12, OC[C@H]1O[C@H]([C@@H](O)[C@H]1O)n1ncc2c1[nH]cnc2=O |a:2,4,7,&1:5|	Phase 2
allylestrenol	steroidal progestin	ESR1, PGR, SLC6A9	obstetrics/gynecology	premature labor	ChemImpex	0	C[C@]12CC[C@H]3[C@@H](CCC4=CCCC[C@H]34)[C@@H]1CC[C@@]2(O)CC=C |t:8|	Launched
allylisothiocyanate	TRPV agonist	TRPA1			MicroSource, Labotest	0	C=CCN=C=S, C=CCN=C=S	Preclinical
allylthiourea	nitrification inhibitor				MedChemEx, Selleck, MicroSource	99.31	NC(=S)NCC=C, NC(=S)NCC=C, NC(=S)NCC=C	Preclinical
almitrine	neurotransmitter agonist	ATP1A1	pulmonary	chronic obstructive pulmonary disease (COPD)	AKSci, AKSci	99.06	Fc1ccc(cc1)C(N1CCN(CC1)c1nc(NCC=C)nc(NCC=C)n1)c1ccc(F)cc1, Fc1ccc(cc1)C(N1CCN(CC1)c1nc(NCC=C)nc(NCC=C)n1)c1ccc(F)cc1	Launched
almorexant	orexin receptor antagonist	HCRTR1, HCRTR2			MedChemEx, MedChemEx	97.62	CNC(=O)[C@H](N1CCc2cc(OC)c(OC)cc2[C@@H]1CCc1ccc(cc1)C(F)(F)F)c1ccccc1, CNC(=O)[C@H](N1CCc2cc(OC)c(OC)cc2[C@@H]1CCc1ccc(cc1)C(F)(F)F)c1ccccc1	Phase 3
almotriptan	serotonin receptor agonist	HTR1B, HTR1D	neurology/psychiatry	migraine headache	MicroSource, Selleck, MedChemEx	98.32	CN(C)CCc1c[nH]c2ccc(CS(=O)(=O)N3CCCC3)cc12, CN(C)CCc1c[nH]c2ccc(CS(=O)(=O)N3CCCC3)cc12, CN(C)CCc1c[nH]c2ccc(CS(=O)(=O)N3CCCC3)cc12	Launched
aloe-emodin	anticancer agent	CASP8			Selleck	94.34	OCc1cc(O)c2C(=O)c3c(O)cccc3C(=O)c2c1	Preclinical
alogliptin	dipeptidyl peptidase inhibitor	DPP4	endocrinology	diabetes mellitus	MedChemEx, Selleck, Selleck, Selleck, Selleck	93.62	Cn1c(=O)cc(N2CCC[C@@H](N)C2)n(Cc2ccccc2C#N)c1=O, Cn1c(=O)cc(N2CCC[C@@H](N)C2)n(Cc2ccccc2C#N)c1=O, Cn1c(=O)cc(N2CCC[C@@H](N)C2)n(Cc2ccccc2C#N)c1=O, Cn1c(=O)cc(N2CCC[C@@H](N)C2)n(Cc2ccccc2C#N)c1=O, Cn1c(=O)cc(N2CCC[C@@H](N)C2)n(Cc2ccccc2C#N)c1=O	Launched
aloin	angiogenesis inhibitor				MedChemEx, MicroSource, Selleck, Selleck	50.52	OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)[C@H]1c2cccc(O)c2C(=O)c2c(O)cc(CO)cc12, OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)[C@H]1c2cccc(O)c2C(=O)c2c(O)cc(CO)cc12, OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)[C@H]1c2cccc(O)c2C(=O)c2c(O)cc(CO)cc12, OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)[C@H]1c2cccc(O)c2C(=O)c2c(O)cc(CO)cc12	Preclinical
aloperine					Selleck, Selleck	100	C1CCN2C[C@H]3C[C@H](C=C4CCCN[C@@H]34)[C@H]2C1 |t:8|, C1CCN2C[C@H]3C[C@H](C=C4CCCN[C@@H]34)[C@H]2C1 |t:8|	Preclinical
alosetron	serotonin receptor antagonist	HTR3A			MedChemEx, MedChemEx, Enzo	99.02	Cc1nc[nH]c1CN1CCc2c(C1=O)c1ccccc1n2C, Cc1nc[nH]c1CN1CCc2c(C1=O)c1ccccc1n2C, Cc1nc[nH]c1CN1CCc2c(C1=O)c1ccccc1n2C	Withdrawn
alovudine	DNA synthesis marker				CombiBlocks	94.48	Cc1cn([C@H]2C[C@H](F)[C@@H](CO)O2)c(=O)[nH]c1=O	Phase 2
aloxistatin	protease inhibitor	CTSG			Adooq, Adooq, Selleck, Selleck, MedChemEx, MedChemEx, Selleck	93.7	CCOC(=O)[C@H]1O[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCCC(C)C, CCOC(=O)[C@H]1O[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCCC(C)C, CCOC(=O)[C@H]1O[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCCC(C)C, CCOC(=O)[C@H]1O[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCCC(C)C, CCOC(=O)[C@H]1O[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCCC(C)C, CCOC(=O)[C@H]1O[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCCC(C)C, CCOC(=O)[C@H]1O[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCCC(C)C	Phase 3
alpelisib	PI3K inhibitor	PIK3CA, PIK3CB, PIK3CD, PIK3CG	oncology	breast cancer	Selleck, Selleck, Selleck, Selleck, Selleck, Selleck	91.09	Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccnc(c1)C(C)(C)C(F)(F)F, Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccnc(c1)C(C)(C)C(F)(F)F, Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccnc(c1)C(C)(C)C(F)(F)F, Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccnc(c1)C(C)(C)C(F)(F)F, Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccnc(c1)C(C)(C)C(F)(F)F, Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccnc(c1)C(C)(C)C(F)(F)F	Launched
alpha-asarone	cytochrome P450 inhibitor, HMGCR inhibitor	HMGCR			Cayman	94.23	COc1cc(OC)c(\C=C\C)cc1OC	Preclinical
alpha-D-glucopyranose					Sigma	0	OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@@H]1O	Preclinical
alpha-glucosyl-hesperidin	antioxidant				ChemImpex	76.75	COc1ccc(cc1O)[C@@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O[C@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)[C@H](O)[C@H]3O)cc2O1	Preclinical
alpha-linolenic-acid	omega 3 fatty acid stimulant	ELOVL4, FADS1, FADS2, FFAR1, FFAR4, PTGS2, SLC8A1, TRPV1			Sigma, Sigma, Sigma, Enzo, Enzo	84.81	CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O, CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O, CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O, CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O, CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O	Phase 3
alpha-methylhistamine-dihydrobromide-(R)-(-)	histamine receptor agonist	HRH3			Tocris, Tocris	100	C[C@@H](N)Cc1cnc[nH]1, C[C@@H](N)Cc1cnc[nH]1	Preclinical
alpha-methylhistamine-dihydrobromide-(S)-(+)	histamine receptor agonist	HRH3			Tocris, Tocris	91.26	C[C@H](N)Cc1cnc[nH]1, C[C@H](N)Cc1cnc[nH]1	Preclinical
alpha-methylserotonin	serotonin receptor agonist	HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR4			Tocris	95.4	C[C@@H](N)Cc1c[nH]c2ccc(O)cc12 |&1:1|	Preclinical
alpha-tochopherol	antioxidant		endocrinology	vitamin E deficiency	MicroSource, Sigma	65.25	CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC[C@@]1(C)CCc2c(C)c(O)c(C)c(C)c2O1 |&1:6,&2:11,&3:16,r|, CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC[C@@]1(C)CCc2c(C)c(O)c(C)c(C)c2O1 |&1:6,&2:11,&3:16,r|	Launched
alpha-tochopheryl-acetate	antioxidant		endocrinology	vitamin E deficiency	MicroSource	93.36	CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC[C@@]1(C)CCc2c(C)c(OC(C)=O)c(C)c(C)c2O1 |&1:6,&2:11,&3:16,r|	Launched
alpidem	benzodiazepine receptor agonist	GABRA1			Sigma, Sigma, Sigma	98.59	CCCN(CCC)C(=O)Cc1c(nc2ccc(Cl)cn12)-c1ccc(Cl)cc1, CCCN(CCC)C(=O)Cc1c(nc2ccc(Cl)cn12)-c1ccc(Cl)cc1, CCCN(CCC)C(=O)Cc1c(nc2ccc(Cl)cn12)-c1ccc(Cl)cc1	Withdrawn
alprenolol	adrenergic receptor antagonist	ADRB1, ADRB2	cardiology	angina pectoris	Tocris, Tocris	96.05	CC(C)NC[C@@H](O)COc1ccccc1CC=C |&1:5,r|, CC(C)NC[C@@H](O)COc1ccccc1CC=C |&1:5,r|	Launched
alprostadil	prostanoid receptor agonist	CATSPER1, CATSPER2, CATSPER3, CATSPER4, PTGDR, PTGER1, PTGER2, PTGER4, PTGIR	cardiology	congenital heart defects	Tocris, Tocris, Tocris, Selleck	100	CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O, CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O, CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O, CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O	Launched
alrestatin	aldose reductase inhibitor	AKR1B1			MicroSource, Tocris, Tocris	98.57	OC(=O)CN1C(=O)c2cccc3cccc(C1=O)c23, OC(=O)CN1C(=O)c2cccc3cccc(C1=O)c23, OC(=O)CN1C(=O)c2cccc3cccc(C1=O)c23	Preclinical
ALS-8112					MedChemEx, MedChemEx, MedChemEx	96.39	Nc1ccn([C@@H]2O[C@@](CO)(CCl)[C@@H](O)[C@H]2F)c(=O)n1, Nc1ccn([C@@H]2O[C@@](CO)(CCl)[C@@H](O)[C@H]2F)c(=O)n1, Nc1ccn([C@@H]2O[C@@](CO)(CCl)[C@@H](O)[C@H]2F)c(=O)n1	Phase 1
ALS-8176	RNA polymerase inhibitor				MedChemEx	92.76	CC(C)C(=O)OC[C@@]1(CCl)O[C@H]([C@H](F)[C@@H]1OC(=O)C(C)C)n1ccc(N)nc1=O	Phase 1
altanserin	serotonin receptor antagonist	HTR2A			Tocris, Tocris, Tocris, Tocris, Tocris	97.52	Fc1ccc(cc1)C(=O)C1CCN(CCn2c(=S)[nH]c3ccccc3c2=O)CC1, Fc1ccc(cc1)C(=O)C1CCN(CCn2c(=S)[nH]c3ccccc3c2=O)CC1, Fc1ccc(cc1)C(=O)C1CCN(CCn2c(=S)[nH]c3ccccc3c2=O)CC1, Fc1ccc(cc1)C(=O)C1CCN(CCn2c(=S)[nH]c3ccccc3c2=O)CC1, Fc1ccc(cc1)C(=O)C1CCN(CCn2c(=S)[nH]c3ccccc3c2=O)CC1	Phase 2
althiazide	diuretic		cardiology	hypertension	Sigma, Sigma, MicroSource	99.56	NS(=O)(=O)c1cc2c(N[C@@H](CSCC=C)NS2(=O)=O)cc1Cl |&1:9,r|, NS(=O)(=O)c1cc2c(N[C@@H](CSCC=C)NS2(=O)=O)cc1Cl |&1:9,r|, NS(=O)(=O)c1cc2c(N[C@@H](CSCC=C)NS2(=O)=O)cc1Cl |&1:9,r|	Launched
altinicline	nicotinic receptor agonist	CHRNA4, CHRNB2			Tocris, Tocris	95.59	CN1CCC[C@H]1c1cncc(c1)C#C, CN1CCC[C@H]1c1cncc(c1)C#C	Phase 2
altiratinib	MET inhibitor, VEGFR inhibitor	KDR, MET, TEK			MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx	93.9	Fc1ccc(NC(=O)C2(CC2)C(=O)Nc2cc(F)c(Oc3ccnc(NC(=O)C4CC4)c3)cc2F)cc1, Fc1ccc(NC(=O)C2(CC2)C(=O)Nc2cc(F)c(Oc3ccnc(NC(=O)C4CC4)c3)cc2F)cc1, Fc1ccc(NC(=O)C2(CC2)C(=O)Nc2cc(F)c(Oc3ccnc(NC(=O)C4CC4)c3)cc2F)cc1, Fc1ccc(NC(=O)C2(CC2)C(=O)Nc2cc(F)c(Oc3ccnc(NC(=O)C4CC4)c3)cc2F)cc1, Fc1ccc(NC(=O)C2(CC2)C(=O)Nc2cc(F)c(Oc3ccnc(NC(=O)C4CC4)c3)cc2F)cc1, Fc1ccc(NC(=O)C2(CC2)C(=O)Nc2cc(F)c(Oc3ccnc(NC(=O)C4CC4)c3)cc2F)cc1, Fc1ccc(NC(=O)C2(CC2)C(=O)Nc2cc(F)c(Oc3ccnc(NC(=O)C4CC4)c3)cc2F)cc1	Phase 1
altrenogest	progestogen hormone	PGR	endocrinology	estrus	MedChemEx, MedChemEx	84.93	C[C@]12C=CC3=C4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@@]2(O)CC=C |c:2,4,10|, C[C@]12C=CC3=C4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@@]2(O)CC=C |c:2,4,10|	Launched
altretamine	DNA synthesis inhibitor		oncology	ovarian cancer	MicroSource, Selleck	99.9	CN(C)c1nc(nc(n1)N(C)C)N(C)C, CN(C)c1nc(nc(n1)N(C)C)N(C)C	Launched
alverine	muscle relaxant	HTR1A	gastroenterology	irritable bowel syndrome, diverticular disease	MicroSource, MedChemEx, Selleck	94.35	CCN(CCCc1ccccc1)CCCc1ccccc1, CCN(CCCc1ccccc1)CCCc1ccccc1, CCN(CCCc1ccccc1)CCCc1ccccc1	Launched
alvespimycin	HSP inhibitor	HSP90AA1			Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, MedChemEx, MedChemEx	96.5	CO[C@H]1C[C@H](C)CC2=C(NCCN(C)C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O |c:7,25,t:17,23,36|, CO[C@H]1C[C@H](C)CC2=C(NCCN(C)C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O |c:7,25,t:17,23,36|, CO[C@H]1C[C@H](C)CC2=C(NCCN(C)C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O |c:7,25,t:17,23,36|, CO[C@H]1C[C@H](C)CC2=C(NCCN(C)C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O |c:7,25,t:17,23,36|, CO[C@H]1C[C@H](C)CC2=C(NCCN(C)C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O |c:7,25,t:17,23,36|, CO[C@H]1C[C@H](C)CC2=C(NCCN(C)C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O |c:7,25,t:17,23,36|, CO[C@H]1C[C@H](C)CC2=C(NCCN(C)C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O |c:7,25,t:17,23,36|, CO[C@H]1C[C@H](C)CC2=C(NCCN(C)C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O |c:7,25,t:17,23,36|	Phase 2
alvimopan	opioid receptor antagonist	OPRD1, OPRK1, OPRM1	gastroenterology	postoperative ileus	MedChemEx, MedChemEx, MedChemEx, MedChemEx	97.74	C[C@H]1CN(C[C@H](Cc2ccccc2)C(=O)NCC(O)=O)CC[C@@]1(C)c1cccc(O)c1, C[C@H]1CN(C[C@H](Cc2ccccc2)C(=O)NCC(O)=O)CC[C@@]1(C)c1cccc(O)c1, C[C@H]1CN(C[C@H](Cc2ccccc2)C(=O)NCC(O)=O)CC[C@@]1(C)c1cccc(O)c1, C[C@H]1CN(C[C@H](Cc2ccccc2)C(=O)NCC(O)=O)CC[C@@]1(C)c1cccc(O)c1	Launched
alvocidib	CDK inhibitor	CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8, CDK9, EGFR, PYGM			Tocris, Tocris, Tocris, Tocris, Tocris, Selleck, Selleck, Selleck, Selleck	96.8	CN1CC[C@@H]([C@H](O)C1)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl, CN1CC[C@@H]([C@H](O)C1)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl, CN1CC[C@@H]([C@H](O)C1)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl, CN1CC[C@@H]([C@H](O)C1)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl, CN1CC[C@@H]([C@H](O)C1)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl, CN1CC[C@@H]([C@H](O)C1)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl, CN1CC[C@@H]([C@H](O)C1)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl, CN1CC[C@@H]([C@H](O)C1)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl, CN1CC[C@@H]([C@H](O)C1)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl	Phase 2
ALX-40-4C	CC chemokine receptor antagonist				MedChemEx	0	CC(=O)N[C@H](CCCNC(N)=N)C(=O)N[C@H](CCCNC(N)=N)C(=O)N[C@H](CCCNC(N)=N)C(=O)N[C@H](CCCNC(N)=N)C(=O)N[C@H](CCCNC(N)=N)C(=O)N[C@H](CCCNC(N)=N)C(=O)N[C@H](CCCNC(N)=N)C(=O)N[C@H](CCCNC(N)=N)C(=O)N[C@H](CCCNC(N)=N)C(N)=O	Preclinical
ALX-5407	glycine transporter inhibitor	SLC6A9			Tocris, Tocris, Tocris	98.56	CN(CC[C@@H](Oc1ccc(cc1)-c1ccccc1)c1ccc(F)cc1)CC(O)=O, CN(CC[C@@H](Oc1ccc(cc1)-c1ccccc1)c1ccc(F)cc1)CC(O)=O, CN(CC[C@@H](Oc1ccc(cc1)-c1ccccc1)c1ccc(F)cc1)CC(O)=O	Phase 1
AM-1241	cannabinoid receptor agonist	CNR1, CNR2			Selleck, Selleck, Selleck	97.4	CN1CCCC[C@@H]1Cn1cc(C(=O)c2cc(ccc2I)[N+]([O-])=O)c2ccccc12 |&1:6,r|, CN1CCCC[C@@H]1Cn1cc(C(=O)c2cc(ccc2I)[N+]([O-])=O)c2ccccc12 |&1:6,r|, CN1CCCC[C@@H]1Cn1cc(C(=O)c2cc(ccc2I)[N+]([O-])=O)c2ccccc12 |&1:6,r|	Preclinical
AM-24	lipoxygenase inhibitor	ALOX5			Enamine, Enamine, Enamine	99.73	Oc1c(I)cc(I)cc1I, Oc1c(I)cc(I)cc1I, Oc1c(I)cc(I)cc1I	Phase 2
AM-251	cannabinoid receptor antagonist	CNR1, GPR18, GPR55			Tocris, Tocris, Selleck, Tocris	98.46	Cc1c(nn(c1-c1ccc(I)cc1)-c1ccc(Cl)cc1Cl)C(=O)NN1CCCCC1, Cc1c(nn(c1-c1ccc(I)cc1)-c1ccc(Cl)cc1Cl)C(=O)NN1CCCCC1, Cc1c(nn(c1-c1ccc(I)cc1)-c1ccc(Cl)cc1Cl)C(=O)NN1CCCCC1, Cc1c(nn(c1-c1ccc(I)cc1)-c1ccc(Cl)cc1Cl)C(=O)NN1CCCCC1	Preclinical
AM-281	cannabinoid receptor antagonist	CNR1, CNR2, GPR55			Tocris, Tocris	95.57	Cc1c(nn(c1-c1ccc(I)cc1)-c1ccc(Cl)cc1Cl)C(=O)NN1CCOCC1, Cc1c(nn(c1-c1ccc(I)cc1)-c1ccc(Cl)cc1Cl)C(=O)NN1CCOCC1	Preclinical
AM-404	cyclooxygenase inhibitor, FAAH inhibitor, TRPV antagonist	CNR1, CNR2, FAAH, TRPV1			Tocris, Tocris, Tocris, Tocris, Tocris	95.22	CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)Nc1ccc(O)cc1, CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)Nc1ccc(O)cc1, CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)Nc1ccc(O)cc1, CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)Nc1ccc(O)cc1, CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)Nc1ccc(O)cc1	Preclinical
AM-580	retinoid receptor agonist	RARA			Tocris, Tocris, Tocris, Tocris, Tocris	98.56	CC1(C)CCC(C)(C)c2cc(ccc12)C(=O)Nc1ccc(cc1)C(O)=O, CC1(C)CCC(C)(C)c2cc(ccc12)C(=O)Nc1ccc(cc1)C(O)=O, CC1(C)CCC(C)(C)c2cc(ccc12)C(=O)Nc1ccc(cc1)C(O)=O, CC1(C)CCC(C)(C)c2cc(ccc12)C(=O)Nc1ccc(cc1)C(O)=O, CC1(C)CCC(C)(C)c2cc(ccc12)C(=O)Nc1ccc(cc1)C(O)=O	Preclinical
AM-630	cannabinoid receptor antagonist	CNR1, CNR2			Tocris, Tocris, Tocris, Tocris, Tocris, Tocris	97.3	COc1ccc(cc1)C(=O)c1c(C)n(CCN2CCOCC2)c2cc(I)ccc12, COc1ccc(cc1)C(=O)c1c(C)n(CCN2CCOCC2)c2cc(I)ccc12, COc1ccc(cc1)C(=O)c1c(C)n(CCN2CCOCC2)c2cc(I)ccc12, COc1ccc(cc1)C(=O)c1c(C)n(CCN2CCOCC2)c2cc(I)ccc12, COc1ccc(cc1)C(=O)c1c(C)n(CCN2CCOCC2)c2cc(I)ccc12, COc1ccc(cc1)C(=O)c1c(C)n(CCN2CCOCC2)c2cc(I)ccc12	Preclinical
AM-92016	potassium channel blocker	GRIN1			Tocris, Tocris, Tocris	94.4	CN(CCc1ccc(Cl)c(Cl)c1)C[C@@H](O)COc1ccc(NS(C)(=O)=O)cc1 |&1:13|, CN(CCc1ccc(Cl)c(Cl)c1)C[C@@H](O)COc1ccc(NS(C)(=O)=O)cc1 |&1:13|, CN(CCc1ccc(Cl)c(Cl)c1)C[C@@H](O)COc1ccc(NS(C)(=O)=O)cc1 |&1:13|	Preclinical
amantadine	glutamate receptor antagonist	DRD2, GRIN2A, GRIN2B, GRIN2C, GRIN2D, GRIN3A	infectious disease, neurology/psychiatry	influenza A virus infection, Parkinson's Disease	MicroSource, MicroSource, Selleck	100	NC12CC3CC(CC(C3)C1)C2, NC12CC3CC(CC(C3)C1)C2, NC12CC3CC(CC(C3)C1)C2	Launched
ambazone	DNA damage inducer				Kemprotec, Vitas-M, Vitas-M	84	NC(=S)NNc1ccc(cc1)N=NC(N)=N, NC(=S)NNc1ccc(cc1)N=NC(N)=N, NC(=S)NNc1ccc(cc1)N=NC(N)=N	Phase 1
ambenonium	cholinesterase inhibitor	ACHE	neurology/psychiatry	myasthenia gravis	Tocris, Tocris, Tocris, Tocris	93.62	CC[N+](CC)(CCNC(=O)C(=O)NCC[N+](CC)(CC)Cc1ccccc1Cl)Cc1ccccc1Cl, CC[N+](CC)(CCNC(=O)C(=O)NCC[N+](CC)(CC)Cc1ccccc1Cl)Cc1ccccc1Cl, CC[N+](CC)(CCNC(=O)C(=O)NCC[N+](CC)(CC)Cc1ccccc1Cl)Cc1ccccc1Cl, CC[N+](CC)(CCNC(=O)C(=O)NCC[N+](CC)(CC)Cc1ccccc1Cl)Cc1ccccc1Cl	Launched
ambrisentan	endothelin receptor antagonist	EDNRA, EDNRB	pulmonary	pulmonary arterial hypertension (PAH)	MedChemEx, Selleck	97.47	COC([C@H](Oc1nc(C)cc(C)n1)C(O)=O)(c1ccccc1)c1ccccc1, COC([C@H](Oc1nc(C)cc(C)n1)C(O)=O)(c1ccccc1)c1ccccc1	Launched
ambroxol	sodium channel blocker	CYP3A4	pulmonary	bronchitis	MicroSource, Tocris, Tocris, Tocris, Tocris, Selleck	97.58	Nc1c(Br)cc(Br)cc1CN[C@H]1CC[C@H](O)CC1 |r|, Nc1c(Br)cc(Br)cc1CN[C@H]1CC[C@H](O)CC1 |r|, Nc1c(Br)cc(Br)cc1CN[C@H]1CC[C@H](O)CC1 |r|, Nc1c(Br)cc(Br)cc1CN[C@H]1CC[C@H](O)CC1 |r|, Nc1c(Br)cc(Br)cc1CN[C@H]1CC[C@H](O)CC1 |r|, Nc1c(Br)cc(Br)cc1CN[C@H]1CC[C@H](O)CC1 |r|	Launched
amcasertib	kinase inhibitor				MedChemEx	89.6	CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2\C(=O)Nc3ccc(cc23)-c2csc(n2)-c2ccccc2)c1C	Phase 2
amcinonide	glucocorticoid receptor agonist	NR3C1	dermatology	corticosteroid-responsive dermatoses	MicroSource	96.95	CC(=O)OCC(=O)[C@@]12OC3(CCCC3)O[C@@H]1C[C@H]1[C@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]21C |a:7,15,27,29,31,34,&1:17,&2:18,c:27,t:23|	Launched
AMD-3465	CC chemokine receptor antagonist	CXCR4			Tocris, Tocris, Tocris	100	C(NCc1ccccn1)c1ccc(CN2CCCNCCNCCCNCC2)cc1, C(NCc1ccccn1)c1ccc(CN2CCCNCCNCCCNCC2)cc1, C(NCc1ccccn1)c1ccc(CN2CCCNCCNCCCNCC2)cc1	Preclinical
amdinocillin	bacterial cell wall synthesis inhibitor		infectious disease	urinary tract infections, gram-negative bacterial infections	Sigma, Sigma	61.16	CC1(C)S[C@@H]2[C@H](\N=C\N3CCCCCC3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](\N=C\N3CCCCCC3)C(=O)N2[C@H]1C(O)=O	Launched
AMD11070	CC chemokine receptor antagonist	CCR5, CXCR4			MedChemEx, MedChemEx, MedChemEx	94.61	NCCCCN(Cc1nc2ccccc2[nH]1)[C@H]1CCCc2cccnc12, NCCCCN(Cc1nc2ccccc2[nH]1)[C@H]1CCCc2cccnc12, NCCCCN(Cc1nc2ccccc2[nH]1)[C@H]1CCCc2cccnc12	Phase 3
ameltolide	anticonvulsant				Vitas-M, Vitas-M	98.29	Cc1cccc(C)c1NC(=O)c1ccc(N)cc1, Cc1cccc(C)c1NC(=O)c1ccc(N)cc1	Preclinical
amenamevir	helicase primase inhibitor				MedChemEx, MedChemEx	87.31	Cc1cccc(C)c1N(CC(=O)Nc1ccc(cc1)-c1ncon1)C(=O)C1CCS(=O)(=O)CC1, Cc1cccc(C)c1N(CC(=O)Nc1ccc(cc1)-c1ncon1)C(=O)C1CCS(=O)(=O)CC1	Phase 1
ametantrone	anticancer agent				Astatech	87.98	OCCNCCNc1ccc(NCCNCCO)c2C(=O)c3ccccc3C(=O)c12	Preclinical
amezinium	adrenergic receptor agonist	ADRB2	cardiology	hypotension	CombiBlocks, CombiBlocks	74.42	COc1cc(N)cn[n+]1-c1ccccc1, COc1cc(N)cn[n+]1-c1ccccc1	Launched
amfenac	cyclooxygenase inhibitor	PTGS1, PTGS2	neurology/psychiatry	pain relief	Selleck, MedChemEx	96.17	Nc1c(CC(O)=O)cccc1C(=O)c1ccccc1, Nc1c(CC(O)=O)cccc1C(=O)c1ccccc1	Launched
amflutizole	xanthine oxidase inhibitor	XDH			Enamine, Enamine, Enamine	96.22	Nc1c(snc1-c1cccc(c1)C(F)(F)F)C(O)=O, Nc1c(snc1-c1cccc(c1)C(F)(F)F)C(O)=O, Nc1c(snc1-c1cccc(c1)C(F)(F)F)C(O)=O	Phase 2
AMG-PERK-44	PERK inhibitor	EIF2AK4			Tocris, Tocris, Tocris	97.69	Cc1ccc2cc(ccc2n1)-c1c(C)ccc(C(=O)c2c(-c3ccccc3)n(C)n(-c3ccccc3)c2=O)c1N, Cc1ccc2cc(ccc2n1)-c1c(C)ccc(C(=O)c2c(-c3ccccc3)n(C)n(-c3ccccc3)c2=O)c1N, Cc1ccc2cc(ccc2n1)-c1c(C)ccc(C(=O)c2c(-c3ccccc3)n(C)n(-c3ccccc3)c2=O)c1N	Preclinical
AMG-176	MCL1 inhibitor				Broad Institute	96.01	CO[C@H]1\C=C\C[C@H](C)[C@@H](C)S(=O)(=O)NC(=O)c2ccc3OC[C@]4(CCCc5cc(Cl)ccc45)CN(C[C@@H]4CC[C@@H]14)c3c2 |t:3|	Phase 1
AMG-208	tyrosine kinase inhibitor	MET			MedChemEx, MedChemEx	99.83	COc1ccc2c(OCc3nnc4ccc(nn34)-c3ccccc3)ccnc2c1, COc1ccc2c(OCc3nnc4ccc(nn34)-c3ccccc3)ccnc2c1	Phase 1
AMG-232	MDM inhibitor	MDM2			MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx	98.92	CC(C)[C@@H](CS(=O)(=O)C(C)C)N1[C@@H]([C@H](C[C@](C)(CC(O)=O)C1=O)c1cccc(Cl)c1)c1ccc(Cl)cc1, CC(C)[C@@H](CS(=O)(=O)C(C)C)N1[C@@H]([C@H](C[C@](C)(CC(O)=O)C1=O)c1cccc(Cl)c1)c1ccc(Cl)cc1, CC(C)[C@@H](CS(=O)(=O)C(C)C)N1[C@@H]([C@H](C[C@](C)(CC(O)=O)C1=O)c1cccc(Cl)c1)c1ccc(Cl)cc1, CC(C)[C@@H](CS(=O)(=O)C(C)C)N1[C@@H]([C@H](C[C@](C)(CC(O)=O)C1=O)c1cccc(Cl)c1)c1ccc(Cl)cc1, CC(C)[C@@H](CS(=O)(=O)C(C)C)N1[C@@H]([C@H](C[C@](C)(CC(O)=O)C1=O)c1cccc(Cl)c1)c1ccc(Cl)cc1, CC(C)[C@@H](CS(=O)(=O)C(C)C)N1[C@@H]([C@H](C[C@](C)(CC(O)=O)C1=O)c1cccc(Cl)c1)c1ccc(Cl)cc1, CC(C)[C@@H](CS(=O)(=O)C(C)C)N1[C@@H]([C@H](C[C@](C)(CC(O)=O)C1=O)c1cccc(Cl)c1)c1ccc(Cl)cc1, CC(C)[C@@H](CS(=O)(=O)C(C)C)N1[C@@H]([C@H](C[C@](C)(CC(O)=O)C1=O)c1cccc(Cl)c1)c1ccc(Cl)cc1, CC(C)[C@@H](CS(=O)(=O)C(C)C)N1[C@@H]([C@H](C[C@](C)(CC(O)=O)C1=O)c1cccc(Cl)c1)c1ccc(Cl)cc1	Phase 2
AMG-319	PI3K inhibitor	PIK3CD			MedChemEx	98.62	C[C@H](Nc1ncnc2nc[nH]c12)c1cc2ccc(F)cc2nc1-c1ccccn1	Phase 2
AMG-337	MET inhibitor	MET			MedChemEx, MedChemEx, MedChemEx	97.7	COCCOc1cnc2ccn([C@H](C)c3nnc4c(F)cc(cn34)-c3cnn(C)c3)c(=O)c2c1, COCCOc1cnc2ccn([C@H](C)c3nnc4c(F)cc(cn34)-c3cnn(C)c3)c(=O)c2c1, COCCOc1cnc2ccn([C@H](C)c3nnc4c(F)cc(cn34)-c3cnn(C)c3)c(=O)c2c1	Phase 2
AMG-487	CC chemokine receptor antagonist				MedChemEx, MedChemEx, MedChemEx, MedChemEx	98.21	CCOc1ccc(cc1)-n1c(nc2ncccc2c1=O)[C@@H](C)N(Cc1cccnc1)C(=O)Cc1ccc(OC(F)(F)F)cc1, CCOc1ccc(cc1)-n1c(nc2ncccc2c1=O)[C@@H](C)N(Cc1cccnc1)C(=O)Cc1ccc(OC(F)(F)F)cc1, CCOc1ccc(cc1)-n1c(nc2ncccc2c1=O)[C@@H](C)N(Cc1cccnc1)C(=O)Cc1ccc(OC(F)(F)F)cc1, CCOc1ccc(cc1)-n1c(nc2ncccc2c1=O)[C@@H](C)N(Cc1cccnc1)C(=O)Cc1ccc(OC(F)(F)F)cc1	Phase 2
AMG-487-(+/-)	CC chemokine receptor antagonist	CXCR3			Tocris, Tocris, Tocris	97.4	CCOc1ccc(cc1)-n1c(nc2ncccc2c1=O)[C@@H](C)N(Cc1cccnc1)C(=O)Cc1ccc(OC(F)(F)F)cc1 |&1:20,r|, CCOc1ccc(cc1)-n1c(nc2ncccc2c1=O)[C@@H](C)N(Cc1cccnc1)C(=O)Cc1ccc(OC(F)(F)F)cc1 |&1:20,r|, CCOc1ccc(cc1)-n1c(nc2ncccc2c1=O)[C@@H](C)N(Cc1cccnc1)C(=O)Cc1ccc(OC(F)(F)F)cc1 |&1:20,r|	Phase 2
AMG-510	K-Ras inhibitor				MedChemEx, MedChemEx	99.17	CC(C)c1nccc(C)c1-n1c2nc(c(F)cc2c(nc1=O)N1CCN(C[C@@H]1C)C(=O)C=C)-c1c(O)cccc1F, CC(C)c1nccc(C)c1-n1c2nc(c(F)cc2c(nc1=O)N1CCN(C[C@@H]1C)C(=O)C=C)-c1c(O)cccc1F	Phase 1/Phase 2
AMG-517	TRPV antagonist	TRPV1			Tocris, Tocris, Selleck, Selleck	98.16	CC(=O)Nc1nc2c(Oc3cc(ncn3)-c3ccc(cc3)C(F)(F)F)cccc2s1, CC(=O)Nc1nc2c(Oc3cc(ncn3)-c3ccc(cc3)C(F)(F)F)cccc2s1, CC(=O)Nc1nc2c(Oc3cc(ncn3)-c3ccc(cc3)C(F)(F)F)cccc2s1, CC(=O)Nc1nc2c(Oc3cc(ncn3)-c3ccc(cc3)C(F)(F)F)cccc2s1	Phase 1
AMG-548	MAP kinase inhibitor	MAPK11, MAPK12, MAPK13, MAPK14			Tocris, Tocris, Tocris	87.61	Cn1c(NC[C@@H](N)Cc2ccccc2)nc(-c2ccncc2)c(-c2ccc3ccccc3c2)c1=O, Cn1c(NC[C@@H](N)Cc2ccccc2)nc(-c2ccncc2)c(-c2ccc3ccccc3c2)c1=O, Cn1c(NC[C@@H](N)Cc2ccccc2)nc(-c2ccncc2)c(-c2ccc3ccccc3c2)c1=O	Phase 1
AMG-837	free fatty acid receptor agonist	FFAR1			Tocris, MedChemEx, MedChemEx, MedChemEx, MedChemEx	97.49	CC#C[C@@H](CC(O)=O)c1ccc(OCc2cccc(c2)-c2ccc(cc2)C(F)(F)F)cc1, CC#C[C@@H](CC(O)=O)c1ccc(OCc2cccc(c2)-c2ccc(cc2)C(F)(F)F)cc1, CC#C[C@@H](CC(O)=O)c1ccc(OCc2cccc(c2)-c2ccc(cc2)C(F)(F)F)cc1, CC#C[C@@H](CC(O)=O)c1ccc(OCc2cccc(c2)-c2ccc(cc2)C(F)(F)F)cc1, CC#C[C@@H](CC(O)=O)c1ccc(OCc2cccc(c2)-c2ccc(cc2)C(F)(F)F)cc1	Phase 1
AMG-925	CDK inhibitor, FLT3 inhibitor	CDK4, CDK6, FLT3			MedChemEx, MedChemEx, MedChemEx, MedChemEx	94.57	C[C@H]1CC[C@@H](CC1)n1c2cnccc2c2cnc(Nc3ccc4CN(CCc4n3)C(=O)CO)nc12 |r|, C[C@H]1CC[C@@H](CC1)n1c2cnccc2c2cnc(Nc3ccc4CN(CCc4n3)C(=O)CO)nc12 |r|, C[C@H]1CC[C@@H](CC1)n1c2cnccc2c2cnc(Nc3ccc4CN(CCc4n3)C(=O)CO)nc12 |r|, C[C@H]1CC[C@@H](CC1)n1c2cnccc2c2cnc(Nc3ccc4CN(CCc4n3)C(=O)CO)nc12 |r|	Phase 1
AMG-9810	TRPV antagonist	TRPV1			Tocris, Tocris, Tocris, Tocris, Tocris	98.34	CC(C)(C)c1ccc(\C=C\C(=O)Nc2ccc3OCCOc3c2)cc1, CC(C)(C)c1ccc(\C=C\C(=O)Nc2ccc3OCCOc3c2)cc1, CC(C)(C)c1ccc(\C=C\C(=O)Nc2ccc3OCCOc3c2)cc1, CC(C)(C)c1ccc(\C=C\C(=O)Nc2ccc3OCCOc3c2)cc1, CC(C)(C)c1ccc(\C=C\C(=O)Nc2ccc3OCCOc3c2)cc1	Preclinical
AMG319	PI3K inhibitor	PIK3CD			Selleck	99.26	C[C@@H](Nc1ncnc2nc[nH]c12)c1cc2ccc(F)cc2nc1-c1ccccn1 |&1:1,r|	Phase 2
AMG458	MET inhibitor	MET			Selleck, Selleck, Selleck	96.9	COc1ccc2c(Oc3ccc(NC(=O)c4c(C)n(CC(C)(C)O)n(-c5ccccc5)c4=O)nc3)ccnc2c1, COc1ccc2c(Oc3ccc(NC(=O)c4c(C)n(CC(C)(C)O)n(-c5ccccc5)c4=O)nc3)ccnc2c1, COc1ccc2c(Oc3ccc(NC(=O)c4c(C)n(CC(C)(C)O)n(-c5ccccc5)c4=O)nc3)ccnc2c1	Preclinical
AMG900	Aurora kinase inhibitor	AURKA, AURKB, AURKC			MedChemEx, Selleck, Selleck, Selleck, Selleck	96.52	Cc1csc(c1)-c1nnc(Nc2ccc(Oc3ncccc3-c3ccnc(N)n3)cc2)c2ccccc12, Cc1csc(c1)-c1nnc(Nc2ccc(Oc3ncccc3-c3ccnc(N)n3)cc2)c2ccccc12, Cc1csc(c1)-c1nnc(Nc2ccc(Oc3ncccc3-c3ccnc(N)n3)cc2)c2ccccc12, Cc1csc(c1)-c1nnc(Nc2ccc(Oc3ncccc3-c3ccnc(N)n3)cc2)c2ccccc12, Cc1csc(c1)-c1nnc(Nc2ccc(Oc3ncccc3-c3ccnc(N)n3)cc2)c2ccccc12	Phase 1
AMI-1	protein arginine N-methyltransferase inhibitor	PRMT1			ChemBridge	83.1	Oc1cc(cc2cc(NC(=O)Nc3ccc4c(O)cc(cc4c3)S(O)(=O)=O)ccc12)S(O)(=O)=O	Preclinical
amibegron	adrenergic receptor agonist	ADRB3			Tocris, Sigma, Sigma	98.31	CCOC(=O)COc1ccc2CC[C@@H](Cc2c1)NC[C@H](O)c1cccc(Cl)c1, CCOC(=O)COc1ccc2CC[C@@H](Cc2c1)NC[C@H](O)c1cccc(Cl)c1, CCOC(=O)COc1ccc2CC[C@@H](Cc2c1)NC[C@H](O)c1cccc(Cl)c1	Phase 3
amidopyrine	analgesic agent		dermatology	dermatitis herpetiformis (DH)	MedChemEx, MicroSource, Selleck, Selleck, Selleck	95.76	CN(C)c1c(C)n(C)n(-c2ccccc2)c1=O, CN(C)c1c(C)n(C)n(-c2ccccc2)c1=O, CN(C)c1c(C)n(C)n(-c2ccccc2)c1=O, CN(C)c1c(C)n(C)n(-c2ccccc2)c1=O, CN(C)c1c(C)n(C)n(-c2ccccc2)c1=O	Launched
amifampridine	potassium channel blocker		neurology/psychiatry	Lambert-Eaton myasthenic syndrome (LEMS)	MedChemEx, MedChemEx	100	Nc1ccncc1N, Nc1ccncc1N	Launched
amiflamine	monoamine oxidase inhibitor	MAOA, SLC6A2			Enamine, Enamine	69.64	C[C@@H](N)Cc1ccc(cc1C)N(C)C |&1:1,r|, C[C@@H](N)Cc1ccc(cc1C)N(C)C |&1:1,r|	Phase 1
amifostine	reducing agent	ALPPL2, ENPP1	nephrology	renal toxicity	MicroSource	0	NCCCNCCSP(O)(O)=O	Launched
amikacin	bacterial 30S ribosomal subunit inhibitor		infectious disease	gram-negative bacterial infections	MicroSource, Selleck, Selleck, MedChemEx, Selleck, Selleck	100	NCC[C@H](O)C(=O)N[C@@H]1C[C@H](N)[C@@H](O[C@H]2O[C@H](CN)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1O[C@H]1O[C@H](CO)[C@@H](O)[C@H](N)[C@H]1O, NCC[C@H](O)C(=O)N[C@@H]1C[C@H](N)[C@@H](O[C@H]2O[C@H](CN)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1O[C@H]1O[C@H](CO)[C@@H](O)[C@H](N)[C@H]1O, NCC[C@H](O)C(=O)N[C@@H]1C[C@H](N)[C@@H](O[C@H]2O[C@H](CN)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1O[C@H]1O[C@H](CO)[C@@H](O)[C@H](N)[C@H]1O, NCC[C@H](O)C(=O)N[C@@H]1C[C@H](N)[C@@H](O[C@H]2O[C@H](CN)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1O[C@H]1O[C@H](CO)[C@@H](O)[C@H](N)[C@H]1O, NCC[C@H](O)C(=O)N[C@@H]1C[C@H](N)[C@@H](O[C@H]2O[C@H](CN)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1O[C@H]1O[C@H](CO)[C@@H](O)[C@H](N)[C@H]1O, NCC[C@H](O)C(=O)N[C@@H]1C[C@H](N)[C@@H](O[C@H]2O[C@H](CN)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1O[C@H]1O[C@H](CO)[C@@H](O)[C@H](N)[C@H]1O	Launched
amiloride	sodium channel blocker	AOC1, ASIC1, ASIC2, ASIC3, PKD2, PKD2L1, PLAU, SCNN1A, SCNN1B, SCNN1D, SCNN1G, SLC9A1, TRPC7, TRPV2	cardiology	hypertension, congestive heart failure	MicroSource, Tocris, Tocris, Tocris, Selleck, Selleck, Tocris	99.74	NC(=N)NC(=O)c1nc(Cl)c(N)nc1N, NC(=N)NC(=O)c1nc(Cl)c(N)nc1N, NC(=N)NC(=O)c1nc(Cl)c(N)nc1N, NC(=N)NC(=O)c1nc(Cl)c(N)nc1N, NC(=N)NC(=O)c1nc(Cl)c(N)nc1N, NC(=N)NC(=O)c1nc(Cl)c(N)nc1N, NC(=N)NC(=O)c1nc(Cl)c(N)nc1N	Launched
amineptine	dopamine receptor agonist	SLC6A2, SLC6A4			MedChemEx, MedChemEx, MedChemEx	97.45	OC(=O)CCCCCCNC1c2ccccc2CCc2ccccc12, OC(=O)CCCCCCNC1c2ccccc2CCc2ccccc12, OC(=O)CCCCCCNC1c2ccccc2CCc2ccccc12	Withdrawn
aminocaproic-acid	plasminogen activator inhibitor	LPA, PLAT, PLG	hematology	fibrinolytic bleeding	MicroSource, Selleck, Selleck	100	NCCCCCC(O)=O, NCCCCCC(O)=O, NCCCCCC(O)=O	Launched
aminoglutethimide	glucocorticoid receptor antagonist	CYP11A1, CYP19A1	endocrinology, oncology	Cushing's syndrome, breast cancer	MicroSource, Selleck, Selleck, Selleck, MedChemEx	94.21	CC[C@]1(CCC(=O)NC1=O)c1ccc(N)cc1 |&1:2,r|, CC[C@]1(CCC(=O)NC1=O)c1ccc(N)cc1 |&1:2,r|, CC[C@]1(CCC(=O)NC1=O)c1ccc(N)cc1 |&1:2,r|, CC[C@]1(CCC(=O)NC1=O)c1ccc(N)cc1 |&1:2,r|, CC[C@]1(CCC(=O)NC1=O)c1ccc(N)cc1 |&1:2,r|	Launched
aminoguanidine	nitric oxide synthase inhibitor	AKR1B1, NOS2, TIMP3			MicroSource, Tocris, Tocris	100	NN=C(N)N, NN=C(N)N, NN=C(N)N	Phase 3
aminohydroxybutyric-acid			neurology/psychiatry	epilepsy	MicroSource, Sigma	78.63	NC[C@@H](O)CC(O)=O |&1:2,r|, NC[C@@H](O)CC(O)=O |&1:2,r|	Launched
aminolevulinic-acid-benzyl-ester					ChemImpex	94.33	NCC(=O)CCC(=O)OCc1ccccc1	Phase 1
aminomethyltransferase	nitric oxide synthase inhibitor	NOS2			Tocris, Tocris, Tocris	96.29	C[C@H]1CCN=C(N)S1 |&1:1,t:4|, C[C@H]1CCN=C(N)S1 |&1:1,t:4|, C[C@H]1CCN=C(N)S1 |&1:1,t:4|	Preclinical
aminopentamide	acetylcholine receptor antagonist	CHRM1	gastroenterology	acute abdominal visceral spasm, hypertrophic gastritis (GHG), nausea	MicroSource	97.37	CC(CC(C(N)=O)(c1ccccc1)c1ccccc1)N(C)C	Launched
aminophylline	adenosine receptor antagonist	ADORA1, ADORA2A, ADORA2B, ADORA3, HDAC2, PDE3A, PDE3B, PDE4A, PDE4B, PDE4C, PDE4D, PDE5A	pulmonary	asthma, bronchitis, emphysema	Key, Key, MicroSource, Selleck, MicroSource, MicroSource	98.81	Cn1c2nc[nH]c2c(=O)n(C)c1=O, Cn1c2nc[nH]c2c(=O)n(C)c1=O, Cn1c2nc[nH]c2c(=O)n(C)c1=O, Cn1c2nc[nH]c2c(=O)n(C)c1=O, Cn1c2nc[nH]c2c(=O)n(C)c1=O, Cn1c2nc[nH]c2c(=O)n(C)c1=O	Launched
aminopterin	dihydrofolate reductase inhibitor	DHFR, SLC46A1			MicroSource, Sigma	0	Nc1nc(N)c2nc(CNc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)cnc2n1, Nc1nc(N)c2nc(CNc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)cnc2n1	Phase 3
aminopurvalanol-a	CDK inhibitor, tyrosine kinase inhibitor	CDK1, CDK2, CDK5			Tocris, Tocris, Tocris	95.56	CC(C)[C@H](CO)Nc1nc(Nc2cc(N)cc(Cl)c2)c2ncn(C(C)C)c2n1, CC(C)[C@H](CO)Nc1nc(Nc2cc(N)cc(Cl)c2)c2ncn(C(C)C)c2n1, CC(C)[C@H](CO)Nc1nc(Nc2cc(N)cc(Cl)c2)c2ncn(C(C)C)c2n1	Preclinical
aminosalicylate	cyclooxygenase inhibitor	ALOX5, CHUK, PLA2G2E, PTGS1, PTGS2	gastroenterology	inflammatory bowel disease, ulcerative colitis	MicroSource, MedChemEx, Selleck, Selleck	97.87	Nc1ccc(C(O)=O)c(O)c1, Nc1ccc(C(O)=O)c(O)c1, Nc1ccc(C(O)=O)c(O)c1, Nc1ccc(C(O)=O)c(O)c1	Launched
aminothiadiazole	inosine monophosphate dehydrogenase inhibitor	ADORA3, IMPDH1			Enamine, Vitas-M	0	Nc1nncs1, Nc1nncs1	Phase 2
aminothiazole	cyclin D inhibitor	NOS2			MicroSource, Selleck, Selleck	98.31	Nc1nccs1, Nc1nccs1, Nc1nccs1	Preclinical
amiodarone	potassium channel blocker	ADRB1, CACNA1H, CACNA2D2, KCNA7, KCNH2	cardiology	ventricular arrhythmias	MicroSource, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck	97.72	CCCCc1oc2ccccc2c1C(=O)c1cc(I)c(OCCN(CC)CC)c(I)c1, CCCCc1oc2ccccc2c1C(=O)c1cc(I)c(OCCN(CC)CC)c(I)c1, CCCCc1oc2ccccc2c1C(=O)c1cc(I)c(OCCN(CC)CC)c(I)c1, CCCCc1oc2ccccc2c1C(=O)c1cc(I)c(OCCN(CC)CC)c(I)c1, CCCCc1oc2ccccc2c1C(=O)c1cc(I)c(OCCN(CC)CC)c(I)c1, CCCCc1oc2ccccc2c1C(=O)c1cc(I)c(OCCN(CC)CC)c(I)c1, CCCCc1oc2ccccc2c1C(=O)c1cc(I)c(OCCN(CC)CC)c(I)c1, CCCCc1oc2ccccc2c1C(=O)c1cc(I)c(OCCN(CC)CC)c(I)c1	Launched
amiprilose	CD antagonist				Prestwick	96.74	CN(C)CCCO[C@H]1[C@H](O[C@@H]2OC(C)(C)O[C@H]12)[C@H](O)CO	Phase 3
amiselimod	sphingosine 1-phosphate receptor modulator				MedChemEx	90.67	CCCCCCCOc1ccc(CCC(N)(CO)CO)cc1C(F)(F)F	Phase 2
amisulpride	dopamine receptor antagonist	DRD2	neurology/psychiatry	psychosis, bipolar disorder, schizophrenia	Selleck, Tocris	94.44	CCN1CCC[C@@H]1CNC(=O)c1cc(c(N)cc1OC)S(=O)(=O)CC |&1:6,r|, CCN1CCC[C@@H]1CNC(=O)c1cc(c(N)cc1OC)S(=O)(=O)CC |&1:6,r|	Launched
amitifadine	serotonin transporter (SERT) inhibitor	SLC6A2, SLC6A3, SLC6A4			TygerSci, TygerSci	97.84	Clc1ccc(cc1Cl)[C@@]12C[C@@H]1CNC2 |&1:8,&2:10|, Clc1ccc(cc1Cl)[C@@]12C[C@@H]1CNC2 |&1:8,&2:10|	Phase 3
amitraz	adrenergic receptor agonist	ADRA1A, ADRA2A	infectious disease	generalized demodicosis	MicroSource, MedChemEx	69.18	CN(\C=N\c1ccc(C)cc1C)\C=N\c1ccc(C)cc1C, CN(\C=N\c1ccc(C)cc1C)\C=N\c1ccc(C)cc1C	Launched
amitriptyline	norepinephrine inhibitor, norepinephrine reuptake inhibitor, serotonin receptor antagonist, serotoninnorepinephrine reuptake inhibitor (SNRI)	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRB1, ADRB2, ADRB3, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, HRH1, HRH2, HRH4, HTR1A, HTR1B, HTR1D, HTR2A, HTR2C, HTR6, HTR7, KCNA1, KCND2, KCND3, KCNQ2, KCNQ3, NTRK1, NTRK2, OPRD1, OPRK1, OPRM1, SIGMAR1, SLC6A2, SLC6A4	neurology/psychiatry	depression	MicroSource, Selleck	98.47	CN(C)CCC=C1c2ccccc2CCc2ccccc12, CN(C)CCC=C1c2ccccc2CCc2ccccc12	Launched
amlexanox	histamine receptor modulator	FGF1, IL3, PDE4A, PDE4B, PDE4C, PDE4D, S100A12, S100A13	dental, pulmonary, ophthalmology, allergy	aphthous ulcers, asthma, conjunctivitis, allergic rhinitis	Tocris, Tocris, MicroSource, Tocris	99.58	CC(C)c1ccc2oc3nc(N)c(cc3c(=O)c2c1)C(O)=O, CC(C)c1ccc2oc3nc(N)c(cc3c(=O)c2c1)C(O)=O, CC(C)c1ccc2oc3nc(N)c(cc3c(=O)c2c1)C(O)=O, CC(C)c1ccc2oc3nc(N)c(cc3c(=O)c2c1)C(O)=O	Launched
amlodipine	calcium channel blocker	CACNA1C, CACNA1D, CACNA1F, CACNA1S, CACNA2D1	cardiology	hypertension, chronic stable angina, vasospastic angina, coronary artery disease (CAD)	Tocris, Selleck, Selleck, Selleck	89.83	CCOC(=O)C1=C(COCCN)NC(C)=C([C@H]1c1ccccc1Cl)C(=O)OC |&1:16,r,c:5,14|, CCOC(=O)C1=C(COCCN)NC(C)=C([C@H]1c1ccccc1Cl)C(=O)OC |&1:16,r,c:5,14|, CCOC(=O)C1=C(COCCN)NC(C)=C([C@H]1c1ccccc1Cl)C(=O)OC |&1:16,r,c:5,14|, CCOC(=O)C1=C(COCCN)NC(C)=C([C@H]1c1ccccc1Cl)C(=O)OC |&1:16,r,c:5,14|	Launched
ammonium-glycyrrhizinate	thrombin inhibitor	HSD11B1, HSD11B2, SLCO1B1, SLCO1B3	dermatology	cosmetic	MedChemEx	66	CC1(C)[C@H](CC[C@@]2(C)[C@H]1CC[C@]1(C)[C@@H]2C(=O)C=C2[C@@H]3C[C@](C)(CC[C@]3(C)CC[C@@]12C)C(O)=O)O[C@H]1O[C@@H]([C@@H](O)[C@H](O)[C@H]1O[C@@H]1O[C@@H]([C@@H](O)[C@H](O)[C@H]1O)C(O)=O)C(O)=O |t:18|	Launched
ammonium-lactate		HCAR1	dermatology	xerosis cutis, ichthyosis vulgaris	MicroSource, Selleck	0	N.C[C@@H](O)C(O)=O |&1:2,r|, N.C[C@@H](O)C(O)=O |&1:2,r|	Launched
ammonium-perfluorocaprylate	Pim kinase inhibitor	PIM1			Sigma, Enamine	100	OC(=O)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F, OC(=O)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F	Phase 1
AMN-082	glutamate receptor modulator	GRM7			Tocris, Tocris, Tocris, Tocris	95.4	C(CNC(c1ccccc1)c1ccccc1)NC(c1ccccc1)c1ccccc1, C(CNC(c1ccccc1)c1ccccc1)NC(c1ccccc1)c1ccccc1, C(CNC(c1ccccc1)c1ccccc1)NC(c1ccccc1)c1ccccc1, C(CNC(c1ccccc1)c1ccccc1)NC(c1ccccc1)c1ccccc1	Preclinical
amodiaquine	histamine receptor agonist	HNMT	infectious disease	malaria	MicroSource, MicroSource, Prestwick, Prestwick, Prestwick, Prestwick	98.24	CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O, CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O, CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O, CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O, CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O, CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O	Launched
amonafide	topoisomerase inhibitor	TOP2A, TOP2B			Selleck, Selleck	90.78	CN(C)CCN1C(=O)c2cccc3cc(N)cc(C1=O)c23, CN(C)CCN1C(=O)c2cccc3cc(N)cc(C1=O)c23	Phase 3
amorolfine	membrane integrity inhibitor		infectious disease	onychomycosis	MicroSource, MicroSource, Selleck, Selleck	97.1	CCC(C)(C)c1ccc(C[C@@H](C)CN2C[C@H](C)O[C@H](C)C2)cc1 |a:15,18,&1:10|, CCC(C)(C)c1ccc(C[C@@H](C)CN2C[C@H](C)O[C@H](C)C2)cc1 |a:15,18,&1:10|, CCC(C)(C)c1ccc(C[C@@H](C)CN2C[C@H](C)O[C@H](C)C2)cc1 |a:15,18,&1:10|, CCC(C)(C)c1ccc(C[C@@H](C)CN2C[C@H](C)O[C@H](C)C2)cc1 |a:15,18,&1:10|	Launched
amoxapine	norepinephrine reputake inhibitor	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD1, DRD2, DRD3, DRD4, DRD5, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, HRH1, HRH4, HTR1A, HTR1B, HTR2A, HTR2B, HTR2C, HTR3A, HTR6, HTR7, SLC6A2, SLC6A3, SLC6A4	neurology/psychiatry	depression	MicroSource, Selleck, Selleck	96.84	Clc1ccc2Oc3ccccc3N=C(N3CCNCC3)c2c1 |t:13|, Clc1ccc2Oc3ccccc3N=C(N3CCNCC3)c2c1 |t:13|, Clc1ccc2Oc3ccccc3N=C(N3CCNCC3)c2c1 |t:13|	Launched
amoxicillin	penicillin binding protein inhibitor	CYP2C19, SLC15A1, SLC15A2, SLC22A6	infectious disease, gastroenterology	skin infections, duodenal ulcer disease, gonorrhea, ear infections, throat infections, genitourinary tract infections, respiratory tract infections	MicroSource, MedChemEx, Selleck, Selleck, Selleck, Selleck	96.19	CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(O)=O	Launched
AMPA-(RS)	glutamate receptor agonist	GRIN1			Tocris, Tocris	100	Cc1o[nH]c(=O)c1C[C@@H](N)C(O)=O |&1:8|, Cc1o[nH]c(=O)c1C[C@@H](N)C(O)=O |&1:8|	Preclinical
AMPA-(S)	glutamate receptor agonist	GRIA2, GRIN1			Tocris, Tocris, Tocris	100	Cc1o[nH]c(=O)c1C[C@H](N)C(O)=O, Cc1o[nH]c(=O)c1C[C@H](N)C(O)=O, Cc1o[nH]c(=O)c1C[C@H](N)C(O)=O	Preclinical
ampalex	glutamate receptor agonist	GRIA1, GRIA2, GRIA3, GRIA4			MedChemEx, MedChemEx, MedChemEx, MedChemEx	99.54	O=C(N1CCCCC1)c1ccc2nccnc2c1, O=C(N1CCCCC1)c1ccc2nccnc2c1, O=C(N1CCCCC1)c1ccc2nccnc2c1, O=C(N1CCCCC1)c1ccc2nccnc2c1	Phase 2
amperozide	dopamine receptor antagonist	FAAH, HTR2A	neurology/psychiatry	psychosis	Enzo, Enzo, SantaCruz	98.96	CCNC(=O)N1CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1, CCNC(=O)N1CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1, CCNC(=O)N1CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1	Launched
amphotericin-b	membrane permeability enhancer		infectious disease	fungal infection	MicroSource, Selleck, Selleck, MedChemEx, Selleck	74.84	C[C@H]1O[C@@H](O[C@@H]2C[C@@H]3O[C@@](O)(C[C@H](O)[C@H]3C(O)=O)C[C@@H](O)C[C@@H](O)[C@H](O)CC[C@@H](O)C[C@@H](O)CC(=O)O[C@@H](C)[C@H](C)[C@H](O)[C@@H](C)\C=C\C=C\C=C\C=C\C=C\C=C\C=C\2)[C@@H](O)[C@@H](N)[C@@H]1O |t:46,48,50,52,54,56,58|, C[C@H]1O[C@@H](O[C@@H]2C[C@@H]3O[C@@](O)(C[C@H](O)[C@H]3C(O)=O)C[C@@H](O)C[C@@H](O)[C@H](O)CC[C@@H](O)C[C@@H](O)CC(=O)O[C@@H](C)[C@H](C)[C@H](O)[C@@H](C)\C=C\C=C\C=C\C=C\C=C\C=C\C=C\2)[C@@H](O)[C@@H](N)[C@@H]1O |t:46,48,50,52,54,56,58|, C[C@H]1O[C@@H](O[C@@H]2C[C@@H]3O[C@@](O)(C[C@H](O)[C@H]3C(O)=O)C[C@@H](O)C[C@@H](O)[C@H](O)CC[C@@H](O)C[C@@H](O)CC(=O)O[C@@H](C)[C@H](C)[C@H](O)[C@@H](C)\C=C\C=C\C=C\C=C\C=C\C=C\C=C\2)[C@@H](O)[C@@H](N)[C@@H]1O |t:46,48,50,52,54,56,58|, C[C@H]1O[C@@H](O[C@@H]2C[C@@H]3O[C@@](O)(C[C@H](O)[C@H]3C(O)=O)C[C@@H](O)C[C@@H](O)[C@H](O)CC[C@@H](O)C[C@@H](O)CC(=O)O[C@@H](C)[C@H](C)[C@H](O)[C@@H](C)\C=C\C=C\C=C\C=C\C=C\C=C\C=C\2)[C@@H](O)[C@@H](N)[C@@H]1O |t:46,48,50,52,54,56,58|, C[C@H]1O[C@@H](O[C@@H]2C[C@@H]3O[C@@](O)(C[C@H](O)[C@H]3C(O)=O)C[C@@H](O)C[C@@H](O)[C@H](O)CC[C@@H](O)C[C@@H](O)CC(=O)O[C@@H](C)[C@H](C)[C@H](O)[C@@H](C)\C=C\C=C\C=C\C=C\C=C\C=C\C=C\2)[C@@H](O)[C@@H](N)[C@@H]1O |t:46,48,50,52,54,56,58|	Launched
ampicillin	bacterial cell wall synthesis inhibitor		infectious disease	respiratory tract infections, meningitis, bacterial septicemia, endocarditis, urinary tract infections, gastrointestinal infections	MedChemEx, MicroSource, MedChemEx, MedChemEx, Sigma, Selleck, Selleck, Selleck, Selleck	84.41	CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccccc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccccc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccccc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccccc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccccc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccccc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccccc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccccc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccccc3)C(=O)N2[C@H]1C(O)=O	Launched
ampiroxicam	cyclooxygenase inhibitor	PTGS1, PTGS2	neurology/psychiatry	pain relief	MedChemEx, MedChemEx, MicroSource, Selleck, Selleck	78.57	CCOC(=O)O[C@@H](C)OC1=C(N(C)S(=O)(=O)c2ccccc12)C(=O)Nc1ccccn1 |&1:6,r,t:9|, CCOC(=O)O[C@@H](C)OC1=C(N(C)S(=O)(=O)c2ccccc12)C(=O)Nc1ccccn1 |&1:6,r,t:9|, CCOC(=O)O[C@@H](C)OC1=C(N(C)S(=O)(=O)c2ccccc12)C(=O)Nc1ccccn1 |&1:6,r,t:9|, CCOC(=O)O[C@@H](C)OC1=C(N(C)S(=O)(=O)c2ccccc12)C(=O)Nc1ccccn1 |&1:6,r,t:9|, CCOC(=O)O[C@@H](C)OC1=C(N(C)S(=O)(=O)c2ccccc12)C(=O)Nc1ccccn1 |&1:6,r,t:9|	Launched
amprenavir	HIV protease inhibitor		infectious disease	human immunodeficiency virus (HIV-1)	Selleck, Selleck, MedChemEx	95.63	CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)c1ccc(N)cc1, CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)c1ccc(N)cc1, CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)c1ccc(N)cc1	Launched
amprolium	thiamine uptake blocker		infectious disease	coccidiosis	MedChemEx, Selleck, MicroSource	95.82	CCCc1ncc(C[n+]2ccccc2C)c(N)n1, CCCc1ncc(C[n+]2ccccc2C)c(N)n1, CCCc1ncc(C[n+]2ccccc2C)c(N)n1	Launched
ampyrone	cyclooxygenase inhibitor				MedChemEx, Prestwick	94.82	Cc1c(N)c(=O)n(-c2ccccc2)n1C, Cc1c(N)c(=O)n(-c2ccccc2)n1C	Preclinical
amrinone	phosphodiesterase inhibitor	PDE3A, PDE3B, PDE4B, TNF	cardiology	congestive heart failure	MicroSource, MicroSource, Sigma, Sigma, Sigma	92.25	Nc1cc(c[nH]c1=O)-c1ccncc1, Nc1cc(c[nH]c1=O)-c1ccncc1, Nc1cc(c[nH]c1=O)-c1ccncc1, Nc1cc(c[nH]c1=O)-c1ccncc1, Nc1cc(c[nH]c1=O)-c1ccncc1	Launched
amrubicin	topoisomerase inhibitor	TOP2A, TOP2B	oncology	small cell lung cancer	MedChemEx, MedChemEx, MedChemEx	74.78	CC(=O)[C@@]1(N)C[C@H](O[C@H]2C[C@H](O)[C@H](O)CO2)c2c(O)c3C(=O)c4ccccc4C(=O)c3c(O)c2C1, CC(=O)[C@@]1(N)C[C@H](O[C@H]2C[C@H](O)[C@H](O)CO2)c2c(O)c3C(=O)c4ccccc4C(=O)c3c(O)c2C1, CC(=O)[C@@]1(N)C[C@H](O[C@H]2C[C@H](O)[C@H](O)CO2)c2c(O)c3C(=O)c4ccccc4C(=O)c3c(O)c2C1	Launched
amsacrine	topoisomerase inhibitor	KCNH2, TOP2A	hematologic malignancy	acute lymphoblastic leukemia (ALL)	MicroSource, MicroSource, MicroSource, Enzo	95.69	COc1cc(NS(C)(=O)=O)ccc1Nc1c2ccccc2nc2ccccc12, COc1cc(NS(C)(=O)=O)ccc1Nc1c2ccccc2nc2ccccc12, COc1cc(NS(C)(=O)=O)ccc1Nc1c2ccccc2nc2ccccc12, COc1cc(NS(C)(=O)=O)ccc1Nc1c2ccccc2nc2ccccc12	Launched
amthamine	histamine receptor agonist	HRH2			Tocris, Tocris	90.06	Cc1nc(N)sc1CCN, Cc1nc(N)sc1CCN	Preclinical
amtolmetin-guacil	cyclooxygenase inhibitor	PTGS1, PTGS2	rheumatology	rheumatoid arthritis, osteoarthritis	OxChem, OxChem, OxChem	94.69	COc1ccccc1OC(=O)CNC(=O)Cc1ccc(C(=O)c2ccc(C)cc2)n1C, COc1ccccc1OC(=O)CNC(=O)Cc1ccc(C(=O)c2ccc(C)cc2)n1C, COc1ccccc1OC(=O)CNC(=O)Cc1ccc(C(=O)c2ccc(C)cc2)n1C	Launched
amuvatinib	FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RAD51 inhibitor, RET tyrosine kinase inhibitor	KIT, MET			Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck	97.82	S=C(NCc1ccc2OCOc2c1)N1CCN(CC1)c1ncnc2c3ccccc3oc12, S=C(NCc1ccc2OCOc2c1)N1CCN(CC1)c1ncnc2c3ccccc3oc12, S=C(NCc1ccc2OCOc2c1)N1CCN(CC1)c1ncnc2c3ccccc3oc12, S=C(NCc1ccc2OCOc2c1)N1CCN(CC1)c1ncnc2c3ccccc3oc12, S=C(NCc1ccc2OCOc2c1)N1CCN(CC1)c1ncnc2c3ccccc3oc12, S=C(NCc1ccc2OCOc2c1)N1CCN(CC1)c1ncnc2c3ccccc3oc12, S=C(NCc1ccc2OCOc2c1)N1CCN(CC1)c1ncnc2c3ccccc3oc12, S=C(NCc1ccc2OCOc2c1)N1CCN(CC1)c1ncnc2c3ccccc3oc12	Phase 2
amygdalin	caspase activator	CASP3			MedChemEx, Selleck, Selleck, Selleck, Selleck, Selleck	95.98	OC[C@H]1O[C@@H](OC[C@H]2O[C@@H](O[C@@H](C#N)c3ccccc3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@@H]1O, OC[C@H]1O[C@@H](OC[C@H]2O[C@@H](O[C@@H](C#N)c3ccccc3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@@H]1O, OC[C@H]1O[C@@H](OC[C@H]2O[C@@H](O[C@@H](C#N)c3ccccc3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@@H]1O, OC[C@H]1O[C@@H](OC[C@H]2O[C@@H](O[C@@H](C#N)c3ccccc3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@@H]1O, OC[C@H]1O[C@@H](OC[C@H]2O[C@@H](O[C@@H](C#N)c3ccccc3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@@H]1O, OC[C@H]1O[C@@H](OC[C@H]2O[C@@H](O[C@@H](C#N)c3ccccc3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@@H]1O	Phase 2
amyl-nitrite	atrial natriuretic peptide receptor agonist				Sigma	0	CCCCCO[NH2+][O-]	Preclinical
amyleine	local anesthetic				Prestwick, Prestwick, Prestwick, Toronto	98.68	CC[C@@](C)(CN(C)C)OC(=O)c1ccccc1 |&1:2|, CC[C@@](C)(CN(C)C)OC(=O)c1ccccc1 |&1:2|, CC[C@@](C)(CN(C)C)OC(=O)c1ccccc1 |&1:2|, CC[C@@](C)(CN(C)C)OC(=O)c1ccccc1 |&1:2|	Preclinical
amylene-hydrate	local anesthetic				Sigma, MicroSource	0	CCC(C)(C)O, CCC(C)(C)O	Preclinical
AMZ30	protein phosphatase inhibitor				MedChemEx	88.11	[O-][N+](=O)c1cccc(c1)S(=O)(=O)n1cccc1\C=C(/C#N)S(=O)(=O)c1ccc(F)cc1	Preclinical
AM095	lysophosphatidic acid receptor antagonist				MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx	97.3	C[C@@H](OC(=O)Nc1c(C)noc1-c1ccc(cc1)-c1ccc(CC(O)=O)cc1)c1ccccc1, C[C@@H](OC(=O)Nc1c(C)noc1-c1ccc(cc1)-c1ccc(CC(O)=O)cc1)c1ccccc1, C[C@@H](OC(=O)Nc1c(C)noc1-c1ccc(cc1)-c1ccc(CC(O)=O)cc1)c1ccccc1, C[C@@H](OC(=O)Nc1c(C)noc1-c1ccc(cc1)-c1ccc(CC(O)=O)cc1)c1ccccc1, C[C@@H](OC(=O)Nc1c(C)noc1-c1ccc(cc1)-c1ccc(CC(O)=O)cc1)c1ccccc1, C[C@@H](OC(=O)Nc1c(C)noc1-c1ccc(cc1)-c1ccc(CC(O)=O)cc1)c1ccccc1, C[C@@H](OC(=O)Nc1c(C)noc1-c1ccc(cc1)-c1ccc(CC(O)=O)cc1)c1ccccc1, C[C@@H](OC(=O)Nc1c(C)noc1-c1ccc(cc1)-c1ccc(CC(O)=O)cc1)c1ccccc1, C[C@@H](OC(=O)Nc1c(C)noc1-c1ccc(cc1)-c1ccc(CC(O)=O)cc1)c1ccccc1, C[C@@H](OC(=O)Nc1c(C)noc1-c1ccc(cc1)-c1ccc(CC(O)=O)cc1)c1ccccc1	Preclinical
AM211	prostaglandin inhibitor				MedChemEx	98.69	CCN(Cc1cc(ccc1-c1cc(CC(O)=O)ccc1OC)C(F)(F)F)C(=O)NCc1ccccc1	Preclinical
AM679	cannabinoid receptor agonist, lipoxygenase inhibitor	ALOX5AP, CNR1, CNR2			MedChemEx	96.62	COc1cnc(nc1)-c1ccc(Cn2c(CC(C)(C)C(O)=O)c(SC(C)(C)C)c3cc(OC[C@@H]4Cc5ccccc5N4C(C)=O)ccc23)cc1	Preclinical
ANA-12	tropomyosin receptor kinase inhibitor	NTRK2			Tocris, Tocris	98.36	O=C(Nc1ccccc1C(=O)N[C@H]1CCCCNC1=O)c1cc2ccccc2s1 |&1:12,r|, O=C(Nc1ccccc1C(=O)N[C@H]1CCCCNC1=O)c1cc2ccccc2s1 |&1:12,r|	Preclinical
anabasine	acetylcholine receptor agonist				Enzo	90.14	C1CC[C@@H](NC1)c1cccnc1 |&1:3,r|	Preclinical
anacetrapib	cholesteryl ester transfer protein inhibitor	CETP			MedChemEx	97.66	COc1cc(F)c(cc1-c1ccc(cc1CN1[C@@H](C)[C@H](OC1=O)c1cc(cc(c1)C(F)(F)F)C(F)(F)F)C(F)(F)F)C(C)C	Phase 3
anagliptin	dipeptidyl peptidase inhibitor	DPP4	endocrinology	diabetes mellitus	MedChemEx, MedChemEx	82.68	Cc1cc2ncc(cn2n1)C(=O)NCC(C)(C)NCC(=O)N1CCC[C@H]1C#N, Cc1cc2ncc(cn2n1)C(=O)NCC(C)(C)NCC(=O)N1CCC[C@H]1C#N	Launched
anagrelide	phosphodiesterase inhibitor	PDE3A	hematology, hematologic malignancy	thrombocythemia, myeloproliferative neoplasms	MicroSource, MicroSource, MicroSource, Selleck, Selleck, Selleck, Selleck, Selleck	98.12	Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl |t:5|, Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl |t:5|, Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl |t:5|, Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl |t:5|, Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl |t:5|, Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl |t:5|, Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl |t:5|, Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl |t:5|	Launched
anamorelin	growth hormone secretagogue receptor agonist	GHSR			MedChemEx, MedChemEx	98	CN(C)N(C)C(=O)[C@@]1(Cc2ccccc2)CCCN(C1)C(=O)[C@@H](Cc1c[nH]c2ccccc12)NC(=O)C(C)(C)N, CN(C)N(C)C(=O)[C@@]1(Cc2ccccc2)CCCN(C1)C(=O)[C@@H](Cc1c[nH]c2ccccc12)NC(=O)C(C)(C)N	Phase 3
anandamide	cannabinoid receptor agonist	CACNA1G, CACNA1H, CACNA1I, CNR1, CNR2, GLRA1, GPR18, GPR55, KCNA2, KCNK3, KCNK9, TRPM8, TRPV1			Enzo, Enzo, Enzo, Enzo, Sigma	97.08	CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)NCCO, CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)NCCO, CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)NCCO, CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)NCCO, CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)NCCO	Phase 2
anastrozole	aromatase inhibitor	CYP19A1	oncology	breast cancer	Tocris, MicroSource, Selleck	99.51	CC(C)(C#N)c1cc(Cn2cncn2)cc(c1)C(C)(C)C#N, CC(C)(C#N)c1cc(Cn2cncn2)cc(c1)C(C)(C)C#N, CC(C)(C#N)c1cc(Cn2cncn2)cc(c1)C(C)(C)C#N	Launched
andarine	androgen receptor modulator	AR			Selleck, Selleck, Selleck, MedChemEx	97.56	CC(=O)Nc1ccc(OC[C@](C)(O)C(=O)Nc2ccc(c(c2)C(F)(F)F)[N+]([O-])=O)cc1, CC(=O)Nc1ccc(OC[C@](C)(O)C(=O)Nc2ccc(c(c2)C(F)(F)F)[N+]([O-])=O)cc1, CC(=O)Nc1ccc(OC[C@](C)(O)C(=O)Nc2ccc(c(c2)C(F)(F)F)[N+]([O-])=O)cc1, CC(=O)Nc1ccc(OC[C@](C)(O)C(=O)Nc2ccc(c(c2)C(F)(F)F)[N+]([O-])=O)cc1	Phase 1
andrographolide	tumor necrosis factor production inhibitor	IL1B, IL6, NFKB1, NFKB2, TNF			Tocris	92.89	C[C@@]1(CO)[C@H](O)CC[C@@]2(C)[C@H](C\C=C3/[C@H](O)COC3=O)C(=C)CC[C@H]12	Phase 2
androstenone	steroid				SantaCruz, SantaCruz, SantaCruz	100	C[C@@]12CC[C@H]3[C@@H](CC[C@H]4CC(=O)CC[C@@]34C)[C@@H]1CC=C2 |&1:1,&2:4,&3:5,&4:8,&5:14,&6:16,r,c:21|, C[C@@]12CC[C@H]3[C@@H](CC[C@H]4CC(=O)CC[C@@]34C)[C@@H]1CC=C2 |&1:1,&2:4,&3:5,&4:8,&5:14,&6:16,r,c:21|, C[C@@]12CC[C@H]3[C@@H](CC[C@H]4CC(=O)CC[C@@]34C)[C@@H]1CC=C2 |&1:1,&2:4,&3:5,&4:8,&5:14,&6:16,r,c:21|	Preclinical
androsterone	androgen receptor agonist				MedChemEx, Prestwick, Prestwick	100	C[C@]12CC[C@H]3[C@@H](CC[C@H]4C[C@H](O)CC[C@]34C)[C@@H]1CCC2=O, C[C@]12CC[C@H]3[C@@H](CC[C@H]4C[C@H](O)CC[C@]34C)[C@@H]1CCC2=O, C[C@]12CC[C@H]3[C@@H](CC[C@H]4C[C@H](O)CC[C@]34C)[C@@H]1CCC2=O	Preclinical
anecortave-acetate	angiogenesis inhibitor		ophthalmology	macular degeneration	Toronto	76.87	CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)C3=CC[C@]12C |c:25,t:15|	Launched
anethole	glutathione transferase stimulant				MedChemEx, MicroSource, MedChemEx	0	COc1ccc(\C=C\C)cc1, COc1ccc(\C=C\C)cc1, COc1ccc(\C=C\C)cc1	Launched
anethole-trithione	glutathione transferase stimulant		dental	xerostomia	Enzo, MedChemEx, MedChemEx	97.57	COc1ccc(cc1)-c1cc(=S)ss1, COc1ccc(cc1)-c1cc(=S)ss1, COc1ccc(cc1)-c1cc(=S)ss1	Launched
anguidine	protein synthesis inhibitor	SLC5A1			Enzo, Enzo, Enzo, Enzo	100	CC(=O)OC[C@]12CCC(C)=C[C@H]1O[C@@H]1[C@H](O)[C@@H](OC(C)=O)[C@@]2(C)[C@@]11CO1 |c:9|, CC(=O)OC[C@]12CCC(C)=C[C@H]1O[C@@H]1[C@H](O)[C@@H](OC(C)=O)[C@@]2(C)[C@@]11CO1 |c:9|, CC(=O)OC[C@]12CCC(C)=C[C@H]1O[C@@H]1[C@H](O)[C@@H](OC(C)=O)[C@@]2(C)[C@@]11CO1 |c:9|, CC(=O)OC[C@]12CCC(C)=C[C@H]1O[C@@H]1[C@H](O)[C@@H](OC(C)=O)[C@@]2(C)[C@@]11CO1 |c:9|	Phase 2
anidulafungin	fungal 1,3-beta-D-glucan synthase inhibitor		infectious disease	candidemia, fungal infection, esophageal candidiasis	MedChemEx	97.45	CCCCCOc1ccc(cc1)-c1ccc(cc1)-c1ccc(cc1)C(=O)N[C@H]1C[C@@H](O)[C@@H](O)NC(=O)[C@@H]2[C@@H](O)[C@@H](C)CN2C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC1=O)[C@@H](C)O)[C@H](O)[C@@H](O)c1ccc(O)cc1)[C@@H](C)O |r|	Launched
aniracetam	glutamate receptor agonist	DRD2, GRIA1, GRIA2, GRIA3, GRIA4, HTR2A			Tocris, Tocris, Tocris, Tocris, Selleck	97.89	COc1ccc(cc1)C(=O)N1CCCC1=O, COc1ccc(cc1)C(=O)N1CCCC1=O, COc1ccc(cc1)C(=O)N1CCCC1=O, COc1ccc(cc1)C(=O)N1CCCC1=O, COc1ccc(cc1)C(=O)N1CCCC1=O	Launched
anisindione	vitamin K antagonist	GGCX	hematology	deep vein thrombosis (DVT)	MedChemEx, Selleck, Vitas-M, Vitas-M, MedChemEx, MicroSource, Selleck	89.62	COc1ccc(cc1)C1C(=O)c2ccccc2C1=O, COc1ccc(cc1)C1C(=O)c2ccccc2C1=O, COc1ccc(cc1)C1C(=O)c2ccccc2C1=O, COc1ccc(cc1)C1C(=O)c2ccccc2C1=O, COc1ccc(cc1)C1C(=O)c2ccccc2C1=O, COc1ccc(cc1)C1C(=O)c2ccccc2C1=O, COc1ccc(cc1)C1C(=O)c2ccccc2C1=O	Launched
anisodamine	lipid peroxidase inhibitor	ADRA1A			MicroSource, MicroSource	86.1	CN1[C@H]2C[C@H](O)[C@H]1C[C@H](C2)OC(=O)[C@H](CO)c1ccccc1 |a:4,6,8,13,&1:2,THB:5:4:1:7.8.9|, CN1[C@H]2C[C@H](O)[C@H]1C[C@H](C2)OC(=O)[C@H](CO)c1ccccc1 |a:4,6,8,13,&1:2,THB:5:4:1:7.8.9|	Phase 3
anisomycin	DNA synthesis inhibitor	NHP2L1, RPL10L, RPL11, RPL13A, RPL15, RPL19, RPL23, RPL23A, RPL26L1, RPL3, RPL37, RPL8, RSL24D1			Tocris, Tocris, Tocris, Tocris, Tocris	94.51	COc1ccc(C[C@H]2NC[C@H](O)[C@H]2OC(C)=O)cc1, COc1ccc(C[C@H]2NC[C@H](O)[C@H]2OC(C)=O)cc1, COc1ccc(C[C@H]2NC[C@H](O)[C@H]2OC(C)=O)cc1, COc1ccc(C[C@H]2NC[C@H](O)[C@H]2OC(C)=O)cc1, COc1ccc(C[C@H]2NC[C@H](O)[C@H]2OC(C)=O)cc1	Preclinical
anisotropine	acetylcholine receptor antagonist		gastroenterology	peptic ulcer disease (PUD)	Oakwood	100	CCCC(CCC)C(=O)O[C@@H]1C[C@@H]2CC[C@H](C1)[N+]2(C)C	Launched
anlotinib	PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	KDR, PDGFRB			MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx	98.34	COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ccnc2cc1OCC1(N)CC1, COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ccnc2cc1OCC1(N)CC1, COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ccnc2cc1OCC1(N)CC1, COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ccnc2cc1OCC1(N)CC1, COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ccnc2cc1OCC1(N)CC1	Launched
anpirtoline	serotonin receptor agonist	HTR1B			Tocris, Tocris, Tocris, Tocris, Tocris	93.59	Clc1cccc(SC2CCNCC2)n1, Clc1cccc(SC2CCNCC2)n1, Clc1cccc(SC2CCNCC2)n1, Clc1cccc(SC2CCNCC2)n1, Clc1cccc(SC2CCNCC2)n1	Phase 1
ANR-94	adenosine receptor antagonist	ADORA2A			Tocris, Tocris	96.91	CCOc1nc2c(N)ncnc2n1CC, CCOc1nc2c(N)ncnc2n1CC	Preclinical
ansamitocin-p-3	apoptosis stimulant				MedChemEx	77.64	[H][C@@]12O[C@@]1(C)[C@H](CC(=O)N(C)c1cc(C\C(C)=C\C=C\[C@@H](OC)[C@@]3(O)C[C@]([H])(OC(=O)N3)[C@H]2C)cc(OC)c1Cl)OC(=O)C(C)C |t:17,19|	Preclinical
antagonist-g	neuropeptide receptor antagonist	MAPK8			Tocris, Tocris	77.63	CSCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1ccccc1)N(C)C(=O)[C@@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H](N)CCCNC(N)=N)C(N)=O, CSCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1ccccc1)N(C)C(=O)[C@@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H](N)CCCNC(N)=N)C(N)=O	Phase 1
antalarmin	corticotropin releasing factor receptor antagonist	CRHR1			Tocris, Tocris, Tocris	95.23	CCCCN(CC)c1nc(C)nc2n(c(C)c(C)c12)-c1c(C)cc(C)cc1C, CCCCN(CC)c1nc(C)nc2n(c(C)c(C)c12)-c1c(C)cc(C)cc1C, CCCCN(CC)c1nc(C)nc2n(c(C)c(C)c12)-c1c(C)cc(C)cc1C	Preclinical
antazoline	antihistamine	HRH1	ophthalmology, otolaryngology	conjunctivitis, nasal congestion	MicroSource, Tocris, Tocris, Selleck	95.88	C(N(Cc1ccccc1)c1ccccc1)C1=NCCN1 |t:17|, C(N(Cc1ccccc1)c1ccccc1)C1=NCCN1 |t:17|, C(N(Cc1ccccc1)c1ccccc1)C1=NCCN1 |t:17|, C(N(Cc1ccccc1)c1ccccc1)C1=NCCN1 |t:17|	Launched
anthralin	DNA synthesis inhibitor		dermatology	psoriasis	MedChemEx, MedChemEx, MicroSource, MedChemEx	21.3	Oc1cccc2Cc3cccc(O)c3C(=O)c12, Oc1cccc2Cc3cccc(O)c3C(=O)c12, Oc1cccc2Cc3cccc(O)c3C(=O)c12, Oc1cccc2Cc3cccc(O)c3C(=O)c12	Launched
anthraquinone	CDC inhibitor	CDC25B			Sigma, Vitas-M	86.59	O=C1c2ccccc2C(=O)c2ccccc12, O=C1c2ccccc2C(=O)c2ccccc12	Preclinical
antimony-potassium					MedChemEx	0	[H][C@]12O[SbH]3(OC1=O)OC(=O)[C@]([H])(O3)[C@@]1([H])O[SbH]3(OC(=O)[C@]2([H])O3)OC1=O |r|	Phase 2
antimonyl					MedChemEx, Sigma	100	O=C1O[SbH]23OC1C1O[SbH]4(OC(C(O2)C(=O)O3)C(=O)O4)OC1=O, O=C1O[SbH]23OC1C1O[SbH]4(OC(C(O2)C(=O)O3)C(=O)O4)OC1=O	Phase 1
antimycin-A	ATP synthase inhibitor	CYCS			Enzo	25.76	CCCCCC[C@@H]1[C@@H](OC(=O)CC(C)C)[C@H](C)OC(=O)[C@@H](NC(=O)c2cccc(NC=O)c2O)[C@@H](C)OC1=O	Preclinical
antioxine					Sigma, Enamine	0	CC(C)c1ccc(C)c(O)c1, CC(C)c1ccc(C)c(O)c1	Launched
AN2718	leucyl-tRNA synthetase inhibitor				Enamine, Enamine	96.45	OB1OCc2cc(Cl)ccc12, OB1OCc2cc(Cl)ccc12	Phase 1
AP-18	transient receptor potential channel antagonist	TRPA1			Tocris, Tocris	96.53	C\C(=C/c1ccc(Cl)cc1)\C(\C)=N\O, C\C(=C/c1ccc(Cl)cc1)\C(\C)=N\O	Preclinical
apabetalone	apolipoprotein expression enhancer	BRD3			Selleck, Selleck	96.24	COc1cc(OC)c2c(c1)[nH]c(nc2=O)-c1cc(C)c(OCCO)c(C)c1, COc1cc(OC)c2c(c1)[nH]c(nc2=O)-c1cc(C)c(OCCO)c(C)c1	Phase 3
apafant	platelet activating factor receptor antagonist	PTAFR			Tocris, Tocris, Tocris	98.5	Cc1nnc2CN=C(c3cc(CCC(=O)N4CCOCC4)sc3-n12)c1ccccc1Cl |c:6|, Cc1nnc2CN=C(c3cc(CCC(=O)N4CCOCC4)sc3-n12)c1ccccc1Cl |c:6|, Cc1nnc2CN=C(c3cc(CCC(=O)N4CCOCC4)sc3-n12)c1ccccc1Cl |c:6|	Phase 3
apalutamide	androgen receptor antagonist		oncology	prostate cancer	Selleck, Selleck, Selleck, MedChemEx	97.61	CNC(=O)c1ccc(cc1F)N1C(=S)N(C(=O)C11CCC1)c1cnc(C#N)c(c1)C(F)(F)F, CNC(=O)c1ccc(cc1F)N1C(=S)N(C(=O)C11CCC1)c1cnc(C#N)c(c1)C(F)(F)F, CNC(=O)c1ccc(cc1F)N1C(=S)N(C(=O)C11CCC1)c1cnc(C#N)c(c1)C(F)(F)F, CNC(=O)c1ccc(cc1F)N1C(=S)N(C(=O)C11CCC1)c1cnc(C#N)c(c1)C(F)(F)F	Launched
apararenone	mineralocorticoid receptor antagonist				MedChemEx	97.55	CC1(C)Oc2cc(NS(C)(=O)=O)ccc2N(C1=O)c1ccc(F)cc1	Preclinical
apatinib	RET tyrosine kinase inhibitor	CSK, KDR, KIT, RET			Selleck, Selleck, MedChemEx	97.58	O=C(Nc1ccc(cc1)C1(CCCC1)C#N)c1cccnc1NCc1ccncc1, O=C(Nc1ccc(cc1)C1(CCCC1)C#N)c1cccnc1NCc1ccncc1, O=C(Nc1ccc(cc1)C1(CCCC1)C#N)c1cccnc1NCc1ccncc1	Phase 3
APC-100	androgen receptor antagonist, anti-inflammatory agent	AR			Sigma, Sigma	93.42	Cc1c(C)c2OC(C)(C)CCc2c(C)c1O, Cc1c(C)c2OC(C)(C)CCc2c(C)c1O	Phase 1/Phase 2
APcK-110	KIT inhibitor	KIT, STAT3			Tocris, Tocris, Tocris	95.57	COc1cc(OC)cc(c1)-c1ccc2c([nH]nc2n1)-c1ccc(F)cc1, COc1cc(OC)cc(c1)-c1ccc2c([nH]nc2n1)-c1ccc(F)cc1, COc1cc(OC)cc(c1)-c1ccc2c([nH]nc2n1)-c1ccc(F)cc1	Preclinical
APD597	glucose dependent insulinotropic receptor agonist	GPR119			MedChemEx	96.93	COc1c(Nc2ccc(nc2C)S(C)(=O)=O)ncnc1OC1CCN(CC1)C(=O)OC(C)C	Phase 1
APD668	glucose dependent insulinotropic receptor agonist	GPR119			MedChemEx, MedChemEx	98.92	CC(C)OC(=O)N1CCC(CC1)Oc1ncnc2n(ncc12)-c1ccc(cc1F)S(C)(=O)=O, CC(C)OC(=O)N1CCC(CC1)Oc1ncnc2n(ncc12)-c1ccc(cc1F)S(C)(=O)=O	Phase 1
aphidicolin	RNA synthesis inhibitor				Enzo, Enzo, Sigma	100	C[C@@]1(CO)[C@H](O)CC[C@@]2(C)[C@H]1CC[C@H]1C[C@@H]3C[C@]21CC[C@]3(O)CO, C[C@@]1(CO)[C@H](O)CC[C@@]2(C)[C@H]1CC[C@H]1C[C@@H]3C[C@]21CC[C@]3(O)CO, C[C@@]1(CO)[C@H](O)CC[C@@]2(C)[C@H]1CC[C@H]1C[C@@H]3C[C@]21CC[C@]3(O)CO	Phase 1
API-001	sigma receptor antagonist	SIGMAR1			MedChemEx, MedChemEx, MedChemEx	99.32	Cc1cc(OCCN2CCOCC2)nn1-c1ccc2ccccc2c1, Cc1cc(OCCN2CCOCC2)nn1-c1ccc2ccccc2c1, Cc1cc(OCCN2CCOCC2)nn1-c1ccc2ccccc2c1	Phase 2
API-1	AKT inhibitor	AKT1, AKT2, AKT3			Tocris, Tocris, Tocris	96.5	NC(=O)c1cn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c2ncnc(N)c2c1=O, NC(=O)c1cn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c2ncnc(N)c2c1=O, NC(=O)c1cn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c2ncnc(N)c2c1=O	Preclinical
apigenin	casein kinase inhibitor, cell proliferation inhibitor	AKR1B1, AR, CDK6, CFTR, CYP19A1, CYP1B1, HSD17B1			Tocris, Tocris, Tocris, Selleck	96.49	Oc1ccc(cc1)-c1cc(=O)c2c(O)cc(O)cc2o1, Oc1ccc(cc1)-c1cc(=O)c2c(O)cc(O)cc2o1, Oc1ccc(cc1)-c1cc(=O)c2c(O)cc(O)cc2o1, Oc1ccc(cc1)-c1cc(=O)c2c(O)cc(O)cc2o1	Preclinical
apixaban	coagulation factor inhibitor	F10	neurology/psychiatry, hematology, cardiology	stroke, systemic embolism, pulmonary embolism (PE), atrial fibrillation (AF), deep vein thrombosis (DVT)	MedChemEx, MedChemEx, Selleck, MicroSource	99.16	COc1ccc(cc1)-n1nc(C(N)=O)c2CCN(C(=O)c12)c1ccc(cc1)N1CCCCC1=O, COc1ccc(cc1)-n1nc(C(N)=O)c2CCN(C(=O)c12)c1ccc(cc1)N1CCCCC1=O, COc1ccc(cc1)-n1nc(C(N)=O)c2CCN(C(=O)c12)c1ccc(cc1)N1CCCCC1=O, COc1ccc(cc1)-n1nc(C(N)=O)c2CCN(C(=O)c12)c1ccc(cc1)N1CCCCC1=O	Launched
apocynin	NADPH oxidase inhibitor	NOX4			MedChemEx, MedChemEx, Selleck, Selleck	96.42	COc1cc(ccc1O)C(C)=O, COc1cc(ccc1O)C(C)=O, COc1cc(ccc1O)C(C)=O, COc1cc(ccc1O)C(C)=O	Phase 1
apoptosis-activator-II	carboxylesterase inhibitor	BCHE, CES1			Tocris, Tocris, Selleck, Tocris	97.54	Clc1ccc(CN2C(=O)C(=O)c3ccccc23)cc1Cl, Clc1ccc(CN2C(=O)C(=O)c3ccccc23)cc1Cl, Clc1ccc(CN2C(=O)C(=O)c3ccccc23)cc1Cl, Clc1ccc(CN2C(=O)C(=O)c3ccccc23)cc1Cl	Preclinical
APR-246	p53 activator	TP53			Adooq	97.6	COC[C@@]1(CO)N2CCC(CC2)C1=O |&1:3,r,TLB:2:3:7.8:10.11|	Phase 3
apraclonidine	adrenergic receptor agonist	ADRA1A, ADRA2A, ADRA2B, ADRA2C	ophthalmology	glaucoma, intraocular pressure	Ark	85.91	Nc1cc(Cl)c(NC2=NCCN2)c(Cl)c1 |t:7|	Launched
apramycin	bacterial 30S ribosomal subunit inhibitor		infectious disease	gram-negative bacterial infections	MedChemEx	22.8	CN[C@H]1[C@@H](O)[C@H]2O[C@H](O[C@@H]3[C@@H](N)C[C@@H](N)[C@H](O)[C@H]3O)[C@H](N)C[C@@H]2O[C@@H]1O[C@H]1O[C@H](CO)[C@@H](N)[C@H](O)[C@H]1O	Launched
apratastat	matrix metalloprotease inhibitor, tumor necrosis factor production inhibitor	ADAM17, MMP1, MMP13, MMP9			Sigma, Sigma, Sigma, Sigma	100	CC1(C)SCCN([C@H]1C(=O)NO)S(=O)(=O)c1ccc(OCC#CCO)cc1, CC1(C)SCCN([C@H]1C(=O)NO)S(=O)(=O)c1ccc(OCC#CCO)cc1, CC1(C)SCCN([C@H]1C(=O)NO)S(=O)(=O)c1ccc(OCC#CCO)cc1, CC1(C)SCCN([C@H]1C(=O)NO)S(=O)(=O)c1ccc(OCC#CCO)cc1	Phase 2
apremilast	phosphodiesterase inhibitor	PDE4A, PDE4B, PDE4C, PDE4D	dermatology, rheumatology	psoriasis, psoriatic arthritis	Selleck, Selleck, Selleck, MedChemEx	97.87	CCOc1cc(ccc1OC)[C@@H](CS(C)(=O)=O)N1C(=O)c2cccc(NC(C)=O)c2C1=O, CCOc1cc(ccc1OC)[C@@H](CS(C)(=O)=O)N1C(=O)c2cccc(NC(C)=O)c2C1=O, CCOc1cc(ccc1OC)[C@@H](CS(C)(=O)=O)N1C(=O)c2cccc(NC(C)=O)c2C1=O, CCOc1cc(ccc1OC)[C@@H](CS(C)(=O)=O)N1C(=O)c2cccc(NC(C)=O)c2C1=O	Launched
aprepitant	tachykinin antagonist	TACR1	gastroenterology	nausea, vomiting	MedChemEx	97.69	C[C@@H](O[C@H]1OCCN(Cc2n[nH]c(=O)[nH]2)[C@H]1c1ccc(F)cc1)c1cc(cc(c1)C(F)(F)F)C(F)(F)F	Launched
apricitabine	nucleoside reverse transcriptase inhibitor				Key	98.8	Nc1ccn([C@H]2CO[C@@H](CO)S2)c(=O)n1	Phase 3
aprindine	voltage-gated sodium channel blocker	CALM1, SCN5A	cardiology	cardiac arrythmia	Sigma, Sigma	93.45	CCN(CC)CCCN(C1Cc2ccccc2C1)c1ccccc1, CCN(CC)CCCN(C1Cc2ccccc2C1)c1ccccc1	Launched
apronal	cytochrome P450 modulator				MedChemEx	94.07	CC(C)[C@H](CC=C)C(=O)NC(N)=O |&1:3,r|	Preclinical
aptiganel	glutamate receptor antagonist	GRIN1			Tocris, EMDBio, EMDBio	99.3	CCc1cccc(c1)N(C)C(=N)Nc1cccc2ccccc12, CCc1cccc(c1)N(C)C(=N)Nc1cccc2ccccc12, CCc1cccc(c1)N(C)C(=N)Nc1cccc2ccccc12	Phase 3
APTO-253	krppel-like factor expression enhancer	KLF4			MedChemEx, MedChemEx, MedChemEx, MedChemEx	96.57	Cc1[nH]c2ccc(F)cc2c1-c1nc2c([nH]1)c1cccnc1c1ncccc21, Cc1[nH]c2ccc(F)cc2c1-c1nc2c([nH]1)c1cccnc1c1ncccc21, Cc1[nH]c2ccc(F)cc2c1-c1nc2c([nH]1)c1cccnc1c1ncccc21, Cc1[nH]c2ccc(F)cc2c1-c1nc2c([nH]1)c1cccnc1c1ncccc21	Phase 1
APY-29	serine/threonine kinase inhibitor	ERN1			Tocris, Tocris, Tocris	97.84	C1CC1c1cc(Nc2ccnc(Nc3ccc4nc[nH]c4c3)n2)[nH]n1, C1CC1c1cc(Nc2ccnc(Nc3ccc4nc[nH]c4c3)n2)[nH]n1, C1CC1c1cc(Nc2ccnc(Nc3ccc4nc[nH]c4c3)n2)[nH]n1	Preclinical
apyramide	cyclooxygenase inhibitor				MedChemEx	94.26	COc1ccc2n(C(=O)c3ccc(Cl)cc3)c(C)c(CC(=O)Oc3ccc(NC(C)=O)cc3)c2c1	Preclinical
APY0201	phosphoinositide dependent kinase inhibitor	IL12A, IL12B, PIKFYVE			MedChemEx, MedChemEx, MedChemEx	88.96	Cc1cccc(\C=N\Nc2cc(N3CCOCC3)n3nc(cc3n2)-c2ccncc2)c1, Cc1cccc(\C=N\Nc2cc(N3CCOCC3)n3nc(cc3n2)-c2ccncc2)c1, Cc1cccc(\C=N\Nc2cc(N3CCOCC3)n3nc(cc3n2)-c2ccncc2)c1	Preclinical
AP1903		MTOR			MedChemEx, MedChemEx	94.14	CC[C@H](C(=O)N1CCCC[C@H]1C(=O)O[C@H](CCc1ccc(OC)c(OC)c1)c1cccc(OCC(=O)NCCNC(=O)COc2cccc(c2)[C@@H](CCc2ccc(OC)c(OC)c2)OC(=O)[C@@H]2CCCCN2C(=O)[C@@H](CC)c2cc(OC)c(OC)c(OC)c2)c1)c1cc(OC)c(OC)c(OC)c1, CC[C@H](C(=O)N1CCCC[C@H]1C(=O)O[C@H](CCc1ccc(OC)c(OC)c1)c1cccc(OCC(=O)NCCNC(=O)COc2cccc(c2)[C@@H](CCc2ccc(OC)c(OC)c2)OC(=O)[C@@H]2CCCCN2C(=O)[C@@H](CC)c2cc(OC)c(OC)c(OC)c2)c1)c1cc(OC)c(OC)c(OC)c1	Phase 1/Phase 2
AP26113	ALK tyrosine kinase receptor inhibitor	ALK, EGFR			Selleck, Selleck, Selleck, Selleck, BayerPharma	96.68	COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N(C)C, COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N(C)C, COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N(C)C, COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N(C)C, COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N(C)C	Phase 2
AQ-RA741	acetylcholine receptor antagonist	CHRM2			Tocris, Tocris, Tocris	96.35	CCN(CC)CCCCC1CCN(CC(=O)N2c3ccccc3C(=O)Nc3cccnc23)CC1, CCN(CC)CCCCC1CCN(CC(=O)N2c3ccccc3C(=O)Nc3cccnc23)CC1, CCN(CC)CCCCC1CCN(CC(=O)N2c3ccccc3C(=O)Nc3cccnc23)CC1	Preclinical
AQ-13	antimalarial agent				MedChemEx	96.51	CCN(CC)CCCNc1ccnc2cc(Cl)ccc12	Phase 2
AQW-051	nicotinic receptor agonist				AMS	77.97	Cc1ccc(cc1)-c1ccc(O[C@H]2CN3CCC2CC3)cn1	Preclinical
AR-A014418	glycogen synthase kinase inhibitor	GSK3B			Tocris, Selleck, Selleck, Selleck, Selleck	96.97	COc1ccc(CNC(=O)Nc2ncc(s2)[N+]([O-])=O)cc1, COc1ccc(CNC(=O)Nc2ncc(s2)[N+]([O-])=O)cc1, COc1ccc(CNC(=O)Nc2ncc(s2)[N+]([O-])=O)cc1, COc1ccc(CNC(=O)Nc2ncc(s2)[N+]([O-])=O)cc1, COc1ccc(CNC(=O)Nc2ncc(s2)[N+]([O-])=O)cc1	Preclinical
AR-C155858	monocarboxylate transporter inhibitor	SLC16A1, SLC16A7			MedChemEx, MedChemEx	93.13	CC(C)Cn1c2sc(Cc3c(C)n[nH]c3C)c(C(=O)N3C[C@H](O)CO3)c2c(=O)n(C)c1=O, CC(C)Cn1c2sc(Cc3c(C)n[nH]c3C)c(C(=O)N3C[C@H](O)CO3)c2c(=O)n(C)c1=O	Preclinical
AR-12	phosphoinositide dependent kinase inhibitor	PDPK1			Tocris, Selleck, Adooq, Selleck	92.43	NCC(=O)Nc1ccc(cc1)-n1nc(cc1-c1ccc2c(ccc3ccccc23)c1)C(F)(F)F, NCC(=O)Nc1ccc(cc1)-n1nc(cc1-c1ccc2c(ccc3ccccc23)c1)C(F)(F)F, NCC(=O)Nc1ccc(cc1)-n1nc(cc1-c1ccc2c(ccc3ccccc23)c1)C(F)(F)F, NCC(=O)Nc1ccc(cc1)-n1nc(cc1-c1ccc2c(ccc3ccccc23)c1)C(F)(F)F	Phase 1
AR-42	HDAC inhibitor	HDAC1			MedChemEx, MedChemEx, Selleck	97.9	CC(C)[C@H](C(=O)Nc1ccc(cc1)C(=O)NO)c1ccccc1, CC(C)[C@H](C(=O)Nc1ccc(cc1)C(=O)NO)c1ccccc1, CC(C)[C@H](C(=O)Nc1ccc(cc1)C(=O)NO)c1ccccc1	Phase 1
arachidonic-acid	cytochrome P450 inhibitor	CLCN2, KCNJ4, KCNK10, KCNK18, KCNK2, PRKCZ, PTGS1, TRPC6, TRPM2			Sigma, Enzo	50.81	CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O, CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O	Phase 1
aramchol	stearoyl-CoA desaturase inhibitor				Sigma	100	CCCCCCCCCCCCCCCCCCCC(=O)N[C@H]1CC[C@@]2(C)[C@H](C[C@@H](O)[C@H]3[C@@H]4CC[C@H]([C@H](C)CCC(O)=O)[C@@]4(C)[C@@H](O)C[C@H]23)C1	Phase 2/Phase 3
arbidol	cytochrome P450 inhibitor	CYP3A4	infectious disease	influenza A virus infection	MedChemEx, Selleck, MedChemEx, Selleck	80.95	CCOC(=O)c1c(CSc2ccccc2)n(C)c2cc(Br)c(O)c(CN(C)C)c12, CCOC(=O)c1c(CSc2ccccc2)n(C)c2cc(Br)c(O)c(CN(C)C)c12, CCOC(=O)c1c(CSc2ccccc2)n(C)c2cc(Br)c(O)c(CN(C)C)c12, CCOC(=O)c1c(CSc2ccccc2)n(C)c2cc(Br)c(O)c(CN(C)C)c12	Launched
arbutin	melanin inhibitor	TYR			MedChemEx, Selleck	100	OC[C@H]1O[C@@H](Oc2ccc(O)cc2)[C@H](O)[C@@H](O)[C@@H]1O, OC[C@H]1O[C@@H](Oc2ccc(O)cc2)[C@H](O)[C@@H](O)[C@@H]1O	Phase 2/Phase 3
ARC-239	adrenergic receptor antagonist	ADRA2A, ADRA2B, ADRA2C			Tocris, Tocris	96.55	COc1ccccc1N1CCN(CCN2C(=O)c3ccccc3C(C)(C)C2=O)CC1, COc1ccccc1N1CCN(CCN2C(=O)c3ccccc3C(C)(C)C2=O)CC1	Preclinical
arctigenin	MEK inhibitor	CHUK, MAP2K1			Tocris, Tocris	98.04	COc1ccc(C[C@H]2COC(=O)[C@@H]2Cc2ccc(O)c(OC)c2)cc1OC, COc1ccc(C[C@H]2COC(=O)[C@@H]2Cc2ccc(O)c(OC)c2)cc1OC	Preclinical
arcyriaflavin-a	CDK inhibitor	CCND1, CDK4			Tocris, Tocris, Tocris, Tocris, Tocris, Tocris, Tocris, Tocris, Tocris	89.04	O=C1NC(=O)c2c1c1c3ccccc3[nH]c1c1[nH]c3ccccc3c21, O=C1NC(=O)c2c1c1c3ccccc3[nH]c1c1[nH]c3ccccc3c21, O=C1NC(=O)c2c1c1c3ccccc3[nH]c1c1[nH]c3ccccc3c21, O=C1NC(=O)c2c1c1c3ccccc3[nH]c1c1[nH]c3ccccc3c21, O=C1NC(=O)c2c1c1c3ccccc3[nH]c1c1[nH]c3ccccc3c21, O=C1NC(=O)c2c1c1c3ccccc3[nH]c1c1[nH]c3ccccc3c21, O=C1NC(=O)c2c1c1c3ccccc3[nH]c1c1[nH]c3ccccc3c21, O=C1NC(=O)c2c1c1c3ccccc3[nH]c1c1[nH]c3ccccc3c21, O=C1NC(=O)c2c1c1c3ccccc3[nH]c1c1[nH]c3ccccc3c21	Preclinical
ardeparin	thrombin inhibitor	SERPIND1			MedChemEx	0	CO[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](O[C@@H]2O[C@H]([C@@H](OC)[C@H](O)[C@H]2OS(O)(=O)=O)C(O)=O)[C@H](O)[C@H]1NS(O)(=O)=O	Withdrawn
arecaidine-but-2-ynyl-ester	acetylcholine receptor agonist	CHRM2			Tocris	87.97	CC#CCOC(=O)C1=CCCN(C)C1 |t:7|	Preclinical
arecaidine-propargyl-ester	acetylcholine receptor agonist	CHRM1, CHRM2, CHRM3, CHRM4			Tocris, Tocris, Tocris, Tocris, Tocris, Tocris	84.89	CN1CCC=C(C1)C(=O)OCC#C |c:4|, CN1CCC=C(C1)C(=O)OCC#C |c:4|, CN1CCC=C(C1)C(=O)OCC#C |c:4|, CN1CCC=C(C1)C(=O)OCC#C |c:4|, CN1CCC=C(C1)C(=O)OCC#C |c:4|, CN1CCC=C(C1)C(=O)OCC#C |c:4|	Preclinical
arecoline	acetylcholine receptor agonist	CHRM1, CHRM2, CHRM3, CHRM4			MedChemEx, Selleck, MicroSource	99.05	COC(=O)C1=CCCN(C)C1 |t:4|, COC(=O)C1=CCCN(C)C1 |t:4|, COC(=O)C1=CCCN(C)C1 |t:4|	Phase 1
argatroban	thrombin inhibitor	F2	hematology	heparin-induced thrombocytopenia (HIT)	Tocris, Selleck, Selleck, Tocris	97.13	C[C@@H]1CCN([C@H](C1)C(O)=O)C(=O)[C@H](CCCNC(N)=N)NS(=O)(=O)c1cccc2C[C@@H](C)CNc12 |a:1,5,12,&1:30|, C[C@@H]1CCN([C@H](C1)C(O)=O)C(=O)[C@H](CCCNC(N)=N)NS(=O)(=O)c1cccc2C[C@@H](C)CNc12 |a:1,5,12,&1:30|, C[C@@H]1CCN([C@H](C1)C(O)=O)C(=O)[C@H](CCCNC(N)=N)NS(=O)(=O)c1cccc2C[C@@H](C)CNc12 |a:1,5,12,&1:30|, C[C@@H]1CCN([C@H](C1)C(O)=O)C(=O)[C@H](CCCNC(N)=N)NS(=O)(=O)c1cccc2C[C@@H](C)CNc12 |a:1,5,12,&1:30|	Launched
argireline	neurotransmitter release inhibitor				MedChemEx	100	CSCC[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(C)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(N)=O	Phase 3
arglabin	farnesyltransferase inhibitor	FNTA, NFKB1			MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx	97.88	CC1=CC[C@]23O[C@@]2(C)CC[C@@H]2[C@H](OC(=O)C2=C)[C@@H]13 |t:1|, CC1=CC[C@]23O[C@@]2(C)CC[C@@H]2[C@H](OC(=O)C2=C)[C@@H]13 |t:1|, CC1=CC[C@]23O[C@@]2(C)CC[C@@H]2[C@H](OC(=O)C2=C)[C@@H]13 |t:1|, CC1=CC[C@]23O[C@@]2(C)CC[C@@H]2[C@H](OC(=O)C2=C)[C@@H]13 |t:1|, CC1=CC[C@]23O[C@@]2(C)CC[C@@H]2[C@H](OC(=O)C2=C)[C@@H]13 |t:1|, CC1=CC[C@]23O[C@@]2(C)CC[C@@H]2[C@H](OC(=O)C2=C)[C@@H]13 |t:1|	Launched
aripiprazole	serotonin receptor agonist, serotonin receptor antagonist	ADRA1A, ADRA1B, ADRA2A, ADRA2B, ADRA2C, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD1, DRD2, DRD3, DRD4, DRD5, HRH1, HTR1A, HTR1B, HTR1D, HTR1E, HTR2A, HTR2C, HTR3A, HTR6, HTR7	neurology/psychiatry	depression, schizophrenia, bipolar disorder	Tocris, MicroSource, Selleck	98.35	Clc1cccc(N2CCN(CCCCOc3ccc4CCC(=O)Nc4c3)CC2)c1Cl, Clc1cccc(N2CCN(CCCCOc3ccc4CCC(=O)Nc4c3)CC2)c1Cl, Clc1cccc(N2CCN(CCCCOc3ccc4CCC(=O)Nc4c3)CC2)c1Cl	Launched
aripiprazole-lauroxil	serotonin receptor agonist		neurology/psychiatry	schizophrenia	Astatech	73.03	CCCCCCCCCCCC(=O)OCN1C(=O)CCc2ccc(OCCCCN3CCN(CC3)c3cccc(Cl)c3Cl)cc12	Launched
arofylline	phosphodiesterase inhibitor	PDE4A			Maybridge, Maybridge	98.45	CCCn1c(=O)n(-c2ccc(Cl)cc2)c2nc[nH]c2c1=O, CCCn1c(=O)n(-c2ccc(Cl)cc2)c2nc[nH]c2c1=O	Phase 3
arotinolol	adrenergic receptor antagonist	ADRB3	cardiology, neurology/psychiatry	hypertension, tremors	AKSci, AKSci	96.65	CC(C)(C)NC[C@@H](O)CSc1nc(cs1)-c1ccc(s1)C(N)=O |&1:6,r|, CC(C)(C)NC[C@@H](O)CSc1nc(cs1)-c1ccc(s1)C(N)=O |&1:6,r|	Launched
ARQ-092	AKT inhibitor	AKT2			MedChemEx, MedChemEx	97.73	Nc1ncccc1-c1nc2ccc(nc2n1-c1ccc(cc1)C1(N)CCC1)-c1ccccc1, Nc1ncccc1-c1nc2ccc(nc2n1-c1ccc(cc1)C1(N)CCC1)-c1ccccc1	Phase 1
ARQ-621	kinesin-like spindle protein inhibitor	KIF11			Selleck, Selleck, Selleck	89.24	NCCCN([C@H](CC#C)c1nc2cc(Cl)ccc2c(=O)n1Nc1ccccc1)C(=O)c1cccc(Cl)c1F, NCCCN([C@H](CC#C)c1nc2cc(Cl)ccc2c(=O)n1Nc1ccccc1)C(=O)c1cccc(Cl)c1F, NCCCN([C@H](CC#C)c1nc2cc(Cl)ccc2c(=O)n1Nc1ccccc1)C(=O)c1cccc(Cl)c1F	Phase 1
ARRY-334543	EGFR inhibitor	ERBB2			MedChemEx, Selleck, Selleck	93.97	C[C@@H]1COC(Nc2ccc3ncnc(Nc4ccc(OCc5nccs5)c(Cl)c4)c3c2)=N1 |c:34|, C[C@@H]1COC(Nc2ccc3ncnc(Nc4ccc(OCc5nccs5)c(Cl)c4)c3c2)=N1 |c:34|, C[C@@H]1COC(Nc2ccc3ncnc(Nc4ccc(OCc5nccs5)c(Cl)c4)c3c2)=N1 |c:34|	Phase 2/Phase 3
arsanilic-acid		LYZ			MedChemEx, MicroSource	100	Nc1ccc(cc1)[As](O)(O)=O, Nc1ccc(cc1)[As](O)(O)=O	Phase 1
arsenic-trioxide	apoptosis stimulant	AKT1, CCND1, IKBKB, JUN, MAPK1, MAPK3, TXNRD1	gastroenterology	diarrhea	Sigma	0	O=[As]O[As]=O	Launched
artemether	antimalarial agent	ATP1A1	infectious disease	malaria	MicroSource, MedChemEx, MedChemEx, Selleck, Selleck	0	CO[C@H]1O[C@@H]2O[C@@]3(C)CC[C@H]4[C@H](C)CC[C@@H]([C@H]1C)[C@@]24OO3, CO[C@H]1O[C@@H]2O[C@@]3(C)CC[C@H]4[C@H](C)CC[C@@H]([C@H]1C)[C@@]24OO3, CO[C@H]1O[C@@H]2O[C@@]3(C)CC[C@H]4[C@H](C)CC[C@@H]([C@H]1C)[C@@]24OO3, CO[C@H]1O[C@@H]2O[C@@]3(C)CC[C@H]4[C@H](C)CC[C@@H]([C@H]1C)[C@@]24OO3, CO[C@H]1O[C@@H]2O[C@@]3(C)CC[C@H]4[C@H](C)CC[C@@H]([C@H]1C)[C@@]24OO3	Launched
artemisinin	DNA synthesis inhibitor	CYP2B6	infectious disease	malaria	MicroSource, Tocris, Tocris, Tocris, Selleck, Selleck	100	C[C@@H]1CC[C@H]2[C@@H](C)C(=O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4, C[C@@H]1CC[C@H]2[C@@H](C)C(=O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4, C[C@@H]1CC[C@H]2[C@@H](C)C(=O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4, C[C@@H]1CC[C@H]2[C@@H](C)C(=O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4, C[C@@H]1CC[C@H]2[C@@H](C)C(=O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4, C[C@@H]1CC[C@H]2[C@@H](C)C(=O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4	Launched
artemotil			infectious disease	malaria	MedChemEx, AKSci, MedChemEx	0	CCO[C@H]1O[C@@H]2O[C@@]3(C)CC[C@H]4[C@H](C)CC[C@@H]([C@H]1C)[C@@]24OO3, CCO[C@H]1O[C@@H]2O[C@@]3(C)CC[C@H]4[C@H](C)CC[C@@H]([C@H]1C)[C@@]24OO3, CCO[C@H]1O[C@@H]2O[C@@]3(C)CC[C@H]4[C@H](C)CC[C@@H]([C@H]1C)[C@@]24OO3	Launched
artesunate	DNA synthesis inhibitor		infectious disease	malaria	MicroSource, MicroSource, MicroSource, Selleck, Selleck	100	C[C@@H]1CC[C@H]2[C@@H](C)[C@H](OC(=O)CCC(O)=O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4, C[C@@H]1CC[C@H]2[C@@H](C)[C@H](OC(=O)CCC(O)=O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4, C[C@@H]1CC[C@H]2[C@@H](C)[C@H](OC(=O)CCC(O)=O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4, C[C@@H]1CC[C@H]2[C@@H](C)[C@H](OC(=O)CCC(O)=O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4, C[C@@H]1CC[C@H]2[C@@H](C)[C@H](OC(=O)CCC(O)=O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4	Launched
articaine	local anesthetic		neurology/psychiatry	local anesthetic	MedChemEx, Selleck	91.48	CCCN[C@@H](C)C(=O)Nc1c(C)csc1C(=O)OC |&1:4|, CCCN[C@@H](C)C(=O)Nc1c(C)csc1C(=O)OC |&1:4|	Launched
arundic-acid	astrocyte modulating agent	PTGS2, S100B			Tocris	17.19	CCCCCC[C@@H](CCC)C(O)=O	Phase 2/Phase 3
ARV-825	bromodomain inhibitor	BRD4			MedChemEx, MedChemEx	96.88	Cc1sc-2c(c1C)C(=N[C@@H](CC(=O)Nc1ccc(OCCOCCOCCOCCNc3cccc4C(=O)N([C@H]5CCC(=O)NC5=O)C(=O)c34)cc1)c1nnc(C)n-21)c1ccc(Cl)cc1 |a:9,&1:39,c:8|, Cc1sc-2c(c1C)C(=N[C@@H](CC(=O)Nc1ccc(OCCOCCOCCOCCNc3cccc4C(=O)N([C@H]5CCC(=O)NC5=O)C(=O)c34)cc1)c1nnc(C)n-21)c1ccc(Cl)cc1 |a:9,&1:39,c:8|	Preclinical
AS-1269574	glucose dependent insulinotropic receptor agonist	GPR119			Tocris, Tocris, Tocris, Tocris	97.58	Cc1cc(NCCO)nc(n1)-c1ccc(Br)cc1, Cc1cc(NCCO)nc(n1)-c1ccc(Br)cc1, Cc1cc(NCCO)nc(n1)-c1ccc(Br)cc1, Cc1cc(NCCO)nc(n1)-c1ccc(Br)cc1	Preclinical
AS-1892802	rho associated kinase inhibitor	ROCK1			Tocris, Tocris, Tocris, Tocris, Tocris	98.94	OC[C@@H](NC(=O)Nc1ccc(cc1)-c1ccncc1)c1ccccc1, OC[C@@H](NC(=O)Nc1ccc(cc1)-c1ccncc1)c1ccccc1, OC[C@@H](NC(=O)Nc1ccc(cc1)-c1ccncc1)c1ccccc1, OC[C@@H](NC(=O)Nc1ccc(cc1)-c1ccncc1)c1ccccc1, OC[C@@H](NC(=O)Nc1ccc(cc1)-c1ccncc1)c1ccccc1	Preclinical
AS-1949490	SHIP2 phosphatase inhibitor	INPP5D			Tocris, Tocris, Tocris, Tocris	98.99	C[C@H](NC(=O)c1sccc1OCc1ccc(Cl)cc1)c1ccccc1, C[C@H](NC(=O)c1sccc1OCc1ccc(Cl)cc1)c1ccccc1, C[C@H](NC(=O)c1sccc1OCc1ccc(Cl)cc1)c1ccccc1, C[C@H](NC(=O)c1sccc1OCc1ccc(Cl)cc1)c1ccccc1	Preclinical
AS-2034178	free fatty acid receptor agonist	FFAR1			Tocris, Tocris, Tocris	95.79	OC(=O)CCc1ccc(NCc2cccc3N(CCOc4ccccc4)CCCc23)cc1F, OC(=O)CCc1ccc(NCc2cccc3N(CCOc4ccccc4)CCCc23)cc1F, OC(=O)CCc1ccc(NCc2cccc3N(CCOc4ccccc4)CCCc23)cc1F	Preclinical
AS-2444697	interleukin inhibitor	IRAK4			Tocris, Tocris, Tocris, Tocris, Tocris	97.27	Cc1cc(ccn1)-c1nc(co1)C(=O)Nc1cn(nc1C(N)=O)C1CCOCC1, Cc1cc(ccn1)-c1nc(co1)C(=O)Nc1cn(nc1C(N)=O)C1CCOCC1, Cc1cc(ccn1)-c1nc(co1)C(=O)Nc1cn(nc1C(N)=O)C1CCOCC1, Cc1cc(ccn1)-c1nc(co1)C(=O)Nc1cn(nc1C(N)=O)C1CCOCC1, Cc1cc(ccn1)-c1nc(co1)C(=O)Nc1cn(nc1C(N)=O)C1CCOCC1	Preclinical
AS-252424	PI3K inhibitor	PIK3CG			Selleck, Selleck, Selleck	93.7	Oc1cc(F)ccc1-c1ccc(\C=C2/SC(=O)NC2=O)o1, Oc1cc(F)ccc1-c1ccc(\C=C2/SC(=O)NC2=O)o1, Oc1cc(F)ccc1-c1ccc(\C=C2/SC(=O)NC2=O)o1	Preclinical
AS-604850	PI3K inhibitor	PIK3CA, PIK3CG			Selleck	94.13	FC1(F)Oc2ccc(\C=C3/SC(=O)NC3=O)cc2O1	Preclinical
AS-703026	MEK inhibitor	MAP2K1, MAP2K2			MedChemEx, MedChemEx, MedChemEx, Selleck, Selleck, Selleck, Selleck	97.12	OC[C@@H](O)CNC(=O)c1ccncc1Nc1ccc(I)cc1F, OC[C@@H](O)CNC(=O)c1ccncc1Nc1ccc(I)cc1F, OC[C@@H](O)CNC(=O)c1ccncc1Nc1ccc(I)cc1F, OC[C@@H](O)CNC(=O)c1ccncc1Nc1ccc(I)cc1F, OC[C@@H](O)CNC(=O)c1ccncc1Nc1ccc(I)cc1F, OC[C@@H](O)CNC(=O)c1ccncc1Nc1ccc(I)cc1F, OC[C@@H](O)CNC(=O)c1ccncc1Nc1ccc(I)cc1F	Phase 2
AS-77	potassium channel blocker	KCNA3, KCNA5, KCNN4			MedChemEx, MedChemEx, MedChemEx	99.13	O=c1ccc2c(OCCCCOc3ccccc3)c3ccoc3cc2o1, O=c1ccc2c(OCCCCOc3ccccc3)c3ccoc3cc2o1, O=c1ccc2c(OCCCCOc3ccccc3)c3ccoc3cc2o1	Phase 1
ASA-404	angiogenesis inhibitor				MedChemEx, Selleck	95.25	Cc1ccc2c(oc3c(CC(O)=O)cccc3c2=O)c1C, Cc1ccc2c(oc3c(CC(O)=O)cccc3c2=O)c1C	Phase 3
asapiprant	prostaglandin inhibitor				MedChemEx	97.14	CC(C)Oc1ccc(cc1)S(=O)(=O)N1CCN(CC1)c1ccc(-c2ncco2)c(OCC(O)=O)c1	Preclinical
asaraldehyde	cyclooxygenase inhibitor	PTGS2			MedChemEx, Selleck	95.62	COc1cc(OC)c(C=O)cc1OC, COc1cc(OC)c(C=O)cc1OC	Preclinical
ASC-J9	androgen receptor enhancer	AR			Sigma, MedChemEx, MedChemEx, Adooq	91.45	COc1ccc(\C=C\C(O)=CC(=O)\C=C\c2ccc(OC)c(OC)c2)cc1OC, COc1ccc(\C=C\C(O)=CC(=O)\C=C\c2ccc(OC)c(OC)c2)cc1OC, COc1ccc(\C=C\C(O)=CC(=O)\C=C\c2ccc(OC)c(OC)c2)cc1OC, COc1ccc(\C=C\C(O)=CC(=O)\C=C\c2ccc(OC)c(OC)c2)cc1OC	Phase 2
asciminib	Bcr-Abl kinase inhibitor				MedChemEx	98.07	O[C@@H]1CCN(C1)c1ncc(cc1-c1cc[nH]n1)C(=O)Nc1ccc(OC(F)(F)Cl)cc1	Phase 2
ascomycin	calcineurin inhibitor	FKBP1A			Selleck	100	CC[C@@H]1\C=C(C)\C[C@H](C)C[C@H](OC)[C@H]2O[C@](O)([C@H](C)C[C@@H]2OC)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@@H]([C@H](C)[C@@H](O)CC1=O)C(\C)=C\[C@@H]1CC[C@@H](O)[C@@H](C1)OC |c:3|	Preclinical
ascorbic-acid	antioxidant	SLC23A1, SLC23A2	endocrinology	scurvy	MedChemEx, MedChemEx, Sigma, MicroSource, Selleck, Selleck	100	OC[C@H](O)[C@H]1OC(=O)C(=O)[C@@H]1O |a:2,4,&1:10|, OC[C@H](O)[C@H]1OC(=O)C(=O)[C@@H]1O |a:2,4,&1:10|, OC[C@H](O)[C@H]1OC(=O)C(=O)[C@@H]1O |a:2,4,&1:10|, OC[C@H](O)[C@H]1OC(=O)C(=O)[C@@H]1O |a:2,4,&1:10|, OC[C@H](O)[C@H]1OC(=O)C(=O)[C@@H]1O |a:2,4,&1:10|, OC[C@H](O)[C@H]1OC(=O)C(=O)[C@@H]1O |a:2,4,&1:10|	Launched
asenapine	dopamine receptor antagonist, serotonin receptor antagonist	DRD2, HRH1, HTR1A, HTR1B, HTR1D, HTR1E, HTR2A	neurology/psychiatry	schizophrenia, bipolar disorder	MedChemEx, Tocris	94.5	[H][C@]12CN(C)C[C@]1([H])c1cc(Cl)ccc1Oc1ccccc21 |&1:1,6|, [H][C@]12CN(C)C[C@]1([H])c1cc(Cl)ccc1Oc1ccccc21 |&1:1,6|	Launched
asiatic-acid	apoptosis stimulant	PYGM			Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck	92.85	C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)C[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]5CC[C@@]34C)[C@@H]2[C@H]1C)C(O)=O |c:9|, C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)C[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]5CC[C@@]34C)[C@@H]2[C@H]1C)C(O)=O |c:9|, C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)C[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]5CC[C@@]34C)[C@@H]2[C@H]1C)C(O)=O |c:9|, C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)C[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]5CC[C@@]34C)[C@@H]2[C@H]1C)C(O)=O |c:9|, C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)C[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]5CC[C@@]34C)[C@@H]2[C@H]1C)C(O)=O |c:9|, C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)C[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]5CC[C@@]34C)[C@@H]2[C@H]1C)C(O)=O |c:9|, C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)C[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]5CC[C@@]34C)[C@@H]2[C@H]1C)C(O)=O |c:9|, C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)C[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]5CC[C@@]34C)[C@@H]2[C@H]1C)C(O)=O |c:9|	Preclinical
asimadoline	opioid receptor agonist	OPRK1			MedChemEx	90.34	CN([C@H](CN1CC[C@H](O)C1)c1ccccc1)C(=O)C(c1ccccc1)c1ccccc1	Phase 3
asivatrep	transient receptor potential channel antagonist				MedChemEx	90.4	CCCc1nc(ccc1\C=C\C(=O)N[C@H](C)c1cc(F)c(NS(C)(=O)=O)c(F)c1)C(F)(F)F	Phase 3
ASP-2535	glycine transporter inhibitor	SLC6A9			Tocris, Tocris	98.79	CC(C)c1nnc(-c2ccc(nc2)-c2ccccc2)n1-c1cccc2nonc12, CC(C)c1nnc(-c2ccc(nc2)-c2ccccc2)n1-c1cccc2nonc12	Phase 1
ASP-6537	cyclooxygenase inhibitor				AMS	95.01	COc1nc(-c2ccc(OC)cc2)n(n1)-c1ccc(OC)cc1	Preclinical
ASP-9521	aldo-keto reductase inhibitor				MedChemEx	84.47	COc1ccc2[nH]c(cc2c1)C(=O)N1CCC(CC(C)(C)O)CC1	Preclinical
aspartame		TAS1R2, TRPV1			MicroSource, Sigma, Selleck, Selleck, Selleck	85.8	COC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](N)CC(O)=O, COC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](N)CC(O)=O, COC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](N)CC(O)=O, COC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](N)CC(O)=O, COC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](N)CC(O)=O	Launched
aspirin	cyclooxygenase inhibitor	AKR1C1, ASIC3, EDNRA, HSPA5, IKBKB, NFKB1, NFKB2, NFKBIA, PRKAA1, PRKAA2, PRKAB1, PRKAB2, PRKAG1, PRKAG2, PRKAG3, PTGS1, PTGS2, RPS6KA3, TP53	neurology/psychiatry, endocrinology, dental	headache, fever, toothache, muscle pain	Tocris, MicroSource, MicroSource, Selleck, Selleck	99.34	CC(=O)Oc1ccccc1C(O)=O, CC(=O)Oc1ccccc1C(O)=O, CC(=O)Oc1ccccc1C(O)=O, CC(=O)Oc1ccccc1C(O)=O, CC(=O)Oc1ccccc1C(O)=O	Launched
ASP3026	ALK tyrosine kinase receptor inhibitor	ALK			Tocris, Tocris, MedChemEx, MedChemEx, MedChemEx, MedChemEx	95.38	COc1cc(ccc1Nc1ncnc(Nc2ccccc2S(=O)(=O)C(C)C)n1)N1CCC(CC1)N1CCN(C)CC1, COc1cc(ccc1Nc1ncnc(Nc2ccccc2S(=O)(=O)C(C)C)n1)N1CCC(CC1)N1CCN(C)CC1, COc1cc(ccc1Nc1ncnc(Nc2ccccc2S(=O)(=O)C(C)C)n1)N1CCC(CC1)N1CCN(C)CC1, COc1cc(ccc1Nc1ncnc(Nc2ccccc2S(=O)(=O)C(C)C)n1)N1CCC(CC1)N1CCN(C)CC1, COc1cc(ccc1Nc1ncnc(Nc2ccccc2S(=O)(=O)C(C)C)n1)N1CCC(CC1)N1CCN(C)CC1, COc1cc(ccc1Nc1ncnc(Nc2ccccc2S(=O)(=O)C(C)C)n1)N1CCC(CC1)N1CCN(C)CC1	Phase 1
AST-1306	EGFR inhibitor	EGFR, ERBB2			MedChemEx, Selleck, Selleck, Selleck	97.14	Fc1cccc(COc2ccc(Nc3ncnc4ccc(NC(=O)C=C)cc34)cc2Cl)c1, Fc1cccc(COc2ccc(Nc3ncnc4ccc(NC(=O)C=C)cc34)cc2Cl)c1, Fc1cccc(COc2ccc(Nc3ncnc4ccc(NC(=O)C=C)cc34)cc2Cl)c1, Fc1cccc(COc2ccc(Nc3ncnc4ccc(NC(=O)C=C)cc34)cc2Cl)c1	Phase 1
astaxanthin	antioxidant				Cayman	26.68	C\C(\C=C\C=C(/C)\C=C\C1=C(C)C(=O)[C@@H](O)CC1(C)C)=C/C=C/C=C(\C)/C=C/C=C(\C)/C=C/C1=C(C)C(=O)[C@@H](O)CC1(C)C |c:9,34|	Launched
astemizole	histamine receptor antagonist	HRH1, KCNH1, KCNH2			MicroSource, Tocris, Tocris, Tocris	98.54	COc1ccc(CCN2CCC(CC2)Nc2nc3ccccc3n2Cc2ccc(F)cc2)cc1, COc1ccc(CCN2CCC(CC2)Nc2nc3ccccc3n2Cc2ccc(F)cc2)cc1, COc1ccc(CCN2CCC(CC2)Nc2nc3ccccc3n2Cc2ccc(F)cc2)cc1, COc1ccc(CCN2CCC(CC2)Nc2nc3ccccc3n2Cc2ccc(F)cc2)cc1	Withdrawn
astilbin	nuclear factor erythroid derived, like (NRF2) activator				MedChemEx	96.64	C[C@@H]1O[C@@H](O[C@@H]2[C@H](Oc3cc(O)cc(O)c3C2=O)c2ccc(O)c(O)c2)[C@H](O)[C@H](O)[C@H]1O	Preclinical
astragaloside-a	anti-inflammatory agent				MedChemEx, Selleck	100	CC(C)(O)[C@H]1CC[C@](C)(O1)[C@H]1[C@@H](O)C[C@@]2(C)[C@@H]3C[C@H](O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)[C@@H]4[C@]5(C[C@@]35CC[C@]12C)CC[C@H](O[C@@H]1OC[C@@H](O)[C@H](O)[C@H]1O)C4(C)C, CC(C)(O)[C@H]1CC[C@](C)(O1)[C@H]1[C@@H](O)C[C@@]2(C)[C@@H]3C[C@H](O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)[C@@H]4[C@]5(C[C@@]35CC[C@]12C)CC[C@H](O[C@@H]1OC[C@@H](O)[C@H](O)[C@H]1O)C4(C)C	Preclinical
ASTX660	apoptosis inhibitor				MedChemEx	92.43	C[C@@H]1CN(CC(=O)N2CC(C)(C)c3nc(CO)c(Cc4ccc(F)cc4)cc23)[C@@H](CN2CCOC[C@H]2C)CN1	Phase 1/Phase 2
asunaprevir	HCV inhibitor				MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx	97.98	COc1cnc(O[C@@H]2C[C@H](N(C2)C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)C(=O)N[C@@]2(C[C@H]2C=C)C(=O)NS(=O)(=O)C2CC2)c2cc(Cl)ccc12, COc1cnc(O[C@@H]2C[C@H](N(C2)C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)C(=O)N[C@@]2(C[C@H]2C=C)C(=O)NS(=O)(=O)C2CC2)c2cc(Cl)ccc12, COc1cnc(O[C@@H]2C[C@H](N(C2)C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)C(=O)N[C@@]2(C[C@H]2C=C)C(=O)NS(=O)(=O)C2CC2)c2cc(Cl)ccc12, COc1cnc(O[C@@H]2C[C@H](N(C2)C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)C(=O)N[C@@]2(C[C@H]2C=C)C(=O)NS(=O)(=O)C2CC2)c2cc(Cl)ccc12, COc1cnc(O[C@@H]2C[C@H](N(C2)C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)C(=O)N[C@@]2(C[C@H]2C=C)C(=O)NS(=O)(=O)C2CC2)c2cc(Cl)ccc12, COc1cnc(O[C@@H]2C[C@H](N(C2)C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)C(=O)N[C@@]2(C[C@H]2C=C)C(=O)NS(=O)(=O)C2CC2)c2cc(Cl)ccc12	Phase 3
asymmetrical-dimethylarginine	nitric oxide synthase inhibitor	NOS2, NOS3			EMDBio, EMDBio	100	CN(C)C(=N)NCCC[C@H](N)C(O)=O, CN(C)C(=N)NCCC[C@H](N)C(O)=O	Phase 1
AT-1015	serotonin receptor antagonist	HTR2A			Tocris, Tocris	95.2	O=CN1CCC(CC1)C(=O)NCCN1CCC(CC1)=C1c2ccccc2C=Cc2ccccc12 |c:29|, O=CN1CCC(CC1)C(=O)NCCN1CCC(CC1)=C1c2ccccc2C=Cc2ccccc12 |c:29|	Preclinical
AT-406	IAP antagonist 				Adooq	93.59	CN[C@@H](C)C(=O)N[C@H]1CN(CC[C@H]2CC[C@H](N2C1=O)C(=O)NC(c1ccccc1)c1ccccc1)C(=O)CC(C)C	Phase 1
AT-7519	CDK inhibitor	CDK1, CDK2, CDK4, CDK5, CDK6, CDK9			MedChemEx, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck	92.34	Clc1cccc(Cl)c1C(=O)Nc1cn[nH]c1C(=O)NC1CCNCC1, Clc1cccc(Cl)c1C(=O)Nc1cn[nH]c1C(=O)NC1CCNCC1, Clc1cccc(Cl)c1C(=O)Nc1cn[nH]c1C(=O)NC1CCNCC1, Clc1cccc(Cl)c1C(=O)Nc1cn[nH]c1C(=O)NC1CCNCC1, Clc1cccc(Cl)c1C(=O)Nc1cn[nH]c1C(=O)NC1CCNCC1, Clc1cccc(Cl)c1C(=O)Nc1cn[nH]c1C(=O)NC1CCNCC1, Clc1cccc(Cl)c1C(=O)Nc1cn[nH]c1C(=O)NC1CCNCC1	Phase 2
AT-9283	Aurora kinase inhibitor, JAK inhibitor	AURKA, AURKB, JAK2, JAK3, RPS6KA6, STK17A			Selleck, Selleck, Selleck, Selleck, Selleck, Adooq, Adooq, Adooq	95.94	O=C(NC1CC1)Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1, O=C(NC1CC1)Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1, O=C(NC1CC1)Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1, O=C(NC1CC1)Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1, O=C(NC1CC1)Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1, O=C(NC1CC1)Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1, O=C(NC1CC1)Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1, O=C(NC1CC1)Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1	Phase 2
ataluren	CFTR channel agonist, dystrophin stimulant	DMD	genetics, pulmonary	duchenne muscular dystrophy (DMD), cystic fibrosis	MedChemEx, Selleck	97.8	OC(=O)c1cccc(c1)-c1noc(n1)-c1ccccc1F, OC(=O)c1cccc(c1)-c1noc(n1)-c1ccccc1F	Launched
atazanavir	HIV protease inhibitor		infectious disease	human immunodeficiency virus (HIV-1)	MedChemEx, Selleck, Selleck	97.98	COC(=O)N[C@H](C(=O)N[C@@H](Cc1ccccc1)[C@@H](O)CN(Cc1ccc(cc1)-c1ccccn1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C(C)(C)C, COC(=O)N[C@H](C(=O)N[C@@H](Cc1ccccc1)[C@@H](O)CN(Cc1ccc(cc1)-c1ccccn1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C(C)(C)C, COC(=O)N[C@H](C(=O)N[C@@H](Cc1ccccc1)[C@@H](O)CN(Cc1ccc(cc1)-c1ccccn1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C(C)(C)C	Launched
ATB-346	cyclooxygenase inhibitor	PTGER2			MedChemEx, MedChemEx	94.79	COc1ccc2cc(ccc2c1)[C@@H](C)C(=O)Oc1ccc(cc1)C(N)=S |&1:12,r|, COc1ccc2cc(ccc2c1)[C@@H](C)C(=O)Oc1ccc(cc1)C(N)=S |&1:12,r|	Phase 2
atenolol-(+)	adrenergic receptor antagonist				Selleck	81.19	CC(C)NC[C@@H](O)COc1ccc(CC(N)=O)cc1	Preclinical
atenolol-(+/-)	adrenergic receptor antagonist	ADRB1, ADRB2, LTF, PLA2G2E	cardiology	hypertension, angina pectoris	MicroSource, MicroSource, Tocris	92.2	CC(C)NC[C@@H](O)COc1ccc(CC(N)=O)cc1 |&1:5,r|, CC(C)NC[C@@H](O)COc1ccc(CC(N)=O)cc1 |&1:5,r|, CC(C)NC[C@@H](O)COc1ccc(CC(N)=O)cc1 |&1:5,r|	Launched
atenolol-(-)	adrenergic receptor antagonist		cardiology	hypertension	Sigma, Sigma, Tocris	92.98	CC(C)NC[C@H](O)COc1ccc(CC(N)=O)cc1, CC(C)NC[C@H](O)COc1ccc(CC(N)=O)cc1, CC(C)NC[C@H](O)COc1ccc(CC(N)=O)cc1	Launched
atglistatin	adipose triglyceride lipase inhibitor				Selleck, Selleck, Selleck, MedChemEx	91.11	CN(C)C(=O)Nc1cccc(c1)-c1ccc(cc1)N(C)C, CN(C)C(=O)Nc1cccc(c1)-c1ccc(cc1)N(C)C, CN(C)C(=O)Nc1cccc(c1)-c1ccc(cc1)N(C)C, CN(C)C(=O)Nc1cccc(c1)-c1ccc(cc1)N(C)C	Preclinical
aticaprant	opioid receptor antagonist				MedChemEx	96.33	Cc1cc(C)cc(c1)[C@@H]1CCCN1Cc1ccc(Oc2ccc(cc2F)C(N)=O)cc1	Phase 2
atipamezole	adrenergic receptor antagonist		neurology/psychiatry	reverse sedative	Tocris, MedChemEx, MedChemEx, Tocris, Tocris	99.36	CCC1(Cc2ccccc2C1)c1cnc[nH]1, CCC1(Cc2ccccc2C1)c1cnc[nH]1, CCC1(Cc2ccccc2C1)c1cnc[nH]1, CCC1(Cc2ccccc2C1)c1cnc[nH]1, CCC1(Cc2ccccc2C1)c1cnc[nH]1	Launched
atiprimod	JAK inhibitor, STAT inhibitor	JAK2, STAT3			Tocris, Tocris, Tocris, Tocris, Tocris, Tocris, Tocris	100	CCCC1(CCC)CCC2(CCN(CCCN(CC)CC)C2)CC1, CCCC1(CCC)CCC2(CCN(CCCN(CC)CC)C2)CC1, CCCC1(CCC)CCC2(CCN(CCCN(CC)CC)C2)CC1, CCCC1(CCC)CCC2(CCN(CCCN(CC)CC)C2)CC1, CCCC1(CCC)CCC2(CCN(CCCN(CC)CC)C2)CC1, CCCC1(CCC)CCC2(CCN(CCCN(CC)CC)C2)CC1, CCCC1(CCC)CCC2(CCN(CCCN(CC)CC)C2)CC1	Phase 2
atizoram	phosphodiesterase inhibitor	PDE4A, PDE4B, PDE4C, PDE4D			Cayman, Cayman	97.53	COc1ccc(cc1O[C@H]1C[C@@H]2CC[C@H]1C2)C1CNC(=O)NC1, COc1ccc(cc1O[C@H]1C[C@@H]2CC[C@H]1C2)C1CNC(=O)NC1	Phase 2
ATN-161	integrin antagonist	ITGA5, ITGAV, ITGB1, ITGB3			MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx	93.15	CC(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(N)=O, CC(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(N)=O, CC(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(N)=O, CC(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(N)=O, CC(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(N)=O	Phase 2
atomoxetine	norepinephrine transporter inhibitor	GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, GRIN3A, GRIN3B, SLC6A2, SLC6A3, SLC6A4	neurology/psychiatry	attention-deficit/hyperactivity disorder (ADHD)	MicroSource, Tocris, Selleck, Tocris	97.04	CNCC[C@@H](Oc1ccccc1C)c1ccccc1, CNCC[C@@H](Oc1ccccc1C)c1ccccc1, CNCC[C@@H](Oc1ccccc1C)c1ccccc1, CNCC[C@@H](Oc1ccccc1C)c1ccccc1	Launched
atorvastatin	HMGCR inhibitor	AHR, DPP4, HMGCR	neurology/psychiatry, cardiology	stroke, heart attack	Pharmeks, Pharmeks, Pharmeks, Tocris, Tocris, Tocris, MicroSource, MicroSource, Selleck, Selleck, Selleck	98.24	CC(C)c1c(C(=O)Nc2ccccc2)c(c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(O)=O)-c1ccccc1, CC(C)c1c(C(=O)Nc2ccccc2)c(c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(O)=O)-c1ccccc1, CC(C)c1c(C(=O)Nc2ccccc2)c(c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(O)=O)-c1ccccc1, CC(C)c1c(C(=O)Nc2ccccc2)c(c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(O)=O)-c1ccccc1, CC(C)c1c(C(=O)Nc2ccccc2)c(c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(O)=O)-c1ccccc1, CC(C)c1c(C(=O)Nc2ccccc2)c(c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(O)=O)-c1ccccc1, CC(C)c1c(C(=O)Nc2ccccc2)c(c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(O)=O)-c1ccccc1, CC(C)c1c(C(=O)Nc2ccccc2)c(c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(O)=O)-c1ccccc1, CC(C)c1c(C(=O)Nc2ccccc2)c(c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(O)=O)-c1ccccc1, CC(C)c1c(C(=O)Nc2ccccc2)c(c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(O)=O)-c1ccccc1, CC(C)c1c(C(=O)Nc2ccccc2)c(c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(O)=O)-c1ccccc1	Launched
atosiban	oxytocin receptor antagonist	AVPR1A, AVPR1B, AVPR2, OXTR	neurology/psychiatry, cardiology, endocrinology	stroke, angina pectoris, myocardial infarction, hyperlipidemia	MedChemEx, MedChemEx, MedChemEx, MedChemEx	87.47	CCOc1ccc(C[C@H]2NC(=O)CCSSC[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC2=O)[C@@H](C)CC)[C@@H](C)O)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCCN)C(=O)NCC(N)=O)cc1 |a:8,17,21,33,37,41,50,54,&1:29|, CCOc1ccc(C[C@H]2NC(=O)CCSSC[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC2=O)[C@@H](C)CC)[C@@H](C)O)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCCN)C(=O)NCC(N)=O)cc1 |a:8,17,21,33,37,41,50,54,&1:29|, CCOc1ccc(C[C@H]2NC(=O)CCSSC[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC2=O)[C@@H](C)CC)[C@@H](C)O)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCCN)C(=O)NCC(N)=O)cc1 |a:8,17,21,33,37,41,50,54,&1:29|, CCOc1ccc(C[C@H]2NC(=O)CCSSC[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC2=O)[C@@H](C)CC)[C@@H](C)O)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCCN)C(=O)NCC(N)=O)cc1 |a:8,17,21,33,37,41,50,54,&1:29|	Launched
atovaquone	mitochondrial electron transport inhibitor		infectious disease	pneumonia	MicroSource, Selleck	97.44	Clc1ccc(cc1)[C@H]1CC[C@@H](CC1)[C@H]1C(=O)C(=O)c2ccccc2C1=O |a:7,10,&1:13,wU:7.7,wD:10.14,13.15,(-11.75,6.01,;-10.68,5.39,;-10.68,3.85,;-9.35,3.08,;-8.02,3.85,;-8.01,5.39,;-9.35,6.16,;-6.68,3.08,;-5.35,3.85,;-4.01,3.08,;-4.01,1.54,;-5.35,.77,;-6.68,1.54,;-2.68,.77,;-2.68,-.77,;-3.75,-1.39,;-1.33,-1.54,;-1.33,-2.77,;,-.77,;1.33,-1.54,;2.66,-.77,;2.66,.77,;1.33,1.54,;,.77,;-1.33,1.54,;-1.33,2.77,)|, Clc1ccc(cc1)[C@H]1CC[C@@H](CC1)[C@H]1C(=O)C(=O)c2ccccc2C1=O |a:7,10,&1:13,wU:7.7,wD:10.14,13.15,(-11.75,6.01,;-10.68,5.39,;-10.68,3.85,;-9.35,3.08,;-8.02,3.85,;-8.01,5.39,;-9.35,6.16,;-6.68,3.08,;-5.35,3.85,;-4.01,3.08,;-4.01,1.54,;-5.35,.77,;-6.68,1.54,;-2.68,.77,;-2.68,-.77,;-3.75,-1.39,;-1.33,-1.54,;-1.33,-2.77,;,-.77,;1.33,-1.54,;2.66,-.77,;2.66,.77,;1.33,1.54,;,.77,;-1.33,1.54,;-1.33,2.77,)|	Launched
ATPA	glutamate receptor agonist	GRIK1			Tocris, Tocris, Tocris, Tocris, Tocris	95.4	CC(C)(C)c1o[nH]c(=O)c1C[C@@H](N)C(O)=O |&1:11,r|, CC(C)(C)c1o[nH]c(=O)c1C[C@@H](N)C(O)=O |&1:11,r|, CC(C)(C)c1o[nH]c(=O)c1C[C@@H](N)C(O)=O |&1:11,r|, CC(C)(C)c1o[nH]c(=O)c1C[C@@H](N)C(O)=O |&1:11,r|, CC(C)(C)c1o[nH]c(=O)c1C[C@@H](N)C(O)=O |&1:11,r|	Preclinical
atractylenolide-i	JAK inhibitor				MedChemEx	39.48	[H][C@@]12CC3=C(C)C(=O)OC3=C[C@@]1(C)CCCC2=C |c:3,10|	Preclinical
atracurium	acetylcholine receptor antagonist		critical care, neurology/psychiatry	endotracheal intubation, muscle relaxant	MedChemEx	68.11	COc1ccc(C[C@H]2c3cc(OC)c(OC)cc3CC[N@@+]2(C)CCC(=O)OCCCCCOC(=O)CC[N@@+]2(C)CCc3cc(OC)c(OC)cc3[C@@H]2Cc2ccc(OC)c(OC)c2)cc1OC |&1:7,&2:20,&3:37,&4:51|	Launched
atrasentan	endothelin receptor antagonist	EDNRA			MedChemEx, MedChemEx, MedChemEx, MedChemEx	97.8	CCCCN(CCCC)C(=O)CN1C[C@@H]([C@H]([C@@H]1c1ccc(OC)cc1)C(O)=O)c1ccc2OCOc2c1, CCCCN(CCCC)C(=O)CN1C[C@@H]([C@H]([C@@H]1c1ccc(OC)cc1)C(O)=O)c1ccc2OCOc2c1, CCCCN(CCCC)C(=O)CN1C[C@@H]([C@H]([C@@H]1c1ccc(OC)cc1)C(O)=O)c1ccc2OCOc2c1, CCCCN(CCCC)C(=O)CN1C[C@@H]([C@H]([C@@H]1c1ccc(OC)cc1)C(O)=O)c1ccc2OCOc2c1	Phase 3
atropine	acetylcholine receptor antagonist	CHRM1, CHRM2, CHRM3	ophthalmology	cycloplegia, mydriasis, amblyopia	MicroSource, MedChemEx, Selleck	97.48	CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@@H](CO)c1ccccc1 |a:2,5,7,&1:12,THB:9:7:1:3.4|, CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@@H](CO)c1ccccc1 |a:2,5,7,&1:12,THB:9:7:1:3.4|, CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@@H](CO)c1ccccc1 |a:2,5,7,&1:12,THB:9:7:1:3.4|	Launched
atropine-oxide	acetylcholine receptor antagonist	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5			Sigma	100	C[N@@+]1([O-])[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@H](CO)c1ccccc1 |&1:3,6,8,&2:1,&3:13|	Preclinical
atuveciclib	CDK9 inhibitor				MedChemEx	97.73	COc1cc(F)ccc1-c1ncnc(Nc2cccc(C[S@](C)(=N)=O)c2)n1	Phase 1
AT13148	protein kinase inhibitor	AKT1, AKT2, AKT3, ROCK1, ROCK2, SGK3			MedChemEx, MedChemEx, Selleck, Selleck, MedChemEx	91.13	NC[C@@](O)(c1ccc(Cl)cc1)c1ccc(cc1)-c1cn[nH]c1, NC[C@@](O)(c1ccc(Cl)cc1)c1ccc(cc1)-c1cn[nH]c1, NC[C@@](O)(c1ccc(Cl)cc1)c1ccc(cc1)-c1cn[nH]c1, NC[C@@](O)(c1ccc(Cl)cc1)c1ccc(cc1)-c1cn[nH]c1, NC[C@@](O)(c1ccc(Cl)cc1)c1ccc(cc1)-c1cn[nH]c1	Phase 1
AT13387	HSP inhibitor	HSP90AA1			Selleck, Selleck, Selleck, Selleck, Selleck, Selleck	94.98	CC(C)c1cc(C(=O)N2Cc3ccc(CN4CCN(C)CC4)cc3C2)c(O)cc1O, CC(C)c1cc(C(=O)N2Cc3ccc(CN4CCN(C)CC4)cc3C2)c(O)cc1O, CC(C)c1cc(C(=O)N2Cc3ccc(CN4CCN(C)CC4)cc3C2)c(O)cc1O, CC(C)c1cc(C(=O)N2Cc3ccc(CN4CCN(C)CC4)cc3C2)c(O)cc1O, CC(C)c1cc(C(=O)N2Cc3ccc(CN4CCN(C)CC4)cc3C2)c(O)cc1O, CC(C)c1cc(C(=O)N2Cc3ccc(CN4CCN(C)CC4)cc3C2)c(O)cc1O	Phase 2
AT7867	AKT inhibitor	AKT2, GSK3B, PKIA, PRKACA			Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck	92.8	Clc1ccc(cc1)C1(CCNCC1)c1ccc(cc1)-c1cn[nH]c1, Clc1ccc(cc1)C1(CCNCC1)c1ccc(cc1)-c1cn[nH]c1, Clc1ccc(cc1)C1(CCNCC1)c1ccc(cc1)-c1cn[nH]c1, Clc1ccc(cc1)C1(CCNCC1)c1ccc(cc1)-c1cn[nH]c1, Clc1ccc(cc1)C1(CCNCC1)c1ccc(cc1)-c1cn[nH]c1, Clc1ccc(cc1)C1(CCNCC1)c1ccc(cc1)-c1cn[nH]c1, Clc1ccc(cc1)C1(CCNCC1)c1ccc(cc1)-c1cn[nH]c1, Clc1ccc(cc1)C1(CCNCC1)c1ccc(cc1)-c1cn[nH]c1	Preclinical
auranofin	NFkB pathway inhibitor	IKBKB, PRDX5, TRPA1	rheumatology	rheumatoid arthritis	MedChemEx, Selleck, Selleck, MedChemEx	73.57	CCP(CC)(CC)=[Au]S[C@@H]1O[C@H](COC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O, CCP(CC)(CC)=[Au]S[C@@H]1O[C@H](COC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O, CCP(CC)(CC)=[Au]S[C@@H]1O[C@H](COC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O, CCP(CC)(CC)=[Au]S[C@@H]1O[C@H](COC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O	Launched
aurora-a-inhibitor-i	Aurora kinase inhibitor	AURKA			Tocris, Tocris, Tocris, Selleck, Selleck	99.42	CCN1CCN(CC1)C(=O)Cc1ccc(Nc2ncc(F)c(Nc3ccc(cc3)C(=O)Nc3ccccc3Cl)n2)cc1, CCN1CCN(CC1)C(=O)Cc1ccc(Nc2ncc(F)c(Nc3ccc(cc3)C(=O)Nc3ccccc3Cl)n2)cc1, CCN1CCN(CC1)C(=O)Cc1ccc(Nc2ncc(F)c(Nc3ccc(cc3)C(=O)Nc3ccccc3Cl)n2)cc1, CCN1CCN(CC1)C(=O)Cc1ccc(Nc2ncc(F)c(Nc3ccc(cc3)C(=O)Nc3ccccc3Cl)n2)cc1, CCN1CCN(CC1)C(=O)Cc1ccc(Nc2ncc(F)c(Nc3ccc(cc3)C(=O)Nc3ccccc3Cl)n2)cc1	Preclinical
aurothioglucose	PKC inhibitor	PRKCI	rheumatology	rheumatoid arthritis	MedChemEx, MedChemEx	25.87	OC[C@H]1O[C@H](S[Au])[C@H](O)[C@@H](O)[C@@H]1O, OC[C@H]1O[C@H](S[Au])[C@H](O)[C@@H](O)[C@@H]1O	Launched
AUT-1	potassium channel activator				MedChemEx	97.89	CC[C@H]1NC(=O)N(C1=O)c1ccc(Oc2ccc(C)c(OC)c2)nc1	Preclinical
autotaxin-modulator-1	autotaxin inhibitor	ENPP2			MedChemEx, MedChemEx	97.37	C[C@@H](N1[C@H]2CC[C@@H]1C[C@@H](C2)C(O)=O)c1ccc2ccc(O[C@H]3CC[C@H](CC3)C(F)(F)F)c(c2c1)C(F)(F)F |a:1,21,24,&1:3,&2:6,&3:8,wU:8.11,21.22,24.29,wD:1.0,3.2,6.6,(6.23,2.09,;5.61,1.02,;4.07,1.02,;3.25,-.38,;2.26,.16,;2.26,1.96,;3.29,2.4,;1.65,2.4,;.83,1.02,;1.62,-.38,;-.71,1.02,;-1.33,2.09,;-1.33,-.04,;6.38,-.31,;5.62,-1.65,;6.4,-2.98,;7.94,-2.98,;8.71,-4.31,;10.25,-4.31,;11.01,-2.97,;12.56,-2.97,;13.33,-4.31,;14.87,-4.31,;15.64,-5.64,;14.86,-6.98,;13.32,-6.97,;12.56,-5.64,;15.63,-8.31,;16.86,-8.31,;15.02,-9.38,;16.25,-9.38,;10.24,-1.64,;8.71,-1.65,;7.94,-.32,;11.01,-.31,;12.24,-.3,;10.39,.76,;11.62,.76,)|, C[C@@H](N1[C@H]2CC[C@@H]1C[C@@H](C2)C(O)=O)c1ccc2ccc(O[C@H]3CC[C@H](CC3)C(F)(F)F)c(c2c1)C(F)(F)F |a:1,21,24,&1:3,&2:6,&3:8,wU:8.11,21.22,24.29,wD:1.0,3.2,6.6,(6.23,2.09,;5.61,1.02,;4.07,1.02,;3.25,-.38,;2.26,.16,;2.26,1.96,;3.29,2.4,;1.65,2.4,;.83,1.02,;1.62,-.38,;-.71,1.02,;-1.33,2.09,;-1.33,-.04,;6.38,-.31,;5.62,-1.65,;6.4,-2.98,;7.94,-2.98,;8.71,-4.31,;10.25,-4.31,;11.01,-2.97,;12.56,-2.97,;13.33,-4.31,;14.87,-4.31,;15.64,-5.64,;14.86,-6.98,;13.32,-6.97,;12.56,-5.64,;15.63,-8.31,;16.86,-8.31,;15.02,-9.38,;16.25,-9.38,;10.24,-1.64,;8.71,-1.65,;7.94,-.32,;11.01,-.31,;12.24,-.3,;10.39,.76,;11.62,.76,)|	Preclinical
AV-412	protein tyrosine kinase inhibitor	EGFR, ERBB2			Tocris, MedChemEx, MedChemEx	96.98	CN1CCN(CC1)C(C)(C)C#Cc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)C=C, CN1CCN(CC1)C(C)(C)C#Cc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)C=C, CN1CCN(CC1)C(C)(C)C#Cc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)C=C	Phase 1
AV-608	tachykinin antagonist	TACR1			MedChemEx, MedChemEx	99.39	FC(F)(F)c1cc(cc(c1)C(F)(F)F)C(=O)N1CC[C@@H](C[C@H]1Cc1ccc(Cl)cc1)NC(=O)c1ccnc2ccccc12, FC(F)(F)c1cc(cc(c1)C(F)(F)F)C(=O)N1CC[C@@H](C[C@H]1Cc1ccc(Cl)cc1)NC(=O)c1ccnc2ccccc12	Phase 2
avacopan	complement inhibitor				MedChemEx	54.12	Cc1ccc(NC(=O)[C@H]2CCCN([C@H]2c2ccc(NC3CCCC3)cc2)C(=O)c2c(C)cccc2F)cc1C(F)(F)F	Phase 2
avadomide	antitumor agent				MedChemEx	95.76	Cc1nc2cccc(N)c2c(=O)n1[C@H]1CCC(=O)NC1=O |&1:13,r|	Phase 2
avagacestat	gamma secretase inhibitor	PSEN1			MedChemEx, MedChemEx, Selleck, Selleck	96.39	NC(=O)[C@@H](CCC(F)(F)F)N(Cc1ccc(cc1F)-c1ncon1)S(=O)(=O)c1ccc(Cl)cc1, NC(=O)[C@@H](CCC(F)(F)F)N(Cc1ccc(cc1F)-c1ncon1)S(=O)(=O)c1ccc(Cl)cc1, NC(=O)[C@@H](CCC(F)(F)F)N(Cc1ccc(cc1F)-c1ncon1)S(=O)(=O)c1ccc(Cl)cc1, NC(=O)[C@@H](CCC(F)(F)F)N(Cc1ccc(cc1F)-c1ncon1)S(=O)(=O)c1ccc(Cl)cc1	Phase 2
avanafil	phosphodiesterase inhibitor	PDE5A	urology	erectile dysfunction	MicroSource, Selleck, Selleck, Selleck	92.35	COc1ccc(CNc2nc(ncc2C(=O)NCc2ncccn2)N2CCC[C@H]2CO)cc1Cl, COc1ccc(CNc2nc(ncc2C(=O)NCc2ncccn2)N2CCC[C@H]2CO)cc1Cl, COc1ccc(CNc2nc(ncc2C(=O)NCc2ncccn2)N2CCC[C@H]2CO)cc1Cl, COc1ccc(CNc2nc(ncc2C(=O)NCc2ncccn2)N2CCC[C@H]2CO)cc1Cl	Launched
avapritinib	KIT inhibitor				MedChemEx	96.7	Cn1cc(cn1)-c1cc2c(ncnn2c1)N1CCN(CC1)c1ncc(cn1)[C@@](C)(N)c1ccc(F)cc1	Launched
avasimibe	ACAT inhibitor	CES1			MedChemEx, Selleck, Selleck, Selleck, Selleck, Selleck	96.76	CC(C)c1cc(C(C)C)c(CC(=O)NS(=O)(=O)Oc2c(cccc2C(C)C)C(C)C)c(c1)C(C)C, CC(C)c1cc(C(C)C)c(CC(=O)NS(=O)(=O)Oc2c(cccc2C(C)C)C(C)C)c(c1)C(C)C, CC(C)c1cc(C(C)C)c(CC(=O)NS(=O)(=O)Oc2c(cccc2C(C)C)C(C)C)c(c1)C(C)C, CC(C)c1cc(C(C)C)c(CC(=O)NS(=O)(=O)Oc2c(cccc2C(C)C)C(C)C)c(c1)C(C)C, CC(C)c1cc(C(C)C)c(CC(=O)NS(=O)(=O)Oc2c(cccc2C(C)C)C(C)C)c(c1)C(C)C, CC(C)c1cc(C(C)C)c(CC(=O)NS(=O)(=O)Oc2c(cccc2C(C)C)C(C)C)c(c1)C(C)C	Phase 3
avatrombopag	thrombopoietin receptor agonist	MPL	hematology	thrombocytopenia	MedChemEx	95.01	OC(=O)C1CCN(CC1)c1ncc(cc1Cl)C(=O)Nc1nc(-c2cc(Cl)cs2)c(s1)N1CCN(CC1)C1CCCCC1	Launched
AVE-0991	angiotensin receptor agonist	MRGPRX1			MedChemEx, MedChemEx	93.56	CCNC(=O)NS(=O)(=O)c1sc(CC(C)C)cc1-c1ccc(Cn2c(C=O)c(OC)nc2-c2ccccc2)cc1, CCNC(=O)NS(=O)(=O)c1sc(CC(C)C)cc1-c1ccc(Cn2c(C=O)c(OC)nc2-c2ccccc2)cc1	Preclinical
AVE-3085	nitric oxide synthase stimulant				MedChemEx	97.28	FC1(F)Oc2ccc(cc2O1)C(=O)NC1Cc2ccccc2C1	Preclinical
AVex-73	sigma receptor agonist				MedChemEx	91.52	CN(C)C[C@H]1CCOC1(c1ccccc1)c1ccccc1 |&1:4,r|	Preclinical
avibactam	beta lactamase inhibitor		infectious disease	intra-abdominal infections, urinary tract infections, pyelonephritis	MedChemEx, MedChemEx, MedChemEx	100	NC(=O)[C@@H]1CC[C@@H]2CN1C(=O)N2OS(O)(=O)=O, NC(=O)[C@@H]1CC[C@@H]2CN1C(=O)N2OS(O)(=O)=O, NC(=O)[C@@H]1CC[C@@H]2CN1C(=O)N2OS(O)(=O)=O	Launched
avitinib	EGFR inhibitor				MedChemEx	91.08	CN1CCN(CC1)c1ccc(Nc2nc(Oc3cccc(NC(=O)C=C)c3)c3cc[nH]c3n2)cc1F	Phase 2
AVL-292	Bruton's tyrosine kinase (BTK) inhibitor	BTK, YES1			MedChemEx, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck	97.44	COCCOc1ccc(Nc2ncc(F)c(Nc3cccc(NC(=O)C=C)c3)n2)cc1, COCCOc1ccc(Nc2ncc(F)c(Nc3cccc(NC(=O)C=C)c3)n2)cc1, COCCOc1ccc(Nc2ncc(F)c(Nc3cccc(NC(=O)C=C)c3)n2)cc1, COCCOc1ccc(Nc2ncc(F)c(Nc3cccc(NC(=O)C=C)c3)n2)cc1, COCCOc1ccc(Nc2ncc(F)c(Nc3cccc(NC(=O)C=C)c3)n2)cc1, COCCOc1ccc(Nc2ncc(F)c(Nc3cccc(NC(=O)C=C)c3)n2)cc1, COCCOc1ccc(Nc2ncc(F)c(Nc3cccc(NC(=O)C=C)c3)n2)cc1	Phase 2
AVN-492	serotonin receptor antagonist				MedChemEx, MedChemEx	95.85	CNc1nn2c(C)c(N(C)C)c(C)nc2c1S(=O)(=O)c1ccccc1, CNc1nn2c(C)c(N(C)C)c(C)nc2c1S(=O)(=O)c1ccccc1	Preclinical
AVN-944	inosine monophosphate dehydrogenase inhibitor	IMPDH1, IMPDH2			MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx	99.41	CC[C@H](CC#N)OC(=O)N[C@@H](C)c1cccc(NC(=O)Nc2ccc(-c3cnco3)c(OC)c2)c1, CC[C@H](CC#N)OC(=O)N[C@@H](C)c1cccc(NC(=O)Nc2ccc(-c3cnco3)c(OC)c2)c1, CC[C@H](CC#N)OC(=O)N[C@@H](C)c1cccc(NC(=O)Nc2ccc(-c3cnco3)c(OC)c2)c1, CC[C@H](CC#N)OC(=O)N[C@@H](C)c1cccc(NC(=O)Nc2ccc(-c3cnco3)c(OC)c2)c1, CC[C@H](CC#N)OC(=O)N[C@@H](C)c1cccc(NC(=O)Nc2ccc(-c3cnco3)c(OC)c2)c1, CC[C@H](CC#N)OC(=O)N[C@@H](C)c1cccc(NC(=O)Nc2ccc(-c3cnco3)c(OC)c2)c1	Phase 2
avobenzone	topical sunscreen agent		dermatology	cosmetic, sunscreen lotion	MedChemEx, MicroSource, Selleck	90.89	COc1ccc(cc1)C(=O)C=C(O)c1ccc(cc1)C(C)(C)C, COc1ccc(cc1)C(=O)C=C(O)c1ccc(cc1)C(C)(C)C, COc1ccc(cc1)C(=O)C=C(O)c1ccc(cc1)C(C)(C)C	Launched
avoralstat	kallikrein inhibitor				MedChemEx	88.22	COc1cc(c(cc1C=C)C(=O)Nc1ccc(cc1)C(N)=N)-c1ccc(nc1C(O)=O)C(=O)NCC1CC1	Phase 3
avridine	immunostimulant				Sigma	0	CCCCCCCCCCCCCCCCCCN(CCCCCCCCCCCCCCCCCC)CCCN(CCO)CCO	Preclinical
AX-024	cytokine production inhibitor				MedChemEx	94.57	COc1ccc2OCC(CN3CCCC3)=C(c3ccc(F)cc3)c2c1 |t:15|	Preclinical
axitinib	PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	CSF1, FLT1, FLT4, KDR, PLK4	oncology	renal cell carcinoma (RCC)	Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Tocris, Selleck, Selleck, Adooq	96.08	CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)[nH]nc2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)[nH]nc2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)[nH]nc2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)[nH]nc2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)[nH]nc2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)[nH]nc2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)[nH]nc2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)[nH]nc2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)[nH]nc2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)[nH]nc2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)[nH]nc2c1	Launched
AY-9944	hedgehog pathway modulator				Tocris, Tocris, Tocris, Tocris	94.24	Clc1ccccc1CNC[C@H]1CC[C@H](CNCc2ccccc2Cl)CC1 |r|, Clc1ccccc1CNC[C@H]1CC[C@H](CNCc2ccccc2Cl)CC1 |r|, Clc1ccccc1CNC[C@H]1CC[C@H](CNCc2ccccc2Cl)CC1 |r|, Clc1ccccc1CNC[C@H]1CC[C@H](CNCc2ccccc2Cl)CC1 |r|	Preclinical
AZ-10417808	caspase inhibitor	CASP3			Tocris, Tocris	97.36	[O-][N+](=O)c1cc(C(=O)NCC=C)c2[nH]c(Nc3ccc(Cl)c(Cl)c3)nc(=O)c2c1, [O-][N+](=O)c1cc(C(=O)NCC=C)c2[nH]c(Nc3ccc(Cl)c(Cl)c3)nc(=O)c2c1	Preclinical
AZ-10606120	purinergic receptor antagonist	P2RX7			Tocris, Tocris	95.84	OCCNCCNc1ccc2c(NC(=O)CC34CC5CC(CC(C5)C3)C4)cccc2n1, OCCNCCNc1ccc2c(NC(=O)CC34CC5CC(CC(C5)C3)C4)cccc2n1	Preclinical
AZ-12080282	hedgehog pathway inhibitor	DHH			Tocris, Tocris	97.72	Cc1ccc(cc1NC(=O)c1ccc(OCc2ccccn2)cc1)-c1ncc[nH]1, Cc1ccc(cc1NC(=O)c1ccc(OCc2ccccn2)cc1)-c1ncc[nH]1	Preclinical
AZ-628	RAF inhibitor	BRAF, RAF1			Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Tocris, Selleck, Selleck, Selleck, Selleck, Selleck	98.18	Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1	Preclinical
AZ-7371	antibacterial 				MedChemEx	99.11	COc1ncnc(Cn2cc(C(=O)NCCO)c3ncc(C)cc23)c1C	Preclinical
azacitidine	DNA methyltransferase inhibitor	DNMT1, DNMT3A	hematologic malignancy, hematology	myelodysplastic diseases (MDS), anemia, chronic myelomonocytic leukemia (CMMoL)	MicroSource, MicroSource, MicroSource, MicroSource, MicroSource, MicroSource, Tocris, Selleck, Selleck, Selleck, Selleck	100	Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1	Launched
azacyclonol	histamine receptor antagonist	HRH1			MedChemEx, Selleck, Selleck	93.2	OC(C1CCNCC1)(c1ccccc1)c1ccccc1, OC(C1CCNCC1)(c1ccccc1)c1ccccc1, OC(C1CCNCC1)(c1ccccc1)c1ccccc1	Preclinical
azaguanine-8	purine antagonist	PNP			Selleck, Selleck	84.14	Nc1nc2nn[nH]c2c(=O)[nH]1, Nc1nc2nn[nH]c2c(=O)[nH]1	Preclinical
azalomycin-B	bacterial 50S ribosomal subunit inhibitor				Selleck	81.4	CC[C@@H]1[C@@H](C)O[C@](O)(C[C@H]1O[C@H]1C[C@H](O)[C@H](O)[C@H](C)O1)[C@@H](C)[C@H](O)[C@H](C)[C@H]1OC(=O)\C=C\C=C\[C@H](C)[C@H](OC(=O)\C=C\C=C\[C@@H]1C)[C@@H](C)[C@@H](O)[C@H](C)[C@@]1(O)C[C@@H](O[C@H]2C[C@H](O)[C@H](O)[C@H](C)O2)[C@H](CC)[C@@H](C)O1 |t:32,34,42,44|	Preclinical
azaperone	dopamine receptor antagonist	DRD2, DRD3	neurology/psychiatry	sedative	MedChemEx, MicroSource, Selleck, Selleck	98.29	Fc1ccc(cc1)C(=O)CCCN1CCN(CC1)c1ccccn1, Fc1ccc(cc1)C(=O)CCCN1CCN(CC1)c1ccccn1, Fc1ccc(cc1)C(=O)CCCN1CCN(CC1)c1ccccn1, Fc1ccc(cc1)C(=O)CCCN1CCN(CC1)c1ccccn1	Launched
azapropazone	cyclooxygenase inhibitor	PTGS2			Broad Institute, Prestwick	98.31	CCC[C@H]1C(=O)N2N(C1=O)c1cc(C)ccc1N=C2N(C)C |r,c:19|, CCC[C@H]1C(=O)N2N(C1=O)c1cc(C)ccc1N=C2N(C)C |r,c:19|	Withdrawn
azaserine	purine antagonist				MedChemEx	100	N[C@@H](COC(=O)C[N+]#N)C(O)=O	Preclinical
azasetron	serotonin receptor antagonist	HTR3A, HTR3B	infectious disease	genitial herpes	Tocris, Selleck	98.4	CN1C(=O)COc2c1cc(Cl)cc2C(=O)N[C@H]1CN2CCC1CC2 |&1:16|, CN1C(=O)COc2c1cc(Cl)cc2C(=O)N[C@H]1CN2CCC1CC2 |&1:16|	Launched
azatadine	histamine receptor antagonist	HRH1	allergy	allergic rhinitis	MicroSource, Selleck, MedChemEx	95.55	CN1CCC(CC1)=C1c2ccccc2CCc2cccnc12, CN1CCC(CC1)=C1c2ccccc2CCc2cccnc12, CN1CCC(CC1)=C1c2ccccc2CCc2cccnc12	Launched
azathioprine	dehydrogenase inhibitor	HPRT1, IMPDH1, PPAT	transplant, rheumatology	renal homotransplantation, rheumatoid arthritis	Tocris, MicroSource, Selleck, Selleck, Selleck, Selleck, Selleck	98.54	Cn1cnc(c1Sc1ncnc2nc[nH]c12)[N+]([O-])=O, Cn1cnc(c1Sc1ncnc2nc[nH]c12)[N+]([O-])=O, Cn1cnc(c1Sc1ncnc2nc[nH]c12)[N+]([O-])=O, Cn1cnc(c1Sc1ncnc2nc[nH]c12)[N+]([O-])=O, Cn1cnc(c1Sc1ncnc2nc[nH]c12)[N+]([O-])=O, Cn1cnc(c1Sc1ncnc2nc[nH]c12)[N+]([O-])=O, Cn1cnc(c1Sc1ncnc2nc[nH]c12)[N+]([O-])=O	Launched
AZD0156	ATM kinase inhibitor				MedChemEx	91.98	CN(C)CCCOc1ccc(cn1)-c1ccc2ncc3n(C)c(=O)n(C4CCOCC4)c3c2c1	Phase 1
AZD1080	glycogen synthase kinase inhibitor	GSK3A, GSK3B			MedChemEx, MedChemEx, Selleck, Selleck, Selleck	71.86	O=C1Nc2ccc(cc2C1c1ccc(CN2CCOCC2)cn1)C#N, O=C1Nc2ccc(cc2C1c1ccc(CN2CCOCC2)cn1)C#N, O=C1Nc2ccc(cc2C1c1ccc(CN2CCOCC2)cn1)C#N, O=C1Nc2ccc(cc2C1c1ccc(CN2CCOCC2)cn1)C#N, O=C1Nc2ccc(cc2C1c1ccc(CN2CCOCC2)cn1)C#N	Phase 1
AZD1208	Pim kinase inhibitor	PIM1, PIM2, PIM3			Tocris, MedChemEx, MedChemEx, MedChemEx, MedChemEx	96.23	N[C@@H]1CCCN(C1)c1c(\C=C2/SC(=O)NC2=O)cccc1-c1ccccc1, N[C@@H]1CCCN(C1)c1c(\C=C2/SC(=O)NC2=O)cccc1-c1ccccc1, N[C@@H]1CCCN(C1)c1c(\C=C2/SC(=O)NC2=O)cccc1-c1ccccc1, N[C@@H]1CCCN(C1)c1c(\C=C2/SC(=O)NC2=O)cccc1-c1ccccc1, N[C@@H]1CCCN(C1)c1c(\C=C2/SC(=O)NC2=O)cccc1-c1ccccc1	Phase 1
AZD1283	purinergic receptor antagonist	P2RY12			Tocris, MedChemEx, MedChemEx	99.81	CCOC(=O)c1cc(C#N)c(nc1C)N1CCC(CC1)C(=O)NS(=O)(=O)Cc1ccccc1, CCOC(=O)c1cc(C#N)c(nc1C)N1CCC(CC1)C(=O)NS(=O)(=O)Cc1ccccc1, CCOC(=O)c1cc(C#N)c(nc1C)N1CCC(CC1)C(=O)NS(=O)(=O)Cc1ccccc1	Preclinical
AZD1390	ATM kinase inhibitor				MedChemEx, MedChemEx	95.58	CC(C)n1c2c(cnc3cc(F)c(cc23)-c2ccc(OCCCN3CCCCC3)nc2)n(C)c1=O, CC(C)n1c2c(cnc3cc(F)c(cc23)-c2ccc(OCCCN3CCCCC3)nc2)n(C)c1=O	Phase 1
AZD1446	acetylcholine receptor agonist	CHRNA4, CHRNB2			Key	81.54	Clc1ccc(o1)C(=O)N1C[C@H]2CNC[C@@H]2C1 |&1:10,&2:14,r|	Phase 2
AZD1480	JAK inhibitor	JAK1, JAK2, JAK3			Tocris, MedChemEx, MedChemEx	98.38	C[C@H](Nc1ncc(Cl)c(Nc2cc(C)n[nH]2)n1)c1ncc(F)cn1, C[C@H](Nc1ncc(Cl)c(Nc2cc(C)n[nH]2)n1)c1ncc(F)cn1, C[C@H](Nc1ncc(Cl)c(Nc2cc(C)n[nH]2)n1)c1ncc(F)cn1	Phase 1
AZD1981	CRTH receptor antagonist	PTGDR2			Selleck, Selleck, MedChemEx	96.49	CC(=O)Nc1cccc2n(CC(O)=O)c(C)c(Sc3ccc(Cl)cc3)c12, CC(=O)Nc1cccc2n(CC(O)=O)c(C)c(Sc3ccc(Cl)cc3)c12, CC(=O)Nc1cccc2n(CC(O)=O)c(C)c(Sc3ccc(Cl)cc3)c12	Phase 2
AZD2014	mTOR inhibitor	MTOR			MedChemEx, Selleck, Selleck, Selleck	95.74	CNC(=O)c1cccc(c1)-c1ccc2c(nc(nc2n1)N1CCOC[C@@H]1C)N1CCOC[C@@H]1C, CNC(=O)c1cccc(c1)-c1ccc2c(nc(nc2n1)N1CCOC[C@@H]1C)N1CCOC[C@@H]1C, CNC(=O)c1cccc(c1)-c1ccc2c(nc(nc2n1)N1CCOC[C@@H]1C)N1CCOC[C@@H]1C, CNC(=O)c1cccc(c1)-c1ccc2c(nc(nc2n1)N1CCOC[C@@H]1C)N1CCOC[C@@H]1C	Phase 2
AZD2461	PARP inhibitor				Tocris, Selleck, Selleck, Selleck	98.71	COC1CCN(CC1)C(=O)c1cc(Cc2n[nH]c(=O)c3ccccc23)ccc1F, COC1CCN(CC1)C(=O)c1cc(Cc2n[nH]c(=O)c3ccccc23)ccc1F, COC1CCN(CC1)C(=O)c1cc(Cc2n[nH]c(=O)c3ccccc23)ccc1F, COC1CCN(CC1)C(=O)c1cc(Cc2n[nH]c(=O)c3ccccc23)ccc1F	Phase 1
AZD2858	glycogen synthase kinase inhibitor	GSK3B			MedChemEx, MedChemEx, Selleck, Selleck, Selleck	94.49	CN1CCN(CC1)S(=O)(=O)c1ccc(cc1)-c1cnc(N)c(n1)C(=O)Nc1cccnc1, CN1CCN(CC1)S(=O)(=O)c1ccc(cc1)-c1cnc(N)c(n1)C(=O)Nc1cccnc1, CN1CCN(CC1)S(=O)(=O)c1ccc(cc1)-c1cnc(N)c(n1)C(=O)Nc1cccnc1, CN1CCN(CC1)S(=O)(=O)c1ccc(cc1)-c1cnc(N)c(n1)C(=O)Nc1cccnc1, CN1CCN(CC1)S(=O)(=O)c1ccc(cc1)-c1cnc(N)c(n1)C(=O)Nc1cccnc1	Preclinical
AZD3264	IKK inhibitor	IKBKB			MedChemEx, MedChemEx	90.75	Cc1noc(C)c1-c1ccc(-c2cc(C(N)=O)c(NC(N)=O)s2)c(O[C@H]2CCNC2)c1, Cc1noc(C)c1-c1ccc(-c2cc(C(N)=O)c(NC(N)=O)s2)c(O[C@H]2CCNC2)c1	Preclinical
AZD3463	ALK tyrosine kinase receptor inhibitor, insulin growth factor receptor inhibitor	ALK, IGF1R			Selleck, Selleck, MedChemEx, MedChemEx, Selleck, Selleck, Selleck, Selleck, Selleck	94.66	COc1cc(ccc1Nc1ncc(Cl)c(n1)-c1c[nH]c2ccccc12)N1CCC(N)CC1, COc1cc(ccc1Nc1ncc(Cl)c(n1)-c1c[nH]c2ccccc12)N1CCC(N)CC1, COc1cc(ccc1Nc1ncc(Cl)c(n1)-c1c[nH]c2ccccc12)N1CCC(N)CC1, COc1cc(ccc1Nc1ncc(Cl)c(n1)-c1c[nH]c2ccccc12)N1CCC(N)CC1, COc1cc(ccc1Nc1ncc(Cl)c(n1)-c1c[nH]c2ccccc12)N1CCC(N)CC1, COc1cc(ccc1Nc1ncc(Cl)c(n1)-c1c[nH]c2ccccc12)N1CCC(N)CC1, COc1cc(ccc1Nc1ncc(Cl)c(n1)-c1c[nH]c2ccccc12)N1CCC(N)CC1, COc1cc(ccc1Nc1ncc(Cl)c(n1)-c1c[nH]c2ccccc12)N1CCC(N)CC1, COc1cc(ccc1Nc1ncc(Cl)c(n1)-c1c[nH]c2ccccc12)N1CCC(N)CC1	Preclinical
AZD3514	androgen receptor modulator	AR			Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, MedChemEx, MedChemEx	97.21	CC(=O)N1CCN(CCOc2ccc(cc2)C2CCN(CC2)C2=Nn3c(CC2)nnc3C(F)(F)F)CC1 |t:24|, CC(=O)N1CCN(CCOc2ccc(cc2)C2CCN(CC2)C2=Nn3c(CC2)nnc3C(F)(F)F)CC1 |t:24|, CC(=O)N1CCN(CCOc2ccc(cc2)C2CCN(CC2)C2=Nn3c(CC2)nnc3C(F)(F)F)CC1 |t:24|, CC(=O)N1CCN(CCOc2ccc(cc2)C2CCN(CC2)C2=Nn3c(CC2)nnc3C(F)(F)F)CC1 |t:24|, CC(=O)N1CCN(CCOc2ccc(cc2)C2CCN(CC2)C2=Nn3c(CC2)nnc3C(F)(F)F)CC1 |t:24|, CC(=O)N1CCN(CCOc2ccc(cc2)C2CCN(CC2)C2=Nn3c(CC2)nnc3C(F)(F)F)CC1 |t:24|, CC(=O)N1CCN(CCOc2ccc(cc2)C2CCN(CC2)C2=Nn3c(CC2)nnc3C(F)(F)F)CC1 |t:24|, CC(=O)N1CCN(CCOc2ccc(cc2)C2CCN(CC2)C2=Nn3c(CC2)nnc3C(F)(F)F)CC1 |t:24|	Phase 1
AZD3759	EGFR inhibitor	EGFR			MedChemEx	98.14	COc1cc2ncnc(Nc3cccc(Cl)c3F)c2cc1OC(=O)N1CCN(C)C[C@H]1C	Phase 2/Phase 3
AZD3839	beta-secretase inhibitor	BACE1			MedChemEx, Selleck	98.3	NC1=N[C@@](c2cccc(F)c12)(c1cccc(c1)-c1cncnc1)c1ccnc(c1)C(F)F |t:1|, NC1=N[C@@](c2cccc(F)c12)(c1cccc(c1)-c1cncnc1)c1ccnc(c1)C(F)F |t:1|	Phase 1
AZD3965	monocarboxylate transporter inhibitor	SLC16A1			MedChemEx	97.59	CC(C)n1c2sc(Cc3c(C)[nH]nc3C(F)(F)F)c(C(=O)N3C[C@](C)(O)CO3)c2c(=O)n(C)c1=O	Phase 1
AZD3988	diacylglycerol kinase inhibitor	DGAT1			Tocris, Tocris	97.67	OC(=O)C[C@H]1CC[C@@H](CC1)c1ccc(NC(=O)c2nnc(Nc3ccc(F)c(F)c3)o2)cc1 |r|, OC(=O)C[C@H]1CC[C@@H](CC1)c1ccc(NC(=O)c2nnc(Nc3ccc(F)c(F)c3)o2)cc1 |r|	Preclinical
AZD4282	glutamate receptor antagonist	AGXT, AGXT2, ALAS1, ALAS2, BAAT, GARS, GATM, GCAT, GCSH, GLDC, GLRA1, GLRA2, GLRA3, GLRB, GLYAT, GLYATL1, GLYATL2, GNMT, GPR18, GPRC6A, GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, GRIN3B, GSS, PIPOX, SHMT1, SHMT2, SLC32A1, SLC36A1, SLC6A5, SLC6A9			Enzo	0	NCC(O)=O	Phase 1
AZD4547	FGFR inhibitor	FGFR1, FGFR2, FGFR3, FGFR4, IGF1R, KDR			Selleck, Selleck	94.33	COc1cc(CCc2cc(NC(=O)c3ccc(cc3)N3C[C@H](C)N[C@H](C)C3)[nH]n2)cc(OC)c1, COc1cc(CCc2cc(NC(=O)c3ccc(cc3)N3C[C@H](C)N[C@H](C)C3)[nH]n2)cc(OC)c1	Phase 2/Phase 3
AZD4573	CDK9 inhibitor				MedChemEx	95.42	CC(=O)N[C@@H]1CCC[C@@H](C1)C(=O)Nc1cc(-c2cnn3CC(C)(C)Cc23)c(Cl)cn1	Phase 1
AZD4635	adenosine receptor antagonist				MedChemEx	96.52	Cc1cc(cc(Cl)n1)-c1nnc(N)nc1-c1ccc(F)cc1	Phase 1/Phase 2
AZD5069	CC chemokine receptor antagonist	CXCR2			MedChemEx	97.69	C[C@@H](Oc1cc(NS(=O)(=O)N2CCC2)nc(SCc2cccc(F)c2F)n1)[C@@H](O)CO	Phase 2
AZD5153	bromodomain inhibitor				MedChemEx	92.79	[H][C@]1(C)N(CCOc2ccc(cc2)C2CCN(CC2)c2ccc3nnc(OC)n3n2)CCN(C)C1=O |r|	Phase 1
AZD5363	AKT inhibitor	AKT1, AKT2, AKT3			Selleck, Selleck, MedChemEx	97.69	NC1(CCN(CC1)c1ncnc2[nH]ccc12)C(=O)N[C@@H](CCO)c1ccc(Cl)cc1, NC1(CCN(CC1)c1ncnc2[nH]ccc12)C(=O)N[C@@H](CCO)c1ccc(Cl)cc1, NC1(CCN(CC1)c1ncnc2[nH]ccc12)C(=O)N[C@@H](CCO)c1ccc(Cl)cc1	Phase 3
AZD5438	CDK inhibitor	KCNH2			Selleck, Tocris, Tocris, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck	97.1	CC(C)n1c(C)ncc1-c1ccnc(Nc2ccc(cc2)S(C)(=O)=O)n1, CC(C)n1c(C)ncc1-c1ccnc(Nc2ccc(cc2)S(C)(=O)=O)n1, CC(C)n1c(C)ncc1-c1ccnc(Nc2ccc(cc2)S(C)(=O)=O)n1, CC(C)n1c(C)ncc1-c1ccnc(Nc2ccc(cc2)S(C)(=O)=O)n1, CC(C)n1c(C)ncc1-c1ccnc(Nc2ccc(cc2)S(C)(=O)=O)n1, CC(C)n1c(C)ncc1-c1ccnc(Nc2ccc(cc2)S(C)(=O)=O)n1, CC(C)n1c(C)ncc1-c1ccnc(Nc2ccc(cc2)S(C)(=O)=O)n1, CC(C)n1c(C)ncc1-c1ccnc(Nc2ccc(cc2)S(C)(=O)=O)n1, CC(C)n1c(C)ncc1-c1ccnc(Nc2ccc(cc2)S(C)(=O)=O)n1	Phase 1
AZD5582	XIAP inhibitor	BIRC2, BIRC3, XIAP			MedChemEx, MedChemEx, MedChemEx, MedChemEx	93.19	CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1C(=O)N[C@@H]1[C@@H](Cc2ccccc12)OCC#CC#CCO[C@@H]1Cc2ccccc2[C@@H]1NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H](C)NC)C1CCCCC1, CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1C(=O)N[C@@H]1[C@@H](Cc2ccccc12)OCC#CC#CCO[C@@H]1Cc2ccccc2[C@@H]1NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H](C)NC)C1CCCCC1, CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1C(=O)N[C@@H]1[C@@H](Cc2ccccc12)OCC#CC#CCO[C@@H]1Cc2ccccc2[C@@H]1NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H](C)NC)C1CCCCC1, CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1C(=O)N[C@@H]1[C@@H](Cc2ccccc12)OCC#CC#CCO[C@@H]1Cc2ccccc2[C@@H]1NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H](C)NC)C1CCCCC1	Preclinical
AZD5991	MCL1 inhibitor				MedChemEx	97.34	Cc1c-2c(CSCc3cc(CSc4cc(OCCCc5c(C(O)=O)n(C)c6c-2c(Cl)ccc56)c2ccccc2c4)n(C)n3)nn1C	Phase 1
AZD6482	PI3K inhibitor	PIK3CA, PIK3CB, PIK3CD, PIK3CG			Tocris, Tocris, Tocris, Tocris, Selleck, Selleck, Selleck	99.6	C[C@@H](Nc1ccccc1C(O)=O)c1cc(C)cn2c1nc(cc2=O)N1CCOCC1, C[C@@H](Nc1ccccc1C(O)=O)c1cc(C)cn2c1nc(cc2=O)N1CCOCC1, C[C@@H](Nc1ccccc1C(O)=O)c1cc(C)cn2c1nc(cc2=O)N1CCOCC1, C[C@@H](Nc1ccccc1C(O)=O)c1cc(C)cn2c1nc(cc2=O)N1CCOCC1, C[C@@H](Nc1ccccc1C(O)=O)c1cc(C)cn2c1nc(cc2=O)N1CCOCC1, C[C@@H](Nc1ccccc1C(O)=O)c1cc(C)cn2c1nc(cc2=O)N1CCOCC1, C[C@@H](Nc1ccccc1C(O)=O)c1cc(C)cn2c1nc(cc2=O)N1CCOCC1	Phase 1
AZD6738	ATR kinase inhibitor	ATR			Selleck	97.61	C[C@@H]1COCCN1c1cc(nc(n1)-c1ccnc2[nH]ccc12)C1(CC1)[S@@](C)(=N)=O |a:1,&1:25|	Phase 2
AZD6765	glutamate receptor antagonist	GRIN1			Enamine, Enamine	84.3	N[C@@H](Cc1ccccn1)c1ccccc1 |&1:1,r|, N[C@@H](Cc1ccccn1)c1ccccc1 |&1:1,r|	Phase 2
AZD7545	pyruvate dehydrogenase kinase inhibitor	PDK1			MedChemEx	96.52	CN(C)C(=O)c1ccc(cc1)S(=O)(=O)c1ccc(NC(=O)[C@@](C)(O)C(F)(F)F)c(Cl)c1	Phase 1
AZD7594	glucocorticoid receptor modulator				MedChemEx	86.17	C[C@H](NC(=O)C(C)(F)F)[C@H](Oc1ccc2n(ncc2c1)-c1cccc(c1)C(=O)N[C@@H]1CCOC1)c1ccc2OCCOc2c1	Phase 2
AZD7687	diacylglycerol O acyltransferase inhibitor	DGAT1			MedChemEx, MedChemEx	99.55	Cc1nc(C)c(nc1C(N)=O)-c1ccc(cc1)[C@H]1CC[C@H](CC(O)=O)CC1 |r|, Cc1nc(C)c(nc1C(N)=O)-c1ccc(cc1)[C@H]1CC[C@H](CC(O)=O)CC1 |r|	Phase 1
AZD7762	CHK inhibitor	CHEK1, CHEK2			Tocris, Selleck, Selleck, Selleck, Tocris, Tocris, Tocris, Selleck, Selleck	94.21	NC(=O)Nc1cc(sc1C(=O)N[C@H]1CCCNC1)-c1cccc(F)c1, NC(=O)Nc1cc(sc1C(=O)N[C@H]1CCCNC1)-c1cccc(F)c1, NC(=O)Nc1cc(sc1C(=O)N[C@H]1CCCNC1)-c1cccc(F)c1, NC(=O)Nc1cc(sc1C(=O)N[C@H]1CCCNC1)-c1cccc(F)c1, NC(=O)Nc1cc(sc1C(=O)N[C@H]1CCCNC1)-c1cccc(F)c1, NC(=O)Nc1cc(sc1C(=O)N[C@H]1CCCNC1)-c1cccc(F)c1, NC(=O)Nc1cc(sc1C(=O)N[C@H]1CCCNC1)-c1cccc(F)c1, NC(=O)Nc1cc(sc1C(=O)N[C@H]1CCCNC1)-c1cccc(F)c1, NC(=O)Nc1cc(sc1C(=O)N[C@H]1CCCNC1)-c1cccc(F)c1	Phase 1
AZD7986	dipeptidyl peptidase inhibitor				MedChemEx	95.46	Cn1c2cc(ccc2oc1=O)-c1ccc(C[C@H](NC(=O)[C@@H]2CNCCCO2)C#N)cc1	Phase 1
AZD8055	mTOR inhibitor	MTOR			Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Focus	98.72	COc1ccc(cc1CO)-c1ccc2c(nc(nc2n1)N1CCOC[C@@H]1C)N1CCOC[C@@H]1C, COc1ccc(cc1CO)-c1ccc2c(nc(nc2n1)N1CCOC[C@@H]1C)N1CCOC[C@@H]1C, COc1ccc(cc1CO)-c1ccc2c(nc(nc2n1)N1CCOC[C@@H]1C)N1CCOC[C@@H]1C, COc1ccc(cc1CO)-c1ccc2c(nc(nc2n1)N1CCOC[C@@H]1C)N1CCOC[C@@H]1C, COc1ccc(cc1CO)-c1ccc2c(nc(nc2n1)N1CCOC[C@@H]1C)N1CCOC[C@@H]1C, COc1ccc(cc1CO)-c1ccc2c(nc(nc2n1)N1CCOC[C@@H]1C)N1CCOC[C@@H]1C, COc1ccc(cc1CO)-c1ccc2c(nc(nc2n1)N1CCOC[C@@H]1C)N1CCOC[C@@H]1C, COc1ccc(cc1CO)-c1ccc2c(nc(nc2n1)N1CCOC[C@@H]1C)N1CCOC[C@@H]1C	Phase 1
AZD8186	PI3K inhibitor	PIK3CB, PIK3CD			Adooq, Adooq, Adooq, Selleck	99.82	C[C@@H](Nc1cc(F)cc(F)c1)c1cc(cc2c1oc(cc2=O)N1CCOCC1)C(=O)N(C)C, C[C@@H](Nc1cc(F)cc(F)c1)c1cc(cc2c1oc(cc2=O)N1CCOCC1)C(=O)N(C)C, C[C@@H](Nc1cc(F)cc(F)c1)c1cc(cc2c1oc(cc2=O)N1CCOCC1)C(=O)N(C)C, C[C@@H](Nc1cc(F)cc(F)c1)c1cc(cc2c1oc(cc2=O)N1CCOCC1)C(=O)N(C)C	Phase 1
AZD8330	MEK inhibitor	MAP3K1			Selleck, Selleck, Selleck, Selleck, Selleck	97.4	Cc1cc(C(=O)NOCCO)c(Nc2ccc(I)cc2F)n(C)c1=O, Cc1cc(C(=O)NOCCO)c(Nc2ccc(I)cc2F)n(C)c1=O, Cc1cc(C(=O)NOCCO)c(Nc2ccc(I)cc2F)n(C)c1=O, Cc1cc(C(=O)NOCCO)c(Nc2ccc(I)cc2F)n(C)c1=O, Cc1cc(C(=O)NOCCO)c(Nc2ccc(I)cc2F)n(C)c1=O	Phase 1
AZD8797	CC chemokine receptor antagonist				MedChemEx	94.44	CC(C)C[C@H](CO)Nc1nc(S[C@@H](C)c2ccccc2)nc2nc(N)sc12	Preclinical
AZD8835	PI3K inhibitor	PIK3CA, PIK3CD			MedChemEx, MedChemEx, MedChemEx	97.11	CCn1nc(nc1-c1cnc(N)c(n1)-c1nnc(o1)C(C)(C)C)C1CCN(CC1)C(=O)CCO, CCn1nc(nc1-c1cnc(N)c(n1)-c1nnc(o1)C(C)(C)C)C1CCN(CC1)C(=O)CCO, CCn1nc(nc1-c1cnc(N)c(n1)-c1nnc(o1)C(C)(C)C)C1CCN(CC1)C(=O)CCO	Phase 1
AZD8931	EGFR inhibitor	EGFR, ERBB2, ERBB3			MedChemEx, MedChemEx, Selleck, Selleck, Selleck	99.3	CNC(=O)CN1CCC(CC1)Oc1cc2c(Nc3cccc(Cl)c3F)ncnc2cc1OC, CNC(=O)CN1CCC(CC1)Oc1cc2c(Nc3cccc(Cl)c3F)ncnc2cc1OC, CNC(=O)CN1CCC(CC1)Oc1cc2c(Nc3cccc(Cl)c3F)ncnc2cc1OC, CNC(=O)CN1CCC(CC1)Oc1cc2c(Nc3cccc(Cl)c3F)ncnc2cc1OC, CNC(=O)CN1CCC(CC1)Oc1cc2c(Nc3cccc(Cl)c3F)ncnc2cc1OC	Phase 2
AZD9056	purinergic receptor antagonist				MedChemEx	95.95	OCCCNCCCc1ccc(Cl)c(c1)C(=O)NCC12CC3CC(CC(C3)C1)C2	Phase 2
AZD9272	glutamate receptor antagonist	GRM5			Tocris, Tocris, Tocris	97.51	Fc1ccc(nc1)-c1noc(n1)-c1cc(F)cc(c1)C#N, Fc1ccc(nc1)-c1noc(n1)-c1cc(F)cc(c1)C#N, Fc1ccc(nc1)-c1noc(n1)-c1cc(F)cc(c1)C#N	Preclinical
AZD9496	estrogen receptor agonist	ESR1			MedChemEx, MedChemEx, MedChemEx	97.14	C[C@@H]1Cc2c([nH]c3ccccc23)[C@H](N1CC(C)(C)F)c1c(F)cc(\C=C\C(O)=O)cc1F, C[C@@H]1Cc2c([nH]c3ccccc23)[C@H](N1CC(C)(C)F)c1c(F)cc(\C=C\C(O)=O)cc1F, C[C@@H]1Cc2c([nH]c3ccccc23)[C@H](N1CC(C)(C)F)c1c(F)cc(\C=C\C(O)=O)cc1F	Phase 1
AZD9668	elastase inhibitor	ELANE			MedChemEx, MedChemEx, MedChemEx	98.48	Cc1c(cc(C(=O)NCc2ccc(cn2)S(C)(=O)=O)c(=O)n1-c1cccc(c1)C(F)(F)F)-c1ccnn1C, Cc1c(cc(C(=O)NCc2ccc(cn2)S(C)(=O)=O)c(=O)n1-c1cccc(c1)C(F)(F)F)-c1ccnn1C, Cc1c(cc(C(=O)NCc2ccc(cn2)S(C)(=O)=O)c(=O)n1-c1cccc(c1)C(F)(F)F)-c1ccnn1C	Phase 2
azelaic-acid	tyrosinase inhibitor	AKR1D1, SRD5A2, TYR	dermatology	rosacea	MicroSource, MicroSource	97.8	OC(=O)CCCCCCCC(O)=O, OC(=O)CCCCCCCC(O)=O	Launched
azelastine	histamine receptor antagonist	HRH1	ophthalmology	conjunctivitis	MicroSource, Selleck, MedChemEx, MedChemEx	98	CN1CCC[C@@H](CC1)n1nc(Cc2ccc(Cl)cc2)c2ccccc2c1=O |&1:5|, CN1CCC[C@@H](CC1)n1nc(Cc2ccc(Cl)cc2)c2ccccc2c1=O |&1:5|, CN1CCC[C@@H](CC1)n1nc(Cc2ccc(Cl)cc2)c2ccccc2c1=O |&1:5|, CN1CCC[C@@H](CC1)n1nc(Cc2ccc(Cl)cc2)c2ccccc2c1=O |&1:5|	Launched
azeliragon	RAGE receptor antagonist	AGER			MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx	90.27	CCCCc1nc(cn1-c1ccc(Oc2ccc(Cl)cc2)cc1)-c1ccc(OCCCN(CC)CC)cc1, CCCCc1nc(cn1-c1ccc(Oc2ccc(Cl)cc2)cc1)-c1ccc(OCCCN(CC)CC)cc1, CCCCc1nc(cn1-c1ccc(Oc2ccc(Cl)cc2)cc1)-c1ccc(OCCCN(CC)CC)cc1, CCCCc1nc(cn1-c1ccc(Oc2ccc(Cl)cc2)cc1)-c1ccc(OCCCN(CC)CC)cc1, CCCCc1nc(cn1-c1ccc(Oc2ccc(Cl)cc2)cc1)-c1ccc(OCCCN(CC)CC)cc1	Phase 3
azelnidipine	calcium channel blocker	CACNA1C	cardiology	hypertension	MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx, Selleck, Selleck	97.13	CC(C)OC(=O)C1=C(C)NC(N)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC1CN(C1)C(c1ccccc1)c1ccccc1 |r,c:6,11|, CC(C)OC(=O)C1=C(C)NC(N)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC1CN(C1)C(c1ccccc1)c1ccccc1 |r,c:6,11|, CC(C)OC(=O)C1=C(C)NC(N)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC1CN(C1)C(c1ccccc1)c1ccccc1 |r,c:6,11|, CC(C)OC(=O)C1=C(C)NC(N)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC1CN(C1)C(c1ccccc1)c1ccccc1 |r,c:6,11|, CC(C)OC(=O)C1=C(C)NC(N)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC1CN(C1)C(c1ccccc1)c1ccccc1 |r,c:6,11|, CC(C)OC(=O)C1=C(C)NC(N)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC1CN(C1)C(c1ccccc1)c1ccccc1 |r,c:6,11|, CC(C)OC(=O)C1=C(C)NC(N)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC1CN(C1)C(c1ccccc1)c1ccccc1 |r,c:6,11|	Launched
azilsartan	angiotensin receptor antagonist	AGTR1, AGTR2	cardiology	hypertension	Tocris, Tocris, Tocris, Selleck, Selleck	97.15	CCOc1nc2cccc(C(O)=O)c2n1Cc1ccc(cc1)-c1ccccc1-c1nc(=O)o[nH]1, CCOc1nc2cccc(C(O)=O)c2n1Cc1ccc(cc1)-c1ccccc1-c1nc(=O)o[nH]1, CCOc1nc2cccc(C(O)=O)c2n1Cc1ccc(cc1)-c1ccccc1-c1nc(=O)o[nH]1, CCOc1nc2cccc(C(O)=O)c2n1Cc1ccc(cc1)-c1ccccc1-c1nc(=O)o[nH]1, CCOc1nc2cccc(C(O)=O)c2n1Cc1ccc(cc1)-c1ccccc1-c1nc(=O)o[nH]1	Launched
azilsartan-medoxomil	angiotensin receptor antagonist	AGTR1, AGTR2	cardiology	hypertension	MicroSource, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck	97.22	CCOc1nc2cccc(C(=O)OCc3oc(=O)oc3C)c2n1Cc1ccc(cc1)-c1ccccc1-c1nc(=O)o[nH]1, CCOc1nc2cccc(C(=O)OCc3oc(=O)oc3C)c2n1Cc1ccc(cc1)-c1ccccc1-c1nc(=O)o[nH]1, CCOc1nc2cccc(C(=O)OCc3oc(=O)oc3C)c2n1Cc1ccc(cc1)-c1ccccc1-c1nc(=O)o[nH]1, CCOc1nc2cccc(C(=O)OCc3oc(=O)oc3C)c2n1Cc1ccc(cc1)-c1ccccc1-c1nc(=O)o[nH]1, CCOc1nc2cccc(C(=O)OCc3oc(=O)oc3C)c2n1Cc1ccc(cc1)-c1ccccc1-c1nc(=O)o[nH]1, CCOc1nc2cccc(C(=O)OCc3oc(=O)oc3C)c2n1Cc1ccc(cc1)-c1ccccc1-c1nc(=O)o[nH]1, CCOc1nc2cccc(C(=O)OCc3oc(=O)oc3C)c2n1Cc1ccc(cc1)-c1ccccc1-c1nc(=O)o[nH]1	Launched
azimilide	potassium channel blocker	KCNA5			Tocris, MedChemEx, MedChemEx	97.19	CN1CCN(CCCCN2C(=O)CN(\N=C\c3ccc(o3)-c3ccc(Cl)cc3)C2=O)CC1, CN1CCN(CCCCN2C(=O)CN(\N=C\c3ccc(o3)-c3ccc(Cl)cc3)C2=O)CC1, CN1CCN(CCCCN2C(=O)CN(\N=C\c3ccc(o3)-c3ccc(Cl)cc3)C2=O)CC1	Phase 3
azithromycin	bacterial 50S ribosomal subunit inhibitor	MLNR	infectious disease	pelvic inflammatory disease, pneumonia	Tocris, Tocris, MicroSource, Selleck, Tocris, Selleck, Selleck	100	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O	Launched
azlocillin	bacterial cell wall synthesis inhibitor		infectious disease	gram-positive bacterial infections, gram-negative bacterial infections	MicroSource, MicroSource, MicroSource, Selleck, MedChemEx	85.42	CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](NC(=O)N3CCNC3=O)c3ccccc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](NC(=O)N3CCNC3=O)c3ccccc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](NC(=O)N3CCNC3=O)c3ccccc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](NC(=O)N3CCNC3=O)c3ccccc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](NC(=O)N3CCNC3=O)c3ccccc3)C(=O)N2[C@H]1C(O)=O	Launched
AZM-475271	SRC inhibitor	SRC			Tocris, Tocris, Tocris, Tocris	98.3	COc1ccc(Cl)c(Nc2ncnc3cc(OCC4CCN(C)CC4)c(OC)cc23)c1, COc1ccc(Cl)c(Nc2ncnc3cc(OCC4CCN(C)CC4)c(OC)cc23)c1, COc1ccc(Cl)c(Nc2ncnc3cc(OCC4CCN(C)CC4)c(OC)cc23)c1, COc1ccc(Cl)c(Nc2ncnc3cc(OCC4CCN(C)CC4)c(OC)cc23)c1	Preclinical
azodicarbonamide	DNA synthesis inhibitor				AMS, MatrixSci	0	NC(=O)\N=N\C(N)=O, NC(=O)\N=N\C(N)=O	Phase 2
azomycin-(2-nitroimidazole)	protein synthesis inhibitor				Selleck, Selleck	96.5	[O-][N+](=O)c1ncc[nH]1, [O-][N+](=O)c1ncc[nH]1	Preclinical
azosemide	electrolyte reabsorption inhibitor	SLC12A1, SLC12A2	cardiology	edema	AKSci, AKSci, AKSci	96.43	NS(=O)(=O)c1cc(-c2nn[nH]n2)c(NCc2cccs2)cc1Cl, NS(=O)(=O)c1cc(-c2nn[nH]n2)c(NCc2cccs2)cc1Cl, NS(=O)(=O)c1cc(-c2nn[nH]n2)c(NCc2cccs2)cc1Cl	Launched
aztreonam	bacterial cell wall synthesis inhibitor		infectious disease	urinary tract infections, respiratory tract infections, bacterial septicemia, skin infections, intra-abdominal infections, gynecologic infections	MedChemEx, MicroSource, Selleck, Selleck, Selleck	100	C[C@H]1[C@H](NC(=O)C(=N/OC(C)(C)C(O)=O)\c2csc(N)n2)C(=O)N1S(O)(=O)=O, C[C@H]1[C@H](NC(=O)C(=N/OC(C)(C)C(O)=O)\c2csc(N)n2)C(=O)N1S(O)(=O)=O, C[C@H]1[C@H](NC(=O)C(=N/OC(C)(C)C(O)=O)\c2csc(N)n2)C(=O)N1S(O)(=O)=O, C[C@H]1[C@H](NC(=O)C(=N/OC(C)(C)C(O)=O)\c2csc(N)n2)C(=O)N1S(O)(=O)=O, C[C@H]1[C@H](NC(=O)C(=N/OC(C)(C)C(O)=O)\c2csc(N)n2)C(=O)N1S(O)(=O)=O	Launched
AZ191	DYRK inhibitor	DYRK1B			Tocris, Tocris, Tocris, Selleck, Selleck, Selleck	97.06	COc1cc(ccc1Nc1nccc(n1)-c1cn(C)c2cnccc12)N1CCN(C)CC1, COc1cc(ccc1Nc1nccc(n1)-c1cn(C)c2cnccc12)N1CCN(C)CC1, COc1cc(ccc1Nc1nccc(n1)-c1cn(C)c2cnccc12)N1CCN(C)CC1, COc1cc(ccc1Nc1nccc(n1)-c1cn(C)c2cnccc12)N1CCN(C)CC1, COc1cc(ccc1Nc1nccc(n1)-c1cn(C)c2cnccc12)N1CCN(C)CC1, COc1cc(ccc1Nc1nccc(n1)-c1cn(C)c2cnccc12)N1CCN(C)CC1	Preclinical
AZ20	ATR kinase inhibitor	ATR, MTOR			Tocris, Selleck	98.44	C[C@@H]1COCCN1c1cc(nc(n1)-c1cccc2[nH]ccc12)C1(CC1)S(C)(=O)=O, C[C@@H]1COCCN1c1cc(nc(n1)-c1cccc2[nH]ccc12)C1(CC1)S(C)(=O)=O	Preclinical
AZ3146	monopolar spindle 1 kinase inhibitor				Selleck, Selleck, Tocris, Tocris	94.31	COc1cc(OC2CCN(C)CC2)ccc1Nc1ncc2n(C)c(=O)n(C3CCCC3)c2n1, COc1cc(OC2CCN(C)CC2)ccc1Nc1ncc2n(C)c(=O)n(C3CCCC3)c2n1, COc1cc(OC2CCN(C)CC2)ccc1Nc1ncc2n(C)c(=O)n(C3CCCC3)c2n1, COc1cc(OC2CCN(C)CC2)ccc1Nc1ncc2n(C)c(=O)n(C3CCCC3)c2n1	Preclinical
AZ505	histone lysine methyltransferase inhibitor	SMYD2			MedChemEx, MedChemEx	97.71	Oc1ccc(CCNCCN(C2CCCCC2)C(=O)CCNCCc2ccc(Cl)c(Cl)c2)c2OCC(=O)Nc12, Oc1ccc(CCNCCN(C2CCCCC2)C(=O)CCNCCc2ccc(Cl)c(Cl)c2)c2OCC(=O)Nc12	Preclinical
AZ5104	EGFR inhibitor	EGFR			Selleck	79.95	COc1cc(N(C)CCN(C)C)c(NC(=O)C=C)cc1Nc1nccc(n1)-c1c[nH]c2ccccc12	Preclinical
AZ7550	insulin growth factor receptor inhibitor				MedChemEx	95.84	CNCCN(C)c1cc(OC)c(Nc2nccc(n2)-c2cn(C)c3ccccc23)cc1NC(=O)C=C	Phase 1
AZ960	JAK inhibitor	JAK2			MedChemEx, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck	94.9	C[C@H](Nc1nc(Nc2cc(C)n[nH]2)c(F)cc1C#N)c1ccc(F)cc1, C[C@H](Nc1nc(Nc2cc(C)n[nH]2)c(F)cc1C#N)c1ccc(F)cc1, C[C@H](Nc1nc(Nc2cc(C)n[nH]2)c(F)cc1C#N)c1ccc(F)cc1, C[C@H](Nc1nc(Nc2cc(C)n[nH]2)c(F)cc1C#N)c1ccc(F)cc1, C[C@H](Nc1nc(Nc2cc(C)n[nH]2)c(F)cc1C#N)c1ccc(F)cc1, C[C@H](Nc1nc(Nc2cc(C)n[nH]2)c(F)cc1C#N)c1ccc(F)cc1, C[C@H](Nc1nc(Nc2cc(C)n[nH]2)c(F)cc1C#N)c1ccc(F)cc1, C[C@H](Nc1nc(Nc2cc(C)n[nH]2)c(F)cc1C#N)c1ccc(F)cc1, C[C@H](Nc1nc(Nc2cc(C)n[nH]2)c(F)cc1C#N)c1ccc(F)cc1, C[C@H](Nc1nc(Nc2cc(C)n[nH]2)c(F)cc1C#N)c1ccc(F)cc1	Preclinical
A0001					Sigma, Enzo	40.81	CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC[C@@](C)(O)CCC1=C(C)C(=O)C(C)=C(C)C1=O |c:21,t:27|, CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC[C@@](C)(O)CCC1=C(C)C(=O)C(C)=C(C)C1=O |c:21,t:27|	Phase 2
A12B4C3	polynucleotide kinase/phosphatase inhibitor	PNKP			Tocris, Tocris	90.41	CCCCCCCCCC[C@@H](O)[C@H]1C=C[C@H]2[C@@H](N1Nc1ccc(cc1)[N+]([O-])=O)C(=O)N(C2=O)c1ccccc1 |&1:10,&2:12,r,c:13|, CCCCCCCCCC[C@@H](O)[C@H]1C=C[C@H]2[C@@H](N1Nc1ccc(cc1)[N+]([O-])=O)C(=O)N(C2=O)c1ccccc1 |&1:10,&2:12,r,c:13|	Preclinical
A205804	ICAM1 expression inhibitor	ICAM1, SELE			Tocris, Tocris, Tocris, Tocris, Tocris, Tocris, Selleck	98.68	Cc1ccc(Sc2cncc3sc(cc23)C(N)=O)cc1, Cc1ccc(Sc2cncc3sc(cc23)C(N)=O)cc1, Cc1ccc(Sc2cncc3sc(cc23)C(N)=O)cc1, Cc1ccc(Sc2cncc3sc(cc23)C(N)=O)cc1, Cc1ccc(Sc2cncc3sc(cc23)C(N)=O)cc1, Cc1ccc(Sc2cncc3sc(cc23)C(N)=O)cc1, Cc1ccc(Sc2cncc3sc(cc23)C(N)=O)cc1	Preclinical
A61603	adrenergic receptor agonist	ADRA1A			Tocris, Tocris	96.39	CS(=O)(=O)Nc1c(O)ccc2[C@@H](CCCc12)C1=NCCN1 |r,t:18|, CS(=O)(=O)Nc1c(O)ccc2[C@@H](CCCc12)C1=NCCN1 |r,t:18|	Preclinical
A66	PI3K inhibitor	PIK3CA			Selleck, Selleck, Tocris	94.01	Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1csc(n1)C(C)(C)C, Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1csc(n1)C(C)(C)C, Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1csc(n1)C(C)(C)C	Preclinical
A740003	purinergic receptor antagonist	P2RX7			Tocris, Tocris, Tocris, Tocris, Tocris, Tocris, Tocris	97.5	COc1ccc(CC(=O)N[C@@H](N\C(Nc2cccc3ncccc23)=N\C#N)C(C)(C)C)cc1OC |&1:10,r|, COc1ccc(CC(=O)N[C@@H](N\C(Nc2cccc3ncccc23)=N\C#N)C(C)(C)C)cc1OC |&1:10,r|, COc1ccc(CC(=O)N[C@@H](N\C(Nc2cccc3ncccc23)=N\C#N)C(C)(C)C)cc1OC |&1:10,r|, COc1ccc(CC(=O)N[C@@H](N\C(Nc2cccc3ncccc23)=N\C#N)C(C)(C)C)cc1OC |&1:10,r|, COc1ccc(CC(=O)N[C@@H](N\C(Nc2cccc3ncccc23)=N\C#N)C(C)(C)C)cc1OC |&1:10,r|, COc1ccc(CC(=O)N[C@@H](N\C(Nc2cccc3ncccc23)=N\C#N)C(C)(C)C)cc1OC |&1:10,r|, COc1ccc(CC(=O)N[C@@H](N\C(Nc2cccc3ncccc23)=N\C#N)C(C)(C)C)cc1OC |&1:10,r|	Preclinical
A77636	dopamine receptor agonist	CALY			Tocris, Tocris, Tocris	89.2	NC[C@@H]1O[C@@H](Cc2c(O)c(O)ccc12)[C@@]12CC3CC(CC(C3)C1)C2, NC[C@@H]1O[C@@H](Cc2c(O)c(O)ccc12)[C@@]12CC3CC(CC(C3)C1)C2, NC[C@@H]1O[C@@H](Cc2c(O)c(O)ccc12)[C@@]12CC3CC(CC(C3)C1)C2	Preclinical
A922500	diacylglycerol O acyltransferase inhibitor	DGAT1			Selleck	92.69	OC(=O)[C@H]1CCC[C@H]1C(=O)c1ccc(cc1)-c1ccc(NC(=O)Nc2ccccc2)cc1	Preclinical
bacampicillin	bacterial cell wall synthesis inhibitor		infectious disease	gram-positive bacterial infections, gram-negative bacterial infections	MicroSource, Sigma, MedChemEx	81.26	CCOC(=O)O[C@@H](C)OC(=O)[C@@H]1N2[C@H](SC1(C)C)[C@H](NC(=O)[C@H](N)c1ccccc1)C2=O |a:11,13,18,22,&1:6|, CCOC(=O)O[C@@H](C)OC(=O)[C@@H]1N2[C@H](SC1(C)C)[C@H](NC(=O)[C@H](N)c1ccccc1)C2=O |a:11,13,18,22,&1:6|, CCOC(=O)O[C@@H](C)OC(=O)[C@@H]1N2[C@H](SC1(C)C)[C@H](NC(=O)[C@H](N)c1ccccc1)C2=O |a:11,13,18,22,&1:6|	Launched
bacitracin	bacterial cell wall synthesis inhibitor	IDE	infectious disease	first-aid antibiotic	Selleck	43.52	CC[C@H](C)[C@H](N)C1=N[C@@H](CS1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H]1CCCCNC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](CC(O)=O)NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H](NC(=O)[C@@H](CCCN)NC1=O)[C@@H](C)CC |t:6|	Launched
bacitracin-zinc	bacterial cell wall synthesis inhibitor		infectious disease	first-aid antibiotic	MedChemEx	51.16	CC[C@H](C)[C@H](N)C1=N[C@@H](CS1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]1CCC(=O)O[Zn]OC(=O)C[C@H]2NC(=O)[C@H](Cc3c[nH]cn3)NC(=O)[C@@H](Cc3ccccc3)NC(=O)[C@@H](NC(=O)[C@@H](CCCN)NC(=O)[C@H](CCCCNC(=O)[C@H](CC(N)=O)NC2=O)NC(=O)[C@@H](NC1=O)[C@@H](C)CC)[C@@H](C)CC |t:6|	Launched
baclofen	benzodiazepine receptor agonist	GABBR1, GABBR2, KCTD12, KCTD16, KCTD8	neurology/psychiatry	multiple sclerosis, spasms	Tocris, MicroSource	47.4	NC[C@@H](CC(O)=O)c1ccc(Cl)cc1 |&1:2|, NC[C@@H](CC(O)=O)c1ccc(Cl)cc1 |&1:2|	Launched
BADGE	PPAR receptor antagonist	PPARG			Sigma, Tocris	94.12	CC(C)(c1ccc(OC[C@H]2CO2)cc1)c1ccc(OC[C@H]2CO2)cc1 |&1:9,&2:20,r|, CC(C)(c1ccc(OC[C@H]2CO2)cc1)c1ccc(OC[C@H]2CO2)cc1 |&1:9,&2:20,r|	Preclinical
bafetinib	Bcr-Abl kinase inhibitor, LYN tyrosine kinase inhibitor	ABL1, BCR, LYN			Selleck, Selleck, Selleck, Selleck, MedChemEx, MedChemEx	93.85	CN(C)[C@H]1CCN(Cc2ccc(cc2C(F)(F)F)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cncnc3)c2)C1, CN(C)[C@H]1CCN(Cc2ccc(cc2C(F)(F)F)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cncnc3)c2)C1, CN(C)[C@H]1CCN(Cc2ccc(cc2C(F)(F)F)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cncnc3)c2)C1, CN(C)[C@H]1CCN(Cc2ccc(cc2C(F)(F)F)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cncnc3)c2)C1, CN(C)[C@H]1CCN(Cc2ccc(cc2C(F)(F)F)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cncnc3)c2)C1, CN(C)[C@H]1CCN(Cc2ccc(cc2C(F)(F)F)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cncnc3)c2)C1	Phase 2
bafilomycin-a1	ATPase inhibitor				MedChemEx, MedChemEx	87.42	[H][C@@]1(OC(=O)\C(OC)=C\C(\C)=C/[C@@H](C)[C@@H](O)[C@@H](C)C\C(C)=C\C=C\[C@@H]1OC)[C@@H](C)[C@@H](O)[C@H](C)[C@@]1(O)C[C@@H](O)[C@H](C)[C@H](O1)C(C)C |c:10,t:7,20,22|, [H][C@@]1(OC(=O)\C(OC)=C\C(\C)=C/[C@@H](C)[C@@H](O)[C@@H](C)C\C(C)=C\C=C\[C@@H]1OC)[C@@H](C)[C@@H](O)[C@H](C)[C@@]1(O)C[C@@H](O)[C@H](C)[C@H](O1)C(C)C |c:10,t:7,20,22|	Preclinical
BAG-956	phosphoinositide dependent kinase inhibitor	PIK3CG			Tocris, Tocris, Tocris	97.92	Cc1nc2cnc3ccc(cc3c2n1-c1ccc(cc1)C(C)(C)C#N)C#Cc1cccnc1, Cc1nc2cnc3ccc(cc3c2n1-c1ccc(cc1)C(C)(C)C#N)C#Cc1cccnc1, Cc1nc2cnc3ccc(cc3c2n1-c1ccc(cc1)C(C)(C)C#N)C#Cc1cccnc1	Preclinical
baicalein	lipoxygenase inhibitor	ALOX5, GLO1, PREP, SELL, SELP, TNF, XDH			Selleck, Selleck, Selleck, Selleck, Selleck, Tocris	97.14	Oc1cc2oc(cc(O)c2c(=O)c1O)-c1ccccc1, Oc1cc2oc(cc(O)c2c(=O)c1O)-c1ccccc1, Oc1cc2oc(cc(O)c2c(=O)c1O)-c1ccccc1, Oc1cc2oc(cc(O)c2c(=O)c1O)-c1ccccc1, Oc1cc2oc(cc(O)c2c(=O)c1O)-c1ccccc1, Oc1cc2oc(cc(O)c2c(=O)c1O)-c1ccccc1	Preclinical
baicalin	beta glucuronidase inhibitor	PREP	neurology/psychiatry	anxiety	MedChemEx, MedChemEx, Selleck, Selleck, Selleck	96.64	O[C@H]1[C@H](Oc2cc3oc(cc(O)c3c(=O)c2O)-c2ccccc2)O[C@@H]([C@@H](O)[C@@H]1O)C(O)=O, O[C@H]1[C@H](Oc2cc3oc(cc(O)c3c(=O)c2O)-c2ccccc2)O[C@@H]([C@@H](O)[C@@H]1O)C(O)=O, O[C@H]1[C@H](Oc2cc3oc(cc(O)c3c(=O)c2O)-c2ccccc2)O[C@@H]([C@@H](O)[C@@H]1O)C(O)=O, O[C@H]1[C@H](Oc2cc3oc(cc(O)c3c(=O)c2O)-c2ccccc2)O[C@@H]([C@@H](O)[C@@H]1O)C(O)=O, O[C@H]1[C@H](Oc2cc3oc(cc(O)c3c(=O)c2O)-c2ccccc2)O[C@@H]([C@@H](O)[C@@H]1O)C(O)=O	Launched
bakuchiol	DNA polymerase inhibitor	HIF1A			MedChemEx, MedChemEx, MedChemEx, Enzo	90.88	CC(C)=CCC[C@@](C)(C=C)\C=C\c1ccc(O)cc1, CC(C)=CCC[C@@](C)(C=C)\C=C\c1ccc(O)cc1, CC(C)=CCC[C@@](C)(C=C)\C=C\c1ccc(O)cc1, CC(C)=CCC[C@@](C)(C=C)\C=C\c1ccc(O)cc1	Phase 2
balaglitazone	insulin sensitizer, PPAR receptor partial agonist	PPARG			MedChemEx, MedChemEx	98.36	Cn1c(COc2ccc(C[C@H]3SC(=O)NC3=O)cc2)nc2ccccc2c1=O |r|, Cn1c(COc2ccc(C[C@H]3SC(=O)NC3=O)cc2)nc2ccccc2c1=O |r|	Phase 3
balapiravir	RNA polymerase inhibitor				MedChemEx, MedChemEx, MedChemEx, MedChemEx	95.37	CC(C)C(=O)OC[C@]1(O[C@H]([C@H](OC(=O)C(C)C)[C@@H]1OC(=O)C(C)C)n1ccc(N)nc1=O)N=[N+]=[N-], CC(C)C(=O)OC[C@]1(O[C@H]([C@H](OC(=O)C(C)C)[C@@H]1OC(=O)C(C)C)n1ccc(N)nc1=O)N=[N+]=[N-], CC(C)C(=O)OC[C@]1(O[C@H]([C@H](OC(=O)C(C)C)[C@@H]1OC(=O)C(C)C)n1ccc(N)nc1=O)N=[N+]=[N-], CC(C)C(=O)OC[C@]1(O[C@H]([C@H](OC(=O)C(C)C)[C@@H]1OC(=O)C(C)C)n1ccc(N)nc1=O)N=[N+]=[N-]	Phase 2
balicatib	cathepsin inhibitor	CTSK			Tocris, Tocris, MedChemEx, MedChemEx, MedChemEx	97.04	CCCN1CCN(CC1)c1ccc(cc1)C(=O)NC1(CCCCC1)C(=O)NCC#N, CCCN1CCN(CC1)c1ccc(cc1)C(=O)NC1(CCCCC1)C(=O)NCC#N, CCCN1CCN(CC1)c1ccc(cc1)C(=O)NC1(CCCCC1)C(=O)NCC#N, CCCN1CCN(CC1)c1ccc(cc1)C(=O)NC1(CCCCC1)C(=O)NCC#N, CCCN1CCN(CC1)c1ccc(cc1)C(=O)NC1(CCCCC1)C(=O)NCC#N	Phase 2
balofloxacin	bacterial DNA gyrase inhibitor		infectious disease	gram-negative bacterial infections	Selleck, MedChemEx, Selleck	97.5	CN[C@H]1CCCN(C1)c1c(F)cc2c(c1OC)n(cc(C(O)=O)c2=O)C1CC1 |&1:2,r|, CN[C@H]1CCCN(C1)c1c(F)cc2c(c1OC)n(cc(C(O)=O)c2=O)C1CC1 |&1:2,r|, CN[C@H]1CCCN(C1)c1c(F)cc2c(c1OC)n(cc(C(O)=O)c2=O)C1CC1 |&1:2,r|	Launched
baloxavir	endonuclease inhibitor				MedChemEx	98.4	[H][C@@]12COCCN1C(=O)c1c(O)c(=O)ccn1N2[C@@H]1c2ccccc2SCc2c(F)c(F)ccc12	Phase 3
baloxavir-marboxil	endonuclease inhibitor		infectious disease	influenza A virus infection	MedChemEx	98.17	[H][C@@]12COCCN1C(=O)c1c(OCOC(=O)OC)c(=O)ccn1N2[C@H]1c2ccc(F)c(F)c2CSc2ccccc12	Launched
balsalazide	cyclooxygenase inhibitor	ALOX5, PPARG, PTGS1, PTGS2	gastroenterology	ulcerative colitis	MedChemEx	86.18	OC(=O)CCNC(=O)c1ccc(cc1)\N=N\c1ccc(O)c(c1)C(O)=O	Launched
bamaquimast	proton pump inhibitor				MedChemEx	97.09	CCCn1c2ccccc2nc(CCCOC(=O)NC)c1=O	Preclinical
bambuterol	adrenergic receptor agonist	ADRB2, BCHE	pulmonary	asthma	MicroSource	97.14	CN(C)C(=O)Oc1cc(OC(=O)N(C)C)cc(c1)C(O)CNC(C)(C)C	Launched
BAM7	BAX activator	BAX			Selleck, Selleck, Selleck, Selleck, Selleck, MedChemEx	97.46	CCOc1ccccc1N\N=C1/C(C)=NN(C1=O)c1nc(cs1)-c1ccccc1 |c:14|, CCOc1ccccc1N\N=C1/C(C)=NN(C1=O)c1nc(cs1)-c1ccccc1 |c:14|, CCOc1ccccc1N\N=C1/C(C)=NN(C1=O)c1nc(cs1)-c1ccccc1 |c:14|, CCOc1ccccc1N\N=C1/C(C)=NN(C1=O)c1nc(cs1)-c1ccccc1 |c:14|, CCOc1ccccc1N\N=C1/C(C)=NN(C1=O)c1nc(cs1)-c1ccccc1 |c:14|, CCOc1ccccc1N\N=C1/C(C)=NN(C1=O)c1nc(cs1)-c1ccccc1 |c:14|	Preclinical
BAN-ORL-24	nociceptin/orphanin FQ receptor antagonist	OPRL1			Tocris, MedChemEx, MedChemEx, Tocris	84.22	O=C(NCCCN1CCC2(CC1)OCc1ccccc21)[C@H]1CCCN1Cc1ccccc1, O=C(NCCCN1CCC2(CC1)OCc1ccccc21)[C@H]1CCCN1Cc1ccccc1, O=C(NCCCN1CCC2(CC1)OCc1ccccc21)[C@H]1CCCN1Cc1ccccc1, O=C(NCCCN1CCC2(CC1)OCc1ccccc21)[C@H]1CCCN1Cc1ccccc1	Preclinical
banoxantrone	topoisomerase inhibitor	TOP2A			MedChemEx	80.96	C[N+](C)([O-])CCNc1ccc(NCC[N+](C)(C)[O-])c2C(=O)c3c(O)ccc(O)c3C(=O)c12	Phase 1/Phase 2
barasertib	Aurora kinase inhibitor	AURKA, AURKB			MedChemEx, MedChemEx, MedChemEx	89.07	CCN(CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)n[nH]3)ncnc2c1)CCOP(O)(O)=O, CCN(CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)n[nH]3)ncnc2c1)CCOP(O)(O)=O, CCN(CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)n[nH]3)ncnc2c1)CCOP(O)(O)=O	Phase 2/Phase 3
barasertib-HQPA	Aurora kinase inhibitor	AURKB			Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck	96.94	CCN(CCO)CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)n[nH]3)ncnc2c1, CCN(CCO)CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)n[nH]3)ncnc2c1, CCN(CCO)CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)n[nH]3)ncnc2c1, CCN(CCO)CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)n[nH]3)ncnc2c1, CCN(CCO)CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)n[nH]3)ncnc2c1, CCN(CCO)CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)n[nH]3)ncnc2c1, CCN(CCO)CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)n[nH]3)ncnc2c1, CCN(CCO)CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)n[nH]3)ncnc2c1, CCN(CCO)CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)n[nH]3)ncnc2c1	Phase 2/Phase 3
bardoxolone	nuclear factor erythroid derived, like (NRF2) activator	NOS2, PPARG			MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx	85.92	CC1(C)CC[C@@]2(CC[C@]3(C)[C@@H]([C@@H]2C1)C(=O)C=C1[C@@]2(C)C=C(C#N)C(=O)C(C)(C)[C@@H]2CC[C@@]31C)C(O)=O |t:17,21|, CC1(C)CC[C@@]2(CC[C@]3(C)[C@@H]([C@@H]2C1)C(=O)C=C1[C@@]2(C)C=C(C#N)C(=O)C(C)(C)[C@@H]2CC[C@@]31C)C(O)=O |t:17,21|, CC1(C)CC[C@@]2(CC[C@]3(C)[C@@H]([C@@H]2C1)C(=O)C=C1[C@@]2(C)C=C(C#N)C(=O)C(C)(C)[C@@H]2CC[C@@]31C)C(O)=O |t:17,21|, CC1(C)CC[C@@]2(CC[C@]3(C)[C@@H]([C@@H]2C1)C(=O)C=C1[C@@]2(C)C=C(C#N)C(=O)C(C)(C)[C@@H]2CC[C@@]31C)C(O)=O |t:17,21|, CC1(C)CC[C@@]2(CC[C@]3(C)[C@@H]([C@@H]2C1)C(=O)C=C1[C@@]2(C)C=C(C#N)C(=O)C(C)(C)[C@@H]2CC[C@@]31C)C(O)=O |t:17,21|	Phase 1
bardoxolone-methyl	nuclear factor erythroid derived, like (NRF2) activator	PPARG, STAT3			Selleck, Selleck, Selleck, MedChemEx	96.2	COC(=O)[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@]4(C)C=C(C#N)C(=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2 |t:16,20|, COC(=O)[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@]4(C)C=C(C#N)C(=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2 |t:16,20|, COC(=O)[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@]4(C)C=C(C#N)C(=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2 |t:16,20|, COC(=O)[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@]4(C)C=C(C#N)C(=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2 |t:16,20|	Phase 3
baricitinib	JAK inhibitor	JAK1, JAK2	rheumatology	rheumatoid arthritis	Selleck, Selleck, Selleck, Selleck	97.36	CCS(=O)(=O)N1CC(CC#N)(C1)n1cc(cn1)-c1ncnc2[nH]ccc12, CCS(=O)(=O)N1CC(CC#N)(C1)n1cc(cn1)-c1ncnc2[nH]ccc12, CCS(=O)(=O)N1CC(CC#N)(C1)n1cc(cn1)-c1ncnc2[nH]ccc12, CCS(=O)(=O)N1CC(CC#N)(C1)n1cc(cn1)-c1ncnc2[nH]ccc12	Launched
barium-6-O-phosphonato-D-glucose					TCI	0	O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@@H](O)C=O	Preclinical
barnidipine	calcium channel blocker		cardiology	hypertension	AKSci, AKSci	96.4	COC(=O)C1=C(C)NC(C)=C([C@H]1c1cccc(c1)[N+]([O-])=O)C(=O)O[C@H]1CCN(Cc2ccccc2)C1 |c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@H]1c1cccc(c1)[N+]([O-])=O)C(=O)O[C@H]1CCN(Cc2ccccc2)C1 |c:4,9|	Launched
basic-fuchsin					SantaCruz	0	CC1=CC(C=CC1=N)=C(c1ccc(N)cc1)c1ccc(N)cc1 |c:4,t:1|	Preclinical
basimglurant	glutamate receptor antagonist	GRM5			MedChemEx	99.2	Cc1nc(C#Cc2ccnc(Cl)c2)c(C)n1-c1ccc(F)cc1	Phase 2
basmisanil	GABA receptor inverse agonist				MedChemEx	98.76	Cc1onc(c1COc1ccc(cn1)C(=O)N1CCS(=O)(=O)CC1)-c1ccc(F)cc1	Phase 2
batefenterol	acetylcholine receptor antagonist, adrenergic receptor agonist				MedChemEx	90.34	COc1cc(NC(=O)CCN2CCC(CC2)OC(=O)Nc2ccccc2-c2ccccc2)c(Cl)cc1CNC[C@H](O)c1ccc(O)c2nc(O)ccc12	Phase 2
batimastat	matrix metalloprotease inhibitor	ADAM28, ADAMTS5, MMP12, MMP16, MMP2, MMP8			Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Tocris, Selleck, Selleck, Selleck, Selleck	95.3	CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)[C@H](CSc1cccs1)C(=O)NO, CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)[C@H](CSc1cccs1)C(=O)NO, CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)[C@H](CSc1cccs1)C(=O)NO, CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)[C@H](CSc1cccs1)C(=O)NO, CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)[C@H](CSc1cccs1)C(=O)NO, CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)[C@H](CSc1cccs1)C(=O)NO, CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)[C@H](CSc1cccs1)C(=O)NO, CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)[C@H](CSc1cccs1)C(=O)NO, CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)[C@H](CSc1cccs1)C(=O)NO, CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)[C@H](CSc1cccs1)C(=O)NO, CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)[C@H](CSc1cccs1)C(=O)NO, CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)[C@H](CSc1cccs1)C(=O)NO	Phase 3
bavisant	histamine receptor antagonist	HRH3			MedChemEx, MedChemEx, MedChemEx	99.79	O=C(N1CCN(CC1)C1CC1)c1ccc(CN2CCOCC2)cc1, O=C(N1CCN(CC1)C1CC1)c1ccc(CN2CCOCC2)cc1, O=C(N1CCN(CC1)C1CC1)c1ccc(CN2CCOCC2)cc1	Phase 2
BAX-channel-blocker	cytochrome C release inhibitor	BAX			Tocris	90.53	O[C@@H](CN1CCNCC1)Cn1c2ccc(Br)cc2c2cc(Br)ccc12 |&1:1|	Preclinical
BAY-K-8644-(+/-)	L-type calcium channel blocker				Tocris, Tocris, Tocris	94.2	COC(=O)C1=C(C)NC(C)=C([C@@H]1c1ccccc1C(F)(F)F)[N+]([O-])=O |r,c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@@H]1c1ccccc1C(F)(F)F)[N+]([O-])=O |r,c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@@H]1c1ccccc1C(F)(F)F)[N+]([O-])=O |r,c:4,9|	Preclinical
BAY-K-8644-(s)-(-)	L-type calcium channel activator	CACNA1C			Tocris	90.62	COC(=O)C1=C(C)NC(C)=C([C@H]1c1ccccc1C(F)(F)F)[N+]([O-])=O |c:4,9|	Preclinical
BAY-W-9798	antioxidant				Vitas-M	98.03	COC(=O)C1=C(C)N(C)C(C)=C(C1c1ccc(cc1)C(F)(F)F)C(=O)OC |c:4,10|	Phase 2
BAY-11-7082	NFkB pathway inhibitor	RELA			Tocris, Tocris, Tocris, Tocris, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck	100	Cc1ccc(cc1)S(=O)(=O)\C=C\C#N, Cc1ccc(cc1)S(=O)(=O)\C=C\C#N, Cc1ccc(cc1)S(=O)(=O)\C=C\C#N, Cc1ccc(cc1)S(=O)(=O)\C=C\C#N, Cc1ccc(cc1)S(=O)(=O)\C=C\C#N, Cc1ccc(cc1)S(=O)(=O)\C=C\C#N, Cc1ccc(cc1)S(=O)(=O)\C=C\C#N, Cc1ccc(cc1)S(=O)(=O)\C=C\C#N, Cc1ccc(cc1)S(=O)(=O)\C=C\C#N, Cc1ccc(cc1)S(=O)(=O)\C=C\C#N, Cc1ccc(cc1)S(=O)(=O)\C=C\C#N, Cc1ccc(cc1)S(=O)(=O)\C=C\C#N, Cc1ccc(cc1)S(=O)(=O)\C=C\C#N	Preclinical
BAY-11-7085	NFkB pathway inhibitor	NFKBIA			Tocris, Tocris	91.4	CC(C)(C)c1ccc(cc1)S(=O)(=O)\C=C\C#N, CC(C)(C)c1ccc(cc1)S(=O)(=O)\C=C\C#N	Preclinical
BAY-1251152	CDK9 inhibitor				MedChemEx	97.4	COc1cc(F)ccc1-c1cc(Nc2cc(C[S@](C)(=N)=O)ccn2)ncc1F |r|	Phase 1
BAY-1436032	isocitrate dehydrogenase inhibitor				MedChemEx	97.89	C[C@H]1C[C@H](CC(C)(C)C1)n1c(Nc2ccc(OC(F)(F)F)cc2)nc2cc(CCC(O)=O)ccc12	Phase 1
BAY-1895344	ATR kinase inhibitor				MedChemEx	91.76	C[C@@H]1COCCN1c1cc(-c2ccnn2C)c2ccnc(-c3ccn[nH]3)c2n1	Phase 1
BAY-2402234	dihydroorotate dehydrogenase inhibitor				MedChemEx, MedChemEx	95.83	CCn1c(CO)nn(-c2cc(O[C@@H](C)C(F)(F)F)c(cc2F)C(=O)Nc2c(F)cccc2Cl)c1=O, CCn1c(CO)nn(-c2cc(O[C@@H](C)C(F)(F)F)c(cc2F)C(=O)Nc2c(F)cccc2Cl)c1=O	Phase 1
BAY-41-2272	guanylyl cyclase activator	GUCY1A3, GUCY1B3			Tocris, Tocris, Tocris, Tocris	99.07	Nc1nc(ncc1C1CC1)-c1nn(Cc2ccccc2F)c2ncccc12, Nc1nc(ncc1C1CC1)-c1nn(Cc2ccccc2F)c2ncccc12, Nc1nc(ncc1C1CC1)-c1nn(Cc2ccccc2F)c2ncccc12, Nc1nc(ncc1C1CC1)-c1nn(Cc2ccccc2F)c2ncccc12	Preclinical
BAY-60-6583	adenosine receptor agonist	ADORA1, ADORA2A, ADORA2B, ADORA3			Tocris, Tocris	96.22	NC(=O)CSc1nc(N)c(C#N)c(-c2ccc(OCC3CC3)cc2)c1C#N, NC(=O)CSc1nc(N)c(C#N)c(-c2ccc(OCC3CC3)cc2)c1C#N	Preclinical
BAY-60-7550	phosphodiesterase inhibitor	PDE2A			MedChemEx	93.86	COc1ccc(Cc2nc(=O)c3c(C)nc([C@@H](CCCc4ccccc4)[C@@H](C)O)n3[nH]2)cc1OC	Preclinical
BAY-61-3606	SYK inhibitor	SYK			MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx	93.77	COc1ccc(cc1OC)-c1cc2nccn2c(Nc2ncccc2C(N)=O)n1, COc1ccc(cc1OC)-c1cc2nccn2c(Nc2ncccc2C(N)=O)n1, COc1ccc(cc1OC)-c1cc2nccn2c(Nc2ncccc2C(N)=O)n1, COc1ccc(cc1OC)-c1cc2nccn2c(Nc2ncccc2C(N)=O)n1, COc1ccc(cc1OC)-c1cc2nccn2c(Nc2ncccc2C(N)=O)n1	Preclinical
BAY-8002	monocarboxylate transporter inhibitor				MedChemEx	91.78	OC(=O)c1ccccc1NC(=O)c1cc(ccc1Cl)S(=O)(=O)c1ccccc1	Preclinical
BAY-85-8050					AlfaAesar	100	N[C@@H](C[C@@H](F)C(O)=O)C(O)=O |&1:1,&2:3,r|	Phase 1
BAY-87-2243	hypoxia inducible factor inhibitor	HIF1A			MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx	96.05	Cc1cc(nn1Cc1ccnc(c1)N1CCN(CC1)C1CC1)-c1nc(no1)-c1ccc(OC(F)(F)F)cc1, Cc1cc(nn1Cc1ccnc(c1)N1CCN(CC1)C1CC1)-c1nc(no1)-c1ccc(OC(F)(F)F)cc1, Cc1cc(nn1Cc1ccnc(c1)N1CCN(CC1)C1CC1)-c1nc(no1)-c1ccc(OC(F)(F)F)cc1, Cc1cc(nn1Cc1ccnc(c1)N1CCN(CC1)C1CC1)-c1nc(no1)-c1ccc(OC(F)(F)F)cc1, Cc1cc(nn1Cc1ccnc(c1)N1CCN(CC1)C1CC1)-c1nc(no1)-c1ccc(OC(F)(F)F)cc1, Cc1cc(nn1Cc1ccnc(c1)N1CCN(CC1)C1CC1)-c1nc(no1)-c1ccc(OC(F)(F)F)cc1, Cc1cc(nn1Cc1ccnc(c1)N1CCN(CC1)C1CC1)-c1nc(no1)-c1ccc(OC(F)(F)F)cc1	Phase 1
BAY1125976	AKT inhibitor				MedChemEx	93.59	NC(=O)c1ccc2nc(c(-c3ccccc3)n2n1)-c1ccc(cc1)C1(N)CCC1	Phase 1
BAY1217389	kinase inhibitor				MedChemEx	97.87	COc1ccc(Oc2cc(NCCC(F)(F)F)c3ncc(-c4ccc(C(=O)NC5CC5)c(C)c4)n3n2)c(F)c1F	Phase 1
bazedoxifene	selective estrogen receptor modulator (SERM)	ESR1, ESR2	orthopedics, endocrinology	osteoporosis, menopause	Tocris, Tocris, Tocris, Tocris, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck	95.6	Cc1c(-c2ccc(O)cc2)n(Cc2ccc(OCCN3CCCCCC3)cc2)c2ccc(O)cc12, Cc1c(-c2ccc(O)cc2)n(Cc2ccc(OCCN3CCCCCC3)cc2)c2ccc(O)cc12, Cc1c(-c2ccc(O)cc2)n(Cc2ccc(OCCN3CCCCCC3)cc2)c2ccc(O)cc12, Cc1c(-c2ccc(O)cc2)n(Cc2ccc(OCCN3CCCCCC3)cc2)c2ccc(O)cc12, Cc1c(-c2ccc(O)cc2)n(Cc2ccc(OCCN3CCCCCC3)cc2)c2ccc(O)cc12, Cc1c(-c2ccc(O)cc2)n(Cc2ccc(OCCN3CCCCCC3)cc2)c2ccc(O)cc12, Cc1c(-c2ccc(O)cc2)n(Cc2ccc(OCCN3CCCCCC3)cc2)c2ccc(O)cc12, Cc1c(-c2ccc(O)cc2)n(Cc2ccc(OCCN3CCCCCC3)cc2)c2ccc(O)cc12, Cc1c(-c2ccc(O)cc2)n(Cc2ccc(OCCN3CCCCCC3)cc2)c2ccc(O)cc12, Cc1c(-c2ccc(O)cc2)n(Cc2ccc(OCCN3CCCCCC3)cc2)c2ccc(O)cc12, Cc1c(-c2ccc(O)cc2)n(Cc2ccc(OCCN3CCCCCC3)cc2)c2ccc(O)cc12, Cc1c(-c2ccc(O)cc2)n(Cc2ccc(OCCN3CCCCCC3)cc2)c2ccc(O)cc12, Cc1c(-c2ccc(O)cc2)n(Cc2ccc(OCCN3CCCCCC3)cc2)c2ccc(O)cc12, Cc1c(-c2ccc(O)cc2)n(Cc2ccc(OCCN3CCCCCC3)cc2)c2ccc(O)cc12	Launched
BAZ2-ICR	bromodomain inhibitor	ZNF215			Tocris, Tocris, Tocris	98.89	Cn1cc(CCn2cnc(-c3cnn(C)c3)c2-c2ccc(cc2)C#N)cn1, Cn1cc(CCn2cnc(-c3cnn(C)c3)c2-c2ccc(cc2)C#N)cn1, Cn1cc(CCn2cnc(-c3cnn(C)c3)c2-c2ccc(cc2)C#N)cn1	Preclinical
BC-11	urokinase inhibitor	PLAU			Tocris, Tocris	95.59	NC(=N)SCc1ccc(cc1)B(O)O, NC(=N)SCc1ccc(cc1)B(O)O	Preclinical
BCI-540	glutamate receptor agonist				MedChemEx, MedChemEx, MedChemEx	99.63	Cc1oc2nc3CCCCc3c(NC(=O)CN3CCCC3=O)c2c1C, Cc1oc2nc3CCCCc3c(NC(=O)CN3CCCC3=O)c2c1C, Cc1oc2nc3CCCCc3c(NC(=O)CN3CCCC3=O)c2c1C	Phase 2
BCTC	TRPV antagonist	TRPV1			Tocris, Tocris	93.69	CC(C)(C)c1ccc(NC(=O)N2CCN(CC2)c2ncccc2Cl)cc1, CC(C)(C)c1ccc(NC(=O)N2CCN(CC2)c2ncccc2Cl)cc1	Preclinical
BCX-1470	complement inhibitor, serine protease inhibitor	CFD			MedChemEx, MedChemEx	94.08	NC(=N)c1cc2ccc(OC(=O)c3cccs3)cc2s1, NC(=N)c1cc2ccc(OC(=O)c3cccs3)cc2s1	Phase 1
BD-1008	sigma receptor antagonist				Tocris, Tocris	91	CN(CCN1CCCC1)CCc1ccc(Cl)c(Cl)c1, CN(CCN1CCCC1)CCc1ccc(Cl)c(Cl)c1	Preclinical
BD-1047	adrenergic receptor antagonist	SIGMAR1			Tocris, Tocris, Tocris	94.48	CN(C)CCN(C)CCc1ccc(Cl)c(Cl)c1, CN(C)CCN(C)CCc1ccc(Cl)c(Cl)c1, CN(C)CCN(C)CCc1ccc(Cl)c(Cl)c1	Preclinical
BD-1063	sigma receptor antagonist	SIGMAR1			Tocris	96.05	CN1CCN(CCc2ccc(Cl)c(Cl)c2)CC1	Preclinical
BE-2254	adrenergic receptor antagonist	ADRA1A			Biotrend, Tocris	32.4	Oc1ccc(CCNC[C@H]2CCc3ccccc3C2=O)cc1 |r|, Oc1ccc(CCNC[C@H]2CCc3ccccc3C2=O)cc1 |r|	Phase 2
BEBT-908	PI3K inhibitor				MedChemEx	92.39	CNc1ccc(cn1)-c1nc(N2CCOCC2)c2sc(CN(C)c3ncc(cn3)C(=O)NO)cc2n1	Preclinical
beclabuvir	antiviral				MedChemEx	95.47	COc1ccc2-c3c(C4CCCCC4)c4ccc(cc4n3C[C@]3(C[C@H]3c2c1)C(=O)N1[C@H]2CC[C@@H]1CN(C)C2)C(=O)NS(=O)(=O)N(C)C |THB:27:29:31.32:34.35.37|	Phase 2
beclamide	anticonvulsant		neurology/psychiatry	sedative, seizures	MedChemEx, MicroSource	96.76	ClCCC(=O)NCc1ccccc1, ClCCC(=O)NCc1ccccc1	Launched
beclomethasone	glucocorticoid receptor agonist	NR3C1, SERPINA6	allergy	allergic rhinitis	AvaChem, AvaChem, AvaChem	92.3	C[C@H]1C[C@H]2[C@H]3CCC4=CC(=O)C=C[C@@]4(C)[C@@]3(Cl)[C@@H](O)C[C@@]2(C)[C@@]1(O)C(=O)CO |&1:1,&2:3,&3:4,&4:13,&5:15,&6:17,&7:20,&8:22,r,c:11,t:7|, C[C@H]1C[C@H]2[C@H]3CCC4=CC(=O)C=C[C@@]4(C)[C@@]3(Cl)[C@@H](O)C[C@@]2(C)[C@@]1(O)C(=O)CO |&1:1,&2:3,&3:4,&4:13,&5:15,&6:17,&7:20,&8:22,r,c:11,t:7|, C[C@H]1C[C@H]2[C@H]3CCC4=CC(=O)C=C[C@@]4(C)[C@@]3(Cl)[C@@H](O)C[C@@]2(C)[C@@]1(O)C(=O)CO |&1:1,&2:3,&3:4,&4:13,&5:15,&6:17,&7:20,&8:22,r,c:11,t:7|	Launched
beclomethasone-dipropionate	glucocorticoid receptor agonist	GPR97, NR3C1	allergy	allergic rhinitis	MicroSource, MedChemEx, MedChemEx, Selleck, Selleck, Selleck	98.04	CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]12C |c:25,t:21|, CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]12C |c:25,t:21|, CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]12C |c:25,t:21|, CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]12C |c:25,t:21|, CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]12C |c:25,t:21|, CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]12C |c:25,t:21|	Launched
bedaquiline	ATPase inhibitor		infectious disease	tuberculosis	MedChemEx, MedChemEx, MedChemEx, MedChemEx	92.56	COc1nc2ccc(Br)cc2cc1[C@@H](c1ccccc1)[C@@](O)(CCN(C)C)c1cccc2ccccc12, COc1nc2ccc(Br)cc2cc1[C@@H](c1ccccc1)[C@@](O)(CCN(C)C)c1cccc2ccccc12, COc1nc2ccc(Br)cc2cc1[C@@H](c1ccccc1)[C@@](O)(CCN(C)C)c1cccc2ccccc12, COc1nc2ccc(Br)cc2cc1[C@@H](c1ccccc1)[C@@](O)(CCN(C)C)c1cccc2ccccc12	Launched
befuraline					Enamine	96.8	O=C(N1CCN(Cc2ccccc2)CC1)c1cc2ccccc2o1	Phase 2
begacestat	gamma secretase inhibitor	PSEN1			Tocris, Sigma, Sigma	89.43	OC[C@@H](NS(=O)(=O)c1ccc(Cl)s1)C(C(F)(F)F)C(F)(F)F, OC[C@@H](NS(=O)(=O)c1ccc(Cl)s1)C(C(F)(F)F)C(F)(F)F, OC[C@@H](NS(=O)(=O)c1ccc(Cl)s1)C(C(F)(F)F)C(F)(F)F	Phase 1
bekanamycin	bacterial 30S ribosomal subunit inhibitor		infectious disease	gram-negative bacterial infections	MedChemEx, Selleck, MicroSource, MicroSource	100	NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](N)[C@@H](O)[C@@H]1O, NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](N)[C@@H](O)[C@@H]1O, NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](N)[C@@H](O)[C@@H]1O, NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](N)[C@@H](O)[C@@H]1O	Launched
belinostat	HDAC inhibitor	HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9	hematologic malignancy	peripheral T-cell lymphoma (PTCL)	Selleck, Selleck, Selleck, Selleck, CMLD/Broad, CMLD/Broad, CMLD/Broad	94.73	ONC(=O)\C=C\c1cccc(c1)S(=O)(=O)Nc1ccccc1, ONC(=O)\C=C\c1cccc(c1)S(=O)(=O)Nc1ccccc1, ONC(=O)\C=C\c1cccc(c1)S(=O)(=O)Nc1ccccc1, ONC(=O)\C=C\c1cccc(c1)S(=O)(=O)Nc1ccccc1, ONC(=O)\C=C\c1cccc(c1)S(=O)(=O)Nc1ccccc1, ONC(=O)\C=C\c1cccc(c1)S(=O)(=O)Nc1ccccc1, ONC(=O)\C=C\c1cccc(c1)S(=O)(=O)Nc1ccccc1	Launched
belizatinib	receptor tyrosine protein kinase inhibitor				MedChemEx	95.9	CC(C)NC(=O)[C@H]1CC[C@H](CC1)n1c(NC(=O)c2ccc(F)cc2)nc2ccc(CN3CCC(CC3)C(C)(C)O)cc12 |r|	Preclinical
belotecan	topoisomerase inhibitor				MedChemEx	97.3	CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccccc4c(CCNC(C)C)c3Cn1c2=O	Phase 3
bemegride	chemoreceptor agonist	GABRA1	critical care	poison antidote	MedChemEx, Selleck, Selleck	90.86	CCC1(C)CC(=O)NC(=O)C1, CCC1(C)CC(=O)NC(=O)C1, CCC1(C)CC(=O)NC(=O)C1	Launched
bemesetron	serotonin receptor antagonist	HTR3A, HTR3B			Tocris	95.61	CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)c1cc(Cl)cc(Cl)c1 |r,THB:0:1:3.4:6.7.8|	Phase 3
bemotrizinol			dermatology	sunscreen lotion	MicroSource, Sigma	0	CCCC[C@H](CC)COc1ccc(c(O)c1)-c1nc(nc(n1)-c1ccc(OC[C@H](CC)CCCC)cc1O)-c1ccc(OC)cc1 |&1:28,&2:4|, CCCC[C@H](CC)COc1ccc(c(O)c1)-c1nc(nc(n1)-c1ccc(OC[C@H](CC)CCCC)cc1O)-c1ccc(OC)cc1 |&1:28,&2:4|	Launched
bempedoic-acid	AMPK inhibitor	ACLY			MedChemEx	98.6	CC(C)(CCCCCC(O)CCCCCC(C)(C)C(O)=O)C(O)=O	Launched
benactyzine	butyrylcholinesterase inhibitor				MedChemEx	93.3	CCN(CC)CCOC(=O)C(O)(c1ccccc1)c1ccccc1	Preclinical
benaxibine					Labotest	100	OC[C@H]1O[C@@H](Nc2ccc(cc2)C(O)=O)[C@H](O)[C@@H](O)[C@@H]1O	Phase 1
benazepril	angiotensin converting enzyme inhibitor	ACE	cardiology	hypertension	MicroSource, Tocris, Tocris, Selleck, Tocris, Tocris	98.86	CCOC(=O)[C@H](CCc1ccccc1)N[C@H]1CCc2ccccc2N(CC(O)=O)C1=O, CCOC(=O)[C@H](CCc1ccccc1)N[C@H]1CCc2ccccc2N(CC(O)=O)C1=O, CCOC(=O)[C@H](CCc1ccccc1)N[C@H]1CCc2ccccc2N(CC(O)=O)C1=O, CCOC(=O)[C@H](CCc1ccccc1)N[C@H]1CCc2ccccc2N(CC(O)=O)C1=O, CCOC(=O)[C@H](CCc1ccccc1)N[C@H]1CCc2ccccc2N(CC(O)=O)C1=O, CCOC(=O)[C@H](CCc1ccccc1)N[C@H]1CCc2ccccc2N(CC(O)=O)C1=O	Launched
bendamustine	DNA inhibitor		hematologic malignancy	chronic lymphocytic leukemia (CLL), non-Hodgkin lymphoma (NHL)	Selleck, Selleck, Selleck	95.54	Cn1c(CCCC(O)=O)nc2cc(ccc12)N(CCCl)CCCl, Cn1c(CCCC(O)=O)nc2cc(ccc12)N(CCCl)CCCl, Cn1c(CCCC(O)=O)nc2cc(ccc12)N(CCCl)CCCl	Launched
bendazac	cyclooxygenase inhibitor	PTGS1, PTGS2	neurology/psychiatry, rheumatology	muscle pain, joint pain	Key	97.29	OC(=O)COc1nn(Cc2ccccc2)c2ccccc12	Launched
bendazol	nitric oxide synthase stimulant				MedChemEx	98.22	C(c1nc2ccccc2[nH]1)c1ccccc1	Launched
bendroflumethiazide	sodium/potassium/chloride transporter inhibitor	SLC12A1, SLC12A3	cardiology	hypertension	MicroSource, Selleck, Selleck, Selleck	98.93	NS(=O)(=O)c1cc2c(N[C@@H](Cc3ccccc3)NS2(=O)=O)cc1C(F)(F)F |&1:9,r|, NS(=O)(=O)c1cc2c(N[C@@H](Cc3ccccc3)NS2(=O)=O)cc1C(F)(F)F |&1:9,r|, NS(=O)(=O)c1cc2c(N[C@@H](Cc3ccccc3)NS2(=O)=O)cc1C(F)(F)F |&1:9,r|, NS(=O)(=O)c1cc2c(N[C@@H](Cc3ccccc3)NS2(=O)=O)cc1C(F)(F)F |&1:9,r|	Launched
benethamine					Enamine	99.27	C(Cc1ccccc1)NCc1ccccc1	Preclinical
benfluorex	gluconeogenesis inhibitor	HMGCR			MedChemEx	96.62	C[C@@H](Cc1cccc(c1)C(F)(F)F)NCCOC(=O)c1ccccc1 |r|	Withdrawn
benfluralin		CYP1A1, CYP1A2, CYP2B6, CYP3A4, ESR1, MMP1, SULT2A1, UGT1A1			Sigma, Sigma	97.41	CCCCN(CC)c1c(cc(cc1[N+]([O-])=O)C(F)(F)F)[N+]([O-])=O, CCCCN(CC)c1c(cc(cc1[N+]([O-])=O)C(F)(F)F)[N+]([O-])=O	Phase 3
benfotiamine	antioxidant	AGER	rheumatology	lumbago	MicroSource, Selleck, MedChemEx, Selleck	93.58	C\C(N(Cc1cnc(C)nc1N)C=O)=C(/CCOP(O)(O)=O)SC(=O)c1ccccc1, C\C(N(Cc1cnc(C)nc1N)C=O)=C(/CCOP(O)(O)=O)SC(=O)c1ccccc1, C\C(N(Cc1cnc(C)nc1N)C=O)=C(/CCOP(O)(O)=O)SC(=O)c1ccccc1, C\C(N(Cc1cnc(C)nc1N)C=O)=C(/CCOP(O)(O)=O)SC(=O)c1ccccc1	Launched
benidipine	calcium channel blocker	CACNA1C, CACNA1G	cardiology	hypertension	Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck	99.21	COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)O[C@@H]1CCCN(Cc2ccccc2)C1, COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)O[C@@H]1CCCN(Cc2ccccc2)C1, COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)O[C@@H]1CCCN(Cc2ccccc2)C1, COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)O[C@@H]1CCCN(Cc2ccccc2)C1, COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)O[C@@H]1CCCN(Cc2ccccc2)C1, COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)O[C@@H]1CCCN(Cc2ccccc2)C1, COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)O[C@@H]1CCCN(Cc2ccccc2)C1	Launched
benperidol	dopamine receptor antagonist	DRD2	neurology/psychiatry	schizophrenia	Sigma, Prestwick	96.81	Fc1ccc(cc1)C(=O)CCCN1CCC(CC1)n1c2ccccc2[nH]c1=O, Fc1ccc(cc1)C(=O)CCCN1CCC(CC1)n1c2ccccc2[nH]c1=O	Launched
benproperine	antitussive	SCN5A	pulmonary	cough suppressant	AvaChem	97.04	C[C@@H](COc1ccccc1Cc1ccccc1)N1CCCCC1 |&1:1,r|	Launched
benserazide	DOPA decarboxylase inhibitor	DDC	neurology/psychiatry	Parkinson's Disease	MicroSource, Selleck	93.52	NC(CO)C(=O)NNCc1ccc(O)c(O)c1O, NC(CO)C(=O)NNCc1ccc(O)c(O)c1O	Launched
bentiromide		HPN	gastroenterology	pancreas diagnostic agent	Selleck, Selleck, Selleck	98.07	OC(=O)c1ccc(NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)c2ccccc2)cc1, OC(=O)c1ccc(NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)c2ccccc2)cc1, OC(=O)c1ccc(NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)c2ccccc2)cc1	Launched
benurestat	urease inhibitor				MicroSource, LifeChem	94.64	ONC(=O)CNC(=O)c1ccc(Cl)cc1, ONC(=O)CNC(=O)c1ccc(Cl)cc1	Phase 1
benzalkonium	cationic surfactant		dermatology	abrasions, superficial cuts	MicroSource, Selleck	0	CCCCCCCCCCCCC[N+](C)(C)Cc1ccccc1, CCCCCCCCCCCCC[N+](C)(C)Cc1ccccc1	Launched
benzamil	sodium channel blocker	ASIC1, PKD2L1, SCNN1A, SCNN1B, SCNN1D, SCNN1G, SLC8A1			Tocris, Enzo, Tocris	97.72	NC(NCc1ccccc1)=NC(=O)c1nc(Cl)c(N)nc1N, NC(NCc1ccccc1)=NC(=O)c1nc(Cl)c(N)nc1N, NC(NCc1ccccc1)=NC(=O)c1nc(Cl)c(N)nc1N	Phase 2
benzbromarone	chloride channel blocker	ABCC1	rheumatology	gout	Tocris, MicroSource, Selleck	96.33	CCc1oc2ccccc2c1C(=O)c1cc(Br)c(O)c(Br)c1, CCc1oc2ccccc2c1C(=O)c1cc(Br)c(O)c(Br)c1, CCc1oc2ccccc2c1C(=O)c1cc(Br)c(O)c(Br)c1	Launched
benzenemethanol,-2,5-dimethyl-[[(1-methylethyl)amino]methyl]					Enamine	83.87	CC(C)NC[C@@H](O)c1cc(C)ccc1C |&1:5,r|	Preclinical
benzethonium	sodium channel blocker	SCN10A	infectious disease	first-aid antiseptic	MicroSource, MicroSource, MicroSource, MicroSource, MicroSource, MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx, Selleck, Selleck	99.48	CC(C)(C)CC(C)(C)c1ccc(OCCOCC[N+](C)(C)Cc2ccccc2)cc1, CC(C)(C)CC(C)(C)c1ccc(OCCOCC[N+](C)(C)Cc2ccccc2)cc1, CC(C)(C)CC(C)(C)c1ccc(OCCOCC[N+](C)(C)Cc2ccccc2)cc1, CC(C)(C)CC(C)(C)c1ccc(OCCOCC[N+](C)(C)Cc2ccccc2)cc1, CC(C)(C)CC(C)(C)c1ccc(OCCOCC[N+](C)(C)Cc2ccccc2)cc1, CC(C)(C)CC(C)(C)c1ccc(OCCOCC[N+](C)(C)Cc2ccccc2)cc1, CC(C)(C)CC(C)(C)c1ccc(OCCOCC[N+](C)(C)Cc2ccccc2)cc1, CC(C)(C)CC(C)(C)c1ccc(OCCOCC[N+](C)(C)Cc2ccccc2)cc1, CC(C)(C)CC(C)(C)c1ccc(OCCOCC[N+](C)(C)Cc2ccccc2)cc1, CC(C)(C)CC(C)(C)c1ccc(OCCOCC[N+](C)(C)Cc2ccccc2)cc1, CC(C)(C)CC(C)(C)c1ccc(OCCOCC[N+](C)(C)Cc2ccccc2)cc1, CC(C)(C)CC(C)(C)c1ccc(OCCOCC[N+](C)(C)Cc2ccccc2)cc1, CC(C)(C)CC(C)(C)c1ccc(OCCOCC[N+](C)(C)Cc2ccccc2)cc1	Launched
benznidazole	DNA synthesis inhibitor		infectious disease	Chagas disease	Toronto	86.94	[O-][N+](=O)c1nccn1CC(=O)NCc1ccccc1	Launched
benzo[d]thiazole-2(3H)-thione					Ark	95.36	S=c1[nH]c2ccccc2s1	Phase 1
benzocaine	sodium channel blocker	SCN10A	infectious disease	first-aid antiseptic	MicroSource, MedChemEx, MedChemEx, Selleck	99.51	CCOC(=O)c1ccc(N)cc1, CCOC(=O)c1ccc(N)cc1, CCOC(=O)c1ccc(N)cc1, CCOC(=O)c1ccc(N)cc1	Launched
benzoclidine					MicroSource	35.21	O=C(O[C@H]1CN2CCC1CC2)c1ccccc1 |&1:3,r|	Preclinical
benzofenac					Sigma, Sigma, Sigma	99.01	OC(=O)Cc1ccc(OCc2ccccc2)c(Cl)c1, OC(=O)Cc1ccc(OCc2ccccc2)c(Cl)c1, OC(=O)Cc1ccc(OCc2ccccc2)c(Cl)c1	Phase 1
benzoic-acid	food preservative	DAO, HRSP12, PRDX5, RAB9A	infectious disease	tinea pedis	MicroSource, MicroSource, Selleck, Selleck	98.16	OC(=O)c1ccccc1, OC(=O)c1ccccc1, OC(=O)c1ccccc1, OC(=O)c1ccccc1	Launched
benzoin		CES1			Enamine, MedChemEx	99.28	O[C@@H](C(=O)c1ccccc1)c1ccccc1 |&1:1,r|, O[C@@H](C(=O)c1ccccc1)c1ccccc1 |&1:1,r|	Preclinical
benzonatate	local anesthetic	SCN5A	pulmonary	cough suppressant	MicroSource	99.74	CCCCNc1ccc(cc1)C(=O)OCCOCCOCCOCCOCCOCCOCCOCCOCCOC	Launched
benzoquinonium-dibromide	cholinergic receptor antagonist	CHRNA1			Tocris, Tocris, Tocris	92.73	CC[N+](CC)(CCCNC1=CC(=O)C(NCCC[N+](CC)(CC)Cc2ccccc2)=CC1=O)Cc1ccccc1 |c:30,t:9|, CC[N+](CC)(CCCNC1=CC(=O)C(NCCC[N+](CC)(CC)Cc2ccccc2)=CC1=O)Cc1ccccc1 |c:30,t:9|, CC[N+](CC)(CCCNC1=CC(=O)C(NCCC[N+](CC)(CC)Cc2ccccc2)=CC1=O)Cc1ccccc1 |c:30,t:9|	Preclinical
benzotript	CCK receptor antagonist	CCKAR, CCKBR			Vitas-M	97.86	OC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)c1ccc(Cl)cc1	Phase 1
benzoxiquine	antiinfective drug				MicroSource	99.67	O=C(Oc1cccc2cccnc12)c1ccccc1	Preclinical
benzoyl-peroxide	oxidizing agent		dermatology	acne vulgaris (AV)	MicroSource, Sigma	0	O=C(OOC(=O)c1ccccc1)c1ccccc1, O=C(OOC(=O)c1ccccc1)c1ccccc1	Launched
benzoylpas					MicroSource, Vitas-M, Vitas-M	97.57	OC(=O)c1ccc(NC(=O)c2ccccc2)cc1O, OC(=O)c1ccc(NC(=O)c2ccccc2)cc1O, OC(=O)c1ccc(NC(=O)c2ccccc2)cc1O	Preclinical
benzthiazide	carbonic anhydrase inhibitor	CA2	cardiology	hypertension, edema	MicroSource, MicroSource, MicroSource, MicroSource, Selleck, Selleck, Selleck	99.29	NS(=O)(=O)c1cc2c(NC(NS2(=O)=O)=CSCc2ccccc2)cc1Cl, NS(=O)(=O)c1cc2c(NC(NS2(=O)=O)=CSCc2ccccc2)cc1Cl, NS(=O)(=O)c1cc2c(NC(NS2(=O)=O)=CSCc2ccccc2)cc1Cl, NS(=O)(=O)c1cc2c(NC(NS2(=O)=O)=CSCc2ccccc2)cc1Cl, NS(=O)(=O)c1cc2c(NC(NS2(=O)=O)=CSCc2ccccc2)cc1Cl, NS(=O)(=O)c1cc2c(NC(NS2(=O)=O)=CSCc2ccccc2)cc1Cl, NS(=O)(=O)c1cc2c(NC(NS2(=O)=O)=CSCc2ccccc2)cc1Cl	Launched
benztropine-mesylate	acetylcholine receptor antagonist	CHRM1, HRH1, SLC6A3	neurology/psychiatry	extrapyramidal symptoms (EPS), Parkinson's Disease	MedChemEx	94.73	CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(c1ccccc1)c1ccccc1	Launched
benzydamine	prostanoid receptor antagonist		dental, otolaryngology	mouth inflammation, throat inflammation	MicroSource, Selleck	98.35	CN(C)CCCOc1nn(Cc2ccccc2)c2ccccc12, CN(C)CCCOc1nn(Cc2ccccc2)c2ccccc12	Launched
benzyl-alcohol	local anesthetic		infectious disease	virus herpes simplex (HSV)	MicroSource, Sigma	0	OCc1ccccc1, OCc1ccccc1	Launched
benzyl-benzoate	lipase inhibitor	LIPE	allergy	sweet itch	MicroSource, MedChemEx, Sigma	0	O=C(OCc1ccccc1)c1ccccc1, O=C(OCc1ccccc1)c1ccccc1, O=C(OCc1ccccc1)c1ccccc1	Launched
benzyl-isothiocyanate	methylazoxymethanol acetate inhibitor				MicroSource, CombiBlocks	2.87	S=C=NCc1ccccc1, S=C=NCc1ccccc1	Preclinical
benzyldimethylhexadecylammonium	cationic surfactant				Acros, Acros, Acros	98.49	CCCCCCCCCCCCCCCC[N+](C)(C)Cc1ccccc1, CCCCCCCCCCCCCCCC[N+](C)(C)Cc1ccccc1, CCCCCCCCCCCCCCCC[N+](C)(C)Cc1ccccc1	Preclinical
benzyldimethyloctylammonium					Sigma	96.76	CCCCCCCC[N+](C)(C)Cc1ccccc1	Preclinical
benzylpenicillin	penicillin binding protein inhibitor		infectious disease	celluitis, meningitis, endocarditis, syphilis, pneumonia, bacterial septicemia	Selleck, MicroSource, Selleck	97.54	CC1(C)S[C@@H]2[C@H](NC(=O)Cc3ccccc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)Cc3ccccc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)Cc3ccccc3)C(=O)N2[C@H]1C(O)=O	Launched
bephenium-hydroxynaphthoate	anthelmintic agent		infectious disease	ascariasis	MedChemEx, MicroSource, Selleck, Selleck	97.09	C[N+](C)(CCOc1ccccc1)Cc1ccccc1, C[N+](C)(CCOc1ccccc1)Cc1ccccc1, C[N+](C)(CCOc1ccccc1)Cc1ccccc1, C[N+](C)(CCOc1ccccc1)Cc1ccccc1	Launched
bepotastine	histamine receptor antagonist	HRH1	ophthalmology	conjunctivitis	Selleck, Selleck, Selleck	99.09	OC(=O)CCCN1CCC(CC1)O[C@@H](c1ccc(Cl)cc1)c1ccccn1, OC(=O)CCCN1CCC(CC1)O[C@@H](c1ccc(Cl)cc1)c1ccccn1, OC(=O)CCCN1CCC(CC1)O[C@@H](c1ccc(Cl)cc1)c1ccccn1	Launched
bepridil	calcium channel blocker	KCNQ4	cardiology	angina pectoris	MicroSource, MicroSource, Tocris, Sigma, Sigma	96.17	CC(C)COCC(CN(Cc1ccccc1)c1ccccc1)N1CCCC1, CC(C)COCC(CN(Cc1ccccc1)c1ccccc1)N1CCCC1, CC(C)COCC(CN(Cc1ccccc1)c1ccccc1)N1CCCC1, CC(C)COCC(CN(Cc1ccccc1)c1ccccc1)N1CCCC1, CC(C)COCC(CN(Cc1ccccc1)c1ccccc1)N1CCCC1	Launched
berberine	LDL receptor activator	LDLR			MedChemEx, MedChemEx, MicroSource, MicroSource, Selleck	95.66	COc1ccc2cc3-c4cc5OCOc5cc4CC[n+]3cc2c1OC, COc1ccc2cc3-c4cc5OCOc5cc4CC[n+]3cc2c1OC, COc1ccc2cc3-c4cc5OCOc5cc4CC[n+]3cc2c1OC, COc1ccc2cc3-c4cc5OCOc5cc4CC[n+]3cc2c1OC, COc1ccc2cc3-c4cc5OCOc5cc4CC[n+]3cc2c1OC	Launched
bergapten					MicroSource, MedChemEx, Selleck	98.83	COc1c2ccoc2cc2oc(=O)ccc12, COc1c2ccoc2cc2oc(=O)ccc12, COc1c2ccoc2cc2oc(=O)ccc12	Phase 3
bergenin	interleukin inhibitor	IL1B, TNF			MicroSource, MedChemEx, Selleck	97.98	COc1c(O)cc2C(=O)O[C@@H]3[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]3c2c1O, COc1c(O)cc2C(=O)O[C@@H]3[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]3c2c1O, COc1c(O)cc2C(=O)O[C@@H]3[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]3c2c1O	Preclinical
besifloxacin	bacterial DNA gyrase inhibitor		ophthalmology	conjunctivitis	Selleck, MedChemEx	93.81	N[C@@H]1CCCCN(C1)c1c(F)cc2c(c1Cl)n(cc(C(O)=O)c2=O)C1CC1, N[C@@H]1CCCCN(C1)c1c(F)cc2c(c1Cl)n(cc(C(O)=O)c2=O)C1CC1	Launched
BET-BAY-002	bromodomain inhibitor				MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx	98.81	Cc1nnc(C[C@@H]2C=C(c3ccc(Cl)cc3)c3ccccc3-n3c(C)nnc23)o1 |t:7|, Cc1nnc(C[C@@H]2C=C(c3ccc(Cl)cc3)c3ccccc3-n3c(C)nnc23)o1 |t:7|, Cc1nnc(C[C@@H]2C=C(c3ccc(Cl)cc3)c3ccccc3-n3c(C)nnc23)o1 |t:7|, Cc1nnc(C[C@@H]2C=C(c3ccc(Cl)cc3)c3ccccc3-n3c(C)nnc23)o1 |t:7|, Cc1nnc(C[C@@H]2C=C(c3ccc(Cl)cc3)c3ccccc3-n3c(C)nnc23)o1 |t:7|, Cc1nnc(C[C@@H]2C=C(c3ccc(Cl)cc3)c3ccccc3-n3c(C)nnc23)o1 |t:7|	Preclinical
beta-amyloid-synthesis-inhibitor	beta amyloid synthesis inhibitor	APP			Maybridge	94.44	Oc1cccc(Nc2ccc(Nc3cccc(O)c3)nn2)c1	Preclinical
beta-carotene					Selleck, Selleck, MedChemEx, MicroSource	0	C\C(\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C=C(\C)/C=C/C=C(\C)/C=C/C1=C(C)CCCC1(C)C |c:9,32|, C\C(\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C=C(\C)/C=C/C=C(\C)/C=C/C1=C(C)CCCC1(C)C |c:9,32|, C\C(\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C=C(\C)/C=C/C=C(\C)/C=C/C1=C(C)CCCC1(C)C |c:9,32|, C\C(\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C=C(\C)/C=C/C=C(\C)/C=C/C1=C(C)CCCC1(C)C |c:9,32|	Launched
beta-CCB	benzodiazepine receptor ligand	GABRA1, GABRG2			Tocris, Tocris	98.04	CCCCOC(=O)c1cc2c(cn1)[nH]c1ccccc21, CCCCOC(=O)c1cc2c(cn1)[nH]c1ccccc21	Launched
beta-elemene	apoptosis stimulant	MMP2, MMP9			Sigma	0	CC(=C)[C@@H]1CC[C@@](C)(C=C)[C@@H](C1)C(C)=C	Launched
beta-funaltrexamine	opioid receptor antagonist	OPRD1, OPRK1, OPRM1			Tocris, Tocris, Tocris, Tocris, Tocris	95.83	COC(=O)\C=C\C(=O)N[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5O[C@@H]1[C@]2(CCN3CC1CC1)c45, COC(=O)\C=C\C(=O)N[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5O[C@@H]1[C@]2(CCN3CC1CC1)c45, COC(=O)\C=C\C(=O)N[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5O[C@@H]1[C@]2(CCN3CC1CC1)c45, COC(=O)\C=C\C(=O)N[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5O[C@@H]1[C@]2(CCN3CC1CC1)c45, COC(=O)\C=C\C(=O)N[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5O[C@@H]1[C@]2(CCN3CC1CC1)c45	Preclinical
beta-glycerophosphoric-acid					Vitas-M	0	OCC(CO)OP(O)(O)=O	Preclinical
beta-hydroxy-beta-methylbutyrate	protein synthesis stimulant	MTOR			CombiBlocks	97.1	CC(C)(O)CC(O)=O.CC(C)(O)CC(O)=O	Launched
beta-hydroxybutyrate		HCAR2			Vitas-M	0	CC(O)CC(O)=O	Phase 1
beta-lapachone	topoisomerase inhibitor	TOP1			MedChemEx, MedChemEx, Selleck, Selleck, Selleck, Selleck, Selleck	82.91	CC1(C)CCC2=C(O1)c1ccccc1C(=O)C2=O |c:5|, CC1(C)CCC2=C(O1)c1ccccc1C(=O)C2=O |c:5|, CC1(C)CCC2=C(O1)c1ccccc1C(=O)C2=O |c:5|, CC1(C)CCC2=C(O1)c1ccccc1C(=O)C2=O |c:5|, CC1(C)CCC2=C(O1)c1ccccc1C(=O)C2=O |c:5|, CC1(C)CCC2=C(O1)c1ccccc1C(=O)C2=O |c:5|, CC1(C)CCC2=C(O1)c1ccccc1C(=O)C2=O |c:5|	Phase 2
beta-naphthol					MicroSource	90.98	Oc1ccc2ccccc2c1	Preclinical
betahistine	histamine receptor agonist, histamine receptor antagonist	HRH1, HRH3	neurology/psychiatry	Meniere's disease	MedChemEx, MicroSource, Selleck	100	CNCCc1ccccn1, CNCCc1ccccn1, CNCCc1ccccn1	Launched
betaine	nitric oxide donor		metabolism	homocystinuria	MicroSource	0	C[N+](C)(C)CC(O)=O	Launched
betamethasone	glucocorticoid receptor agonist	NR3C1	dermatology	corticosteroid-responsive dermatoses	MedChemEx	93.39	C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO |c:11,t:7|	Launched
betamethasone-acetate	glucocorticoid receptor agonist	NR3C1	dermatology	corticosteroid-responsive dermatoses	TCI	93.74	C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COC(C)=O |c:11,t:7|	Launched
betamethasone-butyrate-propionate			rheumatology	rheumatoid arthritis	MedChemEx	81.08	CCCC(=O)O[C@@]1([C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)COC(=O)CC |c:18,t:14|	Launched
betamethasone-dipropionate	anti-inflammatory agent	NR3C1	dermatology	corticosteroid-responsive dermatoses	MicroSource, MedChemEx, Selleck, Selleck	96.86	CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C |c:25,t:21|, CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C |c:25,t:21|, CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C |c:25,t:21|, CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C |c:25,t:21|	Launched
betamethasone-phosphate			rheumatology	rheumatoid arthritis	Toronto	88.21	C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COP(O)(O)=O |c:11,t:7|	Launched
betamethasone-valerate	glucocorticoid receptor agonist	NR3C1	dermatology	corticosteroid-responsive dermatoses	MicroSource, Selleck, Selleck, Selleck	94.78	CCCCC(=O)O[C@@]1([C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)CO |c:19,t:15|, CCCCC(=O)O[C@@]1([C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)CO |c:19,t:15|, CCCCC(=O)O[C@@]1([C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)CO |c:19,t:15|, CCCCC(=O)O[C@@]1([C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)CO |c:19,t:15|	Launched
betamipron	panipenem uptake inhibitor		nephrology	renal toxicity	MedChemEx, MicroSource, Selleck	96.28	OC(=O)CCNC(=O)c1ccccc1, OC(=O)CCNC(=O)c1ccccc1, OC(=O)CCNC(=O)c1ccccc1	Launched
betaxolol	adrenergic receptor antagonist	ADRB1, ADRB2	ophthalmology	intraocular pressure, glaucoma, ocular hypertension	Selleck, Selleck	95.61	CC(C)NC[C@@H](O)COc1ccc(CCOCC2CC2)cc1 |&1:5,r|, CC(C)NC[C@@H](O)COc1ccc(CCOCC2CC2)cc1 |&1:5,r|	Launched
betazole	histamine receptor agonist	HRH2	gastroenterology	gastric hypersecretion diagnostic	Prestwick	97.19	NCCc1ccn[nH]1	Launched
bethanechol	acetylcholine receptor agonist	CHRM1, CHRM2, CHRM3, CHRM4	urology	urinary retention	MedChemEx	68.7	C[C@@H](C[N+](C)(C)C)OC(N)=O |r|	Launched
BETP	GLP receptor positive allosteric modulator	GLP1R			Tocris	96.39	CC[S@](=O)c1nc(cc(n1)C(F)(F)F)-c1cccc(OCc2ccccc2)c1 |&1:2,r|	Preclinical
betrixaban	coagulation factor inhibitor	KCNH2	hematology	deep vein thrombosis (DVT)	MedChemEx, MedChemEx, MedChemEx, MedChemEx	94.98	COc1ccc(NC(=O)c2ccc(cc2)C(=N)N(C)C)c(c1)C(=O)Nc1ccc(Cl)cn1, COc1ccc(NC(=O)c2ccc(cc2)C(=N)N(C)C)c(c1)C(=O)Nc1ccc(Cl)cn1, COc1ccc(NC(=O)c2ccc(cc2)C(=N)N(C)C)c(c1)C(=O)Nc1ccc(Cl)cn1, COc1ccc(NC(=O)c2ccc(cc2)C(=N)N(C)C)c(c1)C(=O)Nc1ccc(Cl)cn1	Launched
betulinic-acid	apoptosis stimulant, NFkB pathway inhibitor	GPBAR1			Tocris, Selleck, Selleck	96.07	CC(=C)[C@@H]1CC[C@@]2(CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(O)=O, CC(=C)[C@@H]1CC[C@@]2(CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(O)=O, CC(=C)[C@@H]1CC[C@@]2(CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(O)=O	Phase 1/Phase 2
bevantolol	adrenergic receptor antagonist		cardiology	angina pectoris, hypertension	AKSci, AKSci	94.05	COc1ccc(CCNC[C@@H](O)COc2cccc(C)c2)cc1OC |&1:10|, COc1ccc(CCNC[C@@H](O)COc2cccc(C)c2)cc1OC |&1:10|	Launched
bevenopran	opioid receptor antagonist				AMS	96.99	COc1cc(CNCCC2CCOCC2)ccc1Oc1cnc(cn1)C(N)=O	Phase 1
bevirimat-dimeglumine	HIV capsid assembly inhibitor				MedChemEx, MedChemEx, MedChemEx	87.82	CC(=C)[C@@H]1CC[C@@]2(CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](OC(=O)CC(C)(C)C(O)=O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(O)=O, CC(=C)[C@@H]1CC[C@@]2(CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](OC(=O)CC(C)(C)C(O)=O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(O)=O, CC(=C)[C@@H]1CC[C@@]2(CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](OC(=O)CC(C)(C)C(O)=O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(O)=O	Phase 2
bexagliflozin	solute carrier family member inhibitor				MedChemEx	97.26	OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)c1ccc(Cl)c(Cc2ccc(OCCOC3CC3)cc2)c1	Phase 3
bexarotene	retinoid receptor agonist	RXRA, RXRB, RXRG	hematologic malignancy	cutaneous T-cell lymphoma (CTCL)	Tocris, Selleck, Selleck, Selleck	98.35	Cc1cc2c(cc1C(=C)c1ccc(cc1)C(O)=O)C(C)(C)CCC2(C)C, Cc1cc2c(cc1C(=C)c1ccc(cc1)C(O)=O)C(C)(C)CCC2(C)C, Cc1cc2c(cc1C(=C)c1ccc(cc1)C(O)=O)C(C)(C)CCC2(C)C, Cc1cc2c(cc1C(=C)c1ccc(cc1)C(O)=O)C(C)(C)CCC2(C)C	Launched
bezafibrate	PPAR receptor agonist	PPARA, PPARD, PPARG	cardiology	cholesterol	MedChemEx, MedChemEx, MicroSource, Selleck	99.25	CC(C)(Oc1ccc(CCNC(=O)c2ccc(Cl)cc2)cc1)C(O)=O, CC(C)(Oc1ccc(CCNC(=O)c2ccc(Cl)cc2)cc1)C(O)=O, CC(C)(Oc1ccc(CCNC(=O)c2ccc(Cl)cc2)cc1)C(O)=O, CC(C)(Oc1ccc(CCNC(=O)c2ccc(Cl)cc2)cc1)C(O)=O	Launched
BFH772	VEGFR inhibitor				MedChemEx	93.37	OCc1cc(Oc2ccc3c(cccc3c2)C(=O)Nc2cccc(c2)C(F)(F)F)ncn1	Phase 2
BGP-15	PARP inhibitor				MedChemEx	97.8	O[C@H](CONC(=N)c1cccnc1)CN1CCCCC1 |&1:1,r|	Phase 2
BGT226	PI3K inhibitor	MTOR, PIK3CA, PIK3CB, PIK3CG			Selleck, Selleck, Selleck, Selleck, Selleck, Selleck	98.31	COc1ccc(cn1)-c1ccc2ncc3n(C)c(=O)n(-c4ccc(N5CCNCC5)c(c4)C(F)(F)F)c3c2c1, COc1ccc(cn1)-c1ccc2ncc3n(C)c(=O)n(-c4ccc(N5CCNCC5)c(c4)C(F)(F)F)c3c2c1, COc1ccc(cn1)-c1ccc2ncc3n(C)c(=O)n(-c4ccc(N5CCNCC5)c(c4)C(F)(F)F)c3c2c1, COc1ccc(cn1)-c1ccc2ncc3n(C)c(=O)n(-c4ccc(N5CCNCC5)c(c4)C(F)(F)F)c3c2c1, COc1ccc(cn1)-c1ccc2ncc3n(C)c(=O)n(-c4ccc(N5CCNCC5)c(c4)C(F)(F)F)c3c2c1, COc1ccc(cn1)-c1ccc2ncc3n(C)c(=O)n(-c4ccc(N5CCNCC5)c(c4)C(F)(F)F)c3c2c1	Phase 1/Phase 2
BHQ	ATPase inhibitor	ATP2A1			Tocris, Tocris	100	CC(C)(C)c1cc(O)c(cc1O)C(C)(C)C, CC(C)(C)c1cc(O)c(cc1O)C(C)(C)C	Preclinical
BI-D1870	ribosomal protein inhibitor	RPS6KA1, RPS6KA2, RPS6KA3, RPS6KA6			MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx, Selleck, Selleck	93.8	CC(C)CCN1[C@@H](C)C(=O)N(C)c2cnc(Nc3cc(F)c(O)c(F)c3)nc12 |&1:6,r|, CC(C)CCN1[C@@H](C)C(=O)N(C)c2cnc(Nc3cc(F)c(O)c(F)c3)nc12 |&1:6,r|, CC(C)CCN1[C@@H](C)C(=O)N(C)c2cnc(Nc3cc(F)c(O)c(F)c3)nc12 |&1:6,r|, CC(C)CCN1[C@@H](C)C(=O)N(C)c2cnc(Nc3cc(F)c(O)c(F)c3)nc12 |&1:6,r|, CC(C)CCN1[C@@H](C)C(=O)N(C)c2cnc(Nc3cc(F)c(O)c(F)c3)nc12 |&1:6,r|, CC(C)CCN1[C@@H](C)C(=O)N(C)c2cnc(Nc3cc(F)c(O)c(F)c3)nc12 |&1:6,r|, CC(C)CCN1[C@@H](C)C(=O)N(C)c2cnc(Nc3cc(F)c(O)c(F)c3)nc12 |&1:6,r|, CC(C)CCN1[C@@H](C)C(=O)N(C)c2cnc(Nc3cc(F)c(O)c(F)c3)nc12 |&1:6,r|	Preclinical
BI-224436	HIV integrase inhibitor				MedChemEx, MedChemEx	93.15	Cc1nc2ccccc2c(-c2ccc3OCCc4ccnc2c34)c1[C@H](OC(C)(C)C)C(O)=O, Cc1nc2ccccc2c(-c2ccc3OCCc4ccnc2c34)c1[C@H](OC(C)(C)C)C(O)=O	Phase 1
BI-2536	PLK inhibitor	BRD4, PLK1, PLK2, PLK3			Selleck, Selleck, Selleck, Selleck, Selleck, Axon, Axon, Axon, Axon	98.47	CC[C@H]1N(C2CCCC2)c2nc(Nc3ccc(cc3OC)C(=O)NC3CCN(C)CC3)ncc2N(C)C1=O, CC[C@H]1N(C2CCCC2)c2nc(Nc3ccc(cc3OC)C(=O)NC3CCN(C)CC3)ncc2N(C)C1=O, CC[C@H]1N(C2CCCC2)c2nc(Nc3ccc(cc3OC)C(=O)NC3CCN(C)CC3)ncc2N(C)C1=O, CC[C@H]1N(C2CCCC2)c2nc(Nc3ccc(cc3OC)C(=O)NC3CCN(C)CC3)ncc2N(C)C1=O, CC[C@H]1N(C2CCCC2)c2nc(Nc3ccc(cc3OC)C(=O)NC3CCN(C)CC3)ncc2N(C)C1=O, CC[C@H]1N(C2CCCC2)c2nc(Nc3ccc(cc3OC)C(=O)NC3CCN(C)CC3)ncc2N(C)C1=O, CC[C@H]1N(C2CCCC2)c2nc(Nc3ccc(cc3OC)C(=O)NC3CCN(C)CC3)ncc2N(C)C1=O, CC[C@H]1N(C2CCCC2)c2nc(Nc3ccc(cc3OC)C(=O)NC3CCN(C)CC3)ncc2N(C)C1=O, CC[C@H]1N(C2CCCC2)c2nc(Nc3ccc(cc3OC)C(=O)NC3CCN(C)CC3)ncc2N(C)C1=O	Phase 2
BI-409306	phosphodiesterase inhibitor				MedChemEx	98.6	Oc1nc(Cc2ccccn2)nc2n(ncc12)C1CCOCC1	Phase 1
BI-78D3	JNK inhibitor	MAPK8			Tocris, Tocris, Tocris, Tocris, Sigma, Sigma, Sigma, Sigma, Sigma	98.15	[O-][N+](=O)c1cnc(Sc2n[nH]c(=O)n2-c2ccc3OCCOc3c2)s1, [O-][N+](=O)c1cnc(Sc2n[nH]c(=O)n2-c2ccc3OCCOc3c2)s1, [O-][N+](=O)c1cnc(Sc2n[nH]c(=O)n2-c2ccc3OCCOc3c2)s1, [O-][N+](=O)c1cnc(Sc2n[nH]c(=O)n2-c2ccc3OCCOc3c2)s1, [O-][N+](=O)c1cnc(Sc2n[nH]c(=O)n2-c2ccc3OCCOc3c2)s1, [O-][N+](=O)c1cnc(Sc2n[nH]c(=O)n2-c2ccc3OCCOc3c2)s1, [O-][N+](=O)c1cnc(Sc2n[nH]c(=O)n2-c2ccc3OCCOc3c2)s1, [O-][N+](=O)c1cnc(Sc2n[nH]c(=O)n2-c2ccc3OCCOc3c2)s1, [O-][N+](=O)c1cnc(Sc2n[nH]c(=O)n2-c2ccc3OCCOc3c2)s1	Preclinical
BI-847325	Aurora kinase inhibitor, MEK inhibitor	AURKA, AURKB, AURKC, MAP2K1, MAP2K2			Selleck, Selleck, Selleck, Selleck, Selleck	93.58	CCNC(=O)C#Cc1ccc2\C(=C(/Nc3ccc(CN(C)C)cc3)c3ccccc3)C(=O)Nc2c1, CCNC(=O)C#Cc1ccc2\C(=C(/Nc3ccc(CN(C)C)cc3)c3ccccc3)C(=O)Nc2c1, CCNC(=O)C#Cc1ccc2\C(=C(/Nc3ccc(CN(C)C)cc3)c3ccccc3)C(=O)Nc2c1, CCNC(=O)C#Cc1ccc2\C(=C(/Nc3ccc(CN(C)C)cc3)c3ccccc3)C(=O)Nc2c1, CCNC(=O)C#Cc1ccc2\C(=C(/Nc3ccc(CN(C)C)cc3)c3ccccc3)C(=O)Nc2c1	Phase 1
BIA-10-2474	Fatty acid hydrolase inhibitor				MedChemEx	94.87	CN(C1CCCCC1)C(=O)n1cnc(c1)-c1ccc[n+]([O-])c1	Preclinical
biapenem	bacterial cell wall synthesis inhibitor		infectious disease	bacterial septicemia, pneumonia, urinary tract infections	MedChemEx, Sigma, MedChemEx, MedChemEx, Selleck, Selleck, Selleck	74.7	C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(SC3Cn4cnc[n+]4C3)=C(N2C1=O)C(O)=O |a:1,3,4,5,&1:9,c:18|, C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(SC3Cn4cnc[n+]4C3)=C(N2C1=O)C(O)=O |a:1,3,4,5,&1:9,c:18|, C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(SC3Cn4cnc[n+]4C3)=C(N2C1=O)C(O)=O |a:1,3,4,5,&1:9,c:18|, C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(SC3Cn4cnc[n+]4C3)=C(N2C1=O)C(O)=O |a:1,3,4,5,&1:9,c:18|, C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(SC3Cn4cnc[n+]4C3)=C(N2C1=O)C(O)=O |a:1,3,4,5,&1:9,c:18|, C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(SC3Cn4cnc[n+]4C3)=C(N2C1=O)C(O)=O |a:1,3,4,5,&1:9,c:18|, C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(SC3Cn4cnc[n+]4C3)=C(N2C1=O)C(O)=O |a:1,3,4,5,&1:9,c:18|	Launched
BIBN4096	calcitonin antagonist	CALCA, CALCRL, RAMP1			MedChemEx, MedChemEx, MedChemEx, MedChemEx	86.32	NCCCC[C@H](NC(=O)[C@@H](Cc1cc(Br)c(O)c(Br)c1)NC(=O)N1CCC(CC1)N1Cc2ccccc2NC1=O)C(=O)N1CCN(CC1)c1ccncc1, NCCCC[C@H](NC(=O)[C@@H](Cc1cc(Br)c(O)c(Br)c1)NC(=O)N1CCC(CC1)N1Cc2ccccc2NC1=O)C(=O)N1CCN(CC1)c1ccncc1, NCCCC[C@H](NC(=O)[C@@H](Cc1cc(Br)c(O)c(Br)c1)NC(=O)N1CCC(CC1)N1Cc2ccccc2NC1=O)C(=O)N1CCN(CC1)c1ccncc1, NCCCC[C@H](NC(=O)[C@@H](Cc1cc(Br)c(O)c(Br)c1)NC(=O)N1CCC(CC1)N1Cc2ccccc2NC1=O)C(=O)N1CCN(CC1)c1ccncc1	Phase 2
BIBR-1532	telomerase inhibitor	TERT			Tocris, Selleck, Selleck, Selleck, Selleck	94.94	C\C(=C/C(=O)Nc1ccccc1C(O)=O)c1ccc2ccccc2c1, C\C(=C/C(=O)Nc1ccccc1C(O)=O)c1ccc2ccccc2c1, C\C(=C/C(=O)Nc1ccccc1C(O)=O)c1ccc2ccccc2c1, C\C(=C/C(=O)Nc1ccccc1C(O)=O)c1ccc2ccccc2c1, C\C(=C/C(=O)Nc1ccccc1C(O)=O)c1ccc2ccccc2c1	Preclinical
BIBU-1361	EGFR inhibitor	EGFR			Tocris, Tocris, Tocris	96.69	CCN(CC)CC1CCN(CC1)c1ncc2ncnc(Nc3ccc(F)c(Cl)c3)c2n1, CCN(CC)CC1CCN(CC1)c1ncc2ncnc(Nc3ccc(F)c(Cl)c3)c2n1, CCN(CC)CC1CCN(CC1)c1ncc2ncnc(Nc3ccc(F)c(Cl)c3)c2n1	Preclinical
BIBX-1382	EGFR inhibitor	EGFR, ERBB2			Tocris, Tocris, Tocris	94.76	CN1CCC(CC1)Nc1ncc2ncnc(Nc3ccc(F)c(Cl)c3)c2n1, CN1CCC(CC1)Nc1ncc2ncnc(Nc3ccc(F)c(Cl)c3)c2n1, CN1CCC(CC1)Nc1ncc2ncnc(Nc3ccc(F)c(Cl)c3)c2n1	Phase 1
bicalutamide	androgen receptor antagonist	AR	oncology	prostate cancer	Tocris, MicroSource, Selleck	98.74	CC(O)(CS(=O)(=O)c1ccc(F)cc1)C(=O)Nc1ccc(C#N)c(c1)C(F)(F)F |&1:1|, CC(O)(CS(=O)(=O)c1ccc(F)cc1)C(=O)Nc1ccc(C#N)c(c1)C(F)(F)F |&1:1|, CC(O)(CS(=O)(=O)c1ccc(F)cc1)C(=O)Nc1ccc(C#N)c(c1)C(F)(F)F |&1:1|	Launched
bicifadine	dopamine reuptake inhibitor, serotonin receptor antagonist				Tocris	83.5	[H][C@@]12C[C@@]1(CNC2)c1ccc(C)cc1 |&1:1,3,r|	Phase 3
bictegravir	HIV integrase inhibitor		infectious disease	human immunodeficiency virus (HIV-1)	MedChemEx	100	[H][C@@]12CC[C@@]([H])(C1)N1C(=O)c3c(O)c(=O)c(cn3C[C@@]1([H])O2)C(=O)NCc1c(F)cc(F)cc1F	Launched
bicuculline-(+)	GABA receptor antagonist	GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, KCNN1			Tocris	97.87	CN1CCc2cc3OCOc3cc2[C@H]1[C@@H]1OC(=O)c2c1ccc1OCOc21	Preclinical
bicuculline-methochloride-(-)	GABA receptor antagonist				Tocris	97.01	C[N+]1(C)CCc2cc3OCOc3cc2[C@H]1[C@@H]1OC(=O)c2c1ccc1OCOc21	Preclinical
bicyclol	NFkB pathway inhibitor	HSPA1A, HSPB1	infectious disease	hepatitis B, hepatitis C	Sigma	98.42	COC(=O)c1cc(OC)c2OCOc2c1-c1c2OCOc2c(OC)cc1CO	Launched
bifemelane	acetylcholine release enhancer	MAOA, MAOB	ophthalmology, neurology/psychiatry	glaucoma, senile dementia	Tocris, Tocris, Tocris	96.76	CNCCCCOc1ccccc1Cc1ccccc1, CNCCCCOc1ccccc1Cc1ccccc1, CNCCCCOc1ccccc1Cc1ccccc1	Launched
bifendate			infectious disease	hepatitis B, hepatitis C	AKSci, AKSci	99.86	COC(=O)c1cc(OC)c2OCOc2c1-c1c2OCOc2c(OC)cc1C(=O)OC, COC(=O)c1cc(OC)c2OCOc2c1-c1c2OCOc2c(OC)cc1C(=O)OC	Launched
bifonazole	sterol demethylase inhibitor		infectious disease	tinea pedis, tinea cruris	MicroSource, MicroSource, MicroSource, MicroSource, Selleck, MedChemEx	99.27	c1cn(cn1)[C@@H](c1ccccc1)c1ccc(cc1)-c1ccccc1 |&1:5,r|, c1cn(cn1)[C@@H](c1ccccc1)c1ccc(cc1)-c1ccccc1 |&1:5,r|, c1cn(cn1)[C@@H](c1ccccc1)c1ccc(cc1)-c1ccccc1 |&1:5,r|, c1cn(cn1)[C@@H](c1ccccc1)c1ccc(cc1)-c1ccccc1 |&1:5,r|, c1cn(cn1)[C@@H](c1ccccc1)c1ccc(cc1)-c1ccccc1 |&1:5,r|, c1cn(cn1)[C@@H](c1ccccc1)c1ccc(cc1)-c1ccccc1 |&1:5,r|	Launched
BIIB021	HSP inhibitor	HSP90AA1			Tocris, Tocris, Tocris, Selleck, Selleck	97.64	COc1c(C)cnc(Cn2cnc3c(Cl)nc(N)nc23)c1C, COc1c(C)cnc(Cn2cnc3c(Cl)nc(N)nc23)c1C, COc1c(C)cnc(Cn2cnc3c(Cl)nc(N)nc23)c1C, COc1c(C)cnc(Cn2cnc3c(Cl)nc(N)nc23)c1C, COc1c(C)cnc(Cn2cnc3c(Cl)nc(N)nc23)c1C	Phase 2
bilastine	histamine receptor antagonist	HRH1	ophthalmology	conjunctivitis	MedChemEx, MedChemEx	99.77	CCOCCn1c(nc2ccccc12)C1CCN(CCc2ccc(cc2)C(C)(C)C(O)=O)CC1, CCOCCn1c(nc2ccccc12)C1CCN(CCc2ccc(cc2)C(C)(C)C(O)=O)CC1	Launched
bilobalide	GABA receptor modulator	GLRA1, GLRA2, GLRB, HTR3A, HTR3B			MedChemEx	100	CC(C)(C)[C@]1(O)C[C@@H]2OC(=O)C[C@@]22C(=O)O[C@@H]3OC(=O)[C@H](O)[C@]123	Preclinical
bimatoprost	prostanoid receptor agonist	AKR1C3, PTGER1, PTGER3, PTGFR	ophthalmology	intraocular pressure, glaucoma, ocular hypertension	MedChemEx	96.15	CCNC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)CCc1ccccc1	Launched
BIMU-8	serotonin receptor agonist	HTR4			Tocris	97.3	CC(C)n1c2ccccc2n(C(=O)N[C@@H]2C[C@@H]3CC[C@H](C2)N3C)c1=O |&1:14,16,19|	Preclinical
BINA	glutamate receptor positive allosteric modulator	GRM2			Tocris	98.64	Cc1c2C(=O)[C@H](Cc2cc(OCc2cccc(c2)-c2ccc(cc2)C(O)=O)c1C)C1CCCC1 |&1:5,r|	Preclinical
bindarit	NFkB pathway inhibitor	CCL2, CCL7, CCL8			MedChemEx, Selleck	97.84	CC(C)(OCc1nn(Cc2ccccc2)c2ccccc12)C(O)=O, CC(C)(OCc1nn(Cc2ccccc2)c2ccccc12)C(O)=O	Phase 2
binimetinib	MEK inhibitor	MAP2K1, MAP2K2	oncology	melanoma	MedChemEx, MedChemEx, Selleck, Selleck, Selleck	97.48	Cn1cnc2c(F)c(Nc3ccc(Br)cc3F)c(cc12)C(=O)NOCCO, Cn1cnc2c(F)c(Nc3ccc(Br)cc3F)c(cc12)C(=O)NOCCO, Cn1cnc2c(F)c(Nc3ccc(Br)cc3F)c(cc12)C(=O)NOCCO, Cn1cnc2c(F)c(Nc3ccc(Br)cc3F)c(cc12)C(=O)NOCCO, Cn1cnc2c(F)c(Nc3ccc(Br)cc3F)c(cc12)C(=O)NOCCO	Launched
BIO-1211	integrin antagonist	ITGA4, ITGB1			Tocris, Tocris	93.1	CC(C)C[C@H](NC(=O)Cc1ccc(NC(=O)Nc2ccccc2C)cc1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(O)=O, CC(C)C[C@H](NC(=O)Cc1ccc(NC(=O)Nc2ccccc2C)cc1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(O)=O	Phase 2
BIO-5192	integrin inhibitor	ITGA4, ITGB1			Tocris, Tocris, Tocris	98.15	CC(C)C[C@H](N(C)C(=O)Cc1ccc(NC(=O)Nc2ccccc2C)cc1)C(=O)NCC[C@H](NC(=O)[C@@H]1CCCN1S(=O)(=O)c1cc(Cl)cc(Cl)c1)C(O)=O, CC(C)C[C@H](N(C)C(=O)Cc1ccc(NC(=O)Nc2ccccc2C)cc1)C(=O)NCC[C@H](NC(=O)[C@@H]1CCCN1S(=O)(=O)c1cc(Cl)cc(Cl)c1)C(O)=O, CC(C)C[C@H](N(C)C(=O)Cc1ccc(NC(=O)Nc2ccccc2C)cc1)C(=O)NCC[C@H](NC(=O)[C@@H]1CCCN1S(=O)(=O)c1cc(Cl)cc(Cl)c1)C(O)=O	Preclinical
biotin	vitamin B	ACACA, ACACB, HLCS, MCCC1, MCCC2, PC, PCCA, PCCB, SLC5A6			MicroSource, MedChemEx, Selleck	100	OC(=O)CCCC[C@@H]1SC[C@@H]2NC(=O)N[C@H]12, OC(=O)CCCC[C@@H]1SC[C@@H]2NC(=O)N[C@H]12, OC(=O)CCCC[C@@H]1SC[C@@H]2NC(=O)N[C@H]12	Launched
bipenamol	dipeptidyl peptidase inhibitor	CTSC			Sigma, Sigma	81.11	NCc1ccccc1Sc1ccccc1CO, NCc1ccccc1Sc1ccccc1CO	Phase 2
biperiden	acetylcholine receptor antagonist	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5	neurology/psychiatry	Parkinson's Disease	MicroSource, MicroSource, Tocris	97.94	O[C@@](CCN1CCCCC1)([C@@H]1C[C@@H]2C[C@H]1C=C2)c1ccccc1 |&1:12,14,&2:10,&3:1,c:17|, O[C@@](CCN1CCCCC1)([C@@H]1C[C@@H]2C[C@H]1C=C2)c1ccccc1 |&1:12,14,&2:10,&3:1,c:17|, O[C@@](CCN1CCCCC1)([C@@H]1C[C@@H]2C[C@H]1C=C2)c1ccccc1 |&1:12,14,&2:10,&3:1,c:17|	Launched
birinapant	XIAP inhibitor	BIRC2, XIAP			Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck	97.74	CC[C@H](NC(=O)[C@H](C)NC)C(=O)N1C[C@@H](O)C[C@H]1Cc1c([nH]c2cc(F)ccc12)-c1[nH]c2cc(F)ccc2c1C[C@@H]1C[C@H](O)CN1C(=O)[C@H](CC)NC(=O)[C@H](C)NC, CC[C@H](NC(=O)[C@H](C)NC)C(=O)N1C[C@@H](O)C[C@H]1Cc1c([nH]c2cc(F)ccc12)-c1[nH]c2cc(F)ccc2c1C[C@@H]1C[C@H](O)CN1C(=O)[C@H](CC)NC(=O)[C@H](C)NC, CC[C@H](NC(=O)[C@H](C)NC)C(=O)N1C[C@@H](O)C[C@H]1Cc1c([nH]c2cc(F)ccc12)-c1[nH]c2cc(F)ccc2c1C[C@@H]1C[C@H](O)CN1C(=O)[C@H](CC)NC(=O)[C@H](C)NC, CC[C@H](NC(=O)[C@H](C)NC)C(=O)N1C[C@@H](O)C[C@H]1Cc1c([nH]c2cc(F)ccc12)-c1[nH]c2cc(F)ccc2c1C[C@@H]1C[C@H](O)CN1C(=O)[C@H](CC)NC(=O)[C@H](C)NC, CC[C@H](NC(=O)[C@H](C)NC)C(=O)N1C[C@@H](O)C[C@H]1Cc1c([nH]c2cc(F)ccc12)-c1[nH]c2cc(F)ccc2c1C[C@@H]1C[C@H](O)CN1C(=O)[C@H](CC)NC(=O)[C@H](C)NC, CC[C@H](NC(=O)[C@H](C)NC)C(=O)N1C[C@@H](O)C[C@H]1Cc1c([nH]c2cc(F)ccc12)-c1[nH]c2cc(F)ccc2c1C[C@@H]1C[C@H](O)CN1C(=O)[C@H](CC)NC(=O)[C@H](C)NC, CC[C@H](NC(=O)[C@H](C)NC)C(=O)N1C[C@@H](O)C[C@H]1Cc1c([nH]c2cc(F)ccc12)-c1[nH]c2cc(F)ccc2c1C[C@@H]1C[C@H](O)CN1C(=O)[C@H](CC)NC(=O)[C@H](C)NC, CC[C@H](NC(=O)[C@H](C)NC)C(=O)N1C[C@@H](O)C[C@H]1Cc1c([nH]c2cc(F)ccc12)-c1[nH]c2cc(F)ccc2c1C[C@@H]1C[C@H](O)CN1C(=O)[C@H](CC)NC(=O)[C@H](C)NC, CC[C@H](NC(=O)[C@H](C)NC)C(=O)N1C[C@@H](O)C[C@H]1Cc1c([nH]c2cc(F)ccc12)-c1[nH]c2cc(F)ccc2c1C[C@@H]1C[C@H](O)CN1C(=O)[C@H](CC)NC(=O)[C@H](C)NC	Phase 2
BIRT-377	lymphocyte function-associated antigen negative modulator	ICAM1			Tocris, Stanley	99.01	CN1C(=O)N(C(=O)[C@@]1(C)Cc1ccc(Br)cc1)c1cc(Cl)cc(Cl)c1, CN1C(=O)N(C(=O)[C@@]1(C)Cc1ccc(Br)cc1)c1cc(Cl)cc(Cl)c1	Preclinical
bis(maltolato)oxovanadium(IV)	tyrosine phosphatase inhibitor	PTPN1			Carbosynth, Carbosynth, Carbosynth, Carbosynth	79.05	Cc1occc(=O)c1O[V](=O)Oc1c(C)occc1=O, Cc1occc(=O)c1O[V](=O)Oc1c(C)occc1=O, Cc1occc(=O)c1O[V](=O)Oc1c(C)occc1=O, Cc1occc(=O)c1O[V](=O)Oc1c(C)occc1=O	Phase 2
bisacodyl	laxative		gastroenterology	constipation	MicroSource, MedChemEx, Selleck	96.97	CC(=O)Oc1ccc(cc1)C(c1ccc(OC(C)=O)cc1)c1ccccn1, CC(=O)Oc1ccc(cc1)C(c1ccc(OC(C)=O)cc1)c1ccccn1, CC(=O)Oc1ccc(cc1)C(c1ccc(OC(C)=O)cc1)c1ccccn1	Launched
bisantrene	topoisomerase inhibitor				MedChemEx	44.78	C1CN=C(N\N=C\c2c3ccccc3c(\C=N\NC3=NCCN3)c3ccccc23)N1 |t:2,19|	Phase 2
bisindolylmaleimide-IX	PKC inhibitor	AKT1, GSK3B, LCK, MAPK1, MAPK11, MAPK12, MAPK14, MAPK8, PRKCA, ROCK1, RPS6KB1, SIRT1			Selleck, Tocris, Tocris, Selleck	95.99	Cn1cc(C2=C(C(=O)NC2=O)c2cn(CCCSC(N)=N)c3ccccc23)c2ccccc12 |t:4|, Cn1cc(C2=C(C(=O)NC2=O)c2cn(CCCSC(N)=N)c3ccccc23)c2ccccc12 |t:4|, Cn1cc(C2=C(C(=O)NC2=O)c2cn(CCCSC(N)=N)c3ccccc23)c2ccccc12 |t:4|, Cn1cc(C2=C(C(=O)NC2=O)c2cn(CCCSC(N)=N)c3ccccc23)c2ccccc12 |t:4|	Preclinical
bismuth(III)-trifluoromethanesulfonate	direct substitution catalyst				AlfaAesar	99.14	[Bi].OS(=O)(=O)C(F)(F)F.OS(=O)(=O)C(F)(F)F.OS(=O)(=O)C(F)(F)F	Preclinical
bismuth-oxalate					MPBio	0	[Bi].[Bi].OC(=O)C(O)=O.OC(=O)C(O)=O.OC(=O)C(O)=O	Preclinical
bismuth-subcitrate-potassium			gastroenterology	duodenal ulcer disease	Selleck	0	OC(=O)C[C@](O)(CC(=O)O[Bi]1OC(=O)C[C@@](O)(CC(O)=O)C(=O)O1)C(O)=O |&1:4,&2:15|	Launched
bismuth-subgallate	nitric oxide synthase inhibitor	NOS1	gastroenterology	internal deoderant	Sigma	0	O[Bi]1Oc2cc(cc(O)c2O1)C(O)=O	Launched
bismuth-subsalicylate	antacid		gastroenterology	diarrhea	MicroSource, MedChemEx, Selleck, MedChemEx, Selleck	5.83	O[Bi]1OC(=O)c2ccccc2O1, O[Bi]1OC(=O)c2ccccc2O1, O[Bi]1OC(=O)c2ccccc2O1, O[Bi]1OC(=O)c2ccccc2O1, O[Bi]1OC(=O)c2ccccc2O1	Launched
bisoctrizole					MedChemEx, MicroSource	0	CC(C)(C)CC(C)(C)c1cc(Cc2cc(cc(c2O)-n2nc3ccccc3n2)C(C)(C)CC(C)(C)C)c(O)c(c1)-n1nc2ccccc2n1, CC(C)(C)CC(C)(C)c1cc(Cc2cc(cc(c2O)-n2nc3ccccc3n2)C(C)(C)CC(C)(C)C)c(O)c(c1)-n1nc2ccccc2n1	Phase 2
bisoprolol	adrenergic receptor antagonist	ADRB1	cardiology	hypertension	MicroSource, Tocris, Selleck, Selleck, Selleck	95.41	CC(C)NC[C@@H](O)COc1ccc(COCCOC(C)C)cc1 |&1:5|, CC(C)NC[C@@H](O)COc1ccc(COCCOC(C)C)cc1 |&1:5|, CC(C)NC[C@@H](O)COc1ccc(COCCOC(C)C)cc1 |&1:5|, CC(C)NC[C@@H](O)COc1ccc(COCCOC(C)C)cc1 |&1:5|, CC(C)NC[C@@H](O)COc1ccc(COCCOC(C)C)cc1 |&1:5|	Launched
bisphenol-A	synthetic estrogen	AR, ESR1, ESR2, ESRRG, PPARG			Sigma, Sigma	95.98	CC(C)(c1ccc(O)cc1)c1ccc(O)cc1, CC(C)(c1ccc(O)cc1)c1ccc(O)cc1	Phase 1
bithionol	autotaxin inhibitor	ESR1, ESR2, MCL1			MicroSource, MicroSource, MicroSource, MicroSource, MicroSource, MicroSource, MicroSource, MicroSource	97.59	Oc1c(Cl)cc(Cl)cc1Sc1cc(Cl)cc(Cl)c1O, Oc1c(Cl)cc(Cl)cc1Sc1cc(Cl)cc(Cl)c1O, Oc1c(Cl)cc(Cl)cc1Sc1cc(Cl)cc(Cl)c1O, Oc1c(Cl)cc(Cl)cc1Sc1cc(Cl)cc(Cl)c1O, Oc1c(Cl)cc(Cl)cc1Sc1cc(Cl)cc(Cl)c1O, Oc1c(Cl)cc(Cl)cc1Sc1cc(Cl)cc(Cl)c1O, Oc1c(Cl)cc(Cl)cc1Sc1cc(Cl)cc(Cl)c1O, Oc1c(Cl)cc(Cl)cc1Sc1cc(Cl)cc(Cl)c1O	Withdrawn
bitopertin	glycine transporter inhibitor	SLC6A5, SLC6A9			MedChemEx, MedChemEx	99.57	C[C@H](Oc1ccc(cc1C(=O)N1CCN(CC1)c1ncc(cc1F)C(F)(F)F)S(C)(=O)=O)C(F)(F)F, C[C@H](Oc1ccc(cc1C(=O)N1CCN(CC1)c1ncc(cc1F)C(F)(F)F)S(C)(=O)=O)C(F)(F)F	Phase 3
bitoscanate	anthelmintic agent				MedChemEx, MicroSource	0	S=C=Nc1ccc(cc1)N=C=S, S=C=Nc1ccc(cc1)N=C=S	Preclinical
bivalirudin	thrombin inhibitor	F2	cardiology	angina pectoris	MedChemEx, Key, Key, MedChemEx, MedChemEx, MedChemEx	93.05	CC[C@H](C)[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](N)Cc1ccccc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(O)=O, CC[C@H](C)[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](N)Cc1ccccc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(O)=O, CC[C@H](C)[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](N)Cc1ccccc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(O)=O, CC[C@H](C)[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](N)Cc1ccccc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(O)=O, CC[C@H](C)[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](N)Cc1ccccc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(O)=O, CC[C@H](C)[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](N)Cc1ccccc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(O)=O	Launched
BIX-01294	histone lysine methyltransferase inhibitor	EHMT1, EHMT2			MedChemEx, MedChemEx, MedChemEx, MedChemEx, Tocris, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck	98.04	COc1cc2nc(nc(NC3CCN(Cc4ccccc4)CC3)c2cc1OC)N1CCCN(C)CC1, COc1cc2nc(nc(NC3CCN(Cc4ccccc4)CC3)c2cc1OC)N1CCCN(C)CC1, COc1cc2nc(nc(NC3CCN(Cc4ccccc4)CC3)c2cc1OC)N1CCCN(C)CC1, COc1cc2nc(nc(NC3CCN(Cc4ccccc4)CC3)c2cc1OC)N1CCCN(C)CC1, COc1cc2nc(nc(NC3CCN(Cc4ccccc4)CC3)c2cc1OC)N1CCCN(C)CC1, COc1cc2nc(nc(NC3CCN(Cc4ccccc4)CC3)c2cc1OC)N1CCCN(C)CC1, COc1cc2nc(nc(NC3CCN(Cc4ccccc4)CC3)c2cc1OC)N1CCCN(C)CC1, COc1cc2nc(nc(NC3CCN(Cc4ccccc4)CC3)c2cc1OC)N1CCCN(C)CC1, COc1cc2nc(nc(NC3CCN(Cc4ccccc4)CC3)c2cc1OC)N1CCCN(C)CC1, COc1cc2nc(nc(NC3CCN(Cc4ccccc4)CC3)c2cc1OC)N1CCCN(C)CC1, COc1cc2nc(nc(NC3CCN(Cc4ccccc4)CC3)c2cc1OC)N1CCCN(C)CC1, COc1cc2nc(nc(NC3CCN(Cc4ccccc4)CC3)c2cc1OC)N1CCCN(C)CC1	Preclinical
BIX-02188	MEK inhibitor	MAP2K5			Selleck, Selleck, MedChemEx, MedChemEx, Selleck, Selleck	96.97	CN(C)Cc1cccc(N\C(=C2/C(=O)Nc3cc(ccc23)C(N)=O)c2ccccc2)c1, CN(C)Cc1cccc(N\C(=C2/C(=O)Nc3cc(ccc23)C(N)=O)c2ccccc2)c1, CN(C)Cc1cccc(N\C(=C2/C(=O)Nc3cc(ccc23)C(N)=O)c2ccccc2)c1, CN(C)Cc1cccc(N\C(=C2/C(=O)Nc3cc(ccc23)C(N)=O)c2ccccc2)c1, CN(C)Cc1cccc(N\C(=C2/C(=O)Nc3cc(ccc23)C(N)=O)c2ccccc2)c1, CN(C)Cc1cccc(N\C(=C2/C(=O)Nc3cc(ccc23)C(N)=O)c2ccccc2)c1	Preclinical
BIX-02189	MEK inhibitor	MAP2K5, MAPK7			Tocris, Selleck, Selleck	98.67	CN(C)Cc1cccc(N\C(=C2/C(=O)Nc3cc(ccc23)C(=O)N(C)C)c2ccccc2)c1, CN(C)Cc1cccc(N\C(=C2/C(=O)Nc3cc(ccc23)C(=O)N(C)C)c2ccccc2)c1, CN(C)Cc1cccc(N\C(=C2/C(=O)Nc3cc(ccc23)C(=O)N(C)C)c2ccccc2)c1	Preclinical
BL-5583	hypercalcaemic agent				Enamine, Enamine, Enamine, Enamine	99.35	OC(=O)c1cc2ccccc2s1, OC(=O)c1cc2ccccc2s1, OC(=O)c1cc2ccccc2s1, OC(=O)c1cc2ccccc2s1	Preclinical
blebbistatin-(+/-)	ATPase inhibitor	MYH14, MYH2			Tocris	98.19	Cc1ccc2N=C3N(CC[C@@]3(O)C(=O)c2c1)c1ccccc1 |&1:10,r,t:5|	Preclinical
blebbistatin-(-)	ATPase inhibitor				Selleck, Selleck	94.77	Cc1ccc2N=C3N(CC[C@@]3(O)C(=O)c2c1)c1ccccc1 |t:5|, Cc1ccc2N=C3N(CC[C@@]3(O)C(=O)c2c1)c1ccccc1 |t:5|	Preclinical
bleomycetin	EGFR expression inhibitor				InterBioScreen	69.56	C[C@@H](O)[C@H](NC(=O)[C@@H](C)[C@H](O)[C@@H](C)NC(=O)[C@@H](NC(=O)c1nc(nc(N)c1C)[C@H](CC(N)=O)NC[C@H](N)C(N)=O)[C@@H](O[C@@H]1O[C@@H](CO)[C@@H](O)[C@H](O)[C@@H]1O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](OC(N)=O)[C@@H]1O)c1c[nH]cn1)C(=O)NCCc1nc(cs1)-c1nc(cs1)C(=O)NCCCNCCCCN	Launched
bleomycin	DNA synthesis inhibitor		hematologic malignancy, pulmonary, oncology	non-Hodgkin lymphoma (NHL), Hodgkin's lymphoma, pleural effusion, testicular carcinoma, squamous cell carcinoma	MedChemEx	0	[H][C@]1(O[C@H]2O[C@H](CO)[C@@H](O)[C@H](OC(N)=O)[C@@H]2O)[C@@H](O[C@H]([C@H](NC(=O)c2nc(nc(N)c2C)[C@H](CC(N)=O)NC[C@@H](N)C(N)=O)C(=O)N[C@@H](C)[C@H](O)[C@@H](C)C(=O)N[C@H]([C@@H](C)O)C(=O)NCCc2nc(cs2)-c2nc(cs2)C(=O)NCCC[S+](C)C)c2c[nH]cn2)O[C@H](CO)[C@H](O)[C@H]1O	Launched
blonanserin	dopamine receptor antagonist, serotonin receptor antagonist	DRD2, HTR2A	neurology/psychiatry	schizophrenia	MedChemEx, Selleck, Selleck, Selleck	98.16	CCN1CCN(CC1)c1cc(-c2ccc(F)cc2)c2CCCCCCc2n1, CCN1CCN(CC1)c1cc(-c2ccc(F)cc2)c2CCCCCCc2n1, CCN1CCN(CC1)c1cc(-c2ccc(F)cc2)c2CCCCCCc2n1, CCN1CCN(CC1)c1cc(-c2ccc(F)cc2)c2CCCCCCc2n1	Launched
BLU9931	FGFR inhibitor	FGFR4			MedChemEx, MedChemEx, MedChemEx, MedChemEx	94.1	COc1cc(OC)c(Cl)c(c1Cl)-c1ccc2nc(Nc3c(C)cccc3NC(=O)C=C)ncc2c1, COc1cc(OC)c(Cl)c(c1Cl)-c1ccc2nc(Nc3c(C)cccc3NC(=O)C=C)ncc2c1, COc1cc(OC)c(Cl)c(c1Cl)-c1ccc2nc(Nc3c(C)cccc3NC(=O)C=C)ncc2c1, COc1cc(OC)c(Cl)c(c1Cl)-c1ccc2nc(Nc3c(C)cccc3NC(=O)C=C)ncc2c1	Preclinical
BLZ945	CSF1R inhibitor				MedChemEx	88.61	CNC(=O)c1cc(Oc2ccc3nc(N[C@@H]4CCCC[C@H]4O)sc3c2)ccn1	Phase 1/Phase 2
BML-190	cannabinoid receptor inverse agonist	CNR2			Selleck, MedChemEx, MedChemEx, MedChemEx, Tocris	98.01	COc1ccc2n(C(=O)c3ccc(Cl)cc3)c(C)c(CC(=O)N3CCOCC3)c2c1, COc1ccc2n(C(=O)c3ccc(Cl)cc3)c(C)c(CC(=O)N3CCOCC3)c2c1, COc1ccc2n(C(=O)c3ccc(Cl)cc3)c(C)c(CC(=O)N3CCOCC3)c2c1, COc1ccc2n(C(=O)c3ccc(Cl)cc3)c(C)c(CC(=O)N3CCOCC3)c2c1, COc1ccc2n(C(=O)c3ccc(Cl)cc3)c(C)c(CC(=O)N3CCOCC3)c2c1	Preclinical
BML-284	WNT agonist				MedChemEx, MedChemEx, MedChemEx	97.93	COc1cccc(c1)-c1cc(NCc2ccc3OCOc3c2)nc(N)n1, COc1cccc(c1)-c1cc(NCc2ccc3OCOc3c2)nc(N)n1, COc1cccc(c1)-c1cc(NCc2ccc3OCOc3c2)nc(N)n1	Preclinical
BMS-CCR2-22	CC chemokine receptor antagonist	CCR2			Tocris, Tocris, Tocris, Tocris	98.82	CSc1ccc(cc1)C(=O)N[C@@H]1CCCC[C@@H]1NC(=O)CNC(=O)c1cc(ccc1NC(=O)NC(C)C)C(F)(F)F, CSc1ccc(cc1)C(=O)N[C@@H]1CCCC[C@@H]1NC(=O)CNC(=O)c1cc(ccc1NC(=O)NC(C)C)C(F)(F)F, CSc1ccc(cc1)C(=O)N[C@@H]1CCCC[C@@H]1NC(=O)CNC(=O)c1cc(ccc1NC(=O)NC(C)C)C(F)(F)F, CSc1ccc(cc1)C(=O)N[C@@H]1CCCC[C@@H]1NC(=O)CNC(=O)c1cc(ccc1NC(=O)NC(C)C)C(F)(F)F	Preclinical
BMS-182874	endothelin receptor antagonist	EDNRA			Tocris, Tocris, Tocris	97.09	CN(C)c1cccc2c(cccc12)S(=O)(=O)Nc1onc(C)c1C, CN(C)c1cccc2c(cccc12)S(=O)(=O)Nc1onc(C)c1C, CN(C)c1cccc2c(cccc12)S(=O)(=O)Nc1onc(C)c1C	Phase 2
BMS-191011	potassium channel activator	KCNMA1			Tocris, Tocris, Tocris, Tocris, Tocris	96.1	Oc1ccc(Cl)cc1Cn1nc(oc1=O)-c1ccc(cc1)C(F)(F)F, Oc1ccc(Cl)cc1Cn1nc(oc1=O)-c1ccc(cc1)C(F)(F)F, Oc1ccc(Cl)cc1Cn1nc(oc1=O)-c1ccc(cc1)C(F)(F)F, Oc1ccc(Cl)cc1Cn1nc(oc1=O)-c1ccc(cc1)C(F)(F)F, Oc1ccc(Cl)cc1Cn1nc(oc1=O)-c1ccc(cc1)C(F)(F)F	Preclinical
BMS-191095	KATP activator, potassium channel agonist				MedChemEx, MedChemEx	96.19	CC1(C)Oc2ccc(cc2[C@@H]([C@H]1O)N(Cc1ncc[nH]1)c1ccc(Cl)cc1)C#N, CC1(C)Oc2ccc(cc2[C@@H]([C@H]1O)N(Cc1ncc[nH]1)c1ccc(Cl)cc1)C#N	Phase 1
BMS-207940	endothelin receptor antagonist				Sigma	96.67	CN(Cc1cc(ccc1-c1ccccc1S(=O)(=O)Nc1noc(C)c1C)-c1ncco1)C(=O)CC(C)(C)C	Preclinical
BMS-214662	farnesyltransferase inhibitor				MedChemEx	98.26	O=S(=O)(N1Cc2cc(ccc2N(Cc2cnc[nH]2)C[C@H]1Cc1ccccc1)C#N)c1cccs1	Phase 1
BMS-265246	CDK inhibitor	CDK1, CDK2			MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx, Selleck, Selleck, Selleck	97.16	CCCCOc1c(cnc2n[nH]cc12)C(=O)c1c(F)cc(C)cc1F, CCCCOc1c(cnc2n[nH]cc12)C(=O)c1c(F)cc(C)cc1F, CCCCOc1c(cnc2n[nH]cc12)C(=O)c1c(F)cc(C)cc1F, CCCCOc1c(cnc2n[nH]cc12)C(=O)c1c(F)cc(C)cc1F, CCCCOc1c(cnc2n[nH]cc12)C(=O)c1c(F)cc(C)cc1F, CCCCOc1c(cnc2n[nH]cc12)C(=O)c1c(F)cc(C)cc1F, CCCCOc1c(cnc2n[nH]cc12)C(=O)c1c(F)cc(C)cc1F, CCCCOc1c(cnc2n[nH]cc12)C(=O)c1c(F)cc(C)cc1F, CCCCOc1c(cnc2n[nH]cc12)C(=O)c1c(F)cc(C)cc1F, CCCCOc1c(cnc2n[nH]cc12)C(=O)c1c(F)cc(C)cc1F	Preclinical
BMS-299897	gamma secretase inhibitor				EMDBio, EMDBio, EMDBio, EMDBio	97.26	C[C@@H](N(c1cc(F)ccc1F)S(=O)(=O)c1ccc(Cl)cc1)c1ccc(F)cc1CCCC(O)=O, C[C@@H](N(c1cc(F)ccc1F)S(=O)(=O)c1ccc(Cl)cc1)c1ccc(F)cc1CCCC(O)=O, C[C@@H](N(c1cc(F)ccc1F)S(=O)(=O)c1ccc(Cl)cc1)c1ccc(F)cc1CCCC(O)=O, C[C@@H](N(c1cc(F)ccc1F)S(=O)(=O)c1ccc(Cl)cc1)c1ccc(F)cc1CCCC(O)=O	Phase 1
BMS-309403	fatty acid binding protein inhibitor	FABP4			Tocris, Tocris	96.68	CCc1c(c(nn1-c1ccccc1-c1cccc(OCC(O)=O)c1)-c1ccccc1)-c1ccccc1, CCc1c(c(nn1-c1ccccc1-c1cccc(OCC(O)=O)c1)-c1ccccc1)-c1ccccc1	Preclinical
BMS-345541	IKK inhibitor	CHUK, IKBKB			Tocris, Selleck, Selleck, Selleck, Selleck, Tocris, Tocris	98.32	Cc1cnc2c(NCCN)nc3ccc(C)cc3n12, Cc1cnc2c(NCCN)nc3ccc(C)cc3n12, Cc1cnc2c(NCCN)nc3ccc(C)cc3n12, Cc1cnc2c(NCCN)nc3ccc(C)cc3n12, Cc1cnc2c(NCCN)nc3ccc(C)cc3n12, Cc1cnc2c(NCCN)nc3ccc(C)cc3n12, Cc1cnc2c(NCCN)nc3ccc(C)cc3n12	Preclinical
BMS-387032	CDK inhibitor, cell cycle inhibitor, MCL1 inhibitor	CDK2, CDK7, CDK9			Selleck, Selleck, Selleck, Selleck	92.86	CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCNCC3)s2)o1, CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCNCC3)s2)o1, CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCNCC3)s2)o1, CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCNCC3)s2)o1	Phase 1
BMS-470539	melanocortin receptor agonist	MC1R			Tocris, Tocris	93.85	CCCC(=O)C1(CCN(CC1)C(=O)[C@@H](Cc1ccc(OC)cc1)NC(=O)[C@@H](N)Cc1cncn1C)c1ccccc1, CCCC(=O)C1(CCN(CC1)C(=O)[C@@H](Cc1ccc(OC)cc1)NC(=O)[C@@H](N)Cc1cncn1C)c1ccccc1	Preclinical
BMS-536924	IGF-1 inhibitor	AKT1, CCNE1, CDK2, CYP3A4, ERBB2, IGF1R, KDR, LCK, MAPK1, MET, PDGFRA, PDGFRB			MedChemEx, MedChemEx, MedChemEx, Tocris, Tocris	96.98	Cc1cc(cc2[nH]c(nc12)-c1c(NC[C@@H](O)c2cccc(Cl)c2)cc[nH]c1=O)N1CCOCC1, Cc1cc(cc2[nH]c(nc12)-c1c(NC[C@@H](O)c2cccc(Cl)c2)cc[nH]c1=O)N1CCOCC1, Cc1cc(cc2[nH]c(nc12)-c1c(NC[C@@H](O)c2cccc(Cl)c2)cc[nH]c1=O)N1CCOCC1, Cc1cc(cc2[nH]c(nc12)-c1c(NC[C@@H](O)c2cccc(Cl)c2)cc[nH]c1=O)N1CCOCC1, Cc1cc(cc2[nH]c(nc12)-c1c(NC[C@@H](O)c2cccc(Cl)c2)cc[nH]c1=O)N1CCOCC1	Preclinical
BMS-566419	inosine monophosphate dehydrogenase inhibitor	IMPDH1, IMPDH2			Tocris, Tocris, Tocris, Tocris, Tocris	97.46	CCN1CCN(CC1)c1ccc(cn1)C(C)(C)NC(=O)c1cc2[nH]c3ccccc3c(=O)c2cc1F, CCN1CCN(CC1)c1ccc(cn1)C(C)(C)NC(=O)c1cc2[nH]c3ccccc3c(=O)c2cc1F, CCN1CCN(CC1)c1ccc(cn1)C(C)(C)NC(=O)c1cc2[nH]c3ccccc3c(=O)c2cc1F, CCN1CCN(CC1)c1ccc(cn1)C(C)(C)NC(=O)c1cc2[nH]c3ccccc3c(=O)c2cc1F, CCN1CCN(CC1)c1ccc(cn1)C(C)(C)NC(=O)c1cc2[nH]c3ccccc3c(=O)c2cc1F	Preclinical
BMS-582949	p38 MAPK inhibitor				MedChemEx	96.9	CCCNC(=O)c1cn2ncnc(Nc3cc(ccc3C)C(=O)NC3CC3)c2c1C	Phase 2
BMS-587101	integrin antagonist	ITGAL, ITGB2			Key	92.65	CN1C(=O)N(C(=O)[C@]11CN(Cc2cc(cs2)C(O)=O)C[C@H]1c1ccc(cc1)C#N)c1cc(Cl)cc(Cl)c1	Phase 2
BMS-599626	EGFR inhibitor, protein tyrosine kinase inhibitor	EGFR, ERBB2, ERBB4			Tocris, Selleck, Selleck	97.06	Cc1c(NC(=O)OC[C@@H]2COCCN2)cn2ncnc(Nc3ccc4n(Cc5cccc(F)c5)ncc4c3)c12, Cc1c(NC(=O)OC[C@@H]2COCCN2)cn2ncnc(Nc3ccc4n(Cc5cccc(F)c5)ncc4c3)c12, Cc1c(NC(=O)OC[C@@H]2COCCN2)cn2ncnc(Nc3ccc4n(Cc5cccc(F)c5)ncc4c3)c12	Phase 1
BMS-626529	HIV attachment inhibitor				MedChemEx, MedChemEx	98.85	COc1cnc(-n2cnc(C)n2)c2[nH]cc(C(=O)C(=O)N3CCN(CC3)C(=O)c3ccccc3)c12, COc1cnc(-n2cnc(C)n2)c2[nH]cc(C(=O)C(=O)N3CCN(CC3)C(=O)c3ccccc3)c12	Phase 3
BMS-626531	p38 MAPK inhibitor				Sigma	85.26	Cc1c(cnn1-c1ncccc1C(F)(F)F)C(=O)Nc1cc(ccc1C)C(=O)NC1CC1	Phase 1
BMS-649	retinoid receptor agonist	RXRA			Tocris, Tocris, Tocris, Tocris, Tocris	99.1	CC1(C)CCC(C)(C)c2cc(ccc12)C1(OCCO1)c1ccc(cc1)C(O)=O, CC1(C)CCC(C)(C)c2cc(ccc12)C1(OCCO1)c1ccc(cc1)C(O)=O, CC1(C)CCC(C)(C)c2cc(ccc12)C1(OCCO1)c1ccc(cc1)C(O)=O, CC1(C)CCC(C)(C)c2cc(ccc12)C1(OCCO1)c1ccc(cc1)C(O)=O, CC1(C)CCC(C)(C)c2cc(ccc12)C1(OCCO1)c1ccc(cc1)C(O)=O	Preclinical
BMS-688521	ICAM1 antagonist, leukocyte function-associated antigen receptor antagonist	ICAM1			Key	99.64	CN1C(=O)N(C(=O)[C@]11CN(C[C@H]1c1ccc(cc1)C#N)c1ccc(cn1)C(O)=O)c1cc(Cl)cc(Cl)c1	Preclinical
BMS-690514	EGFR inhibitor, VEGFR inhibitor	EGFR, ERBB2, FLT3, KDR			MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx	94.87	COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1, COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1, COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1, COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1, COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1, COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1	Phase 2
BMS-707035	HIV integrase inhibitor				Selleck	96.62	Cn1c(nc(C(=O)NCc2ccc(F)cc2)c(O)c1=O)N1CCCCS1(=O)=O	Phase 2
BMS-754807	IGF-1 inhibitor	AKT1, IGF1R			MedChemEx, MedChemEx, MedChemEx, MedChemEx, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck	96.93	C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1, C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1, C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1, C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1, C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1, C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1, C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1, C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1, C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1, C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1, C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1	Phase 2
BMS-770767	11-beta-HSD1 inhibitor				Sigma	94.62	O[C@@]12CC[C@@](CC1)(C2)c1nnc2c(Oc3ccccc3Cl)cccn12 |r|	Phase 2
BMS-777607	AXL kinase inhibitor, c-Met inhibitor, FLT3 inhibitor, hepatocyte growth factor receptor inhibitor, macrophage migration inhibiting factor inhibitor, tyrosine kinase inhibitor	AXL, MERTK, MET, MST1R, TYRO3			Selleck, MedChemEx	98.03	CCOc1ccn(-c2ccc(F)cc2)c(=O)c1C(=O)Nc1ccc(Oc2ccnc(N)c2Cl)c(F)c1, CCOc1ccn(-c2ccc(F)cc2)c(=O)c1C(=O)Nc1ccc(Oc2ccnc(N)c2Cl)c(F)c1	Phase 1/Phase 2
BMS-779788	LXR agonist				MedChemEx	88.43	CC(C)(O)c1cn(c(n1)C(C)(C)c1ccccc1Cl)-c1ccc(cc1)-c1cccc(c1)S(C)(=O)=O	Phase 1
BMS-806	HIV attachment inhibitor				Selleck, MedChemEx, Selleck	97.51	COc1ccnc2[nH]cc(C(=O)C(=O)N3CCN(C[C@H]3C)C(=O)c3ccccc3)c12, COc1ccnc2[nH]cc(C(=O)C(=O)N3CCN(C[C@H]3C)C(=O)c3ccccc3)c12, COc1ccnc2[nH]cc(C(=O)C(=O)N3CCN(C[C@H]3C)C(=O)c3ccccc3)c12	Phase 1
BMS-813160	CC chemokine receptor antagonist				MedChemEx	96.58	CC(=O)N[C@@H]1C[C@@H](CC[C@@H]1N1CC[C@H](Nc2ncnc3cc(nn23)C(C)(C)C)C1=O)NC(C)(C)C	Phase 2
BMS-817378	c-Met inhibitor, VEGFR inhibitor	KDR, MET			MedChemEx	96.68	Nc1nccc(Oc2ccc(NC(=O)c3cn(COP(O)(O)=O)cc(-c4ccc(F)cc4)c3=O)cc2F)c1Cl	Phase 1
BMS-833923	smoothened receptor antagonist	SMO			MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx, Selleck, Selleck	94.83	CNCc1ccc(C)c(NC(=O)c2ccc(Nc3nc(-c4ccccc4)c4ccccc4n3)cc2)c1, CNCc1ccc(C)c(NC(=O)c2ccc(Nc3nc(-c4ccccc4)c4ccccc4n3)cc2)c1, CNCc1ccc(C)c(NC(=O)c2ccc(Nc3nc(-c4ccccc4)c4ccccc4n3)cc2)c1, CNCc1ccc(C)c(NC(=O)c2ccc(Nc3nc(-c4ccccc4)c4ccccc4n3)cc2)c1, CNCc1ccc(C)c(NC(=O)c2ccc(Nc3nc(-c4ccccc4)c4ccccc4n3)cc2)c1, CNCc1ccc(C)c(NC(=O)c2ccc(Nc3nc(-c4ccccc4)c4ccccc4n3)cc2)c1, CNCc1ccc(C)c(NC(=O)c2ccc(Nc3nc(-c4ccccc4)c4ccccc4n3)cc2)c1	Phase 2
BMS-863233	CDC inhibitor	CDC7, PIM1			MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx	98.12	Clc1ccc2oc3c(nc([nH]c3=O)[C@@H]3CCCN3)c2c1, Clc1ccc2oc3c(nc([nH]c3=O)[C@@H]3CCCN3)c2c1, Clc1ccc2oc3c(nc([nH]c3=O)[C@@H]3CCCN3)c2c1, Clc1ccc2oc3c(nc([nH]c3=O)[C@@H]3CCCN3)c2c1, Clc1ccc2oc3c(nc([nH]c3=O)[C@@H]3CCCN3)c2c1	Phase 1/Phase 2
BMS-906024	gamma secretase inhibitor				Sigma	96.07	CN1c2ccccc2C(=N[C@H](NC(=O)[C@H](CCC(F)(F)F)[C@H](CCC(F)(F)F)C(N)=O)C1=O)c1ccccc1 |c:9|	Phase 1
BMS-911543	JAK inhibitor				MedChemEx	92.83	CCn1c(cc2c1nc(Nc1cc(C)n(C)n1)c1ncn(C)c21)C(=O)N(C1CC1)C1CC1	Phase 1/Phase 2
BMS-935177	Bruton's tyrosine kinase (BTK) inhibitor				MedChemEx	97.18	Cc1c(cccc1-n1cnc2ccccc2c1=O)-c1ccc(C(N)=O)c2[nH]c3cc(ccc3c12)C(C)(C)O	Preclinical
BMS-983970	notch signaling inhibitor				MedChemEx, MedChemEx, MedChemEx, MedChemEx	97.52	NC(=O)[C@@H](CC1CC1)[C@@H](CCC(F)(F)F)C(=O)N[C@H]1N=C(c2ccccc2)c2cccc(F)c2NC1=O |t:20|, NC(=O)[C@@H](CC1CC1)[C@@H](CCC(F)(F)F)C(=O)N[C@H]1N=C(c2ccccc2)c2cccc(F)c2NC1=O |t:20|, NC(=O)[C@@H](CC1CC1)[C@@H](CCC(F)(F)F)C(=O)N[C@H]1N=C(c2ccccc2)c2cccc(F)c2NC1=O |t:20|, NC(=O)[C@@H](CC1CC1)[C@@H](CCC(F)(F)F)C(=O)N[C@H]1N=C(c2ccccc2)c2cccc(F)c2NC1=O |t:20|	Phase 1
BMS-986020	lysophosphatidic acid receptor antagonist	LPAR1			MedChemEx	86.34	C[C@@H](OC(=O)Nc1c(C)noc1-c1ccc(cc1)-c1ccc(cc1)C1(CC1)C(O)=O)c1ccccc1	Phase 2
BMS-986142	Bruton's tyrosine kinase (BTK) inhibitor				MedChemEx	96.95	Cc1c(cccc1-n1c(=O)n(C)c2c(F)cccc2c1=O)-c1c(F)cc(C(N)=O)c2[nH]c3C[C@H](CCc3c12)C(C)(C)O	Phase 2
BMS-986158	bromodomain inhibitor				MedChemEx, MedChemEx	94.64	Cc1nnn(C)c1-c1cnc2c(c1)n([C@@H](C1CCOCC1)c1ccccc1)c1cc(ccc21)C(C)(C)O, Cc1nnn(C)c1-c1cnc2c(c1)n([C@@H](C1CCOCC1)c1ccccc1)c1cc(ccc21)C(C)(C)O	Phase 1/Phase 2
BMS-986195	Bruton's tyrosine kinase (BTK) inhibitor				MedChemEx	95.18	CC#CC(=O)N[C@H]1CCCN(C1)c1c(F)cc(C(N)=O)c2[nH]c(C)c(C)c12	Phase 1
BMS-986205	indoleamine 2,3-dioxygenase inhibitor				MedChemEx	95.85	[H][C@]1(CC[C@@H](CC1)c1ccnc2ccc(F)cc12)[C@@H](C)C(=O)Nc1ccc(Cl)cc1	Phase 3
BMY-14802	sigma receptor antagonist	HTR1A			Tocris, Tocris, Tocris, Tocris, Tocris, Tocris	95.41	O[C@@H](CCCN1CCN(CC1)c1ncc(F)cn1)c1ccc(F)cc1 |&1:1|, O[C@@H](CCCN1CCN(CC1)c1ncc(F)cn1)c1ccc(F)cc1 |&1:1|, O[C@@H](CCCN1CCN(CC1)c1ncc(F)cn1)c1ccc(F)cc1 |&1:1|, O[C@@H](CCCN1CCN(CC1)c1ncc(F)cn1)c1ccc(F)cc1 |&1:1|, O[C@@H](CCCN1CCN(CC1)c1ncc(F)cn1)c1ccc(F)cc1 |&1:1|, O[C@@H](CCCN1CCN(CC1)c1ncc(F)cn1)c1ccc(F)cc1 |&1:1|	Phase 2
BMY-45778	IP1 prostacyclin receptor agonist	PTGIR			Tocris, Tocris	97.74	OC(=O)COc1cccc(c1)-c1ocnc1-c1nc(c(o1)-c1ccccc1)-c1ccccc1, OC(=O)COc1cccc(c1)-c1ocnc1-c1nc(c(o1)-c1ccccc1)-c1ccccc1	Preclinical
BMY-7378	adrenergic receptor antagonist, serotonin receptor antagonist	ADRA1A, ADRA1B, ADRA1D, HTR1A			Tocris, Selleck, Tocris, Tocris	97.71	COc1ccccc1N1CCN(CCN2C(=O)CC3(CCCC3)CC2=O)CC1, COc1ccccc1N1CCN(CCN2C(=O)CC3(CCCC3)CC2=O)CC1, COc1ccccc1N1CCN(CCN2C(=O)CC3(CCCC3)CC2=O)CC1, COc1ccccc1N1CCN(CCN2C(=O)CC3(CCCC3)CC2=O)CC1	Preclinical
BNC105	tubulin polymerization inhibitor				MedChemEx, MedChemEx, MedChemEx, MedChemEx	94.71	COc1ccc2c(C(=O)c3cc(OC)c(OC)c(OC)c3)c(C)oc2c1O, COc1ccc2c(C(=O)c3cc(OC)c(OC)c(OC)c3)c(C)oc2c1O, COc1ccc2c(C(=O)c3cc(OC)c(OC)c(OC)c3)c(C)oc2c1O, COc1ccc2c(C(=O)c3cc(OC)c(OC)c(OC)c3)c(C)oc2c1O	Phase 2
BNTX	opioid receptor antagonist	OPRD1, OPRK1, OPRM1				0		Preclinical
boceprevir	HCV inhibitor	CMA1, CTSA, CTSF, CTSK, CTSL, CTSS	infectious disease	hepatitis C	MedChemEx, MedChemEx, MedChemEx, MedChemEx	82.09	CC(C)(C)NC(=O)N[C@H](C(=O)N1C[C@H]2[C@@H]([C@H]1C(=O)N[C@@H](CC1CCC1)C(=O)C(N)=O)C2(C)C)C(C)(C)C |a:8,13,14,15,&1:19|, CC(C)(C)NC(=O)N[C@H](C(=O)N1C[C@H]2[C@@H]([C@H]1C(=O)N[C@@H](CC1CCC1)C(=O)C(N)=O)C2(C)C)C(C)(C)C |a:8,13,14,15,&1:19|, CC(C)(C)NC(=O)N[C@H](C(=O)N1C[C@H]2[C@@H]([C@H]1C(=O)N[C@@H](CC1CCC1)C(=O)C(N)=O)C2(C)C)C(C)(C)C |a:8,13,14,15,&1:19|, CC(C)(C)NC(=O)N[C@H](C(=O)N1C[C@H]2[C@@H]([C@H]1C(=O)N[C@@H](CC1CCC1)C(=O)C(N)=O)C2(C)C)C(C)(C)C |a:8,13,14,15,&1:19|	Launched
bonaphthone					Vitas-M, AMS	14.06	Brc1ccc2C(=O)C(=O)C=Cc2c1 |c:9|, Brc1ccc2C(=O)C(=O)C=Cc2c1 |c:9|	Phase 3
bopindolol	adrenergic receptor antagonist		cardiology	hypertension, coronary artery disease (CAD)	Enzo, Enzo	91.96	Cc1cc2c(OC[C@@H](CNC(C)(C)C)OC(=O)c3ccccc3)cccc2[nH]1 |&1:7|, Cc1cc2c(OC[C@@H](CNC(C)(C)C)OC(=O)c3ccccc3)cccc2[nH]1 |&1:7|	Launched
bornyl-acetate					Vitas-M, MicroSource	0	CC(=O)O[C@H]1C[C@H]2CC[C@@]1(C)C2(C)C |&1:4,&2:6,&3:9,r,TLB:3:4:7.8:11|, CC(=O)O[C@H]1C[C@H]2CC[C@@]1(C)C2(C)C |&1:4,&2:6,&3:9,r,TLB:3:4:7.8:11|	Preclinical
boronophenylalanine					Sigma, Acros	99.4	N[C@@H](Cc1ccc(cc1)B(O)O)C(O)=O, N[C@@H](Cc1ccc(cc1)B(O)O)C(O)=O	Phase 2
bortezomib	NFkB pathway inhibitor, proteasome inhibitor	PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMA8, PSMB1, PSMB10, PSMB11, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9, PSMD1, PSMD2, RELA	hematologic malignancy	multiple myeloma, mantle cell lymphoma (MCL)	MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck	98.4	CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O	Launched
BOS-172722	monopolar spindle 1 kinase inhibitor				MedChemEx	92.49	CCOc1cc(ccc1Nc1ncc2cc(C)nc(NCC(C)(C)C)c2n1)-c1nncn1C	Phase 1
bosentan	endothelin receptor antagonist	EDNRA, EDNRB	pulmonary	pulmonary arterial hypertension (PAH)	Selleck	97.9	COc1ccccc1Oc1c(NS(=O)(=O)c2ccc(cc2)C(C)(C)C)nc(nc1OCCO)-c1ncccn1	Launched
bosutinib	Abl kinase inhibitor, Bcr-Abl kinase inhibitor, SRC inhibitor	ABL1, BCR, CAMK1D, CAMK2G, CDK2, FRK, FYN, HCK, LYN, MAP2K1, MAP2K2, MAP3K2, MAP4K5, SRC, STK10, STK24, STK4, TNK2, TXK	hematologic malignancy	chronic myeloid leukemia (CML)	Tocris, Tocris, Tocris, Selleck, Selleck, Selleck, Selleck	99.19	COc1cc(Nc2c(cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)C#N)c(Cl)cc1Cl, COc1cc(Nc2c(cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)C#N)c(Cl)cc1Cl, COc1cc(Nc2c(cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)C#N)c(Cl)cc1Cl, COc1cc(Nc2c(cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)C#N)c(Cl)cc1Cl, COc1cc(Nc2c(cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)C#N)c(Cl)cc1Cl, COc1cc(Nc2c(cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)C#N)c(Cl)cc1Cl, COc1cc(Nc2c(cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)C#N)c(Cl)cc1Cl	Launched
BP-554	serotonin receptor agonist	HTR1A			Tocris, Tocris, Tocris, Tocris, Tocris	94.59	C(COc1ccc2OCOc2c1)CN1CCN(CC1)c1ccccc1, C(COc1ccc2OCOc2c1)CN1CCN(CC1)c1ccccc1, C(COc1ccc2OCOc2c1)CN1CCN(CC1)c1ccccc1, C(COc1ccc2OCOc2c1)CN1CCN(CC1)c1ccccc1, C(COc1ccc2OCOc2c1)CN1CCN(CC1)c1ccccc1	Preclinical
BP-897	dopamine receptor agonist	ADRA1A, ADRA1D, ADRA2A, DRD1, DRD2, DRD3, DRD4, HTR1A, HTR2B			Sigma, Prestwick	98.77	COc1ccccc1N1CCN(CCCCNC(=O)c2ccc3ccccc3c2)CC1, COc1ccccc1N1CCN(CCCCNC(=O)c2ccc3ccccc3c2)CC1	Phase 2
BQ-123	endothelin receptor antagonist	EDNRA			MedChemEx	83.68	[H][C@@]12CCCN1C(=O)[C@@]([H])(CC(O)=O)NC(=O)[C@@H](Cc1c[nH]c3ccccc13)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](NC2=O)C(C)C	Phase 2
BQ-788	endothelin receptor antagonist	EDNRB			MedChemEx, MedChemEx, MedChemEx	87.22	CCCC[C@@H](NC(=O)[C@@H](Cc1cn(C(=O)OC)c2ccccc12)NC(=O)[C@H](CC(C)(C)C)NC(=O)N1[C@@H](C)CCC[C@H]1C)C(O)=O, CCCC[C@@H](NC(=O)[C@@H](Cc1cn(C(=O)OC)c2ccccc12)NC(=O)[C@H](CC(C)(C)C)NC(=O)N1[C@@H](C)CCC[C@H]1C)C(O)=O, CCCC[C@@H](NC(=O)[C@@H](Cc1cn(C(=O)OC)c2ccccc12)NC(=O)[C@H](CC(C)(C)C)NC(=O)N1[C@@H](C)CCC[C@H]1C)C(O)=O	Phase 1
BQU57	Ras GTPase inhibitor	RALA, RALB			MedChemEx, MedChemEx	91.26	Cc1nn(C)c2OC(=N)C(C#N)[C@@H](c12)c1ccc(cc1)C(F)(F)F |&1:12,r|, Cc1nn(C)c2OC(=N)C(C#N)[C@@H](c12)c1ccc(cc1)C(F)(F)F |&1:12,r|	Preclinical
BRD4770	histone lysine methyltransferase inhibitor	EHMT2			MedChemEx, MedChemEx, MedChemEx	99.57	COC(=O)c1ccc2n(CCCc3ccccc3)c(NC(=O)c3ccccc3)nc2c1, COC(=O)c1ccc2n(CCCc3ccccc3)c(NC(=O)c3ccccc3)nc2c1, COC(=O)c1ccc2n(CCCc3ccccc3)c(NC(=O)c3ccccc3)nc2c1	Preclinical
BRD7389	ribosomal protein inhibitor	RPS6KA1, RPS6KA2, RPS6KA3			Tocris, Aurora, Aurora, Aurora	89.01	O=C1c2ccccc2-c2c(NCCc3ccccc3)c(=O)[nH]c3cccc1c23, O=C1c2ccccc2-c2c(NCCc3ccccc3)c(=O)[nH]c3cccc1c23, O=C1c2ccccc2-c2c(NCCc3ccccc3)c(=O)[nH]c3cccc1c23, O=C1c2ccccc2-c2c(NCCc3ccccc3)c(=O)[nH]c3cccc1c23	Preclinical
BRD9876	kinesin inhibitor	KIF11			Tocris, Tocris	90.59	CC(C)(C)c1ccc2cc(C#N)c(cc2c1)C#N, CC(C)(C)c1ccc2cc(C#N)c(cc2c1)C#N	Preclinical
brefeldin-A	protein synthesis inhibitor	ARF1, CYTH2			Tocris, Tocris, Tocris, Selleck, Selleck, Tocris	97.85	C[C@H]1CCC\C=C\[C@@H]2C[C@H](O)C[C@H]2[C@H](O)\C=C\C(=O)O1 |t:5,16|, C[C@H]1CCC\C=C\[C@@H]2C[C@H](O)C[C@H]2[C@H](O)\C=C\C(=O)O1 |t:5,16|, C[C@H]1CCC\C=C\[C@@H]2C[C@H](O)C[C@H]2[C@H](O)\C=C\C(=O)O1 |t:5,16|, C[C@H]1CCC\C=C\[C@@H]2C[C@H](O)C[C@H]2[C@H](O)\C=C\C(=O)O1 |t:5,16|, C[C@H]1CCC\C=C\[C@@H]2C[C@H](O)C[C@H]2[C@H](O)\C=C\C(=O)O1 |t:5,16|, C[C@H]1CCC\C=C\[C@@H]2C[C@H](O)C[C@H]2[C@H](O)\C=C\C(=O)O1 |t:5,16|	Preclinical
bremelanotide	melanocortin receptor agonist	MC1R, MC2R, MC3R, MC4R, MC5R	neurology/psychiatry	hypoactive sexual desire disorder	MedChemEx, MedChemEx	91.49	CCCC[C@H](NC(C)=O)C(=O)N[C@H]1CC(=O)NCCCC[C@H](NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@H](Cc2cnc[nH]2)NC1=O)C(O)=O, CCCC[C@H](NC(C)=O)C(=O)N[C@H]1CC(=O)NCCCC[C@H](NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@H](Cc2cnc[nH]2)NC1=O)C(O)=O	Launched
brequinar	dihydroorotate dehydrogenase inhibitor	DHODH			EMDBio, EMDBio, EMDBio	98.43	Cc1c(nc2ccc(F)cc2c1C(O)=O)-c1ccc(cc1)-c1ccccc1F, Cc1c(nc2ccc(F)cc2c1C(O)=O)-c1ccc(cc1)-c1ccccc1F, Cc1c(nc2ccc(F)cc2c1C(O)=O)-c1ccc(cc1)-c1ccccc1F	Phase 2
bretazenil	GABA benzodiazepine site receptor partial agonist	GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6			Tocris, Tocris, Tocris	98.49	CC(C)(C)OC(=O)c1ncn-2c1[C@@H]1CCCN1C(=O)c1c(Br)cccc-21, CC(C)(C)OC(=O)c1ncn-2c1[C@@H]1CCCN1C(=O)c1c(Br)cccc-21, CC(C)(C)OC(=O)c1ncn-2c1[C@@H]1CCCN1C(=O)c1c(Br)cccc-21	Phase 2
bretylium	norepinephrine inhibitor	ATP1A1	cardiology	ventricular arrhythmias, ventricular fibrillation (VF), ventricular tachycardia (VT)	Sigma, MicroSource, MedChemEx, MedChemEx	49.99	CC[N+](C)(C)Cc1ccccc1Br, CC[N+](C)(C)Cc1ccccc1Br, CC[N+](C)(C)Cc1ccccc1Br, CC[N+](C)(C)Cc1ccccc1Br	Launched
brexpiprazole	dopamine receptor partial agonist	DRD2	neurology/psychiatry	depression, schizophrenia	MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx	95.38	O=c1ccc2ccc(OCCCCN3CCN(CC3)c3cccc4sccc34)cc2[nH]1, O=c1ccc2ccc(OCCCCN3CCN(CC3)c3cccc4sccc34)cc2[nH]1, O=c1ccc2ccc(OCCCCN3CCN(CC3)c3cccc4sccc34)cc2[nH]1, O=c1ccc2ccc(OCCCCN3CCN(CC3)c3cccc4sccc34)cc2[nH]1, O=c1ccc2ccc(OCCCCN3CCN(CC3)c3cccc4sccc34)cc2[nH]1, O=c1ccc2ccc(OCCCCN3CCN(CC3)c3cccc4sccc34)cc2[nH]1	Launched
briciclib	cyclin D inhibitor	CCND1			MedChemEx, MedChemEx, MedChemEx	94.31	COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(OP(O)(O)=O)c2)c(OC)c1, COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(OP(O)(O)=O)c2)c(OC)c1, COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(OP(O)(O)=O)c2)c(OC)c1	Phase 1
brigatinib	ALK tyrosine kinase receptor inhibitor, EGFR inhibitor	ALK, EGFR	oncology	non-small cell lung cancer (NSCLC)	MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx	93.99	COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N1CCN(C)CC1, COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N1CCN(C)CC1, COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N1CCN(C)CC1, COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N1CCN(C)CC1, COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N1CCN(C)CC1, COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N1CCN(C)CC1, COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N1CCN(C)CC1, COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N1CCN(C)CC1	Launched
brilliant-green			infectious disease	antiseptic	Acros, Acros, Acros, Acros	91.76	CCN(CC)c1ccc(cc1)[C+](c1ccccc1)c1ccc(cc1)N(CC)CC, CCN(CC)c1ccc(cc1)[C+](c1ccccc1)c1ccc(cc1)N(CC)CC, CCN(CC)c1ccc(cc1)[C+](c1ccccc1)c1ccc(cc1)N(CC)CC, CCN(CC)c1ccc(cc1)[C+](c1ccccc1)c1ccc(cc1)N(CC)CC	Launched
brimonidine	adrenergic receptor agonist	ADRA2A, ADRA2B, ADRA2C	ophthalmology	intraocular pressure, glaucoma, ocular hypertension	Tocris, Tocris, Tocris, Tocris, Selleck, Selleck	99	Brc1c(NC2=NCCN2)ccc2nccnc12 |t:4|, Brc1c(NC2=NCCN2)ccc2nccnc12 |t:4|, Brc1c(NC2=NCCN2)ccc2nccnc12 |t:4|, Brc1c(NC2=NCCN2)ccc2nccnc12 |t:4|, Brc1c(NC2=NCCN2)ccc2nccnc12 |t:4|, Brc1c(NC2=NCCN2)ccc2nccnc12 |t:4|	Launched
brincidofovir	antiviral				Adooq	10.93	CCCCCCCCCCCCCCCCOCCCOP(O)(=O)CO[C@H](CO)Cn1ccc(N)nc1=O	Phase 3
brinzolamide	carbonic anhydrase inhibitor	CA1, CA12, CA14, CA2, CA4, CA5A, CA7	ophthalmology	intraocular pressure, glaucoma, ocular hypertension	MicroSource, MedChemEx, Selleck, Selleck	99.04	CCN[C@H]1CN(CCCOC)S(=O)(=O)c2sc(cc12)S(N)(=O)=O, CCN[C@H]1CN(CCCOC)S(=O)(=O)c2sc(cc12)S(N)(=O)=O, CCN[C@H]1CN(CCCOC)S(=O)(=O)c2sc(cc12)S(N)(=O)=O, CCN[C@H]1CN(CCCOC)S(=O)(=O)c2sc(cc12)S(N)(=O)=O	Launched
brivanib	FGFR inhibitor, VEGFR inhibitor	CYP3A4, FGFR1, FLT1, KCNH2, KDR			Selleck, Selleck, Selleck, Selleck	97.4	C[C@@H](O)COc1cn2ncnc(Oc3ccc4[nH]c(C)cc4c3F)c2c1C, C[C@@H](O)COc1cn2ncnc(Oc3ccc4[nH]c(C)cc4c3F)c2c1C, C[C@@H](O)COc1cn2ncnc(Oc3ccc4[nH]c(C)cc4c3F)c2c1C, C[C@@H](O)COc1cn2ncnc(Oc3ccc4[nH]c(C)cc4c3F)c2c1C	Phase 3
brivanib-alaninate	FGFR inhibitor, VEGFR inhibitor	FGFR3			MedChemEx, MedChemEx, Selleck, Selleck, Selleck, Selleck	73.46	C[C@H](COc1cn2ncnc(Oc3ccc4[nH]c(C)cc4c3F)c2c1C)OC(=O)[C@H](C)N, C[C@H](COc1cn2ncnc(Oc3ccc4[nH]c(C)cc4c3F)c2c1C)OC(=O)[C@H](C)N, C[C@H](COc1cn2ncnc(Oc3ccc4[nH]c(C)cc4c3F)c2c1C)OC(=O)[C@H](C)N, C[C@H](COc1cn2ncnc(Oc3ccc4[nH]c(C)cc4c3F)c2c1C)OC(=O)[C@H](C)N, C[C@H](COc1cn2ncnc(Oc3ccc4[nH]c(C)cc4c3F)c2c1C)OC(=O)[C@H](C)N, C[C@H](COc1cn2ncnc(Oc3ccc4[nH]c(C)cc4c3F)c2c1C)OC(=O)[C@H](C)N	Phase 3
brivudine	DNA directed DNA polymerase inhibitor		infectious disease	shingles	TCI	95.52	OC[C@H]1O[C@H](C[C@@H]1O)n1cc(\C=C\Br)c(=O)[nH]c1=O |a:2,4,&1:6|	Launched
BRL-15572	serotonin receptor antagonist	HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR6			Tocris, Tocris, Tocris, Tocris	98.84	O[C@@H](CN1CCN(CC1)c1cccc(Cl)c1)C(c1ccccc1)c1ccccc1 |&1:1|, O[C@@H](CN1CCN(CC1)c1cccc(Cl)c1)C(c1ccccc1)c1ccccc1 |&1:1|, O[C@@H](CN1CCN(CC1)c1cccc(Cl)c1)C(c1ccccc1)c1ccccc1 |&1:1|, O[C@@H](CN1CCN(CC1)c1cccc(Cl)c1)C(c1ccccc1)c1ccccc1 |&1:1|	Preclinical
BRL-26314	cholesterol inhibitor	LPL			Sigma, Sigma, Sigma	97.68	OC(=O)[C@@H](Cc1ccccc1)NCc1ccc(Cl)cc1 |&1:3,r|, OC(=O)[C@@H](Cc1ccccc1)NCc1ccc(Cl)cc1 |&1:3,r|, OC(=O)[C@@H](Cc1ccccc1)NCc1ccc(Cl)cc1 |&1:3,r|	Phase 1
BRL-37344	adrenergic receptor agonist	ADRB1, ADRB2, ADRB3			Tocris, Tocris, Tocris, Tocris	92.21	C[C@H](Cc1ccc(OCC(O)=O)cc1)NC[C@H](O)c1cccc(Cl)c1, C[C@H](Cc1ccc(OCC(O)=O)cc1)NC[C@H](O)c1cccc(Cl)c1, C[C@H](Cc1ccc(OCC(O)=O)cc1)NC[C@H](O)c1cccc(Cl)c1, C[C@H](Cc1ccc(OCC(O)=O)cc1)NC[C@H](O)c1cccc(Cl)c1	Phase 2
BRL-44408	adrenergic receptor antagonist	ADRA2A, ADRA2B, ADRA2C			Tocris, Tocris	95.6	C[C@H]1N(CC2=NCCN2)Cc2ccccc12 |&1:1,t:4|, C[C@H]1N(CC2=NCCN2)Cc2ccccc12 |&1:1,t:4|	Preclinical
BRL-50481	phosphodiesterase inhibitor	PDE7A, PDE7B			Tocris, Tocris, Tocris, Tocris	98.33	CN(C)S(=O)(=O)c1cc(ccc1C)[N+]([O-])=O, CN(C)S(=O)(=O)c1cc(ccc1C)[N+]([O-])=O, CN(C)S(=O)(=O)c1cc(ccc1C)[N+]([O-])=O, CN(C)S(=O)(=O)c1cc(ccc1C)[N+]([O-])=O	Preclinical
BRL-52537	opioid receptor agonist	OPRK1			Tocris, Tocris, Tocris	95.52	Clc1ccc(CC(=O)N2CCCC[C@@H]2CN2CCCC2)cc1Cl |&1:13|, Clc1ccc(CC(=O)N2CCCC[C@@H]2CN2CCCC2)cc1Cl |&1:13|, Clc1ccc(CC(=O)N2CCCC[C@@H]2CN2CCCC2)cc1Cl |&1:13|	Preclinical
BRL-54443	serotonin receptor agonist	HTR1E, HTR1F			Selleck, Tocris, Tocris, Tocris	96.5	CN1CCC(CC1)c1c[nH]c2ccc(O)cc12, CN1CCC(CC1)c1c[nH]c2ccc(O)cc12, CN1CCC(CC1)c1c[nH]c2ccc(O)cc12, CN1CCC(CC1)c1c[nH]c2ccc(O)cc12	Preclinical
brolitene	muscle relaxant	RYR1	rheumatology	lumbago	Vitas-M, ChemBridge	0	OCCNC(=O)\C=C\c1ccccc1, OCCNC(=O)\C=C\c1ccccc1	Launched
bromantan	dopamine reuptake inhibitor, serotonin reuptake inhibitor		neurology/psychiatry	neurasthenia	Enamine, Enamine, Enamine, Enamine	93.06	Brc1ccc(NC2C3CC4CC(C3)CC2C4)cc1, Brc1ccc(NC2C3CC4CC(C3)CC2C4)cc1, Brc1ccc(NC2C3CC4CC(C3)CC2C4)cc1, Brc1ccc(NC2C3CC4CC(C3)CC2C4)cc1	Launched
bromebric-acid	DNA synthesis inhibitor, purine antagonist				Sigma	91.08	COc1ccc(cc1)C(=O)C(\Br)=C\C(O)=O	Preclinical
bromfenac	cyclooxygenase inhibitor	PTGS1, PTGS2			Selleck	96.65	Nc1c(CC(O)=O)cccc1C(=O)c1ccc(Br)cc1	Withdrawn
bromhexine	mucolytic agent		pulmonary	chest congestion	MedChemEx, MicroSource, Selleck, Selleck, Selleck, Selleck	99.28	CN(Cc1cc(Br)cc(Br)c1N)C1CCCCC1, CN(Cc1cc(Br)cc(Br)c1N)C1CCCCC1, CN(Cc1cc(Br)cc(Br)c1N)C1CCCCC1, CN(Cc1cc(Br)cc(Br)c1N)C1CCCCC1, CN(Cc1cc(Br)cc(Br)c1N)C1CCCCC1, CN(Cc1cc(Br)cc(Br)c1N)C1CCCCC1	Launched
bromindione	anticoagulant				MicroSource, Sigma	93.64	Brc1ccc(cc1)C1C(=O)c2ccccc2C1=O, Brc1ccc(cc1)C1C(=O)c2ccccc2C1=O	Phase 2
bromisoval	anti-inflammatory agent				MedChemEx	89.47	CC(C)[C@@H](Br)C(=O)NC(N)=O |&1:3,r|	Preclinical
bromocriptine	dopamine receptor agonist	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C, HTR6, HTR7	endocrinology, neurology/psychiatry	hyperprolactinemia, Parkinson's Disease, acromegaly	Tocris, MicroSource, Tocris, Tocris	94.85	CC(C)C[C@@H]1N2C(=O)[C@](NC(=O)[C@H]3CN(C)[C@@H]4Cc5c(Br)[nH]c6cccc(C4=C3)c56)(O[C@@]2(O)[C@@H]2CCCN2C1=O)C(C)C |c:28|, CC(C)C[C@@H]1N2C(=O)[C@](NC(=O)[C@H]3CN(C)[C@@H]4Cc5c(Br)[nH]c6cccc(C4=C3)c56)(O[C@@]2(O)[C@@H]2CCCN2C1=O)C(C)C |c:28|, CC(C)C[C@@H]1N2C(=O)[C@](NC(=O)[C@H]3CN(C)[C@@H]4Cc5c(Br)[nH]c6cccc(C4=C3)c56)(O[C@@]2(O)[C@@H]2CCCN2C1=O)C(C)C |c:28|, CC(C)C[C@@H]1N2C(=O)[C@](NC(=O)[C@H]3CN(C)[C@@H]4Cc5c(Br)[nH]c6cccc(C4=C3)c56)(O[C@@]2(O)[C@@H]2CCCN2C1=O)C(C)C |c:28|	Launched
bromopride	dopamine receptor antagonist	DRD2	gastroenterology	nausea, vomiting, gastroesophageal reflux disease (GERD)	MicroSource, MicroSource, Key	97.86	CCN(CC)CCNC(=O)c1cc(Br)c(N)cc1OC, CCN(CC)CCNC(=O)c1cc(Br)c(N)cc1OC, CCN(CC)CCNC(=O)c1cc(Br)c(N)cc1OC	Launched
bromosporine	bromodomain inhibitor				Tocris, Tocris, Tocris, Selleck, Selleck, Selleck, Selleck	98.35	CCOC(=O)Nc1cc(nn2c(C)nnc12)-c1ccc(C)c(NS(C)(=O)=O)c1, CCOC(=O)Nc1cc(nn2c(C)nnc12)-c1ccc(C)c(NS(C)(=O)=O)c1, CCOC(=O)Nc1cc(nn2c(C)nnc12)-c1ccc(C)c(NS(C)(=O)=O)c1, CCOC(=O)Nc1cc(nn2c(C)nnc12)-c1ccc(C)c(NS(C)(=O)=O)c1, CCOC(=O)Nc1cc(nn2c(C)nnc12)-c1ccc(C)c(NS(C)(=O)=O)c1, CCOC(=O)Nc1cc(nn2c(C)nnc12)-c1ccc(C)c(NS(C)(=O)=O)c1, CCOC(=O)Nc1cc(nn2c(C)nnc12)-c1ccc(C)c(NS(C)(=O)=O)c1	Preclinical
bromperidol	dopamine receptor antagonist	DRD2	neurology/psychiatry	schizophrenia	MicroSource, MicroSource, MedChemEx, MedChemEx	98.85	OC1(CCN(CCCC(=O)c2ccc(F)cc2)CC1)c1ccc(Br)cc1, OC1(CCN(CCCC(=O)c2ccc(F)cc2)CC1)c1ccc(Br)cc1, OC1(CCN(CCCC(=O)c2ccc(F)cc2)CC1)c1ccc(Br)cc1, OC1(CCN(CCCC(=O)c2ccc(F)cc2)CC1)c1ccc(Br)cc1	Launched
brompheniramine	histamine receptor antagonist	HRH1	allergy, otolaryngology	allergic rhinitis, common cold	MedChemEx	85.77	CN(C)CC[C@@H](c1ccc(Br)cc1)c1ccccn1 |&1:5|	Launched
bronopol			obstetrics/gynecology	mastitis	MedChemEx, MicroSource	90.31	OCC(Br)(CO)[N+]([O-])=O, OCC(Br)(CO)[N+]([O-])=O	Launched
bropirimine	interferon inducer				Sigma, LifeChem, Sigma	99.22	Nc1nc(=O)c(Br)c([nH]1)-c1ccccc1, Nc1nc(=O)c(Br)c([nH]1)-c1ccccc1, Nc1nc(=O)c(Br)c([nH]1)-c1ccccc1	Phase 3
broxaldine					MedChemEx, MicroSource, MicroSource	98.61	Cc1ccc2c(Br)cc(Br)c(OC(=O)c3ccccc3)c2n1, Cc1ccc2c(Br)cc(Br)c(OC(=O)c3ccccc3)c2n1, Cc1ccc2c(Br)cc(Br)c(OC(=O)c3ccccc3)c2n1	Preclinical
broxaterol	adrenergic receptor agonist	ADRB2			Enamine	98.05	CC(C)(C)NC[C@@H](O)c1cc(Br)no1 |&1:6,r|	Phase 3
broxuridine	antimetabolite				Tocris, MedChemEx	94.39	OC[C@H]1O[C@H](C[C@@H]1O)n1cc(Br)c(=O)[nH]c1=O, OC[C@H]1O[C@H](C[C@@H]1O)n1cc(Br)c(=O)[nH]c1=O	Phase 2
broxyquinoline	antiprotozoal agent				MedChemEx, MicroSource, Selleck, Selleck	99.49	Oc1c(Br)cc(Br)c2cccnc12, Oc1c(Br)cc(Br)c2cccnc12, Oc1c(Br)cc(Br)c2cccnc12, Oc1c(Br)cc(Br)c2cccnc12	Phase 1
bruceantin	protein synthesis inhibitor				MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx	94.27	COC(=O)[C@]12OC[C@@]34[C@H]1[C@@H](OC(=O)\C=C(/C)C(C)C)C(=O)O[C@@H]3C[C@H]1[C@@H](C)C(=O)C(=O)C[C@]1(C)[C@H]4[C@@H](O)[C@@H]2O |a:4,7,8,9,22,24,32,34,35,37,&1:25|, COC(=O)[C@]12OC[C@@]34[C@H]1[C@@H](OC(=O)\C=C(/C)C(C)C)C(=O)O[C@@H]3C[C@H]1[C@@H](C)C(=O)C(=O)C[C@]1(C)[C@H]4[C@@H](O)[C@@H]2O |a:4,7,8,9,22,24,32,34,35,37,&1:25|, COC(=O)[C@]12OC[C@@]34[C@H]1[C@@H](OC(=O)\C=C(/C)C(C)C)C(=O)O[C@@H]3C[C@H]1[C@@H](C)C(=O)C(=O)C[C@]1(C)[C@H]4[C@@H](O)[C@@H]2O |a:4,7,8,9,22,24,32,34,35,37,&1:25|, COC(=O)[C@]12OC[C@@]34[C@H]1[C@@H](OC(=O)\C=C(/C)C(C)C)C(=O)O[C@@H]3C[C@H]1[C@@H](C)C(=O)C(=O)C[C@]1(C)[C@H]4[C@@H](O)[C@@H]2O |a:4,7,8,9,22,24,32,34,35,37,&1:25|, COC(=O)[C@]12OC[C@@]34[C@H]1[C@@H](OC(=O)\C=C(/C)C(C)C)C(=O)O[C@@H]3C[C@H]1[C@@H](C)C(=O)C(=O)C[C@]1(C)[C@H]4[C@@H](O)[C@@H]2O |a:4,7,8,9,22,24,32,34,35,37,&1:25|	Phase 2
brucine	glycine receptor antagonist	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5			Selleck	97.56	COc1cc2N3[C@H]4[C@@H]5[C@H](CC3=O)OCC=C3CN6CC[C@]4([C@@H]6C[C@H]53)c2cc1OC |t:15|	Preclinical
BS-181	CDK inhibitor	CDK7			Tocris, Tocris, Selleck, Selleck, Selleck, Selleck, Selleck	96.53	CC(C)c1cnn2c(NCc3ccccc3)cc(NCCCCCCN)nc12, CC(C)c1cnn2c(NCc3ccccc3)cc(NCCCCCCN)nc12, CC(C)c1cnn2c(NCc3ccccc3)cc(NCCCCCCN)nc12, CC(C)c1cnn2c(NCc3ccccc3)cc(NCCCCCCN)nc12, CC(C)c1cnn2c(NCc3ccccc3)cc(NCCCCCCN)nc12, CC(C)c1cnn2c(NCc3ccccc3)cc(NCCCCCCN)nc12, CC(C)c1cnn2c(NCc3ccccc3)cc(NCCCCCCN)nc12	Preclinical
BT-11	cAMP stimulant				MedChemEx	92.84	O=C(N1CCN(CC1)C(=O)c1cccc(n1)-c1nc2ccccc2[nH]1)c1cccc(n1)-c1nc2ccccc2[nH]1	Phase 2
BTB06584	ATPase inhibitor	ATP5F1			Selleck, Selleck, MedChemEx	82.92	[O-][N+](=O)c1ccc(cc1OC(=O)c1ccc(Cl)cc1)S(=O)(=O)c1ccccc1, [O-][N+](=O)c1ccc(cc1OC(=O)c1ccc(Cl)cc1)S(=O)(=O)c1ccccc1, [O-][N+](=O)c1ccc(cc1OC(=O)c1ccc(Cl)cc1)S(=O)(=O)c1ccccc1	Preclinical
BTB1	mitotic kinesin inhibitor	KIF18A			Tocris, Tocris, Tocris	95.75	[O-][N+](=O)c1cc(Cl)ccc1S(=O)(=O)c1ccccc1, [O-][N+](=O)c1cc(Cl)ccc1S(=O)(=O)c1ccccc1, [O-][N+](=O)c1cc(Cl)ccc1S(=O)(=O)c1ccccc1	Preclinical
BTK-IN-1	Bruton's tyrosine kinase (BTK) inhibitor				MedChemEx	93.86	Clc1cccc(NCC(=O)N[C@@H]2CCCN(C2)c2ncnc3[nH]ccc23)c1 |&1:11,r|	Preclinical
BTS					Tocris, Tocris, Tocris	98.75	Cc1ccc(cc1)S(=O)(=O)NCc1ccccc1, Cc1ccc(cc1)S(=O)(=O)NCc1ccccc1, Cc1ccc(cc1)S(=O)(=O)NCc1ccccc1	Preclinical
BTS-54505	dopamine reuptake inhibitor	SLC6A2, SLC6A3, SLC6A4			Tocris, Tocris, Tocris, Tocris, Tocris	94.8	CC(C)C[C@@H](N)C1(CCC1)c1ccc(Cl)cc1 |&1:4|, CC(C)C[C@@H](N)C1(CCC1)c1ccc(Cl)cc1 |&1:4|, CC(C)C[C@@H](N)C1(CCC1)c1ccc(Cl)cc1 |&1:4|, CC(C)C[C@@H](N)C1(CCC1)c1ccc(Cl)cc1 |&1:4|, CC(C)C[C@@H](N)C1(CCC1)c1ccc(Cl)cc1 |&1:4|	Withdrawn
BTS-71321					Enamine	92.03	CC(C)(NCCCn1ccnc1)c1ccc(Cl)cc1	Phase 2
BTS-72664	GABA receptor antagonist	GABBR1			Key	98.2	C[C@@H](Oc1ccc(Cl)cc1)c1ccnc2ncnn12 |&1:1,r|	Phase 1
BTT-3033	integrin inhibitor	ITGA2, ITGB1			Tocris, Tocris, Tocris	98.48	CN(c1ccc(NC(=O)Nc2ccccc2)cc1)S(=O)(=O)c1cnn(c1)-c1ccc(F)cc1, CN(c1ccc(NC(=O)Nc2ccccc2)cc1)S(=O)(=O)c1cnn(c1)-c1ccc(F)cc1, CN(c1ccc(NC(=O)Nc2ccccc2)cc1)S(=O)(=O)c1cnn(c1)-c1ccc(F)cc1	Preclinical
BTZ043-racemate	DPRE1 inhibitor				MedChemEx, Selleck	98.56	C[C@H]1COC2(CCN(CC2)c2nc(=O)c3cc(cc([N+]([O-])=O)c3s2)C(F)(F)F)O1 |&1:1,r|, C[C@H]1COC2(CCN(CC2)c2nc(=O)c3cc(cc([N+]([O-])=O)c3s2)C(F)(F)F)O1 |&1:1,r|	Phase 1/Phase 2
BU-224	imidazoline receptor ligand	MAOA, MAOB			Tocris, Tocris, Tocris	98.23	C1CN=C(N1)c1ccc2ccccc2n1 |c:2|, C1CN=C(N1)c1ccc2ccccc2n1 |c:2|, C1CN=C(N1)c1ccc2ccccc2n1 |c:2|	Preclinical
BU-239	imidazoline receptor agonist, imidazoline receptor ligand				Tocris, Tocris, Tocris, Tocris, Tocris, Tocris, Tocris	97.33	C1CN=C(N1)c1cnc2ccccc2n1 |c:2|, C1CN=C(N1)c1cnc2ccccc2n1 |c:2|, C1CN=C(N1)c1cnc2ccccc2n1 |c:2|, C1CN=C(N1)c1cnc2ccccc2n1 |c:2|, C1CN=C(N1)c1cnc2ccccc2n1 |c:2|, C1CN=C(N1)c1cnc2ccccc2n1 |c:2|, C1CN=C(N1)c1cnc2ccccc2n1 |c:2|	Preclinical
bucetin	analgesic agent				MicroSource, MedChemEx	98.09	CCOc1ccc(NC(=O)C[C@@H](C)O)cc1 |&1:11,r|, CCOc1ccc(NC(=O)C[C@@H](C)O)cc1 |&1:11,r|	Withdrawn
bucillamine	immunosuppressant		rheumatology	rheumatoid arthritis	Kemprotec, AKSci	96.91	CC(C)(S)C(=O)N[C@@H](CS)C(O)=O, CC(C)(S)C(=O)N[C@@H](CS)C(O)=O	Launched
bucladesine	adenosine receptor agonist, cAMP stimulant	PRKACA	dermatology	skin ulcer	Tocris, Tocris, Tocris, Tocris, MicroSource, MicroSource	98.02	CCCC(=O)Nc1ncnc2n(cnc12)[C@@H]1O[C@@H]2CO[P@](O)(=O)O[C@H]2[C@H]1OC(=O)CCC |a:15,17,24,25,&1:20|, CCCC(=O)Nc1ncnc2n(cnc12)[C@@H]1O[C@@H]2CO[P@](O)(=O)O[C@H]2[C@H]1OC(=O)CCC |a:15,17,24,25,&1:20|, CCCC(=O)Nc1ncnc2n(cnc12)[C@@H]1O[C@@H]2CO[P@](O)(=O)O[C@H]2[C@H]1OC(=O)CCC |a:15,17,24,25,&1:20|, CCCC(=O)Nc1ncnc2n(cnc12)[C@@H]1O[C@@H]2CO[P@](O)(=O)O[C@H]2[C@H]1OC(=O)CCC |a:15,17,24,25,&1:20|, CCCC(=O)Nc1ncnc2n(cnc12)[C@@H]1O[C@@H]2CO[P@](O)(=O)O[C@H]2[C@H]1OC(=O)CCC |a:15,17,24,25,&1:20|, CCCC(=O)Nc1ncnc2n(cnc12)[C@@H]1O[C@@H]2CO[P@](O)(=O)O[C@H]2[C@H]1OC(=O)CCC |a:15,17,24,25,&1:20|	Launched
buclizine	histamine receptor antagonist	HRH1	neurology/psychiatry	migraine headache	Key, Key	99.32	CC(C)(C)c1ccc(CN2CCN(CC2)[C@@H](c2ccccc2)c2ccc(Cl)cc2)cc1 |&1:15|, CC(C)(C)c1ccc(CN2CCN(CC2)[C@@H](c2ccccc2)c2ccc(Cl)cc2)cc1 |&1:15|	Launched
budesonide	glucocorticoid receptor agonist	NR3C1	gastroenterology	Crohn's disease	Sigma, Tocris, MedChemEx, MedChemEx, Selleck, Selleck, Tocris, MicroSource, Selleck	54.98	CCC[C@H]1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO |a:5,7,8,17,19,20,23,25,&1:3,c:15,t:11|, CCC[C@H]1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO |a:5,7,8,17,19,20,23,25,&1:3,c:15,t:11|, CCC[C@H]1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO |a:5,7,8,17,19,20,23,25,&1:3,c:15,t:11|, CCC[C@H]1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO |a:5,7,8,17,19,20,23,25,&1:3,c:15,t:11|, CCC[C@H]1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO |a:5,7,8,17,19,20,23,25,&1:3,c:15,t:11|, CCC[C@H]1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO |a:5,7,8,17,19,20,23,25,&1:3,c:15,t:11|, CCC[C@H]1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO |a:5,7,8,17,19,20,23,25,&1:3,c:15,t:11|, CCC[C@H]1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO |a:5,7,8,17,19,20,23,25,&1:3,c:15,t:11|, CCC[C@H]1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO |a:5,7,8,17,19,20,23,25,&1:3,c:15,t:11|	Launched
budipine	glutamate receptor antagonist	GRIN1	neurology/psychiatry	Parkinson's Disease	AQBioPharma, AQBioPharma	94.36	CC(C)(C)N1CCC(CC1)(c1ccccc1)c1ccccc1, CC(C)(C)N1CCC(CC1)(c1ccccc1)c1ccccc1	Launched
bufexamac	cyclooxygenase inhibitor	HDAC10, HDAC6			MedChemEx, MedChemEx, MicroSource, Selleck	98.93	CCCCOc1ccc(CC(=O)NO)cc1, CCCCOc1ccc(CC(=O)NO)cc1, CCCCOc1ccc(CC(=O)NO)cc1, CCCCOc1ccc(CC(=O)NO)cc1	Withdrawn
buflomedil	adrenergic receptor antagonist, calcium channel blocker	ADRA1A	cardiology	peripheral artery disease (PAD)	MedChemEx, MedChemEx, MedChemEx, MedChemEx, MicroSource, Selleck	98.69	COc1cc(OC)c(C(=O)CCCN2CCCC2)c(OC)c1, COc1cc(OC)c(C(=O)CCCN2CCCC2)c(OC)c1, COc1cc(OC)c(C(=O)CCCN2CCCC2)c(OC)c1, COc1cc(OC)c(C(=O)CCCN2CCCC2)c(OC)c1, COc1cc(OC)c(C(=O)CCCN2CCCC2)c(OC)c1, COc1cc(OC)c(C(=O)CCCN2CCCC2)c(OC)c1	Launched
bumetanide	solute carrier family member inhibitor	CFTR, GPR35, SLC12A1, SLC12A2, SLC12A4, SLC12A5	cardiology	edema, congestive heart failure	Tocris, MicroSource, Tocris, Tocris, Selleck	99.54	CCCCNc1cc(cc(c1Oc1ccccc1)S(N)(=O)=O)C(O)=O, CCCCNc1cc(cc(c1Oc1ccccc1)S(N)(=O)=O)C(O)=O, CCCCNc1cc(cc(c1Oc1ccccc1)S(N)(=O)=O)C(O)=O, CCCCNc1cc(cc(c1Oc1ccccc1)S(N)(=O)=O)C(O)=O, CCCCNc1cc(cc(c1Oc1ccccc1)S(N)(=O)=O)C(O)=O	Launched
bunazosin	adrenergic receptor antagonist	ADRA1A	ophthalmology	glaucoma, intraocular pressure	Enamine, Toronto	97.77	CCCC(=O)N1CCCN(CC1)c1nc(N)c2cc(OC)c(OC)cc2n1, CCCC(=O)N1CCCN(CC1)c1nc(N)c2cc(OC)c(OC)cc2n1	Launched
buparlisib	PI3K inhibitor	PIK3CA, PIK3CG			Selleck, Selleck, Selleck	98.65	Nc1cc(c(cn1)-c1cc(nc(n1)N1CCOCC1)N1CCOCC1)C(F)(F)F, Nc1cc(c(cn1)-c1cc(nc(n1)N1CCOCC1)N1CCOCC1)C(F)(F)F, Nc1cc(c(cn1)-c1cc(nc(n1)N1CCOCC1)N1CCOCC1)C(F)(F)F	Phase 3
buparvaquone	antiprotozoal agent		infectious disease	protozoan infection	MedChemEx, MedChemEx	96.77	CC(C)(C)C1CCC(C[C@H]2C(=O)C(=O)c3ccccc3C2=O)CC1 |&1:9,r|, CC(C)(C)C1CCC(C[C@H]2C(=O)C(=O)c3ccccc3C2=O)CC1 |&1:9,r|	Launched
buphenine	adrenergic receptor agonist	ADRB2	rheumatology	Raynaud's disease	MedChemEx, MicroSource	89.35	CC(CCc1ccccc1)NC(C)C(O)c1ccc(O)cc1, CC(CCc1ccccc1)NC(C)C(O)c1ccc(O)cc1	Launched
bupicomide	adrenergic receptor antagonist	ADRB1			Enamine, Enamine	95.4	CCCCc1ccc(nc1)C(N)=O, CCCCc1ccc(nc1)C(N)=O	Phase 1
bupivacaine	sodium channel blocker	KCNA5, SCN10A	neurology/psychiatry	peripheral nerve block, caudal epidural block, lumbar epidural block	MedChemEx	98.85	CCCCN1CCCC[C@H]1C(=O)Nc1c(C)cccc1C |&1:9,r|	Launched
bupranolol	adrenergic receptor antagonist	ADRB1, ADRB2, ADRB3	cardiology, ophthalmology	hypertension, glaucoma	Enamine, Enamine, Enamine, Toronto, Toronto	97.52	Cc1ccc(Cl)c(OC[C@@H](O)CNC(C)(C)C)c1 |&1:9,r|, Cc1ccc(Cl)c(OC[C@@H](O)CNC(C)(C)C)c1 |&1:9,r|, Cc1ccc(Cl)c(OC[C@@H](O)CNC(C)(C)C)c1 |&1:9,r|, Cc1ccc(Cl)c(OC[C@@H](O)CNC(C)(C)C)c1 |&1:9,r|, Cc1ccc(Cl)c(OC[C@@H](O)CNC(C)(C)C)c1 |&1:9,r|	Launched
bupropion	dopamine reuptake inhibitor	SLC6A2, SLC6A3	neurology/psychiatry	depression	Tocris	94.45	C[C@@H](NC(C)(C)C)C(=O)c1cccc(Cl)c1 |&1:1,r|	Launched
buramate	antiepileptic				MicroSource, Enamine	89.56	OCCOC(=O)NCc1ccccc1, OCCOC(=O)NCc1ccccc1	Preclinical
buserelin	gonadotropin releasing factor hormone receptor agonist		oncology, obstetrics/gynecology	prostate cancer, endometriosis	MedChemEx	98.16	CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H]1CCC(=O)N1	Launched
buspirone	serotonin receptor agonist	DRD2, HTR1A	neurology/psychiatry	generalized anxiety disorder (GAD)	MicroSource, Selleck, Tocris, Tocris	99.45	O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(CC1)c1ncccn1, O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(CC1)c1ncccn1, O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(CC1)c1ncccn1, O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(CC1)c1ncccn1	Launched
busulfan	DNA inhibitor		hematologic malignancy	chronic myeloid leukemia (CML)	MicroSource, Selleck, Selleck	89.78	CS(=O)(=O)OCCCCOS(C)(=O)=O, CS(=O)(=O)OCCCCOS(C)(=O)=O, CS(=O)(=O)OCCCCOS(C)(=O)=O	Launched
butabindide	tripeptidyl peptidase inhibitor	TPP2			Tocris, Tocris	90.73	CCCCNC(=O)[C@@H]1Cc2ccccc2N1C(=O)[C@@H](N)CC, CCCCNC(=O)[C@@H]1Cc2ccccc2N1C(=O)[C@@H](N)CC	Preclinical
butacaine	local anesthetic		neurology/psychiatry	local anesthetic	MicroSource, Selleck, Selleck	95.48	CCCCN(CCCC)CCCOC(=O)c1ccc(N)cc1, CCCCN(CCCC)CCCOC(=O)c1ccc(N)cc1, CCCCN(CCCC)CCCOC(=O)c1ccc(N)cc1	Launched
butaclamol	dopamine receptor antagonist	DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR2A			Sigma	97.77	CC(C)(C)[C@]1(O)CCN2C[C@H]3c4ccccc4CCc4cccc([C@@H]2C1)c34	Phase 2
butalbital	GABA receptor antagonist	CHRNA4, CHRNA7, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GRIA2, GRIK2	neurology/psychiatry	headache, muscle relaxant	Prestwick, Prestwick	98.11	CC(C)CC1(CC=C)C(=O)NC(=O)NC1=O, CC(C)CC1(CC=C)C(=O)NC(=O)NC1=O	Launched
butamben	sodium channel blocker				MedChemEx, MicroSource, MicroSource	99.12	CCCCOC(=O)c1ccc(N)cc1, CCCCOC(=O)c1ccc(N)cc1, CCCCOC(=O)c1ccc(N)cc1	Withdrawn
butaprost	prostaglandin receptor agonist				Sigma	100	CCCC1(CCC1)[C@H](O)C\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)OC	Preclinical
butein	EGFR inhibitor, SRC inhibitor	ACE			Selleck, Selleck, Selleck, Selleck	92.44	Oc1ccc(C(=O)\C=C\c2ccc(O)c(O)c2)c(O)c1, Oc1ccc(C(=O)\C=C\c2ccc(O)c(O)c2)c(O)c1, Oc1ccc(C(=O)\C=C\c2ccc(O)c(O)c2)c(O)c1, Oc1ccc(C(=O)\C=C\c2ccc(O)c(O)c2)c(O)c1	Preclinical
butenafine	fungal squalene epoxidase inhibitor	SQLE	infectious disease	tinea pedis, tinea cruris, tinea corporis	Selleck, Selleck, Selleck, MedChemEx	99.5	CN(Cc1ccc(cc1)C(C)(C)C)Cc1cccc2ccccc12, CN(Cc1ccc(cc1)C(C)(C)C)Cc1cccc2ccccc12, CN(Cc1ccc(cc1)C(C)(C)C)Cc1cccc2ccccc12, CN(Cc1ccc(cc1)C(C)(C)C)Cc1cccc2ccccc12	Launched
buthionine-sulfoximine	glutathione transferase inhibitor	GCLM			Enzo	94.36	CCCCS(=N)(=O)CC[C@H](N)C(O)=O |a:9,&1:4|	Phase 1
butibufen	cyclooxygenase inhibitor				Carbosynth, Carbosynth, Toronto	95.48	CC[C@@H](C(O)=O)c1ccc(CC(C)C)cc1 |&1:2,r|, CC[C@@H](C(O)=O)c1ccc(CC(C)C)cc1 |&1:2,r|, CC[C@@H](C(O)=O)c1ccc(CC(C)C)cc1 |&1:2,r|	Withdrawn
butoconazole	bacterial cell wall synthesis inhibitor		infectious disease	vulvovaginal candidiasis	MedChemEx, MicroSource	99.34	Clc1ccc(CC[C@@H](Cn2ccnc2)Sc2c(Cl)cccc2Cl)cc1 |&1:7,r|, Clc1ccc(CC[C@@H](Cn2ccnc2)Sc2c(Cl)cccc2Cl)cc1 |&1:7,r|	Launched
butofilolol	adrenergic receptor antagonist				Sigma	96.62	CCCC(=O)c1cc(F)ccc1OC[C@@H](O)CNC(C)(C)C |&1:14,r|	Phase 2
butyl-paraben	DNA synthesis inhibitor				MicroSource, MicroSource	98.43	CCCCOC(=O)c1ccc(O)cc1, CCCCOC(=O)c1ccc(O)cc1	Preclinical
butylated-hydroxyanisole	antioxidant				MicroSource, Sigma	88.92	COc1ccc(O)c(c1)C(C)(C)C, COc1ccc(O)c(c1)C(C)(C)C	Preclinical
butylated-hydroxytoluene	carbonic anhydrase inhibitor	CA2			MicroSource, MicroSource, MedChemEx	97.99	Cc1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C, Cc1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C, Cc1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C	Phase 1
butylidenephthalide	cyclooxygenase inhibitor				Sigma	0	CCC\C=C1/OC(=O)c2ccccc12	Phase 1/Phase 2
butylphthalide	potassium channel antagonist	KCNK2	neurology/psychiatry	stroke	MedChemEx	94.43	CCCC[C@H]1OC(=O)c2ccccc12 |&1:4,r|	Launched
butylscopolamine-bromide	cholinergic receptor antagonist		gastroenterology	abdominal pain	MedChemEx	97.31	CCCC[N@@+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)c1ccccc1 |a:6,8,10,11,13,17,&1:4,TLB:3:4:7.8.9:11.13,12:11:4:7.8.9,12:13:4:7.8.9,THB:5:4:7.8.9:11.13,14:8:4:11.13|	Launched
BU226	imidazoline receptor ligand				Tocris, Tocris, Tocris, Tocris	97.75	C1CN=C(N1)c1cc2ccccc2cn1 |c:2|, C1CN=C(N1)c1cc2ccccc2cn1 |c:2|, C1CN=C(N1)c1cc2ccccc2cn1 |c:2|, C1CN=C(N1)c1cc2ccccc2cn1 |c:2|	Preclinical
BVD-523	MAP kinase inhibitor				MedChemEx, MedChemEx, MedChemEx	99.21	CC(C)Nc1cc(-c2c[nH]c(c2)C(=O)N[C@H](CO)c2cccc(Cl)c2)c(Cl)cn1, CC(C)Nc1cc(-c2c[nH]c(c2)C(=O)N[C@H](CO)c2cccc(Cl)c2)c(Cl)cn1, CC(C)Nc1cc(-c2c[nH]c(c2)C(=O)N[C@H](CO)c2cccc(Cl)c2)c(Cl)cn1	Phase 2
BVT-2733	11-beta hydroxysteroid dehydrogenase inhibitor	HSD17B1			MedChemEx	96.59	CN1CCN(CC1)C(=O)Cc1csc(NS(=O)(=O)c2cccc(Cl)c2C)n1	Preclinical
BVT-948	tyrosine phosphatase inhibitor	PTPN1, PTPN11, PTPN2			Tocris, Tocris	90.36	CC1(C)C(=O)NC2=C1C(=O)C(=O)c1ccccc21 |c:6|, CC1(C)C(=O)NC2=C1C(=O)C(=O)c1ccccc21 |c:6|	Preclinical
BW-A4C	lipoxygenase inhibitor	ALOX5			Sigma, Sigma	87.05	CC(=O)N(O)C\C=C\c1cccc(Oc2ccccc2)c1, CC(=O)N(O)C\C=C\c1cccc(Oc2ccccc2)c1	Phase 1
BW-B70C	lipoxygenase inhibitor	ALOX5			Sigma, Tocris	86.91	C[C@@H](\C=C\c1cccc(Oc2ccc(F)cc2)c1)N(O)C(N)=O |&1:1,r|, C[C@@H](\C=C\c1cccc(Oc2ccc(F)cc2)c1)N(O)C(N)=O |&1:1,r|	Preclinical
BW-180C	opioid receptor agonist	OPRD1, OPRM1			MedChemEx	89.9	CC(C)C[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)[C@@H](C)NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(O)=O	Phase 2
BW-348U87	antiviral				Key	82.15	C\C(=N/NC(=S)NNC(=S)Nc1ccccc1Cl)c1ccccn1	Preclinical
BW-373U86	opioid receptor agonist	OPRD1			Tocris, Tocris, Tocris	97.24	CCN(CC)C(=O)c1ccc(cc1)[C@@H](N1C[C@@H](C)N(CC=C)C[C@@H]1C)c1cccc(O)c1, CCN(CC)C(=O)c1ccc(cc1)[C@@H](N1C[C@@H](C)N(CC=C)C[C@@H]1C)c1cccc(O)c1, CCN(CC)C(=O)c1ccc(cc1)[C@@H](N1C[C@@H](C)N(CC=C)C[C@@H]1C)c1cccc(O)c1	Preclinical
BW-616U	monoamine oxidase inhibitor	MAOA			Enamine, Enamine	97.3	CNC(=O)c1ccc2C(=O)c3ccccc3S(=O)(=O)c2c1, CNC(=O)c1ccc2C(=O)c3ccccc3S(=O)(=O)c2c1	Preclinical
BW-723C86	serotonin receptor agonist	HTR2A, HTR2B, HTR2C			Tocris, Tocris, Tocris	90.04	C[C@@H](N)Cc1c[nH]c2ccc(OCc3cccs3)cc12 |&1:1|, C[C@@H](N)Cc1c[nH]c2ccc(OCc3cccs3)cc12 |&1:1|, C[C@@H](N)Cc1c[nH]c2ccc(OCc3cccs3)cc12 |&1:1|	Preclinical
BX-795	IKK inhibitor	CDK2, CHEK1, GSK3B, KDR, PDK1, PDPK1			MedChemEx, Selleck, Selleck, MedChemEx	94.52	Ic1cnc(Nc2cccc(NC(=O)N3CCCC3)c2)nc1NCCCNC(=O)c1cccs1, Ic1cnc(Nc2cccc(NC(=O)N3CCCC3)c2)nc1NCCCNC(=O)c1cccs1, Ic1cnc(Nc2cccc(NC(=O)N3CCCC3)c2)nc1NCCCNC(=O)c1cccs1, Ic1cnc(Nc2cccc(NC(=O)N3CCCC3)c2)nc1NCCCNC(=O)c1cccs1	Preclinical
BX-912	pyruvate dehydrogenase kinase inhibitor	CDK2, CHEK1, GSK3B, KDR, PDK1, PDPK1			Selleck, Selleck	95.26	Brc1cnc(Nc2cccc(NC(=O)N3CCCC3)c2)nc1NCCc1cnc[nH]1, Brc1cnc(Nc2cccc(NC(=O)N3CCCC3)c2)nc1NCCc1cnc[nH]1	Preclinical
BYK-204165	PARP inhibitor	PARP1			Tocris, Tocris, Tocris, Tocris, Tocris, Tocris, Tocris	98.46	Cn1cccc1\C=C1/C(=O)NC(=O)c2ccccc12, Cn1cccc1\C=C1/C(=O)NC(=O)c2ccccc12, Cn1cccc1\C=C1/C(=O)NC(=O)c2ccccc12, Cn1cccc1\C=C1/C(=O)NC(=O)c2ccccc12, Cn1cccc1\C=C1/C(=O)NC(=O)c2ccccc12, Cn1cccc1\C=C1/C(=O)NC(=O)c2ccccc12, Cn1cccc1\C=C1/C(=O)NC(=O)c2ccccc12	Preclinical
C-021	CC chemokine receptor antagonist	CCR4			Tocris, Tocris, Tocris, Tocris, Tocris, Tocris	97.39	COc1cc2nc(nc(NC3CCCCCC3)c2cc1OC)N1CCC(CC1)N1CCCCC1, COc1cc2nc(nc(NC3CCCCCC3)c2cc1OC)N1CCC(CC1)N1CCCCC1, COc1cc2nc(nc(NC3CCCCCC3)c2cc1OC)N1CCC(CC1)N1CCCCC1, COc1cc2nc(nc(NC3CCCCCC3)c2cc1OC)N1CCC(CC1)N1CCCCC1, COc1cc2nc(nc(NC3CCCCCC3)c2cc1OC)N1CCC(CC1)N1CCCCC1, COc1cc2nc(nc(NC3CCCCCC3)c2cc1OC)N1CCC(CC1)N1CCCCC1	Preclinical
C-1	protein kinase inhibitor	PRKCA			Tocris, Tocris, Tocris, Tocris	98.34	O=S(=O)(N1CCNCC1)c1cccc2cnccc12, O=S(=O)(N1CCNCC1)c1cccc2cnccc12, O=S(=O)(N1CCNCC1)c1cccc2cnccc12, O=S(=O)(N1CCNCC1)c1cccc2cnccc12	Preclinical
C-751					Key	98.92	CCOC(=O)c1cnc[nH]1	Preclinical
CA-4948	kinase inhibitor				MedChemEx	95.81	Nc1ccc(cn1)-c1cccc(n1)C(=O)Nc1cnc2nc(oc2c1)N1CCOCC1	Phase 1
cabagin			gastroenterology	dyspepsia	AlfaAesar, Toronto	100	C[S+](C)CC[C@H](N)C(O)=O, C[S+](C)CC[C@H](N)C(O)=O	Launched
cabaletta	pharmacological chaperone				Enzo	97.42	OC[C@H]1O[C@H](O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1O	Phase 2
cabazitaxel	microtubule inhibitor	TUBA1A, TUBA1B, TUBA1C, TUBA3C, TUBA3D, TUBA3E, TUBA4A, TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8	oncology	prostate cancer	MedChemEx	95.83	CO[C@H]1C[C@H]2OC[C@@]2(OC(C)=O)[C@H]2[C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C(C)=C([C@@H](OC)C(=O)[C@]12C)C3(C)C |t:51|	Launched
cabergoline	dopamine receptor agonist	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C, HTR7	endocrinology	hyperprolactinemia	Tocris, Tocris, Enzo, Enzo, Enzo, Tocris	94.48	CCNC(=O)N(CCCN(C)C)C(=O)[C@@H]1C[C@H]2[C@@H](Cc3c[nH]c4cccc2c34)N(CC=C)C1, CCNC(=O)N(CCCN(C)C)C(=O)[C@@H]1C[C@H]2[C@@H](Cc3c[nH]c4cccc2c34)N(CC=C)C1, CCNC(=O)N(CCCN(C)C)C(=O)[C@@H]1C[C@H]2[C@@H](Cc3c[nH]c4cccc2c34)N(CC=C)C1, CCNC(=O)N(CCCN(C)C)C(=O)[C@@H]1C[C@H]2[C@@H](Cc3c[nH]c4cccc2c34)N(CC=C)C1, CCNC(=O)N(CCCN(C)C)C(=O)[C@@H]1C[C@H]2[C@@H](Cc3c[nH]c4cccc2c34)N(CC=C)C1, CCNC(=O)N(CCCN(C)C)C(=O)[C@@H]1C[C@H]2[C@@H](Cc3c[nH]c4cccc2c34)N(CC=C)C1	Launched
cabotegravir	HIV integrase inhibitor				MedChemEx, Selleck	97.41	C[C@H]1CO[C@@H]2Cn3cc(C(=O)NCc4ccc(F)cc4F)c(=O)c(O)c3C(=O)N12, C[C@H]1CO[C@@H]2Cn3cc(C(=O)NCc4ccc(F)cc4F)c(=O)c(O)c3C(=O)N12	Phase 3
cabozantinib	RET tyrosine kinase inhibitor, VEGFR inhibitor	KDR, MET, RET	oncology	medullary thyroid cancer (MTC)	Tocris, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck	99.56	COc1cc2nccc(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3)c2cc1OC, COc1cc2nccc(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3)c2cc1OC, COc1cc2nccc(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3)c2cc1OC, COc1cc2nccc(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3)c2cc1OC, COc1cc2nccc(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3)c2cc1OC, COc1cc2nccc(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3)c2cc1OC, COc1cc2nccc(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3)c2cc1OC, COc1cc2nccc(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3)c2cc1OC, COc1cc2nccc(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3)c2cc1OC, COc1cc2nccc(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3)c2cc1OC	Launched
CaCCinh-A01	calcium-activated chloride channel inhibitor	CLCA1			Tocris, Tocris	95.53	CC(C)(C)[C@H]1CCc2c(C1)sc(NC(=O)c1ccco1)c2C(O)=O |&1:4,r|, CC(C)(C)[C@H]1CCc2c(C1)sc(NC(=O)c1ccco1)c2C(O)=O |&1:4,r|	Preclinical
cadazolid	antibacterial 				MedChemEx	91.31	OC[C@H]1CN(C(=O)O1)c1ccc(OCC2(O)CCN(CC2)c2cc3n(cc(C(O)=O)c(=O)c3cc2F)C2CC2)c(F)c1	Phase 3
cadralazine	adrenergic receptor antagonist		cardiology	hypertension	Key, Key	57.47	CCOC(=O)NNc1ccc(nn1)N(CC)C[C@@H](C)O |&1:17,r|, CCOC(=O)NNc1ccc(nn1)N(CC)C[C@@H](C)O |&1:17,r|	Launched
cafestol	pregnane X receptor agonist				Enzo	95.32	C[C@@]12CCc3occc3[C@H]1CC[C@@]13C[C@@H](CC[C@@H]21)[C@@](O)(CO)C3	Launched
caffeic-acid	HIV integrase inhibitor, lipoxygenase inhibitor, nitric oxide production inhibitor, tumor necrosis factor production inhibitor	ALOX5, MIF			MedChemEx, MedChemEx, Selleck, Selleck	95.21	OC(=O)\C=C\c1ccc(O)c(O)c1, OC(=O)\C=C\c1ccc(O)c(O)c1, OC(=O)\C=C\c1ccc(O)c(O)c1, OC(=O)\C=C\c1ccc(O)c(O)c1	Preclinical
caffeic-acid-phenethyl-ester	HIV integrase inhibitor	RELA			Tocris, Tocris, Selleck	97.3	Oc1ccc(\C=C\C(=O)OCCc2ccccc2)cc1O, Oc1ccc(\C=C\C(=O)OCCc2ccccc2)cc1O, Oc1ccc(\C=C\C(=O)OCCc2ccccc2)cc1O	Preclinical
caffeine	adenosine receptor antagonist, phosphodiesterase inhibitor	ADORA1, ADORA2A, ADORA2B, ADORA3, ATM, ITPR1, ITPR2, ITPR3, PDE10A, PDE11A, PDE1A, PDE1B, PDE1C, PDE2A, PDE3A, PDE3B, PDE4A, PDE4B, PDE4C, PDE4D, PDE5A, PDE6A, PDE6B, PDE6C, PDE7A, PDE7B, PDE8A, PDE8B, PDE9A, PIK3CA, PIK3CB, PIK3CD, PRKDC, RYR1, RYR2, RYR3	neurology/psychiatry	fatigue, drowsiness	MicroSource, MicroSource, MicroSource	99.15	Cn1cnc2n(C)c(=O)n(C)c(=O)c12, Cn1cnc2n(C)c(=O)n(C)c(=O)c12, Cn1cnc2n(C)c(=O)n(C)c(=O)c12	Launched
calcifediol	vitamin D receptor agonist	VDR	endocrinology	hyperparathyroidism	Adooq, Adooq, MedChemEx, MedChemEx, Selleck, Selleck	93.66	C[C@H](CCCC(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C, C[C@H](CCCC(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C, C[C@H](CCCC(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C, C[C@H](CCCC(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C, C[C@H](CCCC(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C, C[C@H](CCCC(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C	Launched
calcipotriol	vitamin D receptor agonist	VDR	dermatology	psoriasis	MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx, Tocris	92.24	C[C@H](\C=C\[C@@H](O)C1CC1)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, C[C@H](\C=C\[C@@H](O)C1CC1)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, C[C@H](\C=C\[C@@H](O)C1CC1)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, C[C@H](\C=C\[C@@H](O)C1CC1)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, C[C@H](\C=C\[C@@H](O)C1CC1)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, C[C@H](\C=C\[C@@H](O)C1CC1)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, C[C@H](\C=C\[C@@H](O)C1CC1)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, C[C@H](\C=C\[C@@H](O)C1CC1)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C	Launched
calcitonin	calcitonin agonist		orthopedics	osteoporosis	MedChemEx	93.78	[H]N[C@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CO)NC1=O)[C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(N)=O |r|	Launched
calcitriol	vitamin D receptor agonist	VDR	endocrinology, orthopedics	hypocalcemia, hypoparathyroidism, osteoporosis	Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck	96.4	C[C@H](CCCC(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, C[C@H](CCCC(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, C[C@H](CCCC(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, C[C@H](CCCC(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, C[C@H](CCCC(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, C[C@H](CCCC(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, C[C@H](CCCC(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, C[C@H](CCCC(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, C[C@H](CCCC(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, C[C@H](CCCC(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C	Launched
calcium-gluceptate					MicroSource, MicroSource, TCI, TCI, Selleck	100	OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)C(O)=O, OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)C(O)=O, OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)C(O)=O, OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)C(O)=O, OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)C(O)=O	Launched
calcium-levofolinate					MedChemEx, Selleck, Selleck, Selleck	100	Nc1nc(=O)c2N(C=O)[C@@H](CNc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)CNc2[nH]1, Nc1nc(=O)c2N(C=O)[C@@H](CNc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)CNc2[nH]1, Nc1nc(=O)c2N(C=O)[C@@H](CNc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)CNc2[nH]1, Nc1nc(=O)c2N(C=O)[C@@H](CNc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)CNc2[nH]1	Launched
Calhex-231	calcium sensing receptor negative allosteric modulator	CASR			Tocris, Tocris, Tocris	97.6	C[C@@H](N[C@H]1CCCC[C@@H]1NC(=O)c1ccc(Cl)cc1)c1cccc2ccccc12, C[C@@H](N[C@H]1CCCC[C@@H]1NC(=O)c1ccc(Cl)cc1)c1cccc2ccccc12, C[C@@H](N[C@H]1CCCC[C@@H]1NC(=O)c1ccc(Cl)cc1)c1cccc2ccccc12	Preclinical
calpeptin	calpain inhibitor				Tocris, Tocris, Tocris, Tocris, Tocris, Tocris, Tocris, Tocris	100	CCCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)OCc1ccccc1)C=O, CCCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)OCc1ccccc1)C=O, CCCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)OCc1ccccc1)C=O, CCCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)OCc1ccccc1)C=O, CCCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)OCc1ccccc1)C=O, CCCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)OCc1ccccc1)C=O, CCCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)OCc1ccccc1)C=O, CCCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)OCc1ccccc1)C=O	Preclinical
camicinal	motilin receptor agonist	MLNR			MedChemEx, MedChemEx, MedChemEx	85.54	C[C@H]1CN(Cc2ccc(CC(=O)N3CCC(CC3)Nc3cccc(F)c3)cc2)CCN1, C[C@H]1CN(Cc2ccc(CC(=O)N3CCC(CC3)Nc3cccc(F)c3)cc2)CCN1, C[C@H]1CN(Cc2ccc(CC(=O)N3CCC(CC3)Nc3cccc(F)c3)cc2)CCN1	Phase 2
CaMKII-IN-1	calcium/calmodulin dependent protein kinase inhibitor	AKT1, CAMK2A, CAMK4, MYLK			MedChemEx, MedChemEx	96.28	Cc1c(Cl)cccc1S(=O)(=O)Nc1nc(NCCc2ccccc2)nc2CCN(Cc3ccccc3)Cc12, Cc1c(Cl)cccc1S(=O)(=O)Nc1nc(NCCc2ccccc2)nc2CCN(Cc3ccccc3)Cc12	Preclinical
camobucol	anti-inflammatory agent				MedChemEx	99.03	CC(C)(C)c1cc(SC(C)(C)Sc2cc(c(OCC(O)=O)c(c2)C(C)(C)C)C(C)(C)C)cc(c1O)C(C)(C)C	Preclinical
camostat-mesilate	protease inhibitor	PRSS1	gastroenterology	pancreatitis	Tocris, Tocris, Selleck	96.48	CN(C)C(=O)COC(=O)Cc1ccc(OC(=O)c2ccc(NC(N)=N)cc2)cc1, CN(C)C(=O)COC(=O)Cc1ccc(OC(=O)c2ccc(NC(N)=N)cc2)cc1, CN(C)C(=O)COC(=O)Cc1ccc(OC(=O)c2ccc(NC(N)=N)cc2)cc1	Launched
camphor-(+)					MedChemEx, MedChemEx	0	CC1(C)[C@@H]2CC[C@@]1(C)C(=O)C2, CC1(C)[C@@H]2CC[C@@]1(C)C(=O)C2	Phase 2
camphor-(1R)	TRPV activator	TRPV1			MicroSource	0	CC1(C)[C@@H]2CC[C@]1(C)C(=O)C2	Phase 1
camptothecin	topoisomerase inhibitor	TOP1			Selleck, Selleck, Selleck, Selleck, Selleck, Tocris	90.8	CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccccc4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccccc4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccccc4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccccc4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccccc4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccccc4cc3Cn1c2=O	Phase 3
camylofine-chlorhydrate			gastroenterology	abdominal pain	Selleck, MicroSource, Selleck	96.03	CCN(CC)CCN[C@@H](C(=O)OCCC(C)C)c1ccccc1 |&1:8|, CCN(CC)CCN[C@@H](C(=O)OCCC(C)C)c1ccccc1 |&1:8|, CCN(CC)CCN[C@@H](C(=O)OCCC(C)C)c1ccccc1 |&1:8|	Launched
canagliflozin	sodium/glucose cotransporter inhibitor	SLC5A1, SLC5A2	endocrinology	diabetes mellitus	MedChemEx, MicroSource, Selleck	98.9	Cc1ccc(cc1Cc1ccc(s1)-c1ccc(F)cc1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O, Cc1ccc(cc1Cc1ccc(s1)-c1ccc(F)cc1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O, Cc1ccc(cc1Cc1ccc(s1)-c1ccc(F)cc1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O	Launched
candesartan	angiotensin receptor antagonist	AGTR1	cardiology	hypertension, congestive heart failure	Tocris, Tocris, Tocris, MicroSource, Selleck, Selleck	98.75	CCOc1nc2cccc(C(O)=O)c2n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1, CCOc1nc2cccc(C(O)=O)c2n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1, CCOc1nc2cccc(C(O)=O)c2n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1, CCOc1nc2cccc(C(O)=O)c2n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1, CCOc1nc2cccc(C(O)=O)c2n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1, CCOc1nc2cccc(C(O)=O)c2n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1	Launched
candesartan-cilexetil	angiotensin receptor antagonist		cardiology	hypertension, congestive heart failure, hypertension	MicroSource, Selleck, Selleck, Selleck, Selleck, MedChemEx, MedChemEx	98.63	CCOc1nc2cccc(C(=O)O[C@@H](C)OC(=O)OC3CCCCC3)c2n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1 |&1:13,r|, CCOc1nc2cccc(C(=O)O[C@@H](C)OC(=O)OC3CCCCC3)c2n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1 |&1:13,r|, CCOc1nc2cccc(C(=O)O[C@@H](C)OC(=O)OC3CCCCC3)c2n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1 |&1:13,r|, CCOc1nc2cccc(C(=O)O[C@@H](C)OC(=O)OC3CCCCC3)c2n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1 |&1:13,r|, CCOc1nc2cccc(C(=O)O[C@@H](C)OC(=O)OC3CCCCC3)c2n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1 |&1:13,r|, CCOc1nc2cccc(C(=O)O[C@@H](C)OC(=O)OC3CCCCC3)c2n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1 |&1:13,r|, CCOc1nc2cccc(C(=O)O[C@@H](C)OC(=O)OC3CCCCC3)c2n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1 |&1:13,r|	Launched
candicidin	fungal ergosterol inhibitor		infectious disease	vulvovaginal candidiasis	MicroSource	0	C[C@@H](C[C@@H](C)[C@H]1OC(=O)CC(=O)CCCC(=O)C[C@@H](O)C[C@@H](O)C[C@@H](O)CC(=O)C[C@@H](O)[C@@H]([C@@H](O)C[C@@H](O[C@@H]2O[C@H](C)[C@H](O)[C@@H](O)[C@@H]2N)\C=C\C=C\C=C\C=C\C=C\C=C\C=C\[C@@H]1C)C(O)=O)[C@@H](O)CC(=O)c1ccc(N)cc1 |a:38,40,42,44,46,&1:1,&2:3,&3:5,&4:18,&5:21,&6:24,&7:30,&8:32,&9:33,&10:36,&11:62,&12:67,t:49,51,53,55,57,59,61|	Launched
canertinib	EGFR inhibitor	AKT1, EGFR, ERBB2, ERBB4			Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck	96.46	Fc1ccc(Nc2ncnc3cc(OCCCN4CCOCC4)c(NC(=O)C=C)cc23)cc1Cl, Fc1ccc(Nc2ncnc3cc(OCCCN4CCOCC4)c(NC(=O)C=C)cc23)cc1Cl, Fc1ccc(Nc2ncnc3cc(OCCCN4CCOCC4)c(NC(=O)C=C)cc23)cc1Cl, Fc1ccc(Nc2ncnc3cc(OCCCN4CCOCC4)c(NC(=O)C=C)cc23)cc1Cl, Fc1ccc(Nc2ncnc3cc(OCCCN4CCOCC4)c(NC(=O)C=C)cc23)cc1Cl, Fc1ccc(Nc2ncnc3cc(OCCCN4CCOCC4)c(NC(=O)C=C)cc23)cc1Cl, Fc1ccc(Nc2ncnc3cc(OCCCN4CCOCC4)c(NC(=O)C=C)cc23)cc1Cl	Phase 3
cangrelor	purinergic receptor antagonist		cardiology	myocardial infarction	Adooq	94.41	CSCCNc1nc(SCCC(F)(F)F)nc2n(cnc12)[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)C(Cl)(Cl)P(O)(O)=O)[C@@H](O)[C@H]1O	Launched
canrenone	mineralocorticoid receptor antagonist	NR3C2			Tocris	100	C[C@]12CC[C@H]3[C@@H](C=CC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@]21CCC(=O)O1 |c:6,t:8|	Withdrawn
cantharidin	protein phosphatase inhibitor		dermatology	blisters	MedChemEx, MedChemEx, Sigma, Tocris	47.3	C[C@]12[C@@H]3CC[C@@H](O3)[C@@]1(C)C(=O)OC2=O, C[C@]12[C@@H]3CC[C@@H](O3)[C@@]1(C)C(=O)OC2=O, C[C@]12[C@@H]3CC[C@@H](O3)[C@@]1(C)C(=O)OC2=O, C[C@]12[C@@H]3CC[C@@H](O3)[C@@]1(C)C(=O)OC2=O	Launched
capadenoson	adenosine receptor agonist	ADORA1			MedChemEx, MedChemEx, MedChemEx	99.55	Nc1nc(SCc2csc(n2)-c2ccc(Cl)cc2)c(C#N)c(-c2ccc(OCCO)cc2)c1C#N, Nc1nc(SCc2csc(n2)-c2ccc(Cl)cc2)c(C#N)c(-c2ccc(OCCO)cc2)c1C#N, Nc1nc(SCc2csc(n2)-c2ccc(Cl)cc2)c(C#N)c(-c2ccc(OCCO)cc2)c1C#N	Phase 2
capecitabine	DNA synthesis inhibitor, thymidylate synthase inhibitor	TYMS	oncology	breast cancer, colorectal cancer	Tocris, MicroSource, MicroSource, MicroSource, Selleck, Selleck, Selleck	97.88	CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O	Launched
capobenic-acid					MicroSource	52.98	COc1cc(cc(OC)c1OC)C(=O)NCCCCCC(O)=O	Preclinical
capreomycin	protein synthesis inhibitor		infectious disease	tuberculosis	MedChemEx	0	C[C@@H]1NC(=O)[C@@H](N)CNC(=O)[C@@H](NC(=O)\C(NC(=O)[C@H](CNC(=O)C[C@@H](N)CCCN)NC1=O)=C/NC(N)=O)[C@H]1CCN=C(N)N1 |t:43|	Launched
capromorelin	growth hormone secretagogue receptor agonist				MedChemEx	89.29	CN1N=C2CCN(C[C@@]2(Cc2ccccc2)C1=O)C(=O)[C@@H](COCc1ccccc1)NC(=O)C(C)(C)N |t:2|	Preclinical
caprylic-acid					Enamine, Enamine	8.98	CCCCCCCC(O)=O, CCCCCCCC(O)=O	Launched
capsaicin	TRPV agonist	CFTR, TRPV1	neurology/psychiatry, rheumatology	muscle pain, rheumatoid arthritis	MicroSource, Tocris	95.04	COc1cc(CNC(=O)CCCC\C=C\C(C)C)ccc1O, COc1cc(CNC(=O)CCCC\C=C\C(C)C)ccc1O	Launched
capsazepine	TRPV agonist	TRPV1, TRPV4			Tocris, Tocris, Tocris, Tocris	98	Oc1cc2CCCN(Cc2cc1O)C(=S)NCCc1ccc(Cl)cc1, Oc1cc2CCCN(Cc2cc1O)C(=S)NCCc1ccc(Cl)cc1, Oc1cc2CCCN(Cc2cc1O)C(=S)NCCc1ccc(Cl)cc1, Oc1cc2CCCN(Cc2cc1O)C(=S)NCCc1ccc(Cl)cc1	Preclinical
captamine					MicroSource, SantaCruz	62.6	CN(C)CCS, CN(C)CCS	Preclinical
captan					AKSci	0	ClC(Cl)(Cl)SN1C(=O)[C@H]2CC=CC[C@@H]2C1=O |r,c:10|	Phase 1
captopril	angiotensin converting enzyme inhibitor	ACE, LTA4H, MMP2, MMP9	cardiology, endocrinology, nephrology	hypertension, congestive heart failure, myocardial infarction, diabetes mellitus, diabetic nephropathy	MicroSource, Selleck, Selleck, Selleck, Selleck	100	C[C@H](CS)C(=O)N1CCC[C@H]1C(O)=O, C[C@H](CS)C(=O)N1CCC[C@H]1C(O)=O, C[C@H](CS)C(=O)N1CCC[C@H]1C(O)=O, C[C@H](CS)C(=O)N1CCC[C@H]1C(O)=O, C[C@H](CS)C(=O)N1CCC[C@H]1C(O)=O	Launched
caracemide	ribonucleotide reductase inhibitor	RRM1			Enamine, Enamine	41.64	CNC(=O)ON(C(C)=O)C(=O)NC, CNC(=O)ON(C(C)=O)C(=O)NC	Phase 2
caramiphen	cholinergic receptor antagonist	CHRM1, CHRM2	neurology/psychiatry	Parkinson's Disease	ChemDiv, ChemDiv	87.71	CCN(CC)CCOC(=O)C1(CCCC1)c1ccccc1, CCN(CC)CCOC(=O)C1(CCCC1)c1ccccc1	Launched
carazolol	adrenergic receptor antagonist	ADRB1, ADRB2, ADRB3	cardiology	angina pectoris, cardiac arrythmia, hypertension, myocardial infarction	Cayman, Cayman	95.74	CC(C)NC[C@@H](O)COc1cccc2[nH]c3ccccc3c12 |&1:5,r|, CC(C)NC[C@@H](O)COc1cccc2[nH]c3ccccc3c12 |&1:5,r|	Launched
carbachol	cholinergic receptor agonist	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, CHRNA2	ophthalmology	intraocular pressure	MicroSource, MedChemEx, Selleck	100	C[N+](C)(C)CCOC(N)=O, C[N+](C)(C)CCOC(N)=O, C[N+](C)(C)CCOC(N)=O	Launched
carbadox	other antibiotic		infectious disease, gastroenterology	dysentry, enteritis	MicroSource, MedChemEx, MedChemEx, Selleck, Selleck, Selleck	99.18	COC(=O)N\N=C\c1c[n+]([O-])c2ccccc2[n+]1[O-], COC(=O)N\N=C\c1c[n+]([O-])c2ccccc2[n+]1[O-], COC(=O)N\N=C\c1c[n+]([O-])c2ccccc2[n+]1[O-], COC(=O)N\N=C\c1c[n+]([O-])c2ccccc2[n+]1[O-], COC(=O)N\N=C\c1c[n+]([O-])c2ccccc2[n+]1[O-], COC(=O)N\N=C\c1c[n+]([O-])c2ccccc2[n+]1[O-]	Launched
carbamazepine	carboxamide antiepileptic	SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A	neurology/psychiatry	seizures	Tocris, Tocris, MicroSource, Selleck	99.2	NC(=O)N1c2ccccc2C=Cc2ccccc12 |c:11|, NC(=O)N1c2ccccc2C=Cc2ccccc12 |c:11|, NC(=O)N1c2ccccc2C=Cc2ccccc12 |c:11|, NC(=O)N1c2ccccc2C=Cc2ccccc12 |c:11|	Launched
carbaril	acetylcholinesterase inhibitor				MicroSource, Sigma	94.61	CNC(=O)Oc1cccc2ccccc12, CNC(=O)Oc1cccc2ccccc12	Launched
carbarsone	antiprotozoal agent		infectious disease	amebiasis	MicroSource, FrontierSci	100	NC(=O)Nc1ccc(cc1)[As](O)(O)=O, NC(=O)Nc1ccc(cc1)[As](O)(O)=O	Launched
carbazochrome			hematology	hemorrhage	Selleck, MedChemEx, MedChemEx	97.8	CN1[C@@H](CC2=C\C(=N\NC(N)=O)C(=O)C=C12)S(O)(=O)=O |&1:2,t:4,14|, CN1[C@@H](CC2=C\C(=N\NC(N)=O)C(=O)C=C12)S(O)(=O)=O |&1:2,t:4,14|, CN1[C@@H](CC2=C\C(=N\NC(N)=O)C(=O)C=C12)S(O)(=O)=O |&1:2,t:4,14|	Launched
carbendazim	microtubule inhibitor, tubulin polymerization inhibitor	TP53, TUBB	infectious disease	fungicide	Sigma, Sigma	98.32	COC(=O)Nc1nc2ccccc2[nH]1, COC(=O)Nc1nc2ccccc2[nH]1	Launched
carbenicillin	bacterial cell wall synthesis inhibitor		infectious disease	gram-negative bacterial infections	MedChemEx, MicroSource, MedChemEx, Selleck, Selleck	0	CC1(C)S[C@@H]2[C@H](NC(=O)[C@@H](C(O)=O)c3ccccc3)C(=O)N2[C@H]1C(O)=O |a:4,5,22,&1:9|, CC1(C)S[C@@H]2[C@H](NC(=O)[C@@H](C(O)=O)c3ccccc3)C(=O)N2[C@H]1C(O)=O |a:4,5,22,&1:9|, CC1(C)S[C@@H]2[C@H](NC(=O)[C@@H](C(O)=O)c3ccccc3)C(=O)N2[C@H]1C(O)=O |a:4,5,22,&1:9|, CC1(C)S[C@@H]2[C@H](NC(=O)[C@@H](C(O)=O)c3ccccc3)C(=O)N2[C@H]1C(O)=O |a:4,5,22,&1:9|, CC1(C)S[C@@H]2[C@H](NC(=O)[C@@H](C(O)=O)c3ccccc3)C(=O)N2[C@H]1C(O)=O |a:4,5,22,&1:9|	Launched
carbenoxolone	11-beta hydroxysteroid dehydrogenase inhibitor	GJA1, GJA10, GJA3, GJA4, GJA5, GJA8, GJA9, GJB1, GJB2, GJB3, GJB4, GJB5, GJB6, GJB7, GJC1, GJC2, GJC3, GJD2, GJD3, GJD4, GJE1, HSD11B1, PANX1, PANX2, PANX3	gastroenterology, dental	peptic ulcer disease (PUD), mouth inflammation	Tocris	95	CC1(C)[C@H](CC[C@@]2(C)[C@H]1CC[C@]1(C)[C@@H]2C(=O)C=C2[C@@H]3C[C@](C)(CC[C@]3(C)CC[C@@]12C)C(O)=O)OC(=O)CCC(O)=O |t:18|	Launched
carbetapentane	acetylcholine receptor antagonist	CHRM2	otolaryngology, pulmonary	common cold, nasal congestion, bronchitis	MicroSource, Tocris	93.21	CCN(CC)CCOCCOC(=O)C1(CCCC1)c1ccccc1, CCN(CC)CCOCCOC(=O)C1(CCCC1)c1ccccc1	Launched
carbetocin	oxytocin receptor agonist	OXTR	hematology	hemorrhage	MedChemEx	93.12	CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(OC)cc2)NC(=O)CCCSC[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC1=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O	Launched
carbidopa	aromatic L-amino acid decarboxylase inhibitor	DDC	neurology/psychiatry	Parkinson's Disease	MicroSource, Selleck, Selleck, MedChemEx, Tocris	0	C[C@@](Cc1ccc(O)c(O)c1)(NN)C(O)=O, C[C@@](Cc1ccc(O)c(O)c1)(NN)C(O)=O, C[C@@](Cc1ccc(O)c(O)c1)(NN)C(O)=O, C[C@@](Cc1ccc(O)c(O)c1)(NN)C(O)=O, C[C@@](Cc1ccc(O)c(O)c1)(NN)C(O)=O	Launched
carbimazole	antithyroid agent	TPO	endocrinology	hyperthyroidism	MedChemEx, Selleck, MicroSource, Selleck	94.34	CCOC(=O)n1ccn(C)c1=S, CCOC(=O)n1ccn(C)c1=S, CCOC(=O)n1ccn(C)c1=S, CCOC(=O)n1ccn(C)c1=S	Launched
carbinoxamine	histamine receptor antagonist	HRH1	allergy, ophthalmology, otolaryngology, dermatology	allergic rhinitis, conjunctivitis, vasomotor rhinitis, dermatographism	MedChemEx	94.11	CN(C)CCO[C@@H](c1ccc(Cl)cc1)c1ccccn1 |&1:6|	Launched
carboplatin	DNA alkylating agent, DNA inhibitor		oncology	ovarian cancer	MicroSource, Selleck, Tocris, Tocris, Tocris, Tocris, Selleck	71.13	N[Pt]1(N)OC(=O)C2(CCC2)C(=O)O1, N[Pt]1(N)OC(=O)C2(CCC2)C(=O)O1, N[Pt]1(N)OC(=O)C2(CCC2)C(=O)O1, N[Pt]1(N)OC(=O)C2(CCC2)C(=O)O1, N[Pt]1(N)OC(=O)C2(CCC2)C(=O)O1, N[Pt]1(N)OC(=O)C2(CCC2)C(=O)O1, N[Pt]1(N)OC(=O)C2(CCC2)C(=O)O1	Launched
carboxyamidotriazole	calcium channel blocker	CXCL8			Sigma, Sigma, Sigma, Tocris	99.81	NC(=O)c1nnn(Cc2cc(Cl)c(C(=O)c3ccc(Cl)cc3)c(Cl)c2)c1N, NC(=O)c1nnn(Cc2cc(Cl)c(C(=O)c3ccc(Cl)cc3)c(Cl)c2)c1N, NC(=O)c1nnn(Cc2cc(Cl)c(C(=O)c3ccc(Cl)cc3)c(Cl)c2)c1N, NC(=O)c1nnn(Cc2cc(Cl)c(C(=O)c3ccc(Cl)cc3)c(Cl)c2)c1N	Phase 3
carboxylosartan	angiotensin antagonist	AGTR1			Cayman	98.87	CCCCc1nc(Cl)c(C(O)=O)n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1	Phase 1
carboxypyridine-disulfide					Sigma, Sigma, Sigma	98.3	OC(=O)c1ccc(SSc2ccc(cn2)C(O)=O)nc1, OC(=O)c1ccc(SSc2ccc(cn2)C(O)=O)nc1, OC(=O)c1ccc(SSc2ccc(cn2)C(O)=O)nc1	Phase 2
cardiogenol-C	cardiomyogenesis inducer				Tocris, Tocris, Tocris	95.96	COc1ccc(Nc2nccc(NCCO)n2)cc1, COc1ccc(Nc2nccc(NCCO)n2)cc1, COc1ccc(Nc2nccc(NCCO)n2)cc1	Preclinical
cardionogen-1	WNT signaling inhibitor	CTNNB1			Tocris, Tocris	93.1	C1CCC(CC1)c1nn2c(nnc2s1)-c1ccco1, C1CCC(CC1)c1nn2c(nnc2s1)-c1ccco1	Preclinical
carebastine	histamine receptor antagonist	HRH1			ChemImpex	98.51	CC(C)(C(O)=O)c1ccc(cc1)C(=O)CCCN1CCC(CC1)OC(c1ccccc1)c1ccccc1	Phase 1
carfilzomib	proteasome inhibitor	PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMA8, PSMB1, PSMB10, PSMB11, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9	hematologic malignancy	multiple myeloma	MedChemEx, MedChemEx, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck	98.07	CC(C)C[C@H](NC(=O)[C@H](CCc1ccccc1)NC(=O)CN1CCOCC1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(C)CO1, CC(C)C[C@H](NC(=O)[C@H](CCc1ccccc1)NC(=O)CN1CCOCC1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(C)CO1, CC(C)C[C@H](NC(=O)[C@H](CCc1ccccc1)NC(=O)CN1CCOCC1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(C)CO1, CC(C)C[C@H](NC(=O)[C@H](CCc1ccccc1)NC(=O)CN1CCOCC1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(C)CO1, CC(C)C[C@H](NC(=O)[C@H](CCc1ccccc1)NC(=O)CN1CCOCC1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(C)CO1, CC(C)C[C@H](NC(=O)[C@H](CCc1ccccc1)NC(=O)CN1CCOCC1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(C)CO1, CC(C)C[C@H](NC(=O)[C@H](CCc1ccccc1)NC(=O)CN1CCOCC1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(C)CO1, CC(C)C[C@H](NC(=O)[C@H](CCc1ccccc1)NC(=O)CN1CCOCC1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(C)CO1	Launched
carglumic-acid	carbamoyl phosphate synthase activator	CPS1	metabolism	hyperammonemia	MedChemEx, MicroSource	100	NC(=O)N[C@@H](CCC(O)=O)C(O)=O, NC(=O)N[C@@H](CCC(O)=O)C(O)=O	Launched
caricotamide	NADPH quinone oxidoreductase inhibitor	NQO2			Enamine	0	NC(=O)CN1C=CCC(=C1)C(N)=O |c:5,8|	Phase 2
cariporide	sodium/hydrogen exchanger inhibitor	SLC9A1			SantaCruz	97.4	CC(C)c1ccc(cc1S(C)(=O)=O)C(=O)N=C(N)N	Phase 3
cariprazine	dopamine receptor antagonist	DRD2, DRD3	neurology/psychiatry	schizophrenia	MedChemEx, MedChemEx	98.9	CN(C)C(=O)N[C@H]1CC[C@H](CCN2CCN(CC2)c2cccc(Cl)c2Cl)CC1 |r|, CN(C)C(=O)N[C@H]1CC[C@H](CCN2CCN(CC2)c2cccc(Cl)c2Cl)CC1 |r|	Launched
carmofur	thymidylate synthase inhibitor	TYMS	oncology	breast cancer, colorectal cancer	MicroSource, Selleck, Selleck, Selleck	86.52	CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O, CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O, CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O, CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O	Launched
carmoterol	adrenergic receptor agonist	ADRB2			BidePharm	24.66	COc1ccc(C[C@@H](C)NC[C@H](O)c2ccc(O)c3[nH]c(=O)ccc23)cc1	Phase 2
carmoxirole	dopamine receptor agonist	DRD2			Tocris, Tocris, Tocris	91.82	OC(=O)c1ccc2[nH]cc(CCCCN3CCC(=CC3)c3ccccc3)c2c1 |c:17|, OC(=O)c1ccc2[nH]cc(CCCCN3CCC(=CC3)c3ccccc3)c2c1 |c:17|, OC(=O)c1ccc2[nH]cc(CCCCN3CCC(=CC3)c3ccccc3)c2c1 |c:17|	Phase 2
carmustine	DNA alkylating agent, DNA inhibitor	GSR	hematologic malignancy, oncology	non-Hodgkin lymphoma (NHL), Hodgkin's lymphoma, multiple myeloma, glioblastoma, brainstem glioma, medulloblastoma, astrocytoma, ependymoma	MicroSource, MicroSource	24.61	[O-][NH2+]N(CCCl)C(=O)NCCCl, [O-][NH2+]N(CCCl)C(=O)NCCCl	Launched
carnitine-(D/L)					MicroSource, Selleck, Selleck, Selleck	100	C[N+](C)(C)C[C@@H](O)CC(O)=O |&1:5|, C[N+](C)(C)C[C@@H](O)CC(O)=O |&1:5|, C[N+](C)(C)C[C@@H](O)CC(O)=O |&1:5|, C[N+](C)(C)C[C@@H](O)CC(O)=O |&1:5|	Phase 3
carnosine	antiglycating agent				SantaCruz	0	NCCC(=O)N[C@@H](Cc1cnc[nH]1)C(O)=O |&1:6,r|	Phase 2
caroverin	cytochrome P450 inhibitor				Sigma, AMS	92.73	CCN(CC)CCn1c2ccccc2nc(Cc2ccc(OC)cc2)c1=O, CCN(CC)CCn1c2ccccc2nc(Cc2ccc(OC)cc2)c1=O	Phase 3
caroxazone	monoamine oxidase inhibitor	MAOA, MAOB			Enamine, Enamine, Enamine	97.63	NC(=O)CN1Cc2ccccc2OC1=O, NC(=O)CN1Cc2ccccc2OC1=O, NC(=O)CN1Cc2ccccc2OC1=O	Withdrawn
carprofen	cyclooxygenase inhibitor	PTGS2	rheumatology	osteoarthritis	MicroSource, Selleck, MedChemEx	98.72	C[C@@H](C(O)=O)c1ccc2c(c1)[nH]c1ccc(Cl)cc21 |&1:1,r|, C[C@@H](C(O)=O)c1ccc2c(c1)[nH]c1ccc(Cl)cc21 |&1:1,r|, C[C@@H](C(O)=O)c1ccc2c(c1)[nH]c1ccc(Cl)cc21 |&1:1,r|	Launched
carsalam	analgesic agent				MedChemEx, MicroSource	99.02	O=c1[nH]c(=O)c2ccccc2o1, O=c1[nH]c(=O)c2ccccc2o1	Preclinical
carteolol	adrenergic receptor antagonist	ADRB1, ADRB2, ADRB3	ophthalmology	intraocular pressure, glaucoma, ocular hypertension	MedChemEx	98.62	CC(C)(C)NCC(O)COc1cccc2NC(=O)CCc12	Launched
carumonam	bacterial cell wall synthesis inhibitor		infectious disease	urinary tract infections, gram-negative bacterial infections	Sigma	97.4	NC(=O)OC[C@@H]1[C@H](NC(=O)C(=N/OCC(O)=O)\c2csc(N)n2)C(=O)N1S(O)(=O)=O	Launched
carvedilol	adrenergic receptor antagonist	ADRB1, ADRB2, ADRB3	cardiology	myocardial infarction, hypertension	Tocris, Tocris	98.37	COc1ccccc1OCCNC[C@@H](O)COc1cccc2[nH]c3ccccc3c12 |&1:13|, COc1ccccc1OCCNC[C@@H](O)COc1cccc2[nH]c3ccccc3c12 |&1:13|	Launched
carzenide		CA1, CA12, CA14, CA2, CA6, CA9			MicroSource	92.92	NS(=O)(=O)c1ccc(cc1)C(O)=O	Preclinical
casanthranol-variant			gastroenterology	constipation	MicroSource, Selleck	0	OC[C@H]1O[C@@H](Oc2c3cccc(O)c3c(O)c3c(O)cc(CO)cc23)[C@H](O)[C@H](O)[C@H]1O, OC[C@H]1O[C@@H](Oc2c3cccc(O)c3c(O)c3c(O)cc(CO)cc23)[C@H](O)[C@H](O)[C@H]1O	Launched
casin	GTPase inhibitor	CDC42			Tocris, Tocris	89.58	OCCN[C@H]1CCCc2c1[nH]c1ccc(cc21)-c1ccccc1 |&1:4,r|, OCCN[C@H]1CCCc2c1[nH]c1ccc(cc21)-c1ccccc1 |&1:4,r|	Preclinical
caspofungin	bacterial cell wall synthesis inhibitor, fungal 1,3-beta-D-glucan synthase inhibitor		infectious disease	candidemia, esophageal candidiasis, aspergillosis, peritonitis, fungal infection	MedChemEx	100	[H][C@@]12C[C@@H](O)CN1C(=O)[C@@H](NC(=O)[C@H](C[C@@H](O)[C@@H](NCCN)NC(=O)[C@@H]1[C@@H](O)CCN1C(=O)[C@@H](NC(=O)[C@@H](NC2=O)[C@H](O)[C@@H](O)c1ccc(O)cc1)[C@H](O)CCN)NC(=O)CCCCCCCC[C@@H](C)C[C@@H](C)CC)[C@@H](C)O	Launched
castanospermine	glucosidase inhibitor	GAA, GBA			Tocris, Tocris	100	O[C@H]1CCN2C[C@H](O)[C@@H](O)[C@H](O)[C@@H]12, O[C@H]1CCN2C[C@H](O)[C@@H](O)[C@H](O)[C@@H]12	Phase 2
catharanthine	tubulin polymerization inhibitor				MedChemEx, Selleck, Selleck	82.42	CCC1=C[C@@H]2CN3CCc4c([nH]c5ccccc45)[C@@](C2)([C@@H]13)C(=O)OC |t:2|, CCC1=C[C@@H]2CN3CCc4c([nH]c5ccccc45)[C@@](C2)([C@@H]13)C(=O)OC |t:2|, CCC1=C[C@@H]2CN3CCc4c([nH]c5ccccc45)[C@@](C2)([C@@H]13)C(=O)OC |t:2|	Preclinical
cathepsin-inhibitor-1	cathepsin inhibitor	CTSB, CTSL, CTSV			Selleck, Selleck	98.4	Cn1nc(cc1C(=O)N[C@@H](Cc1cccc(Cl)c1)C(=O)NCC#N)C(C)(C)C, Cn1nc(cc1C(=O)N[C@@H](Cc1cccc(Cl)c1)C(=O)NCC#N)C(C)(C)C	Preclinical
CAY10505	PI3K inhibitor	PIK3CG			MedChemEx, MedChemEx, Selleck, Selleck	92.14	Fc1ccc(cc1)-c1ccc(\C=C2\SC(=O)NC2=O)o1, Fc1ccc(cc1)-c1ccc(\C=C2\SC(=O)NC2=O)o1, Fc1ccc(cc1)-c1ccc(\C=C2\SC(=O)NC2=O)o1, Fc1ccc(cc1)-c1ccc(\C=C2\SC(=O)NC2=O)o1	Preclinical
CB-03-01	androgen receptor antagonist	AR			MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx	85.64	CCC(=O)O[C@@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(=O)CO |t:12|, CCC(=O)O[C@@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(=O)CO |t:12|, CCC(=O)O[C@@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(=O)CO |t:12|, CCC(=O)O[C@@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(=O)CO |t:12|, CCC(=O)O[C@@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(=O)CO |t:12|	Phase 3
CB-10-277	DNA synthesis inhibitor				Labotest, Vitas-M, Vitas-M	99.53	CN(C)\N=N\c1ccc(cc1)C(O)=O, CN(C)\N=N\c1ccc(cc1)C(O)=O, CN(C)\N=N\c1ccc(cc1)C(O)=O	Phase 1
CB-5083	valosin-containing protein inhibitor	VCP			MedChemEx, ApexBio, ApexBio	96.62	Cc1cc2c(cccc2n1-c1nc2CCOCc2c(NCc2ccccc2)n1)C(N)=O, Cc1cc2c(cccc2n1-c1nc2CCOCc2c(NCc2ccccc2)n1)C(N)=O, Cc1cc2c(cccc2n1-c1nc2CCOCc2c(NCc2ccccc2)n1)C(N)=O	Phase 1
CB-839	glutaminase inhibitor	GLS			Broad Institute, Broad Institute, Broad Institute, Broad Institute, MedChemEx	94.65	FC(F)(F)Oc1cccc(CC(=O)Nc2ccc(CCCCc3nnc(NC(=O)Cc4ccccn4)s3)nn2)c1, FC(F)(F)Oc1cccc(CC(=O)Nc2ccc(CCCCc3nnc(NC(=O)Cc4ccccn4)s3)nn2)c1, FC(F)(F)Oc1cccc(CC(=O)Nc2ccc(CCCCc3nnc(NC(=O)Cc4ccccn4)s3)nn2)c1, FC(F)(F)Oc1cccc(CC(=O)Nc2ccc(CCCCc3nnc(NC(=O)Cc4ccccn4)s3)nn2)c1, FC(F)(F)Oc1cccc(CC(=O)Nc2ccc(CCCCc3nnc(NC(=O)Cc4ccccn4)s3)nn2)c1	Phase 2
CBiPES	glutamate receptor positive allosteric modulator	GRM2			Tocris, Tocris, Tocris	98.08	CCS(=O)(=O)N(Cc1cccnc1)c1cccc(c1)-c1ccc(cc1)C#N, CCS(=O)(=O)N(Cc1cccnc1)c1cccc(c1)-c1ccc(cc1)C#N, CCS(=O)(=O)N(Cc1cccnc1)c1cccc(c1)-c1ccc(cc1)C#N	Preclinical
cbl0137	histone chaperone inhibitor				MedChemEx	94.17	CC(C)NCCn1c2ccc(cc2c2cc(ccc12)C(C)=O)C(C)=O	Phase 1
CBS-1114	lipoxygenase inhibitor	ALOX5			Vitas-M	50.58	NC(=NNc1ccccc1)c1ccccc1	Phase 1
CC-115	DNA protein kinase inhibitor, mTOR inhibitor	MTOR			MedChemEx, MedChemEx, MedChemEx, MedChemEx	93.43	CCN1C(=O)CN=C2NC=C(N=C12)c1ccc(nc1C)-c1nnc[nH]1 |c:9,t:6,11|, CCN1C(=O)CN=C2NC=C(N=C12)c1ccc(nc1C)-c1nnc[nH]1 |c:9,t:6,11|, CCN1C(=O)CN=C2NC=C(N=C12)c1ccc(nc1C)-c1nnc[nH]1 |c:9,t:6,11|, CCN1C(=O)CN=C2NC=C(N=C12)c1ccc(nc1C)-c1nnc[nH]1 |c:9,t:6,11|	Phase 2
CC-223	mTOR inhibitor	MTOR			MedChemEx, MedChemEx	84.46	CO[C@H]1CC[C@@H](CC1)N1C(=O)CNc2ncc(nc12)-c1ccc(nc1)C(C)(C)O |r|, CO[C@H]1CC[C@@H](CC1)N1C(=O)CNc2ncc(nc12)-c1ccc(nc1)C(C)(C)O |r|	Phase 2
CC-401	JNK inhibitor	MAPK8			Tocris	97.22	C(CN1CCCCC1)Oc1cccc(c1)-c1n[nH]c2ccc(cc12)-c1nnc[nH]1	Phase 1
CC-90003	MAP kinase inhibitor				MedChemEx	98.09	COc1cc(Nc2ncc(c(Nc3ccc(C)cc3NC(=O)C=C)n2)C(F)(F)F)c(C)cn1	Phase 1
CC-930	JNK inhibitor				MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx	94.72	O[C@H]1CC[C@@H](CC1)Nc1ncc2nc(Nc3c(F)cc(F)cc3F)n([C@H]3CCOC3)c2n1, O[C@H]1CC[C@@H](CC1)Nc1ncc2nc(Nc3c(F)cc(F)cc3F)n([C@H]3CCOC3)c2n1, O[C@H]1CC[C@@H](CC1)Nc1ncc2nc(Nc3c(F)cc(F)cc3F)n([C@H]3CCOC3)c2n1, O[C@H]1CC[C@@H](CC1)Nc1ncc2nc(Nc3c(F)cc(F)cc3F)n([C@H]3CCOC3)c2n1, O[C@H]1CC[C@@H](CC1)Nc1ncc2nc(Nc3c(F)cc(F)cc3F)n([C@H]3CCOC3)c2n1	Phase 2
CCG-1423	apoptosis stimulant	RHOC, SRF			Tocris, Tocris	94.04	C[C@@H](ONC(=O)c1cc(cc(c1)C(F)(F)F)C(F)(F)F)C(=O)Nc1ccc(Cl)cc1 |&1:1,r|, C[C@@H](ONC(=O)c1cc(cc(c1)C(F)(F)F)C(F)(F)F)C(=O)Nc1ccc(Cl)cc1 |&1:1,r|	Preclinical
CCG-50014	G protein signaling inhibitor	RGS4, RGS8			Tocris, Tocris, Selleck, Selleck, Selleck, Selleck	97.23	Cc1ccc(cc1)-n1sc(=O)n(Cc2ccc(F)cc2)c1=O, Cc1ccc(cc1)-n1sc(=O)n(Cc2ccc(F)cc2)c1=O, Cc1ccc(cc1)-n1sc(=O)n(Cc2ccc(F)cc2)c1=O, Cc1ccc(cc1)-n1sc(=O)n(Cc2ccc(F)cc2)c1=O, Cc1ccc(cc1)-n1sc(=O)n(Cc2ccc(F)cc2)c1=O, Cc1ccc(cc1)-n1sc(=O)n(Cc2ccc(F)cc2)c1=O	Preclinical
CCG-63802	G protein signaling inhibitor	RGS4			MedChemEx, MedChemEx	3.27	Cc1cccc(Oc2nc3c(C)cccn3c(=O)c2\C=C(/C#N)c2nc3ccccc3s2)c1, Cc1cccc(Oc2nc3c(C)cccn3c(=O)c2\C=C(/C#N)c2nc3ccccc3s2)c1	Preclinical
CCG-63808	G protein signaling inhibitor	RGS4			MedChemEx, MedChemEx	8.02	Cc1cccn2c1nc(Oc1ccc(F)cc1)c(\C=C(/C#N)c1nc3ccccc3s1)c2=O, Cc1cccn2c1nc(Oc1ccc(F)cc1)c(\C=C(/C#N)c1nc3ccccc3s1)c2=O	Preclinical
CCMI	acetylcholine receptor allosteric modulator	CHRNA7			Tocris, Tocris, Tocris, Tocris, Tocris	93.64	Cc1cc(on1)C(=CNc1ccc(Cl)cc1)C(=O)Nc1ccc(Cl)cc1, Cc1cc(on1)C(=CNc1ccc(Cl)cc1)C(=O)Nc1ccc(Cl)cc1, Cc1cc(on1)C(=CNc1ccc(Cl)cc1)C(=O)Nc1ccc(Cl)cc1, Cc1cc(on1)C(=CNc1ccc(Cl)cc1)C(=O)Nc1ccc(Cl)cc1, Cc1cc(on1)C(=CNc1ccc(Cl)cc1)C(=O)Nc1ccc(Cl)cc1	Preclinical
CCMQ	homoquinolinic acid binding inhibitor				Tocris, Tocris	97.59	OC(=O)Cc1cc2ccccc2nc1C(O)=O, OC(=O)Cc1cc2ccccc2nc1C(O)=O	Preclinical
CCT-031374	WNT signaling inhibitor	CTNNB1			Tocris, Tocris	97.42	O=C(CN1C2=NCCN2c2ccccc12)c1ccc(cc1)-c1ccccc1 |t:4|, O=C(CN1C2=NCCN2c2ccccc12)c1ccc(cc1)-c1ccccc1 |t:4|	Preclinical
CCT018159	HSP inhibitor	HSP90AA1, HSP90AB1			Tocris, Tocris, Tocris	97.39	CCc1cc(-c2n[nH]c(C)c2-c2ccc3OCCOc3c2)c(O)cc1O, CCc1cc(-c2n[nH]c(C)c2-c2ccc3OCCOc3c2)c(O)cc1O, CCc1cc(-c2n[nH]c(C)c2-c2ccc3OCCOc3c2)c(O)cc1O	Preclinical
CCT128930	AKT inhibitor				Selleck, Selleck, Selleck, Selleck, MedChemEx	96.82	NC1(Cc2ccc(Cl)cc2)CCN(CC1)c1ncnc2[nH]ccc12, NC1(Cc2ccc(Cl)cc2)CCN(CC1)c1ncnc2[nH]ccc12, NC1(Cc2ccc(Cl)cc2)CCN(CC1)c1ncnc2[nH]ccc12, NC1(Cc2ccc(Cl)cc2)CCN(CC1)c1ncnc2[nH]ccc12, NC1(Cc2ccc(Cl)cc2)CCN(CC1)c1ncnc2[nH]ccc12	Preclinical
CCT129202	Aurora kinase inhibitor	AURKA, AURKB, AURKC			Selleck, Selleck, MedChemEx	92.03	CN(C)c1ccc(cc1)-c1nc2ncc(Cl)c(N3CCN(CC(=O)Nc4nccs4)CC3)c2[nH]1, CN(C)c1ccc(cc1)-c1nc2ncc(Cl)c(N3CCN(CC(=O)Nc4nccs4)CC3)c2[nH]1, CN(C)c1ccc(cc1)-c1nc2ncc(Cl)c(N3CCN(CC(=O)Nc4nccs4)CC3)c2[nH]1	Preclinical
CCT137690	Aurora kinase inhibitor	AURKA, AURKB, AURKC			Selleck, Selleck, Tocris, Tocris	97.74	CN1CCN(CC1)c1ccc(cc1)-c1nc2ncc(Br)c(N3CCN(Cc4cc(C)on4)CC3)c2[nH]1, CN1CCN(CC1)c1ccc(cc1)-c1nc2ncc(Br)c(N3CCN(Cc4cc(C)on4)CC3)c2[nH]1, CN1CCN(CC1)c1ccc(cc1)-c1nc2ncc(Br)c(N3CCN(Cc4cc(C)on4)CC3)c2[nH]1, CN1CCN(CC1)c1ccc(cc1)-c1nc2ncc(Br)c(N3CCN(Cc4cc(C)on4)CC3)c2[nH]1	Preclinical
CCT196969	RAF inhibitor				MedChemEx, MedChemEx	90.52	CC(C)(C)c1cc(NC(=O)Nc2ccc(Oc3ccnc4nc(O)cnc34)cc2F)n(n1)-c1ccccc1, CC(C)(C)c1cc(NC(=O)Nc2ccc(Oc3ccnc4nc(O)cnc34)cc2F)n(n1)-c1ccccc1	Preclinical
CCT245737	kinase inhibitor				MedChemEx	89.88	FC(F)(F)c1cnc(Nc2cnc(cn2)C#N)cc1NC[C@H]1CNCCO1	Preclinical
CC4	nicotinic receptor agonist	CHRNB2			Tocris, Tocris	89.23	O=c1cccc2[C@@H]3C[C@@H](CN(CCN4C[C@@H]5C[C@H](C4)c4cccc(=O)n4C5)C3)Cn12, O=c1cccc2[C@@H]3C[C@@H](CN(CCN4C[C@@H]5C[C@H](C4)c4cccc(=O)n4C5)C3)Cn12	Preclinical
CD-1530	retinoid receptor agonist	RARG			Tocris, Tocris, Tocris, Tocris, Tocris, Tocris	93.52	OC(=O)c1ccc(cc1)-c1ccc2cc(O)c(cc2c1)C12CC3CC(CC(C3)C1)C2, OC(=O)c1ccc(cc1)-c1ccc2cc(O)c(cc2c1)C12CC3CC(CC(C3)C1)C2, OC(=O)c1ccc(cc1)-c1ccc2cc(O)c(cc2c1)C12CC3CC(CC(C3)C1)C2, OC(=O)c1ccc(cc1)-c1ccc2cc(O)c(cc2c1)C12CC3CC(CC(C3)C1)C2, OC(=O)c1ccc(cc1)-c1ccc2cc(O)c(cc2c1)C12CC3CC(CC(C3)C1)C2, OC(=O)c1ccc(cc1)-c1ccc2cc(O)c(cc2c1)C12CC3CC(CC(C3)C1)C2	Preclinical
CD-437	retinoid receptor agonist	RARG			Tocris, Tocris, Tocris, Tocris, Tocris, Tocris, Tocris	96.59	OC(=O)c1ccc2cc(ccc2c1)-c1ccc(O)c(c1)C12CC3CC(CC(C3)C1)C2, OC(=O)c1ccc2cc(ccc2c1)-c1ccc(O)c(c1)C12CC3CC(CC(C3)C1)C2, OC(=O)c1ccc2cc(ccc2c1)-c1ccc(O)c(c1)C12CC3CC(CC(C3)C1)C2, OC(=O)c1ccc2cc(ccc2c1)-c1ccc(O)c(c1)C12CC3CC(CC(C3)C1)C2, OC(=O)c1ccc2cc(ccc2c1)-c1ccc(O)c(c1)C12CC3CC(CC(C3)C1)C2, OC(=O)c1ccc2cc(ccc2c1)-c1ccc(O)c(c1)C12CC3CC(CC(C3)C1)C2, OC(=O)c1ccc2cc(ccc2c1)-c1ccc(O)c(c1)C12CC3CC(CC(C3)C1)C2	Preclinical
CDBA					EMDBio, EMDBio, EMDBio	97.04	OC[C@H]1O[C@H]2O[C@H]3[C@@H](CO)O[C@@H](O[C@H]4[C@@H](CO)O[C@@H](O[C@H]5[C@@H](CO)O[C@@H](O[C@H]6[C@@H](CO)O[C@@H](O[C@H]7[C@@H](CO)O[C@@H](O[C@H]8[C@@H](CO)O[C@@H](O[C@@H]1[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]8O)[C@@H](O)[C@@H]7O)[C@@H](O)[C@@H]6O)[C@@H](O)[C@@H]5O)[C@@H](O)[C@@H]4O)[C@@H](O)[C@@H]3O |&1:2,&2:4,&3:6,&4:7,&5:11,&6:13,&7:14,&8:18,&9:20,&10:21,&11:25,&12:27,&13:28,&14:32,&15:34,&16:35,&17:39,&18:41,&19:42,&20:46,&21:48,&22:49,&23:51,&24:53,&25:55,&26:57,&27:59,&28:61,&29:63,&30:65,&31:67,&32:69,&33:71,&34:73,&35:75,r|, OC[C@H]1O[C@H]2O[C@H]3[C@@H](CO)O[C@@H](O[C@H]4[C@@H](CO)O[C@@H](O[C@H]5[C@@H](CO)O[C@@H](O[C@H]6[C@@H](CO)O[C@@H](O[C@H]7[C@@H](CO)O[C@@H](O[C@H]8[C@@H](CO)O[C@@H](O[C@@H]1[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]8O)[C@@H](O)[C@@H]7O)[C@@H](O)[C@@H]6O)[C@@H](O)[C@@H]5O)[C@@H](O)[C@@H]4O)[C@@H](O)[C@@H]3O |&1:2,&2:4,&3:6,&4:7,&5:11,&6:13,&7:14,&8:18,&9:20,&10:21,&11:25,&12:27,&13:28,&14:32,&15:34,&16:35,&17:39,&18:41,&19:42,&20:46,&21:48,&22:49,&23:51,&24:53,&25:55,&26:57,&27:59,&28:61,&29:63,&30:65,&31:67,&32:69,&33:71,&34:73,&35:75,r|, OC[C@H]1O[C@H]2O[C@H]3[C@@H](CO)O[C@@H](O[C@H]4[C@@H](CO)O[C@@H](O[C@H]5[C@@H](CO)O[C@@H](O[C@H]6[C@@H](CO)O[C@@H](O[C@H]7[C@@H](CO)O[C@@H](O[C@H]8[C@@H](CO)O[C@@H](O[C@@H]1[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]8O)[C@@H](O)[C@@H]7O)[C@@H](O)[C@@H]6O)[C@@H](O)[C@@H]5O)[C@@H](O)[C@@H]4O)[C@@H](O)[C@@H]3O |&1:2,&2:4,&3:6,&4:7,&5:11,&6:13,&7:14,&8:18,&9:20,&10:21,&11:25,&12:27,&13:28,&14:32,&15:34,&16:35,&17:39,&18:41,&19:42,&20:46,&21:48,&22:49,&23:51,&24:53,&25:55,&26:57,&27:59,&28:61,&29:63,&30:65,&31:67,&32:69,&33:71,&34:73,&35:75,r|	Phase 3
CDK1-5-inhibitor	CDK inhibitor, glycogen synthase kinase inhibitor	CDK1, CDK5, GSK3B			Tocris, Tocris, Tocris, Tocris	97.23	Nc1[nH]nc2nc3ccccc3nc12, Nc1[nH]nc2nc3ccccc3nc12, Nc1[nH]nc2nc3ccccc3nc12, Nc1[nH]nc2nc3ccccc3nc12	Preclinical
CDK9-IN-6	CDK inhibitor	CDK9			MedChemEx, MedChemEx, MedChemEx	96.73	COC[C@H](C)N[C@H]1CC[C@@H](CC1)Nc1cc(c(Cl)cn1)-c1cccc(NCC2(CCOCC2)C#N)n1, COC[C@H](C)N[C@H]1CC[C@@H](CC1)Nc1cc(c(Cl)cn1)-c1cccc(NCC2(CCOCC2)C#N)n1, COC[C@H](C)N[C@H]1CC[C@@H](CC1)Nc1cc(c(Cl)cn1)-c1cccc(NCC2(CCOCC2)C#N)n1	Preclinical
CDPPB	glutamate receptor positive allosteric modulator	GRM5			Tocris, Tocris	96.95	O=C(Nc1cc(nn1-c1ccccc1)-c1ccccc1)c1cccc(c1)C#N, O=C(Nc1cc(nn1-c1ccccc1)-c1ccccc1)c1cccc(c1)C#N	Preclinical
cebranopadol	opioid receptor agonist	OPRL1, OPRM1			MedChemEx, MedChemEx, MedChemEx	95.64	CN(C)[C@]1(CC[C@@]2(CC1)OCCc1c2[nH]c2ccc(F)cc12)c1ccccc1 |r|, CN(C)[C@]1(CC[C@@]2(CC1)OCCc1c2[nH]c2ccc(F)cc12)c1ccccc1 |r|, CN(C)[C@]1(CC[C@@]2(CC1)OCCc1c2[nH]c2ccc(F)cc12)c1ccccc1 |r|	Phase 3
cediranib	KIT inhibitor, VEGFR inhibitor	CSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRA, PDGFRB			MedChemEx, Selleck, Selleck, Selleck, Selleck	96.62	COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1, COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1, COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1, COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1, COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1	Phase 3
cedrol					Vitas-M	0	C[C@H]1CC[C@H]2C(C)(C)[C@H]3C[C@@]12CC[C@@]3(C)O |&1:1,&2:4,&3:8,&4:10,&5:13,r|	Phase 2
cedrol-(+)	sedative				Sigma, Vitas-M	0	C[C@@H]1CC[C@H]2C(C)(C)[C@H]3C[C@@]12CC[C@@]3(C)O, C[C@@H]1CC[C@H]2C(C)(C)[C@H]3C[C@@]12CC[C@@]3(C)O	Phase 2
cefaclor	bacterial cell wall synthesis inhibitor		infectious disease, otolaryngology	pneumonia, skin infections, urinary tract infections, respiratory tract infections, tonsillitis, pharyngitis	MedChemEx, Selleck, MicroSource, Selleck	89.07	N[C@@H](C(=O)N[C@H]1[C@H]2SCC(Cl)=C(N2C1=O)C(O)=O)c1ccccc1 |c:10|, N[C@@H](C(=O)N[C@H]1[C@H]2SCC(Cl)=C(N2C1=O)C(O)=O)c1ccccc1 |c:10|, N[C@@H](C(=O)N[C@H]1[C@H]2SCC(Cl)=C(N2C1=O)C(O)=O)c1ccccc1 |c:10|, N[C@@H](C(=O)N[C@H]1[C@H]2SCC(Cl)=C(N2C1=O)C(O)=O)c1ccccc1 |c:10|	Launched
cefadroxil	bacterial cell wall synthesis inhibitor	SLC15A1, SLC15A2, SLC22A6, SLC22A8	infectious disease, otolaryngology	urinary tract infections, skin infections, tonsillitis, pharyngitis	MedChemEx	70	CC1=C(N2[C@H](SC1)[C@H](NC(=O)[C@H](N)c1ccc(O)cc1)C2=O)C(O)=O |t:1|	Launched
cefalonium	bacterial cell wall synthesis inhibitor		infectious disease	gram-positive bacterial infections	MicroSource, Toronto	58.98	NC(=O)c1cc[n+](CC2=C(N3[C@H](SC2)[C@H](NC(=O)Cc2cccs2)C3=O)C(O)=O)cc1 |t:8|, NC(=O)c1cc[n+](CC2=C(N3[C@H](SC2)[C@H](NC(=O)Cc2cccs2)C3=O)C(O)=O)cc1 |t:8|	Launched
cefamandole	bacterial cell wall synthesis inhibitor		infectious disease	skin infections, urinary tract infections, respiratory tract infections	Sigma, MicroSource	32.02	Cn1nnnc1SCC1=C(N2[C@H](SC1)[C@H](NC(=O)[C@H](O)c1ccccc1)C2=O)C(O)=O |t:9|, Cn1nnnc1SCC1=C(N2[C@H](SC1)[C@H](NC(=O)[C@H](O)c1ccccc1)C2=O)C(O)=O |t:9|	Launched
cefamandole-nafate	bacterial cell wall synthesis inhibitor		infectious disease	skin infections, urinary tract infections, respiratory tract infections	MedChemEx, MedChemEx, MicroSource	43.32	Cn1nnnc1SCC1=C(N2[C@H](SC1)[C@H](NC(=O)[C@H](OC=O)c1ccccc1)C2=O)C(O)=O |t:9|, Cn1nnnc1SCC1=C(N2[C@H](SC1)[C@H](NC(=O)[C@H](OC=O)c1ccccc1)C2=O)C(O)=O |t:9|, Cn1nnnc1SCC1=C(N2[C@H](SC1)[C@H](NC(=O)[C@H](OC=O)c1ccccc1)C2=O)C(O)=O |t:9|	Launched
cefathiamidine	bacterial cell wall synthesis inhibitor		infectious disease	gram-positive bacterial infections	AKSci	68.39	CC(C)N\C(SCC(=O)N[C@H]1[C@H]2SCC(COC(C)=O)=C(N2C1=O)C(O)=O)=N/C(C)C |c:19|	Launched
cefazolin	bacterial cell wall synthesis inhibitor	PON1	infectious disease	urinary tract infections, skin infections, bacterial septicemia, endocarditis, surgical prophylaxis, bone and joint infections	MedChemEx, MicroSource, MedChemEx	87.37	Cc1nnc(SCC2=C(N3[C@H](SC2)[C@H](NC(=O)Cn2cnnn2)C3=O)C(O)=O)s1 |t:7|, Cc1nnc(SCC2=C(N3[C@H](SC2)[C@H](NC(=O)Cn2cnnn2)C3=O)C(O)=O)s1 |t:7|, Cc1nnc(SCC2=C(N3[C@H](SC2)[C@H](NC(=O)Cn2cnnn2)C3=O)C(O)=O)s1 |t:7|	Launched
cefcapene-pivoxil	bacterial cell wall synthesis inhibitor		infectious disease	skin infections, pneumonia, urinary tract infections	Sigma, Sigma, Astatech, AKSci	90.61	CC\C=C(/C(=O)N[C@H]1[C@H]2SCC(COC(N)=O)=C(N2C1=O)C(=O)OCOC(=O)C(C)(C)C)c1csc(N)n1 |c:16|, CC\C=C(/C(=O)N[C@H]1[C@H]2SCC(COC(N)=O)=C(N2C1=O)C(=O)OCOC(=O)C(C)(C)C)c1csc(N)n1 |c:16|, CC\C=C(/C(=O)N[C@H]1[C@H]2SCC(COC(N)=O)=C(N2C1=O)C(=O)OCOC(=O)C(C)(C)C)c1csc(N)n1 |c:16|, CC\C=C(/C(=O)N[C@H]1[C@H]2SCC(COC(N)=O)=C(N2C1=O)C(=O)OCOC(=O)C(C)(C)C)c1csc(N)n1 |c:16|	Launched
cefdinir	bacterial cell wall synthesis inhibitor	MPO	infectious disease, otolaryngology, pulmonary	pneumonia, tonsillitis, pharyngitis, bronchitis, skin infections, otitis, sinusitis	MicroSource, MicroSource, Selleck, Selleck	87.42	Nc1nc(cs1)C(=N\O)\C(=O)N[C@H]1[C@H]2SCC(C=C)=C(N2C1=O)C(O)=O |c:19|, Nc1nc(cs1)C(=N\O)\C(=O)N[C@H]1[C@H]2SCC(C=C)=C(N2C1=O)C(O)=O |c:19|, Nc1nc(cs1)C(=N\O)\C(=O)N[C@H]1[C@H]2SCC(C=C)=C(N2C1=O)C(O)=O |c:19|, Nc1nc(cs1)C(=N\O)\C(=O)N[C@H]1[C@H]2SCC(C=C)=C(N2C1=O)C(O)=O |c:19|	Launched
cefditoren-pivoxil	bacterial cell wall synthesis inhibitor		infectious disease, pulmonary, otolaryngology	pneumonia, bronchitis, skin infections, tonsillitis, pharyngitis	MicroSource, Selleck, Selleck, MedChemEx	90.31	CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(\C=C/c3scnc3C)=C(N2C1=O)C(=O)OCOC(=O)C(C)(C)C)c1csc(N)n1 |c:20|, CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(\C=C/c3scnc3C)=C(N2C1=O)C(=O)OCOC(=O)C(C)(C)C)c1csc(N)n1 |c:20|, CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(\C=C/c3scnc3C)=C(N2C1=O)C(=O)OCOC(=O)C(C)(C)C)c1csc(N)n1 |c:20|, CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(\C=C/c3scnc3C)=C(N2C1=O)C(=O)OCOC(=O)C(C)(C)C)c1csc(N)n1 |c:20|	Launched
cefepime	bacterial cell wall synthesis inhibitor		infectious disease	pneumonia, urinary tract infections, skin infections, intra-abdominal infections	MicroSource	96.32	CO\N=C(\C(=O)N[C@H]1[C@H]2SCC(C[N+]3(C)CCCC3)=C(N2C1=O)C(O)=O)c1csc(N)n1 |&1:7,&2:8,c:19|	Launched
cefetamet	bacterial cell wall synthesis inhibitor		infectious disease, otolaryngology, pulmonary	ear infections, pneumonia, otitis, sinusitis, bronchitis, urinary tract infections	Sigma, Sigma	94.12	CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(C)=C(N2C1=O)C(O)=O)c1csc(N)n1 |c:12|, CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(C)=C(N2C1=O)C(O)=O)c1csc(N)n1 |c:12|	Launched
cefetamet-pivoxil	bacterial cell wall synthesis inhibitor		infectious disease	gram-positive bacterial infections	AvaChem, AKSci, MedChemEx	87.11	CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(C)=C(N2C1=O)C(=O)OCOC(=O)C(C)(C)C)c1csc(N)n1 |c:12|, CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(C)=C(N2C1=O)C(=O)OCOC(=O)C(C)(C)C)c1csc(N)n1 |c:12|, CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(C)=C(N2C1=O)C(=O)OCOC(=O)C(C)(C)C)c1csc(N)n1 |c:12|	Launched
cefiderocol	antibacterial 				MedChemEx	62.5	[H][C@]12SCC(C[N+]3(CCNC(=O)c4ccc(O)c(O)c4Cl)CCCC3)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC(C)(C)C(O)=O)\c1csc(N)n1)C(O)=O |c:26|	Launched
cefixime	bacterial cell wall synthesis inhibitor		infectious disease, otolaryngology, pulmonary	urinary tract infections, otitis, pharyngitis, tonsillitis, gonorrhea, bronchitis	Sigma, Enzo, MedChemEx	93.65	Nc1nc(cs1)C(=N\OCC(O)=O)\C(=O)N[C@H]1[C@H]2SCC(C=C)=C(N2C1=O)C(O)=O |c:23|, Nc1nc(cs1)C(=N\OCC(O)=O)\C(=O)N[C@H]1[C@H]2SCC(C=C)=C(N2C1=O)C(O)=O |c:23|, Nc1nc(cs1)C(=N\OCC(O)=O)\C(=O)N[C@H]1[C@H]2SCC(C=C)=C(N2C1=O)C(O)=O |c:23|	Launched
cefmenoxime	bacterial cell wall synthesis inhibitor		infectious disease	gram-negative bacterial infections	MedChemEx	90.8	[H][C@]12SCC(CSc3nnnn3C)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\c1csc(N)n1)C(O)=O |c:13|	Launched
cefmetazole	bacterial cell wall synthesis inhibitor		infectious disease	urinary tract infections, skin infections	MedChemEx, MedChemEx, MicroSource	89.48	CO[C@]1(NC(=O)CSCC#N)[C@H]2SCC(CSc3nnnn3C)=C(N2C1=O)C(O)=O |c:23|, CO[C@]1(NC(=O)CSCC#N)[C@H]2SCC(CSc3nnnn3C)=C(N2C1=O)C(O)=O |c:23|, CO[C@]1(NC(=O)CSCC#N)[C@H]2SCC(CSc3nnnn3C)=C(N2C1=O)C(O)=O |c:23|	Launched
cefminox	bacterial cell wall synthesis inhibitor		infectious disease	gram-negative bacterial infections	Key, Toronto	83.7	CO[C@]1(NC(=O)CSC[C@@H](N)C(O)=O)[C@H]2SCC(CSc3nnnn3C)=C(N2C1=O)C(O)=O |c:26|, CO[C@]1(NC(=O)CSC[C@@H](N)C(O)=O)[C@H]2SCC(CSc3nnnn3C)=C(N2C1=O)C(O)=O |c:26|	Launched
cefodizime	bacterial cell wall synthesis inhibitor		infectious disease	respiratory tract infections, skin infections, gonorrhea	Kemprotec, Kemprotec, AKSci	73.75	CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(CSc3nc(C)c(CC(O)=O)s3)=C(N2C1=O)C(O)=O)c1csc(N)n1 |c:24|, CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(CSc3nc(C)c(CC(O)=O)s3)=C(N2C1=O)C(O)=O)c1csc(N)n1 |c:24|, CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(CSc3nc(C)c(CC(O)=O)s3)=C(N2C1=O)C(O)=O)c1csc(N)n1 |c:24|	Launched
cefonicid	bacterial cell wall synthesis inhibitor		infectious disease	gram-positive bacterial infections	MicroSource, MedChemEx, MedChemEx	83.1	O[C@@H](C(=O)N[C@H]1[C@H]2SCC(CSc3nnnn3CS(O)(=O)=O)=C(N2C1=O)C(O)=O)c1ccccc1 |c:22|, O[C@@H](C(=O)N[C@H]1[C@H]2SCC(CSc3nnnn3CS(O)(=O)=O)=C(N2C1=O)C(O)=O)c1ccccc1 |c:22|, O[C@@H](C(=O)N[C@H]1[C@H]2SCC(CSc3nnnn3CS(O)(=O)=O)=C(N2C1=O)C(O)=O)c1ccccc1 |c:22|	Launched
cefoperazone	bacterial cell wall synthesis inhibitor		infectious disease	gram-negative bacterial infections	MedChemEx, MicroSource, Selleck	97.29	CCN1CCN(C(=O)N[C@@H](C(=O)N[C@H]2[C@H]3SCC(CSc4nnnn4C)=C(N3C2=O)C(O)=O)c2ccc(O)cc2)C(=O)C1=O |c:26|, CCN1CCN(C(=O)N[C@@H](C(=O)N[C@H]2[C@H]3SCC(CSc4nnnn4C)=C(N3C2=O)C(O)=O)c2ccc(O)cc2)C(=O)C1=O |c:26|, CCN1CCN(C(=O)N[C@@H](C(=O)N[C@H]2[C@H]3SCC(CSc4nnnn4C)=C(N3C2=O)C(O)=O)c2ccc(O)cc2)C(=O)C1=O |c:26|	Launched
ceforanide	penicillin binding protein inhibitor		infectious disease	gram-negative bacterial infections	MicroSource, AvaChem, AvaChem	90.8	NCc1ccccc1CC(=O)N[C@H]1[C@H]2SCC(CSc3nnnn3CC(O)=O)=C(N2C1=O)C(O)=O |c:29|, NCc1ccccc1CC(=O)N[C@H]1[C@H]2SCC(CSc3nnnn3CC(O)=O)=C(N2C1=O)C(O)=O |c:29|, NCc1ccccc1CC(=O)N[C@H]1[C@H]2SCC(CSc3nnnn3CC(O)=O)=C(N2C1=O)C(O)=O |c:29|	Launched
cefoselis	bacterial cell wall synthesis inhibitor		infectious disease	gram-negative bacterial infections, gram-positive bacterial infections	Selleck, MedChemEx, AKSci, Selleck	99.54	CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(Cn3ccc(=N)n3CCO)=C(N2C1=O)C(O)=O)c1csc(N)n1 |c:22|, CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(Cn3ccc(=N)n3CCO)=C(N2C1=O)C(O)=O)c1csc(N)n1 |c:22|, CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(Cn3ccc(=N)n3CCO)=C(N2C1=O)C(O)=O)c1csc(N)n1 |c:22|, CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(Cn3ccc(=N)n3CCO)=C(N2C1=O)C(O)=O)c1csc(N)n1 |c:22|	Launched
cefotaxime	bacterial cell wall synthesis inhibitor		infectious disease	respiratory tract infections, bone and joint infections, pelvic inflammatory disease, intra-abdominal infections, skin infections, meningitis, urinary tract infections, bacterial septicemia, gynecologic infections	MedChemEx, MicroSource, MedChemEx, Sigma	95.77	CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(COC(C)=O)=C(N2C1=O)C(O)=O)c1csc(N)n1 |c:16|, CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(COC(C)=O)=C(N2C1=O)C(O)=O)c1csc(N)n1 |c:16|, CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(COC(C)=O)=C(N2C1=O)C(O)=O)c1csc(N)n1 |c:16|, CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(COC(C)=O)=C(N2C1=O)C(O)=O)c1csc(N)n1 |c:16|	Launched
cefotetan	bacterial cell wall synthesis inhibitor		infectious disease	urinary tract infections, respiratory tract infections, skin infections, gynecologic infections, chlamydia, intra-abdominal infections, bone and joint infections, surgical prophylaxis	MicroSource, MicroSource	88.4	CO[C@]1(NC(=O)C2SC(S2)=C(C(N)=O)C(O)=O)[C@H]2SCC(CSc3nnnn3C)=C(N2C1=O)C(O)=O |a:2,&1:17,c:30|, CO[C@]1(NC(=O)C2SC(S2)=C(C(N)=O)C(O)=O)[C@H]2SCC(CSc3nnnn3C)=C(N2C1=O)C(O)=O |a:2,&1:17,c:30|	Launched
cefotiam	bacterial cell wall synthesis inhibitor		infectious disease	bacterial septicemia, bone and joint infections, respiratory tract infections, skin infections, urinary tract infections	Prestwick, MedChemEx	88.63	CN(C)CCn1nnnc1SCC1=C(N2[C@H](SC1)[C@H](NC(=O)Cc1csc(N)n1)C2=O)C(O)=O |t:13|, CN(C)CCn1nnnc1SCC1=C(N2[C@H](SC1)[C@H](NC(=O)Cc1csc(N)n1)C2=O)C(O)=O |t:13|	Launched
cefotiam-cilexetil	bacterial cell wall synthesis inhibitor		infectious disease	gram-negative bacterial infections, gram-positive bacterial infections	SantaCruz, SantaCruz	23.99	C[C@@H](OC(=O)OC1CCCCC1)OC(=O)C1=C(CSc2nnnn2CCN(C)C)CS[C@H]2[C@@H](NC(=O)Cc3csc(N)n3)C(=O)N12 |&1:1,&2:31,&3:32,c:16|, C[C@@H](OC(=O)OC1CCCCC1)OC(=O)C1=C(CSc2nnnn2CCN(C)C)CS[C@H]2[C@@H](NC(=O)Cc3csc(N)n3)C(=O)N12 |&1:1,&2:31,&3:32,c:16|	Launched
cefoxitin	bacterial cell wall synthesis inhibitor		infectious disease	respiratory tract infections, urinary tract infections, intra-abdominal infections, gynecologic infections, bacterial septicemia, bone and joint infections, skin infections	MedChemEx, MicroSource, MedChemEx, MedChemEx	98.36	CO[C@]1(NC(=O)Cc2cccs2)[C@H]2SCC(COC(N)=O)=C(N2C1=O)C(O)=O |c:21|, CO[C@]1(NC(=O)Cc2cccs2)[C@H]2SCC(COC(N)=O)=C(N2C1=O)C(O)=O |c:21|, CO[C@]1(NC(=O)Cc2cccs2)[C@H]2SCC(COC(N)=O)=C(N2C1=O)C(O)=O |c:21|, CO[C@]1(NC(=O)Cc2cccs2)[C@H]2SCC(COC(N)=O)=C(N2C1=O)C(O)=O |c:21|	Launched
cefozopran	bacterial cell wall synthesis inhibitor		infectious disease	gram-negative bacterial infections, gram-positive bacterial infections	MedChemEx, MedChemEx, MedChemEx	90.83	CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(C[n+]3ccn4ncccc34)=C(N2C1=O)C(O)=O)c1nsc(N)n1 |c:23|, CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(C[n+]3ccn4ncccc34)=C(N2C1=O)C(O)=O)c1nsc(N)n1 |c:23|, CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(C[n+]3ccn4ncccc34)=C(N2C1=O)C(O)=O)c1nsc(N)n1 |c:23|	Launched
cefpiramide	bacterial cell wall synthesis inhibitor		infectious disease	gram-negative bacterial infections	MicroSource, Sigma, MedChemEx	86.38	Cc1cc(=O)c(c[nH]1)C(=O)N[C@@H](C(=O)N[C@H]1[C@H]2SCC(CSc3nnnn3C)=C(N2C1=O)C(O)=O)c1ccc(O)cc1 |c:29|, Cc1cc(=O)c(c[nH]1)C(=O)N[C@@H](C(=O)N[C@H]1[C@H]2SCC(CSc3nnnn3C)=C(N2C1=O)C(O)=O)c1ccc(O)cc1 |c:29|, Cc1cc(=O)c(c[nH]1)C(=O)N[C@@H](C(=O)N[C@H]1[C@H]2SCC(CSc3nnnn3C)=C(N2C1=O)C(O)=O)c1ccc(O)cc1 |c:29|	Launched
cefpirome	bacterial cell wall synthesis inhibitor		infectious disease	gram-negative bacterial infections	ChemImpex, ChemImpex, ChemImpex	91.01	CO\N=C(\C(=O)N[C@H]1[C@H]2SCC(C[n+]3cccc4CCCc34)=C(N2C1=O)C(O)=O)c1csc(N)n1 |c:23|, CO\N=C(\C(=O)N[C@H]1[C@H]2SCC(C[n+]3cccc4CCCc34)=C(N2C1=O)C(O)=O)c1csc(N)n1 |c:23|, CO\N=C(\C(=O)N[C@H]1[C@H]2SCC(C[n+]3cccc4CCCc34)=C(N2C1=O)C(O)=O)c1csc(N)n1 |c:23|	Launched
cefpodoxime	bacterial cell wall synthesis inhibitor		otolaryngology, infectious disease, pulmonary	pharyngitis, pneumonia, bronchitis, gonorrhea, skin infections, urinary tract infections, sinusitis, tonsillitis	Key, Key, MicroSource	49.13	COCC1=C(N2[C@H](SC1)[C@H](NC(=O)C(=N/OC)\c1csc(N)n1)C2=O)C(=O)O[C@@H](C)OC(=O)OC(C)C |a:6,9,&1:28,t:3|, COCC1=C(N2[C@H](SC1)[C@H](NC(=O)C(=N/OC)\c1csc(N)n1)C2=O)C(=O)O[C@@H](C)OC(=O)OC(C)C |a:6,9,&1:28,t:3|, COCC1=C(N2[C@H](SC1)[C@H](NC(=O)C(=N/OC)\c1csc(N)n1)C2=O)C(=O)O[C@@H](C)OC(=O)OC(C)C |a:6,9,&1:28,t:3|	Launched
cefprozil	bacterial cell wall synthesis inhibitor		otolaryngology, infectious disease, pulmonary	pharyngitis, tonsillitis, otitis, sinusitis, respiratory tract infections, skin infections, bronchitis	MicroSource, Selleck, MedChemEx, MedChemEx, Selleck	76.4	C\C=C\C1=C(N2[C@H](SC1)[C@H](NC(=O)[C@H](N)c1ccc(O)cc1)C2=O)C(O)=O |t:3|, C\C=C\C1=C(N2[C@H](SC1)[C@H](NC(=O)[C@H](N)c1ccc(O)cc1)C2=O)C(O)=O |t:3|, C\C=C\C1=C(N2[C@H](SC1)[C@H](NC(=O)[C@H](N)c1ccc(O)cc1)C2=O)C(O)=O |t:3|, C\C=C\C1=C(N2[C@H](SC1)[C@H](NC(=O)[C@H](N)c1ccc(O)cc1)C2=O)C(O)=O |t:3|, C\C=C\C1=C(N2[C@H](SC1)[C@H](NC(=O)[C@H](N)c1ccc(O)cc1)C2=O)C(O)=O |t:3|	Launched
cefradine	bacterial cell wall synthesis inhibitor	CYP3A4	infectious disease, otolaryngology	respiratory tract infections, otitis, skin infections, urinary tract infections, tonsillitis, pharyngitis, pneumonia	MedChemEx, MedChemEx, MedChemEx	65.46	CC1=C(N2[C@H](SC1)[C@H](NC(=O)[C@H](N)C1=CCC=CC1)C2=O)C(O)=O |c:17,t:1,14|, CC1=C(N2[C@H](SC1)[C@H](NC(=O)[C@H](N)C1=CCC=CC1)C2=O)C(O)=O |c:17,t:1,14|, CC1=C(N2[C@H](SC1)[C@H](NC(=O)[C@H](N)C1=CCC=CC1)C2=O)C(O)=O |c:17,t:1,14|	Launched
cefsulodin	bacterial cell wall synthesis inhibitor		infectious disease	gram-negative bacterial infections	MedChemEx, MedChemEx, Sigma, MicroSource	29.68	NC(=O)c1cc[n+](CC2=C(N3[C@H](SC2)[C@H](NC(=O)[C@@H](c2ccccc2)S(O)(=O)=O)C3=O)C(O)=O)cc1 |t:8|, NC(=O)c1cc[n+](CC2=C(N3[C@H](SC2)[C@H](NC(=O)[C@@H](c2ccccc2)S(O)(=O)=O)C3=O)C(O)=O)cc1 |t:8|, NC(=O)c1cc[n+](CC2=C(N3[C@H](SC2)[C@H](NC(=O)[C@@H](c2ccccc2)S(O)(=O)=O)C3=O)C(O)=O)cc1 |t:8|, NC(=O)c1cc[n+](CC2=C(N3[C@H](SC2)[C@H](NC(=O)[C@@H](c2ccccc2)S(O)(=O)=O)C3=O)C(O)=O)cc1 |t:8|	Launched
ceftaroline-fosamil	bacterial cell wall synthesis inhibitor		infectious disease	skin infections, pneumonia	GLSyntech	63.93	CCO\N=C(\C(=O)N[C@H]1[C@H]2SCC(Sc3nc(cs3)-c3cc[n+](C)cc3)=C(N2C1=O)C(O)=O)c1nc(=NP(O)(O)=O)s[nH]1 |c:27|	Launched
ceftazidime	bacterial cell wall synthesis inhibitor		infectious disease	respiratory tract infections, skin infections, bacterial septicemia, bone and joint infections, gynecologic infections, intra-abdominal infections, meningitis	Sigma, MedChemEx, MicroSource, MedChemEx, Selleck	78.15	CC(C)(O\N=C(/C(=O)N[C@H]1[C@H]2SCC(C[n+]3ccccc3)=C(N2C1=O)C(O)=O)c1csc(N)n1)C(O)=O |c:21|, CC(C)(O\N=C(/C(=O)N[C@H]1[C@H]2SCC(C[n+]3ccccc3)=C(N2C1=O)C(O)=O)c1csc(N)n1)C(O)=O |c:21|, CC(C)(O\N=C(/C(=O)N[C@H]1[C@H]2SCC(C[n+]3ccccc3)=C(N2C1=O)C(O)=O)c1csc(N)n1)C(O)=O |c:21|, CC(C)(O\N=C(/C(=O)N[C@H]1[C@H]2SCC(C[n+]3ccccc3)=C(N2C1=O)C(O)=O)c1csc(N)n1)C(O)=O |c:21|, CC(C)(O\N=C(/C(=O)N[C@H]1[C@H]2SCC(C[n+]3ccccc3)=C(N2C1=O)C(O)=O)c1csc(N)n1)C(O)=O |c:21|	Launched
ceftibuten	bacterial cell wall synthesis inhibitor		pulmonary, otolaryngology	bronchitis, otitis, pharyngitis, tonsillitis	MicroSource, MedChemEx, MedChemEx, MedChemEx, Sigma	95.4	Nc1nc(cs1)C(=C\CC(O)=O)\C(=O)N[C@H]1[C@H]2SCC=C(N2C1=O)C(O)=O |c:20|, Nc1nc(cs1)C(=C\CC(O)=O)\C(=O)N[C@H]1[C@H]2SCC=C(N2C1=O)C(O)=O |c:20|, Nc1nc(cs1)C(=C\CC(O)=O)\C(=O)N[C@H]1[C@H]2SCC=C(N2C1=O)C(O)=O |c:20|, Nc1nc(cs1)C(=C\CC(O)=O)\C(=O)N[C@H]1[C@H]2SCC=C(N2C1=O)C(O)=O |c:20|, Nc1nc(cs1)C(=C\CC(O)=O)\C(=O)N[C@H]1[C@H]2SCC=C(N2C1=O)C(O)=O |c:20|	Launched
ceftiofur	bacterial cell wall synthesis inhibitor		infectious disease	pneumonia, respiratory tract infections	MicroSource, MedChemEx, Selleck, Selleck	93.8	CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(CSC(=O)c3ccco3)=C(N2C1=O)C(O)=O)c1csc(N)n1 |c:21|, CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(CSC(=O)c3ccco3)=C(N2C1=O)C(O)=O)c1csc(N)n1 |c:21|, CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(CSC(=O)c3ccco3)=C(N2C1=O)C(O)=O)c1csc(N)n1 |c:21|, CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(CSC(=O)c3ccco3)=C(N2C1=O)C(O)=O)c1csc(N)n1 |c:21|	Launched
ceftizoxim	bacterial cell wall synthesis inhibitor		infectious disease	respiratory tract infections, urinary tract infections, gonorrhea, pelvic inflammatory disease, intra-abdominal infections, bacterial septicemia, skin infections, bone and joint infections, meningitis	MedChemEx, Enzo, MedChemEx	88.85	CO\N=C(/C(=O)N[C@H]1[C@H]2SCC=C(N2C1=O)C(O)=O)c1csc(N)n1 |c:11|, CO\N=C(/C(=O)N[C@H]1[C@H]2SCC=C(N2C1=O)C(O)=O)c1csc(N)n1 |c:11|, CO\N=C(/C(=O)N[C@H]1[C@H]2SCC=C(N2C1=O)C(O)=O)c1csc(N)n1 |c:11|	Launched
ceftobiprole	antiinfective drug				MedChemEx	79	[H][C@]12SCC(\C=C3/CCN([C@@H]4CCNC4)C3=O)=C(N1C(=O)[C@H]2NC(=O)C(=N/O)\c1nsc(N)n1)C(O)=O |c:18|	Phase 3
ceftriaxone	bacterial cell wall synthesis inhibitor		infectious disease, otolaryngology	gonorrhea, pneumonia, otitis, skin infections, urinary tract infections, pelvic inflammatory disease, bacterial septicemia, bone and joint infections, intra-abdominal infections, meningitis, surgical prophylaxis	MicroSource, MedChemEx	85.48	CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(CSc3nc(=O)c(O)nn3C)=C(N2C1=O)C(O)=O)c1csc(N)n1 |c:23|, CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(CSc3nc(=O)c(O)nn3C)=C(N2C1=O)C(O)=O)c1csc(N)n1 |c:23|	Launched
cefuroxime	bacterial cell wall synthesis inhibitor		infectious disease	gram-negative bacterial infections	MedChemEx, MicroSource, MedChemEx	86.53	CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(COC(N)=O)=C(N2C1=O)C(O)=O)c1ccco1 |c:16|, CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(COC(N)=O)=C(N2C1=O)C(O)=O)c1ccco1 |c:16|, CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(COC(N)=O)=C(N2C1=O)C(O)=O)c1ccco1 |c:16|	Launched
cefuroxime-axetil	bacterial cell wall synthesis inhibitor		otolaryngology	pharyngitis, tonsillitis, otitis, sinusitis	Sigma, MicroSource, Sigma	56.52	CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(COC(N)=O)=C(N2C1=O)C(=O)O[C@@H](C)OC(C)=O)c1ccco1 |a:7,8,&1:24,c:16|, CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(COC(N)=O)=C(N2C1=O)C(=O)O[C@@H](C)OC(C)=O)c1ccco1 |a:7,8,&1:24,c:16|, CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(COC(N)=O)=C(N2C1=O)C(=O)O[C@@H](C)OC(C)=O)c1ccco1 |a:7,8,&1:24,c:16|	Launched
celecoxib	cyclooxygenase inhibitor	CA12, PDPK1, PTGS2	rheumatology, endocrinology	osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, primary dysmenorrhea (PD)	Tocris, MicroSource, Selleck	99.47	Cc1ccc(cc1)-c1cc(nn1-c1ccc(cc1)S(N)(=O)=O)C(F)(F)F, Cc1ccc(cc1)-c1cc(nn1-c1ccc(cc1)S(N)(=O)=O)C(F)(F)F, Cc1ccc(cc1)-c1cc(nn1-c1ccc(cc1)S(N)(=O)=O)C(F)(F)F	Launched
celgosivir	glucosidase inhibitor				MedChemEx	98.4	[H][C@]12[C@@H](O)CCN1C[C@H](OC(=O)CCC)[C@@H](O)[C@@H]2O	Phase 2
celiprolol	adrenergic receptor antagonist	ADRA2A, ADRB1, ADRB2	genetics	Ehlers-Danlos syndrome (EDS)	Prestwick, WuXi	97.27	CCN(CC)C(=O)Nc1ccc(OC[C@@H](O)CNC(C)(C)C)c(c1)C(C)=O |&1:14|, CCN(CC)C(=O)Nc1ccc(OC[C@@H](O)CNC(C)(C)C)c(c1)C(C)=O |&1:14|	Launched
cenerimod	sphingosine 1-phosphate receptor modulator				MedChemEx	90.19	CCc1cc(cc(C)c1OC[C@@H](O)CO)-c1noc(n1)-c1cc(OC)nc(c1)C1CCCC1	Phase 2
cenicriviroc	CC chemokine receptor antagonist				MedChemEx	78.24	CCCCOCCOc1ccc(cc1)-c1ccc2N(CC(C)C)CCC\C(=C/c2c1)C(=O)Nc1ccc(cc1)[S@@](=O)Cc1cncn1CCC |c:27|	Phase 3
cenobamate	GABA receptor modulator, voltage-gated sodium channel blocker				MedChemEx	100	NC(=O)O[C@@H](Cn1ncnn1)c1ccccc1Cl	Launched
centanafadine	dopamine reuptake inhibitor				AMS	97.44	C1[C@@H]2CNC[C@]12c1ccc2ccccc2c1	Phase 3
centazolone	monoamine oxidase inhibitor				Enamine, Enamine, Enamine	95.67	Nn1cnc2cc3ccccc3cc2c1=O, Nn1cnc2cc3ccccc3cc2c1=O, Nn1cnc2cc3ccccc3cc2c1=O	Phase 1
centhaquin	analgesic agent				Sigma	96.94	Cc1cccc(c1)N1CCN(CCc2ccc3ccccc3n2)CC1	Phase 1
centpropazine	inositol monophosphatase inhibitor				Enamine, Enamine, Enamine, Enamine	97.67	CCC(=O)c1ccc(OC[C@@H](O)CN2CCN(CC2)c2ccccc2)cc1 |&1:10,r|, CCC(=O)c1ccc(OC[C@@H](O)CN2CCN(CC2)c2ccccc2)cc1 |&1:10,r|, CCC(=O)c1ccc(OC[C@@H](O)CN2CCN(CC2)c2ccccc2)cc1 |&1:10,r|, CCC(=O)c1ccc(OC[C@@H](O)CN2CCN(CC2)c2ccccc2)cc1 |&1:10,r|	Phase 3
CEP-32496	RAF inhibitor	BRAF, RAF1			Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, MedChemEx	98.02	COc1cc2ncnc(Oc3cccc(NC(=O)Nc4cc(on4)C(C)(C)C(F)(F)F)c3)c2cc1OC, COc1cc2ncnc(Oc3cccc(NC(=O)Nc4cc(on4)C(C)(C)C(F)(F)F)c3)c2cc1OC, COc1cc2ncnc(Oc3cccc(NC(=O)Nc4cc(on4)C(C)(C)C(F)(F)F)c3)c2cc1OC, COc1cc2ncnc(Oc3cccc(NC(=O)Nc4cc(on4)C(C)(C)C(F)(F)F)c3)c2cc1OC, COc1cc2ncnc(Oc3cccc(NC(=O)Nc4cc(on4)C(C)(C)C(F)(F)F)c3)c2cc1OC, COc1cc2ncnc(Oc3cccc(NC(=O)Nc4cc(on4)C(C)(C)C(F)(F)F)c3)c2cc1OC, COc1cc2ncnc(Oc3cccc(NC(=O)Nc4cc(on4)C(C)(C)C(F)(F)F)c3)c2cc1OC	Phase 1/Phase 2
CEP-33779	JAK inhibitor	JAK2			Selleck, Selleck, Selleck, Selleck, Selleck, MedChemEx, MedChemEx	97	CN1CCN(CC1)c1cccc(Nc2nc3c(cccn3n2)-c2ccc(cc2)S(C)(=O)=O)c1, CN1CCN(CC1)c1cccc(Nc2nc3c(cccn3n2)-c2ccc(cc2)S(C)(=O)=O)c1, CN1CCN(CC1)c1cccc(Nc2nc3c(cccn3n2)-c2ccc(cc2)S(C)(=O)=O)c1, CN1CCN(CC1)c1cccc(Nc2nc3c(cccn3n2)-c2ccc(cc2)S(C)(=O)=O)c1, CN1CCN(CC1)c1cccc(Nc2nc3c(cccn3n2)-c2ccc(cc2)S(C)(=O)=O)c1, CN1CCN(CC1)c1cccc(Nc2nc3c(cccn3n2)-c2ccc(cc2)S(C)(=O)=O)c1, CN1CCN(CC1)c1cccc(Nc2nc3c(cccn3n2)-c2ccc(cc2)S(C)(=O)=O)c1	Preclinical
CEP-37440	ALK tyrosine kinase receptor inhibitor	ALK			MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx	97.19	CNC(=O)c1ccccc1Nc1nc(Nc2ccc3C[C@H](CCCc3c2OC)N2CCN(CCO)CC2)ncc1Cl, CNC(=O)c1ccccc1Nc1nc(Nc2ccc3C[C@H](CCCc3c2OC)N2CCN(CCO)CC2)ncc1Cl, CNC(=O)c1ccccc1Nc1nc(Nc2ccc3C[C@H](CCCc3c2OC)N2CCN(CCO)CC2)ncc1Cl, CNC(=O)c1ccccc1Nc1nc(Nc2ccc3C[C@H](CCCc3c2OC)N2CCN(CCO)CC2)ncc1Cl, CNC(=O)c1ccccc1Nc1nc(Nc2ccc3C[C@H](CCCc3c2OC)N2CCN(CCO)CC2)ncc1Cl, CNC(=O)c1ccccc1Nc1nc(Nc2ccc3C[C@H](CCCc3c2OC)N2CCN(CCO)CC2)ncc1Cl	Phase 1
CEP-40783	AXL kinase inhibitor				MedChemEx	96.21	COc1cc2nccc(Oc3ccc(NC(=O)c4cn(C(C)C)c(=O)n(-c5ccc(F)cc5)c4=O)cc3F)c2cc1OC	Preclinical
cephalexin	bacterial cell wall synthesis inhibitor		infectious disease, otolaryngology	respiratory tract infections, otitis, skin infections, bone and joint infections, genitourinary tract infections	MedChemEx, MedChemEx, Sigma, MicroSource, Selleck, Selleck	75.26	CC1=C(N2[C@H](SC1)[C@H](NC(=O)[C@H](N)c1ccccc1)C2=O)C(O)=O |t:1|, CC1=C(N2[C@H](SC1)[C@H](NC(=O)[C@H](N)c1ccccc1)C2=O)C(O)=O |t:1|, CC1=C(N2[C@H](SC1)[C@H](NC(=O)[C@H](N)c1ccccc1)C2=O)C(O)=O |t:1|, CC1=C(N2[C@H](SC1)[C@H](NC(=O)[C@H](N)c1ccccc1)C2=O)C(O)=O |t:1|, CC1=C(N2[C@H](SC1)[C@H](NC(=O)[C@H](N)c1ccccc1)C2=O)C(O)=O |t:1|, CC1=C(N2[C@H](SC1)[C@H](NC(=O)[C@H](N)c1ccccc1)C2=O)C(O)=O |t:1|	Launched
cephalomannine	DNA polymerase inhibitor				MedChemEx, Selleck, Selleck	94.06	C\C=C(/C)C(=O)N[C@H]([C@@H](O)C(=O)O[C@H]1C[C@@]2(O)[C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C(=O)[C@H](OC(C)=O)C(=C1C)C2(C)C)OC(C)=O)c1ccccc1 |t:47|, C\C=C(/C)C(=O)N[C@H]([C@@H](O)C(=O)O[C@H]1C[C@@]2(O)[C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C(=O)[C@H](OC(C)=O)C(=C1C)C2(C)C)OC(C)=O)c1ccccc1 |t:47|, C\C=C(/C)C(=O)N[C@H]([C@@H](O)C(=O)O[C@H]1C[C@@]2(O)[C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C(=O)[C@H](OC(C)=O)C(=C1C)C2(C)C)OC(C)=O)c1ccccc1 |t:47|	Preclinical
cephalosporin-c-zn	bacterial cell wall synthesis inhibitor				CombiBlocks	0	CC(=O)OCC1=C2N3[C@H](SC1)[C@H](NC(=O)CCC[C@H](N)C(=O)O[Zn]OC2=O)C3=O |t:5|	Preclinical
cephalothin	bacterial cell wall synthesis inhibitor		infectious disease	skin infections, surgical prophylaxis	MicroSource, MedChemEx	92.86	CC(=O)OCC1=C(N2[C@H](SC1)[C@H](NC(=O)Cc1cccs1)C2=O)C(O)=O |t:5|, CC(=O)OCC1=C(N2[C@H](SC1)[C@H](NC(=O)Cc1cccs1)C2=O)C(O)=O |t:5|	Launched
cephapirin	bacterial cell wall synthesis inhibitor		obstetrics/gynecology	mastitis	MicroSource, Selleck, Selleck	88.36	CC(=O)OCC1=C(N2[C@H](SC1)[C@H](NC(=O)CSc1ccncc1)C2=O)C(O)=O |t:5|, CC(=O)OCC1=C(N2[C@H](SC1)[C@H](NC(=O)CSc1ccncc1)C2=O)C(O)=O |t:5|, CC(=O)OCC1=C(N2[C@H](SC1)[C@H](NC(=O)CSc1ccncc1)C2=O)C(O)=O |t:5|	Launched
cepharanthine	NFkB pathway inhibitor				MicroSource, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck	98.07	COc1ccc2C[C@H]3N(C)CCc4cc(OC)c(Oc5c6OCOc6cc6CCN(C)[C@@H](Cc7ccc(Oc1c2)cc7)c56)cc34, COc1ccc2C[C@H]3N(C)CCc4cc(OC)c(Oc5c6OCOc6cc6CCN(C)[C@@H](Cc7ccc(Oc1c2)cc7)c56)cc34, COc1ccc2C[C@H]3N(C)CCc4cc(OC)c(Oc5c6OCOc6cc6CCN(C)[C@@H](Cc7ccc(Oc1c2)cc7)c56)cc34, COc1ccc2C[C@H]3N(C)CCc4cc(OC)c(Oc5c6OCOc6cc6CCN(C)[C@@H](Cc7ccc(Oc1c2)cc7)c56)cc34, COc1ccc2C[C@H]3N(C)CCc4cc(OC)c(Oc5c6OCOc6cc6CCN(C)[C@@H](Cc7ccc(Oc1c2)cc7)c56)cc34, COc1ccc2C[C@H]3N(C)CCc4cc(OC)c(Oc5c6OCOc6cc6CCN(C)[C@@H](Cc7ccc(Oc1c2)cc7)c56)cc34, COc1ccc2C[C@H]3N(C)CCc4cc(OC)c(Oc5c6OCOc6cc6CCN(C)[C@@H](Cc7ccc(Oc1c2)cc7)c56)cc34	Phase 2
cephradine	bacterial cell wall synthesis inhibitor		infectious disease	skin infections, respiratory tract infections, urinary tract infections	MicroSource	5.47	CC1=C(N2[C@@H](SC1)[C@H](NC(=O)[C@H](N)C1=CCC=CC1)C2=O)C(O)=O |a:7,11,&1:4,c:17,t:1,14|	Launched
ceramide	phosphoenolpyruvate carboxylase activator, serine/threonine protein phosphatase activator		dermatology	cosmetic	Tocris	100	CCCCCCCCCCCCC\C=C\[C@@H](O)[C@H](CO)NC(C)=O	Launched
ceritinib	ALK tyrosine kinase receptor inhibitor	ALK, FLT3, IGF1R, INSR, TSSK1B	oncology	non-small cell lung cancer (NSCLC)	MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck	96.7	CC(C)Oc1cc(C2CCNCC2)c(C)cc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1, CC(C)Oc1cc(C2CCNCC2)c(C)cc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1, CC(C)Oc1cc(C2CCNCC2)c(C)cc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1, CC(C)Oc1cc(C2CCNCC2)c(C)cc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1, CC(C)Oc1cc(C2CCNCC2)c(C)cc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1, CC(C)Oc1cc(C2CCNCC2)c(C)cc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1, CC(C)Oc1cc(C2CCNCC2)c(C)cc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1, CC(C)Oc1cc(C2CCNCC2)c(C)cc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1, CC(C)Oc1cc(C2CCNCC2)c(C)cc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1, CC(C)Oc1cc(C2CCNCC2)c(C)cc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1, CC(C)Oc1cc(C2CCNCC2)c(C)cc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1, CC(C)Oc1cc(C2CCNCC2)c(C)cc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1, CC(C)Oc1cc(C2CCNCC2)c(C)cc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1, CC(C)Oc1cc(C2CCNCC2)c(C)cc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1, CC(C)Oc1cc(C2CCNCC2)c(C)cc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1, CC(C)Oc1cc(C2CCNCC2)c(C)cc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1	Launched
cerulenin	fatty acid synthase inhibitor	FASN	infectious disease	fungal infection	Enzo, Enzo, Enzo	41.25	C\C=C\C\C=C\CCC(=O)[C@H]1O[C@H]1C(N)=O, C\C=C\C\C=C\CCC(=O)[C@H]1O[C@H]1C(N)=O, C\C=C\C\C=C\CCC(=O)[C@H]1O[C@H]1C(N)=O	Launched
ceruletide	CCK receptor agonist	CCKAR			MedChemEx	93.01	[H][C@](NC(=O)[C@H](Cc1ccc(OS(O)(=O)=O)cc1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H]1CCC(=O)N1)([C@@H](C)O)C(=O)NCC(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](Cc1ccccc1)C(N)=O	Preclinical
cetaben	ACAT inhibitor, cholesterol inhibitor	PPARA			Adooq, Adooq, Adooq	81.99	CCCCCCCCCCCCCCCCNc1ccc(cc1)C(O)=O, CCCCCCCCCCCCCCCCNc1ccc(cc1)C(O)=O, CCCCCCCCCCCCCCCCNc1ccc(cc1)C(O)=O	Phase 2
cetilistat	triacylglycerol lipase inhibitor	PNLIP			Key, TCI	17.4	CCCCCCCCCCCCCCCCOc1nc2ccc(C)cc2c(=O)o1, CCCCCCCCCCCCCCCCOc1nc2ccc(C)cc2c(=O)o1	Phase 3
cetirizine	histamine receptor antagonist	HRH1	allergy	allergic rhinitis	Tocris, MicroSource, Selleck	98.06	OC(=O)COCCN1CCN(CC1)[C@@H](c1ccccc1)c1ccc(Cl)cc1 |&1:13|, OC(=O)COCCN1CCN(CC1)[C@@H](c1ccccc1)c1ccc(Cl)cc1 |&1:13|, OC(=O)COCCN1CCN(CC1)[C@@H](c1ccccc1)c1ccc(Cl)cc1 |&1:13|	Launched
cetrimonium			dermatology	cosmetic	MedChemEx, MedChemEx, Selleck, Selleck, Selleck, Selleck, MicroSource	100	CCCCCCCCCCCCCCCC[N+](C)(C)C, CCCCCCCCCCCCCCCC[N+](C)(C)C, CCCCCCCCCCCCCCCC[N+](C)(C)C, CCCCCCCCCCCCCCCC[N+](C)(C)C, CCCCCCCCCCCCCCCC[N+](C)(C)C, CCCCCCCCCCCCCCCC[N+](C)(C)C, CCCCCCCCCCCCCCCC[N+](C)(C)C	Launched
cetrorelix	gonadotropin releasing factor hormone receptor antagonist	GNRHR, LHCGR	endocrinology	premature luteinizing hormone surges	Sigma, Sigma, MedChemEx	98.03	CC(C)C[C@H](NC(=O)[C@@H](CCCNC(N)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@@H](Cc1cccnc1)NC(=O)[C@@H](Cc1ccc(Cl)cc1)NC(=O)[C@@H](Cc1ccc2ccccc2c1)NC(C)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O, CC(C)C[C@H](NC(=O)[C@@H](CCCNC(N)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@@H](Cc1cccnc1)NC(=O)[C@@H](Cc1ccc(Cl)cc1)NC(=O)[C@@H](Cc1ccc2ccccc2c1)NC(C)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O, CC(C)C[C@H](NC(=O)[C@@H](CCCNC(N)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@@H](Cc1cccnc1)NC(=O)[C@@H](Cc1ccc(Cl)cc1)NC(=O)[C@@H](Cc1ccc2ccccc2c1)NC(C)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O	Launched
cetylpyridinium			dental	gingivitis, mouth inflammation	MicroSource, MicroSource, MicroSource, MicroSource, MicroSource, MedChemEx, MedChemEx, MedChemEx, Selleck, Selleck	98.97	CCCCCCCCCCCCCCCC[n+]1ccccc1, CCCCCCCCCCCCCCCC[n+]1ccccc1, CCCCCCCCCCCCCCCC[n+]1ccccc1, CCCCCCCCCCCCCCCC[n+]1ccccc1, CCCCCCCCCCCCCCCC[n+]1ccccc1, CCCCCCCCCCCCCCCC[n+]1ccccc1, CCCCCCCCCCCCCCCC[n+]1ccccc1, CCCCCCCCCCCCCCCC[n+]1ccccc1, CCCCCCCCCCCCCCCC[n+]1ccccc1, CCCCCCCCCCCCCCCC[n+]1ccccc1	Launched
cevimeline	acetylcholine receptor agonist	CHRM3	rheumatology	sjogren's syndrome	Tocris	100	C[C@H]1O[C@]2(CS1)CN1CCC2CC1 |&1:1,3|	Launched
cevipabulin	microtubule stimulant, tubulin polymerization inhibitor	TUBB			MedChemEx	91.03	[H][C@@](C)(Nc1c(c(Cl)nc2ncnn12)-c1c(F)cc(OCCCNC)cc1F)C(F)(F)F	Phase 1
CE3F4	rap guanine nucleotide exchange factor inhibitor	RAPGEF3			Tocris, Tocris	98.53	C[C@H]1CCc2c(Br)c(F)c(Br)cc2N1C=O |&1:1,r|, C[C@H]1CCc2c(Br)c(F)c(Br)cc2N1C=O |&1:1,r|	Preclinical
CFI-400945	serine/threonine kinase inhibitor				MedChemEx	95.21	COc1ccc2NC(=O)[C@@]3(C[C@H]3c3ccc4c(\C=C\c5ccc(CN6C[C@H](C)O[C@H](C)C6)cc5)[nH]nc4c3)c2c1	Phase 2
CFI-402257	dual specificity protein kinase inhibitor				MedChemEx	95.05	Cc1cc(ccc1C(=O)NC1CC1)-c1cnn2c(NC[C@H]3C[C@@](C)(O)C3)cc(Oc3cccnc3)nc12 |r|	Phase 1/Phase 2
CFM-1571	guanylate cyclase activator				Tocris, Tocris	95.4	COc1ccc(NC(=O)c2cc(OCCCN(C)C)nn2Cc2ccccc2)cc1, COc1ccc(NC(=O)c2cc(OCCCN(C)C)nn2Cc2ccccc2)cc1	Preclinical
CFM-2	glutamate receptor antagonist				Tocris, Tocris	89.65	COc1cc2CC(=O)NN=C(c3ccc(N)cc3)c2cc1OC |t:9|, COc1cc2CC(=O)NN=C(c3ccc(N)cc3)c2cc1OC |t:9|	Preclinical
CFTRinh-172	chloride channel blocker	CFTR			Tocris, Tocris, Tocris, Selleck, Selleck	90.32	OC(=O)c1ccc(\C=C2\SC(=S)N(C2=O)c2cccc(c2)C(F)(F)F)cc1, OC(=O)c1ccc(\C=C2\SC(=S)N(C2=O)c2cccc(c2)C(F)(F)F)cc1, OC(=O)c1ccc(\C=C2\SC(=S)N(C2=O)c2cccc(c2)C(F)(F)F)cc1, OC(=O)c1ccc(\C=C2\SC(=S)N(C2=O)c2cccc(c2)C(F)(F)F)cc1, OC(=O)c1ccc(\C=C2\SC(=S)N(C2=O)c2cccc(c2)C(F)(F)F)cc1	Preclinical
CF102	adenosine receptor agonist	ADORA1, ADORA2A, ADORA2B, ADORA3			Tocris, Tocris, Tocris, Tocris	98.78	CNC(=O)[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(NCc3cccc(I)c3)nc(Cl)nc12, CNC(=O)[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(NCc3cccc(I)c3)nc(Cl)nc12, CNC(=O)[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(NCc3cccc(I)c3)nc(Cl)nc12, CNC(=O)[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(NCc3cccc(I)c3)nc(Cl)nc12	Phase 2
CG-400549	FABI inhibitor				Astatech, Astatech	95.34	Cc1c(N)cccc1Cn1ccc(OCCc2cccs2)cc1=O, Cc1c(N)cccc1Cn1ccc(OCCc2cccs2)cc1=O	Phase 2
CGH2466	adenosine receptor antagonist	ADORA1, ADORA2B, ADORA3			Tocris, Tocris, Tocris, Tocris, Tocris	94.17	Nc1nc(c(s1)-c1ccncc1)-c1ccc(Cl)c(Cl)c1, Nc1nc(c(s1)-c1ccncc1)-c1ccc(Cl)c(Cl)c1, Nc1nc(c(s1)-c1ccncc1)-c1ccc(Cl)c(Cl)c1, Nc1nc(c(s1)-c1ccncc1)-c1ccc(Cl)c(Cl)c1, Nc1nc(c(s1)-c1ccncc1)-c1ccc(Cl)c(Cl)c1	Preclinical
CGK-733	ATM kinase inhibitor, ATR kinase inhibitor	ATM, ATR			Tocris, Tocris, Tocris, Selleck, Selleck, Selleck	97.37	[O-][N+](=O)c1cc(NC(=S)N[C@@H](NC(=O)C(c2ccccc2)c2ccccc2)C(Cl)(Cl)Cl)ccc1F |&1:10,r|, [O-][N+](=O)c1cc(NC(=S)N[C@@H](NC(=O)C(c2ccccc2)c2ccccc2)C(Cl)(Cl)Cl)ccc1F |&1:10,r|, [O-][N+](=O)c1cc(NC(=S)N[C@@H](NC(=O)C(c2ccccc2)c2ccccc2)C(Cl)(Cl)Cl)ccc1F |&1:10,r|, [O-][N+](=O)c1cc(NC(=S)N[C@@H](NC(=O)C(c2ccccc2)c2ccccc2)C(Cl)(Cl)Cl)ccc1F |&1:10,r|, [O-][N+](=O)c1cc(NC(=S)N[C@@H](NC(=O)C(c2ccccc2)c2ccccc2)C(Cl)(Cl)Cl)ccc1F |&1:10,r|, [O-][N+](=O)c1cc(NC(=S)N[C@@H](NC(=O)C(c2ccccc2)c2ccccc2)C(Cl)(Cl)Cl)ccc1F |&1:10,r|	Preclinical
CGM097	MDM inhibitor	MDM2			MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx	92.76	COc1cc2CC(=O)N([C@@H](c3ccc(Cl)cc3)c2cc1OC(C)C)c1ccc(cc1)N(C)C[C@H]1CC[C@@H](CC1)N1CCN(C)C(=O)C1, COc1cc2CC(=O)N([C@@H](c3ccc(Cl)cc3)c2cc1OC(C)C)c1ccc(cc1)N(C)C[C@H]1CC[C@@H](CC1)N1CCN(C)C(=O)C1, COc1cc2CC(=O)N([C@@H](c3ccc(Cl)cc3)c2cc1OC(C)C)c1ccc(cc1)N(C)C[C@H]1CC[C@@H](CC1)N1CCN(C)C(=O)C1, COc1cc2CC(=O)N([C@@H](c3ccc(Cl)cc3)c2cc1OC(C)C)c1ccc(cc1)N(C)C[C@H]1CC[C@@H](CC1)N1CCN(C)C(=O)C1, COc1cc2CC(=O)N([C@@H](c3ccc(Cl)cc3)c2cc1OC(C)C)c1ccc(cc1)N(C)C[C@H]1CC[C@@H](CC1)N1CCN(C)C(=O)C1, COc1cc2CC(=O)N([C@@H](c3ccc(Cl)cc3)c2cc1OC(C)C)c1ccc(cc1)N(C)C[C@H]1CC[C@@H](CC1)N1CCN(C)C(=O)C1, COc1cc2CC(=O)N([C@@H](c3ccc(Cl)cc3)c2cc1OC(C)C)c1ccc(cc1)N(C)C[C@H]1CC[C@@H](CC1)N1CCN(C)C(=O)C1	Phase 1
CGP-12177	adrenergic receptor agonist	ADRB1, ADRB2, ADRB3			Tocris, Tocris	96.6	CC(C)(C)NC[C@@H](O)COc1cccc2[nH]c(=O)[nH]c12 |&1:6|, CC(C)(C)NC[C@@H](O)COc1cccc2[nH]c(=O)[nH]c12 |&1:6|	Phase 1
CGP-13501	GABA receptor modulator	GABBR1			Tocris, Tocris, Tocris, Tocris	96.2	CC(C)(C)c1cc(CC(C)(C)C=O)cc(c1O)C(C)(C)C, CC(C)(C)c1cc(CC(C)(C)C=O)cc(c1O)C(C)(C)C, CC(C)(C)c1cc(CC(C)(C)C=O)cc(c1O)C(C)(C)C, CC(C)(C)c1cc(CC(C)(C)C=O)cc(c1O)C(C)(C)C	Preclinical
CGP-20712A	adrenergic receptor antagonist	ADRB1, ADRB3			Sigma	97.65	CS(O)(=O)=O.Cn1cc(nc1-c1ccc(OC[C@H](O)CNCCOc2ccc(O)c(c2)C(N)=O)cc1)C(F)(F)F |&1:17,r|	Preclinical
CGP-25454A	dopamine receptor antagonist				MedChemEx	97.68	CCN(CC)CCNC(=O)c1cc(C#N)c(Cl)cc1OC	Preclinical
CGP-37157	mitochondrial Na+/Ca2+ exchanger antagonist, sodium/calcium exchange inhibitor	SLC8A1			Tocris, Tocris, Tocris, Tocris, Tocris	99.24	Clc1ccc2NC(=O)CS[C@@H](c3ccccc3Cl)c2c1 |&1:10,r|, Clc1ccc2NC(=O)CS[C@@H](c3ccccc3Cl)c2c1 |&1:10,r|, Clc1ccc2NC(=O)CS[C@@H](c3ccccc3Cl)c2c1 |&1:10,r|, Clc1ccc2NC(=O)CS[C@@H](c3ccccc3Cl)c2c1 |&1:10,r|, Clc1ccc2NC(=O)CS[C@@H](c3ccccc3Cl)c2c1 |&1:10,r|	Preclinical
CGP-37849	glutamate receptor antagonist	GRIN2A, GRIN2B, GRIN2C, GRIN2D			Tocris, EMDBio	0	C\C(CP(O)(O)=O)=C/[C@@H](N)C(O)=O |&1:8,r|, C\C(CP(O)(O)=O)=C/[C@@H](N)C(O)=O |&1:8,r|	Phase 1
CGP-39551	NMDA receptor antagonist				Sigma	0	CCOC(=O)[C@H](N)\C=C(/C)CP(O)(O)=O |&1:5,r|	Preclinical
CGP-52411	EGFR inhibitor	EGFR			Tocris, Tocris, Tocris, Tocris	94.94	O=C1NC(=O)c2cc(Nc3ccccc3)c(Nc3ccccc3)cc12, O=C1NC(=O)c2cc(Nc3ccccc3)c(Nc3ccccc3)cc12, O=C1NC(=O)c2cc(Nc3ccccc3)c(Nc3ccccc3)cc12, O=C1NC(=O)c2cc(Nc3ccccc3)c(Nc3ccccc3)cc12	Preclinical
CGP-53353	EGFR inhibitor, PKC inhibitor	EGFR, PRKCB			Tocris, Tocris	94.62	Fc1ccc(Nc2cc3C(=O)NC(=O)c3cc2Nc2ccc(F)cc2)cc1, Fc1ccc(Nc2cc3C(=O)NC(=O)c3cc2Nc2ccc(F)cc2)cc1	Preclinical
CGP-54626	GABA receptor antagonist	GABBR1, GABBR2, KCTD12, KCTD16, KCTD8			Tocris, Tocris, Tocris	93.07	C[C@H](NC[C@H](O)CP(O)(=O)CC1CCCCC1)c1ccc(Cl)c(Cl)c1 |a:1,4,&1:7|, C[C@H](NC[C@H](O)CP(O)(=O)CC1CCCCC1)c1ccc(Cl)c(Cl)c1 |a:1,4,&1:7|, C[C@H](NC[C@H](O)CP(O)(=O)CC1CCCCC1)c1ccc(Cl)c(Cl)c1 |a:1,4,&1:7|	Preclinical
CGP-55845	GABA receptor antagonist	GABBR1, GABBR2, KCTD12, KCTD16, KCTD8			Tocris, Tocris	97.18	C[C@H](NC[C@H](O)CP(O)(=O)Cc1ccccc1)c1ccc(Cl)c(Cl)c1, C[C@H](NC[C@H](O)CP(O)(=O)Cc1ccccc1)c1ccc(Cl)c(Cl)c1	Preclinical
CGP-57380	MAP kinase inhibitor	AURKB, LCK, MKNK1, MKNK2, SGK1			Tocris, Selleck, Tocris	92.47	Nc1ncnc2n[nH]c(Nc3ccc(F)cc3)c12, Nc1ncnc2n[nH]c(Nc3ccc(F)cc3)c12, Nc1ncnc2n[nH]c(Nc3ccc(F)cc3)c12	Preclinical
CGP-60474	CDK inhibitor	CDK1, CDK2			Tocris, Tocris, Tocris, Tocris	98.36	OCCCNc1cc(ccn1)-c1ccnc(Nc2cccc(Cl)c2)n1, OCCCNc1cc(ccn1)-c1ccnc(Nc2cccc(Cl)c2)n1, OCCCNc1cc(ccn1)-c1ccnc(Nc2cccc(Cl)c2)n1, OCCCNc1cc(ccn1)-c1ccnc(Nc2cccc(Cl)c2)n1	Preclinical
CGP-71683	neuropeptide receptor antagonist	NPY5R			Tocris, Tocris, Tocris, Tocris	98.57	Nc1nc(NC[C@H]2CC[C@H](CNS(=O)(=O)c3cccc4ccccc34)CC2)nc2ccccc12 |r|, Nc1nc(NC[C@H]2CC[C@H](CNS(=O)(=O)c3cccc4ccccc34)CC2)nc2ccccc12 |r|, Nc1nc(NC[C@H]2CC[C@H](CNS(=O)(=O)c3cccc4ccccc34)CC2)nc2ccccc12 |r|, Nc1nc(NC[C@H]2CC[C@H](CNS(=O)(=O)c3cccc4ccccc34)CC2)nc2ccccc12 |r|	Preclinical
CGP-74514	CDK inhibitor	CDK1			Tocris, Tocris, Tocris, Tocris	96.7	CCn1cnc2c(Nc3cccc(Cl)c3)nc(N[C@@H]3CCCC[C@@H]3N)nc12, CCn1cnc2c(Nc3cccc(Cl)c3)nc(N[C@@H]3CCCC[C@@H]3N)nc12, CCn1cnc2c(Nc3cccc(Cl)c3)nc(N[C@@H]3CCCC[C@@H]3N)nc12, CCn1cnc2c(Nc3cccc(Cl)c3)nc(N[C@@H]3CCCC[C@@H]3N)nc12	Preclinical
CGP-78608	glutamate receptor antagonist				Tocris, Tocris	97.3	C[C@@H](NCc1cc(Br)cc2[nH]c(=O)c(=O)[nH]c12)P(O)(O)=O, C[C@@H](NCc1cc(Br)cc2[nH]c(=O)c(=O)[nH]c12)P(O)(O)=O	Preclinical
CGP-7930	GABA receptor modulator	GABBR1			Tocris, Tocris, Tocris, Tocris, Tocris, Tocris, Tocris	96.35	CC(C)(CO)Cc1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C, CC(C)(CO)Cc1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C, CC(C)(CO)Cc1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C, CC(C)(CO)Cc1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C, CC(C)(CO)Cc1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C, CC(C)(CO)Cc1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C, CC(C)(CO)Cc1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C	Preclinical
CGS-15943	adenosine receptor antagonist	ADORA1, ADORA2A, ADORA2B, ADORA3			Tocris, Tocris, Tocris, Tocris, Tocris, Tocris, Tocris, WuXi, WuXi, WuXi, WuXi, WuXi, WuXi, WuXi, WuXi, WuXi, WuXi	98.6	Nc1nc2ccc(Cl)cc2c2nc(nn12)-c1ccco1, Nc1nc2ccc(Cl)cc2c2nc(nn12)-c1ccco1, Nc1nc2ccc(Cl)cc2c2nc(nn12)-c1ccco1, Nc1nc2ccc(Cl)cc2c2nc(nn12)-c1ccco1, Nc1nc2ccc(Cl)cc2c2nc(nn12)-c1ccco1, Nc1nc2ccc(Cl)cc2c2nc(nn12)-c1ccco1, Nc1nc2ccc(Cl)cc2c2nc(nn12)-c1ccco1, Nc1nc2ccc(Cl)cc2c2nc(nn12)-c1ccco1, Nc1nc2ccc(Cl)cc2c2nc(nn12)-c1ccco1, Nc1nc2ccc(Cl)cc2c2nc(nn12)-c1ccco1, Nc1nc2ccc(Cl)cc2c2nc(nn12)-c1ccco1, Nc1nc2ccc(Cl)cc2c2nc(nn12)-c1ccco1, Nc1nc2ccc(Cl)cc2c2nc(nn12)-c1ccco1, Nc1nc2ccc(Cl)cc2c2nc(nn12)-c1ccco1, Nc1nc2ccc(Cl)cc2c2nc(nn12)-c1ccco1, Nc1nc2ccc(Cl)cc2c2nc(nn12)-c1ccco1, Nc1nc2ccc(Cl)cc2c2nc(nn12)-c1ccco1	Preclinical
CGS-20625	benzodiazepine receptor agonist, GABA benzodiazepine site receptor partial agonist	GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6			Tocris, Tocris, Tocris, Tocris, Tocris	95.6	COc1ccc(cc1)-n1[nH]c2c3CCCCCc3ncc2c1=O, COc1ccc(cc1)-n1[nH]c2c3CCCCCc3ncc2c1=O, COc1ccc(cc1)-n1[nH]c2c3CCCCCc3ncc2c1=O, COc1ccc(cc1)-n1[nH]c2c3CCCCCc3ncc2c1=O, COc1ccc(cc1)-n1[nH]c2c3CCCCCc3ncc2c1=O	Phase 1
CGS-21680	adenosine receptor agonist	ADORA1, ADORA2A, ADORA2B, ADORA3			Tocris	93.52	CCNC(=O)[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)nc(NCCc3ccc(CCC(O)=O)cc3)nc12	Preclinical
CGS-9896	GABA receptor antagonist	GABRA1, GABRB2, GABRG2			ChemDiv, ChemDiv	96.33	Clc1ccc(cc1)-n1[nH]c2c(cnc3ccccc23)c1=O, Clc1ccc(cc1)-n1[nH]c2c(cnc3ccccc23)c1=O	Preclinical
CH-170					Enamine	99.18	Cc1nc(Cn2cnc3n(C)c(=O)n(C)c(=O)c23)no1	Phase 1
CH-5183284	fibroblast growth factor inhibitor	FGFR1, FGFR2, FGFR3			Selleck, Selleck, Cayman	98.42	Cc1nc2ccc(cc2[nH]1)-n1ncc(C(=O)c2cc3ccccc3[nH]2)c1N, Cc1nc2ccc(cc2[nH]1)-n1ncc(C(=O)c2cc3ccccc3[nH]2)c1N, Cc1nc2ccc(cc2[nH]1)-n1ncc(C(=O)c2cc3ccccc3[nH]2)c1N	Phase 2
CHC	monocarboxylate transporter inhibitor	SLC16A1			Tocris, MicroSource	97.89	OC(=O)C(=C\c1ccc(O)cc1)\C#N, OC(=O)C(=C\c1ccc(O)cc1)\C#N	Preclinical
chenodeoxycholic-acid	11-beta hydroxysteroid dehydrogenase inhibitor, FXR agonist	HSD11B1, NR1H4	cardiology, gastroenterology	cerebral cholesterosis, gallstones	MicroSource, MicroSource, Selleck, Selleck, Selleck	100	C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C, C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C, C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C, C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C, C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C	Launched
CHF5074	gamma secretase modulator	PSEN1			MedChemEx	92.25	OC(=O)C1(CC1)c1ccc(c(F)c1)-c1ccc(Cl)c(Cl)c1	Phase 2
chicago-sky-blue-6b	glutamate inhibitor, macrophage migration inhibiting factor inhibitor	MIF			Prestwick, Selleck	76.61	COc1cc(ccc1NN=C1C=Cc2c(cc(c(N)c2C1=O)S(O)(=O)=O)S(O)(=O)=O)-c1ccc(NN=C2C=Cc3c(cc(c(N)c3C2=O)S(O)(=O)=O)S(O)(=O)=O)c(OC)c1 |c:12,40|, COc1cc(ccc1NN=C1C=Cc2c(cc(c(N)c2C1=O)S(O)(=O)=O)S(O)(=O)=O)-c1ccc(NN=C2C=Cc3c(cc(c(N)c3C2=O)S(O)(=O)=O)S(O)(=O)=O)c(OC)c1 |c:12,40|	Preclinical
chidamide	HDAC inhibitor	HDAC10, HDAC3	hematologic malignancy	peripheral T-cell lymphoma (PTCL)	MedChemEx, MedChemEx, MedChemEx, MedChemEx	91.41	Nc1ccc(F)cc1NC(=O)c1ccc(CNC(=O)\C=C\c2cccnc2)cc1, Nc1ccc(F)cc1NC(=O)c1ccc(CNC(=O)\C=C\c2cccnc2)cc1, Nc1ccc(F)cc1NC(=O)c1ccc(CNC(=O)\C=C\c2cccnc2)cc1, Nc1ccc(F)cc1NC(=O)c1ccc(CNC(=O)\C=C\c2cccnc2)cc1	Launched
chiniofon	antiprotozoal agent		infectious disease	amebiasis	MicroSource, Sigma	97.33	Oc1c(I)cc(c2cccnc12)S(O)(=O)=O, Oc1c(I)cc(c2cccnc12)S(O)(=O)=O	Launched
CHIR-124	CHK inhibitor	CHEK1			Selleck, Selleck, Selleck	95.19	Clc1ccc2[nH]c(=O)c(-c3nc4ccccc4[nH]3)c(N[C@@H]3CN4CCC3CC4)c2c1, Clc1ccc2[nH]c(=O)c(-c3nc4ccccc4[nH]3)c(N[C@@H]3CN4CCC3CC4)c2c1, Clc1ccc2[nH]c(=O)c(-c3nc4ccccc4[nH]3)c(N[C@@H]3CN4CCC3CC4)c2c1	Preclinical
CHIR-98014	glycogen synthase kinase inhibitor	GSK3A, GSK3B			MedChemEx, Selleck, Selleck, Selleck	94.71	Nc1nc(NCCNc2ncc(c(n2)-c2ccc(Cl)cc2Cl)-n2ccnc2)ccc1[N+]([O-])=O, Nc1nc(NCCNc2ncc(c(n2)-c2ccc(Cl)cc2Cl)-n2ccnc2)ccc1[N+]([O-])=O, Nc1nc(NCCNc2ncc(c(n2)-c2ccc(Cl)cc2Cl)-n2ccnc2)ccc1[N+]([O-])=O, Nc1nc(NCCNc2ncc(c(n2)-c2ccc(Cl)cc2Cl)-n2ccnc2)ccc1[N+]([O-])=O	Preclinical
CHIR-99021	glycogen synthase kinase inhibitor	CDK1, GSK3A, GSK3B, MAPK1			Selleck, Selleck, Selleck, Tocris, Stanley, Stanley, Stanley, Stanley, Stanley, Stanley, Stanley, Stanley, Stanley, Stanley, Stanley, Stanley, Stanley, Stanley, Stanley, Stanley, Stanley, Stanley, Stanley, Stanley, Stanley, Stanley, Stanley, Stanley, Stanley, Stanley, Stanley, Stanley, Stanley, Stanley, Stanley, Stanley, Stanley, Stanley, Stanley, Stanley, Stanley, Stanley, Stanley, Stanley, Stanley, Stanley, Stanley, Stanley, Stanley, Stanley, Stanley, Stanley, Stanley, Stanley, Stanley, Stanley, Stanley, Stanley, Stanley, Stanley, Stanley, Stanley, Stanley, Stanley, Stanley, Stanley, Stanley, Stanley, Stanley, Stanley	98.29	Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl	Preclinical
chloralose					MedChemEx	92.6	OC[C@@H](O)[C@H]1O[C@@H]2O[C@@H](O[C@@H]2[C@H]1O)C(Cl)(Cl)Cl	Preclinical
chlorambucil	DNA inhibitor		hematologic malignancy	chronic lymphocytic leukemia (CLL), Hodgkin's lymphoma	MicroSource	94.93	OC(=O)CCCc1ccc(cc1)N(CCCl)CCCl	Launched
chloramine-T			infectious disease	bacterial gill disease	MicroSource, MedChemEx	69.13	Cc1ccc(cc1)S(=O)(=O)NCl, Cc1ccc(cc1)S(=O)(=O)NCl	Launched
chloramphenicol	bacterial 50S ribosomal subunit inhibitor	CD55	infectious disease, endocrinology	meningitis, fever, cholera	MicroSource, MicroSource, MicroSource, Selleck	99.59	OC[C@@H](NC(=O)C(Cl)Cl)[C@H](O)c1ccc(cc1)[N+]([O-])=O, OC[C@@H](NC(=O)C(Cl)Cl)[C@H](O)c1ccc(cc1)[N+]([O-])=O, OC[C@@H](NC(=O)C(Cl)Cl)[C@H](O)c1ccc(cc1)[N+]([O-])=O, OC[C@@H](NC(=O)C(Cl)Cl)[C@H](O)c1ccc(cc1)[N+]([O-])=O	Launched
chloramphenicol-palmitate	protein synthesis inhibitor		infectious disease, endocrinology	meningitis, fever, cholera	TCI	96.32	CCCCCCCCCCCCCCCC(=O)OC[C@@H](NC(=O)C(Cl)Cl)[C@H](O)c1ccc(cc1)[N+]([O-])=O	Launched
chloramphenicol-sodium-succinate	protein synthesis inhibitor		infectious disease	gram-negative bacterial infections	MicroSource	31.43	O[C@@H]([C@@H](COC(=O)CCC(O)=O)NC(=O)C(Cl)Cl)c1ccc(cc1)[N+]([O-])=O	Launched
chlorazanil					MicroSource	98.95	Nc1ncnc(Nc2ccc(Cl)cc2)n1	Preclinical
chlorcyclizine	histamine receptor antagonist		allergy	allergic rhinitis	MedChemEx, Enzo, Enzo	97.82	CN1CCN(CC1)[C@@H](c1ccccc1)c1ccc(Cl)cc1 |&1:7|, CN1CCN(CC1)[C@@H](c1ccccc1)c1ccc(Cl)cc1 |&1:7|, CN1CCN(CC1)[C@@H](c1ccccc1)c1ccc(Cl)cc1 |&1:7|	Launched
chlorfenson	other antifungal				Sigma	0	Clc1ccc(OS(=O)(=O)c2ccc(Cl)cc2)cc1	Phase 2
chlorhexidine	membrane integrity inhibitor		dermatology, infectious disease, dental	cosmetic, skin infections, gingivitis	MicroSource, MicroSource, MicroSource, MicroSource, MicroSource, InterBioScreen, InterBioScreen	97.82	NC(Nc1ccc(Cl)cc1)=NC(=N)NCCCCCCNC(=N)N=C(N)Nc1ccc(Cl)cc1, NC(Nc1ccc(Cl)cc1)=NC(=N)NCCCCCCNC(=N)N=C(N)Nc1ccc(Cl)cc1, NC(Nc1ccc(Cl)cc1)=NC(=N)NCCCCCCNC(=N)N=C(N)Nc1ccc(Cl)cc1, NC(Nc1ccc(Cl)cc1)=NC(=N)NCCCCCCNC(=N)N=C(N)Nc1ccc(Cl)cc1, NC(Nc1ccc(Cl)cc1)=NC(=N)NCCCCCCNC(=N)N=C(N)Nc1ccc(Cl)cc1, NC(Nc1ccc(Cl)cc1)=NC(=N)NCCCCCCNC(=N)N=C(N)Nc1ccc(Cl)cc1, NC(Nc1ccc(Cl)cc1)=NC(=N)NCCCCCCNC(=N)N=C(N)Nc1ccc(Cl)cc1	Launched
chlorindanol					MicroSource, Sigma	94.71	Oc1ccc(Cl)c2CCCc12, Oc1ccc(Cl)c2CCCc12	Preclinical
chlorindione					MedChemEx, MicroSource	96.83	Clc1ccc(cc1)C1C(=O)c2ccccc2C1=O, Clc1ccc(cc1)C1C(=O)c2ccccc2C1=O	Preclinical
chlorisondamine-diiodide	acetylcholine receptor antagonist	CHRNA1			Tocris, Tocris	4.63	C[N+](C)(C)CC[N+]1(C)Cc2c(C1)c(Cl)c(Cl)c(Cl)c2Cl, C[N+](C)(C)CC[N+]1(C)Cc2c(C1)c(Cl)c(Cl)c(Cl)c2Cl	Preclinical
chlormadinone-acetate	5 alpha reductase inhibitor	PGR	endocrinology	hypermenorrhea, amenorrhea, oligomenorrhea, polymenorrhea	MedChemEx	93.83	CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(Cl)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)=O |t:9,12|	Launched
chlormezanone	GABA receptor modulator	GABRA1			MicroSource, MicroSource, Tocris, Tocris, Selleck	98.9	CN1[C@@H](c2ccc(Cl)cc2)S(=O)(=O)CCC1=O |&1:2,r|, CN1[C@@H](c2ccc(Cl)cc2)S(=O)(=O)CCC1=O |&1:2,r|, CN1[C@@H](c2ccc(Cl)cc2)S(=O)(=O)CCC1=O |&1:2,r|, CN1[C@@H](c2ccc(Cl)cc2)S(=O)(=O)CCC1=O |&1:2,r|, CN1[C@@H](c2ccc(Cl)cc2)S(=O)(=O)CCC1=O |&1:2,r|	Withdrawn
chlormidazole	fungal lanosterol demethylase inhibitor		infectious disease	fungal infection	MicroSource, MicroSource, MicroSource, Vitas-M	94.26	Cc1nc2ccccc2n1Cc1ccc(Cl)cc1, Cc1nc2ccccc2n1Cc1ccc(Cl)cc1, Cc1nc2ccccc2n1Cc1ccc(Cl)cc1, Cc1nc2ccccc2n1Cc1ccc(Cl)cc1	Launched
chlorobutanol			neurology/psychiatry	anesthetic, sedative	MicroSource, Enamine, Enamine	0	CC(C)(O)C(Cl)(Cl)Cl, CC(C)(O)C(Cl)(Cl)Cl, CC(C)(O)C(Cl)(Cl)Cl	Launched
chlorocresol	ryanodine receptor activator		infectious disease	first-aid antiseptic	MicroSource, Selleck, Selleck	94.58	Cc1cc(O)ccc1Cl, Cc1cc(O)ccc1Cl, Cc1cc(O)ccc1Cl	Launched
chlorogenic-acid	antioxidant	SLC37A4	neurology/psychiatry, pulmonary, allergy	headache, chest congestion, allergic rhinitis	MedChemEx, Selleck, Selleck, Selleck	95.33	O[C@@H]1C[C@](O)(C[C@@H](OC(=O)\C=C\c2ccc(O)c(O)c2)[C@@H]1O)C(O)=O, O[C@@H]1C[C@](O)(C[C@@H](OC(=O)\C=C\c2ccc(O)c(O)c2)[C@@H]1O)C(O)=O, O[C@@H]1C[C@](O)(C[C@@H](OC(=O)\C=C\c2ccc(O)c(O)c2)[C@@H]1O)C(O)=O, O[C@@H]1C[C@](O)(C[C@@H](OC(=O)\C=C\c2ccc(O)c(O)c2)[C@@H]1O)C(O)=O	Launched
chlorophyllin			urology	urinary incontinence	Adooq	5.35	CCc1c(C)c2cc3nc(cc4[nH]c([C@@H](CCC(O)=O)[C@@H]4C)c(CC(O)=O)c4[nH]c(cc1n2)c(C)c4C(O)=O)c(C)c3C=C	Preclinical
chlorophyllin-copper	cytochrome P450 inhibitor				MedChemEx, Sigma	20.18	CCC1=C(C)\C2=C\c3c(C=C)c(C)c4\C=C5/N=C([C@@H](CCC(O)=O)[C@@H]5C)/C(/CC(O)=O)=c5/c(C(O)=O)c(C)\c(=C\C1=N2)n5[Cu]n34 |&1:18,&2:24,r,c:2,14,16,42,t:5,31,39|, CCC1=C(C)\C2=C\c3c(C=C)c(C)c4\C=C5/N=C([C@@H](CCC(O)=O)[C@@H]5C)/C(/CC(O)=O)=c5/c(C(O)=O)c(C)\c(=C\C1=N2)n5[Cu]n34 |&1:18,&2:24,r,c:2,14,16,42,t:5,31,39|	Phase 1
chloroprocaine	sodium channel blocker	ATP1A1, CHRNA10, GRIN3A, HTR3A, SCN10A, SLC6A3	neurology/psychiatry	local anesthetic	Enamine	88.33	CCN(CC)CCOC(=O)c1ccc(N)cc1Cl	Launched
chloropyramine	histamine receptor antagonist	HRH1	cardiology, ophthalmology, allergy, pulmonary	edema, conjunctivitis, allergic rhinitis, asthma	MedChemEx, MedChemEx, MedChemEx, MicroSource, MicroSource, MicroSource	98.29	CN(C)CCN(Cc1ccc(Cl)cc1)c1ccccn1, CN(C)CCN(Cc1ccc(Cl)cc1)c1ccccn1, CN(C)CCN(Cc1ccc(Cl)cc1)c1ccccn1, CN(C)CCN(Cc1ccc(Cl)cc1)c1ccccn1, CN(C)CCN(Cc1ccc(Cl)cc1)c1ccccn1, CN(C)CCN(Cc1ccc(Cl)cc1)c1ccccn1	Launched
chloroquine	antimalarial agent	MRGPRX1	infectious disease	malaria, amebiasis	MicroSource, Selleck, Selleck, Selleck, Selleck, Selleck	98.06	CCN(CC)CCC[C@@H](C)Nc1ccnc2cc(Cl)ccc12 |&1:8|, CCN(CC)CCC[C@@H](C)Nc1ccnc2cc(Cl)ccc12 |&1:8|, CCN(CC)CCC[C@@H](C)Nc1ccnc2cc(Cl)ccc12 |&1:8|, CCN(CC)CCC[C@@H](C)Nc1ccnc2cc(Cl)ccc12 |&1:8|, CCN(CC)CCC[C@@H](C)Nc1ccnc2cc(Cl)ccc12 |&1:8|, CCN(CC)CCC[C@@H](C)Nc1ccnc2cc(Cl)ccc12 |&1:8|	Launched
chlorothiazide	diuretic	CA1, CA2, CA4, SLC12A3	cardiology	hypertension	MicroSource, MedChemEx, MedChemEx, Selleck	97.48	NS(=O)(=O)c1cc2c(cc1Cl)N=CNS2(=O)=O |c:12|, NS(=O)(=O)c1cc2c(cc1Cl)N=CNS2(=O)=O |c:12|, NS(=O)(=O)c1cc2c(cc1Cl)N=CNS2(=O)=O |c:12|, NS(=O)(=O)c1cc2c(cc1Cl)N=CNS2(=O)=O |c:12|	Launched
chlorothymol					Sigma, Enamine	18.51	CC(C)c1cc(Cl)c(C)cc1O, CC(C)c1cc(Cl)c(C)cc1O	Launched
chlorotrianisene	estrogenic hormone	ESR1, ESR2	endocrinology, oncology	menopause, prostate cancer	Sigma, Prestwick, Prestwick, Prestwick	98.18	COc1ccc(cc1)C(Cl)=C(c1ccc(OC)cc1)c1ccc(OC)cc1, COc1ccc(cc1)C(Cl)=C(c1ccc(OC)cc1)c1ccc(OC)cc1, COc1ccc(cc1)C(Cl)=C(c1ccc(OC)cc1)c1ccc(OC)cc1, COc1ccc(cc1)C(Cl)=C(c1ccc(OC)cc1)c1ccc(OC)cc1	Launched
chloroxine	opioid receptor antagonist	OPRK1	gastroenterology, infectious disease, dermatology	diarrhea, inflammatory bowel disease, giardiasis, dandruff	MicroSource, MicroSource, MicroSource, MicroSource, MicroSource, Selleck, Selleck, Selleck	99.48	Oc1c(Cl)cc(Cl)c2cccnc12, Oc1c(Cl)cc(Cl)c2cccnc12, Oc1c(Cl)cc(Cl)c2cccnc12, Oc1c(Cl)cc(Cl)c2cccnc12, Oc1c(Cl)cc(Cl)c2cccnc12, Oc1c(Cl)cc(Cl)c2cccnc12, Oc1c(Cl)cc(Cl)c2cccnc12, Oc1c(Cl)cc(Cl)c2cccnc12	Launched
chloroxoquinoline					Alinda	97.87	Clc1ccc2c(c1)[nH]ccc2=O	Launched
chloroxylenol	ATP synthase inhibitor		infectious disease	skin infections	MedChemEx, MicroSource	95.32	Cc1cc(O)cc(C)c1Cl, Cc1cc(O)cc(C)c1Cl	Launched
chlorphenamine	histamine receptor antagonist		allergy	allergic rhinitis, urticaria	MedChemEx	95.63	CN(C)CC[C@@H](c1ccc(Cl)cc1)c1ccccn1 |&1:5|	Launched
chlorphenesin	muscle relaxant		neurology/psychiatry	muscle relaxant, sedative	Sigma, Enamine	98.16	OC[C@@H](O)COc1ccc(Cl)cc1 |&1:2,r|, OC[C@@H](O)COc1ccc(Cl)cc1 |&1:2,r|	Launched
chlorphenoxamine	histamine receptor antagonist				MedChemEx	90	CN(C)CCO[C@@](C)(c1ccccc1)c1ccc(Cl)cc1 |r|	Preclinical
chlorphensin-carbamate	muscle relaxant		neurology/psychiatry	spasms	Prestwick	98.03	NC(=O)OC[C@@H](O)COc1ccc(Cl)cc1 |&1:5,r|	Launched
chlorproguanil	dihydrofolate reductase inhibitor	DHFR	infectious disease	malaria	AMS, AMS	97.98	CC(C)NC(=N)N=C(N)Nc1ccc(Cl)c(Cl)c1, CC(C)NC(=N)N=C(N)Nc1ccc(Cl)c(Cl)c1	Launched
chlorpromazine	dopamine receptor antagonist	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, CALM1, CHRM1, CHRM3, DRD1, DRD2, DRD3, DRD4, DRD5, HRH1, HRH4, HTR1A, HTR2A, HTR2B, HTR2C, HTR6, HTR7, KCNH2, ORM1, ORM2, SMPD1, TRPC5	neurology/psychiatry, gastroenterology, hematology, infectious disease	schizophrenia, nausea, vomiting, acute intermittent porphyria (AIP), tetanus	MicroSource, MicroSource, Selleck, Selleck, Selleck	97.33	CN(C)CCCN1c2ccccc2Sc2ccc(Cl)cc12, CN(C)CCCN1c2ccccc2Sc2ccc(Cl)cc12, CN(C)CCCN1c2ccccc2Sc2ccc(Cl)cc12, CN(C)CCCN1c2ccccc2Sc2ccc(Cl)cc12, CN(C)CCCN1c2ccccc2Sc2ccc(Cl)cc12	Launched
chlorpropamide	ATP channel blocker	ABCC8, KCNJ10	endocrinology	diabetes mellitus	MedChemEx, MicroSource, Selleck, Selleck, Selleck	98.37	CCCNC(=O)NS(=O)(=O)c1ccc(Cl)cc1, CCCNC(=O)NS(=O)(=O)c1ccc(Cl)cc1, CCCNC(=O)NS(=O)(=O)c1ccc(Cl)cc1, CCCNC(=O)NS(=O)(=O)c1ccc(Cl)cc1, CCCNC(=O)NS(=O)(=O)c1ccc(Cl)cc1	Launched
chlorpropham	antiviral				Sigma, Sigma	99.44	CC(C)OC(=O)Nc1cccc(Cl)c1, CC(C)OC(=O)Nc1cccc(Cl)c1	Phase 1
chlorprothixene	dopamine receptor antagonist	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD1, DRD2, DRD3, HRH1, HTR2A, HTR2B, HTR2C	neurology/psychiatry	schizophrenia, bipolar disorder	MedChemEx, MicroSource, Selleck, Selleck, Selleck, Selleck, Selleck	97.83	CN(C)CC\C=C1\c2ccccc2Sc2ccc(Cl)cc12, CN(C)CC\C=C1\c2ccccc2Sc2ccc(Cl)cc12, CN(C)CC\C=C1\c2ccccc2Sc2ccc(Cl)cc12, CN(C)CC\C=C1\c2ccccc2Sc2ccc(Cl)cc12, CN(C)CC\C=C1\c2ccccc2Sc2ccc(Cl)cc12, CN(C)CC\C=C1\c2ccccc2Sc2ccc(Cl)cc12, CN(C)CC\C=C1\c2ccccc2Sc2ccc(Cl)cc12	Launched
chlorpyrifos	acetylcholinesterase inhibitor	ACHE			MicroSource, MicroSource, Astatech	89.93	CCOP(=S)(OCC)Oc1nc(Cl)c(Cl)cc1Cl, CCOP(=S)(OCC)Oc1nc(Cl)c(Cl)cc1Cl, CCOP(=S)(OCC)Oc1nc(Cl)c(Cl)cc1Cl	Launched
chlorquinaldol	other antibiotic		infectious disease	fungal infection	MedChemEx, MedChemEx, MicroSource, Selleck, Selleck, Selleck, Selleck	96.93	Cc1ccc2c(Cl)cc(Cl)c(O)c2n1, Cc1ccc2c(Cl)cc(Cl)c(O)c2n1, Cc1ccc2c(Cl)cc(Cl)c(O)c2n1, Cc1ccc2c(Cl)cc(Cl)c(O)c2n1, Cc1ccc2c(Cl)cc(Cl)c(O)c2n1, Cc1ccc2c(Cl)cc(Cl)c(O)c2n1, Cc1ccc2c(Cl)cc(Cl)c(O)c2n1	Launched
chlortetracycline	protein synthesis inhibitor		ophthalmology	conjunctivitis	MedChemEx, MedChemEx	56.1	[H][C@@]12C[C@@]3([H])[C@H](C(=O)c4c(O)ccc(Cl)c4[C@@]3(C)O)C(=O)[C@]1(O)C(=O)[C@H](C(N)=O)C(=O)[C@H]2N(C)C |&1:25,&2:5|, [H][C@@]12C[C@@]3([H])[C@H](C(=O)c4c(O)ccc(Cl)c4[C@@]3(C)O)C(=O)[C@]1(O)C(=O)[C@H](C(N)=O)C(=O)[C@H]2N(C)C |&1:25,&2:5|	Launched
chlorthalidone	carbonic anhydrase inhibitor	CA1, CA12, CA14, CA2, CA4, CA7, SLC12A1	cardiology, gastroenterology, rheumatology, nephrology	hypertension, edema, congestive heart failure, hepatic cirrhosis, nephrotic syndrome, acute glomerulonephritis (AGN), chronic renal failure	MicroSource, MedChemEx, MedChemEx	98.01	NS(=O)(=O)c1cc(ccc1Cl)[C@@]1(O)NC(=O)c2ccccc12 |&1:11,r|, NS(=O)(=O)c1cc(ccc1Cl)[C@@]1(O)NC(=O)c2ccccc12 |&1:11,r|, NS(=O)(=O)c1cc(ccc1Cl)[C@@]1(O)NC(=O)c2ccccc12 |&1:11,r|	Launched
chlorzoxazone	bacterial 30S ribosomal subunit inhibitor	KCNMA1, KCNN4	neurology/psychiatry	muscle relaxant	MedChemEx, MicroSource, Selleck	100	Clc1ccc2oc(=O)[nH]c2c1, Clc1ccc2oc(=O)[nH]c2c1, Clc1ccc2oc(=O)[nH]c2c1	Launched
cholecalciferol		VDR	endocrinology	vitamin D deficiency	MicroSource, Selleck, Selleck, Selleck	92.35	CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C, CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C, CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C, CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C	Launched
cholesterol		RORA			MedChemEx	0	CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C |t:14|	Preclinical
cholic-acid	bile acid	ADH1C, CES1, COX4I1, COX5A, COX5B, COX6A2, COX6B1, COX6C, COX7A1, COX7B, COX7C, COX8A, ESRRG, FABP6, FECH, GPBAR1, MT-CO1, MT-CO2, MT-CO3, PLA2G1B	gastroenterology, neurology/psychiatry, genetics	bile acid synthesis disorders, peroxisomal disorders, Zellweger syndrome	MedChemEx, Enzo	100	C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3C[C@H](O)[C@]12C, C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3C[C@H](O)[C@]12C	Launched
choline	acetylcholine precursor	ACHE, BCHE, CHRNA2, PCYT1A, PCYT1B, PHOSPHO1, PLD1, PLD2			MicroSource, Selleck, MedChemEx	100	C[N+](C)(C)CCO, C[N+](C)(C)CCO, C[N+](C)(C)CCO	Phase 3
choline-alfoscerate	acetylcholine precursor				MedChemEx	100	C[N+](C)(C)CCOP(O)(=O)OC[C@H](O)CO	Launched
CHPG	glutamate receptor agonist	GRM5			Tocris, Tocris, Tocris	1.5	N[C@@H](C(O)=O)c1cc(O)ccc1Cl |&1:1,r|, N[C@@H](C(O)=O)c1cc(O)ccc1Cl |&1:1,r|, N[C@@H](C(O)=O)c1cc(O)ccc1Cl |&1:1,r|	Preclinical
CHR-6494	serine/threonine kinase inhibitor	GSG2			Tocris, Tocris, Tocris, MedChemEx, MedChemEx	99.14	CCCNc1ccc2ncc(-c3ccc4n[nH]cc4c3)n2n1, CCCNc1ccc2ncc(-c3ccc4n[nH]cc4c3)n2n1, CCCNc1ccc2ncc(-c3ccc4n[nH]cc4c3)n2n1, CCCNc1ccc2ncc(-c3ccc4n[nH]cc4c3)n2n1, CCCNc1ccc2ncc(-c3ccc4n[nH]cc4c3)n2n1	Preclinical
chromanol-(+/-)	potassium channel blocker				Tocris	98.74	CCS(=O)(=O)N(C)[C@@H]1[C@@H](O)C(C)(C)Oc2ccc(cc12)C#N.CCS(=O)(=O)N(C)[C@H]1[C@H](O)C(C)(C)Oc2ccc(cc12)C#N	Preclinical
chromanol-293B-(-)-[3R,4S]	potassium channel blocker				Tocris, Tocris	99.19	CCS(=O)(=O)N(C)[C@@H]1[C@@H](O)C(C)(C)Oc2ccc(cc12)C#N, CCS(=O)(=O)N(C)[C@@H]1[C@@H](O)C(C)(C)Oc2ccc(cc12)C#N	Preclinical
chromium-picolinate	insulin sensitizer		endocrinology	diabetes mellitus	Sigma, Vitas-M	99.23	O=C(O[Cr](OC(=O)c1ccccn1)OC(=O)c1ccccn1)c1ccccn1, O=C(O[Cr](OC(=O)c1ccccn1)OC(=O)c1ccccn1)c1ccccn1	Launched
chromocarb	antispasmodic				MedChemEx, MicroSource, MicroSource, Selleck	97.98	OC(=O)c1cc(=O)c2ccccc2o1, OC(=O)c1cc(=O)c2ccccc2o1, OC(=O)c1cc(=O)c2ccccc2o1, OC(=O)c1cc(=O)c2ccccc2o1	Launched
chrysin	breast cancer resistance protein inhibitor	AKR1B1, CDK6, CYP19A1, CYP1B1			MedChemEx, Selleck, Selleck, Selleck	99.22	Oc1cc(O)c2c(c1)oc(cc2=O)-c1ccccc1, Oc1cc(O)c2c(c1)oc(cc2=O)-c1ccccc1, Oc1cc(O)c2c(c1)oc(cc2=O)-c1ccccc1, Oc1cc(O)c2c(c1)oc(cc2=O)-c1ccccc1	Phase 1
chrysophanic-acid	EGFR inhibitor	EGFR, MTOR			MedChemEx, Selleck	96.2	Cc1cc(O)c2C(=O)c3c(O)cccc3C(=O)c2c1, Cc1cc(O)c2C(=O)c3c(O)cccc3C(=O)c2c1	Preclinical
chuanxiongzine					MedChemEx, Enzo	97.8	Cc1nc(C)c(C)nc1C, Cc1nc(C)c(C)nc1C	Phase 2
CH223191	aryl hydrocarbon receptor antagonist	AHR			Tocris	97.94	Cc1ccccc1\N=N\c1ccc(NC(=O)c2ccnn2C)c(C)c1	Preclinical
CH5132799	PI3K inhibitor	MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG			Selleck, Selleck, Selleck, MedChemEx	94.91	CS(=O)(=O)N1CCc2c1nc(nc2-c1cnc(N)nc1)N1CCOCC1, CS(=O)(=O)N1CCc2c1nc(nc2-c1cnc(N)nc1)N1CCOCC1, CS(=O)(=O)N1CCc2c1nc(nc2-c1cnc(N)nc1)N1CCOCC1, CS(=O)(=O)N1CCc2c1nc(nc2-c1cnc(N)nc1)N1CCOCC1	Phase 1
CH55	retinoid receptor binder	RARA, RARB			Tocris, Tocris	92.13	CC(C)(C)c1cc(cc(c1)C(C)(C)C)C(=O)\C=C\c1ccc(cc1)C(O)=O, CC(C)(C)c1cc(cc(c1)C(C)(C)C)C(=O)\C=C\c1ccc(cc1)C(O)=O	Preclinical
CI-844					ChemImpex	98.44	O(c1ccccc1)c1cccnc1	Phase 2
CI-923	acetylcholine receptor antagonist				Sigma, Sigma	86.83	CCN[C@@H](C)CN1CCc2c(C1)c(=O)oc1ccccc21 |&1:3,r|, CCN[C@@H](C)CN1CCc2c(C1)c(=O)oc1ccccc21 |&1:3,r|	Phase 1
CI-953	voltage-gated sodium channel blocker				MedChemEx	96.48	Cc1cccc(Cl)c1NC(=O)Nc1ccncc1	Phase 1
CI-966	GAT inhibitor	SLC6A1			Tocris, Tocris, Tocris, Tocris	98.04	OC(=O)C1=CCCN(CCOC(c2ccc(cc2)C(F)(F)F)c2ccc(cc2)C(F)(F)F)C1 |t:3|, OC(=O)C1=CCCN(CCOC(c2ccc(cc2)C(F)(F)F)c2ccc(cc2)C(F)(F)F)C1 |t:3|, OC(=O)C1=CCCN(CCOC(c2ccc(cc2)C(F)(F)F)c2ccc(cc2)C(F)(F)F)C1 |t:3|, OC(=O)C1=CCCN(CCOC(c2ccc(cc2)C(F)(F)F)c2ccc(cc2)C(F)(F)F)C1 |t:3|	Phase 1
CI-976	ACAT inhibitor	ACAT1, CES1			Tocris, Tocris, Tocris, Tocris, Tocris, Tocris, Tocris	98.4	CCCCCCCCCCC(C)(C)C(=O)Nc1c(OC)cc(OC)cc1OC, CCCCCCCCCCC(C)(C)C(=O)Nc1c(OC)cc(OC)cc1OC, CCCCCCCCCCC(C)(C)C(=O)Nc1c(OC)cc(OC)cc1OC, CCCCCCCCCCC(C)(C)C(=O)Nc1c(OC)cc(OC)cc1OC, CCCCCCCCCCC(C)(C)C(=O)Nc1c(OC)cc(OC)cc1OC, CCCCCCCCCCC(C)(C)C(=O)Nc1c(OC)cc(OC)cc1OC, CCCCCCCCCCC(C)(C)C(=O)Nc1c(OC)cc(OC)cc1OC	Phase 1
ciaftalan-zinc	reactive oxygen species stimulant				Sigma	22.93	[Zn]1n2c3\N=C4/N=C(/N=c5\n1\c(=N/C1=N/C(=N\c2c2ccccc32)/c2ccccc12)c1ccccc51)c1ccccc41 |c:3,7,11,15,t:5,13|	Phase 1
cianidanol	fatty acid synthase inhibitor	PTGS1			MicroSource, MedChemEx	99.09	O[C@H]1Cc2c(O)cc(O)cc2O[C@@H]1c1ccc(O)c(O)c1, O[C@H]1Cc2c(O)cc(O)cc2O[C@@H]1c1ccc(O)c(O)c1	Withdrawn
cibenzoline	sodium channel blocker		cardiology	cardiac arrythmia	Sigma, Sigma, Sigma	98.93	C1[C@@H](C2=NCCN2)C1(c1ccccc1)c1ccccc1 |r,t:2|, C1[C@@H](C2=NCCN2)C1(c1ccccc1)c1ccccc1 |r,t:2|, C1[C@@H](C2=NCCN2)C1(c1ccccc1)c1ccccc1 |r,t:2|	Launched
ciclesonide	glucocorticoid receptor agonist	NR3C1, SERPINA6	allergy	allergic rhinitis	Tocris, Enzo, Enzo, Enzo	98.53	CC(C)C(=O)OCC(=O)[C@@]12O[C@@H](O[C@@H]1C[C@H]1[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]21C)C1CCCCC1 |c:24,t:20|, CC(C)C(=O)OCC(=O)[C@@]12O[C@@H](O[C@@H]1C[C@H]1[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]21C)C1CCCCC1 |c:24,t:20|, CC(C)C(=O)OCC(=O)[C@@]12O[C@@H](O[C@@H]1C[C@H]1[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]21C)C1CCCCC1 |c:24,t:20|, CC(C)C(=O)OCC(=O)[C@@]12O[C@@H](O[C@@H]1C[C@H]1[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]21C)C1CCCCC1 |c:24,t:20|	Launched
ciclopirox	membrane integrity inhibitor	ATP1A1	infectious disease	onychomycosis	MicroSource, Selleck, Sigma, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck	93.13	Cc1cc(C2CCCCC2)n(O)c(=O)c1, Cc1cc(C2CCCCC2)n(O)c(=O)c1, Cc1cc(C2CCCCC2)n(O)c(=O)c1, Cc1cc(C2CCCCC2)n(O)c(=O)c1, Cc1cc(C2CCCCC2)n(O)c(=O)c1, Cc1cc(C2CCCCC2)n(O)c(=O)c1, Cc1cc(C2CCCCC2)n(O)c(=O)c1, Cc1cc(C2CCCCC2)n(O)c(=O)c1, Cc1cc(C2CCCCC2)n(O)c(=O)c1	Launched
cicloprofen	cyclooxygenase inhibitor	PTGS1, PTGS2			Enamine, Enamine	95.97	C[C@@H](C(O)=O)c1ccc-2c(Cc3ccccc-23)c1 |&1:1,r|, C[C@@H](C(O)=O)c1ccc-2c(Cc3ccccc-23)c1 |&1:1,r|	Preclinical
CID-16020046	G protein-coupled receptor antagonist	GPR55			Tocris	98.42	Cc1ccc(cc1)-c1n[nH]c2C(=O)N([C@H](c12)c1cccc(O)c1)c1ccc(cc1)C(O)=O |&1:14,r|	Preclinical
CID-2011756	protein kinase inhibitor	PKD1			Tocris, Tocris	98.57	Clc1cccc(c1)-c1ccc(o1)C(=O)Nc1ccc(CN2CCOCC2)cc1, Clc1cccc(c1)-c1ccc(o1)C(=O)Nc1ccc(CN2CCOCC2)cc1	Preclinical
CID-2745687	G protein-coupled receptor antagonist	GPR35			Tocris, Tocris	95.19	COC(=O)c1cnn(c1\C=N\NC(=S)NC(C)(C)C)-c1ccc(F)cc1F, COC(=O)c1cnn(c1\C=N\NC(=S)NC(C)(C)C)-c1ccc(F)cc1F	Preclinical
CID-5458317	MAP kinase phosphatase inhibitor	MAPK3			EMDBio, EMDBio	96.86	OC1=c2ccccc2=C(NC2CCCCC2)\C1=C/c1ccccc1 |c:1,t:8|, OC1=c2ccccc2=C(NC2CCCCC2)\C1=C/c1ccccc1 |c:1,t:8|	Preclinical
cidofovir	DNA polymerase inhibitor		infectious disease	acquired immunodeficiency syndrome (AIDS), cytomegalovirus retinitis	Selleck, Selleck, MedChemEx	100	Nc1ccn(C[C@@H](CO)OCP(O)(O)=O)c(=O)n1, Nc1ccn(C[C@@H](CO)OCP(O)(O)=O)c(=O)n1, Nc1ccn(C[C@@H](CO)OCP(O)(O)=O)c(=O)n1	Launched
ciglitazone	PPAR receptor agonist	PPARG			Tocris, Tocris, Tocris	96.7	CC1(COc2ccc(C[C@H]3SC(=O)NC3=O)cc2)CCCCC1 |r|, CC1(COc2ccc(C[C@H]3SC(=O)NC3=O)cc2)CCCCC1 |r|, CC1(COc2ccc(C[C@H]3SC(=O)NC3=O)cc2)CCCCC1 |r|	Phase 2
cilastatin	dehydropeptidase inhibitor	DPEP1			AvaChem, Tocris	0	CC1(C)C[C@@H]1C(=O)N\C(=C/CCCCSC[C@H](N)C(O)=O)C(O)=O, CC1(C)C[C@@H]1C(=O)N\C(=C/CCCCSC[C@H](N)C(O)=O)C(O)=O	Launched
cilazapril	angiotensin converting enzyme inhibitor	ACE	cardiology	hypertension, congestive heart failure	MedChemEx, MedChemEx	97.44	CCOC(=O)[C@H](CCc1ccccc1)N[C@H]1CCCN2CCC[C@H](N2C1=O)C(O)=O, CCOC(=O)[C@H](CCc1ccccc1)N[C@H]1CCCN2CCC[C@H](N2C1=O)C(O)=O	Launched
cilengitide	integrin antagonist	ITGAV, ITGB3			Selleck, Selleck, Selleck	96.22	CC(C)[C@@H]1N(C)C(=O)[C@@H](Cc2ccccc2)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CCCNC(N)=N)NC1=O, CC(C)[C@@H]1N(C)C(=O)[C@@H](Cc2ccccc2)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CCCNC(N)=N)NC1=O, CC(C)[C@@H]1N(C)C(=O)[C@@H](Cc2ccccc2)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CCCNC(N)=N)NC1=O	Phase 3
cilnidipine	calcium channel blocker	CACNA1B	cardiology	hypertension	Tocris, Tocris	98.22	COCCOC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC\C=C\c1ccccc1 |&1:14,r,c:7,12|, COCCOC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC\C=C\c1ccccc1 |&1:14,r,c:7,12|	Launched
cilofexor	FXR agonist				MedChemEx	94.88	OC(=O)c1ccnc(c1)N1CC(O)(C1)c1ccc(OCc2c(onc2-c2c(Cl)cccc2Cl)C2CC2)cc1Cl	Phase 3
cilomilast	phosphodiesterase inhibitor	PDE4A, PDE4B, PDE4D			MedChemEx	89.36	COc1ccc(cc1OC1CCCC1)[C@]1(CC[C@@H](CC1)C(O)=O)C#N |r|	Phase 3
cilostamide	phosphodiesterase inhibitor	PDE3A, PDE3B			Tocris, Tocris, Tocris	95.91	CN(C1CCCCC1)C(=O)CCCOc1ccc2[nH]c(=O)ccc2c1, CN(C1CCCCC1)C(=O)CCCOc1ccc2[nH]c(=O)ccc2c1, CN(C1CCCCC1)C(=O)CCCOc1ccc2[nH]c(=O)ccc2c1	Preclinical
cilostazol	phosphodiesterase inhibitor	PDE3A, PDE3B	cardiology	claudication	MicroSource, MicroSource, Tocris, Selleck, Selleck, Tocris	98.71	O=C1CCc2cc(OCCCCc3nnnn3C3CCCCC3)ccc2N1, O=C1CCc2cc(OCCCCc3nnnn3C3CCCCC3)ccc2N1, O=C1CCc2cc(OCCCCc3nnnn3C3CCCCC3)ccc2N1, O=C1CCc2cc(OCCCCc3nnnn3C3CCCCC3)ccc2N1, O=C1CCc2cc(OCCCCc3nnnn3C3CCCCC3)ccc2N1, O=C1CCc2cc(OCCCCc3nnnn3C3CCCCC3)ccc2N1	Launched
ciluprevir	serine protease inhibitor				Adooq, Adooq	0	COc1ccc2c(O[C@@H]3C[C@@H]4N(C3)C(=O)[C@H](CCCCC\C=C/[C@@H]3C[C@]3(NC4=O)C(O)=O)NC(=O)OC3CCCC3)cc(nc2c1)-c1csc(NC(C)C)n1 |c:22|, COc1ccc2c(O[C@@H]3C[C@@H]4N(C3)C(=O)[C@H](CCCCC\C=C/[C@@H]3C[C@]3(NC4=O)C(O)=O)NC(=O)OC3CCCC3)cc(nc2c1)-c1csc(NC(C)C)n1 |c:22|	Preclinical
CIM-0216	transient receptor potential channel agonist	TRPM3			Tocris, Tocris, Tocris	96.8	Cc1cc(NC(=O)[C@@H](N2CCCc3ccccc23)c2ccccc2)no1 |&1:7,r|, Cc1cc(NC(=O)[C@@H](N2CCCc3ccccc23)c2ccccc2)no1 |&1:7,r|, Cc1cc(NC(=O)[C@@H](N2CCCc3ccccc23)c2ccccc2)no1 |&1:7,r|	Preclinical
cimaterol	adrenergic receptor agonist	ADRB1, ADRB2, ADRB3			Tocris, Tocris	96.13	CC(C)NC[C@@H](O)c1ccc(N)c(c1)C#N |&1:5,r|, CC(C)NC[C@@H](O)c1ccc(N)c(c1)C#N |&1:5,r|	Preclinical
cimetidine	histamine receptor antagonist	HRH2, SLC29A4, SLC47A1, SLC47A2	gastroenterology, hematologic malignancy, endocrinology	duodenal ulcer disease, peptic ulcer disease (PUD), gastroesophageal reflux disease (GERD), aggressive systemic mastocytosis (ASM), Zollinger-Ellison syndrome, endocrine adenoma	Tocris, Tocris, Selleck, Selleck, MicroSource	99.16	CN\C(NCCSCc1[nH]cnc1C)=N/C#N, CN\C(NCCSCc1[nH]cnc1C)=N/C#N, CN\C(NCCSCc1[nH]cnc1C)=N/C#N, CN\C(NCCSCc1[nH]cnc1C)=N/C#N, CN\C(NCCSCc1[nH]cnc1C)=N/C#N	Launched
cimetropium	acetylcholine receptor antagonist	CHRM1	gastroenterology	irritable bowel syndrome	Sigma	93.27	C[N@@+]1(CC2CC2)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)c1ccccc1 |a:6,8,10,11,13,17,&1:1,TLB:0:1:7.8.9:11.13,THB:2:1:7.8.9:11.13,12:11:1:7.8.9,12:13:1:7.8.9,14:8:1:11.13|	Launched
cinacalcet	calcium channel activator	CASR	endocrinology, nephrology, oncology	hyperparathyroidism, chronic kidney disease (CKD), parathyroid carcinoma, hypercalcemia	Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck	99.3	C[C@@H](NCCCc1cccc(c1)C(F)(F)F)c1cccc2ccccc12, C[C@@H](NCCCc1cccc(c1)C(F)(F)F)c1cccc2ccccc12, C[C@@H](NCCCc1cccc(c1)C(F)(F)F)c1cccc2ccccc12, C[C@@H](NCCCc1cccc(c1)C(F)(F)F)c1cccc2ccccc12, C[C@@H](NCCCc1cccc(c1)C(F)(F)F)c1cccc2ccccc12, C[C@@H](NCCCc1cccc(c1)C(F)(F)F)c1cccc2ccccc12, C[C@@H](NCCCc1cccc(c1)C(F)(F)F)c1cccc2ccccc12	Launched
cinaciguat	guanylate cyclase activator	GUCY1A3, GUCY1B3			Tocris, MedChemEx, MedChemEx	97.86	OC(=O)CCCCN(CCc1ccccc1OCc1ccc(CCc2ccccc2)cc1)Cc1ccc(cc1)C(O)=O, OC(=O)CCCCN(CCc1ccccc1OCc1ccc(CCc2ccccc2)cc1)Cc1ccc(cc1)C(O)=O, OC(=O)CCCCN(CCc1ccccc1OCc1ccc(CCc2ccccc2)cc1)Cc1ccc(cc1)C(O)=O	Phase 2
cinalukast	leukotriene receptor antagonist	CYSLTR1			Tocris, Tocris, Tocris	92.06	CCC(CC)(CC(=O)Nc1cccc(\C=C\c2nc(cs2)C2CCC2)c1)C(O)=O, CCC(CC)(CC(=O)Nc1cccc(\C=C\c2nc(cs2)C2CCC2)c1)C(O)=O, CCC(CC)(CC(=O)Nc1cccc(\C=C\c2nc(cs2)C2CCC2)c1)C(O)=O	Phase 2
cinanserin	serotonin receptor antagonist	HTR2A			Tocris, Tocris	97.64	CN(C)CCCSc1ccccc1NC(=O)\C=C\c1ccccc1, CN(C)CCCSc1ccccc1NC(=O)\C=C\c1ccccc1	Preclinical
cinchocaine	sodium channel blocker	CALM1, SCN10A, SCN5A	neurology/psychiatry	local anesthetic	MicroSource, MedChemEx, Selleck	97.32	CCCCOc1cc(C(=O)NCCN(CC)CC)c2ccccc2n1, CCCCOc1cc(C(=O)NCCN(CC)CC)c2ccccc2n1, CCCCOc1cc(C(=O)NCCN(CC)CC)c2ccccc2n1	Launched
cinchonidine	P glycoprotein inhibitor				MicroSource, MicroSource, MedChemEx, Selleck	93.36	O[C@@H]([C@@H]1C[C@@H]2CC[N@]1C[C@@H]2C=C)c1ccnc2ccccc12, O[C@@H]([C@@H]1C[C@@H]2CC[N@]1C[C@@H]2C=C)c1ccnc2ccccc12, O[C@@H]([C@@H]1C[C@@H]2CC[N@]1C[C@@H]2C=C)c1ccnc2ccccc12, O[C@@H]([C@@H]1C[C@@H]2CC[N@]1C[C@@H]2C=C)c1ccnc2ccccc12	Phase 1
cinchonine	P glycoprotein inhibitor	CYP2D6			MedChemEx	85.43	O[C@H]([C@H]1C[C@@H]2CC[N@]1C[C@@H]2C=C)c1ccnc2ccccc12	Preclinical
cinchophen	analgesic agent		rheumatology	gout	MedChemEx, MicroSource, Selleck	99.45	OC(=O)c1cc(nc2ccccc12)-c1ccccc1, OC(=O)c1cc(nc2ccccc12)-c1ccccc1, OC(=O)c1cc(nc2ccccc12)-c1ccccc1	Launched
cinepazet	vasodilator				Sigma	95.1	CCOC(=O)CN1CCN(CC1)C(=O)\C=C\c1cc(OC)c(OC)c(OC)c1	Launched
cinepazide	calcium channel activator				MedChemEx, Selleck, Selleck	99.15	COc1cc(\C=C\C(=O)N2CCN(CC(=O)N3CCCC3)CC2)cc(OC)c1OC, COc1cc(\C=C\C(=O)N2CCN(CC(=O)N3CCCC3)CC2)cc(OC)c1OC, COc1cc(\C=C\C(=O)N2CCN(CC(=O)N3CCCC3)CC2)cc(OC)c1OC	Withdrawn
cinflumide	muscle relaxant				Enamine	89.23	Fc1cccc(\C=C\C(=O)NC2CC2)c1	Phase 2
cinnamaldehyde	aldose reductase inhibitor, TRPV agonist	TRPA1			MedChemEx	86.3	O=C\C=C\c1ccccc1	Preclinical
cinnarazine	calcium channel blocker		neurology/psychiatry, gastroenterology, ophthalmology	Meniere's disease, nausea, vomiting, Cogan's syndrome	MedChemEx, MicroSource, ChemDiv, ChemDiv	98.35	C(\C=C\c1ccccc1)N1CCN(CC1)C(c1ccccc1)c1ccccc1, C(\C=C\c1ccccc1)N1CCN(CC1)C(c1ccccc1)c1ccccc1, C(\C=C\c1ccccc1)N1CCN(CC1)C(c1ccccc1)c1ccccc1, C(\C=C\c1ccccc1)N1CCN(CC1)C(c1ccccc1)c1ccccc1	Launched
cinobufotalin	anticancer agent				MedChemEx	89.74	[H][C@@]12CC[C@]3(O)C[C@@H](O)CC[C@]3(C)[C@@]1([H])CC[C@]1(C)[C@H]([C@@H](OC(C)=O)[C@H]3O[C@@]213)c1ccc(=O)oc1	Phase 1
cinoctramide					MicroSource, MedChemEx	95.05	COc1cc(\C=C\C(=O)N2CCCCCCC2)cc(OC)c1OC, COc1cc(\C=C\C(=O)N2CCCCCCC2)cc(OC)c1OC	Preclinical
cinoxacin	topoisomerase inhibitor		infectious disease	urinary tract infections	MicroSource, Selleck	93.53	CCn1nc(C(O)=O)c(=O)c2cc3OCOc3cc12, CCn1nc(C(O)=O)c(=O)c2cc3OCOc3cc12	Launched
cinoxate			dermatology	sunscreen lotion	Sigma, Enamine, Enamine	95.2	CCOCCOC(=O)\C=C\c1ccc(OC)cc1, CCOCCOC(=O)\C=C\c1ccc(OC)cc1, CCOCCOC(=O)\C=C\c1ccc(OC)cc1	Launched
CINPA-1	CAR antagonist	NR1H4, NR1I3, PPARG			Tocris, Tocris	94.15	CCOC(=O)Nc1ccc2CCc3ccccc3N(C(=O)CN(CC)CC)c2c1, CCOC(=O)Nc1ccc2CCc3ccccc3N(C(=O)CN(CC)CC)c2c1	Preclinical
cinromide					MicroSource, MedChemEx	99.12	CCNC(=O)\C=C\c1cccc(Br)c1, CCNC(=O)\C=C\c1cccc(Br)c1	Phase 3
cintirorgon	ROR agonist				MedChemEx	95.2	CC(C)(C[C@H]1CN(c2cc(ccc2O1)-c1cc(F)cc(OC(F)F)c1)S(=O)(=O)c1cccc(c1)C(F)(F)F)C(O)=O	Phase 1/Phase 2
cintriamide					MicroSource	97.46	COc1cc(\C=C\C(N)=O)cc(OC)c1OC	Preclinical
cipamfylline	phosphodiesterase inhibitor				Sigma	85.94	Nc1nc2n(CC3CC3)c(=O)n(CC3CC3)c(=O)c2[nH]1	Phase 2
cipargamin	antimalarial agent				MedChemEx	95.43	C[C@H]1Cc2c([nH]c3cc(Cl)c(F)cc23)[C@@]2(N1)C(=O)Nc1ccc(Cl)cc21	Phase 2
cipemastat	metalloproteinase inhibitor	ADAM17, MMP1, MMP13, MMP2, MMP3, MMP8, MMP9			Tocris	86.65	CN1C(=O)N(C[C@@H]([C@@H](CC2CCCC2)C(=O)N2CCCCC2)C(=O)NO)C(=O)C1(C)C	Phase 3
ciprofibrate	PPAR receptor agonist	PPARA	endocrinology	hyperlipidemia	MicroSource, MicroSource, Selleck	96.78	CC(C)(Oc1ccc(cc1)[C@H]1CC1(Cl)Cl)C(O)=O |&1:10,r|, CC(C)(Oc1ccc(cc1)[C@H]1CC1(Cl)Cl)C(O)=O |&1:10,r|, CC(C)(Oc1ccc(cc1)[C@H]1CC1(Cl)Cl)C(O)=O |&1:10,r|	Launched
ciprofloxacin	bacterial DNA gyrase inhibitor	TOP2A	otolaryngology	otitis	MicroSource, Selleck, Selleck	98.2	OC(=O)c1cn(C2CC2)c2cc(N3CCNCC3)c(F)cc2c1=O, OC(=O)c1cn(C2CC2)c2cc(N3CCNCC3)c(F)cc2c1=O, OC(=O)c1cn(C2CC2)c2cc(N3CCNCC3)c(F)cc2c1=O	Launched
ciproxifan	histamine receptor antagonist	ADRA2A, ADRA2C, HRH3, HRH4, HTR3A			MedChemEx, Selleck	98.18	O=C(C1CC1)c1ccc(OCCCc2cnc[nH]2)cc1, O=C(C1CC1)c1ccc(OCCCc2cnc[nH]2)cc1	Preclinical
CIQ	glutamate receptor potentiator	GRIN2C, GRIN2D			Tocris, Sigma, Sigma	99.27	COc1ccc(OC[C@H]2N(CCc3cc(OC)c(OC)cc23)C(=O)c2cccc(Cl)c2)cc1 |&1:8,r|, COc1ccc(OC[C@H]2N(CCc3cc(OC)c(OC)cc23)C(=O)c2cccc(Cl)c2)cc1 |&1:8,r|, COc1ccc(OC[C@H]2N(CCc3cc(OC)c(OC)cc23)C(=O)c2cccc(Cl)c2)cc1 |&1:8,r|	Preclinical
cirazoline	adrenergic receptor agonist	ADRA1A			Tocris, Tocris	92.59	C(Oc1ccccc1C1CC1)C1=NCCN1 |t:13|, C(Oc1ccccc1C1CC1)C1=NCCN1 |t:13|	Preclinical
cis-aconitic-acid		ACO2			Enamine	0	OC(=O)C\C(=C\C(O)=O)C(O)=O	Preclinical
cis-ACPD	glutamate receptor agonist	GRM2, GRM3, GRM6, GRM7, GRM8			Tocris	100	[H][C@]1(CC[C@@](N)(C1)C(O)=O)C(O)=O |&1:1,4,r|	Preclinical
cis-exo-camphanediol-2,3	nitric oxide stimulant	NOS3			Sigma	0	CC1(C)[C@H]2CC[C@]1(C)[C@@H](O)[C@H]2O	Phase 1
cis-urocanic-acid	serotonin receptor agonist	HTR2A			Enamine, Enamine, Enamine, Sigma	100	OC(=O)\C=C\c1cnc[nH]1, OC(=O)\C=C\c1cnc[nH]1, OC(=O)\C=C\c1cnc[nH]1, OC(=O)\C=C/c1cnc[nH]1	Phase 2
cis-9,trans-11-conjugated-linoleic-acid					Enzo, Enzo, Sigma	96.37	CCCCCC\C=C\C=C/CCCCCCCC(O)=O, CCCCCC\C=C\C=C/CCCCCCCC(O)=O, CCCCCC\C=C\C=C/CCCCCCCC(O)=O	Launched
cisapride	serotonin receptor agonist	HTR2A, HTR3A, HTR4, KCNH2			Tocris, Tocris, Tocris	98.57	CO[C@H]1CN(CCCOc2ccc(F)cc2)CC[C@H]1NC(=O)c1cc(Cl)c(N)cc1OC, CO[C@H]1CN(CCCOc2ccc(F)cc2)CC[C@H]1NC(=O)c1cc(Cl)c(N)cc1OC, CO[C@H]1CN(CCCOc2ccc(F)cc2)CC[C@H]1NC(=O)c1cc(Cl)c(N)cc1OC	Withdrawn
cisatracurium	acetylcholine receptor antagonist	CHRNA2	neurology/psychiatry, critical care	muscle relaxant, endotracheal intubation	MedChemEx, Selleck, Selleck	88.16	COc1ccc(C[C@@H]2c3cc(OC)c(OC)cc3CC[N@+]2(C)CCC(=O)OCCCCCOC(=O)CC[N@@+]2(C)CCc3cc(OC)c(OC)cc3[C@H]2Cc2ccc(OC)c(OC)c2)cc1OC, COc1ccc(C[C@@H]2c3cc(OC)c(OC)cc3CC[N@+]2(C)CCC(=O)OCCCCCOC(=O)CC[N@@+]2(C)CCc3cc(OC)c(OC)cc3[C@H]2Cc2ccc(OC)c(OC)c2)cc1OC, COc1ccc(C[C@@H]2c3cc(OC)c(OC)cc3CC[N@+]2(C)CCC(=O)OCCCCCOC(=O)CC[N@@+]2(C)CCc3cc(OC)c(OC)cc3[C@H]2Cc2ccc(OC)c(OC)c2)cc1OC	Launched
cisplatin	DNA alkylating agent, DNA synthesis inhibitor	XIAP	oncology	testicular carcinoma, ovarian cancer, bladder cancer	MicroSource, Selleck, Tocris, Selleck, Selleck	0	N[Pt](N)(Cl)Cl, N[Pt](N)(Cl)Cl, N[Pt](N)(Cl)Cl, N[Pt](N)(Cl)Cl, N[Pt](N)(Cl)Cl	Launched
citalopram	selective serotonin reuptake inhibitor (SSRI)	ADRA1A, CHRM1, HRH1, SLC6A2, SLC6A3, SLC6A4	neurology/psychiatry	depression	MicroSource, Enamine, Tocris	97.27	CN(C)CCC[C@]1(OCc2cc(ccc12)C#N)c1ccc(F)cc1 |&1:6|, CN(C)CCC[C@]1(OCc2cc(ccc12)C#N)c1ccc(F)cc1 |&1:6|, CN(C)CCC[C@]1(OCc2cc(ccc12)C#N)c1ccc(F)cc1 |&1:6|	Launched
citarinostat	HDAC inhibitor				MedChemEx	96.59	ONC(=O)CCCCCCNC(=O)c1cnc(nc1)N(c1ccccc1)c1ccccc1Cl	Phase 1
CITCO	constitutive androstane receptor (CAR) agonist	NR1I3			Tocris, Tocris, Tocris, Tocris	98.06	Clc1ccc(cc1)-c1nc2sccn2c1\C=N\OCc1ccc(Cl)c(Cl)c1, Clc1ccc(cc1)-c1nc2sccn2c1\C=N\OCc1ccc(Cl)c(Cl)c1, Clc1ccc(cc1)-c1nc2sccn2c1\C=N\OCc1ccc(Cl)c(Cl)c1, Clc1ccc(cc1)-c1nc2sccn2c1\C=N\OCc1ccc(Cl)c(Cl)c1	Preclinical
citicoline	glutathione transferase stimulant, membrane permeability enhancer	ACHE, SLC1A2	neurology/psychiatry, ophthalmology	stroke, Alzheimer's disease, senile dementia, Parkinson's Disease, attention-deficit/hyperactivity disorder (ADHD), glaucoma	MicroSource, MicroSource, Cayman	100	C[N+](C)(C)CCOP(O)(=O)OP(O)(=O)OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1ccc(N)nc1=O |a:16,18,19,21,&1:7,&2:11|, C[N+](C)(C)CCOP(O)(=O)OP(O)(=O)OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1ccc(N)nc1=O |a:16,18,19,21,&1:7,&2:11|, C[N+](C)(C)CCOP(O)(=O)OP(O)(=O)OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1ccc(N)nc1=O |a:16,18,19,21,&1:7,&2:11|	Launched
citiolone	lipotropic, mucolytic agent				MicroSource	94.67	CC(=O)N[C@H]1CCSC1=O |&1:4,r|	Preclinical
citric-acid	coagulation factor inhibitor	AKR1B1, ANG, APRT, BHMT, C8G, CA4, CPB1, CS, CTDSP1, GNMT, HGS, HS3ST3A1, IL4I1, ITPA, LSM6, MDH2, MIF, PDE5A, PKD2L1, PLEKHA1, RNASE1, RNASE3, SRC, TNFSF13B, UCK2			Sigma	0	OC(=O)CC(O)(CC(O)=O)C(O)=O	Preclinical
CJ-033466	serotonin receptor agonist	HTR4			Tocris, Tocris	90.58	CC(C)CN1CCC(CNC(=O)c2cc(Cl)c(N)n3cc(C)nc23)CC1, CC(C)CN1CCC(CNC(=O)c2cc(Cl)c(N)n3cc(C)nc23)CC1	Preclinical
CJ-13610	lipoxygenase inhibitor				Sigma	96.54	Cc1nccn1-c1ccc(Sc2cccc(c2)C2(CCOCC2)C(N)=O)cc1	Phase 2
CK-101	EGFR inhibitor				MedChemEx	95.24	OCCN1CCN(CC1)c1ccc(Nc2ncc3cccc(-c4cccc(NC(=O)C=C)c4)c3n2)c(F)c1F	Preclinical
CK-636	actin related protein inhibitor	ACTR2, ACTR3, ARPC1B, ARPC2, ARPC3, ARPC4, ARPC5			Selleck, Selleck, MedChemEx	95.64	Cc1[nH]c2ccccc2c1CCNC(=O)c1cccs1, Cc1[nH]c2ccccc2c1CCNC(=O)c1cccs1, Cc1[nH]c2ccccc2c1CCNC(=O)c1cccs1	Preclinical
CKD-712	NFkB pathway inhibitor	JAK2, STAT1			MedChemEx, MedChemEx, MedChemEx	93.15	Oc1cc2CCN[C@@H](Cc3cccc4ccccc34)c2cc1O |&1:7|, Oc1cc2CCN[C@@H](Cc3cccc4ccccc34)c2cc1O |&1:7|, Oc1cc2CCN[C@@H](Cc3cccc4ccccc34)c2cc1O |&1:7|	Phase 1
CKI-7	casein kinase inhibitor	CSNK1G2			Tocris	93.33	NCCNS(=O)(=O)c1ccc(Cl)c2ccncc12	Preclinical
CL-218872	benzodiazepine receptor agonist	GABRA1, GABRA2, GABRA3, GABRA5, GABRB2, GABRG2			Tocris, Tocris, Tocris	98.21	Cc1nnc2ccc(nn12)-c1cccc(c1)C(F)(F)F, Cc1nnc2ccc(nn12)-c1cccc(c1)C(F)(F)F, Cc1nnc2ccc(nn12)-c1cccc(c1)C(F)(F)F	Phase 1
CL-225385					Enamine	96.85	O=C(CC#N)c1ccccc1	Phase 2
cladribine	adenosine deaminase inhibitor, ribonucleotide reductase inhibitor	ADA, PNP, POLA1, POLE, POLE2, POLE3, POLE4, RRM1, RRM2, RRM2B	hematologic malignancy	hairy cell leukemia	Tocris, Selleck, Selleck, Selleck, Selleck, Selleck	98.23	Nc1nc(Cl)nc2n(cnc12)[C@H]1C[C@H](O)[C@@H](CO)O1, Nc1nc(Cl)nc2n(cnc12)[C@H]1C[C@H](O)[C@@H](CO)O1, Nc1nc(Cl)nc2n(cnc12)[C@H]1C[C@H](O)[C@@H](CO)O1, Nc1nc(Cl)nc2n(cnc12)[C@H]1C[C@H](O)[C@@H](CO)O1, Nc1nc(Cl)nc2n(cnc12)[C@H]1C[C@H](O)[C@@H](CO)O1, Nc1nc(Cl)nc2n(cnc12)[C@H]1C[C@H](O)[C@@H](CO)O1	Launched
clamikalant	ATP-sensitive potassium channel antagonist				Astatech	95.3	CNC(=S)NS(=O)(=O)c1cc(CCNC(=O)c2cc(Cl)ccc2OC)ccc1OC	Preclinical
clanfenur	anticancer agent				AMS	91.68	CN(C)c1cccc(F)c1C(=O)NC(=O)Nc1ccc(Cl)cc1	Preclinical
clarithromycin	bacterial 50S ribosomal subunit inhibitor	CYP3A4	otolaryngology, pulmonary, infectious disease	pharyngitis, tonsillitis, sinusitis, bronchitis, pneumonia, skin infections, otitis	MicroSource, Selleck, Selleck, Selleck, MedChemEx	100	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O)OC, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O)OC, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O)OC, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O)OC, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O)OC	Launched
clavulanate	beta lactamase inhibitor		otolaryngology	otitis	MicroSource, AvaChem	0	OC\C=C1/O[C@@H]2CC(=O)N2[C@H]1C(O)=O, OC\C=C1/O[C@@H]2CC(=O)N2[C@H]1C(O)=O	Launched
clebopride	dopamine receptor antagonist	ACHE, DRD2	gastroenterology	nausea	Prestwick, Prestwick, MedChemEx	99.18	COc1cc(N)c(Cl)cc1C(=O)NC1CCN(Cc2ccccc2)CC1, COc1cc(N)c(Cl)cc1C(=O)NC1CCN(Cc2ccccc2)CC1, COc1cc(N)c(Cl)cc1C(=O)NC1CCN(Cc2ccccc2)CC1	Launched
clemastine	histamine receptor antagonist	HRH1	allergy	allergic rhinitis, urticaria	Tocris, MicroSource, Tocris, Selleck, Tocris	96.36	CN1CCC[C@@H]1CCO[C@](C)(c1ccccc1)c1ccc(Cl)cc1, CN1CCC[C@@H]1CCO[C@](C)(c1ccccc1)c1ccc(Cl)cc1, CN1CCC[C@@H]1CCO[C@](C)(c1ccccc1)c1ccc(Cl)cc1, CN1CCC[C@@H]1CCO[C@](C)(c1ccccc1)c1ccc(Cl)cc1, CN1CCC[C@@H]1CCO[C@](C)(c1ccccc1)c1ccc(Cl)cc1	Launched
clemizole	HCV inhibitor		allergy	allergic rhinitis	Tocris, Tocris, MicroSource, MicroSource	97.9	Clc1ccc(Cn2c(CN3CCCC3)nc3ccccc23)cc1, Clc1ccc(Cn2c(CN3CCCC3)nc3ccccc23)cc1, Clc1ccc(Cn2c(CN3CCCC3)nc3ccccc23)cc1, Clc1ccc(Cn2c(CN3CCCC3)nc3ccccc23)cc1	Launched
clenbuterol	adrenergic receptor agonist	ABCC8, ADRB2, KCNJ11	pulmonary	chronic obstructive pulmonary disease (COPD), asthma	MedChemEx	98.15	CC(C)(C)NC[C@@H](O)c1cc(Cl)c(N)c(Cl)c1 |r|	Launched
cleviprex	calcium channel blocker	CACNA1C, CACNA1D, CACNA1F, CACNA1S	cardiology	hypertension	Selleck, MedChemEx, MedChemEx, MedChemEx	97.71	CCCC(=O)OCOC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(Cl)c1Cl)C(=O)OC |&1:17,r,c:10,15|, CCCC(=O)OCOC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(Cl)c1Cl)C(=O)OC |&1:17,r,c:10,15|, CCCC(=O)OCOC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(Cl)c1Cl)C(=O)OC |&1:17,r,c:10,15|, CCCC(=O)OCOC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(Cl)c1Cl)C(=O)OC |&1:17,r,c:10,15|	Launched
clevudine	DNA polymerase inhibitor		infectious disease	hepatitis B	MedChemEx	97.96	Cc1cn([C@H]2O[C@@H](CO)[C@H](O)[C@H]2F)c(=O)[nH]c1=O	Launched
clidinium	acetylcholine receptor antagonist	CHRM1, CHRM3	gastroenterology	peptic ulcer disease (PUD), irritable bowel syndrome, enterocolitis	MicroSource, MicroSource, MicroSource, Selleck	99.37	C[N+]12CCC(CC1)[C@@H](C2)OC(=O)C(O)(c1ccccc1)c1ccccc1 |&1:7,THB:9:7:2.3:5.6|, C[N+]12CCC(CC1)[C@@H](C2)OC(=O)C(O)(c1ccccc1)c1ccccc1 |&1:7,THB:9:7:2.3:5.6|, C[N+]12CCC(CC1)[C@@H](C2)OC(=O)C(O)(c1ccccc1)c1ccccc1 |&1:7,THB:9:7:2.3:5.6|, C[N+]12CCC(CC1)[C@@H](C2)OC(=O)C(O)(c1ccccc1)c1ccccc1 |&1:7,THB:9:7:2.3:5.6|	Launched
climbazole	enzyme inducer		dermatology	dandruff, eczema	MicroSource, Selleck	99.56	CC(C)(C)C(=O)[C@@H](Oc1ccc(Cl)cc1)n1ccnc1 |&1:6,r|, CC(C)(C)C(=O)[C@@H](Oc1ccc(Cl)cc1)n1ccnc1 |&1:6,r|	Launched
clinafloxacin	bacterial DNA gyrase inhibitor				Selleck, MicroSource	98.71	N[C@H]1CCN(C1)c1c(F)cc2c(c1Cl)n(cc(C(O)=O)c2=O)C1CC1 |&1:1|, N[C@H]1CCN(C1)c1c(F)cc2c(c1Cl)n(cc(C(O)=O)c2=O)C1CC1 |&1:1|	Phase 3
clindamycin	protein synthesis inhibitor		infectious disease	respiratory tract infections, pneumonia, skin infections, gynecologic infections, intra-abdominal infections, bacterial septicemia, bone and joint infections	Tocris, MicroSource, Selleck, Selleck, Selleck, Selleck	100	CCC[C@@H]1C[C@H](N(C)C1)C(=O)N[C@H]([C@H](C)Cl)[C@H]1O[C@H](SC)[C@H](O)[C@@H](O)[C@H]1O, CCC[C@@H]1C[C@H](N(C)C1)C(=O)N[C@H]([C@H](C)Cl)[C@H]1O[C@H](SC)[C@H](O)[C@@H](O)[C@H]1O, CCC[C@@H]1C[C@H](N(C)C1)C(=O)N[C@H]([C@H](C)Cl)[C@H]1O[C@H](SC)[C@H](O)[C@@H](O)[C@H]1O, CCC[C@@H]1C[C@H](N(C)C1)C(=O)N[C@H]([C@H](C)Cl)[C@H]1O[C@H](SC)[C@H](O)[C@@H](O)[C@H]1O, CCC[C@@H]1C[C@H](N(C)C1)C(=O)N[C@H]([C@H](C)Cl)[C@H]1O[C@H](SC)[C@H](O)[C@@H](O)[C@H]1O, CCC[C@@H]1C[C@H](N(C)C1)C(=O)N[C@H]([C@H](C)Cl)[C@H]1O[C@H](SC)[C@H](O)[C@@H](O)[C@H]1O	Launched
clindamycin-palmitate	bacterial 50S ribosomal subunit inhibitor		infectious disease	intra-abdominal infections, skin infections, pneumonia, peritonitis, gynecologic infections	Selleck	98.5	CCCCCCCCCCCCCCCC(=O)O[C@@H]1[C@@H](O)[C@@H](O)[C@H](O[C@@H]1SC)[C@H](NC(=O)[C@@H]1C[C@@H](CCC)CN1C)[C@H](C)Cl	Launched
clindamycin-phosphate	protein synthesis inhibitor		obstetrics/gynecology	bacterial vaginosis	Selleck, Selleck	100	CCC[C@@H]1C[C@H](N(C)C1)C(=O)N[C@H]([C@H](C)Cl)[C@H]1O[C@H](SC)[C@H](OP(O)(O)=O)[C@@H](O)[C@H]1O, CCC[C@@H]1C[C@H](N(C)C1)C(=O)N[C@H]([C@H](C)Cl)[C@H]1O[C@H](SC)[C@H](OP(O)(O)=O)[C@@H](O)[C@H]1O	Launched
clinofibrate	lipase clearing factor inhibitor	LPL	endocrinology	hypertriglyceridemia	MedChemEx, Selleck	96.83	CCC(C)(Oc1ccc(cc1)C1(CCCCC1)c1ccc(O[C@](C)(CC)C(O)=O)cc1)C(O)=O |&1:22,&2:2,r|, CCC(C)(Oc1ccc(cc1)C1(CCCCC1)c1ccc(O[C@](C)(CC)C(O)=O)cc1)C(O)=O |&1:22,&2:2,r|	Launched
clioquinol	chelating agent	OPRK1			MicroSource, MicroSource, MicroSource	91.44	Oc1c(I)cc(Cl)c2cccnc12, Oc1c(I)cc(Cl)c2cccnc12, Oc1c(I)cc(Cl)c2cccnc12	Withdrawn
clobenpropit	histamine receptor antagonist	HRH1, HRH2, HRH3, HRH4			Tocris, Tocris, Tocris, Tocris, Tocris	98.55	Clc1ccc(CNC(=N)SCCCc2cnc[nH]2)cc1, Clc1ccc(CNC(=N)SCCCc2cnc[nH]2)cc1, Clc1ccc(CNC(=N)SCCCc2cnc[nH]2)cc1, Clc1ccc(CNC(=N)SCCCc2cnc[nH]2)cc1, Clc1ccc(CNC(=N)SCCCc2cnc[nH]2)cc1	Preclinical
clobetasol-propionate	glucocorticoid receptor agonist	NR3C1, PLA2G1B	dermatology	corticosteroid-responsive dermatoses	Sigma, MicroSource, Selleck, Selleck, Selleck	98.73	CCC(=O)O[C@@]1([C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)CCl |c:17,t:13|, CCC(=O)O[C@@]1([C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)CCl |c:17,t:13|, CCC(=O)O[C@@]1([C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)CCl |c:17,t:13|, CCC(=O)O[C@@]1([C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)CCl |c:17,t:13|, CCC(=O)O[C@@]1([C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)CCl |c:17,t:13|	Launched
clobetasone-butyrate	corticosteroid agonist	NR3C1	dermatology	eczema, psoriasis, dermatitis	Sigma, Sigma	93.44	CCCC(=O)O[C@@]1([C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)C(=O)C[C@]12C)C(=O)CCl |c:18,t:14|, CCCC(=O)O[C@@]1([C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)C(=O)C[C@]12C)C(=O)CCl |c:18,t:14|	Launched
clobutinol	antitussive				Prestwick	96.04	C[C@@H](CN(C)C)C(C)(O)Cc1ccc(Cl)cc1 |&1:1,&2:6|	Withdrawn
clocortolone-pivalate	steroid	NR3C1, PLA2G1B	dermatology	corticosteroid-responsive dermatoses	Prestwick, Prestwick, Prestwick, USP, USP	98.68	C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@H]1C(=O)COC(=O)C(C)(C)C |c:12,t:8|, C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@H]1C(=O)COC(=O)C(C)(C)C |c:12,t:8|, C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@H]1C(=O)COC(=O)C(C)(C)C |c:12,t:8|, C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@H]1C(=O)COC(=O)C(C)(C)C |c:12,t:8|, C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@H]1C(=O)COC(=O)C(C)(C)C |c:12,t:8|	Launched
clodronic-acid	bone resorption inhibitor	SLC25A4, SLC25A5, SLC25A6	orthopedics, endocrinology, hematologic malignancy	osteoporosis, hyperparathyroidism, hypercalcemia, multiple myeloma	Selleck, Selleck, Selleck	0	OP(O)(=O)C(Cl)(Cl)P(O)(O)=O, OP(O)(=O)C(Cl)(Cl)P(O)(O)=O, OP(O)(=O)C(Cl)(Cl)P(O)(O)=O	Launched
clofarabine	ribonucleotide reductase inhibitor	POLA1, POLD1, POLE, RRM1, RRM2, RRM2B	hematologic malignancy	acute lymphoblastic leukemia (ALL)	Tocris, Tocris, Tocris, Tocris, Tocris, Tocris, Tocris, Selleck	98.71	Nc1nc(Cl)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F, Nc1nc(Cl)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F, Nc1nc(Cl)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F, Nc1nc(Cl)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F, Nc1nc(Cl)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F, Nc1nc(Cl)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F, Nc1nc(Cl)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F, Nc1nc(Cl)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F	Launched
clofazimine	GK0582 inhibitor		infectious disease	leprosy	MicroSource, Selleck, Selleck, Selleck	86.22	CC(C)\N=c1/cc2n(-c3ccc(Cl)cc3)c3ccccc3nc2cc1Nc1ccc(Cl)cc1, CC(C)\N=c1/cc2n(-c3ccc(Cl)cc3)c3ccccc3nc2cc1Nc1ccc(Cl)cc1, CC(C)\N=c1/cc2n(-c3ccc(Cl)cc3)c3ccccc3nc2cc1Nc1ccc(Cl)cc1, CC(C)\N=c1/cc2n(-c3ccc(Cl)cc3)c3ccccc3nc2cc1Nc1ccc(Cl)cc1	Launched
clofedanol	histamine receptor antagonist	HRH1	pulmonary	cough suppressant	Sigma	97.05	CN(C)CC[C@@](O)(c1ccccc1)c1ccccc1Cl |&1:5,r|	Launched
clofibrate	PPAR receptor agonist	LPL, PPARA	endocrinology, cardiology	hyperlipidemia, cholesterol	MicroSource, Selleck, Selleck, Selleck	99.05	CCOC(=O)C(C)(C)Oc1ccc(Cl)cc1, CCOC(=O)C(C)(C)Oc1ccc(Cl)cc1, CCOC(=O)C(C)(C)Oc1ccc(Cl)cc1, CCOC(=O)C(C)(C)Oc1ccc(Cl)cc1	Launched
clofibric-acid	PPAR receptor agonist	PPARA	endocrinology	hyperlipidemia	MicroSource, Tocris, Tocris, Selleck	98.95	CC(C)(Oc1ccc(Cl)cc1)C(O)=O, CC(C)(Oc1ccc(Cl)cc1)C(O)=O, CC(C)(Oc1ccc(Cl)cc1)C(O)=O, CC(C)(Oc1ccc(Cl)cc1)C(O)=O	Launched
clofilium	potassium channel blocker	KCNA5, KCNH1			Sigma, Prestwick, Prestwick	46.21	CCCCCCC[N+](CC)(CC)CCCCc1ccc(Cl)cc1, CCCCCCC[N+](CC)(CC)CCCCc1ccc(Cl)cc1, CCCCCCC[N+](CC)(CC)CCCCc1ccc(Cl)cc1	Phase 2
clofoctol	protein synthesis inhibitor		infectious disease	gram-positive bacterial infections	Selleck, Selleck, Selleck, MicroSource	97.9	CC(C)(C)CC(C)(C)c1ccc(O)c(Cc2ccc(Cl)cc2Cl)c1, CC(C)(C)CC(C)(C)c1ccc(O)c(Cc2ccc(Cl)cc2Cl)c1, CC(C)(C)CC(C)(C)c1ccc(O)c(Cc2ccc(Cl)cc2Cl)c1, CC(C)(C)CC(C)(C)c1ccc(O)c(Cc2ccc(Cl)cc2Cl)c1	Launched
clomesone	DNA inhibitor				Enamine	0	CS(=O)(=O)CS(=O)(=O)OCCCl	Phase 1
clomethiazole	GABA receptor antagonist, GABA receptor modulator	GABRA1	neurology/psychiatry	Parkinson's Disease, sedative, muscle relaxant	Tocris, Enamine, Enamine	94.39	Cc1ncsc1CCCl, Cc1ncsc1CCCl, Cc1ncsc1CCCl	Launched
clomifene	estrogen receptor antagonist	ESR1	obstetrics/gynecology	infertility	MicroSource, MicroSource, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck	94.9	CCN(CC)CCOc1ccc(cc1)C(=C(/Cl)c1ccccc1)\c1ccccc1, CCN(CC)CCOc1ccc(cc1)C(=C(/Cl)c1ccccc1)\c1ccccc1, CCN(CC)CCOc1ccc(cc1)C(=C(/Cl)c1ccccc1)\c1ccccc1, CCN(CC)CCOc1ccc(cc1)C(=C(/Cl)c1ccccc1)\c1ccccc1, CCN(CC)CCOc1ccc(cc1)C(=C(/Cl)c1ccccc1)\c1ccccc1, CCN(CC)CCOc1ccc(cc1)C(=C(/Cl)c1ccccc1)\c1ccccc1, CCN(CC)CCOc1ccc(cc1)C(=C(/Cl)c1ccccc1)\c1ccccc1, CCN(CC)CCOc1ccc(cc1)C(=C(/Cl)c1ccccc1)\c1ccccc1, CCN(CC)CCOc1ccc(cc1)C(=C(/Cl)c1ccccc1)\c1ccccc1, CCN(CC)CCOc1ccc(cc1)C(=C(/Cl)c1ccccc1)\c1ccccc1	Launched
clomipramine	serotonin transporter (SERT) inhibitor	GSTP1, HTR2A, HTR2B, HTR2C, SLC6A2, SLC6A3, SLC6A4	neurology/psychiatry	obsessive compulsive disorder (OCD)	MicroSource, Tocris, Tocris, Selleck, Selleck	94.52	CN(C)CCCN1c2ccccc2CCc2ccc(Cl)cc12, CN(C)CCCN1c2ccccc2CCc2ccc(Cl)cc12, CN(C)CCCN1c2ccccc2CCc2ccc(Cl)cc12, CN(C)CCCN1c2ccccc2CCc2ccc(Cl)cc12, CN(C)CCCN1c2ccccc2CCc2ccc(Cl)cc12	Launched
clonidine	adrenergic receptor agonist	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C	cardiology, neurology/psychiatry	hypertension, attention-deficit/hyperactivity disorder (ADHD)	MicroSource, Tocris, Tocris, Tocris, Selleck	99.61	Clc1cccc(Cl)c1NC1=NCCN1 |t:10|, Clc1cccc(Cl)c1NC1=NCCN1 |t:10|, Clc1cccc(Cl)c1NC1=NCCN1 |t:10|, Clc1cccc(Cl)c1NC1=NCCN1 |t:10|, Clc1cccc(Cl)c1NC1=NCCN1 |t:10|	Launched
clonixin	cyclooxygenase inhibitor	PTGS1, PTGS2	rheumatology, infectious disease	rheumatoid arthritis, soft tissue infection	CombiBlocks	97.7	Cc1c(Cl)cccc1Nc1ncccc1C(O)=O	Preclinical
clonixin-lysinate	cyclooxygenase inhibitor		neurology/psychiatry	pain relief	Sigma, Sigma, Prestwick	86.5	NCCCC[C@H](N)C(O)=O.Cc1c(Cl)cccc1Nc1ncccc1C(O)=O, NCCCC[C@H](N)C(O)=O.Cc1c(Cl)cccc1Nc1ncccc1C(O)=O, NCCCC[C@H](N)C(O)=O.Cc1c(Cl)cccc1Nc1ncccc1C(O)=O	Launched
clopamide	sodium/chloride cotransporter inhibitor		cardiology	hypertension	Selleck, Selleck	98.33	C[C@H]1CCC[C@@H](C)N1NC(=O)c1ccc(Cl)c(c1)S(N)(=O)=O, C[C@H]1CCC[C@@H](C)N1NC(=O)c1ccc(Cl)c(c1)S(N)(=O)=O	Launched
cloperastine	antitussive		pulmonary	cough suppressant	MicroSource, Selleck	97.64	Clc1ccc(cc1)[C@@H](OCCN1CCCCC1)c1ccccc1 |&1:7|, Clc1ccc(cc1)[C@@H](OCCN1CCCCC1)c1ccccc1 |&1:7|	Launched
cloperastine-fendizoate	potassium channel antagonist					0		Preclinical
clopidogrel	purinergic receptor antagonist	P2RY12	cardiology, neurology/psychiatry	myocardial infarction, stroke, peripheral artery disease (PAD), acute coronary syndrome (ACS)	MicroSource, Selleck, Selleck, Selleck, Selleck, Selleck	99.2	COC(=O)[C@@H](N1CCc2sccc2C1)c1ccccc1Cl, COC(=O)[C@@H](N1CCc2sccc2C1)c1ccccc1Cl, COC(=O)[C@@H](N1CCc2sccc2C1)c1ccccc1Cl, COC(=O)[C@@H](N1CCc2sccc2C1)c1ccccc1Cl, COC(=O)[C@@H](N1CCc2sccc2C1)c1ccccc1Cl, COC(=O)[C@@H](N1CCc2sccc2C1)c1ccccc1Cl	Launched
clopidol			infectious disease	coccidiosis	MicroSource, MedChemEx	97.05	Cc1[nH]c(C)c(Cl)c(=O)c1Cl, Cc1[nH]c(C)c(Cl)c(=O)c1Cl	Launched
cloprostenol-(+/-)	prostaglandin receptor agonist	PTGDR, PTGER1, PTGER3, PTGFR, TBXA2R	obstetrics/gynecology	endometriosis	Tocris	93.34	O[C@@H](COc1cccc(Cl)c1)\C=C\[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O	Launched
cloranolol	adrenergic receptor antagonist	ADRB1, ADRB2, ADRB3	cardiology	hypertension	Sigma	97.23	CC(C)(C)NC[C@@H](O)COc1cc(Cl)ccc1Cl |&1:6|	Launched
clorgiline	monoamine oxidase inhibitor	MAOA			Selleck, MicroSource, MicroSource, MedChemEx	97.41	CN(CCCOc1ccc(Cl)cc1Cl)CC#C, CN(CCCOc1ccc(Cl)cc1Cl)CC#C, CN(CCCOc1ccc(Cl)cc1Cl)CC#C, CN(CCCOc1ccc(Cl)cc1Cl)CC#C	Phase 2
clorotepine	adrenergic receptor antagonist, dopamine receptor antagonist	ADRA1A, ADRA1B, ADRA1D, DRD2, HRH1, HTR2C, HTR6	neurology/psychiatry	psychosis	Sigma, Sigma	99.23	CN1CCN(CC1)[C@H]1Cc2ccccc2Sc2ccc(Cl)cc12 |&1:7|, CN1CCN(CC1)[C@H]1Cc2ccccc2Sc2ccc(Cl)cc12 |&1:7|	Launched
clorprenaline	adrenergic receptor agonist	ADRB1, ADRB2	pulmonary	asthma	Selleck	95.94	CC(C)NC[C@@H](O)c1ccccc1Cl |&1:5|	Launched
clorsulon	glycolysis inhibitor		infectious disease	gastrointestinal roundworms, lungworms, liver flukes, lice, mites	MicroSource, MedChemEx, Selleck	99.05	Nc1cc(C(Cl)=C(Cl)Cl)c(cc1S(N)(=O)=O)S(N)(=O)=O, Nc1cc(C(Cl)=C(Cl)Cl)c(cc1S(N)(=O)=O)S(N)(=O)=O, Nc1cc(C(Cl)=C(Cl)Cl)c(cc1S(N)(=O)=O)S(N)(=O)=O	Launched
closantel	chitinase inhibitor, NFkB pathway inhibitor		infectious disease	liver flukes	MedChemEx, Selleck	98.84	Cc1cc([C@@H](C#N)c2ccc(Cl)cc2)c(Cl)cc1NC(=O)c1cc(I)cc(I)c1O |&1:4|, Cc1cc([C@@H](C#N)c2ccc(Cl)cc2)c(Cl)cc1NC(=O)c1cc(I)cc(I)c1O |&1:4|	Launched
clotiapine			neurology/psychiatry	psychosis	Enzo, Enzo	99.4	CN1CCN(CC1)C1=Nc2ccccc2Sc2ccc(Cl)cc12 |t:8|, CN1CCN(CC1)C1=Nc2ccccc2Sc2ccc(Cl)cc12 |t:8|	Launched
clotrimazole	cytochrome P450 inhibitor, imidazoline receptor ligand	CYP3A4, KCNN4, NR1I2, NR1I3, TRPM2, TRPM4, TRPM8	infectious disease	vulvovaginal candidiasis, oropharyngeal candidiasis	Tocris, MicroSource, Selleck, Tocris	98.93	Clc1ccccc1C(c1ccccc1)(c1ccccc1)n1ccnc1, Clc1ccccc1C(c1ccccc1)(c1ccccc1)n1ccnc1, Clc1ccccc1C(c1ccccc1)(c1ccccc1)n1ccnc1, Clc1ccccc1C(c1ccccc1)(c1ccccc1)n1ccnc1	Launched
cloxacillin	bacterial cell wall synthesis inhibitor		infectious disease	gram-positive bacterial infections	MicroSource, MicroSource, MedChemEx, Selleck, Selleck	94.98	Cc1onc(c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O)-c1ccccc1Cl, Cc1onc(c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O)-c1ccccc1Cl, Cc1onc(c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O)-c1ccccc1Cl, Cc1onc(c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O)-c1ccccc1Cl, Cc1onc(c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O)-c1ccccc1Cl	Launched
cloxyquin	potassium channel activator	KCNK18			MedChemEx, MedChemEx, MicroSource	98.46	Oc1ccc(Cl)c2cccnc12, Oc1ccc(Cl)c2cccnc12, Oc1ccc(Cl)c2cccnc12	Preclinical
clozapine	dopamine receptor antagonist, serotonin receptor antagonist	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, CALY, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD1, DRD2, DRD3, DRD4, DRD5, HRH1, HRH4, HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR3A, HTR5A, HTR6, HTR7	neurology/psychiatry	schizophrenia	MicroSource, Selleck, Tocris, Selleck	95.42	CN1CCN(CC1)C1=Nc2cc(Cl)ccc2Nc2ccccc12 |t:8|, CN1CCN(CC1)C1=Nc2cc(Cl)ccc2Nc2ccccc12 |t:8|, CN1CCN(CC1)C1=Nc2cc(Cl)ccc2Nc2ccccc12 |t:8|, CN1CCN(CC1)C1=Nc2cc(Cl)ccc2Nc2ccccc12 |t:8|	Launched
CL316243	adrenergic receptor agonist	ADRB3, UCP1, UCP2, UCP3			Tocris	96.36	C[C@H](Cc1ccc2OC(Oc2c1)(C(O)=O)C(O)=O)NC[C@H](O)c1cccc(Cl)c1	Phase 2
CM-4620	calcium release activated channel modulator				MedChemEx	97.16	Cc1cccc(F)c1C(=O)Nc1cnc(cn1)-c1cc2OC(F)(F)Oc2cc1Cl	Phase 2
CMPD-1	p38 MAPK inhibitor	GNRHR, MAPK14			Tocris, Tocris, Tocris	96.43	Oc1ccc(NC(=O)CCCc2ccc(cc2)-c2ccccc2F)cc1, Oc1ccc(NC(=O)CCCc2ccc(cc2)-c2ccccc2F)cc1, Oc1ccc(NC(=O)CCCc2ccc(cc2)-c2ccccc2F)cc1	Preclinical
CNQX	glutamate receptor antagonist	GRIA1, GRIA2, GRIA3, GRIA4			Tocris, Tocris, Tocris	97.7	[O-][N+](=O)c1cc2[nH]c(=O)c(=O)[nH]c2cc1C#N, [O-][N+](=O)c1cc2[nH]c(=O)c(=O)[nH]c2cc1C#N, [O-][N+](=O)c1cc2[nH]c(=O)c(=O)[nH]c2cc1C#N	Phase 1
CNX-2006	EGFR inhibitor	EGFR			MedChemEx, MedChemEx	95.62	COc1cc(NC2CN(CCF)C2)ccc1Nc1ncc(c(Nc2cccc(NC(=O)C=C)c2)n1)C(F)(F)F, COc1cc(NC2CN(CCF)C2)ccc1Nc1ncc(c(Nc2cccc(NC(=O)C=C)c2)n1)C(F)(F)F	Preclinical
CNX-774	Bruton's tyrosine kinase (BTK) inhibitor	BTK			MedChemEx, Selleck, Selleck, Selleck, Selleck	96.11	CNC(=O)c1cc(Oc2ccc(Nc3ncc(F)c(Nc4cccc(NC(=O)C=C)c4)n3)cc2)ccn1, CNC(=O)c1cc(Oc2ccc(Nc3ncc(F)c(Nc4cccc(NC(=O)C=C)c4)n3)cc2)ccn1, CNC(=O)c1cc(Oc2ccc(Nc3ncc(F)c(Nc4cccc(NC(=O)C=C)c4)n3)cc2)ccn1, CNC(=O)c1cc(Oc2ccc(Nc3ncc(F)c(Nc4cccc(NC(=O)C=C)c4)n3)cc2)ccn1, CNC(=O)c1cc(Oc2ccc(Nc3ncc(F)c(Nc4cccc(NC(=O)C=C)c4)n3)cc2)ccn1	Preclinical
CO-101244	glutamate receptor antagonist	GRIN2B			Tocris, Tocris, Tocris, Tocris	96.9	Cc1ccc(CC2(O)CCN(CCOc3ccc(O)cc3)CC2)cc1, Cc1ccc(CC2(O)CCN(CCOc3ccc(O)cc3)CC2)cc1, Cc1ccc(CC2(O)CCN(CCOc3ccc(O)cc3)CC2)cc1, Cc1ccc(CC2(O)CCN(CCOc3ccc(O)cc3)CC2)cc1	Preclinical
CO-102862	sodium channel blocker	SCN4A, SCN9A			Tocris, Tocris, Tocris	97.69	NC(=O)N\N=C\c1ccc(Oc2ccc(F)cc2)cc1, NC(=O)N\N=C\c1ccc(Oc2ccc(F)cc2)cc1, NC(=O)N\N=C\c1ccc(Oc2ccc(F)cc2)cc1	Phase 1
cobicistat	cytochrome P450 inhibitor	CYP3A4, CYP3A43, CYP3A5, CYP3A7	infectious disease	human immunodeficiency virus (HIV-1)	MedChemEx, MedChemEx, Selleck, Selleck	97.7	CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1, CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1, CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1, CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1	Launched
cobimetinib	MEK inhibitor	MAP2K1	oncology	melanoma	MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx	96.09	OC1(CN(C1)C(=O)c1ccc(F)c(F)c1Nc1ccc(I)cc1F)[C@@H]1CCCCN1, OC1(CN(C1)C(=O)c1ccc(F)c(F)c1Nc1ccc(I)cc1F)[C@@H]1CCCCN1, OC1(CN(C1)C(=O)c1ccc(F)c(F)c1Nc1ccc(I)cc1F)[C@@H]1CCCCN1, OC1(CN(C1)C(=O)c1ccc(F)c(F)c1Nc1ccc(I)cc1F)[C@@H]1CCCCN1, OC1(CN(C1)C(=O)c1ccc(F)c(F)c1Nc1ccc(I)cc1F)[C@@H]1CCCCN1, OC1(CN(C1)C(=O)c1ccc(F)c(F)c1Nc1ccc(I)cc1F)[C@@H]1CCCCN1, OC1(CN(C1)C(=O)c1ccc(F)c(F)c1Nc1ccc(I)cc1F)[C@@H]1CCCCN1, OC1(CN(C1)C(=O)c1ccc(F)c(F)c1Nc1ccc(I)cc1F)[C@@H]1CCCCN1	Launched
coenzyme-A		ACAT2, CRAT, CS, DBI, HMGCR, KAT2A, KAT2B, KAT5			ChemImpex	0	CC(C)(COP(O)(=O)OP(O)(=O)OC[C@H]1O[C@H]([C@H](O)[C@@H]1OP(O)(O)=O)n1cnc2c(N)ncnc12)[C@@H](O)C(=O)NCCC(=O)NCCS |a:14,16,17,19,35,&1:5,&2:9|	Launched
coenzyme-I		AASS, ACADS, ADH1A, ADH1B, ADH1C, ADH4, ADH5, ADH7, AKR1B1, AKR1C1, AKR1C2, AKR1C3, AKR1C4, ALDH1A1, ALDH1A2, ALDH1A3, ALDH1B1, ALDH2, ALDH3A1, ALDH3A2, ALDH3B1, ALDH3B2, ALDH4A1, ALDH5A1, ALDH6A1, ALDH7A1, ALDH9A1, AMT, BDH1, BLVRA, BLVRB, CDO1, CYB5R3, CYP17A1, CYP4A11, DHCR7, DHFR, DLAT, DLD, EHHADH, GAPDH, GAPDHS, GLUD1, GLUD2, GPD1, GSR, H6PD, HADH, HADHA, HIBADH, HMGCR, HMOX1, HMOX2, HPGD, HSD11B1, HSD11B2, HSD17B1, HSD17B10, HSD17B2, HSD17B3, HSD17B4, HSD17B7, HSD17B8, HSD3B1, HSD3B2, IDH3A, IDH3B, IDH3G, IMPDH1, IMPDH2, LDHA, LDHAL6A, LDHAL6B, LDHB, LDHC, MDH1, MDH2, ME1, ME2, ME3, MSMO1, MT-ND1, MT-ND2, MT-ND3, MT-ND4, MT-ND4L, MT-ND5, MT-ND6, MTHFD1, MTHFD2, NDUFA1, NDUFA10, NDUFA11, NDUFA12, NDUFA13, NDUFA2, NDUFA3, NDUFA4, NDUFA4L2, NDUFA5, NDUFA6, NDUFA7, NDUFA8, NDUFA9, NDUFAB1, NDUFB1, NDUFB10, NDUFB2, NDUFB3, NDUFB4, NDUFB5, NDUFB6, NDUFB7, NDUFB8, NDUFB9, NDUFC1, NDUFC2, NDUFS1, NDUFS2, NDUFS3, NDUFS4, NDUFS5, NDUFS6, NDUFS7, NDUFS8, NDUFV1, NDUFV2, NDUFV3, NNT, NQO2, NSDHL, OGDH, PDHA1, PDHA2, PDHB, PHGDH, PYCR1, PYCR2, QDPR, RDH5, SORD, TSTA3, TYR, UGDH			Apollo, SantaCruz	0	NC(=O)C1=CN(C=CC1)[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)n2cnc3c(N)ncnc23)[C@@H](O)[C@H]1O |a:9,11,23,25,26,28,40,42,&1:14,&2:18,c:6,t:3|, NC(=O)C1=CN(C=CC1)[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)n2cnc3c(N)ncnc23)[C@@H](O)[C@H]1O |a:9,11,23,25,26,28,40,42,&1:14,&2:18,c:6,t:3|	Phase 2
coenzyme-Q10					Sigma, Selleck, Selleck	0	COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O |c:2,t:58|, COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O |c:2,t:58|, COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O |c:2,t:58|	Launched
COH29	ribonucleotide reductase inhibitor				MedChemEx	74.48	Oc1ccc(cc1O)C(=O)Nc1nc(c(s1)-c1ccccc1)-c1ccc(O)c(O)c1	Phase 1
colchicine	microtubule inhibitor	GLRA1, GLRA2, TUBA1A, TUBA1B, TUBA1C, TUBA3C, TUBA3D, TUBA3E, TUBA4A, TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8	rheumatology, endocrinology	gout, fever	MicroSource, Tocris, Tocris	96.57	COc1cc2CC[C@H](NC(C)=O)c3cc(=O)c(OC)ccc3-c2c(OC)c1OC, COc1cc2CC[C@H](NC(C)=O)c3cc(=O)c(OC)ccc3-c2c(OC)c1OC, COc1cc2CC[C@H](NC(C)=O)c3cc(=O)c(OC)ccc3-c2c(OC)c1OC	Launched
colforsin	adenylyl cyclase activator	ADCY2, ADCY5			MicroSource, MicroSource	100	CC(=O)O[C@H]1[C@@H](O)[C@H]2C(C)(C)CC[C@H](O)[C@]2(C)[C@@]2(O)C(=O)C[C@@](C)(O[C@]12C)C=C |a:4,5,13,15,17,22,25,&1:7|, CC(=O)O[C@H]1[C@@H](O)[C@H]2C(C)(C)CC[C@H](O)[C@]2(C)[C@@]2(O)C(=O)C[C@@](C)(O[C@]12C)C=C |a:4,5,13,15,17,22,25,&1:7|	Phase 2
colforsin-daproate	adenylyl cyclase activator				EMDBio, EMDBio, EMDBio, EMDBio, EMDBio, EMDBio	100	CN(C)CCC(=O)O[C@@H]1[C@H](OC(C)=O)[C@@]2(C)O[C@](C)(CC(=O)[C@]2(O)[C@@]2(C)[C@@H](O)CCC(C)(C)[C@H]12)C=C, CN(C)CCC(=O)O[C@@H]1[C@H](OC(C)=O)[C@@]2(C)O[C@](C)(CC(=O)[C@]2(O)[C@@]2(C)[C@@H](O)CCC(C)(C)[C@H]12)C=C, CN(C)CCC(=O)O[C@@H]1[C@H](OC(C)=O)[C@@]2(C)O[C@](C)(CC(=O)[C@]2(O)[C@@]2(C)[C@@H](O)CCC(C)(C)[C@H]12)C=C, CN(C)CCC(=O)O[C@@H]1[C@H](OC(C)=O)[C@@]2(C)O[C@](C)(CC(=O)[C@]2(O)[C@@]2(C)[C@@H](O)CCC(C)(C)[C@H]12)C=C, CN(C)CCC(=O)O[C@@H]1[C@H](OC(C)=O)[C@@]2(C)O[C@](C)(CC(=O)[C@]2(O)[C@@]2(C)[C@@H](O)CCC(C)(C)[C@H]12)C=C, CN(C)CCC(=O)O[C@@H]1[C@H](OC(C)=O)[C@@]2(C)O[C@](C)(CC(=O)[C@]2(O)[C@@]2(C)[C@@H](O)CCC(C)(C)[C@H]12)C=C	Launched
colfosceril-palmitate	pulmonary surfactant		pulmonary	respiratory distress syndrome (RDS)	Acros, Sigma	0	CCCCCCCCCCCCCCCC(=O)OC[C@H](CO[P@](O)(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC |a:19,&1:22|, CCCCCCCCCCCCCCCC(=O)OC[C@H](CO[P@](O)(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC |a:19,&1:22|	Launched
colistimethate	bacterial permeability inducer		infectious disease	gram-negative bacterial infections	USP	0	[H][C@@](CCNCS(O)(=O)=O)(NC(=O)CCCC(C)C)C(=O)N[C@@]([H])([C@@H](C)O)C(=O)N[C@@]([H])(CCNCS(O)(=O)=O)C(=O)N[C@@]1([H])CCNC(=O)[C@@]([H])(NC(=O)[C@]([H])(CCNCS(O)(=O)=O)NC(=O)[C@]([H])(CCNCS(O)(=O)=O)NC(=O)[C@]([H])(CC(C)C)NC(=O)[C@]([H])(CC(C)C)NC(=O)[C@]([H])(CCNCS(O)(=O)=O)NC1=O)[C@@H](C)O	Launched
colistin	bacterial permeability inducer		infectious disease	gram-negative bacterial infections, gram-negative bacterial infections	MedChemEx, Selleck	74.4	CC[C@@H](C)CCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O)[C@@H](C)O |a:10,17,18,24,31,37,41,48,55,63,71,78,&1:2|, CC[C@@H](C)CCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O)[C@@H](C)O |a:10,17,18,24,31,37,41,48,55,63,71,78,&1:2|	Launched
combretastatin-A-4	tubulin polymerization inhibitor				MedChemEx, ChemDiv	97.9	COc1ccc(\C=C/c2cc(OC)c(OC)c(OC)c2)cc1O, COc1ccc(\C=C/c2cc(OC)c(OC)c(OC)c2)cc1O	Phase 2
compound-w	beta-secretase inhibitor	BACE1			Tocris, Tocris, Tocris	98.85	OC(=O)c1cc(Oc2ccc(cc2)[N+]([O-])=O)cc(Oc2ccc(cc2)[N+]([O-])=O)c1, OC(=O)c1cc(Oc2ccc(cc2)[N+]([O-])=O)cc(Oc2ccc(cc2)[N+]([O-])=O)c1, OC(=O)c1cc(Oc2ccc(cc2)[N+]([O-])=O)cc(Oc2ccc(cc2)[N+]([O-])=O)c1	Preclinical
compound-401	DNA dependent protein kinase inhibitor	MTOR, PRKDC			Tocris, Tocris, Tocris	99.02	O=c1cc(nc2c3ccccc3ccn12)N1CCOCC1, O=c1cc(nc2c3ccccc3ccn12)N1CCOCC1, O=c1cc(nc2c3ccccc3ccn12)N1CCOCC1	Preclinical
compound-58112					Sigma, Sigma	97.83	COc1cccc(CN2C[Si](C)(C)O[Si](C)(C)C2)c1, COc1cccc(CN2C[Si](C)(C)O[Si](C)(C)C2)c1	Preclinical
conivaptan	vasopressin receptor antagonist	AVPR1A, AVPR2	endocrinology	hyponatremia	MedChemEx, Selleck	99.33	Cc1nc-2c(CCN(C(=O)c3ccc(NC(=O)c4ccccc4-c4ccccc4)cc3)c3ccccc-23)[nH]1, Cc1nc-2c(CCN(C(=O)c3ccc(NC(=O)c4ccccc4-c4ccccc4)cc3)c3ccccc-23)[nH]1	Launched
convallatoxin	cardiac glycoside				Sigma	78.4	C[C@@H]1O[C@@H](O[C@H]2CC[C@]3(C=O)[C@H]4CC[C@]5(C)[C@H](CC[C@]5(O)[C@@H]4CC[C@]3(O)C2)C2=CC(=O)OC2)[C@H](O)[C@H](O)[C@H]1O |t:31|	Preclinical
copanlisib	PI3K inhibitor	PIK3CA, PIK3CB, PIK3CD, PIK3CG	hematologic malignancy	follicular lymphoma	MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx	97.22	COc1c(OCCCN2CCOCC2)ccc2C3=NCCN3C(NC(=O)c3cnc(N)nc3)=Nc12 |c:35,t:18|, COc1c(OCCCN2CCOCC2)ccc2C3=NCCN3C(NC(=O)c3cnc(N)nc3)=Nc12 |c:35,t:18|, COc1c(OCCCN2CCOCC2)ccc2C3=NCCN3C(NC(=O)c3cnc(N)nc3)=Nc12 |c:35,t:18|, COc1c(OCCCN2CCOCC2)ccc2C3=NCCN3C(NC(=O)c3cnc(N)nc3)=Nc12 |c:35,t:18|, COc1c(OCCCN2CCOCC2)ccc2C3=NCCN3C(NC(=O)c3cnc(N)nc3)=Nc12 |c:35,t:18|, COc1c(OCCCN2CCOCC2)ccc2C3=NCCN3C(NC(=O)c3cnc(N)nc3)=Nc12 |c:35,t:18|, COc1c(OCCCN2CCOCC2)ccc2C3=NCCN3C(NC(=O)c3cnc(N)nc3)=Nc12 |c:35,t:18|	Launched
copper-histidine		SLC15A3, SLC15A4, SLC38A5			Enzo, Vitas-M	100	N[C@H](Cc1cnc[nH]1)C(O)=O, N[C@H](Cc1cnc[nH]1)C(O)=O	Phase 3
COR-170	cannabinoid receptor inverse agonist	CNR2			Tocris, Tocris	98.6	CCCCCn1cc(C(=O)NC23CC4CC(CC(C4)C2)C3)c(=O)c2cc(ccc12)-c1ccccc1, CCCCCn1cc(C(=O)NC23CC4CC(CC(C4)C2)C3)c(=O)c2cc(ccc12)-c1ccccc1	Preclinical
cordycepin	DNA inhibitor				Tocris, Tocris, Tocris, Tocris	98.83	Nc1ncnc2n(cnc12)[C@@H]1O[C@H](CO)C[C@H]1O, Nc1ncnc2n(cnc12)[C@@H]1O[C@H](CO)C[C@H]1O, Nc1ncnc2n(cnc12)[C@@H]1O[C@H](CO)C[C@H]1O, Nc1ncnc2n(cnc12)[C@@H]1O[C@H](CO)C[C@H]1O	Phase 1/Phase 2
corosolic-acid	PKC inhibitor, protein tyrosine kinase inhibitor	HSD11B1, PTPN1			MedChemEx, MedChemEx, MedChemEx	96.17	C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)C[C@@H](O)[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]2[C@H]1C)C(O)=O |c:9|, C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)C[C@@H](O)[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]2[C@H]1C)C(O)=O |c:9|, C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)C[C@@H](O)[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]2[C@H]1C)C(O)=O |c:9|	Phase 2
CORT-108297	glucocorticoid receptor antagonist				AMS	79.93	CCOC[C@@]12CN(CCC1=Cc1c(C2)cnn1-c1ccc(F)cc1)S(=O)(=O)c1ccc(cc1)C(F)(F)F |c:10|	Preclinical
corticosterone	mineralocorticoid receptor agonist	HSD11B1, NCOA1, NR3C2			Tocris, Prestwick, Tocris	98.1	C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@H]2C(=O)CO |t:9|, C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@H]2C(=O)CO |t:9|, C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@H]2C(=O)CO |t:9|	Preclinical
cortisone	glucocorticoid receptor agonist	NR3C1	gastroenterology, rheumatology, dermatology	ulcerative colitis, rheumatoid arthritis, psoriasis, joint inflammation, eczema	Sigma	93.34	C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO |t:9|	Launched
cortisone-acetate	glucocorticoid receptor agonist	NR3C1	pulmonary, rheumatology, allergy, dermatology, ophthalmology, gastroenterology, infectious disease	asthma, rheumatoid arthritis, urticaria, osteoarthritis, psoriasis, allergic rhinitis, conjunctivitis, ulcerative colitis, meningitis	MicroSource, MicroSource, Selleck, Selleck, MedChemEx	94.14	CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3C(=O)C[C@]12C |t:15|, CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3C(=O)C[C@]12C |t:15|, CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3C(=O)C[C@]12C |t:15|, CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3C(=O)C[C@]12C |t:15|, CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3C(=O)C[C@]12C |t:15|	Launched
cortodoxone	androgen receptor antagonist	AR			MedChemEx, MedChemEx, Sigma	94.87	C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO |t:8|, C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO |t:8|, C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO |t:8|	Phase 3
costunolide	telomerase inhibitor				Selleck, Tocris, Tocris, Selleck, Selleck, Selleck, Selleck	89.25	C\C1=C/CC\C(C)=C\[C@H]2OC(=O)C(=C)[C@@H]2CC1 |c:1,t:6|, C\C1=C/CC\C(C)=C\[C@H]2OC(=O)C(=C)[C@@H]2CC1 |c:1,t:6|, C\C1=C/CC\C(C)=C\[C@H]2OC(=O)C(=C)[C@@H]2CC1 |c:1,t:6|, C\C1=C/CC\C(C)=C\[C@H]2OC(=O)C(=C)[C@@H]2CC1 |c:1,t:6|, C\C1=C/CC\C(C)=C\[C@H]2OC(=O)C(=C)[C@@H]2CC1 |c:1,t:6|, C\C1=C/CC\C(C)=C\[C@H]2OC(=O)C(=C)[C@@H]2CC1 |c:1,t:6|, C\C1=C/CC\C(C)=C\[C@H]2OC(=O)C(=C)[C@@H]2CC1 |c:1,t:6|	Preclinical
cot-inhibitor-1	MAPK-interacting kinase inhibitor	MAP3K8			MedChemEx	90.4	Fc1ccc(Nc2c(cnc3c(Cl)cc(NCc4cn(CCN5CCCCCC5)nn4)cc23)C#N)cc1Cl	Preclinical
cot-inhibitor-2	MAPK-interacting kinase inhibitor	MAP3K8			MedChemEx, MedChemEx	93.1	CCN1CCC(CC1)n1cc(CNc2cc(Cl)c3ncc(C#N)c(Nc4ccc(F)c(Cl)c4)c3c2)nn1, CCN1CCC(CC1)n1cc(CNc2cc(Cl)c3ncc(C#N)c(Nc4ccc(F)c(Cl)c4)c3c2)nn1	Preclinical
COTI-2	anticancer agent				MedChemEx	45.94	S=C(N\N=C1/CCCc2cccnc12)N1CCN(CC1)c1ccccn1	Phase 1
cotinine	nicotine metabolite				MedChemEx, MicroSource	97.89	CN1[C@@H](CCC1=O)c1cccnc1, CN1[C@@H](CCC1=O)c1cccnc1	Phase 2
coumarin	vitamin K antagonist	CA1, CA12, CA14, CA2, CA4, CA6, CA9, CYP2A6	gastroenterology, pulmonary	ulcerative colitis, asthma, celiac disease	MicroSource, MicroSource, Selleck	99.45	O=c1ccc2ccccc2o1, O=c1ccc2ccccc2o1, O=c1ccc2ccccc2o1	Launched
coumophos	cholinesterase inhibitor				MicroSource, MicroSource, Sigma	89.12	CCOP(=S)(OCC)Oc1ccc2c(C)c(Cl)c(=O)oc2c1, CCOP(=S)(OCC)Oc1ccc2c(C)c(Cl)c(=O)oc2c1, CCOP(=S)(OCC)Oc1ccc2c(C)c(Cl)c(=O)oc2c1	Preclinical
CP-105,696	leukotriene receptor antagonist				Sigma	97.8	O[C@@H]1[C@@H](Cc2ccc(cc2)-c2ccccc2)COc2cc(ccc12)C1(CCCC1)C(O)=O	Preclinical
CP-316819	glycogen phosphorylase inhibitor	PYGL			Tocris, Tocris, Tocris	96.53	CON(C)C(=O)[C@H](O)[C@H](Cc1ccccc1)NC(=O)c1cc2cc(Cl)ccc2[nH]1, CON(C)C(=O)[C@H](O)[C@H](Cc1ccccc1)NC(=O)c1cc2cc(Cl)ccc2[nH]1, CON(C)C(=O)[C@H](O)[C@H](Cc1ccccc1)NC(=O)c1cc2cc(Cl)ccc2[nH]1	Preclinical
CP-339818	potassium channel blocker	KCNA3			Tocris	98.69	CCCCC\N=c1/ccn(Cc2ccccc2)c2ccccc12	Preclinical
CP-376395	corticotropin releasing factor receptor antagonist	CRHR1			Key, Tocris	98.61	CCC(CC)Nc1cc(C)nc(Oc2c(C)cc(C)cc2C)c1C, CCC(CC)Nc1cc(C)nc(Oc2c(C)cc(C)cc2C)c1C	Phase 1
CP-471474	matrix metalloprotease inhibitor	MMP1, MMP13, MMP2, MMP3, MMP9			Tocris, Tocris, Tocris	93.4	CC(C)(NS(=O)(=O)c1ccc(Oc2ccc(F)cc2)cc1)C(=O)NO, CC(C)(NS(=O)(=O)c1ccc(Oc2ccc(F)cc2)cc1)C(=O)NO, CC(C)(NS(=O)(=O)c1ccc(Oc2ccc(F)cc2)cc1)C(=O)NO	Preclinical
CP-532623	cholesteryl ester transfer protein inhibitor	CETP			Sigma	98.71	CC[C@@H]1C[C@H](N(Cc2cc(cc(c2)C(F)(F)F)C(F)(F)F)C(C)=O)c2cc(ccc2N1C(=O)OC(C)C)C(F)(F)F	Phase 1
CP-547632	kinase inhibitor				Cayman	88.53	NC(=O)c1c(NC(=O)NCCCCN2CCCC2)snc1OCc1c(F)cc(Br)cc1F	Phase 2
CP-640186	acetyl-CoA carboxylase inhibitor	ACACA, ACACB			MedChemEx, MedChemEx	91.31	O=C([C@@H]1CCCN(C1)C1CCN(CC1)C(=O)c1c2ccccc2cc2ccccc12)N1CCOCC1, O=C([C@@H]1CCCN(C1)C1CCN(CC1)C(=O)c1c2ccccc2cc2ccccc12)N1CCOCC1	Preclinical
CP-673451	PDGFR tyrosine kinase receptor inhibitor	KIT, PDGFRA, PDGFRB			Tocris, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck	94.46	COCCOc1ccc2n(cnc2c1)-c1ccc2cccc(N3CCC(N)CC3)c2n1, COCCOc1ccc2n(cnc2c1)-c1ccc2cccc(N3CCC(N)CC3)c2n1, COCCOc1ccc2n(cnc2c1)-c1ccc2cccc(N3CCC(N)CC3)c2n1, COCCOc1ccc2n(cnc2c1)-c1ccc2cccc(N3CCC(N)CC3)c2n1, COCCOc1ccc2n(cnc2c1)-c1ccc2cccc(N3CCC(N)CC3)c2n1, COCCOc1ccc2n(cnc2c1)-c1ccc2cccc(N3CCC(N)CC3)c2n1, COCCOc1ccc2n(cnc2c1)-c1ccc2cccc(N3CCC(N)CC3)c2n1, COCCOc1ccc2n(cnc2c1)-c1ccc2cccc(N3CCC(N)CC3)c2n1, COCCOc1ccc2n(cnc2c1)-c1ccc2cccc(N3CCC(N)CC3)c2n1, COCCOc1ccc2n(cnc2c1)-c1ccc2cccc(N3CCC(N)CC3)c2n1, COCCOc1ccc2n(cnc2c1)-c1ccc2cccc(N3CCC(N)CC3)c2n1	Preclinical
CP-724714	EGFR inhibitor, protein tyrosine kinase inhibitor	ERBB2			Tocris, Selleck, Selleck, Selleck, Selleck	97.14	COCC(=O)NC\C=C\c1ccc2ncnc(Nc3ccc(Oc4ccc(C)nc4)c(C)c3)c2c1, COCC(=O)NC\C=C\c1ccc2ncnc(Nc3ccc(Oc4ccc(C)nc4)c(C)c3)c2c1, COCC(=O)NC\C=C\c1ccc2ncnc(Nc3ccc(Oc4ccc(C)nc4)c(C)c3)c2c1, COCC(=O)NC\C=C\c1ccc2ncnc(Nc3ccc(Oc4ccc(C)nc4)c(C)c3)c2c1, COCC(=O)NC\C=C\c1ccc2ncnc(Nc3ccc(Oc4ccc(C)nc4)c(C)c3)c2c1	Phase 2
CP-775146	PPAR receptor agonist	PPARA			Tocris, Tocris	97.47	CC(C)c1ccc(CC(=O)N2CCC[C@H](C2)c2cccc(OC(C)(C)C(O)=O)c2)cc1, CC(C)c1ccc(CC(=O)N2CCC[C@H](C2)c2cccc(OC(C)(C)C(O)=O)c2)cc1	Preclinical
CP-91149	glycogen phosphorylase inhibitor	PYGL			Selleck, Selleck, Selleck, Selleck	97.95	CN(C)C(=O)[C@H](O)[C@H](Cc1ccccc1)NC(=O)c1cc2cc(Cl)ccc2[nH]1, CN(C)C(=O)[C@H](O)[C@H](Cc1ccccc1)NC(=O)c1cc2cc(Cl)ccc2[nH]1, CN(C)C(=O)[C@H](O)[C@H](Cc1ccccc1)NC(=O)c1cc2cc(Cl)ccc2[nH]1, CN(C)C(=O)[C@H](O)[C@H](Cc1ccccc1)NC(=O)c1cc2cc(Cl)ccc2[nH]1	Preclinical
CP-93129	serotonin receptor agonist	HTR1A			Tocris, Tocris, Tocris	96.73	O=c1ccc2[nH]cc(C3=CCNCC3)c2[nH]1 |t:8|, O=c1ccc2[nH]cc(C3=CCNCC3)c2[nH]1 |t:8|, O=c1ccc2[nH]cc(C3=CCNCC3)c2[nH]1 |t:8|	Preclinical
CP-94253	serotonin receptor agonist	HTR1B			Tocris, Tocris	92.31	CCCOc1ccc2[nH]cc(C3=CCNCC3)c2n1 |t:11|, CCCOc1ccc2[nH]cc(C3=CCNCC3)c2n1 |t:11|	Preclinical
CP-945,598	cannabinoid receptor antagonist	CNR1			MedChemEx, MedChemEx, MedChemEx	98.78	CCNC1(CCN(CC1)c1ncnc2n(c(nc12)-c1ccccc1Cl)-c1ccc(Cl)cc1)C(N)=O, CCNC1(CCN(CC1)c1ncnc2n(c(nc12)-c1ccccc1Cl)-c1ccc(Cl)cc1)C(N)=O, CCNC1(CCN(CC1)c1ncnc2n(c(nc12)-c1ccccc1Cl)-c1ccc(Cl)cc1)C(N)=O	Phase 3
CP-99994	tachykinin antagonist	TACR1			Tocris, Tocris, Tocris	94.58	COc1ccccc1CN[C@H]1CCCN[C@H]1c1ccccc1, COc1ccccc1CN[C@H]1CCCN[C@H]1c1ccccc1, COc1ccccc1CN[C@H]1CCCN[C@H]1c1ccccc1	Phase 2
CPA-inhibitor	carboxypeptidase inhibitor	CPA1, CPA2			MedChemEx, MedChemEx	95.18	ON(C[C@@H](Cc1ccccc1)C(O)=O)C(=O)Cc1ccccc1 |&1:3,r|, ON(C[C@@H](Cc1ccccc1)C(O)=O)C(=O)Cc1ccccc1 |&1:3,r|	Preclinical
CPCCOEt	glutamate receptor antagonist	GRM1			Tocris	91.15	CCOC(=O)[C@]12C[C@H]1\C(=N/O)c1ccccc1O2 |&1:5,7,r|	Preclinical
CPI-0610	bromodomain inhibitor	BRD4			MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx	99.18	Cc1noc2[C@H](CC(N)=O)N=C(c3ccc(Cl)cc3)c3ccccc3-c12 |t:10|, Cc1noc2[C@H](CC(N)=O)N=C(c3ccc(Cl)cc3)c3ccccc3-c12 |t:10|, Cc1noc2[C@H](CC(N)=O)N=C(c3ccc(Cl)cc3)c3ccccc3-c12 |t:10|, Cc1noc2[C@H](CC(N)=O)N=C(c3ccc(Cl)cc3)c3ccccc3-c12 |t:10|, Cc1noc2[C@H](CC(N)=O)N=C(c3ccc(Cl)cc3)c3ccccc3-c12 |t:10|, Cc1noc2[C@H](CC(N)=O)N=C(c3ccc(Cl)cc3)c3ccccc3-c12 |t:10|	Phase 2
CPI-1189	tumor necrosis factor release inhibitor	TNF			Vitas-M, ChemDiv, ChemDiv, ChemDiv	98.62	CC(=O)Nc1ccc(cc1)C(=O)NC(C)(C)C, CC(=O)Nc1ccc(cc1)C(=O)NC(C)(C)C, CC(=O)Nc1ccc(cc1)C(=O)NC(C)(C)C, CC(=O)Nc1ccc(cc1)C(=O)NC(C)(C)C	Phase 2
CPI-1205	EZH2 inhibitor				MedChemEx	96.89	COc1cc(C)[nH]c(=O)c1CNC(=O)c1c(C)n([C@H](C)C2CCN(CC(F)(F)F)CC2)c2ccccc12	Phase 1/Phase 2
CPI-169	histone lysine methyltransferase inhibitor	EZH2			MedChemEx	93.82	CCS(=O)(=O)N1CCC(CC1)[C@@H](C)n1c(C)c(C(=O)NCc2c(OC)cc(C)[nH]c2=O)c2ccccc12	Preclinical
CPI-203	bromodomain inhibitor	BRD4			Tocris, Tocris, MedChemEx, MedChemEx, MedChemEx	96.47	Cc1nnc2[C@H](CC(N)=O)N=C(c3c(C)c(C)sc3-n12)c1ccc(Cl)cc1 |c:10|, Cc1nnc2[C@H](CC(N)=O)N=C(c3c(C)c(C)sc3-n12)c1ccc(Cl)cc1 |c:10|, Cc1nnc2[C@H](CC(N)=O)N=C(c3c(C)c(C)sc3-n12)c1ccc(Cl)cc1 |c:10|, Cc1nnc2[C@H](CC(N)=O)N=C(c3c(C)c(C)sc3-n12)c1ccc(Cl)cc1 |c:10|, Cc1nnc2[C@H](CC(N)=O)N=C(c3c(C)c(C)sc3-n12)c1ccc(Cl)cc1 |c:10|	Preclinical
CPI-360	histone lysine methyltransferase inhibitor	EZH2			MedChemEx, MedChemEx	94.64	COc1cc(C)[nH]c(=O)c1CNC(=O)c1c(C)n([C@H](C)C2CCOCC2)c2ccccc12, COc1cc(C)[nH]c(=O)c1CNC(=O)c1c(C)n([C@H](C)C2CCOCC2)c2ccccc12	Preclinical
CPI-444	adenosine receptor antagonist				MedChemEx	92.74	Cc1ccc(o1)-c1nc(N)nc2n(Cc3cccc(CO[C@H]4CCOC4)n3)nnc12	Phase 1/Phase 2
CPI-613	pyruvate dehydrogenase inhibitor	PDHA1			Tocris, Selleck, Selleck	96.2	OC(=O)CCCC[C@@H](CCSCc1ccccc1)SCc1ccccc1 |&1:7,r|, OC(=O)CCCC[C@@H](CCSCc1ccccc1)SCc1ccccc1 |&1:7,r|, OC(=O)CCCC[C@@H](CCSCc1ccccc1)SCc1ccccc1 |&1:7,r|	Phase 3
CPP	glutamate receptor antagonist	GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D			Tocris, EMDBio, EMDBio	93.04	OC(=O)[C@H]1CN(CCCP(O)(O)=O)CCN1, OC(=O)[C@H]1CN(CCCP(O)(O)=O)CCN1, OC(=O)[C@H]1CN(CCCP(O)(O)=O)CCN1	Phase 2
CPSI-1306-(+/-)	macrophage migration inhibiting factor inhibitor	MIF			Tocris, Tocris, Tocris	96.78	Fc1ccc(C2=NO[C@@H](CC(=O)N3CCOCC3)C2)c(F)c1 |&1:8,r,t:5|, Fc1ccc(C2=NO[C@@H](CC(=O)N3CCOCC3)C2)c(F)c1 |&1:8,r,t:5|, Fc1ccc(C2=NO[C@@H](CC(=O)N3CCOCC3)C2)c(F)c1 |&1:8,r,t:5|	Preclinical
CQS					Sigma	91.22	Nc1ccc(cc1)S(=O)(=O)Nc1cnc2c(Cl)cccc2n1	Preclinical
creatine		CKB, CKM, CKMT1A, CKMT2, GAMT, SLC6A8			Vitas-M	100	CN(CC(O)=O)C(N)=N	Launched
creatinine					MedChemEx, MicroSource, Selleck	100	CN1CC(=O)NC1=N, CN1CC(=O)NC1=N, CN1CC(=O)NC1=N	Preclinical
creatinol-phosphate					CombiBlocks, CombiBlocks	100	CN(CCOP(O)(O)=O)C(N)=N, CN(CCOP(O)(O)=O)C(N)=N	Launched
crenigacestat	notch signaling inhibitor				MedChemEx	95.66	C[C@H](NC(=O)CCC(F)(F)F)C(=O)N[C@H]1c2ccccc2-c2cccnc2N(CCO)C1=O	Preclinical
crenolanib	PDGFR tyrosine kinase receptor inhibitor	CSF1R, FLT3, KIT, PDGFRA, PDGFRB			Selleck, Selleck, Selleck, Selleck, MedChemEx, Selleck, Selleck	93.31	CC1(COc2ccc3n(cnc3c2)-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1, CC1(COc2ccc3n(cnc3c2)-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1, CC1(COc2ccc3n(cnc3c2)-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1, CC1(COc2ccc3n(cnc3c2)-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1, CC1(COc2ccc3n(cnc3c2)-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1, CC1(COc2ccc3n(cnc3c2)-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1, CC1(COc2ccc3n(cnc3c2)-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1	Phase 3
cresol					MicroSource	78.99	Cc1ccc(O)cc1	Launched
cresopirine					MicroSource, Sigma	94.31	CC(=O)Oc1c(C)cccc1C(O)=O, CC(=O)Oc1c(C)cccc1C(O)=O	Preclinical
cridanimod	progesterone receptor agonist	PGR	infectious disease	influenza A virus infection	Sigma, ChemDiv	98.36	OC(=O)Cn1c2ccccc2c(=O)c2ccccc12, OC(=O)Cn1c2ccccc2c(=O)c2ccccc12	Launched
crisaborole	phosphodiesterase inhibitor	PDE4A, PDE4B, PDE4C, PDE4D	dermatology	dermatitis	MedChemEx, MedChemEx	93.42	OB1OCc2cc(Oc3ccc(cc3)C#N)ccc12, OB1OCc2cc(Oc3ccc(cc3)C#N)ccc12	Launched
crisdesalazine	free radical scavenger				Sigma	89.23	OC(=O)c1cc(NCCc2ccc(cc2)C(F)(F)F)ccc1O	Preclinical
crizotinib	ALK tyrosine kinase receptor inhibitor	ALK, MET	oncology	non-small cell lung cancer (NSCLC)	MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck	93.81	C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl	Launched
crizotinib-(S)	MTH1 inhibitor	NUDT1			Tocris, Tocris, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck	96.6	C[C@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl	Preclinical
croconazole	bacterial cell wall synthesis inhibitor		infectious disease	fungal infection	AKSci, SantaCruz	0	Clc1cccc(COc2ccccc2C(=C)n2ccnc2)c1, Clc1cccc(COc2ccccc2C(=C)n2ccnc2)c1	Launched
crolibulin	tubulin polymerization inhibitor				MedChemEx	63.57	COc1cc(cc(Br)c1OC)[C@H]1C(C#N)=C(N)Oc2c(N)c(N)ccc12 |t:15|	Phase 1/Phase 2
cromakalim		KCNJ8			Tocris, Tocris	99.22	CC1(C)Oc2ccc(cc2[C@H]([C@@H]1O)N1CCCC1=O)C#N.CC1(C)Oc2ccc(cc2[C@@H]([C@H]1O)N1CCCC1=O)C#N, CC1(C)Oc2ccc(cc2[C@H]([C@@H]1O)N1CCCC1=O)C#N.CC1(C)Oc2ccc(cc2[C@@H]([C@H]1O)N1CCCC1=O)C#N	Phase 2
cromoglicic-acid	immunosuppressant	KCNMA1, S100P	pulmonary, ophthalmology, allergy, gastroenterology	asthma, conjunctivitis, urticaria, ulcerative colitis	MedChemEx, MicroSource, Selleck	100	OC(COc1cccc2oc(cc(=O)c12)C(O)=O)COc1cccc2oc(cc(=O)c12)C(O)=O, OC(COc1cccc2oc(cc(=O)c12)C(O)=O)COc1cccc2oc(cc(=O)c12)C(O)=O, OC(COc1cccc2oc(cc(=O)c12)C(O)=O)COc1cccc2oc(cc(=O)c12)C(O)=O	Launched
crotamiton	antipruritic		infectious disease	scabies	MicroSource, MedChemEx	95.53	CCN(C(=O)\C=C\C)c1ccccc1C, CCN(C(=O)\C=C\C)c1ccccc1C	Launched
CRT0044876					Selleck, Selleck, Selleck	96.56	OC(=O)c1cc2cccc([N+]([O-])=O)c2[nH]1, OC(=O)c1cc2cccc([N+]([O-])=O)c2[nH]1, OC(=O)c1cc2cccc([N+]([O-])=O)c2[nH]1	Preclinical
cryptotanshinone	acetylcholinesterase inhibitor, STAT inhibitor	STAT3			MedChemEx, MedChemEx, Selleck, Selleck	66.48	C[C@H]1COC2=C1C(=O)C(=O)c1c3CCCC(C)(C)c3ccc21 |c:4|, C[C@H]1COC2=C1C(=O)C(=O)c1c3CCCC(C)(C)c3ccc21 |c:4|, C[C@H]1COC2=C1C(=O)C(=O)c1c3CCCC(C)(C)c3ccc21 |c:4|, C[C@H]1COC2=C1C(=O)C(=O)c1c3CCCC(C)(C)c3ccc21 |c:4|	Preclinical
crystal-violet	other antibiotic				MedChemEx	91.8	CN(C)c1ccc(cc1)C(=C1C=CC(C=C1)=[N+](C)C)c1ccc(cc1)N(C)C |c:12,15|	Launched
CR8-(R)	CDK inhibitor	CCNA2			Tocris, Tocris, Tocris, Tocris, Tocris, Tocris, Tocris	96.87	CC[C@H](CO)Nc1nc(NCc2ccc(cc2)-c2ccccn2)c2ncn(C(C)C)c2n1, CC[C@H](CO)Nc1nc(NCc2ccc(cc2)-c2ccccn2)c2ncn(C(C)C)c2n1, CC[C@H](CO)Nc1nc(NCc2ccc(cc2)-c2ccccn2)c2ncn(C(C)C)c2n1, CC[C@H](CO)Nc1nc(NCc2ccc(cc2)-c2ccccn2)c2ncn(C(C)C)c2n1, CC[C@H](CO)Nc1nc(NCc2ccc(cc2)-c2ccccn2)c2ncn(C(C)C)c2n1, CC[C@H](CO)Nc1nc(NCc2ccc(cc2)-c2ccccn2)c2ncn(C(C)C)c2n1, CC[C@H](CO)Nc1nc(NCc2ccc(cc2)-c2ccccn2)c2ncn(C(C)C)c2n1	Preclinical
CS-110266	dopamine receptor agonist	SLC6A3			Tocris, Tocris, Sigma, Tocris, Tocris, Tocris	96.55	C1CCN(CC1)C1(CCCCC1)c1cc2ccccc2s1, C1CCN(CC1)C1(CCCCC1)c1cc2ccccc2s1, C1CCN(CC1)C1(CCCCC1)c1cc2ccccc2s1, C1CCN(CC1)C1(CCCCC1)c1cc2ccccc2s1, C1CCN(CC1)C1(CCCCC1)c1cc2ccccc2s1, C1CCN(CC1)C1(CCCCC1)c1cc2ccccc2s1	Preclinical
CS-917	fructose biphosphate inhibitor	FBP1			MedChemEx, MedChemEx, MedChemEx, MedChemEx	92.89	CC(C)Cc1sc(N)nc1-c1ccc(o1)P(O)(O)=O, CC(C)Cc1sc(N)nc1-c1ccc(o1)P(O)(O)=O, CC(C)Cc1sc(N)nc1-c1ccc(o1)P(O)(O)=O, CC(C)Cc1sc(N)nc1-c1ccc(o1)P(O)(O)=O	Phase 2
CT-7758	integrin antagonist	ITGA4			MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx	97.57	OC(=O)[C@H](Cc1ccc(Nc2nccc3ccncc23)cc1)NC1=C(Br)C(=O)C11CCCCC1 |c:26|, OC(=O)[C@H](Cc1ccc(Nc2nccc3ccncc23)cc1)NC1=C(Br)C(=O)C11CCCCC1 |c:26|, OC(=O)[C@H](Cc1ccc(Nc2nccc3ccncc23)cc1)NC1=C(Br)C(=O)C11CCCCC1 |c:26|, OC(=O)[C@H](Cc1ccc(Nc2nccc3ccncc23)cc1)NC1=C(Br)C(=O)C11CCCCC1 |c:26|, OC(=O)[C@H](Cc1ccc(Nc2nccc3ccncc23)cc1)NC1=C(Br)C(=O)C11CCCCC1 |c:26|, OC(=O)[C@H](Cc1ccc(Nc2nccc3ccncc23)cc1)NC1=C(Br)C(=O)C11CCCCC1 |c:26|	Phase 2
CTEP	glutamate receptor antagonist	GRM5			Selleck, Selleck, MedChemEx, MedChemEx	97.17	Cc1nc(C#Cc2ccnc(Cl)c2)c(C)n1-c1ccc(OC(F)(F)F)cc1, Cc1nc(C#Cc2ccnc(Cl)c2)c(C)n1-c1ccc(OC(F)(F)F)cc1, Cc1nc(C#Cc2ccnc(Cl)c2)c(C)n1-c1ccc(OC(F)(F)F)cc1, Cc1nc(C#Cc2ccnc(Cl)c2)c(C)n1-c1ccc(OC(F)(F)F)cc1	Preclinical
CTS-1027	metalloproteinase inhibitor	MMP1, MMP13, MMP2, MMP3, MMP9			MedChemEx, MedChemEx, MedChemEx, MedChemEx	97.14	ONC(=O)C1(CS(=O)(=O)c2ccc(Oc3ccc(Cl)cc3)cc2)CCOCC1, ONC(=O)C1(CS(=O)(=O)c2ccc(Oc3ccc(Cl)cc3)cc2)CCOCC1, ONC(=O)C1(CS(=O)(=O)c2ccc(Oc3ccc(Cl)cc3)cc2)CCOCC1, ONC(=O)C1(CS(=O)(=O)c2ccc(Oc3ccc(Cl)cc3)cc2)CCOCC1	Phase 2
CTS21166	beta-secretase inhibitor	BACE1			EMDBio, EMDBio	78.39	CC(C)C[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CCC(O)=O)C(C)C)[C@@H](O)C[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](Cc1ccccc1)C(O)=O, CC(C)C[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CCC(O)=O)C(C)C)[C@@H](O)C[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](Cc1ccccc1)C(O)=O	Phase 1
CT7001	CDK inhibitor				MedChemEx	96.6	CC(C)c1cnn2c(NCc3ccccc3)cc(NC[C@H]3CCNC[C@@H]3O)nc12	Phase 1/Phase 2
CU-CPT-4a	toll-like receptor inhibitor	TLR3			Tocris, Tocris	95.81	OC(=O)[C@@H](Cc1ccccc1)NC(=O)c1sc2cc(F)ccc2c1Cl, OC(=O)[C@@H](Cc1ccccc1)NC(=O)c1sc2cc(F)ccc2c1Cl	Preclinical
CU-T12-9	toll-like receptor agonist	TLR1, TLR2			Tocris, Tocris	97.26	CNc1ccc(cc1-n1cnc(c1)-c1ccc(cc1)C(F)(F)F)[N+]([O-])=O, CNc1ccc(cc1-n1cnc(c1)-c1ccc(cc1)C(F)(F)F)[N+]([O-])=O	Preclinical
CUDC-101	EGFR inhibitor	EGFR, ERBB2			MedChemEx, Selleck, Selleck	95.43	COc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCCCCCC(=O)NO, COc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCCCCCC(=O)NO, COc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCCCCCC(=O)NO	Phase 1
CUDC-427	apoptosis inhibitor	XIAP			MedChemEx, MedChemEx, MedChemEx, MedChemEx	86.1	CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1C(=O)Nc1sc(nc1-c1ccccc1)-c1ncco1, CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1C(=O)Nc1sc(nc1-c1ccccc1)-c1ncco1, CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1C(=O)Nc1sc(nc1-c1ccccc1)-c1ncco1, CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1C(=O)Nc1sc(nc1-c1ccccc1)-c1ncco1	Phase 1
CUDC-907	PI3K inhibitor	HDAC2, PIK3R1			MedChemEx, MedChemEx, Selleck, Selleck, Selleck	95.7	COc1ccc(cn1)-c1nc(N2CCOCC2)c2sc(CN(C)c3ncc(cn3)C(=O)NO)cc2n1, COc1ccc(cn1)-c1nc(N2CCOCC2)c2sc(CN(C)c3ncc(cn3)C(=O)NO)cc2n1, COc1ccc(cn1)-c1nc(N2CCOCC2)c2sc(CN(C)c3ncc(cn3)C(=O)NO)cc2n1, COc1ccc(cn1)-c1nc(N2CCOCC2)c2sc(CN(C)c3ncc(cn3)C(=O)NO)cc2n1, COc1ccc(cn1)-c1nc(N2CCOCC2)c2sc(CN(C)c3ncc(cn3)C(=O)NO)cc2n1	Phase 2
CUR-61414	smoothened receptor antagonist	DHH, IHH, SMO			Cayman	97.61	COc1cccc(CN([C@H]2C[C@H](N(Cc3ccc4OCOc4c3)C2)C(=O)N2CCNCC2)C(=O)CC(C)(C)C)c1	Phase 1
curcumin	cyclooxygenase inhibitor, histone acetyltransferase inhibitor, lipoxygenase inhibitor, NFkB pathway inhibitor	APP, CA1, CA12, CA14, CA2, CA4, CA6, CA9, CHRM3, CYP3A4, DNMT3B, EP300, MMP13, MMP9, NOS2, PTGS1, PTGS2, XDH			Enzo, Selleck, Selleck, Selleck, Selleck, Selleck	91.77	COc1cc(\C=C\C(O)=CC(=O)\C=C\c2ccc(O)c(OC)c2)ccc1O, COc1cc(\C=C\C(O)=CC(=O)\C=C\c2ccc(O)c(OC)c2)ccc1O, COc1cc(\C=C\C(O)=CC(=O)\C=C\c2ccc(O)c(OC)c2)ccc1O, COc1cc(\C=C\C(O)=CC(=O)\C=C\c2ccc(O)c(OC)c2)ccc1O, COc1cc(\C=C\C(O)=CC(=O)\C=C\c2ccc(O)c(OC)c2)ccc1O, COc1cc(\C=C\C(O)=CC(=O)\C=C\c2ccc(O)c(OC)c2)ccc1O	Launched
curcumol	JAK inhibitor	JAK1, JAK2, JAK3			MedChemEx, MedChemEx, Selleck, Selleck, Selleck	86.9	CC(C)[C@@H]1C[C@@]23O[C@]1(O)CC(=C)[C@@H]2CC[C@@H]3C, CC(C)[C@@H]1C[C@@]23O[C@]1(O)CC(=C)[C@@H]2CC[C@@H]3C, CC(C)[C@@H]1C[C@@]23O[C@]1(O)CC(=C)[C@@H]2CC[C@@H]3C, CC(C)[C@@H]1C[C@@]23O[C@]1(O)CC(=C)[C@@H]2CC[C@@H]3C, CC(C)[C@@H]1C[C@@]23O[C@]1(O)CC(=C)[C@@H]2CC[C@@H]3C	Phase 1
cutamesine	sigma receptor agonist	SIGMAR1			Tocris, MedChemEx, MedChemEx, MedChemEx, Tocris	95.88	COc1ccc(CCN2CCN(CCCc3ccccc3)CC2)cc1OC, COc1ccc(CCN2CCN(CCCc3ccccc3)CC2)cc1OC, COc1ccc(CCN2CCN(CCCc3ccccc3)CC2)cc1OC, COc1ccc(CCN2CCN(CCCc3ccccc3)CC2)cc1OC, COc1ccc(CCN2CCN(CCCc3ccccc3)CC2)cc1OC	Phase 2
CV-1808	adenosine receptor agonist	ADORA2A			Tocris, Tocris, Tocris, Tocris	95.83	Nc1nc(Nc2ccccc2)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O, Nc1nc(Nc2ccccc2)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O, Nc1nc(Nc2ccccc2)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O, Nc1nc(Nc2ccccc2)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O	Preclinical
CVT-10216	aldehyde dehydrogenase inhibitor	ALDH2			Sigma, Tocris	96.71	CS(=O)(=O)Nc1ccc(cc1)-c1coc2cc(OCc3cccc(c3)C(O)=O)ccc2c1=O, CS(=O)(=O)Nc1ccc(cc1)-c1coc2cc(OCc3cccc(c3)C(O)=O)ccc2c1=O	Phase 1
CW-008	PKA activator	PRKACA			Tocris, Tocris, Tocris	93.01	COc1ccn2ncc(-c3nc4n[nH]c(NC(=O)c5ccc(F)cc5)c4cc3F)c2c1, COc1ccn2ncc(-c3nc4n[nH]c(NC(=O)c5ccc(F)cc5)c4cc3F)c2c1, COc1ccn2ncc(-c3nc4n[nH]c(NC(=O)c5ccc(F)cc5)c4cc3F)c2c1	Preclinical
CX-4945	casein kinase inhibitor	CSNK2A1, CSNK2A2, DAPK3, HIPK3			MedChemEx, Selleck, Selleck, Selleck, Selleck	98.48	OC(=O)c1ccc2c(c1)nc(Nc1cccc(Cl)c1)c1ccncc21, OC(=O)c1ccc2c(c1)nc(Nc1cccc(Cl)c1)c1ccncc21, OC(=O)c1ccc2c(c1)nc(Nc1cccc(Cl)c1)c1ccncc21, OC(=O)c1ccc2c(c1)nc(Nc1cccc(Cl)c1)c1ccncc21, OC(=O)c1ccc2c(c1)nc(Nc1cccc(Cl)c1)c1ccncc21	Phase 1/Phase 2
CX-516	glutamate receptor modulator				Tocris, Tocris	98.29	O=C(N1CCCCC1)c1ccc2OCOc2c1, O=C(N1CCCCC1)c1ccc2OCOc2c1	Phase 2/Phase 3
CX-5461	RNA polymerase inhibitor				MedChemEx, MedChemEx	96.98	CN1CCCN(CC1)c1ccc2c(n1)n1c3ccccc3sc1c(C(=O)NCc1cnc(C)cn1)c2=O, CN1CCCN(CC1)c1ccc2c(n1)n1c3ccccc3sc1c(C(=O)NCc1cnc(C)cn1)c2=O	Phase 1
CXD101	HDAC inhibitor				MedChemEx	97.26	Cc1nn(C)cc1CN1CCC(CC1)c1ccc(cc1)C(=O)Nc1ccccc1N	Phase 1/Phase 2
cyacetacide					MedChemEx, MicroSource	93.04	NNC(=O)CC#N, NNC(=O)CC#N	Preclinical
cyamemazine	serotonin receptor antagonist	HTR1A, HTR2A, HTR2C, HTR7	neurology/psychiatry	schizophrenia, anxiety	Sigma	87.23	C[C@@H](CN(C)C)CN1c2ccccc2Sc2ccc(cc12)C#N |&1:1,r|	Launched
cyanocobalamin	methylmalonyl CoA mutase stimulant, vitamin B	MUT	hematology, infectious disease, gastroenterology	anemia, fish tapeworm infestation, celiac disease	MicroSource, Sigma, Selleck, Selleck, Selleck	97.22	C[C@H](CNC(=O)CC[C@]1(C)[C@@H](CC(N)=O)[C@H]2N=C1\C(C)=C1/N=C(/C=C3\N=C(\C(\C)=C4\[C@@H](CCC(N)=O)[C@](C)(CC(N)=O)[C@@]2(C)N4[Co+]C#N)[C@@](C)(CC(N)=O)[C@@H]3CCC(N)=O)C(C)(C)[C@@H]1CCC(N)=O)O[P@@](O)(=O)O[C@@H]1[C@@H](CO)O[C@@H]([C@@H]1O)n1cnc2cc(C)c(C)cc12 |a:1,8,10,15,30,36,42,48,54,63,74,75,79,80,&1:70,c:16,20,24,t:22,26,29|, C[C@H](CNC(=O)CC[C@]1(C)[C@@H](CC(N)=O)[C@H]2N=C1\C(C)=C1/N=C(/C=C3\N=C(\C(\C)=C4\[C@@H](CCC(N)=O)[C@](C)(CC(N)=O)[C@@]2(C)N4[Co+]C#N)[C@@](C)(CC(N)=O)[C@@H]3CCC(N)=O)C(C)(C)[C@@H]1CCC(N)=O)O[P@@](O)(=O)O[C@@H]1[C@@H](CO)O[C@@H]([C@@H]1O)n1cnc2cc(C)c(C)cc12 |a:1,8,10,15,30,36,42,48,54,63,74,75,79,80,&1:70,c:16,20,24,t:22,26,29|, C[C@H](CNC(=O)CC[C@]1(C)[C@@H](CC(N)=O)[C@H]2N=C1\C(C)=C1/N=C(/C=C3\N=C(\C(\C)=C4\[C@@H](CCC(N)=O)[C@](C)(CC(N)=O)[C@@]2(C)N4[Co+]C#N)[C@@](C)(CC(N)=O)[C@@H]3CCC(N)=O)C(C)(C)[C@@H]1CCC(N)=O)O[P@@](O)(=O)O[C@@H]1[C@@H](CO)O[C@@H]([C@@H]1O)n1cnc2cc(C)c(C)cc12 |a:1,8,10,15,30,36,42,48,54,63,74,75,79,80,&1:70,c:16,20,24,t:22,26,29|, C[C@H](CNC(=O)CC[C@]1(C)[C@@H](CC(N)=O)[C@H]2N=C1\C(C)=C1/N=C(/C=C3\N=C(\C(\C)=C4\[C@@H](CCC(N)=O)[C@](C)(CC(N)=O)[C@@]2(C)N4[Co+]C#N)[C@@](C)(CC(N)=O)[C@@H]3CCC(N)=O)C(C)(C)[C@@H]1CCC(N)=O)O[P@@](O)(=O)O[C@@H]1[C@@H](CO)O[C@@H]([C@@H]1O)n1cnc2cc(C)c(C)cc12 |a:1,8,10,15,30,36,42,48,54,63,74,75,79,80,&1:70,c:16,20,24,t:22,26,29|, C[C@H](CNC(=O)CC[C@]1(C)[C@@H](CC(N)=O)[C@H]2N=C1\C(C)=C1/N=C(/C=C3\N=C(\C(\C)=C4\[C@@H](CCC(N)=O)[C@](C)(CC(N)=O)[C@@]2(C)N4[Co+]C#N)[C@@](C)(CC(N)=O)[C@@H]3CCC(N)=O)C(C)(C)[C@@H]1CCC(N)=O)O[P@@](O)(=O)O[C@@H]1[C@@H](CO)O[C@@H]([C@@H]1O)n1cnc2cc(C)c(C)cc12 |a:1,8,10,15,30,36,42,48,54,63,74,75,79,80,&1:70,c:16,20,24,t:22,26,29|	Launched
cyanopindolol	adrenergic receptor antagonist	ADRB1, HTR1A, HTR1D			Tocris, Tocris, Tocris	96.81	CC(C)(C)NC[C@@H](O)COc1cccc2[nH]c(cc12)C#N |&1:6|, CC(C)(C)NC[C@@H](O)COc1cccc2[nH]c(cc12)C#N |&1:6|, CC(C)(C)NC[C@@H](O)COc1cccc2[nH]c(cc12)C#N |&1:6|	Phase 2
cyclamic-acid					MicroSource, MedChemEx, MicroSource, Selleck	100	OS(=O)(=O)NC1CCCCC1, OS(=O)(=O)NC1CCCCC1, OS(=O)(=O)NC1CCCCC1, OS(=O)(=O)NC1CCCCC1	Preclinical
cyclandelate	calcium channel blocker		cardiology, rheumatology	claudication, arteriosclerosis, Raynaud's disease	MicroSource, Selleck, Selleck, Selleck, Selleck	96.1	C[C@H]1C[C@@H](CC(C)(C)C1)OC(=O)[C@@H](O)c1ccccc1 |&1:1,&2:3,&3:12,r|, C[C@H]1C[C@@H](CC(C)(C)C1)OC(=O)[C@@H](O)c1ccccc1 |&1:1,&2:3,&3:12,r|, C[C@H]1C[C@@H](CC(C)(C)C1)OC(=O)[C@@H](O)c1ccccc1 |&1:1,&2:3,&3:12,r|, C[C@H]1C[C@@H](CC(C)(C)C1)OC(=O)[C@@H](O)c1ccccc1 |&1:1,&2:3,&3:12,r|, C[C@H]1C[C@@H](CC(C)(C)C1)OC(=O)[C@@H](O)c1ccccc1 |&1:1,&2:3,&3:12,r|	Launched
cyclic-AMP		CNGA3, TRPM7			ChemDiv, ChemDiv	100	Nc1ncnc2n(cnc12)[C@H]1O[C@H]2CO[P@](O)(=O)O[C@@H]2[C@@H]1O |&1:10,&2:12,&3:15,&4:19,&5:20,r|, Nc1ncnc2n(cnc12)[C@H]1O[C@H]2CO[P@](O)(=O)O[C@@H]2[C@@H]1O |&1:10,&2:12,&3:15,&4:19,&5:20,r|	Preclinical
cyclizine	histamine receptor modulator	HRH1, SULT1E1	gastroenterology, neurology/psychiatry	nausea, vomiting, vertigo, motion sickness	MicroSource, Selleck, Selleck	99.27	CN1CCN(CC1)C(c1ccccc1)c1ccccc1, CN1CCN(CC1)C(c1ccccc1)c1ccccc1, CN1CCN(CC1)C(c1ccccc1)c1ccccc1	Launched
cyclobenzaprine	adrenergic receptor agonist, serotonin receptor agonist	HTR2A	neurology/psychiatry	spasms	MicroSource, MedChemEx, MedChemEx	98.15	CN(C)CCC=C1c2ccccc2C=Cc2ccccc12 |c:14|, CN(C)CCC=C1c2ccccc2C=Cc2ccccc12 |c:14|, CN(C)CCC=C1c2ccccc2C=Cc2ccccc12 |c:14|	Launched
cyclocreatine	creatine kinase substrate				Sigma	96.8	NC1=NCCN1CC(O)=O |t:1|	Phase 1
cyclocytidine	DNA synthesis inhibitor, RNA synthesis inhibitor				MicroSource, MedChemEx, Selleck, Selleck	100	OC[C@H]1O[C@@H]2[C@@H](Oc3nc(=N)ccn23)[C@@H]1O, OC[C@H]1O[C@@H]2[C@@H](Oc3nc(=N)ccn23)[C@@H]1O, OC[C@H]1O[C@@H]2[C@@H](Oc3nc(=N)ccn23)[C@@H]1O, OC[C@H]1O[C@@H]2[C@@H](Oc3nc(=N)ccn23)[C@@H]1O	Preclinical
cycloheximide	protein synthesis inhibitor	RPL3			MicroSource, Sigma, Sigma, Sigma	89.79	C[C@H]1C[C@H](C)C(=O)[C@@H](C1)[C@H](O)CC1CC(=O)NC(=O)C1, C[C@H]1C[C@H](C)C(=O)[C@@H](C1)[C@H](O)CC1CC(=O)NC(=O)C1, C[C@H]1C[C@H](C)C(=O)[C@@H](C1)[C@H](O)CC1CC(=O)NC(=O)C1, C[C@H]1C[C@H](C)C(=O)[C@@H](C1)[C@H](O)CC1CC(=O)NC(=O)C1	Preclinical
cyclopamine	hedgehog pathway inhibitor				Apollo	87.32	C[C@@H]1[C@@H]2NC[C@@H](C)C[C@H]2O[C@]11CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC2=C1C |c:32,t:18|	Preclinical
cyclopenthiazide	thiazide diuretic		cardiology	hypertension, congestive heart failure	Prestwick, Toronto, Toronto	99.7	NS(=O)(=O)c1cc2c(N[C@@H](CC3CCCC3)NS2(=O)=O)cc1Cl |&1:9,r|, NS(=O)(=O)c1cc2c(N[C@@H](CC3CCCC3)NS2(=O)=O)cc1Cl |&1:9,r|, NS(=O)(=O)c1cc2c(N[C@@H](CC3CCCC3)NS2(=O)=O)cc1Cl |&1:9,r|	Launched
cyclopentolate	acetylcholine receptor antagonist		ophthalmology	mydriasis, cycloplegia	MicroSource, Sigma	94.68	CN(C)CCOC(=O)[C@@H](c1ccccc1)C1(O)CCCC1 |&1:8|, CN(C)CCOC(=O)[C@@H](c1ccccc1)C1(O)CCCC1 |&1:8|	Launched
cyclophosphamide	DNA alkylating agent	CYP2A6, CYP2B6, CYP2C18, CYP2C19, CYP2C8, CYP2C9, CYP2D6, CYP3A4, CYP3A5, CYP3A7	hematologic malignancy, oncology	Hodgkin's lymphoma, small lymphocytic lymphoma (SLL), breast cancer, neuroblastoma, Burkitt's lymphoma, multiple myeloma, chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myeloid leukemia (CML), true histiocytic lymphoma (THL), retinoblastoma, ovarian cancer	MicroSource, Selleck, Selleck, Selleck	96.1	ClCCN(CCCl)[P@@]1(=O)NCCCO1 |r|, ClCCN(CCCl)[P@@]1(=O)NCCCO1 |r|, ClCCN(CCCl)[P@@]1(=O)NCCCO1 |r|, ClCCN(CCCl)[P@@]1(=O)NCCCO1 |r|	Launched
cyclopiazonic-acid	ATPase inhibitor	ATP2A1			Tocris, Tocris, Tocris	99.1	CC(=O)C1=C(O)[C@@H]2[C@@H]3[C@@H](Cc4cccc5[nH]cc3c45)C(C)(C)N2C1=O |a:6,7,8,&1:3,c:3|, CC(=O)C1=C(O)[C@@H]2[C@@H]3[C@@H](Cc4cccc5[nH]cc3c45)C(C)(C)N2C1=O |a:6,7,8,&1:3,c:3|, CC(=O)C1=C(O)[C@@H]2[C@@H]3[C@@H](Cc4cccc5[nH]cc3c45)C(C)(C)N2C1=O |a:6,7,8,&1:3,c:3|	Preclinical
cycloserine-(D)	bacterial cell wall synthesis inhibitor	GRIN1	infectious disease	tuberculosis, tuberculosis	MedChemEx, MicroSource, MedChemEx, Selleck, Selleck	0	N[C@@H]1CONC1=O, N[C@@H]1CONC1=O, N[C@@H]1CONC1=O, N[C@@H]1CONC1=O, N[C@@H]1CONC1=O	Launched
cyclosporin-A	calcineurin inhibitor	ABCB11, CAMLG, FPR1, PPIA, PPIF, PPP3CA, PPP3R2, SLC10A1, SLCO1B1, SLCO1B3	rheumatology, dermatology	rheumatoid arthritis, psoriasis	MicroSource, MicroSource, Tocris, Tocris, Tocris, Tocris, Tocris, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck	99.52	CC[C@H]1NC(=O)[C@@H]([C@@H](O)[C@@H](C)C\C=C\C)N(C)C(=O)[C@@H](C(C)C)N(C)C(=O)[C@@H](CC(C)C)N(C)C(=O)[C@@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@@H](C)NC(=O)[C@@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C |&1:2,&2:6,&3:7,&4:9,&5:19,&6:27,&7:36,&8:45,&9:50,&10:55,&11:64,&12:68,r|, CC[C@H]1NC(=O)[C@@H]([C@@H](O)[C@@H](C)C\C=C\C)N(C)C(=O)[C@@H](C(C)C)N(C)C(=O)[C@@H](CC(C)C)N(C)C(=O)[C@@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@@H](C)NC(=O)[C@@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C |&1:2,&2:6,&3:7,&4:9,&5:19,&6:27,&7:36,&8:45,&9:50,&10:55,&11:64,&12:68,r|, CC[C@H]1NC(=O)[C@@H]([C@@H](O)[C@@H](C)C\C=C\C)N(C)C(=O)[C@@H](C(C)C)N(C)C(=O)[C@@H](CC(C)C)N(C)C(=O)[C@@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@@H](C)NC(=O)[C@@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C |&1:2,&2:6,&3:7,&4:9,&5:19,&6:27,&7:36,&8:45,&9:50,&10:55,&11:64,&12:68,r|, CC[C@H]1NC(=O)[C@@H]([C@@H](O)[C@@H](C)C\C=C\C)N(C)C(=O)[C@@H](C(C)C)N(C)C(=O)[C@@H](CC(C)C)N(C)C(=O)[C@@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@@H](C)NC(=O)[C@@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C |&1:2,&2:6,&3:7,&4:9,&5:19,&6:27,&7:36,&8:45,&9:50,&10:55,&11:64,&12:68,r|, CC[C@H]1NC(=O)[C@@H]([C@@H](O)[C@@H](C)C\C=C\C)N(C)C(=O)[C@@H](C(C)C)N(C)C(=O)[C@@H](CC(C)C)N(C)C(=O)[C@@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@@H](C)NC(=O)[C@@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C |&1:2,&2:6,&3:7,&4:9,&5:19,&6:27,&7:36,&8:45,&9:50,&10:55,&11:64,&12:68,r|, CC[C@H]1NC(=O)[C@@H]([C@@H](O)[C@@H](C)C\C=C\C)N(C)C(=O)[C@@H](C(C)C)N(C)C(=O)[C@@H](CC(C)C)N(C)C(=O)[C@@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@@H](C)NC(=O)[C@@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C |&1:2,&2:6,&3:7,&4:9,&5:19,&6:27,&7:36,&8:45,&9:50,&10:55,&11:64,&12:68,r|, CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C, CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C, CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C, CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C, CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C, CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C, CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C, CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C	Launched
cyclothiazide	glutamate receptor modulator	CA2, GRIA1, GRIA2, GRIA3, GRIA4, SLC12A3	cardiology	hypertension	Tocris, Tocris, MicroSource, Sigma, DuPont, Tocris	65.61	NS(=O)(=O)c1cc2c(N[C@@H](NS2(=O)=O)[C@H]2C[C@H]3C[C@@H]2C=C3)cc1Cl |&1:9,&2:14,&3:16,&4:18,r,c:21|, NS(=O)(=O)c1cc2c(N[C@@H](NS2(=O)=O)[C@H]2C[C@H]3C[C@@H]2C=C3)cc1Cl |&1:9,&2:14,&3:16,&4:18,r,c:21|, NS(=O)(=O)c1cc2c(N[C@@H](NS2(=O)=O)[C@H]2C[C@H]3C[C@@H]2C=C3)cc1Cl |&1:9,&2:14,&3:16,&4:18,r,c:21|, NS(=O)(=O)c1cc2c(N[C@@H](NS2(=O)=O)[C@H]2C[C@H]3C[C@@H]2C=C3)cc1Cl |&1:9,&2:14,&3:16,&4:18,r,c:21|, NS(=O)(=O)c1cc2c(N[C@@H](NS2(=O)=O)[C@H]2C[C@H]3C[C@@H]2C=C3)cc1Cl |&1:9,&2:14,&3:16,&4:18,r,c:21|, NS(=O)(=O)c1cc2c(N[C@@H](NS2(=O)=O)[C@H]2C[C@H]3C[C@@H]2C=C3)cc1Cl |&1:9,&2:14,&3:16,&4:18,r,c:21|	Launched
cyclovalone	breast cancer resistance protein inhibitor	ABCG2	gastroenterology	bile stimulation	Sigma, Sigma, Sigma, Sigma, Enamine	97.7	COc1cc(\C=C2/CCC\C(=C/c3ccc(O)c(OC)c3)C2=O)ccc1O, COc1cc(\C=C2/CCC\C(=C/c3ccc(O)c(OC)c3)C2=O)ccc1O, COc1cc(\C=C2/CCC\C(=C/c3ccc(O)c(OC)c3)C2=O)ccc1O, COc1cc(\C=C2/CCC\C(=C/c3ccc(O)c(OC)c3)C2=O)ccc1O, COc1cc(\C=C2/CCC\C(=C/c3ccc(O)c(OC)c3)C2=O)ccc1O	Launched
cyclovirobuxin-D	calcium channel modulator				Selleck, Selleck, Selleck	100	CN[C@@H](C)[C@H]1[C@H](O)C[C@@]2(C)[C@@H]3CC[C@@H]4[C@]5(C[C@@]35CC[C@]12C)CC[C@H](NC)C4(C)C, CN[C@@H](C)[C@H]1[C@H](O)C[C@@]2(C)[C@@H]3CC[C@@H]4[C@]5(C[C@@]35CC[C@]12C)CC[C@H](NC)C4(C)C, CN[C@@H](C)[C@H]1[C@H](O)C[C@@]2(C)[C@@H]3CC[C@@H]4[C@]5(C[C@@]35CC[C@]12C)CC[C@H](NC)C4(C)C	Preclinical
CycLuc1					MedChemEx	85.83	OC(=O)[C@H]1CSC(=N1)c1nc2cc3CCNc3cc2s1 |c:6|	Preclinical
CYC065	CDK inhibitor				MedChemEx	95.63	CC[C@H](Nc1nc(NCc2cnc(C)cc2C)c2ncn(C(C)C)c2n1)[C@@H](C)O	Phase 1
CYC116	Aurora kinase inhibitor	AURKA, AURKB, KDR			Selleck, Selleck, Selleck, Selleck, Selleck	93.87	Cc1nc(N)sc1-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1, Cc1nc(N)sc1-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1, Cc1nc(N)sc1-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1, Cc1nc(N)sc1-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1, Cc1nc(N)sc1-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1	Phase 1
CYM-50260	sphingosine 1-phosphate receptor agonist	S1PR4			Tocris, Tocris	96.41	FCc1ccc(OCCOc2ccc(Cl)cc2Cl)c(Cl)n1, FCc1ccc(OCCOc2ccc(Cl)cc2Cl)c(Cl)n1	Preclinical
CYM-50358	sphingosine 1-phosphate receptor antagonist	S1PR4			Tocris, Tocris	97.71	Cc1cc(CN)cc(C)c1NC(=O)c1ccc(o1)-c1cc(Cl)ccc1Cl, Cc1cc(CN)cc(C)c1NC(=O)c1ccc(o1)-c1cc(Cl)ccc1Cl	Preclinical
CYM-50769	neuropeptide receptor antagonist	NPBWR1			Tocris, Tocris	98.77	COc1ccc(Oc2c(Cl)cnn(C3c4ccccc4-c4ccccc34)c2=O)cc1, COc1ccc(Oc2c(Cl)cnn(C3c4ccccc4-c4ccccc34)c2=O)cc1	Preclinical
CYM-5442	sphingosine 1-phosphate receptor agonist	S1PR1			Tocris, Tocris	97.43	CCOc1ccc(cc1OCC)-c1nc(no1)-c1cccc2[C@@H](CCc12)NCCO |&1:22|, CCOc1ccc(cc1OCC)-c1nc(no1)-c1cccc2[C@@H](CCc12)NCCO |&1:22|	Preclinical
CYM-5520	sphingosine 1-phosphate receptor agonist	S1PR2			Tocris, Tocris	98.49	Cc1cc(C(=O)Cn2cc(ccc2=O)C#N)c(C)n1Cc1ccccc1, Cc1cc(C(=O)Cn2cc(ccc2=O)C#N)c(C)n1Cc1ccccc1	Preclinical
CYM-5541	sphingosine 1-phosphate receptor agonist	S1PR3			Tocris, Tocris, Tocris	93.59	O=C(N(C1CCCCC1)C1CCCCC1)c1cc(on1)C1CC1, O=C(N(C1CCCCC1)C1CCCCC1)c1cc(on1)C1CC1, O=C(N(C1CCCCC1)C1CCCCC1)c1cc(on1)C1CC1	Preclinical
cypermethrin			infectious disease	flea control	MicroSource, LKT	42.23	CC1(C)[C@@H](C=C(Cl)Cl)[C@@H]1C(=O)O[C@@H](C#N)c1cccc(Oc2ccccc2)c1 |&1:3,&2:8,&3:12,r|, CC1(C)[C@@H](C=C(Cl)Cl)[C@@H]1C(=O)O[C@@H](C#N)c1cccc(Oc2ccccc2)c1 |&1:3,&2:8,&3:12,r|	Launched
cyproheptadine	histamine receptor antagonist	ADRA1A, ADRA1B, ADRA1D, CHRM1, CHRM2, CHRM3, HRH1, HTR2A, HTR2C, HTR6, HTR7	allergy, otolaryngology, ophthalmology, dermatology	allergic rhinitis, vasomotor rhinitis, conjunctivitis, urticaria, dermatographism	MicroSource, MicroSource, MicroSource, MicroSource, MicroSource, Tocris, Tocris, Selleck	98.68	CN1CCC(CC1)=C1c2ccccc2C=Cc2ccccc12 |c:16|, CN1CCC(CC1)=C1c2ccccc2C=Cc2ccccc12 |c:16|, CN1CCC(CC1)=C1c2ccccc2C=Cc2ccccc12 |c:16|, CN1CCC(CC1)=C1c2ccccc2C=Cc2ccccc12 |c:16|, CN1CCC(CC1)=C1c2ccccc2C=Cc2ccccc12 |c:16|, CN1CCC(CC1)=C1c2ccccc2C=Cc2ccccc12 |c:16|, CN1CCC(CC1)=C1c2ccccc2C=Cc2ccccc12 |c:16|, CN1CCC(CC1)=C1c2ccccc2C=Cc2ccccc12 |c:16|	Launched
cyproterone-acetate	androgen receptor antagonist	ADORA1, AR	oncology	prostate cancer	MicroSource, Sigma, MedChemEx, Selleck	94.11	CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(Cl)C4=CC(=O)[C@@H]5C[C@@H]5[C@]4(C)[C@H]3CC[C@]12C)C(C)=O |t:9,12|, CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(Cl)C4=CC(=O)[C@@H]5C[C@@H]5[C@]4(C)[C@H]3CC[C@]12C)C(C)=O |t:9,12|, CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(Cl)C4=CC(=O)[C@@H]5C[C@@H]5[C@]4(C)[C@H]3CC[C@]12C)C(C)=O |t:9,12|, CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(Cl)C4=CC(=O)[C@@H]5C[C@@H]5[C@]4(C)[C@H]3CC[C@]12C)C(C)=O |t:9,12|	Launched
cyromazine					MicroSource, Selleck	99.31	Nc1nc(N)nc(NC2CC2)n1, Nc1nc(N)nc(NC2CC2)n1	Launched
cysteamine	tissue transglutaminase inhibitor	NPY2R, SST	metabolism	cystinosis	MedChemEx, MicroSource	100	NCCS, NCCS	Launched
CYT-997	tubulin polymerization inhibitor	TUBB			Selleck	96.56	CCC[C@H](Nc1nc(ncc1C)-c1ccc(NC(=O)NCC)c(OC)c1)c1cccnc1	Phase 2
cytarabine	ribonucleotide reductase inhibitor	POLA1, POLB, POLD1, POLE	hematologic malignancy	acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)	Selleck, Selleck	90.88	Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1	Launched
cytidine		UCK2			Selleck, Selleck, MicroSource, MicroSource	100	Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1	Launched
cytisine	acetylcholine receptor agonist	CHRNA2, CHRNA3, CHRNA4, CHRNA6, CHRNA7, CHRNB2, CHRNB4	neurology/psychiatry	nicotinism	MicroSource, MicroSource, Tocris, Selleck, Selleck	98.23	O=c1cccc2[C@H]3CNC[C@H](C3)Cn12, O=c1cccc2[C@H]3CNC[C@H](C3)Cn12, O=c1cccc2[C@H]3CNC[C@H](C3)Cn12, O=c1cccc2[C@H]3CNC[C@H](C3)Cn12, O=c1cccc2[C@H]3CNC[C@H](C3)Cn12	Launched
cytochalasin-B	microtubule inhibitor	ACTB			Tocris	93.35	C[C@H]1[C@H]2[C@H](Cc3ccccc3)NC(=O)[C@]22OC(=O)\C=C\[C@H](O)CCC[C@@H](C)C\C=C\[C@H]2[C@H](O)C1=C |t:20,30|	Phase 2
cytochlor					Berry	100	Nc1nc(=O)n(cc1Cl)[C@H]1C[C@@H](O)[C@@H](CO)O1	Phase 1
cyt387	JAK inhibitor	JAK1, JAK2, JAK3			MedChemEx, Selleck, Selleck, Selleck, Selleck, Selleck	95.48	O=C(NCC#N)c1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1, O=C(NCC#N)c1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1, O=C(NCC#N)c1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1, O=C(NCC#N)c1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1, O=C(NCC#N)c1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1, O=C(NCC#N)c1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1	Phase 3
CY208-243	dopamine receptor agonist	CALY			Tocris, Tocris	66.95	CN1Cc2ccccc2[C@H]2[C@H]1Cc1c[nH]c3cccc2c13, CN1Cc2ccccc2[C@H]2[C@H]1Cc1c[nH]c3cccc2c13	Phase 2
CZC-54252	leucine rich repeat kinase inhibitor	LRRK2			Tocris, Tocris, Tocris, Tocris	98.82	COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2NS(C)(=O)=O)n1)N1CCOCC1, COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2NS(C)(=O)=O)n1)N1CCOCC1, COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2NS(C)(=O)=O)n1)N1CCOCC1, COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2NS(C)(=O)=O)n1)N1CCOCC1	Preclinical
CZC24832	PI3K inhibitor	PIK3CG			Selleck, Tocris	98.69	CC(C)(C)NS(=O)(=O)c1cncc(c1)-c1cc(F)c2nc(N)nn2c1, CC(C)(C)NS(=O)(=O)c1cncc(c1)-c1cc(F)c2nc(N)nn2c1	Preclinical
C106					Enzo	0	CN1CCC[C@@H]1c1cccnc1.Cc1ccc(cc1)C(=O)O[C@@H]([C@@H](OC(=O)c1ccc(C)cc1)C(O)=O)C(O)=O |&1:5,&2:22,&3:23,r|	Phase 3
C11-Acetate		ABAT, ACE, AKR1C3, CA2, CELA1, ESR2, FFAR2, FFAR3, HPRT1, LTA4H, MMP12, NOS1, NOS3, PLA2G1B, PTPN1, SOD1, TXN			SantaCruz	0	[Y+3]	Phase 3
C188-9	STAT inhibitor				MedChemEx	91.21	COc1ccc(cc1)S(=O)(=O)Nc1cc(c(O)c2ccccc12)-c1c(O)ccc2ccccc12	Preclinical
C34	toll-like receptor inhibitor	TLR4			Tocris, Tocris	100	CC(C)O[C@H]1O[C@H](COC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1NC(C)=O, CC(C)O[C@H]1O[C@H](COC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1NC(C)=O	Preclinical
C646	histone acetyltransferase inhibitor	EP300			Selleck, Selleck, Selleck, Tocris, Tocris, Selleck, Selleck, Selleck, Selleck	88.71	CC1=NN(C(=O)C1=Cc1ccc(o1)-c1cc(C)c(C)cc1[N+]([O-])=O)c1ccc(cc1)C(O)=O |t:1|, CC1=NN(C(=O)C1=Cc1ccc(o1)-c1cc(C)c(C)cc1[N+]([O-])=O)c1ccc(cc1)C(O)=O |t:1|, CC1=NN(C(=O)C1=Cc1ccc(o1)-c1cc(C)c(C)cc1[N+]([O-])=O)c1ccc(cc1)C(O)=O |t:1|, CC1=NN(C(=O)C1=Cc1ccc(o1)-c1cc(C)c(C)cc1[N+]([O-])=O)c1ccc(cc1)C(O)=O |t:1|, CC1=NN(C(=O)C1=Cc1ccc(o1)-c1cc(C)c(C)cc1[N+]([O-])=O)c1ccc(cc1)C(O)=O |t:1|, CC1=NN(C(=O)C1=Cc1ccc(o1)-c1cc(C)c(C)cc1[N+]([O-])=O)c1ccc(cc1)C(O)=O |t:1|, CC1=NN(C(=O)C1=Cc1ccc(o1)-c1cc(C)c(C)cc1[N+]([O-])=O)c1ccc(cc1)C(O)=O |t:1|, CC1=NN(C(=O)C1=Cc1ccc(o1)-c1cc(C)c(C)cc1[N+]([O-])=O)c1ccc(cc1)C(O)=O |t:1|, CC1=NN(C(=O)C1=Cc1ccc(o1)-c1cc(C)c(C)cc1[N+]([O-])=O)c1ccc(cc1)C(O)=O |t:1|	Preclinical
D,L-mevalonic-acid-lactone					Prestwick	0	C[C@@]1(O)CCOC(=O)C1 |&1:1,r|	Preclinical
D-(+)-maltose		MGAM			MicroSource, Sigma	100	OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O, OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O	Preclinical
D-alpha-tocopheryl-succinate					SantaCruz, SantaCruz	93.52	CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC[C@]1(C)CCc2c(C)c(OC(=O)CCC(O)=O)c(C)c(C)c2O1, CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC[C@]1(C)CCc2c(C)c(OC(=O)CCC(O)=O)c(C)c(C)c2O1	Launched
D-delta-tocopherol					Acros	91.79	CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC[C@]1(C)CCc2cc(O)cc(C)c2O1	Launched
D-limonene					Sigma, MicroSource	0	CC(=C)[C@@H]1CCC(C)=CC1 |c:7|, CC(=C)[C@@H]1CCC(C)=CC1 |c:7|	Phase 1
D-phenylalanine	enkephalinase inhibitor	CCBL1, CRH, HCAR3			MicroSource, Selleck, Selleck	100	N[C@H](Cc1ccccc1)C(O)=O, N[C@H](Cc1ccccc1)C(O)=O, N[C@H](Cc1ccccc1)C(O)=O	Preclinical
D-serine	glutamate receptor agonist	GLRA1, GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, SERPINB3			Enzo, Tocris	100	N[C@H](CO)C(O)=O, N[C@H](CO)C(O)=O	Launched
D-157495	decapping scavenger enzyme inhibitor				MedChemEx	94.7	Nc1nc(N)c2c(OCC3CCN(Cc4c(Cl)cccc4Cl)CC3)cccc2n1	Preclinical
D-3263	transient receptor potential channel agonist				MedChemEx	90.23	COc1ccc2n(C(=O)[C@@H]3C[C@H](C)CC[C@H]3C(C)C)c(=O)n(CCN)c2c1	Phase 1
D-4476	TGF beta receptor inhibitor	CSNK1A1, CSNK1D, TGFB1			Tocris, Tocris, Tocris	96.91	NC(=O)c1ccc(cc1)-c1nc(c([nH]1)-c1ccc2OCCOc2c1)-c1ccccn1, NC(=O)c1ccc(cc1)-c1nc(c([nH]1)-c1ccc2OCCOc2c1)-c1ccccn1, NC(=O)c1ccc(cc1)-c1nc(c([nH]1)-c1ccc2OCCOc2c1)-c1ccccn1	Preclinical
D-64131	microtubule inhibitor	TUBB			Tocris, Tocris, Tocris, Tocris, Tocris, Tocris	98.74	COc1ccc2[nH]c(cc2c1)C(=O)c1ccccc1, COc1ccc2[nH]c(cc2c1)C(=O)c1ccccc1, COc1ccc2[nH]c(cc2c1)C(=O)c1ccccc1, COc1ccc2[nH]c(cc2c1)C(=O)c1ccccc1, COc1ccc2[nH]c(cc2c1)C(=O)c1ccccc1, COc1ccc2[nH]c(cc2c1)C(=O)c1ccccc1	Preclinical
D-7193					ChemImpex	0	CC(=O)N[C@@H](CSSC[C@H](NC(C)=O)C(O)=O)C(O)=O	Phase 2
DAA-1106	benzodiazepine receptor agonist	TSPO			MedChemEx, MedChemEx	98.31	COc1ccc(OC)c(CN(C(C)=O)c2cc(F)ccc2Oc2ccccc2)c1, COc1ccc(OC)c(CN(C(C)=O)c2cc(F)ccc2Oc2ccccc2)c1	Preclinical
dabigatran	thrombin inhibitor	F2	neurology/psychiatry, hematology	stroke, systemic embolism, pulmonary embolism (PE), deep vein thrombosis (DVT)	MedChemEx, Selleck, MedChemEx, Selleck, Selleck, Selleck	77.34	Cn1c(CNc2ccc(cc2)C(N)=N)nc2cc(ccc12)C(=O)N(CCC(O)=O)c1ccccn1, Cn1c(CNc2ccc(cc2)C(N)=N)nc2cc(ccc12)C(=O)N(CCC(O)=O)c1ccccn1, Cn1c(CNc2ccc(cc2)C(N)=N)nc2cc(ccc12)C(=O)N(CCC(O)=O)c1ccccn1, Cn1c(CNc2ccc(cc2)C(N)=N)nc2cc(ccc12)C(=O)N(CCC(O)=O)c1ccccn1, Cn1c(CNc2ccc(cc2)C(N)=N)nc2cc(ccc12)C(=O)N(CCC(O)=O)c1ccccn1, Cn1c(CNc2ccc(cc2)C(N)=N)nc2cc(ccc12)C(=O)N(CCC(O)=O)c1ccccn1	Launched
dabigatran-etexilate	thrombin inhibitor	F2	neurology/psychiatry, hematology	stroke, systemic embolism, pulmonary embolism (PE), deep vein thrombosis (DVT)	MedChemEx, MicroSource, Selleck	98.31	CCCCCCOC(=O)\N=C(\N)c1ccc(NCc2nc3cc(ccc3n2C)C(=O)N(CCC(=O)OCC)c2ccccn2)cc1, CCCCCCOC(=O)\N=C(\N)c1ccc(NCc2nc3cc(ccc3n2C)C(=O)N(CCC(=O)OCC)c2ccccn2)cc1, CCCCCCOC(=O)\N=C(\N)c1ccc(NCc2nc3cc(ccc3n2C)C(=O)N(CCC(=O)OCC)c2ccccn2)cc1	Launched
dabrafenib	RAF inhibitor	BRAF, LIMK1, NEK11, RAF1, SIK1	oncology	melanoma	Selleck, Selleck, Selleck, Selleck, Selleck, MedChemEx, Selleck, Selleck	98.14	CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F, CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F, CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F, CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F, CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F, CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F, CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F, CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F	Launched
dacarbazine	DNA alkylating agent	PGD, POLA2	oncology, hematologic malignancy	melanoma, Hodgkin's lymphoma	MicroSource, Selleck, Selleck	98.92	CN(C)\N=N\c1nc[nH]c1C(N)=O, CN(C)\N=N\c1nc[nH]c1C(N)=O, CN(C)\N=N\c1nc[nH]c1C(N)=O	Launched
dacinostat	HDAC inhibitor	HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9			Selleck, Selleck, Selleck, Selleck, Selleck, Selleck	87.84	OCCN(CCc1c[nH]c2ccccc12)Cc1ccc(\C=C\C(=O)NO)cc1, OCCN(CCc1c[nH]c2ccccc12)Cc1ccc(\C=C\C(=O)NO)cc1, OCCN(CCc1c[nH]c2ccccc12)Cc1ccc(\C=C\C(=O)NO)cc1, OCCN(CCc1c[nH]c2ccccc12)Cc1ccc(\C=C\C(=O)NO)cc1, OCCN(CCc1c[nH]c2ccccc12)Cc1ccc(\C=C\C(=O)NO)cc1, OCCN(CCc1c[nH]c2ccccc12)Cc1ccc(\C=C\C(=O)NO)cc1	Phase 1
daclatasvir	HCV inhibitor		infectious disease	hepatitis C	Selleck, Selleck, Selleck	94.8	COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1c1nc(c[nH]1)-c1ccc(cc1)-c1ccc(cc1)-c1c[nH]c(n1)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)OC)C(C)C, COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1c1nc(c[nH]1)-c1ccc(cc1)-c1ccc(cc1)-c1c[nH]c(n1)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)OC)C(C)C, COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1c1nc(c[nH]1)-c1ccc(cc1)-c1ccc(cc1)-c1c[nH]c(n1)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)OC)C(C)C	Launched
dacomitinib	EGFR inhibitor	EGFR, ERBB2, ERBB4			Tocris, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck	97.34	COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)\C=C\CN1CCCCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)\C=C\CN1CCCCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)\C=C\CN1CCCCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)\C=C\CN1CCCCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)\C=C\CN1CCCCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)\C=C\CN1CCCCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)\C=C\CN1CCCCC1	Launched
dactinomycin	RNA polymerase inhibitor	POLR2A	oncology	testicular carcinoma, Wilm's tumor, rhabdomyosarcoma, Ewing's sarcoma, gestational trophoblastic disease (GTD)	MicroSource, MicroSource	77.87	CC(C)[C@H]1NC(=O)[C@@H](NC(=O)c2ccc(C)c3oc4c(C)c(=O)c(N)c(C(=O)N[C@H]5[C@@H](C)OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]6CCCN6C(=O)[C@H](NC5=O)C(C)C)c4nc23)[C@@H](C)OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C1=O, CC(C)[C@H]1NC(=O)[C@@H](NC(=O)c2ccc(C)c3oc4c(C)c(=O)c(N)c(C(=O)N[C@H]5[C@@H](C)OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]6CCCN6C(=O)[C@H](NC5=O)C(C)C)c4nc23)[C@@H](C)OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C1=O	Launched
daidzein	estrogen receptor agonist	ESRRA, ESRRB, ESRRG, TRPC5			Tocris, Tocris, Enzo, Selleck, Selleck, Tocris	97.99	Oc1ccc(cc1)-c1coc2cc(O)ccc2c1=O, Oc1ccc(cc1)-c1coc2cc(O)ccc2c1=O, Oc1ccc(cc1)-c1coc2cc(O)ccc2c1=O, Oc1ccc(cc1)-c1coc2cc(O)ccc2c1=O, Oc1ccc(cc1)-c1coc2cc(O)ccc2c1=O, Oc1ccc(cc1)-c1coc2cc(O)ccc2c1=O	Phase 2
daidzin	antioxidant	ALDH2			MedChemEx	90.05	OC[C@H]1O[C@@H](Oc2ccc3c(c2)occ(-c2ccc(O)cc2)c3=O)[C@H](O)[C@@H](O)[C@@H]1O	Phase 1
dalargin	opioid receptor agonist	OPRM1			InterBioScreen, InterBioScreen	79.63	CC(C)C[C@@H](NC(=O)[C@@H](Cc1ccccc1)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@H](CCCNC(N)=N)C(O)=O |a:23,41,&1:4,&2:8,&3:28|, CC(C)C[C@@H](NC(=O)[C@@H](Cc1ccccc1)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@H](CCCNC(N)=N)C(O)=O |a:23,41,&1:4,&2:8,&3:28|	Phase 2
dalbavancin	bacterial cell wall synthesis inhibitor	PNLIP	infectious disease	skin infections	MedChemEx, MedChemEx	92.67	CN[C@@H]1c2ccc(O)c(Oc3cc(O)c(Cl)c(c3)[C@@H]3NC(=O)[C@@H](Cc4ccc(Oc5cc6cc(Oc7ccc(cc7Cl)[C@@H](O)[C@@H]7NC(=O)[C@H](NC(=O)[C@@H]6NC3=O)c3ccc(O)c(c3)-c3c(O[C@H]6O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]6O)cc(O)cc3[C@H](NC7=O)C(=O)NCCCN(C)C)c5O[C@@H]3O[C@@H]([C@@H](O)[C@H](O)[C@H]3NC(=O)CCCCCCCCC(C)C)C(O)=O)cc4)NC1=O)c2, CN[C@@H]1c2ccc(O)c(Oc3cc(O)c(Cl)c(c3)[C@@H]3NC(=O)[C@@H](Cc4ccc(Oc5cc6cc(Oc7ccc(cc7Cl)[C@@H](O)[C@@H]7NC(=O)[C@H](NC(=O)[C@@H]6NC3=O)c3ccc(O)c(c3)-c3c(O[C@H]6O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]6O)cc(O)cc3[C@H](NC7=O)C(=O)NCCCN(C)C)c5O[C@@H]3O[C@@H]([C@@H](O)[C@H](O)[C@H]3NC(=O)CCCCCCCCC(C)C)C(O)=O)cc4)NC1=O)c2	Launched
dalcetrapib	cholesteryl ester transfer protein inhibitor	CETP			MedChemEx, Selleck, Selleck	95.55	CCC(CC)CC1(CCCCC1)C(=O)Nc1ccccc1SC(=O)C(C)C, CCC(CC)CC1(CCCCC1)C(=O)Nc1ccccc1SC(=O)C(C)C, CCC(CC)CC1(CCCCC1)C(=O)Nc1ccccc1SC(=O)C(C)C	Phase 3
dalfampridine	potassium channel blocker	KCNA1, KCNA10, KCNA2, KCNA3, KCNA4, KCNA5, KCNA6, KCNA7, KCNB1, KCNB2, KCNC1, KCNC2, KCNC3, KCNC4, KCND1, KCND2, KCND3, KCNF1, KCNG1, KCNG2, KCNG3, KCNG4, KCNH1, KCNH2, KCNH3, KCNH4, KCNH5, KCNH6, KCNH7, KCNH8, KCNJ13, KCNJ5, KCNQ1, KCNQ2, KCNQ3, KCNQ4, KCNQ5, KCNS1, KCNS2, KCNS3, KCNV1, KCNV2	neurology/psychiatry	multiple sclerosis	MicroSource, MicroSource, Tocris	97.14	Nc1ccncc1, Nc1ccncc1, Nc1ccncc1	Launched
dalfopristin	antibacterial 				MedChemEx	79.72	[H][C@]12[C@@H](CCN1C(=O)c1coc(CC(=O)C[C@H](O)\C=C(/C)\C=C/CNC(=O)\C=C\[C@@H](C)[C@@H](OC2=O)C(C)C)n1)S(=O)(=O)CCN(CC)CC |c:19,22,t:28|	Preclinical
daltroban	thromboxane receptor antagonist	TBXA2R			Sigma	94.94	OC(=O)Cc1ccc(CCNS(=O)(=O)c2ccc(Cl)cc2)cc1	Phase 3
daminozide	KDM2A inhibitor	KDM2A, KDM7A, PHF8			Tocris, Tocris	100	CN(C)NC(=O)CCC(O)=O, CN(C)NC(=O)CCC(O)=O	Preclinical
danazol	estrogen receptor antagonist, progesterone receptor agonist	AR, CCL2, ESR1, GNRHR, GNRHR2, PGR	obstetrics/gynecology, cardiology	endometriosis, angioedema	MedChemEx, MedChemEx	93.15	C[C@]12CC[C@H]3[C@@H](CCC4=Cc5oncc5C[C@]34C)[C@@H]1CC[C@@]2(O)C#C |t:8|, C[C@]12CC[C@H]3[C@@H](CCC4=Cc5oncc5C[C@]34C)[C@@H]1CC[C@@]2(O)C#C |t:8|	Launched
danegaptide	gap junction modulator				MedChemEx, MedChemEx	88.96	NCC(=O)N1C[C@@H](C[C@H]1C(O)=O)NC(=O)c1ccccc1, NCC(=O)N1C[C@@H](C[C@H]1C(O)=O)NC(=O)c1ccccc1	Phase 2
danirixin	CC chemokine receptor antagonist	CXCR2			MedChemEx, MedChemEx	94.48	Cc1c(F)cccc1NC(=O)Nc1ccc(Cl)c(c1O)S(=O)(=O)[C@H]1CCCNC1, Cc1c(F)cccc1NC(=O)Nc1ccc(Cl)c(c1O)S(=O)(=O)[C@H]1CCCNC1	Phase 2
danofloxacin	bacterial DNA gyrase inhibitor		pulmonary	bovine respiratory disease (BRD)	MedChemEx, Selleck, Selleck	95.15	CN1C[C@@H]2C[C@H]1CN2c1cc2n(cc(C(O)=O)c(=O)c2cc1F)C1CC1, CN1C[C@@H]2C[C@H]1CN2c1cc2n(cc(C(O)=O)c(=O)c2cc1F)C1CC1, CN1C[C@@H]2C[C@H]1CN2c1cc2n(cc(C(O)=O)c(=O)c2cc1F)C1CC1	Launched
danoprevir	HCV inhibitor				MedChemEx, MedChemEx, Selleck	94.01	CC(C)(C)OC(=O)N[C@H]1CCCCC\C=C/[C@@H]2C[C@]2(NC(=O)[C@@H]2C[C@H](CN2C1=O)OC(=O)N1Cc2cccc(F)c2C1)C(=O)NS(=O)(=O)C1CC1 |c:14|, CC(C)(C)OC(=O)N[C@H]1CCCCC\C=C/[C@@H]2C[C@]2(NC(=O)[C@@H]2C[C@H](CN2C1=O)OC(=O)N1Cc2cccc(F)c2C1)C(=O)NS(=O)(=O)C1CC1 |c:14|, CC(C)(C)OC(=O)N[C@H]1CCCCC\C=C/[C@@H]2C[C@]2(NC(=O)[C@@H]2C[C@H](CN2C1=O)OC(=O)N1Cc2cccc(F)c2C1)C(=O)NS(=O)(=O)C1CC1 |c:14|	Phase 3
dantrolene	calcium channel blocker	RYR1, RYR3	neurology/psychiatry, endocrinology	spasms, malignant hyperthermia (MH)	MicroSource, Tocris, Tocris, Tocris	97.08	[O-][N+](=O)c1ccc(cc1)-c1ccc(\C=N\N2CC(=O)NC2=O)o1, [O-][N+](=O)c1ccc(cc1)-c1ccc(\C=N\N2CC(=O)NC2=O)o1, [O-][N+](=O)c1ccc(cc1)-c1ccc(\C=N\N2CC(=O)NC2=O)o1, [O-][N+](=O)c1ccc(cc1)-c1ccc(\C=N\N2CC(=O)NC2=O)o1	Launched
dantron	laxative				MicroSource, MicroSource, MicroSource, MedChemEx	96.26	Oc1cccc2C(=O)c3cccc(O)c3C(=O)c12, Oc1cccc2C(=O)c3cccc(O)c3C(=O)c12, Oc1cccc2C(=O)c3cccc(O)c3C(=O)c12, Oc1cccc2C(=O)c3cccc(O)c3C(=O)c12	Withdrawn
danusertib	Aurora kinase inhibitor, growth factor receptor inhibitor	AURKA, AURKB, AURKC, FGFR1, NTRK1, RET, SLK			Selleck, Selleck, Selleck, Selleck	93.08	CO[C@@H](C(=O)N1Cc2n[nH]c(NC(=O)c3ccc(cc3)N3CCN(C)CC3)c2C1)c1ccccc1, CO[C@@H](C(=O)N1Cc2n[nH]c(NC(=O)c3ccc(cc3)N3CCN(C)CC3)c2C1)c1ccccc1, CO[C@@H](C(=O)N1Cc2n[nH]c(NC(=O)c3ccc(cc3)N3CCN(C)CC3)c2C1)c1ccccc1, CO[C@@H](C(=O)N1Cc2n[nH]c(NC(=O)c3ccc(cc3)N3CCN(C)CC3)c2C1)c1ccccc1	Phase 2
dapagliflozin	sodium/glucose cotransporter inhibitor	SLC5A1, SLC5A2	endocrinology	diabetes mellitus	MicroSource, Selleck, Selleck	98	CCOc1ccc(Cc2cc(ccc2Cl)[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc1, CCOc1ccc(Cc2cc(ccc2Cl)[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc1, CCOc1ccc(Cc2cc(ccc2Cl)[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc1	Launched
dapansutrile	anti-inflammatory agent				Enamine	0	CS(=O)(=O)CCC#N	Phase 2
daphnetin	protein kinase inhibitor				Selleck, MedChemEx	96.19	Oc1ccc2ccc(=O)oc2c1O, Oc1ccc2ccc(=O)oc2c1O	Preclinical
dapiprazole	adrenergic receptor antagonist	ADRA1A, ADRA1B, ADRA1D	ophthalmology	mydriasis	AvaChem, AvaChem	99.76	Cc1ccccc1N1CCN(CCc2nnc3CCCCn23)CC1, Cc1ccccc1N1CCN(CCc2nnc3CCCCn23)CC1	Launched
dapivirine	non-nucleoside reverse transcriptase inhibitor	CYP3A4, CYP3A5			Selleck, Selleck, Selleck, Selleck, MedChemEx	99.06	Cc1cc(C)c(Nc2ccnc(Nc3ccc(cc3)C#N)n2)c(C)c1, Cc1cc(C)c(Nc2ccnc(Nc3ccc(cc3)C#N)n2)c(C)c1, Cc1cc(C)c(Nc2ccnc(Nc3ccc(cc3)C#N)n2)c(C)c1, Cc1cc(C)c(Nc2ccnc(Nc3ccc(cc3)C#N)n2)c(C)c1, Cc1cc(C)c(Nc2ccnc(Nc3ccc(cc3)C#N)n2)c(C)c1	Phase 3
dapoxetine	selective serotonin reuptake inhibitor (SSRI)	HTR1A, HTR1B, HTR2C, SLC6A4	urology	premature ejaculation (PE)	Selleck, Selleck, Selleck, Selleck	99.38	CN(C)[C@@H](CCOc1cccc2ccccc12)c1ccccc1, CN(C)[C@@H](CCOc1cccc2ccccc12)c1ccccc1, CN(C)[C@@H](CCOc1cccc2ccccc12)c1ccccc1, CN(C)[C@@H](CCOc1cccc2ccccc12)c1ccccc1	Launched
daprodustat	hypoxia inducible factor inhibitor	EGLN1			MedChemEx, MedChemEx, MedChemEx	94.74	OC(=O)CNC(=O)c1c(O)n(C2CCCCC2)c(=O)n(C2CCCCC2)c1=O, OC(=O)CNC(=O)c1c(O)n(C2CCCCC2)c(=O)n(C2CCCCC2)c1=O, OC(=O)CNC(=O)c1c(O)n(C2CCCCC2)c(=O)n(C2CCCCC2)c1=O	Phase 3
dapsone	bacterial antifolate	DHFR	dermatology, infectious disease	dermatitis herpetiformis (DH), leprosy	MedChemEx, MicroSource	98.4	Nc1ccc(cc1)S(=O)(=O)c1ccc(N)cc1, Nc1ccc(cc1)S(=O)(=O)c1ccc(N)cc1	Launched
DAPT	gamma secretase inhibitor				Tocris, Tocris, Tocris, Tocris, Selleck	96.31	C[C@H](NC(=O)Cc1cc(F)cc(F)c1)C(=O)N[C@H](C(=O)OC(C)(C)C)c1ccccc1, C[C@H](NC(=O)Cc1cc(F)cc(F)c1)C(=O)N[C@H](C(=O)OC(C)(C)C)c1ccccc1, C[C@H](NC(=O)Cc1cc(F)cc(F)c1)C(=O)N[C@H](C(=O)OC(C)(C)C)c1ccccc1, C[C@H](NC(=O)Cc1cc(F)cc(F)c1)C(=O)N[C@H](C(=O)OC(C)(C)C)c1ccccc1, C[C@H](NC(=O)Cc1cc(F)cc(F)c1)C(=O)N[C@H](C(=O)OC(C)(C)C)c1ccccc1	Preclinical
daptomycin	bacterial cell wall synthesis inhibitor		infectious disease	skin infections, endocarditis	MedChemEx	74.27	[H][C@]1(CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](C)NC(=O)[C@]([H])(CC(O)=O)NC(=O)[C@H](CCCN)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](CC(N)=O)NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)CCCCCCCCC)[C@@H](C)OC(=O)[C@]([H])(CC(=O)c2ccccc2N)NC(=O)[C@@]([H])(NC1=O)[C@H](C)CC(O)=O	Launched
darapladib	phospholipase inhibitor	PLA2G7			MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx	97.95	CCN(CC)CCN(Cc1ccc(cc1)-c1ccc(cc1)C(F)(F)F)C(=O)Cn1c2CCCc2c(=O)nc1SCc1ccc(F)cc1, CCN(CC)CCN(Cc1ccc(cc1)-c1ccc(cc1)C(F)(F)F)C(=O)Cn1c2CCCc2c(=O)nc1SCc1ccc(F)cc1, CCN(CC)CCN(Cc1ccc(cc1)-c1ccc(cc1)C(F)(F)F)C(=O)Cn1c2CCCc2c(=O)nc1SCc1ccc(F)cc1, CCN(CC)CCN(Cc1ccc(cc1)-c1ccc(cc1)C(F)(F)F)C(=O)Cn1c2CCCc2c(=O)nc1SCc1ccc(F)cc1, CCN(CC)CCN(Cc1ccc(cc1)-c1ccc(cc1)C(F)(F)F)C(=O)Cn1c2CCCc2c(=O)nc1SCc1ccc(F)cc1, CCN(CC)CCN(Cc1ccc(cc1)-c1ccc(cc1)C(F)(F)F)C(=O)Cn1c2CCCc2c(=O)nc1SCc1ccc(F)cc1, CCN(CC)CCN(Cc1ccc(cc1)-c1ccc(cc1)C(F)(F)F)C(=O)Cn1c2CCCc2c(=O)nc1SCc1ccc(F)cc1, CCN(CC)CCN(Cc1ccc(cc1)-c1ccc(cc1)C(F)(F)F)C(=O)Cn1c2CCCc2c(=O)nc1SCc1ccc(F)cc1	Phase 3
darglitazone	PPAR receptor antagonist	PPARG			Cayman, Cayman	96.47	Cc1oc(nc1CCC(=O)c1ccc(CC2SC(=O)NC2=O)cc1)-c1ccccc1, Cc1oc(nc1CCC(=O)c1ccc(CC2SC(=O)NC2=O)cc1)-c1ccccc1	Phase 2
darifenacin	acetylcholine receptor antagonist	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5	urology	urinary incontinence	MedChemEx, MicroSource, Selleck	98.26	NC(=O)C([C@@H]1CCN(CCc2ccc3OCCc3c2)C1)(c1ccccc1)c1ccccc1, NC(=O)C([C@@H]1CCN(CCc2ccc3OCCc3c2)C1)(c1ccccc1)c1ccccc1, NC(=O)C([C@@H]1CCN(CCc2ccc3OCCc3c2)C1)(c1ccccc1)c1ccccc1	Launched
darolutamide	androgen receptor antagonist	AR	oncology	prostate cancer	MedChemEx, Selleck	98.62	C[C@@H](Cn1ccc(n1)-c1ccc(C#N)c(Cl)c1)NC(=O)c1cc(n[nH]1)[C@@H](C)O |a:1,&1:25|, C[C@@H](Cn1ccc(n1)-c1ccc(C#N)c(Cl)c1)NC(=O)c1cc(n[nH]1)[C@@H](C)O |a:1,&1:25|	Launched
darunavir	HIV protease inhibitor	CYP3A4	infectious disease	human immunodeficiency virus (HIV-1)	Selleck, Selleck, Selleck, MedChemEx, MedChemEx	98.7	CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CO[C@H]2OCC[C@@H]12)S(=O)(=O)c1ccc(N)cc1, CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CO[C@H]2OCC[C@@H]12)S(=O)(=O)c1ccc(N)cc1, CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CO[C@H]2OCC[C@@H]12)S(=O)(=O)c1ccc(N)cc1, CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CO[C@H]2OCC[C@@H]12)S(=O)(=O)c1ccc(N)cc1, CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CO[C@H]2OCC[C@@H]12)S(=O)(=O)c1ccc(N)cc1	Launched
darusentan	endothelin receptor antagonist	EDNRA			Key, Key	98.96	COc1cc(OC)nc(O[C@H](C(O)=O)C(OC)(c2ccccc2)c2ccccc2)n1, COc1cc(OC)nc(O[C@H](C(O)=O)C(OC)(c2ccccc2)c2ccccc2)n1	Phase 3
dasabuvir	HCV inhibitor		infectious disease	hepatitis C	MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx	92.69	COc1c(cc(cc1C(C)(C)C)-n1ccc(=O)[nH]c1=O)-c1ccc2cc(NS(C)(=O)=O)ccc2c1, COc1c(cc(cc1C(C)(C)C)-n1ccc(=O)[nH]c1=O)-c1ccc2cc(NS(C)(=O)=O)ccc2c1, COc1c(cc(cc1C(C)(C)C)-n1ccc(=O)[nH]c1=O)-c1ccc2cc(NS(C)(=O)=O)ccc2c1, COc1c(cc(cc1C(C)(C)C)-n1ccc(=O)[nH]c1=O)-c1ccc2cc(NS(C)(=O)=O)ccc2c1, COc1c(cc(cc1C(C)(C)C)-n1ccc(=O)[nH]c1=O)-c1ccc2cc(NS(C)(=O)=O)ccc2c1	Launched
dasatinib	Bcr-Abl kinase inhibitor, ephrin inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, SRC inhibitor, tyrosine kinase inhibitor	ABL1, ABL2, BLK, EPHA2, FGR, FRK, FYN, HCK, KIT, LCK, LYN, PDGFRB, SRC, SRMS, STAT5B, YES1	hematologic malignancy	chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL)	Selleck, Selleck, Selleck, Selleck	97.6	Cc1nc(Nc2ncc(s2)C(=O)Nc2c(C)cccc2Cl)cc(n1)N1CCN(CCO)CC1, Cc1nc(Nc2ncc(s2)C(=O)Nc2c(C)cccc2Cl)cc(n1)N1CCN(CCO)CC1, Cc1nc(Nc2ncc(s2)C(=O)Nc2c(C)cccc2Cl)cc(n1)N1CCN(CCO)CC1, Cc1nc(Nc2ncc(s2)C(=O)Nc2c(C)cccc2Cl)cc(n1)N1CCN(CCO)CC1	Launched
dasotraline	dopamine-norepinephrine-serotonin reuptake inhibitor				MedChemEx	97.59	N[C@@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc12	Phase 3
DAU-5884	acetylcholine receptor antagonist	CHRM3			Tocris, Tocris, Tocris	97.49	CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)N1Cc2ccccc2NC1=O, CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)N1Cc2ccccc2NC1=O, CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)N1Cc2ccccc2NC1=O	Preclinical
daucosterol	apoptosis stimulant				MedChemEx	89.9	CC[C@H](CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@H](CC[C@]4(C)[C@H]3CC[C@]12C)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)C(C)C |t:13|	Phase 2
daunorubicin	RNA synthesis inhibitor, topoisomerase inhibitor	TOP2A, TOP2B	hematologic malignancy	acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL)	MicroSource, MicroSource, MicroSource, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Tocris, Selleck, Selleck, Selleck, Selleck	95.52	COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O	Launched
dazmegrel	thromboxane synthase inhibitor	TBXAS1			Vitas-M	98.91	Cc1c(Cn2ccnc2)c2ccccc2n1CCC(O)=O	Phase 2
dazoxiben	thromboxane synthase inhibitor	TBXAS1			AKSci	95.24	OC(=O)c1ccc(OCCn2ccnc2)cc1	Phase 2
DBeQ	ATPase inhibitor	CASP3			Tocris, Selleck, Selleck, Selleck	96.56	C(Nc1nc(NCc2ccccc2)c2ccccc2n1)c1ccccc1, C(Nc1nc(NCc2ccccc2)c2ccccc2n1)c1ccccc1, C(Nc1nc(NCc2ccccc2)c2ccccc2n1)c1ccccc1, C(Nc1nc(NCc2ccccc2)c2ccccc2n1)c1ccccc1	Preclinical
DBPR-211	cannabinoid receptor antagonist				AMS	95.16	FC(F)(F)c1ccc(cc1)C#Cc1ccc(s1)-c1c(CNS(=O)(=O)N2CCCC2)c(nn1-c1ccc(Cl)cc1Cl)C(=O)NN1CCCCC1	Preclinical
DBPR108	dipeptidyl peptidase inhibitor	DPP4			MedChemEx, MedChemEx, MedChemEx	95.35	CC(C)(CC(=O)N1CCCC1)NCC(=O)N1C[C@@H](F)C[C@H]1C#N, CC(C)(CC(=O)N1CCCC1)NCC(=O)N1C[C@@H](F)C[C@H]1C#N, CC(C)(CC(=O)N1CCCC1)NCC(=O)N1C[C@@H](F)C[C@H]1C#N	Phase 1
DC-260126	free fatty acid receptor antagonist	FFAR1			Tocris, Tocris, Tocris	95.9	CCCCc1ccc(NS(=O)(=O)c2ccc(F)cc2)cc1, CCCCc1ccc(NS(=O)(=O)c2ccc(F)cc2)cc1, CCCCc1ccc(NS(=O)(=O)c2ccc(F)cc2)cc1	Preclinical
DCC-2618	KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor	KIT, PDGFRA			MedChemEx, MedChemEx	98.4	Cn1cc(cn1)-c1cc(Oc2cc(F)c(NC(=O)C3(CC3)C(=O)Nc3ccccc3)cc2F)ccn1, Cn1cc(cn1)-c1cc(Oc2cc(F)c(NC(=O)C3(CC3)C(=O)Nc3ccccc3)cc2F)ccn1	Phase 1
DCEBIO	potassium channel activator	KCNN2, KCNN3, KCNN4			Tocris, Tocris, Tocris, Tocris, Tocris, Tocris, Tocris	99.81	CCn1c2cc(Cl)c(Cl)cc2[nH]c1=O, CCn1c2cc(Cl)c(Cl)cc2[nH]c1=O, CCn1c2cc(Cl)c(Cl)cc2[nH]c1=O, CCn1c2cc(Cl)c(Cl)cc2[nH]c1=O, CCn1c2cc(Cl)c(Cl)cc2[nH]c1=O, CCn1c2cc(Cl)c(Cl)cc2[nH]c1=O, CCn1c2cc(Cl)c(Cl)cc2[nH]c1=O	Preclinical
DCP-LA	protein kinase activator				MedChemEx	100	CCCCC[C@H]1C[C@H]1C[C@H]1C[C@H]1CCCCCCCC(O)=O |&1:11,&2:9,&3:7,&4:5,r|	Preclinical
DCPIB	chloride channel blocker, gap junction modulator, glutamate inhibitor	SLC1A2			Tocris	88.14	CCCC[C@]1(Cc2cc(OCCCC(O)=O)c(Cl)c(Cl)c2C1=O)C1CCCC1 |&1:4,r|	Preclinical
DDR1-IN-1	discoidin domain receptor inhibitor	DDR1, DDR2			Tocris, Tocris	96.23	CCN1CCN(Cc2ccc(cc2C(F)(F)F)C(=O)Nc2ccc(C)c(Oc3ccc4NC(=O)Cc4c3)c2)CC1, CCN1CCN(Cc2ccc(cc2C(F)(F)F)C(=O)Nc2ccc(C)c(Oc3ccc4NC(=O)Cc4c3)c2)CC1	Preclinical
deazaguanine	DNA synthesis inhibitor				Sigma	73	Nc1cc2[nH]cnc2c(O)n1	Preclinical
Debio-0932	HSP inhibitor				MedChemEx	94.04	CN(C)c1cc2OCOc2cc1Sc1nc2c(N)nccc2n1CCNCC(C)(C)C	Phase 1
debrisoquin	adrenergic neuron blocker	SLC6A2	cardiology	hypertension	PrincetonBio, MicroSource, MicroSource	80.31	NC(=N)N1CCc2ccccc2C1, NC(=N)N1CCc2ccccc2C1, NC(=N)N1CCc2ccccc2C1	Launched
decamethonium	acetylcholine receptor agonist	ACHE, CHRNA2	neurology/psychiatry	muscle relaxant	MedChemEx, MedChemEx, MicroSource, Selleck	99.47	C[N+](C)(C)CCCCCCCCCC[N+](C)(C)C, C[N+](C)(C)CCCCCCCCCC[N+](C)(C)C, C[N+](C)(C)CCCCCCCCCC[N+](C)(C)C, C[N+](C)(C)CCCCCCCCCC[N+](C)(C)C	Launched
decamethoxine	antiseptic				Innovapharm	0	CC(C)[C@H]1CC[C@H](C)C[C@@H]1OC(=O)C[N+](C)(C)CCCCCCCCCC[N+](C)(C)CC(=O)O[C@H]1C[C@H](C)CC[C@@H]1C(C)C |&1:40,&2:36,&3:34,&4:9,&5:6,&6:3|	Phase 2
decernotinib	JAK inhibitor	JAK3			MedChemEx, MedChemEx	97.54	CC[C@@](C)(Nc1ccnc(n1)-c1c[nH]c2ncccc12)C(=O)NCC(F)(F)F |&1:2,r|, CC[C@@](C)(Nc1ccnc(n1)-c1c[nH]c2ncccc12)C(=O)NCC(F)(F)F |&1:2,r|	Phase 2/Phase 3
decitabine	DNA methyltransferase inhibitor	DNMT1, DNMT3A	hematologic malignancy, hematology	myelodysplastic diseases (MDS), anemia, chronic myeloid leukemia (CML)	Tocris, Tocris, Tocris, Tocris, Selleck, Selleck	100	Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1, Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1, Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1, Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1, Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1, Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1	Launched
declopramide	cell cycle inhibitor				Enamine	93.64	CCN(CC)CCNC(=O)c1ccc(N)c(Cl)c1	Preclinical
decloxizine	histamine receptor antagonist				MedChemEx	94.56	OCCOCCN1CCN(CC1)C(c1ccccc1)c1ccccc1	Preclinical
decoquinate	antiprotozoal agent		infectious disease	coccidiosis	MicroSource, MedChemEx, MedChemEx, Selleck, Selleck	100	CCCCCCCCCCOc1cc2c(cc1OCC)[nH]cc(C(=O)OCC)c2=O, CCCCCCCCCCOc1cc2c(cc1OCC)[nH]cc(C(=O)OCC)c2=O, CCCCCCCCCCOc1cc2c(cc1OCC)[nH]cc(C(=O)OCC)c2=O, CCCCCCCCCCOc1cc2c(cc1OCC)[nH]cc(C(=O)OCC)c2=O, CCCCCCCCCCOc1cc2c(cc1OCC)[nH]cc(C(=O)OCC)c2=O	Launched
defactinib	focal adhesion kinase inhibitor	PTK2			MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx	98.24	CNC(=O)c1ccc(Nc2ncc(c(NCc3nccnc3N(C)S(C)(=O)=O)n2)C(F)(F)F)cc1, CNC(=O)c1ccc(Nc2ncc(c(NCc3nccnc3N(C)S(C)(=O)=O)n2)C(F)(F)F)cc1, CNC(=O)c1ccc(Nc2ncc(c(NCc3nccnc3N(C)S(C)(=O)=O)n2)C(F)(F)F)cc1, CNC(=O)c1ccc(Nc2ncc(c(NCc3nccnc3N(C)S(C)(=O)=O)n2)C(F)(F)F)cc1, CNC(=O)c1ccc(Nc2ncc(c(NCc3nccnc3N(C)S(C)(=O)=O)n2)C(F)(F)F)cc1, CNC(=O)c1ccc(Nc2ncc(c(NCc3nccnc3N(C)S(C)(=O)=O)n2)C(F)(F)F)cc1, CNC(=O)c1ccc(Nc2ncc(c(NCc3nccnc3N(C)S(C)(=O)=O)n2)C(F)(F)F)cc1, CNC(=O)c1ccc(Nc2ncc(c(NCc3nccnc3N(C)S(C)(=O)=O)n2)C(F)(F)F)cc1, CNC(=O)c1ccc(Nc2ncc(c(NCc3nccnc3N(C)S(C)(=O)=O)n2)C(F)(F)F)cc1, CNC(=O)c1ccc(Nc2ncc(c(NCc3nccnc3N(C)S(C)(=O)=O)n2)C(F)(F)F)cc1	Phase 2
deferasirox	chelating agent	CYP3A4	hematology	transfusional hemosiderosis, thalassemia, iron overload	Selleck, Selleck, Selleck, MedChemEx	98.55	OC(=O)c1ccc(cc1)-n1nc(nc1-c1ccccc1O)-c1ccccc1O, OC(=O)c1ccc(cc1)-n1nc(nc1-c1ccccc1O)-c1ccccc1O, OC(=O)c1ccc(cc1)-n1nc(nc1-c1ccccc1O)-c1ccccc1O, OC(=O)c1ccc(cc1)-n1nc(nc1-c1ccccc1O)-c1ccccc1O	Launched
deferasirox-iron-chelate					MedChemEx	0.45	OC(=O)c1ccc(cc1)-n1nc-2nc1-c1ccccc1O[Fe]Oc1ccccc-21	Launched
deferiprone	chelating agent	UGT1A6	hematology	transfusional hemosiderosis, thalassemia, iron overload	MedChemEx, MicroSource, Selleck	98.95	Cc1c(O)c(=O)ccn1C, Cc1c(O)c(=O)ccn1C, Cc1c(O)c(=O)ccn1C	Launched
deferoxamine-mesylate	chelating agent		hematology	acute iron intoxication, iron overload	Sigma, MicroSource, MedChemEx	95.48	CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN, CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN, CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN	Launched
deflazacort	glucocorticoid receptor agonist	NR3C1	rheumatology	joint inflammation	MedChemEx	96	CC(=O)OCC(=O)[C@@]12N=C(C)O[C@@H]1C[C@H]1[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]21C |c:23,t:8,19|	Launched
deforolimus	mTOR inhibitor	MTOR			Selleck, Selleck, Selleck	89.39	CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OP(C)(C)=O |c:14,33,t:29,31|, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OP(C)(C)=O |c:14,33,t:29,31|, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OP(C)(C)=O |c:14,33,t:29,31|	Phase 3
degarelix	gonadotropin releasing factor hormone receptor antagonist	GNRHR	oncology	prostate cancer	MedChemEx	93.66	CC(C)C[C@H](NC(=O)[C@@H](Cc1ccc(NC(N)=O)cc1)NC(=O)[C@H](Cc1ccc(NC(=O)[C@@H]2CC(=O)NC(=O)N2)cc1)NC(=O)[C@H](CO)NC(=O)[C@@H](Cc1cccnc1)NC(=O)[C@@H](Cc1ccc(Cl)cc1)NC(=O)[C@@H](Cc1ccc2ccccc2c1)NC(C)=O)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O	Launched
dehydroacetic-acid					MicroSource, MedChemEx	86.69	CC(=O)c1c(O)cc(C)oc1=O, CC(=O)c1c(O)cc(C)oc1=O	Preclinical
dehydrocholate					MicroSource	85.01	C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@H]3[C@@H](CC(=O)[C@]12C)[C@@]1(C)CCC(=O)C[C@@H]1CC3=O |a:1,7,16,18,&1:10,&2:11,&3:12,&4:25|	Preclinical
dehydrocholate-acid					MedChemEx, MedChemEx	79.34	C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@H]3[C@H](CC(=O)[C@]12C)[C@@]1(C)CCC(=O)C[C@H]1CC3=O, C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@H]3[C@H](CC(=O)[C@]12C)[C@@]1(C)CCC(=O)C[C@H]1CC3=O	Preclinical
dehydrocorydaline	acetylcholinesterase inhibitor	ACHE			MedChemEx, MedChemEx, MedChemEx	91.32	COc1ccc2c(C)c3-c4cc(OC)c(OC)cc4CC[n+]3cc2c1OC, COc1ccc2c(C)c3-c4cc(OC)c(OC)cc4CC[n+]3cc2c1OC, COc1ccc2c(C)c3-c4cc(OC)c(OC)cc4CC[n+]3cc2c1OC	Phase 3
dehydroepiandrosterone	protein synthesis stimulant	ESR1, ESR2, G6PD, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, GRIN3A, GRIN3B, HSD17B1, NR1I2, NR1I3, PPARA, SIGMAR1, SULT2A1, SULT2B1	endocrinology	menopause	MicroSource, Selleck	100	C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@]34C)[C@@H]1CCC2=O |t:7|, C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@]34C)[C@@H]1CCC2=O |t:7|	Launched
dehydroepiandrosterone-sulfate	androgen receptor agonist, estrogen receptor agonist	AR, ESR1, ESR2	endocrinology	menopause	Sigma	99.5	C[C@]12CC[C@H]3[C@@H](CC=C4C[C@H](CC[C@]34C)OS(O)(=O)=O)[C@@H]1CCC2=O |t:7|	Launched
delafloxacin	antiinfective drug				MedChemEx	94.91	Nc1nc(c(F)cc1F)-n1cc(C(O)=O)c(=O)c2cc(F)c(N3CC(O)C3)c(Cl)c12	Phase 3
delamanid	bacterial cell wall synthesis inhibitor		infectious disease	tuberculosis	Adooq, Adooq	97.31	C[C@]1(COc2ccc(cc2)N2CCC(CC2)Oc2ccc(OC(F)(F)F)cc2)Cn2cc(nc2O1)[N+]([O-])=O, C[C@]1(COc2ccc(cc2)N2CCC(CC2)Oc2ccc(OC(F)(F)F)cc2)Cn2cc(nc2O1)[N+]([O-])=O	Launched
delanzomib	proteasome inhibitor	CMA1, CTSG, CYP3A4, ELANE			MedChemEx, MedChemEx, MedChemEx, MedChemEx, Selleck, Selleck, Selleck, Selleck, Selleck	92.52	CC(C)C[C@H](NC(=O)[C@@H](NC(=O)c1cccc(n1)-c1ccccc1)[C@@H](C)O)B(O)O, CC(C)C[C@H](NC(=O)[C@@H](NC(=O)c1cccc(n1)-c1ccccc1)[C@@H](C)O)B(O)O, CC(C)C[C@H](NC(=O)[C@@H](NC(=O)c1cccc(n1)-c1ccccc1)[C@@H](C)O)B(O)O, CC(C)C[C@H](NC(=O)[C@@H](NC(=O)c1cccc(n1)-c1ccccc1)[C@@H](C)O)B(O)O, CC(C)C[C@H](NC(=O)[C@@H](NC(=O)c1cccc(n1)-c1ccccc1)[C@@H](C)O)B(O)O, CC(C)C[C@H](NC(=O)[C@@H](NC(=O)c1cccc(n1)-c1ccccc1)[C@@H](C)O)B(O)O, CC(C)C[C@H](NC(=O)[C@@H](NC(=O)c1cccc(n1)-c1ccccc1)[C@@H](C)O)B(O)O, CC(C)C[C@H](NC(=O)[C@@H](NC(=O)c1cccc(n1)-c1ccccc1)[C@@H](C)O)B(O)O, CC(C)C[C@H](NC(=O)[C@@H](NC(=O)c1cccc(n1)-c1ccccc1)[C@@H](C)O)B(O)O	Phase 1/Phase 2
delapril	angiotensin converting enzyme inhibitor	ACE	cardiology	hypertension	AKSci, AKSci, AKSci	100	CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N(CC(O)=O)C1Cc2ccccc2C1, CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N(CC(O)=O)C1Cc2ccccc2C1, CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N(CC(O)=O)C1Cc2ccccc2C1	Launched
delavirdine	non-nucleoside reverse transcriptase inhibitor	CYP3A4	infectious disease	human immunodeficiency virus (HIV-1)	Tocris, Sigma, Enzo, MedChemEx	95.35	CC(C)Nc1cccnc1N1CCN(CC1)C(=O)c1cc2cc(NS(C)(=O)=O)ccc2[nH]1, CC(C)Nc1cccnc1N1CCN(CC1)C(=O)c1cc2cc(NS(C)(=O)=O)ccc2[nH]1, CC(C)Nc1cccnc1N1CCN(CC1)C(=O)c1cc2cc(NS(C)(=O)=O)ccc2[nH]1, CC(C)Nc1cccnc1N1CCN(CC1)C(=O)c1cc2cc(NS(C)(=O)=O)ccc2[nH]1	Launched
delcasertib	PKC inhibitor				MedChemEx	46.99	CC(C)C[C@H](NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CSSC[C@H](N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(O)=O	Phase 1
delgocitinib	JAK inhibitor				MedChemEx	96.08	C[C@H]1CN(C(=O)CC#N)[C@]11CCN(C1)c1ncnc2[nH]ccc12	Phase 2
delivert	angiotensin receptor agonist	AGTR1, AGTR2	critical care	sepsis	MedChemEx, MedChemEx	88.91	CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)[C@@H](CCCNC(N)=N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@@H]1C(=O)N[C@H](Cc1ccccc1)C(O)=O, CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)[C@@H](CCCNC(N)=N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@@H]1C(=O)N[C@H](Cc1ccccc1)C(O)=O	Launched
delpazolid	antibacterial				MedChemEx	92.44	CN1CCN(C=N1)c1ccc(cc1F)N1C[C@H](CO)OC1=O |c:5|	Phase 2
delphinidin	membrane permeability inhibitor	GLO1			Cayman, Cayman, Cayman	0	Oc1cc(O)c2cc(O)c([o+]c2c1)-c1cc(O)c(O)c(O)c1, Oc1cc(O)c2cc(O)c([o+]c2c1)-c1cc(O)c(O)c(O)c1, Oc1cc(O)c2cc(O)c([o+]c2c1)-c1cc(O)c(O)c(O)c1	Phase 2
delta-tocotrienol	HMGCR inhibitor	HMGCR			AnalytiCon, AnalytiCon	0.25	CC(C)=CCC\C(C)=C\CC\C(C)=C\CC[C@]1(C)CCc2cc(O)cc(C)c2O1, CC(C)=CCC\C(C)=C\CC\C(C)=C\CC[C@]1(C)CCc2cc(O)cc(C)c2O1	Phase 1
deltarasin	phosphodiesterase inhibitor	KRAS			Tocris, Tocris, Tocris, Tocris, Tocris	99	C(Oc1ccc(cc1)-c1nc2ccccc2n1Cc1ccccc1)[C@H](C1CCNCC1)n1c(nc2ccccc12)-c1ccccc1, C(Oc1ccc(cc1)-c1nc2ccccc2n1Cc1ccccc1)[C@H](C1CCNCC1)n1c(nc2ccccc12)-c1ccccc1, C(Oc1ccc(cc1)-c1nc2ccccc2n1Cc1ccccc1)[C@H](C1CCNCC1)n1c(nc2ccccc12)-c1ccccc1, C(Oc1ccc(cc1)-c1nc2ccccc2n1Cc1ccccc1)[C@H](C1CCNCC1)n1c(nc2ccccc12)-c1ccccc1, C(Oc1ccc(cc1)-c1nc2ccccc2n1Cc1ccccc1)[C@H](C1CCNCC1)n1c(nc2ccccc12)-c1ccccc1	Preclinical
demecarium	acetylcholinesterase inhibitor	ACHE, BCHE	ophthalmology	intraocular pressure, glaucoma	MedChemEx, Prestwick, Prestwick, Prestwick, Prestwick	94.41	CN(CCCCCCCCCCN(C)C(=O)Oc1cccc(c1)[N+](C)(C)C)C(=O)Oc1cccc(c1)[N+](C)(C)C, CN(CCCCCCCCCCN(C)C(=O)Oc1cccc(c1)[N+](C)(C)C)C(=O)Oc1cccc(c1)[N+](C)(C)C, CN(CCCCCCCCCCN(C)C(=O)Oc1cccc(c1)[N+](C)(C)C)C(=O)Oc1cccc(c1)[N+](C)(C)C, CN(CCCCCCCCCCN(C)C(=O)Oc1cccc(c1)[N+](C)(C)C)C(=O)Oc1cccc(c1)[N+](C)(C)C, CN(CCCCCCCCCCN(C)C(=O)Oc1cccc(c1)[N+](C)(C)C)C(=O)Oc1cccc(c1)[N+](C)(C)C	Launched
demeclocycline	bacterial 30S ribosomal subunit inhibitor		endocrinology, infectious disease, ophthalmology, urology	fever, respiratory tract infections, psittacosis, trachoma, conjunctivitis, urethritis, chancroid, cholera, syphilis, listeria, anthrax, actinomycosis, tularemia, brucellosis	MedChemEx	55.5	[H][C@]12C[C@@]3([H])[C@H](N(C)C)C(=O)[C@@H](C(N)=O)C(=O)[C@@]3(O)C(=O)[C@H]1C(=O)c1c(O)ccc(Cl)c1[C@H]2O |&1:11,&2:21|	Launched
denatonium-benzoate					MicroSource, MedChemEx	81.39	CC[N+](CC)(CC(=O)Nc1c(C)cccc1C)Cc1ccccc1, CC[N+](CC)(CC(=O)Nc1c(C)cccc1C)Cc1ccccc1	Preclinical
denopamine	adrenergic receptor agonist		cardiology	angina pectoris	Sigma	89.63	COc1ccc(CCNC[C@H](O)c2ccc(O)cc2)cc1OC	Launched
denotivir	antiviral		infectious disease	virus herpes simplex (HSV), skin infections	Vitas-M, Vitas-M, Vitas-M	98.5	Cc1nsc(NC(=O)c2ccccc2)c1C(=O)Nc1ccc(Cl)cc1, Cc1nsc(NC(=O)c2ccccc2)c1C(=O)Nc1ccc(Cl)cc1, Cc1nsc(NC(=O)c2ccccc2)c1C(=O)Nc1ccc(Cl)cc1	Launched
deoxyarbutin	tyrosinase inhibitor				Selleck, Selleck	62.84	Oc1ccc(O[C@H]2CCCCO2)cc1 |&1:6,r|, Oc1ccc(O[C@H]2CCCCO2)cc1 |&1:6,r|	Preclinical
deoxycholic-acid	biliverdin reductase A activator, G protein-coupled receptor agonist	FPR1, GPBAR1	endocrinology	submental fat	Enzo	100	C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3CC[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3C[C@H](O)[C@]12C	Launched
deoxycorticosterone-acetate	progestogen hormone	NR3C2			MicroSource, MicroSource, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck	98.53	CC(=O)OCC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C |t:14|, CC(=O)OCC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C |t:14|, CC(=O)OCC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C |t:14|, CC(=O)OCC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C |t:14|, CC(=O)OCC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C |t:14|, CC(=O)OCC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C |t:14|, CC(=O)OCC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C |t:14|, CC(=O)OCC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C |t:14|	Preclinical
deoxyepinephrine	adrenergic receptor agonist, dopamine receptor agonist	ADRA1A, DRD1, DRD2			Enzo, CombiBlocks	94.36	CNCCc1ccc(O)c(O)c1, CNCCc1ccc(O)c(O)c1	Preclinical
deptropine	histamine receptor antagonist	HRH1			Toronto	95.55	CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC1c2ccccc2CCc2ccccc12 |r,THB:0:1:3.4:6.7.8|	Preclinical
dequalinium	PKC inhibitor	KCNN1, KCNN3	infectious disease	first-aid antiseptic	MedChemEx, MedChemEx, MicroSource, MicroSource, MicroSource, Selleck	95.31	Cc1cc(N)c2ccccc2[n+]1CCCCCCCCCC[n+]1c(C)cc(N)c2ccccc12, Cc1cc(N)c2ccccc2[n+]1CCCCCCCCCC[n+]1c(C)cc(N)c2ccccc12, Cc1cc(N)c2ccccc2[n+]1CCCCCCCCCC[n+]1c(C)cc(N)c2ccccc12, Cc1cc(N)c2ccccc2[n+]1CCCCCCCCCC[n+]1c(C)cc(N)c2ccccc12, Cc1cc(N)c2ccccc2[n+]1CCCCCCCCCC[n+]1c(C)cc(N)c2ccccc12, Cc1cc(N)c2ccccc2[n+]1CCCCCCCCCC[n+]1c(C)cc(N)c2ccccc12	Launched
deracoxib	cyclooxygenase inhibitor	PTGS2	rheumatology	osteoarthritis	MicroSource, MedChemEx	99.74	COc1ccc(cc1F)-c1cc(nn1-c1ccc(cc1)S(N)(=O)=O)C(F)F, COc1ccc(cc1F)-c1cc(nn1-c1ccc(cc1)S(N)(=O)=O)C(F)F	Launched
derazantinib	tyrosine kinase inhibitor				MedChemEx	81.15	COCCNCCc1cccc(Nc2ncc3C[C@@H](c4ccccc4F)c4ccccc4-c3n2)c1	Phase 2
deserpidine	angiotensin converting enzyme inhibitor	ACE, SLC18A2	cardiology	hypertension	Key, Key, Key, Key, AKSci, AKSci, AKSci	96.99	CO[C@H]1[C@@H](C[C@@H]2CN3CCc4c([nH]c5ccccc45)[C@H]3C[C@@H]2[C@@H]1C(=O)OC)OC(=O)c1cc(OC)c(OC)c(OC)c1, CO[C@H]1[C@@H](C[C@@H]2CN3CCc4c([nH]c5ccccc45)[C@H]3C[C@@H]2[C@@H]1C(=O)OC)OC(=O)c1cc(OC)c(OC)c(OC)c1, CO[C@H]1[C@@H](C[C@@H]2CN3CCc4c([nH]c5ccccc45)[C@H]3C[C@@H]2[C@@H]1C(=O)OC)OC(=O)c1cc(OC)c(OC)c(OC)c1, CO[C@H]1[C@@H](C[C@@H]2CN3CCc4c([nH]c5ccccc45)[C@H]3C[C@@H]2[C@@H]1C(=O)OC)OC(=O)c1cc(OC)c(OC)c(OC)c1, CO[C@H]1[C@@H](C[C@@H]2CN3CCc4c([nH]c5ccccc45)[C@H]3C[C@@H]2[C@@H]1C(=O)OC)OC(=O)c1cc(OC)c(OC)c(OC)c1, CO[C@H]1[C@@H](C[C@@H]2CN3CCc4c([nH]c5ccccc45)[C@H]3C[C@@H]2[C@@H]1C(=O)OC)OC(=O)c1cc(OC)c(OC)c(OC)c1, CO[C@H]1[C@@H](C[C@@H]2CN3CCc4c([nH]c5ccccc45)[C@H]3C[C@@H]2[C@@H]1C(=O)OC)OC(=O)c1cc(OC)c(OC)c(OC)c1	Launched
desidustat	hypoxia inducible factor prolyl hydroxylase inhibitor				MedChemEx	93.55	OC(=O)CNC(=O)c1c(O)c2ccccc2n(OCC2CC2)c1=O	Preclinical
desipramine	tricyclic antidepressant	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD2, HRH1, HTR1A, HTR2A, HTR2C, SLC6A2, SLC6A4, SMPD1	neurology/psychiatry	depression	MicroSource, Sigma	94.4	CNCCCN1c2ccccc2CCc2ccccc12, CNCCCN1c2ccccc2CCc2ccccc12	Launched
desisobutyryl-ciclesonide	cytochrome P450 inhibitor		allergy	allergic rhinitis	MedChemEx	84.9	[H][C@]12C[C@@]3([H])[C@]4([H])CCC5=CC(=O)C=C[C@]5(C)[C@@]4([H])[C@@H](O)C[C@]3(C)[C@@]1(O[C@@H](O2)C1CCCCC1)C(=O)CO |c:13,t:9|	Launched
deslanoside	Na/K-ATPase inhibitor	ATP1A1, ATP1A2, ATP1A3, ATP1A4, ATP1B1, ATP1B2, ATP1B3, FXYD2	cardiology	congestive heart failure, cardiac arrythmia	AvaChem, AvaChem, AvaChem, AvaChem	98.38	C[C@H]1O[C@H](C[C@H](O)[C@@H]1O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)[C@@H](C)O2)[C@@H](C)O1)O[C@H]1CC[C@@]2(C)[C@H](CC[C@@H]3[C@@H]2C[C@@H](O)[C@]2(C)[C@H](CC[C@]32O)C2=CC(=O)OC2)C1 |t:66|, C[C@H]1O[C@H](C[C@H](O)[C@@H]1O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)[C@@H](C)O2)[C@@H](C)O1)O[C@H]1CC[C@@]2(C)[C@H](CC[C@@H]3[C@@H]2C[C@@H](O)[C@]2(C)[C@H](CC[C@]32O)C2=CC(=O)OC2)C1 |t:66|, C[C@H]1O[C@H](C[C@H](O)[C@@H]1O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)[C@@H](C)O2)[C@@H](C)O1)O[C@H]1CC[C@@]2(C)[C@H](CC[C@@H]3[C@@H]2C[C@@H](O)[C@]2(C)[C@H](CC[C@]32O)C2=CC(=O)OC2)C1 |t:66|, C[C@H]1O[C@H](C[C@H](O)[C@@H]1O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)[C@@H](C)O2)[C@@H](C)O1)O[C@H]1CC[C@@]2(C)[C@H](CC[C@@H]3[C@@H]2C[C@@H](O)[C@]2(C)[C@H](CC[C@]32O)C2=CC(=O)OC2)C1 |t:66|	Launched
desloratadine	histamine receptor antagonist	HRH1	allergy	allergic rhinitis, urticaria	MicroSource, Tocris, Tocris, Selleck, Selleck, Selleck, Selleck	98.28	Clc1ccc2c(CCc3cccnc3C2=C2CCNCC2)c1, Clc1ccc2c(CCc3cccnc3C2=C2CCNCC2)c1, Clc1ccc2c(CCc3cccnc3C2=C2CCNCC2)c1, Clc1ccc2c(CCc3cccnc3C2=C2CCNCC2)c1, Clc1ccc2c(CCc3cccnc3C2=C2CCNCC2)c1, Clc1ccc2c(CCc3cccnc3C2=C2CCNCC2)c1, Clc1ccc2c(CCc3cccnc3C2=C2CCNCC2)c1	Launched
deslorelin	gonadotropin releasing factor hormone receptor agonist				MedChemEx	98.49	CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H]1CCC(=O)N1	Phase 2
desmethylclozapine	acetylcholine receptor agonist	HTR2C			Tocris	67.09	Clc1ccc2Nc3ccccc3C(=Nc2c1)N1CCNCC1 |c:13|	Phase 2
desmopressin-acetate	vasopressin receptor agonist	AVPR1A, AVPR1B, AVPR2, OXTR	endocrinology, urology	central diabetes insipidus, nocturnal enuresis	MedChemEx	90.81	NC(=O)CC[C@@H]1NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)CCSSC[C@@H](NC(=O)[C@H](CC(N)=O)NC1=O)C(=O)N1CCC[C@H]1C(=O)N[C@H](CCCNC(N)=N)C(=O)NCC(N)=O |r|	Launched
desogestrel	progesterone receptor agonist	ESR1, PGR	endocrinology	contraceptive	Enzo, Enzo, Enzo, Enzo, MedChemEx	97.27	CC[C@]12CC(=C)[C@H]3[C@@H](CCC4=CCCC[C@H]34)[C@@H]1CC[C@@]2(O)C#C |t:10|, CC[C@]12CC(=C)[C@H]3[C@@H](CCC4=CCCC[C@H]34)[C@@H]1CC[C@@]2(O)C#C |t:10|, CC[C@]12CC(=C)[C@H]3[C@@H](CCC4=CCCC[C@H]34)[C@@H]1CC[C@@]2(O)C#C |t:10|, CC[C@]12CC(=C)[C@H]3[C@@H](CCC4=CCCC[C@H]34)[C@@H]1CC[C@@]2(O)C#C |t:10|, CC[C@]12CC(=C)[C@H]3[C@@H](CCC4=CCCC[C@H]34)[C@@H]1CC[C@@]2(O)C#C |t:10|	Launched
desonide	glucocorticoid receptor agonist	NR3C1, PLA2G1B	gastroenterology	Crohn's disease	MedChemEx, MedChemEx, MicroSource, MicroSource, Selleck, Selleck, Selleck	97.37	CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO |c:14,t:10|, CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO |c:14,t:10|, CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO |c:14,t:10|, CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO |c:14,t:10|, CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO |c:14,t:10|, CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO |c:14,t:10|, CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO |c:14,t:10|	Launched
desoximetasone	glucocorticoid receptor agonist	NR3C1, PLA2G1B	dermatology	corticosteroid-responsive dermatoses	MedChemEx	92.11	C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@H]1C(=O)CO |c:11,t:7|	Launched
desoxycorticosterone-pivalate	corticosteroid agonist	NR3C2	endocrinology	Addison's disease	InterBioScreen	98.85	CC(C)(C)C(=O)OCC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C |t:17|	Launched
desoxycortone	mineralocorticoid receptor agonist	NR3C1, NR3C2			Prestwick, Prestwick, Prestwick, Prestwick	98.09	C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@H]2C(=O)CO |t:8|, C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@H]2C(=O)CO |t:8|, C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@H]2C(=O)CO |t:8|, C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@H]2C(=O)CO |t:8|	Preclinical
desoxypeganine	acetylcholinesterase inhibitor, monoamine oxidase inhibitor	ACHE			Enzo, Enzo, Enzo, Vitas-M	96.73	C1CN2Cc3ccccc3N=C2C1 |c:11|, C1CN2Cc3ccccc3N=C2C1 |c:11|, C1CN2Cc3ccccc3N=C2C1 |c:11|, C1CN2Cc3ccccc3N=C2C1 |c:11|	Phase 1
desvenlafaxine	serotoninnorepinephrine reuptake inhibitor (SNRI)	SLC6A2, SLC6A3, SLC6A4	neurology/psychiatry	depression	Selleck, Selleck, MicroSource, Tocris, Tocris	92.25	CN(C)C[C@@H](c1ccc(O)cc1)C1(O)CCCCC1 |&1:4|, CN(C)C[C@@H](c1ccc(O)cc1)C1(O)CCCCC1 |&1:4|, CN(C)C[C@@H](c1ccc(O)cc1)C1(O)CCCCC1 |&1:4|, CN(C)C[C@@H](c1ccc(O)cc1)C1(O)CCCCC1 |&1:4|, CN(C)C[C@@H](c1ccc(O)cc1)C1(O)CCCCC1 |&1:4|	Launched
detomidine	adrenergic receptor agonist	ADRA2A	neurology/psychiatry	sedative	MedChemEx, MedChemEx, Selleck	98.34	Cc1cccc(Cc2cnc[nH]2)c1C, Cc1cccc(Cc2cnc[nH]2)c1C, Cc1cccc(Cc2cnc[nH]2)c1C	Launched
devazepide	CCK receptor antagonist				Tocris, Tocris	98.14	CN1c2ccccc2C(=N[C@H](NC(=O)c2cc3ccccc3[nH]2)C1=O)c1ccccc1 |c:9|, CN1c2ccccc2C(=N[C@H](NC(=O)c2cc3ccccc3[nH]2)C1=O)c1ccccc1 |c:9|	Preclinical
dexamethasone	glucocorticoid receptor agonist	ANXA1, NOS2, NR0B1, NR3C1, NR3C2	endocrinology, rheumatology, allergy, gastroenterology, hematology, neurology/psychiatry, dermatology	hypercalcemia, rheumatoid arthritis, psoriatic arthritis, osteoarthritis, allergic rhinitis, ulcerative colitis, anemia, multiple sclerosis, enteritis, lupus, dermatitis herpetiformis (DH), nephrotic syndrome, psoriasis	Tocris, Tocris, Tocris, Tocris, Tocris, Selleck, Selleck	95.93	C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO |c:11,t:7|, C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO |c:11,t:7|, C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO |c:11,t:7|, C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO |c:11,t:7|, C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO |c:11,t:7|, C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO |c:11,t:7|, C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO |c:11,t:7|	Launched
dexamethasone-acetate	glucocorticoid receptor agonist		endocrinology, rheumatology, allergy, gastroenterology, hematology, neurology/psychiatry, dermatology	hypercalcemia, rheumatoid arthritis, psoriatic arthritis, osteoarthritis, allergic rhinitis, ulcerative colitis, anemia, multiple sclerosis, enteritis, lupus, dermatitis herpetiformis (DH), nephrotic syndrome, psoriasis	MicroSource, MedChemEx, MedChemEx, Selleck, Selleck	97.02	C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COC(C)=O |c:11,t:7|, C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COC(C)=O |c:11,t:7|, C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COC(C)=O |c:11,t:7|, C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COC(C)=O |c:11,t:7|, C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COC(C)=O |c:11,t:7|	Launched
dexchlorpheniramine	histamine receptor antagonist		allergy, cardiology	allergic conjunctivitis, allergic rhinitis, urticaria, angioedema	MicroSource, MedChemEx, MedChemEx	99.06	CN(C)CC[C@@H](c1ccc(Cl)cc1)c1ccccn1, CN(C)CC[C@@H](c1ccc(Cl)cc1)c1ccccn1, CN(C)CC[C@@H](c1ccc(Cl)cc1)c1ccccn1	Launched
dexfosfoserine	membrane integrity inhibitor	CFTR, GRM4, GRM6, GRM7, GRM8, KCNC4, PDPK1, PIM1, PRKACA, PRKCQ, PYGL, PYGM, REG1A, RHO, SERPINB3, SMAD2, TAOK2			Sigma, MicroSource	0	N[C@@H](COP(O)(O)=O)C(O)=O, N[C@@H](COP(O)(O)=O)C(O)=O	Preclinical
dexlansoprazole	ATPase inhibitor	ATP4A	gastroenterology	gastroesophageal reflux disease (GERD), erosive esophagitis (EE)	MicroSource, Selleck, Selleck, Selleck	95.4	Cc1c(OCC(F)(F)F)ccnc1C[S@@](=O)c1nc2ccccc2[nH]1, Cc1c(OCC(F)(F)F)ccnc1C[S@@](=O)c1nc2ccccc2[nH]1, Cc1c(OCC(F)(F)F)ccnc1C[S@@](=O)c1nc2ccccc2[nH]1, Cc1c(OCC(F)(F)F)ccnc1C[S@@](=O)c1nc2ccccc2[nH]1	Launched
dexloxiglumide	CCK receptor antagonist	CCKAR			AdvChemBlocks	96.36	CCCCCN(CCCOC)C(=O)[C@@H](CCC(O)=O)NC(=O)c1ccc(Cl)c(Cl)c1	Phase 3
dexmedetomidine	adrenergic receptor agonist	ADRA2A, ADRA2B, ADRA2C	neurology/psychiatry	sedative	Tocris, Tocris, Selleck, Selleck	98.01	C[C@H](c1cnc[nH]1)c1cccc(C)c1C, C[C@H](c1cnc[nH]1)c1cccc(C)c1C, C[C@H](c1cnc[nH]1)c1cccc(C)c1C, C[C@H](c1cnc[nH]1)c1cccc(C)c1C	Launched
dexniguldipine	calmodulin antagonist	ADORA3			Tocris, Tocris, Tocris, Tocris, Tocris	92.38	COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OCCCN1CCC(CC1)(c1ccccc1)c1ccccc1 |c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OCCCN1CCC(CC1)(c1ccccc1)c1ccccc1 |c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OCCCN1CCC(CC1)(c1ccccc1)c1ccccc1 |c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OCCCN1CCC(CC1)(c1ccccc1)c1ccccc1 |c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OCCCN1CCC(CC1)(c1ccccc1)c1ccccc1 |c:4,9|	Phase 2
dexpanthenol			gastroenterology	paralytic ileus	MicroSource, MedChemEx	100	CC(C)(CO)[C@@H](O)C(=O)NCCCO, CC(C)(CO)[C@@H](O)C(=O)NCCCO	Launched
dexrazoxane	chelating agent, topoisomerase inhibitor	TOP2A, TOP2B	cardiology	cardiomyopathy	Selleck, Selleck, Selleck, Selleck, Tocris	100	C[C@@H](CN1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1, C[C@@H](CN1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1, C[C@@H](CN1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1, C[C@@H](CN1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1, C[C@@H](CN1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1	Launched
dextran			hematology, critical care	thrombosis, hypovolemia	ANpharma	100	OC[C@H]1O[C@H](OC[C@H]2O[C@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@@H]1O	Launched
dextromethorphan	glutamate receptor antagonist, sigma receptor agonist	CHRNA2, CHRNA3, CHRNA4, CHRNA7, CHRNB2, CHRNB4, CYBA, CYBB, GRIN3A, NCF1, NCF2, NCF4, OPRD1, OPRK1, OPRM1, PGRMC1, RAC1, RAC2, SIGMAR1, SLC6A2, SLC6A4	pulmonary	cough suppressant	MedChemEx, MicroSource, MicroSource	99.02	COc1ccc2C[C@H]3[C@H]4CCCC[C@@]4(CCN3C)c2c1, COc1ccc2C[C@H]3[C@H]4CCCC[C@@]4(CCN3C)c2c1, COc1ccc2C[C@H]3[C@H]4CCCC[C@@]4(CCN3C)c2c1	Launched
dextrorotation-nimorazole-phosphate-ester	antiinfective drug				MedChemEx	93.3	Cc1ncc(n1C[C@@H](CN1CCOCC1)OP(O)(O)=O)[N+]([O-])=O	Preclinical
dextrose			endocrinology	hypoglycemia	MedChemEx, MedChemEx, Selleck	100	OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O, OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O, OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O	Launched
DFB	glutamate receptor agonist	GRM5			Tocris, Tocris, Tocris, Tocris	98.04	Fc1cccc(\C=N\N=C\c2cccc(F)c2)c1, Fc1cccc(\C=N\N=C\c2cccc(F)c2)c1, Fc1cccc(\C=N\N=C\c2cccc(F)c2)c1, Fc1cccc(\C=N\N=C\c2cccc(F)c2)c1	Preclinical
DG-172	PPAR receptor inverse agonist	PPARD			Tocris, Tocris	87.99	CN1CCN(CC1)c1ccc(\C=C(/C#N)c2ccccc2Br)cc1, CN1CCN(CC1)c1ccc(\C=C(/C#N)c2ccccc2Br)cc1	Preclinical
DG051	leukotriene synthesis inhibitor				MedChemEx	95.07	OC(=O)CCCN1CCC[C@H]1COc1ccc(Oc2ccc(Cl)cc2)cc1	Preclinical
DH-97	melatonin receptor antagonist	MTNR1B			Tocris, Tocris, Tocris	96.23	CCCCC(=O)NCCc1c(Cc2ccccc2)[nH]c2ccccc12, CCCCC(=O)NCCc1c(Cc2ccccc2)[nH]c2ccccc12, CCCCC(=O)NCCc1c(Cc2ccccc2)[nH]c2ccccc12	Preclinical
DHBP	ryanodine receptor blocker				Tocris, Tocris	84.11	CCCCCCC[n+]1ccc(cc1)-c1cc[n+](CCCCCCC)cc1, CCCCCCC[n+]1ccc(cc1)-c1cc[n+](CCCCCCC)cc1	Preclinical
diacerein	interleukin inhibitor	IL1B	rheumatology	osteoarthritis	MicroSource, MedChemEx, MedChemEx, Selleck, Selleck	95.35	CC(=O)Oc1cccc2C(=O)c3cc(cc(OC(C)=O)c3C(=O)c12)C(O)=O, CC(=O)Oc1cccc2C(=O)c3cc(cc(OC(C)=O)c3C(=O)c12)C(O)=O, CC(=O)Oc1cccc2C(=O)c3cc(cc(OC(C)=O)c3C(=O)c12)C(O)=O, CC(=O)Oc1cccc2C(=O)c3cc(cc(OC(C)=O)c3C(=O)c12)C(O)=O, CC(=O)Oc1cccc2C(=O)c3cc(cc(OC(C)=O)c3C(=O)c12)C(O)=O	Launched
diacetamate					MicroSource, Sigma	98.65	CC(=O)Nc1ccc(OC(C)=O)cc1, CC(=O)Nc1ccc(OC(C)=O)cc1	Preclinical
diadenosine-tetraphosphate	adenosine kinase inhibitor	P2RY13, P2RY2			Sigma	100	Nc1ncnc2n(cnc12)[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)n2cnc3c(N)ncnc23)[C@@H](O)[C@H]1O |a:10,12,32,34,35,37,49,51,&1:15,&2:19,&3:23,&4:27|	Phase 1
dianhydrogalactitol	DNA alkylating agent				MedChemEx, MedChemEx, MedChemEx	78.8	O[C@@H]([C@@H](O)[C@H]1CO1)[C@@H]1CO1, O[C@@H]([C@@H](O)[C@H]1CO1)[C@@H]1CO1, O[C@@H]([C@@H](O)[C@H]1CO1)[C@@H]1CO1	Phase 3
diarylpropionitrile	estrogen receptor agonist	ESR2			Tocris, Tocris	94.36	Oc1ccc(C[C@@H](C#N)c2ccc(O)cc2)cc1 |&1:6,r|, Oc1ccc(C[C@@H](C#N)c2ccc(O)cc2)cc1 |&1:6,r|	Preclinical
diatrizoic-acid			radiology	contrast agent	MedChemEx, MicroSource	98.63	CC(=O)Nc1c(I)c(NC(C)=O)c(I)c(C(O)=O)c1I, CC(=O)Nc1c(I)c(NC(C)=O)c(I)c(C(O)=O)c1I	Launched
diaveridine	dihydrofolate reductase inhibitor		infectious disease	coccidiosis	MedChemEx, MicroSource, MicroSource	99.41	COc1ccc(Cc2cnc(N)nc2N)cc1OC, COc1ccc(Cc2cnc(N)nc2N)cc1OC, COc1ccc(Cc2cnc(N)nc2N)cc1OC	Launched
diazoxide	potassium channel activator	ATP1A1, CA1, CA2, KCNJ11, KCNJ8, KCNMA1, SLC12A3	endocrinology	hypoglycemia	Tocris, MicroSource, Tocris, Tocris, Tocris	99.38	CC1=Nc2ccc(Cl)cc2S(=O)(=O)N1 |t:1|, CC1=Nc2ccc(Cl)cc2S(=O)(=O)N1 |t:1|, CC1=Nc2ccc(Cl)cc2S(=O)(=O)N1 |t:1|, CC1=Nc2ccc(Cl)cc2S(=O)(=O)N1 |t:1|, CC1=Nc2ccc(Cl)cc2S(=O)(=O)N1 |t:1|	Launched
dibekacin	bacterial 30S ribosomal subunit inhibitor		infectious disease	gram-negative bacterial infections	MicroSource	0	NC[C@@H]1CC[C@@H](N)[C@@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)O1	Launched
dibenzepine	norepinephrine reputake inhibitor				Selleck, Selleck	99.06	CN(C)CCN1c2ccccc2N(C)c2ccccc2C1=O, CN(C)CCN1c2ccccc2N(C)c2ccccc2C1=O	Preclinical
dibenzothiophene					MicroSource, Selleck, Selleck	99.86	c1ccc2c(c1)sc1ccccc21, c1ccc2c(c1)sc1ccccc21, c1ccc2c(c1)sc1ccccc21	Preclinical
dibutyl-phthalate		TRPA1			MedChemEx, MicroSource	99.18	CCCCOC(=O)c1ccccc1C(=O)OCCCC, CCCCOC(=O)c1ccccc1C(=O)OCCCC	Preclinical
dichlorisone-acetate					MedChemEx, MicroSource, Selleck, Selleck	91.61	CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](Cl)C[C@]12C |c:19,t:15|, CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](Cl)C[C@]12C |c:19,t:15|, CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](Cl)C[C@]12C |c:19,t:15|, CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](Cl)C[C@]12C |c:19,t:15|	Phase 2
dichloroacetate	pyruvate dehydrogenase kinase inhibitor				Sigma, Sigma, Tocris	96.5	[Na].OC(=O)C(Cl)Cl, [Na].OC(=O)C(Cl)Cl, [Na].OC(=O)C(Cl)Cl	Phase 3
dichlorophen	anticestodal agent		infectious disease	hookworm, tapeworm	Sigma, Sigma, Sigma, MicroSource, MicroSource, MicroSource, MicroSource	93.8	Oc1ccc(Cl)cc1Cc1cc(Cl)ccc1O, Oc1ccc(Cl)cc1Cc1cc(Cl)ccc1O, Oc1ccc(Cl)cc1Cc1cc(Cl)ccc1O, Oc1ccc(Cl)cc1Cc1cc(Cl)ccc1O, Oc1ccc(Cl)cc1Cc1cc(Cl)ccc1O, Oc1ccc(Cl)cc1Cc1cc(Cl)ccc1O, Oc1ccc(Cl)cc1Cc1cc(Cl)ccc1O	Launched
dichlorvos	acetylcholinesterase inhibitor				MicroSource, AMS	0	COP(=O)(OC)OC=C(Cl)Cl, COP(=O)(OC)OC=C(Cl)Cl	Launched
diclazuril	antiprotozoal agent		infectious disease	equine protozoal myeloencephalitis (EPM)	MicroSource, MedChemEx, Selleck, Selleck	98.14	Clc1ccc(cc1)[C@@H](C#N)c1c(Cl)cc(cc1Cl)-n1ncc(=O)[nH]c1=O |&1:7,r|, Clc1ccc(cc1)[C@@H](C#N)c1c(Cl)cc(cc1Cl)-n1ncc(=O)[nH]c1=O |&1:7,r|, Clc1ccc(cc1)[C@@H](C#N)c1c(Cl)cc(cc1Cl)-n1ncc(=O)[nH]c1=O |&1:7,r|, Clc1ccc(cc1)[C@@H](C#N)c1c(Cl)cc(cc1Cl)-n1ncc(=O)[nH]c1=O |&1:7,r|	Launched
diclofenac	cyclooxygenase inhibitor	AKR1C3, ALOX5, ASIC1, ASIC3, KCNQ2, KCNQ3, PLA2G2A, PPARG, PTGS1, PTGS2, SCN4A	rheumatology, neurology/psychiatry	rheumatoid arthritis, osteoarthritis, migraine headache	MicroSource, Selleck, Selleck, Selleck	99.61	OC(=O)Cc1ccccc1Nc1c(Cl)cccc1Cl, OC(=O)Cc1ccccc1Nc1c(Cl)cccc1Cl, OC(=O)Cc1ccccc1Nc1c(Cl)cccc1Cl, OC(=O)Cc1ccccc1Nc1c(Cl)cccc1Cl	Launched
diclofenamide	carbonic anhydrase inhibitor	CA1, CA12, CA2, CA4, CA7	ophthalmology, neurology/psychiatry	glaucoma, epilepsy	MedChemEx, Selleck	98.21	NS(=O)(=O)c1cc(Cl)c(Cl)c(c1)S(N)(=O)=O, NS(=O)(=O)c1cc(Cl)c(Cl)c(c1)S(N)(=O)=O	Launched
diclofensine	dopamine reuptake inhibitor	DRD1, MAOA, MAOB			MedChemEx, MedChemEx	97.83	COc1ccc2[C@@H](CN(C)Cc2c1)c1ccc(Cl)c(Cl)c1 |&1:6|, COc1ccc2[C@@H](CN(C)Cc2c1)c1ccc(Cl)c(Cl)c1 |&1:6|	Phase 3
dicloralurea					MicroSource, Labotest	100	O[C@@H](NC(=O)N[C@@H](O)C(Cl)(Cl)Cl)C(Cl)(Cl)Cl |&1:1,&2:6,r|, O[C@@H](NC(=O)N[C@@H](O)C(Cl)(Cl)Cl)C(Cl)(Cl)Cl |&1:1,&2:6,r|	Preclinical
dicloxacillin	bacterial cell wall synthesis inhibitor		infectious disease	gram-positive bacterial infections	MedChemEx, MicroSource, Selleck, Selleck	87.83	Cc1onc(c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O)-c1c(Cl)cccc1Cl, Cc1onc(c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O)-c1c(Cl)cccc1Cl, Cc1onc(c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O)-c1c(Cl)cccc1Cl, Cc1onc(c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O)-c1c(Cl)cccc1Cl	Launched
dicoumarol	NADPH inhibitor	CRYZ, NQO1, VKORC1	hematology	deep vein thrombosis (DVT)	MedChemEx, MicroSource	99.51	Oc1c(Cc2c(O)c3ccccc3oc2=O)c(=O)oc2ccccc12, Oc1c(Cc2c(O)c3ccccc3oc2=O)c(=O)oc2ccccc12	Launched
dicyclohexylamine					Vitas-M, Labotest	96.38	C1CCC(CC1)NC1CCCCC1, C1CCC(CC1)NC1CCCCC1	Preclinical
dicycloverine	acetylcholine receptor antagonist	CHRM1, CHRM2, CHRM3	gastroenterology	irritable bowel syndrome	MicroSource, Selleck, Selleck	100	CCN(CC)CCOC(=O)C1(CCCCC1)C1CCCCC1, CCN(CC)CCOC(=O)C1(CCCCC1)C1CCCCC1, CCN(CC)CCOC(=O)C1(CCCCC1)C1CCCCC1	Launched
didanosine	nucleoside reverse transcriptase inhibitor	PNP	infectious disease	human immunodeficiency virus (HIV-1)	MedChemEx, Selleck, Selleck, Selleck, Selleck, Selleck	99.4	OC[C@@H]1CC[C@@H](O1)n1cnc2c1[nH]cnc2=O, OC[C@@H]1CC[C@@H](O1)n1cnc2c1[nH]cnc2=O, OC[C@@H]1CC[C@@H](O1)n1cnc2c1[nH]cnc2=O, OC[C@@H]1CC[C@@H](O1)n1cnc2c1[nH]cnc2=O, OC[C@@H]1CC[C@@H](O1)n1cnc2c1[nH]cnc2=O, OC[C@@H]1CC[C@@H](O1)n1cnc2c1[nH]cnc2=O	Launched
dideoxyadenosine	nucleoside reverse transcriptase inhibitor				Berry, Berry	97.9	Nc1ncnc2n(cnc12)[C@H]1CC[C@@H](CO)O1, Nc1ncnc2n(cnc12)[C@H]1CC[C@@H](CO)O1	Phase 1
didox	ribonucleotide reductase inhibitor	RRM1	oncology	breast cancer	MedChemEx	95.72	ONC(=O)c1ccc(O)c(O)c1	Launched
dienestrol	estrogen receptor agonist	ESR1	endocrinology	menopause	MedChemEx, MicroSource, MicroSource, MicroSource	93.72	C\C=C(\C(=C\C)\c1ccc(O)cc1)/c1ccc(O)cc1, C\C=C(\C(=C\C)\c1ccc(O)cc1)/c1ccc(O)cc1, C\C=C(\C(=C\C)\c1ccc(O)cc1)/c1ccc(O)cc1, C\C=C(\C(=C\C)\c1ccc(O)cc1)/c1ccc(O)cc1	Launched
dienogest	progesterone receptor agonist	PGR	endocrinology, obstetrics/gynecology	contraceptive, endometriosis	MedChemEx, MedChemEx, Selleck	95.22	C[C@]12CCC3=C4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@@]2(O)CC#N |c:4,10|, C[C@]12CCC3=C4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@@]2(O)CC#N |c:4,10|, C[C@]12CCC3=C4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@@]2(O)CC#N |c:4,10|	Launched
diethylcarbamazine	lipoxygenase inhibitor	ALOX5, PTGS1	infectious disease	filariasis	MedChemEx, MedChemEx, MicroSource	99.23	CCN(CC)C(=O)N1CCN(C)CC1, CCN(CC)C(=O)N1CCN(C)CC1, CCN(CC)C(=O)N1CCN(C)CC1	Launched
diethylstilbestrol	estrogen receptor agonist	ESR1, ESR2, ESRRB, ESRRG			MicroSource, Selleck, Selleck	93.73	CC\C(=C(\CC)c1ccc(O)cc1)c1ccc(O)cc1, CC\C(=C(\CC)c1ccc(O)cc1)c1ccc(O)cc1, CC\C(=C(\CC)c1ccc(O)cc1)c1ccc(O)cc1	Withdrawn
diethyltoluamide	ionotropic receptor IR40a activator		dermatology	sunscreen lotion	MedChemEx, MicroSource, MicroSource	98.89	CCN(CC)C(=O)c1cccc(C)c1, CCN(CC)C(=O)c1cccc(C)c1, CCN(CC)C(=O)c1cccc(C)c1	Launched
difenpiramide	cyclooxygenase inhibitor, prostaglandin inhibitor		neurology/psychiatry	pain relief	Enamine	85.55	O=C(Cc1ccc(cc1)-c1ccccc1)Nc1ccccn1	Launched
diflorasone-diacetate	glucocorticoid receptor agonist	NR3C1	dermatology	corticosteroid-responsive dermatoses		0		Launched
difloxacin	bacterial DNA gyrase inhibitor		infectious disease	skin infections, urinary tract infections	MicroSource, Selleck, Selleck	97.01	CN1CCN(CC1)c1cc2n(cc(C(O)=O)c(=O)c2cc1F)-c1ccc(F)cc1, CN1CCN(CC1)c1cc2n(cc(C(O)=O)c(=O)c2cc1F)-c1ccc(F)cc1, CN1CCN(CC1)c1cc2n(cc(C(O)=O)c(=O)c2cc1F)-c1ccc(F)cc1	Launched
diflunisal	prostanoid receptor antagonist	PTGS1, PTGS2	rheumatology	rheumatoid arthritis, osteoarthritis	MicroSource	98.97	OC(=O)c1cc(ccc1O)-c1ccc(F)cc1F	Launched
difluprednate	glucocorticoid receptor agonist	NR3C1	ophthalmology	endogenous uveitis	MedChemEx	91.09	CCCC(=O)O[C@@]1(CC[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)COC(C)=O |c:18,t:14|	Launched
diftalone	cyclooxygenase inhibitor		endocrinology	thyroiditis	Vitas-M, Vitas-M	98.16	O=C1N2Cc3ccccc3C(=O)N2Cc2ccccc12, O=C1N2Cc3ccccc3C(=O)N2Cc2ccccc12	Launched
digitoxigenin	ATPase inhibitor	ATP1A1			Sigma, Prestwick, Prestwick, Prestwick, Prestwick	93.94	C[C@]12CC[C@H]3[C@@H](CC[C@@H]4C[C@@H](O)CC[C@]34C)[C@@]1(O)CC[C@@H]2C1=CC(=O)OC1 |t:25|, C[C@]12CC[C@H]3[C@@H](CC[C@@H]4C[C@@H](O)CC[C@]34C)[C@@]1(O)CC[C@@H]2C1=CC(=O)OC1 |t:25|, C[C@]12CC[C@H]3[C@@H](CC[C@@H]4C[C@@H](O)CC[C@]34C)[C@@]1(O)CC[C@@H]2C1=CC(=O)OC1 |t:25|, C[C@]12CC[C@H]3[C@@H](CC[C@@H]4C[C@@H](O)CC[C@]34C)[C@@]1(O)CC[C@@H]2C1=CC(=O)OC1 |t:25|, C[C@]12CC[C@H]3[C@@H](CC[C@@H]4C[C@@H](O)CC[C@]34C)[C@@]1(O)CC[C@@H]2C1=CC(=O)OC1 |t:25|	Preclinical
digitoxin	ATPase inhibitor	ATP1A1, ATP1A2, ATP1A3, ATP1A4, ATP1B1, ATP1B2, ATP1B3, FXYD2	cardiology	congestive heart failure, cardiac arrythmia	MedChemEx, MedChemEx	89.4	C[C@H]1O[C@H](C[C@H](O)[C@@H]1O)O[C@H]1[C@@H](O)C[C@H](O[C@H]2[C@@H](O)C[C@H](O[C@H]3CC[C@@]4(C)[C@H](CC[C@@H]5[C@@H]4CC[C@]4(C)[C@H](CC[C@]54O)C4=CC(=O)OC4)C3)O[C@@H]2C)O[C@@H]1C |t:45|, C[C@H]1O[C@H](C[C@H](O)[C@@H]1O)O[C@H]1[C@@H](O)C[C@H](O[C@H]2[C@@H](O)C[C@H](O[C@H]3CC[C@@]4(C)[C@H](CC[C@@H]5[C@@H]4CC[C@]4(C)[C@H](CC[C@]54O)C4=CC(=O)OC4)C3)O[C@@H]2C)O[C@@H]1C |t:45|	Launched
digoxigenin	steroid				MedChemEx, MedChemEx, Selleck	97.81	C[C@@]12[C@H](CC[C@]1(O)[C@@H]1CC[C@@H]3C[C@@H](O)CC[C@]3(C)[C@H]1C[C@H]2O)C1=CC(=O)OC1 |t:26|, C[C@@]12[C@H](CC[C@]1(O)[C@@H]1CC[C@@H]3C[C@@H](O)CC[C@]3(C)[C@H]1C[C@H]2O)C1=CC(=O)OC1 |t:26|, C[C@@]12[C@H](CC[C@]1(O)[C@@H]1CC[C@@H]3C[C@@H](O)CC[C@]3(C)[C@H]1C[C@H]2O)C1=CC(=O)OC1 |t:26|	Preclinical
digoxin	ATPase inhibitor	ATP1A1	cardiology	congestive heart failure, atrial fibrillation (AF)	Tocris, Tocris	96.21	[H][C@@]1(C[C@H](O)[C@H](O[C@@]2([H])C[C@H](O)[C@H](O[C@@]3([H])C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1)O[C@H]1CC[C@@]2(C)[C@]([H])(CC[C@]3([H])[C@]2([H])C[C@@H](O)[C@@]2(C)[C@H](CC[C@]32O)C2=CC(=O)OC2)C1 |t:60|, [H][C@@]1(C[C@H](O)[C@H](O[C@@]2([H])C[C@H](O)[C@H](O[C@@]3([H])C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1)O[C@H]1CC[C@@]2(C)[C@]([H])(CC[C@]3([H])[C@]2([H])C[C@@H](O)[C@@]2(C)[C@H](CC[C@]32O)C2=CC(=O)OC2)C1 |t:60|	Launched
dihomo-gamma-linolenic-acid	prostanoid receptor agonist	PTGS1, PTGS2			Sigma, Sigma, Enzo	81.2	CCCCC\C=C/C\C=C/C\C=C/CCCCCCC(O)=O, CCCCC\C=C/C\C=C/C\C=C/CCCCCCC(O)=O, CCCCC\C=C/C\C=C/C\C=C/CCCCCCC(O)=O	Phase 2
dihydrexidine	dopamine receptor agonist	DRD1, DRD2, DRD3, DRD4, DRD5			Tocris, Tocris, Tocris, Tocris	100	Oc1cc2CC[C@H]3NCc4ccccc4[C@@H]3c2cc1O, Oc1cc2CC[C@H]3NCc4ccccc4[C@@H]3c2cc1O, Oc1cc2CC[C@H]3NCc4ccccc4[C@@H]3c2cc1O, Oc1cc2CC[C@H]3NCc4ccccc4[C@@H]3c2cc1O	Phase 2
dihydroartemisinin	antimalarial agent		infectious disease	malaria	MedChemEx, MicroSource, MicroSource, Selleck	94.91	C[C@@H]1CC[C@H]2[C@@H](C)[C@@H](O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4, C[C@@H]1CC[C@H]2[C@@H](C)[C@@H](O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4, C[C@@H]1CC[C@H]2[C@@H](C)[C@@H](O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4, C[C@@H]1CC[C@H]2[C@@H](C)[C@@H](O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4	Launched
dihydroergocristine	adrenergic receptor antagonist, prolactin inhibitor	ADRA1A, ADRB1, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR2A, HTR3A, HTR4, HTR5A, HTR6, HTR7	neurology/psychiatry	senile dementia, cerebrovascular insufficiency	Tocris, Tocris, Tocris, Tocris, Tocris, Tocris, Tocris	96.31	CC(C)[C@@]1(NC(=O)[C@@H]2C[C@H]3[C@@H](Cc4c[nH]c5cccc3c45)N(C)C2)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O, CC(C)[C@@]1(NC(=O)[C@@H]2C[C@H]3[C@@H](Cc4c[nH]c5cccc3c45)N(C)C2)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O, CC(C)[C@@]1(NC(=O)[C@@H]2C[C@H]3[C@@H](Cc4c[nH]c5cccc3c45)N(C)C2)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O, CC(C)[C@@]1(NC(=O)[C@@H]2C[C@H]3[C@@H](Cc4c[nH]c5cccc3c45)N(C)C2)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O, CC(C)[C@@]1(NC(=O)[C@@H]2C[C@H]3[C@@H](Cc4c[nH]c5cccc3c45)N(C)C2)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O, CC(C)[C@@]1(NC(=O)[C@@H]2C[C@H]3[C@@H](Cc4c[nH]c5cccc3c45)N(C)C2)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O, CC(C)[C@@]1(NC(=O)[C@@H]2C[C@H]3[C@@H](Cc4c[nH]c5cccc3c45)N(C)C2)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O	Launched
dihydroergotamine	serotonin receptor agonist	ADRA2A, DRD2, HTR1B, HTR1D, HTR1E, HTR1F, HTR2B, HTR7	neurology/psychiatry	migraine headache	Tocris, MicroSource, Tocris, Tocris	97.15	CN1C[C@@H](C[C@H]2[C@H]1Cc1c[nH]c3cccc2c13)C(=O)N[C@]1(C)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O, CN1C[C@@H](C[C@H]2[C@H]1Cc1c[nH]c3cccc2c13)C(=O)N[C@]1(C)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O, CN1C[C@@H](C[C@H]2[C@H]1Cc1c[nH]c3cccc2c13)C(=O)N[C@]1(C)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O, CN1C[C@@H](C[C@H]2[C@H]1Cc1c[nH]c3cccc2c13)C(=O)N[C@]1(C)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O	Launched
dihydromyricetin					MedChemEx, MedChemEx, Selleck, Selleck	80.78	O[C@@H]1[C@H](Oc2cc(O)cc(O)c2C1=O)c1cc(O)c(O)c(O)c1, O[C@@H]1[C@H](Oc2cc(O)cc(O)c2C1=O)c1cc(O)c(O)c(O)c1, O[C@@H]1[C@H](Oc2cc(O)cc(O)c2C1=O)c1cc(O)c(O)c(O)c1, O[C@@H]1[C@H](Oc2cc(O)cc(O)c2C1=O)c1cc(O)c(O)c(O)c1	Preclinical
dihydrostreptomycin	bacterial 30S ribosomal subunit inhibitor				Selleck	54.8	CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@H]1[C@H](O[C@@H]2[C@@H](O)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]2NC(N)=N)O[C@@H](C)[C@]1(O)CO.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@H]1[C@H](O[C@@H]2[C@@H](O)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]2NC(N)=N)O[C@@H](C)[C@]1(O)CO	Withdrawn
dihydrotachysterol	vitamin analog	VDR	orthopedics, endocrinology	rickets, hypocalcemia, osteomalacia	Sigma	0	CC(C)[C@@H](C)\C=C\[C@@H](C)[C@H]1CC[C@@H]2\C(CCC[C@@]12C)=C\C=C1/C[C@@H](O)CC[C@@H]1C |&1:3,&2:7,&3:9,&4:12,&5:17,&6:23,&7:27,r|	Launched
dihydroxyacetone			dermatology	skin protectant	Sigma	0	OCC(=O)CO	Launched
dihydroxyphenylglycine	glutamate receptor agonist	GRM1, GRM5			Tocris, Tocris	100	N[C@@H](C(O)=O)c1cc(O)cc(O)c1 |&1:1,r|, N[C@@H](C(O)=O)c1cc(O)cc(O)c1 |&1:1,r|	Preclinical
diiodothyropropionic-acid	thyroid hormone stimulant				Sigma	3.17	OC(=O)CCc1cc(I)c(Oc2ccc(O)cc2)c(I)c1	Phase 2
dilazep	adenosine reuptake inhibitor	SLC29A1	cardiology	coronary heart disease	MicroSource, Tocris	92.84	COc1cc(cc(OC)c1OC)C(=O)OCCCN1CCCN(CCCOC(=O)c2cc(OC)c(OC)c(OC)c2)CC1, COc1cc(cc(OC)c1OC)C(=O)OCCCN1CCCN(CCCOC(=O)c2cc(OC)c(OC)c(OC)c2)CC1	Launched
dilmapimod	p38 MAPK inhibitor				MedChemEx	95.74	Cc1cc(F)ccc1-c1nc(NC(CO)CO)nc2n(-c3c(F)cccc3F)c(=O)ccc12	Phase 1
diloxanide	protein synthesis inhibitor		infectious disease	amebiasis	MicroSource	98.59	CN(C(=O)C(Cl)Cl)c1ccc(OC(=O)c2ccco2)cc1	Launched
diltiazem	calcium channel blocker	CACNA1C, CACNA1S, CACNA2D1, CACNG1, HTR3A, KCNA5	cardiology	hypertension, angina pectoris	Tocris, Tocris, Tocris, Tocris, Selleck, Tocris	99.25	COc1ccc(cc1)[C@@H]1Sc2ccccc2N(CCN(C)C)C(=O)[C@@H]1OC(C)=O, COc1ccc(cc1)[C@@H]1Sc2ccccc2N(CCN(C)C)C(=O)[C@@H]1OC(C)=O, COc1ccc(cc1)[C@@H]1Sc2ccccc2N(CCN(C)C)C(=O)[C@@H]1OC(C)=O, COc1ccc(cc1)[C@@H]1Sc2ccccc2N(CCN(C)C)C(=O)[C@@H]1OC(C)=O, COc1ccc(cc1)[C@@H]1Sc2ccccc2N(CCN(C)C)C(=O)[C@@H]1OC(C)=O, COc1ccc(cc1)[C@@H]1Sc2ccccc2N(CCN(C)C)C(=O)[C@@H]1OC(C)=O	Launched
DIM-C-pPhCO2Me	nuclear receptor antagonist				MedChemEx	95.06	COC(=O)c1ccc(cc1)C(c1c[nH]c2ccccc12)c1c[nH]c2ccccc12	Preclinical
dimaprit	histamine receptor agonist	HRH2, HRH3, HRH4			Selleck, Tocris, Tocris, Tocris	100	CN(C)CCCSC(N)=N, CN(C)CCCSC(N)=N, CN(C)CCCSC(N)=N, CN(C)CCCSC(N)=N	Preclinical
dimemorfan	sigma receptor agonist	SIGMAR1	pulmonary	cough suppressant	Key, Key, Key	98.52	CN1CC[C@@]23CCCC[C@@H]2[C@@H]1Cc1ccc(C)cc31, CN1CC[C@@]23CCCC[C@@H]2[C@@H]1Cc1ccc(C)cc31, CN1CC[C@@]23CCCC[C@@H]2[C@@H]1Cc1ccc(C)cc31	Launched
dimenhydrinate	histamine receptor antagonist	HRH1	neurology/psychiatry, gastroenterology	motion sickness, nausea, vomiting		0		Launched
dimercaprol	chelating agent		neurology/psychiatry	metal toxicity	Sigma, MicroSource	0	OC[C@@H](S)CS |&1:2,r|, OC[C@@H](S)CS |&1:2,r|	Launched
dimercaptosuccinic-acid	chelating agent	DNMT1	neurology/psychiatry	metal toxicity	AlfaAesar, AlfaAesar, AlfaAesar, AlfaAesar	0	OC(=O)[C@@H](S)[C@@H](S)C(O)=O, OC(=O)[C@@H](S)[C@@H](S)C(O)=O, OC(=O)[C@@H](S)[C@@H](S)C(O)=O, OC(=O)[C@@H](S)[C@@H](S)C(O)=O	Launched
dimesna	tubulin polymerization inhibitor				MedChemEx, MicroSource, Selleck	100	OS(=O)(=O)CCSSCCS(O)(=O)=O, OS(=O)(=O)CCSSCCS(O)(=O)=O, OS(=O)(=O)CCSSCCS(O)(=O)=O	Phase 3
dimethadione	oxazolidine antiepileptic				MicroSource	0	CC1(C)OC(=O)NC1=O	Preclinical
dimethicone			dermatology	cosmetic	Sigma	0	C[Si](C)(C)O[Si](C)(C)C	Launched
dimethindene-(S)-(+)	acetylcholine receptor antagonist	HRH1			Tocris, Tocris, Tocris, Tocris, Tocris	97.21	C[C@@H](C1=C(CCN(C)C)Cc2ccccc12)c1ccccn1 |c:2|, C[C@@H](C1=C(CCN(C)C)Cc2ccccc12)c1ccccn1 |c:2|, C[C@@H](C1=C(CCN(C)C)Cc2ccccc12)c1ccccn1 |c:2|, C[C@@H](C1=C(CCN(C)C)Cc2ccccc12)c1ccccn1 |c:2|, C[C@@H](C1=C(CCN(C)C)Cc2ccccc12)c1ccccn1 |c:2|	Preclinical
dimethisoquin	local anesthetic		neurology/psychiatry	local anesthetic	Prestwick, Toronto	97.5	CCCCc1cc2ccccc2c(OCCN(C)C)n1, CCCCc1cc2ccccc2c(OCCN(C)C)n1	Launched
dimethyl-fumarate	nuclear factor erythroid derived, like (NRF2) activator	KEAP1	neurology/psychiatry	multiple sclerosis	MicroSource, MicroSource, Selleck, Selleck, Selleck	97.66	COC(=O)\C=C\C(=O)OC, COC(=O)\C=C\C(=O)OC, COC(=O)\C=C\C(=O)OC, COC(=O)\C=C\C(=O)OC, COC(=O)\C=C\C(=O)OC	Launched
dimethyl-isosorbide	cosmetic moisturizer				AMS	0	CO[C@@H]1CO[C@H]2[C@H](CO[C@@H]12)OC |&1:6,&2:9,&3:2,&4:5,r|	Preclinical
dimetindene	cholinergic receptor antagonist, histamine receptor antagonist	HRH1	allergy	allergic rhinitis	AMS	52.79	C[C@@H](C1=C(CCN(C)C)Cc2ccccc12)c1ccccn1 |&1:1,r,c:2|	Launched
dimetridazole	bacterial DNA inhibitor		infectious disease	protozoan infection	MicroSource	96.89	Cc1ncc(n1C)[N+]([O-])=O	Launched
diminazene-aceturate	angiotensin converting enzyme activator	AOC1, PRDX5, PRSS1			MicroSource, Selleck, Selleck, Selleck	90.29	NC(=N)c1ccc(N\N=N\c2ccc(cc2)C(N)=N)cc1, NC(=N)c1ccc(N\N=N\c2ccc(cc2)C(N)=N)cc1, NC(=N)c1ccc(N\N=N\c2ccc(cc2)C(N)=N)cc1, NC(=N)c1ccc(N\N=N\c2ccc(cc2)C(N)=N)cc1	Phase 3
dimpylate	acetylcholinesterase inhibitor	ACHE	infectious disease	flea control	MicroSource, MicroSource, Sigma	91.18	CCOP(=S)(OCC)Oc1cc(C)nc(n1)C(C)C, CCOP(=S)(OCC)Oc1cc(C)nc(n1)C(C)C, CCOP(=S)(OCC)Oc1cc(C)nc(n1)C(C)C	Launched
dinaciclib	CDK inhibitor	CDK1, CDK2, CDK5, CDK9			Selleck, Selleck, Selleck, Selleck, Selleck, Selleck	98.56	CCc1cnn2c(NCc3ccc[n+]([O-])c3)cc(nc12)N1CCCC[C@H]1CCO, CCc1cnn2c(NCc3ccc[n+]([O-])c3)cc(nc12)N1CCCC[C@H]1CCO, CCc1cnn2c(NCc3ccc[n+]([O-])c3)cc(nc12)N1CCCC[C@H]1CCO, CCc1cnn2c(NCc3ccc[n+]([O-])c3)cc(nc12)N1CCCC[C@H]1CCO, CCc1cnn2c(NCc3ccc[n+]([O-])c3)cc(nc12)N1CCCC[C@H]1CCO, CCc1cnn2c(NCc3ccc[n+]([O-])c3)cc(nc12)N1CCCC[C@H]1CCO	Phase 3
dinitolmide			infectious disease	coccidiosis	MedChemEx, MicroSource	98.55	Cc1c(cc(cc1[N+]([O-])=O)[N+]([O-])=O)C(N)=O, Cc1c(cc(cc1[N+]([O-])=O)[N+]([O-])=O)C(N)=O	Launched
dinoprost	prostacyclin analog	PTGDR, PTGDR2, PTGER1, PTGER2, PTGER3, PTGER4, PTGFR, TBXA2R	obstetrics/gynecology	labor induction	Enzo, Enzo, Tocris	100	CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O, CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O, CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O	Launched
dinoprostone	prostanoid receptor agonist	CATSPER1, CATSPER2, CATSPER3, CATSPER4, PTGDR, PTGDR2, PTGER1, PTGER2, PTGER3, PTGER4, PTGFR, TBXA2R			Tocris, Cayman	98.3	CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O, CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O	Withdrawn
dioscin	apoptosis stimulant	CXCR3			MedChemEx	100	C[C@H]1[C@H]2[C@H](C[C@H]3[C@@H]4CC=C5C[C@H](CC[C@]5(C)[C@H]4CC[C@]23C)O[C@@H]2O[C@H](CO)[C@@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](O)[C@H]3O)[C@H](O)[C@H]2O[C@@H]2O[C@@H](C)[C@H](O)[C@@H](O)[C@H]2O)O[C@]11CC[C@@H](C)CO1 |t:8|	Preclinical
diosgenin	steroid				MedChemEx, Selleck	100	C[C@H]1[C@H]2[C@H](C[C@H]3[C@@H]4CC=C5C[C@@H](O)CC[C@]5(C)[C@H]4CC[C@]23C)O[C@]11CC[C@@H](C)CO1 |t:8|, C[C@H]1[C@H]2[C@H](C[C@H]3[C@@H]4CC=C5C[C@@H](O)CC[C@]5(C)[C@H]4CC[C@]23C)O[C@]11CC[C@@H](C)CO1 |t:8|	Preclinical
diosmetin	aryl hydrocarbon receptor agonist	CYP1B1	dermatology	cosmetic	MedChemEx, Selleck, Selleck, Selleck, Selleck	98.29	COc1ccc(cc1O)-c1cc(=O)c2c(O)cc(O)cc2o1, COc1ccc(cc1O)-c1cc(=O)c2c(O)cc(O)cc2o1, COc1ccc(cc1O)-c1cc(=O)c2c(O)cc(O)cc2o1, COc1ccc(cc1O)-c1cc(=O)c2c(O)cc(O)cc2o1, COc1ccc(cc1O)-c1cc(=O)c2c(O)cc(O)cc2o1	Launched
diosmin	aryl hydrocarbon receptor agonist, capillary stabilizing agent	AHR	cardiology, hematology, dermatology	chronic venous insufficiency (CVI), edema, deep vein thrombosis (DVT), statis dermatitis, heavy leg syndrome	MicroSource, MedChemEx, MedChemEx, Selleck, Selleck	89.97	COc1ccc(cc1O)-c1cc(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2o1, COc1ccc(cc1O)-c1cc(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2o1, COc1ccc(cc1O)-c1cc(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2o1, COc1ccc(cc1O)-c1cc(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2o1, COc1ccc(cc1O)-c1cc(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2o1	Launched
dioxybenzone	topical sunscreen agent				MedChemEx, MicroSource	98.11	COc1ccc(C(=O)c2ccccc2O)c(O)c1, COc1ccc(C(=O)c2ccccc2O)c(O)c1	Preclinical
dipeptamin					ChemImpex, ChemImpex	0	C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(O)=O, C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(O)=O	Launched
diperodon	local anesthetic				Selleck, MicroSource, MicroSource, Selleck	98.2	O=C(Nc1ccccc1)OC[C@@H](CN1CCCCC1)OC(=O)Nc1ccccc1 |&1:11|, O=C(Nc1ccccc1)OC[C@@H](CN1CCCCC1)OC(=O)Nc1ccccc1 |&1:11|, O=C(Nc1ccccc1)OC[C@@H](CN1CCCCC1)OC(=O)Nc1ccccc1 |&1:11|, O=C(Nc1ccccc1)OC[C@@H](CN1CCCCC1)OC(=O)Nc1ccccc1 |&1:11|	Preclinical
diphemanil	acetylcholine receptor antagonist	CHRM3	neurology/psychiatry	spasms	MedChemEx, MedChemEx, Selleck	96.64	C[N+]1(C)CCC(CC1)=C(c1ccccc1)c1ccccc1, C[N+]1(C)CCC(CC1)=C(c1ccccc1)c1ccccc1, C[N+]1(C)CCC(CC1)=C(c1ccccc1)c1ccccc1	Launched
diphencyprone	immunostimulant				Sigma, Vitas-M	98.43	O=c1c(c1-c1ccccc1)-c1ccccc1, O=c1c(c1-c1ccccc1)-c1ccccc1	Phase 2
diphenhydramine	histamine receptor antagonist	HRH1	neurology/psychiatry	headache	MicroSource, MicroSource, Selleck	98.11	CN(C)CCOC(c1ccccc1)c1ccccc1, CN(C)CCOC(c1ccccc1)c1ccccc1, CN(C)CCOC(c1ccccc1)c1ccccc1	Launched
diphenidol	acetylcholine receptor agonist	CHRM1, CHRM2, CHRM3, CHRM4	neurology/psychiatry	vertigo	Enamine, Enamine, Enamine, Selleck, Selleck	99.63	OC(CCCN1CCCCC1)(c1ccccc1)c1ccccc1, OC(CCCN1CCCCC1)(c1ccccc1)c1ccccc1, OC(CCCN1CCCCC1)(c1ccccc1)c1ccccc1, OC(CCCN1CCCCC1)(c1ccccc1)c1ccccc1, OC(CCCN1CCCCC1)(c1ccccc1)c1ccccc1	Launched
diphenyleneiodonium	nitric oxide synthase inhibitor	NOS2, NOS3			Tocris, Tocris, Tocris	100	[I]1c2ccccc2-c2ccccc12 |^1:0|, [I]1c2ccccc2-c2ccccc12 |^1:0|, [I]1c2ccccc2-c2ccccc12 |^1:0|	Preclinical
diphenylguanidine					Vitas-M, Sigma	95.16	N=C(Nc1ccccc1)Nc1ccccc1, N=C(Nc1ccccc1)Nc1ccccc1	Preclinical
diphenylpyraline	dopamine reuptake inhibitor	HRH1, SLC6A3	allergy	allergic rhinitis	MicroSource, MicroSource, Selleck, Selleck	97.93	CN1CCC(CC1)OC(c1ccccc1)c1ccccc1, CN1CCC(CC1)OC(c1ccccc1)c1ccccc1, CN1CCC(CC1)OC(c1ccccc1)c1ccccc1, CN1CCC(CC1)OC(c1ccccc1)c1ccccc1	Launched
dipivefrine	adrenergic receptor agonist		ophthalmology	glaucoma, intraocular pressure	Prestwick	94.37	CNC[C@@H](O)c1ccc(OC(=O)C(C)(C)C)c(OC(=O)C(C)(C)C)c1 |&1:3|	Launched
dipraglurant	glutamate receptor negative allosteric modulator	GRM5			MedChemEx, MedChemEx	94.48	Fc1ccc2nc(CCC#Cc3ccccn3)cn2c1, Fc1ccc2nc(CCC#Cc3ccccn3)cn2c1	Phase 2
DIPT	dopamine reuptake inhibitor, serotonin reuptake inhibitor	HTR1A, HTR2A, HTR2C			Cayman	88.49	CC(C)N(CCc1c[nH]c2ccccc12)C(C)C	Launched
dipyridamole	phosphodiesterase inhibitor	ADA, PDE10A, PDE1A, PDE1B, PDE1C, PDE2A, PDE3A, PDE3B, PDE4A, PDE4B, PDE4C, PDE4D, PDE5A, PDE6A, PDE6B, PDE6C, PDE6D, PDE6G, PDE6H, PDE7A, PDE7B, PDE8A, PDE8B, PDE9A, SLC29A1	cardiology	coronary artery disease (CAD), peripheral artery disease (PAD), hypertension	Tocris, MicroSource, Selleck, Selleck, Tocris, Tocris, Selleck, Tocris	97.6	OCCN(CCO)c1nc(N2CCCCC2)c2nc(nc(N3CCCCC3)c2n1)N(CCO)CCO, OCCN(CCO)c1nc(N2CCCCC2)c2nc(nc(N3CCCCC3)c2n1)N(CCO)CCO, OCCN(CCO)c1nc(N2CCCCC2)c2nc(nc(N3CCCCC3)c2n1)N(CCO)CCO, OCCN(CCO)c1nc(N2CCCCC2)c2nc(nc(N3CCCCC3)c2n1)N(CCO)CCO, OCCN(CCO)c1nc(N2CCCCC2)c2nc(nc(N3CCCCC3)c2n1)N(CCO)CCO, OCCN(CCO)c1nc(N2CCCCC2)c2nc(nc(N3CCCCC3)c2n1)N(CCO)CCO, OCCN(CCO)c1nc(N2CCCCC2)c2nc(nc(N3CCCCC3)c2n1)N(CCO)CCO, OCCN(CCO)c1nc(N2CCCCC2)c2nc(nc(N3CCCCC3)c2n1)N(CCO)CCO	Launched
dipyrocetyl	chelating agent		endocrinology, neurology/psychiatry	fever, pain relief	MedChemEx, MicroSource	80.37	CC(=O)Oc1cccc(C(O)=O)c1OC(C)=O, CC(=O)Oc1cccc(C(O)=O)c1OC(C)=O	Launched
diquafosol	purinergic receptor activator				MedChemEx	97.3	O[C@@H]1[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)n2ccc(=O)[nH]c2=O)O[C@H]([C@@H]1O)n1ccc(=O)[nH]c1=O	Phase 3
dirithromycin	bacterial 50S ribosomal subunit inhibitor		pulmonary	bronchitis	AvaChem, AvaChem, AvaChem, MicroSource, Sigma, MedChemEx, MedChemEx, MedChemEx, Selleck, Selleck	100	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H]([C@H]2C)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H]([C@H]2C)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H]([C@H]2C)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H]([C@H]2C)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H]([C@H]2C)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H]([C@H]2C)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H]([C@H]2C)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H]([C@H]2C)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H]([C@H]2C)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H]([C@H]2C)[C@]1(C)O	Launched
diroximel-fumarate	anti-inflammatory agent				WuXi	97.29	COC(=O)\C=C\C(=O)OCCN1C(=O)CCC1=O	Phase 3
disodium-sebacate		HBB			Sigma	68.1	OC(=O)CCCCCCCCC(O)=O	Phase 1
disopyramide	sodium channel blocker	CHRM1, CHRM2, CHRM3, KCND2, KCND3, KCNH2, SCN5A	cardiology	ventricular tachycardia (VT), ventricular arrhythmias	MicroSource, Selleck, Selleck, Selleck, Selleck	97.94	CC(C)N(CCC(C(N)=O)(c1ccccc1)c1ccccn1)C(C)C |&1:6|, CC(C)N(CCC(C(N)=O)(c1ccccc1)c1ccccn1)C(C)C |&1:6|, CC(C)N(CCC(C(N)=O)(c1ccccc1)c1ccccn1)C(C)C |&1:6|, CC(C)N(CCC(C(N)=O)(c1ccccc1)c1ccccn1)C(C)C |&1:6|, CC(C)N(CCC(C(N)=O)(c1ccccc1)c1ccccn1)C(C)C |&1:6|	Launched
disulfiram	aldehyde dehydrogenase inhibitor, DNA methyltransferase inhibitor, TRPV agonist	ALDH2, DBH	neurology/psychiatry	abstinence from alcohol	MicroSource, MicroSource, MicroSource, MicroSource, MicroSource, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck	100	CCN(CC)C(=S)SSC(=S)N(CC)CC, CCN(CC)C(=S)SSC(=S)N(CC)CC, CCN(CC)C(=S)SSC(=S)N(CC)CC, CCN(CC)C(=S)SSC(=S)N(CC)CC, CCN(CC)C(=S)SSC(=S)N(CC)CC, CCN(CC)C(=S)SSC(=S)N(CC)CC, CCN(CC)C(=S)SSC(=S)N(CC)CC, CCN(CC)C(=S)SSC(=S)N(CC)CC, CCN(CC)C(=S)SSC(=S)N(CC)CC, CCN(CC)C(=S)SSC(=S)N(CC)CC, CCN(CC)C(=S)SSC(=S)N(CC)CC, CCN(CC)C(=S)SSC(=S)N(CC)CC, CCN(CC)C(=S)SSC(=S)N(CC)CC, CCN(CC)C(=S)SSC(=S)N(CC)CC	Launched
dithranol	DNA synthesis inhibitor		dermatology	psoriasis	Sigma	0	Oc1cccc2cc3cccc(O)c3c(O)c12	Launched
ditiocarb-sodium-trihydrate	immunostimulant	CA1, CA2, CA4			Enamine, Enamine	0	CCN(CC)C(S)=S, CCN(CC)C(S)=S	Phase 3
ditolylguanidine	sigma receptor agonist	GRIN1, GRIN2A, GRIN2B, SIGMAR1			Tocris, Tocris	93.56	Cc1ccccc1NC(=N)Nc1ccccc1C, Cc1ccccc1NC(=N)Nc1ccccc1C	Preclinical
dixanthogen					MicroSource, Sigma	0	CCOC(=S)SSC(=S)OCC, CCOC(=S)SSC(=S)OCC	Preclinical
dixyrazine	antipsychotic				MedChemEx	96.92	C[C@H](CN1CCN(CCOCCO)CC1)CN1c2ccccc2Sc2ccccc12 |&1:1,r|	Preclinical
dizocilpine-(+)	glutamate receptor antagonist	GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D			Tocris, Tocris, Tocris, Tocris, Tocris, Selleck	98.82	C[C@]12N[C@H](Cc3ccccc13)c1ccccc21, C[C@]12N[C@H](Cc3ccccc13)c1ccccc21, C[C@]12N[C@H](Cc3ccccc13)c1ccccc21, C[C@]12N[C@H](Cc3ccccc13)c1ccccc21, C[C@]12N[C@H](Cc3ccccc13)c1ccccc21, C[C@]12N[C@H](Cc3ccccc13)c1ccccc21	Preclinical
dizocilpine-(-)	glutamate receptor antagonist				Tocris, Tocris, Tocris, Selleck	99.01	C[C@@]12N[C@@H](Cc3ccccc13)c1ccccc21, C[C@@]12N[C@@H](Cc3ccccc13)c1ccccc21, C[C@@]12N[C@@H](Cc3ccccc13)c1ccccc21, C[C@@]12N[C@@H](Cc3ccccc13)c1ccccc21	Phase 1
DMAB-anabaseine	adrenergic receptor agonist	CHRNA7			Tocris, Tocris, Tocris, Tocris	91.34	CN(C)c1ccc(\C=C2/CCCN=C2c2cccnc2)cc1 |c:12|, CN(C)c1ccc(\C=C2/CCCN=C2c2cccnc2)cc1 |c:12|, CN(C)c1ccc(\C=C2/CCCN=C2c2cccnc2)cc1 |c:12|, CN(C)c1ccc(\C=C2/CCCN=C2c2cccnc2)cc1 |c:12|	Preclinical
DMeOB	glutamate receptor modulator	GRM5			Tocris, Tocris	98.09	COc1cccc(\C=N\N=C\c2cccc(OC)c2)c1, COc1cccc(\C=N\N=C\c2cccc(OC)c2)c1	Preclinical
DMH1	ALK tyrosine kinase receptor inhibitor	ACVR1			Selleck, Selleck, Selleck, Tocris, Tocris, Tocris	98.8	CC(C)Oc1ccc(cc1)-c1cnc2c(cnn2c1)-c1ccnc2ccccc12, CC(C)Oc1ccc(cc1)-c1cnc2c(cnn2c1)-c1ccnc2ccccc12, CC(C)Oc1ccc(cc1)-c1cnc2c(cnn2c1)-c1ccnc2ccccc12, CC(C)Oc1ccc(cc1)-c1cnc2c(cnn2c1)-c1ccnc2ccccc12, CC(C)Oc1ccc(cc1)-c1cnc2c(cnn2c1)-c1ccnc2ccccc12, CC(C)Oc1ccc(cc1)-c1cnc2c(cnn2c1)-c1ccnc2ccccc12	Preclinical
DMH4	VEGFR inhibitor	KDR			Tocris, Tocris, Tocris	97.3	C(CN1CCOCC1)Oc1ccc(cc1)-c1cnc2c(cnn2c1)-c1ccccc1, C(CN1CCOCC1)Oc1ccc(cc1)-c1cnc2c(cnn2c1)-c1ccccc1, C(CN1CCOCC1)Oc1ccc(cc1)-c1cnc2c(cnn2c1)-c1ccccc1	Preclinical
DMNB	DNA dependent protein kinase inhibitor				Tocris, Tocris	94.25	COc1cc(C=O)c(cc1OC)[N+]([O-])=O, COc1cc(C=O)c(cc1OC)[N+]([O-])=O	Preclinical
DMP-543	acetylcholine release enhancer				Tocris, Tocris, Tocris	98.35	Fc1cc(CC2(Cc3ccnc(F)c3)c3ccccc3C(=O)c3ccccc23)ccn1, Fc1cc(CC2(Cc3ccnc(F)c3)c3ccccc3C(=O)c3ccccc23)ccn1, Fc1cc(CC2(Cc3ccnc(F)c3)c3ccccc3C(=O)c3ccccc23)ccn1	Phase 2
DMP-777	elastase inhibitor	MPO			MedChemEx, MedChemEx, MedChemEx	87.92	CCC[C@@H](NC(=O)N1[C@@H](Oc2ccc(cc2)C(=O)N2CCN(C)CC2)C(CC)(CC)C1=O)c1ccc2OCOc2c1, CCC[C@@H](NC(=O)N1[C@@H](Oc2ccc(cc2)C(=O)N2CCN(C)CC2)C(CC)(CC)C1=O)c1ccc2OCOc2c1, CCC[C@@H](NC(=O)N1[C@@H](Oc2ccc(cc2)C(=O)N2CCN(C)CC2)C(CC)(CC)C1=O)c1ccc2OCOc2c1	Phase 2
DMPS	chelating agent				Vitas-M	0	OS(=O)(=O)C[C@@H](S)CS |&1:5,r|	Phase 1
DMSO	control vehicle				Sigma	0	CS(C)=O.CS(C)=O	Preclinical
DNQX	glutamate receptor antagonist	GRIA1, GRIA2, GRIK1, GRIN1, GRIN2A, GRIN2B			Tocris, Tocris, Tocris, Tocris, Tocris, Tocris	95.86	[O-][N+](=O)c1cc2[nH]c(=O)c(=O)[nH]c2cc1[N+]([O-])=O, [O-][N+](=O)c1cc2[nH]c(=O)c(=O)[nH]c2cc1[N+]([O-])=O, [O-][N+](=O)c1cc2[nH]c(=O)c(=O)[nH]c2cc1[N+]([O-])=O, [O-][N+](=O)c1cc2[nH]c(=O)c(=O)[nH]c2cc1[N+]([O-])=O, [O-][N+](=O)c1cc2[nH]c(=O)c(=O)[nH]c2cc1[N+]([O-])=O, [O-][N+](=O)c1cc2[nH]c(=O)c(=O)[nH]c2cc1[N+]([O-])=O	Preclinical
dobutamine	adrenergic receptor agonist	ADRB1, ADRB2	cardiology	congestive heart failure	Tocris, MedChemEx, MedChemEx, Tocris, MedChemEx, MedChemEx, Tocris, Tocris	97.16	CC(CCc1ccc(O)cc1)NCCc1ccc(O)c(O)c1, CC(CCc1ccc(O)cc1)NCCc1ccc(O)c(O)c1, CC(CCc1ccc(O)cc1)NCCc1ccc(O)c(O)c1, CC(CCc1ccc(O)cc1)NCCc1ccc(O)c(O)c1, CC(CCc1ccc(O)cc1)NCCc1ccc(O)c(O)c1, CC(CCc1ccc(O)cc1)NCCc1ccc(O)c(O)c1, CC(CCc1ccc(O)cc1)NCCc1ccc(O)c(O)c1, CC(CCc1ccc(O)cc1)NCCc1ccc(O)c(O)c1	Launched
docebenone	lipoxygenase inhibitor	ALOX5			Enzo	62.9	CC1=C(C)C(=O)C(CCCCC#CCCCC#CCO)=C(C)C1=O |c:1,t:19|	Phase 2
docetaxel	tubulin polymerization inhibitor	BCL2, MAP2, MAP4, MAPT, NR1I2, TUBA1A, TUBA1B, TUBA1C, TUBA3C, TUBA3D, TUBA3E, TUBA4A, TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8	oncology	breast cancer, non-small cell lung cancer (NSCLC), prostate cancer, gastric adenocarcinoma, head and neck squamous cell carcinoma (HNSCC)	MicroSource, MicroSource, Selleck, Selleck, Selleck, Selleck, Selleck	99.62	CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C |t:53|, CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C |t:53|, CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C |t:53|, CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C |t:53|, CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C |t:53|, CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C |t:53|, CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C |t:53|	Launched
doconexent	PPAR receptor agonist	FFAR1, PTGS1, PTGS2			MicroSource, Sigma	56.12	CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O, CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O	Launched
doconexent-ethyl-ester	omega 3 fatty acid stimulant		endocrinology	hypertriglyceridemia	Cayman	0	CCOC(=O)CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC	Launched
docosanol	lipase clearing factor inhibitor	TLR7	dental	cold sore	MedChemEx, MicroSource, Selleck, Selleck	0	CCCCCCCCCCCCCCCCCCCCCCO, CCCCCCCCCCCCCCCCCCCCCCO, CCCCCCCCCCCCCCCCCCCCCCO, CCCCCCCCCCCCCCCCCCCCCCO	Launched
docusate	laxative		gastroenterology	constipation	MedChemEx, MicroSource	93.4	CCCC[C@@H](CC)COC(=O)C[C@@H](C(=O)OC[C@@H](CC)CCCC)S(O)(=O)=O |&1:4,&2:12,&3:17|, CCCC[C@@H](CC)COC(=O)C[C@@H](C(=O)OC[C@@H](CC)CCCC)S(O)(=O)=O |&1:4,&2:12,&3:17|	Launched
dodecyl-sulfate		LYZ			Sigma	0	CCCCCCCCCCCCOS(O)(=O)=O	Preclinical
dofequidar	MRP inhibitor, P glycoprotein inhibitor	ABCB1			MedChemEx, MedChemEx	98.23	OC(COc1cccc2ncccc12)CN1CCN(CC1)C(=O)C(c1ccccc1)c1ccccc1, OC(COc1cccc2ncccc12)CN1CCN(CC1)C(=O)C(c1ccccc1)c1ccccc1	Phase 3
dofetilide	potassium channel blocker	KCNH1, KCNH2, KCNJ12, KCNK2			Tocris, Selleck, Selleck, Tocris, Selleck	95.15	CN(CCOc1ccc(NS(C)(=O)=O)cc1)CCc1ccc(NS(C)(=O)=O)cc1, CN(CCOc1ccc(NS(C)(=O)=O)cc1)CCc1ccc(NS(C)(=O)=O)cc1, CN(CCOc1ccc(NS(C)(=O)=O)cc1)CCc1ccc(NS(C)(=O)=O)cc1, CN(CCOc1ccc(NS(C)(=O)=O)cc1)CCc1ccc(NS(C)(=O)=O)cc1, CN(CCOc1ccc(NS(C)(=O)=O)cc1)CCc1ccc(NS(C)(=O)=O)cc1	Withdrawn
dolasetron	serotonin receptor antagonist	HTR3A	gastroenterology	nausea, vomiting	Tocris, Tocris, Enzo	99.45	O=C(O[C@H]1C[C@H]2C[C@H]3C[C@@H](C1)N2CC3=O)c1c[nH]c2ccccc12, O=C(O[C@H]1C[C@H]2C[C@H]3C[C@@H](C1)N2CC3=O)c1c[nH]c2ccccc12, O=C(O[C@H]1C[C@H]2C[C@H]3C[C@@H](C1)N2CC3=O)c1c[nH]c2ccccc12	Launched
dolastatin-10	tubulin polymerization inhibitor	TUBB			MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx	94.05	CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@@H](Cc1ccccc1)c1nccs1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C)C(C)C, CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@@H](Cc1ccccc1)c1nccs1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C)C(C)C, CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@@H](Cc1ccccc1)c1nccs1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C)C(C)C, CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@@H](Cc1ccccc1)c1nccs1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C)C(C)C, CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@@H](Cc1ccccc1)c1nccs1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C)C(C)C, CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@@H](Cc1ccccc1)c1nccs1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C)C(C)C, CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@@H](Cc1ccccc1)c1nccs1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C)C(C)C	Phase 2
dolutegravir	HIV integrase inhibitor	CYP3A4, CYP3A5, CYP3A7, POU2F2, UGT1A1	infectious disease	human immunodeficiency virus (HIV-1)	MedChemEx	98.59	C[C@@H]1CCO[C@H]2Cn3cc(C(=O)NCc4ccc(F)cc4F)c(=O)c(O)c3C(=O)N12	Launched
domiphen					MedChemEx, MedChemEx, Selleck, Selleck, Selleck, Selleck	98.79	CCCCCCCCCCCC[N+](C)(C)CCOc1ccccc1, CCCCCCCCCCCC[N+](C)(C)CCOc1ccccc1, CCCCCCCCCCCC[N+](C)(C)CCOc1ccccc1, CCCCCCCCCCCC[N+](C)(C)CCOc1ccccc1, CCCCCCCCCCCC[N+](C)(C)CCOc1ccccc1, CCCCCCCCCCCC[N+](C)(C)CCOc1ccccc1	Preclinical
domperidone	dopamine receptor antagonist	DRD2, DRD3	infectious disease	fescue toxicosis	MicroSource, MicroSource, Tocris, Selleck	97.24	Clc1ccc2n(C3CCN(CCCn4c5ccccc5[nH]c4=O)CC3)c(=O)[nH]c2c1, Clc1ccc2n(C3CCN(CCCn4c5ccccc5[nH]c4=O)CC3)c(=O)[nH]c2c1, Clc1ccc2n(C3CCN(CCCn4c5ccccc5[nH]c4=O)CC3)c(=O)[nH]c2c1, Clc1ccc2n(C3CCN(CCCn4c5ccccc5[nH]c4=O)CC3)c(=O)[nH]c2c1	Launched
donepezil	acetylcholinesterase inhibitor	ACHE	neurology/psychiatry	Alzheimer's disease	MicroSource, Selleck	97.71	COc1cc2C[C@@H](CC3CCN(Cc4ccccc4)CC3)C(=O)c2cc1OC |r|, COc1cc2C[C@@H](CC3CCN(Cc4ccccc4)CC3)C(=O)c2cc1OC |r|	Launched
donitriptan	serotonin receptor agonist	HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR5A, HTR6			Tocris, Tocris, Tocris	97.35	NCCc1c[nH]c2ccc(OCC(=O)N3CCN(CC3)c3ccc(cc3)C#N)cc12, NCCc1c[nH]c2ccc(OCC(=O)N3CCN(CC3)c3ccc(cc3)C#N)cc12, NCCc1c[nH]c2ccc(OCC(=O)N3CCN(CC3)c3ccc(cc3)C#N)cc12	Phase 2
dopamine	dopamine receptor agonist	DBH, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR7, SLC6A2, SLC6A3, SLC6A4	cardiology, neurology/psychiatry	ventricular arrhythmias, depression, headache, tremors	MicroSource, Selleck, Selleck, Selleck	100	NCCc1ccc(O)c(O)c1, NCCc1ccc(O)c(O)c1, NCCc1ccc(O)c(O)c1, NCCc1ccc(O)c(O)c1	Launched
doramapimod	p38 MAPK inhibitor	MAPK11, MAPK12, MAPK13, MAPK14			Tocris, Selleck, Selleck, Selleck, Selleck	96.66	Cc1ccc(cc1)-n1nc(cc1NC(=O)Nc1ccc(OCCN2CCOCC2)c2ccccc12)C(C)(C)C, Cc1ccc(cc1)-n1nc(cc1NC(=O)Nc1ccc(OCCN2CCOCC2)c2ccccc12)C(C)(C)C, Cc1ccc(cc1)-n1nc(cc1NC(=O)Nc1ccc(OCCN2CCOCC2)c2ccccc12)C(C)(C)C, Cc1ccc(cc1)-n1nc(cc1NC(=O)Nc1ccc(OCCN2CCOCC2)c2ccccc12)C(C)(C)C, Cc1ccc(cc1)-n1nc(cc1NC(=O)Nc1ccc(OCCN2CCOCC2)c2ccccc12)C(C)(C)C	Phase 2
doramectin			infectious disease	gastrointestinal roundworms	MedChemEx	85.08	[H][C@@]12OC\C3=C/C=C/[C@H](C)[C@H](O[C@@]4([H])C[C@H](OC)[C@@H](O[C@@]5([H])C[C@H](OC)[C@@H](O)[C@H](C)O5)[C@H](C)O4)\C(C)=C\C[C@]4([H])C[C@@]([H])(C[C@@]5(O[C@H](C6CCCCC6)[C@@H](C)C=C5)O4)OC(=O)[C@]([H])(C=C(C)[C@H]1O)[C@@]23O |c:4,58,t:6,37,68|	Launched
doravirine	non-nucleoside reverse transcriptase inhibitor				MedChemEx	88.76	Cn1c(Cn2ccc(c(Oc3cc(Cl)cc(c3)C#N)c2=O)C(F)(F)F)n[nH]c1=O	Launched
doripenem	bacterial cell wall synthesis inhibitor	DPEP1	infectious disease	intra-abdominal infections, urinary tract infections, pyelonephritis	Sigma, MedChemEx, MedChemEx, Selleck, Selleck	42.28	C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(S[C@@H]3CN[C@H](CNS(N)(=O)=O)C3)=C(N2C1=O)C(O)=O |c:20|, C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(S[C@@H]3CN[C@H](CNS(N)(=O)=O)C3)=C(N2C1=O)C(O)=O |c:20|, C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(S[C@@H]3CN[C@H](CNS(N)(=O)=O)C3)=C(N2C1=O)C(O)=O |c:20|, C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(S[C@@H]3CN[C@H](CNS(N)(=O)=O)C3)=C(N2C1=O)C(O)=O |c:20|, C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(S[C@@H]3CN[C@H](CNS(N)(=O)=O)C3)=C(N2C1=O)C(O)=O |c:20|	Launched
dorsomorphin	AMPK inhibitor	ACVR1, BMPR1A, BMPR1B, EPHA2, FKBP1A, FLT1, FLT3, KDR, LCK, MKNK1, PRKAA1, RPS6KA1, SRC			Tocris, Tocris, MedChemEx, MedChemEx, MedChemEx, MedChemEx	98.79	C(CN1CCCCC1)Oc1ccc(cc1)-c1cnc2c(cnn2c1)-c1ccncc1, C(CN1CCCCC1)Oc1ccc(cc1)-c1cnc2c(cnn2c1)-c1ccncc1, C(CN1CCCCC1)Oc1ccc(cc1)-c1cnc2c(cnn2c1)-c1ccncc1, C(CN1CCCCC1)Oc1ccc(cc1)-c1cnc2c(cnn2c1)-c1ccncc1, C(CN1CCCCC1)Oc1ccc(cc1)-c1cnc2c(cnn2c1)-c1ccncc1, C(CN1CCCCC1)Oc1ccc(cc1)-c1cnc2c(cnn2c1)-c1ccncc1	Preclinical
dorzolamide	carbonic anhydrase inhibitor	CA1, CA12, CA14, CA2, CA4, CA7	ophthalmology	intraocular pressure, glaucoma	MedChemEx	78.1	CCN[C@H]1C[C@H](C)S(=O)(=O)c2sc(cc12)S(N)(=O)=O	Launched
dosulepin	norepinephrine reuptake inhibitor, serotoninnorepinephrine reuptake inhibitor (SNRI), tricyclic antidepressant	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, HRH1, SLC6A2, SLC6A4	neurology/psychiatry	depression	Prestwick, Prestwick, SantaCruz	97.97	CN(C)CC\C=C1/c2ccccc2CSc2ccccc12, CN(C)CC\C=C1/c2ccccc2CSc2ccccc12, CN(C)CC\C=C1/c2ccccc2CSc2ccccc12	Launched
DOTMP					AMS	0	OP(O)(=O)CN1CCN(CP(O)(O)=O)CCN(CP(O)(O)=O)CCN(CP(O)(O)=O)CC1	Preclinical
dovitinib	EGFR inhibitor, FGFR inhibitor, FLT3 inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	CSF1R, EGFR, FGFR1, FGFR2, FGFR3, FLT1, FLT3, FLT4, INSR, KDR, KIT, PDGFRA, PDGFRB			Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck	96.83	CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O	Phase 3
doxapram	potassium channel blocker		pulmonary, neurology/psychiatry	respiratory depression, central nervous system depression, acute hypercapnia (AHC)	MedChemEx, Selleck, MicroSource	97.8	CCN1C[C@@H](CCN2CCOCC2)C(C1=O)(c1ccccc1)c1ccccc1 |&1:4|, CCN1C[C@@H](CCN2CCOCC2)C(C1=O)(c1ccccc1)c1ccccc1 |&1:4|, CCN1C[C@@H](CCN2CCOCC2)C(C1=O)(c1ccccc1)c1ccccc1 |&1:4|	Launched
doxazosin	adrenergic receptor antagonist	ADRA1A, ADRA1B, ADRA1D	urology, cardiology	benign prostatic hyperplasia (BPH), hypertension	Tocris, Tocris	98.41	COc1cc2nc(nc(N)c2cc1OC)N1CCN(CC1)C(=O)[C@H]1COc2ccccc2O1 |&1:23,r|, COc1cc2nc(nc(N)c2cc1OC)N1CCN(CC1)C(=O)[C@H]1COc2ccccc2O1 |&1:23,r|	Launched
doxepin	histamine receptor antagonist	HRH1, SLC6A2, SLC6A4	neurology/psychiatry	depression, anxiety	MicroSource, Tocris	98.99	CN(C)CC\C=C1\c2ccccc2COc2ccccc12, CN(C)CC\C=C1\c2ccccc2COc2ccccc12	Launched
doxercalciferol	vitamin D receptor agonist	VDR	nephrology, endocrinology	chronic kidney disease (CKD), hyperparathyroidism	Selleck, Selleck, Selleck, Selleck	95.96	CC(C)[C@H](C)\C=C\[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1/C[C@@H](O)C[C@H](O)C1=C, CC(C)[C@H](C)\C=C\[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1/C[C@@H](O)C[C@H](O)C1=C, CC(C)[C@H](C)\C=C\[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1/C[C@@H](O)C[C@H](O)C1=C, CC(C)[C@H](C)\C=C\[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1/C[C@@H](O)C[C@H](O)C1=C	Launched
doxifluridine	thymidylate synthase inhibitor	TYMS	oncology	colorectal cancer	MedChemEx, MicroSource, MicroSource, Selleck, Selleck	97.12	C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cc(F)c(=O)[nH]c1=O, C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cc(F)c(=O)[nH]c1=O, C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cc(F)c(=O)[nH]c1=O, C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cc(F)c(=O)[nH]c1=O, C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cc(F)c(=O)[nH]c1=O	Launched
doxofylline	adenosine receptor antagonist	ADORA1, PDE4A, PDE4B, PDE4C, PDE4D	pulmonary	asthma	MedChemEx, MicroSource, MicroSource, MicroSource, Selleck	99.7	Cn1c2ncn(CC3OCCO3)c2c(=O)n(C)c1=O, Cn1c2ncn(CC3OCCO3)c2c(=O)n(C)c1=O, Cn1c2ncn(CC3OCCO3)c2c(=O)n(C)c1=O, Cn1c2ncn(CC3OCCO3)c2c(=O)n(C)c1=O, Cn1c2ncn(CC3OCCO3)c2c(=O)n(C)c1=O	Launched
doxorubicin	topoisomerase inhibitor	TOP2A	hematologic malignancy, oncology	acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), Wilm's tumor, breast cancer, ovarian cancer, Hodgkin's lymphoma, bladder cancer, multiple myeloma		0		Launched
doxycycline	bacterial 30S ribosomal subunit inhibitor, metalloproteinase inhibitor	MMP8	dental	periodontitis	MedChemEx, Selleck, Selleck, Selleck, Selleck	99	C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]3(O)C(O)=C2C(=O)c2c(O)cccc12 |a:1,2,3,5,6,18,&1:12,&2:22,c:22,t:11|, C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]3(O)C(O)=C2C(=O)c2c(O)cccc12 |a:1,2,3,5,6,18,&1:12,&2:22,c:22,t:11|, C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]3(O)C(O)=C2C(=O)c2c(O)cccc12 |a:1,2,3,5,6,18,&1:12,&2:22,c:22,t:11|, C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]3(O)C(O)=C2C(=O)c2c(O)cccc12 |a:1,2,3,5,6,18,&1:12,&2:22,c:22,t:11|, C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]3(O)C(O)=C2C(=O)c2c(O)cccc12 |a:1,2,3,5,6,18,&1:12,&2:22,c:22,t:11|	Launched
doxylamine	histamine receptor antagonist	HRH1	neurology/psychiatry	sedative	MicroSource, Selleck	98.3	CN(C)CCOC(C)(c1ccccc1)c1ccccn1, CN(C)CCOC(C)(c1ccccc1)c1ccccn1	Launched
DpC					Sigma	100	CN(C1CCCCC1)C(=S)NN=C(c1ccccn1)c1ccccn1	Phase 1
DPC-681	HIV protease inhibitor				MedChemEx	97.55	CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNCc1cccc(F)c1)C(C)(C)C)S(=O)(=O)c1cccc(N)c1	Phase 1
DPCPX	adenosine receptor antagonist	ADORA1, ADORA2A, ADORA2B, ADORA3			Tocris, Tocris, Tocris	99.02	CCCn1c2nc([nH]c2c(=O)n(CCC)c1=O)C1CCCC1, CCCn1c2nc([nH]c2c(=O)n(CCC)c1=O)C1CCCC1, CCCn1c2nc([nH]c2c(=O)n(CCC)c1=O)C1CCCC1	Phase 1
DPI-201106	sodium channel activator	ADRB2			Enzo	94.82	O[C@@H](COc1cccc2[nH]c(cc12)C#N)CN1CCN(CC1)C(c1ccccc1)c1ccccc1 |&1:1,r|	Phase 2
DPO-1	potassium channel blocker	KCNA5			Tocris, Tocris, Tocris	98.66	CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1P(=O)(c1ccccc1)c1ccccc1, CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1P(=O)(c1ccccc1)c1ccccc1, CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1P(=O)(c1ccccc1)c1ccccc1	Preclinical
DPPE	histamine receptor antagonist	ABCB1, HRH1			Tocris, Tocris, Tocris	94.69	CCN(CC)CCOc1ccc(Cc2ccccc2)cc1, CCN(CC)CCOc1ccc(Cc2ccccc2)cc1, CCN(CC)CCOc1ccc(Cc2ccccc2)cc1	Phase 3
DQP-1105	glutamate receptor antagonist	GRIN2C, GRIN2D			Tocris, Tocris, Tocris	94.9	Cc1ccc2[nH]c(=O)c(C3=NN([C@@H](C3)c3ccc(Br)cc3)C(=O)CCC(O)=O)c(-c3ccccc3)c2c1 |&1:12,r,t:9|, Cc1ccc2[nH]c(=O)c(C3=NN([C@@H](C3)c3ccc(Br)cc3)C(=O)CCC(O)=O)c(-c3ccccc3)c2c1 |&1:12,r,t:9|, Cc1ccc2[nH]c(=O)c(C3=NN([C@@H](C3)c3ccc(Br)cc3)C(=O)CCC(O)=O)c(-c3ccccc3)c2c1 |&1:12,r,t:9|	Preclinical
DR-2313	PARP inhibitor	PARP1, PARP3			Tocris, Tocris	86.89	Cc1nc(=O)c2CSCCc2[nH]1, Cc1nc(=O)c2CSCCc2[nH]1	Preclinical
DR-4485	serotonin receptor antagonist	HTR7			Tocris, Tocris, Tocris	98.04	Clc1ccc(cc1)C1=CCN(CCCC[C@@]23CCCc4c2c(NC3=O)ccc4Cl)CC1 |&1:15,t:8|, Clc1ccc(cc1)C1=CCN(CCCC[C@@]23CCCc4c2c(NC3=O)ccc4Cl)CC1 |&1:15,t:8|, Clc1ccc(cc1)C1=CCN(CCCC[C@@]23CCCc4c2c(NC3=O)ccc4Cl)CC1 |&1:15,t:8|	Preclinical
DRF053-(R)	CDK inhibitor	CSNK1A1			Tocris, Tocris, Tocris	95.49	CC[C@H](CO)Nc1nc(Nc2cccc(c2)-c2ccccn2)c2ncn(C(C)C)c2n1, CC[C@H](CO)Nc1nc(Nc2cccc(c2)-c2ccccn2)c2ncn(C(C)C)c2n1, CC[C@H](CO)Nc1nc(Nc2cccc(c2)-c2ccccn2)c2ncn(C(C)C)c2n1	Preclinical
drofenine			neurology/psychiatry	spasms	MicroSource, MedChemEx	93.04	CCN(CC)CCOC(=O)[C@@H](C1CCCCC1)c1ccccc1 |&1:10|, CCN(CC)CCOC(=O)[C@@H](C1CCCCC1)c1ccccc1 |&1:10|	Launched
droloxifene	selective estrogen receptor modulator (SERM)	ESR1			LKT	82.82	CC\C(=C(\c1ccc(OCCN(C)C)cc1)c1cccc(O)c1)c1ccccc1	Phase 3
dromostanolone-propionate	androgen receptor modulator	AR	oncology	breast cancer	ANpharma, ANpharma	99.15	CCC(=O)O[C@H]1CC[C@H]2[C@H]3CC[C@H]4CC(=O)[C@@H](C)C[C@@]4(C)[C@@H]3CC[C@@]12C |&1:5,&2:8,&3:9,&4:12,&5:16,&6:19,&7:21,&8:24,r|, CCC(=O)O[C@H]1CC[C@H]2[C@H]3CC[C@H]4CC(=O)[C@@H](C)C[C@@]4(C)[C@@H]3CC[C@@]12C |&1:5,&2:8,&3:9,&4:12,&5:16,&6:19,&7:21,&8:24,r|	Launched
dronedarone	adrenergic receptor antagonist	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, CACNA1C, CACNA1D, CACNA1F, CACNA1S, CACNB1, CACNB2, CACNB3, CACNB4, KCNA5, KCNH2, KCNK2, SCN1A	cardiology	atrial fibrillation (AF)	MedChemEx, MedChemEx, Selleck, Selleck, Selleck	98.57	CCCCN(CCCC)CCCOc1ccc(cc1)C(=O)c1c(CCCC)oc2ccc(NS(C)(=O)=O)cc12, CCCCN(CCCC)CCCOc1ccc(cc1)C(=O)c1c(CCCC)oc2ccc(NS(C)(=O)=O)cc12, CCCCN(CCCC)CCCOc1ccc(cc1)C(=O)c1c(CCCC)oc2ccc(NS(C)(=O)=O)cc12, CCCCN(CCCC)CCCOc1ccc(cc1)C(=O)c1c(CCCC)oc2ccc(NS(C)(=O)=O)cc12, CCCCN(CCCC)CCCOc1ccc(cc1)C(=O)c1c(CCCC)oc2ccc(NS(C)(=O)=O)cc12	Launched
droperidol	dopamine receptor antagonist	ADRA1A, DRD2, DRD3, DRD4, HTR2A	gastroenterology	nausea, vomiting	Tocris, MicroSource, Selleck	94.72	Fc1ccc(cc1)C(=O)CCCN1CCC(=CC1)n1c2ccccc2[nH]c1=O |c:16|, Fc1ccc(cc1)C(=O)CCCN1CCC(=CC1)n1c2ccccc2[nH]c1=O |c:16|, Fc1ccc(cc1)C(=O)CCCN1CCC(=CC1)n1c2ccccc2[nH]c1=O |c:16|	Launched
dropropizine	antitussive		pulmonary	cough suppressant	MicroSource, Selleck, MedChemEx, Selleck	95.89	OC[C@@H](O)CN1CCN(CC1)c1ccccc1 |&1:2,r|, OC[C@@H](O)CN1CCN(CC1)c1ccccc1 |&1:2,r|, OC[C@@H](O)CN1CCN(CC1)c1ccccc1 |&1:2,r|, OC[C@@H](O)CN1CCN(CC1)c1ccccc1 |&1:2,r|	Launched
drospirenone	mineralocorticoid receptor antagonist	AR, NR3C2, PGR	endocrinology	contraceptive	Selleck, Selleck, Selleck, Selleck, MicroSource, Selleck, Selleck	99.66	C[C@]12CC[C@H]3[C@@H]([C@H]4C[C@H]4C4=CC(=O)CC[C@]34C)[C@@H]1[C@@H]1C[C@@H]1[C@@]21CCC(=O)O1 |t:10|, C[C@]12CC[C@H]3[C@@H]([C@H]4C[C@H]4C4=CC(=O)CC[C@]34C)[C@@H]1[C@@H]1C[C@@H]1[C@@]21CCC(=O)O1 |t:10|, C[C@]12CC[C@H]3[C@@H]([C@H]4C[C@H]4C4=CC(=O)CC[C@]34C)[C@@H]1[C@@H]1C[C@@H]1[C@@]21CCC(=O)O1 |t:10|, C[C@]12CC[C@H]3[C@@H]([C@H]4C[C@H]4C4=CC(=O)CC[C@]34C)[C@@H]1[C@@H]1C[C@@H]1[C@@]21CCC(=O)O1 |t:10|, C[C@]12CC[C@H]3[C@@H]([C@H]4C[C@H]4C4=CC(=O)CC[C@]34C)[C@@H]1[C@@H]1C[C@@H]1[C@@]21CCC(=O)O1 |t:10|, C[C@]12CC[C@H]3[C@@H]([C@H]4C[C@H]4C4=CC(=O)CC[C@]34C)[C@@H]1[C@@H]1C[C@@H]1[C@@]21CCC(=O)O1 |t:10|, C[C@]12CC[C@H]3[C@@H]([C@H]4C[C@H]4C4=CC(=O)CC[C@]34C)[C@@H]1[C@@H]1C[C@@H]1[C@@]21CCC(=O)O1 |t:10|	Launched
drotaverine	phosphodiesterase inhibitor		obstetrics/gynecology	labor induction	Enamine, Vitas-M, Vitas-M, Vitas-M	88.7	CCOc1ccc(CC2=NCCc3cc(OCC)c(OCC)cc23)cc1OCC |t:8|, CCOc1ccc(CC2=NCCc3cc(OCC)c(OCC)cc23)cc1OCC |t:8|, CCOc1ccc(CC2=NCCc3cc(OCC)c(OCC)cc23)cc1OCC |t:8|, CCOc1ccc(CC2=NCCc3cc(OCC)c(OCC)cc23)cc1OCC |t:8|	Launched
droxicam	cyclooxygenase inhibitor	PTGS1	rheumatology	rheumatoid arthritis, osteoarthritis	Sigma, Ark	0	CN1c2c(oc(=O)n(-c3ccccn3)c2=O)-c2ccccc2S1(=O)=O, CN1c2c(oc(=O)n(-c3ccccn3)c2=O)-c2ccccc2S1(=O)=O	Launched
droxidopa	norepinephrine precursor	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3, PAH	cardiology, neurology/psychiatry	hypertension, Parkinson's Disease	MedChemEx, MedChemEx, Selleck, Selleck, Selleck	100	N[C@@H]([C@H](O)c1ccc(O)c(O)c1)C(O)=O, N[C@@H]([C@H](O)c1ccc(O)c(O)c1)C(O)=O, N[C@@H]([C@H](O)c1ccc(O)c(O)c1)C(O)=O, N[C@@H]([C@H](O)c1ccc(O)c(O)c1)C(O)=O, N[C@@H]([C@H](O)c1ccc(O)c(O)c1)C(O)=O	Launched
droxinostat	HDAC inhibitor	HDAC6, HDAC8			Selleck, Selleck, Selleck, Selleck	95.12	Cc1cc(Cl)ccc1OCCCC(=O)NO, Cc1cc(Cl)ccc1OCCCC(=O)NO, Cc1cc(Cl)ccc1OCCCC(=O)NO, Cc1cc(Cl)ccc1OCCCC(=O)NO	Preclinical
DSM265	dihydroorotate dehydrogenase inhibitor				MedChemEx	97.71	Cc1cc(Nc2ccc(cc2)S(F)(F)(F)(F)F)n2nc(nc2n1)C(C)(F)F	Phase 2
DSPC					ChemImpex	0	CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](COP(O)(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC |&1:21,r|	Preclinical
DSR-6434	toll-like receptor agonist	TLR7			Tocris, Tocris	95.77	CCCCNc1nc(N)c2[nH]c(=O)n(Cc3ccc(OCCN(C)C)nc3)c2n1, CCCCNc1nc(N)c2[nH]c(=O)n(Cc3ccc(OCCN(C)C)nc3)c2n1	Preclinical
DS2-(806622)					Tocris, Tocris, Tocris	90.61	Clc1ccc(cc1)C(=O)Nc1c(nc2ccccn12)-c1cccs1, Clc1ccc(cc1)C(=O)Nc1c(nc2ccccn12)-c1cccs1, Clc1ccc(cc1)C(=O)Nc1c(nc2ccccn12)-c1cccs1	Preclinical
DU-728	structural glycoprotein antagonist	ITGA2B, ITGB3			MedChemEx, MedChemEx	100	N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O, N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O	Phase 1
duloxetine	norepinephrine reuptake inhibitor, serotoninnorepinephrine reuptake inhibitor (SNRI)	HTR2A, HTR2C, HTR6, SLC6A2, SLC6A3, SLC6A4	neurology/psychiatry	depression, generalized anxiety disorder (GAD), muscle pain, peripheral neuropathy	Tocris, MicroSource, MicroSource, MicroSource, Selleck, Selleck	98.66	CNCC[C@H](Oc1cccc2ccccc12)c1cccs1, CNCC[C@H](Oc1cccc2ccccc12)c1cccs1, CNCC[C@H](Oc1cccc2ccccc12)c1cccs1, CNCC[C@H](Oc1cccc2ccccc12)c1cccs1, CNCC[C@H](Oc1cccc2ccccc12)c1cccs1, CNCC[C@H](Oc1cccc2ccccc12)c1cccs1	Launched
DUP-697	cyclooxygenase inhibitor	PTGS2			Tocris, Tocris, Tocris	97.02	CS(=O)(=O)c1ccc(cc1)-c1cc(Br)sc1-c1ccc(F)cc1, CS(=O)(=O)c1ccc(cc1)-c1cc(Br)sc1-c1ccc(F)cc1, CS(=O)(=O)c1ccc(cc1)-c1cc(Br)sc1-c1ccc(F)cc1	Phase 1
dutasteride	5 alpha reductase inhibitor	SRD5A1, SRD5A2, SRD5A3	urology	benign prostatic hyperplasia (BPH)	MedChemEx, Selleck, Selleck	97.58	C[C@]12CC[C@H]3[C@@H](CC[C@H]4NC(=O)C=C[C@]34C)[C@@H]1CC[C@@H]2C(=O)Nc1cc(ccc1C(F)(F)F)C(F)(F)F |c:12|, C[C@]12CC[C@H]3[C@@H](CC[C@H]4NC(=O)C=C[C@]34C)[C@@H]1CC[C@@H]2C(=O)Nc1cc(ccc1C(F)(F)F)C(F)(F)F |c:12|, C[C@]12CC[C@H]3[C@@H](CC[C@H]4NC(=O)C=C[C@]34C)[C@@H]1CC[C@@H]2C(=O)Nc1cc(ccc1C(F)(F)F)C(F)(F)F |c:12|	Launched
duvelisib	PI3K inhibitor	PIK3CA, PIK3CB, PIK3CD, PIK3CG			Selleck, Selleck, Selleck, MedChemEx	98.68	C[C@H](Nc1ncnc2nc[nH]c12)c1cc2cccc(Cl)c2c(=O)n1-c1ccccc1, C[C@H](Nc1ncnc2nc[nH]c12)c1cc2cccc(Cl)c2c(=O)n1-c1ccccc1, C[C@H](Nc1ncnc2nc[nH]c12)c1cc2cccc(Cl)c2c(=O)n1-c1ccccc1, C[C@H](Nc1ncnc2nc[nH]c12)c1cc2cccc(Cl)c2c(=O)n1-c1ccccc1	Launched
DVD-111					MedChemEx, MedChemEx	99.45	CCOC(=O)CNC(=O)[C@@H]1CCCN1C(=O)Cc1ccccc1, CCOC(=O)CNC(=O)[C@@H]1CCCN1C(=O)Cc1ccccc1	Phase 2
DWK-1339	beta amyloid aggregation inhibitor				MedChemEx	95.08	COCCCc1ccc2oc(cc2c1)-c1ccc(OC)c(OC)c1	Preclinical
dyclonine	sodium channel blocker	SCN10A, SCN5A	neurology/psychiatry	local anesthetic	MedChemEx, MedChemEx, MicroSource, Selleck, Selleck, Selleck, MedChemEx	93.29	CCCCOc1ccc(cc1)C(=O)CCN1CCCCC1, CCCCOc1ccc(cc1)C(=O)CCN1CCCCC1, CCCCOc1ccc(cc1)C(=O)CCN1CCCCC1, CCCCOc1ccc(cc1)C(=O)CCN1CCCCC1, CCCCOc1ccc(cc1)C(=O)CCN1CCCCC1, CCCCOc1ccc(cc1)C(=O)CCN1CCCCC1, CCCCOc1ccc(cc1)C(=O)CCN1CCCCC1	Launched
dydrogesterone	progesterone receptor agonist	PGR	obstetrics/gynecology	infertility	MicroSource, MedChemEx, Selleck, Selleck	100	CC(=O)[C@H]1CC[C@H]2[C@@H]3C=CC4=CC(=O)CC[C@@]4(C)[C@@H]3CC[C@]12C |c:8,t:10|, CC(=O)[C@H]1CC[C@H]2[C@@H]3C=CC4=CC(=O)CC[C@@]4(C)[C@@H]3CC[C@]12C |c:8,t:10|, CC(=O)[C@H]1CC[C@H]2[C@@H]3C=CC4=CC(=O)CC[C@@]4(C)[C@@H]3CC[C@]12C |c:8,t:10|, CC(=O)[C@H]1CC[C@H]2[C@@H]3C=CC4=CC(=O)CC[C@@]4(C)[C@@H]3CC[C@]12C |c:8,t:10|	Launched
dynasore	dynamin inhibitor	DNM1, DNM1L, DNM2			Tocris, Selleck, Selleck, Selleck, Selleck, Selleck	89.1	Oc1ccc(\C=N\NC(=O)c2cc3ccccc3cc2O)cc1O, Oc1ccc(\C=N\NC(=O)c2cc3ccccc3cc2O)cc1O, Oc1ccc(\C=N\NC(=O)c2cc3ccccc3cc2O)cc1O, Oc1ccc(\C=N\NC(=O)c2cc3ccccc3cc2O)cc1O, Oc1ccc(\C=N\NC(=O)c2cc3ccccc3cc2O)cc1O, Oc1ccc(\C=N\NC(=O)c2cc3ccccc3cc2O)cc1O	Preclinical
dynole-34-2	dynamin inhibitor	DNM1			Tocris, Tocris	92.06	CCCCCCCCNC(=O)C(=C\c1cn(CCCN(C)C)c2ccccc12)\C#N, CCCCCCCCNC(=O)C(=C\c1cn(CCCN(C)C)c2ccccc12)\C#N	Preclinical
dyphylline	adenosine receptor antagonist, phosphodiesterase inhibitor	PDE4A	pulmonary	asthma, bronchitis, emphysema	MicroSource, Selleck, MedChemEx	99.68	Cn1c2ncn(C[C@@H](O)CO)c2c(=O)n(C)c1=O |&1:7,r|, Cn1c2ncn(C[C@@H](O)CO)c2c(=O)n(C)c1=O |&1:7,r|, Cn1c2ncn(C[C@@H](O)CO)c2c(=O)n(C)c1=O |&1:7,r|	Launched
DY131	estrogen-related receptor agonist	ESRRB, ESRRG			Tocris, Tocris, Tocris	88.82	CCN(CC)c1ccc(\C=N\NC(=O)c2ccc(O)cc2)cc1, CCN(CC)c1ccc(\C=N\NC(=O)c2ccc(O)cc2)cc1, CCN(CC)c1ccc(\C=N\NC(=O)c2ccc(O)cc2)cc1	Preclinical
D609	phospholipase inhibitor				MedChemEx, MedChemEx, Enzo, Tocris	86.67	SC(=S)OC1CC2CC1C1CCCC21, SC(=S)OC1CC2CC1C1CCCC21, SC(=S)OC1CC2CC1C1CCCC21, SC(=S)OC1CC2CC1C1CCCC21	Preclinical
E-2001	antioxidant				Sigma	31.37	Fc1ccc(cc1)C(=O)C1CCN(CC(=O)c2ccc3ccccc3c2)CC1	Preclinical
E-2012	gamma secretase modulator	APH1A, APH1B, PSENEN			MedChemEx, MedChemEx	91.68	COc1cc(\C=C2/CCCN([C@@H](C)c3ccc(F)cc3)C2=O)ccc1-n1cnc(C)c1, COc1cc(\C=C2/CCCN([C@@H](C)c3ccc(F)cc3)C2=O)ccc1-n1cnc(C)c1	Phase 1
E-4031	potassium channel blocker	KCNH1, KCNH2			Tocris, Tocris, Tocris, Tocris	96.27	Cc1cccc(CCN2CCC(CC2)C(=O)c2ccc(NS(C)(=O)=O)cc2)n1, Cc1cccc(CCN2CCC(CC2)C(=O)c2ccc(NS(C)(=O)=O)cc2)n1, Cc1cccc(CCN2CCC(CC2)C(=O)c2ccc(NS(C)(=O)=O)cc2)n1, Cc1cccc(CCN2CCC(CC2)C(=O)c2ccc(NS(C)(=O)=O)cc2)n1	Phase 1
E-64	calpain inhibitor, cysteine protease inhibitor	CTSS			Tocris, Tocris	94.41	CC(C)C[C@H](NC(=O)[C@H]1O[C@@H]1C(O)=O)C(=O)NCCCCNC(N)=N, CC(C)C[C@H](NC(=O)[C@H]1O[C@@H]1C(O)=O)C(=O)NCCCCNC(N)=N	Preclinical
eact	calcium-activated chloride channel inhibitor	ANO1			Tocris, Tocris	97.95	COCCN(C(=O)c1cc(OC)c(OC)c(OC)c1)c1nc(cs1)-c1ccccc1, COCCN(C(=O)c1cc(OC)c(OC)c(OC)c1)c1nc(cs1)-c1ccccc1	Preclinical
EB-47	PARP inhibitor	PARP1			Tocris, Tocris, Tocris, Tocris	96.22	Nc1ncnc2n(cnc12)[C@H]1O[C@H]([C@H](O)[C@@H]1O)C(=O)N1CCN(CC(=O)Nc2cccc3C(=O)NCc23)CC1, Nc1ncnc2n(cnc12)[C@H]1O[C@H]([C@H](O)[C@@H]1O)C(=O)N1CCN(CC(=O)Nc2cccc3C(=O)NCc23)CC1, Nc1ncnc2n(cnc12)[C@H]1O[C@H]([C@H](O)[C@@H]1O)C(=O)N1CCN(CC(=O)Nc2cccc3C(=O)NCc23)CC1, Nc1ncnc2n(cnc12)[C@H]1O[C@H]([C@H](O)[C@@H]1O)C(=O)N1CCN(CC(=O)Nc2cccc3C(=O)NCc23)CC1	Preclinical
ebastine	histamine receptor antagonist	CYP3A4, HRH1	allergy	allergic rhinitis, urticaria	MedChemEx, Selleck, Selleck, Selleck	97.98	CC(C)(C)c1ccc(cc1)C(=O)CCCN1CCC(CC1)OC(c1ccccc1)c1ccccc1, CC(C)(C)c1ccc(cc1)C(=O)CCCN1CCC(CC1)OC(c1ccccc1)c1ccccc1, CC(C)(C)c1ccc(cc1)C(=O)CCCN1CCC(CC1)OC(c1ccccc1)c1ccccc1, CC(C)(C)c1ccc(cc1)C(=O)CCCN1CCC(CC1)OC(c1ccccc1)c1ccccc1	Launched
EBPC	aldose reductase inhibitor	AKR1B1			Tocris	90.37	CCOC(=O)[C@@H]1CN(Cc2ccccc2)C(=O)C1=O |&1:5,r|	Preclinical
ebrotidine	histamine receptor antagonist	HRH2			MedChemEx, MedChemEx, MedChemEx, MedChemEx	83.9	NC(=N)Nc1nc(CSCCN\C=N\S(=O)(=O)c2ccc(Br)cc2)cs1, NC(=N)Nc1nc(CSCCN\C=N\S(=O)(=O)c2ccc(Br)cc2)cs1, NC(=N)Nc1nc(CSCCN\C=N\S(=O)(=O)c2ccc(Br)cc2)cs1, NC(=N)Nc1nc(CSCCN\C=N\S(=O)(=O)c2ccc(Br)cc2)cs1	Withdrawn
ebselen	cyclooxygenase inhibitor, glutathione peroxidase agonist, H+/K+-ATPase inhibitor, nitric oxide synthase inhibitor	ALB			MicroSource, MicroSource, MicroSource	93.11	O=c1n([se]c2ccccc12)-c1ccccc1, O=c1n([se]c2ccccc12)-c1ccccc1, O=c1n([se]c2ccccc12)-c1ccccc1	Phase 2/Phase 3
EC-144	HSP inhibitor	HSP90AA1, HSP90AB1			Tocris, Tocris, Tocris, Tocris	96.8	COc1c(C)cnc(Cn2cc(C#CCC(C)(C)O)c3c(Cl)nc(N)nc23)c1C, COc1c(C)cnc(Cn2cc(C#CCC(C)(C)O)c3c(Cl)nc(N)nc23)c1C, COc1c(C)cnc(Cn2cc(C#CCC(C)(C)O)c3c(Cl)nc(N)nc23)c1C, COc1c(C)cnc(Cn2cc(C#CCC(C)(C)O)c3c(Cl)nc(N)nc23)c1C	Preclinical
EC-23	retinoid receptor agonist	RARA, RARB, RARG			Sigma, Sigma, Tocris	98.05	CC1(C)CCC(C)(C)c2cc(ccc12)C#Cc1ccc(cc1)C(O)=O, CC1(C)CCC(C)(C)c2cc(ccc12)C#Cc1ccc(cc1)C(O)=O, CC1(C)CCC(C)(C)c2cc(ccc12)C#Cc1ccc(cc1)C(O)=O	Preclinical
ecabapide					Enamine, Enamine, Enamine	87.95	CNC(=O)c1cccc(NCC(=O)NCCc2ccc(OC)c(OC)c2)c1, CNC(=O)c1cccc(NCC(=O)NCCc2ccc(OC)c(OC)c2)c1, CNC(=O)c1cccc(NCC(=O)NCCc2ccc(OC)c(OC)c2)c1	Phase 3
ecabet	gastrin inhibitor, urease inhibitor	NOXO1	ophthalmology	dry eye syndrome	OxChem, OxChem	98.28	CC(C)c1cc2CC[C@H]3[C@@](C)(CCC[C@]3(C)c2cc1S(O)(=O)=O)C(O)=O, CC(C)c1cc2CC[C@H]3[C@@](C)(CCC[C@]3(C)c2cc1S(O)(=O)=O)C(O)=O	Launched
ecamsule-triethanolamine			dermatology	skin protectant, sunscreen lotion	Sigma	77.09	CC1(C)[C@H]2CC[C@]1(CS(O)(=O)=O)C(=O)C2=Cc1ccc(C=C2[C@@H]3CC[C@](CS(O)(=O)=O)(C2=O)C3(C)C)cc1 |&1:3,6,&2:22,25,r|	Launched
echinomycin	DNA intercalating agent				Tocris	96.61	[H][C@]1(COC(=O)[C@]([H])(C(C)C)N(C)C(=O)[C@]2([H])N(C)C(=O)[C@H](C)NC(=O)[C@@]([H])(COC(=O)[C@]([H])(C(C)C)N(C)C(=O)[C@]([H])(CS[C@]2([H])SC)N(C)C(=O)[C@H](C)NC1=O)NC(=O)c1cnc2ccccc2n1)NC(=O)c1cnc2ccccc2n1 |&1:45,@:8,34|	Phase 2
econazole	lanosterol demethylase inhibitor, sterol demethylase inhibitor	NPY1R, NPY2R, TRPM2, TRPV5	infectious disease	tinea pedis, tinea cruris, tinea corporis, tinea versicolor, cutaneous candidiasis	MicroSource, MicroSource, MicroSource, MicroSource, MicroSource, MicroSource, MedChemEx, Selleck	100	Clc1ccc(CO[C@@H](Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1 |&1:7|, Clc1ccc(CO[C@@H](Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1 |&1:7|, Clc1ccc(CO[C@@H](Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1 |&1:7|, Clc1ccc(CO[C@@H](Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1 |&1:7|, Clc1ccc(CO[C@@H](Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1 |&1:7|, Clc1ccc(CO[C@@H](Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1 |&1:7|, Clc1ccc(CO[C@@H](Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1 |&1:7|, Clc1ccc(CO[C@@H](Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1 |&1:7|	Launched
ectoine	anti-inflammatory agent				Sigma, Sigma	100	CC1=NCC[C@H](N1)C(O)=O |t:1|, CC1=NCC[C@H](N1)C(O)=O |t:1|	Launched
edaglitazone	PPAR receptor agonist	PPARG			Tocris	97.51	Cc1oc(nc1CCOc1ccc(C[C@@H]2SC(=O)NC2=O)c2sccc12)-c1ccccc1 |&1:14,r|	Phase 2
edaravone	nootropic agent	BCL2	neurology/psychiatry	stroke	MedChemEx, MedChemEx, MicroSource, Sigma, Selleck, Tocris, Selleck	65.37	Cc1cc(=O)n([nH]1)-c1ccccc1, Cc1cc(=O)n([nH]1)-c1ccccc1, Cc1cc(=O)n([nH]1)-c1ccccc1, Cc1cc(=O)n([nH]1)-c1ccccc1, Cc1cc(=O)n([nH]1)-c1ccccc1, Cc1cc(=O)n([nH]1)-c1ccccc1, Cc1cc(=O)n([nH]1)-c1ccccc1	Launched
edasalonexent	NFkB pathway inhibitor				MedChemEx	0	CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(=O)NCCNC(=O)c1ccccc1O	Phase 3
edelfosine	phospholipase inhibitor				Cayman, Enzo	100	CCCCCCCCCCCCCCCCCCOC[C@H](COP(O)(=O)OCC[N+](C)(C)C)OC |a:20,&1:23|, CCCCCCCCCCCCCCCCCCOC[C@H](COP(O)(=O)OCC[N+](C)(C)C)OC |a:20,&1:23|	Phase 2
editol					MicroSource, MedChemEx	100	C[C@@H](O)CN(CCN(C[C@@H](C)O)C[C@@H](C)O)C[C@@H](C)O |&1:1,&2:9,&3:13,&4:17,r|, C[C@@H](O)CN(CCN(C[C@@H](C)O)C[C@@H](C)O)C[C@@H](C)O |&1:1,&2:9,&3:13,&4:17,r|	Preclinical
EDO-S101	HDAC inhibitor				MedChemEx	55.12	Cn1c(CCCCCCC(=O)NO)nc2cc(ccc12)N(CCCl)CCCl	Phase 1/Phase 2
edonerpic-maleate	beta amyloid inhibitor				MedChemEx	94.04	OC1CN(CCCOCCc2ccc3sccc3c2)C1	Preclinical
edoxaban	coagulation factor inhibitor	F10	neurology/psychiatry, hematology, cardiology	stroke, pulmonary embolism (PE), systemic embolism, deep vein thrombosis (DVT), atrial fibrillation (AF)	Selleck, Selleck	89.81	CN(C)C(=O)[C@H]1CC[C@H](NC(=O)C(=O)Nc2ccc(Cl)cn2)[C@@H](C1)NC(=O)c1nc2CCN(C)Cc2s1, CN(C)C(=O)[C@H]1CC[C@H](NC(=O)C(=O)Nc2ccc(Cl)cn2)[C@@H](C1)NC(=O)c1nc2CCN(C)Cc2s1	Launched
edoxudine	DNA directed DNA polymerase inhibitor		infectious disease	virus herpes simplex (HSV)	MedChemEx, MicroSource	98.02	CCc1cn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)[nH]c1=O, CCc1cn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)[nH]c1=O	Launched
edrophonium	acetylcholinesterase inhibitor	ACHE, BCHE	neurology/psychiatry	myasthenia gravis	MedChemEx, MicroSource, MicroSource	98.99	CC[N+](C)(C)c1cccc(O)c1, CC[N+](C)(C)c1cccc(O)c1, CC[N+](C)(C)c1cccc(O)c1	Launched
EDTMP	chelating agent				Vitas-M, Vitas-M	0	OP(O)(=O)CN(CCN(CP(O)(O)=O)CP(O)(O)=O)CP(O)(O)=O, OP(O)(=O)CN(CCN(CP(O)(O)=O)CP(O)(O)=O)CP(O)(O)=O	Preclinical
EED226	polycomb protein inhibitor	EED			MedChemEx, MedChemEx	96.75	CS(=O)(=O)c1ccc(cc1)-c1cnc(NCc2ccco2)n2cnnc12, CS(=O)(=O)c1ccc(cc1)-c1cnc(NCc2ccco2)n2cnnc12	Preclinical
efaproxiral	hemoglobin oxygen release stimulant	HBA1, HBB			MedChemEx, Selleck, Selleck	97.94	Cc1cc(C)cc(NC(=O)Cc2ccc(OC(C)(C)C(O)=O)cc2)c1, Cc1cc(C)cc(NC(=O)Cc2ccc(OC(C)(C)C(O)=O)cc2)c1, Cc1cc(C)cc(NC(=O)Cc2ccc(OC(C)(C)C(O)=O)cc2)c1	Phase 3
efaroxan	adrenergic receptor antagonist	ADORA2A			MicroSource, MicroSource, Tocris	98.28	CCC1(Cc2ccccc2O1)C1=NCCN1, CCC1(Cc2ccccc2O1)C1=NCCN1, CCC1(Cc2ccccc2O1)C1=NCCN1	Phase 2
efatutazone	PPAR receptor agonist	PPARG			MedChemEx, MedChemEx, MedChemEx	96.26	Cc1cc(Oc2ccc3nc(COc4ccc(C[C@H]5SC(=O)NC5=O)cc4)n(C)c3c2)cc(C)c1N |r|, Cc1cc(Oc2ccc3nc(COc4ccc(C[C@H]5SC(=O)NC5=O)cc4)n(C)c3c2)cc(C)c1N |r|, Cc1cc(Oc2ccc3nc(COc4ccc(C[C@H]5SC(=O)NC5=O)cc4)n(C)c3c2)cc(C)c1N |r|	Phase 2
efavirenz	HIV protease inhibitor	CYP1A2, CYP2B6, CYP2C19, CYP2C9, CYP2D6, CYP3A4	infectious disease	human immunodeficiency virus (HIV-1)	MedChemEx, Enzo, Enzo	98.9	FC(F)(F)[C@]1(OC(=O)Nc2ccc(Cl)cc12)C#CC1CC1, FC(F)(F)[C@]1(OC(=O)Nc2ccc(Cl)cc12)C#CC1CC1, FC(F)(F)[C@]1(OC(=O)Nc2ccc(Cl)cc12)C#CC1CC1	Launched
efinaconazole	lanosterol demethylase inhibitor	CYP51A1	infectious disease	onychomycosis	MedChemEx	92.45	C[C@@H](N1CCC(=C)CC1)[C@@](O)(Cn1cncn1)c1ccc(F)cc1F |a:1,&1:9|	Launched
efletirizine	antihistamine				Sigma	100	OC(=O)COCCN1CCN(CC1)C(c1ccc(F)cc1)c1ccc(F)cc1	Phase 3
eflornithine	ornithine decarboxylase inhibitor	ARG2, ODC1	dermatology	facial hair reduction	Enzo	100	NCCCC(N)(C(F)F)C(O)=O |&1:4|	Launched
efloxate	vasodilator				MicroSource	97.67	CCOC(=O)COc1ccc2c(c1)oc(cc2=O)-c1ccccc1	Preclinical
efonidipine	calcium channel blocker		cardiology	hypertension	MedChemEx, Tocris	97.16	CC1=C([C@@H](C(=C(C)N1)P1(=O)OCC(C)(C)CO1)c1cccc(c1)[N+]([O-])=O)C(=O)OCCN(Cc1ccccc1)c1ccccc1 |&1:3,r,t:1,4|, CC1=C([C@@H](C(=C(C)N1)P1(=O)OCC(C)(C)CO1)c1cccc(c1)[N+]([O-])=O)C(=O)OCCN(Cc1ccccc1)c1ccccc1 |&1:3,r,t:1,4|	Launched
EF5	cytochrome P450 activator				Sigma	100	[O-][N+](=O)c1nccn1CC(=O)NCC(F)(F)C(F)(F)F	Phase 2
EGF816	EGFR inhibitor	EGFR			MedChemEx, MedChemEx, MedChemEx	92.84	CN(C)C\C=C\C(=O)N1CCCC[C@H](C1)n1c(NC(=O)c2ccnc(C)c2)nc2cccc(Cl)c12, CN(C)C\C=C\C(=O)N1CCCC[C@H](C1)n1c(NC(=O)c2ccnc(C)c2)nc2cccc(Cl)c12, CN(C)C\C=C\C(=O)N1CCCC[C@H](C1)n1c(NC(=O)c2ccnc(C)c2)nc2cccc(Cl)c12	Phase 2
eglumetad	glutamate receptor agonist	GRM2, GRM3, GRM6, GRM8			MedChemEx, MedChemEx, EMDBio	100	N[C@]1(CC[C@H]2[C@@H]([C@@H]12)C(O)=O)C(O)=O, N[C@]1(CC[C@H]2[C@@H]([C@@H]12)C(O)=O)C(O)=O, N[C@]1(CC[C@H]2[C@@H]([C@@H]12)C(O)=O)C(O)=O	Phase 2
EG00229	neuropilin receptor antagonist	NRP1			MedChemEx, Tocris	96.86	NC(=N)NCCC[C@H](NC(=O)c1sccc1NS(=O)(=O)c1cccc2nsnc12)C(O)=O, NC(=N)NCCC[C@H](NC(=O)c1sccc1NS(=O)(=O)c1cccc2nsnc12)C(O)=O	Preclinical
EHop-016	Ras GTPase inhibitor	RAC1, RAC3			Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck	93.91	CCn1c2ccccc2c2cc(Nc3ccnc(NCCCN4CCOCC4)n3)ccc12, CCn1c2ccccc2c2cc(Nc3ccnc(NCCCN4CCOCC4)n3)ccc12, CCn1c2ccccc2c2cc(Nc3ccnc(NCCCN4CCOCC4)n3)ccc12, CCn1c2ccccc2c2cc(Nc3ccnc(NCCCN4CCOCC4)n3)ccc12, CCn1c2ccccc2c2cc(Nc3ccnc(NCCCN4CCOCC4)n3)ccc12, CCn1c2ccccc2c2cc(Nc3ccnc(NCCCN4CCOCC4)n3)ccc12, CCn1c2ccccc2c2cc(Nc3ccnc(NCCCN4CCOCC4)n3)ccc12	Preclinical
EIPA	sodium/hydrogen exchanger inhibitor, transient receptor potential polycystic inhibitor	ADRA2A, ASIC1, PKD2L1			Tocris, Tocris	93.61	CCN(C(C)C)c1nc(N)c(nc1Cl)C(=O)N=C(N)N, CCN(C(C)C)c1nc(N)c(nc1Cl)C(=O)N=C(N)N	Preclinical
EIT-hydrobromide	nitric oxide synthase inhibitor	NOS2, NOS3			Tocris, Tocris	93.66	CCSC(N)=N, CCSC(N)=N	Preclinical
EI1	histone lysine methyltransferase inhibitor	EZH2			MedChemEx	93.04	CCC(CC)n1ccc2c(cc(cc12)C#N)C(=O)NCc1c(C)cc(C)[nH]c1=O	Preclinical
elacestrant	estrogen receptor degrader				MedChemEx, MedChemEx	97.32	CCNCCc1ccc(CN(CC)c2cc(OC)ccc2[C@@H]2CCc3cc(O)ccc3C2)cc1, CCNCCc1ccc(CN(CC)c2cc(OC)ccc2[C@@H]2CCc3cc(O)ccc3C2)cc1	Phase 3
elacridar	P glycoprotein inhibitor	ABCB1			MedChemEx, MedChemEx, MedChemEx, Selleck, Selleck, MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx	94.19	COc1cc2CCN(CCc3ccc(NC(=O)c4cccc5c4[nH]c4c(OC)cccc4c5=O)cc3)Cc2cc1OC, COc1cc2CCN(CCc3ccc(NC(=O)c4cccc5c4[nH]c4c(OC)cccc4c5=O)cc3)Cc2cc1OC, COc1cc2CCN(CCc3ccc(NC(=O)c4cccc5c4[nH]c4c(OC)cccc4c5=O)cc3)Cc2cc1OC, COc1cc2CCN(CCc3ccc(NC(=O)c4cccc5c4[nH]c4c(OC)cccc4c5=O)cc3)Cc2cc1OC, COc1cc2CCN(CCc3ccc(NC(=O)c4cccc5c4[nH]c4c(OC)cccc4c5=O)cc3)Cc2cc1OC, COc1cc2CCN(CCc3ccc(NC(=O)c4cccc5c4[nH]c4c(OC)cccc4c5=O)cc3)Cc2cc1OC, COc1cc2CCN(CCc3ccc(NC(=O)c4cccc5c4[nH]c4c(OC)cccc4c5=O)cc3)Cc2cc1OC, COc1cc2CCN(CCc3ccc(NC(=O)c4cccc5c4[nH]c4c(OC)cccc4c5=O)cc3)Cc2cc1OC, COc1cc2CCN(CCc3ccc(NC(=O)c4cccc5c4[nH]c4c(OC)cccc4c5=O)cc3)Cc2cc1OC, COc1cc2CCN(CCc3ccc(NC(=O)c4cccc5c4[nH]c4c(OC)cccc4c5=O)cc3)Cc2cc1OC, COc1cc2CCN(CCc3ccc(NC(=O)c4cccc5c4[nH]c4c(OC)cccc4c5=O)cc3)Cc2cc1OC	Phase 1
elactocin	exportin antagonist	XPO1				0		Phase 1
elacytarabine	antineoplastic agent	DCK			MedChemEx	93.33	CCCCCCCC\C=C\CCCCCCCC(=O)OC[C@H]1O[C@H]([C@@H](O)[C@@H]1O)n1ccc(N)nc1=O	Phase 3
elafibranor	PPAR receptor agonist	PPARA, PPARD, PPARG			MedChemEx, MedChemEx	92.97	CSc1ccc(cc1)C(=O)\C=C\c1cc(C)c(OC(C)(C)C(O)=O)c(C)c1, CSc1ccc(cc1)C(=O)\C=C\c1cc(C)c(OC(C)(C)C(O)=O)c(C)c1	Phase 3
elagolix	gonadotropin releasing factor hormone receptor antagonist	GNRHR			MedChemEx, MedChemEx	95.19	COc1cccc(c1F)-c1c(C)n(Cc2c(F)cccc2C(F)(F)F)c(=O)n(C[C@H](NCCCC(O)=O)c2ccccc2)c1=O, COc1cccc(c1F)-c1c(C)n(Cc2c(F)cccc2C(F)(F)F)c(=O)n(C[C@H](NCCCC(O)=O)c2ccccc2)c1=O	Launched
elbasvir	HCV inhibitor		infectious disease	hepatitis C	MedChemEx, MedChemEx	95.63	COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1c1nc(c[nH]1)-c1ccc2-c3cc4cc(ccc4n3[C@@H](Oc2c1)c1ccccc1)-c1c[nH]c(n1)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)OC)C(C)C, COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1c1nc(c[nH]1)-c1ccc2-c3cc4cc(ccc4n3[C@@H](Oc2c1)c1ccccc1)-c1c[nH]c(n1)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)OC)C(C)C	Launched
eldecalcitol	bone formation stimulant	VDR			MedChemEx	94.13	[H][C@@]12CC[C@H]([C@H](C)CCCC(C)(C)O)[C@@]1(C)CCC\C2=C/C=C1/C[C@@H](O)[C@@H](OCCCO)[C@H](O)C1=C	Phase 3
eleclazine	late sodium current inhibitor				MedChemEx	98.9	FC(F)(F)Oc1ccc(cc1)-c1ccc2OCCN(Cc3ncccn3)C(=O)c2c1	Phase 3
elemene	VEGFR inhibitor				Enamine	0	CC(=C)[C@@H]1CC[C@@](C)(C=C)[C@H](C1)C(C)=C	Phase 3
elesclomol	oxidative stress inducer	HSPA1A			Selleck, Selleck, MedChemEx, MedChemEx	96	CN(NC(=O)CC(=O)NN(C)C(=S)c1ccccc1)C(=S)c1ccccc1, CN(NC(=O)CC(=O)NN(C)C(=S)c1ccccc1)C(=S)c1ccccc1, CN(NC(=O)CC(=O)NN(C)C(=S)c1ccccc1)C(=S)c1ccccc1, CN(NC(=O)CC(=O)NN(C)C(=S)c1ccccc1)C(=S)c1ccccc1	Phase 3
eletriptan	serotonin receptor agonist	HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2B, HTR7	neurology/psychiatry	migraine headache	Tocris, Tocris, MicroSource, Selleck, Tocris, Tocris	97.64	CN1CCC[C@@H]1Cc1c[nH]c2ccc(CCS(=O)(=O)c3ccccc3)cc12, CN1CCC[C@@H]1Cc1c[nH]c2ccc(CCS(=O)(=O)c3ccccc3)cc12, CN1CCC[C@@H]1Cc1c[nH]c2ccc(CCS(=O)(=O)c3ccccc3)cc12, CN1CCC[C@@H]1Cc1c[nH]c2ccc(CCS(=O)(=O)c3ccccc3)cc12, CN1CCC[C@@H]1Cc1c[nH]c2ccc(CCS(=O)(=O)c3ccccc3)cc12, CN1CCC[C@@H]1Cc1c[nH]c2ccc(CCS(=O)(=O)c3ccccc3)cc12	Launched
eliglustat	glycosyl transferase inhibitor	UGCG	hematology	Gaucher disease	MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx	93.73	CCCCCCCC(=O)N[C@H](CN1CCCC1)[C@H](O)c1ccc2OCCOc2c1, CCCCCCCC(=O)N[C@H](CN1CCCC1)[C@H](O)c1ccc2OCCOc2c1, CCCCCCCC(=O)N[C@H](CN1CCCC1)[C@H](O)c1ccc2OCCOc2c1, CCCCCCCC(=O)N[C@H](CN1CCCC1)[C@H](O)c1ccc2OCCOc2c1, CCCCCCCC(=O)N[C@H](CN1CCCC1)[C@H](O)c1ccc2OCCOc2c1	Launched
elinogrel	purinergic receptor antagonist	P2RY12			Tocris, Tocris	13.9	CNc1cc2[nH]c(=O)n(-c3ccc(NC(=O)NS(=O)(=O)c4ccc(Cl)s4)cc3)c(=O)c2cc1F, CNc1cc2[nH]c(=O)n(-c3ccc(NC(=O)NS(=O)(=O)c4ccc(Cl)s4)cc3)c(=O)c2cc1F	Phase 2
eliprodil	glutamate receptor antagonist	GRIN1, GRIN2B			Tocris, Tocris, Tocris, Tocris	94.59	O[C@@H](CN1CCC(Cc2ccc(F)cc2)CC1)c1ccc(Cl)cc1 |&1:1,r|, O[C@@H](CN1CCC(Cc2ccc(F)cc2)CC1)c1ccc(Cl)cc1 |&1:1,r|, O[C@@H](CN1CCC(Cc2ccc(F)cc2)CC1)c1ccc(Cl)cc1 |&1:1,r|, O[C@@H](CN1CCC(Cc2ccc(F)cc2)CC1)c1ccc(Cl)cc1 |&1:1,r|	Phase 3
ellagic-acid	glutathione transferase inhibitor, non-nucleoside reverse transcriptase inhibitor	CA1, CA12, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9, CSNK2A1, GSK3B, PRKACA, PRKCA, PRKCB, SQLE, SYK			MedChemEx, MicroSource, MicroSource, Selleck, Selleck	98.25	Oc1cc2c3c(oc(=O)c4cc(O)c(O)c(oc2=O)c34)c1O, Oc1cc2c3c(oc(=O)c4cc(O)c(O)c(oc2=O)c34)c1O, Oc1cc2c3c(oc(=O)c4cc(O)c(O)c(oc2=O)c34)c1O, Oc1cc2c3c(oc(=O)c4cc(O)c(O)c(oc2=O)c34)c1O, Oc1cc2c3c(oc(=O)c4cc(O)c(O)c(oc2=O)c34)c1O	Phase 2
ELN-441958	bradykinin receptor antagonist	BDKRB1			MedChemEx, MedChemEx	97.7	Clc1cccc2CN(C(=O)c12)c1cccc(c1)C(=O)N1CCC2(CC1)CCN(CC2)c1ccncc1, Clc1cccc2CN(C(=O)c12)c1cccc(c1)C(=O)N1CCC2(CC1)CCN(CC2)c1ccncc1	Preclinical
eltanexor	exportin inhibitor				MedChemEx	88.82	NC(=O)C(=C/n1cnc(n1)-c1cc(cc(c1)C(F)(F)F)C(F)(F)F)\c1cncnc1	Preclinical
eltanolone	GABA receptor positive allosteric modulator	GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB2, GABRG2			Tocris, Tocris	97.4	CC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C, CC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C	Phase 3
eltoprazine	serotonin receptor agonist	HTR1A, HTR1B			MedChemEx, MedChemEx, MedChemEx	97.53	C1CN(CCN1)c1cccc2OCCOc12, C1CN(CCN1)c1cccc2OCCOc12, C1CN(CCN1)c1cccc2OCCOc12	Phase 2
eltrombopag	thrombopoietin receptor agonist	MPL	hematology, infectious disease	anemia, hepatitis C, thrombocytopenia	MedChemEx	98.21	CC1=NN(C(=O)\C1=N/Nc1cccc(-c2cccc(c2)C(O)=O)c1O)c1ccc(C)c(C)c1 |t:1|	Launched
eluxadoline	opioid receptor agonist, opioid receptor antagonist	OPRD1, OPRK1, OPRM1	gastroenterology	irritable bowel syndrome	MedChemEx	94.62	COc1ccc(CN([C@@H](C)c2nc(c[nH]2)-c2ccccc2)C(=O)[C@@H](N)Cc2c(C)cc(cc2C)C(N)=O)cc1C(O)=O	Launched
elvitegravir	HIV integrase inhibitor		infectious disease	human immunodeficiency virus (HIV-1)	Selleck	94.69	COc1cc2n(cc(C(O)=O)c(=O)c2cc1Cc1cccc(Cl)c1F)[C@H](CO)C(C)C	Launched
emamectin	GABA receptor agonist				MedChemEx	1.78	[H][C@@]12OC\C3=C/C=C/[C@H](C)[C@]([H])(O[C@H]4C[C@H](OC)[C@@]([H])(O[C@H]5C[C@@H](OC)[C@H](NC)[C@@H](C)O5)[C@H](C)O4)\C(C)=C\C[C@@H]4C[C@@H](C[C@]5(O4)O[C@H](C(C)C)[C@@H](C)C=C5)OC(=O)[C@H](C=C(C)[C@H]1O)[C@@]23O |c:4,55,t:6,38,62|	Preclinical
embelin	HCV inhibitor, XIAP inhibitor	XIAP			Tocris, Tocris, Tocris, Tocris, Tocris, Tocris, Selleck, Selleck	94.95	CCCCCCCCCCCC1C(=O)C(O)=CC(=O)C1=O |c:15|, CCCCCCCCCCCC1C(=O)C(O)=CC(=O)C1=O |c:15|, CCCCCCCCCCCC1C(=O)C(O)=CC(=O)C1=O |c:15|, CCCCCCCCCCCC1C(=O)C(O)=CC(=O)C1=O |c:15|, CCCCCCCCCCCC1C(=O)C(O)=CC(=O)C1=O |c:15|, CCCCCCCCCCCC1C(=O)C(O)=CC(=O)C1=O |c:15|, CCCCCCCCCCCC1C(=O)C(O)=CC(=O)C1=O |c:15|, CCCCCCCCCCCC1C(=O)C(O)=CC(=O)C1=O |c:15|	Preclinical
EMD-1214063	hepatocyte growth factor receptor inhibitor	MET			MedChemEx, MedChemEx, MedChemEx, MedChemEx	95.6	CN1CCC(COc2cnc(nc2)-c2cccc(Cn3nc(ccc3=O)-c3cccc(c3)C#N)c2)CC1, CN1CCC(COc2cnc(nc2)-c2cccc(Cn3nc(ccc3=O)-c3cccc(c3)C#N)c2)CC1, CN1CCC(COc2cnc(nc2)-c2cccc(Cn3nc(ccc3=O)-c3cccc(c3)C#N)c2)CC1, CN1CCC(COc2cnc(nc2)-c2cccc(Cn3nc(ccc3=O)-c3cccc(c3)C#N)c2)CC1	Phase 2
EMD-386088	serotonin receptor agonist	HTR6			Tocris, Tocris, Tocris, Tocris	97.4	Cc1[nH]c2ccc(Cl)cc2c1C1=CCNCC1 |t:13|, Cc1[nH]c2ccc(Cl)cc2c1C1=CCNCC1 |t:13|, Cc1[nH]c2ccc(Cl)cc2c1C1=CCNCC1 |t:13|, Cc1[nH]c2ccc(Cl)cc2c1C1=CCNCC1 |t:13|	Preclinical
EMD-53998	phosphodiesterase inhibitor	TNNC1			EMDBio, EMDBio, EMDBio, EMDBio	97.01	COc1ccc(cc1OC)C(=O)N1CCCc2cc(ccc12)C1=NNC(=O)S[C@@H]1C |r,t:25|, COc1ccc(cc1OC)C(=O)N1CCCc2cc(ccc12)C1=NNC(=O)S[C@@H]1C |r,t:25|, COc1ccc(cc1OC)C(=O)N1CCCc2cc(ccc12)C1=NNC(=O)S[C@@H]1C |r,t:25|, COc1ccc(cc1OC)C(=O)N1CCCc2cc(ccc12)C1=NNC(=O)S[C@@H]1C |r,t:25|	Phase 1
EMD-66684	angiotensin receptor antagonist	AGTR1			Tocris, Tocris, Tocris, Tocris	99.17	CCCCc1nc2ccn(CC(=O)N(C)C)c(=O)c2n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1, CCCCc1nc2ccn(CC(=O)N(C)C)c(=O)c2n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1, CCCCc1nc2ccn(CC(=O)N(C)C)c(=O)c2n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1, CCCCc1nc2ccn(CC(=O)N(C)C)c(=O)c2n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1	Preclinical
EMD534085	kinesin inhibitor				MedChemEx	93.34	[H][C@@]12CC[C@H](CNC(=O)NCCN(C)C)O[C@]1([H])c1cc(ccc1N[C@H]2c1ccccc1)C(F)(F)F	Preclinical
emedastine	histamine receptor antagonist	HRH1	ophthalmology	conjunctivitis	Prestwick, TCI	86.56	CCOCCn1c(nc2ccccc12)N1CCCN(C)CC1, CCOCCn1c(nc2ccccc12)N1CCCN(C)CC1	Launched
emeramide	antioxidant				MedChemEx	29.63	SCCNC(=O)c1cccc(c1)C(=O)NCCS	Phase 2
emetine	protein synthesis inhibitor	RPS2			MedChemEx, MedChemEx, Selleck, Selleck, Selleck, Selleck, Selleck	97.59	CC[C@H]1CN2CCc3cc(OC)c(OC)cc3[C@@H]2C[C@@H]1C[C@H]1NCCc2cc(OC)c(OC)cc12, CC[C@H]1CN2CCc3cc(OC)c(OC)cc3[C@@H]2C[C@@H]1C[C@H]1NCCc2cc(OC)c(OC)cc12, CC[C@H]1CN2CCc3cc(OC)c(OC)cc3[C@@H]2C[C@@H]1C[C@H]1NCCc2cc(OC)c(OC)cc12, CC[C@H]1CN2CCc3cc(OC)c(OC)cc3[C@@H]2C[C@@H]1C[C@H]1NCCc2cc(OC)c(OC)cc12, CC[C@H]1CN2CCc3cc(OC)c(OC)cc3[C@@H]2C[C@@H]1C[C@H]1NCCc2cc(OC)c(OC)cc12, CC[C@H]1CN2CCc3cc(OC)c(OC)cc3[C@@H]2C[C@@H]1C[C@H]1NCCc2cc(OC)c(OC)cc12, CC[C@H]1CN2CCc3cc(OC)c(OC)cc3[C@@H]2C[C@@H]1C[C@H]1NCCc2cc(OC)c(OC)cc12	Phase 2
emiglitate	alpha glucoside inhibitor				MedChemEx	90.99	CCOC(=O)c1ccc(OCCN2C[C@H](O)[C@@H](O)[C@H](O)[C@H]2CO)cc1	Preclinical
emixustat	retinoid isomerohydrolase inhibitor				MedChemEx	92.6	NCC[C@@H](O)c1cccc(OCC2CCCCC2)c1	Phase 3
emodepside	nematocide				MedChemEx	95.47	[H][C@]1(C)OC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](Cc2ccc(cc2)N2CCOCC2)OC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)OC(=O)[C@@H](CC(C)C)N(C)C(=O)[C@@H](Cc2ccc(cc2)N2CCOCC2)OC(=O)[C@H](CC(C)C)N(C)C1=O	Phase 1
emodin	11-beta hydroxysteroid dehydrogenase inhibitor	CSNK2A1			Selleck, Selleck	97.91	Cc1cc(O)c2C(=O)c3c(O)cc(O)cc3C(=O)c2c1, Cc1cc(O)c2C(=O)c3c(O)cc(O)cc3C(=O)c2c1	Preclinical
emorfazone	anti-inflammatory agent, cyclooxygenase inhibitor		dental	mouth inflammation	Sigma	99.42	CCOc1c(cnn(C)c1=O)N1CCOCC1	Launched
emoxipin					Vitas-M	95.96	CCc1nc(C)ccc1O	Phase 3
empagliflozin	sodium/glucose cotransporter inhibitor	SLC5A1, SLC5A2	endocrinology	diabetes mellitus	Selleck, MedChemEx, MedChemEx	97.64	OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)c1ccc(Cl)c(Cc2ccc(O[C@H]3CCOC3)cc2)c1, OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)c1ccc(Cl)c(Cc2ccc(O[C@H]3CCOC3)cc2)c1, OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)c1ccc(Cl)c(Cc2ccc(O[C@H]3CCOC3)cc2)c1	Launched
emricasan	caspase inhibitor	CASP1, CASP3, CASP7			Cayman, Cayman, Cayman	91.7	C[C@H](NC(=O)C(=O)Nc1ccccc1C(C)(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)COc1c(F)c(F)cc(F)c1F, C[C@H](NC(=O)C(=O)Nc1ccccc1C(C)(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)COc1c(F)c(F)cc(F)c1F, C[C@H](NC(=O)C(=O)Nc1ccccc1C(C)(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)COc1c(F)c(F)cc(F)c1F	Phase 2
emtricitabine	nucleoside reverse transcriptase inhibitor		infectious disease	human immunodeficiency virus (HIV-1)	Selleck, MedChemEx	96.41	Nc1nc(=O)n(cc1F)[C@@H]1CS[C@H](CO)O1, Nc1nc(=O)n(cc1F)[C@@H]1CS[C@H](CO)O1	Launched
enalapril	angiotensin converting enzyme inhibitor	ACE	cardiology	hypertension, congestive heart failure, left ventricular systolic dysfunction (LVSD)	Selleck, Selleck, MicroSource, MedChemEx, MedChemEx	94.83	CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O, CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O, CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O, CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O, CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O	Launched
enalaprilat	angiotensin converting enzyme inhibitor	ACE	cardiology	hypertension	MicroSource, MedChemEx, Selleck, MedChemEx, MedChemEx, Selleck, Selleck	94.1	C[C@H](N[C@@H](CCc1ccccc1)C(O)=O)C(=O)N1CCC[C@H]1C(O)=O, C[C@H](N[C@@H](CCc1ccccc1)C(O)=O)C(=O)N1CCC[C@H]1C(O)=O, C[C@H](N[C@@H](CCc1ccccc1)C(O)=O)C(=O)N1CCC[C@H]1C(O)=O, C[C@H](N[C@@H](CCc1ccccc1)C(O)=O)C(=O)N1CCC[C@H]1C(O)=O, C[C@H](N[C@@H](CCc1ccccc1)C(O)=O)C(=O)N1CCC[C@H]1C(O)=O, C[C@H](N[C@@H](CCc1ccccc1)C(O)=O)C(=O)N1CCC[C@H]1C(O)=O, C[C@H](N[C@@H](CCc1ccccc1)C(O)=O)C(=O)N1CCC[C@H]1C(O)=O	Launched
enasidenib	isocitrate dehydrogenase inhibitor	IDH1	hematologic malignancy	acute myeloid leukemia (AML)	MedChemEx, MedChemEx, MedChemEx, MedChemEx	97.57	CC(C)(O)CNc1nc(Nc2ccnc(c2)C(F)(F)F)nc(n1)-c1cccc(n1)C(F)(F)F, CC(C)(O)CNc1nc(Nc2ccnc(c2)C(F)(F)F)nc(n1)-c1cccc(n1)C(F)(F)F, CC(C)(O)CNc1nc(Nc2ccnc(c2)C(F)(F)F)nc(n1)-c1cccc(n1)C(F)(F)F, CC(C)(O)CNc1nc(Nc2ccnc(c2)C(F)(F)F)nc(n1)-c1cccc(n1)C(F)(F)F	Launched
enbucrilate			dermatology	skin lacerations, tissue adhesive	Ark	0	CCCCOC(=O)C(=C)C#N	Launched
enciprazine	GABA receptor modulator	GABRA1			Key, Key, Key	98.17	COc1ccccc1N1CCN(C[C@@H](O)COc2cc(OC)c(OC)c(OC)c2)CC1 |&1:13,r|, COc1ccccc1N1CCN(C[C@@H](O)COc2cc(OC)c(OC)c(OC)c2)CC1 |&1:13,r|, COc1ccccc1N1CCN(C[C@@H](O)COc2cc(OC)c(OC)c(OC)c2)CC1 |&1:13,r|	Phase 3
encorafenib	RAF inhibitor	BRAF	oncology	melanoma	MedChemEx	97.1	COC(=O)N[C@@H](C)CNc1nccc(n1)-c1cn(nc1-c1cc(Cl)cc(NS(C)(=O)=O)c1F)C(C)C	Launched
endo-IWR-1	PARP inhibitor	TNKS, TNKS2			Tocris, Tocris, Tocris, Tocris, Selleck, Selleck, Selleck, Selleck	97.96	O=C(Nc1cccc2cccnc12)c1ccc(cc1)N1C(=O)[C@H]2[C@@H]3C[C@@H](C=C3)[C@H]2C1=O |c:29|, O=C(Nc1cccc2cccnc12)c1ccc(cc1)N1C(=O)[C@H]2[C@@H]3C[C@@H](C=C3)[C@H]2C1=O |c:29|, O=C(Nc1cccc2cccnc12)c1ccc(cc1)N1C(=O)[C@H]2[C@@H]3C[C@@H](C=C3)[C@H]2C1=O |c:29|, O=C(Nc1cccc2cccnc12)c1ccc(cc1)N1C(=O)[C@H]2[C@@H]3C[C@@H](C=C3)[C@H]2C1=O |c:29|, O=C(Nc1cccc2cccnc12)c1ccc(cc1)N1C(=O)[C@H]2[C@@H]3C[C@@H](C=C3)[C@H]2C1=O |c:29|, O=C(Nc1cccc2cccnc12)c1ccc(cc1)N1C(=O)[C@H]2[C@@H]3C[C@@H](C=C3)[C@H]2C1=O |c:29|, O=C(Nc1cccc2cccnc12)c1ccc(cc1)N1C(=O)[C@H]2[C@@H]3C[C@@H](C=C3)[C@H]2C1=O |c:29|, O=C(Nc1cccc2cccnc12)c1ccc(cc1)N1C(=O)[C@H]2[C@@H]3C[C@@H](C=C3)[C@H]2C1=O |c:29|	Preclinical
endoxifen	estrogen receptor antagonist	ESR1			MedChemEx, Selleck	52.03	CC\C(=C(/c1ccc(O)cc1)c1ccc(OCCNC)cc1)c1ccccc1, CC\C(=C(/c1ccc(O)cc1)c1ccc(OCCNC)cc1)c1ccccc1	Phase 2
enflurane	membrane permeability inhibitor	GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GLRA1, GLRB, KCNK10, KCNK18, KCNK2, KCNK3, KCNK9	neurology/psychiatry	anesthetic	Sigma, Apollo, Apollo	0	FC(F)OC(F)(F)[C@@H](F)Cl |&1:7,r|, FC(F)OC(F)(F)[C@@H](F)Cl |&1:7,r|, FC(F)OC(F)(F)[C@@H](F)Cl |&1:7,r|	Launched
enilconazole	sterol demethylase inhibitor	CYP19A1, CYP1A2, CYP2B6, CYP2C9, CYP2J2, CYP3A4, CYP3A5, NR1I2, PPARA, PTGER2	infectious disease	skin infections	MedChemEx, MicroSource	98.23	Clc1ccc([C@@H](Cn2ccnc2)OCC=C)c(Cl)c1 |&1:5|, Clc1ccc([C@@H](Cn2ccnc2)OCC=C)c(Cl)c1 |&1:5|	Launched
eniluracil	dihydropyrimidine dehydrogenase inhibitor	AOX1, DPYD, XDH			Sigma	0	O=c1[nH]cc(C#C)c(=O)[nH]1	Phase 3
eniporide	sodium/hydrogen antiport inhibitor				Sigma	96.24	Cc1cc(c(cc1C(=O)NC(N)=N)S(C)(=O)=O)-n1cccc1	Preclinical
enisamium-iodide					Vitas-M, Broad Institute	97.96	C[n+]1ccc(cc1)C(=O)NCc1ccccc1, C[n+]1ccc(cc1)C(=O)NCc1ccccc1	Launched
ENMD-2076	Aurora kinase inhibitor, FLT3 inhibitor, VEGFR inhibitor	AURKA, FLT3, KDR, PDGFRA, PTK2, SRC			Selleck, Selleck, Selleck	96.02	CN1CCN(CC1)c1cc(Nc2cc(C)n[nH]2)nc(\C=C\c2ccccc2)n1, CN1CCN(CC1)c1cc(Nc2cc(C)n[nH]2)nc(\C=C\c2ccccc2)n1, CN1CCN(CC1)c1cc(Nc2cc(C)n[nH]2)nc(\C=C\c2ccccc2)n1	Phase 2
enocitabine	DNA synthesis inhibitor	CMPK1, RRM1, TYMS	hematologic malignancy	acute myeloid leukemia (AML)	AKSci, Carbosynth	97.2	CCCCCCCCCCCCCCCCCCCCCC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1, CCCCCCCCCCCCCCCCCCCCCC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1	Launched
enoxacin	topoisomerase inhibitor	TOP2A	infectious disease	urinary tract infections, gonorrhea	MedChemEx, MicroSource, Selleck, Selleck	89.69	CCn1cc(C(O)=O)c(=O)c2cc(F)c(nc12)N1CCNCC1, CCn1cc(C(O)=O)c(=O)c2cc(F)c(nc12)N1CCNCC1, CCn1cc(C(O)=O)c(=O)c2cc(F)c(nc12)N1CCNCC1, CCn1cc(C(O)=O)c(=O)c2cc(F)c(nc12)N1CCNCC1	Launched
enoximone	phosphodiesterase inhibitor	PDE3A	cardiology	congestive heart failure	Sigma, Sigma, Sigma, Sigma, Sigma, Sigma, Tocris	96.98	CSc1ccc(cc1)C(=O)c1[nH]c(=O)[nH]c1C, CSc1ccc(cc1)C(=O)c1[nH]c(=O)[nH]c1C, CSc1ccc(cc1)C(=O)c1[nH]c(=O)[nH]c1C, CSc1ccc(cc1)C(=O)c1[nH]c(=O)[nH]c1C, CSc1ccc(cc1)C(=O)c1[nH]c(=O)[nH]c1C, CSc1ccc(cc1)C(=O)c1[nH]c(=O)[nH]c1C, CSc1ccc(cc1)C(=O)c1[nH]c(=O)[nH]c1C	Launched
enoxolone	gap junction modulator	HSD11B1	gastroenterology, otolaryngology	peptic ulcer disease (PUD), common cold	MicroSource, MicroSource, MicroSource, MedChemEx, Selleck	99.76	CC1(C)[C@@H](O)CC[C@@]2(C)[C@H]1CC[C@]1(C)[C@@H]2C(=O)C=C2[C@@H]3C[C@](C)(CC[C@]3(C)CC[C@@]12C)C(O)=O |t:19|, CC1(C)[C@@H](O)CC[C@@]2(C)[C@H]1CC[C@]1(C)[C@@H]2C(=O)C=C2[C@@H]3C[C@](C)(CC[C@]3(C)CC[C@@]12C)C(O)=O |t:19|, CC1(C)[C@@H](O)CC[C@@]2(C)[C@H]1CC[C@]1(C)[C@@H]2C(=O)C=C2[C@@H]3C[C@](C)(CC[C@]3(C)CC[C@@]12C)C(O)=O |t:19|, CC1(C)[C@@H](O)CC[C@@]2(C)[C@H]1CC[C@]1(C)[C@@H]2C(=O)C=C2[C@@H]3C[C@](C)(CC[C@]3(C)CC[C@@]12C)C(O)=O |t:19|, CC1(C)[C@@H](O)CC[C@@]2(C)[C@H]1CC[C@]1(C)[C@@H]2C(=O)C=C2[C@@H]3C[C@](C)(CC[C@]3(C)CC[C@@]12C)C(O)=O |t:19|	Launched
enprofylline	phosphodiesterase inhibitor	ADORA1, ADORA2A, ADORA2B, ADORA3, PDE4A, PDE4B			Enzo, Enzo, Enzo, Enzo, Enzo, Sigma	98.71	CCCn1c2nc[nH]c2c(=O)[nH]c1=O, CCCn1c2nc[nH]c2c(=O)[nH]c1=O, CCCn1c2nc[nH]c2c(=O)[nH]c1=O, CCCn1c2nc[nH]c2c(=O)[nH]c1=O, CCCn1c2nc[nH]c2c(=O)[nH]c1=O, CCCn1c2nc[nH]c2c(=O)[nH]c1=O	Phase 3
enrofloxacin	bacterial DNA gyrase inhibitor		infectious disease	gram-negative bacterial infections	MicroSource, MedChemEx, Selleck	96.46	CCN1CCN(CC1)c1cc2n(cc(C(O)=O)c(=O)c2cc1F)C1CC1, CCN1CCN(CC1)c1cc2n(cc(C(O)=O)c(=O)c2cc1F)C1CC1, CCN1CCN(CC1)c1cc2n(cc(C(O)=O)c(=O)c2cc1F)C1CC1	Launched
entacapone	catechol O methyltransferase inhibitor	COMT	neurology/psychiatry	Parkinson's Disease	Tocris, Tocris, MicroSource, Selleck, Selleck	97.59	CCN(CC)C(=O)C(=C\c1cc(O)c(O)c(c1)[N+]([O-])=O)\C#N, CCN(CC)C(=O)C(=C\c1cc(O)c(O)c(c1)[N+]([O-])=O)\C#N, CCN(CC)C(=O)C(=C\c1cc(O)c(O)c(c1)[N+]([O-])=O)\C#N, CCN(CC)C(=O)C(=C\c1cc(O)c(O)c(c1)[N+]([O-])=O)\C#N, CCN(CC)C(=O)C(=C\c1cc(O)c(O)c(c1)[N+]([O-])=O)\C#N	Launched
entasobulin	tubulin polymerization inhibitor				MedChemEx	97.5	Clc1ccc(Cn2cc(C(=O)C(=O)Nc3ccc4ncccc4c3)c3ccccc23)cc1	Preclinical
entecavir	DNA replication inhibitor, nucleoside reverse transcriptase inhibitor		infectious disease	hepatitis B	Selleck	99.22	Nc1nc(=O)c2ncn([C@H]3C[C@H](O)[C@@H](CO)C3=C)c2[nH]1	Launched
entinostat	HDAC inhibitor	HDAC1, HDAC2, HDAC3, HDAC9			Selleck, Selleck, Selleck, Selleck, MedChemEx, MedChemEx, MedChemEx, Selleck, Selleck	94.4	Nc1ccccc1NC(=O)c1ccc(CNC(=O)OCc2cccnc2)cc1, Nc1ccccc1NC(=O)c1ccc(CNC(=O)OCc2cccnc2)cc1, Nc1ccccc1NC(=O)c1ccc(CNC(=O)OCc2cccnc2)cc1, Nc1ccccc1NC(=O)c1ccc(CNC(=O)OCc2cccnc2)cc1, Nc1ccccc1NC(=O)c1ccc(CNC(=O)OCc2cccnc2)cc1, Nc1ccccc1NC(=O)c1ccc(CNC(=O)OCc2cccnc2)cc1, Nc1ccccc1NC(=O)c1ccc(CNC(=O)OCc2cccnc2)cc1, Nc1ccccc1NC(=O)c1ccc(CNC(=O)OCc2cccnc2)cc1, Nc1ccccc1NC(=O)c1ccc(CNC(=O)OCc2cccnc2)cc1	Phase 3
entrectinib	ALK tyrosine kinase receptor inhibitor, proto-oncogene tyrosine protein kinase inhibitor	ALK, NTRK1, NTRK2, NTRK3, ROS1	oncology	non-small cell lung cancer (NSCLC)	Selleck, Selleck	87.23	CN1CCN(CC1)c1ccc(C(=O)Nc2[nH]nc3ccc(Cc4cc(F)cc(F)c4)cc23)c(NC2CCOCC2)c1, CN1CCN(CC1)c1ccc(C(=O)Nc2[nH]nc3ccc(Cc4cc(F)cc(F)c4)cc23)c(NC2CCOCC2)c1	Launched
enzalutamide	androgen receptor antagonist	AR	oncology	prostate cancer	Selleck	95.96	CNC(=O)c1ccc(cc1F)N1C(=S)N(C(=O)C1(C)C)c1ccc(C#N)c(c1)C(F)(F)F	Launched
enzastaurin	PKC inhibitor	AKT1, GSK3B, PRKCA, PRKCB, PRKCD, PRKCG			Tocris, Selleck, Selleck	98.11	Cn1cc(C2=C(C(=O)NC2=O)c2cn(C3CCN(Cc4ccccn4)CC3)c3ccccc23)c2ccccc12 |t:4|, Cn1cc(C2=C(C(=O)NC2=O)c2cn(C3CCN(Cc4ccccn4)CC3)c3ccccc23)c2ccccc12 |t:4|, Cn1cc(C2=C(C(=O)NC2=O)c2cn(C3CCN(Cc4ccccn4)CC3)c3ccccc23)c2ccccc12 |t:4|	Phase 3
EN460	endoplasmic reticulum oxidation inhibitor	ERO1A			MedChemEx, MedChemEx	49.85	OC(=O)c1cc(ccc1Cl)N1N=C(\C(=C\c2ccc(o2)-c2ccccc2)C1=O)C(F)(F)F |c:12|, OC(=O)c1cc(ccc1Cl)N1N=C(\C(=C\c2ccc(o2)-c2ccccc2)C1=O)C(F)(F)F |c:12|	Preclinical
EO-1428	p38 MAPK inhibitor	MAPK11, MAPK14			Tocris, Tocris, Tocris, Tocris	97.01	Cc1ccccc1C(=O)c1ccc(Nc2ccc(Br)cc2N)cc1Cl, Cc1ccccc1C(=O)c1ccc(Nc2ccc(Br)cc2N)cc1Cl, Cc1ccccc1C(=O)c1ccc(Nc2ccc(Br)cc2N)cc1Cl, Cc1ccccc1C(=O)c1ccc(Nc2ccc(Br)cc2N)cc1Cl	Preclinical
epacadostat	indoleamine 2,3-dioxygenase inhibitor	IDO1			MedChemEx, MedChemEx, MedChemEx, Selleck	97.41	NS(=O)(=O)NCCNc1nonc1C(NO)=Nc1ccc(F)c(Br)c1, NS(=O)(=O)NCCNc1nonc1C(NO)=Nc1ccc(F)c(Br)c1, NS(=O)(=O)NCCNc1nonc1C(NO)=Nc1ccc(F)c(Br)c1, NS(=O)(=O)NCCNc1nonc1C(NO)=Nc1ccc(F)c(Br)c1	Phase 3
epalrestat	aldose reductase inhibitor	AKR1B1	nephrology	diabetic nephropathy	MedChemEx, MedChemEx, Selleck, Selleck, Selleck	81.25	C\C(\C=C1/SC(=S)N(CC(O)=O)C1=O)=C/c1ccccc1, C\C(\C=C1/SC(=S)N(CC(O)=O)C1=O)=C/c1ccccc1, C\C(\C=C1/SC(=S)N(CC(O)=O)C1=O)=C/c1ccccc1, C\C(\C=C1/SC(=S)N(CC(O)=O)C1=O)=C/c1ccccc1, C\C(\C=C1/SC(=S)N(CC(O)=O)C1=O)=C/c1ccccc1	Launched
eperezolid	bacterial 30S ribosomal subunit inhibitor				MedChemEx, MedChemEx, MedChemEx, MedChemEx	91.48	CC(=O)NC[C@H]1CN(C(=O)O1)c1ccc(N2CCN(CC2)C(=O)CO)c(F)c1, CC(=O)NC[C@H]1CN(C(=O)O1)c1ccc(N2CCN(CC2)C(=O)CO)c(F)c1, CC(=O)NC[C@H]1CN(C(=O)O1)c1ccc(N2CCN(CC2)C(=O)CO)c(F)c1, CC(=O)NC[C@H]1CN(C(=O)O1)c1ccc(N2CCN(CC2)C(=O)CO)c(F)c1	Phase 1
eperisone	acetylcholine receptor antagonist	CYP2J2	neurology/psychiatry	amyotrophic lateral sclerosis (ALS), spasms, head injury, spinal injury	CombiBlocks	99	CCc1ccc(cc1)C(=O)[C@@H](C)CN1CCCCC1 |r|	Launched
epetraborole	leucyl-tRNA synthetase inhibitor				MedChemEx	94.68	NC[C@H]1OB(O)c2c1cccc2OCCCO	Preclinical
ephedrine	adrenergic receptor agonist	ACHE, ADRA1A, ADRB2, SLC18A2, SLC6A2	cardiology, pulmonary, neurology/psychiatry, endocrinology	hypotension, asthma, narcolepsy, obesity	MicroSource, MicroSource	97.68	CN[C@@H](C)[C@H](O)c1ccccc1, CN[C@@H](C)[C@H](O)c1ccccc1	Launched
ephedrine-(racemic)	adrenergic receptor agonist	ADRA1A, ADRA2A, ADRB1, ADRB2, ATF1, ATF2, ATF3, ATF4, ATF5, ATF6, ATF7, FOS, IL2, JDP2, JUN, NFATC1, SLC6A2, SLC6A3, SLC6A4, TNF	cardiology, pulmonary, neurology/psychiatry, endocrinology	hypotension, asthma, narcolepsy, obesity	MicroSource, MicroSource	97.69	CN[C@@H](C)[C@@H](O)c1ccccc1 |&1:2,&2:4|, CN[C@@H](C)[C@@H](O)c1ccccc1 |&1:2,&2:4|	Launched
epiandrosterone	steroid	G6PD			MedChemEx	100	C[C@]12CC[C@H]3[C@@H](CC[C@H]4C[C@@H](O)CC[C@]34C)[C@@H]1CCC2=O	Preclinical
epicatechin-gallate-(-)	bacterial DNA gyrase inhibitor	BACE1, FASN			AnalytiCon, MedChemEx	96.2	Oc1cc(O)c2C[C@@H](OC(=O)c3cc(O)c(O)c(O)c3)[C@H](Oc2c1)c1ccc(O)c(O)c1, Oc1cc(O)c2C[C@@H](OC(=O)c3cc(O)c(O)c(O)c3)[C@H](Oc2c1)c1ccc(O)c(O)c1	Phase 2
epiestriol					Toronto	91.12	C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1C[C@H](O)[C@@H]2O	Preclinical
epigallocatechin-(-)					MedChemEx	91.93	O[C@@H]1Cc2c(O)cc(O)cc2O[C@@H]1c1cc(O)c(O)c(O)c1	Phase 2
epigallocatechin-gallate-(-)	bacterial DNA gyrase inhibitor	ELANE, EP300, FASN, KAT2B, MMP14, MMP2			MedChemEx, MedChemEx, MedChemEx, Selleck, Selleck	81.58	Oc1cc(O)c2C[C@@H](OC(=O)c3cc(O)c(O)c(O)c3)[C@H](Oc2c1)c1cc(O)c(O)c(O)c1, Oc1cc(O)c2C[C@@H](OC(=O)c3cc(O)c(O)c(O)c3)[C@H](Oc2c1)c1cc(O)c(O)c(O)c1, Oc1cc(O)c2C[C@@H](OC(=O)c3cc(O)c(O)c(O)c3)[C@H](Oc2c1)c1cc(O)c(O)c(O)c1, Oc1cc(O)c2C[C@@H](OC(=O)c3cc(O)c(O)c(O)c3)[C@H](Oc2c1)c1cc(O)c(O)c(O)c1, Oc1cc(O)c2C[C@@H](OC(=O)c3cc(O)c(O)c(O)c3)[C@H](Oc2c1)c1cc(O)c(O)c(O)c1	Phase 2/Phase 3
epinastine	histamine receptor antagonist	HRH1	ophthalmology	conjunctivitis	Selleck, MedChemEx	98.59	NC1=NC[C@H]2N1c1ccccc1Cc1ccccc21 |&1:4,t:1|, NC1=NC[C@H]2N1c1ccccc1Cc1ccccc21 |&1:4,t:1|	Launched
epinephrine	adrenergic receptor agonist, carbonic anhydrase activator, neurotransmitter	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3, PAH, TNF	cardiology, allergy, pulmonary	cardiac arrest, anaphylactic shock, asthma	MicroSource, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck	100	CNC[C@H](O)c1ccc(O)c(O)c1, CNC[C@H](O)c1ccc(O)c(O)c1, CNC[C@H](O)c1ccc(O)c(O)c1, CNC[C@H](O)c1ccc(O)c(O)c1, CNC[C@H](O)c1ccc(O)c(O)c1, CNC[C@H](O)c1ccc(O)c(O)c1, CNC[C@H](O)c1ccc(O)c(O)c1, CNC[C@H](O)c1ccc(O)c(O)c1	Launched
epirizole	cyclooxygenase inhibitor	PTGS1, PTGS2	neurology/psychiatry	pain relief	Labotest, Prestwick	98.14	COc1cc(C)nn1-c1nc(C)cc(OC)n1, COc1cc(C)nn1-c1nc(C)cc(OC)n1	Launched
epirubicin	topoisomerase inhibitor	CHD1, TOP2A	oncology	breast cancer	MicroSource, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck	94.71	COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO	Launched
epitiostanol	androgen receptor agonist	AR	oncology	breast cancer	Prestwick, Prestwick, Prestwick	90.16	C[C@]12CC[C@H]3[C@@H](CC[C@H]4C[C@@H]5S[C@@H]5C[C@]34C)[C@@H]1CC[C@@H]2O, C[C@]12CC[C@H]3[C@@H](CC[C@H]4C[C@@H]5S[C@@H]5C[C@]34C)[C@@H]1CC[C@@H]2O, C[C@]12CC[C@H]3[C@@H](CC[C@H]4C[C@@H]5S[C@@H]5C[C@]34C)[C@@H]1CC[C@@H]2O	Launched
eplerenone	cytochrome P450 inhibitor	NR3C2	cardiology	congestive heart failure, hypertension	Selleck, Tocris, Tocris, Tocris, Tocris, Selleck, Selleck, Selleck	99.75	COC(=O)[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@@]23O[C@@H]2C[C@@]2(C)[C@@H](CC[C@@]22CCC(=O)O2)[C@H]13 |t:6|, COC(=O)[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@@]23O[C@@H]2C[C@@]2(C)[C@@H](CC[C@@]22CCC(=O)O2)[C@H]13 |t:6|, COC(=O)[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@@]23O[C@@H]2C[C@@]2(C)[C@@H](CC[C@@]22CCC(=O)O2)[C@H]13 |t:6|, COC(=O)[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@@]23O[C@@H]2C[C@@]2(C)[C@@H](CC[C@@]22CCC(=O)O2)[C@H]13 |t:6|, COC(=O)[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@@]23O[C@@H]2C[C@@]2(C)[C@@H](CC[C@@]22CCC(=O)O2)[C@H]13 |t:6|, COC(=O)[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@@]23O[C@@H]2C[C@@]2(C)[C@@H](CC[C@@]22CCC(=O)O2)[C@H]13 |t:6|, COC(=O)[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@@]23O[C@@H]2C[C@@]2(C)[C@@H](CC[C@@]22CCC(=O)O2)[C@H]13 |t:6|, COC(=O)[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@@]23O[C@@H]2C[C@@]2(C)[C@@H](CC[C@@]22CCC(=O)O2)[C@H]13 |t:6|	Launched
epomediol	cholesterol inhibitor	CYP7A1	neurology/psychiatry	itching	TimTec	0	CC1(C)OC2(C)[C@@H](O)C[C@H]1C[C@@H]2O |&1:11,&2:9,&3:6,r,THB:12:11:1.3:8.6,7:6:1.3:11.10|	Launched
epoprostenol	prostacyclin analog	P2RY12, PTGER1, PTGER4, PTGIR, PTGIS	cardiology	hypertension	Enzo, Biomol, Biomol, Biomol	100	CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)C[C@@H]2O\C(C[C@H]12)=C/CCCC(O)=O, CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)C[C@@H]2O\C(C[C@H]12)=C/CCCC(O)=O, CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)C[C@@H]2O\C(C[C@H]12)=C/CCCC(O)=O, CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)C[C@@H]2O\C(C[C@H]12)=C/CCCC(O)=O	Launched
epothilone-A	microtubule stabilizing agent				Selleck, Selleck	97.44	C[C@H]1CCC[C@H]2O[C@H]2C[C@H](OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@H]1O)C(\C)=C\c1csc(C)n1, C[C@H]1CCC[C@H]2O[C@H]2C[C@H](OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@H]1O)C(\C)=C\c1csc(C)n1	Preclinical
epothilone-B	microtubule stabilizing agent, tubulin polymerization inhibitor	TUBB			MedChemEx	95.52	C[C@H]1CCC[C@@]2(C)O[C@H]2C[C@H](OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@H]1O)C(\C)=C\c1csc(C)n1	Phase 3
epothilone-D	microtubule stabilizing agent, tubulin polymerization inhibitor	TUBB			MedChemEx, MedChemEx	97.71	C[C@H]1CCC\C(C)=C/C[C@H](OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@H]1O)C(\C)=C\c1csc(C)n1 |c:6|, C[C@H]1CCC\C(C)=C/C[C@H](OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@H]1O)C(\C)=C\c1csc(C)n1 |c:6|	Phase 2
EPPTB	trace amine associated receptor antagonist	TAAR1			Tocris, Tocris, Tocris	97.76	CCOc1cccc(NC(=O)c2ccc(N3CCCC3)c(c2)C(F)(F)F)c1, CCOc1cccc(NC(=O)c2ccc(N3CCCC3)c(c2)C(F)(F)F)c1, CCOc1cccc(NC(=O)c2ccc(N3CCCC3)c(c2)C(F)(F)F)c1	Preclinical
eprazinone	mucolytic agent		pulmonary	bronchospasm	Selleck, Selleck, Selleck	94.62	CCO[C@@H](CN1CCN(C[C@@H](C)C(=O)c2ccccc2)CC1)c1ccccc1 |a:10,&1:3|, CCO[C@@H](CN1CCN(C[C@@H](C)C(=O)c2ccccc2)CC1)c1ccccc1 |a:10,&1:3|, CCO[C@@H](CN1CCN(C[C@@H](C)C(=O)c2ccccc2)CC1)c1ccccc1 |a:10,&1:3|	Launched
eprinomectin	benzodiazepine receptor agonist		infectious disease	gastrointestinal roundworms, lungworms	MedChemEx	66.82	[H][C@@]12OC\C3=C/C=C/[C@]([H])(C)[C@]([H])(O[C@@]4([H])C[C@H](OC)[C@@H](O[C@@]5([H])C[C@H](OC)[C@@H](NC(C)=O)[C@H](C)O5)[C@H](C)O4)\C(C)=C\C[C@]4([H])C[C@@]([H])(C[C@]5(O4)O[C@]([H])([C@@H](C)CC)[C@@]([H])(C)C=C5)OC(=O)[C@]([H])(C=C(C)[C@@]1([H])O)[C@@]23O |c:4,64,t:6,42,72|	Launched
epristeride	5 alpha reductase inhibitor				MedChemEx	79.7	[H][C@@]12CC[C@H](C(=O)NC(C)(C)C)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C=C(CC[C@]12C)C(O)=O |c:25,t:23|	Preclinical
eprobemide	monoamine oxidase inhibitor	MAOA	neurology/psychiatry	depression	MedChemEx, MicroSource, MicroSource	96.11	Clc1ccc(cc1)C(=O)NCCCN1CCOCC1, Clc1ccc(cc1)C(=O)NCCCN1CCOCC1, Clc1ccc(cc1)C(=O)NCCCN1CCOCC1	Launched
eprodisate	amyloid protein inhibitor, antiamyloidogenic agent	SAA1			MicroSource, Sigma, MedChemEx	95.43	OS(=O)(=O)CCCS(O)(=O)=O, OS(=O)(=O)CCCS(O)(=O)=O, OS(=O)(=O)CCCS(O)(=O)=O	Phase 3
eprosartan	angiotensin receptor antagonist	AGTR1	cardiology	hypertension	Selleck, Selleck, Selleck, Selleck, Selleck	99.15	CCCCc1ncc(\C=C(/Cc2cccs2)C(O)=O)n1Cc1ccc(cc1)C(O)=O, CCCCc1ncc(\C=C(/Cc2cccs2)C(O)=O)n1Cc1ccc(cc1)C(O)=O, CCCCc1ncc(\C=C(/Cc2cccs2)C(O)=O)n1Cc1ccc(cc1)C(O)=O, CCCCc1ncc(\C=C(/Cc2cccs2)C(O)=O)n1Cc1ccc(cc1)C(O)=O, CCCCc1ncc(\C=C(/Cc2cccs2)C(O)=O)n1Cc1ccc(cc1)C(O)=O	Launched
eptifibatide	platelet aggregation inhibitor	ITGA2B, ITGB3	cardiology	acute coronary syndrome (ACS), percutaneous coronary intervention (PCI)	Selleck, Selleck	96.92	NC(=N)NCCCC[C@@H]1NC(=O)CCSSC[C@H](NC(=O)[C@@H]2CCCN2C(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](CC(O)=O)NC(=O)CNC1=O)C(N)=O, NC(=N)NCCCC[C@@H]1NC(=O)CCSSC[C@H](NC(=O)[C@@H]2CCCN2C(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](CC(O)=O)NC(=O)CNC1=O)C(N)=O	Launched
EPZ-5676	histone lysine methyltransferase inhibitor	DOT1L			Selleck, Selleck, Selleck, Selleck, Selleck, MedChemEx, Selleck, Selleck, Selleck, Selleck	95.25	CC(C)N(C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)ncnc12)[C@@H]1C[C@H](CCc2nc3ccc(cc3[nH]2)C(C)(C)C)C1, CC(C)N(C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)ncnc12)[C@@H]1C[C@H](CCc2nc3ccc(cc3[nH]2)C(C)(C)C)C1, CC(C)N(C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)ncnc12)[C@@H]1C[C@H](CCc2nc3ccc(cc3[nH]2)C(C)(C)C)C1, CC(C)N(C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)ncnc12)[C@@H]1C[C@H](CCc2nc3ccc(cc3[nH]2)C(C)(C)C)C1, CC(C)N(C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)ncnc12)[C@@H]1C[C@H](CCc2nc3ccc(cc3[nH]2)C(C)(C)C)C1, CC(C)N(C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)ncnc12)[C@@H]1C[C@H](CCc2nc3ccc(cc3[nH]2)C(C)(C)C)C1, CC(C)N(C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)ncnc12)[C@@H]1C[C@H](CCc2nc3ccc(cc3[nH]2)C(C)(C)C)C1, CC(C)N(C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)ncnc12)[C@@H]1C[C@H](CCc2nc3ccc(cc3[nH]2)C(C)(C)C)C1, CC(C)N(C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)ncnc12)[C@@H]1C[C@H](CCc2nc3ccc(cc3[nH]2)C(C)(C)C)C1, CC(C)N(C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)ncnc12)[C@@H]1C[C@H](CCc2nc3ccc(cc3[nH]2)C(C)(C)C)C1	Phase 1
EPZ004777	histone lysine methyltransferase inhibitor	DOT1L			Selleck, Selleck, Selleck, Selleck, Selleck	94.61	CC(C)N(CCCNC(=O)Nc1ccc(cc1)C(C)(C)C)C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1ccc2c(N)ncnc12, CC(C)N(CCCNC(=O)Nc1ccc(cc1)C(C)(C)C)C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1ccc2c(N)ncnc12, CC(C)N(CCCNC(=O)Nc1ccc(cc1)C(C)(C)C)C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1ccc2c(N)ncnc12, CC(C)N(CCCNC(=O)Nc1ccc(cc1)C(C)(C)C)C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1ccc2c(N)ncnc12, CC(C)N(CCCNC(=O)Nc1ccc(cc1)C(C)(C)C)C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1ccc2c(N)ncnc12	Preclinical
EPZ005687	histone lysine methyltransferase inhibitor	EZH2			Selleck	95.53	Cc1cc(C)c(CNC(=O)c2cc(cc3n(ncc23)C2CCCC2)-c2ccc(CN3CCOCC3)cc2)c(=O)[nH]1	Preclinical
EPZ011989	histone lysine methyltransferase inhibitor	EZH2			MedChemEx, MedChemEx, MedChemEx	95.82	CCN([C@H]1CC[C@@H](CC1)N(C)CCOC)c1cc(cc(C(=O)NCc2c(C)cc(C)[nH]c2=O)c1C)C#CCN1CCOCC1 |r|, CCN([C@H]1CC[C@@H](CC1)N(C)CCOC)c1cc(cc(C(=O)NCc2c(C)cc(C)[nH]c2=O)c1C)C#CCN1CCOCC1 |r|, CCN([C@H]1CC[C@@H](CC1)N(C)CCOC)c1cc(cc(C(=O)NCc2c(C)cc(C)[nH]c2=O)c1C)C#CCN1CCOCC1 |r|	Preclinical
EPZ015666	protein arginine N-methyltransferase inhibitor	PRMT5			MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx	95.64	O[C@@H](CNC(=O)c1cc(NC2COC2)ncn1)CN1CCc2ccccc2C1, O[C@@H](CNC(=O)c1cc(NC2COC2)ncn1)CN1CCc2ccccc2C1, O[C@@H](CNC(=O)c1cc(NC2COC2)ncn1)CN1CCc2ccccc2C1, O[C@@H](CNC(=O)c1cc(NC2COC2)ncn1)CN1CCc2ccccc2C1, O[C@@H](CNC(=O)c1cc(NC2COC2)ncn1)CN1CCc2ccccc2C1, O[C@@H](CNC(=O)c1cc(NC2COC2)ncn1)CN1CCc2ccccc2C1, O[C@@H](CNC(=O)c1cc(NC2COC2)ncn1)CN1CCc2ccccc2C1, O[C@@H](CNC(=O)c1cc(NC2COC2)ncn1)CN1CCc2ccccc2C1, O[C@@H](CNC(=O)c1cc(NC2COC2)ncn1)CN1CCc2ccccc2C1	Preclinical
EPZ020411	protein arginine N-methyltransferase inhibitor	PRMT6			MedChemEx, MedChemEx, MedChemEx, MedChemEx	94.2	CNCCN(C)Cc1c[nH]nc1-c1ccc(O[C@H]2C[C@@H](C2)OCCC2CCOCC2)cc1 |r|, CNCCN(C)Cc1c[nH]nc1-c1ccc(O[C@H]2C[C@@H](C2)OCCC2CCOCC2)cc1 |r|, CNCCN(C)Cc1c[nH]nc1-c1ccc(O[C@H]2C[C@@H](C2)OCCC2CCOCC2)cc1 |r|, CNCCN(C)Cc1c[nH]nc1-c1ccc(O[C@H]2C[C@@H](C2)OCCC2CCOCC2)cc1 |r|	Preclinical
equilin	estrogen receptor agonist	HSD17B1			MicroSource, MicroSource, MicroSource	86.71	C[C@@]12CC[C@H]3C(=CCc4cc(O)ccc34)[C@@H]1CCC2=O |&1:1,&2:4,&3:15,r,c:5|, C[C@@]12CC[C@H]3C(=CCc4cc(O)ccc34)[C@@H]1CCC2=O |&1:1,&2:4,&3:15,r,c:5|, C[C@@]12CC[C@H]3C(=CCc4cc(O)ccc34)[C@@H]1CCC2=O |&1:1,&2:4,&3:15,r,c:5|	Preclinical
equol	estrogen receptor agonist	ESR1, ESR2			Selleck, Selleck, Selleck	94.86	Oc1ccc(cc1)[C@H]1COc2cc(O)ccc2C1, Oc1ccc(cc1)[C@H]1COc2cc(O)ccc2C1, Oc1ccc(cc1)[C@H]1COc2cc(O)ccc2C1	Launched
ER-27319	mediator release inhibitor, SYK inhibitor	SYK			Tocris, Tocris, Tocris, Tocris, Tocris, Tocris	100	Cc1ccc2c(c1C)n(CCCN)c1ccccc1c2=O, Cc1ccc2c(c1C)n(CCCN)c1ccccc1c2=O, Cc1ccc2c(c1C)n(CCCN)c1ccccc1c2=O, Cc1ccc2c(c1C)n(CCCN)c1ccccc1c2=O, Cc1ccc2c(c1C)n(CCCN)c1ccccc1c2=O, Cc1ccc2c(c1C)n(CCCN)c1ccccc1c2=O	Preclinical
ER-50891	retinoid receptor antagonist	RARA			Tocris, Tocris	96.07	CC(C)c1cccc2c(cc(nc12)-c1ccc([nH]1)-c1ccc(cc1)C(O)=O)-c1ccccc1, CC(C)c1cccc2c(cc(nc12)-c1ccc([nH]1)-c1ccc(cc1)C(O)=O)-c1ccccc1	Preclinical
erastin	ion channel antagonist	VDAC2			Selleck, Selleck, Selleck, Selleck, Selleck	98.74	CCOc1ccccc1-n1c(nc2ccccc2c1=O)[C@@H](C)N1CCN(CC1)C(=O)COc1ccc(Cl)cc1 |&1:20,r|, CCOc1ccccc1-n1c(nc2ccccc2c1=O)[C@@H](C)N1CCN(CC1)C(=O)COc1ccc(Cl)cc1 |&1:20,r|, CCOc1ccccc1-n1c(nc2ccccc2c1=O)[C@@H](C)N1CCN(CC1)C(=O)COc1ccc(Cl)cc1 |&1:20,r|, CCOc1ccccc1-n1c(nc2ccccc2c1=O)[C@@H](C)N1CCN(CC1)C(=O)COc1ccc(Cl)cc1 |&1:20,r|, CCOc1ccccc1-n1c(nc2ccccc2c1=O)[C@@H](C)N1CCN(CC1)C(=O)COc1ccc(Cl)cc1 |&1:20,r|	Preclinical
eravacycline	antibacterial				MedChemEx	0	[H][C@@]12Cc3c(F)cc(NC(=O)CN4CCCC4)c(O)c3C(=O)[C@H]1C(=O)[C@]1(O)C(=O)[C@H](C(N)=O)C(=O)[C@@H](N(C)C)[C@]1([H])C2 |&1:29,&2:22|	Launched
erbstatin-analog	EGFR inhibitor, tyrosine kinase inhibitor	EGFR			Tocris	63.51	COC(=O)\C=C\c1cc(O)ccc1O	Preclinical
ercalcitriol	vitamin D receptor agonist	VDR			MedChemEx, MedChemEx, MedChemEx, MedChemEx	92.34	C[C@H](\C=C\[C@H](C)C(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, C[C@H](\C=C\[C@H](C)C(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, C[C@H](\C=C\[C@H](C)C(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, C[C@H](\C=C\[C@H](C)C(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C	Phase 1
erdafitinib	FGFR inhibitor	FGFR1, FGFR2, FGFR3, FGFR4			MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx	95.96	COc1cc(OC)cc(c1)N(CCNC(C)C)c1ccc2ncc(nc2c1)-c1cnn(C)c1, COc1cc(OC)cc(c1)N(CCNC(C)C)c1ccc2ncc(nc2c1)-c1cnn(C)c1, COc1cc(OC)cc(c1)N(CCNC(C)C)c1ccc2ncc(nc2c1)-c1cnn(C)c1, COc1cc(OC)cc(c1)N(CCNC(C)C)c1ccc2ncc(nc2c1)-c1cnn(C)c1, COc1cc(OC)cc(c1)N(CCNC(C)C)c1ccc2ncc(nc2c1)-c1cnn(C)c1	Launched
erdosteine	mucolytic agent		pulmonary, infectious disease	bronchitis, cough suppressant, chronic obstructive pulmonary disease (COPD), respiratory tract infections	MicroSource, Selleck, Selleck, MedChemEx	99.06	OC(=O)CSCC(=O)N[C@H]1CCSC1=O |&1:9,r|, OC(=O)CSCC(=O)N[C@H]1CCSC1=O |&1:9,r|, OC(=O)CSCC(=O)N[C@H]1CCSC1=O |&1:9,r|, OC(=O)CSCC(=O)N[C@H]1CCSC1=O |&1:9,r|	Launched
ergocalciferol	vitamin analog	VDR	endocrinology, orthopedics	hypoparathyroidism, rickets, hypophosphatemia	MicroSource, MicroSource, Sigma, Sigma, Selleck, Selleck, Selleck, Selleck, Selleck	79.58	CC(C)[C@@H](C)\C=C\[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C, CC(C)[C@@H](C)\C=C\[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C, CC(C)[C@@H](C)\C=C\[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C, CC(C)[C@@H](C)\C=C\[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C, CC(C)[C@@H](C)\C=C\[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C, CC(C)[C@@H](C)\C=C\[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C, CC(C)[C@@H](C)\C=C\[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C, CC(C)[C@@H](C)\C=C\[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C, CC(C)[C@@H](C)\C=C\[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C	Launched
ergonovine	adrenergic receptor agonist, serotonin receptor agonist	ADRA1A, HTR1E	hematology	postpartum hemorrhage (PPH)	USP	97.04	C[C@@H](CO)NC(=O)[C@H]1CN(C)[C@@H]2Cc3c[nH]c4cccc(C2=C1)c34 |c:22|	Launched
ergosterol	vitamin D precursor				Selleck, Selleck, Selleck, Selleck, Selleck	0	CC(C)[C@@H](C)\C=C\[C@@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C |t:13,15|, CC(C)[C@@H](C)\C=C\[C@@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C |t:13,15|, CC(C)[C@@H](C)\C=C\[C@@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C |t:13,15|, CC(C)[C@@H](C)\C=C\[C@@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C |t:13,15|, CC(C)[C@@H](C)\C=C\[C@@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C |t:13,15|	Preclinical
ergotamine	adrenergic receptor antagonist	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, DRD1, DRD2, DRD5, HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR5A, HTR6, SLC6A2	neurology/psychiatry	migraine headache	Sigma, Sigma	79	CN1C[C@@H](C=C2[C@H]1Cc1c[nH]c3cccc2c13)C(=O)N[C@]1(C)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O |c:4|, CN1C[C@@H](C=C2[C@H]1Cc1c[nH]c3cccc2c13)C(=O)N[C@]1(C)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O |c:4|	Launched
eribulin	microtubule inhibitor		oncology	breast cancer	MedChemEx	100	[H][C@@]12CC(=C)[C@]([H])(CC[C@@]3([H])C[C@@H](C)C(=C)[C@@]([H])(C[C@]4([H])O[C@H](C[C@H](O)CN)[C@H](OC)[C@@]4([H])CC(=O)C[C@@]4([H])CC[C@]5([H])O[C@@]6([H])[C@@]7([H])O[C@@]8(C[C@@]7([H])O[C@@]6([H])[C@@]([H])(O8)[C@@]5([H])O4)CC1)O3)O2 |THB:43:44:51.53:48.49.56.58,50:49:44:51.53,50:51:44:48.49.56.58,53:54:46.48.49.58:41.43.59,59:56:44:51.53|	Launched
ERK5-IN-1	MAP kinase inhibitor	MAPK7			MedChemEx, MedChemEx, MedChemEx	87.52	COc1cc(ccc1Nc1ncc2N(C)C(=O)c3ccccc3N(C)c2n1)N1CCN(C)CC1, COc1cc(ccc1Nc1ncc2N(C)C(=O)c3ccccc3N(C)c2n1)N1CCN(C)CC1, COc1cc(ccc1Nc1ncc2N(C)C(=O)c3ccccc3N(C)c2n1)N1CCN(C)CC1	Preclinical
erlotinib	EGFR inhibitor	EGFR, NR1I2	oncology	non-small cell lung cancer (NSCLC), pancreatic cancer	Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck	99.27	COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC, COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC, COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC, COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC, COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC, COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC, COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC, COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC, COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC, COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC, COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC, COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC, COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC, COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC, COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC, COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC, COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC	Launched
ertapenem	bacterial cell wall synthesis inhibitor		infectious disease	intra-abdominal infections, skin infections, pneumonia, urinary tract infections, gynecologic infections, postpartum endomyometritis	SantaCruz	0	C[C@@H](O)[C@H]1[C@H]2[C@@H](C)C(S[C@@H]3CN[C@@H](C3)C(=O)Nc3cccc(c3)C(O)=O)=C(N2C1=O)C(O)=O |a:1,4,5,9,12,&1:3,c:27|	Launched
erteberel	estrogen receptor agonist	ESR1, ESR2			Selleck, Selleck	97.54	Oc1ccc(cc1)[C@@H]1Oc2ccc(O)cc2[C@@H]2CCC[C@H]12, Oc1ccc(cc1)[C@@H]1Oc2ccc(O)cc2[C@@H]2CCC[C@H]12	Phase 2
ertugliflozin	sodium/glucose cotransporter inhibitor	SLC5A2	endocrinology	diabetes mellitus	MedChemEx	97.81	CCOc1ccc(Cc2cc(ccc2Cl)[C@]23OC[C@](CO)(O2)[C@@H](O)[C@H](O)[C@H]3O)cc1	Launched
erythritol					MedChemEx, MedChemEx, Selleck, Selleck	100	OC[C@H](O)[C@H](O)CO, OC[C@H](O)[C@H](O)CO, OC[C@H](O)[C@H](O)CO, OC[C@H](O)[C@H](O)CO	Launched
erythromycin	NFkB pathway inhibitor	MLNR	infectious disease	listeria, respiratory tract infections, skin infections, syphilis, amebiasis, pelvic inflammatory disease, chlamydia, diphtheria, erythrasma	MedChemEx, MicroSource, MicroSource, Selleck, Selleck	88.23	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O	Launched
erythromycin-estolate	bacterial 50S ribosomal subunit inhibitor	ABCB1, ALB, CYP3A4, CYP51A1, KCNH2, MLNR, SLC47A1	infectious disease	listeria, respiratory tract infections, skin infections, syphilis, amebiasis, pelvic inflammatory disease, chlamydia, diphtheria, erythrasma	AlfaAesar, MicroSource	66.36	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2OC(=O)CC)N(C)C)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2OC(=O)CC)N(C)C)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O	Launched
erythromycin-ethylsuccinate	cytochrome P450 inhibitor, protein synthesis inhibitor	ABCB1, ALB, CYP3A4, CYP51A1, KCNH2, MLNR, SLC47A1	infectious disease	listeria, respiratory tract infections, skin infections, syphilis, amebiasis, pelvic inflammatory disease, chlamydia, diphtheria, erythrasma	MedChemEx, MicroSource, Selleck, Selleck	93.05	CCOC(=O)CCC(=O)O[C@H]1[C@H](O[C@@H]2[C@@H](C)[C@H](O[C@H]3C[C@@](C)(OC)[C@@H](O)[C@H](C)O3)[C@@H](C)C(=O)O[C@H](CC)[C@@](C)(O)[C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@]2(C)O)O[C@H](C)C[C@@H]1N(C)C, CCOC(=O)CCC(=O)O[C@H]1[C@H](O[C@@H]2[C@@H](C)[C@H](O[C@H]3C[C@@](C)(OC)[C@@H](O)[C@H](C)O3)[C@@H](C)C(=O)O[C@H](CC)[C@@](C)(O)[C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@]2(C)O)O[C@H](C)C[C@@H]1N(C)C, CCOC(=O)CCC(=O)O[C@H]1[C@H](O[C@@H]2[C@@H](C)[C@H](O[C@H]3C[C@@](C)(OC)[C@@H](O)[C@H](C)O3)[C@@H](C)C(=O)O[C@H](CC)[C@@](C)(O)[C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@]2(C)O)O[C@H](C)C[C@@H]1N(C)C, CCOC(=O)CCC(=O)O[C@H]1[C@H](O[C@@H]2[C@@H](C)[C@H](O[C@H]3C[C@@](C)(OC)[C@@H](O)[C@H](C)O3)[C@@H](C)C(=O)O[C@H](CC)[C@@](C)(O)[C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@]2(C)O)O[C@H](C)C[C@@H]1N(C)C	Launched
erythrosine	coloring agent				MedChemEx	92.35	Oc1c(I)cc2c(Oc3c(I)c(O)c(I)cc3C22OC(=O)c3ccccc23)c1I	Preclinical
esaprazole					Enamine, Enamine	89.47	O=C(CN1CCNCC1)NC1CCCCC1, O=C(CN1CCNCC1)NC1CCCCC1	Phase 2
esaxerenone	mineralocorticoid receptor antagonist				MedChemEx	95.72	Cc1c(cn(CCO)c1-c1ccccc1C(F)(F)F)C(=O)Nc1ccc(cc1)S(C)(=O)=O	Preclinical
escin	nitric oxide synthase stimulant		dermatology	varicose veins	Sigma	34.39	CC=C(C)C(=O)O[C@H]1[C@H](OC(C)=O)[C@]2(CO)[C@H](O)C[C@]3(C)C(=CC[C@@H]4[C@@]5(C)CC[C@H](O[C@@H]6O[C@@H]([C@@H](O[C@@H]7O[C@H](CO)[C@@H](O)[C@H](O)[C@H]7O)[C@H](O)[C@H]6O[C@@H]6O[C@H](CO)[C@@H](O)[C@H](O)[C@H]6O)C(O)=O)[C@](C)(CO)[C@@H]5CC[C@@]34C)[C@@H]2CC1(C)C |c:21|	Launched
escitalopram	selective serotonin reuptake inhibitor (SSRI)	SLC6A4	neurology/psychiatry	depression, generalized anxiety disorder (GAD)	MicroSource, MicroSource, Tocris, Tocris, Selleck	98.5	CN(C)CCC[C@]1(OCc2cc(ccc12)C#N)c1ccc(F)cc1, CN(C)CCC[C@]1(OCc2cc(ccc12)C#N)c1ccc(F)cc1, CN(C)CCC[C@]1(OCc2cc(ccc12)C#N)c1ccc(F)cc1, CN(C)CCC[C@]1(OCc2cc(ccc12)C#N)c1ccc(F)cc1, OC(=O)C(O)=O.CN(C)CCC[C@]1(OCc2cc(ccc12)C#N)c1ccc(F)cc1 |&1:12,r|	Launched
esculin	antioxidant				Selleck	89.73	OC[C@H]1O[C@@H](Oc2cc3ccc(=O)oc3cc2O)[C@H](O)[C@@H](O)[C@@H]1O	Phase 1
eseroline-(-)	acetylcholinesterase inhibitor	OPRD1, OPRM1			Prestwick	0	CN1CC[C@]2(C)[C@H]1N(C)c1ccc(O)cc21	Preclinical
ESI-09	EPAC inhibitor	RAPGEF3, RAPGEF4			MedChemEx, Tocris	96.93	CC(C)(C)c1cc(no1)C(=O)C(=N\Nc1cccc(Cl)c1)\C#N, CC(C)(C)c1cc(no1)C(=O)C(=N\Nc1cccc(Cl)c1)\C#N	Preclinical
eslicarbazepine-acetate	sodium channel blocker	SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A	neurology/psychiatry	seizures	MedChemEx, MedChemEx	99.86	CC(=O)O[C@H]1Cc2ccccc2N(C(N)=O)c2ccccc12, CC(=O)O[C@H]1Cc2ccccc2N(C(N)=O)c2ccccc12	Launched
esmolol	adrenergic receptor antagonist	ADRB1	cardiology	ventricular tachycardia (VT), hypertension	MedChemEx, MedChemEx	96.13	COC(=O)CCc1ccc(OC[C@@H](O)CNC(C)C)cc1 |&1:12,r|, COC(=O)CCc1ccc(OC[C@@H](O)CNC(C)C)cc1 |&1:12,r|	Launched
esomeprazole	ATPase inhibitor	ATP4A	gastroenterology	gastroesophageal reflux disease (GERD), Zollinger-Ellison syndrome, peptic ulcer disease (PUD)	Selleck, MicroSource, Selleck, MedChemEx	98.67	COc1ccc2nc([nH]c2c1)[S@@](=O)Cc1ncc(C)c(OC)c1C, COc1ccc2nc([nH]c2c1)[S@@](=O)Cc1ncc(C)c(OC)c1C, COc1ccc2nc([nH]c2c1)[S@@](=O)Cc1ncc(C)c(OC)c1C, COc1ccc2nc([nH]c2c1)[S@@](=O)Cc1ncc(C)c(OC)c1C	Launched
esonarimod	antirheumatic drug				MedChemEx	96.22	CC(=O)SC[C@H](CC(=O)c1ccc(C)cc1)C(O)=O |&1:5,r|	Preclinical
estetrol	selective estrogen receptor modulator (SERM)	ESR1			Sigma	86.38	C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1[C@@H](O)[C@@H](O)[C@@H]2O	Phase 3
estradiol	estrogen receptor agonist	ESR1, ESR2, GPER1, KCNMA1, NR1I2	endocrinology	contraceptive	MicroSource, MicroSource, MicroSource, MicroSource, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck	93.41	C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O, C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O, C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O, C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O, C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O, C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O, C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O, C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O, C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O, C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O	Launched
estradiol-acetate	estrogen receptor agonist	ESR1	endocrinology, obstetrics/gynecology	menopause, vaginal atrophy	Sigma	96.27	CC(=O)Oc1ccc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2c1	Launched
estradiol-benzoate	contraceptive agent	ESR1			MedChemEx	87.32	C[C@]12CC[C@H]3[C@@H](CCc4cc(OC(=O)c5ccccc5)ccc34)[C@@H]1CC[C@@H]2O	Preclinical
estradiol-cypionate	estrogen receptor agonist	ESR1	endocrinology	hypoestrogenism, menopause	MedChemEx	97.01	C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2OC(=O)CCC1CCCC1	Launched
estradiol-valerate	estrogen receptor agonist	ESR1	oncology, endocrinology, obstetrics/gynecology	prostate cancer, hypoestrogenism, menopause, vaginal atrophy	MedChemEx, MicroSource, MicroSource, MicroSource, Selleck, Selleck, Selleck	96.27	CCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCc4cc(O)ccc4[C@H]3CC[C@]12C, CCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCc4cc(O)ccc4[C@H]3CC[C@]12C, CCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCc4cc(O)ccc4[C@H]3CC[C@]12C, CCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCc4cc(O)ccc4[C@H]3CC[C@]12C, CCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCc4cc(O)ccc4[C@H]3CC[C@]12C, CCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCc4cc(O)ccc4[C@H]3CC[C@]12C, CCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCc4cc(O)ccc4[C@H]3CC[C@]12C	Launched
estradiol-3-O-sulfamate	steryl sulfatase inhibitor				MedChemEx	81.52	C[C@]12CC[C@H]3[C@@H](CCc4cc(OS(N)(=O)=O)ccc34)[C@@H]1CC[C@@H]2O	Phase 2
estramustine	DNA alkylating agent	ESR1, ESR2, MAP1A, MAP2	oncology	prostate cancer		0		Launched
estramustine-phosphate	DNA synthesis inhibitor, microtubule inhibitor	ESR1, ESR2, MAP1A, MAP2	oncology	prostate cancer	Enzo, MedChemEx, MedChemEx	93.37	C[C@]12CC[C@H]3[C@@H](CCc4cc(OC(=O)N(CCCl)CCCl)ccc34)[C@@H]1CC[C@@H]2OP(O)(O)=O, C[C@]12CC[C@H]3[C@@H](CCc4cc(OC(=O)N(CCCl)CCCl)ccc34)[C@@H]1CC[C@@H]2OP(O)(O)=O, C[C@]12CC[C@H]3[C@@H](CCc4cc(OC(=O)N(CCCl)CCCl)ccc34)[C@@H]1CC[C@@H]2OP(O)(O)=O	Launched
estriol	estrogen receptor agonist	ESR1, ESR2	endocrinology, obstetrics/gynecology, infectious disease	menopause, vaginal atrophy, urinary tract infections	MedChemEx, MicroSource, Selleck, Selleck	88.19	C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1C[C@@H](O)[C@@H]2O, C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1C[C@@H](O)[C@@H]2O, C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1C[C@@H](O)[C@@H]2O, C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1C[C@@H](O)[C@@H]2O	Launched
estrone	estrogen receptor agonist, estrogenic hormone	ESR1, ESR2	endocrinology	menopause	MedChemEx, MicroSource, Selleck, Selleck, Selleck, Selleck	95.52	C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CCC2=O, C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CCC2=O, C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CCC2=O, C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CCC2=O, C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CCC2=O, C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CCC2=O	Launched
estropipate	estrogen receptor agonist	ESR1, ESR2	orthopedics, endocrinology, obstetrics/gynecology	osteoporosis, menopause, vaginal atrophy, hypoestrogenism	Tocris	90.34	C[C@]12CC[C@H]3[C@@H](CCc4cc(OS(O)(=O)=O)ccc34)[C@@H]1CCC2=O	Launched
etacrynic-acid	sodium/potassium/chloride transporter inhibitor	ATP1A1, SLC12A1	cardiology, gastroenterology, nephrology, rheumatology	hypertension, congestive heart failure, edema, hepatic cirrhosis, chronic renal failure, nephrotic syndrome	MedChemEx, MedChemEx, MicroSource	98.7	CCC(=C)C(=O)c1ccc(OCC(O)=O)c(Cl)c1Cl, CCC(=C)C(=O)c1ccc(OCC(O)=O)c(Cl)c1Cl, CCC(=C)C(=O)c1ccc(OCC(O)=O)c(Cl)c1Cl	Launched
etafenone	calcium channel blocker				Vitas-M, Vitas-M, Vitas-M, Vitas-M, Vitas-M, Vitas-M	100	CCN(CC)CCOc1ccccc1C(=O)CCc1ccccc1, CCN(CC)CCOc1ccccc1C(=O)CCc1ccccc1, CCN(CC)CCOc1ccccc1C(=O)CCc1ccccc1, CCN(CC)CCOc1ccccc1C(=O)CCc1ccccc1, CCN(CC)CCOc1ccccc1C(=O)CCc1ccccc1, CCN(CC)CCOc1ccccc1C(=O)CCc1ccccc1	Launched
etamsylate	hemostatic agent		hematology	hemorrhage	MedChemEx, MedChemEx, Selleck, Selleck	100	Oc1ccc(O)c(c1)S(O)(=O)=O, Oc1ccc(O)c(c1)S(O)(=O)=O, Oc1ccc(O)c(c1)S(O)(=O)=O, Oc1ccc(O)c(c1)S(O)(=O)=O	Launched
etanidazole	bacterial cell wall synthesis inhibitor				Prestwick, Toronto	100	OCCNC(=O)Cn1ccnc1[N+]([O-])=O, OCCNC(=O)Cn1ccnc1[N+]([O-])=O	Phase 3
etazolate	phosphodiesterase inhibitor	GABRB3, PDE4A			Tocris, Tocris, Tocris	91.77	CCOC(=O)c1cnc2n(CC)ncc2c1NN=C(C)C, CCOC(=O)c1cnc2n(CC)ncc2c1NN=C(C)C, CCOC(=O)c1cnc2n(CC)ncc2c1NN=C(C)C	Phase 2
ETC-159	beta catenin inhibitor, porcupine inhibitor	PORCN			MedChemEx	97.74	Cn1c2ncn(CC(=O)Nc3ccc(nn3)-c3ccccc3)c2c(=O)n(C)c1=O	Phase 1
ETC-206	MAPK-interacting kinase inhibitor				MedChemEx	97.55	O=C(N1CCOCC1)c1ccc(cc1)-c1ccc2ncc(-c3ccc(cc3)C#N)n2c1	Phase 1
etebenecid	uricosuric blocker				MicroSource	98.34	CCN(CC)S(=O)(=O)c1ccc(cc1)C(O)=O	Preclinical
eterobarb	anticonvulsant				Vitas-M, Vitas-M	94.62	CCC1(C(=O)N(COC)C(=O)N(COC)C1=O)c1ccccc1, CCC1(C(=O)N(COC)C(=O)N(COC)C1=O)c1ccccc1	Phase 2
ethacizin	anticonvulsant		cardiology	ventricular tachycardia (VT), Wolff-Parkinson-White Syndrome (WPW)	Vitas-M, Vitas-M	97.95	CCOC(=O)Nc1ccc2Sc3ccccc3N(C(=O)CCN(CC)CC)c2c1, CCOC(=O)Nc1ccc2Sc3ccccc3N(C(=O)CCN(CC)CC)c2c1	Launched
ethacridine-lactate-monohydrate	DNA intercalating agent				MicroSource, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck	91.12	CCOc1ccc2nc3cc(N)ccc3c(N)c2c1, CCOc1ccc2nc3cc(N)ccc3c(N)c2c1, CCOc1ccc2nc3cc(N)ccc3c(N)c2c1, CCOc1ccc2nc3cc(N)ccc3c(N)c2c1, CCOc1ccc2nc3cc(N)ccc3c(N)c2c1, CCOc1ccc2nc3cc(N)ccc3c(N)c2c1, CCOc1ccc2nc3cc(N)ccc3c(N)c2c1, CCOc1ccc2nc3cc(N)ccc3c(N)c2c1	Preclinical
ethambutol	bacterial cell wall synthesis inhibitor		infectious disease	tuberculosis	MicroSource, MedChemEx, Selleck	100	CC[C@@H](CO)NCCN[C@@H](CC)CO, CC[C@@H](CO)NCCN[C@@H](CC)CO, CC[C@@H](CO)NCCN[C@@H](CC)CO	Launched
ethamivan	respiratory stimulant				Sigma, MicroSource	87.48	CCN(CC)C(=O)c1ccc(O)c(OC)c1, CCN(CC)C(=O)c1ccc(O)c(OC)c1	Preclinical
ethanolamine-oleate	immunostimulant	F12, FABP4, FFAR1, FFAR4, PLD2	gastroenterology	esophageal varices	MicroSource	0	NCCO.CCCCCCCC\C=C/CCCCCCCC(O)=O	Launched
ethaverine	calcium channel blocker		neurology/psychiatry	muscle relaxant, spasms	MicroSource, Toronto	99.19	CCOc1ccc(Cc2nccc3cc(OCC)c(OCC)cc23)cc1OCC, CCOc1ccc(Cc2nccc3cc(OCC)c(OCC)cc23)cc1OCC	Launched
ethenzamide	analgesic agent		neurology/psychiatry, endocrinology, otolaryngology	headache, fever, common cold	MedChemEx, MicroSource, MicroSource	99.07	CCOc1ccccc1C(N)=O, CCOc1ccccc1C(N)=O, CCOc1ccccc1C(N)=O	Launched
ethimizol					MedChemEx, MedChemEx	99.78	CCn1cnc(C(=O)NC)c1C(=O)NC, CCn1cnc(C(=O)NC)c1C(=O)NC	Phase 1
ethinyl-estradiol	estrogen receptor agonist, estrogenic hormone	ESR1, ESR2, NR1I2	endocrinology	contraceptive	MicroSource, MicroSource, MicroSource, MicroSource, Selleck, Selleck	96.04	C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@]2(O)C#C, C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@]2(O)C#C, C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@]2(O)C#C, C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@]2(O)C#C, C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@]2(O)C#C, C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@]2(O)C#C	Launched
ethionamide	mycolic synthesis inhibitor		infectious disease	tuberculosis	MicroSource, Selleck, MedChemEx	98.1	CCc1cc(ccn1)C(N)=S, CCc1cc(ccn1)C(N)=S, CCc1cc(ccn1)C(N)=S	Launched
ethisterone	progestogen hormone	TYR	endocrinology	amenorrhea	Selleck, MedChemEx, Selleck	83.11	C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@]2(O)C#C |t:8|, C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@]2(O)C#C |t:8|, C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@]2(O)C#C |t:8|	Launched
ethopabate	antiprotozoal agent		infectious disease	coccidiosis	MicroSource, MedChemEx, MedChemEx	97.78	CCOc1cc(NC(C)=O)ccc1C(=O)OC, CCOc1cc(NC(C)=O)ccc1C(=O)OC, CCOc1cc(NC(C)=O)ccc1C(=O)OC	Launched
ethosuximide	succinimide antiepileptic	CACNA1G, CACNA1H, CACNA1I	neurology/psychiatry	epilepsy	Sigma, MicroSource	99.47	CC[C@@]1(C)CC(=O)NC1=O |&1:2,r|, CC[C@@]1(C)CC(=O)NC1=O |&1:2,r|	Launched
ethotoin	hydantoin antiepileptic	SCN5A	neurology/psychiatry	seizures	MicroSource, AMS, AMS	97.23	CCN1C(=O)N[C@@H](C1=O)c1ccccc1 |r|, CCN1C(=O)N[C@@H](C1=O)c1ccccc1 |r|, CCN1C(=O)N[C@@H](C1=O)c1ccccc1 |r|	Launched
ethoxyquin	antioxidant				MedChemEx, Prestwick	93.42	CCOc1ccc2NC(C)(C)C=C(C)c2c1 |t:11|, CCOc1ccc2NC(C)(C)C=C(C)c2c1 |t:11|	Preclinical
ethoxzolamide	carbonic anhydrase inhibitor	CA1, CA12, CA13, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9	ophthalmology, gastroenterology	glaucoma, duodenal ulcer disease	MicroSource, Selleck, Selleck	96.7	CCOc1ccc2nc(sc2c1)S(N)(=O)=O, CCOc1ccc2nc(sc2c1)S(N)(=O)=O, CCOc1ccc2nc(sc2c1)S(N)(=O)=O	Launched
ethyl-paraben					MedChemEx, MicroSource	99.39	CCOC(=O)c1ccc(O)cc1, CCOC(=O)c1ccc(O)cc1	Preclinical
ethyl-pyruvate	tumor necrosis factor production inhibitor				Sigma, Sigma	0	CCOC(=O)C(O)=C, CCOC(=O)C(O)=C	Phase 2
ethyl-vanillin					MedChemEx, MicroSource	97.9	CCOc1cc(C=O)ccc1O, CCOc1cc(C=O)ccc1O	Preclinical
ethyl-2-(carbamoyloxy)benzoate					Enamine	0	CCOC(=O)c1ccccc1OC(N)=O	Phase 1
ethylenediaminetetraacetic-acid	PKC inhibitor		neurology/psychiatry	metal toxicity	MicroSource, MedChemEx	100	OC(=O)CN(CCN(CC(O)=O)CC(O)=O)CC(O)=O, OC(=O)CN(CCN(CC(O)=O)CC(O)=O)CC(O)=O	Launched
ethylnorepinephrine	bronchodilator				MicroSource	95.14	CC[C@@H](N)[C@@H](O)c1ccc(O)c(O)c1 |&1:2,&2:4|	Preclinical
ethynodiol-diacetate		ESR1, PGR	endocrinology	contraceptive	MedChemEx, MicroSource, MicroSource, Selleck, Selleck	99.51	CC(=O)O[C@H]1CC[C@@H]2[C@H]3CC[C@@]4(C)[C@@H](CC[C@@]4(OC(C)=O)C#C)[C@@H]3CCC2=C1 |c:29|, CC(=O)O[C@H]1CC[C@@H]2[C@H]3CC[C@@]4(C)[C@@H](CC[C@@]4(OC(C)=O)C#C)[C@@H]3CCC2=C1 |c:29|, CC(=O)O[C@H]1CC[C@@H]2[C@H]3CC[C@@]4(C)[C@@H](CC[C@@]4(OC(C)=O)C#C)[C@@H]3CCC2=C1 |c:29|, CC(=O)O[C@H]1CC[C@@H]2[C@H]3CC[C@@]4(C)[C@@H](CC[C@@]4(OC(C)=O)C#C)[C@@H]3CCC2=C1 |c:29|, CC(=O)O[C@H]1CC[C@@H]2[C@H]3CC[C@@]4(C)[C@@H](CC[C@@]4(OC(C)=O)C#C)[C@@H]3CCC2=C1 |c:29|	Launched
ethynylcytidine	antimetabolite				MedChemEx	88.5	Nc1ccn([C@@H]2O[C@H](CO)[C@](O)(C#C)[C@H]2O)c(=O)n1	Preclinical
eticlopride	dopamine receptor antagonist	DRD2, DRD3, DRD4			Tocris, Tocris, Tocris	98.13	CCN1CCC[C@H]1CNC(=O)c1c(O)c(CC)cc(Cl)c1OC, CCN1CCC[C@H]1CNC(=O)c1c(O)c(CC)cc(Cl)c1OC, CCN1CCC[C@H]1CNC(=O)c1c(O)c(CC)cc(Cl)c1OC	Preclinical
etidronic-acid	bone resorption inhibitor	ATP6V1A, PTPRS	endocrinology, orthopedics	Paget's disease, heterotopic ossification	MicroSource, MedChemEx, Selleck, Selleck, Selleck	100	CC(O)(P(O)(O)=O)P(O)(O)=O, CC(O)(P(O)(O)=O)P(O)(O)=O, CC(O)(P(O)(O)=O)P(O)(O)=O, CC(O)(P(O)(O)=O)P(O)(O)=O, CC(O)(P(O)(O)=O)P(O)(O)=O	Launched
etifenin	renal function diagnostic agent				CombiBlocks, Prestwick	90.72	CCc1cccc(CC)c1NC(=O)CN(CC(O)=O)CC(O)=O, CCc1cccc(CC)c1NC(=O)CN(CC(O)=O)CC(O)=O	Preclinical
etifoxine	GABA receptor modulator	GABRA1, GABRA2, GABRA3, GABRA5	neurology/psychiatry	anxiety	MedChemEx	98.68	CCNC1=Nc2ccc(Cl)cc2[C@@](C)(O1)c1ccccc1 |&1:12,r,t:3|	Launched
etilefrine	adrenergic receptor agonist	ADRA1A, ADRB1	neurology/psychiatry, otolaryngology, endocrinology, pulmonary	headache, nasal congestion, fever, cough suppressant, common cold	Prestwick	88.17	CCNCC(O)c1cccc(O)c1	Launched
etilevodopa	dopamine receptor agonist	DRD3			Enamine, Sigma, Sigma	95.55	CCOC(=O)[C@@H](N)Cc1ccc(O)c(O)c1, CCOC(=O)[C@@H](N)Cc1ccc(O)c(O)c1, CCOC(=O)[C@@H](N)Cc1ccc(O)c(O)c1	Phase 3
etizolam	benzodiazepine receptor agonist	GABRA1	neurology/psychiatry	insomnia, anxiety	MedChemEx, MedChemEx, MedChemEx, MedChemEx	99.78	CCc1cc2c(s1)-n1c(C)nnc1CN=C2c1ccccc1Cl |c:16|, CCc1cc2c(s1)-n1c(C)nnc1CN=C2c1ccccc1Cl |c:16|, CCc1cc2c(s1)-n1c(C)nnc1CN=C2c1ccccc1Cl |c:16|, CCc1cc2c(s1)-n1c(C)nnc1CN=C2c1ccccc1Cl |c:16|	Launched
etodolac	cyclooxygenase inhibitor	PTGS2	rheumatology	osteoarthritis, rheumatoid arthritis	Selleck, MicroSource, Tocris	99.16	CCc1cccc2c3CCO[C@@](CC)(CC(O)=O)c3[nH]c12 |&1:11,r|, CCc1cccc2c3CCO[C@@](CC)(CC(O)=O)c3[nH]c12 |&1:11,r|, CCc1cccc2c3CCO[C@@](CC)(CC(O)=O)c3[nH]c12 |&1:11,r|	Launched
etofenamate	cyclooxygenase inhibitor	PTGS1, PTGS2	neurology/psychiatry, rheumatology	muscle pain, joint pain	MedChemEx, MedChemEx	98.02	OCCOCCOC(=O)c1ccccc1Nc1cccc(c1)C(F)(F)F, OCCOCCOC(=O)c1ccccc1Nc1cccc(c1)C(F)(F)F	Launched
etofibrate	PPAR receptor agonist	PPARA	endocrinology	hypertriglyceridemia	Selleck	95.38	CC(C)(Oc1ccc(Cl)cc1)C(=O)OCCOC(=O)c1cccnc1	Launched
etofylline	adenosine receptor antagonist	ADORA1	pulmonary	asthma, bronchitis	MedChemEx, MedChemEx, Enzo, Enzo, Enzo	99.1	Cn1c2ncn(CCO)c2c(=O)n(C)c1=O, Cn1c2ncn(CCO)c2c(=O)n(C)c1=O, Cn1c2ncn(CCO)c2c(=O)n(C)c1=O, Cn1c2ncn(CCO)c2c(=O)n(C)c1=O, Cn1c2ncn(CCO)c2c(=O)n(C)c1=O	Launched
etofylline-clofibrate	platelet aggregation inhibitor	PPARA	endocrinology	hyperlipidemia	Enamine, Enamine, SantaCruz	99.43	Cn1c2ncn(CCOC(=O)C(C)(C)Oc3ccc(Cl)cc3)c2c(=O)n(C)c1=O, Cn1c2ncn(CCOC(=O)C(C)(C)Oc3ccc(Cl)cc3)c2c(=O)n(C)c1=O, Cn1c2ncn(CCOC(=O)C(C)(C)Oc3ccc(Cl)cc3)c2c(=O)n(C)c1=O	Launched
etomidate	GABA receptor modulator	ADRA2B, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ	neurology/psychiatry	general anaesthetic	MicroSource, Selleck, Tocris	95.99	CCOC(=O)c1cncn1[C@H](C)c1ccccc1, CCOC(=O)c1cncn1[C@H](C)c1ccccc1, CCOC(=O)c1cncn1[C@H](C)c1ccccc1	Launched
etomoxir	carnitine palmitoyltransferase inhibitor	CPT1A			MedChemEx, MedChemEx	98.66	CCOC(=O)[C@@]1(CCCCCCOc2ccc(Cl)cc2)CO1, CCOC(=O)[C@@]1(CCCCCCOc2ccc(Cl)cc2)CO1	Phase 2
etonogestrel	progesterone receptor agonist	ESR1, PGR	endocrinology	contraceptive	MedChemEx	76.12	[H][C@@]12CC[C@@](O)(C#C)[C@@]1(CC)CC(=C)[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H] |c:23|	Launched
etoposide	topoisomerase inhibitor	TOP2A, TOP2B	oncology	non-small cell lung cancer (NSCLC)	Tocris, MedChemEx, Selleck, MicroSource, MicroSource, Selleck, Tocris	99.86	COc1cc(cc(OC)c1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@@H](C)O[C@H]3[C@H](O)[C@H]2O)c2cc3OCOc3cc12, COc1cc(cc(OC)c1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@@H](C)O[C@H]3[C@H](O)[C@H]2O)c2cc3OCOc3cc12, COc1cc(cc(OC)c1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@@H](C)O[C@H]3[C@H](O)[C@H]2O)c2cc3OCOc3cc12, COc1cc(cc(OC)c1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@@H](C)O[C@H]3[C@H](O)[C@H]2O)c2cc3OCOc3cc12, COc1cc(cc(OC)c1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@@H](C)O[C@H]3[C@H](O)[C@H]2O)c2cc3OCOc3cc12, COc1cc(cc(OC)c1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@@H](C)O[C@H]3[C@H](O)[C@H]2O)c2cc3OCOc3cc12, COc1cc(cc(OC)c1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@@H](C)O[C@H]3[C@H](O)[C@H]2O)c2cc3OCOc3cc12	Launched
etoposide-phosphate	topoisomerase inhibitor	TOP2A	oncology	testicular carcinoma, small cell lung cancer	ChemImpex, ChemImpex, ChemImpex	94.37	COc1cc(cc(OC)c1OP(O)(O)=O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@@H](C)O[C@H]3[C@H](O)[C@H]2O)c2cc3OCOc3cc12, COc1cc(cc(OC)c1OP(O)(O)=O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@@H](C)O[C@H]3[C@H](O)[C@H]2O)c2cc3OCOc3cc12, COc1cc(cc(OC)c1OP(O)(O)=O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@@H](C)O[C@H]3[C@H](O)[C@H]2O)c2cc3OCOc3cc12	Launched
etoricoxib	cyclooxygenase inhibitor	PTGS2	rheumatology	rheumatoid arthritis, psoriatic arthritis, osteoarthritis, gout, ankylosing spondylitis	MedChemEx, MedChemEx	99.25	Cc1ccc(cn1)-c1ncc(Cl)cc1-c1ccc(cc1)S(C)(=O)=O, Cc1ccc(cn1)-c1ncc(Cl)cc1-c1ccc(cc1)S(C)(=O)=O	Launched
etosalamide	anti-inflammatory agent				MicroSource, MedChemEx	95.92	CCOCCOc1ccccc1C(N)=O, CCOCCOc1ccccc1C(N)=O	Preclinical
etoxybamide					Sigma	69.8	OCCCC(=O)NCCO	Phase 2
ETP-45658	PI3K inhibitor	PIK3CA, PIK3CB, PIK3CD, PIK3CG			Tocris, Tocris, Tocris	97.88	Cn1ncc2c(nc(nc12)-c1cccc(O)c1)N1CCOCC1, Cn1ncc2c(nc(nc12)-c1cccc(O)c1)N1CCOCC1, Cn1ncc2c(nc(nc12)-c1cccc(O)c1)N1CCOCC1	Preclinical
ETP-46464	ATR kinase inhibitor				Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, CNIO, CNIO, CNIO	98.25	CC(C)(C#N)c1ccc(cc1)N1C(=O)OCc2cnc3ccc(cc3c12)-c1cnc2ccccc2c1, CC(C)(C#N)c1ccc(cc1)N1C(=O)OCc2cnc3ccc(cc3c12)-c1cnc2ccccc2c1, CC(C)(C#N)c1ccc(cc1)N1C(=O)OCc2cnc3ccc(cc3c12)-c1cnc2ccccc2c1, CC(C)(C#N)c1ccc(cc1)N1C(=O)OCc2cnc3ccc(cc3c12)-c1cnc2ccccc2c1, CC(C)(C#N)c1ccc(cc1)N1C(=O)OCc2cnc3ccc(cc3c12)-c1cnc2ccccc2c1, CC(C)(C#N)c1ccc(cc1)N1C(=O)OCc2cnc3ccc(cc3c12)-c1cnc2ccccc2c1, CC(C)(C#N)c1ccc(cc1)N1C(=O)OCc2cnc3ccc(cc3c12)-c1cnc2ccccc2c1, CC(C)(C#N)c1ccc(cc1)N1C(=O)OCc2cnc3ccc(cc3c12)-c1cnc2ccccc2c1, CC(C)(C#N)c1ccc(cc1)N1C(=O)OCc2cnc3ccc(cc3c12)-c1cnc2ccccc2c1, CC(C)(C#N)c1ccc(cc1)N1C(=O)OCc2cnc3ccc(cc3c12)-c1cnc2ccccc2c1, CC(C)(C#N)c1ccc(cc1)N1C(=O)OCc2cnc3ccc(cc3c12)-c1cnc2ccccc2c1	Preclinical
etrabamine	dopamine receptor agonist				Enamine	100	CN[C@H]1CCc2ncsc2C1 |&1:2,r|	Phase 2
etrasimod	sphingosine 1-phosphate receptor antagonist				MedChemEx	95.59	OC(=O)C[C@H]1CCc2c1[nH]c1ccc(OCc3ccc(C4CCCC4)c(c3)C(F)(F)F)cc21	Phase 3
etravirine	non-nucleoside reverse transcriptase inhibitor	CYP2C19, CYP2C9, CYP3A4	infectious disease	human immunodeficiency virus (HIV-1)	MedChemEx, Selleck, Selleck, Selleck	97.45	Cc1cc(cc(C)c1Oc1nc(Nc2ccc(cc2)C#N)nc(N)c1Br)C#N, Cc1cc(cc(C)c1Oc1nc(Nc2ccc(cc2)C#N)nc(N)c1Br)C#N, Cc1cc(cc(C)c1Oc1nc(Nc2ccc(cc2)C#N)nc(N)c1Br)C#N, Cc1cc(cc(C)c1Oc1nc(Nc2ccc(cc2)C#N)nc(N)c1Br)C#N	Launched
etretinate	protein synthesis inhibitor	RARA, RXRG			MedChemEx, MedChemEx, Prestwick, MedChemEx	87.97	CCOC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\c1c(C)cc(OC)c(C)c1C, CCOC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\c1c(C)cc(OC)c(C)c1C, CCOC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\c1c(C)cc(OC)c(C)c1C, CCOC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\c1c(C)cc(OC)c(C)c1C	Withdrawn
eucalyptol	acetylcholinesterase inhibitor	ACHE	dental	gingivitis	MicroSource, AMS	0	CC12CCC(CC1)C(C)(C)O2, CC12CCC(CC1)C(C)(C)O2	Launched
eucatropine	acetylcholine receptor antagonist				AMS, Prestwick	54.26	C[C@H]1C[C@@H](CC(C)(C)N1C)OC(=O)[C@@H](O)c1ccccc1 |&1:1,&2:3,&3:13|, C[C@H]1C[C@@H](CC(C)(C)N1C)OC(=O)[C@@H](O)c1ccccc1 |&1:1,&2:3,&3:13|	Preclinical
eugenol	androgen receptor antagonist	AR	dental	toothache	MicroSource, MedChemEx	92.11	COc1cc(CC=C)ccc1O, COc1cc(CC=C)ccc1O	Launched
EUK-134	catalase stimulant	APP, SOD2			Selleck, Selleck, Selleck, Selleck	59.9	COc1cccc2C=[N+]3CC[N+]4=Cc5cccc(OC)c5O[Mn]34(Cl)Oc12 |t:7,11|, COc1cccc2C=[N+]3CC[N+]4=Cc5cccc(OC)c5O[Mn]34(Cl)Oc12 |t:7,11|, COc1cccc2C=[N+]3CC[N+]4=Cc5cccc(OC)c5O[Mn]34(Cl)Oc12 |t:7,11|, COc1cccc2C=[N+]3CC[N+]4=Cc5cccc(OC)c5O[Mn]34(Cl)Oc12 |t:7,11|	Preclinical
eupatilin	mucus protecting agent				MedChemEx, MedChemEx, Astatech	94.26	COc1ccc(cc1OC)-c1cc(=O)c2c(O)c(OC)c(O)cc2o1, COc1ccc(cc1OC)-c1cc(=O)c2c(O)c(OC)c(O)cc2o1, COc1ccc(cc1OC)-c1cc(=O)c2c(O)c(OC)c(O)cc2o1	Launched
evacetrapib	cholesteryl ester transfer protein inhibitor	CETP			MedChemEx, Selleck, Selleck, Selleck	94.86	Cc1cc(C)c2N(C[C@H]3CC[C@@H](CC3)C(O)=O)CCC[C@H](N(Cc3cc(cc(c3)C(F)(F)F)C(F)(F)F)c3nnn(C)n3)c2c1, Cc1cc(C)c2N(C[C@H]3CC[C@@H](CC3)C(O)=O)CCC[C@H](N(Cc3cc(cc(c3)C(F)(F)F)C(F)(F)F)c3nnn(C)n3)c2c1, Cc1cc(C)c2N(C[C@H]3CC[C@@H](CC3)C(O)=O)CCC[C@H](N(Cc3cc(cc(c3)C(F)(F)F)C(F)(F)F)c3nnn(C)n3)c2c1, Cc1cc(C)c2N(C[C@H]3CC[C@@H](CC3)C(O)=O)CCC[C@H](N(Cc3cc(cc(c3)C(F)(F)F)C(F)(F)F)c3nnn(C)n3)c2c1	Phase 3
evans-blue	glutamate receptor negative allosteric modulator	GRIA1, PTPN1			MicroSource, MicroSource, MicroSource, Tocris, Tocris	92.8	Cc1cc(ccc1NN=C1C=Cc2c(cc(c(N)c2C1=O)S(O)(=O)=O)S(O)(=O)=O)-c1ccc(NN=C2C=Cc3c(cc(c(N)c3C2=O)S(O)(=O)=O)S(O)(=O)=O)c(C)c1 |c:11,39|, Cc1cc(ccc1NN=C1C=Cc2c(cc(c(N)c2C1=O)S(O)(=O)=O)S(O)(=O)=O)-c1ccc(NN=C2C=Cc3c(cc(c(N)c3C2=O)S(O)(=O)=O)S(O)(=O)=O)c(C)c1 |c:11,39|, Cc1cc(ccc1NN=C1C=Cc2c(cc(c(N)c2C1=O)S(O)(=O)=O)S(O)(=O)=O)-c1ccc(NN=C2C=Cc3c(cc(c(N)c3C2=O)S(O)(=O)=O)S(O)(=O)=O)c(C)c1 |c:11,39|, Cc1cc(ccc1NN=C1C=Cc2c(cc(c(N)c2C1=O)S(O)(=O)=O)S(O)(=O)=O)-c1ccc(NN=C2C=Cc3c(cc(c(N)c3C2=O)S(O)(=O)=O)S(O)(=O)=O)c(C)c1 |c:11,39|, Cc1cc(ccc1NN=C1C=Cc2c(cc(c(N)c2C1=O)S(O)(=O)=O)S(O)(=O)=O)-c1ccc(NN=C2C=Cc3c(cc(c(N)c3C2=O)S(O)(=O)=O)S(O)(=O)=O)c(C)c1 |c:11,39|	Launched
evatanepag	prostaglandin inhibitor	PTGER2, PTGER4			MedChemEx, MedChemEx	96.84	CC(C)(C)c1ccc(CN(Cc2cccc(OCC(O)=O)c2)S(=O)(=O)c2cccnc2)cc1, CC(C)(C)c1ccc(CN(Cc2cccc(OCC(O)=O)c2)S(=O)(=O)c2cccnc2)cc1	Phase 2
evenamide	voltage-gated sodium channel blocker				Astatech	87.12	CCCCOc1cccc(CCNCC(=O)N(C)C)c1	Phase 2
everolimus	mTOR inhibitor	MTOR	oncology, neurology/psychiatry, genetics, urology	breast cancer, neuroendocrine tumors of pancreatic origin (PNET), renal cell carcinoma (RCC), subependymal giant cell astrocytoma (SEGA), tuberous sclerosis complex (TSC), renal angiomyolipoma	Tocris, Tocris, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck	95.59	CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OCCO |c:14,33,t:29,31|, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OCCO |c:14,33,t:29,31|, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OCCO |c:14,33,t:29,31|, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OCCO |c:14,33,t:29,31|, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OCCO |c:14,33,t:29,31|, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OCCO |c:14,33,t:29,31|, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OCCO |c:14,33,t:29,31|, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OCCO |c:14,33,t:29,31|, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OCCO |c:14,33,t:29,31|, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OCCO |c:14,33,t:29,31|	Launched
evobrutinib	Bruton's tyrosine kinase (BTK) inhibitor				MedChemEx	97.4	Nc1ncnc(NCC2CCN(CC2)C(=O)C=C)c1-c1ccc(Oc2ccccc2)cc1	Phase 2
evocalcet	calcium sensitizer				MedChemEx	96.3	C[C@@H](N[C@H]1CCN(C1)c1ccc(CC(O)=O)cc1)c1cccc2ccccc12	Phase 3
evodiamine	ATPase inhibitor, TRPV agonist	TRPV1			Selleck, Selleck, Selleck, Selleck	99	CN1[C@H]2N(CCc3c2[nH]c2ccccc32)C(=O)c2ccccc12 |&1:2,r|, CN1[C@H]2N(CCc3c2[nH]c2ccccc32)C(=O)c2ccccc12 |&1:2,r|, CN1[C@H]2N(CCc3c2[nH]c2ccccc32)C(=O)c2ccccc12 |&1:2,r|, CN1[C@H]2N(CCc3c2[nH]c2ccccc32)C(=O)c2ccccc12 |&1:2,r|	Preclinical
EVP-6124	acetylcholine receptor agonist	CHRNA7			MedChemEx, MedChemEx, MedChemEx, MedChemEx	95.74	Clc1cccc2cc(sc12)C(=O)N[C@H]1CN2CCC1CC2, Clc1cccc2cc(sc12)C(=O)N[C@H]1CN2CCC1CC2, Clc1cccc2cc(sc12)C(=O)N[C@H]1CN2CCC1CC2, Clc1cccc2cc(sc12)C(=O)N[C@H]1CN2CCC1CC2	Phase 3
EVP4593	NFkB pathway inhibitor				MedChemEx, MedChemEx, Selleck, Selleck	95.8	Nc1ccc2ncnc(NCCc3ccc(Oc4ccccc4)cc3)c2c1, Nc1ccc2ncnc(NCCc3ccc(Oc4ccccc4)cc3)c2c1, Nc1ccc2ncnc(NCCc3ccc(Oc4ccccc4)cc3)c2c1, Nc1ccc2ncnc(NCCc3ccc(Oc4ccccc4)cc3)c2c1	Preclinical
EW-7197	TGF beta receptor inhibitor	ACVR1B, TGFBR1			Selleck, Selleck, Selleck, Selleck, Selleck	89.86	Cc1cccc(n1)-c1nc(CNc2ccccc2F)[nH]c1-c1ccc2ncnn2c1, Cc1cccc(n1)-c1nc(CNc2ccccc2F)[nH]c1-c1ccc2ncnn2c1, Cc1cccc(n1)-c1nc(CNc2ccccc2F)[nH]c1-c1ccc2ncnn2c1, Cc1cccc(n1)-c1nc(CNc2ccccc2F)[nH]c1-c1ccc2ncnn2c1, Cc1cccc(n1)-c1nc(CNc2ccccc2F)[nH]c1-c1ccc2ncnn2c1	Phase 2
EX-527	SIRT inhibitor	SIRT1			Selleck, Selleck, Selleck	94.26	NC(=O)[C@H]1CCCc2c1[nH]c1ccc(Cl)cc21 |&1:3,r|, NC(=O)[C@H]1CCCc2c1[nH]c1ccc(Cl)cc21 |&1:3,r|, NC(=O)[C@H]1CCCc2c1[nH]c1ccc(Cl)cc21 |&1:3,r|	Phase 2
exalamide	membrane permeability inhibitor				MicroSource, MedChemEx	98.99	CCCCCCOc1ccccc1C(N)=O, CCCCCCOc1ccccc1C(N)=O	Launched
examorelin	growth hormone releasing factor agonist	GHRHR, GHSR			Sigma	85.7	C[C@H](NC(=O)[C@@H](Cc1c(C)[nH]c2ccccc12)NC(=O)[C@@H](N)Cc1cnc[nH]1)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@H](Cc1ccccc1)C(=O)N[C@@H](CCCCN)C(N)=O	Phase 2
exatecan-mesylate	topoisomerase inhibitor	TOP1			MedChemEx, MedChemEx, MedChemEx, MedChemEx	91.3	CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4cc(F)c(C)c5CC[C@H](N)c(c3Cn1c2=O)c45, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4cc(F)c(C)c5CC[C@H](N)c(c3Cn1c2=O)c45, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4cc(F)c(C)c5CC[C@H](N)c(c3Cn1c2=O)c45, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4cc(F)c(C)c5CC[C@H](N)c(c3Cn1c2=O)c45	Phase 3
exemestane	aromatase inhibitor	CYP19A1	oncology	breast cancer	Tocris, MicroSource, Selleck, Selleck	98.07	C[C@]12CC[C@H]3[C@@H](CC(=C)C4=CC(=O)C=C[C@]34C)[C@@H]1CCC2=O |c:13,t:9|, C[C@]12CC[C@H]3[C@@H](CC(=C)C4=CC(=O)C=C[C@]34C)[C@@H]1CCC2=O |c:13,t:9|, C[C@]12CC[C@H]3[C@@H](CC(=C)C4=CC(=O)C=C[C@]34C)[C@@H]1CCC2=O |c:13,t:9|, C[C@]12CC[C@H]3[C@@H](CC(=C)C4=CC(=O)C=C[C@]34C)[C@@H]1CCC2=O |c:13,t:9|	Launched
exenatide	GLP receptor agonist	GLP1R	endocrinology	diabetes mellitus	MedChemEx	79.7	[H]N[C@@H](Cc1c[nH]cn1)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(N)=O |r|	Launched
exherin	cadherin antagonist	CDH2			MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx	94.47	CC(C)[C@@H]1NC(=O)[C@H](C)NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)[C@H](CSSC[C@H](NC1=O)C(N)=O)NC(C)=O, CC(C)[C@@H]1NC(=O)[C@H](C)NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)[C@H](CSSC[C@H](NC1=O)C(N)=O)NC(C)=O, CC(C)[C@@H]1NC(=O)[C@H](C)NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)[C@H](CSSC[C@H](NC1=O)C(N)=O)NC(C)=O, CC(C)[C@@H]1NC(=O)[C@H](C)NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)[C@H](CSSC[C@H](NC1=O)C(N)=O)NC(C)=O, CC(C)[C@@H]1NC(=O)[C@H](C)NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)[C@H](CSSC[C@H](NC1=O)C(N)=O)NC(C)=O	Phase 2
exifone	nootropic agent	TYR			Sigma, Enzo	95.11	Oc1ccc(C(=O)c2cc(O)c(O)c(O)c2)c(O)c1O, Oc1ccc(C(=O)c2cc(O)c(O)c(O)c2)c(O)c1O	Withdrawn
exisulind	phosphodiesterase inhibitor	PDE5A			LKT, LKT, LKT	96.77	CC1=C(CC(O)=O)c2cc(F)ccc2\C1=C/c1ccc(cc1)S(C)(=O)=O |c:1|, CC1=C(CC(O)=O)c2cc(F)ccc2\C1=C/c1ccc(cc1)S(C)(=O)=O |c:1|, CC1=C(CC(O)=O)c2cc(F)ccc2\C1=C/c1ccc(cc1)S(C)(=O)=O |c:1|	Phase 3
exo-IWR-1	WNT signaling inhibitor negative control	TNKS			Tocris, Tocris	95.46	O=C(Nc1cccc2cccnc12)c1ccc(cc1)N1C(=O)[C@H]2[C@H]3C[C@H](C=C3)[C@H]2C1=O |c:29|, O=C(Nc1cccc2cccnc12)c1ccc(cc1)N1C(=O)[C@H]2[C@H]3C[C@H](C=C3)[C@H]2C1=O |c:29|	Preclinical
EXO-1	ARF inhibitor				Tocris, Tocris, Tocris	99.03	COC(=O)c1ccccc1NC(=O)c1ccc(F)cc1, COC(=O)c1ccccc1NC(=O)c1ccc(F)cc1, COC(=O)c1ccccc1NC(=O)c1ccc(F)cc1	Preclinical
ezatiostat	glutathione transferase inhibitor	GSTP1			MedChemEx, MedChemEx, MedChemEx, MedChemEx	88.92	CCOC(=O)[C@@H](N)CCC(=O)N[C@@H](CSCc1ccccc1)C(=O)N[C@@H](C(=O)OCC)c1ccccc1, CCOC(=O)[C@@H](N)CCC(=O)N[C@@H](CSCc1ccccc1)C(=O)N[C@@H](C(=O)OCC)c1ccccc1, CCOC(=O)[C@@H](N)CCC(=O)N[C@@H](CSCc1ccccc1)C(=O)N[C@@H](C(=O)OCC)c1ccccc1, CCOC(=O)[C@@H](N)CCC(=O)N[C@@H](CSCc1ccccc1)C(=O)N[C@@H](C(=O)OCC)c1ccccc1	Phase 2
ezetimibe	cholesterol inhibitor, Niemann-Pick C1-like 1 protein antagonist	ANPEP, NPC1L1, SOAT1	endocrinology, metabolism	hyperlipidemia, hypercholesterolemia, sitosterolemia	Adooq, Selleck, Selleck, Selleck, Selleck, MedChemEx, MedChemEx, Selleck	97.97	O[C@@H](CC[C@@H]1[C@H](N(C1=O)c1ccc(F)cc1)c1ccc(O)cc1)c1ccc(F)cc1, O[C@@H](CC[C@@H]1[C@H](N(C1=O)c1ccc(F)cc1)c1ccc(O)cc1)c1ccc(F)cc1, O[C@@H](CC[C@@H]1[C@H](N(C1=O)c1ccc(F)cc1)c1ccc(O)cc1)c1ccc(F)cc1, O[C@@H](CC[C@@H]1[C@H](N(C1=O)c1ccc(F)cc1)c1ccc(O)cc1)c1ccc(F)cc1, O[C@@H](CC[C@@H]1[C@H](N(C1=O)c1ccc(F)cc1)c1ccc(O)cc1)c1ccc(F)cc1, O[C@@H](CC[C@@H]1[C@H](N(C1=O)c1ccc(F)cc1)c1ccc(O)cc1)c1ccc(F)cc1, O[C@@H](CC[C@@H]1[C@H](N(C1=O)c1ccc(F)cc1)c1ccc(O)cc1)c1ccc(F)cc1, O[C@@H](CC[C@@H]1[C@H](N(C1=O)c1ccc(F)cc1)c1ccc(O)cc1)c1ccc(F)cc1	Launched
ezutromid	utrophin enhancer	UTRN			Vitas-M	77.14	CCN(CC)c1ccc(cc1)-n1nc2cc(C)c(N)cc2n1	Phase 2
E3330	NFkB pathway inhibitor				Sigma	79.51	CCCCCCCCC\C(=C/C1=C(C)C(=O)C(OC)=C(OC)C1=O)C(O)=O |c:11,t:18|	Preclinical
E7046	prostanoid receptor antagonist				MedChemEx	97.54	C[C@H](NC(=O)c1c(nn(C)c1Oc1cccc(c1)C(F)(F)F)C(F)F)c1ccc(cc1)C(O)=O	Phase 1
E7449	PARP inhibitor	PARP1, PARP2, TNKS, TNKS2			MedChemEx, MedChemEx, MedChemEx, MedChemEx	94.48	O=c1[nH][nH]c2nc(CN3Cc4ccccc4C3)nc3cccc1c23, O=c1[nH][nH]c2nc(CN3Cc4ccccc4C3)nc3cccc1c23, O=c1[nH][nH]c2nc(CN3Cc4ccccc4C3)nc3cccc1c23, O=c1[nH][nH]c2nc(CN3Cc4ccccc4C3)nc3cccc1c23	Phase 2
E7820	angiogenesis inhibitor				MedChemEx	97.34	Cc1ccc(NS(=O)(=O)c2cccc(c2)C#N)c2[nH]cc(C#N)c12	Phase 2
F-11440	serotonin receptor agonist	HTR1A			MedChemEx, MedChemEx	92.26	Cn1c(=O)cnn(CCCCN2CCN(CC2)c2ncccn2)c1=O, Cn1c(=O)cnn(CCCCN2CCN(CC2)c2ncccn2)c1=O	Phase 2
F-16915					MedChemEx	100	CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(=O)OCc1cccnc1	Preclinical
fadrozole	aromatase inhibitor	CYP11B1, CYP19A1	oncology	breast cancer	SantaCruz, SantaCruz	98.89	N#Cc1ccc(cc1)[C@H]1CCCc2cncn12 |&1:8|, N#Cc1ccc(cc1)[C@H]1CCCc2cncn12 |&1:8|	Launched
fagomine	glucosidase inhibitor	GLB1			MedChemEx	99.3	OC[C@H]1NCC[C@@H](O)[C@@H]1O	Phase 2
falecalcitriol	vitamin D receptor agonist	VDR	endocrinology	hyperparathyroidism	MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx	89.51	C[C@H](CCCC(O)(C(F)(F)F)C(F)(F)F)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, C[C@H](CCCC(O)(C(F)(F)F)C(F)(F)F)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, C[C@H](CCCC(O)(C(F)(F)F)C(F)(F)F)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, C[C@H](CCCC(O)(C(F)(F)F)C(F)(F)F)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, C[C@H](CCCC(O)(C(F)(F)F)C(F)(F)F)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, C[C@H](CCCC(O)(C(F)(F)F)C(F)(F)F)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C	Launched
famciclovir	DNA polymerase inhibitor		dental, infectious disease	cold sore, genitial herpes, shingles	MicroSource, Selleck, MedChemEx	99.1	CC(=O)OCC(CCn1cnc2cnc(N)nc12)COC(C)=O, CC(=O)OCC(CCn1cnc2cnc(N)nc12)COC(C)=O, CC(=O)OCC(CCn1cnc2cnc(N)nc12)COC(C)=O	Launched
famotidine	histamine receptor antagonist	HRH2	gastroenterology	heartburn	Selleck, MicroSource	99.08	NC(=N)Nc1nc(CSCC\C(N)=N/S(N)(=O)=O)cs1, NC(=N)Nc1nc(CSCC\C(N)=N/S(N)(=O)=O)cs1	Launched
famprofazone	cyclooxygenase inhibitor				Selleck, MicroSource, Selleck	95.25	CC(C)c1c(CN(C)[C@@H](C)Cc2ccccc2)n(C)n(-c2ccccc2)c1=O |&1:8,r|, CC(C)c1c(CN(C)[C@@H](C)Cc2ccccc2)n(C)n(-c2ccccc2)c1=O |&1:8,r|, CC(C)c1c(CN(C)[C@@H](C)Cc2ccccc2)n(C)n(-c2ccccc2)c1=O |&1:8,r|	Preclinical
fananserin	dopamine receptor antagonist, serotonin receptor antagonist	HTR2A			Tocris, Tocris	93.07	Fc1ccc(cc1)N1CCN(CCCN2c3cccc4cccc(c34)S2(=O)=O)CC1, Fc1ccc(cc1)N1CCN(CCCN2c3cccc4cccc(c34)S2(=O)=O)CC1	Phase 2
fanetizole	neutrophil superoxide production				Enamine	94.26	C(Cc1ccccc1)Nc1nc(cs1)-c1ccccc1	Phase 3
fantofarone	calcium channel blocker				MedChemEx	96.18	COc1ccc(CCN(C)CCCOc2ccc(cc2)S(=O)(=O)c2c(cn3ccccc23)C(C)C)cc1OC	Preclinical
farampator	ionotropic glutamate receptor agonist				MedChemEx	98.96	O=C(N1CCCCC1)c1ccc2nonc2c1	Preclinical
farnesyl-thiosalicylic-acid-amide	Ras GTPase inhibitor	HRAS			Cayman, Cayman, Cayman	96.81	CC(C)=CCC\C(C)=C\CC\C(C)=C\CSc1ccccc1C(N)=O, CC(C)=CCC\C(C)=C\CC\C(C)=C\CSc1ccccc1C(N)=O, CC(C)=CCC\C(C)=C\CC\C(C)=C\CSc1ccccc1C(N)=O	Phase 1
faropenem	lactamase inhibitor		infectious disease, pulmonary, otolaryngology	pneumonia, bronchitis, skin infections, urinary tract infections, sinusitis	Astatech	98.06	C[C@@H](O)[C@H]1[C@H]2SC([C@H]3CCCO3)=C(N2C1=O)C(O)=O |&1:1,&2:3,&3:4,&4:7,r,c:12|	Launched
faropenem-medoxomil	lactamase inhibitor		otolaryngology, infectious disease, pulmonary	sinusitis, pneumonia, bronchitis, skin infections, urinary tract infections	MedChemEx, MedChemEx, MedChemEx	82.42	C[C@@H](O)[C@@H]1[C@H]2SC([C@H]3CCCO3)=C(N2C1=O)C(=O)OCc1oc(=O)oc1C |c:12|, C[C@@H](O)[C@@H]1[C@H]2SC([C@H]3CCCO3)=C(N2C1=O)C(=O)OCc1oc(=O)oc1C |c:12|, C[C@@H](O)[C@@H]1[C@H]2SC([C@H]3CCCO3)=C(N2C1=O)C(=O)OCc1oc(=O)oc1C |c:12|	Launched
fasoracetam	GABA receptor antagonist				Astatech	92.33	O=C([C@H]1CCC(=O)N1)N1CCCCC1	Preclinical
fasudil	rho associated kinase inhibitor	PKIA, PRKACA, ROCK1, ROCK2	neurology/psychiatry	cerebral vasospasm	MicroSource, Tocris, Selleck, Tocris, Tocris, Tocris, Tocris	98.59	O=S(=O)(N1CCCNCC1)c1cccc2cnccc12, O=S(=O)(N1CCCNCC1)c1cccc2cnccc12, O=S(=O)(N1CCCNCC1)c1cccc2cnccc12, O=S(=O)(N1CCCNCC1)c1cccc2cnccc12, O=S(=O)(N1CCCNCC1)c1cccc2cnccc12, O=S(=O)(N1CCCNCC1)c1cccc2cnccc12, O=S(=O)(N1CCCNCC1)c1cccc2cnccc12	Launched
favipiravir	RNA polymerase inhibitor				AdvChemBlocks, AdvChemBlocks	95.67	NC(=O)c1nc(F)c[nH]c1=O, NC(=O)c1nc(F)c[nH]c1=O	Phase 3
FCE-22250	DNA directed DNA polymerase inhibitor				Vitas-M	68.34	CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c(O)c(\C=N\N=C\N4CCCCC4)c(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C |c:34,t:3,36|	Phase 1
fdcyd	DNA methyltransferase inhibitor				SantaCruz, SantaCruz	94.9	Nc1nc(=O)n(cc1F)[C@H]1C[C@H](O)[C@@H](CO)O1, Nc1nc(=O)n(cc1F)[C@H]1C[C@H](O)[C@@H](CO)O1	Phase 2
febuprol	choleretic agent				Sigma	93.98	CCCCOC[C@@H](O)COc1ccccc1 |&1:6,r|	Launched
febuxostat	xanthine oxidase inhibitor	XDH	nephrology	hyperuricemia	Tocris, Tocris, MicroSource, Selleck	98.36	CC(C)COc1ccc(cc1C#N)-c1nc(C)c(s1)C(O)=O, CC(C)COc1ccc(cc1C#N)-c1nc(C)c(s1)C(O)=O, CC(C)COc1ccc(cc1C#N)-c1nc(C)c(s1)C(O)=O, CC(C)COc1ccc(cc1C#N)-c1nc(C)c(s1)C(O)=O	Launched
fedratinib	FLT3 inhibitor, JAK inhibitor	BRD4, JAK1, JAK2, JAK3, TYK2	hematologic malignancy	myelofibrosis	Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck	91.26	Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(c1)S(=O)(=O)NC(C)(C)C, Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(c1)S(=O)(=O)NC(C)(C)C, Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(c1)S(=O)(=O)NC(C)(C)C, Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(c1)S(=O)(=O)NC(C)(C)C, Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(c1)S(=O)(=O)NC(C)(C)C, Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(c1)S(=O)(=O)NC(C)(C)C, Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(c1)S(=O)(=O)NC(C)(C)C, Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(c1)S(=O)(=O)NC(C)(C)C, Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(c1)S(=O)(=O)NC(C)(C)C, Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(c1)S(=O)(=O)NC(C)(C)C, Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(c1)S(=O)(=O)NC(C)(C)C	Launched
felbamate	glutamate receptor antagonist	GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, GRIN3A, GRIN3B	neurology/psychiatry	epilepsy	Tocris, Tocris, Tocris, Tocris, Tocris, Tocris, Tocris, Selleck, Selleck, Selleck	100	NC(=O)OCC(COC(N)=O)c1ccccc1, NC(=O)OCC(COC(N)=O)c1ccccc1, NC(=O)OCC(COC(N)=O)c1ccccc1, NC(=O)OCC(COC(N)=O)c1ccccc1, NC(=O)OCC(COC(N)=O)c1ccccc1, NC(=O)OCC(COC(N)=O)c1ccccc1, NC(=O)OCC(COC(N)=O)c1ccccc1, NC(=O)OCC(COC(N)=O)c1ccccc1, NC(=O)OCC(COC(N)=O)c1ccccc1, NC(=O)OCC(COC(N)=O)c1ccccc1	Launched
felbinac	cyclooxygenase inhibitor	CTSL	rheumatology, neurology/psychiatry	rheumatoid arthritis, muscle pain	MedChemEx, MicroSource	99.79	OC(=O)Cc1ccc(cc1)-c1ccccc1, OC(=O)Cc1ccc(cc1)-c1ccccc1	Launched
felbinac-ethyl	cyclooxygenase inhibitor	PTGS1, PTGS2			AMS	47.98	CCOC(=O)Cc1ccc(cc1)-c1ccccc1	Launched
felodipine	calcium channel blocker	CFTR	cardiology	hypertension	Tocris, MicroSource, Selleck, Selleck	98.85	CCOC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(Cl)c1Cl)C(=O)OC |&1:12,r,c:5,10|, CCOC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(Cl)c1Cl)C(=O)OC |&1:12,r,c:5,10|, CCOC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(Cl)c1Cl)C(=O)OC |&1:12,r,c:5,10|, CCOC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(Cl)c1Cl)C(=O)OC |&1:12,r,c:5,10|	Launched
felypressin	vasopressin receptor agonist				MedChemEx	82.6	[H][C@@]1(Cc2ccccc2)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@@H](N)CSSC[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC1=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)NCC(N)=O	Preclinical
fenaclon					MicroSource, MicroSource, Enamine	89.95	ClCCC(=O)NCCc1ccccc1, ClCCC(=O)NCCc1ccccc1, ClCCC(=O)NCCc1ccccc1	Preclinical
fenbendazole	tubulin polymerization inhibitor	TUBB	infectious disease	gastrointestinal parasites, gastrointestinal roundworms	Selleck, MicroSource, MicroSource	98.69	COC(=O)Nc1nc2ccc(Sc3ccccc3)cc2[nH]1, COC(=O)Nc1nc2ccc(Sc3ccccc3)cc2[nH]1, COC(=O)Nc1nc2ccc(Sc3ccccc3)cc2[nH]1	Launched
fenbufen	cyclooxygenase inhibitor	PTGS1, PTGS2	neurology/psychiatry	pain relief	MedChemEx, MicroSource	99.5	OC(=O)CCC(=O)c1ccc(cc1)-c1ccccc1, OC(=O)CCC(=O)c1ccc(cc1)-c1ccccc1	Launched
fenclonine-(+/-)	tryptophan hydroxylase inhibitor	PAH, TPH1, TPH2			MicroSource, Tocris	89.42	N[C@@H](Cc1ccc(Cl)cc1)C(O)=O |&1:1|, N[C@@H](Cc1ccc(Cl)cc1)C(O)=O |&1:1|	Preclinical
fendiline	calcium channel blocker	HTR2B			Tocris, Tocris, Tocris, MicroSource, MicroSource, MicroSource	97.8	C[C@@H](NCCC(c1ccccc1)c1ccccc1)c1ccccc1 |&1:1|, C[C@@H](NCCC(c1ccccc1)c1ccccc1)c1ccccc1 |&1:1|, C[C@@H](NCCC(c1ccccc1)c1ccccc1)c1ccccc1 |&1:1|, C[C@@H](NCCC(c1ccccc1)c1ccccc1)c1ccccc1 |&1:1|, C[C@@H](NCCC(c1ccccc1)c1ccccc1)c1ccccc1 |&1:1|, C[C@@H](NCCC(c1ccccc1)c1ccccc1)c1ccccc1 |&1:1|	Preclinical
fenebrutinib	Bruton's tyrosine kinase (BTK) inhibitor				MedChemEx	95.35	C[C@H]1CN(CCN1c1ccc(Nc2cc(cn(C)c2=O)-c2ccnc(N3CCn4c5CC(C)(C)Cc5cc4C3=O)c2CO)nc1)C1COC1	Phase 2
fenigam	benzodiazepine receptor agonist	GABBR1, GABBR2	neurology/psychiatry	posttraumatic stress disorder, anxiety, depression	Vitas-M, Enamine, Enamine	92.36	NC[C@@H](CC(O)=O)c1ccccc1 |&1:2,r|, NC[C@@H](CC(O)=O)c1ccccc1 |&1:2,r|, NC[C@@H](CC(O)=O)c1ccccc1 |&1:2,r|	Launched
fenipentol	choleretic agent		gastroenterology	bile stimulation	MicroSource, Sigma	0	CCCC[C@@H](O)c1ccccc1 |&1:4,r|, CCCC[C@@H](O)c1ccccc1 |&1:4,r|	Launched
fenobam	glutamate receptor antagonist	GRM5			Tocris, Tocris, Tocris, Tocris	96.49	CN1CC(=O)N=C1NC(=O)Nc1cccc(Cl)c1 |c:5|, CN1CC(=O)N=C1NC(=O)Nc1cccc(Cl)c1 |c:5|, CN1CC(=O)N=C1NC(=O)Nc1cccc(Cl)c1 |c:5|, CN1CC(=O)N=C1NC(=O)Nc1cccc(Cl)c1 |c:5|	Phase 2
fenofibrate	PPAR receptor agonist	MMP25, PPARA	endocrinology	hypercholesterolemia, hypertriglyceridemia	Tocris, MicroSource, Selleck	99.56	CC(C)OC(=O)C(C)(C)Oc1ccc(cc1)C(=O)c1ccc(Cl)cc1, CC(C)OC(=O)C(C)(C)Oc1ccc(cc1)C(=O)c1ccc(Cl)cc1, CC(C)OC(=O)C(C)(C)Oc1ccc(cc1)C(=O)c1ccc(Cl)cc1	Launched
fenofibric-acid	cytochrome P450 inhibitor	CLCN1, PPARA	cardiology	dyslipidemia	MicroSource, MedChemEx, MedChemEx	98.41	CC(C)(Oc1ccc(cc1)C(=O)c1ccc(Cl)cc1)C(O)=O, CC(C)(Oc1ccc(cc1)C(=O)c1ccc(Cl)cc1)C(O)=O, CC(C)(Oc1ccc(cc1)C(=O)c1ccc(Cl)cc1)C(O)=O	Launched
fenoldopam	dopamine receptor agonist	DRD1, DRD4	cardiology	hypertension	MicroSource, MicroSource	98.42	Oc1ccc(cc1)[C@H]1CNCCc2c(Cl)c(O)c(O)cc12 |&1:7|, Oc1ccc(cc1)[C@H]1CNCCc2c(Cl)c(O)c(O)cc12 |&1:7|	Launched
fenoprofen	prostaglandin inhibitor	PTGS1, SLC5A8	rheumatology	rheumatoid arthritis, osteoarthritis	MedChemEx	95.93	C[C@@H](C(O)=O)c1cccc(Oc2ccccc2)c1 |&1:1|	Launched
fenoterol	adrenergic receptor agonist	ADRB2			MedChemEx	96.59	C[C@@H](Cc1ccc(O)cc1)NC[C@@H](O)c1cc(O)cc(O)c1 |&1:1,12,r|	Withdrawn
fenoverine	acetylcholine receptor antagonist		neurology/psychiatry	spasms	Vitas-M	94.91	O=C(CN1CCN(Cc2ccc3OCOc3c2)CC1)N1c2ccccc2Sc2ccccc12	Launched
fenoxaprop-p-ethyl		NOS3			MedChemEx	94.27	CCOC(=O)[C@@H](C)Oc1ccc(Oc2nc3ccc(Cl)cc3o2)cc1	Preclinical
fenretinide	apoptosis stimulant, retinoid receptor agonist	RARA			MedChemEx, MedChemEx, MedChemEx, MedChemEx, Adooq, Tocris	82.51	C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C/C(=O)Nc1ccc(O)cc1 |c:4|, C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C/C(=O)Nc1ccc(O)cc1 |c:4|, C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C/C(=O)Nc1ccc(O)cc1 |c:4|, C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C/C(=O)Nc1ccc(O)cc1 |c:4|, C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C/C(=O)Nc1ccc(O)cc1 |c:4|, C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C/C(=O)Nc1ccc(O)cc1 |c:4|	Phase 3
fenspiride	bronchodilator		pulmonary, otolaryngology	asthma, otitis, sinusitis, rhinopharyngitis, laryngitis	MedChemEx, Selleck, MicroSource	98.6	O=C1NCC2(CCN(CCc3ccccc3)CC2)O1, O=C1NCC2(CCN(CCc3ccccc3)CC2)O1, O=C1NCC2(CCN(CCc3ccccc3)CC2)O1	Launched
fenthion	cholinesterase inhibitor				MicroSource	78.04	COP(=S)(OC)Oc1ccc(SC)c(C)c1	Launched
fentiazac	cyclooxygenase inhibitor	PTGS1, PTGS2	neurology/psychiatry, rheumatology	muscle pain, joint pain	PrincetonBio, Prestwick	97.7	OC(=O)Cc1sc(nc1-c1ccc(Cl)cc1)-c1ccccc1, OC(=O)Cc1sc(nc1-c1ccc(Cl)cc1)-c1ccccc1	Launched
fenticonazole	bacterial cell wall synthesis inhibitor		infectious disease	vulvovaginal candidiasis	MedChemEx, Selleck, Selleck	98.76	Clc1ccc([C@@H](Cn2ccnc2)OCc2ccc(Sc3ccccc3)cc2)c(Cl)c1 |&1:5|, Clc1ccc([C@@H](Cn2ccnc2)OCc2ccc(Sc3ccccc3)cc2)c(Cl)c1 |&1:5|, Clc1ccc([C@@H](Cn2ccnc2)OCc2ccc(Sc3ccccc3)cc2)c(Cl)c1 |&1:5|	Launched
FERb-033	EGFR inhibitor	ERBB2			Tocris, Tocris, Tocris	94.02	O\N=C\c1ccc(c(Cl)c1O)-c1ccc(O)c(F)c1, O\N=C\c1ccc(c(Cl)c1O)-c1ccc(O)c(F)c1, O\N=C\c1ccc(c(Cl)c1O)-c1ccc(O)c(F)c1	Preclinical
ferroquine	antimalarial agent				MedChemEx	97.4	CN(C)CC1=CC=C[C@@]1(CNc1ccnc2cc(Cl)ccc12)[Fe]C1C=CC=C1 |&1:8,r,c:6,27,29,t:4|	Phase 2
ferrostatin-1	ferroptosis inhibitor				Tocris, Selleck, Tocris, Selleck	87.75	CCOC(=O)c1ccc(NC2CCCCC2)c(N)c1, CCOC(=O)c1ccc(NC2CCCCC2)c(N)c1, CCOC(=O)c1ccc(NC2CCCCC2)c(N)c1, CCOC(=O)c1ccc(NC2CCCCC2)c(N)c1	Preclinical
ferulic-acid	antioxidant	CA1, CA12, CA14, CA2, CA4, CA6, CA9			MedChemEx, MedChemEx, Selleck, Selleck, Selleck	95.29	COc1cc(\C=C\C(O)=O)ccc1O, COc1cc(\C=C\C(O)=O)ccc1O, COc1cc(\C=C\C(O)=O)ccc1O, COc1cc(\C=C\C(O)=O)ccc1O, COc1cc(\C=C\C(O)=O)ccc1O	Phase 2
fesoterodine	acetylcholine receptor antagonist	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5	urology	urinary incontinence	MedChemEx, Selleck, Selleck	91.18	CC(C)N(CC[C@H](c1ccccc1)c1cc(CO)ccc1OC(=O)C(C)C)C(C)C, CC(C)N(CC[C@H](c1ccccc1)c1cc(CO)ccc1OC(=O)C(C)C)C(C)C, CC(C)N(CC[C@H](c1ccccc1)c1cc(CO)ccc1OC(=O)C(C)C)C(C)C	Launched
fevipiprant	prostaglandin inhibitor				MedChemEx	95.33	Cc1c(CC(O)=O)c2cccnc2n1Cc1ccc(cc1C(F)(F)F)S(C)(=O)=O	Phase 2
fexaramine	FXR agonist	NR1H4			Tocris, Tocris, Tocris	86.74	COC(=O)\C=C\c1cccc(c1)N(Cc1ccc(cc1)-c1ccc(cc1)N(C)C)C(=O)C1CCCCC1, COC(=O)\C=C\c1cccc(c1)N(Cc1ccc(cc1)-c1ccc(cc1)N(C)C)C(=O)C1CCCCC1, COC(=O)\C=C\c1cccc(c1)N(Cc1ccc(cc1)-c1ccc(cc1)N(C)C)C(=O)C1CCCCC1	Preclinical
fexinidazole					Ark	99.04	CSc1ccc(OCc2ncc(n2C)[N+]([O-])=O)cc1	Phase 3
fexofenadine	histamine receptor antagonist	HRH1	allergy	allergic rhinitis, urticaria	MicroSource, Tocris, Tocris, Selleck	98.09	CC(C)(C(O)=O)c1ccc(cc1)[C@@H](O)CCCN1CCC(CC1)C(O)(c1ccccc1)c1ccccc1 |&1:12|, CC(C)(C(O)=O)c1ccc(cc1)[C@@H](O)CCCN1CCC(CC1)C(O)(c1ccccc1)c1ccccc1 |&1:12|, CC(C)(C(O)=O)c1ccc(cc1)[C@@H](O)CCCN1CCC(CC1)C(O)(c1ccccc1)c1ccccc1 |&1:12|, CC(C)(C(O)=O)c1ccc(cc1)[C@@H](O)CCCN1CCC(CC1)C(O)(c1ccccc1)c1ccccc1 |&1:12|	Launched
fezolinetant	neurokinin receptor antagonist				MedChemEx	95.34	C[C@H]1N(CCn2c1nnc2-c1nc(C)ns1)C(=O)c1ccc(F)cc1	Phase 2
FG-2216	hypoxia inducible factor prolyl hydroxylase inhibitor	EGLN1, EGLN2, HIF1A			MedChemEx	96.03	OC(=O)CNC(=O)c1nc(Cl)c2ccccc2c1O	Phase 2
FG-4592	hypoxia inducible factor prolyl hydroxylase inhibitor	EGLN1, EGLN2, EGLN3			Selleck, Selleck, Selleck, Selleck, Selleck	93.33	Cc1nc(C(=O)NCC(O)=O)c(O)c2ccc(Oc3ccccc3)cc12, Cc1nc(C(=O)NCC(O)=O)c(O)c2ccc(Oc3ccccc3)cc12, Cc1nc(C(=O)NCC(O)=O)c(O)c2ccc(Oc3ccccc3)cc12, Cc1nc(C(=O)NCC(O)=O)c(O)c2ccc(Oc3ccccc3)cc12, Cc1nc(C(=O)NCC(O)=O)c(O)c2ccc(Oc3ccccc3)cc12	Phase 3
FG-7142	GABA benzodiazepine site receptor inverse agonist				Tocris, Tocris, Tocris, Tocris	97.73	CNC(=O)c1cc2c(cn1)[nH]c1ccccc21, CNC(=O)c1cc2c(cn1)[nH]c1ccccc21, CNC(=O)c1cc2c(cn1)[nH]c1ccccc21, CNC(=O)c1cc2c(cn1)[nH]c1ccccc21	Preclinical
FGIN-1-27	inositol monophosphatase inhibitor	TSPO			Tocris, Tocris, Tocris, Tocris	96.53	CCCCCCN(CCCCCC)C(=O)Cc1c([nH]c2ccccc12)-c1ccc(F)cc1, CCCCCCN(CCCCCC)C(=O)Cc1c([nH]c2ccccc12)-c1ccc(F)cc1, CCCCCCN(CCCCCC)C(=O)Cc1c([nH]c2ccccc12)-c1ccc(F)cc1, CCCCCCN(CCCCCC)C(=O)Cc1c([nH]c2ccccc12)-c1ccc(F)cc1	Preclinical
FGIN-1-43	benzodiazepine receptor agonist	TSPO			Tocris, Tocris, Tocris, Tocris, Tocris	98.62	CCCCCCN(CCCCCC)C(=O)Cc1c([nH]c2ccc(Cl)cc12)-c1ccc(Cl)cc1, CCCCCCN(CCCCCC)C(=O)Cc1c([nH]c2ccc(Cl)cc12)-c1ccc(Cl)cc1, CCCCCCN(CCCCCC)C(=O)Cc1c([nH]c2ccc(Cl)cc12)-c1ccc(Cl)cc1, CCCCCCN(CCCCCC)C(=O)Cc1c([nH]c2ccc(Cl)cc12)-c1ccc(Cl)cc1, CCCCCCN(CCCCCC)C(=O)Cc1c([nH]c2ccc(Cl)cc12)-c1ccc(Cl)cc1	Preclinical
FH-535	PPAR receptor antagonist, WNT signaling inhibitor	PPARD, PPARG			Tocris, Tocris	95.44	Cc1cc(ccc1NS(=O)(=O)c1cc(Cl)ccc1Cl)[N+]([O-])=O, Cc1cc(ccc1NS(=O)(=O)c1cc(Cl)ccc1Cl)[N+]([O-])=O	Preclinical
FH1	hepatocyte function enhancer				Selleck, Tocris	97.97	CC(=O)Nc1ccc(Cc2ccc(NC(C)=O)cc2)cc1, CC(=O)Nc1ccc(Cc2ccc(NC(C)=O)cc2)cc1	Preclinical
fiacitabine	DNA synthesis inhibitor				MedChemEx, MedChemEx	99.3	Nc1nc(=O)n(cc1I)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F, Nc1nc(=O)n(cc1I)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F	Phase 2
fidarestat	aldose reductase inhibitor	AKR1B1			Vitas-M, Vitas-M	88.01	NC(=O)[C@H]1C[C@]2(NC(=O)NC2=O)c2cc(F)ccc2O1 |&1:3,&2:5,r|, NC(=O)[C@H]1C[C@]2(NC(=O)NC2=O)c2cc(F)ccc2O1 |&1:3,&2:5,r|	Phase 3
fidaxomicin	RNA polymerase inhibitor		gastroenterology	diarrhea	MedChemEx	88.01	CC[C@H]1\C=C(C)\[C@@H](O)C\C=C\C=C(CO[C@@H]2O[C@H](C)[C@@H](OC(=O)c3c(O)c(Cl)c(O)c(Cl)c3CC)[C@H](O)[C@@H]2OC)\C(=O)O[C@@H](C\C=C(/C)\C=C(C)\[C@@H]1O[C@@H]1OC(C)(C)[C@@H](OC(=O)C(C)C)[C@H](O)[C@@H]1O)[C@@H](C)O |c:3,11,47,50,t:9|	Launched
filanesib	kinesin inhibitor, kinesin-like spindle protein inhibitor	KIF11			MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx	85.47	CON(C)C(=O)N1N=C(S[C@@]1(CCCN)c1ccccc1)c1cc(F)ccc1F |c:7|, CON(C)C(=O)N1N=C(S[C@@]1(CCCN)c1ccccc1)c1cc(F)ccc1F |c:7|, CON(C)C(=O)N1N=C(S[C@@]1(CCCN)c1ccccc1)c1cc(F)ccc1F |c:7|, CON(C)C(=O)N1N=C(S[C@@]1(CCCN)c1ccccc1)c1cc(F)ccc1F |c:7|, CON(C)C(=O)N1N=C(S[C@@]1(CCCN)c1ccccc1)c1cc(F)ccc1F |c:7|, CON(C)C(=O)N1N=C(S[C@@]1(CCCN)c1ccccc1)c1cc(F)ccc1F |c:7|	Phase 3
filgotinib	JAK inhibitor	JAK1, JAK2, JAK3, TYK2			MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx	96.83	O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1, O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1, O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1, O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1, O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1	Phase 3
fimasartan	angiotensin receptor antagonist	AGTR1	cardiology	hypertension, congestive heart failure	MedChemEx, MedChemEx, MedChemEx	89.33	CCCCc1nc(C)c(CC(=S)N(C)C)c(=O)n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1, CCCCc1nc(C)c(CC(=S)N(C)C)c(=O)n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1, CCCCc1nc(C)c(CC(=S)N(C)C)c(=O)n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1	Launched
finafloxacin	bacterial DNA gyrase inhibitor		infectious disease, pulmonary	intra-abdominal infections, chronic obstructive pulmonary disease (COPD), cystic fibrosis	MedChemEx, SantaCruz, SantaCruz	95.28	OC(=O)c1cn(C2CC2)c2c(C#N)c(N3C[C@@H]4NCCO[C@H]4C3)c(F)cc2c1=O, OC(=O)c1cn(C2CC2)c2c(C#N)c(N3C[C@@H]4NCCO[C@H]4C3)c(F)cc2c1=O, OC(=O)c1cn(C2CC2)c2c(C#N)c(N3C[C@@H]4NCCO[C@H]4C3)c(F)cc2c1=O	Launched
finasteride	5 alpha reductase inhibitor	AKR1D1, SRD5A1, SRD5A2	endocrinology	androgenetic alopecia	MicroSource, MicroSource, Tocris, Tocris, Selleck	98.29	CC(C)(C)NC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4NC(=O)C=C[C@]4(C)[C@H]3CC[C@]12C |c:18|, CC(C)(C)NC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4NC(=O)C=C[C@]4(C)[C@H]3CC[C@]12C |c:18|, CC(C)(C)NC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4NC(=O)C=C[C@]4(C)[C@H]3CC[C@]12C |c:18|, CC(C)(C)NC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4NC(=O)C=C[C@]4(C)[C@H]3CC[C@]12C |c:18|, CC(C)(C)NC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4NC(=O)C=C[C@]4(C)[C@H]3CC[C@]12C |c:18|	Launched
fingolimod	immunosuppressant, sphingosine 1-phosphate receptor agonist	S1PR1, S1PR5	neurology/psychiatry	multiple sclerosis	MedChemEx, MedChemEx, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck	95.28	CCCCCCCCc1ccc(CCC(N)(CO)CO)cc1, CCCCCCCCc1ccc(CCC(N)(CO)CO)cc1, CCCCCCCCc1ccc(CCC(N)(CO)CO)cc1, CCCCCCCCc1ccc(CCC(N)(CO)CO)cc1, CCCCCCCCc1ccc(CCC(N)(CO)CO)cc1, CCCCCCCCc1ccc(CCC(N)(CO)CO)cc1, CCCCCCCCc1ccc(CCC(N)(CO)CO)cc1, CCCCCCCCc1ccc(CCC(N)(CO)CO)cc1, CCCCCCCCc1ccc(CCC(N)(CO)CO)cc1, CCCCCCCCc1ccc(CCC(N)(CO)CO)cc1, CCCCCCCCc1ccc(CCC(N)(CO)CO)cc1	Launched
fipexide	psychoactive drug				MicroSource	98.95	Clc1ccc(OCC(=O)N2CCN(Cc3ccc4OCOc4c3)CC2)cc1	Withdrawn
FIPI	phospholipase inhibitor	PLD1, PLD2			Tocris, Tocris	97.99	Fc1ccc2[nH]c(cc2c1)C(=O)NCCN1CCC(CC1)n1c2ccccc2[nH]c1=O, Fc1ccc2[nH]c(cc2c1)C(=O)NCCN1CCC(CC1)n1c2ccccc2[nH]c1=O	Preclinical
fipronil	chloride channel blocker, GABA gated chloride channel blocker		infectious disease	flea control	MicroSource, Sigma	97.11	Nc1c(c(nn1-c1c(Cl)cc(cc1Cl)C(F)(F)F)C#N)[S@@](=O)C(F)(F)F |&1:20,r|, Nc1c(c(nn1-c1c(Cl)cc(cc1Cl)C(F)(F)F)C#N)[S@@](=O)C(F)(F)F |&1:20,r|	Launched
firategrast	integrin antagonist	ITGA4			MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx	99.31	CCOCc1cc(OC)c(c(OC)c1)-c1ccc(C[C@H](NC(=O)c2c(F)cccc2F)C(O)=O)cc1, CCOCc1cc(OC)c(c(OC)c1)-c1ccc(C[C@H](NC(=O)c2c(F)cccc2F)C(O)=O)cc1, CCOCc1cc(OC)c(c(OC)c1)-c1ccc(C[C@H](NC(=O)c2c(F)cccc2F)C(O)=O)cc1, CCOCc1cc(OC)c(c(OC)c1)-c1ccc(C[C@H](NC(=O)c2c(F)cccc2F)C(O)=O)cc1, CCOCc1cc(OC)c(c(OC)c1)-c1ccc(C[C@H](NC(=O)c2c(F)cccc2F)C(O)=O)cc1, CCOCc1cc(OC)c(c(OC)c1)-c1ccc(C[C@H](NC(=O)c2c(F)cccc2F)C(O)=O)cc1, CCOCc1cc(OC)c(c(OC)c1)-c1ccc(C[C@H](NC(=O)c2c(F)cccc2F)C(O)=O)cc1, CCOCc1cc(OC)c(c(OC)c1)-c1ccc(C[C@H](NC(=O)c2c(F)cccc2F)C(O)=O)cc1	Phase 2
firocoxib	cyclooxygenase inhibitor	PTGS2	rheumatology	osteoarthritis	MicroSource	99.46	CC1(C)OC(=O)C(OCC2CC2)=C1c1ccc(cc1)S(C)(=O)=O |c:12|	Launched
firsocostat	acetyl-CoA carboxylase inhibitor				MedChemEx	94.78	COc1ccccc1[C@H](Cn1c2sc(c(C)c2c(=O)n(c1=O)C(C)(C)C(O)=O)-c1ncco1)OC1CCOCC1	Phase 2
fisetin	Aurora kinase inhibitor	CDK6, FASN			MedChemEx, MedChemEx, Selleck, Selleck	99.4	Oc1ccc2c(c1)oc(-c1ccc(O)c(O)c1)c(O)c2=O, Oc1ccc2c(c1)oc(-c1ccc(O)c(O)c1)c(O)c2=O, Oc1ccc2c(c1)oc(-c1ccc(O)c(O)c1)c(O)c2=O, Oc1ccc2c(c1)oc(-c1ccc(O)c(O)c1)c(O)c2=O	Preclinical
fisogatinib	fibroblast growth factor inhibitor				MedChemEx	93.64	COc1cc(OC)c(Cl)c(c1Cl)-c1ccc2nc(N[C@@H]3COCC[C@@H]3NC(=O)C=C)ncc2c1	Phase 1
FIT	opioid receptor agonist	OPRD1			Tocris	8.53	CCC(=O)N(C1CCN(CCc2ccc(cc2)N=C=S)CC1)c1ccccc1	Preclinical
FK-33-824	opioid receptor agonist	OPRM1			Enzo, Enzo	81.78	C[C@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)NCC(=O)N(C)[C@@H](Cc1ccccc1)C(=O)N[C@H](CO)CC[S@@](C)=O |a:1,5,23,34,&1:39|, C[C@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)NCC(=O)N(C)[C@@H](Cc1ccccc1)C(=O)N[C@H](CO)CC[S@@](C)=O |a:1,5,23,34,&1:39|	Phase 2
FK-3311	cyclooxygenase inhibitor	PTGS2			MedChemEx, MedChemEx, Tocris	95.84	CC(=O)c1ccc(NS(C)(=O)=O)c(Oc2ccc(F)cc2F)c1, CC(=O)c1ccc(NS(C)(=O)=O)c(Oc2ccc(F)cc2F)c1, CC(=O)c1ccc(NS(C)(=O)=O)c(Oc2ccc(F)cc2F)c1	Phase 2
FK-409	guanylyl cyclase activator				Sigma	100	CC\C(=C/C(=N/O)/C(N)=O)[C@@H](C)[N+]([O-])=O |&1:10,r|	Phase 2
FK-866	niacinamide phosphoribosyltransferase inhibitor	NAMPT			Enzo, Enzo	93.54	O=C(NCCCCC1CCN(CC1)C(=O)c1ccccc1)\C=C\c1cccnc1, O=C(NCCCCC1CCN(CC1)C(=O)c1ccccc1)\C=C\c1cccnc1	Phase 2
FK-888	tachykinin antagonist	TACR1, TACR2			Tocris, Tocris, Tocris, Tocris	97.91	CN(Cc1ccccc1)C(=O)[C@H](Cc1ccc2ccccc2c1)NC(=O)[C@@H]1C[C@@H](O)CN1C(=O)c1cn(C)c2ccccc12, CN(Cc1ccccc1)C(=O)[C@H](Cc1ccc2ccccc2c1)NC(=O)[C@@H]1C[C@@H](O)CN1C(=O)c1cn(C)c2ccccc12, CN(Cc1ccccc1)C(=O)[C@H](Cc1ccc2ccccc2c1)NC(=O)[C@@H]1C[C@@H](O)CN1C(=O)c1cn(C)c2ccccc12, CN(Cc1ccccc1)C(=O)[C@H](Cc1ccc2ccccc2c1)NC(=O)[C@@H]1C[C@@H](O)CN1C(=O)c1cn(C)c2ccccc12	Phase 2
FK-962	somatostatin receptor agonist				Enamine, Enamine	98.54	CC(=O)N1CCC(CC1)NC(=O)c1ccc(F)cc1, CC(=O)N1CCC(CC1)NC(=O)c1ccc(F)cc1	Phase 2
flavin-adenine-dinucleotide		ACAD8, ACADM, ACADS, ACOX1, AIFM1, CYB5R1, CYB5R3, DAO, DLD, DPYD, ERO1LB, FDXR, GCDH, GFER, GSR, IL4I1, IVD, MAOA, MAOB, NOS1, NQO1, NQO2, POR, TXNRD1, XDH			CombiBlocks	73.4	Cc1cc2nc3c(nc(=O)[nH]c3=O)n(C[C@H](O)[C@H](O)[C@H](O)CO[P@@](O)(=O)O[P@@](O)(=O)OC[C@H]3O[C@H]([C@H](O)[C@@H]3O)n3cnc4c(N)ncnc34)c2cc1C |a:15,17,19,32,34,35,37,&1:23,&2:27|	Preclinical
flavoxate	acetylcholine receptor antagonist	CHRM1, CHRM2	urology	urinary incontinence, interstitial cystitis (IC), urethritis, prostatitis	Selleck, Selleck	96.85	Cc1c(oc2c(cccc2c1=O)C(=O)OCCN1CCCCC1)-c1ccccc1, Cc1c(oc2c(cccc2c1=O)C(=O)OCCN1CCCCC1)-c1ccccc1	Launched
flecainide	sodium channel blocker	KCNA5, KCNA7, SCN5A	cardiology	ventricular tachycardia (VT), atrial fibrillation (AF), ventricular arrhythmias	Tocris, Tocris, MicroSource, MicroSource, Tocris, Tocris	96.6	FC(F)(F)COc1ccc(OCC(F)(F)F)c(c1)C(=O)NCC1CCCCN1, FC(F)(F)COc1ccc(OCC(F)(F)F)c(c1)C(=O)NCC1CCCCN1, FC(F)(F)COc1ccc(OCC(F)(F)F)c(c1)C(=O)NCC1CCCCN1, FC(F)(F)COc1ccc(OCC(F)(F)F)c(c1)C(=O)NCC1CCCCN1, FC(F)(F)COc1ccc(OCC(F)(F)F)c(c1)C(=O)NCC1CCCCN1, FC(F)(F)COc1ccc(OCC(F)(F)F)c(c1)C(=O)NCC1CCCCN1	Launched
fleroxacin	topoisomerase inhibitor	TOP2A	infectious disease, gastroenterology	gonorrhea, enteritis, diarrhea, respiratory tract infections	MedChemEx, Selleck, Selleck, Selleck	99.55	CN1CCN(CC1)c1c(F)cc2c(c1F)n(CCF)cc(C(O)=O)c2=O, CN1CCN(CC1)c1c(F)cc2c(c1F)n(CCF)cc(C(O)=O)c2=O, CN1CCN(CC1)c1c(F)cc2c(c1F)n(CCF)cc(C(O)=O)c2=O, CN1CCN(CC1)c1c(F)cc2c(c1F)n(CCF)cc(C(O)=O)c2=O	Launched
FLI-06	notch signaling inhibitor				Tocris, Tocris, Selleck, Selleck, Tocris, Tocris, Selleck, Selleck	97.33	CC1=NC2=C([C@@H](C1C(=O)OC1CCCCC1)c1ccc(cc1)[N+]([O-])=O)C(=O)CC(C)(C)C2 |&1:5,r,c:3,t:1|, CC1=NC2=C([C@@H](C1C(=O)OC1CCCCC1)c1ccc(cc1)[N+]([O-])=O)C(=O)CC(C)(C)C2 |&1:5,r,c:3,t:1|, CC1=NC2=C([C@@H](C1C(=O)OC1CCCCC1)c1ccc(cc1)[N+]([O-])=O)C(=O)CC(C)(C)C2 |&1:5,r,c:3,t:1|, CC1=NC2=C([C@@H](C1C(=O)OC1CCCCC1)c1ccc(cc1)[N+]([O-])=O)C(=O)CC(C)(C)C2 |&1:5,r,c:3,t:1|, CC1=NC2=C([C@@H](C1C(=O)OC1CCCCC1)c1ccc(cc1)[N+]([O-])=O)C(=O)CC(C)(C)C2 |&1:5,r,c:3,t:1|, CC1=NC2=C([C@@H](C1C(=O)OC1CCCCC1)c1ccc(cc1)[N+]([O-])=O)C(=O)CC(C)(C)C2 |&1:5,r,c:3,t:1|, CC1=NC2=C([C@@H](C1C(=O)OC1CCCCC1)c1ccc(cc1)[N+]([O-])=O)C(=O)CC(C)(C)C2 |&1:5,r,c:3,t:1|, CC1=NC2=C([C@@H](C1C(=O)OC1CCCCC1)c1ccc(cc1)[N+]([O-])=O)C(=O)CC(C)(C)C2 |&1:5,r,c:3,t:1|	Preclinical
flibanserin	serotonin receptor agonist	DRD4, HTR1A, HTR2A	neurology/psychiatry	hypoactive sexual desire disorder	MedChemEx	96.14	FC(F)(F)c1cccc(c1)N1CCN(CCn2c3ccccc3[nH]c2=O)CC1	Launched
flindokalner	potassium channel agonist	KCNMA1, KCNN4, KCNQ2, KCNQ4, KCNQ5			Tocris, Tocris, Sigma	98.77	COc1ccc(Cl)cc1[C@]1(F)C(=O)Nc2cc(ccc12)C(F)(F)F, COc1ccc(Cl)cc1[C@]1(F)C(=O)Nc2cc(ccc12)C(F)(F)F, COc1ccc(Cl)cc1[C@]1(F)C(=O)Nc2cc(ccc12)C(F)(F)F	Phase 3
floctafenine	cyclooxygenase inhibitor	PTGS1, PTGS2	neurology/psychiatry	pain relief	Carbosynth, Carbosynth, Carbosynth	99.43	OC[C@@H](O)COC(=O)c1ccccc1Nc1ccnc2c(cccc12)C(F)(F)F |&1:2,r|, OC[C@@H](O)COC(=O)c1ccccc1Nc1ccnc2c(cccc12)C(F)(F)F |&1:2,r|, OC[C@@H](O)COC(=O)c1ccccc1Nc1ccnc2c(cccc12)C(F)(F)F |&1:2,r|	Launched
flopropione	serotonin receptor antagonist	HTR1A	neurology/psychiatry	spasms	MicroSource, MicroSource, MicroSource, Selleck	98.95	CCC(=O)c1c(O)cc(O)cc1O, CCC(=O)c1c(O)cc(O)cc1O, CCC(=O)c1c(O)cc(O)cc1O, CCC(=O)c1c(O)cc(O)cc1O	Launched
florfenicol	protein synthesis inhibitor		pulmonary	bovine respiratory disease (BRD)	MedChemEx, Selleck, Selleck	97.3	CS(=O)(=O)c1ccc(cc1)[C@@H](O)[C@@H](CF)NC(=O)C(Cl)Cl, CS(=O)(=O)c1ccc(cc1)[C@@H](O)[C@@H](CF)NC(=O)C(Cl)Cl, CS(=O)(=O)c1ccc(cc1)[C@@H](O)[C@@H](CF)NC(=O)C(Cl)Cl	Launched
florifenine	anti-inflammatory agent				Sigma	75.09	FC(F)(F)c1ccc2c(Nc3ccccc3C(=O)OCCN3CCCC3)ccnc2c1	Preclinical
flosequinan	phosphodiesterase inhibitor				Key	99.63	Cn1cc([S@@](C)=O)c(=O)c2ccc(F)cc12 |r|	Withdrawn
floxuridine	DNA synthesis inhibitor	TYMS	oncology	colorectal cancer	Selleck, Selleck, Selleck	100	OC[C@H]1O[C@H](C[C@@H]1O)n1cc(F)c(=O)[nH]c1=O, OC[C@H]1O[C@H](C[C@@H]1O)n1cc(F)c(=O)[nH]c1=O, OC[C@H]1O[C@H](C[C@@H]1O)n1cc(F)c(=O)[nH]c1=O	Launched
FLT3-IN-1	FLT3 inhibitor				MedChemEx	97.13	CCCNc1nc(Nc2ccc(cc2)C#N)ncc1C#CCCCNC(=O)[C@H](C)N(C)C(=O)\C=C\CN(C)C	Preclinical
flubendazole	tubulin polymerization inhibitor	TUBB	infectious disease	gastrointestinal parasites	MicroSource, MicroSource, MicroSource, MedChemEx, Selleck	97.49	COC(=O)Nc1nc2ccc(cc2[nH]1)C(=O)c1ccc(F)cc1, COC(=O)Nc1nc2ccc(cc2[nH]1)C(=O)c1ccc(F)cc1, COC(=O)Nc1nc2ccc(cc2[nH]1)C(=O)c1ccc(F)cc1, COC(=O)Nc1nc2ccc(cc2[nH]1)C(=O)c1ccc(F)cc1, COC(=O)Nc1nc2ccc(cc2[nH]1)C(=O)c1ccc(F)cc1	Launched
flucloxacillin	bacterial cell wall synthesis inhibitor		infectious disease, otolaryngology, dermatology, gastroenterology	gram-positive bacterial infections, tonsillitis, sinusitis, pneumonia, eczema, endocarditis, meningitis, enteritis, bacterial septicemia	Sigma, Prestwick	78.07	Cc1onc(c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O)-c1c(F)cccc1Cl, Cc1onc(c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O)-c1c(F)cccc1Cl	Launched
fluconazole	sterol demethylase inhibitor	CYP51A1	infectious disease	esophageal candidiasis, meningitis	MicroSource, Sigma, Selleck	97.95	OC(Cn1cncn1)(Cn1cncn1)c1ccc(F)cc1F, OC(Cn1cncn1)(Cn1cncn1)c1ccc(F)cc1F, OC(Cn1cncn1)(Cn1cncn1)c1ccc(F)cc1F	Launched
flucytosine	other antifungal	DNMT1	infectious disease	bacterial septicemia, endocarditis, urinary tract infections, meningitis	MedChemEx, MicroSource, Selleck, Selleck	100	Nc1nc(=O)[nH]cc1F, Nc1nc(=O)[nH]cc1F, Nc1nc(=O)[nH]cc1F, Nc1nc(=O)[nH]cc1F	Launched
fludarabine	ribonucleotide reductase inhibitor	ADA, DCK, POLA1, RRM1, RRM2	hematologic malignancy	chronic lymphocytic leukemia (CLL)	Tocris, Tocris, Tocris, Tocris, Selleck, Selleck	98.32	Nc1nc(F)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O, Nc1nc(F)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O, Nc1nc(F)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O, Nc1nc(F)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O, Nc1nc(F)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O, Nc1nc(F)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O	Launched
fludarabine-phosphate	ribonucleotide reductase inhibitor	POLA1, POLD1, POLE, RRM1, RRM2, RRM2B	hematologic malignancy	chronic lymphocytic leukemia (CLL)	MicroSource, MicroSource, Selleck, Selleck	96.99	Nc1nc(F)nc2n(cnc12)[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O, Nc1nc(F)nc2n(cnc12)[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O, Nc1nc(F)nc2n(cnc12)[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O, Nc1nc(F)nc2n(cnc12)[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O	Launched
fludrocortisone-acetate		NR3C2	endocrinology	Addison's disease, adrenogenital syndrome	MicroSource, MicroSource, MedChemEx, MedChemEx, Sigma	92.71	CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C |t:15|, CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C |t:15|, CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C |t:15|, CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C |t:15|, CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C |t:15|	Launched
fludroxycortide	glucocorticoid receptor agonist	NR3C1, SERPINA6	infectious disease, dermatology	skin infections, psoriasis	MedChemEx	91.88	CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)CC[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO |t:11|	Launched
flufenamic-acid	chloride channel blocker	AKR1C3, ANO1, AR, GJA1, GJA10, GJA3, GJA4, GJA5, GJA8, GJA9, GJB1, GJB2, GJB3, GJB4, GJB5, GJB6, GJB7, GJC1, GJC2, GJC3, GJD2, GJD3, GJD4, GJE1, PANX1, PANX2, PANX3, PKD2L1, PTGS1, PTGS2, TRPC5, TRPM2, TRPM5			MicroSource, Selleck	99.37	OC(=O)c1ccccc1Nc1cccc(c1)C(F)(F)F, OC(=O)c1ccccc1Nc1cccc(c1)C(F)(F)F	Preclinical
flumatinib	Bcr-Abl kinase inhibitor	ABL1, PDGFRB			MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx	97.8	CN1CCN(Cc2ccc(cc2C(F)(F)F)C(=O)Nc2cnc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2C(F)(F)F)C(=O)Nc2cnc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2C(F)(F)F)C(=O)Nc2cnc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2C(F)(F)F)C(=O)Nc2cnc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2C(F)(F)F)C(=O)Nc2cnc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2C(F)(F)F)C(=O)Nc2cnc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1	Phase 3
flumazenil	benzodiazepine receptor antagonist	GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ	neurology/psychiatry	sedative	Tocris, MicroSource, Tocris, Selleck, Tocris	99.3	CCOC(=O)c1ncn-2c1CN(C)C(=O)c1cc(F)ccc-21, CCOC(=O)c1ncn-2c1CN(C)C(=O)c1cc(F)ccc-21, CCOC(=O)c1ncn-2c1CN(C)C(=O)c1cc(F)ccc-21, CCOC(=O)c1ncn-2c1CN(C)C(=O)c1cc(F)ccc-21, CCOC(=O)c1ncn-2c1CN(C)C(=O)c1cc(F)ccc-21	Launched
flumecinol					Enamine	97.8	CC[C@@](O)(c1ccccc1)c1cccc(c1)C(F)(F)F |&1:2,r|	Launched
flumequine	topoisomerase inhibitor		infectious disease	urinary tract infections	MicroSource, MedChemEx, Selleck, Selleck, Selleck	98.1	C[C@H]1CCc2cc(F)cc3c2n1cc(C(O)=O)c3=O |&1:1,r|, C[C@H]1CCc2cc(F)cc3c2n1cc(C(O)=O)c3=O |&1:1,r|, C[C@H]1CCc2cc(F)cc3c2n1cc(C(O)=O)c3=O |&1:1,r|, C[C@H]1CCc2cc(F)cc3c2n1cc(C(O)=O)c3=O |&1:1,r|, C[C@H]1CCc2cc(F)cc3c2n1cc(C(O)=O)c3=O |&1:1,r|	Launched
flumethasone	glucocorticoid receptor agonist	NR3C1, PLA2G1B	otolaryngology, infectious disease, dermatology	otitis, ear infections, corticosteroid-responsive dermatoses	MedChemEx, MicroSource, Selleck, Selleck, Selleck, Selleck	97.76	C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO |c:12,t:8|, C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO |c:12,t:8|, C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO |c:12,t:8|, C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO |c:12,t:8|, C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO |c:12,t:8|, C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO |c:12,t:8|	Launched
flumethasone-pivalate	glucocorticoid receptor agonist	NR3C1, SERPINA6	allergy	allergic rhinitis	Sigma	94.44	C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COC(=O)C(C)(C)C |c:12,t:8|	Launched
flumexadol					Enamine, Enamine	29.46	FC(F)(F)c1cccc(c1)[C@H]1CNCCO1 |&1:10,r|, FC(F)(F)c1cccc(c1)[C@H]1CNCCO1 |&1:10,r|	Preclinical
flunarizine	calcium channel blocker	CACNA1G, CACNA1H, CACNA1I, CALM1, HRH1	neurology/psychiatry, cardiology	migraine headache, vertigo, peripheral artery disease (PAD)	Tocris, Selleck, Selleck, Selleck, Selleck, MicroSource, MicroSource, Tocris	98.96	Fc1ccc(cc1)C(N1CCN(C\C=C\c2ccccc2)CC1)c1ccc(F)cc1, Fc1ccc(cc1)C(N1CCN(C\C=C\c2ccccc2)CC1)c1ccc(F)cc1, Fc1ccc(cc1)C(N1CCN(C\C=C\c2ccccc2)CC1)c1ccc(F)cc1, Fc1ccc(cc1)C(N1CCN(C\C=C\c2ccccc2)CC1)c1ccc(F)cc1, Fc1ccc(cc1)C(N1CCN(C\C=C\c2ccccc2)CC1)c1ccc(F)cc1, Fc1ccc(cc1)C(N1CCN(C\C=C\c2ccccc2)CC1)c1ccc(F)cc1, Fc1ccc(cc1)C(N1CCN(C\C=C\c2ccccc2)CC1)c1ccc(F)cc1, Fc1ccc(cc1)C(N1CCN(C\C=C\c2ccccc2)CC1)c1ccc(F)cc1	Launched
flunisolide	cytochrome P450 inhibitor	NR3C1	allergy	allergic rhinitis	MedChemEx	91.32	CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO |c:15,t:11|	Launched
flunixin-meglumin	prostanoid receptor antagonist		pulmonary	bovine respiratory disease (BRD)	MicroSource, MedChemEx, Selleck	99.53	Cc1c(Nc2ncccc2C(O)=O)cccc1C(F)(F)F, Cc1c(Nc2ncccc2C(O)=O)cccc1C(F)(F)F, Cc1c(Nc2ncccc2C(O)=O)cccc1C(F)(F)F	Launched
fluocinolone-acetonide	glucocorticoid receptor agonist	NR3C1, SERPINA6	dermatology	seborrheic dermatitis	MedChemEx, MedChemEx, MicroSource, Selleck, Selleck	97.2	CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO |c:15,t:11|, CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO |c:15,t:11|, CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO |c:15,t:11|, CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO |c:15,t:11|, CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO |c:15,t:11|	Launched
fluocinonide	glucocorticoid receptor agonist	NR3C1, SERPINA6, SMO	dermatology	seborrheic dermatitis, eczema	MedChemEx, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck	93.28	CC(=O)OCC(=O)[C@@]12OC(C)(C)O[C@@H]1C[C@H]1[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]21C |c:25,t:21|, CC(=O)OCC(=O)[C@@]12OC(C)(C)O[C@@H]1C[C@H]1[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]21C |c:25,t:21|, CC(=O)OCC(=O)[C@@]12OC(C)(C)O[C@@H]1C[C@H]1[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]21C |c:25,t:21|, CC(=O)OCC(=O)[C@@]12OC(C)(C)O[C@@H]1C[C@H]1[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]21C |c:25,t:21|, CC(=O)OCC(=O)[C@@]12OC(C)(C)O[C@@H]1C[C@H]1[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]21C |c:25,t:21|, CC(=O)OCC(=O)[C@@]12OC(C)(C)O[C@@H]1C[C@H]1[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]21C |c:25,t:21|, CC(=O)OCC(=O)[C@@]12OC(C)(C)O[C@@H]1C[C@H]1[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]21C |c:25,t:21|	Launched
fluorescein		SLC22A6	ophthalmology	ophthalmology diagnostic	MicroSource, MedChemEx	95.86	Oc1ccc2c(Oc3cc(O)ccc3C22OC(=O)c3ccccc23)c1, Oc1ccc2c(Oc3cc(O)ccc3C22OC(=O)c3ccccc23)c1	Launched
fluorometholone	glucocorticoid receptor agonist	NR3C1	ophthalmology	eye inflammation		0		Launched
fluorometholone-acetate		NR3C1	ophthalmology	eye inflammation	Selleck, Selleck, Selleck, Selleck	97.54	C[C@H]1C[C@H]2[C@@H]3CC[C@](OC(C)=O)(C(C)=O)[C@@]3(C)C[C@H](O)[C@]2(F)[C@@]2(C)C=CC(=O)C=C12 |c:26,t:30|, C[C@H]1C[C@H]2[C@@H]3CC[C@](OC(C)=O)(C(C)=O)[C@@]3(C)C[C@H](O)[C@]2(F)[C@@]2(C)C=CC(=O)C=C12 |c:26,t:30|, C[C@H]1C[C@H]2[C@@H]3CC[C@](OC(C)=O)(C(C)=O)[C@@]3(C)C[C@H](O)[C@]2(F)[C@@]2(C)C=CC(=O)C=C12 |c:26,t:30|, C[C@H]1C[C@H]2[C@@H]3CC[C@](OC(C)=O)(C(C)=O)[C@@]3(C)C[C@H](O)[C@]2(F)[C@@]2(C)C=CC(=O)C=C12 |c:26,t:30|	Launched
fluoromethylcholine					MatrixSci	100	C[N+](C)(CF)CCO	Launched
fluoxetine	selective serotonin reuptake inhibitor (SSRI)	ANO1, HTR2B, SLC6A4	neurology/psychiatry	depression, obsessive compulsive disorder (OCD), bulimia nervosa, panic disorders, bipolar disorder	MicroSource, Selleck, Tocris, Tocris	98.86	CNCCC(Oc1ccc(cc1)C(F)(F)F)c1ccccc1, CNCCC(Oc1ccc(cc1)C(F)(F)F)c1ccccc1, CNCCC(Oc1ccc(cc1)C(F)(F)F)c1ccccc1, CNCCC(Oc1ccc(cc1)C(F)(F)F)c1ccccc1	Launched
flupentixol	dopamine receptor antagonist	ADRA1A, CHRM1, DRD1, DRD2, DRD3, DRD5, HTR2A	neurology/psychiatry	schizophrenia, depression	Enzo, Enzo	93.69	OCCN1CCN(CC\C=C2\c3ccccc3Sc3ccc(cc23)C(F)(F)F)CC1, OCCN1CCN(CC\C=C2\c3ccccc3Sc3ccc(cc23)C(F)(F)F)CC1	Launched
fluphenazine	dopamine receptor antagonist	CALM1, DRD1, DRD2, DRD5, HRH1, HTR2A, HTR6, HTR7	neurology/psychiatry	schizophrenia	MicroSource, MicroSource, MicroSource	95.33	OCCN1CCN(CCCN2c3ccccc3Sc3ccc(cc23)C(F)(F)F)CC1, OCCN1CCN(CCCN2c3ccccc3Sc3ccc(cc23)C(F)(F)F)CC1, OCCN1CCN(CCCN2c3ccccc3Sc3ccc(cc23)C(F)(F)F)CC1	Launched
fluphenazine-decanoate	dopamine receptor antagonist	DRD2, HTR1B, HTR4	neurology/psychiatry	schizophrenia	AKSci	59.41	CCCCCCCCCC(=O)OCCN1CCN(CCCN2c3ccccc3Sc3ccc(cc23)C(F)(F)F)CC1	Launched
flupirtine	glutamate receptor antagonist	ADRA2A, KCNQ1, KCNQ2	neurology/psychiatry	pain relief	Tocris, MedChemEx, Selleck, Selleck, MedChemEx, Selleck	85.76	CCOC(=O)Nc1ccc(NCc2ccc(F)cc2)nc1N, CCOC(=O)Nc1ccc(NCc2ccc(F)cc2)nc1N, CCOC(=O)Nc1ccc(NCc2ccc(F)cc2)nc1N, CCOC(=O)Nc1ccc(NCc2ccc(F)cc2)nc1N, CCOC(=O)Nc1ccc(NCc2ccc(F)cc2)nc1N, CCOC(=O)Nc1ccc(NCc2ccc(F)cc2)nc1N	Launched
fluprazine	serotonin receptor agonist	HTR1A, HTR1B			Enamine, Enamine	92.16	NC(=O)NCCN1CCN(CC1)c1cccc(c1)C(F)(F)F, NC(=O)NCCN1CCN(CC1)c1cccc(c1)C(F)(F)F	Phase 1
fluralaner	GABA receptor antagonist				MedChemEx	99.1	Cc1cc(ccc1C(=O)NCC(=O)NCC(F)(F)F)C1=NO[C@](C1)(c1cc(Cl)cc(Cl)c1)C(F)(F)F |&1:22,r,t:20|	Preclinical
flurbiprofen-(+/-)	cyclooxygenase inhibitor		rheumatology	rheumatoid arthritis, osteoarthritis	Tocris, Tocris, MicroSource	98.21	C[C@@H](C(O)=O)c1ccc(c(F)c1)-c1ccccc1 |&1:1,r|, C[C@@H](C(O)=O)c1ccc(c(F)c1)-c1ccccc1 |&1:1,r|, C[C@@H](C(O)=O)c1ccc(c(F)c1)-c1ccccc1 |&1:1,r|	Launched
flurbiprofen-(S)-(+)	cyclooxygenase inhibitor	PTGS1, PTGS2	rheumatology	rheumatoid arthritis, osteoarthritis	Selleck, Selleck	99.2	C[C@H](C(O)=O)c1ccc(c(F)c1)-c1ccccc1, C[C@H](C(O)=O)c1ccc(c(F)c1)-c1ccccc1	Launched
flurbiprofen-axetil	analgesic agent				CombiBlocks	50.9	C[C@H](OC(C)=O)OC(=O)[C@H](C)c1ccc(c(F)c1)-c1ccccc1 |&1:9,&2:1,r|	Launched
flurizan	gamma secretase inhibitor	APH1B, BACE1, IKBKG, PSEN1, PSEN2, PTGS1, PTGS2			Tocris, Tocris, Tocris, Tocris	98.84	C[C@@H](C(O)=O)c1ccc(c(F)c1)-c1ccccc1, C[C@@H](C(O)=O)c1ccc(c(F)c1)-c1ccccc1, C[C@@H](C(O)=O)c1ccc(c(F)c1)-c1ccccc1, C[C@@H](C(O)=O)c1ccc(c(F)c1)-c1ccccc1	Phase 3
flurofamide	urease inhibitor				Tocris, Tocris, Tocris	73.24	NP(N)(=O)NC(=O)c1ccc(F)cc1, NP(N)(=O)NC(=O)c1ccc(F)cc1, NP(N)(=O)NC(=O)c1ccc(F)cc1	Preclinical
flurothyl					MicroSource, MicroSource, TCI	0	FC(F)(F)COCC(F)(F)F, FC(F)(F)COCC(F)(F)F, FC(F)(F)COCC(F)(F)F	Preclinical
fluroxene	local anesthetic				MicroSource, MedChemEx	0	FC(F)(F)COC=C, FC(F)(F)COC=C	Preclinical
fluspirilene	dopamine receptor antagonist	CACNG1, DRD2, HRH1, HTR1A, HTR1D, HTR1E, HTR2A	neurology/psychiatry	schizophrenia	Enzo, Enzo, Enzo, Sigma	96.22	Fc1ccc(cc1)C(CCCN1CCC2(CC1)N(CNC2=O)c1ccccc1)c1ccc(F)cc1, Fc1ccc(cc1)C(CCCN1CCC2(CC1)N(CNC2=O)c1ccccc1)c1ccc(F)cc1, Fc1ccc(cc1)C(CCCN1CCC2(CC1)N(CNC2=O)c1ccccc1)c1ccc(F)cc1, Fc1ccc(cc1)C(CCCN1CCC2(CC1)N(CNC2=O)c1ccccc1)c1ccc(F)cc1	Launched
flutamide	androgen receptor antagonist	AHR, AR	oncology	prostate cancer	Tocris, MicroSource, Selleck	99.28	CC(C)C(=O)Nc1ccc(c(c1)C(F)(F)F)[N+]([O-])=O, CC(C)C(=O)Nc1ccc(c(c1)C(F)(F)F)[N+]([O-])=O, CC(C)C(=O)Nc1ccc(c(c1)C(F)(F)F)[N+]([O-])=O	Launched
fluticasone-propionate	glucocorticoid receptor agonist	NR3C1, NR3C2, PGR, PLA2G4A	dermatology	corticosteroid-responsive dermatoses	Tocris, Tocris, Selleck, Selleck, Selleck, Tocris	96.66	CCC(=O)O[C@@]1([C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)SCF |c:18,t:14|, CCC(=O)O[C@@]1([C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)SCF |c:18,t:14|, CCC(=O)O[C@@]1([C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)SCF |c:18,t:14|, CCC(=O)O[C@@]1([C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)SCF |c:18,t:14|, CCC(=O)O[C@@]1([C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)SCF |c:18,t:14|, CCC(=O)O[C@@]1([C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)SCF |c:18,t:14|	Launched
flutrimazole	sterol demethylase inhibitor		infectious disease	mycosis	SantaCruz	99.39	Fc1ccc(cc1)C(c1ccccc1)(c1ccccc1F)n1ccnc1 |&1:7|	Launched
fluvastatin	HMGCR inhibitor	HMGCR	endocrinology, cardiology	hypercholesterolemia, congenital heart defects	MicroSource, Tocris, Tocris, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck	97.47	CC(C)n1c(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)c(-c2ccc(F)cc2)c2ccccc12, CC(C)n1c(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)c(-c2ccc(F)cc2)c2ccccc12, CC(C)n1c(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)c(-c2ccc(F)cc2)c2ccccc12, CC(C)n1c(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)c(-c2ccc(F)cc2)c2ccccc12, CC(C)n1c(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)c(-c2ccc(F)cc2)c2ccccc12, CC(C)n1c(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)c(-c2ccc(F)cc2)c2ccccc12, CC(C)n1c(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)c(-c2ccc(F)cc2)c2ccccc12, CC(C)n1c(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)c(-c2ccc(F)cc2)c2ccccc12, CC(C)n1c(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)c(-c2ccc(F)cc2)c2ccccc12, CC(C)n1c(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)c(-c2ccc(F)cc2)c2ccccc12	Launched
fluvoxamine	selective serotonin reuptake inhibitor (SSRI)	SLC6A4	neurology/psychiatry	obsessive compulsive disorder (OCD)	MicroSource, Tocris, Tocris, Selleck, Selleck	95.13	COCCCC\C(=N/OCCN)c1ccc(cc1)C(F)(F)F, COCCCC\C(=N/OCCN)c1ccc(cc1)C(F)(F)F, COCCCC\C(=N/OCCN)c1ccc(cc1)C(F)(F)F, COCCCC\C(=N/OCCN)c1ccc(cc1)C(F)(F)F, COCCCC\C(=N/OCCN)c1ccc(cc1)C(F)(F)F	Launched
fmoc-L-leucine	PPAR receptor agonist				Sigma, Sigma	99.78	CC(C)C[C@H](NC(=O)OCC1c2ccccc2-c2ccccc12)C(O)=O, CC(C)C[C@H](NC(=O)OCC1c2ccccc2-c2ccccc12)C(O)=O	Phase 2
FN-1501	tyrosine kinase inhibitor				MedChemEx, MedChemEx	95.77	CN1CCN(Cc2ccc(NC(=O)c3[nH]ncc3Nc3ncnc4[nH]ccc34)cc2)CC1, CN1CCN(Cc2ccc(NC(=O)c3[nH]ncc3Nc3ncnc4[nH]ccc34)cc2)CC1	Phase 1
folic-acid	folate receptor ligand	FOLR2, FOLR3, SLC19A1, SLC46A1	hematology	megaloblastic anemia	MicroSource	89.21	Nc1nc(=O)c2nc(CNc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)cnc2[nH]1	Launched
fomepizole	alcohol dehydrogenase inhibitor	ADH1A, ADH1B, ADH1C, AKR1A1, CAT	critical care	poison antidote	MicroSource, MicroSource, MedChemEx, MedChemEx, MicroSource	98.99	Cc1cn[nH]c1, Cc1cn[nH]c1, Cc1cn[nH]c1, Cc1cn[nH]c1, Cc1cn[nH]c1	Launched
fomocaine	voltage-gated sodium channel modulator		neurology/psychiatry	local anesthetic	Sigma, ChemDiv	96.22	C(CN1CCOCC1)Cc1ccc(COc2ccccc2)cc1, C(CN1CCOCC1)Cc1ccc(COc2ccccc2)cc1	Launched
fondaparinux	coagulation factor inhibitor	F10, SERPINC1	hematology	deep vein thrombosis (DVT)	MedChemEx	93.3	[H][C@@]1(O[C@@H]2[C@@H](COS(O)(=O)=O)O[C@H](O[C@@]3([H])[C@H](O)[C@@H](OS(O)(=O)=O)[C@H](O[C@@]4([H])[C@H](O)[C@@H](NS(O)(=O)=O)[C@@H](OC)O[C@@H]4COS(O)(=O)=O)O[C@H]3C(O)=O)[C@H](NS(O)(=O)=O)[C@H]2OS(O)(=O)=O)O[C@@H]([C@@H](O[C@@]2([H])O[C@H](COS(O)(=O)=O)[C@@H](O)[C@H](O)[C@H]2NS(O)(=O)=O)[C@H](O)[C@H]1O)C(O)=O	Launched
foretinib	VEGFR inhibitor	FLT1, FLT4, KDR, MET			Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck	98.42	COc1cc2c(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3F)ccnc2cc1OCCCN1CCOCC1, COc1cc2c(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3F)ccnc2cc1OCCCN1CCOCC1, COc1cc2c(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3F)ccnc2cc1OCCCN1CCOCC1, COc1cc2c(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3F)ccnc2cc1OCCCN1CCOCC1, COc1cc2c(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3F)ccnc2cc1OCCCN1CCOCC1, COc1cc2c(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3F)ccnc2cc1OCCCN1CCOCC1, COc1cc2c(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3F)ccnc2cc1OCCCN1CCOCC1	Phase 2
formestane	aromatase inhibitor	CYP19A1	oncology	breast cancer	MicroSource, MicroSource, MedChemEx, Selleck	100	C[C@]12CC[C@H]3[C@@H](CC[C@H]4C(=O)C(=O)CC[C@]34C)[C@@H]1CCC2=O |a:1,4,5,15,17,&1:8|, C[C@]12CC[C@H]3[C@@H](CC[C@H]4C(=O)C(=O)CC[C@]34C)[C@@H]1CCC2=O |a:1,4,5,15,17,&1:8|, C[C@]12CC[C@H]3[C@@H](CC[C@H]4C(=O)C(=O)CC[C@]34C)[C@@H]1CCC2=O |a:1,4,5,15,17,&1:8|, C[C@]12CC[C@H]3[C@@H](CC[C@H]4C(=O)C(=O)CC[C@]34C)[C@@H]1CCC2=O |a:1,4,5,15,17,&1:8|	Launched
formononetin	alcohol dehydrogenase inhibitor	ADH1C, SLC5A2			MedChemEx, Selleck, Selleck	96.93	COc1ccc(cc1)-c1coc2cc(O)ccc2c1=O, COc1ccc(cc1)-c1coc2cc(O)ccc2c1=O, COc1ccc(cc1)-c1coc2cc(O)ccc2c1=O	Preclinical
formoterol	adrenergic receptor agonist	ADRB2	pulmonary	asthma, chronic obstructive pulmonary disease (COPD), bronchospasm	Tocris, Tocris, Selleck, Tocris, Selleck, Selleck, Tocris	98.09	COc1ccc(C[C@H](C)NC[C@@H](O)c2ccc(O)c(NC=O)c2)cc1, COc1ccc(C[C@H](C)NC[C@@H](O)c2ccc(O)c(NC=O)c2)cc1, COc1ccc(C[C@H](C)NC[C@@H](O)c2ccc(O)c(NC=O)c2)cc1, COc1ccc(C[C@H](C)NC[C@@H](O)c2ccc(O)c(NC=O)c2)cc1, COc1ccc(C[C@H](C)NC[C@@H](O)c2ccc(O)c(NC=O)c2)cc1, COc1ccc(C[C@H](C)NC[C@@H](O)c2ccc(O)c(NC=O)c2)cc1, COc1ccc(C[C@H](C)NC[C@@H](O)c2ccc(O)c(NC=O)c2)cc1	Launched
forodesine	purinergic receptor antagonist	PNP	hematologic malignancy	peripheral T-cell lymphoma (PTCL)	MedChemEx, MedChemEx, MedChemEx, MedChemEx	100	OC[C@H]1N[C@H]([C@H](O)[C@@H]1O)c1c[nH]c2c1[nH]cnc2=O, OC[C@H]1N[C@H]([C@H](O)[C@@H]1O)c1c[nH]c2c1[nH]cnc2=O, OC[C@H]1N[C@H]([C@H](O)[C@@H]1O)c1c[nH]c2c1[nH]cnc2=O, OC[C@H]1N[C@H]([C@H](O)[C@@H]1O)c1c[nH]c2c1[nH]cnc2=O	Launched
foropafant	platelet activating factor receptor antagonist	PTAFR			Sigma, Sigma, Sigma	97.36	CC(C)c1cc(C(C)C)c(-c2csc(n2)N(CCN(C)C)Cc2cccnc2)c(c1)C(C)C, CC(C)c1cc(C(C)C)c(-c2csc(n2)N(CCN(C)C)Cc2cccnc2)c(c1)C(C)C, CC(C)c1cc(C(C)C)c(-c2csc(n2)N(CCN(C)C)Cc2cccnc2)c(c1)C(C)C	Phase 3
forskolin	adenylyl cyclase activator	ADCY2, ADCY5, GNAS			Tocris, Tocris, Tocris, Selleck, Selleck, Selleck	100	CC(=O)O[C@H]1[C@@H](O)[C@H]2C(C)(C)CC[C@H](O)[C@]2(C)[C@@]2(O)C(=O)C[C@@](C)(O[C@]12C)C=C, CC(=O)O[C@H]1[C@@H](O)[C@H]2C(C)(C)CC[C@H](O)[C@]2(C)[C@@]2(O)C(=O)C[C@@](C)(O[C@]12C)C=C, CC(=O)O[C@H]1[C@@H](O)[C@H]2C(C)(C)CC[C@H](O)[C@]2(C)[C@@]2(O)C(=O)C[C@@](C)(O[C@]12C)C=C, CC(=O)O[C@H]1[C@@H](O)[C@H]2C(C)(C)CC[C@H](O)[C@]2(C)[C@@]2(O)C(=O)C[C@@](C)(O[C@]12C)C=C, CC(=O)O[C@H]1[C@@H](O)[C@H]2C(C)(C)CC[C@H](O)[C@]2(C)[C@@]2(O)C(=O)C[C@@](C)(O[C@]12C)C=C, CC(=O)O[C@H]1[C@@H](O)[C@H]2C(C)(C)CC[C@H](O)[C@]2(C)[C@@]2(O)C(=O)C[C@@](C)(O[C@]12C)C=C	Launched
fosamprenavir	HIV protease inhibitor		infectious disease	human immunodeficiency virus (HIV-1)	MedChemEx, MedChemEx, MedChemEx, MedChemEx	96.18	CC(C)CN(C[C@@H](OP(O)(O)=O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)c1ccc(N)cc1, CC(C)CN(C[C@@H](OP(O)(O)=O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)c1ccc(N)cc1, CC(C)CN(C[C@@H](OP(O)(O)=O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)c1ccc(N)cc1, CC(C)CN(C[C@@H](OP(O)(O)=O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)c1ccc(N)cc1	Launched
fosaprepitant-dimeglumine	tachykinin antagonist	TACR1	gastroenterology	nausea, vomiting	MedChemEx, MedChemEx, Selleck, Selleck, Selleck	78.2	C[C@@H](O[C@H]1OCCN(Cc2nn(c(=O)[nH]2)P(O)(O)=O)[C@H]1c1ccc(F)cc1)c1cc(cc(c1)C(F)(F)F)C(F)(F)F, C[C@@H](O[C@H]1OCCN(Cc2nn(c(=O)[nH]2)P(O)(O)=O)[C@H]1c1ccc(F)cc1)c1cc(cc(c1)C(F)(F)F)C(F)(F)F, C[C@@H](O[C@H]1OCCN(Cc2nn(c(=O)[nH]2)P(O)(O)=O)[C@H]1c1ccc(F)cc1)c1cc(cc(c1)C(F)(F)F)C(F)(F)F, C[C@@H](O[C@H]1OCCN(Cc2nn(c(=O)[nH]2)P(O)(O)=O)[C@H]1c1ccc(F)cc1)c1cc(cc(c1)C(F)(F)F)C(F)(F)F, C[C@@H](O[C@H]1OCCN(Cc2nn(c(=O)[nH]2)P(O)(O)=O)[C@H]1c1ccc(F)cc1)c1cc(cc(c1)C(F)(F)F)C(F)(F)F	Launched
fosbretabulin	tubulin polymerization inhibitor, VE-cadherin antagonist	CDH5			MedChemEx, MedChemEx, MedChemEx, MedChemEx	90.79	COc1ccc(\C=C/c2cc(OC)c(OC)c(OC)c2)cc1OP(O)(O)=O, COc1ccc(\C=C/c2cc(OC)c(OC)c(OC)c2)cc1OP(O)(O)=O, COc1ccc(\C=C/c2cc(OC)c(OC)c(OC)c2)cc1OP(O)(O)=O, COc1ccc(\C=C/c2cc(OC)c(OC)c(OC)c2)cc1OP(O)(O)=O	Phase 3
foscarnet	DNA polymerase inhibitor		infectious disease	cytomegalovirus retinitis, acquired immunodeficiency syndrome (AIDS), virus herpes simplex (HSV)	MicroSource, Selleck, Selleck, Selleck	0	OC(=O)P(O)(O)=O, OC(=O)P(O)(O)=O, OC(=O)P(O)(O)=O, OC(=O)P(O)(O)=O	Launched
fosfestrol	synthetic estrogen	ESR1, ESR2	oncology	prostate cancer	MatrixSci	0	CC\C(=C(\CC)c1ccc(OP(O)(O)=O)cc1)c1ccc(OP(O)(O)=O)cc1	Launched
fosfluconazole	other antifungal				MedChemEx	63.38	OP(O)(=O)OC(Cn1cncn1)(Cn1cncn1)c1ccc(F)cc1F	Preclinical
fosfomycin	bacterial cell wall synthesis inhibitor		infectious disease	urinary tract infections	MedChemEx, Selleck, CombiBlocks	100	C[C@@H]1O[C@@H]1P(O)(O)=O, C[C@@H]1O[C@@H]1P(O)(O)=O, C[C@@H]1O[C@@H]1P(O)(O)=O	Launched
fosfosal	phosphodiesterase inhibitor	PTGS1, PTGS2	neurology/psychiatry	pain relief	MicroSource, Sigma, Sigma	84.64	OC(=O)c1ccccc1OP(O)(O)=O, OC(=O)c1ccccc1OP(O)(O)=O, OC(=O)c1ccccc1OP(O)(O)=O	Launched
fosfructose	fructose diphosphate stimulant				CombiBlocks	1.47	O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)C(=O)COP(O)(O)=O	Phase 3
fosinopril	angiotensin converting enzyme inhibitor	ACE	cardiology	hypertension, congestive heart failure	Selleck, Selleck, Selleck, Selleck, Selleck	97.48	CCC(=O)O[C@@H](OP(=O)(CCCCc1ccccc1)CC(=O)N1C[C@@H](C[C@H]1C(O)=O)C1CCCCC1)C(C)C |a:5,24,26,&1:7|, CCC(=O)O[C@@H](OP(=O)(CCCCc1ccccc1)CC(=O)N1C[C@@H](C[C@H]1C(O)=O)C1CCCCC1)C(C)C |a:5,24,26,&1:7|, CCC(=O)O[C@@H](OP(=O)(CCCCc1ccccc1)CC(=O)N1C[C@@H](C[C@H]1C(O)=O)C1CCCCC1)C(C)C |a:5,24,26,&1:7|, CCC(=O)O[C@@H](OP(=O)(CCCCc1ccccc1)CC(=O)N1C[C@@H](C[C@H]1C(O)=O)C1CCCCC1)C(C)C |a:5,24,26,&1:7|, CCC(=O)O[C@@H](OP(=O)(CCCCc1ccccc1)CC(=O)N1C[C@@H](C[C@H]1C(O)=O)C1CCCCC1)C(C)C |a:5,24,26,&1:7|	Launched
fosinoprilat	angiotensin converting enzyme inhibitor	ACE	cardiology	hypertension	AvaChem	61.88	OC(=O)[C@@H]1C[C@H](CN1C(=O)C[P@](O)(=O)CCCCc1ccccc1)C1CCCCC1 |a:3,5,&1:11|	Launched
fosphenytoin	sodium channel blocker	SCN5A	neurology/psychiatry	epilepsy, seizures	CombiBlocks, CombiBlocks, AKSci	94.91	OP(O)(=O)OCN1C(=O)NC(C1=O)(c1ccccc1)c1ccccc1, OP(O)(=O)OCN1C(=O)NC(C1=O)(c1ccccc1)c1ccccc1, OP(O)(=O)OCN1C(=O)NC(C1=O)(c1ccccc1)c1ccccc1	Launched
fostamatinib	SYK inhibitor	SYK	hematology	chronic immune thrombocytopenia (ITP)	Selleck, MedChemEx, Selleck	92.92	COc1cc(Nc2ncc(F)c(Nc3ccc4OC(C)(C)C(=O)N(COP(O)(O)=O)c4n3)n2)cc(OC)c1OC, COc1cc(Nc2ncc(F)c(Nc3ccc4OC(C)(C)C(=O)N(COP(O)(O)=O)c4n3)n2)cc(OC)c1OC, COc1cc(Nc2ncc(F)c(Nc3ccc4OC(C)(C)C(=O)N(COP(O)(O)=O)c4n3)n2)cc(OC)c1OC	Launched
fostemsavir	antiviral				MedChemEx	97.19	COc1cnc(-n2cnc(C)n2)c2n(COP(O)(O)=O)cc(C(=O)C(=O)N3CCN(CC3)C(=O)c3ccccc3)c12	Phase 3
fotemustine	thioredoxin inhibitor		oncology	melanoma	MedChemEx, MedChemEx	36.92	CCOP(=O)(OCC)[C@@H](C)NC(=O)N(CCCl)[NH2+][O-] |&1:8,r|, CCOP(=O)(OCC)[C@@H](C)NC(=O)N(CCCl)[NH2+][O-] |&1:8,r|	Launched
foxy-5	WNT5a peptide mimetic	WNT5A			Tocris, Tocris	99.26	CSCC[C@H](NC=O)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O, CSCC[C@H](NC=O)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O	Phase 2
FPA-124	AKT inhibitor					0		Preclinical
FPH1-(BRD-6125)	hepatocyte function enhancer				Selleck, Selleck	96.07	Cc1ccc(Cl)cc1N(CC(=O)Nc1c(F)cccc1F)S(C)(=O)=O, Cc1ccc(Cl)cc1N(CC(=O)Nc1c(F)cccc1F)S(C)(=O)=O	Preclinical
FPL-12495	glutamate receptor antagonist				Enamine, Enamine, Enamine	92.23	CC(N)(Cc1ccccc1)c1ccccc1 |&1:1|, CC(N)(Cc1ccccc1)c1ccccc1 |&1:1|, CC(N)(Cc1ccccc1)c1ccccc1 |&1:1|	Phase 1
FPL-55712	leukotriene receptor antagonist				Tocris, Tocris, Tocris, Tocris	97.14	CCCc1c(OC[C@@H](O)COc2ccc3c(oc(cc3=O)C(O)=O)c2CCC)ccc(C(C)=O)c1O |&1:7,r|, CCCc1c(OC[C@@H](O)COc2ccc3c(oc(cc3=O)C(O)=O)c2CCC)ccc(C(C)=O)c1O |&1:7,r|, CCCc1c(OC[C@@H](O)COc2ccc3c(oc(cc3=O)C(O)=O)c2CCC)ccc(C(C)=O)c1O |&1:7,r|, CCCc1c(OC[C@@H](O)COc2ccc3c(oc(cc3=O)C(O)=O)c2CCC)ccc(C(C)=O)c1O |&1:7,r|	Phase 1
FPL-62064	cyclooxygenase inhibitor, lipoxygenase inhibitor				Astatech, Astatech, Astatech	86.14	COc1ccc(Nc2ccn(n2)-c2ccccc2)cc1, COc1ccc(Nc2ccn(n2)-c2ccccc2)cc1, COc1ccc(Nc2ccn(n2)-c2ccccc2)cc1	Phase 2
FPL-64176	calcium channel activator	CACNA1C, CACNA1S			Tocris, Tocris, Tocris, Tocris, Tocris	98.96	COC(=O)c1c(C)[nH]c(C)c1C(=O)c1ccccc1Cc1ccccc1, COC(=O)c1c(C)[nH]c(C)c1C(=O)c1ccccc1Cc1ccccc1, COC(=O)c1c(C)[nH]c(C)c1C(=O)c1ccccc1Cc1ccccc1, COC(=O)c1c(C)[nH]c(C)c1C(=O)c1ccccc1Cc1ccccc1, COC(=O)c1c(C)[nH]c(C)c1C(=O)c1ccccc1Cc1ccccc1	Preclinical
FPS-ZM1	RAGE receptor antagonist	AGER			MedChemEx, MedChemEx	97.01	Clc1ccc(cc1)C(=O)N(Cc1ccccc1)C1CCCCC1, Clc1ccc(cc1)C(=O)N(Cc1ccccc1)C1CCCCC1	Preclinical
FR-122047	cyclooxygenase inhibitor				Tocris, Tocris	98.1	COc1ccc(cc1)-c1nc(sc1-c1ccc(OC)cc1)C(=O)N1CCN(C)CC1, COc1ccc(cc1)-c1nc(sc1-c1ccc(OC)cc1)C(=O)N1CCN(C)CC1	Preclinical
FR-139317	endothelin receptor antagonist	EDNRA			Tocris, Tocris, Tocris, Tocris	97.59	CC(C)C[C@H](NC(=O)N1CCCCCC1)C(=O)N[C@H](Cc1cn(C)c2ccccc12)C(=O)N[C@H](Cc1ccccn1)C(O)=O, CC(C)C[C@H](NC(=O)N1CCCCCC1)C(=O)N[C@H](Cc1cn(C)c2ccccc12)C(=O)N[C@H](Cc1ccccn1)C(O)=O, CC(C)C[C@H](NC(=O)N1CCCCCC1)C(=O)N[C@H](Cc1cn(C)c2ccccc12)C(=O)N[C@H](Cc1ccccn1)C(O)=O, CC(C)C[C@H](NC(=O)N1CCCCCC1)C(=O)N[C@H](Cc1cn(C)c2ccccc12)C(=O)N[C@H](Cc1ccccn1)C(O)=O	Phase 1
FR-180204	MAP kinase inhibitor	MAPK1, MAPK3			Tocris, Tocris, Tocris, Adooq	97.63	Nc1[nH]nc2nnc(cc12)-c1c(nn2ccccc12)-c1ccccc1, Nc1[nH]nc2nnc(cc12)-c1c(nn2ccccc12)-c1ccccc1, Nc1[nH]nc2nnc(cc12)-c1c(nn2ccccc12)-c1ccccc1, Nc1[nH]nc2nnc(cc12)-c1c(nn2ccccc12)-c1ccccc1	Preclinical
FRAX486	serine/threonine kinase inhibitor	PAK1, PAK2, PAK3, PAK4			Tocris, MedChemEx, MedChemEx, MedChemEx, MedChemEx	93.24	CCn1c2nc(Nc3ccc(N4CCNCC4)c(F)c3)ncc2cc(-c2ccc(Cl)cc2Cl)c1=O, CCn1c2nc(Nc3ccc(N4CCNCC4)c(F)c3)ncc2cc(-c2ccc(Cl)cc2Cl)c1=O, CCn1c2nc(Nc3ccc(N4CCNCC4)c(F)c3)ncc2cc(-c2ccc(Cl)cc2Cl)c1=O, CCn1c2nc(Nc3ccc(N4CCNCC4)c(F)c3)ncc2cc(-c2ccc(Cl)cc2Cl)c1=O, CCn1c2nc(Nc3ccc(N4CCNCC4)c(F)c3)ncc2cc(-c2ccc(Cl)cc2Cl)c1=O	Preclinical
frentizole	immunosuppressant				MedChemEx, MedChemEx, MedChemEx	87.55	COc1ccc2nc(NC(=O)Nc3ccccc3)sc2c1, COc1ccc2nc(NC(=O)Nc3ccccc3)sc2c1, COc1ccc2nc(NC(=O)Nc3ccccc3)sc2c1	Phase 1
freselestat	elastase inhibitor	CELA1, ELANE			Adooq	92.52	CC(C)[C@@H](NC(=O)Cn1c(ncc(N)c1=O)-c1ccccc1)[C@@H](O)c1nnc(o1)C(C)(C)C	Preclinical
frovatriptan	serotonin receptor agonist	HTR1A, HTR1B, HTR1D	neurology/psychiatry	migraine headache	Sigma	91.96	CN[C@@H]1CCc2[nH]c3ccc(cc3c2C1)C(N)=O	Launched
fruquintinib	VEGFR inhibitor	KDR	oncology	colorectal cancer	MedChemEx, MedChemEx, MedChemEx	97.88	CNC(=O)c1c(C)oc2cc(Oc3ncnc4cc(OC)c(OC)cc34)ccc12, CNC(=O)c1c(C)oc2cc(Oc3ncnc4cc(OC)c(OC)cc34)ccc12, CNC(=O)c1c(C)oc2cc(Oc3ncnc4cc(OC)c(OC)cc34)ccc12	Launched
ftaxilide					MedChemEx, MicroSource	91.41	Cc1cccc(C)c1NC(=O)c1ccccc1C(O)=O, Cc1cccc(C)c1NC(=O)c1ccccc1C(O)=O	Preclinical
ftorafur	thymidylate synthase inhibitor	TYMS	oncology	colorectal cancer	Selleck, Selleck, Selleck, Selleck, MedChemEx	100	Fc1cn([C@H]2CCCO2)c(=O)[nH]c1=O, Fc1cn([C@H]2CCCO2)c(=O)[nH]c1=O, Fc1cn([C@H]2CCCO2)c(=O)[nH]c1=O, Fc1cn([C@H]2CCCO2)c(=O)[nH]c1=O, Fc1cn([C@H]2CCCO2)c(=O)[nH]c1=O	Launched
FT011	TGF beta receptor inhibitor				MedChemEx	95.13	COc1cc(\C=C\C(=O)Nc2ccccc2C(O)=O)ccc1OCC#C	Preclinical
fucoxanthin	anticancer agent				MedChemEx	100	[H]C(=[C@@]=C1C(C)(C)C[C@@H](C[C@@]1(C)O)OC(C)=O)C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)C(=O)C[C@]12O[C@@]1(C)C[C@H](O)CC2(C)C	Phase 2
fudosteine	mucolytic agent		pulmonary	chest congestion	MedChemEx, Selleck, Selleck	100	N[C@@H](CSCCCO)C(O)=O, N[C@@H](CSCCCO)C(O)=O, N[C@@H](CSCCCO)C(O)=O	Launched
fulvestrant	estrogen receptor antagonist	ESR1, ESR2, GPER1	oncology	breast cancer	Tocris, Tocris, MicroSource, MicroSource, MicroSource, Tocris, Tocris, Tocris, Tocris, Tocris, Selleck, Selleck, Selleck	97.7	C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)[C@H](CCCCCCCCC[S@@](=O)CCCC(F)(F)C(F)(F)F)Cc1cc(O)ccc31 |a:1,4,5,6,9,11,&1:21|, C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)[C@H](CCCCCCCCC[S@@](=O)CCCC(F)(F)C(F)(F)F)Cc1cc(O)ccc31 |a:1,4,5,6,9,11,&1:21|, C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)[C@H](CCCCCCCCC[S@@](=O)CCCC(F)(F)C(F)(F)F)Cc1cc(O)ccc31 |a:1,4,5,6,9,11,&1:21|, C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)[C@H](CCCCCCCCC[S@@](=O)CCCC(F)(F)C(F)(F)F)Cc1cc(O)ccc31 |a:1,4,5,6,9,11,&1:21|, C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)[C@H](CCCCCCCCC[S@@](=O)CCCC(F)(F)C(F)(F)F)Cc1cc(O)ccc31 |a:1,4,5,6,9,11,&1:21|, C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)[C@H](CCCCCCCCC[S@@](=O)CCCC(F)(F)C(F)(F)F)Cc1cc(O)ccc31 |a:1,4,5,6,9,11,&1:21|, C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)[C@H](CCCCCCCCC[S@@](=O)CCCC(F)(F)C(F)(F)F)Cc1cc(O)ccc31 |a:1,4,5,6,9,11,&1:21|, C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)[C@H](CCCCCCCCC[S@@](=O)CCCC(F)(F)C(F)(F)F)Cc1cc(O)ccc31 |a:1,4,5,6,9,11,&1:21|, C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)[C@H](CCCCCCCCC[S@@](=O)CCCC(F)(F)C(F)(F)F)Cc1cc(O)ccc31 |a:1,4,5,6,9,11,&1:21|, C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)[C@H](CCCCCCCCC[S@@](=O)CCCC(F)(F)C(F)(F)F)Cc1cc(O)ccc31 |a:1,4,5,6,9,11,&1:21|, C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)[C@H](CCCCCCCCC[S@@](=O)CCCC(F)(F)C(F)(F)F)Cc1cc(O)ccc31 |a:1,4,5,6,9,11,&1:21|, C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)[C@H](CCCCCCCCC[S@@](=O)CCCC(F)(F)C(F)(F)F)Cc1cc(O)ccc31 |a:1,4,5,6,9,11,&1:21|, C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)[C@H](CCCCCCCCC[S@@](=O)CCCC(F)(F)C(F)(F)F)Cc1cc(O)ccc31 |a:1,4,5,6,9,11,&1:21|	Launched
fumagillin	methionine aminopeptidase inhibitor	METAP2	infectious disease	microsporidiosis	MedChemEx, Enzo, MedChemEx, MedChemEx	86.8	CO[C@@H]1[C@@H](CC[C@]2(CO2)[C@@H]1[C@@]1(C)O[C@@H]1CC=C(C)C)OC(=O)\C=C\C=C\C=C\C=C\C(O)=O |a:2,3,6,10,13,&1:9|, CO[C@@H]1[C@@H](CC[C@]2(CO2)[C@@H]1[C@@]1(C)O[C@@H]1CC=C(C)C)OC(=O)\C=C\C=C\C=C\C=C\C(O)=O |a:2,3,6,10,13,&1:9|, CO[C@@H]1[C@@H](CC[C@]2(CO2)[C@@H]1[C@@]1(C)O[C@@H]1CC=C(C)C)OC(=O)\C=C\C=C\C=C\C=C\C(O)=O |a:2,3,6,10,13,&1:9|, CO[C@@H]1[C@@H](CC[C@]2(CO2)[C@@H]1[C@@]1(C)O[C@@H]1CC=C(C)C)OC(=O)\C=C\C=C\C=C\C=C\C(O)=O |a:2,3,6,10,13,&1:9|	Launched
fumonisin-B1		CERS1			MedChemEx	0	CCCC[C@@H](C)[C@@H](OC(=O)C[C@@H](CC(O)=O)C(O)=O)[C@H](C[C@@H](C)C[C@H](O)CCCC[C@@H](O)C[C@H](O)[C@H](C)N)OC(=O)C[C@@H](CC(O)=O)C(O)=O	Preclinical
funapide	sodium channel blocker				AMS	94.46	FC(F)(F)c1ccc(CN2C(=O)[C@@]3(COc4cc5OCOc5cc34)c3ccccc23)o1	Preclinical
furagin	antibacterial				MedChemEx	84.97	[O-][N+](=O)c1ccc(\C=C\C=N\N2CC(=O)NC2=O)o1	Preclinical
furaltadone	bacterial DNA inhibitor		infectious disease	gram-negative bacterial infections	MedChemEx, MicroSource	83.59	[O-][N+](=O)c1ccc(\C=N\N2C[C@@H](CN3CCOCC3)OC2=O)o1 |&1:11,r|, [O-][N+](=O)c1ccc(\C=N\N2C[C@@H](CN3CCOCC3)OC2=O)o1 |&1:11,r|	Launched
furamidine	protein arginine N-methyltransferase inhibitor	PRMT1			Tocris, Tocris	93.75	NC(=N)c1ccc(cc1)-c1ccc(o1)-c1ccc(cc1)C(N)=N, NC(=N)c1ccc(cc1)-c1ccc(o1)-c1ccc(cc1)C(N)=N	Preclinical
furazolidone	bacterial DNA inhibitor		gastroenterology, infectious disease	diarrhea, enteritis, cholera	MedChemEx, MicroSource	91.67	[O-][N+](=O)c1ccc(\C=N\N2CCOC2=O)o1, [O-][N+](=O)c1ccc(\C=N\N2CCOC2=O)o1	Launched
furegrelate	thromboxane synthase inhibitor	TBXAS1			Cayman, Cayman	98.91	OC(=O)c1cc2cc(Cc3cccnc3)ccc2o1, OC(=O)c1cc2cc(Cc3cccnc3)ccc2o1	Phase 1
furosemide	diuretic	CA2, GPR35, SLC12A1, SLC12A2	cardiology, rheumatology	edema, hypertension, congestive heart failure, nephrotic syndrome	Tocris, Selleck, Tocris, Tocris, Tocris, MicroSource	99.55	NS(=O)(=O)c1cc(C(O)=O)c(NCc2ccco2)cc1Cl, NS(=O)(=O)c1cc(C(O)=O)c(NCc2ccco2)cc1Cl, NS(=O)(=O)c1cc(C(O)=O)c(NCc2ccco2)cc1Cl, NS(=O)(=O)c1cc(C(O)=O)c(NCc2ccco2)cc1Cl, NS(=O)(=O)c1cc(C(O)=O)c(NCc2ccco2)cc1Cl, NS(=O)(=O)c1cc(C(O)=O)c(NCc2ccco2)cc1Cl	Launched
fursultiamine	vitamin B		metabolism	thiamine deficiency	Prestwick, MedChemEx	99.61	C\C(N(Cc1cnc(C)nc1N)C=O)=C(\CCO)SSC[C@H]1CCCO1 |&1:21|, C\C(N(Cc1cnc(C)nc1N)C=O)=C(\CCO)SSC[C@H]1CCCO1 |&1:21|	Launched
furvina	quorum sensing signaling inhibitor				Labotest	0	[O-][N+](=O)C(\Br)=C/c1ccc(Br)o1	Preclinical
fusidic-acid	bacterial 30S ribosomal subunit inhibitor		dermatology	acne vulgaris (AV)	MedChemEx	94.82	C[C@@H]1[C@H](O)CC[C@@]2(C)[C@H]1CC[C@@]1(C)[C@H]2[C@H](O)C[C@H]2\C([C@H](C[C@]12C)OC(C)=O)=C(/CCC=C(C)C)C(O)=O	Launched
futibatinib	FGFR inhibitor				MedChemEx	96.33	COc1cc(OC)cc(c1)C#Cc1nn([C@H]2CCN(C2)C(=O)C=C)c2ncnc(N)c12	Phase 3
F351	TGF beta receptor inhibitor	TGFB1			Carbosynth, Toronto	95.15	Cc1ccc(=O)n(c1)-c1ccc(O)cc1, Cc1ccc(=O)n(c1)-c1ccc(O)cc1	Phase 2
g-caryophyllene	acetylcholinesterase inhibitor	ACHE			Sigma, Sigma	0	C\C1=C/CCC(=C)[C@H]2CC(C)(C)[C@@H]2CC1 |c:1|, C\C1=C/CCC(=C)[C@H]2CC(C)(C)[C@@H]2CC1 |c:1|	Preclinical
G-1	G protein-coupled receptor agonist	GPER1			Tocris, Tocris	97.15	CC(=O)c1ccc2N[C@H]([C@H]3CC=C[C@H]3c2c1)c1cc2OCOc2cc1Br |c:11|, CC(=O)c1ccc2N[C@H]([C@H]3CC=C[C@H]3c2c1)c1cc2OCOc2cc1Br |c:11|	Preclinical
G-15	estrogen receptor antagonist	GPER1			Tocris	95.87	Brc1cc2OCOc2cc1[C@H]1Nc2ccccc2[C@H]2C=CC[C@@H]12 |&1:10,18,22,c:22|	Preclinical
G-749	tyrosine kinase inhibitor				MedChemEx	92.89	CN1CCC(CC1)Nc1nc(Nc2ccc(Oc3ccccc3)cc2)c2c(O)ncc(Br)c2n1	Preclinical
GABA-linoleamide	benzodiazepine receptor agonist				Enzo	0	CCCCC\C=C/C\C=C/CCCCCCCC(=O)NCCCC(O)=O	Phase 2
gabapentin	calcium channel blocker	ADORA1, CACNA1A, CACNA1B, CACNA1C, CACNA1D, CACNA1E, CACNA1F, CACNA1G, CACNA1H, CACNA1I, CACNA1S, CACNA2D1, CACNA2D2, CACNA2D3, CACNA2D4, CACNB1, CACNB2, CACNB3, CACNB4, CACNG1, CACNG2, CACNG3, CACNG4, CACNG5, CACNG6, CACNG7, CACNG8, GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, GRIN3A, GRIN3B	infectious disease, neurology/psychiatry	virus herpes simplex (HSV), shingles, seizures, restless leg syndrome	Selleck, MicroSource, MicroSource, Selleck	100	NCC1(CC(O)=O)CCCCC1, NCC1(CC(O)=O)CCCCC1, NCC1(CC(O)=O)CCCCC1, NCC1(CC(O)=O)CCCCC1	Launched
gabapentin-enacarbil	adrenergic receptor agonist	CACNA1G	neurology/psychiatry	restless leg syndrome, postherpetic neuralgia	AdvChemBlocks	89.16	CC(C)C(=O)O[C@@H](C)OC(=O)NCC1(CC(O)=O)CCCCC1 |&1:6,r|	Launched
gabazine	GABA receptor antagonist	GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRG2			Tocris, Tocris, Tocris, Tocris, Tocris	98.53	COc1ccc(cc1)-c1ccc(=N)n(CCCC(O)=O)n1, COc1ccc(cc1)-c1ccc(=N)n(CCCC(O)=O)n1, COc1ccc(cc1)-c1ccc(=N)n(CCCC(O)=O)n1, COc1ccc(cc1)-c1ccc(=N)n(CCCC(O)=O)n1, COc1ccc(cc1)-c1ccc(=N)n(CCCC(O)=O)n1	Preclinical
gabexate	serine protease inhibitor	PRSS1, TPSAB1	gastroenterology	pancreatitis	MedChemEx, Selleck, MedChemEx, Selleck, Selleck, Tocris	85.7	CCOC(=O)c1ccc(OC(=O)CCCCCNC(N)=N)cc1, CCOC(=O)c1ccc(OC(=O)CCCCCNC(N)=N)cc1, CCOC(=O)c1ccc(OC(=O)CCCCCNC(N)=N)cc1, CCOC(=O)c1ccc(OC(=O)CCCCCNC(N)=N)cc1, CCOC(=O)c1ccc(OC(=O)CCCCCNC(N)=N)cc1, CCOC(=O)c1ccc(OC(=O)CCCCCNC(N)=N)cc1	Launched
gaboxadol	benzodiazepine receptor agonist	GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRD, GABRR1, GABRR2, GABRR3			Tocris, Tocris, MicroSource, Tocris, Tocris	100	O=c1[nH]oc2CNCCc12, O=c1[nH]oc2CNCCc12, O=c1[nH]oc2CNCCc12, O=c1[nH]oc2CNCCc12, O=c1[nH]oc2CNCCc12	Phase 3
gadobutrol	radiopaque medium		radiology	MRI contrast agent	MedChemEx	81.6	[H]O[C@@H](CO)[C@H](CO)N1CCN2CCN3CCN(CC1)CC(=O)O[Gd](OC(=O)C3)OC(=O)C2 |&1:2,5|	Launched
gadodiamide	radiopaque medium		radiology	MRI contrast agent	MedChemEx, Selleck	100	CNC(=O)CN1CCN2CCN(CC(=O)NC)CC(=O)O[Gd](OC(=O)C1)OC(=O)C2, CNC(=O)CN1CCN2CCN(CC(=O)NC)CC(=O)O[Gd](OC(=O)C1)OC(=O)C2	Launched
gadopentetic-acid	contrast agent	PGD	radiology	contrast agent	Sigma	0	OC(=O)CN1CCN2CCN(CC(O)=O)CC(=O)O[Gd](OC(=O)C1)OC(=O)C2	Launched
gadoterate-meglumine	radiopaque medium		radiology	MRI contrast agent	Sigma, TCI	97.1	OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1, OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1	Launched
gadoteridol	radiopaque medium		radiology	MRI contrast agent	Kemprotec, MicroSource	86.8	C[C@@H](O)CN1CCN2CCN3CCN(CC1)CC(=O)O[Gd](OC(=O)C2)OC(=O)C3 |&1:1,r|, C[C@@H](O)CN1CCN2CCN3CCN(CC1)CC(=O)O[Gd](OC(=O)C2)OC(=O)C3 |&1:1,r|	Launched
GAL-021	calcium channel blocker				MedChemEx	95.98	CCCNc1nc(NCCC)nc(n1)N(C)OC	Preclinical
galantamine	acetylcholinesterase inhibitor	ACHE, BCHE, CHRNA1, CHRNA10, CHRNA2, CHRNA3, CHRNA4, CHRNA5, CHRNA6, CHRNA7, CHRNA9, CHRNB1, CHRNB2, CHRNB3, CHRNB4, CHRND, CHRNE, CHRNG	neurology/psychiatry	senile dementia	MicroSource, Tocris, Tocris, Tocris	98.59	COc1ccc2CN(C)CC[C@@]34C=C[C@H](O)C[C@@H]3Oc1c24 |c:12|, COc1ccc2CN(C)CC[C@@]34C=C[C@H](O)C[C@@H]3Oc1c24 |c:12|, COc1ccc2CN(C)CC[C@@]34C=C[C@H](O)C[C@@H]3Oc1c24 |c:12|, COc1ccc2CN(C)CC[C@@]34C=C[C@H](O)C[C@@H]3Oc1c24 |c:12|	Launched
galeterone	androgen receptor modulator	AR, CYP17A1			Tocris	95.97	[H][C@@]12CC=C(n3cnc4ccccc34)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@H](O)CC[C@]12C |t:3,27|	Phase 3
galidesivir	antiviral				MedChemEx	100	Nc1ncnc2c(c[nH]c12)[C@@H]1N[C@H](CO)[C@@H](O)[C@H]1O	Phase 1
gallamine-triethiodide	acetylcholine receptor antagonist	CHRM2, CHRNA1	neurology/psychiatry	muscle relaxant	MedChemEx, MedChemEx, MedChemEx, Selleck, MicroSource, Selleck	98.46	CC[N+](CC)(CC)CCOc1cccc(OCC[N+](CC)(CC)CC)c1OCC[N+](CC)(CC)CC, CC[N+](CC)(CC)CCOc1cccc(OCC[N+](CC)(CC)CC)c1OCC[N+](CC)(CC)CC, CC[N+](CC)(CC)CCOc1cccc(OCC[N+](CC)(CC)CC)c1OCC[N+](CC)(CC)CC, CC[N+](CC)(CC)CCOc1cccc(OCC[N+](CC)(CC)CC)c1OCC[N+](CC)(CC)CC, CC[N+](CC)(CC)CCOc1cccc(OCC[N+](CC)(CC)CC)c1OCC[N+](CC)(CC)CC, CC[N+](CC)(CC)CCOc1cccc(OCC[N+](CC)(CC)CC)c1OCC[N+](CC)(CC)CC	Launched
gallic-acid	beta amyloid protein neurotoxicity inhibitor, PPAR receptor agonist	CA1, CA12, CA14, CA2, CA4, CA6, CA9, SELP			MicroSource, MedChemEx	99	OC(=O)c1cc(O)c(O)c(O)c1, OC(=O)c1cc(O)c(O)c(O)c1	Preclinical
gallium-triquinolin-8-olate					Sigma	0	O([Ga](Oc1cccc2cccnc12)Oc1cccc2cccnc12)c1cccc2cccnc12	Phase 1
gallopamil	L-type calcium channel blocker	ATP2A2	cardiology	hypertension, cardiac arrythmia	Enzo, Sigma, Sigma, Sigma, Sigma	99.31	COc1ccc(CCN(C)CCCC(C#N)(C(C)C)c2cc(OC)c(OC)c(OC)c2)cc1OC |&1:13|, COc1ccc(CCN(C)CCCC(C#N)(C(C)C)c2cc(OC)c(OC)c(OC)c2)cc1OC |&1:13|, COc1ccc(CCN(C)CCCC(C#N)(C(C)C)c2cc(OC)c(OC)c(OC)c2)cc1OC |&1:13|, COc1ccc(CCN(C)CCCC(C#N)(C(C)C)c2cc(OC)c(OC)c(OC)c2)cc1OC |&1:13|, COc1ccc(CCN(C)CCCC(C#N)(C(C)C)c2cc(OC)c(OC)c(OC)c2)cc1OC |&1:13|	Launched
gambogic-acid	caspase activator	BCL2			MedChemEx, MedChemEx, MedChemEx, MedChemEx, Enzo	81.89	CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C |c:22,33|, CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C |c:22,33|, CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C |c:22,33|, CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C |c:22,33|, CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C |c:22,33|	Phase 2
gamithromycin	antibacterial 				MedChemEx	98.9	[H][C@@]1(C[C@@](C)(OC)[C@@H](O)[C@H](C)O1)O[C@H]1[C@H](C)[C@@H](O[C@]2([H])O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)N(CCC)C[C@H](C)[C@@H](O)[C@](C)(O)[C@@H](CC)OC(=O)[C@@H]1C	Preclinical
gamma-aminobutyric-acid	benzodiazepine receptor agonist	GABBR1, GABBR2, GABRA1, GABRA2, GABRA3, GABRA5, GABRB2, GABRG2, GATM, KCTD12, KCTD16, KCTD8, SLC6A1			MicroSource, MicroSource, MedChemEx, MedChemEx	100	NCCCC(O)=O, NCCCC(O)=O, NCCCC(O)=O, NCCCC(O)=O	Preclinical
gamma-linolenic-acid	cyclooxygenase inhibitor, prostanoid receptor agonist	PTGS1, PTGS2			Sigma, Sigma, Enzo, Enzo, Cayman	87.22	CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O, CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O, CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O, CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O, CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O	Phase 2
ganaxolone	GABA receptor modulator	GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6			Tocris, Tocris, Tocris	100	CC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4C[C@](C)(O)CC[C@]4(C)[C@H]3CC[C@]12C, CC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4C[C@](C)(O)CC[C@]4(C)[C@H]3CC[C@]12C, CC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4C[C@](C)(O)CC[C@]4(C)[C@H]3CC[C@]12C	Phase 3
ganciclovir	DNA polymerase inhibitor		infectious disease	cytomegalovirus (CMV)	MicroSource, Selleck, Selleck, Selleck	100	Nc1nc(=O)c2ncn(COC(CO)CO)c2[nH]1, Nc1nc(=O)c2ncn(COC(CO)CO)c2[nH]1, Nc1nc(=O)c2ncn(COC(CO)CO)c2[nH]1, Nc1nc(=O)c2ncn(COC(CO)CO)c2[nH]1	Launched
ganetespib	HSP inhibitor	HSP90AA1			Selleck, Selleck, Selleck, Selleck, MedChemEx, MedChemEx, MedChemEx	98.5	CC(C)c1cc(-c2n[nH]c(=O)n2-c2ccc3n(C)ccc3c2)c(O)cc1O, CC(C)c1cc(-c2n[nH]c(=O)n2-c2ccc3n(C)ccc3c2)c(O)cc1O, CC(C)c1cc(-c2n[nH]c(=O)n2-c2ccc3n(C)ccc3c2)c(O)cc1O, CC(C)c1cc(-c2n[nH]c(=O)n2-c2ccc3n(C)ccc3c2)c(O)cc1O, CC(C)c1cc(-c2n[nH]c(=O)n2-c2ccc3n(C)ccc3c2)c(O)cc1O, CC(C)c1cc(-c2n[nH]c(=O)n2-c2ccc3n(C)ccc3c2)c(O)cc1O, CC(C)c1cc(-c2n[nH]c(=O)n2-c2ccc3n(C)ccc3c2)c(O)cc1O	Phase 3
ganoderic-acid-a	JAK inhibitor				MedChemEx	66.53	[H][C@@]12C[C@H](O)C3=C(C(=O)C[C@]4(C)[C@H](C[C@H](O)[C@@]34C)[C@H](C)CC(=O)C[C@@H](C)C(O)=O)[C@@]1(C)CCC(=O)C2(C)C |t:5|	Preclinical
GANT-58	GLI antagonist	GLI1			Tocris, Tocris	96.49	c1cc(ccn1)-c1sc(c(c1-c1ccncc1)-c1ccncc1)-c1ccncc1, c1cc(ccn1)-c1sc(c(c1-c1ccncc1)-c1ccncc1)-c1ccncc1	Preclinical
GANT-61	GLI antagonist	GLI1, GLI2			Tocris, Tocris, Tocris, Tocris, Tocris, Tocris, Tocris, Tocris	100	CN(C)c1ccccc1CN1CCCN(Cc2ccccc2N(C)C)C1c1ccncc1, CN(C)c1ccccc1CN1CCCN(Cc2ccccc2N(C)C)C1c1ccncc1, CN(C)c1ccccc1CN1CCCN(Cc2ccccc2N(C)C)C1c1ccncc1, CN(C)c1ccccc1CN1CCCN(Cc2ccccc2N(C)C)C1c1ccncc1, CN(C)c1ccccc1CN1CCCN(Cc2ccccc2N(C)C)C1c1ccncc1, CN(C)c1ccccc1CN1CCCN(Cc2ccccc2N(C)C)C1c1ccncc1, CN(C)c1ccccc1CN1CCCN(Cc2ccccc2N(C)C)C1c1ccncc1, CN(C)c1ccccc1CN1CCCN(Cc2ccccc2N(C)C)C1c1ccncc1	Preclinical
garenoxacin	topoisomerase inhibitor	TOP2A	infectious disease	respiratory tract infections	MedChemEx, MedChemEx	96.9	C[C@H]1NCc2cc(ccc12)-c1ccc2c(c1OC(F)F)n(cc(C(O)=O)c2=O)C1CC1, C[C@H]1NCc2cc(ccc12)-c1ccc2c(c1OC(F)F)n(cc(C(O)=O)c2=O)C1CC1	Launched
gastrodin					MedChemEx	91.72	OC[C@H]1O[C@@H](Oc2ccc(CO)cc2)[C@H](O)[C@@H](O)[C@@H]1O	Phase 2
gatifloxacin	bacterial DNA gyrase inhibitor				MicroSource, Tocris	94.86	COc1c(N2CCN[C@@H](C)C2)c(F)cc2c1n(cc(C(O)=O)c2=O)C1CC1 |&1:8|, COc1c(N2CCN[C@@H](C)C2)c(F)cc2c1n(cc(C(O)=O)c2=O)C1CC1 |&1:8|	Withdrawn
gavestinel	glutamate receptor antagonist	GLRB, GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, GRIN3A, GRIN3B			Tocris, Tocris, Tocris, Tocris	92.51	OC(=O)c1[nH]c2cc(Cl)cc(Cl)c2c1\C=C\C(=O)Nc1ccccc1, OC(=O)c1[nH]c2cc(Cl)cc(Cl)c2c1\C=C\C(=O)Nc1ccccc1, OC(=O)c1[nH]c2cc(Cl)cc(Cl)c2c1\C=C\C(=O)Nc1ccccc1, OC(=O)c1[nH]c2cc(Cl)cc(Cl)c2c1\C=C\C(=O)Nc1ccccc1	Phase 3
GBR-12783	dopamine reuptake inhibitor				Tocris, Tocris, Tocris, Tocris, Tocris, Tocris	97.22	C(CN1CCN(C\C=C\c2ccccc2)CC1)OC(c1ccccc1)c1ccccc1, C(CN1CCN(C\C=C\c2ccccc2)CC1)OC(c1ccccc1)c1ccccc1, C(CN1CCN(C\C=C\c2ccccc2)CC1)OC(c1ccccc1)c1ccccc1, C(CN1CCN(C\C=C\c2ccccc2)CC1)OC(c1ccccc1)c1ccccc1, C(CN1CCN(C\C=C\c2ccccc2)CC1)OC(c1ccccc1)c1ccccc1, C(CN1CCN(C\C=C\c2ccccc2)CC1)OC(c1ccccc1)c1ccccc1	Preclinical
GBR-12935	dopamine reuptake inhibitor	AGTR1, SLC6A3			Tocris, Tocris	97.4	C(CN1CCN(CCOC(c2ccccc2)c2ccccc2)CC1)Cc1ccccc1, C(CN1CCN(CCOC(c2ccccc2)c2ccccc2)CC1)Cc1ccccc1	Preclinical
GBR-13069	dopamine reuptake inhibitor	SLC6A3			Tocris, Tocris, Tocris, Tocris	95.51	Fc1ccc(cc1)C(OCCN1CCN(C\C=C\c2ccccc2)CC1)c1ccc(F)cc1, Fc1ccc(cc1)C(OCCN1CCN(C\C=C\c2ccccc2)CC1)c1ccc(F)cc1, Fc1ccc(cc1)C(OCCN1CCN(C\C=C\c2ccccc2)CC1)c1ccc(F)cc1, Fc1ccc(cc1)C(OCCN1CCN(C\C=C\c2ccccc2)CC1)c1ccc(F)cc1	Preclinical
GDC-0068	AKT inhibitor	AKT1, AKT2, AKT3, PRKG1			MedChemEx	75.09	CC(C)NC[C@@H](C(=O)N1CCN(CC1)c1ncnc2[C@H](O)C[C@@H](C)c12)c1ccc(Cl)cc1	Phase 3
GDC-0077	PI3K inhibitor				MedChemEx	87.83	C[C@H](Nc1ccc2-c3nc(cn3CCOc2c1)N1[C@@H](COC1=O)C(F)F)C(N)=O	Phase 1
GDC-0084	mTOR inhibitor, PI3K inhibitor				MedChemEx	94.21	CC1(C)OCCn2c1nc1c(nc(nc21)-c1cnc(N)nc1)N1CCOCC1	Phase 2
GDC-0152	XIAP inhibitor	BIRC2, BIRC3, BIRC7, XIAP			Selleck, Selleck, Selleck, Selleck, MedChemEx, MedChemEx	97.08	CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1C(=O)Nc1snnc1-c1ccccc1, CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1C(=O)Nc1snnc1-c1ccccc1, CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1C(=O)Nc1snnc1-c1ccccc1, CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1C(=O)Nc1snnc1-c1ccccc1, CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1C(=O)Nc1snnc1-c1ccccc1, CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1C(=O)Nc1snnc1-c1ccccc1	Phase 1
GDC-0349	Pim kinase inhibitor	PIK3CA			Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, MedChemEx	89.78	CCNC(=O)Nc1ccc(cc1)-c1nc2CN(CCc2c(n1)N1CCOC[C@@H]1C)C1COC1, CCNC(=O)Nc1ccc(cc1)-c1nc2CN(CCc2c(n1)N1CCOC[C@@H]1C)C1COC1, CCNC(=O)Nc1ccc(cc1)-c1nc2CN(CCc2c(n1)N1CCOC[C@@H]1C)C1COC1, CCNC(=O)Nc1ccc(cc1)-c1nc2CN(CCc2c(n1)N1CCOC[C@@H]1C)C1COC1, CCNC(=O)Nc1ccc(cc1)-c1nc2CN(CCc2c(n1)N1CCOC[C@@H]1C)C1COC1, CCNC(=O)Nc1ccc(cc1)-c1nc2CN(CCc2c(n1)N1CCOC[C@@H]1C)C1COC1, CCNC(=O)Nc1ccc(cc1)-c1nc2CN(CCc2c(n1)N1CCOC[C@@H]1C)C1COC1	Phase 1
GDC-0575	CHK inhibitor				MedChemEx	93.2	N[C@@H]1CCCN(C1)c1c(Br)cnc2[nH]cc(NC(=O)C3CC3)c12	Phase 1
GDC-0623	MEK inhibitor				MedChemEx, MedChemEx, Selleck, Selleck, MedChemEx	92.75	OCCONC(=O)c1ccc2cncn2c1Nc1ccc(I)cc1F, OCCONC(=O)c1ccc2cncn2c1Nc1ccc(I)cc1F, OCCONC(=O)c1ccc2cncn2c1Nc1ccc(I)cc1F, OCCONC(=O)c1ccc2cncn2c1Nc1ccc(I)cc1F, OCCONC(=O)c1ccc2cncn2c1Nc1ccc(I)cc1F	Phase 1
GDC-0810	selective estrogen receptor destabilizer	ESR1			MedChemEx, MedChemEx	96.55	CC\C(=C(\c1ccc(\C=C\C(O)=O)cc1)c1ccc2n[nH]cc2c1)c1ccc(F)cc1Cl, CC\C(=C(\c1ccc(\C=C\C(O)=O)cc1)c1ccc2n[nH]cc2c1)c1ccc(F)cc1Cl	Phase 2
GDC-0834	Bruton's tyrosine kinase (BTK) inhibitor	BTK			MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx	90.56	CN1CCN(C)C(=O)[C@@H]1c1ccc(Nc2nc(cn(C)c2=O)-c2cccc(NC(=O)c3cc4CCCCc4s3)c2C)cc1 |&1:8,r|, CN1CCN(C)C(=O)[C@@H]1c1ccc(Nc2nc(cn(C)c2=O)-c2cccc(NC(=O)c3cc4CCCCc4s3)c2C)cc1 |&1:8,r|, CN1CCN(C)C(=O)[C@@H]1c1ccc(Nc2nc(cn(C)c2=O)-c2cccc(NC(=O)c3cc4CCCCc4s3)c2C)cc1 |&1:8,r|, CN1CCN(C)C(=O)[C@@H]1c1ccc(Nc2nc(cn(C)c2=O)-c2cccc(NC(=O)c3cc4CCCCc4s3)c2C)cc1 |&1:8,r|, CN1CCN(C)C(=O)[C@@H]1c1ccc(Nc2nc(cn(C)c2=O)-c2cccc(NC(=O)c3cc4CCCCc4s3)c2C)cc1 |&1:8,r|, CN1CCN(C)C(=O)[C@@H]1c1ccc(Nc2nc(cn(C)c2=O)-c2cccc(NC(=O)c3cc4CCCCc4s3)c2C)cc1 |&1:8,r|, CN1CCN(C)C(=O)[C@@H]1c1ccc(Nc2nc(cn(C)c2=O)-c2cccc(NC(=O)c3cc4CCCCc4s3)c2C)cc1 |&1:8,r|, CN1CCN(C)C(=O)[C@@H]1c1ccc(Nc2nc(cn(C)c2=O)-c2cccc(NC(=O)c3cc4CCCCc4s3)c2C)cc1 |&1:8,r|	Phase 1
GDC-0879	RAF inhibitor	BRAF			Tocris, Selleck, Selleck, Selleck	97.55	OCCn1cc(c(n1)-c1ccncc1)-c1ccc2\C(CCc2c1)=N\O, OCCn1cc(c(n1)-c1ccncc1)-c1ccc2\C(CCc2c1)=N\O, OCCn1cc(c(n1)-c1ccncc1)-c1ccc2\C(CCc2c1)=N\O, OCCn1cc(c(n1)-c1ccncc1)-c1ccc2\C(CCc2c1)=N\O	Preclinical
GDC-0927	estrogen receptor antagonist				MedChemEx, MedChemEx	92.6	CC1=C([C@@H](Oc2ccc(O)cc12)c1ccc(OCCN2CC(CF)C2)cc1)c1cccc(O)c1 |t:1|, CC1=C([C@@H](Oc2ccc(O)cc12)c1ccc(OCCN2CC(CF)C2)cc1)c1cccc(O)c1 |t:1|	Phase 1
GDC-0941	PI3K inhibitor	PIK3CA, PIK3CB, PIK3CD, PIK3CG			Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck	97.79	CS(=O)(=O)N1CCN(Cc2cc3nc(nc(N4CCOCC4)c3s2)-c2cccc3n[nH]cc23)CC1, CS(=O)(=O)N1CCN(Cc2cc3nc(nc(N4CCOCC4)c3s2)-c2cccc3n[nH]cc23)CC1, CS(=O)(=O)N1CCN(Cc2cc3nc(nc(N4CCOCC4)c3s2)-c2cccc3n[nH]cc23)CC1, CS(=O)(=O)N1CCN(Cc2cc3nc(nc(N4CCOCC4)c3s2)-c2cccc3n[nH]cc23)CC1, CS(=O)(=O)N1CCN(Cc2cc3nc(nc(N4CCOCC4)c3s2)-c2cccc3n[nH]cc23)CC1, CS(=O)(=O)N1CCN(Cc2cc3nc(nc(N4CCOCC4)c3s2)-c2cccc3n[nH]cc23)CC1, CS(=O)(=O)N1CCN(Cc2cc3nc(nc(N4CCOCC4)c3s2)-c2cccc3n[nH]cc23)CC1	Phase 2
GDC-0980	mTOR inhibitor, PI3K inhibitor	FGR, MAP3K9, MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG, SYK			Selleck, Selleck, Selleck, Selleck, MedChemEx, MedChemEx, Selleck, Selleck, Selleck	97.29	C[C@H](O)C(=O)N1CCN(Cc2sc3c(nc(nc3c2C)-c2cnc(N)nc2)N2CCOCC2)CC1, C[C@H](O)C(=O)N1CCN(Cc2sc3c(nc(nc3c2C)-c2cnc(N)nc2)N2CCOCC2)CC1, C[C@H](O)C(=O)N1CCN(Cc2sc3c(nc(nc3c2C)-c2cnc(N)nc2)N2CCOCC2)CC1, C[C@H](O)C(=O)N1CCN(Cc2sc3c(nc(nc3c2C)-c2cnc(N)nc2)N2CCOCC2)CC1, C[C@H](O)C(=O)N1CCN(Cc2sc3c(nc(nc3c2C)-c2cnc(N)nc2)N2CCOCC2)CC1, C[C@H](O)C(=O)N1CCN(Cc2sc3c(nc(nc3c2C)-c2cnc(N)nc2)N2CCOCC2)CC1, C[C@H](O)C(=O)N1CCN(Cc2sc3c(nc(nc3c2C)-c2cnc(N)nc2)N2CCOCC2)CC1, C[C@H](O)C(=O)N1CCN(Cc2sc3c(nc(nc3c2C)-c2cnc(N)nc2)N2CCOCC2)CC1, C[C@H](O)C(=O)N1CCN(Cc2sc3c(nc(nc3c2C)-c2cnc(N)nc2)N2CCOCC2)CC1	Phase 2
GDC-0994	MAP kinase inhibitor	MAPK1, MAPK3			Selleck, Selleck	98.7	Cn1nccc1Nc1nccc(n1)-c1ccn([C@@H](CO)c2ccc(Cl)c(F)c2)c(=O)c1 |&1:17,r|, Cn1nccc1Nc1nccc(n1)-c1ccn([C@@H](CO)c2ccc(Cl)c(F)c2)c(=O)c1 |&1:17,r|	Phase 1
gedunin	HSP inhibitor	HSP90AA1			Tocris	95.65	CC(=O)O[C@@H]1C[C@H]2C(C)(C)C(=O)C=C[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](OC(=O)[C@H]4O[C@@]34[C@]12C)c1ccoc1 |c:12|	Preclinical
gefapixant	purinergic receptor antagonist				MedChemEx	97.87	COc1cc(C(C)C)c(Oc2cnc(N)nc2N)cc1S(N)(=O)=O	Phase 3
gefitinib	EGFR inhibitor	EGFR	oncology	non-small cell lung cancer (NSCLC)	Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Tocris, Tocris, Tocris, Selleck, Tocris	99.54	COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1	Launched
geldanamycin	HSP inhibitor	HSP90AA1			Selleck, Selleck, Selleck, MedChemEx	85.51	CO[C@H]1C[C@H](C)CC2=C(OC)C(=O)C=C(NC(=O)\C(C)=C\C=C\[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O |c:7,t:13,19,21,32|, CO[C@H]1C[C@H](C)CC2=C(OC)C(=O)C=C(NC(=O)\C(C)=C\C=C\[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O |c:7,t:13,19,21,32|, CO[C@H]1C[C@H](C)CC2=C(OC)C(=O)C=C(NC(=O)\C(C)=C\C=C\[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O |c:7,t:13,19,21,32|, CO[C@H]1C[C@H](C)CC2=C(OC)C(=O)C=C(NC(=O)\C(C)=C\C=C\[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O |c:7,t:13,19,21,32|	Preclinical
gemcadiol	antilipemic				Sigma, Sigma, Sigma	100	CC(C)(CO)CCCCCCC(C)(C)CO, CC(C)(CO)CCCCCCC(C)(C)CO, CC(C)(CO)CCCCCCC(C)(C)CO	Phase 2
gemcitabine	ribonucleotide reductase inhibitor	CMPK1, RRM1, RRM2, TYMS	oncology	ovarian cancer, breast cancer, non-small cell lung cancer (NSCLC), pancreatic cancer	MedChemEx, MedChemEx, MedChemEx, MedChemEx, Tocris, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck	100	Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1	Launched
gemcitabine-elaidate	apoptosis inhibitor, DNA synthesis inhibitor	CMPK1, RRM1, TYMS			MedChemEx, MedChemEx, MedChemEx, MedChemEx	94.93	CCCCCCCC\C=C\CCCCCCCC(=O)OC[C@H]1O[C@@H](n2ccc(N)nc2=O)C(F)(F)[C@@H]1O, CCCCCCCC\C=C\CCCCCCCC(=O)OC[C@H]1O[C@@H](n2ccc(N)nc2=O)C(F)(F)[C@@H]1O, CCCCCCCC\C=C\CCCCCCCC(=O)OC[C@H]1O[C@@H](n2ccc(N)nc2=O)C(F)(F)[C@@H]1O, CCCCCCCC\C=C\CCCCCCCC(=O)OC[C@H]1O[C@@H](n2ccc(N)nc2=O)C(F)(F)[C@@H]1O	Phase 1
gemfibrozil	lipoprotein lipase activator	LPL, PPARA, SLCO1B1, SLCO1B3, SLCO2B1	endocrinology, cardiology	hyperlipidemia, coronary heart disease	Selleck, MicroSource, MicroSource, MicroSource	97.18	Cc1ccc(C)c(OCCCC(C)(C)C(O)=O)c1, Cc1ccc(C)c(OCCCC(C)(C)C(O)=O)c1, Cc1ccc(C)c(OCCCC(C)(C)C(O)=O)c1, Cc1ccc(C)c(OCCCC(C)(C)C(O)=O)c1	Launched
gemifloxacin	bacterial DNA gyrase inhibitor		pulmonary, infectious disease	bronchitis, pneumonia	MicroSource	94.6	CO\N=C1/CN(C[C@@H]1CN)c1nc2n(cc(C(O)=O)c(=O)c2cc1F)C1CC1 |&1:7|	Launched
gemigliptin	dipeptidyl peptidase inhibitor				MedChemEx	23.21	N[C@H](CN1CC(F)(F)CCC1=O)CC(=O)N1CCc2c(C1)nc(nc2C(F)(F)F)C(F)(F)F	Launched
genipin	choleretic agent				MedChemEx, MedChemEx, Selleck, Selleck	99.08	COC(=O)C1=CO[C@@H](O)[C@H]2[C@@H]1CC=C2CO |c:13,t:4|, COC(=O)C1=CO[C@@H](O)[C@H]2[C@@H]1CC=C2CO |c:13,t:4|, COC(=O)C1=CO[C@@H](O)[C@H]2[C@@H]1CC=C2CO |c:13,t:4|, COC(=O)C1=CO[C@@H](O)[C@H]2[C@@H]1CC=C2CO |c:13,t:4|	Preclinical
geniposide	GLP receptor agonist	GLP1R			MedChemEx, Selleck, Selleck, Selleck	97.9	COC(=O)C1=CO[C@@H](O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@H]2[C@@H]1CC=C2CO |c:25,t:4|, COC(=O)C1=CO[C@@H](O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@H]2[C@@H]1CC=C2CO |c:25,t:4|, COC(=O)C1=CO[C@@H](O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@H]2[C@@H]1CC=C2CO |c:25,t:4|, COC(=O)C1=CO[C@@H](O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@H]2[C@@H]1CC=C2CO |c:25,t:4|	Preclinical
geniposidic-acid	cyclooxygenase inhibitor				Selleck, Selleck, MedChemEx, Selleck	97.09	OC[C@H]1O[C@@H](O[C@@H]2OC=C([C@H]3CC=C(CO)[C@@H]23)C(O)=O)[C@H](O)[C@@H](O)[C@@H]1O |c:8,t:12|, OC[C@H]1O[C@@H](O[C@@H]2OC=C([C@H]3CC=C(CO)[C@@H]23)C(O)=O)[C@H](O)[C@@H](O)[C@@H]1O |c:8,t:12|, OC[C@H]1O[C@@H](O[C@@H]2OC=C([C@H]3CC=C(CO)[C@@H]23)C(O)=O)[C@H](O)[C@@H](O)[C@@H]1O |c:8,t:12|, OC[C@H]1O[C@@H](O[C@@H]2OC=C([C@H]3CC=C(CO)[C@@H]23)C(O)=O)[C@H](O)[C@@H](O)[C@@H]1O |c:8,t:12|	Preclinical
genistein	tyrosine kinase inhibitor	CFTR, ESR1, ESR2, ESRRA, ESRRB, ESRRG, NCOA1, NCOA2, PPARG, PTK2B, TOP2A, TRPC5			Selleck, Selleck, MicroSource, Tocris, Tocris	97.71	Oc1ccc(cc1)-c1coc2cc(O)cc(O)c2c1=O, Oc1ccc(cc1)-c1coc2cc(O)cc(O)c2c1=O, Oc1ccc(cc1)-c1coc2cc(O)cc(O)c2c1=O, Oc1ccc(cc1)-c1coc2cc(O)cc(O)c2c1=O, Oc1ccc(cc1)-c1coc2cc(O)cc(O)c2c1=O	Phase 2/Phase 3
gentamycin	bacterial 50S ribosomal subunit inhibitor	HSPA8	infectious disease, critical care	bone and joint infections, endocarditis, pelvic inflammatory disease, meningitis, pneumonia, urinary tract infections, sepsis	MedChemEx	0	CN[C@H](C)[C@@H]1CC[C@@H](N)[C@@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3OC[C@](C)(O)[C@H](NC)[C@H]3O)[C@H]2O)O1	Launched
gentiopicrin	glutamate receptor downregulator	GRIN2B			Sigma	97.46	OC[C@H]1O[C@@H](O[C@@H]2OC=C3C(=O)OCC=C3[C@H]2C=C)[C@H](O)[C@@H](O)[C@@H]1O |c:14,t:8|	Phase 3
genz-123346	glucosylceramidase inhibitor	UGCG			MedChemEx, MedChemEx	85.93	CCCCCCCCC(=O)N[C@H](CN1CCCC1)[C@H](O)c1ccc2OCCOc2c1, CCCCCCCCC(=O)N[C@H](CN1CCCC1)[C@H](O)c1ccc2OCCOc2c1	Preclinical
genz-644282	topoisomerase inhibitor	TOP1			MedChemEx, MedChemEx, MedChemEx	97.15	CNCCn1c2c3cc4OCOc4cc3ncc2c2cc(OC)c(OC)cc2c1=O, CNCCn1c2c3cc4OCOc4cc3ncc2c2cc(OC)c(OC)cc2c1=O, CNCCn1c2c3cc4OCOc4cc3ncc2c2cc(OC)c(OC)cc2c1=O	Phase 1
gepefrine	adrenergic receptor agonist		cardiology	hypotension	Sigma, Sigma	84.77	C[C@@H](N)Cc1cccc(O)c1 |&1:1,r|, C[C@@H](N)Cc1cccc(O)c1 |&1:1,r|	Launched
gepon					InterBioScreen, InterBioScreen	99.2	CC(C)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](CCCNC(N)=N)NC(=O)[C@@H](CCCCN)NC(=O)[C@@H](CCCCN)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](N)[C@@H](C)O)[C@@H](C)O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(O)=O |a:3,11,20,51,69,80,100,118,&1:7,&2:31,&3:42,&4:60,&5:71,&6:74,&7:89,&8:109|, CC(C)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](CCCNC(N)=N)NC(=O)[C@@H](CCCCN)NC(=O)[C@@H](CCCCN)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](N)[C@@H](C)O)[C@@H](C)O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(O)=O |a:3,11,20,51,69,80,100,118,&1:7,&2:31,&3:42,&4:60,&5:71,&6:74,&7:89,&8:109|	Phase 1
gepotidacin	topoisomerase inhibitor				MedChemEx	94.47	O=c1ccc2ncc(=O)n3[C@H](CN4CCC(CC4)NCc4cc5CCCOc5cn4)Cn1c23	Phase 2
geranyl-farnesylacetate	mucin production enhancer				Adooq, AKSci	49.56	CC(C)=CCC\C(C)=C\CC\C(C)=C\CCC(=O)OC\C=C(/C)CCC=C(C)C, CC(C)=CCC\C(C)=C\CC\C(C)=C\CCC(=O)OC\C=C(/C)CCC=C(C)C	Phase 2
gestodene	contraceptive agent		endocrinology	contraceptive	MedChemEx, Selleck	95.03	CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1C=C[C@@]2(O)C#C |c:20,t:9|, CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1C=C[C@@]2(O)C#C |c:20,t:9|	Launched
gestrinone	progesterone receptor antagonist	AR, ESR1, PGR	obstetrics/gynecology	endometriosis	MedChemEx, Prestwick, Prestwick, Prestwick, Prestwick	95.29	CC[C@]12C=CC3=C4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@@]2(O)C#C |c:3,5,11|, CC[C@]12C=CC3=C4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@@]2(O)C#C |c:3,5,11|, CC[C@]12C=CC3=C4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@@]2(O)C#C |c:3,5,11|, CC[C@]12C=CC3=C4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@@]2(O)C#C |c:3,5,11|, CC[C@]12C=CC3=C4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@@]2(O)C#C |c:3,5,11|	Launched
GF109203X	PKC inhibitor	PDPK1, PIM1, PRKCI, PRKCZ			Tocris, Tocris, Tocris, Tocris, Tocris, Tocris, Tocris	94.62	CN(C)CCCn1cc(C2=C(C(=O)NC2=O)c2c[nH]c3ccccc23)c2ccccc12 |t:9|, CN(C)CCCn1cc(C2=C(C(=O)NC2=O)c2c[nH]c3ccccc23)c2ccccc12 |t:9|, CN(C)CCCn1cc(C2=C(C(=O)NC2=O)c2c[nH]c3ccccc23)c2ccccc12 |t:9|, CN(C)CCCn1cc(C2=C(C(=O)NC2=O)c2c[nH]c3ccccc23)c2ccccc12 |t:9|, CN(C)CCCn1cc(C2=C(C(=O)NC2=O)c2c[nH]c3ccccc23)c2ccccc12 |t:9|, CN(C)CCCn1cc(C2=C(C(=O)NC2=O)c2c[nH]c3ccccc23)c2ccccc12 |t:9|, CN(C)CCCn1cc(C2=C(C(=O)NC2=O)c2c[nH]c3ccccc23)c2ccccc12 |t:9|	Preclinical
GGsTop	gamma glutamyltransferase Inhibitor	GGT1			Tocris, Tocris	82.42	COP(=O)(CC[C@@H](N)C(O)=O)Oc1cccc(CC(O)=O)c1 |&1:2,&2:6,r|, COP(=O)(CC[C@@H](N)C(O)=O)Oc1cccc(CC(O)=O)c1 |&1:2,&2:6,r|	Preclinical
GGTI-298	GGTase inhibitor	CDKN1A			MedChemEx, EMDBio	51.61	COC(=O)[C@H](CC(C)C)NC(=O)c1ccc(NC[C@@H](N)CS)cc1-c1cccc2ccccc12, COC(=O)[C@H](CC(C)C)NC(=O)c1ccc(NC[C@@H](N)CS)cc1-c1cccc2ccccc12	Preclinical
gilteritinib	FLT3 inhibitor	FLT3			MedChemEx, MedChemEx, MedChemEx, MedChemEx	90.94	CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(CC3)N3CCN(C)CC3)c(OC)c2)nc1NC1CCOCC1, CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(CC3)N3CCN(C)CC3)c(OC)c2)nc1NC1CCOCC1, CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(CC3)N3CCN(C)CC3)c(OC)c2)nc1NC1CCOCC1, CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(CC3)N3CCN(C)CC3)c(OC)c2)nc1NC1CCOCC1	Launched
gimeracil	dihydropyrimidine dehydrogenase inhibitor	DPYD	oncology	gastric adenocarcinoma	Selleck, Selleck	98.28	Oc1cc(=O)[nH]cc1Cl, Oc1cc(=O)[nH]cc1Cl	Launched
ginkgolide-A	GABA receptor antagonist	GLRA1, GLRB			MedChemEx	99.2	C[C@@H]1C(=O)O[C@H]2C[C@@]34[C@H]5C[C@@H](C(C)(C)C)[C@@]33[C@@H](O)C(=O)O[C@H]3O[C@@]4(C(=O)O5)[C@@]12O	Preclinical
ginkgolide-B	platelet activating factor receptor antagonist	GLRA1, GLRA2, GLRA3, GLRB, HTR3A, HTR3B			Tocris, Tocris, Selleck, Selleck, Tocris, Tocris	100	C[C@@H]1C(=O)O[C@H]2[C@H](O)[C@@]34[C@H]5C[C@@H](C(C)(C)C)[C@@]33[C@@H](O)C(=O)O[C@H]3O[C@@]4(C(=O)O5)[C@@]12O, C[C@@H]1C(=O)O[C@H]2[C@H](O)[C@@]34[C@H]5C[C@@H](C(C)(C)C)[C@@]33[C@@H](O)C(=O)O[C@H]3O[C@@]4(C(=O)O5)[C@@]12O, C[C@@H]1C(=O)O[C@H]2[C@H](O)[C@@]34[C@H]5C[C@@H](C(C)(C)C)[C@@]33[C@@H](O)C(=O)O[C@H]3O[C@@]4(C(=O)O5)[C@@]12O, C[C@@H]1C(=O)O[C@H]2[C@H](O)[C@@]34[C@H]5C[C@@H](C(C)(C)C)[C@@]33[C@@H](O)C(=O)O[C@H]3O[C@@]4(C(=O)O5)[C@@]12O, C[C@@H]1C(=O)O[C@H]2[C@H](O)[C@@]34[C@H]5C[C@@H](C(C)(C)C)[C@@]33[C@@H](O)C(=O)O[C@H]3O[C@@]4(C(=O)O5)[C@@]12O, C[C@@H]1C(=O)O[C@H]2[C@H](O)[C@@]34[C@H]5C[C@@H](C(C)(C)C)[C@@]33[C@@H](O)C(=O)O[C@H]3O[C@@]4(C(=O)O5)[C@@]12O	Phase 3
ginsenoside-C-K	NFkB pathway inhibitor, nitric oxide synthase inhibitor	PTGS2			MedChemEx, MedChemEx	99.5	CC(C)=CCC[C@](C)(O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)[C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@@H]1[C@@]3(C)CC[C@H](O)C(C)(C)[C@@H]3CC[C@@]21C, CC(C)=CCC[C@](C)(O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)[C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@@H]1[C@@]3(C)CC[C@H](O)C(C)(C)[C@@H]3CC[C@@]21C	Phase 1
ginsenoside-RD	calcium channel blocker				MedChemEx, MedChemEx	100	CC(C)=CCC[C@@](C)(O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)[C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@@H]1[C@@]3(C)CC[C@H](O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)C(C)(C)[C@@H]3CC[C@@]21C |a:9,11,14,16,18,20,23,25,26,29,30,34,36,38,41,43,45,47,49,52,54,56,61,64,&1:6|, CC(C)=CCC[C@@](C)(O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)[C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@@H]1[C@@]3(C)CC[C@H](O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)C(C)(C)[C@@H]3CC[C@@]21C |a:9,11,14,16,18,20,23,25,26,29,30,34,36,38,41,43,45,47,49,52,54,56,61,64,&1:6|	Phase 3
ginsenoside-RE	anti-inflammatory agent				MedChemEx	100	[H][C@@]1(CC[C@]2(C)[C@]1([H])[C@H](O)C[C@]1([H])[C@@]3(C)CC[C@H](O)C(C)(C)[C@]3([H])[C@H](C[C@@]21C)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O)[C@](C)(CCC=C(C)C)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O	Phase 1
ginsenoside-RE3	angiogenesis inhibitor, apoptosis stimulant	KCNH2			MedChemEx	99.4	CC(C)=CCC[C@@](C)(O)[C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@@H]1[C@@]3(C)CC[C@H](O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)C(C)(C)[C@@H]3CC[C@@]21C |a:9,12,14,15,18,19,23,25,27,30,32,34,36,38,41,43,45,50,53,&1:6|	Launched
givinostat	HDAC inhibitor	HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9			Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Stanley, Stanley, Stanley, Stanley, Stanley	100	CCN(CC)Cc1ccc2cc(COC(=O)Nc3ccc(cc3)C(=O)NO)ccc2c1, CCN(CC)Cc1ccc2cc(COC(=O)Nc3ccc(cc3)C(=O)NO)ccc2c1, CCN(CC)Cc1ccc2cc(COC(=O)Nc3ccc(cc3)C(=O)NO)ccc2c1, CCN(CC)Cc1ccc2cc(COC(=O)Nc3ccc(cc3)C(=O)NO)ccc2c1, CCN(CC)Cc1ccc2cc(COC(=O)Nc3ccc(cc3)C(=O)NO)ccc2c1, CCN(CC)Cc1ccc2cc(COC(=O)Nc3ccc(cc3)C(=O)NO)ccc2c1, CCN(CC)Cc1ccc2cc(COC(=O)Nc3ccc(cc3)C(=O)NO)ccc2c1, CCN(CC)Cc1ccc2cc(COC(=O)Nc3ccc(cc3)C(=O)NO)ccc2c1, CCN(CC)Cc1ccc2cc(COC(=O)Nc3ccc(cc3)C(=O)NO)ccc2c1, CCN(CC)Cc1ccc2cc(COC(=O)Nc3ccc(cc3)C(=O)NO)ccc2c1, CCN(CC)Cc1ccc2cc(COC(=O)Nc3ccc(cc3)C(=O)NO)ccc2c1, CCN(CC)Cc1ccc2cc(COC(=O)Nc3ccc(cc3)C(=O)NO)ccc2c1	Phase 3
GKA-50	glucokinase activator	GCK			Tocris, Tocris, Tocris	96.9	COC[C@H](C)Oc1cc(O[C@@H](C)Cc2ccccc2)cc(c1)C(=O)Nc1ccc(cn1)C(O)=O, COC[C@H](C)Oc1cc(O[C@@H](C)Cc2ccccc2)cc(c1)C(=O)Nc1ccc(cn1)C(O)=O, COC[C@H](C)Oc1cc(O[C@@H](C)Cc2ccccc2)cc(c1)C(=O)Nc1ccc(cn1)C(O)=O	Preclinical
GKT137831	NADPH oxidase inhibitor	NOX1, NOX4			MedChemEx, Selleck, MedChemEx	90	CN(C)c1cccc(c1)-c1n(C)c(=O)cc2[nH]n(-c3ccccc3Cl)c(=O)c12, CN(C)c1cccc(c1)-c1n(C)c(=O)cc2[nH]n(-c3ccccc3Cl)c(=O)c12, CN(C)c1cccc(c1)-c1n(C)c(=O)cc2[nH]n(-c3ccccc3Cl)c(=O)c12	Phase 2
GK921	transglutaminase inhibitor	TGM2			MedChemEx, MedChemEx	94.48	C(CN1CCCC1)Oc1nc2cccnc2nc1C#Cc1ccccc1, C(CN1CCCC1)Oc1nc2cccnc2nc1C#Cc1ccccc1	Preclinical
glafenine	DeltaF508-CFTR Correctors	CFTR			MedChemEx, Selleck	98.69	OC[C@@H](O)COC(=O)c1ccccc1Nc1ccnc2cc(Cl)ccc12 |&1:2|, OC[C@@H](O)COC(=O)c1ccccc1Nc1ccnc2cc(Cl)ccc12 |&1:2|	Withdrawn
glasdegib	hedgehog pathway inhibitor	SMO	hematologic malignancy	acute myeloid leukemia (AML)	MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx	96	CN1CC[C@H](C[C@@H]1c1nc2ccccc2[nH]1)NC(=O)Nc1ccc(cc1)C#N, CN1CC[C@H](C[C@@H]1c1nc2ccccc2[nH]1)NC(=O)Nc1ccc(cc1)C#N, CN1CC[C@H](C[C@@H]1c1nc2ccccc2[nH]1)NC(=O)Nc1ccc(cc1)C#N, CN1CC[C@H](C[C@@H]1c1nc2ccccc2[nH]1)NC(=O)Nc1ccc(cc1)C#N, CN1CC[C@H](C[C@@H]1c1nc2ccccc2[nH]1)NC(=O)Nc1ccc(cc1)C#N	Launched
glecaprevir	serine protease inhibitor		infectious disease	hepatitis C	MedChemEx, MedChemEx	96.9	[H]\C1=C([H])/C(F)(F)c2nc3ccccc3nc2O[C@@]2([H])CN(C(=O)[C@@]([H])(NC(=O)O[C@]3([H])CCC[C@@]3([H])OC1)C(C)(C)C)[C@@]([H])(C2)C(=O)N[C@@]1(C[C@@]1([H])C(F)F)C(=O)NS(=O)(=O)C1(C)CC1 |t:1|, [H]\C1=C([H])/C(F)(F)c2nc3ccccc3nc2O[C@@]2([H])CN(C(=O)[C@@]([H])(NC(=O)O[C@]3([H])CCC[C@@]3([H])OC1)C(C)(C)C)[C@@]([H])(C2)C(=O)N[C@@]1(C[C@@]1([H])C(F)F)C(=O)NS(=O)(=O)C1(C)CC1 |t:1|	Launched
glesatinib	tyrosine kinase inhibitor				MedChemEx	76.83	COCCNCc1ccc(nc1)-c1cc2nccc(Oc3ccc(NC(=S)NC(=O)Cc4ccc(F)cc4)cc3F)c2s1	Phase 2
gliclazide	ATP channel blocker, insulin secretagogue		endocrinology	diabetes mellitus	MicroSource, Selleck, MedChemEx, Selleck	88.04	Cc1ccc(cc1)S(=O)(=O)NC(=O)NN1C[C@H]2CCC[C@@H]2C1 |&1:16,&2:20,r|, Cc1ccc(cc1)S(=O)(=O)NC(=O)NN1C[C@H]2CCC[C@@H]2C1 |&1:16,&2:20,r|, Cc1ccc(cc1)S(=O)(=O)NC(=O)NN1C[C@H]2CCC[C@@H]2C1 |&1:16,&2:20,r|, Cc1ccc(cc1)S(=O)(=O)NC(=O)NN1C[C@H]2CCC[C@@H]2C1 |&1:16,&2:20,r|	Launched
glimepiride	insulin secretagogue	ABCC8, KCNJ1, KCNJ11	endocrinology	diabetes mellitus	MicroSource, Tocris, Tocris, Tocris, Selleck, Selleck	97.4	CCC1=C(C)CN(C(=O)NCCc2ccc(cc2)S(=O)(=O)NC(=O)N[C@H]2CC[C@H](C)CC2)C1=O |r,c:2|, CCC1=C(C)CN(C(=O)NCCc2ccc(cc2)S(=O)(=O)NC(=O)N[C@H]2CC[C@H](C)CC2)C1=O |r,c:2|, CCC1=C(C)CN(C(=O)NCCc2ccc(cc2)S(=O)(=O)NC(=O)N[C@H]2CC[C@H](C)CC2)C1=O |r,c:2|, CCC1=C(C)CN(C(=O)NCCc2ccc(cc2)S(=O)(=O)NC(=O)N[C@H]2CC[C@H](C)CC2)C1=O |r,c:2|, CCC1=C(C)CN(C(=O)NCCc2ccc(cc2)S(=O)(=O)NC(=O)N[C@H]2CC[C@H](C)CC2)C1=O |r,c:2|, CCC1=C(C)CN(C(=O)NCCc2ccc(cc2)S(=O)(=O)NC(=O)N[C@H]2CC[C@H](C)CC2)C1=O |r,c:2|	Launched
glipizide	sulfonylurea	ABCC8, KCNJ10, KCNJ11, PPARG	endocrinology	diabetes mellitus, hyperglycemia	MedChemEx, MicroSource, Selleck	98.53	Cc1cnc(cn1)C(=O)NCCc1ccc(cc1)S(=O)(=O)NC(=O)NC1CCCCC1, Cc1cnc(cn1)C(=O)NCCc1ccc(cc1)S(=O)(=O)NC(=O)NC1CCCCC1, Cc1cnc(cn1)C(=O)NCCc1ccc(cc1)S(=O)(=O)NC(=O)NC1CCCCC1	Launched
gliquidone	sulfonylurea	ABCC8, KCNJ10, KCNJ8	endocrinology	diabetes mellitus	MedChemEx, Selleck, Selleck, Selleck	98.3	COc1ccc2c(c1)C(=O)N(CCc1ccc(cc1)S(=O)(=O)NC(=O)NC1CCCCC1)C(=O)C2(C)C, COc1ccc2c(c1)C(=O)N(CCc1ccc(cc1)S(=O)(=O)NC(=O)NC1CCCCC1)C(=O)C2(C)C, COc1ccc2c(c1)C(=O)N(CCc1ccc(cc1)S(=O)(=O)NC(=O)NC1CCCCC1)C(=O)C2(C)C, COc1ccc2c(c1)C(=O)N(CCc1ccc(cc1)S(=O)(=O)NC(=O)NC1CCCCC1)C(=O)C2(C)C	Launched
Gln-1062	cholinesterase inhibitor				MedChemEx	97.73	COc1ccc2CN(C)CC[C@@]34C=C[C@@H](C[C@@H]3Oc1c24)OC(=O)c1ccccc1 |c:12|	Preclinical
GLPG0187	integrin antagonist				MedChemEx	100	COc1ccc(cc1)S(=O)(=O)N[C@@H](CNc1nc(C)nc(N2CCC(CC2)c2ccc3CCCNc3n2)c1C)C(O)=O	Phase 1
GLPG0492	androgen receptor modulator	AR			MedChemEx, MedChemEx	95.84	CN1C(=O)N(C(=O)[C@@]1(CO)c1ccccc1)c1ccc(C#N)c(c1)C(F)(F)F, CN1C(=O)N(C(=O)[C@@]1(CO)c1ccccc1)c1ccc(C#N)c(c1)C(F)(F)F	Phase 1
GLPG0492-R-enantiomer	androgen receptor modulator	AR			MedChemEx, MedChemEx	90.37	CN1C(=O)N(C(=O)[C@]1(CO)c1ccccc1)c1ccc(C#N)c(c1)C(F)(F)F, CN1C(=O)N(C(=O)[C@]1(CO)c1ccccc1)c1ccc(C#N)c(c1)C(F)(F)F	Phase 1
GLPG1837	CFTR channel potentiator				MedChemEx	95.97	CC1(C)Cc2c(sc(NC(=O)c3cc[nH]n3)c2C(N)=O)C(C)(C)O1	Phase 2
glucaric-acid					Sigma	0	O[C@@H]([C@H](O)[C@@H](O)C(O)=O)[C@H](O)C(O)=O	Phase 1
gluconolactone		LCT			MicroSource	0	OC[C@@H]1OC(=O)[C@@H](O)[C@H](O)[C@H]1O	Launched
glucosamine	glycosylated protein precursor	IL1B	neurology/psychiatry, rheumatology	muscle pain, rheumatoid arthritis, joint pain, backache	MicroSource, MicroSource, MedChemEx	100	N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O, N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O, N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O	Launched
glutathione	antioxidant	ESD, GGT1, GLO1, GLRX, GLRX2, GPX1, GPX2, GPX3, GPX4, GPX5, GPX6, GPX7, GPX8, GSR, GSS, GSTA1, GSTA2, GSTA3, GSTA4, GSTA5, GSTK1, GSTM1, GSTM2, GSTM3, GSTM4, GSTM5, GSTO1, GSTO2, GSTP1, GSTT1, GSTZ1, HAGH, HPGDS, LTC4S, MGST1, MGST2, MGST3, TXNDC12			MicroSource	0	N[C@@H](CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O)C(O)=O	Phase 3
glutathione-monoisopropyl-ester	lipid peroxidase inhibitor				Sigma, ChemImpex	79.96	CC(C)OC(=O)CNC(=O)[C@H](CS)NC(=O)CC[C@H](N)C(O)=O, CC(C)OC(=O)CNC(=O)[C@H](CS)NC(=O)CC[C@H](N)C(O)=O	Phase 2
gly-gln					Ark	100	NCC(=O)N[C@@H](CCC(N)=O)C(O)=O	Phase 2
glyburide	ATP channel blocker, insulin secretagogue, sulfonylurea	ABCA1, ABCB11, ABCC8, ABCC9, CFTR, CPT1A, KCNJ1, KCNJ11, KCNJ5, KCNJ8, SLCO2B1	endocrinology	diabetes mellitus, hyperglycemia	Tocris, Selleck, Selleck, MicroSource, Tocris	97.94	COc1ccc(Cl)cc1C(=O)NCCc1ccc(cc1)S(=O)(=O)NC(=O)NC1CCCCC1, COc1ccc(Cl)cc1C(=O)NCCc1ccc(cc1)S(=O)(=O)NC(=O)NC1CCCCC1, COc1ccc(Cl)cc1C(=O)NCCc1ccc(cc1)S(=O)(=O)NC(=O)NC1CCCCC1, COc1ccc(Cl)cc1C(=O)NCCc1ccc(cc1)S(=O)(=O)NC(=O)NC1CCCCC1, COc1ccc(Cl)cc1C(=O)NCCc1ccc(cc1)S(=O)(=O)NC(=O)NC1CCCCC1	Launched
glycerol-monolaurate	beta lactamase inhibitor				Sigma	98.1	CCCCCCCCCCCC(=O)OC[C@@H](O)CO |&1:15,r|	Launched
glycerol-phenylbutyrate	sigma receptor ligand				MedChemEx	88.43	O=C(CCCc1ccccc1)OCC(COC(=O)CCCc1ccccc1)OC(=O)CCCc1ccccc1	Phase 1
glycitein	tumor necrosis factor release inhibitor	TNF			Cayman, Cayman	97.95	COc1cc2c(cc1O)occ(-c1ccc(O)cc1)c2=O, COc1cc2c(cc1O)occ(-c1ccc(O)cc1)c2=O	Phase 3
glycopyrrolate	acetylcholine receptor antagonist	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5	gastroenterology	peptic ulcer disease (PUD)	MicroSource, MedChemEx	100	C[N+]1(C)CC[C@@H](C1)OC(=O)[C@@](O)(C1CCCC1)c1ccccc1 |&1:5,&2:10|, C[N+]1(C)CC[C@@H](C1)OC(=O)[C@@](O)(C1CCCC1)c1ccccc1 |&1:5,&2:10|	Launched
GM-1485	immunophilin ligand	FKBP1A			Key	67.58	CCC(C)(C)C(=O)C(=O)N1CCC[C@H]1C(O)=O	Preclinical
GMX1778	NAMPT inhibitor	NAMPT			MedChemEx, MedChemEx, MedChemEx	97.04	Clc1ccc(OCCCCCCN\C(NC#N)=N\c2ccncc2)cc1, Clc1ccc(OCCCCCCN\C(NC#N)=N\c2ccncc2)cc1, Clc1ccc(OCCCCCCN\C(NC#N)=N\c2ccncc2)cc1	Phase 1/Phase 2
GNE-7915	leucine rich repeat kinase inhibitor				Adooq	97.87	CCNc1nc(Nc2cc(F)c(cc2OC)C(=O)N2CCOCC2)ncc1C(F)(F)F	Preclinical
GNF-2	Bcr-Abl kinase inhibitor	ABL1, BCR			Tocris, Tocris, Selleck, Selleck	96.9	NC(=O)c1cccc(c1)-c1cc(Nc2ccc(OC(F)(F)F)cc2)ncn1, NC(=O)c1cccc(c1)-c1cc(Nc2ccc(OC(F)(F)F)cc2)ncn1, NC(=O)c1cccc(c1)-c1cc(Nc2ccc(OC(F)(F)F)cc2)ncn1, NC(=O)c1cccc(c1)-c1cc(Nc2ccc(OC(F)(F)F)cc2)ncn1	Preclinical
GNF-5	Bcr-Abl kinase inhibitor	ABL1, BCR			Tocris, Tocris, Tocris	99.44	OCCNC(=O)c1cccc(c1)-c1cc(Nc2ccc(OC(F)(F)F)cc2)ncn1, OCCNC(=O)c1cccc(c1)-c1cc(Nc2ccc(OC(F)(F)F)cc2)ncn1, OCCNC(=O)c1cccc(c1)-c1cc(Nc2ccc(OC(F)(F)F)cc2)ncn1	Preclinical
GNF-5837	growth factor receptor inhibitor	NTRK1, NTRK2, NTRK3			Tocris, MedChemEx	75.24	Cc1ccc(NC(=O)Nc2cc(ccc2F)C(F)(F)F)cc1Nc1ccc2\C(=C\c3ccc[nH]3)C(=O)Nc2c1, Cc1ccc(NC(=O)Nc2cc(ccc2F)C(F)(F)F)cc1Nc1ccc2\C(=C\c3ccc[nH]3)C(=O)Nc2c1	Preclinical
GNF-7	glucokinase inhibitor, protein kinase inhibitor	GCK, TNK2			Tocris, Tocris, Tocris	95.94	CN1C(=O)N(Cc2cnc(Nc3ccc(C)nc3)nc12)c1cc(NC(=O)c2cccc(c2)C(F)(F)F)ccc1C, CN1C(=O)N(Cc2cnc(Nc3ccc(C)nc3)nc12)c1cc(NC(=O)c2cccc(c2)C(F)(F)F)ccc1C, CN1C(=O)N(Cc2cnc(Nc3ccc(C)nc3)nc12)c1cc(NC(=O)c2cccc(c2)C(F)(F)F)ccc1C	Preclinical
GNTI	opioid receptor antagonist	OPRK1, OPRM1			Tocris, Tocris	91.42	NC(=N)Nc1ccc2[nH]c3[C@@H]4Oc5c6c(C[C@H]7N(CC8CC8)CC[C@@]46[C@@]7(O)Cc3c2c1)ccc5O, NC(=N)Nc1ccc2[nH]c3[C@@H]4Oc5c6c(C[C@H]7N(CC8CC8)CC[C@@]46[C@@]7(O)Cc3c2c1)ccc5O	Preclinical
go-6983	protein kinase inhibitor	PRKCA, PRKCB, PRKCD, PRKCG, PRKCZ			Selleck, Selleck, Selleck	93.45	COc1ccc2n(CCCN(C)C)cc(C3=C(C(=O)NC3=O)c3c[nH]c4ccccc34)c2c1 |t:15|, COc1ccc2n(CCCN(C)C)cc(C3=C(C(=O)NC3=O)c3c[nH]c4ccccc34)c2c1 |t:15|, COc1ccc2n(CCCN(C)C)cc(C3=C(C(=O)NC3=O)c3c[nH]c4ccccc34)c2c1 |t:15|	Preclinical
golgicide-A	ARF inhibitor	GBF1			Tocris, Tocris, Selleck, Selleck, Tocris	97.26	Fc1cc(F)c2N[C@@H]([C@@H]3CC=C[C@@H]3c2c1)c1cccnc1 |a:8,12,&1:7,c:10|, Fc1cc(F)c2N[C@@H]([C@@H]3CC=C[C@@H]3c2c1)c1cccnc1 |a:8,12,&1:7,c:10|, Fc1cc(F)c2N[C@@H]([C@@H]3CC=C[C@@H]3c2c1)c1cccnc1 |a:8,12,&1:7,c:10|, Fc1cc(F)c2N[C@@H]([C@@H]3CC=C[C@@H]3c2c1)c1cccnc1 |a:8,12,&1:7,c:10|, Fc1cc(F)c2N[C@@H]([C@@H]3CC=C[C@@H]3c2c1)c1cccnc1 |a:8,12,&1:7,c:10|	Preclinical
golvatinib	VEGFR inhibitor	KDR, MET			MedChemEx, Selleck, Selleck, Selleck	97.57	CN1CCN(CC1)C1CCN(CC1)C(=O)Nc1cc(Oc2ccc(NC(=O)C3(CC3)C(=O)Nc3ccc(F)cc3)c(F)c2)ccn1, CN1CCN(CC1)C1CCN(CC1)C(=O)Nc1cc(Oc2ccc(NC(=O)C3(CC3)C(=O)Nc3ccc(F)cc3)c(F)c2)ccn1, CN1CCN(CC1)C1CCN(CC1)C(=O)Nc1cc(Oc2ccc(NC(=O)C3(CC3)C(=O)Nc3ccc(F)cc3)c(F)c2)ccn1, CN1CCN(CC1)C1CCN(CC1)C(=O)Nc1cc(Oc2ccc(NC(=O)C3(CC3)C(=O)Nc3ccc(F)cc3)c(F)c2)ccn1	Phase 2
gonadorelin	gonadotropin releasing factor hormone receptor agonist	GNRHR	obstetrics/gynecology	cystic ovaries, reproductive synchrony	MedChemEx	95.93	CC(C)C[C@H](NC(=O)CNC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)NCC(N)=O	Launched
goserelin-acetate	gonadotropin releasing factor hormone receptor agonist	GNRHR, LHCGR	oncology, obstetrics/gynecology	prostate cancer, breast cancer, endometriosis	Enzo, MedChemEx	97.19	CC(C)C[C@H](NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)NNC(N)=O, CC(C)C[C@H](NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)NNC(N)=O	Launched
gossypol	BCL inhibitor, MCL1 inhibitor	BCL2			Tocris, Selleck, Tocris, Selleck, Selleck, Selleck, Selleck, Selleck	96.16	CC(C)c1c(O)c(O)c(C=O)c2c(O)c(c(C)cc12)-c1c(C)cc2c(C(C)C)c(O)c(O)c(C=O)c2c1O, CC(C)c1c(O)c(O)c(C=O)c2c(O)c(c(C)cc12)-c1c(C)cc2c(C(C)C)c(O)c(O)c(C=O)c2c1O, CC(C)c1c(O)c(O)c(C=O)c2c(O)c(c(C)cc12)-c1c(C)cc2c(C(C)C)c(O)c(O)c(C=O)c2c1O, CC(C)c1c(O)c(O)c(C=O)c2c(O)c(c(C)cc12)-c1c(C)cc2c(C(C)C)c(O)c(O)c(C=O)c2c1O, CC(C)c1c(O)c(O)c(C=O)c2c(O)c(c(C)cc12)-c1c(C)cc2c(C(C)C)c(O)c(O)c(C=O)c2c1O, CC(C)c1c(O)c(O)c(C=O)c2c(O)c(c(C)cc12)-c1c(C)cc2c(C(C)C)c(O)c(O)c(C=O)c2c1O, CC(C)c1c(O)c(O)c(C=O)c2c(O)c(c(C)cc12)-c1c(C)cc2c(C(C)C)c(O)c(O)c(C=O)c2c1O, CC(C)c1c(O)c(O)c(C=O)c2c(O)c(c(C)cc12)-c1c(C)cc2c(C(C)C)c(O)c(O)c(C=O)c2c1O	Phase 2
GPBAR-A	G protein-coupled receptor agonist	GPBAR1			Tocris, Tocris, Tocris	98.67	Fc1ccccc1-c1ccnc2OCC(=O)N(Cc3cc(cc(c3)C(F)(F)F)C(F)(F)F)Cc12, Fc1ccccc1-c1ccnc2OCC(=O)N(Cc3cc(cc(c3)C(F)(F)F)C(F)(F)F)Cc12, Fc1ccccc1-c1ccnc2OCC(=O)N(Cc3cc(cc(c3)C(F)(F)F)C(F)(F)F)Cc12	Preclinical
GPI-1046	FKBP inhibitor	FKBP1A			Key	97.78	CCC(C)(C)C(=O)C(=O)N1CCC[C@H]1C(=O)OCCCc1cccnc1	Preclinical
GPi-688	glycogen phosphorylase inhibitor				Tocris, Tocris	96.63	OC[C@H](O)CN1C(=O)[C@@H](Cc2ccccc12)NC(=O)c1cc2cc(Cl)sc2[nH]1 |a:2,&1:8|, OC[C@H](O)CN1C(=O)[C@@H](Cc2ccccc12)NC(=O)c1cc2cc(Cl)sc2[nH]1 |a:2,&1:8|	Preclinical
GPP-78	NAMPT inhibitor	NAMPT			Tocris, Tocris, Tocris	98.04	O=C(CCCCCCCn1cc(nn1)-c1cccnc1)Nc1ccccc1-c1ccccc1, O=C(CCCCCCCn1cc(nn1)-c1cccnc1)Nc1ccccc1-c1ccccc1, O=C(CCCCCCCn1cc(nn1)-c1cccnc1)Nc1ccccc1-c1ccccc1	Preclinical
GPR120-modulator-1	G protein-coupled receptor modulator	FFAR4			MedChemEx	96.16	Cc1cc(OCc2nc(cs2)-c2ccccc2Cl)ccc1OCC(O)=O	Preclinical
GP1a	cannabinoid receptor agonist	CNR2			Tocris, Tocris, Tocris, Tocris, Tocris, SantaCruz	98	Cc1ccc-2c(Cc3c(nn(c-23)-c2ccc(Cl)cc2Cl)C(=O)NN2CCCCC2)c1, Cc1ccc-2c(Cc3c(nn(c-23)-c2ccc(Cl)cc2Cl)C(=O)NN2CCCCC2)c1, Cc1ccc-2c(Cc3c(nn(c-23)-c2ccc(Cl)cc2Cl)C(=O)NN2CCCCC2)c1, Cc1ccc-2c(Cc3c(nn(c-23)-c2ccc(Cl)cc2Cl)C(=O)NN2CCCCC2)c1, Cc1ccc-2c(Cc3c(nn(c-23)-c2ccc(Cl)cc2Cl)C(=O)NN2CCCCC2)c1, Cc1ccc-2c(Cc3c(nn(c-23)-c2ccc(Cl)cc2Cl)C(=O)NN2CCCCC2)c1	Preclinical
GP2a	cannabinoid receptor agonist	CNR2			Tocris, Tocris, Tocris	98.57	Cc1ccc-2c(Cc3c(nn(c-23)-c2ccc(Cl)cc2Cl)C(=O)NC2CCCCC2)c1, Cc1ccc-2c(Cc3c(nn(c-23)-c2ccc(Cl)cc2Cl)C(=O)NC2CCCCC2)c1, Cc1ccc-2c(Cc3c(nn(c-23)-c2ccc(Cl)cc2Cl)C(=O)NC2CCCCC2)c1	Preclinical
GR-103691	dopamine receptor antagonist	DRD3			Tocris, Tocris	93.2	COc1ccccc1N1CCN(CCCCNC(=O)c2ccc(cc2)-c2ccc(cc2)C(C)=O)CC1, COc1ccccc1N1CCN(CCCCNC(=O)c2ccc(cc2)-c2ccc(cc2)C(C)=O)CC1	Preclinical
GR-113808	serotonin receptor antagonist	HTR4			Tocris, Tocris	96.58	Cn1cc(C(=O)OCC2CCN(CCNS(C)(=O)=O)CC2)c2ccccc12, Cn1cc(C(=O)OCC2CCN(CCNS(C)(=O)=O)CC2)c2ccccc12	Preclinical
GR-127935	serotonin receptor antagonist	HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR6			Tocris, Tocris, Tocris, Tocris, Tocris	98.3	COc1ccc(NC(=O)c2ccc(cc2)-c2ccc(cc2C)-c2noc(C)n2)cc1N1CCN(C)CC1, COc1ccc(NC(=O)c2ccc(cc2)-c2ccc(cc2C)-c2noc(C)n2)cc1N1CCN(C)CC1, COc1ccc(NC(=O)c2ccc(cc2)-c2ccc(cc2C)-c2noc(C)n2)cc1N1CCN(C)CC1, COc1ccc(NC(=O)c2ccc(cc2)-c2ccc(cc2C)-c2noc(C)n2)cc1N1CCN(C)CC1, COc1ccc(NC(=O)c2ccc(cc2)-c2ccc(cc2C)-c2noc(C)n2)cc1N1CCN(C)CC1	Preclinical
GR-135531	melatonin receptor agonist				Tocris, Tocris	90.72	COC(=O)Nc1ccc2[nH]cc(CCNC(C)=O)c2c1, COC(=O)Nc1ccc2[nH]cc(CCNC(C)=O)c2c1	Preclinical
GR-144053	integrin antagonist	ITGA2B, ITGB3			Tocris, Tocris, Tocris	94.59	NC(=N)c1ccc(cc1)N1CCN(CC1)C1CCN(CC(O)=O)CC1, NC(=N)c1ccc(cc1)N1CCN(CC1)C1CCN(CC(O)=O)CC1, NC(=N)c1ccc(cc1)N1CCN(CC1)C1CCN(CC(O)=O)CC1	Preclinical
GR-159897	tachykinin antagonist	TAC1, TACR2			Tocris, Tocris, Tocris, Tocris, Tocris	95.15	COC1(C[S@@](=O)c2ccccc2)CCN(CCc2c[nH]c3ccc(F)cc23)CC1, COC1(C[S@@](=O)c2ccccc2)CCN(CCc2c[nH]c3ccc(F)cc23)CC1, COC1(C[S@@](=O)c2ccccc2)CCN(CCc2c[nH]c3ccc(F)cc23)CC1, COC1(C[S@@](=O)c2ccccc2)CCN(CCc2c[nH]c3ccc(F)cc23)CC1, COC1(C[S@@](=O)c2ccccc2)CCN(CCc2c[nH]c3ccc(F)cc23)CC1	Preclinical
GR-235	estrogen receptor agonist, FXR antagonist, progesterone receptor agonist	NR1H4			Tocris	51.94	[H][C@@]12CC(=O)C(=CC)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C |t:20|	Launched
GR-79236	adenosine receptor agonist	ADORA1, ADORA2A			Tocris, Tocris, Tocris	98.53	OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N[C@H]3CCC[C@@H]3O)ncnc12, OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N[C@H]3CCC[C@@H]3O)ncnc12, OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N[C@H]3CCC[C@@H]3O)ncnc12	Phase 1
gramicidin	bacterial permeability inducer		infectious disease	first-aid antibiotic	Enzo	50.33	CC(C)C[C@@H](NC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H](NC=O)C(C)C)C(=O)N[C@@H](C)C(=O)N[C@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(C)C)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)NCCO	Launched
gramine	norepinephrine reputake inhibitor				Selleck	90.98	CN(C)Cc1c[nH]c2ccccc12	Preclinical
granisetron	serotonin receptor antagonist	HTR3A	gastroenterology	nausea, vomiting	MicroSource, Selleck	97.08	CN1[C@H]2CCC[C@@H]1C[C@@H](C2)NC(=O)c1nn(C)c2ccccc12 |&1:2,&2:6,&3:8|, CN1[C@H]2CCC[C@@H]1C[C@@H](C2)NC(=O)c1nn(C)c2ccccc12 |&1:2,&2:6,&3:8|	Launched
grapiprant	prostaglandin inhibitor	PTGER4	rheumatology	osteoarthritis	MedChemEx, MedChemEx	96.45	CCc1nc2c(C)nc(C)cc2n1-c1ccc(CCNC(=O)NS(=O)(=O)c2ccc(C)cc2)cc1, CCc1nc2c(C)nc(C)cc2n1-c1ccc(CCNC(=O)NS(=O)(=O)c2ccc(C)cc2)cc1	Launched
grazoprevir	HCV inhibitor		infectious disease	hepatitis C	MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx	98.97	COc1ccc2nc3CCCCC[C@@H]4C[C@H]4OC(=O)N[C@H](C(=O)N4C[C@@H](C[C@H]4C(=O)N[C@@]4(C[C@H]4C=C)C(=O)NS(=O)(=O)C4CC4)Oc3nc2c1)C(C)(C)C, COc1ccc2nc3CCCCC[C@@H]4C[C@H]4OC(=O)N[C@H](C(=O)N4C[C@@H](C[C@H]4C(=O)N[C@@]4(C[C@H]4C=C)C(=O)NS(=O)(=O)C4CC4)Oc3nc2c1)C(C)(C)C, COc1ccc2nc3CCCCC[C@@H]4C[C@H]4OC(=O)N[C@H](C(=O)N4C[C@@H](C[C@H]4C(=O)N[C@@]4(C[C@H]4C=C)C(=O)NS(=O)(=O)C4CC4)Oc3nc2c1)C(C)(C)C, COc1ccc2nc3CCCCC[C@@H]4C[C@H]4OC(=O)N[C@H](C(=O)N4C[C@@H](C[C@H]4C(=O)N[C@@]4(C[C@H]4C=C)C(=O)NS(=O)(=O)C4CC4)Oc3nc2c1)C(C)(C)C, COc1ccc2nc3CCCCC[C@@H]4C[C@H]4OC(=O)N[C@H](C(=O)N4C[C@@H](C[C@H]4C(=O)N[C@@]4(C[C@H]4C=C)C(=O)NS(=O)(=O)C4CC4)Oc3nc2c1)C(C)(C)C	Launched
griseofulvin	tubulin polymerization inhibitor	KRT12	infectious disease	ringworm, tinea pedis	MicroSource, MicroSource, Selleck	95.44	COC1=CC(=O)C[C@@H](C)[C@]11Oc2c(C1=O)c(OC)cc(OC)c2Cl |t:2|, COC1=CC(=O)C[C@@H](C)[C@]11Oc2c(C1=O)c(OC)cc(OC)c2Cl |t:2|, COC1=CC(=O)C[C@@H](C)[C@]11Oc2c(C1=O)c(OC)cc(OC)c2Cl |t:2|	Launched
GR125487	serotonin receptor antagonist	HTR4			Tocris, Tocris, Tocris, Tocris	98.3	COc1[nH]c2ccc(F)cc2c1C(=O)OCC1CCN(CCNS(C)(=O)=O)CC1, COc1[nH]c2ccc(F)cc2c1C(=O)OCC1CCN(CCNS(C)(=O)=O)CC1, COc1[nH]c2ccc(F)cc2c1C(=O)OCC1CCN(CCNS(C)(=O)=O)CC1, COc1[nH]c2ccc(F)cc2c1C(=O)OCC1CCN(CCNS(C)(=O)=O)CC1	Preclinical
GR46611	serotonin receptor agonist	HTR1D			Tocris, Tocris, Tocris, Tocris	97.7	COc1ccc(CNC(=O)\C=C\c2ccc3[nH]cc(CCN(C)C)c3c2)cc1, COc1ccc(CNC(=O)\C=C\c2ccc3[nH]cc(CCN(C)C)c3c2)cc1, COc1ccc(CNC(=O)\C=C\c2ccc3[nH]cc(CCN(C)C)c3c2)cc1, COc1ccc(CNC(=O)\C=C\c2ccc3[nH]cc(CCN(C)C)c3c2)cc1	Preclinical
GS-143	ubiquitin ligase inhibitor	BTRC, NFKBIA			Tocris, Tocris, Tocris, Tocris	75.7	OC(=O)c1ccc(cc1)N1N=C(Cc2ccccc2)\C(=C/c2ccc(o2)-c2ccccc2F)C1=O |t:11|, OC(=O)c1ccc(cc1)N1N=C(Cc2ccccc2)\C(=C/c2ccc(o2)-c2ccccc2F)C1=O |t:11|, OC(=O)c1ccc(cc1)N1N=C(Cc2ccccc2)\C(=C/c2ccc(o2)-c2ccccc2F)C1=O |t:11|, OC(=O)c1ccc(cc1)N1N=C(Cc2ccccc2)\C(=C/c2ccc(o2)-c2ccccc2F)C1=O |t:11|	Preclinical
GS-39783	GABA receptor modulator	GABBR1			Tocris, Tocris, Tocris	98.14	CSc1nc(NC2CCCC2)c(c(NC2CCCC2)n1)[N+]([O-])=O, CSc1nc(NC2CCCC2)c(c(NC2CCCC2)n1)[N+]([O-])=O, CSc1nc(NC2CCCC2)c(c(NC2CCCC2)n1)[N+]([O-])=O	Preclinical
GS-6201	adenosine receptor antagonist	ADORA1, ADORA2A, ADORA2B, ADORA3			Tocris, Tocris, Tocris	99.12	CCCn1c(=O)n(CC)c2nc([nH]c2c1=O)-c1cnn(Cc2cccc(c2)C(F)(F)F)c1, CCCn1c(=O)n(CC)c2nc([nH]c2c1=O)-c1cnn(Cc2cccc(c2)C(F)(F)F)c1, CCCn1c(=O)n(CC)c2nc([nH]c2c1=O)-c1cnn(Cc2cccc(c2)C(F)(F)F)c1	Phase 1
GS-9620	toll-like receptor agonist	TLR7			MedChemEx, MedChemEx	86.83	CCCCOc1nc(N)c2NC(=O)CN(Cc3cccc(CN4CCCC4)c3)c2n1, CCCCOc1nc(N)c2NC(=O)CN(Cc3cccc(CN4CCCC4)c3)c2n1	Phase 2
GS-967	voltage-gated sodium channel blocker				Adooq	92.97	FC(F)(F)Oc1ccc(cc1)-c1ccc2nnc(n2c1)C(F)(F)F	Preclinical
GS-9973	SYK inhibitor	SYK			MedChemEx, MedChemEx, Selleck, MedChemEx, MedChemEx, Selleck, Selleck, Selleck	95.21	C1CN(CCO1)c1ccc(Nc2nc(cn3ccnc23)-c2ccc3c[nH]nc3c2)cc1, C1CN(CCO1)c1ccc(Nc2nc(cn3ccnc23)-c2ccc3c[nH]nc3c2)cc1, C1CN(CCO1)c1ccc(Nc2nc(cn3ccnc23)-c2ccc3c[nH]nc3c2)cc1, C1CN(CCO1)c1ccc(Nc2nc(cn3ccnc23)-c2ccc3c[nH]nc3c2)cc1, C1CN(CCO1)c1ccc(Nc2nc(cn3ccnc23)-c2ccc3c[nH]nc3c2)cc1, C1CN(CCO1)c1ccc(Nc2nc(cn3ccnc23)-c2ccc3c[nH]nc3c2)cc1, C1CN(CCO1)c1ccc(Nc2nc(cn3ccnc23)-c2ccc3c[nH]nc3c2)cc1, C1CN(CCO1)c1ccc(Nc2nc(cn3ccnc23)-c2ccc3c[nH]nc3c2)cc1	Phase 2
GSK-J1	histone demethylase inhibitor	KDM6B			MedChemEx, MedChemEx, Tocris	94.8	OC(=O)CCNc1cc(nc(n1)-c1ccccn1)N1CCc2ccccc2CC1, OC(=O)CCNc1cc(nc(n1)-c1ccccn1)N1CCc2ccccc2CC1, OC(=O)CCNc1cc(nc(n1)-c1ccccn1)N1CCc2ccccc2CC1	Preclinical
GSK-J2	histone demethylase inhibitor				Tocris, MedChemEx, MedChemEx	95.52	OC(=O)CCNc1cc(nc(n1)-c1cccnc1)N1CCc2ccccc2CC1, OC(=O)CCNc1cc(nc(n1)-c1cccnc1)N1CCc2ccccc2CC1, OC(=O)CCNc1cc(nc(n1)-c1cccnc1)N1CCc2ccccc2CC1	Preclinical
GSK-J4	histone lysine demethylase inhibitor	KDM6A, KDM6B			Tocris, Tocris, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck	95.75	CCOC(=O)CCNc1cc(nc(n1)-c1ccccn1)N1CCc2ccccc2CC1, CCOC(=O)CCNc1cc(nc(n1)-c1ccccn1)N1CCc2ccccc2CC1, CCOC(=O)CCNc1cc(nc(n1)-c1ccccn1)N1CCc2ccccc2CC1, CCOC(=O)CCNc1cc(nc(n1)-c1ccccn1)N1CCc2ccccc2CC1, CCOC(=O)CCNc1cc(nc(n1)-c1ccccn1)N1CCc2ccccc2CC1, CCOC(=O)CCNc1cc(nc(n1)-c1ccccn1)N1CCc2ccccc2CC1, CCOC(=O)CCNc1cc(nc(n1)-c1ccccn1)N1CCc2ccccc2CC1, CCOC(=O)CCNc1cc(nc(n1)-c1ccccn1)N1CCc2ccccc2CC1	Preclinical
GSK-J5	histone demethylase control				Tocris, Tocris	95.18	CCOC(=O)CCNc1cc(nc(n1)-c1cccnc1)N1CCc2ccccc2CC1, CCOC(=O)CCNc1cc(nc(n1)-c1cccnc1)N1CCc2ccccc2CC1	Preclinical
GSK-LSD-1	histone lysine demethylase inhibitor	KDM1A			Tocris, Cayman	94.74	C1[C@@H](NC2CCNCC2)[C@@H]1c1ccccc1, C1[C@@H](NC2CCNCC2)[C@@H]1c1ccccc1	Preclinical
GSK-3-inhibitor-IX	glycogen synthase kinase inhibitor, lipoxygenase inhibitor	GSK3A, GSK3B			Tocris, Tocris, Tocris, Tocris, Selleck, Selleck, Selleck, Selleck, Selleck	96.66	O\N=C1/C(/Nc2ccccc/12)=C1/C(=O)Nc2cc(Br)ccc12, O\N=C1/C(/Nc2ccccc/12)=C1/C(=O)Nc2cc(Br)ccc12, O\N=C1/C(/Nc2ccccc/12)=C1/C(=O)Nc2cc(Br)ccc12, O\N=C1/C(/Nc2ccccc/12)=C1/C(=O)Nc2cc(Br)ccc12, O\N=C1/C(/Nc2ccccc/12)=C1/C(=O)Nc2cc(Br)ccc12, O\N=C1/C(/Nc2ccccc/12)=C1/C(=O)Nc2cc(Br)ccc12, O\N=C1/C(/Nc2ccccc/12)=C1/C(=O)Nc2cc(Br)ccc12, O\N=C1/C(/Nc2ccccc/12)=C1/C(=O)Nc2cc(Br)ccc12, O\N=C1/C(/Nc2ccccc/12)=C1/C(=O)Nc2cc(Br)ccc12	Preclinical
GSK0660	PPAR receptor antagonist	PPARD			Tocris, Tocris, Tocris	96.98	COC(=O)c1sccc1S(=O)(=O)Nc1ccc(Nc2ccccc2)cc1OC, COC(=O)c1sccc1S(=O)(=O)Nc1ccc(Nc2ccccc2)cc1OC, COC(=O)c1sccc1S(=O)(=O)Nc1ccc(Nc2ccccc2)cc1OC	Preclinical
GSK1059615	PI3K inhibitor	PIK3CG			Selleck, Selleck, Selleck	82.73	O=C1NC(=O)\C(S1)=C\c1ccc2nccc(-c3ccncc3)c2c1, O=C1NC(=O)\C(S1)=C\c1ccc2nccc(-c3ccncc3)c2c1, O=C1NC(=O)\C(S1)=C\c1ccc2nccc(-c3ccncc3)c2c1	Phase 1
GSK1070916	Aurora kinase inhibitor	AURKA, AURKB, AURKC, CYP2D6, CYP3A4			MedChemEx, Selleck, Selleck, Selleck	96.68	CCn1cc(c(n1)-c1ccc(NC(=O)N(C)C)cc1)-c1ccnc2[nH]c(cc12)-c1cccc(CN(C)C)c1, CCn1cc(c(n1)-c1ccc(NC(=O)N(C)C)cc1)-c1ccnc2[nH]c(cc12)-c1cccc(CN(C)C)c1, CCn1cc(c(n1)-c1ccc(NC(=O)N(C)C)cc1)-c1ccnc2[nH]c(cc12)-c1cccc(CN(C)C)c1, CCn1cc(c(n1)-c1ccc(NC(=O)N(C)C)cc1)-c1ccnc2[nH]c(cc12)-c1cccc(CN(C)C)c1	Phase 1
GSK1292263	glucose dependent insulinotropic receptor agonist	GRPR			MedChemEx, Selleck	97.16	CC(C)c1noc(n1)N1CCC(COc2ccc(nc2)-c2ccc(cc2)S(C)(=O)=O)CC1, CC(C)c1noc(n1)N1CCC(COc2ccc(nc2)-c2ccc(cc2)S(C)(=O)=O)CC1	Phase 2
GSK1562590	urotensin receptor antagonist	UTS2R			Tocris, Tocris	96.68	CN([C@@H](CN1CCCC1)c1ccc(cc1)-c1cccc(c1)C(N)=O)C(=O)CN1C(=O)COc2cc(Cl)c(Cl)cc12, CN([C@@H](CN1CCCC1)c1ccc(cc1)-c1cccc(c1)C(N)=O)C(=O)CN1C(=O)COc2cc(Cl)c(Cl)cc12	Preclinical
GSK163090	serotonin receptor antagonist	HTR1A, HTR1B, HTR1D			MedChemEx, MedChemEx	98.29	Cc1ccc2c(cccc2n1)N1CCN(CCc2cccc(c2)N2CCNC2=O)CC1, Cc1ccc2c(cccc2n1)N1CCN(CCc2cccc(c2)N2CCNC2=O)CC1	Phase 2
GSK1838705A	insulin growth factor receptor inhibitor	ALK, IGF1R, INSR, RPS6KA1			Tocris, Tocris, Selleck, Selleck, Selleck, Selleck, Selleck	94.21	CNC(=O)c1c(F)cccc1Nc1nc(Nc2cc3N(CCc3cc2OC)C(=O)CN(C)C)nc2[nH]ccc12, CNC(=O)c1c(F)cccc1Nc1nc(Nc2cc3N(CCc3cc2OC)C(=O)CN(C)C)nc2[nH]ccc12, CNC(=O)c1c(F)cccc1Nc1nc(Nc2cc3N(CCc3cc2OC)C(=O)CN(C)C)nc2[nH]ccc12, CNC(=O)c1c(F)cccc1Nc1nc(Nc2cc3N(CCc3cc2OC)C(=O)CN(C)C)nc2[nH]ccc12, CNC(=O)c1c(F)cccc1Nc1nc(Nc2cc3N(CCc3cc2OC)C(=O)CN(C)C)nc2[nH]ccc12, CNC(=O)c1c(F)cccc1Nc1nc(Nc2cc3N(CCc3cc2OC)C(=O)CN(C)C)nc2[nH]ccc12, CNC(=O)c1c(F)cccc1Nc1nc(Nc2cc3N(CCc3cc2OC)C(=O)CN(C)C)nc2[nH]ccc12	Preclinical
GSK189254	histamine receptor antagonist				MedChemEx	96.08	CNC(=O)c1ccc(Oc2ccc3CCN(CCc3c2)C2CCC2)nc1	Phase 2
GSK1904529A	IGF-1 inhibitor, insulin growth factor receptor inhibitor, insulin receptor ligand	IGF1R, INSR			MedChemEx, Selleck, Selleck	93.76	CCc1cc(Nc2nccc(n2)-c2c(nc3ccccn23)-c2ccc(OC)c(c2)C(=O)Nc2c(F)cccc2F)c(OC)cc1N1CCC(CC1)N1CCN(CC1)S(C)(=O)=O, CCc1cc(Nc2nccc(n2)-c2c(nc3ccccn23)-c2ccc(OC)c(c2)C(=O)Nc2c(F)cccc2F)c(OC)cc1N1CCC(CC1)N1CCN(CC1)S(C)(=O)=O, CCc1cc(Nc2nccc(n2)-c2c(nc3ccccn23)-c2ccc(OC)c(c2)C(=O)Nc2c(F)cccc2F)c(OC)cc1N1CCC(CC1)N1CCN(CC1)S(C)(=O)=O	Preclinical
GSK2110183	AKT inhibitor	AKT1, AKT2, AKT3			MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx	86.22	Cn1ncc(Cl)c1-c1cc(sc1Cl)C(=O)N[C@H](CN)Cc1cccc(F)c1, Cn1ncc(Cl)c1-c1cc(sc1Cl)C(=O)N[C@H](CN)Cc1cccc(F)c1, Cn1ncc(Cl)c1-c1cc(sc1Cl)C(=O)N[C@H](CN)Cc1cccc(F)c1, Cn1ncc(Cl)c1-c1cc(sc1Cl)C(=O)N[C@H](CN)Cc1cccc(F)c1, Cn1ncc(Cl)c1-c1cc(sc1Cl)C(=O)N[C@H](CN)Cc1cccc(F)c1	Phase 2
GSK2126458	mTOR inhibitor, PI3K inhibitor	MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG			MedChemEx, MedChemEx, Selleck, Selleck, Selleck, Selleck, Selleck	97.23	COc1ncc(cc1NS(=O)(=O)c1ccc(F)cc1F)-c1ccc2nccc(-c3ccnnc3)c2c1, COc1ncc(cc1NS(=O)(=O)c1ccc(F)cc1F)-c1ccc2nccc(-c3ccnnc3)c2c1, COc1ncc(cc1NS(=O)(=O)c1ccc(F)cc1F)-c1ccc2nccc(-c3ccnnc3)c2c1, COc1ncc(cc1NS(=O)(=O)c1ccc(F)cc1F)-c1ccc2nccc(-c3ccnnc3)c2c1, COc1ncc(cc1NS(=O)(=O)c1ccc(F)cc1F)-c1ccc2nccc(-c3ccnnc3)c2c1, COc1ncc(cc1NS(=O)(=O)c1ccc(F)cc1F)-c1ccc2nccc(-c3ccnnc3)c2c1, COc1ncc(cc1NS(=O)(=O)c1ccc(F)cc1F)-c1ccc2nccc(-c3ccnnc3)c2c1	Phase 1
GSK2190915	lipoxygenase inhibitor	ALOX5AP			MedChemEx	97.5	CCOc1ccc(cn1)-c1ccc(Cn2c(CC(C)(C)C(O)=O)c(SC(C)(C)C)c3cc(OCc4ccc(C)cn4)ccc23)cc1	Phase 2
GSK2193874	transient receptor potential channel antagonist	TRPV4			Tocris, Tocris, Tocris	98.2	FC(F)(F)c1cccc(c1)-c1nc2cc(Br)ccc2c(C(=O)NC2(CC2)c2ccccc2)c1CN1CCC(CC1)N1CCCCC1, FC(F)(F)c1cccc(c1)-c1nc2cc(Br)ccc2c(C(=O)NC2(CC2)c2ccccc2)c1CN1CCC(CC1)N1CCCCC1, FC(F)(F)c1cccc(c1)-c1nc2cc(Br)ccc2c(C(=O)NC2(CC2)c2ccccc2)c1CN1CCC(CC1)N1CCCCC1	Preclinical
GSK2194069	fatty acid synthase inhibitor	FASN			Tocris, Tocris, Tocris, Tocris	98.77	O=C(C1CC1)N1CC[C@@H](Cc2n[nH]c(=O)n2-c2ccc(cc2)-c2ccc3occc3c2)C1, O=C(C1CC1)N1CC[C@@H](Cc2n[nH]c(=O)n2-c2ccc(cc2)-c2ccc3occc3c2)C1, O=C(C1CC1)N1CC[C@@H](Cc2n[nH]c(=O)n2-c2ccc(cc2)-c2ccc3occc3c2)C1, O=C(C1CC1)N1CC[C@@H](Cc2n[nH]c(=O)n2-c2ccc(cc2)-c2ccc3occc3c2)C1	Preclinical
GSK2239633A	CC chemokine receptor antagonist				MedChemEx	93.36	COc1cccc2n(Cc3cccc(CNC(=O)C(C)(C)O)c3)nc(NS(=O)(=O)c3ccc(Cl)s3)c12	Preclinical
GSK2256098	kinase inhibitor				MedChemEx	94.24	CONC(=O)c1ccccc1Nc1cc(Nc2cc(C)nn2C(C)C)ncc1Cl	Phase 2
GSK2256294A	epoxide hydolase inhibitor	EPHX2			MedChemEx	96.85	CNc1nc(C)nc(N[C@H]2CCC[C@H](C2)C(=O)NCc2ccc(cc2C(F)(F)F)C#N)n1	Phase 1
GSK2330672	bile acid transporter inhibitor	SLC10A2			MedChemEx	96.72	CCCC[C@]1(CC)CS(=O)(=O)c2cc(CNC(CC(O)=O)CC(O)=O)c(OC)cc2[C@H](N1)c1ccccc1	Phase 2
GSK2334470	phosphoinositide dependent kinase inhibitor	AURKA, AURKB, PDPK1			Tocris, Tocris, Focus	97.09	CNc1nc(cc(n1)-c1ccc2c(N)[nH]nc2c1)N1C[C@H](CC[C@H]1C)C(=O)NC1CCCCC1, CNc1nc(cc(n1)-c1ccc2c(N)[nH]nc2c1)N1C[C@H](CC[C@H]1C)C(=O)NC1CCCCC1, CNc1nc(cc(n1)-c1ccc2c(N)[nH]nc2c1)N1C[C@H](CC[C@H]1C)C(=O)NC1CCCCC1	Preclinical
GSK239512	histamine receptor antagonist				AMS	87.06	O=C1CCCN1c1ccc(Oc2ccc3CCN(CCc3c2)C2CCC2)nc1	Preclinical
GSK256066	phosphodiesterase inhibitor	PDE4A			MedChemEx, Selleck, Selleck	95.91	COc1cccc(Nc2c(cnc3c(C)cc(cc23)S(=O)(=O)c2cccc(c2)C(=O)N(C)C)C(N)=O)c1, COc1cccc(Nc2c(cnc3c(C)cc(cc23)S(=O)(=O)c2cccc(c2)C(=O)N(C)C)C(N)=O)c1, COc1cccc(Nc2c(cnc3c(C)cc(cc23)S(=O)(=O)c2cccc(c2)C(=O)N(C)C)C(N)=O)c1	Phase 2
GSK2578215A	leucine rich repeat kinase inhibitor	LRRK2			Tocris, Tocris	98.57	Fc1cc(ccn1)-c1ccc(OCc2ccccc2)c(c1)C(=O)Nc1cccnc1, Fc1cc(ccn1)-c1ccc(OCc2ccccc2)c(c1)C(=O)Nc1cccnc1	Preclinical
GSK2606414	protein kinase inhibitor	EIF2AK3, MYLK2			MedChemEx, MedChemEx, MedChemEx, Tocris, MedChemEx	90.4	Cn1cc(-c2ccc3N(CCc3c2)C(=O)Cc2cccc(c2)C(F)(F)F)c2c(N)ncnc12, Cn1cc(-c2ccc3N(CCc3c2)C(=O)Cc2cccc(c2)C(F)(F)F)c2c(N)ncnc12, Cn1cc(-c2ccc3N(CCc3c2)C(=O)Cc2cccc(c2)C(F)(F)F)c2c(N)ncnc12, Cn1cc(-c2ccc3N(CCc3c2)C(=O)Cc2cccc(c2)C(F)(F)F)c2c(N)ncnc12, Cn1cc(-c2ccc3N(CCc3c2)C(=O)Cc2cccc(c2)C(F)(F)F)c2c(N)ncnc12	Preclinical
GSK2636771	PI3K inhibitor	PIK3CB			Selleck, Selleck, Selleck, Selleck	94.3	Cc1nc2c(cc(cc2n1Cc1cccc(c1C)C(F)(F)F)N1CCOCC1)C(O)=O, Cc1nc2c(cc(cc2n1Cc1cccc(c1C)C(F)(F)F)N1CCOCC1)C(O)=O, Cc1nc2c(cc(cc2n1Cc1cccc(c1C)C(F)(F)F)N1CCOCC1)C(O)=O, Cc1nc2c(cc(cc2n1Cc1cccc(c1C)C(F)(F)F)N1CCOCC1)C(O)=O	Phase 2
GSK2656157	PERK inhibitor				Selleck	95.49	Cc1cccc(CC(=O)N2CCc3c2ccc(-c2cn(C)c4ncnc(N)c24)c3F)n1	Preclinical
GSK269962	rho associated kinase inhibitor	ROCK1, ROCK2			Tocris, Tocris, Tocris, Tocris	98.12	CCn1c(nc2cnc(Oc3cccc(NC(=O)c4ccc(OCCN5CCOCC5)cc4)c3)cc12)-c1nonc1N, CCn1c(nc2cnc(Oc3cccc(NC(=O)c4ccc(OCCN5CCOCC5)cc4)c3)cc12)-c1nonc1N, CCn1c(nc2cnc(Oc3cccc(NC(=O)c4ccc(OCCN5CCOCC5)cc4)c3)cc12)-c1nonc1N, CCn1c(nc2cnc(Oc3cccc(NC(=O)c4ccc(OCCN5CCOCC5)cc4)c3)cc12)-c1nonc1N	Preclinical
GSK2801	bromodomain inhibitor	BAZ2A, BAZ2B			MedChemEx, MedChemEx	97.85	CCCOc1ccn2c(cc(-c3ccccc3S(C)(=O)=O)c2c1)C(C)=O, CCCOc1ccn2c(cc(-c3ccccc3S(C)(=O)=O)c2c1)C(C)=O	Preclinical
GSK2816126	histone lysine methyltransferase inhibitor	EZH2			MedChemEx, MedChemEx	88.86	CC[C@H](C)n1cc(C)c2c(cc(cc12)-c1ccc(nc1)N1CCNCC1)C(=O)NCc1c(C)cc(C)[nH]c1=O, CC[C@H](C)n1cc(C)c2c(cc(cc12)-c1ccc(nc1)N1CCNCC1)C(=O)NCc1c(C)cc(C)[nH]c1=O	Phase 1
GSK2830371	protein phosphatase inhibitor	PPM1D			MedChemEx, MedChemEx, Tocris	93.44	Cc1ncc(Cl)cc1NCc1ccc(s1)C(=O)N[C@@H](CC1CCCC1)C(=O)NC1CC1, Cc1ncc(Cl)cc1NCc1ccc(s1)C(=O)N[C@@H](CC1CCCC1)C(=O)NC1CC1, Cc1ncc(Cl)cc1NCc1ccc(s1)C(=O)N[C@@H](CC1CCCC1)C(=O)NC1CC1	Preclinical
GSK2837808A	lactate dehydrogenase inhibitor	LDHA			Tocris, Tocris	97.34	COc1ncc(-c2ccc3c(Nc4cc(Oc5cc(F)cc(F)c5)cc(c4)C(O)=O)c(cnc3c2)S(=O)(=O)NC2CC2)c(OC)n1, COc1ncc(-c2ccc3c(Nc4cc(Oc5cc(F)cc(F)c5)cc(c4)C(O)=O)c(cnc3c2)S(=O)(=O)NC2CC2)c(OC)n1	Preclinical
GSK2838232	HIV gag inhibitor				MedChemEx, MedChemEx, MedChemEx	81.68	CC(C)C1=C2[C@H]3CC[C@@H]4[C@@]5(C)CC[C@H](OC(=O)CC(C)(C)C(O)=O)C(C)(C)[C@@H]5CC[C@@]4(C)[C@]3(C)CC[C@]2(CC1=O)[C@@H](O)CN(CCN(C)C)Cc1ccc(Cl)cc1 |c:3|, CC(C)C1=C2[C@H]3CC[C@@H]4[C@@]5(C)CC[C@H](OC(=O)CC(C)(C)C(O)=O)C(C)(C)[C@@H]5CC[C@@]4(C)[C@]3(C)CC[C@]2(CC1=O)[C@@H](O)CN(CCN(C)C)Cc1ccc(Cl)cc1 |c:3|, CC(C)C1=C2[C@H]3CC[C@@H]4[C@@]5(C)CC[C@H](OC(=O)CC(C)(C)C(O)=O)C(C)(C)[C@@H]5CC[C@@]4(C)[C@]3(C)CC[C@]2(CC1=O)[C@@H](O)CN(CCN(C)C)Cc1ccc(Cl)cc1 |c:3|	Phase 2
GSK2879552	histone lysine demethylase inhibitor	KDM1A			MedChemEx, MedChemEx, MedChemEx, MedChemEx	97.24	OC(=O)c1ccc(CN2CCC(CN[C@@H]3C[C@H]3c3ccccc3)CC2)cc1, OC(=O)c1ccc(CN2CCC(CN[C@@H]3C[C@H]3c3ccccc3)CC2)cc1, OC(=O)c1ccc(CN2CCC(CN[C@@H]3C[C@H]3c3ccccc3)CC2)cc1, OC(=O)c1ccc(CN2CCC(CN[C@@H]3C[C@H]3c3ccccc3)CC2)cc1	Phase 1/Phase 2
GSK2881078	androgen receptor modulator				MedChemEx	95.08	C[C@H](CS(C)(=O)=O)n1ccc2c(c(ccc12)C#N)C(F)(F)F	Phase 2
GSK2981278	ROR modulator				MedChemEx	97.67	CCc1ccc(cc1)N(CC(C)C)S(=O)(=O)c1ccc(OCC2CCOCC2)c(CO)c1	Phase 1/Phase 2
GSK2982772	RIPK inhibitor				MedChemEx	89.05	CN1c2ccccc2OC[C@H](NC(=O)c2nc(Cc3ccccc3)n[nH]2)C1=O	Phase 2
GSK3117391	HDAC inhibitor				MedChemEx	94.45	ONC(=O)CCc1ccc(CN[C@@H](C2CCCCC2)C(=O)OC2CCCC2)cn1	Phase 1/Phase 2
GSK3179106	RET tyrosine kinase inhibitor				MedChemEx	98.7	CCOc1cc(=O)[nH]cc1-c1ccc(CC(=O)Nc2cc(on2)C(C)(C)C(F)(F)F)c(F)c1	Phase 1
GSK3326595	protein arginine N-methyltransferase inhibitor				MedChemEx	92.53	CC(=O)N1CCC(CC1)Nc1cc(ncn1)C(=O)NC[C@H](O)CN1CCc2ccccc2C1	Phase 1/Phase 2
GSK356278	phosphodiesterase inhibitor				AMS	86.68	CCn1ncc2c(NC3CCOCC3)c(cnc12)-c1nnc(Cc2sc(C)nc2C)o1	Preclinical
GSK369796	potassium channel antagonist				MedChemEx	98.23	CC(C)(C)NCc1ccc(Nc2ccnc3cc(Cl)ccc23)cc1O	Phase 1
GSK37647	free fatty acid receptor agonist	FFAR4			Tocris, Tocris, Tocris	98.11	COc1ccc(cc1)S(=O)(=O)Nc1c(C)cc(C)cc1C, COc1ccc(cc1)S(=O)(=O)Nc1c(C)cc(C)cc1C, COc1ccc(cc1)S(=O)(=O)Nc1c(C)cc(C)cc1C	Preclinical
GSK3787	PPAR receptor antagonist	PPARD			Tocris, Selleck, Tocris	95.61	FC(F)(F)c1ccc(nc1)S(=O)(=O)CCNC(=O)c1ccc(Cl)cc1, FC(F)(F)c1ccc(nc1)S(=O)(=O)CCNC(=O)c1ccc(Cl)cc1, FC(F)(F)c1ccc(nc1)S(=O)(=O)CCNC(=O)c1ccc(Cl)cc1	Preclinical
GSK429286A	rho associated kinase inhibitor	ROCK1			MedChemEx, Tocris, Selleck	96.54	CC1=C([C@@H](CC(=O)N1)c1ccc(cc1)C(F)(F)F)C(=O)Nc1cc2c[nH]nc2cc1F |&1:3,r,t:1|, CC1=C([C@@H](CC(=O)N1)c1ccc(cc1)C(F)(F)F)C(=O)Nc1cc2c[nH]nc2cc1F |&1:3,r,t:1|, CC1=C([C@@H](CC(=O)N1)c1ccc(cc1)C(F)(F)F)C(=O)Nc1cc2c[nH]nc2cc1F |&1:3,r,t:1|	Preclinical
GSK461364	PLK inhibitor	PLK1			MedChemEx, Selleck, Selleck, Selleck	97.9	C[C@@H](Oc1cc(sc1C(N)=O)-n1cnc2ccc(CN3CCN(C)CC3)cc12)c1ccccc1C(F)(F)F, C[C@@H](Oc1cc(sc1C(N)=O)-n1cnc2ccc(CN3CCN(C)CC3)cc12)c1ccccc1C(F)(F)F, C[C@@H](Oc1cc(sc1C(N)=O)-n1cnc2ccc(CN3CCN(C)CC3)cc12)c1ccccc1C(F)(F)F, C[C@@H](Oc1cc(sc1C(N)=O)-n1cnc2ccc(CN3CCN(C)CC3)cc12)c1ccccc1C(F)(F)F	Phase 1
GSK503	histone lysine methyltransferase inhibitor	EZH2			MedChemEx, MedChemEx	94.9	CC(C)n1cc(C)c2c(cc(cc12)-c1ccc(nc1)N1CCN(C)CC1)C(=O)NCc1c(C)cc(C)[nH]c1=O, CC(C)n1cc(C)c2c(cc(cc12)-c1ccc(nc1)N1CCN(C)CC1)C(=O)NCc1c(C)cc(C)[nH]c1=O	Preclinical
GSK650394	serum/glucocorticoid regulated kinase inhibitor	SGK1, SGK2			MedChemEx, Tocris, Tocris, Tocris, Tocris, Tocris, Tocris, Tocris	97.79	OC(=O)c1ccc(cc1C1CCCC1)-c1c[nH]c2ncc(cc12)-c1ccccc1, OC(=O)c1ccc(cc1C1CCCC1)-c1c[nH]c2ncc(cc12)-c1ccccc1, OC(=O)c1ccc(cc1C1CCCC1)-c1c[nH]c2ncc(cc12)-c1ccccc1, OC(=O)c1ccc(cc1C1CCCC1)-c1c[nH]c2ncc(cc12)-c1ccccc1, OC(=O)c1ccc(cc1C1CCCC1)-c1c[nH]c2ncc(cc12)-c1ccccc1, OC(=O)c1ccc(cc1C1CCCC1)-c1c[nH]c2ncc(cc12)-c1ccccc1, OC(=O)c1ccc(cc1C1CCCC1)-c1c[nH]c2ncc(cc12)-c1ccccc1, OC(=O)c1ccc(cc1C1CCCC1)-c1c[nH]c2ncc(cc12)-c1ccccc1	Preclinical
GSK656	leucyl-tRNA synthetase inhibitor				MedChemEx	73.31	NC[C@H]1OB(O)c2c1c(Cl)ccc2OCCO	Preclinical
GSK690693	AKT inhibitor	AKT1, AKT2, AKT3, PAK4, PAK6, PAK7, PRKCQ, PRKG1, PRKX			Selleck, Selleck, Selleck, Selleck, Selleck, Tocris	97.21	CCn1c(nc2c(ncc(OC[C@H]3CCCNC3)c12)C#CC(C)(C)O)-c1nonc1N, CCn1c(nc2c(ncc(OC[C@H]3CCCNC3)c12)C#CC(C)(C)O)-c1nonc1N, CCn1c(nc2c(ncc(OC[C@H]3CCCNC3)c12)C#CC(C)(C)O)-c1nonc1N, CCn1c(nc2c(ncc(OC[C@H]3CCCNC3)c12)C#CC(C)(C)O)-c1nonc1N, CCn1c(nc2c(ncc(OC[C@H]3CCCNC3)c12)C#CC(C)(C)O)-c1nonc1N, CCn1c(nc2c(ncc(OC[C@H]3CCCNC3)c12)C#CC(C)(C)O)-c1nonc1N	Phase 1
GSK9027	glucocorticoid receptor agonist	NR3C1			Tocris, Tocris, Tocris	97.08	Fc1ccc(cc1)-n1ncc2cc(ccc12)-c1ccc(NS(=O)(=O)Cc2ccccc2)cc1C(F)(F)F, Fc1ccc(cc1)-n1ncc2cc(ccc12)-c1ccc(NS(=O)(=O)Cc2ccccc2)cc1C(F)(F)F, Fc1ccc(cc1)-n1ncc2cc(ccc12)-c1ccc(NS(=O)(=O)Cc2ccccc2)cc1C(F)(F)F	Preclinical
GSK923295	centromere associated protein inhibitor	CENPE			MedChemEx, MedChemEx	97.04	CC(C)Oc1ccc(cc1Cl)C(=O)N[C@H](CNC(=O)CN(C)C)Cc1ccc(cc1)-c1cn2cccc([C@H](C)O)c2n1, CC(C)Oc1ccc(cc1Cl)C(=O)N[C@H](CNC(=O)CN(C)C)Cc1ccc(cc1)-c1cn2cccc([C@H](C)O)c2n1	Phase 1
GTP-14564	FLT3 inhibitor, tyrosine kinase inhibitor	CSF1R, FLT3, KIT, PDGFRB			Tocris, Tocris, Tocris, Tocris, Tocris	98.68	c1ccc(cc1)-c1[nH]nc2c3ccccc3oc12, c1ccc(cc1)-c1[nH]nc2c3ccccc3oc12, c1ccc(cc1)-c1[nH]nc2c3ccccc3oc12, c1ccc(cc1)-c1[nH]nc2c3ccccc3oc12, c1ccc(cc1)-c1[nH]nc2c3ccccc3oc12	Preclinical
GTS21	cholinergic receptor agonist	CHRNA7			ChemDiv, MedChemEx	98.14	COc1ccc(\C=C2/CCCN=C2c2cccnc2)c(OC)c1 |c:11|, COc1ccc(\C=C2/CCCN=C2c2cccnc2)c(OC)c1 |c:11|	Phase 1/Phase 2
guacetisal	immunosuppressant		pulmonary	cough suppressant	AvaChem	96.88	COc1ccccc1OC(=O)c1ccccc1OC(C)=O	Launched
guadecitabine	DNA methyltransferase inhibitor				MedChemEx	100	Nc1ncn([C@H]2C[C@H](OP(O)(=O)OC[C@H]3O[C@H](C[C@@H]3O)n3cnc4c3[nH]c(N)nc4=O)[C@@H](CO)O2)c(=O)n1	Phase 3
guaiacol	local anesthetic	CA2	pulmonary	cough suppressant	MicroSource, MedChemEx	0	COc1ccccc1O, COc1ccccc1O	Launched
guaifenesin	expectorant		pulmonary	cough suppressant	MedChemEx, MicroSource, Selleck	98.9	COc1ccccc1OC[C@@H](O)CO |&1:10,r|, COc1ccccc1OC[C@@H](O)CO |&1:10,r|, COc1ccccc1OC[C@@H](O)CO |&1:10,r|	Launched
guanaben-acetate	adrenergic receptor agonist	ADRA2A, ADRA2B, ADRA2C	cardiology	hypertension	Tocris, Selleck, MicroSource, MicroSource, Selleck	95.27	NC(=N)N\N=C\c1c(Cl)cccc1Cl, NC(=N)N\N=C\c1c(Cl)cccc1Cl, NC(=N)N\N=C\c1c(Cl)cccc1Cl, NC(=N)N\N=C\c1c(Cl)cccc1Cl, NC(=N)N\N=C\c1c(Cl)cccc1Cl	Launched
guanadrel	adrenergic inhibitor		cardiology	hypertension	MicroSource, MicroSource, MicroSource, MicroSource, MicroSource	100	NC(=N)NC[C@H]1COC2(CCCCC2)O1 |&1:5|, NC(=N)NC[C@H]1COC2(CCCCC2)O1 |&1:5|, NC(=N)NC[C@H]1COC2(CCCCC2)O1 |&1:5|, NC(=N)NC[C@H]1COC2(CCCCC2)O1 |&1:5|, NC(=N)NC[C@H]1COC2(CCCCC2)O1 |&1:5|	Launched
guancydine	antihypertensive agent				MedChemEx	90.34	CCC(C)(C)NC(=N)NC#N	Preclinical
guanethidine	adrenergic inhibitor	SLC6A2	cardiology	hypertension	MicroSource, Selleck, Selleck, MedChemEx, MedChemEx	100	NC(=N)NCCN1CCCCCCC1, NC(=N)NCCN1CCCCCCC1, NC(=N)NCCN1CCCCCCC1, NC(=N)NCCN1CCCCCCC1, NC(=N)NCCN1CCCCCCC1	Launched
guanfacine	adrenergic receptor agonist	ADRA2A, ADRA2B, ADRA2C	cardiology	hypertension	MicroSource, MicroSource, MicroSource, Tocris, Tocris	100	NC(=N)NC(=O)Cc1c(Cl)cccc1Cl, NC(=N)NC(=O)Cc1c(Cl)cccc1Cl, NC(=N)NC(=O)Cc1c(Cl)cccc1Cl, NC(=N)NC(=O)Cc1c(Cl)cccc1Cl, NC(=N)NC(=O)Cc1c(Cl)cccc1Cl	Launched
guanidine	HSP inhibitor	ALDH2, DLG4, GAMT, RNASE1	neurology/psychiatry	Lambert-Eaton myasthenic syndrome (LEMS)	MedChemEx, MicroSource, Selleck	100	NC(N)=N, NC(N)=N, NC(N)=N	Launched
guanidinoethyldisulfide-bicarbonate	nitric oxide synthase inhibitor	NOS2			TygerSci	0	NC(=N)NCCSSCCNC(N)=N	Phase 2
guanidinopropionic-acid	creatine kinase inhibitor	CKM			Sigma	0	NC(=N)NCCC(O)=O	Phase 2
guanosine		PNP			MedChemEx	91.3	Nc1nc(=O)c2ncn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c2[nH]1	Preclinical
Gue-1654	oxoeicosanoid receptor modulator	OXER1			Tocris, Tocris	96.81	CSc1nc2ccc3nc(NC(=O)C(c4ccccc4)c4ccccc4)sc3c2s1, CSc1nc2ccc3nc(NC(=O)C(c4ccccc4)c4ccccc4)sc3c2s1	Preclinical
guvacine	GABA uptake inhibitor	SLC6A1, SLC6A11, SLC6A12, SLC6A13			Tocris, Tocris, Tocris, Tocris	100	OC(=O)C1=CCCNC1 |t:3|, OC(=O)C1=CCCNC1 |t:3|, OC(=O)C1=CCCNC1 |t:3|, OC(=O)C1=CCCNC1 |t:3|	Preclinical
GW-0742	PPAR receptor agonist	PPARD			Tocris, Tocris, Tocris, Selleck, Tocris	96.73	Cc1nc(sc1CSc1ccc(OCC(O)=O)c(C)c1)-c1ccc(c(F)c1)C(F)(F)F, Cc1nc(sc1CSc1ccc(OCC(O)=O)c(C)c1)-c1ccc(c(F)c1)C(F)(F)F, Cc1nc(sc1CSc1ccc(OCC(O)=O)c(C)c1)-c1ccc(c(F)c1)C(F)(F)F, Cc1nc(sc1CSc1ccc(OCC(O)=O)c(C)c1)-c1ccc(c(F)c1)C(F)(F)F, Cc1nc(sc1CSc1ccc(OCC(O)=O)c(C)c1)-c1ccc(c(F)c1)C(F)(F)F	Preclinical
GW-1100	G protein-coupled receptor agonist	FFAR1			MedChemEx	93.14	CCOC(=O)c1ccc(cc1)-n1cc(Cc2cnc(OCC)nc2)c(=O)nc1SCc1ccc(F)cc1	Preclinical
GW-1929	PPAR receptor agonist	PPARG			Tocris	94.94	CN(CCOc1ccc(C[C@H](Nc2ccccc2C(=O)c2ccccc2)C(O)=O)cc1)c1ccccn1	Preclinical
GW-2580	cFMS kinase inhibitor	CSF1R			Selleck, Selleck	94.93	COc1ccc(COc2ccc(Cc3cnc(N)nc3N)cc2OC)cc1, COc1ccc(COc2ccc(Cc3cnc(N)nc3N)cc2OC)cc1	Preclinical
GW-311616	elastase inhibitor, leukocyte elastase inhibitor	ELANE			MedChemEx, MedChemEx, MedChemEx	97.39	CC(C)[C@H]1[C@H]2[C@@H](CCN2C(=O)\C=C\CN2CCCCC2)N(C1=O)S(C)(=O)=O, CC(C)[C@H]1[C@H]2[C@@H](CCN2C(=O)\C=C\CN2CCCCC2)N(C1=O)S(C)(=O)=O, CC(C)[C@H]1[C@H]2[C@@H](CCN2C(=O)\C=C\CN2CCCCC2)N(C1=O)S(C)(=O)=O	Phase 1
GW-3965	LXR agonist	NR1H2, NR1H3			Tocris, Tocris, Tocris, Tocris, Tocris, Selleck	98.12	OC(=O)Cc1cccc(OCCCN(CC(c2ccccc2)c2ccccc2)Cc2cccc(c2Cl)C(F)(F)F)c1, OC(=O)Cc1cccc(OCCCN(CC(c2ccccc2)c2ccccc2)Cc2cccc(c2Cl)C(F)(F)F)c1, OC(=O)Cc1cccc(OCCCN(CC(c2ccccc2)c2ccccc2)Cc2cccc(c2Cl)C(F)(F)F)c1, OC(=O)Cc1cccc(OCCCN(CC(c2ccccc2)c2ccccc2)Cc2cccc(c2Cl)C(F)(F)F)c1, OC(=O)Cc1cccc(OCCCN(CC(c2ccccc2)c2ccccc2)Cc2cccc(c2Cl)C(F)(F)F)c1, OC(=O)Cc1cccc(OCCCN(CC(c2ccccc2)c2ccccc2)Cc2cccc(c2Cl)C(F)(F)F)c1	Preclinical
GW-405833	cannabinoid receptor agonist	CNR2			Tocris	95.83	COc1ccc2n(C(=O)c3cccc(Cl)c3Cl)c(C)c(CCN3CCOCC3)c2c1	Preclinical
GW-4064	FXR agonist	NR1H4			Tocris, Selleck, Selleck, Selleck, Selleck, Tocris	98.07	CC(C)c1onc(c1COc1ccc(\C=C\c2cccc(c2)C(O)=O)c(Cl)c1)-c1c(Cl)cccc1Cl, CC(C)c1onc(c1COc1ccc(\C=C\c2cccc(c2)C(O)=O)c(Cl)c1)-c1c(Cl)cccc1Cl, CC(C)c1onc(c1COc1ccc(\C=C\c2cccc(c2)C(O)=O)c(Cl)c1)-c1c(Cl)cccc1Cl, CC(C)c1onc(c1COc1ccc(\C=C\c2cccc(c2)C(O)=O)c(Cl)c1)-c1c(Cl)cccc1Cl, CC(C)c1onc(c1COc1ccc(\C=C\c2cccc(c2)C(O)=O)c(Cl)c1)-c1c(Cl)cccc1Cl, CC(C)c1onc(c1COc1ccc(\C=C\c2cccc(c2)C(O)=O)c(Cl)c1)-c1c(Cl)cccc1Cl	Preclinical
GW-438014A	neuropeptide receptor antagonist	NPY5R			Tocris, Tocris, Sigma	98.07	O=C(Nc1nc2ccccc2n1CCc1ccccc1)c1ccccc1, O=C(Nc1nc2ccccc2n1CCc1ccccc1)c1ccccc1, O=C(Nc1nc2ccccc2n1CCc1ccccc1)c1ccccc1	Preclinical
GW-441756	growth factor receptor inhibitor	NTRK1			Tocris, Selleck	96.24	Cn1cc(\C=C2/C(=O)Nc3cccnc23)c2ccccc12, Cn1cc(\C=C2/C(=O)Nc3cccnc23)c2ccccc12	Preclinical
GW-501516	PPAR receptor agonist	PPARA, PPARD			MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx	97.5	Cc1nc(sc1CSc1ccc(OCC(O)=O)c(C)c1)-c1ccc(cc1)C(F)(F)F, Cc1nc(sc1CSc1ccc(OCC(O)=O)c(C)c1)-c1ccc(cc1)C(F)(F)F, Cc1nc(sc1CSc1ccc(OCC(O)=O)c(C)c1)-c1ccc(cc1)C(F)(F)F, Cc1nc(sc1CSc1ccc(OCC(O)=O)c(C)c1)-c1ccc(cc1)C(F)(F)F, Cc1nc(sc1CSc1ccc(OCC(O)=O)c(C)c1)-c1ccc(cc1)C(F)(F)F, Cc1nc(sc1CSc1ccc(OCC(O)=O)c(C)c1)-c1ccc(cc1)C(F)(F)F	Phase 2
GW-5074	leucine rich repeat kinase inhibitor, RAF inhibitor	NTRK1, RAF1			Tocris, Selleck, Selleck, Tocris, Tocris, Selleck	58.05	Oc1c(Br)cc(C=C2C(=O)Nc3ccc(I)cc23)cc1Br, Oc1c(Br)cc(C=C2C(=O)Nc3ccc(I)cc23)cc1Br, Oc1c(Br)cc(C=C2C(=O)Nc3ccc(I)cc23)cc1Br, Oc1c(Br)cc(C=C2C(=O)Nc3ccc(I)cc23)cc1Br, Oc1c(Br)cc(C=C2C(=O)Nc3ccc(I)cc23)cc1Br, Oc1c(Br)cc(C=C2C(=O)Nc3ccc(I)cc23)cc1Br	Phase 1/Phase 2
GW-542573X	calcium channel activator	KCNN1			Tocris, Tocris, Tocris	95.23	COc1ccccc1NC(=O)OCC1CCN(CC1)C(=O)OC(C)(C)C, COc1ccccc1NC(=O)OCC1CCN(CC1)C(=O)OC(C)(C)C, COc1ccccc1NC(=O)OCC1CCN(CC1)C(=O)OC(C)(C)C	Preclinical
GW-583340	EGFR inhibitor	EGFR, ERBB2			Tocris, Tocris, Tocris	94.85	CS(=O)(=O)CCNCc1nc(cs1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1, CS(=O)(=O)CCNCc1nc(cs1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1, CS(=O)(=O)CCNCc1nc(cs1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1	Preclinical
GW-627368	prostanoid receptor antagonist	PTGER4			Tocris, Tocris	99.49	CCOc1c2CN(C(=O)c2c(OCC)c2ccccc12)c1ccc(CC(=O)NS(=O)(=O)c2ccccc2)cc1, CCOc1c2CN(C(=O)c2c(OCC)c2ccccc12)c1ccc(CC(=O)NS(=O)(=O)c2ccccc2)cc1	Preclinical
GW-6471	PPAR receptor antagonist	PPARA			Tocris, Tocris, Tocris, Tocris	97.24	CCC(=O)NC[C@H](Cc1ccc(OCCc2nc(oc2C)-c2ccccc2)cc1)N\C(C)=C/C(=O)c1ccc(cc1)C(F)(F)F, CCC(=O)NC[C@H](Cc1ccc(OCCc2nc(oc2C)-c2ccccc2)cc1)N\C(C)=C/C(=O)c1ccc(cc1)C(F)(F)F, CCC(=O)NC[C@H](Cc1ccc(OCCc2nc(oc2C)-c2ccccc2)cc1)N\C(C)=C/C(=O)c1ccc(cc1)C(F)(F)F, CCC(=O)NC[C@H](Cc1ccc(OCCc2nc(oc2C)-c2ccccc2)cc1)N\C(C)=C/C(=O)c1ccc(cc1)C(F)(F)F	Preclinical
GW-7647	PPAR receptor agonist	PPARA			Tocris, Tocris, Tocris	97.97	CC(C)(Sc1ccc(CCN(CCCCC2CCCCC2)C(=O)NC2CCCCC2)cc1)C(O)=O, CC(C)(Sc1ccc(CCN(CCCCC2CCCCC2)C(=O)NC2CCCCC2)cc1)C(O)=O, CC(C)(Sc1ccc(CCN(CCCCC2CCCCC2)C(=O)NC2CCCCC2)cc1)C(O)=O	Preclinical
GW-788388	ALK tyrosine kinase receptor inhibitor	LCK, MAPK14, TGFBR1			Tocris, Tocris, Selleck, Selleck	97.82	O=C(NC1CCOCC1)c1ccc(cc1)-c1cc(ccn1)-c1c[nH]nc1-c1ccccn1, O=C(NC1CCOCC1)c1ccc(cc1)-c1cc(ccn1)-c1c[nH]nc1-c1ccccn1, O=C(NC1CCOCC1)c1ccc(cc1)-c1cc(ccn1)-c1c[nH]nc1-c1ccccn1, O=C(NC1CCOCC1)c1ccc(cc1)-c1cc(ccn1)-c1c[nH]nc1-c1ccccn1	Preclinical
GW-803430	melanin inhibitor	KCNH2, MCHR1			Tocris, Tocris	93.27	COc1cc(ccc1OCCN1CCCC1)-n1cnc2cc(sc2c1=O)-c1ccc(Cl)cc1, COc1cc(ccc1OCCN1CCCC1)-n1cnc2cc(sc2c1=O)-c1ccc(Cl)cc1	Phase 1
GW-842166	cannabinoid receptor agonist	CNR2			MedChemEx, MedChemEx, Selleck	97.52	FC(F)(F)c1nc(Nc2ccc(Cl)cc2Cl)ncc1C(=O)NCC1CCOCC1, FC(F)(F)c1nc(Nc2ccc(Cl)cc2Cl)ncc1C(=O)NCC1CCOCC1, FC(F)(F)c1nc(Nc2ccc(Cl)cc2Cl)ncc1C(=O)NCC1CCOCC1	Phase 2
GW-843682X	PLK inhibitor	PLK1, PLK3			Tocris, Tocris, Tocris, Tocris, Tocris	98.98	COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(s3)C(N)=O)c2cc1OC, COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(s3)C(N)=O)c2cc1OC, COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(s3)C(N)=O)c2cc1OC, COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(s3)C(N)=O)c2cc1OC, COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(s3)C(N)=O)c2cc1OC	Preclinical
GW-9508	free fatty acid receptor agonist, G protein-coupled receptor agonist	FFAR1, FFAR4			Tocris, Tocris, Tocris, Selleck	94.17	OC(=O)CCc1ccc(NCc2cccc(Oc3ccccc3)c2)cc1, OC(=O)CCc1ccc(NCc2cccc(Oc3ccccc3)c2)cc1, OC(=O)CCc1ccc(NCc2cccc(Oc3ccccc3)c2)cc1, OC(=O)CCc1ccc(NCc2cccc(Oc3ccccc3)c2)cc1	Preclinical
GW-9662	PPAR receptor antagonist	NCOA2, PPARG, RXRA			Tocris, Selleck, Tocris	98.73	[O-][N+](=O)c1ccc(Cl)c(c1)C(=O)Nc1ccccc1, [O-][N+](=O)c1ccc(Cl)c(c1)C(=O)Nc1ccccc1, [O-][N+](=O)c1ccc(Cl)c(c1)C(=O)Nc1ccccc1	Preclinical
GW274150	nitric oxide synthase inhibitor				MedChemEx	0	CC(=N)NCCSCC[C@H](N)C(O)=O	Phase 2
GYKI-52466	glutamate receptor antagonist	GRIA1, GRIA2, GRIA3, GRIA4			Tocris, Tocris, Tocris, Tocris	99	CC1=NN=C(c2ccc(N)cc2)c2cc3OCOc3cc2C1 |t:1,3|, CC1=NN=C(c2ccc(N)cc2)c2cc3OCOc3cc2C1 |t:1,3|, CC1=NN=C(c2ccc(N)cc2)c2cc3OCOc3cc2C1 |t:1,3|, CC1=NN=C(c2ccc(N)cc2)c2cc3OCOc3cc2C1 |t:1,3|	Preclinical
gynostemma-extract	calcium channel modulator				MedChemEx, Selleck, Selleck	2.21	CC(C)=CCC[C@](C)(O[C@@H]1O[C@H](CO[C@@H]2OC[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@H](O)[C@H]1O)[C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@@H]1[C@@]3(C)CC[C@H](O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)C(C)(C)[C@@H]3CC[C@@]21C, CC(C)=CCC[C@](C)(O[C@@H]1O[C@H](CO[C@@H]2OC[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@H](O)[C@H]1O)[C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@@H]1[C@@]3(C)CC[C@H](O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)C(C)(C)[C@@H]3CC[C@@]21C, CC(C)=CCC[C@](C)(O[C@@H]1O[C@H](CO[C@@H]2OC[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@H](O)[C@H]1O)[C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@@H]1[C@@]3(C)CC[C@H](O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)C(C)(C)[C@@H]3CC[C@@]21C	Phase 2
GZD824	Bcr-Abl kinase inhibitor	ABL1, BCR			Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck	96.81	CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4n[nH]cc4c3)cc2C(F)(F)F)CC1, CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4n[nH]cc4c3)cc2C(F)(F)F)CC1, CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4n[nH]cc4c3)cc2C(F)(F)F)CC1, CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4n[nH]cc4c3)cc2C(F)(F)F)CC1, CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4n[nH]cc4c3)cc2C(F)(F)F)CC1, CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4n[nH]cc4c3)cc2C(F)(F)F)CC1, CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4n[nH]cc4c3)cc2C(F)(F)F)CC1	Preclinical
G007-LK	tankyrase inhibitor	TNKS, TNKS2			MedChemEx	97.94	CS(=O)(=O)c1ccc(nc1)-c1nnc(\C=C\c2nnc(o2)-c2ccc(cc2)C#N)n1-c1ccccc1Cl	Preclinical
H-151	STING antagonist				MedChemEx	84.87	CCc1ccc(NC(=O)Nc2c[nH]c3ccccc23)cc1	Preclinical
H-89	PKA inhibitor	GSG2, PKIA, PRKACA			Selleck, Selleck, Selleck, Selleck, Selleck, Tocris, Tocris	97.93	Brc1ccc(\C=C\CNCCNS(=O)(=O)c2cccc3cnccc23)cc1, Brc1ccc(\C=C\CNCCNS(=O)(=O)c2cccc3cnccc23)cc1, Brc1ccc(\C=C\CNCCNS(=O)(=O)c2cccc3cnccc23)cc1, Brc1ccc(\C=C\CNCCNS(=O)(=O)c2cccc3cnccc23)cc1, Brc1ccc(\C=C\CNCCNS(=O)(=O)c2cccc3cnccc23)cc1, Brc1ccc(\C=C\CNCCNS(=O)(=O)c2cccc3cnccc23)cc1, Brc1ccc(\C=C\CNCCNS(=O)(=O)c2cccc3cnccc23)cc1	Preclinical
HA-1004	calcium channel blocker				Enzo, Enzo, Enzo	98.82	NC(=N)NCCNS(=O)(=O)c1cccc2cnccc12, NC(=N)NCCNS(=O)(=O)c1cccc2cnccc12, NC(=N)NCCNS(=O)(=O)c1cccc2cnccc12	Phase 2
HA-130	autotaxin inhibitor	ENPP2			Tocris, Tocris	97.61	OB(O)c1cccc(COc2ccc(\C=C3/SC(=O)N(Cc4ccc(F)cc4)C3=O)cc2)c1, OB(O)c1cccc(COc2ccc(\C=C3/SC(=O)N(Cc4ccc(F)cc4)C3=O)cc2)c1	Preclinical
HA-966-(R)-(+)	glutamate receptor agonist	GRIA1			Tocris, Tocris, Tocris	100	N[C@@H]1CCN(O)C1=O, N[C@@H]1CCN(O)C1=O, N[C@@H]1CCN(O)C1=O	Preclinical
HA-966-(S)-(-)	glutamate receptor antagonist	GRIA1			Tocris, Tocris	100	N[C@H]1CCN(O)C1=O, N[C@H]1CCN(O)C1=O	Preclinical
halazone			infectious disease	disinfectant	Sigma, MicroSource	0	OC(=O)c1ccc(cc1)S(=O)(=O)N(Cl)Cl, OC(=O)c1ccc(cc1)S(=O)(=O)N(Cl)Cl	Launched
halcinonide	glucocorticoid receptor agonist	NR3C1	dermatology	corticosteroid-responsive dermatoses	MedChemEx, Selleck, Selleck, Selleck, Selleck, Selleck	93.96	CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)CC[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CCl |t:10|, CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)CC[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CCl |t:10|, CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)CC[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CCl |t:10|, CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)CC[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CCl |t:10|, CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)CC[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CCl |t:10|, CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)CC[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CCl |t:10|	Launched
halobetasol-propionate	glucocorticoid receptor agonist	NR3C1, PLA2G1B	dermatology	corticosteroid-responsive dermatoses	Selleck	88.69	CCC(=O)O[C@@]1([C@@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)CCl |c:18,t:14|	Launched
halofantrine	antimalarial agent	KCNN4	infectious disease	malaria	Enzo, MedChemEx	98.32	CCCCN(CCCC)CC[C@@H](O)c1cc2c(Cl)cc(Cl)cc2c2cc(ccc12)C(F)(F)F |&1:11|, CCCCN(CCCC)CC[C@@H](O)c1cc2c(Cl)cc(Cl)cc2c2cc(ccc12)C(F)(F)F |&1:11|	Launched
halofuginone	collagenase inhibitor	COL1A1, MMP2	rheumatology	scleroderma	EMDBio, EMDBio, EMDBio, EMDBio, EMDBio	96.04	O[C@H]1CCCN[C@@H]1CC(=O)Cn1cnc2cc(Br)c(Cl)cc2c1=O, O[C@H]1CCCN[C@@H]1CC(=O)Cn1cnc2cc(Br)c(Cl)cc2c1=O, O[C@H]1CCCN[C@@H]1CC(=O)Cn1cnc2cc(Br)c(Cl)cc2c1=O, O[C@H]1CCCN[C@@H]1CC(=O)Cn1cnc2cc(Br)c(Cl)cc2c1=O, O[C@H]1CCCN[C@@H]1CC(=O)Cn1cnc2cc(Br)c(Cl)cc2c1=O	Launched
halopemide	phospholipase inhibitor	PLD1, PLD2			Sigma, Sigma, Sigma, Sigma	97.2	Fc1ccc(cc1)C(=O)NCCN1CCC(CC1)n1c2ccc(Cl)cc2[nH]c1=O, Fc1ccc(cc1)C(=O)NCCN1CCC(CC1)n1c2ccc(Cl)cc2[nH]c1=O, Fc1ccc(cc1)C(=O)NCCN1CCC(CC1)n1c2ccc(Cl)cc2[nH]c1=O, Fc1ccc(cc1)C(=O)NCCN1CCC(CC1)n1c2ccc(Cl)cc2[nH]c1=O	Phase 2
haloperidol	dopamine receptor antagonist	DRD1, DRD2, DRD3, DRD4, DRD5, GRIN2B, HRH1, HTR1A, HTR1D, HTR2A, HTR2B, HTR7, KCNH1	neurology/psychiatry	schizophrenia, Tourette's disorder	Tocris, Selleck, MicroSource, MicroSource	99.67	OC1(CCN(CCCC(=O)c2ccc(F)cc2)CC1)c1ccc(Cl)cc1, OC1(CCN(CCCC(=O)c2ccc(F)cc2)CC1)c1ccc(Cl)cc1, OC1(CCN(CCCC(=O)c2ccc(F)cc2)CC1)c1ccc(Cl)cc1, OC1(CCN(CCCC(=O)c2ccc(F)cc2)CC1)c1ccc(Cl)cc1	Launched
haloperidol-decanoate	psychoactive drug	DRD2, DRD3, DRD4, HTR2A	neurology/psychiatry	schizophrenia	Key, Key	99.05	CCCCCCCCCC(=O)OC1(CCN(CCCC(=O)c2ccc(F)cc2)CC1)c1ccc(Cl)cc1, CCCCCCCCCC(=O)OC1(CCN(CCCC(=O)c2ccc(F)cc2)CC1)c1ccc(Cl)cc1	Launched
haloprogin	other antifungal		infectious disease	tinea pedis	Prestwick, Prestwick, Prestwick	98.19	Clc1cc(Cl)c(OCC#CI)cc1Cl, Clc1cc(Cl)c(OCC#CI)cc1Cl, Clc1cc(Cl)c(OCC#CI)cc1Cl	Launched
halothane	glutamate receptor antagonist	GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GLRA1, GLRB, KCNK10, KCNK12, KCNK13, KCNK15, KCNK18, KCNK2, KCNK3, KCNK9	neurology/psychiatry	general anaesthetic	MicroSource, MedChemEx	0	FC(F)(F)[C@@H](Cl)Br |&1:4,r|, FC(F)(F)[C@@H](Cl)Br |&1:4,r|	Launched
harmane	monoamine oxidase inhibitor	MAOA, MAOB			Tocris	97.3	Cc1nccc2c3ccccc3[nH]c12	Preclinical
harringtonine	protein synthesis inhibitor				MedChemEx, MedChemEx	79.53	[H][C@@]12[C@H](OC(=O)[C@@](O)(CCC(C)(C)O)CC(=O)OC)C(OC)=C[C@@]11CCCN1CCc1cc3OCOc3cc21 |c:21|, [H][C@@]12[C@H](OC(=O)[C@@](O)(CCC(C)(C)O)CC(=O)OC)C(OC)=C[C@@]11CCCN1CCc1cc3OCOc3cc21 |c:21|	Phase 3
HA14-1	BCL inhibitor	BCL2			Selleck, Selleck, Selleck	95.14	CCOC(=O)[C@@H](C#N)[C@H]1C(C(=O)OCC)=C(N)Oc2ccc(Br)cc12 |&1:5,8,r,t:14|, CCOC(=O)[C@@H](C#N)[C@H]1C(C(=O)OCC)=C(N)Oc2ccc(Br)cc12 |&1:5,8,r,t:14|, CCOC(=O)[C@@H](C#N)[C@H]1C(C(=O)OCC)=C(N)Oc2ccc(Br)cc12 |&1:5,8,r,t:14|	Preclinical
HBED	chelating agent				Sigma	77.96	OC(=O)CN(CCN(CC(O)=O)Cc1ccccc1O)Cc1ccccc1O	Phase 3
HC-030031	TRPA1 channel blocker	TRPA1			Tocris, Tocris, Selleck, Selleck, Selleck, Selleck	98.73	CC(C)c1ccc(NC(=O)Cn2cnc3n(C)c(=O)n(C)c(=O)c23)cc1, CC(C)c1ccc(NC(=O)Cn2cnc3n(C)c(=O)n(C)c(=O)c23)cc1, CC(C)c1ccc(NC(=O)Cn2cnc3n(C)c(=O)n(C)c(=O)c23)cc1, CC(C)c1ccc(NC(=O)Cn2cnc3n(C)c(=O)n(C)c(=O)c23)cc1, CC(C)c1ccc(NC(=O)Cn2cnc3n(C)c(=O)n(C)c(=O)c23)cc1, CC(C)c1ccc(NC(=O)Cn2cnc3n(C)c(=O)n(C)c(=O)c23)cc1	Phase 1
HC-067047	transient receptor potential channel antagonist	TRPV4			Tocris, Tocris, Tocris, Tocris, Tocris, Tocris, Tocris, Tocris, Tocris	99.51	Cc1c(cc(-c2ccccc2)n1CCCN1CCOCC1)C(=O)Nc1cccc(c1)C(F)(F)F, Cc1c(cc(-c2ccccc2)n1CCCN1CCOCC1)C(=O)Nc1cccc(c1)C(F)(F)F, Cc1c(cc(-c2ccccc2)n1CCCN1CCOCC1)C(=O)Nc1cccc(c1)C(F)(F)F, Cc1c(cc(-c2ccccc2)n1CCCN1CCOCC1)C(=O)Nc1cccc(c1)C(F)(F)F, Cc1c(cc(-c2ccccc2)n1CCCN1CCOCC1)C(=O)Nc1cccc(c1)C(F)(F)F, Cc1c(cc(-c2ccccc2)n1CCCN1CCOCC1)C(=O)Nc1cccc(c1)C(F)(F)F, Cc1c(cc(-c2ccccc2)n1CCCN1CCOCC1)C(=O)Nc1cccc(c1)C(F)(F)F, Cc1c(cc(-c2ccccc2)n1CCCN1CCOCC1)C(=O)Nc1cccc(c1)C(F)(F)F, Cc1c(cc(-c2ccccc2)n1CCCN1CCOCC1)C(=O)Nc1cccc(c1)C(F)(F)F	Preclinical
HC-070	transient receptor potential channel antagonist				MedChemEx	96.18	Cn1c2nc(Oc3cccc(Cl)c3)n(Cc3ccc(Cl)cc3)c2c(=O)n(CCCO)c1=O	Preclinical
heclin	ubiquitin ligase inhibitor	NEDD4, SMURF2, WWP1			Tocris, Tocris, Tocris, Tocris	98.29	CCc1ccc(\C=C\C(=O)Nc2ccc(cc2)C(C)=O)o1, CCc1ccc(\C=C\C(=O)Nc2ccc(cc2)C(C)=O)o1, CCc1ccc(\C=C\C(=O)Nc2ccc(cc2)C(C)=O)o1, CCc1ccc(\C=C\C(=O)Nc2ccc(cc2)C(C)=O)o1	Preclinical
HEMADO	adenosine receptor agonist	ADORA1, ADORA2A, ADORA2B, ADORA3			Tocris, Tocris, Tocris	96.56	CCCCC#Cc1nc(NC)c2ncn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c2n1, CCCCC#Cc1nc(NC)c2ncn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c2n1, CCCCC#Cc1nc(NC)c2ncn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c2n1	Preclinical
hematoporphyrin			neurology/psychiatry	depression, psychosis	Sigma, Sigma	16.61	C[C@@H](O)c1c(C)c2cc3[nH]c(cc4[nH]c(cc5nc(cc1n2)c(C)c5[C@@H](C)O)c(C)c4CCC(O)=O)c(CCC(O)=O)c3C |&1:25,&2:1,r|, C[C@@H](O)c1c(C)c2cc3[nH]c(cc4[nH]c(cc5nc(cc1n2)c(C)c5[C@@H](C)O)c(C)c4CCC(O)=O)c(CCC(O)=O)c3C |&1:25,&2:1,r|	Launched
hematoxylin					Selleck, Selleck, Selleck	94.58	Oc1ccc2[C@H]3c4cc(O)c(O)cc4C[C@@]3(O)COc2c1O, Oc1ccc2[C@H]3c4cc(O)c(O)cc4C[C@@]3(O)COc2c1O, Oc1ccc2[C@H]3c4cc(O)c(O)cc4C[C@@]3(O)COc2c1O	Preclinical
hemin	enzyme inducer		hematology, cardiology	acute intermittent porphyria (AIP), hypertension, ventricular tachycardia (VT)	Sigma, Sigma, Sigma	93.7	CC1=C(CCC(O)=O)\C2=C\c3c(CCC(O)=O)c(C)c4\C=C5/N=C(/C=c6/c(C=C)c(C)\c(=C\C1=N2)n6[Fe](O)n34)C(C)=C5C=C |c:1,20,34,45,t:8,22,24,31|, CC1=C(CCC(O)=O)\C2=C\c3c(CCC(O)=O)c(C)c4\C=C5/N=C(/C=c6/c(C=C)c(C)\c(=C\C1=N2)n6[Fe](O)n34)C(C)=C5C=C |c:1,20,34,45,t:8,22,24,31|, CC1=C(CCC(O)=O)\C2=C\c3c(CCC(O)=O)c(C)c4\C=C5/N=C(/C=c6/c(C=C)c(C)\c(=C\C1=N2)n6[Fe](O)n34)C(C)=C5C=C |c:1,20,34,45,t:8,22,24,31|	Launched
hemomex-s		PPARG			MedChemEx, MedChemEx, MedChemEx	90.75	CC(C)=CCC[C@](C)(O)[C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@@H]1[C@@]3(C)CC[C@H](O)C(C)(C)[C@@H]3[C@@H](O)C[C@@]21C, CC(C)=CCC[C@](C)(O)[C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@@H]1[C@@]3(C)CC[C@H](O)C(C)(C)[C@@H]3[C@@H](O)C[C@@]21C, CC(C)=CCC[C@](C)(O)[C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@@H]1[C@@]3(C)CC[C@H](O)C(C)(C)[C@@H]3[C@@H](O)C[C@@]21C	Launched
hepsulfam	DNA cross-linking				MedChemEx	85.4	NS(=O)(=O)OCCCCCCCOS(N)(=O)=O	Preclinical
heptaminol	vasoconstrictor		cardiology	hypotension	MicroSource, MedChemEx, MedChemEx	100	C[C@@H](N)CCCC(C)(C)O |&1:1|, C[C@@H](N)CCCC(C)(C)O |&1:1|, C[C@@H](N)CCCC(C)(C)O |&1:1|	Launched
HER2-Inhibitor-1	EGFR inhibitor				MedChemEx, Selleck	92.93	Cc1cc(Nc2ncnc3ccc(cc23)-c2ccc(CNCCS(C)(=O)=O)o2)ccc1Oc1ccn2ncnc2c1, Cc1cc(Nc2ncnc3ccc(cc23)-c2ccc(CNCCS(C)(=O)=O)o2)ccc1Oc1ccn2ncnc2c1	Preclinical
hesperadin	Aurora kinase inhibitor	AURKB			Selleck, Selleck, Selleck, Tocris, Tocris, Tocris, Tocris, Tocris	96.66	CCS(=O)(=O)Nc1ccc2NC(=O)\C(=C(/Nc3ccc(CN4CCCCC4)cc3)c3ccccc3)c2c1, CCS(=O)(=O)Nc1ccc2NC(=O)\C(=C(/Nc3ccc(CN4CCCCC4)cc3)c3ccccc3)c2c1, CCS(=O)(=O)Nc1ccc2NC(=O)\C(=C(/Nc3ccc(CN4CCCCC4)cc3)c3ccccc3)c2c1, CCS(=O)(=O)Nc1ccc2NC(=O)\C(=C(/Nc3ccc(CN4CCCCC4)cc3)c3ccccc3)c2c1, CCS(=O)(=O)Nc1ccc2NC(=O)\C(=C(/Nc3ccc(CN4CCCCC4)cc3)c3ccccc3)c2c1, CCS(=O)(=O)Nc1ccc2NC(=O)\C(=C(/Nc3ccc(CN4CCCCC4)cc3)c3ccccc3)c2c1, CCS(=O)(=O)Nc1ccc2NC(=O)\C(=C(/Nc3ccc(CN4CCCCC4)cc3)c3ccccc3)c2c1, CCS(=O)(=O)Nc1ccc2NC(=O)\C(=C(/Nc3ccc(CN4CCCCC4)cc3)c3ccccc3)c2c1	Preclinical
hesperetin	ACAT inhibitor	DGAT1, MTTP, SOAT1, SOAT2			MedChemEx, MedChemEx, Selleck, Selleck	98.16	COc1ccc(cc1O)[C@@H]1CC(=O)c2c(O)cc(O)cc2O1, COc1ccc(cc1O)[C@@H]1CC(=O)c2c(O)cc(O)cc2O1, COc1ccc(cc1O)[C@@H]1CC(=O)c2c(O)cc(O)cc2O1, COc1ccc(cc1O)[C@@H]1CC(=O)c2c(O)cc(O)cc2O1	Launched
hesperidin	flavanone glycoside	AURKB, CACNA1B			Selleck, Selleck, Selleck, Selleck, Selleck, MedChemEx	91.49	COc1ccc(cc1O)[C@@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1, COc1ccc(cc1O)[C@@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1, COc1ccc(cc1O)[C@@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1, COc1ccc(cc1O)[C@@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1, COc1ccc(cc1O)[C@@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1, COc1ccc(cc1O)[C@@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1	Launched
hetacillin	bacterial cell wall synthesis inhibitor		obstetrics/gynecology	mastitis	Toronto	62.75	CC1(C)S[C@@H]2[C@H](N3C(=O)[C@H](NC3(C)C)c3ccccc3)C(=O)N2[C@H]1C(O)=O	Launched
hexachlorophene	potassium channel activator	GLUD1, SDHD	infectious disease	gram-positive bacterial infections	MicroSource, MicroSource, MicroSource, MicroSource, MicroSource, MicroSource, MicroSource, MicroSource, MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx	98.49	Oc1c(Cl)cc(Cl)c(Cl)c1Cc1c(O)c(Cl)cc(Cl)c1Cl, Oc1c(Cl)cc(Cl)c(Cl)c1Cc1c(O)c(Cl)cc(Cl)c1Cl, Oc1c(Cl)cc(Cl)c(Cl)c1Cc1c(O)c(Cl)cc(Cl)c1Cl, Oc1c(Cl)cc(Cl)c(Cl)c1Cc1c(O)c(Cl)cc(Cl)c1Cl, Oc1c(Cl)cc(Cl)c(Cl)c1Cc1c(O)c(Cl)cc(Cl)c1Cl, Oc1c(Cl)cc(Cl)c(Cl)c1Cc1c(O)c(Cl)cc(Cl)c1Cl, Oc1c(Cl)cc(Cl)c(Cl)c1Cc1c(O)c(Cl)cc(Cl)c1Cl, Oc1c(Cl)cc(Cl)c(Cl)c1Cc1c(O)c(Cl)cc(Cl)c1Cl, Oc1c(Cl)cc(Cl)c(Cl)c1Cc1c(O)c(Cl)cc(Cl)c1Cl, Oc1c(Cl)cc(Cl)c(Cl)c1Cc1c(O)c(Cl)cc(Cl)c1Cl, Oc1c(Cl)cc(Cl)c(Cl)c1Cc1c(O)c(Cl)cc(Cl)c1Cl, Oc1c(Cl)cc(Cl)c(Cl)c1Cc1c(O)c(Cl)cc(Cl)c1Cl, Oc1c(Cl)cc(Cl)c(Cl)c1Cc1c(O)c(Cl)cc(Cl)c1Cl	Launched
hexamethonium	cholinergic receptor antagonist	CHRNA2, CHRNA3, CHRNA4, CHRNA6			MedChemEx, MicroSource, Selleck, Selleck, Selleck, Selleck	100	C[N+](C)(C)CCCCCC[N+](C)(C)C, C[N+](C)(C)CCCCCC[N+](C)(C)C, C[N+](C)(C)CCCCCC[N+](C)(C)C, C[N+](C)(C)CCCCCC[N+](C)(C)C, C[N+](C)(C)CCCCCC[N+](C)(C)C, C[N+](C)(C)CCCCCC[N+](C)(C)C	Preclinical
hexamethylenebisacetamide	AKT inhibitor, differentiation inducer, NFKB pathway inhibitor	AKT1			Sigma, Sigma, Sigma	87.14	CC(=O)NCCCCCCNC(C)=O, CC(=O)NCCCCCCNC(C)=O, CC(=O)NCCCCCCNC(C)=O	Phase 2
hexaminolevulinate			radiology	diagnostic agent	MedChemEx, MedChemEx	100	CCCCCCOC(=O)CCC(=O)CN, CCCCCCOC(=O)CCC(=O)CN	Launched
hexasodium-phytate					TCI	0	OP(O)(=O)O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O	Phase 2
hexestrol	synthetic estrogen	AKR1C1, ESR1, ESR2	endocrinology	hypoestrogenism	Selleck, Selleck, Selleck, Selleck	96.98	CC[C@@H]([C@@H](CC)c1ccc(O)cc1)c1ccc(O)cc1, CC[C@@H]([C@@H](CC)c1ccc(O)cc1)c1ccc(O)cc1, CC[C@@H]([C@@H](CC)c1ccc(O)cc1)c1ccc(O)cc1, CC[C@@H]([C@@H](CC)c1ccc(O)cc1)c1ccc(O)cc1	Launched
hexetidine	local anesthetic		otolaryngology, infectious disease, dental, gastroenterology	pharyngitis, meningitis, laryngitis, gingivitis, ulcerative colitis	MicroSource, MedChemEx, MedChemEx	25.25	CCCC[C@H](CC)CN1CN(C[C@H](CC)CCCC)C[C@](C)(N)C1 |&1:12,&2:4,&3:20,r|, CCCC[C@H](CC)CN1CN(C[C@H](CC)CCCC)C[C@](C)(N)C1 |&1:12,&2:4,&3:20,r|, CCCC[C@H](CC)CN1CN(C[C@H](CC)CCCC)C[C@](C)(N)C1 |&1:12,&2:4,&3:20,r|	Launched
hexonic-acid					Sigma, AMS	100	OC[C@@H](O)[C@@H](O)[C@@H](O)[C@@H](O)C(O)=O |&1:2,&2:4,&3:6,&4:8,r|, OC[C@@H](O)[C@@H](O)[C@@H](O)[C@@H](O)C(O)=O |&1:2,&2:4,&3:6,&4:8,r|	Preclinical
hexoprenaline	adrenergic receptor agonist	ADRB2	pulmonary	asthma	Carbosynth	79.95	O[C@@H](CNCCCCCCNC[C@@H](O)c1ccc(O)c(O)c1)c1ccc(O)c(O)c1 |&1:1,&2:12|	Launched
hexylcaine	sodium channel blocker	SCN5A	neurology/psychiatry	local anesthetic	Prestwick, Toronto	96.16	C[C@@H](CNC1CCCCC1)OC(=O)c1ccccc1 |&1:1|, C[C@@H](CNC1CCCCC1)OC(=O)c1ccccc1 |&1:1|	Launched
hexylene-glycol		AKR1C3, CTPS1, DLG4, HSP90AA1, NOS3, PGF, PLA2G1B, PTPN1, SELP			MicroSource, MedChemEx	15.17	C[C@@H](O)CC(C)(C)O |&1:1,r|, C[C@@H](O)CC(C)(C)O |&1:1,r|	Preclinical
hexylresorcinol	local anesthetic	TYR	infectious disease	skin infections, first-aid antiseptic	MedChemEx, MicroSource, MicroSource, MicroSource	98.8	CCCCCCc1ccc(O)cc1O, CCCCCCc1ccc(O)cc1O, CCCCCCc1ccc(O)cc1O, CCCCCCc1ccc(O)cc1O	Launched
higenamine	adrenergic receptor agonist	ADRB2			Accela, Accela, Accela, Accela	94.65	Oc1ccc(C[C@H]2NCCc3cc(O)c(O)cc23)cc1 |&1:6|, Oc1ccc(C[C@H]2NCCc3cc(O)c(O)cc23)cc1 |&1:6|, Oc1ccc(C[C@H]2NCCc3cc(O)c(O)cc23)cc1 |&1:6|, Oc1ccc(C[C@H]2NCCc3cc(O)c(O)cc23)cc1 |&1:6|	Phase 1
hippuric-acid					CombiBlocks	97.62	OC(=O)CNC(=O)c1ccccc1	Preclinical
histamine	histamine receptor agonist	HRH1, HRH2, HRH3, HRH4	allergy	allergic rhinitis	Tocris, Tocris, Selleck, MicroSource, Selleck, Selleck	100	NCCc1cnc[nH]1, NCCc1cnc[nH]1, NCCc1cnc[nH]1, NCCc1cnc[nH]1, NCCc1cnc[nH]1, NCCc1cnc[nH]1	Launched
HJC-0350	GTPase inhibitor	RAPGEF4			Tocris, Tocris, Tocris	95.86	Cc1cc(C)n(c1)S(=O)(=O)c1c(C)cc(C)cc1C, Cc1cc(C)n(c1)S(=O)(=O)c1c(C)cc(C)cc1C, Cc1cc(C)n(c1)S(=O)(=O)c1c(C)cc(C)cc1C	Preclinical
HKI-357	EGFR inhibitor	EGFR			Tocris, Tocris	98.23	CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C, CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C	Phase 1
HLCL-61	protein arginine N-methyltransferase inhibitor	PRMT5			MedChemEx, MedChemEx, MedChemEx	95.64	CCn1c2ccccc2c2cc(CNCc3ccccc3OC)ccc12, CCn1c2ccccc2c2cc(CNCc3ccccc3OC)ccc12, CCn1c2ccccc2c2cc(CNCc3ccccc3OC)ccc12	Preclinical
HM-30181	P glycoprotein inhibitor				MedChemEx	51.49	COc1cc2CCN(CCc3ccc(cc3)-n3nnc(n3)-c3cc(OC)c(OC)cc3NC(=O)c3cc(=O)c4ccccc4o3)Cc2cc1OC	Phase 1
HMN-214	PLK inhibitor	PLK1			Selleck	90.91	COc1ccc(cc1)S(=O)(=O)N(C(C)=O)c1ccccc1\C=C\c1cc[n+]([O-])cc1	Phase 1
HOKU-81	bronchodilator				MedChemEx	95.17	CC(C)(C)NC[C@H](O)c1ccc(O)cc1Cl |r|	Preclinical
homatropine	acetylcholine receptor antagonist	CHRM1	ophthalmology	uveal tract inflammation, pupil dilation	MedChemEx, MicroSource, MicroSource, Selleck, Selleck	93.54	CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@@H](O)c1ccccc1 |a:2,5,7,&1:12,THB:9:7:1:3.4|, CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@@H](O)c1ccccc1 |a:2,5,7,&1:12,THB:9:7:1:3.4|, CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@@H](O)c1ccccc1 |a:2,5,7,&1:12,THB:9:7:1:3.4|, CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@@H](O)c1ccccc1 |a:2,5,7,&1:12,THB:9:7:1:3.4|, CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@@H](O)c1ccccc1 |a:2,5,7,&1:12,THB:9:7:1:3.4|	Launched
homatropine-methylbromide	acetylcholine receptor antagonist	CHRM5	ophthalmology	uveal tract inflammation	MedChemEx	97.64	C[N+]1(C)[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@@H](O)c1ccccc1 |a:3,6,8,&1:13,THB:10:8:1:4.5|	Launched
homidium					MicroSource, AMS	91.36	CC[n+]1c(-c2ccccc2)c2cc(N)ccc2c2ccc(N)cc12, CC[n+]1c(-c2ccccc2)c2cc(N)ccc2c2ccc(N)cc12	Preclinical
homochlorcyclizine	antihistamine	HRH1	allergy	allergic rhinitis		0		Launched
homoharringtonine	protein synthesis inhibitor	RPL3	hematologic malignancy	chronic myeloid leukemia (CML)	Tocris, Tocris, Tocris, Tocris, Tocris, Tocris	95.23	COC(=O)C[C@](O)(CCCC(C)(C)O)C(=O)O[C@H]1[C@H]2c3cc4OCOc4cc3CCN3CCC[C@]23C=C1OC |c:39|, COC(=O)C[C@](O)(CCCC(C)(C)O)C(=O)O[C@H]1[C@H]2c3cc4OCOc4cc3CCN3CCC[C@]23C=C1OC |c:39|, COC(=O)C[C@](O)(CCCC(C)(C)O)C(=O)O[C@H]1[C@H]2c3cc4OCOc4cc3CCN3CCC[C@]23C=C1OC |c:39|, COC(=O)C[C@](O)(CCCC(C)(C)O)C(=O)O[C@H]1[C@H]2c3cc4OCOc4cc3CCN3CCC[C@]23C=C1OC |c:39|, COC(=O)C[C@](O)(CCCC(C)(C)O)C(=O)O[C@H]1[C@H]2c3cc4OCOc4cc3CCN3CCC[C@]23C=C1OC |c:39|, COC(=O)C[C@](O)(CCCC(C)(C)O)C(=O)O[C@H]1[C@H]2c3cc4OCOc4cc3CCN3CCC[C@]23C=C1OC |c:39|	Launched
homoquinolinic-acid	glutamate receptor agonist	GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D			Tocris, Tocris, Tocris	100	OC(=O)Cc1cccnc1C(O)=O, OC(=O)Cc1cccnc1C(O)=O, OC(=O)Cc1cccnc1C(O)=O	Preclinical
homosalate	HSP inducer				MicroSource, MedChemEx	85.67	C[C@H]1C[C@@H](CC(C)(C)C1)OC(=O)c1ccccc1O |&1:1,&2:3,r|, C[C@H]1C[C@@H](CC(C)(C)C1)OC(=O)c1ccccc1O |&1:1,&2:3,r|	Preclinical
homoveratrylamine	monoamine oxidase inhibitor				MedChemEx, Prestwick	77.78	COc1ccc(CCN)cc1OC, COc1ccc(CCN)cc1OC	Preclinical
honokiol	AKT inhibitor	ALOX5, PTGS1, PTGS2			Tocris, Selleck, Selleck	97.8	Oc1ccc(cc1CC=C)-c1cc(CC=C)ccc1O, Oc1ccc(cc1CC=C)-c1cc(CC=C)ccc1O, Oc1ccc(cc1CC=C)-c1cc(CC=C)ccc1O	Phase 3
hordenine					Selleck, Selleck	88.33	CN(C)CCc1ccc(O)cc1, CN(C)CCc1ccc(O)cc1	Preclinical
HP-228	nitric oxide synthase inhibitor				ChemImpex	95.69	CCCC[C@H](NC(C)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](Cc1c[nH]c2ccccc12)C(=O)NCC(N)=O	Preclinical
hPGDS-IN-1	prostaglandin inhibitor				MedChemEx	98.83	CC(C)(O)c1nc(no1)-c1cccc(CNC(=O)c2cnc(nc2)-c2ccccn2)c1	Preclinical
HPPH	photosensitizing agent				MedChemEx	95.16	CCCCCCO[C@H](C)c1c(C)c2cc3nc([C@@H](CCC(O)=O)[C@@H]3C)c3CC(=O)c4c(C)c(cc5nc(cc1[nH]2)c(C)c5CC)[nH]c34 |&1:7|	Phase 2
HQK-1001					Enamine, Enamine	0	CCC(C)(C)C(O)=O, CCC(C)(C)C(O)=O	Phase 2
HSR6071	antiallergic agent				MedChemEx	96.28	O=C(Nc1nnn[nH]1)c1cncc(n1)N1CCCC1	Preclinical
HT-2157	galanin receptor 3 antagonist				MedChemEx	51.12	FC(F)(F)c1cccc(c1)\N=C1/C(=O)N(c2ccccc12)c1ccccc1	Phase 1/Phase 2
HTH-01-015	protein kinase inhibitor	NUAK1			Tocris, ApexBio	90.24	CN1c2cc3ccccc3cc2C(=O)N(C)c2c(C)nc(Nc3cnn(c3)C3CCNCC3)nc12, CN1c2cc3ccccc3cc2C(=O)N(C)c2c(C)nc(Nc3cnn(c3)C3CCNCC3)nc12	Preclinical
HTHQ	antioxidant				MedChemEx	91.66	CCCCCCOc1cc(C)c(O)c(C)c1C	Preclinical
HTMT	histamine receptor agonist	HRH4			Tocris, Tocris	86.57	C[C@@H](CCCCC(=O)Nc1ccc(cc1)C(F)(F)F)NCCc1cnc[nH]1 |&1:1|, C[C@@H](CCCCC(=O)Nc1ccc(cc1)C(F)(F)F)NCCc1cnc[nH]1 |&1:1|	Preclinical
huperzine-A	acetylcholinesterase inhibitor	ACHE			MedChemEx, MedChemEx, MedChemEx, Selleck, Selleck, Selleck	86.35	C\C=C1/[C@@H]2Cc3[nH]c(=O)ccc3[C@@]1(N)CC(C)=C2 |c:18|, C\C=C1/[C@@H]2Cc3[nH]c(=O)ccc3[C@@]1(N)CC(C)=C2 |c:18|, C\C=C1/[C@@H]2Cc3[nH]c(=O)ccc3[C@@]1(N)CC(C)=C2 |c:18|, C\C=C1/[C@@H]2Cc3[nH]c(=O)ccc3[C@@]1(N)CC(C)=C2 |c:18|, C\C=C1/[C@@H]2Cc3[nH]c(=O)ccc3[C@@]1(N)CC(C)=C2 |c:18|, C\C=C1/[C@@H]2Cc3[nH]c(=O)ccc3[C@@]1(N)CC(C)=C2 |c:18|	Phase 2
hyaluronic-acid		C1QBP, CD44, HABP2, HAPLN1, HAPLN3, HAPLN4, HMMR, ICAM1, NCAN, VCAN	rheumatology, urology	osteoarthritis, interstitial cystitis (IC)	Sigma	0	CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)O[C@@H]1C(O)=O	Launched
hycanthone	RNA synthesis inhibitor		infectious disease	schistosomiasis	MicroSource, MicroSource	88.6	CCN(CC)CCNc1ccc(CO)c2sc3ccccc3c(=O)c12, CCN(CC)CCNc1ccc(CO)c2sc3ccccc3c(=O)c12	Launched
hydralazine	vasodilator		cardiology	hypertension	MicroSource, MedChemEx, MedChemEx, Selleck, Selleck	96.45	NNc1nncc2ccccc12, NNc1nncc2ccccc12, NNc1nncc2ccccc12, N\N=c1/[nH]ncc2ccccc12, N\N=c1/[nH]ncc2ccccc12	Launched
hydrastine-(1R,9S)	tyrosine hydroxylase inhibitor				MedChemEx, MicroSource, MicroSource	99.03	COc1ccc2[C@H](OC(=O)c2c1OC)[C@@H]1N(C)CCc2cc3OCOc3cc12, COc1ccc2[C@H](OC(=O)c2c1OC)[C@@H]1N(C)CCc2cc3OCOc3cc12, COc1ccc2[C@H](OC(=O)c2c1OC)[C@@H]1N(C)CCc2cc3OCOc3cc12	Preclinical
hydrastinine	hemostatic agent				Sigma	83.97	C[N+]1=Cc2cc3OCOc3cc2CC1 |t:1|	Preclinical
hydrochlorothiazide	thiazide diuretic	CA1, CA12, CA2, CA4, CA9, KCNMA1, SLC12A3	cardiology	hypertension, congestive heart failure	Selleck, MicroSource, MicroSource	98.34	NS(=O)(=O)c1cc2c(NCNS2(=O)=O)cc1Cl, NS(=O)(=O)c1cc2c(NCNS2(=O)=O)cc1Cl, NS(=O)(=O)c1cc2c(NCNS2(=O)=O)cc1Cl	Launched
hydrocortisone	glucocorticoid receptor agonist	ANXA1, NOS2, NR3C1, NR3C2	dermatology, neurology/psychiatry	eczema, psoriasis, seborrheic dermatitis, itching	Tocris, MicroSource, MicroSource, Selleck, Selleck, Tocris	97.33	C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO |t:9|, C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO |t:9|, C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO |t:9|, C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO |t:9|, C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO |t:9|, C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO |t:9|	Launched
hydrocortisone-acetate	glucocorticoid receptor agonist	NR3C1	dermatology	corticosteroid-responsive dermatoses	MedChemEx	92.06	CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@]12C |t:15|	Launched
hydrocortisone-butyrate	glucocorticoid receptor agonist	NR3C1	dermatology	corticosteroid-responsive dermatoses, eczema	MicroSource, Sigma	85.87	CCCC(=O)O[C@@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@]12C)C(=O)CO |t:13|, CCCC(=O)O[C@@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@]12C)C(=O)CO |t:13|	Launched
hydrocortisone-hemisuccinate					Sigma	93.51	C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@]2(O)C(=O)COC(=O)CCC(O)=O |t:9|	Phase 2/Phase 3
hydrocortisone-phosphate			pulmonary, gastroenterology, hematologic malignancy, ophthalmology	asthma, nausea, vomiting, multiple myeloma, contact dermatitis, enteritis, colitis	MicroSource	79.61	C[C@@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]34C)[C@@H]1CC[C@]2(O)C(=O)COP(O)(O)=O |a:3,20,&1:1,&2:5,&3:6,&4:15,&5:17,t:9|	Launched
hydrocortisone-valerate	glucocorticoid receptor agonist	NR3C1	dermatology	corticosteroid-responsive dermatoses	USP	90.33	CCCCC(=O)O[C@@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@]12C)C(=O)CO |t:14|	Launched
hydroflumethiazide	sodium/potassium/chloride transporter inhibitor	ATP1A1, CA1, CA12, CA2, CA4, CA9, KCNMA1, SLC12A1, SLC12A3	cardiology, gastroenterology, rheumatology, nephrology	edema, congestive heart failure, hepatic cirrhosis, nephrotic syndrome, chronic renal failure, acute glomerulonephritis (AGN), hypertension	Sigma, Sigma, MicroSource	98.02	NS(=O)(=O)c1cc2c(NCNS2(=O)=O)cc1C(F)(F)F, NS(=O)(=O)c1cc2c(NCNS2(=O)=O)cc1C(F)(F)F, NS(=O)(=O)c1cc2c(NCNS2(=O)=O)cc1C(F)(F)F	Launched
hydroquinidine	antiarrhythmic		cardiology	cardiac arrythmia	MedChemEx, MedChemEx	85.97	CC[C@H]1C[N@@]2CC[C@H]1C[C@@H]2[C@@H](O)c1ccnc2ccc(OC)cc12, CC[C@H]1C[N@@]2CC[C@H]1C[C@@H]2[C@@H](O)c1ccnc2ccc(OC)cc12	Launched
hydroquinone	melanin inhibitor	TYR	dermatology	dyschromia	MicroSource, MedChemEx	49.83	Oc1ccc(O)cc1, Oc1ccc(O)cc1	Launched
hydroxocobalamin	vitamin B				MedChemEx	59.19	[H]O[Co+]N1\C2=C(C)/C3=N/C(=C/C4=N/C(=C(C)\C5=N[C@@](C)([C@@]1([H])[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@@H]1[C@@H](CO)O[C@@H]([C@@H]1O)n1cnc2cc(C)c(C)cc12)[C@@](C)(CC(N)=O)[C@@H]5CCC(N)=O)/[C@@](C)(CC(N)=O)[C@@H]4CCC(N)=O)/C(C)(C)[C@@H]3CCC(N)=O |r,t:4,7,9,11,13,16|	Launched
hydroxyamphetamine	trace amine associated receptor agonist	TAAR1	ophthalmology	mydriasis	MicroSource, MicroSource, Enamine	100	C[C@@H](N)Cc1ccc(O)cc1 |&1:1|, C[C@@H](N)Cc1ccc(O)cc1 |&1:1|, C[C@@H](N)Cc1ccc(O)cc1 |&1:1|	Launched
hydroxychloroquine	antimalarial agent	TLR7, TLR9	infectious disease	malaria	MicroSource, Sigma, Sigma	98.39	CCN(CCO)CCCC(C)Nc1ccnc2cc(Cl)ccc12, CCN(CCO)CCCC(C)Nc1ccnc2cc(Cl)ccc12, CCN(CCO)CCCC(C)Nc1ccnc2cc(Cl)ccc12	Launched
hydroxyfasudil	rho associated kinase inhibitor	PKIA, PRKACA, ROCK1			Tocris, Tocris, Tocris, Tocris	97.11	O=c1[nH]ccc2c(cccc12)S(=O)(=O)N1CCCNCC1, O=c1[nH]ccc2c(cccc12)S(=O)(=O)N1CCCNCC1, O=c1[nH]ccc2c(cccc12)S(=O)(=O)N1CCCNCC1, O=c1[nH]ccc2c(cccc12)S(=O)(=O)N1CCCNCC1	Preclinical
hydroxyprogesterone	progesterone receptor agonist	PGR	obstetrics/gynecology	spontaneous preterm birth	TCI	89.44	CC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C |t:11|	Launched
hydroxyprogesterone-acetate	progesterone receptor agonist	PGR			Sigma	94	CC(=O)O[C@@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)=O |t:11|	Launched
hydroxypropyl-beta-cyclodextrin					Cayman, Cayman, Cayman	98.32	C[C@@H](O)COC[C@H]1O[C@@H]2O[C@@H]3[C@@H](COC[C@@H](C)O)O[C@H](O[C@@H]4[C@@H](COC[C@@H](C)O)O[C@H](O[C@@H]5[C@@H](COC[C@@H](C)O)O[C@H](O[C@@H]6[C@@H](COC[C@@H](C)O)O[C@H](O[C@@H]7[C@@H](COC[C@@H](C)O)O[C@H](O[C@@H]8[C@@H](COC[C@@H](C)O)O[C@H](O[C@H]1[C@H](O)[C@H]2O)[C@H](O)[C@H]8O)[C@H](O)[C@H]7O)[C@H](O)[C@H]6O)[C@H](O)[C@H]5O)[C@H](O)[C@H]4O)[C@H](O)[C@H]3O |a:6,8,10,11,19,21,22,30,32,33,41,43,44,52,54,55,63,65,66,74,76,77,79,81,83,85,87,89,91,93,95,97,99,101,103,&1:1,&2:15,&3:26,&4:37,&5:48,&6:59,&7:70|, C[C@@H](O)COC[C@H]1O[C@@H]2O[C@@H]3[C@@H](COC[C@@H](C)O)O[C@H](O[C@@H]4[C@@H](COC[C@@H](C)O)O[C@H](O[C@@H]5[C@@H](COC[C@@H](C)O)O[C@H](O[C@@H]6[C@@H](COC[C@@H](C)O)O[C@H](O[C@@H]7[C@@H](COC[C@@H](C)O)O[C@H](O[C@@H]8[C@@H](COC[C@@H](C)O)O[C@H](O[C@H]1[C@H](O)[C@H]2O)[C@H](O)[C@H]8O)[C@H](O)[C@H]7O)[C@H](O)[C@H]6O)[C@H](O)[C@H]5O)[C@H](O)[C@H]4O)[C@H](O)[C@H]3O |a:6,8,10,11,19,21,22,30,32,33,41,43,44,52,54,55,63,65,66,74,76,77,79,81,83,85,87,89,91,93,95,97,99,101,103,&1:1,&2:15,&3:26,&4:37,&5:48,&6:59,&7:70|, C[C@@H](O)COC[C@H]1O[C@@H]2O[C@@H]3[C@@H](COC[C@@H](C)O)O[C@H](O[C@@H]4[C@@H](COC[C@@H](C)O)O[C@H](O[C@@H]5[C@@H](COC[C@@H](C)O)O[C@H](O[C@@H]6[C@@H](COC[C@@H](C)O)O[C@H](O[C@@H]7[C@@H](COC[C@@H](C)O)O[C@H](O[C@@H]8[C@@H](COC[C@@H](C)O)O[C@H](O[C@H]1[C@H](O)[C@H]2O)[C@H](O)[C@H]8O)[C@H](O)[C@H]7O)[C@H](O)[C@H]6O)[C@H](O)[C@H]5O)[C@H](O)[C@H]4O)[C@H](O)[C@H]3O |a:6,8,10,11,19,21,22,30,32,33,41,43,44,52,54,55,63,65,66,74,76,77,79,81,83,85,87,89,91,93,95,97,99,101,103,&1:1,&2:15,&3:26,&4:37,&5:48,&6:59,&7:70|	Phase 2/Phase 3
hydroxysafflor-yellow-A	antitumor agent				MedChemEx	92.8	[H][C@]1(O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)[C@]1(O)C(=O)[C@@H]([C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)C(=O)[C@H](C(=O)\C=C\c2ccc(O)cc2)C1=O |&1:12,&2:30,&3:16|	Preclinical
hydroxystilbamidine					Enzo	93.1	NC(=N)c1ccc(\C=C\c2ccc(cc2O)C(N)=N)cc1	Launched
hydroxytacrine-maleate-(R,S)	cholinesterase inhibitor	ACHE			AMS	95.7	Nc1c2[C@@H](O)CCCc2nc2ccccc12 |&1:3|	Preclinical
hydroxytoluic-acid					MedChemEx, MedChemEx, MicroSource	99.14	Cc1cccc(C(O)=O)c1O, Cc1cccc(C(O)=O)c1O, Cc1cccc(C(O)=O)c1O	Preclinical
hydroxyurea	ribonucleotide reductase inhibitor	RRM1, RRM2, RRM2B	hematologic malignancy, oncology	chronic myeloid leukemia (CML), head and neck squamous cell carcinoma (HNSCC)	Selleck, Selleck, Selleck, Selleck, Selleck, MicroSource	98.2	NC(=O)NO, NC(=O)NO, NC(=O)NO, NC(=O)NO, NC(=O)NO, NC(=O)NO	Launched
hydroxyzine	antihistamine	HRH1	neurology/psychiatry, allergy, dermatology	anxiety, urticaria, itching, dermatosis	Selleck, Selleck	96.59	OCCOCCN1CCN(CC1)[C@@H](c1ccccc1)c1ccc(Cl)cc1 |&1:12|, OCCOCCN1CCN(CC1)[C@@H](c1ccccc1)c1ccc(Cl)cc1 |&1:12|	Launched
hygromycin-B	polypeptide synthesis inhibitor				MedChemEx	100	CN[C@H]1C[C@@H](N)[C@H](O)[C@@H](O[C@@H]2O[C@H](CO)[C@H](O)[C@@H]3O[C@@]4(O[C@H]23)O[C@H]([C@@H](N)CO)[C@H](O)[C@H](O)[C@H]4O)[C@@H]1O |a:2,4,6,8,10,12,15,17,21,23,24,28,30,32,34,&1:19|	Preclinical
hymecromone	monoamine oxidase inhibitor	MAOA, MAOB			MicroSource, MedChemEx, Selleck, Selleck	100	Cc1cc(=O)oc2cc(O)ccc12, Cc1cc(=O)oc2cc(O)ccc12, Cc1cc(=O)oc2cc(O)ccc12, Cc1cc(=O)oc2cc(O)ccc12	Phase 2
hyodeoxycholic-acid	atherosclerosis formation inhibitor				Selleck, Selleck, Selleck	100	C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3C[C@H](O)[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C, C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3C[C@H](O)[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C, C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3C[C@H](O)[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C	Phase 1
hyoscyamine	acetylcholine receptor antagonist	CHRM1, CHRM2, CHRM3, CHRM4	gastroenterology, urology, neurology/psychiatry, allergy	peptic ulcer disease (PUD), acute abdominal visceral spasm, ulcerative colitis, interstitial cystitis (IC), enterocolitis, irritable bowel syndrome, tremors, allergic rhinitis	MedChemEx, MicroSource, Selleck	97.93	CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@H](CO)c1ccccc1, CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@H](CO)c1ccccc1, CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@H](CO)c1ccccc1	Launched
hypericin	tyrosine kinase inhibitor				MedChemEx, MedChemEx, Enzo, Enzo	98.33	Cc1cc(O)c2c3c1c1c(C)cc(O)c4c1c1c3c3c(c(O)cc(O)c3c2=O)c2c(O)cc(O)c(c12)c4=O, Cc1cc(O)c2c3c1c1c(C)cc(O)c4c1c1c3c3c(c(O)cc(O)c3c2=O)c2c(O)cc(O)c(c12)c4=O, Cc1cc(O)c2c3c1c1c(C)cc(O)c4c1c1c3c3c(c(O)cc(O)c3c2=O)c2c(O)cc(O)c(c12)c4=O, Cc1cc(O)c2c3c1c1c(C)cc(O)c4c1c1c3c3c(c(O)cc(O)c3c2=O)c2c(O)cc(O)c(c12)c4=O	Phase 3
hyperin	aldose reductase inhibitor	ACE, AKR1B1			ChemDiv, ChemDiv, ChemDiv, ChemDiv	97.26	OC[C@H]1O[C@@H](Oc2c(oc3cc(O)cc(O)c3c2=O)-c2ccc(O)c(O)c2)[C@@H](O)[C@@H](O)[C@@H]1O |&1:2,&2:4,&3:27,&4:29,&5:31,r|, OC[C@H]1O[C@@H](Oc2c(oc3cc(O)cc(O)c3c2=O)-c2ccc(O)c(O)c2)[C@@H](O)[C@@H](O)[C@@H]1O |&1:2,&2:4,&3:27,&4:29,&5:31,r|, OC[C@H]1O[C@@H](Oc2c(oc3cc(O)cc(O)c3c2=O)-c2ccc(O)c(O)c2)[C@@H](O)[C@@H](O)[C@@H]1O |&1:2,&2:4,&3:27,&4:29,&5:31,r|, OC[C@H]1O[C@@H](Oc2c(oc3cc(O)cc(O)c3c2=O)-c2ccc(O)c(O)c2)[C@@H](O)[C@@H](O)[C@@H]1O |&1:2,&2:4,&3:27,&4:29,&5:31,r|	Preclinical
hypoestoxide	IKK inhibitor	IKBKB, IL1B, TNF			EMD	87.38	CC(=O)O[C@@H]1C[C@]2(C)O[C@H]2CC[C@]2(C)O[C@H]2C[C@@H]2CC(=O)C(=C)[C@@H]1C2(C)C	Phase 1
hypoxanthine	PARP inhibitor	PNP			Selleck, Selleck	96.41	O=c1nc[nH]c2nc[nH]c12, O=c1nc[nH]c2nc[nH]c12	Preclinical
H2L-5765834	lysophosphatidic acid receptor antagonist	LPAR1, LPAR3			Tocris, Tocris, Tocris	95.78	OC(=O)c1ccc2C(=O)N(C(=O)c2c1)c1cccc(Oc2ccc(cc2)[N+]([O-])=O)c1, OC(=O)c1ccc2C(=O)N(C(=O)c2c1)c1cccc(Oc2ccc(cc2)[N+]([O-])=O)c1, OC(=O)c1ccc2C(=O)N(C(=O)c2c1)c1cccc(Oc2ccc(cc2)[N+]([O-])=O)c1	Preclinical
I-BET-762	bromodomain inhibitor	BRD2, BRD3, BRD4			Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck	99.33	CCNC(=O)C[C@@H]1N=C(c2ccc(Cl)cc2)c2cc(OC)ccc2-n2c(C)nnc12 |t:7|, CCNC(=O)C[C@@H]1N=C(c2ccc(Cl)cc2)c2cc(OC)ccc2-n2c(C)nnc12 |t:7|, CCNC(=O)C[C@@H]1N=C(c2ccc(Cl)cc2)c2cc(OC)ccc2-n2c(C)nnc12 |t:7|, CCNC(=O)C[C@@H]1N=C(c2ccc(Cl)cc2)c2cc(OC)ccc2-n2c(C)nnc12 |t:7|, CCNC(=O)C[C@@H]1N=C(c2ccc(Cl)cc2)c2cc(OC)ccc2-n2c(C)nnc12 |t:7|, CCNC(=O)C[C@@H]1N=C(c2ccc(Cl)cc2)c2cc(OC)ccc2-n2c(C)nnc12 |t:7|, CCNC(=O)C[C@@H]1N=C(c2ccc(Cl)cc2)c2cc(OC)ccc2-n2c(C)nnc12 |t:7|	Phase 2
I-BET151	bromodomain inhibitor	BRD2, BRD3, BRD4			Tocris, Selleck, Selleck, Selleck, Selleck, Selleck	96.17	COc1cc2c3n([C@H](C)c4ccccn4)c(=O)[nH]c3cnc2cc1-c1c(C)noc1C, COc1cc2c3n([C@H](C)c4ccccn4)c(=O)[nH]c3cnc2cc1-c1c(C)noc1C, COc1cc2c3n([C@H](C)c4ccccn4)c(=O)[nH]c3cnc2cc1-c1c(C)noc1C, COc1cc2c3n([C@H](C)c4ccccn4)c(=O)[nH]c3cnc2cc1-c1c(C)noc1C, COc1cc2c3n([C@H](C)c4ccccn4)c(=O)[nH]c3cnc2cc1-c1c(C)noc1C, COc1cc2c3n([C@H](C)c4ccccn4)c(=O)[nH]c3cnc2cc1-c1c(C)noc1C	Preclinical
I-BRD9	bromodomain inhibitor	BRD9			Tocris, MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx	95.93	CCn1cc(-c2cccc(c2)C(F)(F)F)c2sc(cc2c1=O)C(=N)NC1CCS(=O)(=O)CC1, CCn1cc(-c2cccc(c2)C(F)(F)F)c2sc(cc2c1=O)C(=N)NC1CCS(=O)(=O)CC1, CCn1cc(-c2cccc(c2)C(F)(F)F)c2sc(cc2c1=O)C(=N)NC1CCS(=O)(=O)CC1, CCn1cc(-c2cccc(c2)C(F)(F)F)c2sc(cc2c1=O)C(=N)NC1CCS(=O)(=O)CC1, CCn1cc(-c2cccc(c2)C(F)(F)F)c2sc(cc2c1=O)C(=N)NC1CCS(=O)(=O)CC1, CCn1cc(-c2cccc(c2)C(F)(F)F)c2sc(cc2c1=O)C(=N)NC1CCS(=O)(=O)CC1	Preclinical
I-BZA					Enamine, Enamine	89.11	CCN(CC)CCNC(=O)c1ccc(I)cc1, CCN(CC)CCNC(=O)c1ccc(I)cc1	Phase 2
I-BZA2					Vitas-M, ChemBridge	98.45	CCN(CC)CCNC(=O)c1ccccc1I, CCN(CC)CCNC(=O)c1ccccc1I	Phase 3
I-CBP-112	bromodomain inhibitor	CREBBP, EP300			Tocris, Tocris	92.81	CCC(=O)N1CCOc2c(C1)cc(cc2OC[C@H]1CCCN(C)C1)-c1ccc(OC)c(OC)c1, CCC(=O)N1CCOc2c(C1)cc(cc2OC[C@H]1CCCN(C)C1)-c1ccc(OC)c(OC)c1	Preclinical
IACS-10759	mitochondrial complex I inhibitor				MedChemEx	96.15	Cc1nc(nn1Cc1cccc(c1)N1CCC(CC1)S(C)(=O)=O)-c1nc(no1)-c1ccc(OC(F)(F)F)cc1	Preclinical
IB-MECA	adenosine receptor agonist	ADORA1, ADORA2A, ADORA2B, ADORA3			Tocris, Tocris, Tocris	96.28	CNC(=O)[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(NCc3cccc(I)c3)ncnc12, CNC(=O)[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(NCc3cccc(I)c3)ncnc12, CNC(=O)[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(NCc3cccc(I)c3)ncnc12	Phase 3
ibandronate	bone resorption inhibitor	FDPS	orthopedics	osteoporosis	MicroSource, MedChemEx, Selleck, Selleck	0	CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O, CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O, CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O, CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O	Launched
IBC-293	hydroxycarboxylic acid receptor agonist	HCAR3			Tocris, Tocris	98.64	CC(C)n1nnc2cc(ccc12)C(O)=O, CC(C)n1nnc2cc(ccc12)C(O)=O	Preclinical
iberdomide	cereblon modulator				MedChemEx	96.98	O=C1N(Cc2c1cccc2OCc1ccc(CN2CCOCC2)cc1)[C@H]1CCC(=O)NC1=O	Preclinical
ibiglustat	glucosylceramidase inhibitor				MedChemEx	90.71	CC(C)(NC(=O)O[C@@H]1CN2CCC1CC2)c1csc(n1)-c1ccc(F)cc1	Preclinical
IBMX	phosphodiesterase inhibitor	ADORA1, PDE2A, PDE3B, PDE4D, PDE5A, PDE6G, PDE7A, PDE8A, PDE9A			Tocris, Tocris, Tocris, Tocris	97.36	CC(C)Cn1c2nc[nH]c2c(=O)n(C)c1=O, CC(C)Cn1c2nc[nH]c2c(=O)n(C)c1=O, CC(C)Cn1c2nc[nH]c2c(=O)n(C)c1=O, CC(C)Cn1c2nc[nH]c2c(=O)n(C)c1=O	Preclinical
ibotenic-acid	glutamate receptor agonist	GRIN1			Tocris, Tocris	100	N[C@@H](C(O)=O)c1cc(=O)[nH]o1 |&1:1,r|, N[C@@H](C(O)=O)c1cc(=O)[nH]o1 |&1:1,r|	Preclinical
ibrolipim	lipoprotein lipase activator	LPL			Sigma, Sigma	97.73	CCOP(=O)(Cc1ccc(cc1)C(=O)Nc1ccc(Br)cc1C#N)OCC, CCOP(=O)(Cc1ccc(cc1)C(=O)Nc1ccc(Br)cc1C#N)OCC	Phase 2
ibrutinib	Bruton's tyrosine kinase (BTK) inhibitor	BLK, BMX, BTK	hematologic malignancy	chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), Waldenstrom's macroglobulinemia (WM)	Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck	99.58	Nc1ncnc2n(nc(-c3ccc(Oc4ccccc4)cc3)c12)[C@@H]1CCCN(C1)C(=O)C=C, Nc1ncnc2n(nc(-c3ccc(Oc4ccccc4)cc3)c12)[C@@H]1CCCN(C1)C(=O)C=C, Nc1ncnc2n(nc(-c3ccc(Oc4ccccc4)cc3)c12)[C@@H]1CCCN(C1)C(=O)C=C, Nc1ncnc2n(nc(-c3ccc(Oc4ccccc4)cc3)c12)[C@@H]1CCCN(C1)C(=O)C=C, Nc1ncnc2n(nc(-c3ccc(Oc4ccccc4)cc3)c12)[C@@H]1CCCN(C1)C(=O)C=C, Nc1ncnc2n(nc(-c3ccc(Oc4ccccc4)cc3)c12)[C@@H]1CCCN(C1)C(=O)C=C, Nc1ncnc2n(nc(-c3ccc(Oc4ccccc4)cc3)c12)[C@@H]1CCCN(C1)C(=O)C=C, Nc1ncnc2n(nc(-c3ccc(Oc4ccccc4)cc3)c12)[C@@H]1CCCN(C1)C(=O)C=C, Nc1ncnc2n(nc(-c3ccc(Oc4ccccc4)cc3)c12)[C@@H]1CCCN(C1)C(=O)C=C	Launched
ibudilast	leukotriene receptor antagonist, phosphodiesterase inhibitor	IL1B, IL6, PDE3A, PDE4A, PDE4B, PDE4C, PDE4D, PDE5A	pulmonary, neurology/psychiatry	asthma, stroke	Tocris, Tocris, Tocris, Tocris	96.95	CC(C)C(=O)c1c(nn2ccccc12)C(C)C, CC(C)C(=O)c1c(nn2ccccc12)C(C)C, CC(C)C(=O)c1c(nn2ccccc12)C(C)C, CC(C)C(=O)c1c(nn2ccccc12)C(C)C	Launched
ibuprofen	cyclooxygenase inhibitor		neurology/psychiatry, rheumatology, otolaryngology, obstetrics/gynecology, endocrinology, dental	headache, muscle pain, rheumatoid arthritis, backache, common cold, menstrual pain, fever, toothache	MicroSource, Selleck	99.41	CC(C)Cc1ccc(cc1)[C@@H](C)C(O)=O |&1:10,r|, CC(C)Cc1ccc(cc1)[C@@H](C)C(O)=O |&1:10,r|	Launched
ibuprofen-(S)	cyclooxygenase inhibitor	ASIC1, PTGS1, PTGS2, SLC5A8	neurology/psychiatry	pain relief	Tocris, MicroSource, Tocris	99.44	CC(C)Cc1ccc(cc1)[C@H](C)C(O)=O, CC(C)Cc1ccc(cc1)[C@H](C)C(O)=O, CC(C)Cc1ccc(cc1)[C@H](C)C(O)=O	Launched
ibuprofen-lysine	cyclooxygenase inhibitor		cardiology	patent ductus arteriosus (PDA)	Selleck, Selleck, Selleck, Selleck	0	NCCCC[C@H](N)C(O)=O.CC(C)Cc1ccc(cc1)[C@@H](C)C(O)=O |a:5,&1:20|, NCCCC[C@H](N)C(O)=O.CC(C)Cc1ccc(cc1)[C@@H](C)C(O)=O |a:5,&1:20|, NCCCC[C@H](N)C(O)=O.CC(C)Cc1ccc(cc1)[C@@H](C)C(O)=O |a:5,&1:20|, NCCCC[C@H](N)C(O)=O.CC(C)Cc1ccc(cc1)[C@@H](C)C(O)=O |a:5,&1:20|	Launched
ibuprofen-piconol	cyclooxygenase inhibitor	PTGS1, PTGS2	neurology/psychiatry	pain relief	Enamine, Enamine, Enamine	95.32	CC(C)Cc1ccc(cc1)[C@@H](C)C(=O)OCc1ccccn1 |&1:10,r|, CC(C)Cc1ccc(cc1)[C@@H](C)C(=O)OCc1ccccn1 |&1:10,r|, CC(C)Cc1ccc(cc1)[C@@H](C)C(=O)OCc1ccccn1 |&1:10,r|	Launched
ibuproxam	cyclooxygenase inhibitor, prostaglandin inhibitor	ALOX5	endocrinology, rheumatology, neurology/psychiatry	fever, joint inflammation, pain relief	Enzo	80.93	CC(C)Cc1ccc(cc1)[C@@H](C)C(=O)NO |r|	Launched
ibutamoren	growth hormone secretagogue receptor agonist	GHR, GHSR			Tocris, Tocris, MedChemEx	94.74	CC(C)(N)C(=O)N[C@H](COCc1ccccc1)C(=O)N1CCC2(CN(c3ccccc23)S(C)(=O)=O)CC1, CC(C)(N)C(=O)N[C@H](COCc1ccccc1)C(=O)N1CCC2(CN(c3ccccc23)S(C)(=O)=O)CC1, CC(C)(N)C(=O)N[C@H](COCc1ccccc1)C(=O)N1CCC2(CN(c3ccccc23)S(C)(=O)=O)CC1	Phase 2
ibutilide	potassium channel blocker	CACNA1C, KCNH2	cardiology	atrial fibrillation (AF)	Tocris, Selleck, Tocris, Tocris, Tocris, Selleck, Selleck	98.7	CCCCCCCN(CC)CCC[C@@H](O)c1ccc(NS(C)(=O)=O)cc1 |&1:13|, CCCCCCCN(CC)CCC[C@@H](O)c1ccc(NS(C)(=O)=O)cc1 |&1:13|, CCCCCCCN(CC)CCC[C@@H](O)c1ccc(NS(C)(=O)=O)cc1 |&1:13|, CCCCCCCN(CC)CCC[C@@H](O)c1ccc(NS(C)(=O)=O)cc1 |&1:13|, CCCCCCCN(CC)CCC[C@@H](O)c1ccc(NS(C)(=O)=O)cc1 |&1:13|, CCCCCCCN(CC)CCC[C@@H](O)c1ccc(NS(C)(=O)=O)cc1 |&1:13|, CCCCCCCN(CC)CCC[C@@H](O)c1ccc(NS(C)(=O)=O)cc1 |&1:13|	Launched
ICA-069673	voltage-gated potassium channel activator	KCNQ2, KCNQ3			Tocris, Tocris, Tocris	96.8	Fc1ccc(cc1F)C(=O)Nc1cnc(Cl)nc1, Fc1ccc(cc1F)C(=O)Nc1cnc(Cl)nc1, Fc1ccc(cc1F)C(=O)Nc1cnc(Cl)nc1	Preclinical
ICA-110381	voltage-gated potassium channel activator	KCNQ2			Tocris, Tocris, Tocris	98	Clc1ccc(cc1)C(=O)Nc1ccc(Cl)nc1, Clc1ccc(cc1)C(=O)Nc1ccc(Cl)nc1, Clc1ccc(cc1)C(=O)Nc1ccc(Cl)nc1	Preclinical
ICA-121431	sodium channel blocker	SCN1A, SCN3A			Tocris, Stanley, Stanley, Stanley	99.45	O=C(Nc1ccc(cc1)S(=O)(=O)Nc1nccs1)C(c1ccccc1)c1ccccc1, O=C(Nc1ccc(cc1)S(=O)(=O)Nc1nccs1)C(c1ccccc1)c1ccccc1, O=C(Nc1ccc(cc1)S(=O)(=O)Nc1nccs1)C(c1ccccc1)c1ccccc1, O=C(Nc1ccc(cc1)S(=O)(=O)Nc1nccs1)C(c1ccccc1)c1ccccc1	Preclinical
icariin	phosphodiesterase inhibitor	PDE5A			MedChemEx, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck	93.32	COc1ccc(cc1)-c1oc2c(CC=C(C)C)c(O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)cc(O)c2c(=O)c1O[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O, COc1ccc(cc1)-c1oc2c(CC=C(C)C)c(O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)cc(O)c2c(=O)c1O[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O, COc1ccc(cc1)-c1oc2c(CC=C(C)C)c(O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)cc(O)c2c(=O)c1O[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O, COc1ccc(cc1)-c1oc2c(CC=C(C)C)c(O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)cc(O)c2c(=O)c1O[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O, COc1ccc(cc1)-c1oc2c(CC=C(C)C)c(O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)cc(O)c2c(=O)c1O[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O, COc1ccc(cc1)-c1oc2c(CC=C(C)C)c(O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)cc(O)c2c(=O)c1O[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O, COc1ccc(cc1)-c1oc2c(CC=C(C)C)c(O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)cc(O)c2c(=O)c1O[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O, COc1ccc(cc1)-c1oc2c(CC=C(C)C)c(O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)cc(O)c2c(=O)c1O[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O	Phase 3
icaritin	PPAR receptor antagonist	PDE5A			MedChemEx, MedChemEx, Sigma	88.81	COc1ccc(cc1)-c1oc2c(CC=C(C)C)c(O)cc(O)c2c(=O)c1O, COc1ccc(cc1)-c1oc2c(CC=C(C)C)c(O)cc(O)c2c(=O)c1O, COc1ccc(cc1)-c1oc2c(CC=C(C)C)c(O)cc(O)c2c(=O)c1O	Phase 3
icatibant-acetate	bradykinin receptor antagonist	BDKRB2	cardiology	angioedema	MedChemEx, MedChemEx, MedChemEx, MedChemEx	95.63	N[C@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N1C[C@H](O)C[C@H]1C(=O)NCC(=O)N[C@@H](Cc1cccs1)C(=O)N[C@@H](CO)C(=O)N1Cc2ccccc2C[C@@H]1C(=O)N1[C@H]2CCCC[C@H]2C[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(O)=O, N[C@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N1C[C@H](O)C[C@H]1C(=O)NCC(=O)N[C@@H](Cc1cccs1)C(=O)N[C@@H](CO)C(=O)N1Cc2ccccc2C[C@@H]1C(=O)N1[C@H]2CCCC[C@H]2C[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(O)=O, N[C@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N1C[C@H](O)C[C@H]1C(=O)NCC(=O)N[C@@H](Cc1cccs1)C(=O)N[C@@H](CO)C(=O)N1Cc2ccccc2C[C@@H]1C(=O)N1[C@H]2CCCC[C@H]2C[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(O)=O, N[C@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N1C[C@H](O)C[C@H]1C(=O)NCC(=O)N[C@@H](Cc1cccs1)C(=O)N[C@@H](CO)C(=O)N1Cc2ccccc2C[C@@H]1C(=O)N1[C@H]2CCCC[C@H]2C[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(O)=O	Launched
ICG-001	beta-catenin inhibitor	CTNNB1			Tocris	91.46	Oc1ccc(C[C@@H]2N3[C@H](CN(Cc4cccc5ccccc45)C2=O)N(CCC3=O)C(=O)NCc2ccccc2)cc1	Preclinical
ICI-118,551	adrenergic receptor antagonist	ADRB2, ADRB3			Tocris, Tocris, Tocris	97.18	CC(C)N[C@@H](C)[C@H](O)COc1ccc(C)c2CCCc12, CC(C)N[C@@H](C)[C@H](O)COc1ccc(C)c2CCCc12, CC(C)N[C@@H](C)[C@H](O)COc1ccc(C)c2CCCc12	Phase 2
ICI-162846	histamine receptor antagonist	HRH2			Tocris, Tocris	91.43	NC(=O)CCCCn1ccc(NC(=N)NCC(F)(F)F)n1, NC(=O)CCCCn1ccc(NC(=N)NCC(F)(F)F)n1	Phase 1
ICI-169369	serotonin receptor antagonist				Sigma	90.63	CN(C)CCSc1nc2ccccc2cc1-c1ccccc1	Phase 2
ICI-185,282	thromboxane receptor antagonist				Tocris, Tocris, Tocris	96.78	OC(=O)CCC\C=C/C[C@@H]1CO[C@@H](O[C@@H]1c1ccccc1O)C(F)(F)F, OC(=O)CCC\C=C/C[C@@H]1CO[C@@H](O[C@@H]1c1ccccc1O)C(F)(F)F, OC(=O)CCC\C=C/C[C@@H]1CO[C@@H](O[C@@H]1c1ccccc1O)C(F)(F)F	Phase 1
ICI-192605	thromboxane receptor antagonist	TBXA2R			Tocris, Tocris, Tocris	96.71	OC(=O)CC\C=C/C[C@@H]1CO[C@@H](O[C@@H]1c1ccccc1O)c1ccccc1Cl, OC(=O)CC\C=C/C[C@@H]1CO[C@@H](O[C@@H]1c1ccccc1O)c1ccccc1Cl, OC(=O)CC\C=C/C[C@@H]1CO[C@@H](O[C@@H]1c1ccccc1O)c1ccccc1Cl	Phase 2
ICI-199441	opioid receptor agonist	CYP2D6, OPRD1, OPRK1, OPRM1, UTS2R			Tocris, Tocris, Tocris	97.12	CN([C@H](CN1CCCC1)c1ccccc1)C(=O)Cc1ccc(Cl)c(Cl)c1, CN([C@H](CN1CCCC1)c1ccccc1)C(=O)Cc1ccc(Cl)c(Cl)c1, CN([C@H](CN1CCCC1)c1ccccc1)C(=O)Cc1ccc(Cl)c(Cl)c1	Preclinical
ICI-215,001	adrenergic receptor agonist	ADRB3			Tocris	98.33	O[C@@H](CNCCOc1ccc(OCC(O)=O)cc1)COc1ccccc1	Preclinical
ICI-63197	phosphodiesterase inhibitor				Tocris, Tocris, Tocris, Tocris	97.43	CCCn1c2nc(N)nn2cc(C)c1=O, CCCn1c2nc(N)nn2cc(C)c1=O, CCCn1c2nc(N)nn2cc(C)c1=O, CCCn1c2nc(N)nn2cc(C)c1=O	Preclinical
ICI-89406	adrenergic receptor antagonist	ADRB1, ADRB2			Tocris, Tocris	93.98	O[C@@H](CNCCNC(=O)Nc1ccccc1)COc1ccccc1C#N |&1:1,r|, O[C@@H](CNCCNC(=O)Nc1ccccc1)COc1ccccc1C#N |&1:1,r|	Phase 1
icilin	TRPV agonist	TRPA1, TRPM8			Tocris	10.14	Oc1ccccc1N1CC=C(NC1=O)c1cccc(c1)[N+]([O-])=O |c:10|	Phase 1
iclaprim	dihydrofolate reductase inhibitor				MedChemEx	98.18	COc1cc(Cc2cnc(N)nc2N)c2C=C[C@H](Oc2c1OC)C1CC1 |&1:17,r,c:16|	Phase 3
icomucret	mucin production enhancer	LTB4R2			Enzo	44	CCCCC[C@H](O)\C=C\C=C/C\C=C/C\C=C/CCCC(O)=O	Phase 3
icosapent	platelet aggregation inhibitor	ACSL3, ACSL4, FADS1, FFAR1, PPARD, PPARG, PTGS1, PTGS2, SLC8A1, TRPV1	endocrinology	hypertriglyceridemia	Enzo, Enzo, Sigma, Sigma	87.46	CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O, CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O, CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O, CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O	Launched
icotinib	EGFR inhibitor	EGFR	oncology	non-small cell lung cancer (NSCLC)	MedChemEx, Selleck, Selleck, Selleck	96.95	C#Cc1cccc(Nc2ncnc3cc4OCCOCCOCCOc4cc23)c1, C#Cc1cccc(Nc2ncnc3cc4OCCOCCOCCOc4cc23)c1, C#Cc1cccc(Nc2ncnc3cc4OCCOCCOCCOc4cc23)c1, C#Cc1cccc(Nc2ncnc3cc4OCCOCCOCCOc4cc23)c1	Launched
iCRT-14	beta catenin inhibitor, WNT signaling inhibitor	CTNNB1, TCF4			Tocris, Tocris	93.93	Cc1cc(\C=C2/SC(=O)N(C2=O)c2ccccc2)c(C)n1-c1cccnc1, Cc1cc(\C=C2/SC(=O)N(C2=O)c2ccccc2)c(C)n1-c1cccnc1	Preclinical
IC261	casein kinase inhibitor	CSNK1A1, CSNK1D, CSNK1E, CSNK1G2			MedChemEx, MedChemEx	74.58	COc1cc(OC)c(\C=C2\C(=O)Nc3ccccc23)c(OC)c1, COc1cc(OC)c(\C=C2\C(=O)Nc3ccccc23)c(OC)c1	Preclinical
ID-1101	insulin sensitizer	INS			Sigma, Sigma	78.9	C[C@H](O)[C@H](C)[C@H](N)C(O)=O, C[C@H](O)[C@H](C)[C@H](N)C(O)=O	Phase 1
ID-8					Tocris, Tocris, Selleck, Selleck, Selleck, Selleck, Tocris	98.74	COc1ccc(cc1)-n1c(C)c([N+]([O-])=O)c2ccc(O)cc12, COc1ccc(cc1)-n1c(C)c([N+]([O-])=O)c2ccc(O)cc12, COc1ccc(cc1)-n1c(C)c([N+]([O-])=O)c2ccc(O)cc12, COc1ccc(cc1)-n1c(C)c([N+]([O-])=O)c2ccc(O)cc12, COc1ccc(cc1)-n1c(C)c([N+]([O-])=O)c2ccc(O)cc12, COc1ccc(cc1)-n1c(C)c([N+]([O-])=O)c2ccc(O)cc12, COc1ccc(cc1)-n1c(C)c([N+]([O-])=O)c2ccc(O)cc12	Preclinical
idalopirdine	serotonin receptor antagonist	HTR6			MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx	97.15	FC(F)C(F)(F)COc1cccc(CNCCc2c[nH]c3cc(F)ccc23)c1, FC(F)C(F)(F)COc1cccc(CNCCc2c[nH]c3cc(F)ccc23)c1, FC(F)C(F)(F)COc1cccc(CNCCc2c[nH]c3cc(F)ccc23)c1, FC(F)C(F)(F)COc1cccc(CNCCc2c[nH]c3cc(F)ccc23)c1, FC(F)C(F)(F)COc1cccc(CNCCc2c[nH]c3cc(F)ccc23)c1	Phase 3
idarubicin	topoisomerase inhibitor	TOP2A	hematologic malignancy	acute myeloid leukemia (AML)	Selleck, Selleck, Selleck, Selleck, Selleck	98.01	C[C@@H]1O[C@H](C[C@H](N)[C@@H]1O)O[C@H]1C[C@@](O)(Cc2c(O)c3C(=O)c4ccccc4C(=O)c3c(O)c12)C(C)=O, C[C@@H]1O[C@H](C[C@H](N)[C@@H]1O)O[C@H]1C[C@@](O)(Cc2c(O)c3C(=O)c4ccccc4C(=O)c3c(O)c12)C(C)=O, C[C@@H]1O[C@H](C[C@H](N)[C@@H]1O)O[C@H]1C[C@@](O)(Cc2c(O)c3C(=O)c4ccccc4C(=O)c3c(O)c12)C(C)=O, C[C@@H]1O[C@H](C[C@H](N)[C@@H]1O)O[C@H]1C[C@@](O)(Cc2c(O)c3C(=O)c4ccccc4C(=O)c3c(O)c12)C(C)=O, C[C@@H]1O[C@H](C[C@H](N)[C@@H]1O)O[C@H]1C[C@@](O)(Cc2c(O)c3C(=O)c4ccccc4C(=O)c3c(O)c12)C(C)=O	Launched
idasanutlin	MDM inhibitor	MDM2, TP53			MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx, Cayman, Cayman	98.5	COc1cc(ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@@](C#N)([C@H]1c1cccc(Cl)c1F)c1ccc(Cl)cc1F)C(O)=O, COc1cc(ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@@](C#N)([C@H]1c1cccc(Cl)c1F)c1ccc(Cl)cc1F)C(O)=O, COc1cc(ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@@](C#N)([C@H]1c1cccc(Cl)c1F)c1ccc(Cl)cc1F)C(O)=O, COc1cc(ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@@](C#N)([C@H]1c1cccc(Cl)c1F)c1ccc(Cl)cc1F)C(O)=O, COc1cc(ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@@](C#N)([C@H]1c1cccc(Cl)c1F)c1ccc(Cl)cc1F)C(O)=O, COc1cc(ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@@](C#N)([C@H]1c1cccc(Cl)c1F)c1ccc(Cl)cc1F)C(O)=O, COc1cc(ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@@](C#N)([C@H]1c1cccc(Cl)c1F)c1ccc(Cl)cc1F)C(O)=O, COc1cc(ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@@](C#N)([C@H]1c1cccc(Cl)c1F)c1ccc(Cl)cc1F)C(O)=O	Phase 3
idazoxan	adrenergic receptor antagonist	ADRA2A, PTGS2			AMS, MicroSource, Tocris	96.56	C1CN=C(N1)[C@H]1COc2ccccc2O1 |r,c:2|, C1CN=C(N1)[C@H]1COc2ccccc2O1 |r,c:2|, C1CN=C(N1)[C@H]1COc2ccccc2O1 |r,c:2|	Phase 3
idebenone	calcium channel modulator		neurology/psychiatry, ophthalmology	Alzheimer's disease, Friedreich's ataxia, Leber hereditary optic neuropathy (LHON)	MicroSource, MicroSource, Selleck, Tocris, Tocris, Tocris, Selleck	96.59	COC1=C(OC)C(=O)C(CCCCCCCCCCO)=C(C)C1=O |c:2,t:19|, COC1=C(OC)C(=O)C(CCCCCCCCCCO)=C(C)C1=O |c:2,t:19|, COC1=C(OC)C(=O)C(CCCCCCCCCCO)=C(C)C1=O |c:2,t:19|, COC1=C(OC)C(=O)C(CCCCCCCCCCO)=C(C)C1=O |c:2,t:19|, COC1=C(OC)C(=O)C(CCCCCCCCCCO)=C(C)C1=O |c:2,t:19|, COC1=C(OC)C(=O)C(CCCCCCCCCCO)=C(C)C1=O |c:2,t:19|, COC1=C(OC)C(=O)C(CCCCCCCCCCO)=C(C)C1=O |c:2,t:19|	Launched
idelalisib	PI3K inhibitor	PIK3CA, PIK3CB, PIK3CD, PIK3CG	hematologic malignancy	chronic lymphocytic leukemia (CLL)	Selleck, Selleck, Selleck, Selleck	96.97	CC[C@H](Nc1ncnc2nc[nH]c12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1, CC[C@H](Nc1ncnc2nc[nH]c12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1, CC[C@H](Nc1ncnc2nc[nH]c12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1, CC[C@H](Nc1ncnc2nc[nH]c12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1	Launched
IDF-11774	hypoxia inducible factor inhibitor				MedChemEx	91.96	CN1CCN(CC1)C(=O)COc1ccc(cc1)C12CC3CC(CC(C3)C1)C2	Preclinical
IDH-305	isocitrate dehydrogenase inhibitor				MedChemEx	95.98	C[C@H](F)[C@H]1COC(=O)N1c1ccnc(N[C@@H](C)c2cc(C)c(cn2)-c2ccnc(c2)C(F)(F)F)n1	Phase 2
idoxuridine	DNA directed DNA polymerase inhibitor, DNA synthesis inhibitor		infectious disease	virus herpes simplex (HSV)	MedChemEx, Selleck, Selleck, MicroSource, MicroSource	100	OC[C@H]1O[C@H](C[C@@H]1O)n1cc(I)c(=O)[nH]c1=O, OC[C@H]1O[C@H](C[C@@H]1O)n1cc(I)c(=O)[nH]c1=O, OC[C@H]1O[C@H](C[C@@H]1O)n1cc(I)c(=O)[nH]c1=O, OC[C@H]1O[C@H](C[C@@H]1O)n1cc(I)c(=O)[nH]c1=O, OC[C@H]1O[C@H](C[C@@H]1O)n1cc(I)c(=O)[nH]c1=O	Launched
IDO5L	indoleamine 2,3-dioxygenase inhibitor	IDO1			MedChemEx, MedChemEx, MedChemEx	95.26	Nc1nonc1\C(NO)=N/c1ccc(F)c(Cl)c1, Nc1nonc1\C(NO)=N/c1ccc(F)c(Cl)c1, Nc1nonc1\C(NO)=N/c1ccc(F)c(Cl)c1	Preclinical
IDRA-21	glutamate receptor positive allosteric modulator	GRIA1, GRIA2, GRIA3, GRIA4			Tocris, Tocris, Tocris, Tocris, Tocris	97.41	C[C@H]1Nc2ccc(Cl)cc2S(=O)(=O)N1 |&1:1,r|, C[C@H]1Nc2ccc(Cl)cc2S(=O)(=O)N1 |&1:1,r|, C[C@H]1Nc2ccc(Cl)cc2S(=O)(=O)N1 |&1:1,r|, C[C@H]1Nc2ccc(Cl)cc2S(=O)(=O)N1 |&1:1,r|, C[C@H]1Nc2ccc(Cl)cc2S(=O)(=O)N1 |&1:1,r|	Preclinical
idramantone					MedChemEx	100	[H][C@@]12C[C@@]3([H])C[C@@](O)(C1)C[C@@]([H])(C2)C3=O |&1:1,3,6,10|	Preclinical
idronoxil	XIAP inhibitor	ENOX2, SPHK1			Sigma, Sigma, Sigma	92.71	Oc1ccc(cc1)C1=Cc2ccc(O)cc2OC1 |t:8|, Oc1ccc(cc1)C1=Cc2ccc(O)cc2OC1 |t:8|, Oc1ccc(cc1)C1=Cc2ccc(O)cc2OC1 |t:8|	Phase 3
IEM1460	glutamate receptor antagonist	GRIA2			Tocris, Tocris, Tocris, Tocris, Tocris	100	C[N+](C)(C)CCCCCNCC12CC3CC(CC(C3)C1)C2, C[N+](C)(C)CCCCCNCC12CC3CC(CC(C3)C1)C2, C[N+](C)(C)CCCCCNCC12CC3CC(CC(C3)C1)C2, C[N+](C)(C)CCCCCNCC12CC3CC(CC(C3)C1)C2, C[N+](C)(C)CCCCCNCC12CC3CC(CC(C3)C1)C2	Preclinical
IEM1754	glutamate receptor antagonist	GRIA1			Selleck, Selleck, Tocris, Tocris	100	NCCCCCNCC12CC3CC(CC(C3)C1)C2, NCCCCCNCC12CC3CC(CC(C3)C1)C2, NCCCCCNCC12CC3CC(CC(C3)C1)C2, NCCCCCNCC12CC3CC(CC(C3)C1)C2	Preclinical
ifenprodil	adrenergic receptor antagonist, glutamate receptor antagonist	GRIN2B			Tocris	94.12	C[C@@H]([C@H](O)c1ccc(O)cc1)N1CCC(Cc2ccccc2)CC1 |&1:1,2|	Launched
ifosfamide	DNA alkylating agent	CYP2A6, CYP2B6, CYP2C18, CYP2C19, CYP2C8, CYP2C9, CYP3A4, CYP3A5, CYP3A7, PTGS1	oncology, urology	testicular carcinoma, hemorrhagic cystitis	MicroSource, Selleck	100	ClCCN[P@@]1(=O)OCCCN1CCCl |r|, ClCCN[P@@]1(=O)OCCCN1CCCl |r|	Launched
igmesine	sigma receptor agonist	SIGMAR1			Tocris, Tocris	95.83	CCC(C\C=C\c1ccccc1)(N(C)CC1CC1)c1ccccc1 |&1:2|, CCC(C\C=C\c1ccccc1)(N(C)CC1CC1)c1ccccc1 |&1:2|	Phase 2
iguratimod	cyclooxygenase inhibitor, NFkB pathway inhibitor	PTGS2	rheumatology	rheumatoid arthritis	MedChemEx, MedChemEx	96.01	CS(=O)(=O)Nc1cc2occ(NC=O)c(=O)c2cc1Oc1ccccc1, CS(=O)(=O)Nc1cc2occ(NC=O)c(=O)c2cc1Oc1ccccc1	Launched
IKK-16	IKK inhibitor	IKBKB			Tocris, Tocris, Tocris, Tocris, Tocris, Tocris, Tocris, Selleck	95.84	O=C(N1CCC(CC1)N1CCCC1)c1ccc(Nc2nccc(n2)-c2cc3ccccc3s2)cc1, O=C(N1CCC(CC1)N1CCCC1)c1ccc(Nc2nccc(n2)-c2cc3ccccc3s2)cc1, O=C(N1CCC(CC1)N1CCCC1)c1ccc(Nc2nccc(n2)-c2cc3ccccc3s2)cc1, O=C(N1CCC(CC1)N1CCCC1)c1ccc(Nc2nccc(n2)-c2cc3ccccc3s2)cc1, O=C(N1CCC(CC1)N1CCCC1)c1ccc(Nc2nccc(n2)-c2cc3ccccc3s2)cc1, O=C(N1CCC(CC1)N1CCCC1)c1ccc(Nc2nccc(n2)-c2cc3ccccc3s2)cc1, O=C(N1CCC(CC1)N1CCCC1)c1ccc(Nc2nccc(n2)-c2cc3ccccc3s2)cc1, O=C(N1CCC(CC1)N1CCCC1)c1ccc(Nc2nccc(n2)-c2cc3ccccc3s2)cc1	Preclinical
IKK-2-inhibitor	IKK inhibitor, SYK inhibitor	IKBKB			Tocris, Selleck, Selleck, Selleck	94.68	NC(=O)c1sc(cc1N)-c1ccsc1, NC(=O)c1sc(cc1N)-c1ccsc1, NC(=O)c1sc(cc1N)-c1ccsc1, NC(=O)c1sc(cc1N)-c1ccsc1	Preclinical
IKK-2-inhibitor-V	IKK inhibitor, NFkB pathway inhibitor	IKBKB			Tocris, Selleck, Selleck, Selleck, Selleck	97.99	Oc1ccc(Cl)cc1C(=O)Nc1cc(cc(c1)C(F)(F)F)C(F)(F)F, Oc1ccc(Cl)cc1C(=O)Nc1cc(cc(c1)C(F)(F)F)C(F)(F)F, Oc1ccc(Cl)cc1C(=O)Nc1cc(cc(c1)C(F)(F)F)C(F)(F)F, Oc1ccc(Cl)cc1C(=O)Nc1cc(cc(c1)C(F)(F)F)C(F)(F)F, Oc1ccc(Cl)cc1C(=O)Nc1cc(cc(c1)C(F)(F)F)C(F)(F)F	Phase 1
ilaprazole	proton pump inhibitor		gastroenterology	gastroesophageal reflux disease (GERD)	MedChemEx	41.08	COc1ccnc(C[S@@](=O)c2nc3ccc(cc3[nH]2)-n2cccc2)c1C |&1:8,r|	Launched
ilepcimide	anticonvulsant				Vitas-M	95.17	O=C(\C=C\c1ccc2OCOc2c1)N1CCCCC1	Phase 3
ilomastat	matrix metalloprotease inhibitor	ACAN, ADAM28, MMP1, MMP12, MMP13, MMP14, MMP2, MMP3, MMP8, MMP9			Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck	94.49	CNC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(C)C)CC(=O)NO, CNC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(C)C)CC(=O)NO, CNC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(C)C)CC(=O)NO, CNC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(C)C)CC(=O)NO, CNC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(C)C)CC(=O)NO, CNC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(C)C)CC(=O)NO, CNC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(C)C)CC(=O)NO	Phase 3
iloperidone	dopamine receptor antagonist, serotonin receptor antagonist	ADRA1A, ADRA2C, DRD1, DRD2, DRD3, DRD4, HRH1, HTR1A, HTR2A, HTR6, HTR7	neurology/psychiatry	schizophrenia	Selleck	97.56	COc1cc(ccc1OCCCN1CCC(CC1)c1noc2cc(F)ccc12)C(C)=O	Launched
iloprost	platelet aggregation inhibitor, prostanoid receptor agonist	PTGDR, PTGER1, PTGER2, PTGER3, PTGER4, PTGFR, PTGIR, TBXA2R	pulmonary	pulmonary arterial hypertension (PAH)	MedChemEx	50.79	CC#CC[C@@H](C)[C@H](O)\C=C\[C@H]1[C@H](O)C[C@@H]2C\C(C[C@H]12)=C/CCCC(O)=O |a:6,10,11,14,18,&1:4|	Launched
imatinib	Bcr-Abl kinase inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor	ABL1, CSF1R, DDR1, KIT, NTRK1, PDGFRA, PDGFRB, RET	hematologic malignancy, oncology	chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), myelodysplastic diseases (MDS), aggressive systemic mastocytosis (ASM), hypereosinophilic syndrome (HES), chronic eosinophilic leukemia (CEL), dermatofibrosarcoma protuberans (DFSP), gastrointestinal stromal tumors (GIST)	Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, MedChemEx	99.23	CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1	Launched
Imazodan	phosphodiesterase inhibitor				AMS	91.48	O=C1CCC(=NN1)c1ccc(cc1)-n1ccnc1 |c:4|	Phase 1
imeglimin	gluconeogenesis inhibitor				MedChemEx, MedChemEx, MedChemEx	97.85	C[C@H]1NC(=NC(N)=N1)N(C)C |c:3,6|, C[C@H]1NC(=NC(N)=N1)N(C)C |c:3,6|, C[C@H]1NC(=NC(N)=N1)N(C)C |c:3,6|	Phase 2
imetit	histamine receptor agonist	HRH3, HRH4			Tocris, Tocris	90.26	NC(=N)SCCc1cnc[nH]1, NC(=N)SCCc1cnc[nH]1	Preclinical
imexon	apoptosis stimulant, ribonucleotide reductase inhibitor				MicroSource, MicroSource, MicroSource, MicroSource	100	NC1=NC(=O)N2C[C@@H]12 |r,t:1|, NC1=NC(=O)N2C[C@@H]12 |r,t:1|, NC1=NC(=O)N2C[C@@H]12 |r,t:1|, NC1=NC(=O)N2C[C@@H]12 |r,t:1|	Phase 2
imidacloprid	acetylcholine receptor antagonist				SantaCruz	99.22	[O-][N+](=O)N=C1NCCN1Cc1ccc(Cl)nc1	Launched
imidafenacin	acetylcholine receptor antagonist	CHRM1, CHRM3	neurology/psychiatry	spasms	MedChemEx, MedChemEx, MedChemEx	97.97	Cc1nccn1CCC(C(N)=O)(c1ccccc1)c1ccccc1, Cc1nccn1CCC(C(N)=O)(c1ccccc1)c1ccccc1, Cc1nccn1CCC(C(N)=O)(c1ccccc1)c1ccccc1	Launched
imidapril	angiotensin converting enzyme inhibitor	ACE	cardiology	hypertension, congestive heart failure	Selleck, Selleck	98.03	CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1[C@@H](CN(C)C1=O)C(O)=O, CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1[C@@H](CN(C)C1=O)C(O)=O	Launched
imidazoacridinone	anticancer agent				Sigma	57.63	CCN(CC)CCNc1ccc2ncn3c2c1c(=O)c1cc(O)ccc31	Preclinical
imidurea	other antibiotic				MedChemEx	100	OCN1[C@@H](NC(=O)NCNC(=O)N[C@@H]2N(CO)C(=O)NC2=O)C(=O)NC1=O |&1:3,&2:13,r|	Preclinical
imiloxan	adrenergic receptor antagonist	ADRA2A, ADRA2B			Tocris, Tocris	97.18	CCn1ccnc1C[C@H]1COc2ccccc2O1 |&1:8|, CCn1ccnc1C[C@H]1COc2ccccc2O1 |&1:8|	Phase 1
imipenem	bacterial cell wall synthesis inhibitor		infectious disease	pneumonia, urinary tract infections, intra-abdominal infections, gynecologic infections, bacterial septicemia, bone and joint infections, skin infections, endocarditis	MicroSource, Sigma	0	C[C@@H](O)[C@@H]1[C@H]2CC(SCCNC=N)=C(N2C1=O)C(O)=O |c:12|, C[C@@H](O)[C@@H]1[C@H]2CC(SCCNC=N)=C(N2C1=O)C(O)=O |c:12|	Launched
imipramine	norepinephrine reputake inhibitor, serotonin reuptake inhibitor	ADRA1A, ADRA1B, ADRA1D, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD1, DRD2, DRD5, HRH1, HTR1A, HTR2A, HTR2C, HTR6, HTR7, KCND2, KCND3, KCNH1, KCNH2, SLC6A2, SLC6A3, SLC6A4	neurology/psychiatry, urology	depression, nocturnal enuresis	Selleck, MicroSource, MicroSource, MicroSource, Selleck	92.52	CN(C)CCCN1c2ccccc2CCc2ccccc12, CN(C)CCCN1c2ccccc2CCc2ccccc12, CN(C)CCCN1c2ccccc2CCc2ccccc12, CN(C)CCCN1c2ccccc2CCc2ccccc12, CN(C)CCCN1c2ccccc2CCc2ccccc12	Launched
imiquimod	interferon inducer, toll-like receptor agonist	TLR7, TLR8	dermatology, infectious disease, oncology	actinic keratosis (AK), genital warts, basal cell carcinoma (BCC)	MicroSource, Selleck, Selleck, Selleck, Selleck	98.69	CC(C)Cn1cnc2c(N)nc3ccccc3c12, CC(C)Cn1cnc2c(N)nc3ccccc3c12, CC(C)Cn1cnc2c(N)nc3ccccc3c12, CC(C)Cn1cnc2c(N)nc3ccccc3c12, CC(C)Cn1cnc2c(N)nc3ccccc3c12	Launched
imirestat	aldose reductase inhibitor				MedChemEx	95.55	Fc1ccc2-c3ccc(F)cc3C3(NC(=O)NC3=O)c2c1	Preclinical
imisopasem-manganese	superoxide dismutase mimetic				MedChemEx	0	[H][C@@]12CCCC[C@@]1([H])N1Cc3cccc(CN4[C@]5([H])CCCC[C@@]5([H])N5CCN2[Mn]145(Cl)Cl)n3	Preclinical
immepip	histamine receptor agonist	HRH3, HRH4			Tocris, Tocris	91.38	C(C1CCNCC1)c1cnc[nH]1, C(C1CCNCC1)c1cnc[nH]1	Preclinical
immethridine	histamine receptor agonist	HRH3			Tocris, Tocris, Tocris	97.64	C(c1cnc[nH]1)c1ccncc1, C(c1cnc[nH]1)c1ccncc1, C(c1cnc[nH]1)c1ccncc1	Phase 1
impentamine	histamine receptor antagonist	HRH3			Tocris, Tocris, Tocris	87.55	NCCCCCc1cnc[nH]1, NCCCCCc1cnc[nH]1, NCCCCCc1cnc[nH]1	Preclinical
IMREG-1					ChemImpex, ChemImpex	97.29	N[C@@H](Cc1ccc(O)cc1)C(=O)NCC(=O)NCC(O)=O, N[C@@H](Cc1ccc(O)cc1)C(=O)NCC(=O)NCC(O)=O	Phase 3
inarigivir	antiviral				MedChemEx	61.1	CO[C@@H]1[C@H](O[P@](S)(=O)OC[C@H]2O[C@H](C[C@@H]2O)n2cnc3c(N)ncnc23)[C@@H](CO)O[C@H]1n1ccc(=O)[nH]c1=O |a:2,3,10,12,14,26,30,&1:5|	Phase 2
inarigivir-soproxil	antiviral				MedChemEx	93.11	[H][C@]1(O)C[C@@]([H])(O[C@]1([H])CO[P@](=O)(O[C@]1([H])[C@@]([H])(CO)O[C@@]([H])(n2ccc(=O)[nH]c2=O)[C@]1([H])OC)SCOC(=O)OC(C)C)n1cnc2c(N)ncnc12 |&1:11,r|	Phase 2
INC-280	c-Met inhibitor	MET			MedChemEx, Selleck, Selleck, Selleck, Selleck	95.86	CNC(=O)c1ccc(cc1F)-c1cnc2ncc(Cc3ccc4ncccc4c3)n2n1, CNC(=O)c1ccc(cc1F)-c1cnc2ncc(Cc3ccc4ncccc4c3)n2n1, CNC(=O)c1ccc(cc1F)-c1cnc2ncc(Cc3ccc4ncccc4c3)n2n1, CNC(=O)c1ccc(cc1F)-c1cnc2ncc(Cc3ccc4ncccc4c3)n2n1, CNC(=O)c1ccc(cc1F)-c1cnc2ncc(Cc3ccc4ncccc4c3)n2n1	Phase 3
INCA-6	calcineurin inhibitor	NFATC1			Tocris, Tocris, Tocris	58.26	O=C1C=CC(=O)C2=C1C1c3ccccc3C2c2ccccc12 |c:2,6|, O=C1C=CC(=O)C2=C1C1c3ccccc3C2c2ccccc12 |c:2,6|, O=C1C=CC(=O)C2=C1C1c3ccccc3C2c2ccccc12 |c:2,6|	Preclinical
INCB-003284	CC chemokine receptor antagonist				EMDBio	83.66	COc1ccc(cn1)C1(O)CCC(CC1)N1CC[C@H](C1)NC(=O)CNC(=O)c1cccc(c1)C(F)(F)F	Phase 2
INCB-057643	bromodomain inhibitor				MedChemEx	95.91	CN1C(=O)C(C)(C)Oc2c1cc(cc2-c1cn(C)c(O)c2nccc12)S(C)(=O)=O	Phase 1/Phase 2
INCB-3284	CC chemokine receptor antagonist	CCR2			MedChemEx, MedChemEx	92.32	COc1ccc(cn1)[C@]1(O)CC[C@@H](CC1)N1CC[C@H](C1)NC(=O)CNC(=O)c1cccc(c1)C(F)(F)F, COc1ccc(cn1)[C@]1(O)CC[C@@H](CC1)N1CC[C@H](C1)NC(=O)CNC(=O)c1cccc(c1)C(F)(F)F	Phase 2
incyclinide	matrix metalloprotease inhibitor				MedChemEx	92.17	[H][C@@]12Cc3cccc(O)c3C(=O)[C@@H]1C(=O)[C@]1(O)C(=O)[C@H](C(N)=O)C(=O)C[C@]1([H])C2 |&1:19,&2:12|	Phase 2
indacaterol	adrenergic receptor agonist	ADRB1, ADRB2	pulmonary	chronic obstructive pulmonary disease (COPD)	MedChemEx, Selleck	98.27	CCc1cc2CC(Cc2cc1CC)NC[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12, CCc1cc2CC(Cc2cc1CC)NC[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12	Launched
indalpine	selective serotonin reuptake inhibitor (SSRI)	SLC6A4			Sigma, Sigma	90.29	C(Cc1c[nH]c2ccccc12)C1CCNCC1, C(Cc1c[nH]c2ccccc12)C1CCNCC1	Withdrawn
indapamide	thiazide diuretic	CA2, HTR3A, KCNQ1	cardiology	hypertension, congestive heart failure	MedChemEx, MedChemEx, MicroSource, Selleck	99.2	C[C@H]1Cc2ccccc2N1NC(=O)c1ccc(Cl)c(c1)S(N)(=O)=O |&1:1,r|, C[C@H]1Cc2ccccc2N1NC(=O)c1ccc(Cl)c(c1)S(N)(=O)=O |&1:1,r|, C[C@H]1Cc2ccccc2N1NC(=O)c1ccc(Cl)c(c1)S(N)(=O)=O |&1:1,r|, C[C@H]1Cc2ccccc2N1NC(=O)c1ccc(Cl)c(c1)S(N)(=O)=O |&1:1,r|	Launched
indatraline	norepinephrine transporter inhibitor	MAOA, MAOB			Tocris, Tocris, Tocris, Tocris, Tocris	96.95	CN[C@@H]1C[C@H](c2ccccc12)c1ccc(Cl)c(Cl)c1, CN[C@@H]1C[C@H](c2ccccc12)c1ccc(Cl)c(Cl)c1, CN[C@@H]1C[C@H](c2ccccc12)c1ccc(Cl)c(Cl)c1, CN[C@@H]1C[C@H](c2ccccc12)c1ccc(Cl)c(Cl)c1, CN[C@@H]1C[C@H](c2ccccc12)c1ccc(Cl)c(Cl)c1	Preclinical
indeglitazar	PPAR receptor agonist	NCOA1, PPARA, PPARD, PPARG			MedChemEx	97.99	COc1ccc(cc1)S(=O)(=O)n1cc(CCC(O)=O)c2cc(OC)ccc12	Phase 2
indeloxazine	norepinephrine reuptake inhibitor, serotonin reuptake inhibitor				Sigma	99.26	C(Oc1cccc2C=CCc12)[C@H]1CNCCO1 |&1:11,c:7|	Withdrawn
indibulin	tubulin polymerization inhibitor				AMS, Vitas-M, Vitas-M, SantaCruz	98.47	Clc1ccc(Cn2cc(C(=O)C(=O)Nc3ccncc3)c3ccccc23)cc1, Clc1ccc(Cn2cc(C(=O)C(=O)Nc3ccncc3)c3ccccc23)cc1, Clc1ccc(Cn2cc(C(=O)C(=O)Nc3ccncc3)c3ccccc23)cc1, Clc1ccc(Cn2cc(C(=O)C(=O)Nc3ccncc3)c3ccccc23)cc1	Phase 1/Phase 2
indinavir	HIV protease inhibitor	CYP3A4, CYP3A5, CYP3A7	infectious disease	human immunodeficiency virus (HIV-1)	Enzo, Enzo, Enzo, Enzo, Enzo, Enzo, MedChemEx	98.44	CC(C)(C)NC(=O)[C@@H]1CN(Cc2cccnc2)CCN1C[C@@H](O)C[C@@H](Cc1ccccc1)C(=O)N[C@@H]1[C@H](O)Cc2ccccc12, CC(C)(C)NC(=O)[C@@H]1CN(Cc2cccnc2)CCN1C[C@@H](O)C[C@@H](Cc1ccccc1)C(=O)N[C@@H]1[C@H](O)Cc2ccccc12, CC(C)(C)NC(=O)[C@@H]1CN(Cc2cccnc2)CCN1C[C@@H](O)C[C@@H](Cc1ccccc1)C(=O)N[C@@H]1[C@H](O)Cc2ccccc12, CC(C)(C)NC(=O)[C@@H]1CN(Cc2cccnc2)CCN1C[C@@H](O)C[C@@H](Cc1ccccc1)C(=O)N[C@@H]1[C@H](O)Cc2ccccc12, CC(C)(C)NC(=O)[C@@H]1CN(Cc2cccnc2)CCN1C[C@@H](O)C[C@@H](Cc1ccccc1)C(=O)N[C@@H]1[C@H](O)Cc2ccccc12, CC(C)(C)NC(=O)[C@@H]1CN(Cc2cccnc2)CCN1C[C@@H](O)C[C@@H](Cc1ccccc1)C(=O)N[C@@H]1[C@H](O)Cc2ccccc12, CC(C)(C)NC(=O)[C@@H]1CN(Cc2cccnc2)CCN1C[C@@H](O)C[C@@H](Cc1ccccc1)C(=O)N[C@@H]1[C@H](O)Cc2ccccc12	Launched
indiplon	benzodiazepine receptor agonist	GABRA1			Tocris, Tocris, Tocris, Tocris, Tocris	99.26	CN(C(C)=O)c1cccc(c1)-c1ccnc2c(cnn12)C(=O)c1cccs1, CN(C(C)=O)c1cccc(c1)-c1ccnc2c(cnn12)C(=O)c1cccs1, CN(C(C)=O)c1cccc(c1)-c1ccnc2c(cnn12)C(=O)c1cccs1, CN(C(C)=O)c1cccc(c1)-c1ccnc2c(cnn12)C(=O)c1cccs1, CN(C(C)=O)c1cccc(c1)-c1ccnc2c(cnn12)C(=O)c1cccs1	Phase 3
indirubin	CDK inhibitor, glycogen synthase kinase inhibitor	CDK1, CDK5, GSK3A			Selleck, Selleck, Selleck	99.41	O=C1Nc2ccccc2\C1=C1\Nc2ccccc2C1=O, O=C1Nc2ccccc2\C1=C1\Nc2ccccc2C1=O, O=C1Nc2ccccc2\C1=C1\Nc2ccccc2C1=O	Phase 2/Phase 3
indirubin-3-monoxime	CDK inhibitor, glycogen synthase kinase inhibitor	CDK1, CDK2, CDK5, CDK5R1, GSK3B			Tocris, Tocris, Tocris	97.75	O\N=C1\C(\Nc2ccccc\12)=C1\C(=O)Nc2ccccc12, O\N=C1\C(\Nc2ccccc\12)=C1\C(=O)Nc2ccccc12, O\N=C1\C(\Nc2ccccc\12)=C1\C(=O)Nc2ccccc12	Preclinical
indisulam	CDK inhibitor	CA1, CA12, CA14, CA2, CA6, CA7, CA9			Sigma, Sigma, Sigma, Sigma	98.25	NS(=O)(=O)c1ccc(cc1)S(=O)(=O)Nc1cccc2c(Cl)c[nH]c12, NS(=O)(=O)c1ccc(cc1)S(=O)(=O)Nc1cccc2c(Cl)c[nH]c12, NS(=O)(=O)c1ccc(cc1)S(=O)(=O)Nc1cccc2c(Cl)c[nH]c12, NS(=O)(=O)c1ccc(cc1)S(=O)(=O)Nc1cccc2c(Cl)c[nH]c12	Phase 2
indium(III)-isopropoxide					AlfaAesar	0	[In].CC(C)O.CC(C)O.CC(C)O	Preclinical
indium-tri(2-propanolate)					AlfaAesar	0	CC(C)O[In](OC(C)C)OC(C)C	Preclinical
indobufen	cyclooxygenase inhibitor, platelet aggregation inhibitor	PTGS1, PTGS2	hematology	thrombosis	AKSci	99.21	CC[C@@H](C(O)=O)c1ccc(cc1)N1Cc2ccccc2C1=O |&1:2,r|	Launched
indocyanine-green	contrast agent	SLCO1B1	cardiology	vascular imaging agent	Sigma, MedChemEx, MedChemEx, MedChemEx	92.75	CC1(C)\C(=C/C=C/C=C/C=C/C2=[N+](CCCCS(O)(=O)=O)c3ccc4ccccc4c3C2(C)C)N(CCCCS(O)(=O)=O)c2ccc3ccccc3c12 |c:11|, CC1(C)\C(=C/C=C/C=C/C=C/C2=[N+](CCCCS(O)(=O)=O)c3ccc4ccccc4c3C2(C)C)N(CCCCS(O)(=O)=O)c2ccc3ccccc3c12 |c:11|, CC1(C)\C(=C/C=C/C=C/C=C/C2=[N+](CCCCS(O)(=O)=O)c3ccc4ccccc4c3C2(C)C)N(CCCCS(O)(=O)=O)c2ccc3ccccc3c12 |c:11|, CC1(C)\C(=C/C=C/C=C/C=C/C2=[N+](CCCCS(O)(=O)=O)c3ccc4ccccc4c3C2(C)C)N(CCCCS(O)(=O)=O)c2ccc3ccccc3c12 |c:11|	Launched
indole-3-carbinol	aryl hydrocarbon receptor agonist, indoleamine 2,3-dioxygenase inhibitor	AHR			Selleck, Selleck	96.69	OCc1c[nH]c2ccccc12, OCc1c[nH]c2ccccc12	Phase 2/Phase 3
indole-3-pyrubate	melatonin receptor agonist				Sigma	0	OC(=O)C(O)=Cc1c[nH]c2ccccc12	Phase 2
indomethacin	cyclooxygenase inhibitor	GLO1, PLA2G2A, PPARA, PPARG, PTGDR2, PTGR2, PTGS1, PTGS2, SLC46A1	rheumatology, orthopedics	rheumatoid arthritis, ankylosing spondylitis, osteoarthritis, bursitis, tendinitis	Tocris, MicroSource, MicroSource, Selleck	99.45	COc1ccc2n(C(=O)c3ccc(Cl)cc3)c(C)c(CC(O)=O)c2c1, COc1ccc2n(C(=O)c3ccc(Cl)cc3)c(C)c(CC(O)=O)c2c1, COc1ccc2n(C(=O)c3ccc(Cl)cc3)c(C)c(CC(O)=O)c2c1, COc1ccc2n(C(=O)c3ccc(Cl)cc3)c(C)c(CC(O)=O)c2c1	Launched
indoprofen	cyclooxygenase inhibitor, prostanoid receptor antagonist	CXCR1, CXCR2, PTGS1, PTGS2			MicroSource, MicroSource, MicroSource, MicroSource, MedChemEx	99.31	C[C@@H](C(O)=O)c1ccc(cc1)N1Cc2ccccc2C1=O |&1:1,r|, C[C@@H](C(O)=O)c1ccc(cc1)N1Cc2ccccc2C1=O |&1:1,r|, C[C@@H](C(O)=O)c1ccc(cc1)N1Cc2ccccc2C1=O |&1:1,r|, C[C@@H](C(O)=O)c1ccc(cc1)N1Cc2ccccc2C1=O |&1:1,r|, C[C@@H](C(O)=O)c1ccc(cc1)N1Cc2ccccc2C1=O |&1:1,r|	Withdrawn
indoramin	adrenergic receptor antagonist	ADRA1A, ADRA1B, ADRA1D, ADRA2B, ADRA2C	urology, cardiology	benign prostatic hyperplasia (BPH), hypertension	Key, Key, Maybridge	98.41	O=C(NC1CCN(CCc2c[nH]c3ccccc23)CC1)c1ccccc1, O=C(NC1CCN(CCc2c[nH]c3ccccc23)CC1)c1ccccc1, O=C(NC1CCN(CCc2c[nH]c3ccccc23)CC1)c1ccccc1	Launched
indoximod	indoleamine 2,3-dioxygenase inhibitor	IDO1			Cayman, Cayman, Cayman, MedChemEx	98.79	Cn1cc(C[C@@H](N)C(O)=O)c2ccccc12, Cn1cc(C[C@@H](N)C(O)=O)c2ccccc12, Cn1cc(C[C@@H](N)C(O)=O)c2ccccc12, Cn1cc(C[C@@H](N)C(O)=O)c2ccccc12	Phase 2
ingenol	PKC activator	PRKCD, PRKCE	dermatology	keratosis	MedChemEx	95.71	[H][C@]12C=C(CO)[C@@H](O)[C@]3(O)[C@@H](O)C(C)=C[C@]3([C@H](C)C[C@@H]3[C@H]1C3(C)C)C2=O |c:13,t:2|	Launched
ingenol-mebutate	PKC activator	PRKCA, PRKCB, PRKCD, PRKCE, PRKCG	dermatology	actinic keratosis (AK)	MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx	97.23	C\C=C(\C)C(=O)O[C@H]1C(C)=C[C@@]23[C@H](C)C[C@@H]4[C@H]([C@H](C=C(CO)[C@@H](O)[C@]12O)C3=O)C4(C)C |c:9,t:18|, C\C=C(\C)C(=O)O[C@H]1C(C)=C[C@@]23[C@H](C)C[C@@H]4[C@H]([C@H](C=C(CO)[C@@H](O)[C@]12O)C3=O)C4(C)C |c:9,t:18|, C\C=C(\C)C(=O)O[C@H]1C(C)=C[C@@]23[C@H](C)C[C@@H]4[C@H]([C@H](C=C(CO)[C@@H](O)[C@]12O)C3=O)C4(C)C |c:9,t:18|, C\C=C(\C)C(=O)O[C@H]1C(C)=C[C@@]23[C@H](C)C[C@@H]4[C@H]([C@H](C=C(CO)[C@@H](O)[C@]12O)C3=O)C4(C)C |c:9,t:18|, C\C=C(\C)C(=O)O[C@H]1C(C)=C[C@@]23[C@H](C)C[C@@H]4[C@H]([C@H](C=C(CO)[C@@H](O)[C@]12O)C3=O)C4(C)C |c:9,t:18|, C\C=C(\C)C(=O)O[C@H]1C(C)=C[C@@]23[C@H](C)C[C@@H]4[C@H]([C@H](C=C(CO)[C@@H](O)[C@]12O)C3=O)C4(C)C |c:9,t:18|	Launched
INH1	Hec1 inhibitor	NDC80			Tocris, Tocris, Tocris, Tocris	98.69	Cc1ccc(-c2csc(NC(=O)c3ccccc3)n2)c(C)c1, Cc1ccc(-c2csc(NC(=O)c3ccccc3)n2)c(C)c1, Cc1ccc(-c2csc(NC(=O)c3ccccc3)n2)c(C)c1, Cc1ccc(-c2csc(NC(=O)c3ccccc3)n2)c(C)c1	Preclinical
inimur	other antifungal				MedChemEx, MedChemEx	86.95	CSC[C@H]1CN(\N=C\c2ccc(o2)[N+]([O-])=O)C(=O)O1 |&1:3,r|, CSC[C@H]1CN(\N=C\c2ccc(o2)[N+]([O-])=O)C(=O)O1 |&1:3,r|	Launched
iniparib	PARP inhibitor	PARP1			Selleck, Selleck, Selleck	97.59	NC(=O)c1ccc(I)c(c1)[N+]([O-])=O, NC(=O)c1ccc(I)c(c1)[N+]([O-])=O, NC(=O)c1ccc(I)c(c1)[N+]([O-])=O	Phase 3
inosine	neurotrophic agent	PARP1, PNP			MedChemEx, MicroSource, Selleck, Selleck	94.71	OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c1[nH]cnc2=O, OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c1[nH]cnc2=O, OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c1[nH]cnc2=O, OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c1[nH]cnc2=O	Launched
inositol	insulin sensitizer	CDIPT	obstetrics/gynecology	polycystic ovary syndrom (PCOS)	MedChemEx, MicroSource	100	O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O, O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O	Launched
inositol-hexanicotinate			dermatology, cardiology, rheumatology, neurology/psychiatry	statis dermatitis, claudication, Raynaud's disease, hypertension, insomnia, atherosclerosis, restless leg syndrome, schizophrenia, psoriasis, acne vulgaris (AV)	Sigma, Sigma, AKSci	89.29	O=C(O[C@H]1[C@H](OC(=O)c2cccnc2)[C@@H](OC(=O)c2cccnc2)[C@H](OC(=O)c2cccnc2)[C@H](OC(=O)c2cccnc2)[C@@H]1OC(=O)c1cccnc1)c1cccnc1, O=C(O[C@H]1[C@H](OC(=O)c2cccnc2)[C@@H](OC(=O)c2cccnc2)[C@H](OC(=O)c2cccnc2)[C@H](OC(=O)c2cccnc2)[C@@H]1OC(=O)c1cccnc1)c1cccnc1, O=C(O[C@H]1[C@H](OC(=O)c2cccnc2)[C@@H](OC(=O)c2cccnc2)[C@H](OC(=O)c2cccnc2)[C@H](OC(=O)c2cccnc2)[C@@H]1OC(=O)c1cccnc1)c1cccnc1	Launched
INS316	purinergic receptor antagonist				Enzo	0	O[C@H]1[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]([C@@H]1O)n1ccc(=O)[nH]c1=O |a:2,18,&1:1,&2:5,&3:9,&4:19|	Phase 2
INT-747	FXR agonist				MedChemEx, MedChemEx	98.9	CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCC(O)=O)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12, CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCC(O)=O)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12	Phase 3
INT-767	FXR agonist	GPBAR1			MedChemEx, MedChemEx	98.4	CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCOS(O)(=O)=O)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12, CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCOS(O)(=O)=O)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12	Phase 1
integrin-antagonist-1	integrin antagonist	ITGAV, ITGB6			MedChemEx, MedChemEx	93.77	Cc1cc(C)n(n1)-c1cccc(c1)[C@@H](CN1CC[C@@H](CCc2ccc3CCCNc3n2)C1)CC(O)=O, Cc1cc(C)n(n1)-c1cccc(c1)[C@@H](CN1CC[C@@H](CCc2ccc3CCCNc3n2)C1)CC(O)=O	Phase 1
INX-08189	antiviral				AMS	49.13	[H][C@@](C)(N[P@](=O)(OC[C@@]1([H])O[C@@]([H])(n2cnc3c(OC)nc(N)nc23)[C@](C)(O)[C@]1([H])O)Oc1cccc2ccccc12)C(=O)OCC(C)(C)C |r|	Phase 2
iobenguane	antineoplastic agent		oncology, cardiology, endocrinology	neuroblastoma, congestive heart failure, pheochromocytoma	Prestwick, Prestwick, Axon	98.26	NC(=N)NCc1cccc(I)c1, NC(=N)NCc1cccc(I)c1, NC(=N)NCc1cccc(I)c1	Launched
iocetamic-acid	radiopaque medium		radiology	contrast agent	Prestwick	85.31	C[C@@H](CN(C(C)=O)c1c(I)cc(I)c(N)c1I)C(O)=O |&1:1,r|	Launched
iodipamide	radiopaque medium	ALB	radiology	contrast agent	MedChemEx, MicroSource	99.2	OC(=O)c1c(I)cc(I)c(NC(=O)CCCCC(=O)Nc2c(I)cc(I)c(C(O)=O)c2I)c1I, OC(=O)c1c(I)cc(I)c(NC(=O)CCCCC(=O)Nc2c(I)cc(I)c(C(O)=O)c2I)c1I	Launched
iodixanol	radiopaque medium		radiology	contrast agent	Sigma, MicroSource, Sigma	79.95	CC(=O)N(CC(O)CN(C(C)=O)c1c(I)c(C(=O)NC[C@@H](O)CO)c(I)c(C(=O)NC[C@@H](O)CO)c1I)c1c(I)c(C(=O)NC[C@@H](O)CO)c(I)c(C(=O)NC[C@@H](O)CO)c1I |&1:20,&2:31,&3:45,&4:56,r|, CC(=O)N(CC(O)CN(C(C)=O)c1c(I)c(C(=O)NC[C@@H](O)CO)c(I)c(C(=O)NC[C@@H](O)CO)c1I)c1c(I)c(C(=O)NC[C@@H](O)CO)c(I)c(C(=O)NC[C@@H](O)CO)c1I |&1:20,&2:31,&3:45,&4:56,r|, CC(=O)N(CC(O)CN(C(C)=O)c1c(I)c(C(=O)NC[C@@H](O)CO)c(I)c(C(=O)NC[C@@H](O)CO)c1I)c1c(I)c(C(=O)NC[C@@H](O)CO)c(I)c(C(=O)NC[C@@H](O)CO)c1I |&1:20,&2:31,&3:45,&4:56,r|	Launched
iodoantipyrine					AlfaAesar	98.81	Cc1c(I)c(=O)n(-c2ccccc2)n1C	Preclinical
iododexetimide	acetylcholine receptor antagonist				MedChemEx, MedChemEx	96.72	Ic1ccc(CN2CCC(CC2)[C@]2(CCC(=O)NC2=O)c2ccccc2)cc1 |&1:12,r|, Ic1ccc(CN2CCC(CC2)[C@]2(CCC(=O)NC2=O)c2ccccc2)cc1 |&1:12,r|	Phase 2
iodophenpropit	histamine receptor antagonist	HRH3, HRH4			Tocris	95.9	Ic1ccc(CCNC(=N)SCCCc2cnc[nH]2)cc1	Preclinical
iodoquinol	antiseptic		infectious disease	amebiasis	MedChemEx, MedChemEx, MicroSource, MicroSource	97.07	Oc1c(I)cc(I)c2cccnc12, Oc1c(I)cc(I)c2cccnc12, Oc1c(I)cc(I)c2cccnc12, Oc1c(I)cc(I)c2cccnc12	Launched
iohexol	radiopaque medium		radiology	contrast agent	MicroSource, MedChemEx	99.01	CC(=O)N(C[C@@H](O)CO)c1c(I)c(C(=O)NC[C@@H](O)CO)c(I)c(C(=O)NC[C@@H](O)CO)c1I |&1:5,&2:17,&3:28,r|, CC(=O)N(C[C@@H](O)CO)c1c(I)c(C(=O)NC[C@@H](O)CO)c(I)c(C(=O)NC[C@@H](O)CO)c1I |&1:5,&2:17,&3:28,r|	Launched
iopamidol	radiopaque medium		radiology	contrast agent	MedChemEx, MedChemEx	100	C[C@H](O)C(=O)Nc1c(I)c(C(=O)NC(CO)CO)c(I)c(C(=O)NC(CO)CO)c1I, C[C@H](O)C(=O)Nc1c(I)c(C(=O)NC(CO)CO)c(I)c(C(=O)NC(CO)CO)c1I	Launched
iopanic-acid	thyroid hormone inhibitor				MicroSource, MedChemEx	98.49	CC[C@@H](Cc1c(I)cc(I)c(N)c1I)C(O)=O |&1:2,r|, CC[C@@H](Cc1c(I)cc(I)c(N)c1I)C(O)=O |&1:2,r|	Withdrawn
iopodic-acid			radiology	contrast agent	Vitas-M, Vitas-M, Vitas-M	98.86	CN(C)\C=N\c1c(I)cc(I)c(CCC(O)=O)c1I, CN(C)\C=N\c1c(I)cc(I)c(CCC(O)=O)c1I, CN(C)\C=N\c1c(I)cc(I)c(CCC(O)=O)c1I	Launched
iopromide	radiopaque medium		radiology	contrast agent	Prestwick, Sigma, MedChemEx	64.8	COCC(=O)Nc1c(I)c(C(=O)NC[C@@H](O)CO)c(I)c(C(=O)N(C)C[C@@H](O)CO)c1I |&1:14,&2:26,r|, COCC(=O)Nc1c(I)c(C(=O)NC[C@@H](O)CO)c(I)c(C(=O)N(C)C[C@@H](O)CO)c1I |&1:14,&2:26,r|, COCC(=O)Nc1c(I)c(C(=O)NC[C@@H](O)CO)c(I)c(C(=O)N(C)C[C@@H](O)CO)c1I |&1:14,&2:26,r|	Launched
iothalamic-acid-d3	radiopaque medium				Toronto	0	CNC(=O)c1c(I)c(NC(C)=O)c(I)c(C(O)=O)c1I	Preclinical
ioversol	radiopaque medium		radiology	contrast agent	MicroSource, MedChemEx	97.06	OCCN(C(=O)CO)c1c(I)c(C(=O)NC[C@@H](O)CO)c(I)c(C(=O)NC[C@@H](O)CO)c1I |&1:16,&2:27,r|, OCCN(C(=O)CO)c1c(I)c(C(=O)NC[C@@H](O)CO)c(I)c(C(=O)NC[C@@H](O)CO)c1I |&1:16,&2:27,r|	Launched
IOWH032	CFTR channel antagonist	CFTR			MedChemEx, Selleck, Selleck, Selleck	98.55	Oc1c(Br)cc(cc1Br)-c1noc(n1)C(=O)NCc1ccc(Oc2ccccc2)cc1, Oc1c(Br)cc(cc1Br)-c1noc(n1)C(=O)NCc1ccc(Oc2ccccc2)cc1, Oc1c(Br)cc(cc1Br)-c1noc(n1)C(=O)NCc1ccc(Oc2ccccc2)cc1, Oc1c(Br)cc(cc1Br)-c1noc(n1)C(=O)NCc1ccc(Oc2ccccc2)cc1	Phase 2
ioxaglic-acid	radiopaque medium		radiology	contrast agent	Prestwick, Toronto	92.49	CNC(=O)c1c(I)c(N(C)C(C)=O)c(I)c(C(=O)NCC(=O)Nc2c(I)c(C(O)=O)c(I)c(C(=O)NCCO)c2I)c1I, CNC(=O)c1c(I)c(N(C)C(C)=O)c(I)c(C(=O)NCC(=O)Nc2c(I)c(C(O)=O)c(I)c(C(=O)NCCO)c2I)c1I	Launched
ioxilan	radiopaque medium		radiology	angiography	USP, USP, MicroSource	88.58	CC(=O)N(C[C@@H](O)CO)c1c(I)c(C(=O)NCCO)c(I)c(C(=O)NC[C@@H](O)CO)c1I |&1:5,&2:26,r|, CC(=O)N(C[C@@H](O)CO)c1c(I)c(C(=O)NCCO)c(I)c(C(=O)NC[C@@H](O)CO)c1I |&1:5,&2:26,r|, CC(=O)N(C[C@@H](O)CO)c1c(I)c(C(=O)NCCO)c(I)c(C(=O)NC[C@@H](O)CO)c1I |&1:5,&2:26,r|	Launched
IOX1	histone demethylase inhibitor	EGLN1, KDM3A, KDM4C, KDM6B			Tocris, MedChemEx	87.15	OC(=O)c1ccc(O)c2ncccc12, OC(=O)c1ccc(O)c2ncccc12	Preclinical
IOX2	hypoxia inducible factor inhibitor	EGLN1, KDM2A, KDM5C			Tocris, Tocris, Tocris, Selleck, Selleck	97.46	OC(=O)CNC(=O)c1c(O)c2ccccc2n(Cc2ccccc2)c1=O, OC(=O)CNC(=O)c1c(O)c2ccccc2n(Cc2ccccc2)c1=O, OC(=O)CNC(=O)c1c(O)c2ccccc2n(Cc2ccccc2)c1=O, OC(=O)CNC(=O)c1c(O)c2ccccc2n(Cc2ccccc2)c1=O, OC(=O)CNC(=O)c1c(O)c2ccccc2n(Cc2ccccc2)c1=O	Preclinical
IPA-3	p21 activated kinase inhibitor	PAK1			Tocris, Selleck, Tocris, Selleck	79.92	Oc1ccc2ccccc2c1SSc1c(O)ccc2ccccc12, Oc1ccc2ccccc2c1SSc1c(O)ccc2ccccc12, Oc1ccc2ccccc2c1SSc1c(O)ccc2ccccc12, Oc1ccc2ccccc2c1SSc1c(O)ccc2ccccc12	Preclinical
IPAG					Tocris, Tocris, Tocris, Tocris	95.16	Ic1ccc(NC(=N)NC2C3CC4CC(C3)CC2C4)cc1, Ic1ccc(NC(=N)NC2C3CC4CC(C3)CC2C4)cc1, Ic1ccc(NC(=N)NC2C3CC4CC(C3)CC2C4)cc1, Ic1ccc(NC(=N)NC2C3CC4CC(C3)CC2C4)cc1	Preclinical
ipidacrine	acetylcholinesterase inhibitor	ACHE			ChemDiv, ChemDiv	98.46	Nc1c2CCCc2nc2CCCCc12, Nc1c2CCCc2nc2CCCCc12	Phase 3
IPI549	PI3K inhibitor				MedChemEx	94.19	C[C@H](NC(=O)c1c(N)nn2cccnc12)c1cc2cccc(C#Cc3cnn(C)c3)c2c(=O)n1-c1ccccc1	Phase 2
ipragliflozin-L-proline	sodium/glucose cotransporter inhibitor	SLC5A2	endocrinology	diabetes mellitus	MedChemEx, MedChemEx, MedChemEx	98.3	OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)c1ccc(F)c(Cc2cc3ccccc3s2)c1, OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)c1ccc(F)c(Cc2cc3ccccc3s2)c1, OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)c1ccc(F)c(Cc2cc3ccccc3s2)c1	Launched
ipratropium	acetylcholine receptor antagonist	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5	pulmonary	bronchospasm, chronic obstructive pulmonary disease (COPD), bronchitis, emphysema	Tocris	87.46	CC(C)[N@@+]1(C)[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@@H](CO)c1ccccc1 |a:5,8,10,&1:3,&2:15,TLB:4:3:6.7:9.10.11,THB:1:3:6.7:9.10.11,12:10:3:6.7|	Launched
ipriflavone	bone resorption inhibitor		orthopedics	osteoporosis	MedChemEx, MicroSource, Selleck	98.07	CC(C)Oc1ccc2c(c1)occ(-c1ccccc1)c2=O, CC(C)Oc1ccc2c(c1)occ(-c1ccccc1)c2=O, CC(C)Oc1ccc2c(c1)occ(-c1ccccc1)c2=O	Launched
iproniazid	monoamine oxidase inhibitor	MAOA, MAOB			MicroSource, MedChemEx, MedChemEx	98.08	CC(C)NNC(=O)c1ccncc1, CC(C)NNC(=O)c1ccncc1, CC(C)NNC(=O)c1ccncc1	Withdrawn
ipsapirone	serotonin receptor agonist	HTR1A			Tocris, Tocris	96.7	O=C1N(CCCCN2CCN(CC2)c2ncccn2)S(=O)(=O)c2ccccc12, O=C1N(CCCCN2CCN(CC2)c2ncccn2)S(=O)(=O)c2ccccc12	Phase 3
irbesartan	angiotensin receptor antagonist	AGTR1, JUN, SLC10A1	cardiology, nephrology	hypertension, diabetic nephropathy	MicroSource, MicroSource, Tocris, Tocris, Selleck	99.09	CCCCC1=NC2(CCCC2)C(=O)N1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1 |t:4|, CCCCC1=NC2(CCCC2)C(=O)N1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1 |t:4|, CCCCC1=NC2(CCCC2)C(=O)N1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1 |t:4|, CCCCC1=NC2(CCCC2)C(=O)N1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1 |t:4|, CCCCC1=NC2(CCCC2)C(=O)N1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1 |t:4|	Launched
irganox-1010	antioxidant				Sigma	0	CC(C)(C)c1cc(CCC(=O)OCC(COC(=O)CCc2cc(c(O)c(c2)C(C)(C)C)C(C)(C)C)(COC(=O)CCc2cc(c(O)c(c2)C(C)(C)C)C(C)(C)C)COC(=O)CCc2cc(c(O)c(c2)C(C)(C)C)C(C)(C)C)cc(c1O)C(C)(C)C	Preclinical
iRGD-peptide	integrin signaling activator				MedChemEx	92.64	[H][C@@]12CCCN1C(=O)CNC(=O)[C@H](CCCCN)NC(=O)[C@]([H])(CC(O)=O)NC(=O)CNC(=O)[C@]([H])(CCCNC(N)=N)NC(=O)[C@@H](N)CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC2=O)C(O)=O	Preclinical
irinotecan	topoisomerase inhibitor	TOP1, TOP1MT	oncology	colorectal cancer	Tocris, MedChemEx, MedChemEx, MicroSource, Selleck, Selleck, Tocris, Selleck, Selleck	98.48	CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12	Launched
IRL-2500	endothelin receptor antagonist	EDNRB			Tocris, Tocris	96.86	CN([C@H](Cc1ccc(cc1)-c1ccccc1)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(O)=O)C(=O)c1cc(C)cc(C)c1, CN([C@H](Cc1ccc(cc1)-c1ccccc1)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(O)=O)C(=O)c1cc(C)cc(C)c1	Preclinical
irosustat	steroid sulfatase inhibitor	CA2, STS			Sigma	0	NS(=O)(=O)Oc1ccc2c3CCCCCc3c(=O)oc2c1	Phase 2
irsogladine	phosphodiesterase inhibitor	PDE4A	gastroenterology	peptic ulcer disease (PUD)	Tocris, Tocris, Tocris, Tocris, Selleck	99.31	Nc1nc(N)nc(n1)-c1cc(Cl)ccc1Cl, Nc1nc(N)nc(n1)-c1cc(Cl)ccc1Cl, Nc1nc(N)nc(n1)-c1cc(Cl)ccc1Cl, Nc1nc(N)nc(n1)-c1cc(Cl)ccc1Cl, Nc1nc(N)nc(n1)-c1cc(Cl)ccc1Cl	Launched
isamoltane	adrenergic receptor antagonist	HTR1A, HTR1B			Tocris, Tocris	89.47	CC(C)NC[C@@H](O)COc1ccccc1-n1cccc1 |&1:5|, CC(C)NC[C@@H](O)COc1ccccc1-n1cccc1 |&1:5|	Phase 1
isavuconazole	cytochrome P450 inhibitor	CYP3A4			MedChemEx	98.14	C[C@@H](c1nc(cs1)-c1ccc(cc1)C#N)[C@@](O)(Cn1cncn1)c1cc(F)ccc1F |a:1,&1:15|	Phase 3
isaxonine	nerve growth factor agonist				MicroSource, AMS	81.09	CC(C)Nc1ncccn1, CC(C)Nc1ncccn1	Withdrawn
isbufylline	phosphodiesterase inhibitor				Vitas-M, Vitas-M, Vitas-M	97.28	CC(C)Cn1cnc2n(C)c(=O)n(C)c(=O)c12, CC(C)Cn1cnc2n(C)c(=O)n(C)c(=O)c12, CC(C)Cn1cnc2n(C)c(=O)n(C)c(=O)c12	Phase 2
isepamicin	protein synthesis inhibitor		infectious disease	pneumonia, peritonitis	Carbosynth, Sigma	95.5	CN[C@@H]1[C@@H](O)[C@@H](O[C@H]2[C@@H](C[C@H](N)[C@@H](O[C@H]3O[C@H](CN)[C@@H](O)[C@H](O)[C@H]3O)[C@@H]2O)NC(=O)[C@@H](O)CN)OC[C@]1(C)O, CN[C@@H]1[C@@H](O)[C@@H](O[C@H]2[C@@H](C[C@H](N)[C@@H](O[C@H]3O[C@H](CN)[C@@H](O)[C@H](O)[C@H]3O)[C@@H]2O)NC(=O)[C@@H](O)CN)OC[C@]1(C)O	Launched
ISO-1	macrophage migration inhibiting factor inhibitor	MIF			Tocris, Tocris	95.84	COC(=O)C[C@H]1CC(=NO1)c1ccc(O)cc1 |&1:5,r,c:7|, COC(=O)C[C@H]1CC(=NO1)c1ccc(O)cc1 |&1:5,r,c:7|	Preclinical
isobutamben	local anesthetic				MicroSource, Sigma	99.03	CC(C)COC(=O)c1ccc(N)cc1, CC(C)COC(=O)c1ccc(N)cc1	Preclinical
isobutyramide	gene expression stimulant	HBE1, HBG1			Otava	0	CC(C)C(N)=O	Phase 2
isocarboxazid	monoamine oxidase inhibitor	MAOA, MAOB	neurology/psychiatry	depression	Sigma, Sigma, Sigma, Enzo, Enzo	74.82	Cc1cc(no1)C(=O)NNCc1ccccc1, Cc1cc(no1)C(=O)NNCc1ccccc1, Cc1cc(no1)C(=O)NNCc1ccccc1, Cc1cc(no1)C(=O)NNCc1ccccc1, Cc1cc(no1)C(=O)NNCc1ccccc1	Launched
isoconazole	fungal lanosterol demethylase inhibitor	CYP17A1	infectious disease	gram-positive bacterial infections	MedChemEx, Selleck	99.12	Clc1ccc([C@@H](Cn2ccnc2)OCc2c(Cl)cccc2Cl)c(Cl)c1 |&1:5|, Clc1ccc([C@@H](Cn2ccnc2)OCc2c(Cl)cccc2Cl)c(Cl)c1 |&1:5|	Launched
isodibut	aldehyde reductase inhibitor				Sigma, Sigma, Enamine	99.18	OC(=O)CCCN1C(=O)c2cccc3cccc(C1=O)c23, OC(=O)CCCN1C(=O)c2cccc3cccc(C1=O)c23, OC(=O)CCCN1C(=O)c2cccc3cccc(C1=O)c23	Phase 2
isoetharine	adrenergic receptor agonist		pulmonary	bronchospasm, asthma	Selleck, MicroSource, Selleck, Selleck	94.7	CC[C@@H](NC(C)C)[C@@H](O)c1ccc(O)c(O)c1 |&1:2,&2:7|, CC[C@@H](NC(C)C)[C@@H](O)c1ccc(O)c(O)c1 |&1:2,&2:7|, CC[C@@H](NC(C)C)[C@@H](O)c1ccc(O)c(O)c1 |&1:2,&2:7|, CC[C@@H](NC(C)C)[C@@H](O)c1ccc(O)c(O)c1 |&1:2,&2:7|	Launched
isofloxythepin	dopamine receptor antagonist				Specs, Specs, Specs	85.83	CC(C)c1ccc2Sc3cc(F)ccc3C[C@@H](N3CCN(CCO)CC3)c2c1 |&1:16,r|, CC(C)c1ccc2Sc3cc(F)ccc3C[C@@H](N3CCN(CCO)CC3)c2c1 |&1:16,r|, CC(C)c1ccc2Sc3cc(F)ccc3C[C@@H](N3CCN(CCO)CC3)c2c1 |&1:16,r|	Phase 2
isoflupredone-acetate		NR3C1			Prestwick, Prestwick, Toronto	91.96	CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C |c:19,t:15|, CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C |c:19,t:15|, CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C |c:19,t:15|	Preclinical
isoflurane	inhaled anaesthetic	GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GLRA1, GLRB, KCNK10, KCNK18, KCNK2, KCNK3, KCNK9	neurology/psychiatry	general anaesthetic	Sigma, Enamine	0	FC(F)O[C@@H](Cl)C(F)(F)F |&1:4,r|, FC(F)O[C@@H](Cl)C(F)(F)F |&1:4,r|	Launched
isoflurophate	cholinesterase inhibitor	ACHE, BCHE	ophthalmology	glaucoma	Sigma, Sigma, Sigma	0	CC(C)OP(F)(=O)OC(C)C, CC(C)OP(F)(=O)OC(C)C, CC(C)OP(F)(=O)OC(C)C	Launched
isoguvacine	benzodiazepine receptor agonist	GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRR1, GABRR2, GABRR3			Tocris, Tocris, Tocris	100	OC(=O)C1=CCNCC1 |t:3|, OC(=O)C1=CCNCC1 |t:3|, OC(=O)C1=CCNCC1 |t:3|	Preclinical
isoleucine					Enamine	89.82	CC[C@@H](C)[C@@H](N)C(O)=O |&1:2,&2:4,r|	Launched
isoliquiritigenin	guanylate cyclase activator	GABBR1			Selleck, Selleck	90.32	Oc1ccc(\C=C\C(=O)c2ccc(O)cc2O)cc1, Oc1ccc(\C=C\C(=O)c2ccc(O)cc2O)cc1	Preclinical
isometheptene-mucate			neurology/psychiatry	headache	Prestwick	81.13	CN[C@@H](C)CCC=C(C)C |&1:2,r|	Launched
isoniazid	FABI inhibitor	CYP1A2, CYP2C19, CYP2C8, CYP2E1, CYP3A4	infectious disease	tuberculosis	MedChemEx, MicroSource, Selleck, MicroSource, Selleck	100	NNC(=O)c1ccncc1, NNC(=O)c1ccncc1, NNC(=O)c1ccncc1, NNC(=O)c1ccncc1, NNC(=O)c1ccncc1	Launched
isopentyl-4-methoxycinnamate			dermatology	sunscreen lotion	Enamine, Sigma	87.91	COc1ccc(\C=C\C(=O)OCCC(C)C)cc1, COc1ccc(\C=C\C(=O)OCCC(C)C)cc1	Launched
isoprenaline	adrenergic receptor agonist	ADRB1, ADRB2, ADRB3	cardiology, pulmonary	bradycardia, heart block, asthma	Selleck, Selleck, Selleck, MicroSource, Tocris	94.79	CC(C)NC[C@@H](O)c1ccc(O)c(O)c1 |&1:5|, CC(C)NC[C@@H](O)c1ccc(O)c(O)c1 |&1:5|, CC(C)NC[C@@H](O)c1ccc(O)c(O)c1 |&1:5|, CC(C)NC[C@@H](O)c1ccc(O)c(O)c1 |&1:5|, CC(C)NC[C@@H](O)c1ccc(O)c(O)c1 |&1:5|	Launched
isopropamide-iodide	acetylcholine receptor antagonist	CHRM3, CHRM4	gastroenterology	peptic ulcer disease (PUD), gastrointestinal acidosis	USP, USP, MicroSource, MicroSource, MicroSource	100	CC(C)[N+](C)(CCC(C(N)=O)(c1ccccc1)c1ccccc1)C(C)C, CC(C)[N+](C)(CCC(C(N)=O)(c1ccccc1)c1ccccc1)C(C)C, CC(C)[N+](C)(CCC(C(N)=O)(c1ccccc1)c1ccccc1)C(C)C, CC(C)[N+](C)(CCC(C(N)=O)(c1ccccc1)c1ccccc1)C(C)C, CC(C)[N+](C)(CCC(C(N)=O)(c1ccccc1)c1ccccc1)C(C)C	Launched
isopropyl-myristate			dermatology	cosmetic	Sigma, Acros, Acros	0	CCCCCCCCCCCCCC(=O)OC(C)C, CCCCCCCCCCCCCC(=O)OC(C)C, CCCCCCCCCCCCCC(=O)OC(C)C	Launched
isopropyl-palmitate	cosmetic moisturizer		dermatology	cosmetic	Sigma, TCI	0	CCCCCCCCCCCCCCCC(=O)OC(C)C, CCCCCCCCCCCCCCCC(=O)OC(C)C	Launched
isoquercitrin	antioxidant				ChemDiv	91.07	OC[C@H]1O[C@@H](Oc2c(oc3cc(O)cc(O)c3c2=O)-c2ccc(O)c(O)c2)[C@H](O)[C@@H](O)[C@@H]1O	Phase 2/Phase 3
Isoquinoline,-6,7-dimethoxy-1-methyl-1,2,3,4-tetrahydro,					MedChemEx, Prestwick	98.3	COc1cc2CCN[C@@H](C)c2cc1OC |&1:8|, COc1cc2CCN[C@@H](C)c2cc1OC |&1:8|	Preclinical
isosorbide	nitric oxide stimulant		cardiology	angina pectoris, coronary artery disease (CAD)	MedChemEx, MedChemEx, Selleck, Selleck, Selleck, Selleck	54.94	O[C@H]1CO[C@@H]2[C@H](O)CO[C@H]12, O[C@H]1CO[C@@H]2[C@H](O)CO[C@H]12, O[C@H]1CO[C@@H]2[C@H](O)CO[C@H]12, O[C@H]1CO[C@@H]2[C@H](O)CO[C@H]12, O[C@H]1CO[C@@H]2[C@H](O)CO[C@H]12, O[C@H]1CO[C@@H]2[C@H](O)CO[C@H]12	Launched
isosorbide-dinitrate	nitric oxide stimulant	GUCY1A2, GUCY1A3, GUCY1B2, GUCY1B3, NPR1	cardiology	angina pectoris, coronary artery disease (CAD)	Enamine, MicroSource, MicroSource	0	[O-][N+](=O)O[C@@H]1CO[C@@H]2[C@H](CO[C@H]12)O[N+]([O-])=O, [O-][N+](=O)O[C@@H]1CO[C@@H]2[C@H](CO[C@H]12)O[N+]([O-])=O, [O-][N+](=O)O[C@@H]1CO[C@@H]2[C@H](CO[C@H]12)O[N+]([O-])=O	Launched
isosorbide-mononitrate	nitric oxide stimulant	GUCY1A2, GUCY1A3, GUCY1B2, GUCY1B3	cardiology	angina pectoris, coronary artery disease (CAD)	MicroSource, MedChemEx, MedChemEx	97.55	O[C@H]1CO[C@@H]2[C@@H](CO[C@H]12)O[N+]([O-])=O, O[C@H]1CO[C@@H]2[C@@H](CO[C@H]12)O[N+]([O-])=O, O[C@H]1CO[C@@H]2[C@@H](CO[C@H]12)O[N+]([O-])=O	Launched
isosteviol					ChemDiv	100	C[C@]12C[C@@]3(CC1=O)CC[C@H]1[C@@](C)(CCC[C@@]1(C)C(O)=O)[C@@H]3CC2 |a:1,3,9,10,15,&1:20|	Phase 2
isotiquimide					Enamine, Enamine	92.3	Cc1ccnc2[C@@H](CCCc12)C(N)=S |&1:6,r|, Cc1ccnc2[C@@H](CCCc12)C(N)=S |&1:6,r|	Phase 1
isotretinoin	retinoid receptor agonist	RARA, RARB, RARG	dermatology	acne vulgaris (AV)	MicroSource, Selleck, Selleck, MedChemEx, Selleck	51.38	C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C\C(O)=O |c:4|, C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C\C(O)=O |c:4|, C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C\C(O)=O |c:4|, C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C\C(O)=O |c:4|, C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C\C(O)=O |c:4|	Launched
isovaleramide	alcohol dehydrogenase inhibitor				PrincetonBio, Selleck, MicroSource, Selleck, Selleck	79.17	CC(C)CC(N)=O, CC(C)CC(N)=O, CC(C)CC(N)=O, CC(C)CC(N)=O, CC(C)CC(N)=O	Phase 2
isoxepac	anti-inflammatory agent				Ark	99.77	OC(=O)Cc1ccc2OCc3ccccc3C(=O)c2c1	Phase 2
isoxicam	cyclooxygenase inhibitor	PTGS1, PTGS2			MicroSource, Selleck, Selleck	98.14	CN1C(C(=O)Nc2cc(C)on2)=C(O)c2ccccc2S1(=O)=O |t:12|, CN1C(C(=O)Nc2cc(C)on2)=C(O)c2ccccc2S1(=O)=O |t:12|, CN1C(C(=O)Nc2cc(C)on2)=C(O)c2ccccc2S1(=O)=O |t:12|	Withdrawn
isoxsuprine	adrenergic receptor agonist	ADRB2	rheumatology, cardiology	Raynaud's disease, arteriosclerosis, Buerger's disease	MedChemEx, MedChemEx	95.03	C[C@@H](COc1ccccc1)N[C@H](C)[C@@H](O)c1ccc(O)cc1 |&1:13,&2:11,&3:1|, C[C@@H](COc1ccccc1)N[C@H](C)[C@@H](O)c1ccc(O)cc1 |&1:13,&2:11,&3:1|	Launched
ispinesib	kinesin inhibitor	KIF11			Tocris, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck	88.16	CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1, CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1, CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1, CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1, CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1, CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1, CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1, CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1	Phase 2
isradipine	calcium channel blocker	CACNA1D, CACNA1F, CACNA2D1	cardiology	hypertension	Tocris, MicroSource, Selleck, Selleck, Selleck, Tocris	97.4	COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc2nonc12)C(=O)OC(C)C |r,c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc2nonc12)C(=O)OC(C)C |r,c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc2nonc12)C(=O)OC(C)C |r,c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc2nonc12)C(=O)OC(C)C |r,c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc2nonc12)C(=O)OC(C)C |r,c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc2nonc12)C(=O)OC(C)C |r,c:4,9|	Launched
ISRIB	eukaryotic translation initiation factor inhibitor, PERK inhibitor	EIF2A, EIF2AK3			MedChemEx, MedChemEx, MedChemEx	90.08	Clc1ccc(OCC(=O)N[C@H]2CC[C@@H](CC2)NC(=O)COc2ccc(Cl)cc2)cc1 |r|, Clc1ccc(OCC(=O)N[C@H]2CC[C@@H](CC2)NC(=O)COc2ccc(Cl)cc2)cc1 |r|, Clc1ccc(OCC(=O)N[C@H]2CC[C@@H](CC2)NC(=O)COc2ccc(Cl)cc2)cc1 |r|	Preclinical
istaroxime	ATPase inhibitor	ATP1A1			MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx	97.6	C[C@]12CC[C@H]3[C@@H](CC(=O)[C@H]4C\C(CC[C@]34C)=N\OCCN)[C@@H]1CCC2=O, C[C@]12CC[C@H]3[C@@H](CC(=O)[C@H]4C\C(CC[C@]34C)=N\OCCN)[C@@H]1CCC2=O, C[C@]12CC[C@H]3[C@@H](CC(=O)[C@H]4C\C(CC[C@]34C)=N\OCCN)[C@@H]1CCC2=O, C[C@]12CC[C@H]3[C@@H](CC(=O)[C@H]4C\C(CC[C@]34C)=N\OCCN)[C@@H]1CCC2=O, C[C@]12CC[C@H]3[C@@H](CC(=O)[C@H]4C\C(CC[C@]34C)=N\OCCN)[C@@H]1CCC2=O	Phase 2
istradefylline	adenosine receptor antagonist	ADORA1, ADORA2A, ADORA2B, ADORA3	neurology/psychiatry	Parkinson's Disease, dyskinesia	MedChemEx, MedChemEx, MedChemEx, Selleck, Selleck, Selleck, Selleck	95.36	CCn1c2nc(\C=C\c3ccc(OC)c(OC)c3)n(C)c2c(=O)n(CC)c1=O, CCn1c2nc(\C=C\c3ccc(OC)c(OC)c3)n(C)c2c(=O)n(CC)c1=O, CCn1c2nc(\C=C\c3ccc(OC)c(OC)c3)n(C)c2c(=O)n(CC)c1=O, CCn1c2nc(\C=C\c3ccc(OC)c(OC)c3)n(C)c2c(=O)n(CC)c1=O, CCn1c2nc(\C=C\c3ccc(OC)c(OC)c3)n(C)c2c(=O)n(CC)c1=O, CCn1c2nc(\C=C\c3ccc(OC)c(OC)c3)n(C)c2c(=O)n(CC)c1=O, CCn1c2nc(\C=C\c3ccc(OC)c(OC)c3)n(C)c2c(=O)n(CC)c1=O	Launched
ISX-9	neural stem cell inducer	NEUROD1			Tocris, EMDBio, EMDBio, EMDBio, EMDBio, EMDBio	100	O=C(NC1CC1)c1cc(on1)-c1cccs1, O=C(NC1CC1)c1cc(on1)-c1cccs1, O=C(NC1CC1)c1cc(on1)-c1cccs1, O=C(NC1CC1)c1cc(on1)-c1cccs1, O=C(NC1CC1)c1cc(on1)-c1cccs1, O=C(NC1CC1)c1cc(on1)-c1cccs1	Preclinical
itacitinib	JAK inhibitor	JAK1			MedChemEx, MedChemEx	96.98	Fc1c(ccnc1C(F)(F)F)C(=O)N1CCC(CC1)N1CC(CC#N)(C1)n1cc(cn1)-c1ncnc2[nH]ccc12, Fc1c(ccnc1C(F)(F)F)C(=O)N1CCC(CC1)N1CC(CC#N)(C1)n1cc(cn1)-c1ncnc2[nH]ccc12	Phase 3
ITD-1	TGF beta receptor inhibitor	TGFBR2			Tocris, Tocris	96.52	CCOC(=O)C1=C(C)NC2=C([C@@H]1c1ccc(cc1)-c1ccccc1)C(=O)CC(C)(C)C2 |&1:11,r,c:5,9|, CCOC(=O)C1=C(C)NC2=C([C@@H]1c1ccc(cc1)-c1ccccc1)C(=O)CC(C)(C)C2 |&1:11,r,c:5,9|	Preclinical
ITE	aryl hydrocarbon receptor agonist	AHR			Tocris, Tocris, Tocris	97.76	COC(=O)c1csc(n1)C(=O)c1c[nH]c2ccccc12, COC(=O)c1csc(n1)C(=O)c1c[nH]c2ccccc12, COC(=O)c1csc(n1)C(=O)c1c[nH]c2ccccc12	Preclinical
ITI214	phosphodiesterase inhibitor	PDE1A			MedChemEx, MedChemEx, MedChemEx	95.75	CN1C2=N[C@@H]3CCC[C@@H]3N2c2nn(Cc3ccc(cc3)-c3cccc(F)n3)c(Nc3ccccc3)c2C1=O |t:2|, CN1C2=N[C@@H]3CCC[C@@H]3N2c2nn(Cc3ccc(cc3)-c3cccc(F)n3)c(Nc3ccccc3)c2C1=O |t:2|, CN1C2=N[C@@H]3CCC[C@@H]3N2c2nn(Cc3ccc(cc3)-c3cccc(F)n3)c(Nc3ccccc3)c2C1=O |t:2|	Phase 1/Phase 2
itopride	dopamine receptor antagonist	CHRM3, DRD2	gastroenterology, neurology/psychiatry	dyspepsia, gastroparesis, heartburn, nausea, vomiting, anorexia	MedChemEx, MedChemEx, MicroSource, MicroSource, MicroSource	98.7	COc1ccc(cc1OC)C(=O)NCc1ccc(OCCN(C)C)cc1, COc1ccc(cc1OC)C(=O)NCc1ccc(OCCN(C)C)cc1, COc1ccc(cc1OC)C(=O)NCc1ccc(OCCN(C)C)cc1, COc1ccc(cc1OC)C(=O)NCc1ccc(OCCN(C)C)cc1, COc1ccc(cc1OC)C(=O)NCc1ccc(OCCN(C)C)cc1	Launched
itraconazole	cytochrome P450 inhibitor		infectious disease	onychomycosis, histoplasmosis, blastomycosis, aspergillosis	Tocris	96.35	CC[C@H](C)n1ncn(-c2ccc(cc2)N2CCN(CC2)c2ccc(OC[C@H]3CO[C@@](Cn4cncn4)(O3)c3ccc(Cl)cc3Cl)cc2)c1=O |&1:26,29,&2:2|	Launched
ITX3	GEF inhibitor	TRIO			MedChemEx, MedChemEx	84.43	Cc1cc(\C=c2\sc3nc4ccccc4n3c2=O)c(C)n1-c1ccccc1, Cc1cc(\C=c2\sc3nc4ccccc4n3c2=O)c(C)n1-c1ccccc1	Preclinical
ITX5061	SR-BI inhibitor				MedChemEx	96.17	COc1c(NC(=O)C(=O)c2ccc(OCCN3CCOCC3)c3ccccc23)cc(cc1NS(C)(=O)=O)C(C)(C)C	Phase 1
IT1t	CC chemokine receptor antagonist	CXCR4			Tocris, Tocris	81.68	CC1(C)CN2C(CS\C(NC3CCCCC3)=N\C3CCCCC3)=CSC2=N1 |c:24,28|, CC1(C)CN2C(CS\C(NC3CCCCC3)=N\C3CCCCC3)=CSC2=N1 |c:24,28|	Preclinical
IU1	ubiquitin C-terminal hydrolase inhibitor	USP14			Tocris, Selleck, Selleck	87.3	Cc1cc(C(=O)CN2CCCC2)c(C)n1-c1ccc(F)cc1, Cc1cc(C(=O)CN2CCCC2)c(C)n1-c1ccc(F)cc1, Cc1cc(C(=O)CN2CCCC2)c(C)n1-c1ccc(F)cc1	Preclinical
ivabradine	HCN channel blocker, potassium channel blocker, sodium channel blocker	HCN1, HCN3, HCN4	cardiology	angina pectoris	MedChemEx, MedChemEx	98.66	COc1cc2C[C@H](CN(C)CCCN3CCc4cc(OC)c(OC)cc4CC3=O)c2cc1OC, COc1cc2C[C@H](CN(C)CCCN3CCc4cc(OC)c(OC)cc4CC3=O)c2cc1OC	Launched
ivacaftor	CFTR channel potentiator	CFTR	pulmonary	cystic fibrosis	MedChemEx, Selleck, Selleck, Selleck	99.16	CC(C)(C)c1cc(c(NC(=O)c2c[nH]c3ccccc3c2=O)cc1O)C(C)(C)C, CC(C)(C)c1cc(c(NC(=O)c2c[nH]c3ccccc3c2=O)cc1O)C(C)(C)C, CC(C)(C)c1cc(c(NC(=O)c2c[nH]c3ccccc3c2=O)cc1O)C(C)(C)C, CC(C)(C)c1cc(c(NC(=O)c2c[nH]c3ccccc3c2=O)cc1O)C(C)(C)C	Launched
ivermectin	benzodiazepine receptor agonist	CHRNA7, P2RX7	infectious disease	gastrointestinal roundworms, lungworms, cattle grubs, mites, lice, horn flies	MicroSource, MicroSource, MicroSource, Tocris, Tocris, Selleck, Selleck, Selleck	94.01	CC[C@H](C)[C@H]1O[C@]2(CC[C@@H]1C)C[C@@H]1C[C@@H](C\C=C(C)\[C@@H](O[C@H]3C[C@H](OC)[C@@H](O[C@H]4C[C@H](OC)[C@@H](O)[C@H](C)O4)[C@H](C)O3)[C@@H](C)\C=C\C=C3/CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O1)[C@]34O)O2 |c:17,48,56,t:46|, CC[C@H](C)[C@H]1O[C@]2(CC[C@@H]1C)C[C@@H]1C[C@@H](C\C=C(C)\[C@@H](O[C@H]3C[C@H](OC)[C@@H](O[C@H]4C[C@H](OC)[C@@H](O)[C@H](C)O4)[C@H](C)O3)[C@@H](C)\C=C\C=C3/CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O1)[C@]34O)O2 |c:17,48,56,t:46|, CC[C@H](C)[C@H]1O[C@]2(CC[C@@H]1C)C[C@@H]1C[C@@H](C\C=C(C)\[C@@H](O[C@H]3C[C@H](OC)[C@@H](O[C@H]4C[C@H](OC)[C@@H](O)[C@H](C)O4)[C@H](C)O3)[C@@H](C)\C=C\C=C3/CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O1)[C@]34O)O2 |c:17,48,56,t:46|, CC[C@H](C)[C@H]1O[C@]2(CC[C@@H]1C)C[C@@H]1C[C@@H](C\C=C(C)\[C@@H](O[C@H]3C[C@H](OC)[C@@H](O[C@H]4C[C@H](OC)[C@@H](O)[C@H](C)O4)[C@H](C)O3)[C@@H](C)\C=C\C=C3/CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O1)[C@]34O)O2 |c:17,48,56,t:46|, CC[C@H](C)[C@H]1O[C@]2(CC[C@@H]1C)C[C@@H]1C[C@@H](C\C=C(C)\[C@@H](O[C@H]3C[C@H](OC)[C@@H](O[C@H]4C[C@H](OC)[C@@H](O)[C@H](C)O4)[C@H](C)O3)[C@@H](C)\C=C\C=C3/CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O1)[C@]34O)O2 |c:17,48,56,t:46|, CC[C@H](C)[C@H]1O[C@]2(CC[C@@H]1C)C[C@@H]1C[C@@H](C\C=C(C)\[C@@H](O[C@H]3C[C@H](OC)[C@@H](O[C@H]4C[C@H](OC)[C@@H](O)[C@H](C)O4)[C@H](C)O3)[C@@H](C)\C=C\C=C3/CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O1)[C@]34O)O2 |c:17,48,56,t:46|, CC[C@H](C)[C@H]1O[C@]2(CC[C@@H]1C)C[C@@H]1C[C@@H](C\C=C(C)\[C@@H](O[C@H]3C[C@H](OC)[C@@H](O[C@H]4C[C@H](OC)[C@@H](O)[C@H](C)O4)[C@H](C)O3)[C@@H](C)\C=C\C=C3/CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O1)[C@]34O)O2 |c:17,48,56,t:46|, CC[C@H](C)[C@H]1O[C@]2(CC[C@@H]1C)C[C@@H]1C[C@@H](C\C=C(C)\[C@@H](O[C@H]3C[C@H](OC)[C@@H](O[C@H]4C[C@H](OC)[C@@H](O)[C@H](C)O4)[C@H](C)O3)[C@@H](C)\C=C\C=C3/CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O1)[C@]34O)O2 |c:17,48,56,t:46|	Launched
ivosidenib	isocitrate dehydrogenase inhibitor	IDH1	hematologic malignancy	acute myeloid leukemia (AML)	MedChemEx, MedChemEx	97.39	Fc1cncc(c1)N([C@H](C(=O)NC1CC(F)(F)C1)c1ccccc1Cl)C(=O)[C@@H]1CCC(=O)N1c1cc(ccn1)C#N, Fc1cncc(c1)N([C@H](C(=O)NC1CC(F)(F)C1)c1ccccc1Cl)C(=O)[C@@H]1CCC(=O)N1c1cc(ccn1)C#N	Launched
IWP-L6	porcupine inhibitor	PORCN			Tocris, Selleck, Selleck	97.09	O=C(CSc1nc2CCSc2c(=O)n1-c1ccccc1)Nc1ccc(cn1)-c1ccccc1, O=C(CSc1nc2CCSc2c(=O)n1-c1ccccc1)Nc1ccc(cn1)-c1ccccc1, O=C(CSc1nc2CCSc2c(=O)n1-c1ccccc1)Nc1ccc(cn1)-c1ccccc1	Preclinical
ixabepilone	microtubule stabilizing agent	TUBB	oncology	breast cancer	MedChemEx, MedChemEx, MedChemEx	98.98	C[C@H]1CCC[C@@]2(C)O[C@H]2C[C@H](NC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@H]1O)C(\C)=C\c1csc(C)n1, C[C@H]1CCC[C@@]2(C)O[C@H]2C[C@H](NC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@H]1O)C(\C)=C\c1csc(C)n1, C[C@H]1CCC[C@@]2(C)O[C@H]2C[C@H](NC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@H]1O)C(\C)=C\c1csc(C)n1	Launched
ixazomib	proteasome inhibitor		hematologic malignancy	multiple myeloma	MedChemEx, MedChemEx, MedChemEx, Selleck, Selleck, Selleck, Selleck	99.3	CC(C)C[C@H](NC(=O)CNC(=O)c1cc(Cl)ccc1Cl)B(O)O, CC(C)C[C@H](NC(=O)CNC(=O)c1cc(Cl)ccc1Cl)B(O)O, CC(C)C[C@H](NC(=O)CNC(=O)c1cc(Cl)ccc1Cl)B(O)O, CC(C)C[C@H](NC(=O)CNC(=O)c1cc(Cl)ccc1Cl)B(O)O, CC(C)C[C@H](NC(=O)CNC(=O)c1cc(Cl)ccc1Cl)B(O)O, CC(C)C[C@H](NC(=O)CNC(=O)c1cc(Cl)ccc1Cl)B(O)O, CC(C)C[C@H](NC(=O)CNC(=O)c1cc(Cl)ccc1Cl)B(O)O	Launched
ixazomib-citrate	proteasome inhibitor		hematologic malignancy	multiple myeloma	Selleck, Selleck, Selleck, Selleck	92.47	CC(C)C[C@H](NC(=O)CNC(=O)c1cc(Cl)ccc1Cl)B1OC(=O)C[C@@](CC(O)=O)(O1)C(O)=O |a:4,&1:25|, CC(C)C[C@H](NC(=O)CNC(=O)c1cc(Cl)ccc1Cl)B1OC(=O)C[C@@](CC(O)=O)(O1)C(O)=O |a:4,&1:25|, CC(C)C[C@H](NC(=O)CNC(=O)c1cc(Cl)ccc1Cl)B1OC(=O)C[C@@](CC(O)=O)(O1)C(O)=O |a:4,&1:25|, CC(C)C[C@H](NC(=O)CNC(=O)c1cc(Cl)ccc1Cl)B1OC(=O)C[C@@](CC(O)=O)(O1)C(O)=O |a:4,&1:25|	Launched
JAK3-inhibitor-V	JAK inhibitor	JAK3			Tocris, Tocris	61.67	C=CC(=O)c1ccc2ccccc2c1, C=CC(=O)c1ccc2ccccc2c1	Preclinical
JD-5037	cannabinoid receptor antagonist				MedChemEx	100	CC(C)[C@H](\N=C(\NS(=O)(=O)c1ccc(Cl)cc1)N1C[C@@H](C(=N1)c1ccc(Cl)cc1)c1ccccc1)C(N)=O |c:21|	Preclinical
JDTic	opioid receptor antagonist	OPRK1			MedChemEx, MedChemEx	94.46	CC(C)[C@@H](CN1CC[C@](C)([C@@H](C)C1)c1cccc(O)c1)NC(=O)[C@H]1Cc2ccc(O)cc2CN1, CC(C)[C@@H](CN1CC[C@](C)([C@@H](C)C1)c1cccc(O)c1)NC(=O)[C@H]1Cc2ccc(O)cc2CN1	Phase 1
JHW-007	dopamine reuptake inhibitor	SLC6A3			Tocris, Tocris	92.32	CCCCN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(c1ccc(F)cc1)c1ccc(F)cc1, CCCCN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(c1ccc(F)cc1)c1ccc(F)cc1	Preclinical
JI-101	kinase inhibitor				MedChemEx	99.03	COc1ccc(Br)cc1NC(=O)Nc1cccc2n(Cc3ccnc(N)c3)ccc12	Phase 1/Phase 2
JIB04	histone lysine demethylase inhibitor	KDM4E			Tocris, Tocris, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck	94.7	Clc1ccc(N\N=C(/c2ccccc2)c2ccccn2)nc1, Clc1ccc(N\N=C(/c2ccccc2)c2ccccn2)nc1, Clc1ccc(N\N=C(/c2ccccc2)c2ccccn2)nc1, Clc1ccc(N\N=C(/c2ccccc2)c2ccccn2)nc1, Clc1ccc(N\N=C(/c2ccccc2)c2ccccn2)nc1, Clc1ccc(N\N=C(/c2ccccc2)c2ccccn2)nc1, Clc1ccc(N\N=C(/c2ccccc2)c2ccccn2)nc1, Clc1ccc(N\N=C(/c2ccccc2)c2ccccn2)nc1, Clc1ccc(N\N=C(/c2ccccc2)c2ccccn2)nc1	Preclinical
JK-184	hedgehog pathway inhibitor				Tocris, Tocris, Tocris, Tocris, Tocris, Tocris	81.15	CCOc1ccc(Nc2nc(cs2)-c2c(C)nc3ccccn23)cc1, CCOc1ccc(Nc2nc(cs2)-c2c(C)nc3ccccn23)cc1, CCOc1ccc(Nc2nc(cs2)-c2c(C)nc3ccccn23)cc1, CCOc1ccc(Nc2nc(cs2)-c2c(C)nc3ccccn23)cc1, CCOc1ccc(Nc2nc(cs2)-c2c(C)nc3ccccn23)cc1, CCOc1ccc(Nc2nc(cs2)-c2c(C)nc3ccccn23)cc1	Preclinical
JLK-6	gamma secretase inhibitor	PSEN1			Tocris	0	COc1oc(=O)c2cc(N)ccc2c1Cl	Preclinical
JNJ-10191584	histamine receptor antagonist	HRH4			Tocris, Tocris, Tocris, Tocris	99.26	CN1CCN(CC1)C(=O)c1nc2ccc(Cl)cc2[nH]1, CN1CCN(CC1)C(=O)c1nc2ccc(Cl)cc2[nH]1, CN1CCN(CC1)C(=O)c1nc2ccc(Cl)cc2[nH]1, CN1CCN(CC1)C(=O)c1nc2ccc(Cl)cc2[nH]1	Preclinical
JNJ-10397049	orexin receptor antagonist	HCRTR1, HCRTR2			Tocris, Tocris	98.74	CC1(C)OC[C@H](NC(=O)Nc2ccc(Br)cc2Br)[C@@H](O1)c1ccccc1, CC1(C)OC[C@H](NC(=O)Nc2ccc(Br)cc2Br)[C@@H](O1)c1ccccc1	Preclinical
JNJ-16259685	glutamate receptor antagonist	GRM1			Tocris, Tocris, Tocris	97.98	CO[C@H]1CC[C@H](CC1)C(=O)c1ccc2nc3OCCCc3cc2c1 |r|, CO[C@H]1CC[C@H](CC1)C(=O)c1ccc2nc3OCCCc3cc2c1 |r|, CO[C@H]1CC[C@H](CC1)C(=O)c1ccc2nc3OCCCc3cc2c1 |r|	Preclinical
JNJ-1661010	FAAH inhibitor	FAAH			Tocris, Selleck, Selleck, Tocris	97.03	O=C(Nc1ccccc1)N1CCN(CC1)c1nc(ns1)-c1ccccc1, O=C(Nc1ccccc1)N1CCN(CC1)c1nc(ns1)-c1ccccc1, O=C(Nc1ccccc1)N1CCN(CC1)c1nc(ns1)-c1ccccc1, O=C(Nc1ccccc1)N1CCN(CC1)c1nc(ns1)-c1ccccc1	Preclinical
JNJ-17203212	TRPV antagonist	TRPV1			Tocris, Tocris, Tocris, Tocris	94.57	FC(F)(F)c1ccc(NC(=O)N2CCN(CC2)c2ncccc2C(F)(F)F)nc1, FC(F)(F)c1ccc(NC(=O)N2CCN(CC2)c2ncccc2C(F)(F)F)nc1, FC(F)(F)c1ccc(NC(=O)N2CCN(CC2)c2ncccc2C(F)(F)F)nc1, FC(F)(F)c1ccc(NC(=O)N2CCN(CC2)c2ncccc2C(F)(F)F)nc1	Preclinical
JNJ-26481585	HDAC inhibitor	HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9, MDM2			Selleck, Selleck, Selleck, MedChemEx, MedChemEx	94.07	Cn1cc(CNCC2CCN(CC2)c2ncc(cn2)C(=O)NO)c2ccccc12, Cn1cc(CNCC2CCN(CC2)c2ncc(cn2)C(=O)NO)c2ccccc12, Cn1cc(CNCC2CCN(CC2)c2ncc(cn2)C(=O)NO)c2ccccc12, Cn1cc(CNCC2CCN(CC2)c2ncc(cn2)C(=O)NO)c2ccccc12, Cn1cc(CNCC2CCN(CC2)c2ncc(cn2)C(=O)NO)c2ccccc12	Phase 2
JNJ-26990990	anticonvulsant				Enamine	93.07	NS(=O)(=O)NCc1csc2ccccc12	Phase 2
JNJ-27141491	CC chemokine receptor antagonist	CCR2			Tocris, Tocris	92.79	CC[C@@H](c1ccc(F)c(F)c1)n1c(C(=O)OC)c([nH]c1=S)-c1ccno1, CC[C@@H](c1ccc(F)c(F)c1)n1c(C(=O)OC)c([nH]c1=S)-c1ccno1	Preclinical
JNJ-37822681	dopamine receptor antagonist	DRD2			Enamine, Enamine	89	Fc1ccc(CN2CCC(CC2)Nc2ccc(nn2)C(F)(F)F)cc1F, Fc1ccc(CN2CCC(CC2)Nc2ccc(nn2)C(F)(F)F)cc1F	Phase 2
JNJ-38877605	tyrosine kinase inhibitor	MET			Selleck	97.35	Cn1cc(cn1)-c1ccc2nnc(n2n1)C(F)(F)c1ccc2ncccc2c1	Phase 1
JNJ-38877618	c-Met inhibitor				MedChemEx	97.64	FC(F)(c1nnc2ccc(nn12)-c1ccncc1)c1ccc2ncccc2c1	Phase 1
JNJ-39758979	histamine receptor antagonist				MedChemEx	96.5	CC(C)c1cc(nc(N)n1)N1CC[C@@H](N)C1	Phase 2
JNJ-40411813	glutamate receptor positive allosteric modulator	GRM2			MedChemEx	95.69	CCCCn1ccc(N2CCC(CC2)c2ccccc2)c(Cl)c1=O	Phase 2
JNJ-42041935	hypoxia inducible factor prolyl hydroxylase inhibitor	PDK2			MedChemEx, MedChemEx	98.43	OC(=O)c1cnn(c1)-c1nc2cc(Cl)c(OC(F)(F)F)cc2[nH]1, OC(=O)c1cnn(c1)-c1nc2cc(Cl)c(OC(F)(F)F)cc2[nH]1	Preclinical
JNJ-42165279	FAAH inhibitor	FAAH			MedChemEx, MedChemEx	97.53	FC1(F)Oc2ccc(CN3CCN(CC3)C(=O)Nc3cnccc3Cl)cc2O1, FC1(F)Oc2ccc(CN3CCN(CC3)C(=O)Nc3cnccc3Cl)cc2O1	Phase 2
JNJ-47965567	purinergic receptor antagonist	P2RX7			Tocris, Tocris	96.63	O=C(NCC1(CCOCC1)N1CCN(CC1)c1ccccc1)c1cccnc1Sc1ccccc1, O=C(NCC1(CCOCC1)N1CCN(CC1)c1ccccc1)c1cccnc1Sc1ccccc1	Preclinical
JNJ-54175446	purinergic receptor antagonist				Astatech	97.94	C[C@H]1N(CCc2c1nnn2-c1ncc(F)cn1)C(=O)c1cccc(c1Cl)C(F)(F)F	Phase 1
JNJ-63533054	G protein-coupled receptor agonist	GPR139			Tocris, MedChemEx, MedChemEx	98.12	C[C@H](NC(=O)CNC(=O)c1cccc(Cl)c1)c1ccccc1, C[C@H](NC(=O)CNC(=O)c1cccc(Cl)c1)c1ccccc1, C[C@H](NC(=O)CNC(=O)c1cccc(Cl)c1)c1ccccc1	Preclinical
JNJ-64619178	protein arginine N-methyltransferase inhibitor				Adooq	97.97	Nc1nc2cc(CC[C@H]3C[C@H]([C@H](O)[C@@H]3O)n3ccc4c(N)ncnc34)ccc2cc1Br	Phase 1
JNJ-678	RSV fusion inhibitor				MedChemEx	95.6	CS(=O)(=O)CCCn1c(Cn2c3cnccc3n(CC(F)(F)F)c2=O)cc2cc(Cl)ccc12	Phase 1
JNJ-7706621	CDK inhibitor	AURKA, AURKB, CDK1, CDK2			Selleck, Selleck, Selleck, Selleck, Selleck, Adooq, Adooq, Adooq	99.39	Nc1nc(Nc2ccc(cc2)S(N)(=O)=O)nn1C(=O)c1c(F)cccc1F, Nc1nc(Nc2ccc(cc2)S(N)(=O)=O)nn1C(=O)c1c(F)cccc1F, Nc1nc(Nc2ccc(cc2)S(N)(=O)=O)nn1C(=O)c1c(F)cccc1F, Nc1nc(Nc2ccc(cc2)S(N)(=O)=O)nn1C(=O)c1c(F)cccc1F, Nc1nc(Nc2ccc(cc2)S(N)(=O)=O)nn1C(=O)c1c(F)cccc1F, Nc1nc(Nc2ccc(cc2)S(N)(=O)=O)nn1C(=O)c1c(F)cccc1F, Nc1nc(Nc2ccc(cc2)S(N)(=O)=O)nn1C(=O)c1c(F)cccc1F, Nc1nc(Nc2ccc(cc2)S(N)(=O)=O)nn1C(=O)c1c(F)cccc1F	Preclinical
JNJ-7777120	histamine receptor antagonist	HRH4			Tocris, Selleck, Tocris, Tocris	97.84	CN1CCN(CC1)C(=O)c1cc2cc(Cl)ccc2[nH]1, CN1CCN(CC1)C(=O)c1cc2cc(Cl)ccc2[nH]1, CN1CCN(CC1)C(=O)c1cc2cc(Cl)ccc2[nH]1, CN1CCN(CC1)C(=O)c1cc2cc(Cl)ccc2[nH]1	Preclinical
josamycin	bacterial 50S ribosomal subunit inhibitor		pulmonary	bronchitis	MedChemEx	89.99	[H][C@@]1(C[C@@](C)(O)[C@@H](OC(=O)CC(C)C)[C@H](C)O1)O[C@@H]1[C@@H](C)O[C@@]([H])(O[C@H]2[C@@H](CC=O)C[C@@H](C)[C@@H](O)\C=C\C=C\C[C@@H](C)OC(=O)C[C@@]([H])(OC(C)=O)[C@@H]2OC)[C@H](O)[C@H]1N(C)C |t:36,38|	Launched
JPH203	solute carrier family member inhibitor				MedChemEx	92.99	N[C@@H](Cc1cc(Cl)c(OCc2cc(N)cc3nc(oc23)-c2ccccc2)c(Cl)c1)C(O)=O	Preclinical
JQ1-(+)	bromodomain inhibitor	BRD4, BRDT			Tocris, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck	97.16	Cc1nnc2[C@H](CC(=O)OC(C)(C)C)N=C(c3c(C)c(C)sc3-n12)c1ccc(Cl)cc1 |c:14|, Cc1nnc2[C@H](CC(=O)OC(C)(C)C)N=C(c3c(C)c(C)sc3-n12)c1ccc(Cl)cc1 |c:14|, Cc1nnc2[C@H](CC(=O)OC(C)(C)C)N=C(c3c(C)c(C)sc3-n12)c1ccc(Cl)cc1 |c:14|, Cc1nnc2[C@H](CC(=O)OC(C)(C)C)N=C(c3c(C)c(C)sc3-n12)c1ccc(Cl)cc1 |c:14|, Cc1nnc2[C@H](CC(=O)OC(C)(C)C)N=C(c3c(C)c(C)sc3-n12)c1ccc(Cl)cc1 |c:14|, Cc1nnc2[C@H](CC(=O)OC(C)(C)C)N=C(c3c(C)c(C)sc3-n12)c1ccc(Cl)cc1 |c:14|, Cc1nnc2[C@H](CC(=O)OC(C)(C)C)N=C(c3c(C)c(C)sc3-n12)c1ccc(Cl)cc1 |c:14|	Preclinical
JTC-801	opioid receptor antagonist	OPRL1			Tocris, Tocris, Selleck, Selleck	97.3	CCc1ccc(OCc2ccccc2C(=O)Nc2ccc3nc(C)cc(N)c3c2)cc1, CCc1ccc(OCc2ccccc2C(=O)Nc2ccc3nc(C)cc(N)c3c2)cc1, CCc1ccc(OCc2ccccc2C(=O)Nc2ccc3nc(C)cc(N)c3c2)cc1, CCc1ccc(OCc2ccccc2C(=O)Nc2ccc3nc(C)cc(N)c3c2)cc1	Phase 2
JTE-013	lysophospholipid receptor antagonist	P2RY10, S1PR2			Tocris, Tocris, Tocris	87.11	CC(C)c1cc(NNC(=O)Nc2cc(Cl)nc(Cl)c2)nc2n(C)nc(C)c12, CC(C)c1cc(NNC(=O)Nc2cc(Cl)nc(Cl)c2)nc2n(C)nc(C)c12, CC(C)c1cc(NNC(=O)Nc2cc(Cl)nc(Cl)c2)nc2n(C)nc(C)c12	Preclinical
JTE-607	cytokine production inhibitor	IL10, IL1B, IL6, TNF			Tocris, Tocris, Tocris, Tocris, Tocris	98.12	CCOC(=O)[C@H](Cc1ccccc1)NC(=O)c1cc(Cl)c(OCCN2CCN(C)CC2)c(Cl)c1O, CCOC(=O)[C@H](Cc1ccccc1)NC(=O)c1cc(Cl)c(OCCN2CCN(C)CC2)c(Cl)c1O, CCOC(=O)[C@H](Cc1ccccc1)NC(=O)c1cc(Cl)c(OCCN2CCN(C)CC2)c(Cl)c1O, CCOC(=O)[C@H](Cc1ccccc1)NC(=O)c1cc(Cl)c(OCCN2CCN(C)CC2)c(Cl)c1O, CCOC(=O)[C@H](Cc1ccccc1)NC(=O)c1cc(Cl)c(OCCN2CCN(C)CC2)c(Cl)c1O	Phase 2
JTE-907	cannabinoid receptor inverse agonist	CNR2			Tocris, Tocris, Tocris	98.31	CCCCCOc1c(OC)ccc2cc(C(=O)NCc3ccc4OCOc4c3)c(=O)[nH]c12, CCCCCOc1c(OC)ccc2cc(C(=O)NCc3ccc4OCOc4c3)c(=O)[nH]c12, CCCCCOc1c(OC)ccc2cc(C(=O)NCc3ccc4OCOc4c3)c(=O)[nH]c12	Phase 1
JW-55	tankyrase inhibitor	TNKS, TNKS2			Tocris, Tocris, ChemBridge, ChemBridge, ChemBridge, ChemBridge, ChemBridge	96.32	COc1ccc(cc1)C1(CNC(=O)c2ccc(NC(=O)c3ccco3)cc2)CCOCC1, COc1ccc(cc1)C1(CNC(=O)c2ccc(NC(=O)c3ccco3)cc2)CCOCC1, COc1ccc(cc1)C1(CNC(=O)c2ccc(NC(=O)c3ccco3)cc2)CCOCC1, COc1ccc(cc1)C1(CNC(=O)c2ccc(NC(=O)c3ccco3)cc2)CCOCC1, COc1ccc(cc1)C1(CNC(=O)c2ccc(NC(=O)c3ccco3)cc2)CCOCC1, COc1ccc(cc1)C1(CNC(=O)c2ccc(NC(=O)c3ccco3)cc2)CCOCC1, COc1ccc(cc1)C1(CNC(=O)c2ccc(NC(=O)c3ccco3)cc2)CCOCC1	Preclinical
JW-642	monoacylglycerol lipase inhibitor	MGLL			Tocris, Tocris	95.25	FC(F)(F)C(OC(=O)N1CCN(Cc2cccc(Oc3ccccc3)c2)CC1)C(F)(F)F, FC(F)(F)C(OC(=O)N1CCN(Cc2cccc(Oc3ccccc3)c2)CC1)C(F)(F)F	Preclinical
JW-67	WNT pathway inhibitor	APC, AXIN1, GSK3B			Tocris, Tocris, Tocris	96.6	O=C1Nc2ccccc2C11OCC2(CO1)COC1(OC2)C(=O)Nc2ccccc12, O=C1Nc2ccccc2C11OCC2(CO1)COC1(OC2)C(=O)Nc2ccccc12, O=C1Nc2ccccc2C11OCC2(CO1)COC1(OC2)C(=O)Nc2ccccc12	Preclinical
JW-74	tankyrase inhibitor, WNT signaling inhibitor	TNKS, TNKS2			PrincetonBio, Tocris, Tocris	99.87	COc1ccc(cc1)-n1c(SCc2nc(no2)-c2ccc(C)cc2)nnc1-c1ccncc1, COc1ccc(cc1)-n1c(SCc2nc(no2)-c2ccc(C)cc2)nnc1-c1ccncc1, COc1ccc(cc1)-n1c(SCc2nc(no2)-c2ccc(C)cc2)nnc1-c1ccncc1	Preclinical
JX-401	p38 MAPK inhibitor	MAPK14			Tocris, Tocris, Tocris	98.22	COc1cc(SC)ccc1C(=O)N1CCC(Cc2ccccc2)CC1, COc1cc(SC)ccc1C(=O)N1CCC(Cc2ccccc2)CC1, COc1cc(SC)ccc1C(=O)N1CCC(Cc2ccccc2)CC1	Preclinical
JZL-184	monoacylglucerol lipase inhibitor	MGLL			Tocris, Selleck	96.24	OC(C1CCN(CC1)C(=O)Oc1ccc(cc1)[N+]([O-])=O)(c1ccc2OCOc2c1)c1ccc2OCOc2c1, OC(C1CCN(CC1)C(=O)Oc1ccc(cc1)[N+]([O-])=O)(c1ccc2OCOc2c1)c1ccc2OCOc2c1	Preclinical
JZL-195	FAAH inhibitor, monoacylglycerol lipase inhibitor	FAAH, MGLL			Tocris, Tocris	98.35	[O-][N+](=O)c1ccc(OC(=O)N2CCN(Cc3cccc(Oc4ccccc4)c3)CC2)cc1, [O-][N+](=O)c1ccc(OC(=O)N2CCN(Cc3cccc(Oc4ccccc4)c3)CC2)cc1	Preclinical
J147	BDNF inducer				AMS	89.09	COc1cccc(\C=N\N(C(=O)C(F)(F)F)c2ccc(C)cc2C)c1	Phase 1
K-MAP					ChemBridge	92.13	OC[C@H]1O[C@@H](Nc2ccc(cc2)C(O)=O)[C@@H](O)[C@@H](O)[C@@H]1O |&1:2,&2:4,&3:15,&4:17,&5:19,r|	Phase 2
K-Ras(G12C)-inhibitor-12	K-Ras inhibitor	KRAS			MedChemEx, MedChemEx, MedChemEx	82.19	Oc1cc(Cl)c(I)cc1NCC(=O)N1CCN(CC1)C(=O)C=C, Oc1cc(Cl)c(I)cc1NCC(=O)N1CCN(CC1)C(=O)C=C, Oc1cc(Cl)c(I)cc1NCC(=O)N1CCN(CC1)C(=O)C=C	Preclinical
K-Ras(G12C)-inhibitor-6	K-Ras inhibitor				Selleck, Selleck, Selleck, Selleck	94.21	SCCCC(=O)NC1CCN(CC1)C(=O)COc1ccc(Cl)cc1Cl, SCCCC(=O)NC1CCN(CC1)C(=O)COc1ccc(Cl)cc1Cl, SCCCC(=O)NC1CCN(CC1)C(=O)COc1ccc(Cl)cc1Cl, SCCCC(=O)NC1CCN(CC1)C(=O)COc1ccc(Cl)cc1Cl	Preclinical
K-strophanthidin	ATPase inhibitor	ATP1A1			Sigma, Sigma	94.49	C[C@]12CC[C@H]3[C@@H](CC[C@]4(O)C[C@@H](O)CC[C@]34C=O)[C@@]1(O)CC[C@@H]2C1=CC(=O)OC1 |t:27|, C[C@]12CC[C@H]3[C@@H](CC[C@]4(O)C[C@@H](O)CC[C@]34C=O)[C@@]1(O)CC[C@@H]2C1=CC(=O)OC1 |t:27|	Phase 2
K-247					ChemBridge	62.72	OC[C@H]1O[C@@H](Nc2ccc(cc2)C(O)=O)[C@@H](O)[C@@H]1O |&1:2,&2:4,&3:15,&4:17,r|	Phase 1
K-858	kinesin-like spindle protein inhibitor	KIF11			Tocris, Tocris	98.42	CC(=O)NC1=NN(C(C)=O)[C@@](C)(S1)c1ccccc1 |&1:10,r,t:4|, CC(=O)NC1=NN(C(C)=O)[C@@](C)(S1)c1ccccc1 |&1:10,r,t:4|	Preclinical
kaempferol	bone resorption inhibitor, estrogen-related receptor inverse agonist	AKR1B1, ALOX15B, ALOX5, AR, CYP1B1, GLO1, HSD17B1, UGT3A1			Tocris, Selleck, Tocris, Selleck	97.71	Oc1ccc(cc1)-c1oc2cc(O)cc(O)c2c(=O)c1O, Oc1ccc(cc1)-c1oc2cc(O)cc(O)c2c(=O)c1O, Oc1ccc(cc1)-c1oc2cc(O)cc(O)c2c(=O)c1O, Oc1ccc(cc1)-c1oc2cc(O)cc(O)c2c(=O)c1O	Preclinical
KAF-156	antimalarial agent				Astatech	93.34	CC1(C)N(CCn2c(Nc3ccc(F)cc3)c(nc12)-c1ccc(F)cc1)C(=O)CN	Preclinical
kainic-acid	kainate receptor agonist	GRIA1, GRIK1, GRIK2, GRIK3, GRIK4, GRIK5			Tocris, Tocris	100	CC(=C)[C@H]1CN[C@@H]([C@H]1CC(O)=O)C(O)=O, CC(=C)[C@H]1CN[C@@H]([C@H]1CC(O)=O)C(O)=O	Preclinical
kakonein	GABA receptor antagonist, serotonin receptor antagonist				Vitas-M, Vitas-M	97.6	OC[C@H]1O[C@@H]([C@@H](O)[C@@H](O)[C@@H]1O)c1c(O)ccc2c1occ(-c1ccc(O)cc1)c2=O |&1:2,&2:4,&3:5,&4:7,&5:9,r|, OC[C@H]1O[C@@H]([C@@H](O)[C@@H](O)[C@@H]1O)c1c(O)ccc2c1occ(-c1ccc(O)cc1)c2=O |&1:2,&2:4,&3:5,&4:7,&5:9,r|	Phase 2
kanamycin	bacterial 30S ribosomal subunit inhibitor		infectious disease	gram-negative bacterial infections	MedChemEx, MedChemEx, MicroSource	0	NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1O, NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1O, NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1O	Launched
karenitecin	topoisomerase inhibitor	TOP1			MedChemEx	95.49	CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccccc4c(CC[Si](C)(C)C)c3Cn1c2=O	Phase 3
kartogenin	chondrocyte differentiation stimulator	FLNA			Tocris, Tocris	94.22	OC(=O)c1ccccc1C(=O)Nc1ccc(cc1)-c1ccccc1, OC(=O)c1ccccc1C(=O)Nc1ccc(cc1)-c1ccccc1	Preclinical
kasugamycin	bacterial 30S ribosomal subunit inhibitor				MedChemEx	100	C[C@H]1O[C@H](O[C@@H]2[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@H]2O)[C@@H](N)C[C@@H]1NC(=N)C(O)=O	Preclinical
KB-R7943	sodium/calcium exchange inhibitor	SLC8A1, TRPC3, TRPC5, TRPC6			Tocris, Tocris, Tocris	95.96	NC(=N)SCCc1ccc(OCc2ccc(cc2)[N+]([O-])=O)cc1, NC(=N)SCCc1ccc(OCc2ccc(cc2)[N+]([O-])=O)cc1, NC(=N)SCCc1ccc(OCc2ccc(cc2)[N+]([O-])=O)cc1	Preclinical
KB-SRC-4	SRC inhibitor	SRC			Tocris, Tocris, Tocris	98.82	Nc1ncnc2n(nc(-c3ccc(Cl)cc3)c12)-c1cccc(c1)-c1cnnn1Cc1cccc(c1)-c1ccccc1, Nc1ncnc2n(nc(-c3ccc(Cl)cc3)c12)-c1cccc(c1)-c1cnnn1Cc1cccc(c1)-c1ccccc1, Nc1ncnc2n(nc(-c3ccc(Cl)cc3)c12)-c1cccc(c1)-c1cnnn1Cc1cccc(c1)-c1ccccc1	Preclinical
KBG	neprilysin inhibitor	MME			SantaCruz, SantaCruz	97.5	O[C@H]1O[C@@H]2CO[C@@H](O[C@H]2[C@H](O)[C@H]1O)c1ccccc1 |a:3,8,9,11,&1:1,&2:6|, O[C@H]1O[C@@H]2CO[C@@H](O[C@H]2[C@H](O)[C@H]1O)c1ccccc1 |a:3,8,9,11,&1:1,&2:6|	Phase 2
KD-023	ACAT inhibitor	ACACA, ACACB			EMDBio, EMDBio	100	CCCCCCCCCCCCCCOc1ccc(o1)C(O)=O, CCCCCCCCCCCCCCOc1ccc(o1)C(O)=O	Phase 2
KD025	rho associated kinase inhibitor	ROCK2			MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx	98.4	CC(C)NC(=O)COc1cccc(c1)-c1nc(Nc2ccc3n[nH]cc3c2)c2ccccc2n1, CC(C)NC(=O)COc1cccc(c1)-c1nc(Nc2ccc3n[nH]cc3c2)c2ccccc2n1, CC(C)NC(=O)COc1cccc(c1)-c1nc(Nc2ccc3n[nH]cc3c2)c2ccccc2n1, CC(C)NC(=O)COc1cccc(c1)-c1nc(Nc2ccc3n[nH]cc3c2)c2ccccc2n1, CC(C)NC(=O)COc1cccc(c1)-c1nc(Nc2ccc3n[nH]cc3c2)c2ccccc2n1, CC(C)NC(=O)COc1cccc(c1)-c1nc(Nc2ccc3n[nH]cc3c2)c2ccccc2n1	Phase 2
kenpaullone	CDK inhibitor, glycogen synthase kinase inhibitor	CCNB1, CDK1, CDK5, GSK3B			Tocris, Tocris, Tocris	96.42	Brc1ccc2[nH]c-3c(CC(=O)Nc4ccccc-34)c2c1, Brc1ccc2[nH]c-3c(CC(=O)Nc4ccccc-34)c2c1, Brc1ccc2[nH]c-3c(CC(=O)Nc4ccccc-34)c2c1	Preclinical
ketanserin	serotonin receptor antagonist	ADRA1A, ADRA1B, ADRA1D, DRD1, DRD5, HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C, HTR5A, HTR7, SLC18A1, SLC18A2	cardiology	hypertension	MicroSource, Tocris, Tocris, Tocris, Selleck	98.5	Fc1ccc(cc1)C(=O)C1CCN(CCn2c(=O)[nH]c3ccccc3c2=O)CC1, Fc1ccc(cc1)C(=O)C1CCN(CCn2c(=O)[nH]c3ccccc3c2=O)CC1, Fc1ccc(cc1)C(=O)C1CCN(CCn2c(=O)[nH]c3ccccc3c2=O)CC1, Fc1ccc(cc1)C(=O)C1CCN(CCn2c(=O)[nH]c3ccccc3c2=O)CC1, Fc1ccc(cc1)C(=O)C1CCN(CCn2c(=O)[nH]c3ccccc3c2=O)CC1	Launched
ketoconazole	sterol demethylase inhibitor	KCNA10	dermatology	seborrheic dermatitis	Selleck, Selleck, Tocris, Tocris, Tocris, Tocris, Tocris	96.08	CC(=O)N1CCN(CC1)c1ccc(OC[C@@H]2CO[C@](Cn3ccnc3)(O2)c2ccc(Cl)cc2Cl)cc1 |&1:15,18|, CC(=O)N1CCN(CC1)c1ccc(OC[C@@H]2CO[C@](Cn3ccnc3)(O2)c2ccc(Cl)cc2Cl)cc1 |&1:15,18|, CC(=O)N1CCN(CC1)c1ccc(OC[C@@H]2CO[C@](Cn3ccnc3)(O2)c2ccc(Cl)cc2Cl)cc1 |&1:15,18|, CC(=O)N1CCN(CC1)c1ccc(OC[C@@H]2CO[C@](Cn3ccnc3)(O2)c2ccc(Cl)cc2Cl)cc1 |&1:15,18|, CC(=O)N1CCN(CC1)c1ccc(OC[C@@H]2CO[C@](Cn3ccnc3)(O2)c2ccc(Cl)cc2Cl)cc1 |&1:15,18|, CC(=O)N1CCN(CC1)c1ccc(OC[C@@H]2CO[C@](Cn3ccnc3)(O2)c2ccc(Cl)cc2Cl)cc1 |&1:15,18|, CC(=O)N1CCN(CC1)c1ccc(OC[C@@H]2CO[C@](Cn3ccnc3)(O2)c2ccc(Cl)cc2Cl)cc1 |&1:15,18|	Launched
ketohexokinase-inhibitor-1	kinase inhibitor				MedChemEx	86.61	[H][C@@]12CN(C[C@]1([H])[C@H]2CC(O)=O)c1cc(nc(n1)N1CC[C@@H]1C)C(F)(F)F	Preclinical
ketoprofen	cyclooxygenase inhibitor	PTGS1, PTGS2, SLC5A8	rheumatology	rheumatoid arthritis, osteoarthritis	MicroSource, Selleck, MedChemEx	99.39	C[C@@H](C(O)=O)c1cccc(c1)C(=O)c1ccccc1 |&1:1,r|, C[C@@H](C(O)=O)c1cccc(c1)C(=O)c1ccccc1 |&1:1,r|, C[C@@H](C(O)=O)c1cccc(c1)C(=O)c1ccccc1 |&1:1,r|	Launched
ketorolac	cyclooxygenase inhibitor	PTGS1, PTGS2	neurology/psychiatry	pain relief	MedChemEx, Selleck, Selleck	95.72	OC(=O)[C@H]1CCn2c1ccc2C(=O)c1ccccc1 |&1:3,r|, OC(=O)[C@H]1CCn2c1ccc2C(=O)c1ccccc1 |&1:3,r|, OC(=O)[C@H]1CCn2c1ccc2C(=O)c1ccccc1 |&1:3,r|	Launched
ketotifen	histamine receptor agonist, leukotriene receptor antagonist, phosphodiesterase inhibitor	HRH1	neurology/psychiatry	itching	Tocris, Tocris, MicroSource, Selleck	98.24	CN1CCC(CC1)=C1c2ccsc2C(O)=Cc2ccccc12 |c:16|, CN1CCC(CC1)=C1c2ccsc2C(O)=Cc2ccccc12 |c:16|, CN1CCC(CC1)=C1c2ccsc2C(O)=Cc2ccccc12 |c:16|, CN1CCC(CC1)=C1c2ccsc2C(O)=Cc2ccccc12 |c:16|	Launched
kevetrin	p53 activator				MedChemEx, MedChemEx	95.3	NC(=N)SCCCC#N, NC(=N)SCCCC#N	Phase 1
KF-38789	P selectin inhibitor	SELP			Tocris, Tocris, Tocris	93.49	COc1ccc([C@H]2CC(=NCCS2)c2c(O)cc(C)oc2=O)c(OC)c1 |&1:6,r,c:8|, COc1ccc([C@H]2CC(=NCCS2)c2c(O)cc(C)oc2=O)c(OC)c1 |&1:6,r,c:8|, COc1ccc([C@H]2CC(=NCCS2)c2c(O)cc(C)oc2=O)c(OC)c1 |&1:6,r,c:8|	Preclinical
KG-5	RAF inhibitor	BRAF, FLT3, KIT, PDGFRB			Tocris, Tocris, Tocris	99.59	CSc1nc(N)cc(Oc2ccc(cc2)-c2nnc(Nc3cccc(c3)C(F)(F)F)[nH]2)n1, CSc1nc(N)cc(Oc2ccc(cc2)-c2nnc(Nc3cccc(c3)C(F)(F)F)[nH]2)n1, CSc1nc(N)cc(Oc2ccc(cc2)-c2nnc(Nc3cccc(c3)C(F)(F)F)[nH]2)n1	Preclinical
KH-CB19	CDC inhibitor	CLK1, CLK3, DYRK1A			MedChemEx, MedChemEx, MedChemEx	54.76	CCOC(=O)c1c(C(C=N)C#N)c2ccc(Cl)c(Cl)c2n1C, CCOC(=O)c1c(C(C=N)C#N)c2ccc(Cl)c(Cl)c2n1C, CCOC(=O)c1c(C(C=N)C#N)c2ccc(Cl)c(Cl)c2n1C	Preclinical
khellin	vasodilator				MicroSource, Sigma	99.43	COc1c2ccoc2c(OC)c2oc(C)cc(=O)c12, COc1c2ccoc2c(OC)c2oc(C)cc(=O)c12	Phase 2
KHK-IN-1	hexokinase inhibitor	KHK			MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx	93.66	CSc1ccccc1Nc1nc(nc2c(NCC3CC3)ncnc12)N1CCNCC1, CSc1ccccc1Nc1nc(nc2c(NCC3CC3)ncnc12)N1CCNCC1, CSc1ccccc1Nc1nc(nc2c(NCC3CC3)ncnc12)N1CCNCC1, CSc1ccccc1Nc1nc(nc2c(NCC3CC3)ncnc12)N1CCNCC1, CSc1ccccc1Nc1nc(nc2c(NCC3CC3)ncnc12)N1CCNCC1	Preclinical
KHS-101	neural stem cell inducer	TACC3			Tocris, Tocris, Tocris	97.85	CC(C)CNc1ccnc(NCc2csc(n2)-c2ccccc2)n1, CC(C)CNc1ccnc(NCc2csc(n2)-c2ccccc2)n1, CC(C)CNc1ccnc(NCc2csc(n2)-c2ccccc2)n1	Preclinical
KI-16425	lysophosphatidic acid receptor antagonist	LPAR1, LPAR3			Selleck	96.73	C[C@@H](OC(=O)Nc1c(C)noc1-c1ccc(CSCCC(O)=O)cc1)c1ccccc1Cl |&1:1,r|	Preclinical
KI-20227	c-Fms inhibitor	CSF1R, KDR, KIT, PDGFRB			Tocris, Tocris	97.77	COc1cc(Oc2ccnc3cc(OC)c(OC)cc23)ccc1NC(=O)N[C@@H](C)c1nccs1 |&1:27,r|, COc1cc(Oc2ccnc3cc(OC)c(OC)cc23)ccc1NC(=O)N[C@@H](C)c1nccs1 |&1:27,r|	Preclinical
KI-8751	KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	KDR			Tocris, Selleck, Selleck, Tocris	97.42	COc1cc2nccc(Oc3ccc(NC(=O)Nc4ccc(F)cc4F)c(F)c3)c2cc1OC, COc1cc2nccc(Oc3ccc(NC(=O)Nc4ccc(F)cc4F)c(F)c3)c2cc1OC, COc1cc2nccc(Oc3ccc(NC(=O)Nc4ccc(F)cc4F)c(F)c3)c2cc1OC, COc1cc2nccc(Oc3ccc(NC(=O)Nc4ccc(F)cc4F)c(F)c3)c2cc1OC	Preclinical
kifunensine	mannosidase inhibitor	MAN1B1, MAN2A1			EMDBio, EMDBio, Tocris, Tocris	100	OC[C@@H]1[C@@H](O)[C@H](O)[C@H](O)[C@H]2NC(=O)C(=O)N12, OC[C@@H]1[C@@H](O)[C@H](O)[C@H](O)[C@H]2NC(=O)C(=O)N12, OC[C@@H]1[C@@H](O)[C@H](O)[C@H](O)[C@H]2NC(=O)C(=O)N12, OC[C@@H]1[C@@H](O)[C@H](O)[C@H](O)[C@H]2NC(=O)C(=O)N12	Phase 1
kinetin	cell division inducer		dermatology	sunburn	Selleck, Selleck	98.18	C(Nc1ncnc2nc[nH]c12)c1ccco1, C(Nc1ncnc2nc[nH]c12)c1ccco1	Launched
ki16198	lipoprotein antagonist	LPA			Selleck, Selleck, Selleck	96.6	COC(=O)CCSCc1ccc(cc1)-c1onc(C)c1NC(=O)O[C@@H](C)c1ccccc1Cl |&1:24,r|, COC(=O)CCSCc1ccc(cc1)-c1onc(C)c1NC(=O)O[C@@H](C)c1ccccc1Cl |&1:24,r|, COC(=O)CCSCc1ccc(cc1)-c1onc(C)c1NC(=O)O[C@@H](C)c1ccccc1Cl |&1:24,r|	Preclinical
KL-001	proteasome inhibitor	CRY1, CRY2			Tocris, Tocris, Tocris	98.65	CS(=O)(=O)N(C[C@@H](O)Cn1c2ccccc2c2ccccc12)Cc1ccco1 |&1:6,r|, CS(=O)(=O)N(C[C@@H](O)Cn1c2ccccc2c2ccccc12)Cc1ccco1 |&1:6,r|, CS(=O)(=O)N(C[C@@H](O)Cn1c2ccccc2c2ccccc12)Cc1ccco1 |&1:6,r|	Preclinical
KM-0118	anticancer agent				MedChemEx	82.7	CN(C)CCNC(=O)COc1c2Cc3cccc(Cc4cccc(Cc5cccc(Cc1ccc2)c5OCC(=O)NCCN(C)C)c4OCC(=O)NCCN(C)C)c3OCC(=O)NCCN(C)C	Phase 1
KME-4	prostaglandin inhibitor				MedChemEx	89.36	CC(C)(C)c1cc(\C=C2/CCOC2=O)cc(c1O)C(C)(C)C	Preclinical
KML29	monoacylglucerol lipase inhibitor	MGLL			MedChemEx	96.99	OC(C1CCN(CC1)C(=O)OC(C(F)(F)F)C(F)(F)F)(c1ccc2OCOc2c1)c1ccc2OCOc2c1	Preclinical
KN-62	calcium/calmodulin dependent protein kinase inhibitor, purinergic receptor antagonist	AKT1, CAMK2A, CHEK1, LCK, MAPK1, MAPK11, MAPK12, MAPK14, MAPK8, P2RX7, PRKCA, ROCK1, RPS6KB1, SGK1			MedChemEx	96.68	CN([C@@H](Cc1ccc(OS(=O)(=O)c2cccc3cnccc23)cc1)C(=O)N1CCN(CC1)c1ccccc1)S(=O)(=O)c1cccc2cnccc12 |&1:2,r|	Preclinical
KN-93	calcium/calmodulin dependent protein kinase inhibitor	CAMK2A			MedChemEx, MedChemEx, MedChemEx	98.69	COc1ccc(cc1)S(=O)(=O)N(CCO)c1ccccc1CN(C)C\C=C\c1ccc(Cl)cc1, COc1ccc(cc1)S(=O)(=O)N(CCO)c1ccccc1CN(C)C\C=C\c1ccc(Cl)cc1, COc1ccc(cc1)S(=O)(=O)N(CCO)c1ccccc1CN(C)C\C=C\c1ccc(Cl)cc1	Preclinical
Ko143	BCRP inhibitor	ABCB1, ABCC1			Tocris, MedChemEx, MedChemEx	97.42	COc1ccc2c3C[C@@H]4N([C@@H](CC(C)C)c3[nH]c2c1)C(=O)[C@H](CCC(=O)OC(C)(C)C)NC4=O, COc1ccc2c3C[C@@H]4N([C@@H](CC(C)C)c3[nH]c2c1)C(=O)[C@H](CCC(=O)OC(C)(C)C)NC4=O, COc1ccc2c3C[C@@H]4N([C@@H](CC(C)C)c3[nH]c2c1)C(=O)[C@H](CCC(=O)OC(C)(C)C)NC4=O	Preclinical
KP-1212					Berry	100	NC1=NC(=O)N(CN1)[C@H]1C[C@@H](O)[C@@H](CO)O1 |t:1|	Phase 2
KPT-185	exportin antagonist	XPO1			Selleck, Selleck, Selleck	95.93	COc1cc(cc(c1)C(F)(F)F)-c1ncn(\C=C/C(=O)OC(C)C)n1, COc1cc(cc(c1)C(F)(F)F)-c1ncn(\C=C/C(=O)OC(C)C)n1, COc1cc(cc(c1)C(F)(F)F)-c1ncn(\C=C/C(=O)OC(C)C)n1	Preclinical
KPT-276	exportin antagonist	XPO1			MedChemEx, Selleck, Selleck, Selleck	95.86	FC(F)(F)c1cc(cc(c1)C(F)(F)F)-c1ncn(\C=C/C(=O)N2CC(F)(F)C2)n1, FC(F)(F)c1cc(cc(c1)C(F)(F)F)-c1ncn(\C=C/C(=O)N2CC(F)(F)C2)n1, FC(F)(F)c1cc(cc(c1)C(F)(F)F)-c1ncn(\C=C/C(=O)N2CC(F)(F)C2)n1, FC(F)(F)c1cc(cc(c1)C(F)(F)F)-c1ncn(\C=C/C(=O)N2CC(F)(F)C2)n1	Preclinical
KPT-9274	NAMPT inhibitor				AMS	90.7	Nc1ccc(\C=C\C(=O)NCc2cc3cc(cc(-c4ccc(F)cc4)c3o2)-c2ccc(cc2)C(=O)N2CCC(F)(F)CC2)cn1	Phase 1
KR-33494	cell death inhibitor 				MedChemEx	97.06	OC(=O)c1nn(CCc2ccccc2)cc1NC(=O)CSc1ccc(Br)cc1	Preclinical
KRCA-0008	ALK inihibitor	ALK			Tocris, Tocris	93.41	COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccc(cc2OC)N2CCN(CC2)C(C)=O)n1)N1CCN(CC1)C(C)=O, COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccc(cc2OC)N2CCN(CC2)C(C)=O)n1)N1CCN(CC1)C(C)=O	Preclinical
KRN-633	VEGFR inhibitor	FLT1, FLT4, KDR			MedChemEx, Selleck, Selleck	96.26	CCCNC(=O)Nc1ccc(Oc2ncnc3cc(OC)c(OC)cc23)cc1Cl, CCCNC(=O)Nc1ccc(Oc2ncnc3cc(OC)c(OC)cc23)cc1Cl, CCCNC(=O)Nc1ccc(Oc2ncnc3cc(OC)c(OC)cc23)cc1Cl	Preclinical
KS-176	BCRP inhibitor	ABCG2			Tocris, Tocris	97.1	OCCc1ccc(NC(=O)c2ccccc2NC(=O)c2ccc(cc2)[N+]([O-])=O)cc1, OCCc1ccc(NC(=O)c2ccccc2NC(=O)c2ccc(cc2)[N+]([O-])=O)cc1	Preclinical
KT-433	uricosuric agent				Sigma	97.5	CCc1oc2ccccc2c1C(=O)c1ccc(OCC(O)=O)cc1	Phase 2
KU-0063794	mTOR inhibitor	MTOR			Selleck, Selleck, Selleck	95.33	COc1ccc(cc1CO)-c1ccc2c(nc(nc2n1)N1C[C@H](C)O[C@H](C)C1)N1CCOCC1, COc1ccc(cc1CO)-c1ccc2c(nc(nc2n1)N1C[C@H](C)O[C@H](C)C1)N1CCOCC1, COc1ccc(cc1CO)-c1ccc2c(nc(nc2n1)N1C[C@H](C)O[C@H](C)C1)N1CCOCC1	Preclinical
KU-55933	ATM kinase inhibitor	ATM, PRKDC			Tocris, Selleck	98.75	O=c1cc(oc(c1)-c1cccc2Sc3ccccc3Sc12)N1CCOCC1, O=c1cc(oc(c1)-c1cccc2Sc3ccccc3Sc12)N1CCOCC1	Preclinical
KU-60019	ATM kinase inhibitor	ATM			Tocris, Tocris, Tocris, Selleck, Selleck	96.77	C[C@H]1CN(CC(=O)Nc2ccc3Sc4c(Cc3c2)cccc4-c2cc(=O)cc(o2)N2CCOCC2)C[C@@H](C)O1, C[C@H]1CN(CC(=O)Nc2ccc3Sc4c(Cc3c2)cccc4-c2cc(=O)cc(o2)N2CCOCC2)C[C@@H](C)O1, C[C@H]1CN(CC(=O)Nc2ccc3Sc4c(Cc3c2)cccc4-c2cc(=O)cc(o2)N2CCOCC2)C[C@@H](C)O1, C[C@H]1CN(CC(=O)Nc2ccc3Sc4c(Cc3c2)cccc4-c2cc(=O)cc(o2)N2CCOCC2)C[C@@H](C)O1, C[C@H]1CN(CC(=O)Nc2ccc3Sc4c(Cc3c2)cccc4-c2cc(=O)cc(o2)N2CCOCC2)C[C@@H](C)O1	Preclinical
kuromanin	ribosyl cyclase inhibitor	CD38			MedChemEx	98.1	OC[C@H]1O[C@@H](Oc2cc3c(O)cc(O)cc3[o+]c2-c2ccc(O)c(O)c2)[C@H](O)[C@@H](O)[C@@H]1O	Preclinical
KU14R	imidazoline receptor antagonist				Tocris, Tocris, Tocris, Tocris, Tocris	98.56	CC[C@]1(Cc2ccccc2O1)c1ncc[nH]1 |&1:2,r|, CC[C@]1(Cc2ccccc2O1)c1ncc[nH]1 |&1:2,r|, CC[C@]1(Cc2ccccc2O1)c1ncc[nH]1 |&1:2,r|, CC[C@]1(Cc2ccccc2O1)c1ncc[nH]1 |&1:2,r|, CC[C@]1(Cc2ccccc2O1)c1ncc[nH]1 |&1:2,r|	Preclinical
KW-2449	Abl kinase inhibitor, Aurora kinase inhibitor, FLT3 inhibitor	ABL1, AURKA, AURKB, FLT3			Selleck, Selleck, Selleck	93.46	O=C(N1CCNCC1)c1ccc(\C=C\c2[nH]nc3ccccc23)cc1, O=C(N1CCNCC1)c1ccc(\C=C\c2[nH]nc3ccccc23)cc1, O=C(N1CCNCC1)c1ccc(\C=C\c2[nH]nc3ccccc23)cc1	Phase 1
KW-2478	HSP inhibitor				MedChemEx, MedChemEx, Selleck, Selleck	97.02	CCc1c(O)cc(O)c(C(=O)c2ccc(OCCN3CCOCC3)c(OC)c2)c1CC(=O)N(CCOC)CCOC, CCc1c(O)cc(O)c(C(=O)c2ccc(OCCN3CCOCC3)c(OC)c2)c1CC(=O)N(CCOC)CCOC, CCc1c(O)cc(O)c(C(=O)c2ccc(OCCN3CCOCC3)c(OC)c2)c1CC(=O)N(CCOC)CCOC, CCc1c(O)cc(O)c(C(=O)c2ccc(OCCN3CCOCC3)c(OC)c2)c1CC(=O)N(CCOC)CCOC	Phase 1/Phase 2
KW-3902	adenosine receptor antagonist	ADORA1, ADORA2A, ADORA2B, ADORA3			Tocris, Tocris, Axon	98.8	CCCn1c2nc([nH]c2c(=O)n(CCC)c1=O)C12C[C@@H]3C[C@H]1C[C@H](C2)C3 |&1:23,&2:21,&3:19,r|, CCCn1c2nc([nH]c2c(=O)n(CCC)c1=O)C12C[C@@H]3C[C@H]1C[C@H](C2)C3 |&1:23,&2:21,&3:19,r|, CCCn1c2nc([nH]c2c(=O)n(CCC)c1=O)C12C[C@@H]3C[C@H]1C[C@H](C2)C3 |&1:23,&2:21,&3:19,r|	Phase 3
KX2-391	SRC inhibitor, tubulin polymerization inhibitor	SRC			Selleck, Selleck, Selleck, Selleck	99.07	O=C(Cc1ccc(cn1)-c1ccc(OCCN2CCOCC2)cc1)NCc1ccccc1, O=C(Cc1ccc(cn1)-c1ccc(OCCN2CCOCC2)cc1)NCc1ccccc1, O=C(Cc1ccc(cn1)-c1ccc(OCCN2CCOCC2)cc1)NCc1ccccc1, O=C(Cc1ccc(cn1)-c1ccc(OCCN2CCOCC2)cc1)NCc1ccccc1	Phase 3
kynurenic-acid	glutamate receptor antagonist	GPR35, GRIN1, GRIN2A, GRIN2B			Tocris, Tocris, Tocris	98.64	OC(=O)c1cc(=O)c2ccccc2[nH]1, OC(=O)c1cc(=O)c2ccccc2[nH]1, OC(=O)c1cc(=O)c2ccccc2[nH]1	Phase 1
KY02111	WNT pathway inhibitor	DKK1			Tocris, Tocris, Tocris, Tocris, Selleck	98.9	COc1ccc(CCC(=O)Nc2nc3ccc(Cl)cc3s2)cc1OC, COc1ccc(CCC(=O)Nc2nc3ccc(Cl)cc3s2)cc1OC, COc1ccc(CCC(=O)Nc2nc3ccc(Cl)cc3s2)cc1OC, COc1ccc(CCC(=O)Nc2nc3ccc(Cl)cc3s2)cc1OC, COc1ccc(CCC(=O)Nc2nc3ccc(Cl)cc3s2)cc1OC	Preclinical
K02288	bone morphogenic protein inhibitor	BMP1			MedChemEx, MedChemEx, MedChemEx, Tocris, Selleck, Selleck	99.48	COc1cc(cc(OC)c1OC)-c1cc(cnc1N)-c1cccc(O)c1, COc1cc(cc(OC)c1OC)-c1cc(cnc1N)-c1cccc(O)c1, COc1cc(cc(OC)c1OC)-c1cc(cnc1N)-c1cccc(O)c1, COc1cc(cc(OC)c1OC)-c1cc(cnc1N)-c1cccc(O)c1, COc1cc(cc(OC)c1OC)-c1cc(cnc1N)-c1cccc(O)c1, COc1cc(cc(OC)c1OC)-c1cc(cnc1N)-c1cccc(O)c1	Preclinical
K145	sphingosine kinase inhibitor	SPHK2			MedChemEx, MedChemEx, MedChemEx	87.48	CCCCOc1ccc(CC\C=C2/SC(=O)N(CCN)C2=O)cc1, CCCCOc1ccc(CC\C=C2/SC(=O)N(CCN)C2=O)cc1, CCCCOc1ccc(CC\C=C2/SC(=O)N(CCN)C2=O)cc1	Preclinical
L-(+)-rhamnose-monohydrate					MedChemEx	100	C[C@@H]1O[C@@H](O)[C@H](O)[C@H](O)[C@H]1O	Preclinical
L-alanine		AARS, AARS2, ABAT, AGXT, AGXT2, GPRC6A, GPT, GPT2, KYNU, NFS1, PHYKPL, SLC1A4, SLC36A1, SLC7A8			Sigma	0	C[C@H](N)C(O)=O	Launched
L-arginine	nitric oxide precursor	ARG2, ASL, ASS1, AZIN2, GPRC6A, NOS2, NOS3, SLC7A1, SLC7A3, SLC7A4	cardiology, neurology/psychiatry, urology, obstetrics/gynecology, otolaryngology	congestive heart failure, hypertension, coronary artery disease (CAD), claudication, senile dementia, erectile dysfunction, infertility, common cold	Selleck, Selleck	100	N[C@@H](CCCNC(N)=N)C(O)=O, N[C@@H](CCCNC(N)=N)C(O)=O	Launched
L-ascorbyl-6-palmitate					MicroSource, Selleck, Selleck, MedChemEx, MedChemEx	76.78	CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(=O)[C@@H]1O |a:19,21,&1:27|, CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(=O)[C@@H]1O |a:19,21,&1:27|, CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(=O)[C@@H]1O |a:19,21,&1:27|, CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(=O)[C@@H]1O |a:19,21,&1:27|, CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(=O)[C@@H]1O |a:19,21,&1:27|	Preclinical
L-asparagine		ASNS, ASRGL1, NARS, NARS2, SLC1A5, SLC38A3			Sigma	0	N[C@@H](CC(N)=O)C(O)=O	Phase 3
L-asparagine-N-hydroxy					Sigma	98.6	N[C@@H](CC(=O)NO)C(O)=O	Preclinical
L-aspartic-acid	metallic radical formation stimulant	ACY1, ACY3, ADSS, ADSSL1, ASNS, ASPA, ASPH, ASRGL1, ASS1, CAD, DARS, DARS2, GOT1, GOT2, GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, LYZ, PAICS, RNASE1, SLC1A1, SLC25A12, SLC25A13			Sigma, Sigma, Enzo	98.1	N[C@@H](CC(O)=O)C(O)=O, N[C@@H](CC(O)=O)C(O)=O, N[C@@H](CC(O)=O)C(O)=O	Launched
L-citrulline	nitric oxide stimulant	ASS1, DDAH1, DDAH2, GPRC6A, NOS1, NOS2, NOS3, OTC, PADI1, PADI2, PADI3, PADI4, PADI6	cardiology, urology	hypertension, erectile dysfunction	Sigma, Sigma, Vitas-M, Vitas-M	100	N[C@@H](CCCNC(N)=O)C(O)=O |&1:1,r|, N[C@@H](CCCNC(N)=O)C(O)=O |&1:1,r|, N[C@@H](CCCNC(N)=O)C(O)=O |&1:1,r|, N[C@@H](CCCNC(N)=O)C(O)=O |&1:1,r|	Launched
L-cysteine		CARS, CARS2, CBS, CDO-1, CDO1, CSAD, CTH, GCLC, GCLM, GOT1, GSS, MGMT, NFS1, SLC19A3	rheumatology	osteoarthritis, rheumatoid arthritis	Sigma	0	N[C@@H](CS)C(O)=O	Launched
L-cysteinesulfinic-acid	glutamate receptor agonist	GRM1, GRM5, GSR, HMGCS2, PAPOLA, PRDX2			Tocris, Tocris	100	N[C@@H](C[S@@](O)=O)C(O)=O |a:1,&1:3|, N[C@@H](C[S@@](O)=O)C(O)=O |a:1,&1:3|	Preclinical
L-cystine		CTNS, SLC3A1, SLC7A11, SLC7A9			Sigma	0	N[C@@H](CSSC[C@H](N)C(O)=O)C(O)=O	Launched
L-ergothioneine	free radical scavenger				Enzo	100	C[N+](C)(C)[C@@H](Cc1c[nH]c(=S)[nH]1)C(O)=O	Phase 3
L-glutamic-acid	glutamate receptor agonist	AADAT, AASS, ABAT, ALDH18A1, ASNS, BCAT1, BCAT2, CCBL2, DNPEP, EARS2, ENPEP, EPRS, FOLH1, FPGS, FTCD, GAD1, GAD2, GATB, GCLC, GCLM, GGCX, GLS, GLS2, GLUD1, GLUD2, GLUL, GMPS, GOT1, GOT2, GPT, GPT2, GRIA1, GRIA2, GRIA3, GRIA4, GRID1, GRID2, GRIK1, GRIK2, GRIK3, GRIK4, GRIK5, GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, GRIN3A, GRIN3B, GRM1, GRM2, GRM3, GRM4, GRM6, GRM7, GRM8, LGSN, NADSYN1, NAGS, OPLAH, PFAS, PGCP, PSAT1, SLC1A1, SLC1A2, SLC1A3, SLC1A6, SLC1A7, SLC25A18, SLC25A22, SLC7A11, TAT			Sigma, Sigma	98.26	N[C@@H](CCC(O)=O)C(O)=O, N[C@@H](CCC(O)=O)C(O)=O	Launched
L-glutamine		CTPS1, GLUL, GPRC6A, PPAT	gastroenterology, dental, neurology/psychiatry, rheumatology	diarrhea, mucositis, muscle pain, joint pain, peptic ulcer disease (PUD), ulcerative colitis, Crohn's disease, anxiety, insomnia	Selleck, Selleck	93.22	N[C@@H](CCC(N)=O)C(O)=O, N[C@@H](CCC(N)=O)C(O)=O	Launched
L-hydroxyproline					Enamine	0	O[C@H]1CN[C@@H](C1)C(O)=O |&1:1,&2:4,r|	Launched
L-kynurenine	aryl hydrocarbon receptor agonist				MedChemEx	93.27	N[C@@H](CC(=O)c1ccccc1N)C(O)=O	Phase 1
L-leucine		BCAT1, BCAT2, LARS, LARS2, LCMT1, LCMT2			Sigma	58.9	CC(C)C[C@H](N)C(O)=O	Phase 3
L-lysine	serotonin receptor agonist	GPRC6A, KARS, SLC7A1, SLC7A2, SLC7A3, SLC7A4			Sigma	0	NCCCC[C@H](N)C(O)=O	Phase 2
L-methionine	voltage-gated calcium channel ligand	BHMT, BHMT2, METAP2, MTR, MTRR	pulmonary, allergy, neurology/psychiatry	asthma, allergic rhinitis, depression, Parkinson's Disease, schizophrenia	Sigma	97.7	CSCC[C@H](N)C(O)=O	Launched
L-mimosine	dopamine beta hydroxylase inhibitor, eukaryotic translation initiation factor inhibitor	DBH, EIF5A			Sigma	0	N[C@@H](CN1CC(=O)C(=O)C=C1)C(O)=O |c:9|	Preclinical
L-monomethylarginine	nitric oxide synthase inhibitor	NOS1, NOS2			Tocris	0	CN[C@@H](CCCNC(N)=N)C(O)=O	Phase 3
L-NAME	nitric oxide synthase inhibitor	NOS3			Tocris, Tocris, Tocris	96.03	COC(=O)[C@@H](N)CCCNC(N)=N[N+]([O-])=O, COC(=O)[C@@H](N)CCCNC(N)=N[N+]([O-])=O, COC(=O)[C@@H](N)CCCNC(N)=N[N+]([O-])=O	Phase 2/Phase 3
L-NIL	nitric oxide synthase inhibitor	NOS1, NOS2, NOS3			Tocris, Tocris	100	CC(=N)NCCCC[C@H](N)C(O)=O, CC(=N)NCCCC[C@H](N)C(O)=O	Preclinical
L-phenylisopropyladenosine					Sigma	86.39	C[C@H](Cc1ccccc1)Nc1ncnc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O	Preclinical
L-proline	glutamate receptor agonist	EPRS, L3HYPDH, P3H1, P3H2, P3H3, P4HA1, P4HA2, PARS2, PPIA, PPIB, PPIC, PPIF, PPIG, PPIH, PRODH, PROSC, PYCR1, PYCR2, PYCRL, SLC6A14, SLC6A7			Sigma	99.2	OC(=O)[C@@H]1CCCN1	Launched
L-quisqualic-acid	glutamate receptor agonist	FOLH1, GRIA2, GRIK1, GRIK2, GRM1, GRM2, GRM3, GRM5, GRM7, GRM8			Tocris, Tocris, Tocris, Tocris, Tocris	100	N[C@@H](Cn1oc(=O)[nH]c1=O)C(O)=O, N[C@@H](Cn1oc(=O)[nH]c1=O)C(O)=O, N[C@@H](Cn1oc(=O)[nH]c1=O)C(O)=O, N[C@@H](Cn1oc(=O)[nH]c1=O)C(O)=O, N[C@@H](Cn1oc(=O)[nH]c1=O)C(O)=O	Preclinical
L-theanine	glutamate receptor antagonist				LKT	100	CCNC(=O)CC[C@H](N)C(O)=O	Launched
L-threonine		TARS, TARS2, THNSL1			Sigma	0	C[C@@H](O)[C@H](N)C(O)=O	Phase 2
L-valine					MedChemEx, Enzo	100	CC(C)[C@@H](N)C(O)=O, CC(C)[C@@H](N)C(O)=O	Phase 2
L-152804	neuropeptide receptor antagonist	NPY5R			Tocris, Tocris, Tocris	94.15	CC1(C)CC(=O)C([C@@H]2C3=C(CC(C)(C)CC3=O)Oc3ccccc23)C(=O)C1 |&1:7,r,t:8|, CC1(C)CC(=O)C([C@@H]2C3=C(CC(C)(C)CC3=O)Oc3ccccc23)C(=O)C1 |&1:7,r,t:8|, CC1(C)CC(=O)C([C@@H]2C3=C(CC(C)(C)CC3=O)Oc3ccccc23)C(=O)C1 |&1:7,r,t:8|	Preclinical
L-161982	prostanoid receptor antagonist	PTGER4			Tocris, Tocris, Tocris, Tocris	98.41	CCCCc1nn(-c2ccccc2C(F)(F)F)c(=O)n1Cc1ccc(cc1)-c1ccccc1S(=O)(=O)NC(=O)c1sccc1C, CCCCc1nn(-c2ccccc2C(F)(F)F)c(=O)n1Cc1ccc(cc1)-c1ccccc1S(=O)(=O)NC(=O)c1sccc1C, CCCCc1nn(-c2ccccc2C(F)(F)F)c(=O)n1Cc1ccc(cc1)-c1ccccc1S(=O)(=O)NC(=O)c1sccc1C, CCCCc1nn(-c2ccccc2C(F)(F)F)c(=O)n1Cc1ccc(cc1)-c1ccccc1S(=O)(=O)NC(=O)c1sccc1C	Preclinical
L-165041	PPAR receptor agonist	PPARD			Tocris, Tocris, Tocris, Tocris	98.7	CCCc1c(O)c(ccc1OCCCOc1ccc(OCC(O)=O)cc1)C(C)=O, CCCc1c(O)c(ccc1OCCCOc1ccc(OCC(O)=O)cc1)C(C)=O, CCCc1c(O)c(ccc1OCCCOc1ccc(OCC(O)=O)cc1)C(C)=O, CCCc1c(O)c(ccc1OCCCOc1ccc(OCC(O)=O)cc1)C(C)=O	Preclinical
L-168049	glucagon receptor antagonist	GCGR			Tocris, Tocris, Tocris, Tocris	96.62	CCCOc1ccc(Br)cc1-c1cc([nH]c1-c1ccncc1)-c1ccc(Cl)cc1, CCCOc1ccc(Br)cc1-c1cc([nH]c1-c1ccncc1)-c1ccc(Cl)cc1, CCCOc1ccc(Br)cc1-c1cc([nH]c1-c1ccncc1)-c1ccc(Cl)cc1, CCCOc1ccc(Br)cc1-c1cc([nH]c1-c1ccncc1)-c1ccc(Cl)cc1	Preclinical
L-365260	CCK receptor antagonist	CCKAR, CCKBR, KCNQ1			Tocris	98.98	CN1c2ccccc2C(=N[C@@H](NC(=O)Nc2cccc(C)c2)C1=O)c1ccccc1 |c:9|	Phase 2
L-368899	oxytocin receptor antagonist	AVPR1A, AVPR2, OXTR			Tocris	95.02	Cc1ccccc1N1CCN(CC1)S(=O)(=O)C[C@]12CC[C@H](C[C@@H]1NC(=O)[C@@H](N)CCS(C)(=O)=O)C2(C)C	Phase 1
L-655,708	GABA receptor inverse agonist	GABRA1, GABRA2, GABRA3, GABRA5, GABRG2			Tocris, Tocris, Tocris, Tocris, Tocris	98.39	CCOC(=O)c1ncn-2c1[C@@H]1CCCN1C(=O)c1cc(OC)ccc-21, CCOC(=O)c1ncn-2c1[C@@H]1CCCN1C(=O)c1cc(OC)ccc-21, CCOC(=O)c1ncn-2c1[C@@H]1CCCN1C(=O)c1cc(OC)ccc-21, CCOC(=O)c1ncn-2c1[C@@H]1CCCN1C(=O)c1cc(OC)ccc-21, CCOC(=O)c1ncn-2c1[C@@H]1CCCN1C(=O)c1cc(OC)ccc-21	Preclinical
L-655240	thromboxane receptor antagonist	PTGES			Tocris, Tocris	98.81	Cc1c(CC(C)(C)C(O)=O)n(Cc2ccc(Cl)cc2)c2ccc(F)cc12, Cc1c(CC(C)(C)C(O)=O)n(Cc2ccc(Cl)cc2)c2ccc(F)cc12	Phase 1
L-670596	prostanoid receptor antagonist				Tocris, Tocris, Tocris	98.01	CS(=O)(=O)c1ccc(Cn2c3[C@@H](CC(O)=O)CCCc3c3cc(F)cc(F)c23)cc1 |&1:11,r|, CS(=O)(=O)c1ccc(Cn2c3[C@@H](CC(O)=O)CCCc3c3cc(F)cc(F)c23)cc1 |&1:11,r|, CS(=O)(=O)c1ccc(Cn2c3[C@@H](CC(O)=O)CCCc3c3cc(F)cc(F)c23)cc1 |&1:11,r|	Preclinical
L-689560	glutamate receptor antagonist	GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D			Tocris, Tocris, Tocris	98.1	OC(=O)[C@H]1C[C@H](NC(=O)Nc2ccccc2)c2c(Cl)cc(Cl)cc2N1, OC(=O)[C@H]1C[C@H](NC(=O)Nc2ccccc2)c2c(Cl)cc(Cl)cc2N1, OC(=O)[C@H]1C[C@H](NC(=O)Nc2ccccc2)c2c(Cl)cc(Cl)cc2N1	Preclinical
L-690330	inositol monophosphatase inhibitor	IMPA1			Tocris	0	CC(Oc1ccc(O)cc1)(P(O)(O)=O)P(O)(O)=O	Preclinical
L-693403	sigma receptor agonist, sigma receptor antagonist	DRD2, SIGMAR1			Tocris, Tocris, Tocris, Tocris, Tocris	96.18	C(N1CCC2(CCc3ccccc23)CC1)c1ccccc1, C(N1CCC2(CCc3ccccc23)CC1)c1ccccc1, C(N1CCC2(CCc3ccccc23)CC1)c1ccccc1, C(N1CCC2(CCc3ccccc23)CC1)c1ccccc1, C(N1CCC2(CCc3ccccc23)CC1)c1ccccc1	Preclinical
L-694247	serotonin receptor agonist	HTR1A, HTR1B, HTR1D			Tocris, Tocris	91.42	CS(=O)(=O)Nc1ccc(Cc2noc(n2)-c2ccc3[nH]cc(CCN)c3c2)cc1, CS(=O)(=O)Nc1ccc(Cc2noc(n2)-c2ccc3[nH]cc(CCN)c3c2)cc1	Preclinical
L-701252	glutamate receptor antagonist	GRIN1			Tocris	97.91	Oc1c(C(=O)C2CC2)c(=O)[nH]c2cc(Cl)ccc12	Preclinical
L-701324	glutamate receptor antagonist	GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D			Tocris, Tocris, Tocris, Tocris	98.44	Oc1c(-c2cccc(Oc3ccccc3)c2)c(=O)[nH]c2cc(Cl)ccc12, Oc1c(-c2cccc(Oc3ccccc3)c2)c(=O)[nH]c2cc(Cl)ccc12, Oc1c(-c2cccc(Oc3ccccc3)c2)c(=O)[nH]c2cc(Cl)ccc12, Oc1c(-c2cccc(Oc3ccccc3)c2)c(=O)[nH]c2cc(Cl)ccc12	Preclinical
L-732,138	tachykinin antagonist	TACR1, TACR2			Tocris, Tocris, Tocris, Tocris	97.96	CC(=O)N[C@H](Cc1c[nH]c2ccccc12)C(=O)OCc1cc(cc(c1)C(F)(F)F)C(F)(F)F, CC(=O)N[C@H](Cc1c[nH]c2ccccc12)C(=O)OCc1cc(cc(c1)C(F)(F)F)C(F)(F)F, CC(=O)N[C@H](Cc1c[nH]c2ccccc12)C(=O)OCc1cc(cc(c1)C(F)(F)F)C(F)(F)F, CC(=O)N[C@H](Cc1c[nH]c2ccccc12)C(=O)OCc1cc(cc(c1)C(F)(F)F)C(F)(F)F	Preclinical
L-733060	tachykinin antagonist	TACR1			Tocris, Tocris, Tocris, Tocris	96.09	FC(F)(F)c1cc(CO[C@H]2CCCN[C@H]2c2ccccc2)cc(c1)C(F)(F)F, FC(F)(F)c1cc(CO[C@H]2CCCN[C@H]2c2ccccc2)cc(c1)C(F)(F)F, FC(F)(F)c1cc(CO[C@H]2CCCN[C@H]2c2ccccc2)cc(c1)C(F)(F)F, FC(F)(F)c1cc(CO[C@H]2CCCN[C@H]2c2ccccc2)cc(c1)C(F)(F)F	Preclinical
L-741742	dopamine receptor antagonist	DRD3, DRD4, SCN1A, SCN3A			Tocris, Tocris	97.25	Cc1c(noc1-c1ccc(Cl)cc1)C1CCN(CCc2ccccc2)CC1, Cc1c(noc1-c1ccc(Cl)cc1)C1CCN(CCc2ccccc2)CC1	Preclinical
L-745870	dopamine receptor antagonist	DRD1, DRD2, DRD3, DRD4, HTR1A, HTR2A, HTR6, HTR7			Tocris, Tocris, Tocris	93.03	Clc1ccc(cc1)N1CCN(Cc2c[nH]c3ncccc23)CC1, Clc1ccc(cc1)N1CCN(Cc2c[nH]c3ncccc23)CC1, Clc1ccc(cc1)N1CCN(Cc2c[nH]c3ncccc23)CC1	Preclinical
L-755507	adrenergic receptor agonist	ADRB1, ADRB2, ADRB3			Tocris, Tocris, Tocris	96.7	CCCCCCNC(=O)Nc1ccc(cc1)S(=O)(=O)Nc1ccc(CCNC[C@H](O)COc2ccc(O)cc2)cc1, CCCCCCNC(=O)Nc1ccc(cc1)S(=O)(=O)Nc1ccc(CCNC[C@H](O)COc2ccc(O)cc2)cc1, CCCCCCNC(=O)Nc1ccc(cc1)S(=O)(=O)Nc1ccc(CCNC[C@H](O)COc2ccc(O)cc2)cc1	Preclinical
L-760735	tachykinin antagonist	TACR1			Tocris, Tocris	92.01	C[C@@H](O[C@H]1OCCN(Cc2n[nH]nc2CN(C)C)[C@H]1c1ccc(F)cc1)c1cc(cc(c1)C(F)(F)F)C(F)(F)F, C[C@@H](O[C@H]1OCCN(Cc2n[nH]nc2CN(C)C)[C@H]1c1ccc(F)cc1)c1cc(cc(c1)C(F)(F)F)C(F)(F)F	Preclinical
L-778123	farnesyltransferase inhibitor	FNTA, FNTB, PGGT1B			MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx	96.64	Clc1cccc(c1)N1CCN(Cc2cncn2Cc2ccc(cc2)C#N)CC1=O, Clc1cccc(c1)N1CCN(Cc2cncn2Cc2ccc(cc2)C#N)CC1=O, Clc1cccc(c1)N1CCN(Cc2cncn2Cc2ccc(cc2)C#N)CC1=O, Clc1cccc(c1)N1CCN(Cc2cncn2Cc2ccc(cc2)C#N)CC1=O, Clc1cccc(c1)N1CCN(Cc2cncn2Cc2ccc(cc2)C#N)CC1=O	Phase 1
L-798106	prostanoid receptor antagonist	PTGER3			Tocris, Tocris, Tocris	99.28	COc1ccc(Br)cc1S(=O)(=O)NC(=O)\C=C\c1ccccc1Cc1ccc2ccccc2c1, COc1ccc(Br)cc1S(=O)(=O)NC(=O)\C=C\c1ccccc1Cc1ccc2ccccc2c1, COc1ccc(Br)cc1S(=O)(=O)NC(=O)\C=C\c1ccccc1Cc1ccc2ccccc2c1	Preclinical
L-838417	GABA receptor partial agonist	GABRA1, GABRA2, GABRA3, GABRA5			Tocris, Tocris, Tocris	97.33	Cn1ncnc1COc1nn2c(nnc2cc1C(C)(C)C)-c1cc(F)ccc1F, Cn1ncnc1COc1nn2c(nnc2cc1C(C)(C)C)-c1cc(F)ccc1F, Cn1ncnc1COc1nn2c(nnc2cc1C(C)(C)C)-c1cc(F)ccc1F	Preclinical
labetalol	adrenergic receptor antagonist	ADRA1D, ADRB1, ADRB2	cardiology	hypertension	CombiBlocks, CombiBlocks	97.47	C[C@@H](CCc1ccccc1)NC[C@@H](O)c1ccc(O)c(c1)C(N)=O |&1:1,&2:12,r|, C[C@@H](CCc1ccccc1)NC[C@@H](O)c1ccc(O)c(c1)C(N)=O |&1:1,&2:12,r|	Launched
lacidipine	calcium channel blocker	CACNA1C	cardiology	hypertension	MedChemEx, MedChemEx, MedChemEx, Selleck, Selleck, Selleck	97.25	CCOC(=O)C1=C(C)NC(C)=C(C1c1ccccc1\C=C\C(=O)OC(C)(C)C)C(=O)OCC |c:5,10|, CCOC(=O)C1=C(C)NC(C)=C(C1c1ccccc1\C=C\C(=O)OC(C)(C)C)C(=O)OCC |c:5,10|, CCOC(=O)C1=C(C)NC(C)=C(C1c1ccccc1\C=C\C(=O)OC(C)(C)C)C(=O)OCC |c:5,10|, CCOC(=O)C1=C(C)NC(C)=C(C1c1ccccc1\C=C\C(=O)OC(C)(C)C)C(=O)OCC |c:5,10|, CCOC(=O)C1=C(C)NC(C)=C(C1c1ccccc1\C=C\C(=O)OC(C)(C)C)C(=O)OCC |c:5,10|, CCOC(=O)C1=C(C)NC(C)=C(C1c1ccccc1\C=C\C(=O)OC(C)(C)C)C(=O)OCC |c:5,10|	Launched
lacitol	laxative		gastroenterology	constipation	MicroSource, MicroSource, Sigma	100	OC[C@H](O)[C@@H](O)[C@H](O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O)[C@H](O)CO, OC[C@H](O)[C@@H](O)[C@H](O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O)[C@H](O)CO, OC[C@H](O)[C@@H](O)[C@H](O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O)[C@H](O)CO	Launched
lactulose	laxative		gastroenterology	portal-systemic encephalopathy (PSE)	MedChemEx, MicroSource, MicroSource	100	OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O, OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O, OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O	Launched
lafutidine	histamine receptor antagonist	HRH2	gastroenterology	duodenal ulcer disease, peptic ulcer disease (PUD)	MedChemEx	98.46	O=C(C[S@@](=O)Cc1ccco1)NC\C=C/COc1cc(CN2CCCCC2)ccn1 |&1:3|	Launched
lamivudine	nucleoside reverse transcriptase inhibitor		infectious disease	human immunodeficiency virus (HIV-1), acquired immunodeficiency syndrome (AIDS), hepatitis B	Selleck, MedChemEx	98.68	Nc1ccn([C@@H]2CS[C@H](CO)O2)c(=O)n1, Nc1ccn([C@@H]2CS[C@H](CO)O2)c(=O)n1	Launched
lamotrigine	serotonin receptor antagonist, sodium channel blocker	SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A	neurology/psychiatry	epilepsy, bipolar disorder	MicroSource, Selleck, Tocris, Tocris	99.52	Nc1nnc(c(N)n1)-c1cccc(Cl)c1Cl, Nc1nnc(c(N)n1)-c1cccc(Cl)c1Cl, Nc1nnc(c(N)n1)-c1cccc(Cl)c1Cl, Nc1nnc(c(N)n1)-c1cccc(Cl)c1Cl	Launched
lanabecestat	beta secretase inhibitor				MedChemEx	97.66	CO[C@H]1CC[C@@]2(Cc3ccc(cc3[C@@]22N=C(C)C(N)=N2)-c2cncc(c2)C#CC)CC1 |c:20,t:16|	Phase 3
lanatoside-C	cardiac glycoside				MicroSource, MicroSource	98.52	C[C@H]1O[C@H](C[C@H](O)[C@@H]1O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](OC(C)=O)[C@H](O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)[C@@H](C)O2)[C@@H](C)O1)O[C@H]1CC[C@@]2(C)[C@@H](CC[C@H]3[C@@H]2C[C@@H](O)[C@]2(C)[C@H](CC[C@]32O)C2=CC(=O)OC2)C1 |a:1,3,5,7,9,11,13,15,17,22,24,26,29,31,33,35,38,42,45,53,55,57,60,&1:47,&2:50,&3:51,t:69|, C[C@H]1O[C@H](C[C@H](O)[C@@H]1O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](OC(C)=O)[C@H](O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)[C@@H](C)O2)[C@@H](C)O1)O[C@H]1CC[C@@]2(C)[C@@H](CC[C@H]3[C@@H]2C[C@@H](O)[C@]2(C)[C@H](CC[C@]32O)C2=CC(=O)OC2)C1 |a:1,3,5,7,9,11,13,15,17,22,24,26,29,31,33,35,38,42,45,53,55,57,60,&1:47,&2:50,&3:51,t:69|	Preclinical
landiolol	adrenergic receptor antagonist	ADRB1	cardiology	cardiac arrythmia	AKSci, AKSci	98.94	CC1(C)OC[C@@H](COC(=O)CCc2ccc(OC[C@@H](O)CNCCNC(=O)N3CCOCC3)cc2)O1, CC1(C)OC[C@@H](COC(=O)CCc2ccc(OC[C@@H](O)CNCCNC(=O)N3CCOCC3)cc2)O1	Launched
lanifibranor	PPAR receptor agonist				MedChemEx	90.62	OC(=O)CCCc1cc2cc(Cl)ccc2n1S(=O)(=O)c1ccc2ncsc2c1	Phase 2
lanoconazole	sterol demethylase inhibitor		infectious disease	fungal infection	AKSci	96.68	Clc1ccccc1[C@H]1CS\C(S1)=C(\C#N)n1ccnc1 |&1:7,r|	Launched
lansoprazole	ATPase inhibitor	ATP4A, ATP4B	gastroenterology	heartburn	Tocris	95.82	Cc1c(OCC(F)(F)F)ccnc1C[S@@](=O)c1nc2ccccc2[nH]1 |&1:14,r|	Launched
lapatinib	EGFR inhibitor	EGFR, ERBB2	oncology	breast cancer	Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck	97.32	CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1, CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1, CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1, CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1, CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1, CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1, CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1, CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1	Launched
lappaconite	sodium channel blocker				Selleck	89.72	CCN1C[C@@]2(CC[C@H](OC)[C@@]34[C@@H]5C[C@H]6[C@H](OC)[C@]5(O)[C@](O)(C[C@@H]6OC)[C@@H](C[C@H]23)[C@@H]14)OC(=O)c1ccccc1NC(C)=O	Phase 2
laquinimod	immunosuppressant	CXCL2			Selleck, MedChemEx, MedChemEx, Selleck, Selleck	86.53	CCN(C(=O)c1c(O)c2c(Cl)cccc2n(C)c1=O)c1ccccc1, CCN(C(=O)c1c(O)c2c(Cl)cccc2n(C)c1=O)c1ccccc1, CCN(C(=O)c1c(O)c2c(Cl)cccc2n(C)c1=O)c1ccccc1, CCN(C(=O)c1c(O)c2c(Cl)cccc2n(C)c1=O)c1ccccc1, CCN(C(=O)c1c(O)c2c(Cl)cccc2n(C)c1=O)c1ccccc1	Phase 3
larazotide-acetate	tight junction regulator				MedChemEx	79.47	CC(C)C[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)CN)C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O	Phase 2
laropiprant	prostanoid receptor antagonist	PTGDR, PTGDR2, PTGER1, PTGER2, PTGER3, PTGFR, PTGIR, TBXA2R	cardiology	cholesterol	MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx	98.78	CS(=O)(=O)c1cc(F)cc2c3CC[C@H](CC(O)=O)c3n(Cc3ccc(Cl)cc3)c12, CS(=O)(=O)c1cc(F)cc2c3CC[C@H](CC(O)=O)c3n(Cc3ccc(Cl)cc3)c12, CS(=O)(=O)c1cc(F)cc2c3CC[C@H](CC(O)=O)c3n(Cc3ccc(Cl)cc3)c12, CS(=O)(=O)c1cc(F)cc2c3CC[C@H](CC(O)=O)c3n(Cc3ccc(Cl)cc3)c12, CS(=O)(=O)c1cc(F)cc2c3CC[C@H](CC(O)=O)c3n(Cc3ccc(Cl)cc3)c12	Launched
larotrectinib	tropomyosin receptor kinase inhibitor	NTRK1, NTRK2, NTRK3			MedChemEx, MedChemEx	96.21	O[C@H]1CCN(C1)C(=O)Nc1cnn2ccc(nc12)N1CCC[C@@H]1c1cc(F)ccc1F, O[C@H]1CCN(C1)C(=O)Nc1cnn2ccc(nc12)N1CCC[C@@H]1c1cc(F)ccc1F	Launched
lasalocid	bacterial permeability inducer		infectious disease	coccidiosis	MedChemEx	88.82	CC[C@H]([C@H]1O[C@@](CC)(C[C@@H]1C)[C@H]1CC[C@](O)(CC)[C@H](C)O1)C(=O)[C@@H](C)[C@@H](O)[C@H](C)CCc1ccc(C)c(O)c1C(O)=O	Launched
lasmiditan	serotonin receptor agonist				MedChemEx	93.04	CN1CCC(CC1)C(=O)c1cccc(NC(=O)c2c(F)cc(F)cc2F)n1	Launched
lasofoxifene	selective estrogen receptor modulator (SERM)	ESR1, ESR2	orthopedics, oncology	osteoporosis, breast cancer	MedChemEx, MedChemEx	98.71	O[C@@H]([C@H](O)C(O)=O)C(O)=O.Oc1ccc2[C@H]([C@H](CCc2c1)c1ccccc1)c1ccc(OCCN2CCCC2)cc1, O[C@@H]([C@H](O)C(O)=O)C(O)=O.Oc1ccc2[C@H]([C@H](CCc2c1)c1ccccc1)c1ccc(OCCN2CCCC2)cc1	Launched
latanoprost	prostanoid receptor agonist	PTGFR	ophthalmology	ocular hypertension, glaucoma	Enzo, Enzo	98.27	CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCc1ccccc1, CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCc1ccccc1	Launched
latrepirdine	glutamate receptor antagonist	HRH1, HTR6			Tocris, ChemDiv, ChemDiv, Adooq, Adooq	95.21	CN1CCc2c(C1)c1cc(C)ccc1n2CCc1ccc(C)nc1, CN1CCc2c(C1)c1cc(C)ccc1n2CCc1ccc(C)nc1, CN1CCc2c(C1)c1cc(C)ccc1n2CCc1ccc(C)nc1, CN1CCc2c(C1)c1cc(C)ccc1n2CCc1ccc(C)nc1, CN1CCc2c(C1)c1cc(C)ccc1n2CCc1ccc(C)nc1	Phase 3
latrunculin-B	actin polymerization inhibitor	ACTA1, MKL1, SPIRE2			EMDBio, EMD	68.21	C[C@H]1CC[C@@H]2C[C@H](C[C@@](O)(O2)[C@@H]2CSC(=O)N2)OC(=O)\C=C(C)/CC\C=C/1 |c:27,t:22|, C[C@H]1CC[C@@H]2C[C@H](C[C@@](O)(O2)[C@@H]2CSC(=O)N2)OC(=O)\C=C(C)/CC\C=C/1 |c:27,t:22|	Phase 1
lauric-acid	bacterial permeability inducer	GPR84, HNF4A, LTF, LY96, PLA2G2A, TLR4			Enzo	58.87	CCCCCCCCCCCC(O)=O	Phase 3
lauric-diethanolamide					MedChemEx, Enamine	97.68	CCCCCCCCCCCC(=O)N(CCO)CCO, CCCCCCCCCCCC(=O)N(CCO)CCO	Preclinical
laurocapram					CombiBlocks, InterBioScreen	94.26	CCCCCCCCCCCCN1CCCCCC1=O, CCCCCCCCCCCCN1CCCCCC1=O	Phase 3
lazabemide	monoamine oxidase inhibitor	MAOB			Tocris, Tocris, Tocris	89.6	NCCNC(=O)c1ccc(Cl)cn1, NCCNC(=O)c1ccc(Cl)cn1, NCCNC(=O)c1ccc(Cl)cn1	Phase 3
lazertinib	tyrosine kinase inhibitor				MedChemEx	96.15	COc1cc(N2CCOCC2)c(NC(=O)C=C)cc1Nc1nccc(n1)-n1cc(CN(C)C)c(n1)-c1ccccc1	Phase 1/Phase 2
LB-100	protein phosphatase inhibitor				MedChemEx	29.5	CN1CCN(CC1)C(=O)[C@@H]1[C@H]2CC[C@H](O2)[C@@H]1C(O)=O |&1:10,13,&2:15,&3:9|	Phase 2
LB42708	farnesyltransferase inhibitor				Tocris, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Tocris, Selleck	97.41	Brc1ccc(Cn2cncc2Cn2cc(C(=O)N3CCOCC3)c(c2)-c2cccc3ccccc23)cc1, Brc1ccc(Cn2cncc2Cn2cc(C(=O)N3CCOCC3)c(c2)-c2cccc3ccccc23)cc1, Brc1ccc(Cn2cncc2Cn2cc(C(=O)N3CCOCC3)c(c2)-c2cccc3ccccc23)cc1, Brc1ccc(Cn2cncc2Cn2cc(C(=O)N3CCOCC3)c(c2)-c2cccc3ccccc23)cc1, Brc1ccc(Cn2cncc2Cn2cc(C(=O)N3CCOCC3)c(c2)-c2cccc3ccccc23)cc1, Brc1ccc(Cn2cncc2Cn2cc(C(=O)N3CCOCC3)c(c2)-c2cccc3ccccc23)cc1, Brc1ccc(Cn2cncc2Cn2cc(C(=O)N3CCOCC3)c(c2)-c2cccc3ccccc23)cc1, Brc1ccc(Cn2cncc2Cn2cc(C(=O)N3CCOCC3)c(c2)-c2cccc3ccccc23)cc1, Brc1ccc(Cn2cncc2Cn2cc(C(=O)N3CCOCC3)c(c2)-c2cccc3ccccc23)cc1, Brc1ccc(Cn2cncc2Cn2cc(C(=O)N3CCOCC3)c(c2)-c2cccc3ccccc23)cc1	Preclinical
LCL-161	XIAP inhibitor	BIRC2, XIAP			MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx	95.17	CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1c1nc(cs1)C(=O)c1ccc(F)cc1, CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1c1nc(cs1)C(=O)c1ccc(F)cc1, CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1c1nc(cs1)C(=O)c1ccc(F)cc1, CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1c1nc(cs1)C(=O)c1ccc(F)cc1, CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1c1nc(cs1)C(=O)c1ccc(F)cc1, CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1c1nc(cs1)C(=O)c1ccc(F)cc1, CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1c1nc(cs1)C(=O)c1ccc(F)cc1, CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1c1nc(cs1)C(=O)c1ccc(F)cc1	Phase 2
LCQ908	diacylglycerol O acyltransferase inhibitor	DGAT1			MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx	91.79	OC(=O)C[C@H]1CC[C@@H](CC1)c1ccc(cc1)-c1ccc(Nc2ccc(nc2)C(F)(F)F)cn1 |r|, OC(=O)C[C@H]1CC[C@@H](CC1)c1ccc(cc1)-c1ccc(Nc2ccc(nc2)C(F)(F)F)cn1 |r|, OC(=O)C[C@H]1CC[C@@H](CC1)c1ccc(cc1)-c1ccc(Nc2ccc(nc2)C(F)(F)F)cn1 |r|, OC(=O)C[C@H]1CC[C@@H](CC1)c1ccc(cc1)-c1ccc(Nc2ccc(nc2)C(F)(F)F)cn1 |r|, OC(=O)C[C@H]1CC[C@@H](CC1)c1ccc(cc1)-c1ccc(Nc2ccc(nc2)C(F)(F)F)cn1 |r|, OC(=O)C[C@H]1CC[C@@H](CC1)c1ccc(cc1)-c1ccc(Nc2ccc(nc2)C(F)(F)F)cn1 |r|	Phase 3
LCZ696	angiotensin receptor antagonist		cardiology	angioedema, hypotension		0		Launched
LDC1267	protein tyrosine kinase inhibitor	AXL, MERTK, TYRO3			MedChemEx, MedChemEx	98.38	CCOc1cn(nc1C(=O)Nc1ccc(Oc2ccnc3cc(OC)c(OC)cc23)c(F)c1)-c1ccc(F)cc1C, CCOc1cn(nc1C(=O)Nc1ccc(Oc2ccnc3cc(OC)c(OC)cc23)c(F)c1)-c1ccc(F)cc1C	Preclinical
LDN-209929	haspin kinase inhibitor	GSG2			Tocris, Tocris	72.25	COc1ccc2nc3ccc(Cl)cc3c(SCCCN)c2c1, COc1ccc2nc3ccc(Cl)cc3c(SCCCN)c2c1	Preclinical
LDN-212854	bone morphogenic protein inhibitor	ABL1, ACVR1, RIPK2			Tocris, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck	97.26	C1CN(CCN1)c1ccc(cc1)-c1cnc2c(cnn2c1)-c1cccc2ncccc12, C1CN(CCN1)c1ccc(cc1)-c1cnc2c(cnn2c1)-c1cccc2ncccc12, C1CN(CCN1)c1ccc(cc1)-c1cnc2c(cnn2c1)-c1cccc2ncccc12, C1CN(CCN1)c1ccc(cc1)-c1cnc2c(cnn2c1)-c1cccc2ncccc12, C1CN(CCN1)c1ccc(cc1)-c1cnc2c(cnn2c1)-c1cccc2ncccc12, C1CN(CCN1)c1ccc(cc1)-c1cnc2c(cnn2c1)-c1cccc2ncccc12, C1CN(CCN1)c1ccc(cc1)-c1cnc2c(cnn2c1)-c1cccc2ncccc12, C1CN(CCN1)c1ccc(cc1)-c1cnc2c(cnn2c1)-c1cccc2ncccc12, C1CN(CCN1)c1ccc(cc1)-c1cnc2c(cnn2c1)-c1cccc2ncccc12, C1CN(CCN1)c1ccc(cc1)-c1cnc2c(cnn2c1)-c1cccc2ncccc12	Preclinical
LDN-27219	tissue transglutaminase inhibitor	TGM2			Tocris, Tocris	90.91	NNC(=O)CSc1nc2scc(-c3ccccc3)c2c(=O)n1-c1ccccc1, NNC(=O)CSc1nc2scc(-c3ccccc3)c2c(=O)n1-c1ccccc1	Preclinical
LDN-57444	ubiquitin C-terminal hydrolase inhibitor				Selleck, MedChemEx, Selleck, Selleck	99.35	CC(=O)O\N=C1\C(=O)N(Cc2cc(Cl)ccc2Cl)c2ccc(Cl)cc12, CC(=O)O\N=C1\C(=O)N(Cc2cc(Cl)ccc2Cl)c2ccc(Cl)cc12, CC(=O)O\N=C1\C(=O)N(Cc2cc(Cl)ccc2Cl)c2ccc(Cl)cc12, CC(=O)O\N=C1\C(=O)N(Cc2cc(Cl)ccc2Cl)c2ccc(Cl)cc12	Preclinical
LDN193189	bone morphogenic protein inhibitor	ACVR1, BMPR1A			MedChemEx, MedChemEx, MedChemEx, MedChemEx	97.1	C1CN(CCN1)c1ccc(cc1)-c1cnc2c(cnn2c1)-c1ccnc2ccccc12, C1CN(CCN1)c1ccc(cc1)-c1cnc2c(cnn2c1)-c1ccnc2ccccc12, C1CN(CCN1)c1ccc(cc1)-c1cnc2c(cnn2c1)-c1ccnc2ccccc12, C1CN(CCN1)c1ccc(cc1)-c1cnc2c(cnn2c1)-c1ccnc2ccccc12	Preclinical
LE-135	retinoid receptor agonist	RARB			Tocris, Tocris, Tocris	95.85	CN1c2cc3c(cc2N=C(c2ccc(cc2)C(O)=O)c2ccccc12)C(C)(C)CCC3(C)C |t:9|, CN1c2cc3c(cc2N=C(c2ccc(cc2)C(O)=O)c2ccccc12)C(C)(C)CCC3(C)C |t:9|, CN1c2cc3c(cc2N=C(c2ccc(cc2)C(O)=O)c2ccccc12)C(C)(C)CCC3(C)C |t:9|	Preclinical
ledipasvir	HCV inhibitor		infectious disease	hepatitis C	MedChemEx, MedChemEx, MedChemEx, MedChemEx	99.19	COC(=O)N[C@@H](C(C)C)C(=O)N1CC2(CC2)C[C@H]1c1nc(c[nH]1)-c1ccc2-c3ccc(cc3C(F)(F)c2c1)-c1ccc2nc([nH]c2c1)[C@@H]1[C@H]2CC[C@H](C2)N1C(=O)[C@@H](NC(=O)OC)C(C)C, COC(=O)N[C@@H](C(C)C)C(=O)N1CC2(CC2)C[C@H]1c1nc(c[nH]1)-c1ccc2-c3ccc(cc3C(F)(F)c2c1)-c1ccc2nc([nH]c2c1)[C@@H]1[C@H]2CC[C@H](C2)N1C(=O)[C@@H](NC(=O)OC)C(C)C, COC(=O)N[C@@H](C(C)C)C(=O)N1CC2(CC2)C[C@H]1c1nc(c[nH]1)-c1ccc2-c3ccc(cc3C(F)(F)c2c1)-c1ccc2nc([nH]c2c1)[C@@H]1[C@H]2CC[C@H](C2)N1C(=O)[C@@H](NC(=O)OC)C(C)C, COC(=O)N[C@@H](C(C)C)C(=O)N1CC2(CC2)C[C@H]1c1nc(c[nH]1)-c1ccc2-c3ccc(cc3C(F)(F)c2c1)-c1ccc2nc([nH]c2c1)[C@@H]1[C@H]2CC[C@H](C2)N1C(=O)[C@@H](NC(=O)OC)C(C)C	Launched
leflunomide	dihydroorotate dehydrogenase inhibitor, PDGFR tyrosine kinase receptor inhibitor	AHR, DHODH, PTK2B	rheumatology	rheumatoid arthritis	MicroSource, Tocris, Tocris, Selleck	94.48	Cc1oncc1C(=O)Nc1ccc(cc1)C(F)(F)F, Cc1oncc1C(=O)Nc1ccc(cc1)C(F)(F)F, Cc1oncc1C(=O)Nc1ccc(cc1)C(F)(F)F, Cc1oncc1C(=O)Nc1ccc(cc1)C(F)(F)F	Launched
lemborexant	orexin receptor antagonist	HCRTR1, HCRTR2			MedChemEx	96.65	Cc1ncc(OC[C@]2(C[C@H]2C(=O)Nc2ccc(F)cn2)c2cccc(F)c2)c(C)n1	Launched
lenalidomide	anticancer agent	TNF	hematologic malignancy	multiple myeloma, mantle cell lymphoma (MCL), myelodysplastic diseases (MDS)	Selleck	98.9	Nc1cccc2C(=O)N(Cc12)[C@H]1CCC(=O)NC1=O |&1:11,r|	Launched
leniolisib	PI3K inhibitor				MedChemEx	96.68	CCC(=O)N1CC[C@@H](C1)Nc1ncnc2CCN(Cc12)c1cnc(OC)c(c1)C(F)(F)F	Phase 2/Phase 3
lenvatinib	FGFR inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	FLT4, KDR	oncology	thyroid cancer	Selleck, Selleck, Selleck, Selleck, Selleck	98.78	COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O, COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O, COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O, COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O, COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O	Launched
leonurine	anti-inflammatory agent				CombiBlocks	93.59	COc1cc(cc(OC)c1O)C(=O)OCCCCNC(N)=N	Preclinical
LEQ506	G protein signaling inhibitor				MedChemEx	88.91	C[C@@H]1CN(CCN1c1cnc(cn1)C(C)(C)O)c1nnc(Cc2ccccc2)c(C)c1C	Phase 1
lercanidipine	calcium channel blocker	CACNA2D1	cardiology	hypertension	Sigma, Sigma, Sigma	98.4	COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC(C)(C)CN(C)CCC(c1ccccc1)c1ccccc1 |r,c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC(C)(C)CN(C)CCC(c1ccccc1)c1ccccc1 |r,c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC(C)(C)CN(C)CCC(c1ccccc1)c1ccccc1 |r,c:4,9|	Launched
lerisetron	serotonin receptor antagonist	HTR3A			Enamine, LifeChem, Enamine	98.73	C(c1ccccc1)n1c(nc2ccccc12)N1CCNCC1, C(c1ccccc1)n1c(nc2ccccc12)N1CCNCC1, C(c1ccccc1)n1c(nc2ccccc12)N1CCNCC1	Phase 3
lersivirine	non-nucleoside reverse transcriptase inhibitor				MedChemEx, MedChemEx	96.3	CCc1nn(CCO)c(CC)c1Oc1cc(cc(c1)C#N)C#N, CCc1nn(CCO)c(CC)c1Oc1cc(cc(c1)C#N)C#N	Phase 2
lesinurad	uric acid diuretic	SLC22A12	rheumatology	gout	MedChemEx, MedChemEx	99.19	OC(=O)CSc1nnc(Br)n1-c1ccc(C2CC2)c2ccccc12, OC(=O)CSc1nnc(Br)n1-c1ccc(C2CC2)c2ccccc12	Launched
lestaurtinib	FLT3 inhibitor, growth factor receptor inhibitor, JAK inhibitor	FLT3, NTRK1			EMDBio, EMDBio, EMDBio, EMDBio, EMDBio, EMDBio, EMDBio, EMDBio, EMDBio, EMDBio, EMDBio	97.47	C[C@]12O[C@@H](C[C@]1(O)CO)n1c3ccccc3c3c4C(=O)NCc4c4c5ccccc5n2c4c13 |a:1,5,&1:3|, C[C@]12O[C@@H](C[C@]1(O)CO)n1c3ccccc3c3c4C(=O)NCc4c4c5ccccc5n2c4c13 |a:1,5,&1:3|, C[C@]12O[C@@H](C[C@]1(O)CO)n1c3ccccc3c3c4C(=O)NCc4c4c5ccccc5n2c4c13 |a:1,5,&1:3|, C[C@]12O[C@@H](C[C@]1(O)CO)n1c3ccccc3c3c4C(=O)NCc4c4c5ccccc5n2c4c13 |a:1,5,&1:3|, C[C@]12O[C@@H](C[C@]1(O)CO)n1c3ccccc3c3c4C(=O)NCc4c4c5ccccc5n2c4c13 |a:1,5,&1:3|, C[C@]12O[C@@H](C[C@]1(O)CO)n1c3ccccc3c3c4C(=O)NCc4c4c5ccccc5n2c4c13 |a:1,5,&1:3|, C[C@]12O[C@@H](C[C@]1(O)CO)n1c3ccccc3c3c4C(=O)NCc4c4c5ccccc5n2c4c13 |a:1,5,&1:3|, C[C@]12O[C@@H](C[C@]1(O)CO)n1c3ccccc3c3c4C(=O)NCc4c4c5ccccc5n2c4c13 |a:1,5,&1:3|, C[C@]12O[C@@H](C[C@]1(O)CO)n1c3ccccc3c3c4C(=O)NCc4c4c5ccccc5n2c4c13 |a:1,5,&1:3|, C[C@]12O[C@@H](C[C@]1(O)CO)n1c3ccccc3c3c4C(=O)NCc4c4c5ccccc5n2c4c13 |a:1,5,&1:3|, C[C@]12O[C@@H](C[C@]1(O)CO)n1c3ccccc3c3c4C(=O)NCc4c4c5ccccc5n2c4c13 |a:1,5,&1:3|	Phase 3
leteprinim	nerve growth factor agonist				Sigma	97.65	OC(=O)c1ccc(NC(=O)CCn2cnc3c2[nH]cnc3=O)cc1	Phase 2
letermovir	CMV terminase inhibitor		infectious disease	cytomegalovirus (CMV)	MedChemEx, MedChemEx, MedChemEx	96.6	COc1cccc(c1)N1CCN(CC1)C1=Nc2c(F)cccc2[C@H](CC(O)=O)N1c1cc(ccc1OC)C(F)(F)F |t:16|, COc1cccc(c1)N1CCN(CC1)C1=Nc2c(F)cccc2[C@H](CC(O)=O)N1c1cc(ccc1OC)C(F)(F)F |t:16|, COc1cccc(c1)N1CCN(CC1)C1=Nc2c(F)cccc2[C@H](CC(O)=O)N1c1cc(ccc1OC)C(F)(F)F |t:16|	Launched
letosteine	mucolytic agent		pulmonary, infectious disease	bronchitis, pneumonia	AKSci	96.97	CCOC(=O)CSCC[C@H]1N[C@@H](CS1)C(O)=O |&1:9,&2:11,r|	Launched
letrazuril	antiinfective drug				MedChemEx	98.49	Fc1ccc(cc1)[C@@H](C#N)c1c(Cl)cc(cc1Cl)-n1ncc(=O)[nH]c1=O |&1:7,r|	Phase 1
letrozole	aromatase inhibitor	CYP19A1	oncology	breast cancer	Tocris, Tocris, Selleck	96.85	N#Cc1ccc(cc1)C(c1ccc(cc1)C#N)n1cncn1, N#Cc1ccc(cc1)C(c1ccc(cc1)C#N)n1cncn1, N#Cc1ccc(cc1)C(c1ccc(cc1)C#N)n1cncn1	Launched
leucomethylene-blue	nitric oxide production inhibitor, tau aggregation inhibitor	MAPT			MedChemEx	0	CN(C)c1ccc2Nc3ccc(cc3Sc2c1)N(C)C	Phase 3
leucovorin	folate receptor ligand		oncology	osteosarcoma	MedChemEx, Selleck, Selleck, Selleck, Selleck	97.3	Nc1nc(=O)c2N(C=O)[C@@H](CNc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)CNc2[nH]1 |a:21,&1:9|, Nc1nc(=O)c2N(C=O)[C@@H](CNc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)CNc2[nH]1 |a:21,&1:9|, Nc1nc(=O)c2N(C=O)[C@@H](CNc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)CNc2[nH]1 |a:21,&1:9|, Nc1nc(=O)c2N(C=O)[C@@H](CNc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)CNc2[nH]1 |a:21,&1:9|, Nc1nc(=O)c2N(C=O)[C@@H](CNc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)CNc2[nH]1 |a:21,&1:9|	Launched
leucylleucine-methyl-ester					ChemImpex	100	COC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC(C)C	Phase 2
leuprolide	gonadotropin releasing factor hormone receptor agonist	GNRHR	oncology	prostate cancer	Sigma, Sigma	94.29	CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H]1CCC(=O)N1, CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H]1CCC(=O)N1	Launched
levalbuterol	adrenergic receptor agonist	ADRB2	pulmonary	bronchospasm	MicroSource, MicroSource, Vitas-M	97.04	CC(C)(C)NC[C@H](O)c1ccc(O)c(CO)c1, CC(C)(C)NC[C@H](O)c1ccc(O)c(CO)c1, CC(C)(C)NC[C@H](O)c1ccc(O)c(CO)c1	Launched
levallorphan	opioid receptor antagonist	CHRNA2, OPRM1	pulmonary	respiratory depression	Enzo, Enzo, Sigma	93.45	Oc1ccc2C[C@@H]3[C@@H]4CCCC[C@]4(CCN3CC=C)c2c1, Oc1ccc2C[C@@H]3[C@@H]4CCCC[C@]4(CCN3CC=C)c2c1, Oc1ccc2C[C@@H]3[C@@H]4CCCC[C@]4(CCN3CC=C)c2c1	Launched
levamisole	acetylcholine receptor agonist	ALPL			MicroSource, MedChemEx, MedChemEx, Selleck	99.45	C1CN2C[C@@H](N=C2S1)c1ccccc1 |c:5|, C1CN2C[C@@H](N=C2S1)c1ccccc1 |c:5|, C1CN2C[C@@H](N=C2S1)c1ccccc1 |c:5|, C1CN2C[C@@H](N=C2S1)c1ccccc1 |c:5|	Withdrawn
levamlodipine	calcium channel blocker		cardiology	hypertension	MedChemEx	96.68	CCOC(=O)C1=C(COCCN)NC(C)=C([C@@H]1c1ccccc1Cl)C(=O)OC |c:5,14|	Launched
levcromakalim	potassium channel activator	KCNJ5			Sigma, Tocris, Tocris, Tocris, Tocris	99.04	CC1(C)Oc2ccc(cc2[C@H]([C@@H]1O)N1CCCC1=O)C#N, CC1(C)Oc2ccc(cc2[C@H]([C@@H]1O)N1CCCC1=O)C#N, CC1(C)Oc2ccc(cc2[C@H]([C@@H]1O)N1CCCC1=O)C#N, CC1(C)Oc2ccc(cc2[C@H]([C@@H]1O)N1CCCC1=O)C#N, CC1(C)Oc2ccc(cc2[C@H]([C@@H]1O)N1CCCC1=O)C#N	Phase 3
levetiracetam	calcium channel blocker	CACNA1B, SCN1A, SV2A	neurology/psychiatry	seizures	Tocris, MicroSource, MicroSource, Selleck, Selleck, Selleck	95.46	CC[C@H](N1CCCC1=O)C(N)=O, CC[C@H](N1CCCC1=O)C(N)=O, CC[C@H](N1CCCC1=O)C(N)=O, CC[C@H](N1CCCC1=O)C(N)=O, CC[C@H](N1CCCC1=O)C(N)=O, CC[C@H](N1CCCC1=O)C(N)=O	Launched
levo-phencynonate	acetylcholine receptor antagonist	CHRM1			ChemPacific	87.3	CN1C[C@@H]2CCC[C@H](C1)[C@H]2OC(=O)[C@@](O)(C1CCCC1)c1ccccc1 |&1:7,&2:3,&3:9,&4:13|	Launched
levobetaxolol	adrenergic receptor antagonist	ADRB1, ADRB2	ophthalmology	intraocular pressure, glaucoma	MedChemEx, MedChemEx, Selleck	97.62	CC(C)NC[C@H](O)COc1ccc(CCOCC2CC2)cc1, CC(C)NC[C@H](O)COc1ccc(CCOCC2CC2)cc1, CC(C)NC[C@H](O)COc1ccc(CCOCC2CC2)cc1	Launched
levobunolol	adrenergic receptor antagonist	ADRB1, ADRB2, ADRB3	ophthalmology	glaucoma, ocular hypertension	MedChemEx, Enzo, Prestwick	99.36	CC(C)(C)NC[C@H](O)COc1cccc2C(=O)CCCc12, CC(C)(C)NC[C@H](O)COc1cccc2C(=O)CCCc12, CC(C)(C)NC[C@H](O)COc1cccc2C(=O)CCCc12	Launched
levobunolol-(+)	adrenergic receptor antagonist				Prestwick, Prestwick, Prestwick, Prestwick	99.32	CC(C)(C)NC[C@@H](O)COc1cccc2C(=O)CCCc12, CC(C)(C)NC[C@@H](O)COc1cccc2C(=O)CCCc12, CC(C)(C)NC[C@@H](O)COc1cccc2C(=O)CCCc12, CC(C)(C)NC[C@@H](O)COc1cccc2C(=O)CCCc12	Preclinical
levobunolol-(+/-)	adrenergic receptor antagonist				MicroSource, MicroSource	98.4	CC(C)(C)NC[C@@H](O)COc1cccc2C(=O)CCCc12 |&1:6|, CC(C)(C)NC[C@@H](O)COc1cccc2C(=O)CCCc12 |&1:6|	Preclinical
levocabastine	histamine receptor antagonist	HRH1, NTSR2	ophthalmology	conjunctivitis	Prestwick	98.8	C[C@@H]1CN(CC[C@]1(C(O)=O)c1ccccc1)[C@H]1CC[C@](CC1)(C#N)c1ccc(F)cc1	Launched
levocarnitine		CRAT, CROT	endocrinology	carnitine deficiency	MicroSource, Selleck	100	C[N+](C)(C)C[C@H](O)CC(O)=O, C[N+](C)(C)C[C@H](O)CC(O)=O	Launched
levocarnitine-propionate	carnitine palmitoyltransferase inhibitor	CRAT	neurology/psychiatry, endocrinology	peripheral neuropathy, carnitine deficiency	MedChemEx	61.9	CCC(=O)O[C@H](CC(O)=O)C[N+](C)(C)C	Launched
levocetirizine	histamine receptor antagonist	HRH1	allergy	allergic rhinitis, urticaria	MicroSource, MicroSource, MicroSource, TCI	97.42	OC(=O)COCCN1CCN(CC1)[C@H](c1ccccc1)c1ccc(Cl)cc1, OC(=O)COCCN1CCN(CC1)[C@H](c1ccccc1)c1ccc(Cl)cc1, OC(=O)COCCN1CCN(CC1)[C@H](c1ccccc1)c1ccc(Cl)cc1, OC(=O)COCCN1CCN(CC1)[C@H](c1ccccc1)c1ccc(Cl)cc1	Launched
levodopa	dopamine precursor	DRD1, DRD2, DRD3, DRD4, DRD5, GPR143	neurology/psychiatry	Parkinson's Disease	MicroSource, Selleck, Selleck	92.55	N[C@@H](Cc1ccc(O)c(O)c1)C(O)=O, N[C@@H](Cc1ccc(O)c(O)c1)C(O)=O, N[C@@H](Cc1ccc(O)c(O)c1)C(O)=O	Launched
levodropropizine	antitussive		pulmonary	cough suppressant	MedChemEx, Selleck, Selleck	95.16	OC[C@@H](O)CN1CCN(CC1)c1ccccc1, OC[C@@H](O)CN1CCN(CC1)c1ccccc1, OC[C@@H](O)CN1CCN(CC1)c1ccccc1	Launched
levofloxacin	bacterial DNA gyrase inhibitor	TOP2A	infectious disease, otolaryngology, pulmonary, urology	pneumonia, sinusitis, bronchitis, skin infections, prostatitis, urinary tract infections, pyelonephritis, anthrax, plague	MicroSource, Selleck	97.7	C[C@H]1COc2c(N3CCN(C)CC3)c(F)cc3c2n1cc(C(O)=O)c3=O, C[C@H]1COc2c(N3CCN(C)CC3)c(F)cc3c2n1cc(C(O)=O)c3=O	Launched
levomenol			neurology/psychiatry, infectious disease	spasms, skin infections	Sigma	0	CC(C)=CCC[C@](C)(O)[C@H]1CCC(C)=CC1 |c:13|	Launched
levomenthol		OPRK1, TRPA1, TRPM8, TRPV3	neurology/psychiatry	pain relief	MicroSource, Sigma	32.51	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O, CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O	Launched
levomepromazine	dopamine receptor antagonist	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD1, DRD2, DRD3, DRD4, DRD5, HRH1, HTR2A, HTR2C	neurology/psychiatry, gastroenterology	psychosis, schizophrenia, bipolar disorder, nausea, insomnia	Sigma, Prestwick, Prestwick	96.44	COc1ccc2Sc3ccccc3N(C[C@H](C)CN(C)C)c2c1, COc1ccc2Sc3ccccc3N(C[C@H](C)CN(C)C)c2c1, COc1ccc2Sc3ccccc3N(C[C@H](C)CN(C)C)c2c1	Launched
levomequitazine	histamine receptor antagonist	HRH1			Vitas-M, Vitas-M, Vitas-M, Vitas-M, MedChemEx	96.71	C([C@H]1CN2CCC1CC2)N1c2ccccc2Sc2ccccc12 |&1:1,r|, C([C@H]1CN2CCC1CC2)N1c2ccccc2Sc2ccccc12 |&1:1,r|, C([C@H]1CN2CCC1CC2)N1c2ccccc2Sc2ccccc12 |&1:1,r|, C([C@H]1CN2CCC1CC2)N1c2ccccc2Sc2ccccc12 |&1:1,r|, C([C@H]1CN2CCC1CC2)N1c2ccccc2Sc2ccccc12 |&1:1,r|	Phase 2
levonordefrin	vasodilator	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, SLC6A2	hematology	hemorrhage	Sigma, MicroSource	0	C[C@H](N)[C@H](O)c1ccc(O)c(O)c1, C[C@H](N)[C@H](O)c1ccc(O)c(O)c1	Launched
levonorgestrel	estrogen receptor agonist, glucocorticoid receptor antagonist, progesterone receptor agonist, progesterone receptor antagonist	PGR	endocrinology	contraceptive	Tocris, Tocris, Selleck, Selleck, Selleck, MicroSource, MicroSource, Selleck, Selleck, Selleck	98.56	CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C |t:9|, CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C |t:9|, CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C |t:9|, CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C |t:9|, CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C |t:9|, CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C |t:9|, CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C |t:9|, CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C |t:9|, CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C |t:9|, CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C |t:9|	Launched
levopropoxyphene	antitussive		pulmonary	cough suppressant	Prestwick	28.74	CCC(=O)OC(Cc1ccccc1)([C@@H](C)CN(C)C)c1ccccc1 |&1:5,&2:13|	Launched
levosimendan	calcium sensitizer	KCNJ11, KCNJ8, PDE3A, TNNC1	cardiology	congestive heart failure	MicroSource, MicroSource, MedChemEx, MedChemEx, MedChemEx, Selleck	99.1	C[C@@H]1CC(=O)NN=C1c1ccc(NN=C(C#N)C#N)cc1 |c:6|, C[C@@H]1CC(=O)NN=C1c1ccc(NN=C(C#N)C#N)cc1 |c:6|, C[C@@H]1CC(=O)NN=C1c1ccc(NN=C(C#N)C#N)cc1 |c:6|, C[C@@H]1CC(=O)NN=C1c1ccc(NN=C(C#N)C#N)cc1 |c:6|, C[C@@H]1CC(=O)NN=C1c1ccc(NN=C(C#N)C#N)cc1 |c:6|, C[C@@H]1CC(=O)NN=C1c1ccc(NN=C(C#N)C#N)cc1 |c:6|	Launched
levosulpiride	dopamine receptor antagonist	CA1, CA12, CA7, DRD2, DRD3	neurology/psychiatry, gastroenterology, urology	schizophrenia, psychosis, anxiety, vertigo, dyspepsia, irritable bowel syndrome, premature ejaculation (PE)	Tocris, Tocris, Tocris, Selleck, Tocris, Tocris	98.1	CCN1CCC[C@H]1CNC(=O)c1cc(ccc1OC)S(N)(=O)=O, CCN1CCC[C@H]1CNC(=O)c1cc(ccc1OC)S(N)(=O)=O, CCN1CCC[C@H]1CNC(=O)c1cc(ccc1OC)S(N)(=O)=O, CCN1CCC[C@H]1CNC(=O)c1cc(ccc1OC)S(N)(=O)=O, CCN1CCC[C@H]1CNC(=O)c1cc(ccc1OC)S(N)(=O)=O, CCN1CCC[C@H]1CNC(=O)c1cc(ccc1OC)S(N)(=O)=O	Launched
levothyroxine	thyroid hormone stimulant	THRA, THRB	endocrinology	myxedema coma	Sigma, Selleck, MicroSource, Selleck	96.14	N[C@@H](Cc1cc(I)c(Oc2cc(I)c(O)c(I)c2)c(I)c1)C(O)=O, N[C@@H](Cc1cc(I)c(Oc2cc(I)c(O)c(I)c2)c(I)c1)C(O)=O, N[C@@H](Cc1cc(I)c(Oc2cc(I)c(O)c(I)c2)c(I)c1)C(O)=O, N[C@@H](Cc1cc(I)c(Oc2cc(I)c(O)c(I)c2)c(I)c1)C(O)=O	Launched
LFM-A13	Bruton's tyrosine kinase (BTK) inhibitor	BTK			Tocris, Tocris	94.77	CC(=O)[C@@H](C#N)C(=O)Nc1cc(Br)ccc1Br |&1:3,r|, CC(=O)[C@@H](C#N)C(=O)Nc1cc(Br)ccc1Br |&1:3,r|	Preclinical
LGD-6972	glucagon receptor antagonist				MedChemEx, MedChemEx	100	Cc1cc(C)c(c(C)c1)-c1ccc(NC(=O)[C@H](Cc2ccc(cc2)C(=O)NCCS(O)(=O)=O)c2ccc(cc2)-c2ccc(cc2)C(C)(C)C)cc1, Cc1cc(C)c(c(C)c1)-c1ccc(NC(=O)[C@H](Cc2ccc(cc2)C(=O)NCCS(O)(=O)=O)c2ccc(cc2)-c2ccc(cc2)C(C)(C)C)cc1	Phase 2
LGK-974	porcupine inhibitor	PORCN			MedChemEx, Selleck, Selleck, Selleck, Selleck, Selleck	97.22	Cc1cc(ccn1)-c1ncc(CC(=O)Nc2ccc(cn2)-c2cnccn2)cc1C, Cc1cc(ccn1)-c1ncc(CC(=O)Nc2ccc(cn2)-c2cnccn2)cc1C, Cc1cc(ccn1)-c1ncc(CC(=O)Nc2ccc(cn2)-c2cnccn2)cc1C, Cc1cc(ccn1)-c1ncc(CC(=O)Nc2ccc(cn2)-c2cnccn2)cc1C, Cc1cc(ccn1)-c1ncc(CC(=O)Nc2ccc(cn2)-c2cnccn2)cc1C, Cc1cc(ccn1)-c1ncc(CC(=O)Nc2ccc(cn2)-c2cnccn2)cc1C	Phase 2
LH846	casein kinase inhibitor	CSNK1D			MedChemEx, Tocris	97.64	Cc1cc2sc(NC(=O)Cc3ccccc3)nc2cc1Cl, Cc1cc2sc(NC(=O)Cc3ccccc3)nc2cc1Cl	Preclinical
liarozole	cytochrome P450 inhibitor	CYP19A1, CYP26A1			Tocris	95.35	Clc1cccc(c1)[C@H](c1ccc2nc[nH]c2c1)n1ccnc1 |&1:7,r|	Phase 2/Phase 3
licarbazepine	voltage-gated sodium channel blocker	SCN5A			Tocris, Tocris, Tocris, Tocris, Tocris	98.65	NC(=O)N1c2ccccc2C[C@@H](O)c2ccccc12 |&1:11,r|, NC(=O)N1c2ccccc2C[C@@H](O)c2ccccc12 |&1:11,r|, NC(=O)N1c2ccccc2C[C@@H](O)c2ccccc12 |&1:11,r|, NC(=O)N1c2ccccc2C[C@@H](O)c2ccccc12 |&1:11,r|, NC(=O)N1c2ccccc2C[C@@H](O)c2ccccc12 |&1:11,r|	Phase 3
licochalcone-A	topoisomerase inhibitor	PTPN1			MedChemEx	95.93	COc1cc(O)c(cc1\C=C\C(=O)c1ccc(O)cc1)C(C)(C)C=C	Phase 3
licofelone	cyclooxygenase inhibitor, lipoxygenase inhibitor	ALOX5, PLA2G2E, PTGS2			Adooq, Selleck, Selleck	43.46	CC1(C)Cc2c(c(c(CC(O)=O)n2C1)-c1ccc(Cl)cc1)-c1ccccc1, CC1(C)Cc2c(c(c(CC(O)=O)n2C1)-c1ccc(Cl)cc1)-c1ccccc1, CC1(C)Cc2c(c(c(CC(O)=O)n2C1)-c1ccc(Cl)cc1)-c1ccccc1	Phase 3
licogliflozin	sodium/glucose cotransporter inhibitor				MedChemEx	96.89	CCc1ccc(cc1Cc1ccc2OCCOc2c1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O	Preclinical
licostinel	NMDA receptor antagonist 				Sigma	91.53	[O-][N+](=O)c1c(Cl)c(Cl)cc2[nH]c(=O)c(=O)[nH]c12	Phase 1
lidamidine	adrenergic receptor agonist		gastroenterology	diarrhea	ChemDiv, ChemDiv	93.96	CNC(=N)NC(=O)Nc1c(C)cccc1C, CNC(=N)NC(=O)Nc1c(C)cccc1C	Launched
lidocaine	histamine receptor agonist	EGFR, SCN10A, SCN5A, SCN9A	neurology/psychiatry, dermatology, hematology	itching, eczema, hemorrhage	Selleck, MicroSource, MicroSource	99.22	CCN(CC)CC(=O)Nc1c(C)cccc1C, CCN(CC)CC(=O)Nc1c(C)cccc1C, CCN(CC)CC(=O)Nc1c(C)cccc1C	Launched
lidoflazine	calcium channel blocker	SCN1A, SCN3A, SLC29A1	cardiology	coronary artery disease (CAD)	Sigma, Sigma, Prestwick	98.4	Cc1cccc(C)c1NC(=O)CN1CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1, Cc1cccc(C)c1NC(=O)CN1CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1, Cc1cccc(C)c1NC(=O)CN1CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1	Launched
lifirafenib	RAF inhibitor				MedChemEx	96.41	FC(F)(F)c1ccc2nc([nH]c2c1)[C@@H]1[C@H]2Oc3ccc(Oc4ccnc5NC(=O)CCc45)cc3[C@@H]12	Phase 1/Phase 2
lifitegrast	lymphocyte function-associated antigen negative modulator		ophthalmology	dry eye syndrome	MedChemEx	97.98	CS(=O)(=O)c1cccc(C[C@H](NC(=O)c2c(Cl)cc3CN(CCc3c2Cl)C(=O)c2ccc3ccoc3c2)C(O)=O)c1	Launched
ligustilide	tumor necrosis factor production inhibitor	TNF			MedChemEx, MedChemEx	87.42	CCC\C=C1/OC(=O)C2=C1CCC=C2 |c:8,13|, CCC\C=C1/OC(=O)C2=C1CCC=C2 |c:8,13|	Preclinical
limaprost-alfadex	prostanoid receptor agonist	PTGER1	cardiology	claudication	MedChemEx, MedChemEx, MedChemEx	94.67	CCCC[C@H](C)C[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCC\C=C\C(O)=O, CCCC[C@H](C)C[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCC\C=C\C(O)=O, CCCC[C@H](C)C[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCC\C=C\C(O)=O	Launched
LIMKi-3	LIM kinase inhibitor	LIMK1			Tocris, Tocris	98.06	CC(C)C(=O)Nc1ncc(s1)-c1cc(nn1-c1c(Cl)cccc1Cl)C(F)F, CC(C)C(=O)Nc1ncc(s1)-c1cc(nn1-c1c(Cl)cccc1Cl)C(F)F	Preclinical
limonin	HIV protease inhibitor				Selleck, Selleck, MedChemEx	92.68	CC1(C)O[C@H]2CC(=O)OC[C@@]22[C@H]1CC(=O)[C@]1(C)[C@@H]2CC[C@@]2(C)[C@@H](OC(=O)[C@H]3O[C@@]123)c1ccoc1, CC1(C)O[C@H]2CC(=O)OC[C@@]22[C@H]1CC(=O)[C@]1(C)[C@@H]2CC[C@@]2(C)[C@@H](OC(=O)[C@H]3O[C@@]123)c1ccoc1, CC1(C)O[C@H]2CC(=O)OC[C@@]22[C@H]1CC(=O)[C@]1(C)[C@@H]2CC[C@@]2(C)[C@@H](OC(=O)[C@H]3O[C@@]123)c1ccoc1	Preclinical
linaclotide	guanylate cyclase activator	GUCY2C	gastroenterology	irritable bowel syndrome, constipation	MedChemEx	0	[H][C@@]12CCCN1C(=O)[C@H](CC(N)=O)NC(=O)[C@]1([H])CSSC[C@H](N)C(=O)N[C@@]3([H])CSSC[C@]([H])(NC(=O)[C@H](C)NC2=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CSSC[C@]([H])(NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CCC(O)=O)NC3=O)C(=O)N1)C(=O)N[C@@H](Cc1ccc(O)cc1)C(O)=O	Launched
linagliptin	dipeptidyl peptidase inhibitor	DPP4	endocrinology	diabetes mellitus	MicroSource, MicroSource, MicroSource, MedChemEx, Selleck, Selleck, Selleck	95.25	CC#CCn1c(nc2n(C)c(=O)n(Cc3nc(C)c4ccccc4n3)c(=O)c12)N1CCC[C@@H](N)C1, CC#CCn1c(nc2n(C)c(=O)n(Cc3nc(C)c4ccccc4n3)c(=O)c12)N1CCC[C@@H](N)C1, CC#CCn1c(nc2n(C)c(=O)n(Cc3nc(C)c4ccccc4n3)c(=O)c12)N1CCC[C@@H](N)C1, CC#CCn1c(nc2n(C)c(=O)n(Cc3nc(C)c4ccccc4n3)c(=O)c12)N1CCC[C@@H](N)C1, CC#CCn1c(nc2n(C)c(=O)n(Cc3nc(C)c4ccccc4n3)c(=O)c12)N1CCC[C@@H](N)C1, CC#CCn1c(nc2n(C)c(=O)n(Cc3nc(C)c4ccccc4n3)c(=O)c12)N1CCC[C@@H](N)C1, CC#CCn1c(nc2n(C)c(=O)n(Cc3nc(C)c4ccccc4n3)c(=O)c12)N1CCC[C@@H](N)C1	Launched
linalool	anticonvulsant				InterBioScreen, Sigma	0	CC(C)=CCC[C@@](C)(O)C=C |&1:6,r|, CC(C)=CCC[C@@](C)(O)C=C |&1:6,r|	Phase 1
linaprazan	ATP-sensitive potassium channel inhibitor				MedChemEx	96.59	Cc1nc2c(NCc3c(C)cccc3C)cc(cn2c1C)C(=O)NCCO	Preclinical
lincomycin	bacterial 30S ribosomal subunit inhibitor		gastroenterology	enteritis	MedChemEx, Selleck	97.1	CCC[C@@H]1C[C@H](N(C)C1)C(=O)N[C@H]([C@@H](C)O)[C@H]1O[C@H](SC)[C@H](O)[C@@H](O)[C@H]1O, CCC[C@@H]1C[C@H](N(C)C1)C(=O)N[C@H]([C@@H](C)O)[C@H]1O[C@H](SC)[C@H](O)[C@@H](O)[C@H]1O	Launched
lindane		GABRB1, GLRA1, GLRA2, GLRA3, GLRB	infectious disease	scabies	MedChemEx, MedChemEx, MicroSource	0	Cl[C@H]1[C@H](Cl)[C@@H](Cl)[C@@H](Cl)[C@H](Cl)[C@H]1Cl, Cl[C@H]1[C@H](Cl)[C@@H](Cl)[C@@H](Cl)[C@H](Cl)[C@H]1Cl, Cl[C@H]1[C@H](Cl)[C@@H](Cl)[C@@H](Cl)[C@H](Cl)[C@H]1Cl	Launched
linezolid	bacterial 50S ribosomal subunit inhibitor	MAOA, MAOB	infectious disease	pneumonia, skin infections	Tocris, Tocris, MicroSource, Selleck, Selleck	98.39	CC(=O)NC[C@H]1CN(C(=O)O1)c1ccc(N2CCOCC2)c(F)c1, CC(=O)NC[C@H]1CN(C(=O)O1)c1ccc(N2CCOCC2)c(F)c1, CC(=O)NC[C@H]1CN(C(=O)O1)c1ccc(N2CCOCC2)c(F)c1, CC(=O)NC[C@H]1CN(C(=O)O1)c1ccc(N2CCOCC2)c(F)c1, CC(=O)NC[C@H]1CN(C(=O)O1)c1ccc(N2CCOCC2)c(F)c1	Launched
linifanib	PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	CSF1, CSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RET, TEK			MedChemEx, Selleck, Selleck, Selleck, Selleck, Selleck	99.13	Cc1ccc(F)c(NC(=O)Nc2ccc(cc2)-c2cccc3n[nH]c(N)c23)c1, Cc1ccc(F)c(NC(=O)Nc2ccc(cc2)-c2cccc3n[nH]c(N)c23)c1, Cc1ccc(F)c(NC(=O)Nc2ccc(cc2)-c2cccc3n[nH]c(N)c23)c1, Cc1ccc(F)c(NC(=O)Nc2ccc(cc2)-c2cccc3n[nH]c(N)c23)c1, Cc1ccc(F)c(NC(=O)Nc2ccc(cc2)-c2cccc3n[nH]c(N)c23)c1, Cc1ccc(F)c(NC(=O)Nc2ccc(cc2)-c2cccc3n[nH]c(N)c23)c1	Phase 3
linoleic-acid	oxidative stress inducer	FABP4, FFAR1, FFAR4, HNF4A, KCNB1, PPARG, TRPM8			Sigma	0	CCCCC\C=C/C\C=C/CCCCCCCC(O)=O	Phase 3
linopirdine	potassium channel blocker	KCNQ2, KCNQ3, KCNQ4, KCNQ5			Tocris, Tocris, Tocris, Tocris	98.54	O=C1N(c2ccccc2C1(Cc1ccncc1)Cc1ccncc1)c1ccccc1, O=C1N(c2ccccc2C1(Cc1ccncc1)Cc1ccncc1)c1ccccc1, O=C1N(c2ccccc2C1(Cc1ccncc1)Cc1ccncc1)c1ccccc1, O=C1N(c2ccccc2C1(Cc1ccncc1)Cc1ccncc1)c1ccccc1	Phase 3
linsidomine	nitric oxide donor		urology	erectile dysfunction	EMDBio, EMDBio, Cayman	94.73	Nc1c[n+](no1)N1CCOCC1, Nc1c[n+](no1)N1CCOCC1, Nc1c[n+](no1)N1CCOCC1	Launched
linsitinib	IGF-1 inhibitor	IGF1R, INSR, INSRR			MedChemEx, MedChemEx, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck	95.36	C[C@@]1(O)C[C@@H](C1)c1nc(-c2ccc3ccc(nc3c2)-c2ccccc2)c2c(N)nccn12 |r|, C[C@@]1(O)C[C@@H](C1)c1nc(-c2ccc3ccc(nc3c2)-c2ccccc2)c2c(N)nccn12 |r|, C[C@@]1(O)C[C@@H](C1)c1nc(-c2ccc3ccc(nc3c2)-c2ccccc2)c2c(N)nccn12 |r|, C[C@@]1(O)C[C@@H](C1)c1nc(-c2ccc3ccc(nc3c2)-c2ccccc2)c2c(N)nccn12 |r|, C[C@@]1(O)C[C@@H](C1)c1nc(-c2ccc3ccc(nc3c2)-c2ccccc2)c2c(N)nccn12 |r|, C[C@@]1(O)C[C@@H](C1)c1nc(-c2ccc3ccc(nc3c2)-c2ccccc2)c2c(N)nccn12 |r|, C[C@@]1(O)C[C@@H](C1)c1nc(-c2ccc3ccc(nc3c2)-c2ccccc2)c2c(N)nccn12 |r|, C[C@@]1(O)C[C@@H](C1)c1nc(-c2ccc3ccc(nc3c2)-c2ccccc2)c2c(N)nccn12 |r|	Phase 3
lintopride	serotonin receptor antagonist				MedChemEx	42.76	CCN1CCN=C1CNC(=O)c1cc(Cl)c(N)cc1OC |c:5|	Preclinical
liothyronine	thyroid hormone stimulant	THRA, THRB	endocrinology	hypothyroidism, myxedema coma	Tocris, MicroSource, MicroSource, Sigma, Selleck, Selleck, Selleck	94.37	N[C@@H](Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1)C(O)=O, N[C@@H](Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1)C(O)=O, N[C@@H](Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1)C(O)=O, N[C@@H](Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1)C(O)=O, N[C@@H](Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1)C(O)=O, N[C@@H](Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1)C(O)=O, N[C@@H](Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1)C(O)=O	Launched
liothyronine-(isomer)					MicroSource	94.02	N[C@H](Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1)C(O)=O	Preclinical
lipoamide					MicroSource, MedChemEx	80.3	NC(=O)CCCC[C@H]1CCSS1 |&1:7,r|, NC(=O)CCCC[C@H]1CCSS1 |&1:7,r|	Preclinical
liquiritin	antioxidant				MedChemEx	0	OC[C@H]1O[C@@H](Oc2ccc(cc2)[C@@H]2CC(=O)c3ccc(O)cc3O2)[C@H](O)[C@@H](O)[C@@H]1O	Preclinical
liraglutide	GLP receptor agonist	GLP1R	endocrinology	weight-loss aid, diabetes mellitus	MedChemEx	88.44	CCCCCCCCCCCCCCCC(=O)N[C@@H](CCC(=O)NCCCC[C@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)Cc1cnc[nH]1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)C(O)=O	Launched
liranaftate	fungal squalene epoxidase inhibitor		infectious disease	fungal infection	MedChemEx, Selleck	99.2	COc1cccc(n1)N(C)C(=S)Oc1ccc2CCCCc2c1, COc1cccc(n1)N(C)C(=S)Oc1ccc2CCCCc2c1	Launched
lirimilast	phosphodiesterase inhibitor				Enamine, Enamine	87.13	CS(=O)(=O)Oc1ccc2c(NC(N)=O)c(oc2c1)C(=O)c1ccc(Cl)cc1Cl, CS(=O)(=O)Oc1ccc2c(NC(N)=O)c(oc2c1)C(=O)c1ccc(Cl)cc1Cl	Phase 2
lisadimate	topical sunscreen agent		dermatology	sunscreen lotion	Sigma	78.91	Nc1ccc(cc1)C(=O)OC[C@@H](O)CO |&1:11,r|	Launched
lisinopril	angiotensin converting enzyme inhibitor	ACE, ACE2	cardiology, endocrinology	hypertension, congestive heart failure, diabetes mellitus	MedChemEx, MedChemEx, MedChemEx, MicroSource, MicroSource, Selleck, Selleck, Selleck, Selleck	100	NCCCC[C@H](N[C@@H](CCc1ccccc1)C(O)=O)C(=O)N1CCC[C@H]1C(O)=O, NCCCC[C@H](N[C@@H](CCc1ccccc1)C(O)=O)C(=O)N1CCC[C@H]1C(O)=O, NCCCC[C@H](N[C@@H](CCc1ccccc1)C(O)=O)C(=O)N1CCC[C@H]1C(O)=O, NCCCC[C@H](N[C@@H](CCc1ccccc1)C(O)=O)C(=O)N1CCC[C@H]1C(O)=O, NCCCC[C@H](N[C@@H](CCc1ccccc1)C(O)=O)C(=O)N1CCC[C@H]1C(O)=O, NCCCC[C@H](N[C@@H](CCc1ccccc1)C(O)=O)C(=O)N1CCC[C@H]1C(O)=O, NCCCC[C@H](N[C@@H](CCc1ccccc1)C(O)=O)C(=O)N1CCC[C@H]1C(O)=O, NCCCC[C@H](N[C@@H](CCc1ccccc1)C(O)=O)C(=O)N1CCC[C@H]1C(O)=O, NCCCC[C@H](N[C@@H](CCc1ccccc1)C(O)=O)C(=O)N1CCC[C@H]1C(O)=O	Launched
lisofylline	interleukin receptor antagonist, STAT inhibitor				Enzo, AMS	99.2	C[C@@H](O)CCCCn1c(=O)n(C)c2ncn(C)c2c1=O |&1:1,r|, C[C@@H](O)CCCCn1c(=O)n(C)c2ncn(C)c2c1=O |&1:1,r|	Phase 2
lisuride	dopamine receptor agonist	ADRA1A, ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C, HTR6	neurology/psychiatry	Parkinson's Disease	Enzo, Enzo, Tocris	94.64	CCN(CC)C(=O)N[C@@H]1CN(C)[C@@H]2Cc3c[nH]c4cccc(C2=C1)c34 |c:23|, CCN(CC)C(=O)N[C@@H]1CN(C)[C@@H]2Cc3c[nH]c4cccc(C2=C1)c34 |c:23|, CCN(CC)C(=O)N[C@@H]1CN(C)[C@@H]2Cc3c[nH]c4cccc(C2=C1)c34 |c:23|	Launched
lithium-acetoacetate		FAH			SantaCruz	0	CC(=O)CC(O)=O	Preclinical
lithium-citrate			neurology/psychiatry	bipolar disorder, depression	MicroSource, Selleck, Selleck, Selleck	0	[Li].[Li].[Li].OC(=O)CC(O)(CC(O)=O)C(O)=O, [Li].[Li].[Li].OC(=O)CC(O)(CC(O)=O)C(O)=O, [Li].[Li].[Li].OC(=O)CC(O)(CC(O)=O)C(O)=O, [Li].[Li].[Li].OC(=O)CC(O)(CC(O)=O)C(O)=O	Launched
lithocholic-acid	FXR antagonist, vitamin D receptor agonist	GPBAR1, NR1H4, NR1I2, VDR			MedChemEx	98.5	C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3CC[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C	Preclinical
litronesib	kinesin-like spindle protein inhibitor	KIF11			MedChemEx, MedChemEx, MedChemEx	94.34	CCNCCS(=O)(=O)NC[C@]1(SC(NC(=O)C(C)(C)C)=NN1C(=O)C(C)(C)C)c1ccccc1 |c:19|, CCNCCS(=O)(=O)NC[C@]1(SC(NC(=O)C(C)(C)C)=NN1C(=O)C(C)(C)C)c1ccccc1 |c:19|, CCNCCS(=O)(=O)NC[C@]1(SC(NC(=O)C(C)(C)C)=NN1C(=O)C(C)(C)C)c1ccccc1 |c:19|	Phase 2
lixivaptan	vasopressin receptor antagonist	AVPR2			Carbosynth, Carbosynth, Carbosynth	89.39	Cc1ccc(F)cc1C(=O)Nc1ccc(C(=O)N2Cc3cccn3Cc3ccccc23)c(Cl)c1, Cc1ccc(F)cc1C(=O)Nc1ccc(C(=O)N2Cc3cccn3Cc3ccccc23)c(Cl)c1, Cc1ccc(F)cc1C(=O)Nc1ccc(C(=O)N2Cc3cccn3Cc3ccccc23)c(Cl)c1	Phase 3
LM-22A4	tropomyosin receptor kinase inhibitor	NTRK2			Tocris, Tocris, Tocris	98.49	OCCNC(=O)c1cc(cc(c1)C(=O)NCCO)C(=O)NCCO, OCCNC(=O)c1cc(cc(c1)C(=O)NCCO)C(=O)NCCO, OCCNC(=O)c1cc(cc(c1)C(=O)NCCO)C(=O)NCCO	Preclinical
LMI070	survival motor neuron protein modulator	SMN1			MedChemEx, MedChemEx	96.92	CC1(C)CC(CC(C)(C)N1)Oc1ccc(nn1)-c1ccc(cc1O)-c1cn[nH]c1, CC1(C)CC(CC(C)(C)N1)Oc1ccc(nn1)-c1ccc(cc1O)-c1cn[nH]c1	Phase 1/Phase 2
LMK-235	HDAC inhibitor	HDAC4, HDAC5			Tocris, Tocris, Selleck	97.1	Cc1cc(C)cc(c1)C(=O)NOCCCCCC(=O)NO, Cc1cc(C)cc(c1)C(=O)NOCCCCCC(=O)NO, Cc1cc(C)cc(c1)C(=O)NOCCCCCC(=O)NO	Preclinical
LM11A-31	neurotrophic agent	NGFR			Enamine, Enamine	94.1	CC[C@@H](C)[C@@H](N)C(=O)NCCN1CCOCC1 |&1:2,&2:4,r|, CC[C@@H](C)[C@@H](N)C(=O)NCCN1CCOCC1 |&1:2,&2:4,r|	Phase 1
lobeline	acetylcholine receptor antagonist	CHRNA10, CHRNA9, SLC18A2	neurology/psychiatry	smoking cessation	MedChemEx, Sigma, Tocris, Enzo, MedChemEx	65.76	CN1[C@H](C[C@H](O)c2ccccc2)CCC[C@@H]1CC(=O)c1ccccc1, CN1[C@H](C[C@H](O)c2ccccc2)CCC[C@@H]1CC(=O)c1ccccc1, CN1[C@H](C[C@H](O)c2ccccc2)CCC[C@@H]1CC(=O)c1ccccc1, CN1[C@H](C[C@H](O)c2ccccc2)CCC[C@@H]1CC(=O)c1ccccc1, CN1[C@H](C[C@H](O)c2ccccc2)CCC[C@@H]1CC(=O)c1ccccc1	Launched
lobendazole	anthelmintic agent				MicroSource, MicroSource, AMS	96.55	CCOC(=O)Nc1nc2ccccc2[nH]1, CCOC(=O)Nc1nc2ccccc2[nH]1, CCOC(=O)Nc1nc2ccccc2[nH]1	Preclinical
lobenzarit	immunosuppressant		rheumatology	rheumatoid arthritis	AKSci	98.34	OC(=O)c1ccccc1Nc1cc(Cl)ccc1C(O)=O	Launched
lodenosine	antiretroviral 				Sigma	90.21	Nc1ncnc2n(cnc12)[C@@H]1O[C@H](CO)C[C@@H]1F	Phase 2
lodoxamide	histamine receptor antagonist		ophthalmology	vernal keratoconjunctivitis (VKC)	Prestwick, MedChemEx, MedChemEx	94.05	OC(=O)C(=O)Nc1cc(cc(NC(=O)C(O)=O)c1Cl)C#N, OC(=O)C(=O)Nc1cc(cc(NC(=O)C(O)=O)c1Cl)C#N, OC(=O)C(=O)Nc1cc(cc(NC(=O)C(O)=O)c1Cl)C#N	Launched
lofemizole	cyclooxygenase inhibitor				AMS, AMS	98.71	Cc1[nH]cnc1-c1ccc(Cl)cc1, Cc1[nH]cnc1-c1ccc(Cl)cc1	Phase 3
lofepramine	norepinephrine reuptake inhibitor, serotoninnorepinephrine reuptake inhibitor (SNRI)	HTR1A, SLC6A2, SLC6A4	neurology/psychiatry	depression	Key, Tocris	46.37	CN(CCCN1c2ccccc2CCc2ccccc12)CC(=O)c1ccc(Cl)cc1, CN(CCCN1c2ccccc2CCc2ccccc12)CC(=O)c1ccc(Cl)cc1	Launched
lofexidine	adrenergic receptor agonist		neurology/psychiatry	opioid withdrawal	Selleck, MicroSource, MicroSource, Selleck	97.02	C[C@@H](Oc1c(Cl)cccc1Cl)C1=NCCN1 |r,t:12|, C[C@@H](Oc1c(Cl)cccc1Cl)C1=NCCN1 |r,t:12|, C[C@@H](Oc1c(Cl)cccc1Cl)C1=NCCN1 |r,t:12|, C[C@@H](Oc1c(Cl)cccc1Cl)C1=NCCN1 |r,t:12|	Launched
lomefloxacin	bacterial DNA gyrase inhibitor		infectious disease	respiratory tract infections, urinary tract infections	MedChemEx, MicroSource, MicroSource	98.31	CCn1cc(C(O)=O)c(=O)c2cc(F)c(N3CCN[C@@H](C)C3)c(F)c12 |&1:19|, CCn1cc(C(O)=O)c(=O)c2cc(F)c(N3CCN[C@@H](C)C3)c(F)c12 |&1:19|, CCn1cc(C(O)=O)c(=O)c2cc(F)c(N3CCN[C@@H](C)C3)c(F)c12 |&1:19|	Launched
lomeguatrib	O6-alkylguanine-DNA alkyltransferase inhibitor	MGMT			Tocris, Selleck, Selleck, Selleck	97.23	Nc1nc(OCc2cc(Br)cs2)c2[nH]cnc2n1, Nc1nc(OCc2cc(Br)cs2)c2[nH]cnc2n1, Nc1nc(OCc2cc(Br)cs2)c2[nH]cnc2n1, Nc1nc(OCc2cc(Br)cs2)c2[nH]cnc2n1	Phase 2
lomerizine	calcium channel blocker	CACNA1B, SCN5A	neurology/psychiatry	migraine headache	MicroSource, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck	97.88	COc1ccc(CN2CCN(CC2)C(c2ccc(F)cc2)c2ccc(F)cc2)c(OC)c1OC, COc1ccc(CN2CCN(CC2)C(c2ccc(F)cc2)c2ccc(F)cc2)c(OC)c1OC, COc1ccc(CN2CCN(CC2)C(c2ccc(F)cc2)c2ccc(F)cc2)c(OC)c1OC, COc1ccc(CN2CCN(CC2)C(c2ccc(F)cc2)c2ccc(F)cc2)c(OC)c1OC, COc1ccc(CN2CCN(CC2)C(c2ccc(F)cc2)c2ccc(F)cc2)c(OC)c1OC, COc1ccc(CN2CCN(CC2)C(c2ccc(F)cc2)c2ccc(F)cc2)c(OC)c1OC, COc1ccc(CN2CCN(CC2)C(c2ccc(F)cc2)c2ccc(F)cc2)c(OC)c1OC, COc1ccc(CN2CCN(CC2)C(c2ccc(F)cc2)c2ccc(F)cc2)c(OC)c1OC	Launched
lometrexol	glycinamide ribonucleotide formyltransferase inhibitor	GART			Cayman	66.91	Nc1nc(=O)c2C[C@@H](CCc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)CNc2[nH]1	Phase 2
lomitapide	microsomal trigylceride transfer protein inhibitor	MTTP	endocrinology	hypercholesterolemia	MedChemEx, MedChemEx, MedChemEx, MedChemEx	97.29	FC(F)(F)CNC(=O)C1(CCCCN2CCC(CC2)NC(=O)c2ccccc2-c2ccc(cc2)C(F)(F)F)c2ccccc2-c2ccccc12, FC(F)(F)CNC(=O)C1(CCCCN2CCC(CC2)NC(=O)c2ccccc2-c2ccc(cc2)C(F)(F)F)c2ccccc2-c2ccccc12, FC(F)(F)CNC(=O)C1(CCCCN2CCC(CC2)NC(=O)c2ccccc2-c2ccc(cc2)C(F)(F)F)c2ccccc2-c2ccccc12, FC(F)(F)CNC(=O)C1(CCCCN2CCC(CC2)NC(=O)c2ccccc2-c2ccc(cc2)C(F)(F)F)c2ccccc2-c2ccccc12	Launched
lomustine	DNA synthesis inhibitor		hematologic malignancy, oncology	Hodgkin's lymphoma, brain tumors	MedChemEx, MedChemEx, Selleck, Selleck, MicroSource, Selleck	0	[O-][NH2+]N(CCCl)C(=O)NC1CCCCC1, [O-][NH2+]N(CCCl)C(=O)NC1CCCCC1, [O-][NH2+]N(CCCl)C(=O)NC1CCCCC1, [O-][NH2+]N(CCCl)C(=O)NC1CCCCC1, [O-][NH2+]N(CCCl)C(=O)NC1CCCCC1, [O-][NH2+]N(CCCl)C(=O)NC1CCCCC1	Launched
lonafarnib	farnesyltransferase inhibitor	FNTA, HRAS, KRAS, NRAS			Selleck, Selleck, Selleck, Selleck, Selleck, Cayman	98.27	NC(=O)N1CCC(CC(=O)N2CCC(CC2)[C@H]2c3ncc(Br)cc3CCc3cc(Cl)cc(Br)c23)CC1, NC(=O)N1CCC(CC(=O)N2CCC(CC2)[C@H]2c3ncc(Br)cc3CCc3cc(Cl)cc(Br)c23)CC1, NC(=O)N1CCC(CC(=O)N2CCC(CC2)[C@H]2c3ncc(Br)cc3CCc3cc(Cl)cc(Br)c23)CC1, NC(=O)N1CCC(CC(=O)N2CCC(CC2)[C@H]2c3ncc(Br)cc3CCc3cc(Cl)cc(Br)c23)CC1, NC(=O)N1CCC(CC(=O)N2CCC(CC2)[C@H]2c3ncc(Br)cc3CCc3cc(Cl)cc(Br)c23)CC1, NC(=O)N1CCC(CC(=O)N2CCC(CC2)[C@H]2c3ncc(Br)cc3CCc3cc(Cl)cc(Br)c23)CC1	Phase 3
lonidamine	glucokinase inhibitor	GCK			Tocris, MicroSource, Tocris, Selleck, Tocris	98.47	OC(=O)c1nn(Cc2ccc(Cl)cc2Cl)c2ccccc12, OC(=O)c1nn(Cc2ccc(Cl)cc2Cl)c2ccccc12, OC(=O)c1nn(Cc2ccc(Cl)cc2Cl)c2ccccc12, OC(=O)c1nn(Cc2ccc(Cl)cc2Cl)c2ccccc12, OC(=O)c1nn(Cc2ccc(Cl)cc2Cl)c2ccccc12	Launched
loperamide	opioid receptor agonist	CACNA1A, CALM1, OPRD1, OPRK1, OPRM1, POMC	gastroenterology	diarrhea	MicroSource, MicroSource, MicroSource, MicroSource, Tocris, Tocris, Selleck, Selleck	98.87	CN(C)C(=O)C(CCN1CCC(O)(CC1)c1ccc(Cl)cc1)(c1ccccc1)c1ccccc1, CN(C)C(=O)C(CCN1CCC(O)(CC1)c1ccc(Cl)cc1)(c1ccccc1)c1ccccc1, CN(C)C(=O)C(CCN1CCC(O)(CC1)c1ccc(Cl)cc1)(c1ccccc1)c1ccccc1, CN(C)C(=O)C(CCN1CCC(O)(CC1)c1ccc(Cl)cc1)(c1ccccc1)c1ccccc1, CN(C)C(=O)C(CCN1CCC(O)(CC1)c1ccc(Cl)cc1)(c1ccccc1)c1ccccc1, CN(C)C(=O)C(CCN1CCC(O)(CC1)c1ccc(Cl)cc1)(c1ccccc1)c1ccccc1, CN(C)C(=O)C(CCN1CCC(O)(CC1)c1ccc(Cl)cc1)(c1ccccc1)c1ccccc1, CN(C)C(=O)C(CCN1CCC(O)(CC1)c1ccc(Cl)cc1)(c1ccccc1)c1ccccc1	Launched
lopinavir	HIV protease inhibitor		infectious disease	human immunodeficiency virus (HIV-1)	Selleck, Selleck, Selleck, MedChemEx, MedChemEx	98.9	CC(C)[C@H](N1CCCNC1=O)C(=O)N[C@H](C[C@H](O)[C@H](Cc1ccccc1)NC(=O)COc1c(C)cccc1C)Cc1ccccc1, CC(C)[C@H](N1CCCNC1=O)C(=O)N[C@H](C[C@H](O)[C@H](Cc1ccccc1)NC(=O)COc1c(C)cccc1C)Cc1ccccc1, CC(C)[C@H](N1CCCNC1=O)C(=O)N[C@H](C[C@H](O)[C@H](Cc1ccccc1)NC(=O)COc1c(C)cccc1C)Cc1ccccc1, CC(C)[C@H](N1CCCNC1=O)C(=O)N[C@H](C[C@H](O)[C@H](Cc1ccccc1)NC(=O)COc1c(C)cccc1C)Cc1ccccc1, CC(C)[C@H](N1CCCNC1=O)C(=O)N[C@H](C[C@H](O)[C@H](Cc1ccccc1)NC(=O)COc1c(C)cccc1C)Cc1ccccc1	Launched
loracarbef	bacterial cell wall synthesis inhibitor		infectious disease, otolaryngology, pulmonary	ear infections, laryngitis, bronchitis, pneumonia, urinary tract infections, skin infections	Prestwick, Toronto	90.89	N[C@@H](C(=O)N[C@H]1[C@H]2CCC(Cl)=C(N2C1=O)C(O)=O)c1ccccc1 |c:10|, N[C@@H](C(=O)N[C@H]1[C@H]2CCC(Cl)=C(N2C1=O)C(O)=O)c1ccccc1 |c:10|	Launched
loratadine	histamine receptor antagonist	HRH1	allergy, neurology/psychiatry	allergic rhinitis, itching	Tocris, MicroSource, Selleck, Tocris, Tocris	99.62	CCOC(=O)N1CCC(CC1)=C1c2ccc(Cl)cc2CCc2cccnc12, CCOC(=O)N1CCC(CC1)=C1c2ccc(Cl)cc2CCc2cccnc12, CCOC(=O)N1CCC(CC1)=C1c2ccc(Cl)cc2CCc2cccnc12, CCOC(=O)N1CCC(CC1)=C1c2ccc(Cl)cc2CCc2cccnc12, CCOC(=O)N1CCC(CC1)=C1c2ccc(Cl)cc2CCc2cccnc12	Launched
loreclezole	benzodiazepine receptor agonist	GABRB2, GABRB3			Tocris, Tocris	98.11	Cl\C(=C/n1cncn1)c1ccc(Cl)cc1Cl, Cl\C(=C/n1cncn1)c1ccc(Cl)cc1Cl	Phase 2
lorediplon	GABA receptor modulator	GABRA1			MedChemEx	97.58	CN(C(C)=O)c1cc(ccc1F)-c1ccnc2c(cnn12)C(=O)c1cccs1	Phase 2
lorglumide	CCK receptor antagonist	CCKAR, CCKBR			MedChemEx	98.26	CCCCCN(CCCCC)C(=O)[C@@H](CCC(O)=O)NC(=O)c1ccc(Cl)c(Cl)c1 |&1:13,r|	Phase 1
lorlatinib	ALK tyrosine kinase receptor inhibitor	ALK	oncology	non-small cell lung cancer (NSCLC)	Tocris, MedChemEx, MedChemEx, MedChemEx, MedChemEx	98.73	C[C@H]1Oc2cc(cnc2N)-c2c(CN(C)C(=O)c3ccc(F)cc13)nn(C)c2C#N, C[C@H]1Oc2cc(cnc2N)-c2c(CN(C)C(=O)c3ccc(F)cc13)nn(C)c2C#N, C[C@H]1Oc2cc(cnc2N)-c2c(CN(C)C(=O)c3ccc(F)cc13)nn(C)c2C#N, C[C@H]1Oc2cc(cnc2N)-c2c(CN(C)C(=O)c3ccc(F)cc13)nn(C)c2C#N, C[C@H]1Oc2cc(cnc2N)-c2c(CN(C)C(=O)c3ccc(F)cc13)nn(C)c2C#N	Launched
lornoxicam	cyclooxygenase inhibitor	PTGS1, PTGS2	rheumatology, neurology/psychiatry	osteoarthritis, sciata	Selleck, MicroSource, MicroSource	97.64	CN1C(C(=O)Nc2ccccn2)=C(O)c2sc(Cl)cc2S1(=O)=O |t:12|, CN1C(C(=O)Nc2ccccn2)=C(O)c2sc(Cl)cc2S1(=O)=O |t:12|, CN1C(C(=O)Nc2ccccn2)=C(O)c2sc(Cl)cc2S1(=O)=O |t:12|	Launched
losartan	angiotensin receptor antagonist	AGTR1	cardiology, nephrology	hypertension, diabetic nephropathy, hypertension	MedChemEx, MedChemEx, MedChemEx, MicroSource, MicroSource, Tocris, Selleck, Pharmeks	99.17	CCCCc1nc(Cl)c(CO)n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1, CCCCc1nc(Cl)c(CO)n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1, CCCCc1nc(Cl)c(CO)n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1, CCCCc1nc(Cl)c(CO)n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1, CCCCc1nc(Cl)c(CO)n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1, CCCCc1nc(Cl)c(CO)n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1, CCCCc1nc(Cl)c(CO)n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1, CCCCc1nc(Cl)c(CO)n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1	Launched
losmapimod	p38 MAPK inhibitor	MAPK14			MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx	96.05	Cc1c(F)cc(cc1-c1ccc(cn1)C(=O)NCC(C)(C)C)C(=O)NC1CC1, Cc1c(F)cc(cc1-c1ccc(cn1)C(=O)NCC(C)(C)C)C(=O)NC1CC1, Cc1c(F)cc(cc1-c1ccc(cn1)C(=O)NCC(C)(C)C)C(=O)NC1CC1, Cc1c(F)cc(cc1-c1ccc(cn1)C(=O)NCC(C)(C)C)C(=O)NC1CC1, Cc1c(F)cc(cc1-c1ccc(cn1)C(=O)NCC(C)(C)C)C(=O)NC1CC1, Cc1c(F)cc(cc1-c1ccc(cn1)C(=O)NCC(C)(C)C)C(=O)NC1CC1	Phase 3
lotamilast	phosphodiesterase inhibitor				MedChemEx	90.93	CNc1nc(-c2cccc(NC(=O)c3ccc(cc3)C(=O)OC)c2)c2cc(OC)c(OC)cc2n1	Preclinical
loteprednol	glucocorticoid receptor agonist, phospholipase inhibitor	NR3C1	ophthalmology	conjunctivitis	Selleck, Selleck, Selleck, MedChemEx, MedChemEx	95.55	CCOC(=O)O[C@@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C)C(=O)OCCl |c:17,t:13|, CCOC(=O)O[C@@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C)C(=O)OCCl |c:17,t:13|, CCOC(=O)O[C@@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C)C(=O)OCCl |c:17,t:13|, CCOC(=O)O[C@@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C)C(=O)OCCl |c:17,t:13|, CCOC(=O)O[C@@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C)C(=O)OCCl |c:17,t:13|	Launched
lovastatin	HMGCR inhibitor	HDAC2, HMGCR, ITGAL, NR1I2	cardiology, endocrinology	coronary heart disease, myocardial infarction, hypercholesterolemia	Tocris, Tocris, Tocris, MicroSource, MicroSource, MicroSource, Selleck, Selleck, Tocris	95.58	CC[C@H](C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:13,t:11|, CC[C@H](C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:13,t:11|, CC[C@H](C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:13,t:11|, CC[C@H](C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:13,t:11|, CC[C@H](C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:13,t:11|, CC[C@H](C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:13,t:11|, CC[C@H](C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:13,t:11|, CC[C@H](C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:13,t:11|, CC[C@H](C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:13,t:11|	Launched
loxapine	dopamine receptor antagonist, serotonin receptor antagonist	ADRA1A, ADRA1B, ADRA2A, ADRA2B, ADRA2C, ADRB1, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD1, DRD2, DRD3, DRD4, DRD5, HRH1, HRH2, HRH4, HTR1A, HTR1B, HTR1D, HTR1E, HTR2A, HTR2C, HTR3A, HTR5A, HTR6, HTR7, SLC6A2, SLC6A3, SLC6A4	neurology/psychiatry	schizophrenia	MicroSource, Selleck, MedChemEx	98.55	CN1CCN(CC1)C1=Nc2ccccc2Oc2ccc(Cl)cc12 |t:8|, CN1CCN(CC1)C1=Nc2ccccc2Oc2ccc(Cl)cc12 |t:8|, CN1CCN(CC1)C1=Nc2ccccc2Oc2ccc(Cl)cc12 |t:8|	Launched
loxistatin-acid	cysteine peptidase inhibitor	CTSB			Selleck, Selleck, Selleck	98.39	CC(C)CCNC(=O)[C@H](CC(C)C)NC(=O)[C@H]1O[C@@H]1C(O)=O, CC(C)CCNC(=O)[C@H](CC(C)C)NC(=O)[C@H]1O[C@@H]1C(O)=O, CC(C)CCNC(=O)[C@H](CC(C)C)NC(=O)[C@H]1O[C@@H]1C(O)=O	Preclinical
loxoprofen	cyclooxygenase inhibitor, prostanoid receptor antagonist	PTGS2	neurology/psychiatry	pain relief	MedChemEx, MicroSource, MicroSource, MedChemEx	98.61	C[C@@H](C(O)=O)c1ccc(C[C@H]2CCCC2=O)cc1 |&1:1,&2:10,r|, C[C@@H](C(O)=O)c1ccc(C[C@H]2CCCC2=O)cc1 |&1:1,&2:10,r|, C[C@@H](C(O)=O)c1ccc(C[C@H]2CCCC2=O)cc1 |&1:1,&2:10,r|, C[C@@H](C(O)=O)c1ccc(C[C@H]2CCCC2=O)cc1 |&1:1,&2:10,r|	Launched
LP-533401	tryptophan hydroxylase inhibitor				Adooq	93.29	N[C@@H](Cc1ccc(cc1)-c1cc(O[C@@H](c2ccc(cc2)-c2cccc(F)c2)C(F)(F)F)nc(N)n1)C(O)=O |&1:13|	Preclinical
LPA2-antagonist-1	lysophosphatidic acid receptor antagonist	LPAR2			MedChemEx, MedChemEx	97.22	C[C@@H](CN1CCN(CC1)S(=O)(=O)c1ccc(Cl)c(Cl)c1)Nc1ncnc2c(C)csc12, C[C@@H](CN1CCN(CC1)S(=O)(=O)c1ccc(Cl)c(Cl)c1)Nc1ncnc2c(C)csc12	Preclinical
LRRK2-IN-1	leucine rich repeat kinase inhibitor	LRRK2			Tocris, MedChemEx	98.57	COc1cc(ccc1Nc1ncc2N(C)C(=O)c3ccccc3N(C)c2n1)C(=O)N1CCC(CC1)N1CCN(C)CC1, COc1cc(ccc1Nc1ncc2N(C)C(=O)c3ccccc3N(C)c2n1)C(=O)N1CCC(CC1)N1CCN(C)CC1	Preclinical
LSN-2463359	glutamate receptor positive allosteric modulator	GRM5			Tocris, Tocris, Tocris	96.1	CC(C)NC(=O)c1ccc(cn1)C#Cc1ccncc1, CC(C)NC(=O)c1ccc(cn1)C#Cc1ccncc1, CC(C)NC(=O)c1ccc(cn1)C#Cc1ccncc1	Preclinical
LSZ-102	selective estrogen receptor modulator (SERM)				MedChemEx, MedChemEx	93.38	CC(F)(F)c1cc(F)ccc1-c1sc2cc(O)ccc2c1Oc1ccc(\C=C\C(O)=O)cc1, CC(F)(F)c1cc(F)ccc1-c1sc2cc(O)ccc2c1Oc1ccc(\C=C\C(O)=O)cc1	Phase 1
LTA					Enamine	94.91	N=C(Nc1ccccc1)c1cccs1	Phase 2
LTB4	leukocyte activator	LTB4R, LTB4R2			Enzo	8.37	CCCCC\C=C/C[C@@H](O)\C=C\C=C\C=C/[C@@H](O)CCCC(O)=O	Phase 2
LTX-315	anticancer agent				MedChemEx	95.27	NCCCC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](C(c1ccccc1)c1ccccc1)C(=O)N[C@@H](CCCCN)C(N)=O	Phase 2
Lu-AA-47070	adenosine receptor antagonist	ADORA2A			Tocris, Tocris, Tocris	88.17	CC(C)(C)CC(=O)Nc1c(F)cc(cc1F)C(=O)\N=c1/sccn1COP(O)(O)=O, CC(C)(C)CC(=O)Nc1c(F)cc(cc1F)C(=O)\N=c1/sccn1COP(O)(O)=O, CC(C)(C)CC(=O)Nc1c(F)cc(cc1F)C(=O)\N=c1/sccn1COP(O)(O)=O	Phase 2
lubiprostone	chloride channel activator	CLCN2	gastroenterology	constipation, irritable bowel syndrome	MedChemEx, Selleck, Selleck	98.91	CCCCC(F)(F)C(=O)CC[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O, CCCCC(F)(F)C(=O)CC[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O, CCCCC(F)(F)C(=O)CC[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O	Launched
lucanthone	endonuclease inhibitor	APEX1, TOP1, TOP2A			MedChemEx	96.37	CCN(CC)CCNc1ccc(C)c2sc3ccccc3c(=O)c12	Phase 2
lucitanib	FGFR inhibitor, VEGFR inhibitor	FGFR1, FLT1, KDR, KIT, PDGFRA, PDGFRB, RET			MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx	92.94	CNC(=O)c1cccc2cc(Oc3ccnc4cc(OCC5(N)CC5)c(OC)cc34)ccc12, CNC(=O)c1cccc2cc(Oc3ccnc4cc(OCC5(N)CC5)c(OC)cc34)ccc12, CNC(=O)c1cccc2cc(Oc3ccnc4cc(OCC5(N)CC5)c(OC)cc34)ccc12, CNC(=O)c1cccc2cc(Oc3ccnc4cc(OCC5(N)CC5)c(OC)cc34)ccc12, CNC(=O)c1cccc2cc(Oc3ccnc4cc(OCC5(N)CC5)c(OC)cc34)ccc12, CNC(=O)c1cccc2cc(Oc3ccnc4cc(OCC5(N)CC5)c(OC)cc34)ccc12, CNC(=O)c1cccc2cc(Oc3ccnc4cc(OCC5(N)CC5)c(OC)cc34)ccc12, CNC(=O)c1cccc2cc(Oc3ccnc4cc(OCC5(N)CC5)c(OC)cc34)ccc12, CNC(=O)c1cccc2cc(Oc3ccnc4cc(OCC5(N)CC5)c(OC)cc34)ccc12, CNC(=O)c1cccc2cc(Oc3ccnc4cc(OCC5(N)CC5)c(OC)cc34)ccc12, CNC(=O)c1cccc2cc(Oc3ccnc4cc(OCC5(N)CC5)c(OC)cc34)ccc12, CNC(=O)c1cccc2cc(Oc3ccnc4cc(OCC5(N)CC5)c(OC)cc34)ccc12, CNC(=O)c1cccc2cc(Oc3ccnc4cc(OCC5(N)CC5)c(OC)cc34)ccc12	Phase 2
LUF-5834	adenosine receptor agonist	ADORA2A, ADORA2B			Tocris, Tocris	98.27	Nc1nc(SCc2ncc[nH]2)c(C#N)c(-c2ccc(O)cc2)c1C#N, Nc1nc(SCc2ncc[nH]2)c(C#N)c(-c2ccc(O)cc2)c1C#N	Preclinical
lufenuron	chitin inhibitor		infectious disease	flea control	MicroSource, MicroSource, Sigma	97.89	F[C@@H](C(F)(F)F)C(F)(F)Oc1cc(Cl)c(NC(=O)NC(=O)c2c(F)cccc2F)cc1Cl |&1:1,r|, F[C@@H](C(F)(F)F)C(F)(F)Oc1cc(Cl)c(NC(=O)NC(=O)c2c(F)cccc2F)cc1Cl |&1:1,r|, F[C@@H](C(F)(F)F)C(F)(F)Oc1cc(Cl)c(NC(=O)NC(=O)c2c(F)cccc2F)cc1Cl |&1:1,r|	Launched
luliconazole	sterol demethylase inhibitor		infectious disease	tinea pedis, tinea cruris, tinea corporis	MedChemEx, Selleck, Selleck	98.72	Clc1ccc([C@@H]2CS\C(S2)=C(\C#N)n2ccnc2)c(Cl)c1, Clc1ccc([C@@H]2CS\C(S2)=C(\C#N)n2ccnc2)c(Cl)c1, Clc1ccc([C@@H]2CS\C(S2)=C(\C#N)n2ccnc2)c(Cl)c1	Launched
lumacaftor	CFTR channel agonist	CFTR	pulmonary	cystic fibrosis	MedChemEx, Selleck	98.26	Cc1ccc(NC(=O)C2(CC2)c2ccc3OC(F)(F)Oc3c2)nc1-c1cccc(c1)C(O)=O, Cc1ccc(NC(=O)C2(CC2)c2ccc3OC(F)(F)Oc3c2)nc1-c1cccc(c1)C(O)=O	Launched
lumateperone	dopamine receptor modulator, serotonin receptor antagonist	DRD2, HTR2A			MedChemEx, MedChemEx, MedChemEx	81.32	CN1CCN2[C@H]3CCN(CCCC(=O)c4ccc(F)cc4)C[C@H]3c3cccc1c23, CN1CCN2[C@H]3CCN(CCCC(=O)c4ccc(F)cc4)C[C@H]3c3cccc1c23, CN1CCN2[C@H]3CCN(CCCC(=O)c4ccc(F)cc4)C[C@H]3c3cccc1c23	Launched
lumefantrine	antimalarial agent	ATP1A1	infectious disease	malaria	MedChemEx, Enamine, MedChemEx	58.57	CCCCN(CCCC)C[C@@H](O)c1cc(Cl)cc2\C(=C/c3ccc(Cl)cc3)c3cc(Cl)ccc3-c12 |&1:10,r|, CCCCN(CCCC)C[C@@H](O)c1cc(Cl)cc2\C(=C/c3ccc(Cl)cc3)c3cc(Cl)ccc3-c12 |&1:10,r|, CCCCN(CCCC)C[C@@H](O)c1cc(Cl)cc2\C(=C/c3ccc(Cl)cc3)c3cc(Cl)ccc3-c12 |&1:10,r|	Launched
lumiracoxib	cyclooxygenase inhibitor	PTGS1, PTGS2			MicroSource, MicroSource, Selleck	97.35	Cc1ccc(Nc2c(F)cccc2Cl)c(CC(O)=O)c1, Cc1ccc(Nc2c(F)cccc2Cl)c(CC(O)=O)c1, Cc1ccc(Nc2c(F)cccc2Cl)c(CC(O)=O)c1	Withdrawn
lupanine	sodium channel blocker	INS			ChemDiv	91.3	[H][C@@]12CCCCN1C[C@@H]1C[C@H]2CN2C(=O)CCC[C@]12[H]	Phase 1
lurasidone	dopamine receptor antagonist, serotonin receptor antagonist	ADRA2A, ADRA2C, DRD2, HTR1A, HTR2A, HTR7	neurology/psychiatry	schizophrenia	Selleck, Selleck, Selleck, Selleck	97.97	O=C1[C@H]2[C@@H]3CC[C@@H](C3)[C@H]2C(=O)N1C[C@@H]1CCCC[C@H]1CN1CCN(CC1)c1nsc2ccccc12, O=C1[C@H]2[C@@H]3CC[C@@H](C3)[C@H]2C(=O)N1C[C@@H]1CCCC[C@H]1CN1CCN(CC1)c1nsc2ccccc12, O=C1[C@H]2[C@@H]3CC[C@@H](C3)[C@H]2C(=O)N1C[C@@H]1CCCC[C@H]1CN1CCN(CC1)c1nsc2ccccc12, O=C1[C@H]2[C@@H]3CC[C@@H](C3)[C@H]2C(=O)N1C[C@@H]1CCCC[C@H]1CN1CCN(CC1)c1nsc2ccccc12	Launched
lurbinectedin	DNA binding agent				MedChemEx	93.93	[H][C@@]12Cc3cc(C)c(OC)c(O)c3[C@@]([H])(N1C)[C@@]1([H])N([C@H]2O)[C@@]2([H])COC(=O)[C@]3(CS[C@]1([H])c1c(OC(C)=O)c(C)c4OCOc4c21)NCCc1c3[nH]c2ccc(OC)cc12 |THB:16:15:2.3.12:20.19.17|	Phase 3
lusaperidone	adrenergic receptor antagonist				MedChemEx	92.42	Cc1nc2ccccn2c(=O)c1CCN1CCc2oc3ccccc3c2C1	Preclinical
lusutrombopag	thrombopoietin receptor agonist				MedChemEx	97.11	CCCCCCO[C@@H](C)c1cccc(-c2csc(NC(=O)c3cc(Cl)c(\C=C(/C)C(O)=O)c(Cl)c3)n2)c1OC	Launched
lutein	antioxidant		ophthalmology	macular degeneration, cataracts, retinitis pigmentosa (RP)	Sigma, AKSci	0	C\C(\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C)=C/C=C/C=C(\C)/C=C/C=C(\C)/C=C/C1=C(C)C[C@@H](O)CC1(C)C |c:11,33|, C\C(\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C)=C/C=C/C=C(\C)/C=C/C=C(\C)/C=C/C1=C(C)C[C@@H](O)CC1(C)C |c:11,33|	Launched
luteolin	glucosidase inhibitor	TOP1			Selleck, Selleck	92.4	Oc1cc(O)c2c(c1)oc(cc2=O)-c1ccc(O)c(O)c1, Oc1cc(O)c2c(c1)oc(cc2=O)-c1ccc(O)c(O)c1	Phase 2
luzindole	melatonin receptor antagonist	MTNR1A, MTNR1B			Tocris, Tocris, Tocris	89.41	CC(=O)NCCc1c(Cc2ccccc2)[nH]c2ccccc12, CC(=O)NCCc1c(Cc2ccccc2)[nH]c2ccccc12, CC(=O)NCCc1c(Cc2ccccc2)[nH]c2ccccc12	Preclinical
LXH254	RAF inhibitor				MedChemEx	97.62	Cc1ccc(NC(=O)c2ccnc(c2)C(F)(F)F)cc1-c1cc(OCCO)nc(c1)N1CCOCC1	Phase 1
LXR-623	LXR agonist	AR, NR1H2, NR1H3, NR1I2, NR3C1			MedChemEx, MedChemEx	99.59	Fc1ccc(cc1)-c1n(Cc2ccc(F)cc2Cl)nc2c(cccc12)C(F)(F)F, Fc1ccc(cc1)-c1n(Cc2ccc(F)cc2Cl)nc2c(cccc12)C(F)(F)F	Phase 1
LXS196	PKC inhibitor				MedChemEx	94.13	CC1(N)CCN(CC1)c1cccnc1NC(=O)c1nc(cnc1N)-c1ncccc1C(F)(F)F	Phase 1
LX1031	tryptophan hydroxylase inhibitor	TPH1			MedChemEx, MedChemEx	93.2	COc1cccc(c1)-c1ccc(cc1)[C@@H](Oc1cc(nc(N)n1)-c1ccc(C[C@H](N)C(O)=O)cc1)C(F)(F)F, COc1cccc(c1)-c1ccc(cc1)[C@@H](Oc1cc(nc(N)n1)-c1ccc(C[C@H](N)C(O)=O)cc1)C(F)(F)F	Phase 2
LX7101	LIM kinase inhibitor, rho associated kinase inhibitor	LIMK2, ROCK1, ROCK2			MedChemEx, MedChemEx, MedChemEx	81.88	CN(C)C(=O)Oc1cccc(NC(=O)C2(CN)CCN(CC2)c2ncnc3[nH]cc(C)c23)c1, CN(C)C(=O)Oc1cccc(NC(=O)C2(CN)CCN(CC2)c2ncnc3[nH]cc(C)c23)c1, CN(C)C(=O)Oc1cccc(NC(=O)C2(CN)CCN(CC2)c2ncnc3[nH]cc(C)c23)c1	Phase 1/Phase 2
lycopene	free radical scavenger				AKSci	0	CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C	Launched
lylamine	cannabinoid receptor agonist	CNR1			Tocris, Tocris, Tocris, Tocris	100	CC(C)c1ccc2c(CC[C@H]3[C@](C)(CN)CCC[C@]23C)c1, CC(C)c1ccc2c(CC[C@H]3[C@](C)(CN)CCC[C@]23C)c1, CC(C)c1ccc2c(CC[C@H]3[C@](C)(CN)CCC[C@]23C)c1, CC(C)c1ccc2c(CC[C@H]3[C@](C)(CN)CCC[C@]23C)c1	Preclinical
lymecycline	bacterial 50S ribosomal subunit inhibitor		dermatology	acne vulgaris (AV)	Key	0	CN(C)[C@H]1[C@@H]2C[C@H]3[C@@H](C(=O)c4c(O)cccc4[C@@]3(C)O)C(=O)[C@]2(O)C(=O)[C@H](C(=O)NCNCCCC[C@H](N)C(O)=O)C1=O |&1:7,&2:26|	Launched
lynestrenol	progestogen hormone		endocrinology	contraceptive	Sigma, Prestwick	0	C[C@]12CC[C@H]3[C@@H](CCC4=CCCC[C@H]34)[C@@H]1CC[C@@]2(O)C#C |t:8|, C[C@]12CC[C@H]3[C@@H](CCC4=CCCC[C@H]34)[C@@H]1CC[C@@]2(O)C#C |t:8|	Launched
lypressin	vasopressin receptor agonist	AVPR1A, AVPR1B, AVPR2	endocrinology	central diabetes insipidus	MedChemEx, Apollo, Apollo	70.31	NCCCC[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N1)C(=O)NCC(N)=O, NCCCC[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N1)C(=O)NCC(N)=O, NCCCC[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N1)C(=O)NCC(N)=O	Launched
LY2090314	glycogen synthase kinase inhibitor	GSK3B			MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx	98.37	Fc1cc2CN(CCn3cc(C4=C(C(=O)NC4=O)c4cnc5ccccn45)c(c1)c23)C(=O)N1CCCCC1 |t:11|, Fc1cc2CN(CCn3cc(C4=C(C(=O)NC4=O)c4cnc5ccccn45)c(c1)c23)C(=O)N1CCCCC1 |t:11|, Fc1cc2CN(CCn3cc(C4=C(C(=O)NC4=O)c4cnc5ccccn45)c(c1)c23)C(=O)N1CCCCC1 |t:11|, Fc1cc2CN(CCn3cc(C4=C(C(=O)NC4=O)c4cnc5ccccn45)c(c1)c23)C(=O)N1CCCCC1 |t:11|, Fc1cc2CN(CCn3cc(C4=C(C(=O)NC4=O)c4cnc5ccccn45)c(c1)c23)C(=O)N1CCCCC1 |t:11|	Phase 2
LY2109761	TGF beta receptor inhibitor	TGFBR1, TGFBR2			Selleck, Selleck, Selleck, Selleck, Selleck, MedChemEx	98.4	C(CN1CCOCC1)Oc1ccc2c(ccnc2c1)-c1c2CCCn2nc1-c1ccccn1, C(CN1CCOCC1)Oc1ccc2c(ccnc2c1)-c1c2CCCn2nc1-c1ccccn1, C(CN1CCOCC1)Oc1ccc2c(ccnc2c1)-c1c2CCCn2nc1-c1ccccn1, C(CN1CCOCC1)Oc1ccc2c(ccnc2c1)-c1c2CCCn2nc1-c1ccccn1, C(CN1CCOCC1)Oc1ccc2c(ccnc2c1)-c1c2CCCn2nc1-c1ccccn1, C(CN1CCOCC1)Oc1ccc2c(ccnc2c1)-c1c2CCCn2nc1-c1ccccn1	Preclinical
LY2140023	glutamate receptor agonist	GRM3			Selleck, Selleck, Selleck, Selleck, Selleck	100	N[C@]1(CS(=O)(=O)[C@H]2[C@@H]([C@@H]12)C(O)=O)C(O)=O, N[C@]1(CS(=O)(=O)[C@H]2[C@@H]([C@@H]12)C(O)=O)C(O)=O, N[C@]1(CS(=O)(=O)[C@H]2[C@@H]([C@@H]12)C(O)=O)C(O)=O, N[C@]1(CS(=O)(=O)[C@H]2[C@@H]([C@@H]12)C(O)=O)C(O)=O, N[C@]1(CS(=O)(=O)[C@H]2[C@@H]([C@@H]12)C(O)=O)C(O)=O	Phase 3
LY215490	glutamate receptor antagonist	GRIA1, GRIA2, GRIA3, GRIA4, GRIK1			MedChemEx	100	OC(=O)[C@@H]1C[C@H]2C[C@@H](CCc3nn[nH]n3)CC[C@H]2CN1	Phase 1
LY2157299	TGF beta receptor inhibitor	TGFBR1			Selleck, Selleck, Selleck, MedChemEx	97.81	Cc1cccc(n1)-c1nn2CCCc2c1-c1ccnc2ccc(cc12)C(N)=O, Cc1cccc(n1)-c1nn2CCCc2c1-c1ccnc2ccc(cc12)C(N)=O, Cc1cccc(n1)-c1nn2CCCc2c1-c1ccnc2ccc(cc12)C(N)=O, Cc1cccc(n1)-c1nn2CCCc2c1-c1ccnc2ccc(cc12)C(N)=O	Phase 2/Phase 3
LY2183240	FAAH inhibitor, FAAH reuptake inhibitor	FAAH			Tocris, Tocris, Tocris, Tocris	96.05	CN(C)C(=O)n1nnnc1Cc1ccc(cc1)-c1ccccc1, CN(C)C(=O)n1nnnc1Cc1ccc(cc1)-c1ccccc1, CN(C)C(=O)n1nnnc1Cc1ccc(cc1)-c1ccccc1, CN(C)C(=O)n1nnnc1Cc1ccc(cc1)-c1ccccc1	Preclinical
LY2228820	p38 MAPK inhibitor	MAPK14			Selleck, Selleck, Selleck, Selleck, MedChemEx	99.32	CC(C)(C)Cn1c(N)nc2ccc(nc12)-c1nc([nH]c1-c1ccc(F)cc1)C(C)(C)C, CC(C)(C)Cn1c(N)nc2ccc(nc12)-c1nc([nH]c1-c1ccc(F)cc1)C(C)(C)C, CC(C)(C)Cn1c(N)nc2ccc(nc12)-c1nc([nH]c1-c1ccc(F)cc1)C(C)(C)C, CC(C)(C)Cn1c(N)nc2ccc(nc12)-c1nc([nH]c1-c1ccc(F)cc1)C(C)(C)C, CC(C)(C)Cn1c(N)nc2ccc(nc12)-c1nc([nH]c1-c1ccc(F)cc1)C(C)(C)C	Phase 2
LY223982	leukotriene receptor antagonist	LTB4R			Cayman, Cayman	95.19	COc1ccc(\C=C\CCCCOc2ccc(cc2CCC(O)=O)C(=O)c2cccc(c2)C(O)=O)cc1, COc1ccc(\C=C\CCCCOc2ccc(cc2CCC(O)=O)C(=O)c2cccc(c2)C(O)=O)cc1	Phase 2
LY225910	CCK receptor antagonist	CCKBR			Tocris, Tocris, Tocris, Tocris, Tocris, Tocris	98.13	CC(C)Oc1cccc(c1)-n1c(CCc2c[nH]c3ccc(Br)cc23)nc2ccccc2c1=O, CC(C)Oc1cccc(c1)-n1c(CCc2c[nH]c3ccc(Br)cc23)nc2ccccc2c1=O, CC(C)Oc1cccc(c1)-n1c(CCc2c[nH]c3ccc(Br)cc23)nc2ccccc2c1=O, CC(C)Oc1cccc(c1)-n1c(CCc2c[nH]c3ccc(Br)cc23)nc2ccccc2c1=O, CC(C)Oc1cccc(c1)-n1c(CCc2c[nH]c3ccc(Br)cc23)nc2ccccc2c1=O, CC(C)Oc1cccc(c1)-n1c(CCc2c[nH]c3ccc(Br)cc23)nc2ccccc2c1=O	Preclinical
LY231617	lipid peroxidase inhibitor				Otava, Otava	90.52	CCNCc1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C, CCNCc1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C	Preclinical
LY2334737	antitumor agent, ribonucleotide reductase inhibitor				MedChemEx, MedChemEx, MedChemEx	95.83	CCCC(CCC)C(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1, CCCC(CCC)C(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1, CCCC(CCC)C(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1	Phase 1
LY2365109	glycine transporter inhibitor	SLC6A9			Tocris, Tocris	97.65	CN(CCOc1ccc(cc1C(C)(C)C)-c1ccc2OCOc2c1)CC(O)=O, CN(CCOc1ccc(cc1C(C)(C)C)-c1ccc2OCOc2c1)CC(O)=O	Preclinical
LY2452473	androgen receptor modulator	AR			Sigma	82.38	CC(C)OC(=O)N[C@@H]1Cc2c(C1)c1cc(ccc1n2Cc1ccccn1)C#N	Phase 2
LY2510924	CC chemokine receptor antagonist				MedChemEx	97.77	[H][C@]1(CCCN=C(N)N)NC(=O)[C@H](CCCCNC(C)C)NC(=O)[C@@H](Cc2ccc(O)cc2)NC(=O)[C@H](Cc2ccccc2)NC(=O)CC[C@@H](NC(=O)CNC(=O)[C@H](Cc2ccc3ccccc3c2)NC1=O)C(=O)N[C@@H](CCCCNC(C)C)C(N)=O	Phase 2
LY255283	leukotriene receptor antagonist	LTB4R, LTB4R2			Tocris, Tocris, Tocris, Tocris	97.51	CCc1cc(C(C)=O)c(O)cc1OCCCCCC(C)(C)c1nn[nH]n1, CCc1cc(C(C)=O)c(O)cc1OCCCCCC(C)(C)c1nn[nH]n1, CCc1cc(C(C)=O)c(O)cc1OCCCCCC(C)(C)c1nn[nH]n1, CCc1cc(C(C)=O)c(O)cc1OCCCCCC(C)(C)c1nn[nH]n1	Preclinical
LY2584702	ribosomal protein inhibitor	RPS6KB1			Selleck, Adooq	98.81	Cn1cc(nc1C1CCN(CC1)c1ncnc2n[nH]cc12)-c1ccc(F)c(c1)C(F)(F)F, Cn1cc(nc1C1CCN(CC1)c1ncnc2n[nH]cc12)-c1ccc(F)c(c1)C(F)(F)F	Phase 1
LY2603618	CHK inhibitor	CHEK1			Selleck, Selleck, MedChemEx, Selleck, Selleck	90.89	Cc1cnc(NC(=O)Nc2cc(Br)c(C)cc2OC[C@@H]2CNCCO2)cn1, Cc1cnc(NC(=O)Nc2cc(Br)c(C)cc2OC[C@@H]2CNCCO2)cn1, Cc1cnc(NC(=O)Nc2cc(Br)c(C)cc2OC[C@@H]2CNCCO2)cn1, Cc1cnc(NC(=O)Nc2cc(Br)c(C)cc2OC[C@@H]2CNCCO2)cn1, Cc1cnc(NC(=O)Nc2cc(Br)c(C)cc2OC[C@@H]2CNCCO2)cn1	Phase 2
LY2606368	CHK inhibitor	CHEK1			MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx	97.61	COc1cccc(OCCCN)c1-c1cc(Nc2cnc(cn2)C#N)[nH]n1, COc1cccc(OCCCN)c1-c1cc(Nc2cnc(cn2)C#N)[nH]n1, COc1cccc(OCCCN)c1-c1cc(Nc2cnc(cn2)C#N)[nH]n1, COc1cccc(OCCCN)c1-c1cc(Nc2cnc(cn2)C#N)[nH]n1, COc1cccc(OCCCN)c1-c1cc(Nc2cnc(cn2)C#N)[nH]n1	Phase 2
LY2608204	glucokinase activator	GCK			MedChemEx, MedChemEx, Selleck, Selleck, Selleck, Selleck, Selleck	97.57	O=C(Nc1ncc(SCCN2CCCC2)s1)[C@@]1(C[C@H]1C1CCCCC1)c1ccc(cc1)S(=O)(=O)C1CC1, O=C(Nc1ncc(SCCN2CCCC2)s1)[C@@]1(C[C@H]1C1CCCCC1)c1ccc(cc1)S(=O)(=O)C1CC1, O=C(Nc1ncc(SCCN2CCCC2)s1)[C@@]1(C[C@H]1C1CCCCC1)c1ccc(cc1)S(=O)(=O)C1CC1, O=C(Nc1ncc(SCCN2CCCC2)s1)[C@@]1(C[C@H]1C1CCCCC1)c1ccc(cc1)S(=O)(=O)C1CC1, O=C(Nc1ncc(SCCN2CCCC2)s1)[C@@]1(C[C@H]1C1CCCCC1)c1ccc(cc1)S(=O)(=O)C1CC1, O=C(Nc1ncc(SCCN2CCCC2)s1)[C@@]1(C[C@H]1C1CCCCC1)c1ccc(cc1)S(=O)(=O)C1CC1, O=C(Nc1ncc(SCCN2CCCC2)s1)[C@@]1(C[C@H]1C1CCCCC1)c1ccc(cc1)S(=O)(=O)C1CC1	Phase 2
LY266097	serotonin receptor antagonist	HTR2B			Tocris, Tocris, Tocris	94.88	COc1ccc(C[C@H]2NCCc3c2[nH]c2ccc(C)cc32)c(Cl)c1OC |&1:7|, COc1ccc(C[C@H]2NCCc3c2[nH]c2ccc(C)cc32)c(Cl)c1OC |&1:7|, COc1ccc(C[C@H]2NCCc3c2[nH]c2ccc(C)cc32)c(Cl)c1OC |&1:7|	Preclinical
LY2784544	JAK inhibitor	JAK2, JAK3			Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck	97.67	Cc1cc(Nc2cc(CN3CCOCC3)c3nc(C)c(Cc4ccc(Cl)cc4F)n3n2)[nH]n1, Cc1cc(Nc2cc(CN3CCOCC3)c3nc(C)c(Cc4ccc(Cl)cc4F)n3n2)[nH]n1, Cc1cc(Nc2cc(CN3CCOCC3)c3nc(C)c(Cc4ccc(Cl)cc4F)n3n2)[nH]n1, Cc1cc(Nc2cc(CN3CCOCC3)c3nc(C)c(Cc4ccc(Cl)cc4F)n3n2)[nH]n1, Cc1cc(Nc2cc(CN3CCOCC3)c3nc(C)c(Cc4ccc(Cl)cc4F)n3n2)[nH]n1, Cc1cc(Nc2cc(CN3CCOCC3)c3nc(C)c(Cc4ccc(Cl)cc4F)n3n2)[nH]n1, Cc1cc(Nc2cc(CN3CCOCC3)c3nc(C)c(Cc4ccc(Cl)cc4F)n3n2)[nH]n1, Cc1cc(Nc2cc(CN3CCOCC3)c3nc(C)c(Cc4ccc(Cl)cc4F)n3n2)[nH]n1, Cc1cc(Nc2cc(CN3CCOCC3)c3nc(C)c(Cc4ccc(Cl)cc4F)n3n2)[nH]n1	Phase 2
LY2795050	opioid receptor antagonist				MedChemEx	95.77	NC(=O)c1ccc(Oc2ccc(CN3CCC[C@H]3c3cccnc3)cc2)c(Cl)c1	Preclinical
LY2801653	MET inhibitor	MET			MedChemEx, MedChemEx, MedChemEx, MedChemEx	99.53	Cc1ccc(C(=O)Nc2ccc(Oc3cc4cnn(C)c4cc3-c3cn[nH]c3)c(F)c2)c(=O)n1-c1ccc(F)cc1, Cc1ccc(C(=O)Nc2ccc(Oc3cc4cnn(C)c4cc3-c3cn[nH]c3)c(F)c2)c(=O)n1-c1ccc(F)cc1, Cc1ccc(C(=O)Nc2ccc(Oc3cc4cnn(C)c4cc3-c3cn[nH]c3)c(F)c2)c(=O)n1-c1ccc(F)cc1, Cc1ccc(C(=O)Nc2ccc(Oc3cc4cnn(C)c4cc3-c3cn[nH]c3)c(F)c2)c(=O)n1-c1ccc(F)cc1	Phase 2
LY2811376	beta-secretase inhibitor	BACE1			MedChemEx, Selleck, Selleck, Selleck, Selleck, Selleck	96.96	C[C@]1(CCSC(N)=N1)c1cc(c(F)cc1F)-c1cncnc1 |c:6|, C[C@]1(CCSC(N)=N1)c1cc(c(F)cc1F)-c1cncnc1 |c:6|, C[C@]1(CCSC(N)=N1)c1cc(c(F)cc1F)-c1cncnc1 |c:6|, C[C@]1(CCSC(N)=N1)c1cc(c(F)cc1F)-c1cncnc1 |c:6|, C[C@]1(CCSC(N)=N1)c1cc(c(F)cc1F)-c1cncnc1 |c:6|, C[C@]1(CCSC(N)=N1)c1cc(c(F)cc1F)-c1cncnc1 |c:6|	Phase 1
LY2828360	cannabinoid receptor agonist				MedChemEx	95.34	CN1CCN(CC1)c1nc(C)nc2n(C3CCOCC3)c(nc12)-c1ccccc1Cl	Phase 2
LY2857785	CDK inhibitor	CDK9			MedChemEx, MedChemEx, MedChemEx	96.88	CC(C)c1n(C)nc2ccc(cc12)-c1ccnc(N[C@H]2CC[C@@H](CC2)NC2CCOCC2)n1 |r|, CC(C)c1n(C)nc2ccc(cc12)-c1ccnc(N[C@H]2CC[C@@H](CC2)NC2CCOCC2)n1 |r|, CC(C)c1n(C)nc2ccc(cc12)-c1ccnc(N[C@H]2CC[C@@H](CC2)NC2CCOCC2)n1 |r|	Preclinical
LY2874455	FGFR antagonist	FGFR1, FGFR2, FGFR3, FGFR4, KDR			MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx	94.98	C[C@@H](Oc1ccc2n[nH]c(\C=C\c3cnn(CCO)c3)c2c1)c1c(Cl)cncc1Cl, C[C@@H](Oc1ccc2n[nH]c(\C=C\c3cnn(CCO)c3)c2c1)c1c(Cl)cncc1Cl, C[C@@H](Oc1ccc2n[nH]c(\C=C\c3cnn(CCO)c3)c2c1)c1c(Cl)cncc1Cl, C[C@@H](Oc1ccc2n[nH]c(\C=C\c3cnn(CCO)c3)c2c1)c1c(Cl)cncc1Cl, C[C@@H](Oc1ccc2n[nH]c(\C=C\c3cnn(CCO)c3)c2c1)c1c(Cl)cncc1Cl, C[C@@H](Oc1ccc2n[nH]c(\C=C\c3cnn(CCO)c3)c2c1)c1c(Cl)cncc1Cl, C[C@@H](Oc1ccc2n[nH]c(\C=C\c3cnn(CCO)c3)c2c1)c1c(Cl)cncc1Cl, C[C@@H](Oc1ccc2n[nH]c(\C=C\c3cnn(CCO)c3)c2c1)c1c(Cl)cncc1Cl	Phase 1
LY288513	CCK receptor antagonist	CCKBR			Tocris, Tocris	92.87	Brc1ccc(NC(=O)N2NC(=O)[C@H]([C@@H]2c2ccccc2)c2ccccc2)cc1, Brc1ccc(NC(=O)N2NC(=O)[C@H]([C@@H]2c2ccccc2)c2ccccc2)cc1	Preclinical
LY2886721	beta-secretase inhibitor	BACE1			MedChemEx	99.23	NC1=N[C@]2(COC[C@H]2CS1)c1cc(NC(=O)c2ccc(F)cn2)ccc1F |t:1|	Phase 1/Phase 2
LY294002	DNA dependent protein kinase inhibitor, mTOR inhibitor, phosphodiesterase inhibitor, PI3K inhibitor, PLK inhibitor	AKT1, CHEK1, GSK3B, LCK, MAPK1, MAPK11, MAPK12, MAPK14, MAPK8, MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG, PIM1, PLK1, PRKCA, PRKDC, ROCK1, RPS6KB1, SGK1			Selleck, Selleck, Tocris, Tocris	96.09	O=c1cc(oc2c(cccc12)-c1ccccc1)N1CCOCC1, O=c1cc(oc2c(cccc12)-c1ccccc1)N1CCOCC1, O=c1cc(oc2c(cccc12)-c1ccccc1)N1CCOCC1, O=c1cc(oc2c(cccc12)-c1ccccc1)N1CCOCC1	Preclinical
LY2979165	glutamate receptor agonist	GRM2			MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx	97.2	C[C@H](N)C(=O)N[C@]1(C[C@@H](Sc2nnc[nH]2)[C@H]2[C@@H]([C@@H]12)C(O)=O)C(O)=O, C[C@H](N)C(=O)N[C@]1(C[C@@H](Sc2nnc[nH]2)[C@H]2[C@@H]([C@@H]12)C(O)=O)C(O)=O, C[C@H](N)C(=O)N[C@]1(C[C@@H](Sc2nnc[nH]2)[C@H]2[C@@H]([C@@H]12)C(O)=O)C(O)=O, C[C@H](N)C(=O)N[C@]1(C[C@@H](Sc2nnc[nH]2)[C@H]2[C@@H]([C@@H]12)C(O)=O)C(O)=O, C[C@H](N)C(=O)N[C@]1(C[C@@H](Sc2nnc[nH]2)[C@H]2[C@@H]([C@@H]12)C(O)=O)C(O)=O	Phase 1
LY3000328	cathepsin inhibitor	CTSS			MedChemEx, MedChemEx, MedChemEx	96.06	CNC(=O)O[C@H]1COc2ccc(cc2[C@@H]1NC(=O)c1ccc(F)cc1)N1CCN(CC1)C1COC1, CNC(=O)O[C@H]1COc2ccc(cc2[C@@H]1NC(=O)c1ccc(F)cc1)N1CCN(CC1)C1COC1, CNC(=O)O[C@H]1COc2ccc(cc2[C@@H]1NC(=O)c1ccc(F)cc1)N1CCN(CC1)C1COC1	Phase 1
LY3009120	RAF inhibitor	BRAF, RAF1			MedChemEx, MedChemEx, Selleck	95.74	CNc1ncc2cc(c(C)nc2n1)-c1cc(NC(=O)NCCC(C)(C)C)c(F)cc1C, CNc1ncc2cc(c(C)nc2n1)-c1cc(NC(=O)NCCC(C)(C)C)c(F)cc1C, CNc1ncc2cc(c(C)nc2n1)-c1cc(NC(=O)NCCC(C)(C)C)c(F)cc1C	Phase 1
LY3023414	mTOR inhibitor, PI3K inhibitor	MTOR			MedChemEx, MedChemEx, MedChemEx	96.66	CO[C@@H](C)Cn1c2c(cnc3ccc(cc23)-c2cncc(c2)C(C)(C)O)n(C)c1=O, CO[C@@H](C)Cn1c2c(cnc3ccc(cc23)-c2cncc(c2)C(C)(C)O)n(C)c1=O, CO[C@@H](C)Cn1c2c(cnc3ccc(cc23)-c2cncc(c2)C(C)(C)O)n(C)c1=O	Phase 2
LY303511	casein kinase inhibitor, mTOR inhibitor, PI3K inhibitor	BRD2, BRD3, BRD4			Tocris, Tocris, Tocris, Tocris, Tocris, Tocris, Tocris, Tocris	95.98	O=c1cc(oc2c(cccc12)-c1ccccc1)N1CCNCC1, O=c1cc(oc2c(cccc12)-c1ccccc1)N1CCNCC1, O=c1cc(oc2c(cccc12)-c1ccccc1)N1CCNCC1, O=c1cc(oc2c(cccc12)-c1ccccc1)N1CCNCC1, O=c1cc(oc2c(cccc12)-c1ccccc1)N1CCNCC1, O=c1cc(oc2c(cccc12)-c1ccccc1)N1CCNCC1, O=c1cc(oc2c(cccc12)-c1ccccc1)N1CCNCC1, O=c1cc(oc2c(cccc12)-c1ccccc1)N1CCNCC1	Preclinical
LY310762	serotonin receptor antagonist	HTR1D			MedChemEx, MedChemEx, MedChemEx, MedChemEx	97.19	CC1(C)C(=O)N(CCN2CCC(CC2)C(=O)c2ccc(F)cc2)c2ccccc12, CC1(C)C(=O)N(CCN2CCC(CC2)C(=O)c2ccc(F)cc2)c2ccccc12, CC1(C)C(=O)N(CCN2CCC(CC2)C(=O)c2ccc(F)cc2)c2ccccc12, CC1(C)C(=O)N(CCN2CCC(CC2)C(=O)c2ccc(F)cc2)c2ccccc12	Preclinical
LY311727	phospholipase inhibitor				Sigma	91.26	CCc1c(CC(N)=O)c2cc(OCCCP(O)(O)=O)ccc2n1Cc1ccccc1	Preclinical
LY3200882	TGF beta receptor inhibitor				MedChemEx	97.88	CC(C)(O)c1cc(Nc2cc(Oc3cn(nc3C3CCOCC3)C3CC3)ccn2)ccn1	Phase 1
LY320135	cannabinoid receptor antagonist	CNR1			Tocris, Tocris, Tocris	98.54	COc1ccc(cc1)-c1oc2cc(OC)ccc2c1C(=O)c1ccc(cc1)C#N, COc1ccc(cc1)-c1oc2cc(OC)ccc2c1C(=O)c1ccc(cc1)C#N, COc1ccc(cc1)-c1oc2cc(OC)ccc2c1C(=O)c1ccc(cc1)C#N	Preclinical
LY3214996	ERK inhibitor				MedChemEx	95.21	Cn1nccc1Nc1nccc(n1)-c1cc2C(=O)N(CCN3CCOCC3)C(C)(C)c2s1	Phase 1
LY3295668	Aurora kinase inhibitor				MedChemEx	86.53	C[C@@H]1C[C@@](Cc2nc(Nc3cc(C)[nH]n3)ccc2F)(CCN1Cc1cccc(Cl)c1F)C(O)=O	Phase 1/Phase 2
LY334370	serotonin receptor agonist				MedChemEx	96.67	CN1CCC(CC1)c1c[nH]c2ccc(NC(=O)c3ccc(F)cc3)cc12	Preclinical
LY344864	serotonin receptor agonist	HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR7			Tocris, Tocris, Tocris	88.86	CN(C)[C@@H]1CCc2[nH]c3ccc(NC(=O)c4ccc(F)cc4)cc3c2C1, CN(C)[C@@H]1CCc2[nH]c3ccc(NC(=O)c4ccc(F)cc4)cc3c2C1, CN(C)[C@@H]1CCc2[nH]c3ccc(NC(=O)c4ccc(F)cc4)cc3c2C1	Preclinical
LY364947	p38 MAPK inhibitor, TGF beta receptor inhibitor	TGFBR1			Tocris, Tocris, Tocris, Tocris, Selleck, Tocris	98.09	c1[nH]nc(c1-c1ccnc2ccccc12)-c1ccccn1, c1[nH]nc(c1-c1ccnc2ccccc12)-c1ccccn1, c1[nH]nc(c1-c1ccnc2ccccc12)-c1ccccn1, c1[nH]nc(c1-c1ccnc2ccccc12)-c1ccccn1, c1[nH]nc(c1-c1ccnc2ccccc12)-c1ccccn1, c1[nH]nc(c1-c1ccnc2ccccc12)-c1ccccn1	Preclinical
LY393558	serotonin receptor antagonist	HTR1B, HTR1D, HTR2A, HTR2B			Tocris, Tocris	66.97	CC(C)N1Cc2cc(ccc2N(CCN2CCC(=CC2)c2c[nH]c3cc(F)ccc23)S1(=O)=O)S(C)(=O)=O |c:18|, CC(C)N1Cc2cc(ccc2N(CCN2CCC(=CC2)c2c[nH]c3cc(F)ccc23)S1(=O)=O)S(C)(=O)=O |c:18|	Preclinical
LY404187	glutamate receptor positive allosteric modulator	GRIA1, GRIA2, GRIA3, GRIA4			Tocris, Tocris	94.79	CC(C)S(=O)(=O)NC[C@H](C)c1ccc(cc1)-c1ccc(cc1)C#N |&1:8,r|, CC(C)S(=O)(=O)NC[C@H](C)c1ccc(cc1)-c1ccc(cc1)C#N |&1:8,r|	Preclinical
LY411575	gamma secretase inhibitor				MedChemEx, Selleck	97.7	C[C@H](NC(=O)[C@@H](O)c1cc(F)cc(F)c1)C(=O)N[C@H]1c2ccccc2-c2ccccc2N(C)C1=O, C[C@H](NC(=O)[C@@H](O)c1cc(F)cc(F)c1)C(=O)N[C@H]1c2ccccc2-c2ccccc2N(C)C1=O	Preclinical
LY450108	glutamate receptor modulator				MedChemEx, MedChemEx	94.81	CC(C)S(=O)(=O)NC[C@H](C)c1ccc(NC(=O)c2cc(F)cc(F)c2)cc1, CC(C)S(=O)(=O)NC[C@H](C)c1ccc(NC(=O)c2cc(F)cc(F)c2)cc1	Phase 1
LY456236	glutamate receptor antagonist	GRM1			Tocris, Tocris, Tocris, Tocris	97.15	COc1ccc(Nc2ncnc3ccc(OC)cc23)cc1, COc1ccc(Nc2ncnc3ccc(OC)cc23)cc1, COc1ccc(Nc2ncnc3ccc(OC)cc23)cc1, COc1ccc(Nc2ncnc3ccc(OC)cc23)cc1	Preclinical
m-chlorophenylbiguanide	serotonin receptor agonist	HTR3A, HTR3B			Tocris, Tocris	96.25	NC(N)=NC(=N)Nc1cccc(Cl)c1, NC(N)=NC(=N)Nc1cccc(Cl)c1	Preclinical
m-THP					FrontierSci	88.76	Oc1cccc(c1)-c1c2ccc(n2)c(-c2cccc(O)c2)c2ccc([nH]2)c(-c2cccc(O)c2)c2ccc([nH]2)c(-c2cccc(O)c2)c2ccc1n2	Phase 1
M-14157	ATP-sensitive potassium channel antagonist	KCNQ1			Enzo	0	CCCCCC(O)CCCC(O)=O	Phase 2
M-25	smoothened receptor antagonist	DHH, IHH, SMO			Tocris, Tocris	98.59	CCCC(CCC)C(=O)NCc1ccc2n(ncc2c1)-c1ccccc1OC, CCCC(CCC)C(=O)NCc1ccc2n(ncc2c1)-c1ccccc1OC	Preclinical
m-3M3FBS	phospholipase activator	PLCB2, PLCB3, PLCD1, PLCG1, PLCG2			Tocris, Tocris	98.86	Cc1cc(C)c(c(C)c1)S(=O)(=O)Nc1cccc(c1)C(F)(F)F, Cc1cc(C)c(c(C)c1)S(=O)(=O)Nc1cccc(c1)C(F)(F)F	Preclinical
M-344	HDAC inhibitor	HDAC8			Tocris, Tocris, Selleck, Selleck	97.25	CN(C)c1ccc(cc1)C(=O)NCCCCCCC(=O)NO, CN(C)c1ccc(cc1)C(=O)NCCCCCCC(=O)NO, CN(C)c1ccc(cc1)C(=O)NCCCCCCC(=O)NO, CN(C)c1ccc(cc1)C(=O)NCCCCCCC(=O)NO	Preclinical
mabuprofen	cyclooxygenase inhibitor		neurology/psychiatry	pain relief	Enamine, Enamine, Enamine	91.14	CC(C)Cc1ccc(cc1)[C@@H](C)C(=O)NCCO |&1:10,r|, CC(C)Cc1ccc(cc1)[C@@H](C)C(=O)NCCO |&1:10,r|, CC(C)Cc1ccc(cc1)[C@@H](C)C(=O)NCCO |&1:10,r|	Launched
mabuterol	adrenergic receptor agonist	ADRB2	pulmonary	asthma	Sigma	98.26	CC(C)(C)NC[C@@H](O)c1cc(Cl)c(N)c(c1)C(F)(F)F |&1:6|	Launched
macelignan	anti-inflammatory agent, antioxidant				MedChemEx	97.67	COc1cc(C[C@H](C)[C@H](C)Cc2ccc3OCOc3c2)ccc1O	Preclinical
macitentan	endothelin receptor antagonist	EDNRA, EDNRB	endocrinology	contraceptive	Selleck, MedChemEx, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck	95.48	CCCNS(=O)(=O)Nc1ncnc(OCCOc2ncc(Br)cn2)c1-c1ccc(Br)cc1, CCCNS(=O)(=O)Nc1ncnc(OCCOc2ncc(Br)cn2)c1-c1ccc(Br)cc1, CCCNS(=O)(=O)Nc1ncnc(OCCOc2ncc(Br)cn2)c1-c1ccc(Br)cc1, CCCNS(=O)(=O)Nc1ncnc(OCCOc2ncc(Br)cn2)c1-c1ccc(Br)cc1, CCCNS(=O)(=O)Nc1ncnc(OCCOc2ncc(Br)cn2)c1-c1ccc(Br)cc1, CCCNS(=O)(=O)Nc1ncnc(OCCOc2ncc(Br)cn2)c1-c1ccc(Br)cc1, CCCNS(=O)(=O)Nc1ncnc(OCCOc2ncc(Br)cn2)c1-c1ccc(Br)cc1, CCCNS(=O)(=O)Nc1ncnc(OCCOc2ncc(Br)cn2)c1-c1ccc(Br)cc1	Launched
macitentan-n-butyl-analogue	endothelin receptor antagonist				MedChemEx	96.96	CCCCS(=O)(=O)Nc1ncnc(OCCOc2ncc(Br)cn2)c1-c1ccc(Br)cc1	Preclinical
macozinone	DPRE1 inhibitor				MedChemEx	91.6	[O-][N+](=O)c1cc(cc2c1sc(nc2=O)N1CCN(CC2CCCCC2)CC1)C(F)(F)F	Preclinical
madecassoside	anti-inflammatory agent				MedChemEx	74.02	[H][C@]12CC=C3[C@]4([H])[C@@H](C)[C@H](C)CC[C@@]4(CC[C@@]3(C)[C@]1(C)C[C@@H](O)[C@@]1([H])[C@](C)(CO)[C@@H](O)[C@H](O)C[C@]21C)C(=O)O[C@@H]1O[C@H](CO[C@@H]2O[C@H](CO)[C@@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](O)[C@H]3O)[C@H](O)[C@H]2O)[C@@H](O)[C@H](O)[C@H]1O |t:3|	Preclinical
madrasin	cell splicing inhibitor				PrincetonBio, PrincetonBio, PrincetonBio, PrincetonBio, PrincetonBio	96.14	COc1ccc2c(C)nc(Nc3nc(=O)c(C)c(C)[nH]3)nc2c1, COc1ccc2c(C)nc(Nc3nc(=O)c(C)c(C)[nH]3)nc2c1, COc1ccc2c(C)nc(Nc3nc(=O)c(C)c(C)[nH]3)nc2c1, COc1ccc2c(C)nc(Nc3nc(=O)c(C)c(C)[nH]3)nc2c1, COc1ccc2c(C)nc(Nc3nc(=O)c(C)c(C)[nH]3)nc2c1	Preclinical
mafenide	carbonic anhydrase inhibitor	CA12, CA14, CA2, CA4, CA6, CA9	infectious disease	first-aid antibiotic, skin infections	MedChemEx, MicroSource	100	NCc1ccc(cc1)S(N)(=O)=O, NCc1ccc(cc1)S(N)(=O)=O	Launched
magnolol	PPAR receptor agonist	GABRA1, PPARG			Selleck, Selleck	98	Oc1ccc(CC=C)cc1-c1cc(CC=C)ccc1O, Oc1ccc(CC=C)cc1-c1cc(CC=C)ccc1O	Preclinical
malathion	cholinesterase inhibitor	ACHE	infectious disease	lice	MedChemEx, MedChemEx, MicroSource, MedChemEx	78.47	CCOC(=O)C[C@@H](SP(=S)(OC)OC)C(=O)OCC |&1:6,r|, CCOC(=O)C[C@@H](SP(=S)(OC)OC)C(=O)OCC |&1:6,r|, CCOC(=O)C[C@@H](SP(=S)(OC)OC)C(=O)OCC |&1:6,r|, CCOC(=O)C[C@@H](SP(=S)(OC)OC)C(=O)OCC |&1:6,r|	Launched
malic-acid		PKD2L1			Enamine, Enamine	100	O[C@@H](CC(O)=O)C(O)=O |&1:1,r|, O[C@@H](CC(O)=O)C(O)=O |&1:1,r|	Launched
malotilate	protein synthesis stimulant		gastroenterology	hepatic cirrhosis	MedChemEx, Selleck	96.64	CC(C)OC(=O)C(C(=O)OC(C)C)=C1SC=CS1 |c:15|, CC(C)OC(=O)C(C(=O)OC(C)C)=C1SC=CS1 |c:15|	Launched
maltobionic-acid	matrix metalloprotease inhibitor		dermatology	cosmetic	CombiBlocks, CombiBlocks, CombiBlocks, CombiBlocks	100	OC[C@@H](O)[C@@H](O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O)[C@H](O)[C@@H](O)C(O)=O, OC[C@@H](O)[C@@H](O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O)[C@H](O)[C@@H](O)C(O)=O, OC[C@@H](O)[C@@H](O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O)[C@H](O)[C@@H](O)C(O)=O, OC[C@@H](O)[C@@H](O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O)[C@H](O)[C@@H](O)C(O)=O	Launched
mandelic-acid					Enamine, MedChemEx	97.99	O[C@@H](C(O)=O)c1ccccc1 |&1:1,r|, O[C@@H](C(O)=O)c1ccccc1 |&1:1,r|	Launched
mangafodipir	contrast agent		radiology	contrast agent	MicroSource, MedChemEx, MedChemEx	0	Cc1nc(COP(O)(O)=O)cc2CN(CC(O)=O)CCN(CC(O)=O)Cc3cc(COP(O)(O)=O)nc(C)c3O[Mn]Oc12, Cc1nc(COP(O)(O)=O)cc2CN(CC(O)=O)CCN(CC(O)=O)Cc3cc(COP(O)(O)=O)nc(C)c3O[Mn]Oc12, Cc1nc(COP(O)(O)=O)cc2CN(CC(O)=O)CCN(CC(O)=O)Cc3cc(COP(O)(O)=O)nc(C)c3O[Mn]Oc12	Launched
manidipine	calcium channel blocker	CACNA1C, CACNA1D	cardiology	hypertension	Selleck, Selleck	96.11	COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OCCN1CCN(CC1)C(c1ccccc1)c1ccccc1 |r,c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OCCN1CCN(CC1)C(c1ccccc1)c1ccccc1 |r,c:4,9|	Launched
manitimus	dehydrogenase inhibitor				MedChemEx	92.37	FC(F)(F)c1ccc(NC(=O)[C@H](C#N)C(=O)CCC#C)cc1 |&1:11,r|	Preclinical
mannitol-D	diuretic		neurology/psychiatry, ophthalmology, gastroenterology	intracranial pressure, intraocular pressure, constipation	Selleck, Selleck	100	OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO, OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO	Launched
maprotiline	norepinephrine reputake inhibitor, tricyclic antidepressant	SLC6A2	neurology/psychiatry	depression, dysthymic disorder	Tocris, Tocris	98.66	CNCCC[C@@]12CC[C@@H](c3ccccc13)c1ccccc21 |r|, CNCCC[C@@]12CC[C@@H](c3ccccc13)c1ccccc21 |r|	Launched
maraviroc	CC chemokine receptor antagonist	CCR5	infectious disease	human immunodeficiency virus (HIV-1)	Tocris	93.43	CC(C)c1nnc(C)n1[C@H]1C[C@@H]2CC[C@H](C1)N2CC[C@H](NC(=O)C1CCC(F)(F)CC1)c1ccccc1	Launched
marbofloxacin	bacterial DNA gyrase inhibitor		infectious disease	gram-negative bacterial infections	MicroSource, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck	99.41	CN1CCN(CC1)c1c(F)cc2c3c1OCN(C)n3cc(C(O)=O)c2=O, CN1CCN(CC1)c1c(F)cc2c3c1OCN(C)n3cc(C(O)=O)c2=O, CN1CCN(CC1)c1c(F)cc2c3c1OCN(C)n3cc(C(O)=O)c2=O, CN1CCN(CC1)c1c(F)cc2c3c1OCN(C)n3cc(C(O)=O)c2=O, CN1CCN(CC1)c1c(F)cc2c3c1OCN(C)n3cc(C(O)=O)c2=O, CN1CCN(CC1)c1c(F)cc2c3c1OCN(C)n3cc(C(O)=O)c2=O, CN1CCN(CC1)c1c(F)cc2c3c1OCN(C)n3cc(C(O)=O)c2=O	Launched
maribavir	cytomegalovirus inhibitor, protein kinase inhibitor	PYGM			MedChemEx, MedChemEx, MedChemEx	96.75	CC(C)Nc1nc2cc(Cl)c(Cl)cc2n1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O, CC(C)Nc1nc2cc(Cl)c(Cl)cc2n1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O, CC(C)Nc1nc2cc(Cl)c(Cl)cc2n1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O	Phase 3
marimastat	matrix metalloprotease inhibitor	MMP1, MMP10, MMP11, MMP12, MMP13, MMP14, MMP15, MMP16, MMP17, MMP19, MMP2, MMP20, MMP21, MMP23A, MMP24, MMP25, MMP26, MMP27, MMP28, MMP3, MMP7, MMP8, MMP9			MedChemEx, MedChemEx, MedChemEx, MedChemEx, EMDBio	94.62	CNC(=O)[C@@H](NC(=O)[C@H](CC(C)C)[C@H](O)C(=O)NO)C(C)(C)C, CNC(=O)[C@@H](NC(=O)[C@H](CC(C)C)[C@H](O)C(=O)NO)C(C)(C)C, CNC(=O)[C@@H](NC(=O)[C@H](CC(C)C)[C@H](O)C(=O)NO)C(C)(C)C, CNC(=O)[C@@H](NC(=O)[C@H](CC(C)C)[C@H](O)C(=O)NO)C(C)(C)C, CNC(=O)[C@@H](NC(=O)[C@H](CC(C)C)[C@H](O)C(=O)NO)C(C)(C)C	Phase 3
maropitant	neurokinin receptor antagonist	TACR1	gastroenterology	vomiting	MedChemEx, MedChemEx	97.11	COc1ccc(cc1CN[C@H]1C2CCN(CC2)[C@H]1C(c1ccccc1)c1ccccc1)C(C)(C)C, COc1ccc(cc1CN[C@H]1C2CCN(CC2)[C@H]1C(c1ccccc1)c1ccccc1)C(C)(C)C	Launched
masitinib	KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, SRC inhibitor	FGFR3, KIT, PDGFRA, PDGFRB	dermatology	mastocytoma	Selleck, Selleck, Selleck, Selleck, Selleck, Selleck	94.17	CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nc(cs3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nc(cs3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nc(cs3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nc(cs3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nc(cs3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nc(cs3)-c3cccnc3)c2)CC1	Launched
masoprocol	lipoxygenase inhibitor	ALOX5	dermatology	actinic keratosis (AK)	Enzo, Enzo, Enzo, MedChemEx	97.16	C[C@@H](Cc1ccc(O)c(O)c1)[C@@H](C)Cc1ccc(O)c(O)c1 |&1:1,&2:11,r|, C[C@@H](Cc1ccc(O)c(O)c1)[C@@H](C)Cc1ccc(O)c(O)c1 |&1:1,&2:11,r|, C[C@@H](Cc1ccc(O)c(O)c1)[C@@H](C)Cc1ccc(O)c(O)c1 |&1:1,&2:11,r|, C[C@@H](Cc1ccc(O)c(O)c1)[C@@H](C)Cc1ccc(O)c(O)c1 |&1:1,&2:11,r|	Launched
matrine	opioid receptor agonist	OPRK1			Selleck	91.99	O=C1CCC[C@@H]2[C@H]3CCCN4CCC[C@@H](CN12)[C@@H]34	Phase 2
mavacamten	myosin inhibitor 				MedChemEx	95.99	CC(C)n1c(=O)cc(N[C@@H](C)c2ccccc2)[nH]c1=O	Phase 3
mavatrep	transient receptor potential channel antagonist				MedChemEx	99.07	CC(C)(O)c1ccccc1-c1ccc2nc(\C=C\c3ccc(cc3)C(F)(F)F)[nH]c2c1	Preclinical
mavoglurant	glutamate receptor antagonist	GRM5			MedChemEx, MedChemEx	93	COC(=O)N1CC[C@@H]2[C@H]1CCC[C@@]2(O)C#Cc1cccc(C)c1, COC(=O)N1CC[C@@H]2[C@H]1CCC[C@@]2(O)C#Cc1cccc(C)c1	Phase 2
maxacalcitol	vitamin D receptor agonist	VDR	endocrinology	hyperparathyroidism	MedChemEx	91.47	C[C@H](OCCC(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C	Launched
maytansinol-isobutyrate					MedChemEx, MedChemEx	78.12	CO[C@@H]1\C=C\C=C(C)\Cc2cc(OC)c(Cl)c(c2)N(C)C(=O)C[C@H](OC(=O)C(C)C)[C@]2(C)O[C@H]2[C@H](C)[C@@H]2C[C@@]1(O)NC(=O)O2 |c:5,t:3|, CO[C@@H]1\C=C\C=C(C)\Cc2cc(OC)c(Cl)c(c2)N(C)C(=O)C[C@H](OC(=O)C(C)C)[C@]2(C)O[C@H]2[C@H](C)[C@@H]2C[C@@]1(O)NC(=O)O2 |c:5,t:3|	Preclinical
MBX-2982	glucose dependent insulinotropic receptor agonist	GPR119			MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx	98.92	CCc1cnc(nc1)N1CCC(CC1)c1nc(COc2ccc(cc2)-n2cnnn2)cs1, CCc1cnc(nc1)N1CCC(CC1)c1nc(COc2ccc(cc2)-n2cnnn2)cs1, CCc1cnc(nc1)N1CCC(CC1)c1nc(COc2ccc(cc2)-n2cnnn2)cs1, CCc1cnc(nc1)N1CCC(CC1)c1nc(COc2ccc(cc2)-n2cnnn2)cs1, CCc1cnc(nc1)N1CCC(CC1)c1nc(COc2ccc(cc2)-n2cnnn2)cs1, CCc1cnc(nc1)N1CCC(CC1)c1nc(COc2ccc(cc2)-n2cnnn2)cs1, CCc1cnc(nc1)N1CCC(CC1)c1nc(COc2ccc(cc2)-n2cnnn2)cs1	Phase 2
MC-1		AADAT, ABAT, AGXT, AGXT2, ALAS1, AZIN2, BCAT1, BCAT2, CBS, CCBL1, CCBL2, CSAD, CTH, DDC, FTCD, GAD1, GAD2, GADL1, GCAT, GLDC, GOT1, GOT2, GPT, GPT2, HDC, IGSF10, KYNU, MOCOS, NFS1, OAT, ODC1, PDXDC1, PDXP, PHYKPL, PNPO, PROSC, PSAT1, PYGB, PYGL, PYGM, SCLY, SDS, SDSL, SEPSECS, SGPL1, SHMT1, SHMT2, SPTLC1, SPTLC2, SPTLC3, SRR, TAT, THNSL1			Sigma, Vitas-M	0	Cc1ncc(COP(O)(O)=O)c(C=O)c1O, Cc1ncc(COP(O)(O)=O)c(C=O)c1O	Phase 3
MCC950	NOD like receptor inhibitor	NLRP3			MedChemEx, MedChemEx	37.23	CC(C)(O)c1coc(c1)S(=O)(=O)NC(=O)Nc1c2CCCc2cc2CCCc12, CC(C)(O)c1coc(c1)S(=O)(=O)NC(=O)Nc1c2CCCc2cc2CCCc12	Preclinical
McN-5652-(+/-)	selective serotonin reuptake inhibitor (SSRI)				Tocris, Tocris	85.79	CSc1ccc(cc1)[C@H]1CN2CCC[C@H]2c2ccccc12, CSc1ccc(cc1)[C@H]1CN2CCC[C@H]2c2ccccc12	Preclinical
MCOPPB	nociceptin/orphanin FQ receptor agonist	OPRL1			Tocris, Tocris	96.78	CC1(CCCCCCC1)N1CCC(CC1)n1c(nc2ccccc12)[C@@H]1CCCNC1, CC1(CCCCCCC1)N1CCC(CC1)n1c(nc2ccccc12)[C@@H]1CCCNC1	Preclinical
mCPP	serotonin receptor agonist	HTR1A, HTR1D, HTR1E, HTR2A, HTR2B, HTR2C, HTR6			Sigma, Enzo	95.44	Clc1cccc(c1)N1CCNCC1, Clc1cccc(c1)N1CCNCC1	Phase 2
MC1568	HDAC inhibitor	HDAC2			MedChemEx, Selleck, Selleck, Selleck	89.02	Cn1c(\C=C\C(=O)NO)ccc1\C=C\C(=O)c1cccc(F)c1, Cn1c(\C=C\C(=O)NO)ccc1\C=C\C(=O)c1cccc(F)c1, Cn1c(\C=C\C(=O)NO)ccc1\C=C\C(=O)c1cccc(F)c1, Cn1c(\C=C\C(=O)NO)ccc1\C=C\C(=O)c1cccc(F)c1	Preclinical
MD-920	NFkB pathway inhibitor	AADACL2			Enzo, Sigma	96.77	C[C@@]12[C@H]3[C@H](C(O)=O)[C@@]45CC(=C)[C@@](O)(C4)CC[C@H]5[C@]3(OC1=O)C=C[C@@H]2O |c:25|, C[C@@]12[C@H]3[C@H](C(O)=O)[C@@]45CC(=C)[C@@](O)(C4)CC[C@H]5[C@]3(OC1=O)C=C[C@@H]2O |c:25|	Phase 1
mdivi-1	dynamin inhibitor	DNM1			Selleck, Selleck, Selleck	97.44	COc1cc(c(Cl)cc1Cl)-n1c(=S)[nH]c2ccccc2c1=O, COc1cc(c(Cl)cc1Cl)-n1c(=S)[nH]c2ccccc2c1=O, COc1cc(c(Cl)cc1Cl)-n1c(=S)[nH]c2ccccc2c1=O	Preclinical
MDL-11939	serotonin receptor antagonist	HTR2A, HTR2B, HTR2C			Tocris, Tocris	98.53	O[C@@H](C1CCN(CCc2ccccc2)CC1)c1ccccc1 |&1:1,r|, O[C@@H](C1CCN(CCc2ccccc2)CC1)c1ccccc1 |&1:1,r|	Phase 2
MDL-27531	glycine receptor agonist				Otava	84.16	Cn1c(nnc1S(C)(=O)=O)-c1ccccc1	Preclinical
MDL-29951	glutamate receptor antagonist	FBP1			MedChemEx, MedChemEx, MedChemEx, MedChemEx	96.68	OC(=O)CCc1c([nH]c2cc(Cl)cc(Cl)c12)C(O)=O, OC(=O)CCc1c([nH]c2cc(Cl)cc(Cl)c12)C(O)=O, OC(=O)CCc1c([nH]c2cc(Cl)cc(Cl)c12)C(O)=O, OC(=O)CCc1c([nH]c2cc(Cl)cc(Cl)c12)C(O)=O	Preclinical
MDL-72832	serotonin receptor agonist	HTR1A			Tocris, Tocris	96.3	O=C1CC2(CCCC2)CC(=O)N1CCCCNC[C@H]1COc2ccccc2O1 |&1:18|, O=C1CC2(CCCC2)CC(=O)N1CCCCNC[C@H]1COc2ccccc2O1 |&1:18|	Preclinical
MDL-73005EF	serotonin receptor antagonist	HTR1A			Tocris, Tocris	96.76	O=C1CC2(CCCC2)CC(=O)N1CCNC[C@H]1COc2ccccc2O1 |&1:16|, O=C1CC2(CCCC2)CC(=O)N1CCNC[C@H]1COc2ccccc2O1 |&1:16|	Phase 1
MDMS	DNA inhibitor				Enamine	0	CS(=O)(=O)OCOS(C)(=O)=O	Phase 2
ME-0328	PPAR receptor antagonist	PARP3			MedChemEx, Tocris, Tocris	97.84	C[C@H](NC(=O)CCc1nc(=O)c2ccccc2[nH]1)c1ccccc1, C[C@H](NC(=O)CCc1nc(=O)c2ccccc2[nH]1)c1ccccc1, C[C@H](NC(=O)CCc1nc(=O)c2ccccc2[nH]1)c1ccccc1	Preclinical
mebendazole	tubulin polymerization inhibitor	TUBA1A, TUBB, TUBB4B	infectious disease	pinworm, whipworm, hookworm, ascariasis	MedChemEx, MicroSource	97.04	COC(=O)Nc1nc2ccc(cc2[nH]1)C(=O)c1ccccc1, COC(=O)Nc1nc2ccc(cc2[nH]1)C(=O)c1ccccc1	Launched
mebeverine	acetylcholine receptor antagonist	CHRM1	gastroenterology	irritable bowel syndrome	MedChemEx, MicroSource	95.61	CCN(CCCCOC(=O)c1ccc(OC)c(OC)c1)[C@@H](C)Cc1ccc(OC)cc1 |&1:20|, CCN(CCCCOC(=O)c1ccc(OC)c(OC)c1)[C@@H](C)Cc1ccc(OC)cc1 |&1:20|	Launched
mebhydrolin	antihistamine		allergy	allergic rhinitis, urticaria	MedChemEx, MicroSource, Prestwick	98.78	CN1CCc2c(C1)c1ccccc1n2Cc1ccccc1, CN1CCc2c(C1)c1ccccc1n2Cc1ccccc1, CN1CCc2c(C1)c1ccccc1n2Cc1ccccc1	Launched
mebicar	anxiolytic		neurology/psychiatry	anxiety	Pharmeks, ChemDiv, ChemDiv	100	CN1C2C(N(C)C1=O)N(C)C(=O)N2C, CN1C2C(N(C)C1=O)N(C)C(=O)N2C, CN1C2C(N(C)C1=O)N(C)C(=O)N2C	Launched
mebrofenin			radiology	diagnostic agent	Sigma	69.8	Cc1cc(C)c(NC(=O)CN(CC(O)=O)CC(O)=O)c(C)c1Br	Launched
mecamylamine	acetylcholine receptor antagonist	CHRNA1, CHRNA2, CHRNA3, CHRNA4, CHRNA6, CHRNA7, CHRNB4	cardiology	hypertension	MicroSource, MicroSource, MicroSource	100	CNC1(C)C2CCC(C2)C1(C)C, CNC1(C)C2CCC(C2)C1(C)C, CNC1(C)C2CCC(C2)C1(C)C	Launched
mecarbinate					Selleck	97.97	CCOC(=O)c1c(C)n(C)c2ccc(O)cc12	Preclinical
meclinertant	neurotensin receptor antagonist	NTSR1, NTSR2			Sigma, Sigma	98.44	COc1cccc(OC)c1-c1cc(nn1-c1ccnc2cc(Cl)ccc12)C(=O)NC1(C2CC3CC(C2)CC1C3)C(O)=O, COc1cccc(OC)c1-c1cc(nn1-c1ccnc2cc(Cl)ccc12)C(=O)NC1(C2CC3CC(C2)CC1C3)C(O)=O	Phase 2/Phase 3
meclizine	constitutive androstane receptor (CAR) agonist	NR1I3	gastroenterology, neurology/psychiatry	nausea, vomiting, motion sickness	Tocris	96.5	Cc1cccc(CN2CCN(CC2)[C@@H](c2ccccc2)c2ccc(Cl)cc2)c1 |&1:13|	Launched
meclocycline-sulfosalicylate	bacterial 50S ribosomal subunit inhibitor		dermatology, infectious disease	acne vulgaris (AV), skin infections	MicroSource, DuPont, Selleck	82.79	CN(C)[C@H]1[C@@H]2[C@@H](O)[C@@H]3C(=C)c4c(Cl)ccc(O)c4C(=O)C3=C(O)[C@]2(O)C(O)=C(C(N)=O)C1=O |a:3,4,5,7,23,&1:20,&2:27,t:22,29|, CN(C)[C@H]1[C@@H]2[C@@H](O)[C@@H]3C(=C)c4c(Cl)ccc(O)c4C(=O)C3=C(O)[C@]2(O)C(O)=C(C(N)=O)C1=O |a:3,4,5,7,23,&1:20,&2:27,t:22,29|, CN(C)[C@H]1[C@@H]2[C@@H](O)[C@@H]3C(=C)c4c(Cl)ccc(O)c4C(=O)C3=C(O)[C@]2(O)C(O)=C(C(N)=O)C1=O |a:3,4,5,7,23,&1:20,&2:27,t:22,29|	Launched
meclofenamic-acid	cyclooxygenase inhibitor, prostanoid receptor antagonist	ALOX5, CNR1, KCNQ2, KCNQ3, PTGS1, PTGS2	rheumatology, neurology/psychiatry, endocrinology	joint pain, muscle pain, rheumatoid arthritis, primary dysmenorrhea (PD)	Sigma, MicroSource	99.02	Cc1ccc(Cl)c(Nc2ccccc2C(O)=O)c1Cl, Cc1ccc(Cl)c(Nc2ccccc2C(O)=O)c1Cl	Launched
meclofenoxate	nootropic agent		neurology/psychiatry	senile dementia, Alzheimer's disease	MedChemEx, MicroSource	88.5	CN(C)CCOC(=O)COc1ccc(Cl)cc1, CN(C)CCOC(=O)COc1ccc(Cl)cc1	Launched
mecysteine	analgesic agent		pulmonary	chest congestion	CombiBlocks	100	COC(=O)[C@@H](N)CS	Launched
medetomidine	adrenergic receptor agonist	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C	neurology/psychiatry	sedative	Tocris, Selleck, Tocris, Tocris	98.61	C[C@@H](c1cnc[nH]1)c1cccc(C)c1C |r|, C[C@@H](c1cnc[nH]1)c1cccc(C)c1C |r|, C[C@@H](c1cnc[nH]1)c1cccc(C)c1C |r|, C[C@@H](c1cnc[nH]1)c1cccc(C)c1C |r|	Launched
medica-16	ATP citrase lyase inhibitor	FFAR1			Cayman	98.1	CC(C)(CCCCCCCCCCC(C)(C)CC(O)=O)CC(O)=O	Phase 2
medorinone					Key, Key	97.74	Cc1nccc2[nH]c(=O)ccc12, Cc1nccc2[nH]c(=O)ccc12	Phase 1
medronic-acid	bone resorption inhibitor		radiology	skeletal imaging agent	Sigma, Sigma	98.4	OP(O)(=O)CP(O)(O)=O, OP(O)(=O)CP(O)(O)=O	Launched
medroxyprogesterone	progesterone receptor agonist	PGR	endocrinology	contraceptive	MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx	95.16	C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(C)=O)[C@@]3(C)CC[C@@H]2[C@@]2(C)CCC(=O)C=C12 |t:25|, C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(C)=O)[C@@]3(C)CC[C@@H]2[C@@]2(C)CCC(=O)C=C12 |t:25|, C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(C)=O)[C@@]3(C)CC[C@@H]2[C@@]2(C)CCC(=O)C=C12 |t:25|, C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(C)=O)[C@@]3(C)CC[C@@H]2[C@@]2(C)CCC(=O)C=C12 |t:25|, C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(C)=O)[C@@]3(C)CC[C@@H]2[C@@]2(C)CCC(=O)C=C12 |t:25|	Launched
medroxyprogesterone-acetate	progesterone receptor agonist	ESR1, PGR	endocrinology	contraceptive	MedChemEx	88.18	C[C@H]1C[C@H]2[C@@H]3CC[C@](OC(C)=O)(C(C)=O)[C@@]3(C)CC[C@@H]2[C@@]2(C)CCC(=O)C=C12 |t:28|	Launched
medrysone	glucocorticoid receptor agonist	NR3C1	ophthalmology	conjunctivitis, episcleritis	MedChemEx, MicroSource, Selleck	95.45	C[C@H]1C[C@H]2[C@@H]3CC[C@H](C(C)=O)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)CCC(=O)C=C12 |t:25|, C[C@H]1C[C@H]2[C@@H]3CC[C@H](C(C)=O)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)CCC(=O)C=C12 |t:25|, C[C@H]1C[C@H]2[C@@H]3CC[C@H](C(C)=O)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)CCC(=O)C=C12 |t:25|	Launched
mefenamic-acid	cyclooxygenase inhibitor	KCNQ1, PTGS1, PTGS2, TRPM3	endocrinology	primary dysmenorrhea (PD)	MedChemEx, MicroSource, Selleck	99.15	Cc1cccc(Nc2ccccc2C(O)=O)c1C, Cc1cccc(Nc2ccccc2C(O)=O)c1C, Cc1cccc(Nc2ccccc2C(O)=O)c1C	Launched
mefexamide	psychoactive drug				Vitas-M, MicroSource, MicroSource	99.12	CCN(CC)CCNC(=O)COc1ccc(OC)cc1, CCN(CC)CCNC(=O)COc1ccc(OC)cc1, CCN(CC)CCNC(=O)COc1ccc(OC)cc1	Preclinical
mefloquine	adenosine receptor antagonist, hemoglobin antagonist		infectious disease	malaria	MedChemEx	97.93	O[C@H]([C@H]1CCCCN1)c1cc(nc2c(cccc12)C(F)(F)F)C(F)(F)F	Launched
megestrol	progesterone receptor agonist		oncology	breast cancer	CombiBlocks	100	CC(=O)[C@@]1(O)CC[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C |t:9,12|	Launched
megestrol-acetate	progesterone receptor agonist	NR3C1, PGR	neurology/psychiatry, endocrinology	anorexia, cachexia	Tocris, TCI, Selleck, MedChemEx, Selleck, Selleck	98.58	CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)=O |t:9,12|, CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)=O |t:9,12|, CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)=O |t:9,12|, CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)=O |t:9,12|, CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)=O |t:9,12|, CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)=O |t:9,12|	Launched
meglitinide	potassium channel blocker	CCR2			Enamine	99.32	COc1ccc(Cl)cc1C(=O)NCCc1ccc(cc1)C(O)=O	Phase 2
meglumine	excipient				MicroSource, Selleck, Selleck, Selleck	100	CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO, CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO, CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO, CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO	Launched
meglutol	HMGCR inhibitor	HMGCR			MicroSource	0	CC(O)(CC(O)=O)CC(O)=O	Launched
meisoindigo	STAT inhibitor	STAT3			MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx	97.04	CN1C(=O)\C(=C2\C(=O)Nc3ccccc23)c2ccccc12, CN1C(=O)\C(=C2\C(=O)Nc3ccccc23)c2ccccc12, CN1C(=O)\C(=C2\C(=O)Nc3ccccc23)c2ccccc12, CN1C(=O)\C(=C2\C(=O)Nc3ccccc23)c2ccccc12, CN1C(=O)\C(=C2\C(=O)Nc3ccccc23)c2ccccc12	Phase 3
MEK1-2-inhibitor	MEK inhibitor	MAP2K2			Tocris, Selleck	95.74	Nc1ccc(SC(=N)C(C#N)c2ccccc2C(F)(F)F)cc1, Nc1ccc(SC(=N)C(C#N)c2ccccc2C(F)(F)F)cc1	Preclinical
melanotan-ii	melanocortin receptor agonist				MedChemEx	95.58	CCCC[C@H](NC(C)=O)C(=O)N[C@H]1CC(=O)NCCCC[C@H](NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@H](Cc2cnc[nH]2)NC1=O)C(N)=O	Launched
melatonin	melatonin receptor agonist, nitric oxide synthase inhibitor	ASMT, CALM1, CALR, EPX, ESR1, HTR2B, MPO, MTNR1A, MTNR1B, NQO2, RORB	neurology/psychiatry	sleep cycle support	Tocris, Tocris, Selleck, Tocris	95.93	COc1ccc2[nH]cc(CCNC(C)=O)c2c1, COc1ccc2[nH]cc(CCNC(C)=O)c2c1, COc1ccc2[nH]cc(CCNC(C)=O)c2c1, COc1ccc2[nH]cc(CCNC(C)=O)c2c1	Launched
meldonium	gamma butyrobetaine hydroxylase inhibitor	BBOX1	cardiology	coronary artery disease (CAD)	LifeChem, LifeChem	100	C[N+](C)(C)NCCC(O)=O, C[N+](C)(C)NCCC(O)=O	Launched
melengestrol-acetate	progesterone receptor agonist				MicroSource	86.88	CC(=O)O[C@]1(C(C)=O)C(=C)C[C@H]2[C@H]3C=C(C)C4=CC(=O)CC[C@]4(C)[C@@H]3CC[C@]12C |a:4,22,27,&1:11,&2:12,&3:24,t:13,16|	Preclinical
melevodopa	dopamine precursor, dopamine receptor agonist	DDC	neurology/psychiatry	Parkinson's Disease	Vitas-M, Sigma	90.21	COC(=O)[C@@H](N)Cc1ccc(O)c(O)c1, COC(=O)[C@@H](N)Cc1ccc(O)c(O)c1	Launched
meloxicam	cyclooxygenase inhibitor	PTGS1, PTGS2	rheumatology	osteoarthritis, rheumatoid arthritis	Sigma, Sigma, Sigma	98.16	CN1C(C(=O)Nc2ncc(C)s2)=C(O)c2ccccc2S1(=O)=O |t:12|, CN1C(C(=O)Nc2ncc(C)s2)=C(O)c2ccccc2S1(=O)=O |t:12|, CN1C(C(=O)Nc2ncc(C)s2)=C(O)c2ccccc2S1(=O)=O |t:12|	Launched
melperone	dopamine receptor antagonist, serotonin receptor antagonist	DRD2, HTR2A	neurology/psychiatry	psychosis	Tocris, Tocris, Tocris	96.46	CC1CCN(CCCC(=O)c2ccc(F)cc2)CC1, CC1CCN(CCCC(=O)c2ccc(F)cc2)CC1, CC1CCN(CCCC(=O)c2ccc(F)cc2)CC1	Launched
melphalan	DNA alkylating agent, DNA inhibitor		hematologic malignancy	multiple myeloma	MicroSource, MicroSource, MicroSource, MicroSource	93.38	N[C@@H](Cc1ccc(cc1)N(CCCl)CCCl)C(O)=O, N[C@@H](Cc1ccc(cc1)N(CCCl)CCCl)C(O)=O, N[C@@H](Cc1ccc(cc1)N(CCCl)CCCl)C(O)=O, N[C@@H](Cc1ccc(cc1)N(CCCl)CCCl)C(O)=O	Launched
melphalan-n-oxide	hypoxia inducible factor inhibitor	HIF1A			Adooq	67.76	N[C@@H](Cc1ccc(cc1)[N+]([O-])(CCCl)CCCl)C(O)=O	Phase 1
meluadrine					MedChemEx	98.2	CC(C)(C)NC[C@@H](O)c1ccc(O)cc1Cl |&1:6,r|	Preclinical
memantine	glutamate receptor antagonist		neurology/psychiatry	Alzheimer's disease, senile dementia	Tocris	100	C[C@@]12C[C@H]3C[C@@](C)(C1)C[C@](N)(C3)C2	Launched
menadione	mitochondrial DNA polymerase inhibitor, phosphatase inhibitor	AOX1, BGLAP, F10, F2, F7, F9, GGCX, NQO1, NQO2, PROC, PROS1, PROZ, VKORC1, VKORC1L1	gastroenterology, neurology/psychiatry, dermatology, rheumatology	ulcerative colitis, diarrhea, headache, varicose veins, rheumatoid arthritis	MedChemEx, MicroSource, MicroSource, MicroSource, Selleck, Selleck, Selleck	98.17	CC1=CC(=O)c2ccccc2C1=O |t:1|, CC1=CC(=O)c2ccccc2C1=O |t:1|, CC1=CC(=O)c2ccccc2C1=O |t:1|, CC1=CC(=O)c2ccccc2C1=O |t:1|, CC1=CC(=O)c2ccccc2C1=O |t:1|, CC1=CC(=O)c2ccccc2C1=O |t:1|, CC1=CC(=O)c2ccccc2C1=O |t:1|	Launched
menadione-bisulfite	vitamin K	GGCX, VKORC1, VKORC1L1			Sigma, Sigma	98.12	C[C@]1(CC(=O)c2ccccc2C1=O)S(O)(=O)=O |&1:1|, C[C@]1(CC(=O)c2ccccc2C1=O)S(O)(=O)=O |&1:1|	Phase 2
menatetrenone	bone resorption inhibitor		orthopedics	osteoporosis	Sigma, Sigma	48.49	CC(C)=CCC\C(C)=C\CC\C(C)=C\CC\C(C)=C\CC1=C(C)C(=O)c2ccccc2C1=O |c:20|, CC(C)=CCC\C(C)=C\CC\C(C)=C\CC\C(C)=C\CC1=C(C)C(=O)c2ccccc2C1=O |c:20|	Launched
menbutone			gastroenterology	bile stimulation	MedChemEx, MicroSource	95.74	COc1ccc(C(=O)CCC(O)=O)c2ccccc12, COc1ccc(C(=O)CCC(O)=O)c2ccccc12	Launched
mepacrine	cytokine production inhibitor, NFkB pathway inhibitor, TP53 activator	PLA2G1B	infectious disease	giardiasis	Selleck, MicroSource, MicroSource, MicroSource, Selleck, Selleck	95.48	CCN(CC)CCC[C@@H](C)Nc1c2ccc(Cl)cc2nc2ccc(OC)cc12 |&1:8|, CCN(CC)CCC[C@@H](C)Nc1c2ccc(Cl)cc2nc2ccc(OC)cc12 |&1:8|, CCN(CC)CCC[C@@H](C)Nc1c2ccc(Cl)cc2nc2ccc(OC)cc12 |&1:8|, CCN(CC)CCC[C@@H](C)Nc1c2ccc(Cl)cc2nc2ccc(OC)cc12 |&1:8|, CCN(CC)CCC[C@@H](C)Nc1c2ccc(Cl)cc2nc2ccc(OC)cc12 |&1:8|, CCN(CC)CCC[C@@H](C)Nc1c2ccc(Cl)cc2nc2ccc(OC)cc12 |&1:8|	Launched
meparfylon					MicroSource	0	CCC(C)(O)C#C |&1:2|	Preclinical
mepazine	MALT1 inhibitor (JH)	MALT1			ChemDiv, ChemDiv, ChemDiv	90.48	CN1CCC[C@@H](CN2c3ccccc3Sc3ccccc23)C1 |&1:5,r|, CN1CCC[C@@H](CN2c3ccccc3Sc3ccccc23)C1 |&1:5,r|, CN1CCC[C@@H](CN2c3ccccc3Sc3ccccc23)C1 |&1:5,r|	Phase 2
mepenzolate	acetylcholine receptor antagonist		gastroenterology	peptic ulcer disease (PUD)	MedChemEx, MicroSource, Selleck	99.17	C[N+]1(C)CCC[C@@H](C1)OC(=O)C(O)(c1ccccc1)c1ccccc1 |&1:6|, C[N+]1(C)CCC[C@@H](C1)OC(=O)C(O)(c1ccccc1)c1ccccc1 |&1:6|, C[N+]1(C)CCC[C@@H](C1)OC(=O)C(O)(c1ccccc1)c1ccccc1 |&1:6|	Launched
mephenesin	muscle relaxant		neurology/psychiatry	muscle relaxant	MicroSource, MedChemEx	99.05	Cc1ccccc1OC[C@@H](O)CO |&1:9,r|, Cc1ccccc1OC[C@@H](O)CO |&1:9,r|	Launched
mephentermine	adrenergic receptor agonist	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3	cardiology	hypotension	MicroSource, Toronto, Toronto	94.54	CNC(C)(C)Cc1ccccc1, CNC(C)(C)Cc1ccccc1, CNC(C)(C)Cc1ccccc1	Launched
mephenytoin	hydantoin antiepileptic	SCN5A	neurology/psychiatry	seizures	MicroSource, MicroSource, MicroSource, Tocris	98.67	CC[C@]1(NC(=O)N(C)C1=O)c1ccccc1 |&1:2,r|, CC[C@]1(NC(=O)N(C)C1=O)c1ccccc1 |&1:2,r|, CC[C@]1(NC(=O)N(C)C1=O)c1ccccc1 |&1:2,r|, CC[C@]1(NC(=O)N(C)C1=O)c1ccccc1 |&1:2,r|	Launched
mepiroxol					MicroSource, Selleck, Selleck	98.37	OCc1ccc[n+]([O-])c1, OCc1ccc[n+]([O-])c1, OCc1ccc[n+]([O-])c1	Preclinical
mepivacaine	potassium channel blocker, sodium channel blocker		neurology/psychiatry	local anesthetic	MicroSource, Selleck, MedChemEx, MedChemEx	97.82	CN1CCCC[C@@H]1C(=O)Nc1c(C)cccc1C |&1:6|, CN1CCCC[C@@H]1C(=O)Nc1c(C)cccc1C |&1:6|, CN1CCCC[C@@H]1C(=O)Nc1c(C)cccc1C |&1:6|, CN1CCCC[C@@H]1C(=O)Nc1c(C)cccc1C |&1:6|	Launched
meprednisone		NR3C1			MedChemEx, Selleck	96.1	C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3C(=O)C[C@]2(C)[C@@]1(O)C(=O)CO |c:11,t:7|, C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3C(=O)C[C@]2(C)[C@@]1(O)C(=O)CO |c:11,t:7|	Launched
meprylcaine	local anesthetic				MicroSource, Toronto	87.77	CCCNC(C)(C)COC(=O)c1ccccc1, CCCNC(C)(C)COC(=O)c1ccccc1	Preclinical
meptazinol	opioid receptor agonist	BCHE	neurology/psychiatry	pain relief	Tocris, Selleck, Selleck, Selleck	98.1	CC[C@]1(CCCCN(C)C1)c1cccc(O)c1 |&1:2|, CC[C@]1(CCCCN(C)C1)c1cccc(O)c1 |&1:2|, CC[C@]1(CCCCN(C)C1)c1cccc(O)c1 |&1:2|, CC[C@]1(CCCCN(C)C1)c1cccc(O)c1 |&1:2|	Launched
mepyramine	histamine receptor antagonist	HRH1	otolaryngology, obstetrics/gynecology	common cold, menstrual pain	Selleck, Tocris, MicroSource, MicroSource, MicroSource, Tocris	99.13	COc1ccc(CN(CCN(C)C)c2ccccn2)cc1, COc1ccc(CN(CCN(C)C)c2ccccn2)cc1, COc1ccc(CN(CCN(C)C)c2ccccn2)cc1, COc1ccc(CN(CCN(C)C)c2ccccn2)cc1, COc1ccc(CN(CCN(C)C)c2ccccn2)cc1, COc1ccc(CN(CCN(C)C)c2ccccn2)cc1	Launched
mequinol		TYR	dermatology	skin depigmentation	MicroSource, Selleck, Selleck	99.23	COc1ccc(O)cc1, COc1ccc(O)cc1, COc1ccc(O)cc1	Launched
merbarone	topoisomerase inhibitor	TOP2A			AMS, EMDBio	100	Oc1[nH]c(=S)[nH]c(=O)c1C(=O)Nc1ccccc1, Oc1[nH]c(=S)[nH]c(=O)c1C(=O)Nc1ccccc1	Phase 2
merbromin	antiseptic		infectious disease	first-aid antiseptic	MicroSource	0	O[Hg]c1c(O)c(Br)cc2c(-c3ccccc3C(O)=O)c3cc(Br)c(=O)cc3oc12	Launched
mercaptopurine	immunosuppressant, protein synthesis inhibitor, purine antagonist	HPRT1, IMPDH1, IMPDH2, PPAT	hematologic malignancy	acute lymphoblastic leukemia (ALL)	Selleck, Selleck, Selleck, MicroSource	100	S=c1nc[nH]c2nc[nH]c12, S=c1nc[nH]c2nc[nH]c12, S=c1nc[nH]c2nc[nH]c12, S=c1nc[nH]c2nc[nH]c12	Launched
mercaptosuccinic-acid					Enamine, Enamine	100	OC(=O)C[C@@H](S)C(O)=O |&1:4,r|, OC(=O)C[C@@H](S)C(O)=O |&1:4,r|	Launched
Merck60	HDAC inhibitor	HDAC1, HDAC2				0		Preclinical
mericitabine	HCV inhibitor				MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx	98	CC(C)C(=O)OC[C@H]1O[C@@H](n2ccc(N)nc2=O)[C@](C)(F)[C@@H]1OC(=O)C(C)C, CC(C)C(=O)OC[C@H]1O[C@@H](n2ccc(N)nc2=O)[C@](C)(F)[C@@H]1OC(=O)C(C)C, CC(C)C(=O)OC[C@H]1O[C@@H](n2ccc(N)nc2=O)[C@](C)(F)[C@@H]1OC(=O)C(C)C, CC(C)C(=O)OC[C@H]1O[C@@H](n2ccc(N)nc2=O)[C@](C)(F)[C@@H]1OC(=O)C(C)C, CC(C)C(=O)OC[C@H]1O[C@@H](n2ccc(N)nc2=O)[C@](C)(F)[C@@H]1OC(=O)C(C)C, CC(C)C(=O)OC[C@H]1O[C@@H](n2ccc(N)nc2=O)[C@](C)(F)[C@@H]1OC(=O)C(C)C	Phase 2
merimepodib	inosine monophosphate dehydrogenase inhibitor	IMPDH1			MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx	98.21	COc1cc(NC(=O)Nc2cccc(CNC(=O)O[C@H]3CCOC3)c2)ccc1-c1cnco1, COc1cc(NC(=O)Nc2cccc(CNC(=O)O[C@H]3CCOC3)c2)ccc1-c1cnco1, COc1cc(NC(=O)Nc2cccc(CNC(=O)O[C@H]3CCOC3)c2)ccc1-c1cnco1, COc1cc(NC(=O)Nc2cccc(CNC(=O)O[C@H]3CCOC3)c2)ccc1-c1cnco1, COc1cc(NC(=O)Nc2cccc(CNC(=O)O[C@H]3CCOC3)c2)ccc1-c1cnco1, COc1cc(NC(=O)Nc2cccc(CNC(=O)O[C@H]3CCOC3)c2)ccc1-c1cnco1, COc1cc(NC(=O)Nc2cccc(CNC(=O)O[C@H]3CCOC3)c2)ccc1-c1cnco1	Phase 2
meropenem	bacterial cell wall synthesis inhibitor		infectious disease	skin infections, intra-abdominal infections, meningitis	Key, MicroSource, Selleck, Selleck	23.73	C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(S[C@@H]3CN[C@@H](C3)C(=O)N(C)C)=C(N2C1=O)C(O)=O |c:19|, C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(S[C@@H]3CN[C@@H](C3)C(=O)N(C)C)=C(N2C1=O)C(O)=O |c:19|, C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(S[C@@H]3CN[C@@H](C3)C(=O)N(C)C)=C(N2C1=O)C(O)=O |c:19|, C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(S[C@@H]3CN[C@@H](C3)C(=O)N(C)C)=C(N2C1=O)C(O)=O |c:19|	Launched
mertansine	microtubule inhibitor				MedChemEx	91.36	[H][C@@]12C[C@@](O)(NC(=O)O1)[C@]([H])(OC)\C=C\C=C(C)\Cc1cc(OC)c(Cl)c(c1)N(C)C(=O)C[C@]([H])(OC(=O)[C@H](C)N(C)C(=O)CCS)[C@]1(C)O[C@H]1[C@@H]2C |c:16,t:14|	Phase 2
mesalazine	cyclooxygenase inhibitor, lipoxygenase inhibitor, prostanoid receptor antagonist	ALOX5, CHUK, IKBKB, MPO, PPARG, PTGS1, PTGS2	gastroenterology	ulcerative colitis, inflammatory bowel disease	MicroSource, Selleck, Selleck, Selleck, Selleck	90.1	Nc1ccc(O)c(c1)C(O)=O, Nc1ccc(O)c(c1)C(O)=O, Nc1ccc(O)c(c1)C(O)=O, Nc1ccc(O)c(c1)C(O)=O, Nc1ccc(O)c(c1)C(O)=O	Launched
mesna	antioxidant		urology	hemorrhagic cystitis	MicroSource, Selleck, Selleck	92.74	OS(=O)(=O)CCS, OS(=O)(=O)CCS, OS(=O)(=O)CCS	Launched
mesoridazine	dopamine receptor antagonist	DRD2, HTR2A	neurology/psychiatry	schizophrenia	Selleck, Selleck, Selleck, MicroSource, MicroSource, MicroSource	96.87	CN1CCCC[C@@H]1CCN1c2ccccc2Sc2ccc(cc12)[S@@](C)=O |a:23,&1:6|, CN1CCCC[C@@H]1CCN1c2ccccc2Sc2ccc(cc12)[S@@](C)=O |a:23,&1:6|, CN1CCCC[C@@H]1CCN1c2ccccc2Sc2ccc(cc12)[S@@](C)=O |a:23,&1:6|, CN1CCCC[C@@H]1CCN1c2ccccc2Sc2ccc(cc12)[S@@](C)=O |a:23,&1:6|, CN1CCCC[C@@H]1CCN1c2ccccc2Sc2ccc(cc12)[S@@](C)=O |a:23,&1:6|, CN1CCCC[C@@H]1CCN1c2ccccc2Sc2ccc(cc12)[S@@](C)=O |a:23,&1:6|	Launched
mestinon	cholinesterase inhibitor	ACHE, BCHE	neurology/psychiatry	myasthenia gravis	MedChemEx, MicroSource, MicroSource, MicroSource, Selleck	100	CN(C)C(=O)Oc1ccc[n+](C)c1, CN(C)C(=O)Oc1ccc[n+](C)c1, CN(C)C(=O)Oc1ccc[n+](C)c1, CN(C)C(=O)Oc1ccc[n+](C)c1, CN(C)C(=O)Oc1ccc[n+](C)c1	Launched
mestranol	estrogen receptor agonist	ESR1	endocrinology	contraceptive	MedChemEx, Selleck, Selleck, MicroSource	98.35	COc1ccc2[C@H]3CC[C@@]4(C)[C@@H](CC[C@@]4(O)C#C)[C@@H]3CCc2c1, COc1ccc2[C@H]3CC[C@@]4(C)[C@@H](CC[C@@]4(O)C#C)[C@@H]3CCc2c1, COc1ccc2[C@H]3CC[C@@]4(C)[C@@H](CC[C@@]4(O)C#C)[C@@H]3CCc2c1, COc1ccc2[C@H]3CC[C@@]4(C)[C@@H](CC[C@@]4(O)C#C)[C@@H]3CCc2c1	Launched
mesulergine	dopamine receptor agonist	HTR2A, HTR2B, HTR2C, HTR3A, HTR3B, HTR6, HTR7			Enzo, Tocris	95.09	CN(C)S(=O)(=O)N[C@H]1C[C@H]2[C@@H](Cc3cn(C)c4cccc2c34)N(C)C1, CN(C)S(=O)(=O)N[C@H]1C[C@H]2[C@@H](Cc3cn(C)c4cccc2c34)N(C)C1	Phase 2
meta-cresyl-acetate					MicroSource	0	CC(=O)Oc1cccc(C)c1	Preclinical
metacetamol	analgesic agent				MicroSource	99.02	CC(=O)Nc1cccc(O)c1	Preclinical
metacresol		INS			MicroSource, MicroSource, MedChemEx	96.37	Cc1cccc(O)c1, Cc1cccc(O)c1, Cc1cccc(O)c1	Launched
metafolin					MedChemEx, MedChemEx, MedChemEx	67.8	CN1[C@@H](CNc2ccc(cc2)C(=O)N[C@@H](CCC(O)=O)C(O)=O)CNc2[nH]c(N)nc(=O)c12, CN1[C@@H](CNc2ccc(cc2)C(=O)N[C@@H](CCC(O)=O)C(O)=O)CNc2[nH]c(N)nc(=O)c12, CN1[C@@H](CNc2ccc(cc2)C(=O)N[C@@H](CCC(O)=O)C(O)=O)CNc2[nH]c(N)nc(=O)c12	Launched
metamizole	cyclooxygenase inhibitor, opioid receptor agonist	PTGS1			MicroSource	93.08	CN(CS(O)(=O)=O)c1c(C)n(C)n(-c2ccccc2)c1=O	Withdrawn
metaphit	phencyclidine receptor acylator				SantaCruz, Tocris	36.49	S=C=Nc1cccc(c1)C1(CCCCC1)N1CCCCC1, S=C=Nc1cccc(c1)C1(CCCCC1)N1CCCCC1	Preclinical
metaproterenol	adrenergic receptor agonist	ADRB2	pulmonary	bronchospasm, asthma, bronchitis, emphysema	Selleck, Selleck, Selleck, Selleck	98.07	CC(C)NC[C@@H](O)c1cc(O)cc(O)c1 |&1:5|, CC(C)NC[C@@H](O)c1cc(O)cc(O)c1 |&1:5|, CC(C)NC[C@@H](O)c1cc(O)cc(O)c1 |&1:5|, CC(C)NC[C@@H](O)c1cc(O)cc(O)c1 |&1:5|	Launched
metaraminol	adrenergic receptor agonist	ADRA1A	cardiology	hypotension	MicroSource, Selleck, Selleck, Selleck, Selleck	99.15	C[C@H](N)[C@H](O)c1cccc(O)c1, C[C@H](N)[C@H](O)c1cccc(O)c1, C[C@H](N)[C@H](O)c1cccc(O)c1, C[C@H](N)[C@H](O)c1cccc(O)c1, C[C@H](N)[C@H](O)c1cccc(O)c1	Launched
metatinib	Bcr-Abl kinase inhibitor	ABL1, BCR			MedChemEx, Selleck, Selleck, Selleck	98.07	Nc1nccc(Oc2ccc(NC(=O)c3c[nH]cc(-c4ccc(F)cc4)c3=O)cc2F)c1Cl, Nc1nccc(Oc2ccc(NC(=O)c3c[nH]cc(-c4ccc(F)cc4)c3=O)cc2F)c1Cl, Nc1nccc(Oc2ccc(NC(=O)c3c[nH]cc(-c4ccc(F)cc4)c3=O)cc2F)c1Cl, Nc1nccc(Oc2ccc(NC(=O)c3c[nH]cc(-c4ccc(F)cc4)c3=O)cc2F)c1Cl	Phase 1
metaxalone	muscle relaxant		neurology/psychiatry	muscle pain	MicroSource	99.54	Cc1cc(C)cc(OC[C@H]2CNC(=O)O2)c1 |&1:9,r|	Launched
metazosin	adrenergic receptor antagonist	ADRA1A			Sigma	98.7	CO[C@@H](C)C(=O)N1CCN(CC1)c1nc(N)c2cc(OC)c(OC)cc2n1 |&1:2,r|	Phase 2
metenkephalin	immunostimulant	OPRD1			MPBio, MPBio	91.27	CSCC[C@@H](NC(=O)[C@@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)Cc1ccc(O)cc1)C(O)=O |&1:4,&2:8,&3:27,r|, CSCC[C@@H](NC(=O)[C@@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)Cc1ccc(O)cc1)C(O)=O |&1:4,&2:8,&3:27,r|	Phase 2
metergoline	dopamine receptor agonist, serotonin receptor antagonist	HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR5A, HTR6, HTR7	neurology/psychiatry, endocrinology	seasonal affective disorder, anxiety, hyperprolactinemia	Tocris, Tocris, Tocris, Tocris	94	CN1C[C@H](CNC(=O)OCc2ccccc2)C[C@H]2[C@H]1Cc1cn(C)c3cccc2c13, CN1C[C@H](CNC(=O)OCc2ccccc2)C[C@H]2[C@H]1Cc1cn(C)c3cccc2c13, CN1C[C@H](CNC(=O)OCc2ccccc2)C[C@H]2[C@H]1Cc1cn(C)c3cccc2c13, CN1C[C@H](CNC(=O)OCc2ccccc2)C[C@H]2[C@H]1Cc1cn(C)c3cccc2c13	Launched
metformin	insulin sensitizer	ACACB, PRKAB1	endocrinology	diabetes mellitus	MicroSource, Tocris, Selleck, Selleck, Tocris, Tocris	95.76	CN(C)C(=N)N=C(N)N, CN(C)C(=N)N=C(N)N, CN(C)C(=N)N=C(N)N, CN(C)C(=N)N=C(N)N, CN(C)C(=N)N=C(N)N, CN(C)C(=N)N=C(N)N	Launched
methacholine	acetylcholine receptor agonist	CHRM2, CHRM4	pulmonary	bronchial hyperresponsiveness diagnostic	MedChemEx, MedChemEx, MicroSource	100	C[C@@H](C[N+](C)(C)C)OC(C)=O |&1:1|, C[C@@H](C[N+](C)(C)C)OC(C)=O |&1:1|, C[C@@H](C[N+](C)(C)C)OC(C)=O |&1:1|	Launched
methacycline	protein synthesis inhibitor		pulmonary	bronchitis	MedChemEx	86.43	[H][C@]12[C@H](O)[C@@]3([H])[C@H](N(C)C)C(=O)[C@H](C(N)=O)C(=O)[C@@]3(O)C(=O)[C@H]1C(=O)c1c(O)cccc1C2=C |&1:22,&2:12|	Preclinical
methanesulfonyl-fluoride	acetylcholinesterase inhibitor	ACHE			Sigma, Sigma	0	CS(F)(=O)=O, CS(F)(=O)=O	Phase 2
methantheline	acetylcholine receptor antagonist	CHRM1, HRH2	gastroenterology, neurology/psychiatry, urology	peptic ulcer disease (PUD), irritable bowel syndrome, pancreatitis, dyskinesia, neurogenic bladder	Prestwick, Toronto	95.7	CC[N+](C)(CC)CCOC(=O)C1c2ccccc2Oc2ccccc12, CC[N+](C)(CC)CCOC(=O)C1c2ccccc2Oc2ccccc12	Launched
methapyrilene	histamine receptor antagonist	HRH1			MicroSource, Selleck	93.74	CN(C)CCN(Cc1cccs1)c1ccccn1, CN(C)CCN(Cc1cccs1)c1ccccn1	Withdrawn
metharbital	GABA receptor modulator	CHRNA4, CHRNA7, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GRIA2, GRIK2	neurology/psychiatry	epilepsy	Enamine, Enamine, Enamine, Enamine	99.64	CCC1(CC)C(=O)NC(=O)N(C)C1=O, CCC1(CC)C(=O)NC(=O)N(C)C1=O, CCC1(CC)C(=O)NC(=O)N(C)C1=O, CCC1(CC)C(=O)NC(=O)N(C)C1=O	Launched
methazolamide	carbonic anhydrase inhibitor	CA1, CA12, CA14, CA2, CA4, CA7	ophthalmology	glaucoma, intraocular pressure	MedChemEx	90.21	CC(=O)N=c1sc(nn1C)S(N)(=O)=O	Launched
methenamine	bacterial DNA inhibitor		infectious disease	urinary tract infections	Selleck, MicroSource	100	C1N2CN3CN1CN(C2)C3, C1N2CN3CN1CN(C2)C3	Launched
methiazole	anthelmintic agent				Prestwick, Prestwick	95.06	COC(=O)Nc1nc2ccc(SC(C)C)cc2[nH]1, COC(=O)Nc1nc2ccc(SC(C)C)cc2[nH]1	Preclinical
methicillin	bacterial cell wall synthesis inhibitor		infectious disease	gram-negative bacterial infections, gram-positive bacterial infections	Sigma, MicroSource	85.33	COc1cccc(OC)c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O, COc1cccc(OC)c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O	Launched
methimazole	antithyroid agent	TPO	endocrinology	hyperthyroidism	Selleck, MicroSource, MicroSource	100	Cn1cc[nH]c1=S, Cn1cc[nH]c1=S, Cn1cc[nH]c1=S	Launched
methionine		METAP2			Sigma	47.29	CSCC[C@@H](N)C(O)=O |&1:4,r|	Launched
methiopril	angiotensin converting enzyme inhibitor	ACE			Vitas-M	91.68	C[C@@H]1CCC[C@@H](N1C(=O)CCSC(C)=O)C(O)=O |&1:1,5,r|	Phase 2
methocarbamol	muscle relaxant	CA1	neurology/psychiatry	muscle relaxant	Selleck, MedChemEx, MicroSource, MicroSource	99.36	COc1ccccc1OC[C@@H](O)COC(N)=O |&1:10,r|, COc1ccccc1OC[C@@H](O)COC(N)=O |&1:10,r|, COc1ccccc1OC[C@@H](O)COC(N)=O |&1:10,r|, COc1ccccc1OC[C@@H](O)COC(N)=O |&1:10,r|	Launched
methoprene-(s)					MicroSource, Sigma	86.73	COC(C)(C)CCC[C@H](C)C\C=C\C(\C)=C\C(=O)OC(C)C, COC(C)(C)CCC[C@H](C)C\C=C\C(\C)=C\C(=O)OC(C)C	Preclinical
methotrexate	dihydrofolate reductase inhibitor	DHFR	oncology, hematologic malignancy, dermatology, rheumatology	gestational choriocarcinoma, hydatidiform mole, acute lymphoblastic leukemia (ALL), psoriasis, rheumatoid arthritis	Selleck, Selleck, Selleck, Selleck, Selleck, Tocris, Tocris, Tocris, Tocris	98.9	CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(cc1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(cc1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(cc1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(cc1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(cc1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(cc1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(cc1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(cc1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(cc1)C(=O)N[C@@H](CCC(O)=O)C(O)=O	Launched
methoxamine	adrenergic receptor agonist	ADRA1A, ADRA1B, ADRA1D	cardiology	hypotension	Selleck, MicroSource, Selleck, Selleck, Selleck	97.81	COc1ccc(OC)c(c1)C(O)C(C)N, COc1ccc(OC)c(c1)C(O)C(C)N, COc1ccc(OC)c(c1)C(O)C(C)N, COc1ccc(OC)c(c1)C(O)C(C)N, COc1ccc(OC)c(c1)C(O)C(C)N	Launched
methoxsalen	DNA synthesis inhibitor	CYP1A1, CYP1A2, CYP2A13, CYP2A6, CYP3A4	dermatology	psoriasis	Selleck, MicroSource	99.46	COc1c2occc2cc2ccc(=O)oc12, COc1c2occc2cc2ccc(=O)oc12	Launched
methoxyamine	DNA repair enzyme inhibitor	APEX1			Otava	0	CON	Phase 2
methoxyflurane	membrane permeability inhibitor	ATP2C1, ATP5D, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GLRA1, GLRB, GRIA1, KCNA1, MT-ND1	neurology/psychiatry	general anaesthetic	Sigma, Sigma, MatrixSci, MatrixSci, MatrixSci	0	COC(F)(F)C(Cl)Cl, COC(F)(F)C(Cl)Cl, COC(F)(F)C(Cl)Cl, COC(F)(F)C(Cl)Cl, COC(F)(F)C(Cl)Cl	Launched
methoxyphenamine	adrenergic receptor agonist		pulmonary	asthma	Sigma	98.67	CN[C@@H](C)Cc1ccccc1OC |&1:2,r|	Launched
methscopolamine	acetylcholine receptor antagonist	CHRM1, CHRM2, CHRM3	gastroenterology	peptic ulcer disease (PUD)	MedChemEx, MedChemEx, Selleck, Selleck, Selleck	98.54	C[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)c1ccccc1, C[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)c1ccccc1, C[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)c1ccccc1, C[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)c1ccccc1, C[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)c1ccccc1	Launched
methsuximide	T-type calcium channel blocker	CACNA1G, CACNA1H, CACNA1I	neurology/psychiatry	seizures	MicroSource, AMS, AMS	99.54	CN1C(=O)C[C@@](C)(C1=O)c1ccccc1 |&1:5,r|, CN1C(=O)C[C@@](C)(C1=O)c1ccccc1 |&1:5,r|, CN1C(=O)C[C@@](C)(C1=O)c1ccccc1 |&1:5,r|	Launched
methyclothiazide	chloride reabsorption inhibitor	SLC12A1, SLC12A3	cardiology	hypertension, edema	Selleck, Selleck	97.93	CN1[C@@H](CCl)Nc2cc(Cl)c(cc2S1(=O)=O)S(N)(=O)=O |&1:2,r|, CN1[C@@H](CCl)Nc2cc(Cl)c(cc2S1(=O)=O)S(N)(=O)=O |&1:2,r|	Launched
methyl-aminolevulinate	oxidizing agent	FCGR1A, FECH	dermatology	actinic keratosis (AK)	Enzo	0	COC(=O)CCC(=O)CN	Launched
methyl-nicotinate					Sigma, Vitas-M	0	COC(=O)c1cccnc1, COC(=O)c1cccnc1	Phase 2
methyl-salicylate			endocrinology, neurology/psychiatry	fever, pain relief	MedChemEx, Enamine	0	COC(=O)c1ccccc1O, COC(=O)c1ccccc1O	Launched
methyl-5-hydroxytryptamine					Tocris, Tocris	64.4	C[C@@H](N)Cc1c[nH]c2ccc(O)cc12 |&1:1|, C[C@@H](N)Cc1c[nH]c2ccc(O)cc12 |&1:1|	Preclinical
methylatropine-nitrate	acetylcholine receptor antagonist	CHRM1			Vitas-M	82.69	C[N+]1(C)[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@@H](CO)c1ccccc1 |&1:3,6,8,&2:13|	Preclinical
methylbenactyzium-bromide	cholinergic receptor antagonist				MedChemEx	98.62	CC[N+](C)(CC)CCOC(=O)C(O)(c1ccccc1)c1ccccc1	Preclinical
methylbenzethonium-chloride	other antibiotic				MicroSource, Sigma	97.14	Cc1cc(ccc1OCCOCC[N+](C)(C)Cc1ccccc1)C(C)(C)CC(C)(C)C, Cc1cc(ccc1OCCOCC[N+](C)(C)Cc1ccccc1)C(C)(C)CC(C)(C)C	Preclinical
methylcobalamin	vitamin B				MedChemEx	27.21	[H][C@]1(CO)O[C@]([H])(n2cnc3cc(C)c(C)cc23)[C@]([H])(O)[C@]1([H])OP(O)(=O)O[C@H](C)CNC(=O)CC[C@@]1(C)\C2=C(C)\C3=N\C(=C\C4=N\C(=C(C)/C5=N[C@@](C)([C@@]([H])(N2[Co+]C)[C@]1([H])CC(N)=O)[C@@](C)(CC(N)=O)[C@]5([H])CCC(N)=O)\[C@@](C)(CC(N)=O)[C@]4([H])CCC(N)=O)\C(C)(C)[C@]3([H])CCC(N)=O |c:41,t:44,46,48,50,53|	Phase 3
methyldopa	adrenergic receptor agonist	ADRA2A, ADRA2B, ADRA2C, DDC	cardiology	hypertension	Selleck, Tocris, Tocris, Selleck, Tocris, MicroSource	100	C[C@](N)(Cc1ccc(O)c(O)c1)C(O)=O, C[C@](N)(Cc1ccc(O)c(O)c1)C(O)=O, C[C@](N)(Cc1ccc(O)c(O)c1)C(O)=O, C[C@](N)(Cc1ccc(O)c(O)c1)C(O)=O, C[C@](N)(Cc1ccc(O)c(O)c1)C(O)=O, C[C@](N)(Cc1ccc(O)c(O)c1)C(O)=O	Launched
methyldopate			cardiology	hypertension	Prestwick, Prestwick	92.17	CCOC(=O)[C@@](C)(N)Cc1ccc(O)c(O)c1, CCOC(=O)[C@@](C)(N)Cc1ccc(O)c(O)c1	Launched
methylene-blue	guanylyl cyclase inhibitor, nitric oxide production inhibitor	ACHE	hematology	methemoglobinemia	MicroSource, MedChemEx	47.14	CN(C)c1ccc2nc3ccc(cc3sc2c1)=[N+](C)C, CN(C)c1ccc2nc3ccc(cc3sc2c1)=[N+](C)C	Launched
methylergometrine	dopamine receptor antagonist, serotonin receptor antagonist	DRD1, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C	hematology, neurology/psychiatry	postpartum hemorrhage (PPH), migraine headache	Tocris, Tocris, MicroSource	92.76	CC[C@@H](CO)NC(=O)[C@H]1CN(C)[C@@H]2Cc3c[nH]c4cccc(C2=C1)c34 |c:23|, CC[C@@H](CO)NC(=O)[C@H]1CN(C)[C@@H]2Cc3c[nH]c4cccc(C2=C1)c34 |c:23|, CC[C@@H](CO)NC(=O)[C@H]1CN(C)[C@@H]2Cc3c[nH]c4cccc(C2=C1)c34 |c:23|	Launched
methyllycaconitine	acetylcholine receptor antagonist	CHRNA7			Tocris, Tocris, Tocris, Tocris	93.67	CCN1C[C@]2(COC(=O)c3ccccc3N3C(=O)C[C@H](C)C3=O)CC[C@H](OC)[C@@]34[C@@H]5C[C@H]6[C@H](OC)[C@@H]5[C@](O)(C[C@@H]6OC)[C@@](O)([C@@H](OC)[C@H]23)[C@@H]14, CCN1C[C@]2(COC(=O)c3ccccc3N3C(=O)C[C@H](C)C3=O)CC[C@H](OC)[C@@]34[C@@H]5C[C@H]6[C@H](OC)[C@@H]5[C@](O)(C[C@@H]6OC)[C@@](O)([C@@H](OC)[C@H]23)[C@@H]14, CCN1C[C@]2(COC(=O)c3ccccc3N3C(=O)C[C@H](C)C3=O)CC[C@H](OC)[C@@]34[C@@H]5C[C@H]6[C@H](OC)[C@@H]5[C@](O)(C[C@@H]6OC)[C@@](O)([C@@H](OC)[C@H]23)[C@@H]14, CCN1C[C@]2(COC(=O)c3ccccc3N3C(=O)C[C@H](C)C3=O)CC[C@H](OC)[C@@]34[C@@H]5C[C@H]6[C@H](OC)[C@@H]5[C@](O)(C[C@@H]6OC)[C@@](O)([C@@H](OC)[C@H]23)[C@@H]14	Preclinical
methylnaltrexone	opioid receptor antagonist	OPRD1, OPRK1, OPRM1	gastroenterology	constipation	MedChemEx	92.79	[H][C@]12Oc3c4c(C[C@]5([H])[C@](O)(CCC1=O)[C@]24CC[N@+]5(C)CC1CC1)ccc3O	Launched
methylparaben	other antifungal		dermatology	cosmetic	MedChemEx, Enamine	98.44	COC(=O)c1ccc(O)cc1, COC(=O)c1ccc(O)cc1	Launched
methylprednisolone	glucocorticoid receptor agonist	NR3C1	endocrinology, rheumatology, dermatology, infectious disease, allergy, hematology, neurology/psychiatry, gastroenterology	hypercalcemia, thyroiditis, ankylosing spondylitis, bursitis, osteoarthritis, psoriatic arthritis, seborrheic dermatitis, mycosis, allergic rhinitis, psoriasis, anemia, multiple sclerosis, ulcerative colitis, enteritis	Tocris, Selleck, Selleck, Selleck, MicroSource, MicroSource	95.49	C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12 |c:23,t:27|, C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12 |c:23,t:27|, C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12 |c:23,t:27|, C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12 |c:23,t:27|, C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12 |c:23,t:27|, C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12 |c:23,t:27|	Launched
methylprednisolone-aceponate	anti-inflammatory agent, glucocorticoid receptor agonist	NR3C1	endocrinology, rheumatology, infectious disease, allergy, pulmonary, gastroenterology, dermatology, neurology/psychiatry, hematology	congenital adrenal hyperplasia, thyroiditis, hypercalcemia, rheumatoid arthritis, bursitis, epicondylitis, allergic rhinitis, asthma, ulcerative colitis, enteritis, osteoarthritis, psoriasis, multiple sclerosis, anemia	Alinda, Alinda, Sigma	97.13	CCC(=O)O[C@@]1(CC[C@H]2[C@@H]3C[C@H](C)C4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C)C(=O)COC(C)=O |c:17,t:13|, CCC(=O)O[C@@]1(CC[C@H]2[C@@H]3C[C@H](C)C4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C)C(=O)COC(C)=O |c:17,t:13|, CCC(=O)O[C@@]1(CC[C@H]2[C@@H]3C[C@H](C)C4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C)C(=O)COC(C)=O |c:17,t:13|	Launched
methylprednisolone-sodium-succinate	glucocorticoid receptor agonist		endocrinology, rheumatology, dermatology, pulmonary, allergy, infectious disease, ophthalmology, gastroenterology, hematology, neurology/psychiatry	hypercalcemia, thyroiditis, osteoarthritis, rheumatoid arthritis, seborrheic dermatitis, asthma, allergic rhinitis, shingles, conjunctivitis, ulcerative colitis, enteritis, anemia, multiple sclerosis, mycosis	MedChemEx	83.97	[H][C@@]12CC[C@](O)(C(=O)COC(=O)CCC(O)=O)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])C[C@H](C)C2=CC(=O)C=C[C@]12C |c:35,t:31|	Launched
methylthiouracil			endocrinology	hyperthyroidism	MicroSource, Selleck	100	Cc1cc(=O)[nH]c(=S)[nH]1, Cc1cc(=O)[nH]c(=S)[nH]1	Launched
methysergide	serotonin receptor antagonist	HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR5A, HTR6, HTR7	neurology/psychiatry	headache	Tocris, Tocris, Tocris	95.7	CC[C@@H](CO)NC(=O)[C@H]1CN(C)[C@@H]2Cc3cn(C)c4cccc(C2=C1)c34 |c:24|, CC[C@@H](CO)NC(=O)[C@H]1CN(C)[C@@H]2Cc3cn(C)c4cccc(C2=C1)c34 |c:24|, CC[C@@H](CO)NC(=O)[C@H]1CN(C)[C@@H]2Cc3cn(C)c4cccc(C2=C1)c34 |c:24|	Launched
meticrane	diuretic		cardiology	edema	MedChemEx, MedChemEx, Selleck, MicroSource	97.99	Cc1cc2CCCS(=O)(=O)c2cc1S(N)(=O)=O, Cc1cc2CCCS(=O)(=O)c2cc1S(N)(=O)=O, Cc1cc2CCCS(=O)(=O)c2cc1S(N)(=O)=O, Cc1cc2CCCS(=O)(=O)c2cc1S(N)(=O)=O	Launched
metipranolol	adrenergic receptor antagonist				Aronis	96.55	CC(C)NC[C@@H](O)COc1cc(C)c(OC(C)=O)c(C)c1C |&1:5,r|	Withdrawn
metirosine	tyrosine hydroxylase inhibitor	TH	cardiology	hypertension	Sigma, Sigma, Enamine	100	C[C@](N)(Cc1ccc(O)cc1)C(O)=O, C[C@](N)(Cc1ccc(O)cc1)C(O)=O, C[C@](N)(Cc1ccc(O)cc1)C(O)=O	Launched
metitepine	anti-HCVE2	HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR5A, HTR6, HTR7			Tocris, Tocris	96.88	CSc1ccc2Sc3ccccc3C[C@@H](N3CCN(C)CC3)c2c1 |&1:14,r|, CSc1ccc2Sc3ccccc3C[C@@H](N3CCN(C)CC3)c2c1 |&1:14,r|	Preclinical
metixene	acetylcholine receptor antagonist	CHRM5	neurology/psychiatry	Parkinson's Disease	Sigma	99.05	CN1CCC[C@@H](CC2c3ccccc3Sc3ccccc23)C1 |&1:5|	Launched
metoclopramide	dopamine receptor antagonist, serotonin receptor antagonist	CHRM1, DRD2, HTR3A, HTR3B, HTR4	gastroenterology	gastroparesis, nausea, vomiting	MicroSource, MedChemEx	98.84	CCN(CC)CCNC(=O)c1cc(Cl)c(N)cc1OC, CCN(CC)CCNC(=O)c1cc(Cl)c(N)cc1OC	Launched
metocurine	acetylcholine receptor antagonist	CHRM2, CHRNA2	neurology/psychiatry	muscle relaxant	Specs	96.67	COc1ccc2C[C@@H]3c4c(CC[N+]3(C)C)cc(OC)c(OC)c4Oc3ccc(C[C@H]4c5cc(Oc1c2)c(OC)cc5CC[N+]4(C)C)cc3	Launched
metolazone	carbonic anhydrase inhibitor	SLC12A3	cardiology	edema, hypertension	MicroSource, Selleck, Selleck, MedChemEx, MedChemEx	97.76	C[C@H]1Nc2cc(Cl)c(cc2C(=O)N1c1ccccc1C)S(N)(=O)=O |&1:1,r|, C[C@H]1Nc2cc(Cl)c(cc2C(=O)N1c1ccccc1C)S(N)(=O)=O |&1:1,r|, C[C@H]1Nc2cc(Cl)c(cc2C(=O)N1c1ccccc1C)S(N)(=O)=O |&1:1,r|, C[C@H]1Nc2cc(Cl)c(cc2C(=O)N1c1ccccc1C)S(N)(=O)=O |&1:1,r|, C[C@H]1Nc2cc(Cl)c(cc2C(=O)N1c1ccccc1C)S(N)(=O)=O |&1:1,r|	Launched
metoprolol	adrenergic receptor antagonist	ADRB1, ADRB2	cardiology	hypertension, angina pectoris, myocardial infarction	Tocris, Tocris, Selleck	94.72	COCCc1ccc(OC[C@@H](O)CNC(C)C)cc1 |&1:10|, COCCc1ccc(OC[C@@H](O)CNC(C)C)cc1 |&1:10|, COCCc1ccc(OC[C@@H](O)CNC(C)C)cc1 |&1:10|	Launched
metoxibutropate	cyclooxygenase inhibitor	PTGS1, PTGS2			Specs, Specs	96.65	COc1ccccc1OC(=O)[C@@H](C)c1ccc(CC(C)C)cc1 |&1:11,r|, COc1ccccc1OC(=O)[C@@H](C)c1ccc(CC(C)C)cc1 |&1:11,r|	Launched
metrifonate	acetylcholinesterase inhibitor	ACHE			MedChemEx, MicroSource, MedChemEx, MedChemEx	58.32	COP(=O)(OC)[C@@H](O)C(Cl)(Cl)Cl |&1:6,r|, COP(=O)(OC)[C@@H](O)C(Cl)(Cl)Cl |&1:6,r|, COP(=O)(OC)[C@@H](O)C(Cl)(Cl)Cl |&1:6,r|, COP(=O)(OC)[C@@H](O)C(Cl)(Cl)Cl |&1:6,r|	Phase 3
metrizamide	radiopaque medium		radiology	contrast agent	Sigma, Selleck	91.39	CN(C(C)=O)c1c(I)c(NC(C)=O)c(I)c(C(=O)N[C@H]2[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]2O)c1I |a:19,23,26,28,&1:20|, CN(C(C)=O)c1c(I)c(NC(C)=O)c(I)c(C(=O)N[C@H]2[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]2O)c1I |a:19,23,26,28,&1:20|	Launched
metrizoic-acid	radiopaque medium		radiology	contrast agent	Sigma, Sigma, TCI	89.37	CN(C(C)=O)c1c(I)c(NC(C)=O)c(I)c(C(O)=O)c1I, CN(C(C)=O)c1c(I)c(NC(C)=O)c(I)c(C(O)=O)c1I, CN(C(C)=O)c1c(I)c(NC(C)=O)c(I)c(C(O)=O)c1I	Launched
metronidazole	DNA inhibitor	CYP2C9, CYP3A4	dermatology	rosacea	Selleck, MicroSource	99.43	Cc1ncc(n1CCO)[N+]([O-])=O, Cc1ncc(n1CCO)[N+]([O-])=O	Launched
metyrapone	cytochrome P450 inhibitor	CYP11B1	nephrology	adrenal diagnostic agent	Tocris, MicroSource, MedChemEx, MedChemEx	92.16	CC(C)(C(=O)c1cccnc1)c1cccnc1, CC(C)(C(=O)c1cccnc1)c1cccnc1, CC(C)(C(=O)c1cccnc1)c1cccnc1, CC(C)(C(=O)c1cccnc1)c1cccnc1	Launched
mevastatin	HMGCR inhibitor	HMGCR			Tocris, Tocris, Tocris, MicroSource, MicroSource, MicroSource, Tocris, Selleck, Selleck, Tocris, Tocris, Tocris, Tocris, Tocris	93.53	CC[C@H](C)C(=O)O[C@H]1CCC=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:12,t:10|, CC[C@H](C)C(=O)O[C@H]1CCC=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:12,t:10|, CC[C@H](C)C(=O)O[C@H]1CCC=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:12,t:10|, CC[C@H](C)C(=O)O[C@H]1CCC=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:12,t:10|, CC[C@H](C)C(=O)O[C@H]1CCC=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:12,t:10|, CC[C@H](C)C(=O)O[C@H]1CCC=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:12,t:10|, CC[C@H](C)C(=O)O[C@H]1CCC=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:12,t:10|, CC[C@H](C)C(=O)O[C@H]1CCC=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:12,t:10|, CC[C@H](C)C(=O)O[C@H]1CCC=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:12,t:10|, CC[C@H](C)C(=O)O[C@H]1CCC=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:12,t:10|, CC[C@H](C)C(=O)O[C@H]1CCC=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:12,t:10|, CC[C@H](C)C(=O)O[C@H]1CCC=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:12,t:10|, CC[C@H](C)C(=O)O[C@H]1CCC=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:12,t:10|, CC[C@H](C)C(=O)O[C@H]1CCC=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:12,t:10|	Preclinical
mexeneone					MicroSource, MicroSource, MicroSource	97.41	COc1ccc(C(=O)c2ccc(C)cc2)c(O)c1, COc1ccc(C(=O)c2ccc(C)cc2)c(O)c1, COc1ccc(C(=O)c2ccc(C)cc2)c(O)c1	Preclinical
mexiletine	sodium channel blocker	PLAU, SCN4A, SCN5A	cardiology	ventricular arrhythmias, ventricular tachycardia (VT)	MicroSource, Tocris, Tocris, Tocris, Tocris, Tocris, Selleck	98.76	C[C@@H](N)COc1c(C)cccc1C |&1:1|, C[C@@H](N)COc1c(C)cccc1C |&1:1|, C[C@@H](N)COc1c(C)cccc1C |&1:1|, C[C@@H](N)COc1c(C)cccc1C |&1:1|, C[C@@H](N)COc1c(C)cccc1C |&1:1|, C[C@@H](N)COc1c(C)cccc1C |&1:1|, C[C@@H](N)COc1c(C)cccc1C |&1:1|	Launched
mezlocillin	bacterial cell wall synthesis inhibitor		infectious disease	gram-negative bacterial infections, gram-positive bacterial infections	Selleck, Selleck, Selleck	88.63	CC1(C)S[C@H]2[C@@H](NC(=O)[C@@H](NC(=O)N3CCN(C3=O)S(C)(=O)=O)c3ccccc3)C(=O)N2[C@@H]1C(O)=O, CC1(C)S[C@H]2[C@@H](NC(=O)[C@@H](NC(=O)N3CCN(C3=O)S(C)(=O)=O)c3ccccc3)C(=O)N2[C@@H]1C(O)=O, CC1(C)S[C@H]2[C@@H](NC(=O)[C@@H](NC(=O)N3CCN(C3=O)S(C)(=O)=O)c3ccccc3)C(=O)N2[C@@H]1C(O)=O	Launched
ME0328	PARP inhibitor	PARP3			Selleck, Selleck, Selleck	99.08	C[C@@H](NC(=O)CCc1nc(=O)c2ccccc2[nH]1)c1ccccc1 |&1:1,r|, C[C@@H](NC(=O)CCc1nc(=O)c2ccccc2[nH]1)c1ccccc1 |&1:1,r|, C[C@@H](NC(=O)CCc1nc(=O)c2ccccc2[nH]1)c1ccccc1 |&1:1,r|	Preclinical
MF-101	estrogen receptor agonist	CYP19A1, XDH			MedChemEx, InterBioScreen	98.01	Oc1ccc(cc1)[C@@H]1CC(=O)c2ccc(O)cc2O1, Oc1ccc(cc1)[C@@H]1CC(=O)c2ccc(O)cc2O1	Phase 3
MG-132	proteasome inhibitor	PSMB1			Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck	100	CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)OCc1ccccc1)C=O, CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)OCc1ccccc1)C=O, CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)OCc1ccccc1)C=O, CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)OCc1ccccc1)C=O, CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)OCc1ccccc1)C=O, CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)OCc1ccccc1)C=O, CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)OCc1ccccc1)C=O, CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)OCc1ccccc1)C=O, CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)OCc1ccccc1)C=O	Preclinical
MG-624	acetylcholine receptor antagonist	CHRNA7			Tocris, Tocris, Tocris	94.39	CC[N+](CC)(CC)CCOc1ccc(\C=C\c2ccccc2)cc1, CC[N+](CC)(CC)CCOc1ccc(\C=C\c2ccccc2)cc1, CC[N+](CC)(CC)CCOc1ccc(\C=C\c2ccccc2)cc1	Preclinical
MGCD-265	VEGFR inhibitor	AXL, MET			Selleck, Selleck	92.2	Cn1cnc(c1)-c1cc2nccc(Oc3ccc(NC(=S)NC(=O)Cc4ccccc4)cc3F)c2s1, Cn1cnc(c1)-c1cc2nccc(Oc3ccc(NC(=S)NC(=O)Cc4ccccc4)cc3F)c2s1	Preclinical
MI-14	PI4K inhibitor	PI4KB			Tocris, Tocris	93.76	CN(C)S(=O)(=O)c1cccc(c1)-c1c(C)nc2c(NCCNC(C)=O)cc(Cl)nn12, CN(C)S(=O)(=O)c1cccc(c1)-c1c(C)nc2c(NCCNC(C)=O)cc(Cl)nn12	Preclinical
mianserin	serotonin receptor antagonist	ADRA1A, ADRA1B, ADRA1D, HRH1, HRH2, HTR2A, HTR2B, HTR2C, HTR6, HTR7	neurology/psychiatry	depression	MicroSource, Selleck, Tocris, Selleck	98.04	CN1CCN2C(C1)c1ccccc1Cc1ccccc21, CN1CCN2C(C1)c1ccccc1Cc1ccccc21, CN1CCN2C(C1)c1ccccc1Cc1ccccc21, CN1CCN2C(C1)c1ccccc1Cc1ccccc21	Launched
mibampator	glutamate receptor modulator	GRIA1			MedChemEx, MedChemEx, MedChemEx, MedChemEx	99.84	CC(C)S(=O)(=O)NC[C@H](C)c1ccc(cc1)-c1ccc(CCNS(C)(=O)=O)cc1, CC(C)S(=O)(=O)NC[C@H](C)c1ccc(cc1)-c1ccc(CCNS(C)(=O)=O)cc1, CC(C)S(=O)(=O)NC[C@H](C)c1ccc(cc1)-c1ccc(CCNS(C)(=O)=O)cc1, CC(C)S(=O)(=O)NC[C@H](C)c1ccc(cc1)-c1ccc(CCNS(C)(=O)=O)cc1	Phase 2
mibefradil	T-type calcium channel blocker	ANO1, CACNA1C, CACNA1D, CACNA1F, CACNA1G, CACNA1H, CACNA1I, CACNA1S, CACNB1, CACNB2, CACNB3, CACNB4, CATSPER1, CATSPER2, CATSPER3, CATSPER4			Tocris, Tocris, Tocris, Tocris, Tocris, Tocris, Tocris	97.32	COCC(=O)O[C@]1(CCN(C)CCCc2nc3ccccc3[nH]2)CCc2cc(F)ccc2[C@@H]1C(C)C, COCC(=O)O[C@]1(CCN(C)CCCc2nc3ccccc3[nH]2)CCc2cc(F)ccc2[C@@H]1C(C)C, COCC(=O)O[C@]1(CCN(C)CCCc2nc3ccccc3[nH]2)CCc2cc(F)ccc2[C@@H]1C(C)C, COCC(=O)O[C@]1(CCN(C)CCCc2nc3ccccc3[nH]2)CCc2cc(F)ccc2[C@@H]1C(C)C, COCC(=O)O[C@]1(CCN(C)CCCc2nc3ccccc3[nH]2)CCc2cc(F)ccc2[C@@H]1C(C)C, COCC(=O)O[C@]1(CCN(C)CCCc2nc3ccccc3[nH]2)CCc2cc(F)ccc2[C@@H]1C(C)C, COCC(=O)O[C@]1(CCN(C)CCCc2nc3ccccc3[nH]2)CCc2cc(F)ccc2[C@@H]1C(C)C	Withdrawn
micafungin	fungal 1,3-beta-D-glucan synthase inhibitor		infectious disease	candidemia, peritonitis, esophageal candidiasis	MedChemEx, MedChemEx, MedChemEx	94.45	CCCCCOc1ccc(cc1)-c1cc(no1)-c1ccc(cc1)C(=O)N[C@H]1C[C@@H](O)[C@@H](O)NC(=O)[C@@H]2[C@@H](O)[C@@H](C)CN2C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC1=O)[C@@H](C)O)[C@H](O)[C@@H](O)c1ccc(O)c(OS(O)(=O)=O)c1)[C@H](O)CC(N)=O, CCCCCOc1ccc(cc1)-c1cc(no1)-c1ccc(cc1)C(=O)N[C@H]1C[C@@H](O)[C@@H](O)NC(=O)[C@@H]2[C@@H](O)[C@@H](C)CN2C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC1=O)[C@@H](C)O)[C@H](O)[C@@H](O)c1ccc(O)c(OS(O)(=O)=O)c1)[C@H](O)CC(N)=O, CCCCCOc1ccc(cc1)-c1cc(no1)-c1ccc(cc1)C(=O)N[C@H]1C[C@@H](O)[C@@H](O)NC(=O)[C@@H]2[C@@H](O)[C@@H](C)CN2C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC1=O)[C@@H](C)O)[C@H](O)[C@@H](O)c1ccc(O)c(OS(O)(=O)=O)c1)[C@H](O)CC(N)=O	Launched
miconazole	bacterial cell wall synthesis inhibitor	TRPM2, TRPV5	infectious disease, neurology/psychiatry	yeast infection, itching	Selleck, Tocris	98.41	Clc1ccc(CO[C@@H](Cn2ccnc2)c2ccc(Cl)cc2Cl)c(Cl)c1 |&1:7,r|, Clc1ccc(CO[C@@H](Cn2ccnc2)c2ccc(Cl)cc2Cl)c(Cl)c1 |&1:7,r|	Launched
micronomicin	protein synthesis inhibitor		infectious disease	gram-negative bacterial infections	AvaChem, AlfaAesar	0	CNC[C@@H]1CC[C@@H](N)[C@@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3OC[C@](C)(O)[C@H](NC)[C@H]3O)[C@H]2O)O1, CNC[C@@H]1CC[C@@H](N)[C@@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3OC[C@](C)(O)[C@H](NC)[C@H]3O)[C@H]2O)O1	Launched
midafotel	glutamate receptor antagonist	GRIN2A, GRIN2B, GRIN2C, GRIN2D			Tocris, EMDBio	100	OC(=O)[C@H]1CN(C\C=C\P(O)(O)=O)CCN1, OC(=O)[C@H]1CN(C\C=C\P(O)(O)=O)CCN1	Phase 3
midecamycin	protein synthesis inhibitor		infectious disease	respiratory tract infections, ear infections, skin infections	AvaChem	0	CCC(=O)O[C@H]1[C@H](C)O[C@H](C[C@@]1(C)O)O[C@@H]1[C@@H](C)O[C@@H](O[C@H]2[C@@H](CC=O)C[C@@H](C)[C@@H](O)\C=C\C=C\C[C@@H](C)OC(=O)C[C@@H](OC(=O)CC)[C@@H]2OC)[C@H](O)[C@H]1N(C)C |t:32,34|	Launched
midodrine	adrenergic receptor agonist		cardiology	hypotension	MicroSource, MicroSource, PrincetonBio, PrincetonBio	96.09	COc1ccc(OC)c(c1)[C@@H](O)CNC(=O)CN |&1:10|, COc1ccc(OC)c(c1)[C@@H](O)CNC(=O)CN |&1:10|, COc1ccc(OC)c(c1)[C@@H](O)CNC(=O)CN |&1:10|, COc1ccc(OC)c(c1)[C@@H](O)CNC(=O)CN |&1:10|	Launched
midostaurin	FLT3 inhibitor, KIT inhibitor, PKC inhibitor	FLT3, PRKCG	hematologic malignancy	acute myeloid leukemia (AML)	Enzo, Enzo, Enzo, Enzo, Enzo, Enzo, Enzo, Enzo, Enzo, Enzo, Enzo, Enzo	95.95	CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)n1c3ccccc3c3c4CNC(=O)c4c4c5ccccc5n2c4c13)N(C)C(=O)c1ccccc1, CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)n1c3ccccc3c3c4CNC(=O)c4c4c5ccccc5n2c4c13)N(C)C(=O)c1ccccc1, CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)n1c3ccccc3c3c4CNC(=O)c4c4c5ccccc5n2c4c13)N(C)C(=O)c1ccccc1, CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)n1c3ccccc3c3c4CNC(=O)c4c4c5ccccc5n2c4c13)N(C)C(=O)c1ccccc1, CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)n1c3ccccc3c3c4CNC(=O)c4c4c5ccccc5n2c4c13)N(C)C(=O)c1ccccc1, CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)n1c3ccccc3c3c4CNC(=O)c4c4c5ccccc5n2c4c13)N(C)C(=O)c1ccccc1, CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)n1c3ccccc3c3c4CNC(=O)c4c4c5ccccc5n2c4c13)N(C)C(=O)c1ccccc1, CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)n1c3ccccc3c3c4CNC(=O)c4c4c5ccccc5n2c4c13)N(C)C(=O)c1ccccc1, CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)n1c3ccccc3c3c4CNC(=O)c4c4c5ccccc5n2c4c13)N(C)C(=O)c1ccccc1, CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)n1c3ccccc3c3c4CNC(=O)c4c4c5ccccc5n2c4c13)N(C)C(=O)c1ccccc1, CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)n1c3ccccc3c3c4CNC(=O)c4c4c5ccccc5n2c4c13)N(C)C(=O)c1ccccc1, CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)n1c3ccccc3c3c4CNC(=O)c4c4c5ccccc5n2c4c13)N(C)C(=O)c1ccccc1	Launched
mifepristone	glucocorticoid receptor antagonist, progesterone receptor antagonist	AR, NR1I2, NR3C1, PGR	endocrinology	hyperglycemia, diabetes mellitus	Tocris, Tocris, MicroSource, MicroSource, Selleck, Selleck, Selleck, Selleck, Tocris, Tocris, Selleck, Tocris	97.07	CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)c1ccc(cc1)N(C)C |c:18,t:11|, CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)c1ccc(cc1)N(C)C |c:18,t:11|, CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)c1ccc(cc1)N(C)C |c:18,t:11|, CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)c1ccc(cc1)N(C)C |c:18,t:11|, CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)c1ccc(cc1)N(C)C |c:18,t:11|, CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)c1ccc(cc1)N(C)C |c:18,t:11|, CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)c1ccc(cc1)N(C)C |c:18,t:11|, CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)c1ccc(cc1)N(C)C |c:18,t:11|, CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)c1ccc(cc1)N(C)C |c:18,t:11|, CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)c1ccc(cc1)N(C)C |c:18,t:11|, CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)c1ccc(cc1)N(C)C |c:18,t:11|, CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)c1ccc(cc1)N(C)C |c:18,t:11|	Launched
mifobate	PPAR receptor antagonist	PPARG			Tocris	92.31	COP(=O)(OC)O[C@@H](c1ccc(Cl)cc1)P(=O)(OC)OC |&1:7,r|	Phase 2
miglitol	glucosidase inhibitor	GAA, GANAB, GANC, MGAM	endocrinology	diabetes mellitus	Tocris, Tocris, Tocris, Selleck	100	OCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO, OCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO, OCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO, OCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO	Launched
miglustat	glycosyl transferase inhibitor	UGCG	hematology	Gaucher disease	Enzo, MedChemEx	100	CCCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO, CCCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO	Launched
milacemide	monoamine oxidase inhibitor	MAOB			Enamine, Enamine, Enamine, Enamine	100	CCCCCNCC(N)=O, CCCCCNCC(N)=O, CCCCCNCC(N)=O, CCCCCNCC(N)=O	Phase 3
milademetan	MDM inhibitor				MedChemEx	94.54	CC1(C)CCC2(CC1)N[C@H]([C@H](c1ccnc(Cl)c1F)[C@]21C(=O)Nc2cc(Cl)ccc12)C(=O)N[C@@H]1CC[C@H](OC1)C(N)=O	Phase 1
milnacipran	serotoninnorepinephrine reuptake inhibitor (SNRI)	SLC6A2, SLC6A4	rheumatology	fibromyalgia	Tocris	96.28	CCN(CC)C(=O)[C@]1(C[C@H]1CN)c1ccccc1 |r|	Launched
milrinone	phosphodiesterase inhibitor	PDE2A, PDE3A, PDE3B, PDE5A	cardiology	congestive heart failure	MicroSource, MicroSource, Selleck, Selleck, Tocris, Tocris	100	Cc1[nH]c(=O)c(cc1-c1ccncc1)C#N, Cc1[nH]c(=O)c(cc1-c1ccncc1)C#N, Cc1[nH]c(=O)c(cc1-c1ccncc1)C#N, Cc1[nH]c(=O)c(cc1-c1ccncc1)C#N, Cc1[nH]c(=O)c(cc1-c1ccncc1)C#N, Cc1[nH]c(=O)c(cc1-c1ccncc1)C#N	Launched
miltefosine	membrane integrity inhibitor	PLA2G1B	infectious disease	leishmaniasis	MicroSource	92.47	CCCCCCCCCCCCCCCCOP(O)(=O)OCC[N+](C)(C)C |&1:17|	Launched
mimosine	DNA replication inhibitor	CCL2, SHMT1, SHMT2, TYR			Sigma, Enzo	50.1	N[C@@H](Cn1ccc(=O)c(O)c1)C(O)=O, N[C@@H](Cn1ccc(=O)c(O)c1)C(O)=O	Preclinical
minaprine	serotonin reuptake inhibitor	ACHE, CHRM1, DRD1, DRD2, HTR2A, HTR2B, HTR2C, MAOA, SLC6A4			MedChemEx, MicroSource	99.62	Cc1cc(nnc1NCCN1CCOCC1)-c1ccccc1, Cc1cc(nnc1NCCN1CCOCC1)-c1ccccc1	Withdrawn
minerval	FAAH inhibitor				Sigma, Sigma, Sigma	100	CCCCCCCC\C=C/CCCCCC[C@@H](O)C(O)=O |&1:16,r|, CCCCCCCC\C=C/CCCCCC[C@@H](O)C(O)=O |&1:16,r|, CCCCCCCC\C=C/CCCCCC[C@@H](O)C(O)=O |&1:16,r|	Phase 1/Phase 2
minocycline	bacterial 30S ribosomal subunit inhibitor		endocrinology, infectious disease, ophthalmology, urology	fever, respiratory tract infections, psittacosis, trachoma, conjunctivitis, urethritis, chancroid, tularemia, cholera, brucellosis	MedChemEx	95.77	[H][C@@]12Cc3c(ccc(O)c3C(=O)[C@@H]1C(=O)[C@]1(O)C(=O)[C@H](C(N)=O)C(=O)[C@@H](N(C)C)[C@]1([H])C2)N(C)C |&1:19,&2:12|	Launched
minodronic-acid	bone resorption inhibitor	FDPS, GGPS1	orthopedics	osteoporosis	AKSci, AvaChem, AvaChem	0	OC(Cc1cnc2ccccn12)(P(O)(O)=O)P(O)(O)=O, OC(Cc1cnc2ccccn12)(P(O)(O)=O)P(O)(O)=O, OC(Cc1cnc2ccccn12)(P(O)(O)=O)P(O)(O)=O	Launched
minoxidil	KATP activator, Kir6 channel (KATP) activator, vasodilator	ABCC9, KCNJ1, KCNJ10, KCNJ11, KCNJ8, PTGS1	endocrinology	androgenetic alopecia	Tocris, MicroSource, Selleck, Sigma, Tocris	96.36	Nc1cc(nc(N)[n+]1[O-])N1CCCCC1, Nc1cc(nc(N)[n+]1[O-])N1CCCCC1, Nc1cc(nc(N)[n+]1[O-])N1CCCCC1, Nc1cc(nc(N)[n+]1[O-])N1CCCCC1, Nc1cc(nc(N)[n+]1[O-])N1CCCCC1	Launched
miocamycin	other antibiotic		infectious disease	urinary tract infections, chlamydia	AvaChem	92.27	CCC(=O)O[C@H]1[C@H](C)O[C@H](C[C@@]1(C)OC(C)=O)O[C@@H]1[C@@H](C)O[C@@H](O[C@H]2[C@@H](CC=O)C[C@@H](C)[C@@H](OC(C)=O)\C=C\C=C\C[C@@H](C)OC(=O)C[C@@H](OC(=O)CC)[C@@H]2OC)[C@H](O)[C@H]1N(C)C |t:38,40|	Launched
MIRA-1	apoptosis stimulant				Tocris	0	CCC(=O)OCN1C(=O)C=CC1=O |c:9|	Preclinical
mirabegron	adrenergic receptor agonist	ADRB1, ADRB2, ADRB3	urology	urinary incontinence	Selleck, Selleck, MedChemEx, Selleck, Selleck	95.25	Nc1nc(CC(=O)Nc2ccc(CCNC[C@H](O)c3ccccc3)cc2)cs1, Nc1nc(CC(=O)Nc2ccc(CCNC[C@H](O)c3ccccc3)cc2)cs1, Nc1nc(CC(=O)Nc2ccc(CCNC[C@H](O)c3ccccc3)cc2)cs1, Nc1nc(CC(=O)Nc2ccc(CCNC[C@H](O)c3ccccc3)cc2)cs1, Nc1nc(CC(=O)Nc2ccc(CCNC[C@H](O)c3ccccc3)cc2)cs1	Launched
miridesap	amyloid protein inhibitor				MedChemEx	91.03	OC(=O)[C@H]1CCCN1C(=O)CCCCC(=O)N1CCC[C@@H]1C(O)=O	Preclinical
mirin	MRE11A exonuclease inhibitor	MRE11A			Tocris, Sigma	96.61	NC1=NC(=O)\C(S1)=C\c1ccc(O)cc1 |t:1|, NC1=NC(=O)\C(S1)=C\c1ccc(O)cc1 |t:1|	Preclinical
miriplatin	DNA synthesis inhibitor		oncology	hepatocellular carcinoma (HCC)	MedChemEx, MedChemEx	0	[Pt++].N[C@H]1CCCC[C@@H]1N.CCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCC(O)=O |&1:2,&2:7,r|, [Pt++].N[C@H]1CCCC[C@@H]1N.CCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCC(O)=O |&1:2,&2:7,r|	Launched
mirodenafil	phosphodiesterase inhibitor	PDE5A	urology	erectile dysfunction	MedChemEx, MedChemEx, MedChemEx	97.2	CCCOc1ccc(cc1-c1nc2c(CCC)cn(CC)c2c(=O)[nH]1)S(=O)(=O)N1CCN(CCO)CC1, CCCOc1ccc(cc1-c1nc2c(CCC)cn(CC)c2c(=O)[nH]1)S(=O)(=O)N1CCN(CCO)CC1, CCCOc1ccc(cc1-c1nc2c(CCC)cn(CC)c2c(=O)[nH]1)S(=O)(=O)N1CCN(CCO)CC1	Launched
mirogabalin-besylate	calcium channel antagonist				MedChemEx	91.92	[H][C@@]12C[C@](CN)(CC(O)=O)[C@]1([H])C=C(CC)C2 |t:13|	Preclinical
mirtazapine	adrenergic receptor antagonist, serotonin receptor antagonist	ADRA2A, ADRA2B, ADRA2C, HTR2A, HTR2C	neurology/psychiatry	depression	Tocris, MicroSource, Tocris, Selleck, Tocris	98.93	CN1CCN2[C@@H](C1)c1ccccc1Cc1cccnc21 |&1:5,r|, CN1CCN2[C@@H](C1)c1ccccc1Cc1cccnc21 |&1:5,r|, CN1CCN2[C@@H](C1)c1ccccc1Cc1cccnc21 |&1:5,r|, CN1CCN2[C@@H](C1)c1ccccc1Cc1cccnc21 |&1:5,r|, CN1CCN2[C@@H](C1)c1ccccc1Cc1cccnc21 |&1:5,r|	Launched
misonidazole					Cayman	96.47	COC[C@@H](O)Cn1ccnc1[N+]([O-])=O |&1:3,r|	Phase 3
misoprostol	prostanoid receptor agonist	PTGER2, PTGER3, PTGER4, PTGIR	gastroenterology	duodenal ulcer disease	Sigma	99.4	CCCCC(C)(O)C\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)OC |a:10,11,16,&1:4|	Launched
mitapivat	pyruvate kinase isozyme activator				MedChemEx	98.12	O=C(N1CCN(CC2CC2)CC1)c1ccc(NS(=O)(=O)c2cccc3cccnc23)cc1	Preclinical
mitiglinide	insulin secretagogue	ABCC8, KCNJ10, PPARG	endocrinology	diabetes mellitus	Selleck, MedChemEx	98.47	OC(=O)[C@H](CC(=O)N1C[C@H]2CCCC[C@H]2C1)Cc1ccccc1, OC(=O)[C@H](CC(=O)N1C[C@H]2CCCC[C@H]2C1)Cc1ccccc1	Launched
mitoflaxone	antitumor agent	VWF			Specs	98.8	OC(=O)Cc1cccc2c1oc(cc2=O)-c1ccccc1	Phase 2
mitomycin-C	DNA alkylating agent, DNA synthesis inhibitor		oncology	pancreatic cancer, gastric adenocarcinoma	Tocris	94.66	CO[C@]12[C@H]3N[C@H]3CN1C1=C([C@H]2COC(N)=O)C(=O)C(N)=C(C)C1=O |c:10,t:22|	Launched
mitoquinone	antioxidant				MedChemEx, MedChemEx	51.8	COC1=C(OC)C(=O)C(CCCCCCCCCC[P+](c2ccccc2)(c2ccccc2)c2ccccc2)=C(C)C1=O |c:2,t:40|, COC1=C(OC)C(=O)C(CCCCCCCCCC[P+](c2ccccc2)(c2ccccc2)c2ccccc2)=C(C)C1=O |c:2,t:40|	Launched
mitotane	antineoplastic agent	CYP11A1, CYP11B1, ESR1	oncology	adrenal cortical carcinoma	MedChemEx, MicroSource, MicroSource, MedChemEx, Selleck, Selleck	96.39	ClC(Cl)[C@@H](c1ccc(Cl)cc1)c1ccccc1Cl |&1:3,r|, ClC(Cl)[C@@H](c1ccc(Cl)cc1)c1ccccc1Cl |&1:3,r|, ClC(Cl)[C@@H](c1ccc(Cl)cc1)c1ccccc1Cl |&1:3,r|, ClC(Cl)[C@@H](c1ccc(Cl)cc1)c1ccccc1Cl |&1:3,r|, ClC(Cl)[C@@H](c1ccc(Cl)cc1)c1ccccc1Cl |&1:3,r|, ClC(Cl)[C@@H](c1ccc(Cl)cc1)c1ccccc1Cl |&1:3,r|	Launched
mitoxantrone	topoisomerase inhibitor	TOP2A	neurology/psychiatry, oncology, hematologic malignancy	multiple sclerosis, prostate cancer, acute myeloid leukemia (AML)	MicroSource, MicroSource, MicroSource, Selleck, Selleck, Selleck, Selleck, Selleck	96.79	OCCNCCNc1ccc(NCCNCCO)c2C(=O)c3c(O)ccc(O)c3C(=O)c12, OCCNCCNc1ccc(NCCNCCO)c2C(=O)c3c(O)ccc(O)c3C(=O)c12, OCCNCCNc1ccc(NCCNCCO)c2C(=O)c3c(O)ccc(O)c3C(=O)c12, OCCNCCNc1ccc(NCCNCCO)c2C(=O)c3c(O)ccc(O)c3C(=O)c12, OCCNCCNc1ccc(NCCNCCO)c2C(=O)c3c(O)ccc(O)c3C(=O)c12, OCCNCCNc1ccc(NCCNCCO)c2C(=O)c3c(O)ccc(O)c3C(=O)c12, OCCNCCNc1ccc(NCCNCCO)c2C(=O)c3c(O)ccc(O)c3C(=O)c12, OCCNCCNc1ccc(NCCNCCO)c2C(=O)c3c(O)ccc(O)c3C(=O)c12	Launched
mivacurium	acetylcholine receptor antagonist	CHRNA2	critical care, neurology/psychiatry	endotracheal intubation, muscle relaxant	AKSci	47.83	COc1cc2CC[N@@+](C)(CCCOC(=O)CC\C=C\CCC(=O)OCCC[N@@+]3(C)CCc4cc(OC)c(OC)cc4[C@H]3Cc3cc(OC)c(OC)c(OC)c3)[C@H](Cc3cc(OC)c(OC)c(OC)c3)c2cc1OC |a:41,55,&1:7,&2:27|	Launched
mivebresib	bromodomain inhibitor				MedChemEx, MedChemEx	98.2	CCS(=O)(=O)Nc1ccc(Oc2ccc(F)cc2F)c(c1)-c1cn(C)c(=O)c2[nH]ccc12, CCS(=O)(=O)Nc1ccc(Oc2ccc(F)cc2F)c(c1)-c1cn(C)c(=O)c2[nH]ccc12	Phase 1
mivobulin	microtubule inhibitor				Sigma	80.61	CCOC(=O)Nc1cc2N=C(C)C(Nc2c(N)n1)c1ccccc1 |t:9|	Phase 2
MIW-815	interferon inducer				MedChemEx	96.81	[H][C@]12CO[P@](S)(=O)O[C@@]3([H])[C@@H](O)[C@@H](O[C@]3([H])CO[P@](S)(=O)O[C@@]([H])([C@@H](O1)n1cnc3c(N)ncnc13)[C@]2([H])O)n1cnc2c(N)ncnc12	Preclinical
mizolastine	histamine receptor antagonist	HRH1	allergy	urticaria, allergic rhinitis	MedChemEx, Selleck	98.97	CN(C1CCN(CC1)c1nc2ccccc2n1Cc1ccc(F)cc1)c1nc(=O)cc[nH]1, CN(C1CCN(CC1)c1nc2ccccc2n1Cc1ccc(F)cc1)c1nc(=O)cc[nH]1	Launched
mizoribine	immunosuppressant, inosine monophosphate dehydrogenase inhibitor	IMPDH1	transplant, rheumatology	organ rejection, nephrotic syndrome	MicroSource, Selleck, Selleck, MedChemEx	100	NC(=O)C1N=CN([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)C1=O |c:4|, NC(=O)C1N=CN([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)C1=O |c:4|, NC(=O)C1N=CN([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)C1=O |c:4|, NC(=O)C1N=CN([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)C1=O |c:4|	Launched
MJ-15	cannabinoid receptor antagonist	CNR1			Tocris, Tocris	97.94	Cc1c(nn(c1-c1ccc(Cl)cc1)-c1ccc(Cl)cc1Cl)C(=O)NCc1cccnc1, Cc1c(nn(c1-c1ccc(Cl)cc1)-c1ccc(Cl)cc1Cl)C(=O)NCc1cccnc1	Preclinical
MK-0354	niacin receptor agonist	HCAR2, HCAR3			MedChemEx	94.22	C1Cc2[nH]nc(-c3nn[nH]n3)c2C1	Phase 2
MK-0557	neuropeptide receptor antagonist				MedChemEx	97.35	Fc1ccccc1-n1ccc(NC(=O)[C@H]2CC[C@]3(CC2)OC(=O)c2ccncc32)n1 |r|	Phase 3
MK-0608	antiviral				Sigma	94.93	C[C@@]1(O)[C@H](O)[C@@H](CO)O[C@H]1n1ccc2c(N)ncnc12	Phase 1
MK-0752	gamma secretase inhibitor				Selleck, Selleck	93.39	OC(=O)CC[C@H]1CC[C@@](CC1)(c1cc(F)ccc1F)S(=O)(=O)c1ccc(Cl)cc1 |r|, OC(=O)CC[C@H]1CC[C@@](CC1)(c1cc(F)ccc1F)S(=O)(=O)c1ccc(Cl)cc1 |r|	Phase 1/Phase 2
MK-0773	androgen receptor modulator	AR			MedChemEx, MedChemEx, MedChemEx	97.69	CN1[C@@H]2CC[C@H]3[C@@H]4CC[C@H](C(=O)NCc5nc6ncccc6[nH]5)[C@@]4(C)CC[C@@H]3[C@@]2(C)C=C(F)C1=O |t:35|, CN1[C@@H]2CC[C@H]3[C@@H]4CC[C@H](C(=O)NCc5nc6ncccc6[nH]5)[C@@]4(C)CC[C@@H]3[C@@]2(C)C=C(F)C1=O |t:35|, CN1[C@@H]2CC[C@H]3[C@@H]4CC[C@H](C(=O)NCc5nc6ncccc6[nH]5)[C@@]4(C)CC[C@@H]3[C@@]2(C)C=C(F)C1=O |t:35|	Phase 2
MK-0812	CC chemokine receptor antagonist	CCR2			MedChemEx, MedChemEx, MedChemEx	97.78	CO[C@@H]1COCC[C@@H]1N[C@@H]1CC[C@](C1)(C(C)C)C(=O)N1CCc2ncc(cc2C1)C(F)(F)F, CO[C@@H]1COCC[C@@H]1N[C@@H]1CC[C@](C1)(C(C)C)C(=O)N1CCc2ncc(cc2C1)C(F)(F)F, CO[C@@H]1COCC[C@@H]1N[C@@H]1CC[C@](C1)(C(C)C)C(=O)N1CCc2ncc(cc2C1)C(F)(F)F	Phase 2
MK-0893	glucagon receptor antagonist	GCGR			MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx	98.42	COc1ccc2cc(ccc2c1)-c1cc(nn1[C@@H](C)c1ccc(cc1)C(=O)NCCC(O)=O)-c1cc(Cl)cc(Cl)c1, COc1ccc2cc(ccc2c1)-c1cc(nn1[C@@H](C)c1ccc(cc1)C(=O)NCCC(O)=O)-c1cc(Cl)cc(Cl)c1, COc1ccc2cc(ccc2c1)-c1cc(nn1[C@@H](C)c1ccc(cc1)C(=O)NCCC(O)=O)-c1cc(Cl)cc(Cl)c1, COc1ccc2cc(ccc2c1)-c1cc(nn1[C@@H](C)c1ccc(cc1)C(=O)NCCC(O)=O)-c1cc(Cl)cc(Cl)c1, COc1ccc2cc(ccc2c1)-c1cc(nn1[C@@H](C)c1ccc(cc1)C(=O)NCCC(O)=O)-c1cc(Cl)cc(Cl)c1	Phase 2
MK-1064	orexin receptor antagonist				MedChemEx	98.07	COc1ccc(CNC(=O)c2cc(cnc2-c2ccccn2)-c2cncc(Cl)c2)nc1OC	Phase 1
MK-1775	WEE1 kinase inhibitor	WEE1			Selleck, Selleck, Selleck, Selleck	91.74	CN1CCN(CC1)c1ccc(Nc2ncc3c(n2)n(-c2cccc(n2)C(C)(C)O)n(CC=C)c3=O)cc1, CN1CCN(CC1)c1ccc(Nc2ncc3c(n2)n(-c2cccc(n2)C(C)(C)O)n(CC=C)c3=O)cc1, CN1CCN(CC1)c1ccc(Nc2ncc3c(n2)n(-c2cccc(n2)C(C)(C)O)n(CC=C)c3=O)cc1, CN1CCN(CC1)c1ccc(Nc2ncc3c(n2)n(-c2cccc(n2)C(C)(C)O)n(CC=C)c3=O)cc1	Phase 2
MK-1903	niacin receptor agonist				Enamine	100	OC(=O)c1n[nH]c2[C@@H]3C[C@@H]3Cc12	Phase 2
MK-2048	HIV integrase inhibitor				Selleck, Selleck, Selleck	71.99	CCN1C[C@H](C)n2c(c(O)c3c2c(nn(Cc2ccc(F)c(Cl)c2)c3=O)C(=O)NC)C1=O, CCN1C[C@H](C)n2c(c(O)c3c2c(nn(Cc2ccc(F)c(Cl)c2)c3=O)C(=O)NC)C1=O, CCN1C[C@H](C)n2c(c(O)c3c2c(nn(Cc2ccc(F)c(Cl)c2)c3=O)C(=O)NC)C1=O	Preclinical
MK-2206	AKT inhibitor	AKT1, AKT2, AKT3			Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck	99.32	NC1(CCC1)c1ccc(cc1)-c1nc2ccn3c(n[nH]c3=O)c2cc1-c1ccccc1, NC1(CCC1)c1ccc(cc1)-c1nc2ccn3c(n[nH]c3=O)c2cc1-c1ccccc1, NC1(CCC1)c1ccc(cc1)-c1nc2ccn3c(n[nH]c3=O)c2cc1-c1ccccc1, NC1(CCC1)c1ccc(cc1)-c1nc2ccn3c(n[nH]c3=O)c2cc1-c1ccccc1, NC1(CCC1)c1ccc(cc1)-c1nc2ccn3c(n[nH]c3=O)c2cc1-c1ccccc1, NC1(CCC1)c1ccc(cc1)-c1nc2ccn3c(n[nH]c3=O)c2cc1-c1ccccc1, NC1(CCC1)c1ccc(cc1)-c1nc2ccn3c(n[nH]c3=O)c2cc1-c1ccccc1, NC1(CCC1)c1ccc(cc1)-c1nc2ccn3c(n[nH]c3=O)c2cc1-c1ccccc1, NC1(CCC1)c1ccc(cc1)-c1nc2ccn3c(n[nH]c3=O)c2cc1-c1ccccc1, NC1(CCC1)c1ccc(cc1)-c1nc2ccn3c(n[nH]c3=O)c2cc1-c1ccccc1, NC1(CCC1)c1ccc(cc1)-c1nc2ccn3c(n[nH]c3=O)c2cc1-c1ccccc1, NC1(CCC1)c1ccc(cc1)-c1nc2ccn3c(n[nH]c3=O)c2cc1-c1ccccc1	Phase 2
MK-2295	TRPV antagonist	TRPV1			DuPont	97.5	FC(F)(F)c1ccc(Nc2ncnc3cc(ccc23)-c2ncccc2C(F)(F)F)cc1	Phase 2
MK-2461	FGFR inhibitor, VEGFR inhibitor	FGFR1, FGFR2, FGFR3, FLT1, FLT3, FLT4, KDR, MERTK, MET, MST1R, NTRK1, NTRK2, PDGFRB			MedChemEx, Selleck	95.82	CN(C[C@@H]1COCCO1)S(=O)(=O)Nc1ccc2ccc3ncc(cc3c(=O)c2c1)-c1cnn(C)c1, CN(C[C@@H]1COCCO1)S(=O)(=O)Nc1ccc2ccc3ncc(cc3c(=O)c2c1)-c1cnn(C)c1	Phase 1/Phase 2
MK-2894	prostaglandin inhibitor	PTGER4			MedChemEx	92.79	Cc1sc(C)c(C(=O)NC2(CC2)c2ccc(cc2)C(O)=O)c1Cc1ccc(cc1)C(F)(F)F	Preclinical
MK-3207	calcitonin antagonist	CALCA			MedChemEx, MedChemEx, MedChemEx	98.79	Fc1cc(F)cc(c1)[C@@H]1CNC2(CCCC2)C(=O)N1CC(=O)Nc1ccc2C[C@]3(Cc2c1)C(=O)Nc1ncccc31, Fc1cc(F)cc(c1)[C@@H]1CNC2(CCCC2)C(=O)N1CC(=O)Nc1ccc2C[C@]3(Cc2c1)C(=O)Nc1ncccc31, Fc1cc(F)cc(c1)[C@@H]1CNC2(CCCC2)C(=O)N1CC(=O)Nc1ccc2C[C@]3(Cc2c1)C(=O)Nc1ncccc31	Phase 2
MK-3697	orexin receptor antagonist	HCRTR2			MedChemEx, MedChemEx	97.36	COc1ccc(CNC(=O)c2cc(ncc2-c2nccs2)-c2cncc(C)c2)nc1OC, COc1ccc(CNC(=O)c2cc(ncc2-c2nccs2)-c2cncc(C)c2)nc1OC	Phase 2
MK-4074	acetyl-CoA carboxylase inhibitor				MedChemEx	97.17	COc1cc(cc2n(cc(C)c12)C1CC1)C(=O)N1CCC2(CC1)CC(=O)c1cc(ccc1O2)-c1cncc(c1)C(O)=O	Phase 1
MK-5046	bombesin receptor agonist	BRS3, GRPR, NMBR			MedChemEx	90.83	O[C@@](Cc1ncc(CC2(CC2)C(F)(F)F)[nH]1)(c1ccc(cc1)-n1cccn1)C(F)(F)F	Preclinical
MK-5108	Aurora kinase inhibitor	AURKA, AURKB, AURKC			Selleck, Selleck, Selleck, Selleck, Focus, Focus	94.03	OC(=O)[C@@]1(Cc2cccc(Nc3nccs3)n2)CC[C@@H](CC1)Oc1cccc(Cl)c1F |r|, OC(=O)[C@@]1(Cc2cccc(Nc3nccs3)n2)CC[C@@H](CC1)Oc1cccc(Cl)c1F |r|, OC(=O)[C@@]1(Cc2cccc(Nc3nccs3)n2)CC[C@@H](CC1)Oc1cccc(Cl)c1F |r|, OC(=O)[C@@]1(Cc2cccc(Nc3nccs3)n2)CC[C@@H](CC1)Oc1cccc(Cl)c1F |r|, OC(=O)[C@@]1(Cc2cccc(Nc3nccs3)n2)CC[C@@H](CC1)Oc1cccc(Cl)c1F |r|, OC(=O)[C@@]1(Cc2cccc(Nc3nccs3)n2)CC[C@@H](CC1)Oc1cccc(Cl)c1F |r|	Phase 1
MK-571	leukotriene receptor antagonist	ABCC2, CYSLTR1			MedChemEx, MedChemEx	94.07	CN(C)C(=O)CCS[C@@H](SCCC(O)=O)c1cccc(\C=C\c2ccc3ccc(Cl)cc3n2)c1 |&1:8|, CN(C)C(=O)CCS[C@@H](SCCC(O)=O)c1cccc(\C=C\c2ccc3ccc(Cl)cc3n2)c1 |&1:8|	Phase 2
MK-6096	orexin receptor antagonist	HCRTR1, HCRTR2			MedChemEx	97.98	C[C@@H]1CC[C@@H](COc2ccc(F)cn2)CN1C(=O)c1cc(C)ccc1-c1ncccn1	Phase 2
MK-7246	CRTH receptor antagonist				MedChemEx	92.5	CN([C@@H]1CCc2c(CC(O)=O)c3ccccc3n2C1)S(=O)(=O)c1ccc(F)cc1	Preclinical
MK-7622	cholinergic receptor agonist				MedChemEx	92.11	Cc1ccc(Cc2cc3c(ncn([C@H]4CCCC[C@@H]4O)c3=O)c3ccccc23)cn1	Phase 2
MK-8033	c-Met inhibitor	MET			MedChemEx, MedChemEx, MedChemEx	91.91	Cn1cc(cn1)-c1cnc2ccc3ccc(CS(=O)(=O)NCc4ccccn4)cc3c(=O)c2c1, Cn1cc(cn1)-c1cnc2ccc3ccc(CS(=O)(=O)NCc4ccccn4)cc3c(=O)c2c1, Cn1cc(cn1)-c1cnc2ccc3ccc(CS(=O)(=O)NCc4ccccn4)cc3c(=O)c2c1	Phase 1
MK-8245	stearoyl-CoA desaturase inhibitor	SCD			Selleck, Selleck, Selleck, Selleck, MedChemEx	97.44	OC(=O)Cn1nnc(n1)-c1cc(no1)N1CCC(CC1)Oc1cc(F)ccc1Br, OC(=O)Cn1nnc(n1)-c1cc(no1)N1CCC(CC1)Oc1cc(F)ccc1Br, OC(=O)Cn1nnc(n1)-c1cc(no1)N1CCC(CC1)Oc1cc(F)ccc1Br, OC(=O)Cn1nnc(n1)-c1cc(no1)N1CCC(CC1)Oc1cc(F)ccc1Br, OC(=O)Cn1nnc(n1)-c1cc(no1)N1CCC(CC1)Oc1cc(F)ccc1Br	Phase 2
MK-8617	hypoxia inducible factor prolyl hydroxylase inhibitor				MedChemEx	93.74	COc1ccc(cc1)C(NC(=O)c1cnc(nc1O)-c1cccnn1)c1ccc(OC)cc1	Preclinical
MK-8745	Aurora kinase inhibitor	AURKA			Selleck, MedChemEx	97.88	Fc1c(Cl)cccc1C(=O)N1CCN(Cc2cccc(Nc3nccs3)n2)CC1, Fc1c(Cl)cccc1C(=O)N1CCN(Cc2cccc(Nc3nccs3)n2)CC1	Preclinical
MK-886	lipoxygenase inhibitor				MedChemEx	98.24	CC(C)c1ccc2n(Cc3ccc(Cl)cc3)c(CC(C)(C)C(O)=O)c(SC(C)(C)C)c2c1	Preclinical
MK-8998	T-type calcium channel blocker				MedChemEx	97.27	CC(C)c1ccc(CC(=O)N[C@H](C)c2ccc(OCC(F)(F)F)cn2)cc1	Phase 2
MKT-077	HSP inhibitor				Tocris, Cayman	49.21	CCn1\c(=C/c2cccc[n+]2CC)s\c(=C2\Sc3ccccc3N2C)c1=O, CCn1\c(=C/c2cccc[n+]2CC)s\c(=C2\Sc3ccccc3N2C)c1=O	Phase 1
MK2-IN-1	MAP kinase inhibitor	MAPKAPK2			MedChemEx	91.11	Clc1ccc(cc1)-c1ccc(o1)C(=O)N(Cc1ccccn1)c1ccc(cc1)N1CCNCC1	Preclinical
MLN0128	mTOR inhibitor	MTOR, PIK3CA, PIK3CD, PIK3CG			Selleck, Selleck, Selleck, Selleck, MedChemEx	97.6	CC(C)n1nc(-c2ccc3oc(N)nc3c2)c2c(N)ncnc12, CC(C)n1nc(-c2ccc3oc(N)nc3c2)c2c(N)ncnc12, CC(C)n1nc(-c2ccc3oc(N)nc3c2)c2c(N)ncnc12, CC(C)n1nc(-c2ccc3oc(N)nc3c2)c2c(N)ncnc12, CC(C)n1nc(-c2ccc3oc(N)nc3c2)c2c(N)ncnc12	Phase 2
MLN1117	PI3K inhibitor	PIK3CA			MedChemEx, MedChemEx	97.33	Nc1nc2cc(ccc2o1)-c1ccc2ncc(C(=O)N3CCOCC3)n2c1, Nc1nc2cc(ccc2o1)-c1ccc2ncc(C(=O)N3CCOCC3)n2c1	Phase 2
MLN2480	RAF inhibitor				MedChemEx, MedChemEx	94.64	C[C@@H](NC(=O)c1ncnc(N)c1Cl)c1ncc(s1)C(=O)Nc1cc(c(Cl)cn1)C(F)(F)F, C[C@@H](NC(=O)c1ncnc(N)c1Cl)c1ncc(s1)C(=O)Nc1cc(c(Cl)cn1)C(F)(F)F	Phase 1/Phase 2
MLN8054	Aurora kinase inhibitor	AURKA			MedChemEx, Selleck, Selleck, Selleck	93.63	OC(=O)c1ccc(Nc2ncc3CN=C(c4cc(Cl)ccc4-c3n2)c2c(F)cccc2F)cc1 |c:13|, OC(=O)c1ccc(Nc2ncc3CN=C(c4cc(Cl)ccc4-c3n2)c2c(F)cccc2F)cc1 |c:13|, OC(=O)c1ccc(Nc2ncc3CN=C(c4cc(Cl)ccc4-c3n2)c2c(F)cccc2F)cc1 |c:13|, OC(=O)c1ccc(Nc2ncc3CN=C(c4cc(Cl)ccc4-c3n2)c2c(F)cccc2F)cc1 |c:13|	Phase 1
MLN9708	proteasome inhibitor				MedChemEx, MedChemEx	17.51	CC(C)C[C@H](NC(=O)CNC(=O)c1cc(Cl)ccc1Cl)B1OC(=O)C(CC(O)=O)(CC(O)=O)O1, CC(C)C[C@H](NC(=O)CNC(=O)c1cc(Cl)ccc1Cl)B1OC(=O)C(CC(O)=O)(CC(O)=O)O1	Phase 3
ML10302	serotonin receptor partial agonist	HTR3A, HTR3B, HTR4			Tocris, Tocris, Tocris	97.7	COc1cc(N)c(Cl)cc1C(=O)OCCN1CCCCC1, COc1cc(N)c(Cl)cc1C(=O)OCCN1CCCCC1, COc1cc(N)c(Cl)cc1C(=O)OCCN1CCCCC1	Preclinical
ML130	NOD1 inhibitor				Tocris, Selleck, Tocris	96.9	Cc1ccc(cc1)S(=O)(=O)n1c(N)nc2ccccc12, Cc1ccc(cc1)S(=O)(=O)n1c(N)nc2ccccc12, Cc1ccc(cc1)S(=O)(=O)n1c(N)nc2ccccc12	Preclinical
ML133	potassium channel blocker				Tocris, Selleck	97.57	COc1ccc(CNCc2cccc3ccccc23)cc1, COc1ccc(CNCc2cccc3ccccc23)cc1	Preclinical
ML141	GTPase inhibitor	CDC42			Tocris, Tocris	88.19	COc1ccc(cc1)[C@H]1CC(=NN1c1ccc(cc1)S(N)(=O)=O)c1ccccc1 |&1:8,r,c:11|, COc1ccc(cc1)[C@H]1CC(=NN1c1ccc(cc1)S(N)(=O)=O)c1ccccc1 |&1:8,r,c:11|	Preclinical
ML161	protease-activated receptor inhibitor				Tocris, Selleck	98.28	CCCC(=O)Nc1cccc(NC(=O)c2ccccc2Br)c1, CCCC(=O)Nc1cccc(NC(=O)c2ccccc2Br)c1	Preclinical
ML167	CLK inhibitor, DYRK inhibitor	CLK4, DYRK1B			Selleck, Selleck	90.04	Cc1ccc(CNc2ncnc3ccc(cc23)-c2ccc(CO)o2)o1, Cc1ccc(CNc2ncnc3ccc(cc23)-c2ccc(CO)o2)o1	Preclinical
ML179	liver receptor homolog inverse agonist	NR5A2			Tocris, Tocris	97.61	FC(F)(F)c1cccc(c1)N1CCN(CC1)c1cc(=O)n(C2CCCCC2)c(=O)[nH]1, FC(F)(F)c1cccc(c1)N1CCN(CC1)c1cc(=O)n(C2CCCCC2)c(=O)[nH]1	Preclinical
ML193	G protein-coupled receptor antagonist	GPR55			Tocris, Tocris, Tocris	99.09	Cc1noc(NS(=O)(=O)c2ccc(NC(=O)c3cc(nc4c(C)cc(C)cc34)-c3ccccn3)cc2)c1C, Cc1noc(NS(=O)(=O)c2ccc(NC(=O)c3cc(nc4c(C)cc(C)cc34)-c3ccccn3)cc2)c1C, Cc1noc(NS(=O)(=O)c2ccc(NC(=O)c3cc(nc4c(C)cc(C)cc34)-c3ccccn3)cc2)c1C	Preclinical
ML204	transient receptor potential channel antagonist	TRPC4, TRPC5			MedChemEx, MedChemEx	97.27	Cc1cc(nc2ccccc12)N1CCCCC1, Cc1cc(nc2ccccc12)N1CCCCC1	Preclinical
ML213	potassium channel activator	KCNQ4			Tocris	95.71	Cc1cc(C)c(NC(=O)[C@@H]2C[C@H]3CC[C@@H]2C3)c(C)c1 |&1:11,14,&2:9,r|	Preclinical
ML218	T-type calcium channel blocker	CACNA1G, CACNA1H, CACNA1I			Tocris, Tocris	96.35	CC(C)(C)CCN1C[C@H]2[C@H](CNC(=O)c3cc(Cl)cc(Cl)c3)[C@H]2C1, CC(C)(C)CCN1C[C@H]2[C@H](CNC(=O)c3cc(Cl)cc(Cl)c3)[C@H]2C1	Preclinical
ML228	hypoxia inducible factor activator	HIF1A			Tocris, Tocris, MLSC/Vanderbilt, MLSC/Vanderbilt, MLSC/Vanderbilt, MLSC/Vanderbilt, MLSC/Vanderbilt	97.16	C(Nc1nc(nnc1-c1ccccc1)-c1ccccn1)c1ccc(cc1)-c1ccccc1, C(Nc1nc(nnc1-c1ccccc1)-c1ccccn1)c1ccc(cc1)-c1ccccc1, C(Nc1nc(nnc1-c1ccccc1)-c1ccccn1)c1ccc(cc1)-c1ccccc1, C(Nc1nc(nnc1-c1ccccc1)-c1ccccn1)c1ccc(cc1)-c1ccccc1, C(Nc1nc(nnc1-c1ccccc1)-c1ccccn1)c1ccc(cc1)-c1ccccc1, C(Nc1nc(nnc1-c1ccccc1)-c1ccccn1)c1ccc(cc1)-c1ccccc1, C(Nc1nc(nnc1-c1ccccc1)-c1ccccn1)c1ccc(cc1)-c1ccccc1	Preclinical
ML277	potassium channel activator	KCNQ1			Tocris, Tocris, Tocris	97.2	COc1ccc(cc1)-c1csc(NC(=O)[C@H]2CCCCN2S(=O)(=O)c2ccc(C)cc2)n1, COc1ccc(cc1)-c1csc(NC(=O)[C@H]2CCCCN2S(=O)(=O)c2ccc(C)cc2)n1, COc1ccc(cc1)-c1csc(NC(=O)[C@H]2CCCCN2S(=O)(=O)c2ccc(C)cc2)n1	Preclinical
ML281	serine/threonine kinase inhibitor	STK33			Tocris, Tocris, Broad Institute, Broad Institute, Broad Institute, Broad Institute, Broad Institute, Broad Institute, Broad Institute	98.78	CC(C)c1ccc(NC(=O)c2cccs2)c(c1)-c1nc2ccccc2[nH]c1=O, CC(C)c1ccc(NC(=O)c2cccs2)c(c1)-c1nc2ccccc2[nH]c1=O, CC(C)c1ccc(NC(=O)c2cccs2)c(c1)-c1nc2ccccc2[nH]c1=O, CC(C)c1ccc(NC(=O)c2cccs2)c(c1)-c1nc2ccccc2[nH]c1=O, CC(C)c1ccc(NC(=O)c2cccs2)c(c1)-c1nc2ccccc2[nH]c1=O, CC(C)c1ccc(NC(=O)c2cccs2)c(c1)-c1nc2ccccc2[nH]c1=O, CC(C)c1ccc(NC(=O)c2cccs2)c(c1)-c1nc2ccccc2[nH]c1=O, CC(C)c1ccc(NC(=O)c2cccs2)c(c1)-c1nc2ccccc2[nH]c1=O, CC(C)c1ccc(NC(=O)c2cccs2)c(c1)-c1nc2ccccc2[nH]c1=O	Preclinical
ML297	inward rectifier potassium channel activator	KCNJ3			Tocris, Sigma, Sigma, Sigma, Sigma, Sigma	95.37	Cc1cc(NC(=O)Nc2ccc(F)c(F)c2)n(n1)-c1ccccc1, Cc1cc(NC(=O)Nc2ccc(F)c(F)c2)n(n1)-c1ccccc1, Cc1cc(NC(=O)Nc2ccc(F)c(F)c2)n(n1)-c1ccccc1, Cc1cc(NC(=O)Nc2ccc(F)c(F)c2)n(n1)-c1ccccc1, Cc1cc(NC(=O)Nc2ccc(F)c(F)c2)n(n1)-c1ccccc1, Cc1cc(NC(=O)Nc2ccc(F)c(F)c2)n(n1)-c1ccccc1	Preclinical
ML298	phospholipase inhibitor	PLD2			Tocris, Tocris, Tocris	96.73	Fc1cccc(c1)N1CNC(=O)C11CCN(CCNC(=O)c2ccc(F)c(F)c2)CC1, Fc1cccc(c1)N1CNC(=O)C11CCN(CCNC(=O)c2ccc(F)c(F)c2)CC1, Fc1cccc(c1)N1CNC(=O)C11CCN(CCNC(=O)c2ccc(F)c(F)c2)CC1	Preclinical
ML314	neurotensin agonist	NTSR1			MedChemEx	96.62	COc1ccccc1N1CCN(CC1)c1nc(nc2cc(OC)c(OC)cc12)C1CC1	Preclinical
ML323	ubiquitin specific protease inhibitor	USP1			MedChemEx, MedChemEx	96.64	CC(C)c1ccccc1-c1ncc(C)c(NCc2ccc(cc2)-n2ccnn2)n1, CC(C)c1ccccc1-c1ncc(C)c(NCc2ccc(cc2)-n2ccnn2)n1	Preclinical
ML324	histone lysine demethylase inhibitor	KDM4A			MedChemEx, MedChemEx	86.85	CN(C)CCCNC(=O)c1ccc(cc1)-c1cc(O)c2ncccc2c1, CN(C)CCCNC(=O)c1ccc(cc1)-c1cc(O)c2ncccc2c1	Preclinical
ML3403	MAP kinase inhibitor	CYP3A4, MAPK11, MAPK12, MAPK14			Tocris, Tocris, Tocris	97.3	CSc1nc(c([nH]1)-c1ccc(F)cc1)-c1ccnc(N[C@@H](C)c2ccccc2)c1 |&1:20,r|, CSc1nc(c([nH]1)-c1ccc(F)cc1)-c1ccnc(N[C@@H](C)c2ccccc2)c1 |&1:20,r|, CSc1nc(c([nH]1)-c1ccc(F)cc1)-c1ccnc(N[C@@H](C)c2ccccc2)c1 |&1:20,r|	Preclinical
ML347	ALK tyrosine kinase receptor inhibitor	ACVR1, ACVRL1, BMPR1A			Tocris, Selleck, Selleck, Selleck, Selleck, Tocris	99.36	COc1ccc(cc1)-c1cnc2c(cnn2c1)-c1cccc2ncccc12, COc1ccc(cc1)-c1cnc2c(cnn2c1)-c1cccc2ncccc12, COc1ccc(cc1)-c1cnc2c(cnn2c1)-c1cccc2ncccc12, COc1ccc(cc1)-c1cnc2c(cnn2c1)-c1cccc2ncccc12, COc1ccc(cc1)-c1cnc2c(cnn2c1)-c1cccc2ncccc12, COc1ccc(cc1)-c1cnc2c(cnn2c1)-c1cccc2ncccc12	Preclinical
ML348	lysophospholipase inhibitor	LYPLA1			Tocris, Tocris	98.15	FC(F)(F)c1ccc(Cl)c(NC(=O)CN2CCN(CC2)C(=O)c2ccco2)c1, FC(F)(F)c1ccc(Cl)c(NC(=O)CN2CCN(CC2)C(=O)c2ccco2)c1	Preclinical
ML365	potassium channel blocker	KCNK3, KCNK9			Tocris, Tocris	98.91	COc1ccccc1C(=O)Nc1cccc(NC(=O)c2cccc(C)c2)c1, COc1ccccc1C(=O)Nc1cccc(NC(=O)c2cccc(C)c2)c1	Preclinical
ML786	RAF inhibitor	BRAF, RAF1			Tocris, Tocris	91.56	CC(C)(N)c1cc(cc(c1)C(F)(F)F)C(=O)N[C@@H]1CCc2ccc(Oc3ccnc4NC(=O)CCc34)cc2C1, CC(C)(N)c1cc(cc(c1)C(F)(F)F)C(=O)N[C@@H]1CCc2ccc(Oc3ccnc4NC(=O)CCc34)cc2C1	Preclinical
ML9	myosin light chain kinase inhibitor	TRPC6			Tocris, Tocris, Tocris, Tocris	98.37	Clc1cccc2c(cccc12)S(=O)(=O)N1CCCNCC1, Clc1cccc2c(cccc12)S(=O)(=O)N1CCCNCC1, Clc1cccc2c(cccc12)S(=O)(=O)N1CCCNCC1, Clc1cccc2c(cccc12)S(=O)(=O)N1CCCNCC1	Preclinical
MM-102	WDR5/MLL interaction inhibitor				Tocris, Selleck	96.53	CCC(CC)(NC(=O)C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NC1(CCCC1)C(=O)NC(c1ccc(F)cc1)c1ccc(F)cc1, CCC(CC)(NC(=O)C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NC1(CCCC1)C(=O)NC(c1ccc(F)cc1)c1ccc(F)cc1	Preclinical
MM-11253	retinoid receptor antagonist	RARG			Tocris, Tocris, Tocris	98.06	CC1(C)CCC(C)(C)c2cc(ccc12)C1(SCCS1)c1ccc2cc(ccc2c1)C(O)=O, CC1(C)CCC(C)(C)c2cc(ccc12)C1(SCCS1)c1ccc2cc(ccc2c1)C(O)=O, CC1(C)CCC(C)(C)c2cc(ccc12)C1(SCCS1)c1ccc2cc(ccc2c1)C(O)=O	Preclinical
MM-206	STAT inhibitor				Sigma	80.34	Oc1c(Sc2ccccc2)cc(NS(=O)(=O)c2c(F)c(F)c(F)c(F)c2F)c2ccccc12	Preclinical
MMPX	phosphodiesterase inhibitor				Tocris, Tocris, Tocris	99.04	COCc1nc2n(CC(C)C)c(=O)n(C)c(=O)c2[nH]1, COCc1nc2n(CC(C)C)c(=O)n(C)c(=O)c2[nH]1, COCc1nc2n(CC(C)C)c(=O)n(C)c(=O)c2[nH]1	Preclinical
MMV-390048	PI4K inhibitor				AMS	92.66	CS(=O)(=O)c1ccc(cc1)-c1cnc(N)c(c1)-c1ccc(nc1)C(F)(F)F	Preclinical
MM77	serotonin receptor antagonist	HTR1A			Tocris, Tocris	94.34	COc1ccccc1N1CCN(CCCCN2C(=O)CCC2=O)CC1, COc1ccccc1N1CCN(CCCCN2C(=O)CCC2=O)CC1	Preclinical
MN-64	tankyrase inhibitor	TNKS			Tocris, MedChemEx	96.16	CC(C)c1ccc(cc1)-c1cc(=O)c2ccccc2o1, CC(C)c1ccc(cc1)-c1cc(=O)c2ccccc2o1	Preclinical
MNITMT	lymphocyte inhibitor				Tocris, Tocris	98.32	Cn1cnnc1Sc1c(ncn1C)[N+]([O-])=O, Cn1cnnc1Sc1c(ncn1C)[N+]([O-])=O	Preclinical
mocetinostat	HDAC inhibitor	HDAC1, HDAC11, HDAC2, HDAC3			MedChemEx, MedChemEx, Selleck, Selleck, Selleck, Selleck	98.26	Nc1ccccc1NC(=O)c1ccc(CNc2nccc(n2)-c2cccnc2)cc1, Nc1ccccc1NC(=O)c1ccc(CNc2nccc(n2)-c2cccnc2)cc1, Nc1ccccc1NC(=O)c1ccc(CNc2nccc(n2)-c2cccnc2)cc1, Nc1ccccc1NC(=O)c1ccc(CNc2nccc(n2)-c2cccnc2)cc1, Nc1ccccc1NC(=O)c1ccc(CNc2nccc(n2)-c2cccnc2)cc1, Nc1ccccc1NC(=O)c1ccc(CNc2nccc(n2)-c2cccnc2)cc1	Phase 2
moclobemide	monoamine oxidase inhibitor	MAOA, MAOB	neurology/psychiatry	depression, anxiety	Tocris, Tocris, Tocris, Selleck	94.41	Clc1ccc(cc1)C(=O)NCCN1CCOCC1, Clc1ccc(cc1)C(=O)NCCN1CCOCC1, Clc1ccc(cc1)C(=O)NCCN1CCOCC1, Clc1ccc(cc1)C(=O)NCCN1CCOCC1	Launched
modaline					MicroSource	98.29	Cc1nccnc1N1CCCCC1	Preclinical
moexipril	angiotensin converting enzyme inhibitor	ACE, ACE2	cardiology	hypertension	Tocris, Tocris, Tocris, Selleck, Selleck	93.18	CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1Cc2cc(OC)c(OC)cc2C[C@H]1C(O)=O, CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1Cc2cc(OC)c(OC)cc2C[C@H]1C(O)=O, CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1Cc2cc(OC)c(OC)cc2C[C@H]1C(O)=O, CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1Cc2cc(OC)c(OC)cc2C[C@H]1C(O)=O, CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1Cc2cc(OC)c(OC)cc2C[C@H]1C(O)=O	Launched
mofegiline	monoamine oxidase inhibitor	MAOA, MAOB			MedChemEx, MedChemEx, MedChemEx	88.73	NC\C(CCc1ccc(F)cc1)=C\F, NC\C(CCc1ccc(F)cc1)=C\F, NC\C(CCc1ccc(F)cc1)=C\F	Phase 1
mofezolac	cyclooxygenase inhibitor	PTGS1	rheumatology, orthopedics	rheumatoid arthritis, osteoporosis	Sigma	99.58	COc1ccc(cc1)-c1noc(CC(O)=O)c1-c1ccc(OC)cc1	Launched
moguisteine	ATP-sensitive potassium channel inhibitor				Selleck	97.02	CCOC(=O)CC(=O)N1CCS[C@@H]1COc1ccccc1OC |&1:12,r|	Phase 2
molidustat	hypoxia inducible factor inhibitor	EGLN2			MedChemEx, MedChemEx, MedChemEx	90.41	O=c1c(c[nH]n1-c1cc(ncn1)N1CCOCC1)-n1ccnn1, O=c1c(c[nH]n1-c1cc(ncn1)N1CCOCC1)-n1ccnn1, O=c1c(c[nH]n1-c1cc(ncn1)N1CCOCC1)-n1ccnn1	Phase 3
molindone	dopamine receptor antagonist	DRD2, HRH1, HTR2A	neurology/psychiatry	schizophrenia	MicroSource, MedChemEx	98.2	CCc1c(C)[nH]c2CC[C@@H](CN3CCOCC3)C(=O)c12 |r|, CCc1c(C)[nH]c2CC[C@@H](CN3CCOCC3)C(=O)c12 |r|	Launched
molsidomine	guanylate cyclase stimulant	GUCY1A3	cardiology	coronary artery disease (CAD)	MedChemEx, MedChemEx, MicroSource	98.74	CCOC(=O)Nc1c[n+](no1)N1CCOCC1, CCOC(=O)Nc1c[n+](no1)N1CCOCC1, CCOC(=O)Nc1c[n+](no1)N1CCOCC1	Launched
mometasone	glucocorticoid receptor agonist	NR3C1	dermatology	corticosteroid-responsive dermatoses	Sigma	0	C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CCl |c:11,t:7|	Launched
mometasone-furoate	glucocorticoid receptor agonist	NR3C1	dermatology	corticosteroid-responsive dermatoses	MicroSource, MicroSource, Selleck, Selleck, Selleck, Tocris, Tocris	100	C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)c1ccco1)C(=O)CCl |c:11,t:7|, C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)c1ccco1)C(=O)CCl |c:11,t:7|, C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)c1ccco1)C(=O)CCl |c:11,t:7|, C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)c1ccco1)C(=O)CCl |c:11,t:7|, C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)c1ccco1)C(=O)CCl |c:11,t:7|, C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)c1ccco1)C(=O)CCl |c:11,t:7|, C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)c1ccco1)C(=O)CCl |c:11,t:7|	Launched
monastrol	kinesin inhibitor	KIF11			Tocris, Tocris, Tocris, Tocris, Tocris	97.94	CCOC(=O)C1=C(C)NC(=S)N[C@@H]1c1cccc(O)c1 |r,c:5|, CCOC(=O)C1=C(C)NC(=S)N[C@@H]1c1cccc(O)c1 |r,c:5|, CCOC(=O)C1=C(C)NC(=S)N[C@@H]1c1cccc(O)c1 |r,c:5|, CCOC(=O)C1=C(C)NC(=S)N[C@@H]1c1cccc(O)c1 |r,c:5|, CCOC(=O)C1=C(C)NC(=S)N[C@@H]1c1cccc(O)c1 |r,c:5|	Preclinical
monensin	bacterial permeability inducer		infectious disease	gastrointestinal parasites	MedChemEx	78.9	CC[C@]1(CC[C@@H](O1)[C@]1(C)CC[C@]2(C[C@H](O)[C@@H](C)[C@H](O2)[C@@H](C)[C@@H](OC)[C@H](C)C(O)=O)O1)[C@@H]1O[C@H](C[C@@H]1C)[C@H]1O[C@@](O)(CO)[C@H](C)C[C@@H]1C	Launched
monepantel	mTOR inhibitor				MedChemEx	97.55	C[C@](COc1cc(ccc1C(F)(F)F)C#N)(NC(=O)c1ccc(SC(F)(F)F)cc1)C#N	Preclinical
monobenzone	melanin inhibitor	TYR	dermatology	skin depigmentation	MicroSource, Sigma, Selleck, Selleck, Selleck	83.75	Oc1ccc(OCc2ccccc2)cc1, Oc1ccc(OCc2ccccc2)cc1, Oc1ccc(OCc2ccccc2)cc1, Oc1ccc(OCc2ccccc2)cc1, Oc1ccc(OCc2ccccc2)cc1	Launched
monocrotaline	antitumor agent				MedChemEx	87.05	C[C@H]1C(=O)O[C@@H]2CCN3CC=C(COC(=O)[C@](C)(O)[C@]1(C)O)[C@H]23 |t:10|	Preclinical
monoctanoin			gastroenterology	gallstones	Sigma, Sigma	84.6	CCCCCCCC(=O)OC[C@@H](O)CO |&1:11,r|, CCCCCCCC(=O)OC[C@@H](O)CO |&1:11,r|	Launched
monomethyl-fumarate			neurology/psychiatry	multiple sclerosis	CombiBlocks	97.69	COC(=O)\C=C\C(O)=O	Launched
monosodium-alpha-luminol					MedChemEx, Enamine, Enamine, MedChemEx	97.04	Nc1cccc2c1c(=O)[nH][nH]c2=O, Nc1cccc2c1c(=O)[nH][nH]c2=O, Nc1cccc2c1c(=O)[nH][nH]c2=O, Nc1cccc2c1c(=O)[nH][nH]c2=O	Launched
monostearin					TCI	92.85	CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)CO |&1:21,r|	Preclinical
montelukast	leukotriene receptor antagonist	ALOX5, CYSLTR1	pulmonary, allergy	asthma, allergic rhinitis, exercise-induced bronchoconstriction (EIB)	Tocris, MicroSource, MicroSource, Selleck, Selleck, Selleck, Selleck, Selleck	98.68	CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(O)=O)CC1)c1cccc(\C=C\c2ccc3ccc(Cl)cc3n2)c1, CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(O)=O)CC1)c1cccc(\C=C\c2ccc3ccc(Cl)cc3n2)c1, CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(O)=O)CC1)c1cccc(\C=C\c2ccc3ccc(Cl)cc3n2)c1, CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(O)=O)CC1)c1cccc(\C=C\c2ccc3ccc(Cl)cc3n2)c1, CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(O)=O)CC1)c1cccc(\C=C\c2ccc3ccc(Cl)cc3n2)c1, CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(O)=O)CC1)c1cccc(\C=C\c2ccc3ccc(Cl)cc3n2)c1, CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(O)=O)CC1)c1cccc(\C=C\c2ccc3ccc(Cl)cc3n2)c1, CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(O)=O)CC1)c1cccc(\C=C\c2ccc3ccc(Cl)cc3n2)c1	Launched
moprolol	adrenergic receptor antagonist		cardiology, ophthalmology, neurology/psychiatry	hypertension, glaucoma, anxiety	LifeChem, LifeChem	95.27	COc1ccccc1OC[C@@H](O)CNC(C)C |&1:10|, COc1ccccc1OC[C@@H](O)CNC(C)C |&1:10|	Launched
moracizine	sodium channel blocker	SCN5A	cardiology	ventricular arrhythmias	Vitas-M, Vitas-M, Prestwick	99.39	CCOC(=O)Nc1ccc2Sc3ccccc3N(C(=O)CCN3CCOCC3)c2c1, CCOC(=O)Nc1ccc2Sc3ccccc3N(C(=O)CCN3CCOCC3)c2c1, CCOC(=O)Nc1ccc2Sc3ccccc3N(C(=O)CCN3CCOCC3)c2c1	Withdrawn
morantel	acetylcholine receptor agonist		infectious disease	tapeworm	MicroSource, Selleck	94.05	CN1CCCN=C1\C=C\c1sccc1C |c:5|, CN1CCCN=C1\C=C\c1sccc1C |c:5|	Launched
morin	cytochrome P450 inhibitor	ADORA2A, ESR2, FASN, MCL1, SLC22A12			Selleck, Selleck, Selleck, Selleck, Selleck, Selleck	100	Oc1ccc(c(O)c1)-c1oc2cc(O)cc(O)c2c(=O)c1O, Oc1ccc(c(O)c1)-c1oc2cc(O)cc(O)c2c(=O)c1O, Oc1ccc(c(O)c1)-c1oc2cc(O)cc(O)c2c(=O)c1O, Oc1ccc(c(O)c1)-c1oc2cc(O)cc(O)c2c(=O)c1O, Oc1ccc(c(O)c1)-c1oc2cc(O)cc(O)c2c(=O)c1O, Oc1ccc(c(O)c1)-c1oc2cc(O)cc(O)c2c(=O)c1O	Preclinical
morinidazole	other antibiotic	CYP51A1			MedChemEx	85.47	Cc1ncc(n1C[C@@H](O)CN1CCOCC1)[N+]([O-])=O |&1:7,r|	Launched
morniflumate	anti-inflammatory agent		neurology/psychiatry	pain relief	AKSci	97.89	FC(F)(F)c1cccc(Nc2ncccc2C(=O)OCCN2CCOCC2)c1	Launched
moroxydine	antiviral		infectious disease	influenza A virus infection	MedChemEx	86.9	NC(=N)\N=C(/N)N1CCOCC1	Launched
morphothiadin	antiinfective drug				MedChemEx	94.57	CCOC(=O)C1=C(CN2CCOCC2)NC(=N[C@@H]1c1ccc(F)cc1Br)c1nccs1 |&1:17,r,c:5,16|	Preclinical
mosapride	serotonin receptor agonist	HTR4	gastroenterology	hypertrophic gastritis (GHG), gastroesophageal reflux disease (GERD), dyspepsia, irritable bowel syndrome	Tocris, Selleck	98.7	CCOc1cc(N)c(Cl)cc1C(=O)NC[C@H]1CN(Cc2ccc(F)cc2)CCO1 |&1:15|, CCOc1cc(N)c(Cl)cc1C(=O)NC[C@H]1CN(Cc2ccc(F)cc2)CCO1 |&1:15|	Launched
motapizone	phosphodiesterase inhibitor				Enamine	93.45	CC1=C(NNC(=O)C1)c1cc(cs1)-n1ccnc1 |t:1|	Preclinical
motesanib	KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	FLT1, FLT4, KDR, KIT			MedChemEx, MedChemEx, MedChemEx, MedChemEx, Selleck, MedChemEx, MedChemEx, Selleck	95.52	CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12	Phase 3
motolimod	toll-like receptor agonist	TLR8			MedChemEx, MedChemEx	87.75	CCCN(CCC)C(=O)C1=Cc2ccc(cc2N=C(N)C1)-c1ccc(cc1)C(=O)N1CCCC1 |t:9,18|, CCCN(CCC)C(=O)C1=Cc2ccc(cc2N=C(N)C1)-c1ccc(cc1)C(=O)N1CCCC1 |t:9,18|	Phase 2
moxalactam	bacterial cell wall synthesis inhibitor		infectious disease	gram-positive bacterial infections, gram-negative bacterial infections, skin infections, bone and joint infections, pneumonia, urinary tract infections, meningitis	Sigma, MicroSource	0	CO[C@]1(NC(=O)[C@@H](C(O)=O)c2ccc(O)cc2)[C@H]2OCC(CSc3nnnn3C)=C(N2C1=O)C(O)=O |a:2,17,&1:6,c:30|, CO[C@]1(NC(=O)[C@@H](C(O)=O)c2ccc(O)cc2)[C@H]2OCC(CSc3nnnn3C)=C(N2C1=O)C(O)=O |a:2,17,&1:6,c:30|	Launched
moxaverine	phosphodiesterase inhibitor		neurology/psychiatry	spasms	Innovapharm, Innovapharm	99.2	CCc1cc2cc(OC)c(OC)cc2c(Cc2ccccc2)n1, CCc1cc2cc(OC)c(OC)cc2c(Cc2ccccc2)n1	Launched
moxidectin	chloride channel antagonist		infectious disease	gastrointestinal parasites	MedChemEx	89.94	[H][C@@]12OC\C3=C/C=C/[C@H](C)C\C(C)=C\C[C@]4([H])C[C@@]([H])(C[C@]5(C\C(=N/OC)[C@H](C)[C@H](O5)C(\C)=C\C(C)C)O4)OC(=O)[C@]([H])(C=C(C)[C@H]1O)[C@@]23O |c:4,t:6,12,45|	Launched
moxifloxacin	bacterial DNA gyrase inhibitor	TOP2A	otolaryngology, pulmonary, infectious disease	sinusitis, bronchitis, pneumonia, skin infections, intra-abdominal infections	MicroSource, MicroSource, Selleck	94.14	COc1c(N2C[C@@H]3CCCN[C@@H]3C2)c(F)cc2c1n(cc(C(O)=O)c2=O)C1CC1, COc1c(N2C[C@@H]3CCCN[C@@H]3C2)c(F)cc2c1n(cc(C(O)=O)c2=O)C1CC1, COc1c(N2C[C@@H]3CCCN[C@@H]3C2)c(F)cc2c1n(cc(C(O)=O)c2=O)C1CC1	Launched
moxisylyte	adrenergic receptor antagonist				MedChemEx, MicroSource	95.95	CC(C)c1cc(OC(C)=O)c(C)cc1OCCN(C)C, CC(C)c1cc(OC(C)=O)c(C)cc1OCCN(C)C	Withdrawn
moxonidine	imidazoline receptor agonist	ADRA2A, ADRA2B, ADRA2C	cardiology	hypertension	Tocris, Tocris, Selleck, Selleck, Selleck, Tocris, Tocris	96.96	COc1nc(C)nc(Cl)c1NC1=NCCN1 |t:12|, COc1nc(C)nc(Cl)c1NC1=NCCN1 |t:12|, COc1nc(C)nc(Cl)c1NC1=NCCN1 |t:12|, COc1nc(C)nc(Cl)c1NC1=NCCN1 |t:12|, COc1nc(C)nc(Cl)c1NC1=NCCN1 |t:12|, COc1nc(C)nc(Cl)c1NC1=NCCN1 |t:12|, COc1nc(C)nc(Cl)c1NC1=NCCN1 |t:12|	Launched
mozavaptan	vasopressin receptor antagonist	AVPR1A, AVPR1B, AVPR2	endocrinology	hyponatremia	MedChemEx, Selleck, Selleck	97.07	CN(C)[C@H]1CCCN(C(=O)c2ccc(NC(=O)c3ccccc3C)cc2)c2ccccc12 |&1:3,r|, CN(C)[C@H]1CCCN(C(=O)c2ccc(NC(=O)c3ccccc3C)cc2)c2ccccc12 |&1:3,r|, CN(C)[C@H]1CCCN(C(=O)c2ccc(NC(=O)c3ccccc3C)cc2)c2ccccc12 |&1:3,r|	Launched
MPEP	glutamate receptor antagonist	GRM1, GRM4, GRM5			Tocris, Selleck, Selleck, Tocris	97.59	Cc1cccc(n1)C#Cc1ccccc1, Cc1cccc(n1)C#Cc1ccccc1, Cc1cccc(n1)C#Cc1ccccc1, Cc1cccc(n1)C#Cc1ccccc1	Preclinical
MPI-0479605	mitotic kinase inhibitor	TTK			MedChemEx, MedChemEx, MedChemEx, Selleck, MedChemEx, Selleck	94.28	Cc1cc(ccc1Nc1nc(NC2CCCCC2)c2[nH]cnc2n1)N1CCOCC1, Cc1cc(ccc1Nc1nc(NC2CCCCC2)c2[nH]cnc2n1)N1CCOCC1, Cc1cc(ccc1Nc1nc(NC2CCCCC2)c2[nH]cnc2n1)N1CCOCC1, Cc1cc(ccc1Nc1nc(NC2CCCCC2)c2[nH]cnc2n1)N1CCOCC1, Cc1cc(ccc1Nc1nc(NC2CCCCC2)c2[nH]cnc2n1)N1CCOCC1, Cc1cc(ccc1Nc1nc(NC2CCCCC2)c2[nH]cnc2n1)N1CCOCC1	Preclinical
Mps-BAY-2a	monopolar spindle 1 kinase inhibitor	TTK			Tocris, Tocris	97.37	CC(C)CNc1nc(cn2c(cnc12)-c1ccc(cc1)C(=O)NC1CC1)-c1cccc2ncccc12, CC(C)CNc1nc(cn2c(cnc12)-c1ccc(cc1)C(=O)NC1CC1)-c1cccc2ncccc12	Preclinical
Mps1-IN-1	monopolar spindle 1 kinase inhibitor	TTK			Tocris, Tocris, Tocris	95.35	COc1cc(ccc1Nc1cc(Nc2ccccc2S(=O)(=O)C(C)C)c2cc[nH]c2n1)N1CCC(O)CC1, COc1cc(ccc1Nc1cc(Nc2ccccc2S(=O)(=O)C(C)C)c2cc[nH]c2n1)N1CCC(O)CC1, COc1cc(ccc1Nc1cc(Nc2ccccc2S(=O)(=O)C(C)C)c2cc[nH]c2n1)N1CCC(O)CC1	Preclinical
Mps1-IN-5	protein kinase inhibitor				MedChemEx, MedChemEx	94.51	COc1cc(ccc1Nc1nc2ccc(cn2n1)-c1ccc(NC(=O)[C@H](C)c2ccc(F)cc2)cc1)S(C)(=O)=O, COc1cc(ccc1Nc1nc2ccc(cn2n1)-c1ccc(NC(=O)[C@H](C)c2ccc(F)cc2)cc1)S(C)(=O)=O	Phase 1
MR-16728	acetylcholine release enhancer				Tocris, Tocris	93.83	O=C(NCCCN1CCCCCC1)[C@@H](C1CCCCC1)c1ccccc1 |&1:13|, O=C(NCCCN1CCCCCC1)[C@@H](C1CCCCC1)c1ccccc1 |&1:13|	Preclinical
MR-948	thromboxane synthase inhibitor	TBXAS1			Enamine	98.9	OCCc1ccc(OCCn2ccnc2)cc1	Phase 1
MRK-016	GABA receptor inverse agonist	GABRA1, GABRA2, GABRA3, GABRA5			Tocris, Tocris, Tocris	98.16	Cc1cc(no1)-c1nncc2c(c(OCc3ncnn3C)nn12)C(C)(C)C, Cc1cc(no1)-c1nncc2c(c(OCc3ncnn3C)nn12)C(C)(C)C, Cc1cc(no1)-c1nncc2c(c(OCc3ncnn3C)nn12)C(C)(C)C	Phase 1
MRK-409	benzodiazepine receptor agonist				Tocris, Sigma	99.45	Cn1ncnc1COc1nn2c(nnc2cc1C1CCC1)-c1c(F)cccc1F, Cn1ncnc1COc1nn2c(nnc2cc1C1CCC1)-c1c(F)cccc1F	Phase 1
MRK-560	gamma secretase inhibitor	APP			Tocris, Tocris, Tocris, Tocris	97.52	Fc1ccc(F)c(c1)[C@]1(CC[C@@H](CC1)NS(=O)(=O)C(F)(F)F)S(=O)(=O)c1ccc(Cl)cc1 |r|, Fc1ccc(F)c(c1)[C@]1(CC[C@@H](CC1)NS(=O)(=O)C(F)(F)F)S(=O)(=O)c1ccc(Cl)cc1 |r|, Fc1ccc(F)c(c1)[C@]1(CC[C@@H](CC1)NS(=O)(=O)C(F)(F)F)S(=O)(=O)c1ccc(Cl)cc1 |r|, Fc1ccc(F)c(c1)[C@]1(CC[C@@H](CC1)NS(=O)(=O)C(F)(F)F)S(=O)(=O)c1ccc(Cl)cc1 |r|	Preclinical
MRS-1220	adenosine receptor antagonist	ADORA2B, ADORA3			Tocris, Tocris, Tocris, Tocris, Tocris, Tocris, Tocris	92.13	Clc1ccc2nc(NC(=O)Cc3ccccc3)n3nc(nc3c2c1)-c1ccco1, Clc1ccc2nc(NC(=O)Cc3ccccc3)n3nc(nc3c2c1)-c1ccco1, Clc1ccc2nc(NC(=O)Cc3ccccc3)n3nc(nc3c2c1)-c1ccco1, Clc1ccc2nc(NC(=O)Cc3ccccc3)n3nc(nc3c2c1)-c1ccco1, Clc1ccc2nc(NC(=O)Cc3ccccc3)n3nc(nc3c2c1)-c1ccco1, Clc1ccc2nc(NC(=O)Cc3ccccc3)n3nc(nc3c2c1)-c1ccco1, Clc1ccc2nc(NC(=O)Cc3ccccc3)n3nc(nc3c2c1)-c1ccco1	Preclinical
MRS-1334	adenosine receptor antagonist	ADORA3			Tocris, Tocris, Tocris	96.08	CCOC(=O)C1=C(C)NC(=C([C@@H]1C#Cc1ccccc1)C(=O)OCc1ccc(cc1)[N+]([O-])=O)c1ccccc1 |&1:11,r,c:5,9|, CCOC(=O)C1=C(C)NC(=C([C@@H]1C#Cc1ccccc1)C(=O)OCc1ccc(cc1)[N+]([O-])=O)c1ccccc1 |&1:11,r,c:5,9|, CCOC(=O)C1=C(C)NC(=C([C@@H]1C#Cc1ccccc1)C(=O)OCc1ccc(cc1)[N+]([O-])=O)c1ccccc1 |&1:11,r,c:5,9|	Preclinical
MRS-1845	calcium channel blocker				Tocris, Tocris, Tocris	95.8	CCOC(=O)C1=C(C)N(CC#C)C(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC |&1:15,r,c:5,13|, CCOC(=O)C1=C(C)N(CC#C)C(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC |&1:15,r,c:5,13|, CCOC(=O)C1=C(C)N(CC#C)C(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC |&1:15,r,c:5,13|	Preclinical
MRS-2578	purinergic receptor antagonist	P2RY6			Tocris, Tocris, Selleck, Selleck	27.78	S=C=Nc1cccc(NC(=S)NCCCCNC(=S)Nc2cccc(c2)N=C=S)c1, S=C=Nc1cccc(NC(=S)NCCCCNC(=S)Nc2cccc(c2)N=C=S)c1, S=C=Nc1cccc(NC(=S)NCCCCNC(=S)Nc2cccc(c2)N=C=S)c1, S=C=Nc1cccc(NC(=S)NCCCCNC(=S)Nc2cccc(c2)N=C=S)c1	Preclinical
MRS-3777	adenosine receptor antagonist	ADORA1, ADORA2A, ADORA2B, ADORA3			Tocris, Tocris, SantaCruz, Tocris, Tocris, Tocris, Tocris	97.69	C1CCC(CC1)Nc1nc(Oc2ccccc2)nc2nc[nH]c12.C1CCC(CC1)Nc1nc(Oc2ccccc2)nc2nc[nH]c12, C1CCC(CC1)Nc1nc(Oc2ccccc2)nc2nc[nH]c12.C1CCC(CC1)Nc1nc(Oc2ccccc2)nc2nc[nH]c12, C1CCC(CC1)Nc1nc(Oc2ccccc2)nc2nc[nH]c12.C1CCC(CC1)Nc1nc(Oc2ccccc2)nc2nc[nH]c12, C1CCC(CC1)Nc1nc(Oc2ccccc2)nc2nc[nH]c12, C1CCC(CC1)Nc1nc(Oc2ccccc2)nc2nc[nH]c12, C1CCC(CC1)Nc1nc(Oc2ccccc2)nc2nc[nH]c12, C1CCC(CC1)Nc1nc(Oc2ccccc2)nc2nc[nH]c12	Preclinical
MRX-2843	MER tyrosine kinase inhibitor				MedChemEx	92.39	CN1CCN(Cc2ccc(cc2)-c2cn([C@H]3CC[C@H](O)CC3)c3nc(NCCC4CC4)ncc23)CC1 |r|	Phase 1
MS-424	glutamate transporter modulator				Astatech	92.08	C[C@@H]1C=CNN1C(=O)c1cccnc1 |c:2|	Phase 2
MSDC-0160	insulin sensitizer				MedChemEx	98.66	CCc1ccc(nc1)C(=O)COc1ccc(C[C@@H]2SC(=O)NC2=O)cc1 |&1:17,r|	Phase 2
MSDC-0602K	mitochondrial pyruvate carrier modulator				AMS	91.85	COc1cccc(c1)C(=O)COc1ccc(Cc2sc(O)nc2O)cc1	Phase 2
MSX-122	CC chemokine receptor antagonist	CXCR4			MedChemEx, MedChemEx, MedChemEx	93.92	C(Nc1ncccn1)c1ccc(CNc2ncccn2)cc1, C(Nc1ncccn1)c1ccc(CNc2ncccn2)cc1, C(Nc1ncccn1)c1ccc(CNc2ncccn2)cc1	Phase 2
MTPG	glutamate receptor antagonist	GRM2, GRM3			Tocris, Tocris	100	C[C@@](N)(C(O)=O)c1ccc(cc1)-c1nn[nH]n1 |&1:1|, C[C@@](N)(C(O)=O)c1ccc(cc1)-c1nn[nH]n1 |&1:1|	Preclinical
mubritinib	protein tyrosine kinase inhibitor	EGFR, ERBB2			Tocris, Tocris, Tocris, Selleck	96.61	FC(F)(F)c1ccc(\C=C\c2nc(COc3ccc(CCCCn4ccnn4)cc3)co2)cc1, FC(F)(F)c1ccc(\C=C\c2nc(COc3ccc(CCCCn4ccnn4)cc3)co2)cc1, FC(F)(F)c1ccc(\C=C\c2nc(COc3ccc(CCCCn4ccnn4)cc3)co2)cc1, FC(F)(F)c1ccc(\C=C\c2nc(COc3ccc(CCCCn4ccnn4)cc3)co2)cc1	Phase 1
mupirocin	isoleucyl-tRNA synthetase inhibitor		infectious disease	impetigo	MicroSource, Selleck, MedChemEx	93.41	C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@H]1CO[C@@H](C\C(C)=C\C(=O)OCCCCCCCCC(O)=O)[C@H](O)[C@@H]1O, C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@H]1CO[C@@H](C\C(C)=C\C(=O)OCCCCCCCCC(O)=O)[C@H](O)[C@@H]1O, C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@H]1CO[C@@H](C\C(C)=C\C(=O)OCCCCCCCCC(O)=O)[C@H](O)[C@@H]1O	Launched
muscimol	benzodiazepine receptor agonist	GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRR1, GABRR2, GABRR3			Tocris, Tocris	100	NCc1cc(=O)[nH]o1, NCc1cc(=O)[nH]o1	Phase 1
MUT056399	FABI inhibitor				MedChemEx, MedChemEx	93.76	CCc1cc(O)c(Oc2ccc(cc2F)C(N)=O)cc1F, CCc1cc(O)c(Oc2ccc(cc2F)C(N)=O)cc1F	Phase 1
MY-5445	phosphodiesterase inhibitor, platelet aggregation inhibitor	PDE5A			Tocris, Tocris, Tocris, Tocris	99.38	Clc1cccc(Nc2nnc(-c3ccccc3)c3ccccc23)c1, Clc1cccc(Nc2nnc(-c3ccccc3)c3ccccc23)c1, Clc1cccc(Nc2nnc(-c3ccccc3)c3ccccc23)c1, Clc1cccc(Nc2nnc(-c3ccccc3)c3ccccc23)c1	Preclinical
mycophenolate-mofetil	dehydrogenase inhibitor, inositol monophosphatase inhibitor	IMPDH1, IMPDH2	transplant	organ rejection	Tocris, Tocris, MicroSource, Selleck, Selleck, Tocris	97.77	COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(=O)OCCN1CCOCC1, COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(=O)OCCN1CCOCC1, COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(=O)OCCN1CCOCC1, COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(=O)OCCN1CCOCC1, COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(=O)OCCN1CCOCC1, COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(=O)OCCN1CCOCC1	Launched
mycophenolic-acid	dehydrogenase inhibitor, inositol monophosphatase inhibitor	IMPDH1, IMPDH2	transplant	organ rejection	Tocris, Tocris, MicroSource, Selleck, Selleck, Selleck, Selleck, Tocris	98.39	COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(O)=O, COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(O)=O, COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(O)=O, COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(O)=O, COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(O)=O, COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(O)=O, COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(O)=O, COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(O)=O	Launched
myricetin	androgen receptor agonist, cytochrome P450 inhibitor	PIK3CG			Selleck, Selleck, Selleck	94.44	Oc1cc(O)c2c(c1)oc(-c1cc(O)c(O)c(O)c1)c(O)c2=O, Oc1cc(O)c2c(c1)oc(-c1cc(O)c(O)c(O)c1)c(O)c2=O, Oc1cc(O)c2c(c1)oc(-c1cc(O)c(O)c(O)c1)c(O)c2=O	Preclinical
myricitrin	PKC inhibitor	NOS1, PRKCA			Selleck	96.98	C[C@@H]1O[C@@H](Oc2c(oc3cc(O)cc(O)c3c2=O)-c2cc(O)c(O)c(O)c2)[C@H](O)[C@H](O)[C@H]1O	Preclinical
myristyl-nicotinate	topical sunscreen agent				Accela	0	CCCCCCCCCCCCCCOC(=O)c1cccnc1	Phase 1
M8-B	transient receptor potential channel antagonist	TRPM8			Tocris, Tocris, Tocris	97.89	COc1cc(CN(CCN)C(=O)c2cccs2)ccc1OCc1ccccc1, COc1cc(CN(CCN)C(=O)c2cccs2)ccc1OCc1ccccc1, COc1cc(CN(CCN)C(=O)c2cccs2)ccc1OCc1ccccc1	Preclinical
N-(p-amylcinnamoyl)-anthranilic-acid	phospholipase inhibitor				MedChemEx	93.29	CCCCCc1ccc(\C=C\C(=O)Nc2ccccc2C(O)=O)cc1	Preclinical
N-(2-chlorophenyl)-2-({(2E)-2-[1-(2-pyridinyl)ethylidene]hydrazino}carbothioyl)hydrazinecarbothioamide					Key	20.21	CC(=NNC(=S)NNC(=S)Nc1ccccc1Cl)c1ccccn1	Preclinical
N-[2-(piperidinylamino)ethyl]-4-iodobenzamide	sigma receptor ligand				Tocris, Tocris, Tocris	98.14	Ic1ccc(cc1)C(=O)NCCN1CCCCC1, Ic1ccc(cc1)C(=O)NCCN1CCCCC1, Ic1ccc(cc1)C(=O)NCCN1CCCCC1	Preclinical
N-acetyl-D-glucosamine		B4GALT1, B4GALT2, B4GALT3, B4GALT4, NAGK, NAGLU, NAGPA, RENBP			MedChemEx, Vitas-M	100	CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO, CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO	Phase 2/Phase 3
N-acetyl-tyrosine					Enamine, Enamine	96.39	CC(=O)N[C@@H](Cc1ccc(O)cc1)C(O)=O |&1:4,r|, CC(=O)N[C@@H](Cc1ccc(O)cc1)C(O)=O |&1:4,r|	Launched
N-acetylcarnosine					AKSci	100	CC(=O)NCCC(=O)N[C@@H](Cc1cnc[nH]1)C(O)=O	Launched
N-acetylglycyl-D-glutamic-acid	glutamate receptor agonist				Tocris, Tocris	100	CC(=O)NCC(=O)N[C@H](CCC(O)=O)C(O)=O, CC(=O)NCC(=O)N[C@H](CCC(O)=O)C(O)=O	Preclinical
N-acetylmannosamine					Vitas-M	100	CC(=O)N[C@H]1[C@@H](O)O[C@@H](CO)[C@@H](O)[C@H]1O |a:5,11,13,&1:4,&2:8|	Phase 2
N-acetyltryptamine	melatonin receptor agonist				Tocris, Tocris, Tocris, Tocris	98.63	CC(=O)NCCc1c[nH]c2ccccc12, CC(=O)NCCc1c[nH]c2ccccc12, CC(=O)NCCc1c[nH]c2ccccc12, CC(=O)NCCc1c[nH]c2ccccc12	Preclinical
N-alpha-methylhistamine-dihydrochloride	histamine receptor agonist	HRH4			Tocris, Tocris	100	CNCCc1cnc[nH]1, CNCCc1cnc[nH]1	Phase 3
N-benzylnaltrindole	opioid receptor antagonist				Tocris	98.7	Oc1ccc2C[C@H]3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)c1c(C[C@@]35O)c2ccccc2n1Cc1ccccc1 |TLB:21:22:7.12.13:4.5.18,23:22:7.12.13:4.5.18|	Preclinical
N-cyclohexyl-2-benzothiazolesulfenamide					AKSci	98.95	C1CCC(CC1)NSc1nc2ccccc2s1	Preclinical
N-hydroxynicotinamide					Sigma	96.8	ONC(=O)c1cccnc1	Preclinical
N-methyl-(-)ephedrine-[1R,2S]					Sigma, MicroSource	84.7	C[C@@H]([C@H](O)c1ccccc1)N(C)C, C[C@@H]([C@H](O)c1ccccc1)N(C)C	Preclinical
N-methylformamide					Sigma	0	CNC=O	Phase 2
N-methyllidocaine-iodide	antiarrhythmic medication				Tocris	98.14	CC[N+](C)(CC)CC(=O)Nc1c(C)cccc1C	Preclinical
N-methylpyrrolidone					Sigma	0	CN1CCCC1=O	Phase 1
N-methylquipazine	serotonin receptor agonist				Tocris, Tocris	98.26	CN1CCN(CC1)c1ccc2ccccc2n1, CN1CCN(CC1)c1ccc2ccccc2n1	Preclinical
N-MPPP	opioid receptor agonist				Tocris, Tocris, Tocris, Tocris	97.35	CN([C@H](CN1CCCC1)c1ccccc1)C(=O)Cc1ccccc1, CN([C@H](CN1CCCC1)c1ccccc1)C(=O)Cc1ccccc1, CN([C@H](CN1CCCC1)c1ccccc1)C(=O)Cc1ccccc1, CN([C@H](CN1CCCC1)c1ccccc1)C(=O)Cc1ccccc1	Preclinical
N-oxydiethylenebenzothiazole-2-sulfenamide					Sigma, Enamine	3.71	C1CN(CCO1)Sc1nc2ccccc2s1, C1CN(CCO1)Sc1nc2ccccc2s1	Preclinical
N-salicoylaminophenol	ribonucleotide reductase inhibitor				CombiBlocks	99.07	Oc1ccc(NC(=O)c2ccccc2O)cc1	Phase 1/Phase 2
NAB-2	ubiquitin ligase transport promoter	NEDD4			Tocris, Tocris, Tocris	99.23	Cc1ccc(C)c(c1)-n1cnc2cc(ccc12)C(=O)NCc1ccccc1Cl, Cc1ccc(C)c(c1)-n1cnc2cc(ccc12)C(=O)NCc1ccccc1Cl, Cc1ccc(C)c(c1)-n1cnc2cc(ccc12)C(=O)NCc1ccccc1Cl	Preclinical
nabumetone	cyclooxygenase inhibitor	PTGS1, PTGS2	rheumatology	rheumatoid arthritis, osteoarthritis	MicroSource, MedChemEx, MedChemEx, Selleck	99.57	COc1ccc2cc(CCC(C)=O)ccc2c1, COc1ccc2cc(CCC(C)=O)ccc2c1, COc1ccc2cc(CCC(C)=O)ccc2c1, COc1ccc2cc(CCC(C)=O)ccc2c1	Launched
nadide	free radical scavenger	AHCY, AKR1A1, ALDH2, BLVRA, DHPS, DLD, GALE, HMGCR, HSD17B1, HSD17B4, IMPDH2, MGAM, P2RY11, SORD, TRPM2			Selleck, MicroSource, MicroSource	87.7	NC(=O)c1ccc[n+](c1)[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)n2cnc3c(N)ncnc23)[C@@H](O)[C@H]1O |a:9,11,23,25,26,28,40,42,&1:14,&2:18|, NC(=O)c1ccc[n+](c1)[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)n2cnc3c(N)ncnc23)[C@@H](O)[C@H]1O |a:9,11,23,25,26,28,40,42,&1:14,&2:18|, NC(=O)c1ccc[n+](c1)[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)n2cnc3c(N)ncnc23)[C@@H](O)[C@H]1O |a:9,11,23,25,26,28,40,42,&1:14,&2:18|	Launched
nadifloxacin	bacterial DNA gyrase inhibitor		dermatology, infectious disease	acne vulgaris (AV), skin infections	MicroSource, MedChemEx, Selleck	99.02	C[C@H]1CCc2c(N3CCC(O)CC3)c(F)cc3c2n1cc(C(O)=O)c3=O |&1:1,r|, C[C@H]1CCc2c(N3CCC(O)CC3)c(F)cc3c2n1cc(C(O)=O)c3=O |&1:1,r|, C[C@H]1CCc2c(N3CCC(O)CC3)c(F)cc3c2n1cc(C(O)=O)c3=O |&1:1,r|	Launched
nadolol	adrenergic receptor antagonist	ADRB1, ADRB2, ADRB3	cardiology	angina pectoris, hypertension	MicroSource, Sigma	63.89	CC(C)(C)NC[C@@H](O)COc1cccc2C[C@@H](O)[C@@H](O)Cc12 |a:16,18,&1:6|, CC(C)(C)NC[C@@H](O)COc1cccc2C[C@@H](O)[C@@H](O)Cc12 |a:16,18,&1:6|	Launched
NADPH		DRD2, DRD3, DRD4, GHSR, HTR2A, HTR2C				0		Preclinical
nafadotride	dopamine receptor antagonist	DRD2, DRD3, HTR1A			Tocris	86.99	CCCCN1CCC[C@@H]1CNC(=O)c1cc(C#N)c2ccccc2c1OC |&1:8,r|	Preclinical
nafamostat	serine protease inhibitor	ASIC1, ASIC2, ASIC3, C1R, PRSS1, TPSAB1, TRPM7	cardiology	anticoagulent	Tocris, Selleck, Selleck, Selleck	89.75	NC(=N)Nc1ccc(cc1)C(=O)Oc1ccc2cc(ccc2c1)C(N)=N, NC(=N)Nc1ccc(cc1)C(=O)Oc1ccc2cc(ccc2c1)C(N)=N, NC(=N)Nc1ccc(cc1)C(=O)Oc1ccc2cc(ccc2c1)C(N)=N, NC(=N)Nc1ccc(cc1)C(=O)Oc1ccc2cc(ccc2c1)C(N)=N	Launched
nafcillin	bacterial cell wall synthesis inhibitor	CYP1A2, CYP3A4, SLC22A6	infectious disease	gram-positive bacterial infections	MedChemEx, MicroSource, Selleck, Selleck	96.54	CCOc1ccc2ccccc2c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O, CCOc1ccc2ccccc2c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O, CCOc1ccc2ccccc2c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O, CCOc1ccc2ccccc2c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O	Launched
naftidrofuryl	adrenergic receptor antagonist		cardiology	claudication	MicroSource, MedChemEx, MedChemEx	94.28	CCN(CC)CCOC(=O)[C@@H](C[C@H]1CCCO1)Cc1cccc2ccccc12 |&1:10,&2:12|, CCN(CC)CCOC(=O)[C@@H](C[C@H]1CCCO1)Cc1cccc2ccccc12 |&1:10,&2:12|, CCN(CC)CCOC(=O)[C@@H](C[C@H]1CCCO1)Cc1cccc2ccccc12 |&1:10,&2:12|	Launched
naftifine	fungal squalene epoxidase inhibitor		infectious disease	tinea pedis, tinea cruris, tinea corporis	MicroSource, MicroSource, MicroSource, MicroSource, MedChemEx, Selleck	99.05	CN(C\C=C\c1ccccc1)Cc1cccc2ccccc12, CN(C\C=C\c1ccccc1)Cc1cccc2ccccc12, CN(C\C=C\c1ccccc1)Cc1cccc2ccccc12, CN(C\C=C\c1ccccc1)Cc1cccc2ccccc12, CN(C\C=C\c1ccccc1)Cc1cccc2ccccc12, CN(C\C=C\c1ccccc1)Cc1cccc2ccccc12	Launched
naftopidil	adrenergic receptor antagonist	ADRA1A	urology	benign prostatic hyperplasia (BPH)	Tocris, Tocris, Tocris	99.08	COc1ccccc1N1CCN(C[C@@H](O)COc2cccc3ccccc23)CC1 |&1:13|, COc1ccccc1N1CCN(C[C@@H](O)COc2cccc3ccccc23)CC1 |&1:13|, COc1ccccc1N1CCN(C[C@@H](O)COc2cccc3ccccc23)CC1 |&1:13|	Launched
nalbuphine	opioid receptor agonist, opioid receptor antagonist	OPRD1, OPRK1, OPRM1	neurology/psychiatry	pain relief	MicroSource, Enzo, Enzo, Sigma	98.22	O[C@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5O[C@@H]1[C@]2(CCN3CC1CCC1)c45, O[C@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5O[C@@H]1[C@]2(CCN3CC1CCC1)c45, O[C@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5O[C@@H]1[C@]2(CCN3CC1CCC1)c45, O[C@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5O[C@@H]1[C@]2(CCN3CC1CCC1)c45	Launched
nalfurafine	opioid receptor agonist	OPRK1, OPRM1	nephrology	uremic pruritus	MedChemEx, MedChemEx	97.5	CN([C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5O[C@@H]1[C@]2(CCN3CC1CC1)c45)C(=O)\C=C\c1ccoc1, CN([C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5O[C@@H]1[C@]2(CCN3CC1CC1)c45)C(=O)\C=C\c1ccoc1	Launched
nalidixic-acid	bacterial DNA gyrase inhibitor		infectious disease	urinary tract infections	MedChemEx, MicroSource, Selleck	97.94	CCn1cc(C(O)=O)c(=O)c2ccc(C)nc12, CCn1cc(C(O)=O)c(=O)c2ccc(C)nc12, CCn1cc(C(O)=O)c(=O)c2ccc(C)nc12	Launched
nalmefene	opioid receptor antagonist	OPRD1, OPRK1, OPRM1	pulmonary	respiratory depression	Tocris, Tocris, Tocris, Selleck	97.66	Oc1ccc2C[C@H]3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)C(=C)CC[C@@]35O, Oc1ccc2C[C@H]3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)C(=C)CC[C@@]35O, Oc1ccc2C[C@H]3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)C(=C)CC[C@@]35O, Oc1ccc2C[C@H]3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)C(=C)CC[C@@]35O	Launched
naloxegol	opioid receptor antagonist	OPRM1	gastroenterology	constipation	MedChemEx, MedChemEx	96.9	COCCOCCOCCOCCOCCOCCOCCO[C@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5O[C@@H]1[C@]2(CCN3CC=C)c45, COCCOCCOCCOCCOCCOCCOCCO[C@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5O[C@@H]1[C@]2(CCN3CC=C)c45	Launched
naloxone	opioid receptor antagonist	CREB1, ESR1, OPRD1, OPRK1, OPRM1, TLR4	pulmonary	respiratory depression	Selleck, Selleck, Selleck, Tocris, MicroSource, MicroSource	89.5	Oc1ccc2C[C@H]3N(CC=C)CC[C@@]45[C@@H](Oc1c24)C(=O)CC[C@@]35O, Oc1ccc2C[C@H]3N(CC=C)CC[C@@]45[C@@H](Oc1c24)C(=O)CC[C@@]35O, Oc1ccc2C[C@H]3N(CC=C)CC[C@@]45[C@@H](Oc1c24)C(=O)CC[C@@]35O, Oc1ccc2C[C@H]3N(CC=C)CC[C@@]45[C@@H](Oc1c24)C(=O)CC[C@@]35O, Oc1ccc2C[C@H]3N(CC=C)CC[C@@]45[C@@H](Oc1c24)C(=O)CC[C@@]35O, Oc1ccc2C[C@H]3N(CC=C)CC[C@@]45[C@@H](Oc1c24)C(=O)CC[C@@]35O	Launched
naloxone-benzoylhydrazone	opioid receptor antagonist	OPRK1, OPRM1			Tocris, Tocris, Tocris, Tocris	80.29	Oc1ccc2C[C@H]3N(CC=C)CC[C@@]45[C@@H](Oc1c24)\C(CC[C@@]35O)=N\NC(=O)c1ccccc1, Oc1ccc2C[C@H]3N(CC=C)CC[C@@]45[C@@H](Oc1c24)\C(CC[C@@]35O)=N\NC(=O)c1ccccc1, Oc1ccc2C[C@H]3N(CC=C)CC[C@@]45[C@@H](Oc1c24)\C(CC[C@@]35O)=N\NC(=O)c1ccccc1, Oc1ccc2C[C@H]3N(CC=C)CC[C@@]45[C@@H](Oc1c24)\C(CC[C@@]35O)=N\NC(=O)c1ccccc1	Preclinical
naltrexone	opioid receptor antagonist	OPRD1, OPRK1, OPRM1, SIGMAR1	neurology/psychiatry	abstinence from alcohol	MicroSource, Tocris, Selleck, Selleck	93.54	Oc1ccc2C[C@H]3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)C(=O)CC[C@@]35O, Oc1ccc2C[C@H]3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)C(=O)CC[C@@]35O, Oc1ccc2C[C@H]3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)C(=O)CC[C@@]35O, Oc1ccc2C[C@H]3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)C(=O)CC[C@@]35O	Launched
naltriben	opioid receptor antagonist	OPRD1, OPRK1, OPRM1			Tocris	94.03	Oc1ccc2C[C@H]3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)c1oc2ccccc2c1C[C@@]35O	Preclinical
naltrindole	opioid receptor antagonist	OPRD1, OPRK1, OPRM1			Tocris	92.02	Oc1ccc2C[C@H]3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)c1[nH]c2ccccc2c1C[C@@]35O	Preclinical
Nampt-IN-1					MedChemEx	97.45	CC(C)(O)CS(=O)(=O)Nc1ccc2CN(CCc2c1)C(=O)COc1cccnc1	Preclinical
NAN-190	serotonin receptor agonist	ADRA1A, ADRA1B, ADRA1D, HTR1A, HTR1F			Tocris, Tocris	95.35	COc1ccccc1N1CCN(CCCCN2C(=O)c3ccccc3C2=O)CC1, COc1ccccc1N1CCN(CCCCN2C(=O)c3ccccc3C2=O)CC1	Preclinical
nanchangmycin	other antibiotic				Selleck, Selleck, Selleck, Selleck	98.79	CO[C@H]1CC[C@@H](O[C@H]2C[C@@H](O[C@]3(O[C@H](C[C@@H]3C)[C@H]3O[C@@](O)(CO)[C@H](C)C[C@@H]3C)[C@@H]2C)[C@]2(C)CC[C@]3(C[C@H](O)[C@@H](C)[C@H](O3)[C@@H](C)\C=C(/C)C(=O)[C@H](C)C[C@H](C)C(O)=O)O2)O[C@@H]1C |a:2,7,11,13,15,19,23,26,28,30,34,36,38,40,42,49,52,59,&1:5,&2:9,&3:17|, CO[C@H]1CC[C@@H](O[C@H]2C[C@@H](O[C@]3(O[C@H](C[C@@H]3C)[C@H]3O[C@@](O)(CO)[C@H](C)C[C@@H]3C)[C@@H]2C)[C@]2(C)CC[C@]3(C[C@H](O)[C@@H](C)[C@H](O3)[C@@H](C)\C=C(/C)C(=O)[C@H](C)C[C@H](C)C(O)=O)O2)O[C@@H]1C |a:2,7,11,13,15,19,23,26,28,30,34,36,38,40,42,49,52,59,&1:5,&2:9,&3:17|, CO[C@H]1CC[C@@H](O[C@H]2C[C@@H](O[C@]3(O[C@H](C[C@@H]3C)[C@H]3O[C@@](O)(CO)[C@H](C)C[C@@H]3C)[C@@H]2C)[C@]2(C)CC[C@]3(C[C@H](O)[C@@H](C)[C@H](O3)[C@@H](C)\C=C(/C)C(=O)[C@H](C)C[C@H](C)C(O)=O)O2)O[C@@H]1C |a:2,7,11,13,15,19,23,26,28,30,34,36,38,40,42,49,52,59,&1:5,&2:9,&3:17|, CO[C@H]1CC[C@@H](O[C@H]2C[C@@H](O[C@]3(O[C@H](C[C@@H]3C)[C@H]3O[C@@](O)(CO)[C@H](C)C[C@@H]3C)[C@@H]2C)[C@]2(C)CC[C@]3(C[C@H](O)[C@@H](C)[C@H](O3)[C@@H](C)\C=C(/C)C(=O)[C@H](C)C[C@H](C)C(O)=O)O2)O[C@@H]1C |a:2,7,11,13,15,19,23,26,28,30,34,36,38,40,42,49,52,59,&1:5,&2:9,&3:17|	Preclinical
napabucasin	STAT inhibitor	STAT3			MedChemEx, MedChemEx, MedChemEx, Tocris	91.09	CC(=O)c1cc2c(o1)C(=O)c1ccccc1C2=O, CC(=O)c1cc2c(o1)C(=O)c1ccccc1C2=O, CC(=O)c1cc2c(o1)C(=O)c1ccccc1C2=O, CC(=O)c1cc2c(o1)C(=O)c1ccccc1C2=O	Phase 3
napamezole	adrenergic receptor antagonist, monoamine reuptake inhibitor				Sigma	74.76	C(C1=NCCN1)C1=Cc2ccccc2CC1 |t:1,7|	Preclinical
naphazoline	adrenergic receptor agonist	ADRA1A, ADRA2A	ophthalmology	eye irritation	MedChemEx, MedChemEx, Selleck, MicroSource	98.84	C(C1=NCCN1)c1cccc2ccccc12 |t:1|, C(C1=NCCN1)c1cccc2ccccc12 |t:1|, C(C1=NCCN1)c1cccc2ccccc12 |t:1|, C(C1=NCCN1)c1cccc2ccccc12 |t:1|	Launched
naphthoquine-phosphate	antimalarial agent		infectious disease	malaria	MedChemEx, MedChemEx, MedChemEx	79.04	CC(C)(C)NCc1cc(Nc2ccnc3cc(Cl)ccc23)c2CCCCc2c1O, CC(C)(C)NCc1cc(Nc2ccnc3cc(Cl)ccc23)c2CCCCc2c1O, CC(C)(C)NCc1cc(Nc2ccnc3cc(Cl)ccc23)c2CCCCc2c1O	Launched
napirimus	immunosuppressant				Enamine	98.99	Cn1cc(cc1C(O)=O)C(=O)c1cccc2ccccc12	Phase 1
naproxen	cyclooxygenase inhibitor	PTGS1, PTGS2	neurology/psychiatry, rheumatology, dental, otolaryngology, endocrinology	pain relief, rheumatoid arthritis, headache, toothache, backache, muscle pain, common cold, fever	Selleck, Selleck, Tocris, Selleck, MicroSource	99.66	COc1ccc2cc(ccc2c1)[C@H](C)C(O)=O, COc1ccc2cc(ccc2c1)[C@H](C)C(O)=O, COc1ccc2cc(ccc2c1)[C@H](C)C(O)=O, COc1ccc2cc(ccc2c1)[C@H](C)C(O)=O, COc1ccc2cc(ccc2c1)[C@H](C)C(O)=O	Launched
naquotinib	EGFR inhibitor				MedChemEx	89.03	CCc1nc(C(N)=O)c(Nc2ccc(cc2)N2CCC(CC2)N2CCN(C)CC2)nc1O[C@@H]1CCN(C1)C(=O)C=C	Phase 3
narasin	antiprotozoal agent		infectious disease	coccidiosis	MicroSource, MicroSource, MicroSource, MicroSource	100	CC[C@H]([C@@H]1O[C@@H]([C@@H](C)[C@H](O)[C@H](C)C(=O)[C@H](CC)[C@H]2O[C@@]3(O[C@@]4(CC[C@](C)(O4)[C@H]4CC[C@](O)(CC)[C@H](C)O4)[C@H](O)C=C3)[C@H](C)C[C@@H]2C)[C@@H](C)C[C@H]1C)C(O)=O |a:2,3,5,6,8,10,14,17,19,21,24,30,34,37,41,44,46,49,&1:27,c:41|, CC[C@H]([C@@H]1O[C@@H]([C@@H](C)[C@H](O)[C@H](C)C(=O)[C@H](CC)[C@H]2O[C@@]3(O[C@@]4(CC[C@](C)(O4)[C@H]4CC[C@](O)(CC)[C@H](C)O4)[C@H](O)C=C3)[C@H](C)C[C@@H]2C)[C@@H](C)C[C@H]1C)C(O)=O |a:2,3,5,6,8,10,14,17,19,21,24,30,34,37,41,44,46,49,&1:27,c:41|, CC[C@H]([C@@H]1O[C@@H]([C@@H](C)[C@H](O)[C@H](C)C(=O)[C@H](CC)[C@H]2O[C@@]3(O[C@@]4(CC[C@](C)(O4)[C@H]4CC[C@](O)(CC)[C@H](C)O4)[C@H](O)C=C3)[C@H](C)C[C@@H]2C)[C@@H](C)C[C@H]1C)C(O)=O |a:2,3,5,6,8,10,14,17,19,21,24,30,34,37,41,44,46,49,&1:27,c:41|, CC[C@H]([C@@H]1O[C@@H]([C@@H](C)[C@H](O)[C@H](C)C(=O)[C@H](CC)[C@H]2O[C@@]3(O[C@@]4(CC[C@](C)(O4)[C@H]4CC[C@](O)(CC)[C@H](C)O4)[C@H](O)C=C3)[C@H](C)C[C@@H]2C)[C@@H](C)C[C@H]1C)C(O)=O |a:2,3,5,6,8,10,14,17,19,21,24,30,34,37,41,44,46,49,&1:27,c:41|	Launched
naratriptan	serotonin receptor agonist	HTR1A, HTR1B, HTR1D, HTR1E, HTR1F	neurology/psychiatry	migraine headache	MedChemEx, Selleck, Selleck	98.58	CNS(=O)(=O)CCc1ccc2[nH]cc(C3CCN(C)CC3)c2c1, CNS(=O)(=O)CCc1ccc2[nH]cc(C3CCN(C)CC3)c2c1, CNS(=O)(=O)CCc1ccc2[nH]cc(C3CCN(C)CC3)c2c1	Launched
naringenin	aromatase inhibitor, TRPV antagonist	CYP19A1, CYP1B1, ESR2, GLO1, HSD17B1			MedChemEx, Selleck	96.8	Oc1ccc(cc1)[C@@H]1CC(=O)c2c(O)cc(O)cc2O1, Oc1ccc(cc1)[C@@H]1CC(=O)c2c(O)cc(O)cc2O1	Phase 1
naringeninic-acid		HCAR2, PTGR1			Sigma, Vitas-M	97.59	OC(=O)\C=C\c1ccc(O)cc1, OC(=O)\C=C\c1ccc(O)cc1	Phase 1
naringin	cytochrome P450 inhibitor	SLCO1A2			MedChemEx, Selleck	94.5	C[C@@H]1O[C@@H](O[C@@H]2[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]2Oc2cc(O)c3C(=O)C[C@H](Oc3c2)c2ccc(O)cc2)[C@H](O)[C@H](O)[C@H]1O, C[C@@H]1O[C@@H](O[C@@H]2[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]2Oc2cc(O)c3C(=O)C[C@H](Oc3c2)c2ccc(O)cc2)[C@H](O)[C@H](O)[C@H]1O	Preclinical
naringin-dihydrochalcone	cytochrome P450 inhibitor				MedChemEx	96.69	C[C@@H]1O[C@@H](O[C@@H]2[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]2Oc2cc(O)c(C(=O)CCc3ccc(O)cc3)c(O)c2)[C@H](O)[C@H](O)[C@H]1O	Preclinical
narlaprevir	HCV inhibitor				MedChemEx, MedChemEx, MedChemEx, MedChemEx	95.2	CCCC[C@H](NC(=O)[C@@H]1[C@@H]2[C@H](CN1C(=O)[C@@H](NC(=O)NC1(CS(=O)(=O)C(C)(C)C)CCCCC1)C(C)(C)C)C2(C)C)C(=O)C(=O)NC1CC1, CCCC[C@H](NC(=O)[C@@H]1[C@@H]2[C@H](CN1C(=O)[C@@H](NC(=O)NC1(CS(=O)(=O)C(C)(C)C)CCCCC1)C(C)(C)C)C2(C)C)C(=O)C(=O)NC1CC1, CCCC[C@H](NC(=O)[C@@H]1[C@@H]2[C@H](CN1C(=O)[C@@H](NC(=O)NC1(CS(=O)(=O)C(C)(C)C)CCCCC1)C(C)(C)C)C2(C)C)C(=O)C(=O)NC1CC1, CCCC[C@H](NC(=O)[C@@H]1[C@@H]2[C@H](CN1C(=O)[C@@H](NC(=O)NC1(CS(=O)(=O)C(C)(C)C)CCCCC1)C(C)(C)C)C2(C)C)C(=O)C(=O)NC1CC1	Phase 3
NAS-181	serotonin receptor antagonist	HTR1B			Tocris	87.91	C(Oc1cccc2C=C(CN3CCOCC3)COc12)[C@H]1CNCCO1 |t:7|	Preclinical
nastorazepide	CCK receptor antagonist	CCKBR			MedChemEx, Adooq, MedChemEx	98.62	CC(C)(C)C(=O)CN1c2ccccc2N(C[C@@H](NC(=O)Nc2cccc(c2)C(O)=O)C1=O)C1CCCCC1, CC(C)(C)C(=O)CN1c2ccccc2N(C[C@@H](NC(=O)Nc2cccc(c2)C(O)=O)C1=O)C1CCCCC1, CC(C)(C)C(=O)CN1c2ccccc2N(C[C@@H](NC(=O)Nc2cccc(c2)C(O)=O)C1=O)C1CCCCC1	Phase 2
natamycin	fungal ergosterol inhibitor		ophthalmology, infectious disease	conjunctivitis, fungal keratosis, blepharitis	MicroSource, MedChemEx, MedChemEx, Sigma, Selleck, Selleck	91.43	C[C@H]1O[C@@H](O[C@@H]2C[C@@H]3O[C@@](O)(C[C@H](O)[C@H]3C(O)=O)C[C@@H](O)C[C@H]3O[C@@H]3\C=C\C(=O)O[C@H](C)C\C=C\C=C\C=C\C=C\2)[C@@H](O)[C@@H](N)[C@@H]1O |t:27,35,37,39,41|, C[C@H]1O[C@@H](O[C@@H]2C[C@@H]3O[C@@](O)(C[C@H](O)[C@H]3C(O)=O)C[C@@H](O)C[C@H]3O[C@@H]3\C=C\C(=O)O[C@H](C)C\C=C\C=C\C=C\C=C\2)[C@@H](O)[C@@H](N)[C@@H]1O |t:27,35,37,39,41|, C[C@H]1O[C@@H](O[C@@H]2C[C@@H]3O[C@@](O)(C[C@H](O)[C@H]3C(O)=O)C[C@@H](O)C[C@H]3O[C@@H]3\C=C\C(=O)O[C@H](C)C\C=C\C=C\C=C\C=C\2)[C@@H](O)[C@@H](N)[C@@H]1O |t:27,35,37,39,41|, C[C@H]1O[C@@H](O[C@@H]2C[C@@H]3O[C@@](O)(C[C@H](O)[C@H]3C(O)=O)C[C@@H](O)C[C@H]3O[C@@H]3\C=C\C(=O)O[C@H](C)C\C=C\C=C\C=C\C=C\2)[C@@H](O)[C@@H](N)[C@@H]1O |t:27,35,37,39,41|, C[C@H]1O[C@@H](O[C@@H]2C[C@@H]3O[C@@](O)(C[C@H](O)[C@H]3C(O)=O)C[C@@H](O)C[C@H]3O[C@@H]3\C=C\C(=O)O[C@H](C)C\C=C\C=C\C=C\C=C\2)[C@@H](O)[C@@H](N)[C@@H]1O |t:27,35,37,39,41|, C[C@H]1O[C@@H](O[C@@H]2C[C@@H]3O[C@@](O)(C[C@H](O)[C@H]3C(O)=O)C[C@@H](O)C[C@H]3O[C@@H]3\C=C\C(=O)O[C@H](C)C\C=C\C=C\C=C\C=C\2)[C@@H](O)[C@@H](N)[C@@H]1O |t:27,35,37,39,41|	Launched
nateglinide	insulin secretagogue	ABCC8, KCNJ10, KCNJ11, PPARG	endocrinology	diabetes mellitus	Tocris, Tocris, Tocris, Selleck, Selleck	98.07	CC(C)[C@H]1CC[C@@H](CC1)C(=O)N[C@H](Cc1ccccc1)C(O)=O, CC(C)[C@H]1CC[C@@H](CC1)C(=O)N[C@H](Cc1ccccc1)C(O)=O, CC(C)[C@H]1CC[C@@H](CC1)C(=O)N[C@H](Cc1ccccc1)C(O)=O, CC(C)[C@H]1CC[C@@H](CC1)C(=O)N[C@H](Cc1ccccc1)C(O)=O, CC(C)[C@H]1CC[C@@H](CC1)C(=O)N[C@H](Cc1ccccc1)C(O)=O	Launched
NAV-26	voltage-gated sodium channel blocker	SCN9A			Tocris, Tocris, Tocris	97.97	FC(F)(F)Oc1ccc(CNC(=O)[C@H]2N(C3CCOCC3)C(=O)c3ccccc23)cc1 |&1:13,r|, FC(F)(F)Oc1ccc(CNC(=O)[C@H]2N(C3CCOCC3)C(=O)c3ccccc23)cc1 |&1:13,r|, FC(F)(F)Oc1ccc(CNC(=O)[C@H]2N(C3CCOCC3)C(=O)c3ccccc23)cc1 |&1:13,r|	Preclinical
navarixin	CC chemokine receptor antagonist	CXCR1, CXCR2			MedChemEx, MedChemEx, MedChemEx	93.85	CC[C@@H](Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1ccc(C)o1, CC[C@@H](Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1ccc(C)o1, CC[C@@H](Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1ccc(C)o1	Phase 2
navitoclax	BCL inhibitor	BCL2, BCL2L1, BCL2L2			MedChemEx, MedChemEx, MedChemEx, Selleck, Selleck, Selleck, Selleck, Selleck	97	CC1(C)CCC(=C(CN2CCN(CC2)c2ccc(cc2)C(=O)NS(=O)(=O)c2ccc(N[C@H](CCN3CCOCC3)CSc3ccccc3)c(c2)S(=O)(=O)C(F)(F)F)C1)c1ccc(Cl)cc1 |t:5|, CC1(C)CCC(=C(CN2CCN(CC2)c2ccc(cc2)C(=O)NS(=O)(=O)c2ccc(N[C@H](CCN3CCOCC3)CSc3ccccc3)c(c2)S(=O)(=O)C(F)(F)F)C1)c1ccc(Cl)cc1 |t:5|, CC1(C)CCC(=C(CN2CCN(CC2)c2ccc(cc2)C(=O)NS(=O)(=O)c2ccc(N[C@H](CCN3CCOCC3)CSc3ccccc3)c(c2)S(=O)(=O)C(F)(F)F)C1)c1ccc(Cl)cc1 |t:5|, CC1(C)CCC(=C(CN2CCN(CC2)c2ccc(cc2)C(=O)NS(=O)(=O)c2ccc(N[C@H](CCN3CCOCC3)CSc3ccccc3)c(c2)S(=O)(=O)C(F)(F)F)C1)c1ccc(Cl)cc1 |t:5|, CC1(C)CCC(=C(CN2CCN(CC2)c2ccc(cc2)C(=O)NS(=O)(=O)c2ccc(N[C@H](CCN3CCOCC3)CSc3ccccc3)c(c2)S(=O)(=O)C(F)(F)F)C1)c1ccc(Cl)cc1 |t:5|, CC1(C)CCC(=C(CN2CCN(CC2)c2ccc(cc2)C(=O)NS(=O)(=O)c2ccc(N[C@H](CCN3CCOCC3)CSc3ccccc3)c(c2)S(=O)(=O)C(F)(F)F)C1)c1ccc(Cl)cc1 |t:5|, CC1(C)CCC(=C(CN2CCN(CC2)c2ccc(cc2)C(=O)NS(=O)(=O)c2ccc(N[C@H](CCN3CCOCC3)CSc3ccccc3)c(c2)S(=O)(=O)C(F)(F)F)C1)c1ccc(Cl)cc1 |t:5|, CC1(C)CCC(=C(CN2CCN(CC2)c2ccc(cc2)C(=O)NS(=O)(=O)c2ccc(N[C@H](CCN3CCOCC3)CSc3ccccc3)c(c2)S(=O)(=O)C(F)(F)F)C1)c1ccc(Cl)cc1 |t:5|	Phase 2
naxagolide	dopamine receptor agonist				Adooq	92.36	CCCN1CCO[C@H]2[C@H]1CCc1ccc(O)cc21	Phase 3
NB-001	antiviral				Sigma	93.1	Nc1ncnc2n(CCNCCCCCO)cnc12	Preclinical
NBI-27914	corticotropin releasing factor receptor antagonist	CRHR1			Tocris, Tocris, Tocris, Tocris	97.86	CCCN(CC1CC1)c1nc(C)nc(Nc2c(Cl)cc(Cl)cc2Cl)c1Cl, CCCN(CC1CC1)c1nc(C)nc(Nc2c(Cl)cc(Cl)cc2Cl)c1Cl, CCCN(CC1CC1)c1nc(C)nc(Nc2c(Cl)cc(Cl)cc2Cl)c1Cl, CCCN(CC1CC1)c1nc(C)nc(Nc2c(Cl)cc(Cl)cc2Cl)c1Cl	Preclinical
NBI-74330-(+/-)	CC chemokine receptor antagonist	CXCR3			Tocris, Tocris	98.26	CCOc1ccc(cc1)-n1c(nc2ncccc2c1=O)[C@@H](C)N(Cc1cccnc1)C(=O)Cc1ccc(F)c(c1)C(F)(F)F |&1:20,r|, CCOc1ccc(cc1)-n1c(nc2ncccc2c1=O)[C@@H](C)N(Cc1cccnc1)C(=O)Cc1ccc(F)c(c1)C(F)(F)F |&1:20,r|	Preclinical
NBI-98782	vesicular monoamine transporter inhibitor				MedChemEx	85.41	COc1cc2CCN3C[C@@H](CC(C)C)[C@H](O)C[C@@H]3c2cc1OC	Preclinical
NBQX	glutamate receptor antagonist	GRIA1, GRIA2, GRIA3, GRIA4, GRIK1, GRIN1, GRIN2A, GRIN2B			Tocris, Tocris, Tocris, Tocris, Tocris, Tocris	98.85	NS(=O)(=O)c1cccc2c1c(cc1[nH]c(=O)c(=O)[nH]c21)[N+]([O-])=O, NS(=O)(=O)c1cccc2c1c(cc1[nH]c(=O)c(=O)[nH]c21)[N+]([O-])=O, NS(=O)(=O)c1cccc2c1c(cc1[nH]c(=O)c(=O)[nH]c21)[N+]([O-])=O, NS(=O)(=O)c1cccc2c1c(cc1[nH]c(=O)c(=O)[nH]c21)[N+]([O-])=O, NS(=O)(=O)c1cccc2c1c(cc1[nH]c(=O)c(=O)[nH]c21)[N+]([O-])=O, NS(=O)(=O)c1cccc2c1c(cc1[nH]c(=O)c(=O)[nH]c21)[N+]([O-])=O	Preclinical
NCS-382	GABA receptor antagonist	GABBR1, GABBR2, SLC52A2			Tocris	96.9	O[C@@H]1c2ccccc2CCC\C1=C/C(O)=O |&1:1|	Preclinical
NCX-1015	interleukin sythesis stimulator				MedChemEx	16.19	C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1CC[C@]2(O)C(=O)COC(=O)c1ccc(CO[N+]([O-])=O)cc1 |c:13,t:9|	Preclinical
NDD-094					Enamine	91.14	Cc1nccn1Cc1ccccn1	Preclinical
NDT-9513727	complement antagonist	C5AR1			Tocris, Tocris	96.42	CCCCn1c(CN(Cc2ccc3OCOc3c2)Cc2ccc3OCOc3c2)c(nc1-c1ccccc1)-c1ccccc1, CCCCn1c(CN(Cc2ccc3OCOc3c2)Cc2ccc3OCOc3c2)c(nc1-c1ccccc1)-c1ccccc1	Preclinical
NE-100	sigma receptor antagonist	SIGMAR1			Tocris, Tocris, Tocris	92.52	CCCN(CCC)CCc1ccc(OC)c(OCCc2ccccc2)c1, CCCN(CCC)CCc1ccc(OC)c(OCCc2ccccc2)c1, CCCN(CCC)CCc1ccc(OC)c(OCCc2ccccc2)c1	Phase 2
nebivolol	adrenergic receptor antagonist	ADRB1	cardiology	hypertension	MedChemEx, MedChemEx	96.86	O[C@H](CNC[C@@H](O)[C@@H]1CCc2cc(F)ccc2O1)[C@H]1CCc2cc(F)ccc2O1 |&1:1,5,7,18|, O[C@H](CNC[C@@H](O)[C@@H]1CCc2cc(F)ccc2O1)[C@H]1CCc2cc(F)ccc2O1 |&1:1,5,7,18|	Launched
nebracetam	acetylcholine receptor agonist	CHRM1			Enamine, Enamine	98.57	NC[C@H]1CN(Cc2ccccc2)C(=O)C1 |&1:2|, NC[C@H]1CN(Cc2ccccc2)C(=O)C1 |&1:2|	Phase 3
NECA	adenosine receptor agonist	ADORA1, ADORA2A, ADORA2B, ADORA3			Tocris, Tocris, Tocris, Tocris	98.69	CCNC(=O)[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)ncnc12, CCNC(=O)[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)ncnc12, CCNC(=O)[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)ncnc12, CCNC(=O)[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)ncnc12	Launched
necrostatin-1	RIPK inhibitor	RIPK1			Tocris, Selleck, Selleck, Tocris	94.54	CN1C(=S)N[C@@H](Cc2c[nH]c3ccccc23)C1=O |r|, CN1C(=S)N[C@@H](Cc2c[nH]c3ccccc23)C1=O |r|, CN1C(=S)N[C@@H](Cc2c[nH]c3ccccc23)C1=O |r|, CN1C(=S)N[C@@H](Cc2c[nH]c3ccccc23)C1=O |r|	Preclinical
necrostatin-2	necroptosis inhibitor, RIPK inhibitor	RIPK2			MedChemEx, MedChemEx	98.11	CN1C(=O)N[C@H](Cc2c[nH]c3c(Cl)cccc23)C1=O, CN1C(=O)N[C@H](Cc2c[nH]c3c(Cl)cccc23)C1=O	Preclinical
nedaplatin	DNA inhibitor		oncology	non-small cell lung cancer (NSCLC), small cell lung cancer, esophageal cancer	MedChemEx, MedChemEx, MedChemEx	0	N[Pt]1(N)OC=C(O)O1 |t:4|, N[Pt]1(N)OC=C(O)O1 |t:4|, N[Pt]1(N)OC=C(O)O1 |t:4|	Launched
nedocromil	histamine receptor antagonist	CYSLTR1, CYSLTR2, FPR1, HSP90AA1, PTGDR	neurology/psychiatry, ophthalmology	itching, conjunctivitis	MedChemEx, MedChemEx, MedChemEx	91.97	CCCc1c2oc(cc(=O)c2cc2c1n(CC)c(cc2=O)C(O)=O)C(O)=O, CCCc1c2oc(cc(=O)c2cc2c1n(CC)c(cc2=O)C(O)=O)C(O)=O, CCCc1c2oc(cc(=O)c2cc2c1n(CC)c(cc2=O)C(O)=O)C(O)=O	Launched
nefazodone	adrenergic inhibitor, norepinephrine reuptake inhibitor, serotonin receptor antagonist, serotonin reuptake inhibitor	ADRA1A, ADRA1B, ADRA2A, CYP3A4, HTR1A, HTR2A, HTR2C, SLC6A2, SLC6A3, SLC6A4			MicroSource, MicroSource, Tocris, Tocris	97.66	CCc1nn(CCCN2CCN(CC2)c2cccc(Cl)c2)c(=O)n1CCOc1ccccc1, CCc1nn(CCCN2CCN(CC2)c2cccc(Cl)c2)c(=O)n1CCOc1ccccc1, CCc1nn(CCCN2CCN(CC2)c2cccc(Cl)c2)c(=O)n1CCOc1ccccc1, CCc1nn(CCCN2CCN(CC2)c2cccc(Cl)c2)c(=O)n1CCOc1ccccc1	Withdrawn
nefiracetam	acetylcholine receptor agonist, benzodiazepine receptor agonist	CHRM1			Tocris, MicroSource, Selleck, Selleck	99.27	Cc1cccc(C)c1NC(=O)CN1CCCC1=O, Cc1cccc(C)c1NC(=O)CN1CCCC1=O, Cc1cccc(C)c1NC(=O)CN1CCCC1=O, Cc1cccc(C)c1NC(=O)CN1CCCC1=O	Phase 3
nefopam	cyclooxygenase inhibitor		neurology/psychiatry	pain relief	Selleck, Selleck	98.62	CN1CCO[C@@H](c2ccccc2)c2ccccc2C1 |&1:5|, CN1CCO[C@@H](c2ccccc2)c2ccccc2C1 |&1:5|	Launched
nelarabine	DNA synthesis inhibitor, T cell inhibitor	POLA1	hematologic malignancy	acute lymphoblastic leukemia (ALL)	Tocris, Tocris, Selleck	98.83	COc1nc(N)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O, COc1nc(N)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O, COc1nc(N)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O	Launched
nelfinavir	HIV protease inhibitor	CYP1A2, CYP2B6, CYP2C19, CYP2C9, CYP2D6, CYP3A4, CYP3A7	infectious disease	human immunodeficiency virus (HIV-1)	Enzo, Enzo, Enzo, Enzo, Enzo, MedChemEx, MedChemEx	98.14	Cc1c(O)cccc1C(=O)N[C@@H](CSc1ccccc1)[C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C, Cc1c(O)cccc1C(=O)N[C@@H](CSc1ccccc1)[C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C, Cc1c(O)cccc1C(=O)N[C@@H](CSc1ccccc1)[C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C, Cc1c(O)cccc1C(=O)N[C@@H](CSc1ccccc1)[C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C, Cc1c(O)cccc1C(=O)N[C@@H](CSc1ccccc1)[C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C, Cc1c(O)cccc1C(=O)N[C@@H](CSc1ccccc1)[C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C, Cc1c(O)cccc1C(=O)N[C@@H](CSc1ccccc1)[C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C	Launched
nelociguat	guanylate cyclase stimulant				MedChemEx	95.75	COC(=O)Nc1c(N)nc(nc1N)-c1nn(Cc2ccccc2F)c2ncccc12	Preclinical
nelotanserin	serotonin receptor inverse agonist				MedChemEx	96.92	COc1ccc(NC(=O)Nc2ccc(F)cc2F)cc1-c1c(Br)cnn1C	Phase 2
nemazoline	adrenergic receptor agonist, adrenergic receptor antagonist				Enamine	72.14	Nc1c(Cl)cc(C=C2NCCN2)cc1Cl	Phase 2
nemiralisib					MedChemEx	97.29	CC(C)N1CCN(Cc2cnc(o2)-c2cc(cc3[nH]ncc23)-c2cccc3[nH]ccc23)CC1	Phase 2
nemonapride	dopamine receptor antagonist	DRD2, DRD3, DRD4	neurology/psychiatry	schizophrenia	Tocris	96.96	CNc1cc(OC)c(cc1Cl)C(=O)N[C@@H]1CCN(Cc2ccccc2)[C@@H]1C |&1:14,25|	Launched
nemorexant	orexin receptor antagonist				MedChemEx	98.29	COc1ccc(c(c1)C(=O)N1CCC[C@@]1(C)c1nc2ccc(Cl)c(C)c2[nH]1)-n1nccn1	Preclinical
nemorubicin	topoisomerase inhibitor	TOP1, TOP2A			MedChemEx, MedChemEx, MedChemEx, MedChemEx	90.61	CO[C@@H]1CN(CCO1)[C@H]1C[C@H](O[C@H]2C[C@@](O)(Cc3c(O)c4C(=O)c5cccc(OC)c5C(=O)c4c(O)c23)C(=O)CO)O[C@@H](C)[C@H]1O, CO[C@@H]1CN(CCO1)[C@H]1C[C@H](O[C@H]2C[C@@](O)(Cc3c(O)c4C(=O)c5cccc(OC)c5C(=O)c4c(O)c23)C(=O)CO)O[C@@H](C)[C@H]1O, CO[C@@H]1CN(CCO1)[C@H]1C[C@H](O[C@H]2C[C@@](O)(Cc3c(O)c4C(=O)c5cccc(OC)c5C(=O)c4c(O)c23)C(=O)CO)O[C@@H](C)[C@H]1O, CO[C@@H]1CN(CCO1)[C@H]1C[C@H](O[C@H]2C[C@@](O)(Cc3c(O)c4C(=O)c5cccc(OC)c5C(=O)c4c(O)c23)C(=O)CO)O[C@@H](C)[C@H]1O	Phase 2
neo-gilurytmal			cardiology	cardiac arrythmia	InterBioScreen, InterBioScreen	83.33	CCC[N@@+]12[C@H]3C[C@]45[C@@H](O)[C@@H]3[C@@H](C[C@@H]1[C@@H]4N(C)c1ccccc51)[C@H](CC)[C@H]2O |a:4,6,10,13,22,25,&1:3,&2:7,&3:9,&4:12|, CCC[N@@+]12[C@H]3C[C@]45[C@@H](O)[C@@H]3[C@@H](C[C@@H]1[C@@H]4N(C)c1ccccc51)[C@H](CC)[C@H]2O |a:4,6,10,13,22,25,&1:3,&2:7,&3:9,&4:12|	Launched
neohesperidin					MedChemEx	92.43	[H][C@@]1(O[C@@H]2[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]2Oc2cc(O)c3C(=O)C[C@H](Oc3c2)c2ccc(OC)c(O)c2)O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O	Preclinical
neohesperidin-dihydrochalcone					MedChemEx, Selleck, Selleck	94.52	COc1ccc(CCC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](O)[C@H]3O)cc2O)cc1O, COc1ccc(CCC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](O)[C@H]3O)cc2O)cc1O, COc1ccc(CCC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](O)[C@H]3O)cc2O)cc1O	Preclinical
neomycin	bacterial 30S ribosomal subunit inhibitor	CXCR4	infectious disease, gastroenterology	first-aid antibiotic, hepatic encephalopathy (HE), intra-abdominal infections	MedChemEx, Sigma, Selleck, MedChemEx, MicroSource, Selleck	0	NC[C@@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@@H](O[C@@H]3[C@@H](O)[C@H](N)C[C@H](N)[C@H]3O[C@H]3O[C@H](CN)[C@@H](O)[C@H](O)[C@H]3N)[C@@H]2O)[C@H](N)[C@@H](O)[C@@H]1O, NC[C@@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@@H](O[C@@H]3[C@@H](O)[C@H](N)C[C@H](N)[C@H]3O[C@H]3O[C@H](CN)[C@@H](O)[C@H](O)[C@H]3N)[C@@H]2O)[C@H](N)[C@@H](O)[C@@H]1O, NC[C@@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@@H](O[C@@H]3[C@@H](O)[C@H](N)C[C@H](N)[C@H]3O[C@H]3O[C@H](CN)[C@@H](O)[C@H](O)[C@H]3N)[C@@H]2O)[C@H](N)[C@@H](O)[C@@H]1O, NC[C@@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@@H](O[C@@H]3[C@@H](O)[C@H](N)C[C@H](N)[C@H]3O[C@H]3O[C@H](CN)[C@@H](O)[C@H](O)[C@H]3N)[C@@H]2O)[C@H](N)[C@@H](O)[C@@H]1O, NC[C@@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@@H](O[C@@H]3[C@@H](O)[C@H](N)C[C@H](N)[C@H]3O[C@H]3O[C@H](CN)[C@@H](O)[C@H](O)[C@H]3N)[C@@H]2O)[C@H](N)[C@@H](O)[C@@H]1O, NC[C@@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@@H](O[C@@H]3[C@@H](O)[C@H](N)C[C@H](N)[C@H]3O[C@H]3O[C@H](CN)[C@@H](O)[C@H](O)[C@H]3N)[C@@H]2O)[C@H](N)[C@@H](O)[C@@H]1O	Launched
neostigmine	acetylcholinesterase inhibitor	ACHE	neurology/psychiatry	myasthenia gravis	MedChemEx, Selleck, Selleck, MicroSource, MicroSource	98.23	CN(C)C(=O)Oc1cccc(c1)[N+](C)(C)C, CN(C)C(=O)Oc1cccc(c1)[N+](C)(C)C, CN(C)C(=O)Oc1cccc(c1)[N+](C)(C)C, CN(C)C(=O)Oc1cccc(c1)[N+](C)(C)C, CN(C)C(=O)Oc1cccc(c1)[N+](C)(C)C	Launched
nepafenac	cyclooxygenase inhibitor	PTGS1, PTGS2	ophthalmology	eye inflammation	Selleck	97.8	NC(=O)Cc1cccc(C(=O)c2ccccc2)c1N	Launched
nepicastat	dopamine beta hydroxylase inhibitor	DBH			MedChemEx, MedChemEx, Sigma	91.33	NCc1c[nH]c(=S)n1[C@H]1CCc2c(F)cc(F)cc2C1, NCc1c[nH]c(=S)n1[C@H]1CCc2c(F)cc(F)cc2C1, NCc1c[nH]c(=S)n1[C@H]1CCc2c(F)cc(F)cc2C1	Phase 2
neratinib	EGFR inhibitor	EGFR, ERBB2, KDR	oncology	breast cancer	MedChemEx, Selleck, Selleck, Selleck, Selleck, Selleck	90.47	CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C, CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C, CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C, CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C, CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C, CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C	Launched
nerbacadol	cyclooxygenase inhibitor				Enamine	85.08	Cc1oncc1C(=O)N1CCCCC1	Phase 3
neridronic-acid	bone resorption inhibitor	FDPS	endocrinology	brittle bone disease, Paget's disease	Sigma, Toronto, Toronto	0	NCCCCCC(O)(P(O)(O)=O)P(O)(O)=O, NCCCCCC(O)(P(O)(O)=O)P(O)(O)=O, NCCCCCC(O)(P(O)(O)=O)P(O)(O)=O	Launched
nesbuvir	RNA polymerase inhibitor				MedChemEx, MedChemEx, MedChemEx	98.31	CNC(=O)c1c(oc2cc(N(CCO)S(C)(=O)=O)c(cc12)C1CC1)-c1ccc(F)cc1, CNC(=O)c1c(oc2cc(N(CCO)S(C)(=O)=O)c(cc12)C1CC1)-c1ccc(F)cc1, CNC(=O)c1c(oc2cc(N(CCO)S(C)(=O)=O)c(cc12)C1CC1)-c1ccc(F)cc1	Phase 2
netilmicin	protein synthesis inhibitor		infectious disease	gram-negative bacterial infections	MedChemEx	0	[H][C@]1(O[C@@H]2[C@@H](N)C[C@@H](NCC)[C@H](O[C@@]3([H])OC[C@](C)(O)[C@H](NC)[C@H]3O)[C@H]2O)OC(CN)=CC[C@H]1N |c:32|	Launched
netupitant	tachykinin antagonist	TACR1	gastroenterology	nausea, vomiting	MedChemEx, MedChemEx, MedChemEx, MedChemEx	97.52	CN(C(=O)C(C)(C)c1cc(cc(c1)C(F)(F)F)C(F)(F)F)c1cnc(cc1-c1ccccc1C)N1CCN(C)CC1, CN(C(=O)C(C)(C)c1cc(cc(c1)C(F)(F)F)C(F)(F)F)c1cnc(cc1-c1ccccc1C)N1CCN(C)CC1, CN(C(=O)C(C)(C)c1cc(cc(c1)C(F)(F)F)C(F)(F)F)c1cnc(cc1-c1ccccc1C)N1CCN(C)CC1, CN(C(=O)C(C)(C)c1cc(cc(c1)C(F)(F)F)C(F)(F)F)c1cnc(cc1-c1ccccc1C)N1CCN(C)CC1	Launched
neurodazine	neurogenesis of non-pluripotent C2C12 myoblast inducer				Tocris, Tocris, Tocris	97.5	COc1ccc(cc1)-c1nc([nH]c1-c1ccc(OC)cc1)-c1ccc(o1)-c1cccc(Cl)c1, COc1ccc(cc1)-c1nc([nH]c1-c1ccc(OC)cc1)-c1ccc(o1)-c1cccc(Cl)c1, COc1ccc(cc1)-c1nc([nH]c1-c1ccc(OC)cc1)-c1ccc(o1)-c1cccc(Cl)c1	Preclinical
neuropathiazol	neural stem cell inducer	BMP2, LIF			Tocris, Broad Institute, Broad Institute, Broad Institute, Broad Institute	100	CCOC(=O)c1ccc(cc1)N(C)c1csc(n1)-c1ccccc1, CCOC(=O)c1ccc(cc1)N(C)c1csc(n1)-c1ccccc1, CCOC(=O)c1ccc(cc1)N(C)c1csc(n1)-c1ccccc1, CCOC(=O)c1ccc(cc1)N(C)c1csc(n1)-c1ccccc1, CCOC(=O)c1ccc(cc1)N(C)c1csc(n1)-c1ccccc1	Preclinical
Neu2000	ionotropic glutamate receptor antagonist				MedChemEx	96.58	OC(=O)c1cc(NCc2c(F)c(F)c(c(F)c2F)C(F)(F)F)ccc1O	Phase 2
nevirapine	non-nucleoside reverse transcriptase inhibitor	CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2D6, CYP3A4, CYP3A5	infectious disease	human immunodeficiency virus (HIV-1)	MicroSource, Selleck	99.37	Cc1ccnc2N(C3CC3)c3ncccc3C(=O)Nc12, Cc1ccnc2N(C3CC3)c3ncccc3C(=O)Nc12	Launched
nexturastat-A	HDAC inhibitor	HDAC1, HDAC6			Selleck, Selleck, Selleck, MedChemEx, MedChemEx	93.27	CCCCN(Cc1ccc(cc1)C(=O)NO)C(=O)Nc1ccccc1, CCCCN(Cc1ccc(cc1)C(=O)NO)C(=O)Nc1ccccc1, CCCCN(Cc1ccc(cc1)C(=O)NO)C(=O)Nc1ccccc1, CCCCN(Cc1ccc(cc1)C(=O)NO)C(=O)Nc1ccccc1, CCCCN(Cc1ccc(cc1)C(=O)NO)C(=O)Nc1ccccc1	Preclinical
NFKB-activation-inhibitor-II	NFkB pathway inhibitor	RELA			MedChemEx, Selleck, Selleck	87.14	Cc1ccc(NCCCc2ccccc2)c(N)c1, Cc1ccc(NCCCc2ccccc2)c(N)c1, Cc1ccc(NCCCc2ccccc2)c(N)c1	Preclinical
NG-nitro-arginine	nitric oxide synthase inhibitor	NOS1, NOS2, NOS3			Sigma, ChemDiv	98.3	N[C@@H](CCCNC(N)=N[N+]([O-])=O)C(O)=O, N[C@@H](CCCNC(N)=N[N+]([O-])=O)C(O)=O	Phase 1
NGB-2904	dopamine receptor antagonist	DRD3			Tocris, Tocris, Tocris, Tocris	97.4	Clc1cccc(N2CCN(CCCCNC(=O)c3ccc-4c(Cc5ccccc-45)c3)CC2)c1Cl, Clc1cccc(N2CCN(CCCCNC(=O)c3ccc-4c(Cc5ccccc-45)c3)CC2)c1Cl, Clc1cccc(N2CCN(CCCCNC(=O)c3ccc-4c(Cc5ccccc-45)c3)CC2)c1Cl, Clc1cccc(N2CCN(CCCCNC(=O)c3ccc-4c(Cc5ccccc-45)c3)CC2)c1Cl	Preclinical
NGD-94-1	dopamine receptor antagonist	DRD4			Tocris, Tocris	97.29	C(N1CCN(CC1)c1ncccn1)c1cnc([nH]1)-c1ccccc1, C(N1CCN(CC1)c1ncccn1)c1cnc([nH]1)-c1ccccc1	Phase 1
NGD-98-2	corticotropin releasing factor receptor antagonist	CRHR1			Tocris, Tocris	85.62	CCC(CC)Nc1nc(C)c(nc1OC)-c1ccc(OC(F)(F)F)cc1OC, CCC(CC)Nc1nc(C)c(nc1OC)-c1ccc(OC(F)(F)F)cc1OC	Preclinical
NGP555	gamma secretase modulator				MedChemEx	91.35	CCc1cc(Nc2nc(cs2)-c2ccc(c(F)c2)-n2cnc(C)c2)c(C)cc1C	Phase 1
NHI-2	lactate dehydrogenase inhibitor	LDHA			Tocris, Tocris	84.97	COC(=O)c1cc2c(cc(cc2n1O)-c1ccccc1)C(F)(F)F, COC(=O)c1cc2c(cc(cc2n1O)-c1ccccc1)C(F)(F)F	Preclinical
NH125	eukaryotic translation elongation factor 2 inhibitor				Selleck, Selleck, Selleck, Selleck, Tocris	97.8	CCCCCCCCCCCCCCCC[n+]1ccn(Cc2ccccc2)c1C, CCCCCCCCCCCCCCCC[n+]1ccn(Cc2ccccc2)c1C, CCCCCCCCCCCCCCCC[n+]1ccn(Cc2ccccc2)c1C, CCCCCCCCCCCCCCCC[n+]1ccn(Cc2ccccc2)c1C, CCCCCCCCCCCCCCCC[n+]1ccn(Cc2ccccc2)c1C	Preclinical
NI-57	bromodomain inhibitor	BRD1, BRPF1, BRPF3			Tocris, Tocris, Cayman	98.42	COc1cc(ccc1S(=O)(=O)Nc1ccc2n(C)c(=O)c(C)cc2c1)C#N, COc1cc(ccc1S(=O)(=O)Nc1ccc2n(C)c(=O)c(C)cc2c1)C#N, COc1cc(ccc1S(=O)(=O)Nc1ccc2n(C)c(=O)c(C)cc2c1)C#N	Preclinical
niacin	NAD precursor, vitamin B	DGAT2, HCAR1, HCAR2, HCAR3, NNMT, QPRT	endocrinology	hypertriglyceridemia	Selleck, Selleck, MicroSource, MicroSource, MicroSource	91.85	OC(=O)c1cccnc1, OC(=O)c1cccnc1, OC(=O)c1cccnc1, OC(=O)c1cccnc1, OC(=O)c1cccnc1	Launched
nialamide	monoamine oxidase inhibitor	COMT, MAOA, MAOB			MedChemEx, MicroSource, Selleck	95.02	O=C(CCNNC(=O)c1ccncc1)NCc1ccccc1, O=C(CCNNC(=O)c1ccncc1)NCc1ccccc1, O=C(CCNNC(=O)c1ccncc1)NCc1ccccc1	Withdrawn
nibentan	potassium channel blocker				Vitas-M, Vitas-M	96.69	CCN(CC)CCCC[C@@H](NC(=O)c1ccc(cc1)[N+]([O-])=O)c1ccccc1 |&1:9,r|, CCN(CC)CCCC[C@@H](NC(=O)c1ccc(cc1)[N+]([O-])=O)c1ccccc1 |&1:9,r|	Phase 2
nicainoprol	angiotensin converting enzyme inhibitor				MedChemEx	91.7	CC(C)NC[C@H](O)COc1cccc2CCCN(C(=O)c3cccnc3)c12 |&1:5,r|	Preclinical
nicaraven	free radical scavenger				MedChemEx, Selleck	96.43	C[C@@H](CNC(=O)c1cccnc1)NC(=O)c1cccnc1 |&1:1,r|, C[C@@H](CNC(=O)c1cccnc1)NC(=O)c1cccnc1 |&1:1,r|	Phase 3
nicardipine	calcium channel blocker	ADORA3	cardiology	chronic stable angina, hypertension	MicroSource, MicroSource, MicroSource, Selleck	97.24	COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OCCN(C)Cc1ccccc1 |r,c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OCCN(C)Cc1ccccc1 |r,c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OCCN(C)Cc1ccccc1 |r,c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OCCN(C)Cc1ccccc1 |r,c:4,9|	Launched
nicergoline	adrenergic receptor antagonist	ADRA1A	rheumatology, neurology/psychiatry, cardiology, hematology	Raynaud's disease, migraine headache, atherosclerosis, thrombosis	MicroSource, Tocris, Tocris, Tocris	97.06	CO[C@]12C[C@@H](COC(=O)c3cncc(Br)c3)CN(C)[C@@H]1Cc1cn(C)c3cccc2c13, CO[C@]12C[C@@H](COC(=O)c3cncc(Br)c3)CN(C)[C@@H]1Cc1cn(C)c3cccc2c13, CO[C@]12C[C@@H](COC(=O)c3cncc(Br)c3)CN(C)[C@@H]1Cc1cn(C)c3cccc2c13, CO[C@]12C[C@@H](COC(=O)c3cncc(Br)c3)CN(C)[C@@H]1Cc1cn(C)c3cccc2c13	Launched
niceritrol	NAD precursor		endocrinology	hyperlipidemia	Kemprotec, Kemprotec	97.89	O=C(OCC(COC(=O)c1cccnc1)(COC(=O)c1cccnc1)COC(=O)c1cccnc1)c1cccnc1, O=C(OCC(COC(=O)c1cccnc1)(COC(=O)c1cccnc1)COC(=O)c1cccnc1)c1cccnc1	Launched
niclosamide	DNA replication inhibitor, STAT inhibitor	STAT3	infectious disease	tapeworm	MicroSource, MicroSource, MicroSource, MicroSource, Selleck, Selleck	97.63	Oc1ccc(Cl)cc1C(=O)Nc1ccc(cc1Cl)[N+]([O-])=O, Oc1ccc(Cl)cc1C(=O)Nc1ccc(cc1Cl)[N+]([O-])=O, Oc1ccc(Cl)cc1C(=O)Nc1ccc(cc1Cl)[N+]([O-])=O, Oc1ccc(Cl)cc1C(=O)Nc1ccc(cc1Cl)[N+]([O-])=O, Oc1ccc(Cl)cc1C(=O)Nc1ccc(cc1Cl)[N+]([O-])=O, Oc1ccc(Cl)cc1C(=O)Nc1ccc(cc1Cl)[N+]([O-])=O	Launched
nicodicosapent	sterol regulatory element binding protein (SREBP) inhibitor				MedChemEx	90.76	CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)NCCNC(=O)c1cccnc1	Preclinical
nicorandil	nitric oxide donor, potassium channel activator	KCNJ11	cardiology	angina pectoris	MicroSource, Tocris, Tocris, Tocris, Tocris, Selleck, Selleck, Selleck, Selleck	93	[O-][N+](=O)OCCNC(=O)c1cccnc1, [O-][N+](=O)OCCNC(=O)c1cccnc1, [O-][N+](=O)OCCNC(=O)c1cccnc1, [O-][N+](=O)OCCNC(=O)c1cccnc1, [O-][N+](=O)OCCNC(=O)c1cccnc1, [O-][N+](=O)OCCNC(=O)c1cccnc1, [O-][N+](=O)OCCNC(=O)c1cccnc1, [O-][N+](=O)OCCNC(=O)c1cccnc1, [O-][N+](=O)OCCNC(=O)c1cccnc1	Launched
nicotinamide	protein synthesis stimulant	BST1, LDHA, PARP1, SIRT5	dermatology	acne vulgaris (AV)	MicroSource, Selleck, Selleck	96.39	NC(=O)c1cccnc1, NC(=O)c1cccnc1, NC(=O)c1cccnc1	Launched
nicotine	acetylcholine receptor agonist	CHAT, CHRNA10, CHRNA2, CHRNA3, CHRNA4, CHRNA5, CHRNA6, CHRNA7, CHRNA9, CHRNB2, CHRNB3, CHRNB4, CYP19A1, TBXAS1, TRPA1	neurology/psychiatry	smoking cessation	MicroSource	87.94	CN1CCC[C@H]1c1cccnc1	Launched
nicotinyl-alcohol-tartrate			cardiology, neurology/psychiatry	vascular spasm, vertigo	MicroSource, MedChemEx	92.65	OCc1cccnc1, OCc1cccnc1	Launched
NIDA-41020	cannabinoid receptor antagonist	CNR1			Tocris, Tocris, Tocris	97.58	COc1ccc(cc1)-c1c(C)c(nn1-c1ccc(Cl)cc1Cl)C(=O)NN1CCCCC1, COc1ccc(cc1)-c1c(C)c(nn1-c1ccc(Cl)cc1Cl)C(=O)NN1CCCCC1, COc1ccc(cc1)-c1c(C)c(nn1-c1ccc(Cl)cc1Cl)C(=O)NN1CCCCC1	Preclinical
nifedipine	calcium channel blocker	CACNA1C, CACNA1D, CACNA1F, CACNA1H, CACNA1S, CACNA2D1, CACNB2, CALM1, GLRA1, GLRA3, GLRB, KCNA1, KCNA5, NR1I2, TRPM3	cardiology	vasospastic angina, chronic stable angina	MedChemEx, MedChemEx, MedChemEx, Tocris, Selleck, MicroSource, Selleck	100	COC(=O)C1=C(C)NC(C)=C(C1c1ccccc1[N+]([O-])=O)C(=O)OC |c:4,9|, COC(=O)C1=C(C)NC(C)=C(C1c1ccccc1[N+]([O-])=O)C(=O)OC |c:4,9|, COC(=O)C1=C(C)NC(C)=C(C1c1ccccc1[N+]([O-])=O)C(=O)OC |c:4,9|, COC(=O)C1=C(C)NC(C)=C(C1c1ccccc1[N+]([O-])=O)C(=O)OC |c:4,9|, COC(=O)C1=C(C)NC(C)=C(C1c1ccccc1[N+]([O-])=O)C(=O)OC |c:4,9|, COC(=O)C1=C(C)NC(C)=C(C1c1ccccc1[N+]([O-])=O)C(=O)OC |c:4,9|, COC(=O)C1=C(C)NC(C)=C(C1c1ccccc1[N+]([O-])=O)C(=O)OC |c:4,9|	Launched
nifekalant	potassium channel blocker		cardiology	ventricular arrhythmias, ventricular tachycardia (VT)	Prestwick, Prestwick	97.89	Cn1c(NCCN(CCO)CCCc2ccc(cc2)[N+]([O-])=O)cc(=O)n(C)c1=O, Cn1c(NCCN(CCO)CCCc2ccc(cc2)[N+]([O-])=O)cc(=O)n(C)c1=O	Launched
nifenalol	adrenergic receptor antagonist	ADRB1, ADRB2			Enamine	87.38	CC(C)NC[C@@H](O)c1ccc(cc1)[N+]([O-])=O |&1:5,r|	Launched
nifenazone	analgesic agent		neurology/psychiatry	pain relief	Selleck, MicroSource, MedChemEx	99.25	Cc1c(NC(=O)c2cccnc2)c(=O)n(-c2ccccc2)n1C, Cc1c(NC(=O)c2cccnc2)c(=O)n(-c2ccccc2)n1C, Cc1c(NC(=O)c2cccnc2)c(=O)n(-c2ccccc2)n1C	Launched
niflumic-acid	cyclooxygenase inhibitor	ANO1, CLCN1, CLCNKA, CLCNKB, KCNQ1, PLA2G1B, PLA2G4A, PTGS1, PTGS2, UGT1A9	rheumatology, neurology/psychiatry	joint pain, muscle pain	MicroSource, Selleck, Tocris	97.55	OC(=O)c1cccnc1Nc1cccc(c1)C(F)(F)F, OC(=O)c1cccnc1Nc1cccc(c1)C(F)(F)F, OC(=O)c1cccnc1Nc1cccc(c1)C(F)(F)F	Launched
nifuroxazide	bacterial DNA inhibitor		gastroenterology	colitis, diarrhea	MicroSource, MicroSource, MicroSource, Selleck, Selleck, Selleck, Selleck	98.14	Oc1ccc(cc1)C(=O)N\N=C\c1ccc(o1)[N+]([O-])=O, Oc1ccc(cc1)C(=O)N\N=C\c1ccc(o1)[N+]([O-])=O, Oc1ccc(cc1)C(=O)N\N=C\c1ccc(o1)[N+]([O-])=O, Oc1ccc(cc1)C(=O)N\N=C\c1ccc(o1)[N+]([O-])=O, Oc1ccc(cc1)C(=O)N\N=C\c1ccc(o1)[N+]([O-])=O, Oc1ccc(cc1)C(=O)N\N=C\c1ccc(o1)[N+]([O-])=O, Oc1ccc(cc1)C(=O)N\N=C\c1ccc(o1)[N+]([O-])=O	Launched
nifursol	bacterial DNA inhibitor				MedChemEx, MedChemEx, MicroSource	96.23	Oc1c(cc(cc1[N+]([O-])=O)[N+]([O-])=O)C(=O)N\N=C\c1ccc(o1)[N+]([O-])=O, Oc1c(cc(cc1[N+]([O-])=O)[N+]([O-])=O)C(=O)N\N=C\c1ccc(o1)[N+]([O-])=O, Oc1c(cc(cc1[N+]([O-])=O)[N+]([O-])=O)C(=O)N\N=C\c1ccc(o1)[N+]([O-])=O	Launched
nifurtimox	DNA inhibitor		infectious disease	Chagas disease, African trypanosomiasis	Sigma	88.24	C[C@H]1CS(=O)(=O)CCN1\N=C\c1ccc(o1)[N+]([O-])=O |&1:1,r|	Launched
niguldipine-(R)-(-)					Tocris	90.73	COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OCCCN1CCC(CC1)(c1ccccc1)c1ccccc1 |r,c:4,9|	Preclinical
niguldipine-(S)-(+)	adrenergic receptor antagonist	ADRA1A			Tocris, Tocris, Tocris, Tocris, Tocris, Tocris	94.55	COC(=O)C1=C(C)NC(C)=C([C@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OCCCN1CCC(CC1)(c1ccccc1)c1ccccc1 |c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OCCCN1CCC(CC1)(c1ccccc1)c1ccccc1 |c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OCCCN1CCC(CC1)(c1ccccc1)c1ccccc1 |c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OCCCN1CCC(CC1)(c1ccccc1)c1ccccc1 |c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OCCCN1CCC(CC1)(c1ccccc1)c1ccccc1 |c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OCCCN1CCC(CC1)(c1ccccc1)c1ccccc1 |c:4,9|	Preclinical
nikethamide	immunostimulant				MedChemEx, MicroSource	96.18	CCN(CC)C(=O)c1cccnc1, CCN(CC)C(=O)c1cccnc1	Withdrawn
nilotinib	Abl kinase inhibitor, Bcr-Abl kinase inhibitor	ABL1, KIT	hematologic malignancy	chronic myeloid leukemia (CML)	MedChemEx, Selleck	98.83	Cc1cn(cn1)-c1cc(NC(=O)c2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)cc(c1)C(F)(F)F, Cc1cn(cn1)-c1cc(NC(=O)c2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)cc(c1)C(F)(F)F	Launched
nilutamide	androgen receptor antagonist	AR	oncology	prostate cancer	MicroSource, Tocris, Tocris	99.22	CC1(C)NC(=O)N(C1=O)c1ccc(c(c1)C(F)(F)F)[N+]([O-])=O, CC1(C)NC(=O)N(C1=O)c1ccc(c(c1)C(F)(F)F)[N+]([O-])=O, CC1(C)NC(=O)N(C1=O)c1ccc(c(c1)C(F)(F)F)[N+]([O-])=O	Launched
nilvadipine	calcium channel blocker	CACNA1C, CACNA1D	cardiology	hypertension, cerebral artery occlusion	MedChemEx, MedChemEx, MedChemEx, MedChemEx, Selleck, Selleck, Selleck, Selleck	96.75	COC(=O)C1=C(NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC(C)C)C#N |&1:10,r,c:8,t:4|, COC(=O)C1=C(NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC(C)C)C#N |&1:10,r,c:8,t:4|, COC(=O)C1=C(NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC(C)C)C#N |&1:10,r,c:8,t:4|, COC(=O)C1=C(NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC(C)C)C#N |&1:10,r,c:8,t:4|, COC(=O)C1=C(NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC(C)C)C#N |&1:10,r,c:8,t:4|, COC(=O)C1=C(NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC(C)C)C#N |&1:10,r,c:8,t:4|, COC(=O)C1=C(NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC(C)C)C#N |&1:10,r,c:8,t:4|, COC(=O)C1=C(NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC(C)C)C#N |&1:10,r,c:8,t:4|	Launched
nimesulide	cyclooxygenase inhibitor	LTF, PLA2G2E, PTGS1, PTGS2	rheumatology, obstetrics/gynecology	osteoarthritis, menstrual pain	MicroSource, Tocris, Selleck, Tocris, Tocris, Tocris	99.29	CS(=O)(=O)Nc1ccc(cc1Oc1ccccc1)[N+]([O-])=O, CS(=O)(=O)Nc1ccc(cc1Oc1ccccc1)[N+]([O-])=O, CS(=O)(=O)Nc1ccc(cc1Oc1ccccc1)[N+]([O-])=O, CS(=O)(=O)Nc1ccc(cc1Oc1ccccc1)[N+]([O-])=O, CS(=O)(=O)Nc1ccc(cc1Oc1ccccc1)[N+]([O-])=O, CS(=O)(=O)Nc1ccc(cc1Oc1ccccc1)[N+]([O-])=O	Launched
nimodipine	calcium channel blocker	CFTR, NR3C2	hematology	hemorrhage	MicroSource, Selleck, Tocris	93.03	COCCOC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC(C)C |r,c:7,12|, COCCOC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC(C)C |r,c:7,12|, COCCOC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC(C)C |r,c:7,12|	Launched
nimorazole	bacterial DNA inhibitor		oncology	head and neck squamous cell carcinoma (HNSCC)	MedChemEx, MedChemEx	96.86	[O-][N+](=O)c1cncn1CCN1CCOCC1, [O-][N+](=O)c1cncn1CCN1CCOCC1	Launched
nimustine	DNA alkylating agent				MicroSource, Sigma	37.86	Cc1ncc(CNC(=O)N(CCCl)[NH2+][O-])c(N)n1, Cc1ncc(CNC(=O)N(CCCl)[NH2+][O-])c(N)n1	Launched
NIM811	mitochondrial permeability transition inhibitor				MedChemEx	87.81	[H][C@]1(NC(=O)[C@]([H])([C@@H](C)CC)N(C)C(=O)CN(C)C(=O)[C@H](CC)NC(=O)[C@]([H])([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@]([H])(C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@]([H])(CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C1=O)C(C)C	Phase 2
ningetinib-tosylate	protein tyrosine kinase inhibitor				MedChemEx	81.78	Cc1c(C(=O)Nc2ccc(Oc3ccnc4cc(OCC(C)(C)O)ccc34)c(F)c2)c(=O)n(-c2ccccc2)n1C	Preclinical
nintedanib	FGFR inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	FGFR1, FGFR2, FGFR3, FGFR4, FLT1, FLT4, KDR, PDGFRA, PDGFRB	pulmonary	idiopathic pulmonary fibrosis (IPF)	Selleck, Selleck, Selleck	90.8	COC(=O)c1ccc2\C(=C(\Nc3ccc(cc3)N(C)C(=O)CN3CCN(C)CC3)c3ccccc3)C(=O)Nc2c1, COC(=O)c1ccc2\C(=C(\Nc3ccc(cc3)N(C)C(=O)CN3CCN(C)CC3)c3ccccc3)C(=O)Nc2c1, COC(=O)c1ccc2\C(=C(\Nc3ccc(cc3)N(C)C(=O)CN3CCN(C)CC3)c3ccccc3)C(=O)Nc2c1	Launched
niraparib	PARP inhibitor	PARP1	oncology	primary peritoneal cancer (PPC)	MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx	95.87	NC(=O)c1cccc2cn(nc12)-c1ccc(cc1)[C@@H]1CCCNC1, NC(=O)c1cccc2cn(nc12)-c1ccc(cc1)[C@@H]1CCCNC1, NC(=O)c1cccc2cn(nc12)-c1ccc(cc1)[C@@H]1CCCNC1, NC(=O)c1cccc2cn(nc12)-c1ccc(cc1)[C@@H]1CCCNC1, NC(=O)c1cccc2cn(nc12)-c1ccc(cc1)[C@@H]1CCCNC1, NC(=O)c1cccc2cn(nc12)-c1ccc(cc1)[C@@H]1CCCNC1, NC(=O)c1cccc2cn(nc12)-c1ccc(cc1)[C@@H]1CCCNC1	Launched
niridazole	phosphofructokinase inhibitor		infectious disease	schistosomiasis	Prestwick, Prestwick, Prestwick	94.95	[O-][N+](=O)c1cnc(s1)N1CCNC1=O, [O-][N+](=O)c1cnc(s1)N1CCNC1=O, [O-][N+](=O)c1cnc(s1)N1CCNC1=O	Launched
nisin	bacterial cell wall synthesis inhibitor					0		Phase 1
nisoldipine	calcium channel blocker	CACNA1C, CACNA1D, CACNA1F, CACNA1S	cardiology	hypertension	MicroSource, MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx, Selleck, Selleck	87.46	COC(=O)C1=C(C)NC(C)=C([C@@H]1c1ccccc1[N+]([O-])=O)C(=O)OCC(C)C |r,c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@@H]1c1ccccc1[N+]([O-])=O)C(=O)OCC(C)C |r,c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@@H]1c1ccccc1[N+]([O-])=O)C(=O)OCC(C)C |r,c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@@H]1c1ccccc1[N+]([O-])=O)C(=O)OCC(C)C |r,c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@@H]1c1ccccc1[N+]([O-])=O)C(=O)OCC(C)C |r,c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@@H]1c1ccccc1[N+]([O-])=O)C(=O)OCC(C)C |r,c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@@H]1c1ccccc1[N+]([O-])=O)C(=O)OCC(C)C |r,c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@@H]1c1ccccc1[N+]([O-])=O)C(=O)OCC(C)C |r,c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@@H]1c1ccccc1[N+]([O-])=O)C(=O)OCC(C)C |r,c:4,9|	Launched
nisoxetine	norepinephrine reuptake inhibitor	SLC6A2, SLC6A3, SLC6A4			Tocris	88.54	CNCC[C@@H](Oc1ccccc1OC)c1ccccc1 |&1:4,r|	Phase 1
nitarsone			dermatology	blackhead disease	MicroSource, Selleck, Selleck	100	O[As](O)(=O)c1ccc(cc1)[N+]([O-])=O, O[As](O)(=O)c1ccc(cc1)[N+]([O-])=O, O[As](O)(=O)c1ccc(cc1)[N+]([O-])=O	Launched
nitazoxanide	pyruvate ferredoxin oxidoreductase inhibitor		gastroenterology	diarrhea	MicroSource, MedChemEx, MedChemEx, Selleck, Selleck, Selleck	87.36	CC(=O)Oc1ccccc1C(=O)Nc1ncc(s1)[N+]([O-])=O, CC(=O)Oc1ccccc1C(=O)Nc1ncc(s1)[N+]([O-])=O, CC(=O)Oc1ccccc1C(=O)Nc1ncc(s1)[N+]([O-])=O, CC(=O)Oc1ccccc1C(=O)Nc1ncc(s1)[N+]([O-])=O, CC(=O)Oc1ccccc1C(=O)Nc1ncc(s1)[N+]([O-])=O, CC(=O)Oc1ccccc1C(=O)Nc1ncc(s1)[N+]([O-])=O	Launched
nitecapone	catechol O methyltransferase inhibitor	COMT			Cayman	31.32	CC(=O)C(=Cc1cc(O)c(O)c(c1)[N+]([O-])=O)C(C)=O	Phase 2
nitenpyram			infectious disease	flea control	Selleck	93.18	CCN(Cc1ccc(Cl)nc1)C(\NC)=C\[N+]([O-])=O	Launched
nithiamide	bacterial DNA inhibitor				MicroSource, Selleck, Selleck	100	CC(=O)Nc1ncc(s1)[N+]([O-])=O, CC(=O)Nc1ncc(s1)[N+]([O-])=O, CC(=O)Nc1ncc(s1)[N+]([O-])=O	Preclinical
nitisinone	hydroxyphenylpyruvate dioxygenase inhibitor		metabolism	tyrosinemia	Enzo, MedChemEx, MedChemEx	87.67	OC(=C1C(=O)CCCC1=O)c1ccc(cc1[N+]([O-])=O)C(F)(F)F, OC(=C1C(=O)CCCC1=O)c1ccc(cc1[N+]([O-])=O)C(F)(F)F, OC(=C1C(=O)CCCC1=O)c1ccc(cc1[N+]([O-])=O)C(F)(F)F	Launched
nitrendipine	calcium channel blocker	CACNA1D, CACNA2D1, KCNN4	cardiology	hypertension	Tocris, MicroSource, Selleck, Selleck, Tocris, Tocris	97.81	CCOC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC |r,c:5,10|, CCOC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC |r,c:5,10|, CCOC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC |r,c:5,10|, CCOC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC |r,c:5,10|, CCOC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC |r,c:5,10|, CCOC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC |r,c:5,10|	Launched
nitrocaramiphen	cholinergic receptor antagonist	CHRM1			Tocris, Tocris	92.79	CCN(CC)CCOC(=O)C1(CCCC1)c1ccc(cc1)[N+]([O-])=O, CCN(CC)CCOC(=O)C1(CCCC1)c1ccc(cc1)[N+]([O-])=O	Preclinical
nitroflurbiprofen	cyclooxygenase inhibitor				MedChemEx	94.51	C[C@@H](C(=O)OCCCCO[N+]([O-])=O)c1ccc(c(F)c1)-c1ccccc1 |&1:1,r|	Preclinical
nitrofurantoin	DNA inhibitor		infectious disease	urinary tract infections, pyelonephritis	MedChemEx, MedChemEx, MicroSource	83.96	[O-][N+](=O)c1ccc(\C=N\N2CC(=O)NC2=O)o1, [O-][N+](=O)c1ccc(\C=N\N2CC(=O)NC2=O)o1, [O-][N+](=O)c1ccc(\C=N\N2CC(=O)NC2=O)o1	Launched
nitrofurazone	bacterial DNA inhibitor		infectious disease	first-aid antibiotic	MedChemEx, Selleck, MicroSource, MicroSource	98.77	NC(=O)N\N=C\c1ccc(o1)[N+]([O-])=O, NC(=O)N\N=C\c1ccc(o1)[N+]([O-])=O, NC(=O)N\N=C\c1ccc(o1)[N+]([O-])=O, NC(=O)N\N=C\c1ccc(o1)[N+]([O-])=O	Launched
nitromide			infectious disease	coccidiosis	MedChemEx, MedChemEx, MicroSource	99.72	NC(=O)c1cc(cc(c1)[N+]([O-])=O)[N+]([O-])=O, NC(=O)c1cc(cc(c1)[N+]([O-])=O)[N+]([O-])=O, NC(=O)c1cc(cc(c1)[N+]([O-])=O)[N+]([O-])=O	Launched
nitrosodimethylurea	DNA synthesis inhibitor				Enamine	0	CNC(=O)N(C)[NH2+][O-]	Preclinical
nitroxoline	cathepsin inhibitor	METAP2	infectious disease	urinary tract infections	MedChemEx, MicroSource	62.54	Oc1ccc([N+]([O-])=O)c2cccnc12, Oc1ccc([N+]([O-])=O)c2cccnc12	Launched
nizatidine	histamine receptor antagonist	HRH2	gastroenterology	duodenal ulcer disease, erosive esophagitis (EE), ulcerative esophagitis (UE), gastroesophageal reflux disease (GERD)	MedChemEx, MedChemEx, MicroSource, MicroSource, MicroSource, Selleck	93.79	CN\C(NCCSCc1csc(CN(C)C)n1)=C/[N+]([O-])=O, CN\C(NCCSCc1csc(CN(C)C)n1)=C/[N+]([O-])=O, CN\C(NCCSCc1csc(CN(C)C)n1)=C/[N+]([O-])=O, CN\C(NCCSCc1csc(CN(C)C)n1)=C/[N+]([O-])=O, CN\C(NCCSCc1csc(CN(C)C)n1)=C/[N+]([O-])=O, CN\C(NCCSCc1csc(CN(C)C)n1)=C/[N+]([O-])=O	Launched
nizofenone	ion channel antagonist		neurology/psychiatry	stroke	AKSci	99.4	CCN(CC)Cc1nccn1-c1ccc(cc1C(=O)c1ccccc1Cl)[N+]([O-])=O	Launched
NK-252	nuclear factor erythroid derived, like (NRF2) activator	NFE2L2			Tocris, Tocris	93.73	O=C(NCc1ccccn1)Nc1nnc(o1)-c1ccco1, O=C(NCc1ccccn1)Nc1nnc(o1)-c1ccco1	Preclinical
NKP-1339	HSP inhibitor				MedChemEx, MedChemEx	83.77	Cl[Ru+3](Cl)(Cl)(Cl)([n+]1cc2ccccc2[nH]1)[n+]1cc2ccccc2[nH]1, Cl[Ru+3](Cl)(Cl)(Cl)([n+]1cc2ccccc2[nH]1)[n+]1cc2ccccc2[nH]1	Phase 1
NKY-80	adenylyl cyclase inhibitor	ADCY5			Tocris, Tocris	93.25	Nc1ncc2C(=O)C[C@@H](Cc2n1)c1ccco1 |&1:8,r|, Nc1ncc2C(=O)C[C@@H](Cc2n1)c1ccco1 |&1:8,r|	Preclinical
NLG919	indoleamine 2,3-dioxygenase inhibitor	IDO1			MedChemEx, MedChemEx, MedChemEx, Selleck, Selleck	79.93	O[C@@H](C[C@H]1c2ccccc2-c2cncn12)C1CCCCC1 |&1:1,&2:3,r|, O[C@@H](C[C@H]1c2ccccc2-c2cncn12)C1CCCCC1 |&1:1,&2:3,r|, O[C@@H](C[C@H]1c2ccccc2-c2cncn12)C1CCCCC1 |&1:1,&2:3,r|, O[C@@H](C[C@H]1c2ccccc2-c2cncn12)C1CCCCC1 |&1:1,&2:3,r|, O[C@@H](C[C@H]1c2ccccc2-c2cncn12)C1CCCCC1 |&1:1,&2:3,r|	Phase 1
NMDA	glutamate receptor agonist	GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D			Tocris, Tocris, Selleck, Tocris, Tocris	100	CN[C@H](CC(O)=O)C(O)=O, CN[C@H](CC(O)=O)C(O)=O, CN[C@H](CC(O)=O)C(O)=O, CN[C@H](CC(O)=O)C(O)=O, CN[C@H](CC(O)=O)C(O)=O	Preclinical
NMS-E973	HSP inhibitor				Selleck, Selleck, Selleck, Selleck, Selleck	97.24	CN1CCC(CC1)NC(=O)c1cc(on1)-c1c(O)cc(O)cc1Oc1ccc(cc1)[N+]([O-])=O, CN1CCC(CC1)NC(=O)c1cc(on1)-c1c(O)cc(O)cc1Oc1ccc(cc1)[N+]([O-])=O, CN1CCC(CC1)NC(=O)c1cc(on1)-c1c(O)cc(O)cc1Oc1ccc(cc1)[N+]([O-])=O, CN1CCC(CC1)NC(=O)c1cc(on1)-c1c(O)cc(O)cc1Oc1ccc(cc1)[N+]([O-])=O, CN1CCC(CC1)NC(=O)c1cc(on1)-c1c(O)cc(O)cc1Oc1ccc(cc1)[N+]([O-])=O	Preclinical
NMS-P715	protein kinase inhibitor				MedChemEx	96.6	CCc1cccc(CC)c1NC(=O)c1nn(C)c-2c1CCc1cnc(Nc3ccc(cc3OC(F)(F)F)C(=O)NC3CCN(C)CC3)nc-21	Preclinical
NMS-1286937	PLK inhibitor	FLT3, PLK1, PLK2, PLK3			MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx	96.61	CN1CCN(CC1)c1ccc(OC(F)(F)F)c(Nc2ncc3CCc4c(nn(CCO)c4-c3n2)C(N)=O)c1, CN1CCN(CC1)c1ccc(OC(F)(F)F)c(Nc2ncc3CCc4c(nn(CCO)c4-c3n2)C(N)=O)c1, CN1CCN(CC1)c1ccc(OC(F)(F)F)c(Nc2ncc3CCc4c(nn(CCO)c4-c3n2)C(N)=O)c1, CN1CCN(CC1)c1ccc(OC(F)(F)F)c(Nc2ncc3CCc4c(nn(CCO)c4-c3n2)C(N)=O)c1, CN1CCN(CC1)c1ccc(OC(F)(F)F)c(Nc2ncc3CCc4c(nn(CCO)c4-c3n2)C(N)=O)c1, CN1CCN(CC1)c1ccc(OC(F)(F)F)c(Nc2ncc3CCc4c(nn(CCO)c4-c3n2)C(N)=O)c1, CN1CCN(CC1)c1ccc(OC(F)(F)F)c(Nc2ncc3CCc4c(nn(CCO)c4-c3n2)C(N)=O)c1, CN1CCN(CC1)c1ccc(OC(F)(F)F)c(Nc2ncc3CCc4c(nn(CCO)c4-c3n2)C(N)=O)c1, CN1CCN(CC1)c1ccc(OC(F)(F)F)c(Nc2ncc3CCc4c(nn(CCO)c4-c3n2)C(N)=O)c1	Phase 2
NMS-873	ATPase inhibitor	VCP			MedChemEx, Selleck	98.64	Cc1cc(OCc2nnc(SC3CCCC3)n2-c2cccnc2)ccc1-c1ccc(cc1)S(C)(=O)=O, Cc1cc(OCc2nnc(SC3CCCC3)n2-c2cccnc2)ccc1-c1ccc(cc1)S(C)(=O)=O	Preclinical
NM107	RNA polymerase inhibitor				LifeChem	92.3	C[C@@]1(O)[C@H](O)[C@@H](CO)O[C@H]1n1ccc(N)nc1=O	Phase 2
NN-DNJ	glucosidase inhibitor	GBA			Sigma	100	CCCCCCCCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO	Preclinical
NNC-05-2090	GABA uptake inhibitor, GAT inhibitor	SLC6A12			Tocris, Tocris, Tocris, Tocris, Tocris, Tocris, Tocris, Tocris, Tocris	98.5	COc1ccccc1C1(O)CCN(CCCn2c3ccccc3c3ccccc23)CC1, COc1ccccc1C1(O)CCN(CCCn2c3ccccc3c3ccccc23)CC1, COc1ccccc1C1(O)CCN(CCCn2c3ccccc3c3ccccc23)CC1, COc1ccccc1C1(O)CCN(CCCn2c3ccccc3c3ccccc23)CC1, COc1ccccc1C1(O)CCN(CCCn2c3ccccc3c3ccccc23)CC1, COc1ccccc1C1(O)CCN(CCCn2c3ccccc3c3ccccc23)CC1, COc1ccccc1C1(O)CCN(CCCn2c3ccccc3c3ccccc23)CC1, COc1ccccc1C1(O)CCN(CCCn2c3ccccc3c3ccccc23)CC1, COc1ccccc1C1(O)CCN(CCCn2c3ccccc3c3ccccc23)CC1	Preclinical
NNC-55-0396	T-type calcium channel blocker	CATSPER1, CATSPER2, CATSPER3, CATSPER4			Tocris, Tocris, Tocris, Tocris, Tocris, Tocris, Tocris, Tocris, Tocris	97.64	CC(C)[C@H]1c2ccc(F)cc2CC[C@@]1(CCN(C)CCCc1nc2ccccc2[nH]1)OC(=O)C1CC1, CC(C)[C@H]1c2ccc(F)cc2CC[C@@]1(CCN(C)CCCc1nc2ccccc2[nH]1)OC(=O)C1CC1, CC(C)[C@H]1c2ccc(F)cc2CC[C@@]1(CCN(C)CCCc1nc2ccccc2[nH]1)OC(=O)C1CC1, CC(C)[C@H]1c2ccc(F)cc2CC[C@@]1(CCN(C)CCCc1nc2ccccc2[nH]1)OC(=O)C1CC1, CC(C)[C@H]1c2ccc(F)cc2CC[C@@]1(CCN(C)CCCc1nc2ccccc2[nH]1)OC(=O)C1CC1, CC(C)[C@H]1c2ccc(F)cc2CC[C@@]1(CCN(C)CCCc1nc2ccccc2[nH]1)OC(=O)C1CC1, CC(C)[C@H]1c2ccc(F)cc2CC[C@@]1(CCN(C)CCCc1nc2ccccc2[nH]1)OC(=O)C1CC1, CC(C)[C@H]1c2ccc(F)cc2CC[C@@]1(CCN(C)CCCc1nc2ccccc2[nH]1)OC(=O)C1CC1, CC(C)[C@H]1c2ccc(F)cc2CC[C@@]1(CCN(C)CCCc1nc2ccccc2[nH]1)OC(=O)C1CC1	Preclinical
NNC-63-0532	opioid receptor agonist	OPRL1			Tocris, Tocris, Tocris, Tocris, Tocris, Tocris	97.28	COC(=O)CN1CN(c2ccccc2)C2(CCN(Cc3cccc4ccccc34)CC2)C1=O, COC(=O)CN1CN(c2ccccc2)C2(CCN(Cc3cccc4ccccc34)CC2)C1=O, COC(=O)CN1CN(c2ccccc2)C2(CCN(Cc3cccc4ccccc34)CC2)C1=O, COC(=O)CN1CN(c2ccccc2)C2(CCN(Cc3cccc4ccccc34)CC2)C1=O, COC(=O)CN1CN(c2ccccc2)C2(CCN(Cc3cccc4ccccc34)CC2)C1=O, COC(=O)CN1CN(c2ccccc2)C2(CCN(Cc3cccc4ccccc34)CC2)C1=O	Preclinical
NNC-711	GABA uptake inhibitor	SIGMAR1, SLC6A1			Tocris, Tocris, Tocris	99.12	OC(=O)C1=CCCN(CCON=C(c2ccccc2)c2ccccc2)C1 |t:3|, OC(=O)C1=CCCN(CCON=C(c2ccccc2)c2ccccc2)C1 |t:3|, OC(=O)C1=CCCN(CCON=C(c2ccccc2)c2ccccc2)C1 |t:3|	Preclinical
NO-ASA	cyclooxygenase inhibitor	PTGS2			Enzo, Sigma	2.28	CC(=O)Oc1ccccc1C(=O)Oc1cccc(CO[N+]([O-])=O)c1, CC(=O)Oc1ccccc1C(=O)Oc1cccc(CO[N+]([O-])=O)c1	Phase 2
nobiletin	MEK inhibitor	MAP2K1			Selleck, Selleck	97.88	COc1ccc(cc1OC)-c1cc(=O)c2c(OC)c(OC)c(OC)c(OC)c2o1, COc1ccc(cc1OC)-c1cc(=O)c2c(OC)c(OC)c(OC)c(OC)c2o1	Preclinical
nocodazole	tubulin polymerization inhibitor	HPGDS			Tocris, Tocris, MicroSource, Selleck, Tocris	95.61	COC(=O)Nc1nc2ccc(cc2[nH]1)C(=O)c1cccs1, COC(=O)Nc1nc2ccc(cc2[nH]1)C(=O)c1cccs1, COC(=O)Nc1nc2ccc(cc2[nH]1)C(=O)c1cccs1, COC(=O)Nc1nc2ccc(cc2[nH]1)C(=O)c1cccs1, COC(=O)Nc1nc2ccc(cc2[nH]1)C(=O)c1cccs1	Preclinical
nolatrexed	thymidylate synthase inhibitor	TYMS			AvaChem	95.58	Cc1ccc2[nH]c(N)nc(=O)c2c1Sc1ccncc1	Phase 3
nomegestrol-acetate	progesterone receptor agonist	PGR	endocrinology	contraceptive	Sigma, Prestwick, Toronto, Toronto	100	CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@@H]4[C@H]3CC[C@]12C)C(C)=O |t:9,12|, CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@@H]4[C@H]3CC[C@]12C)C(C)=O |t:9,12|, CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@@H]4[C@H]3CC[C@]12C)C(C)=O |t:9,12|, CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@@H]4[C@H]3CC[C@]12C)C(C)=O |t:9,12|	Launched
nomifensine	dopamine reuptake inhibitor, noradrenaline uptake inhibitor	DRD2, SLC6A2, SLC6A3			MicroSource, Selleck, Selleck	97.52	CN1C[C@@H](c2ccccc2)c2cccc(N)c2C1 |&1:3|, CN1C[C@@H](c2ccccc2)c2cccc(N)c2C1 |&1:3|, CN1C[C@@H](c2ccccc2)c2cccc(N)c2C1 |&1:3|	Withdrawn
nonivamide	TRPV agonist	TRPV1	rheumatology, neurology/psychiatry	rheumatoid arthritis, muscle pain	MedChemEx, MedChemEx, MicroSource	92	CCCCCCCCC(=O)NCc1ccc(O)c(OC)c1, CCCCCCCCC(=O)NCc1ccc(O)c(OC)c1, CCCCCCCCC(=O)NCc1ccc(O)c(OC)c1	Launched
nonoxynol-9	membrane integrity inhibitor		endocrinology	contraceptive	MicroSource, LKT, MedChemEx, MedChemEx, MedChemEx	82.85	CCCCCCCCCc1ccc(OCCOCCOCCOCCOCCOCCOCCOCCOCCO)cc1, CCCCCCCCCc1ccc(OCCOCCOCCOCCOCCOCCOCCOCCOCCO)cc1, CCCCCCCCCc1ccc(OCCOCCOCCOCCOCCOCCOCCOCCOCCO)cc1, CCCCCCCCCc1ccc(OCCOCCOCCOCCOCCOCCOCCOCCOCCO)cc1, CCCCCCCCCc1ccc(OCCOCCOCCOCCOCCOCCOCCOCCOCCO)cc1	Launched
nor-binaltorphimine	opioid receptor antagonist	OPRD1, OPRK1, OPRM1			Tocris, Tocris, Tocris	82.82	Oc1ccc2C[C@H]3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)c1[nH]c2[C@@H]4Oc6c7c(C[C@H]8N(CC9CC9)CC[C@@]47[C@@]8(O)Cc2c1C[C@@]35O)ccc6O, Oc1ccc2C[C@H]3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)c1[nH]c2[C@@H]4Oc6c7c(C[C@H]8N(CC9CC9)CC[C@@]47[C@@]8(O)Cc2c1C[C@@]35O)ccc6O, Oc1ccc2C[C@H]3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)c1[nH]c2[C@@H]4Oc6c7c(C[C@H]8N(CC9CC9)CC[C@@]47[C@@]8(O)Cc2c1C[C@@]35O)ccc6O	Preclinical
norcyclobenzaprine	adrenergic receptor agonist, serotonin receptor antagonist				Prestwick, Prestwick, Toronto, Toronto	99.3	CNCCC=C1c2ccccc2C=Cc2ccccc12 |c:13|, CNCCC=C1c2ccccc2C=Cc2ccccc12 |c:13|, CNCCC=C1c2ccccc2C=Cc2ccccc12 |c:13|, CNCCC=C1c2ccccc2C=Cc2ccccc12 |c:13|	Preclinical
norelgestromin		PGR	endocrinology	contraceptive	MedChemEx	88.48	CC[C@]12CC[C@H]3[C@@H](CCC4=C\C(CC[C@H]34)=N\O)[C@@H]1CC[C@@]2(O)C#C |t:9|	Launched
norepinephrine	adrenergic receptor agonist	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3, PAH, SLC18A1, SLC18A2	cardiology, allergy, neurology/psychiatry	hypertension, urticaria, headache, seasonal affective disorder	MedChemEx, MedChemEx, Selleck, Selleck, MicroSource	100	NC[C@H](O)c1ccc(O)c(O)c1, NC[C@H](O)c1ccc(O)c(O)c1, NC[C@H](O)c1ccc(O)c(O)c1, NC[C@H](O)c1ccc(O)c(O)c1, NC[C@H](O)c1ccc(O)c(O)c1	Launched
norethindrone	progesterone receptor agonist	PGR	obstetrics/gynecology	endometriosis	Selleck, Selleck, Selleck, Selleck, MicroSource, MicroSource, Selleck	98.2	C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C |t:8|, C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C |t:8|, C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C |t:8|, C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C |t:8|, C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C |t:8|, C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C |t:8|, C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C |t:8|	Launched
norethindrone-acetate	progesterone receptor agonist	PGR	endocrinology, orthopedics, obstetrics/gynecology	menopause, osteoporosis, vaginal atrophy	MedChemEx	90.57	CC(=O)O[C@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3CC[C@]12C)C#C |t:11|	Launched
norethisterone-enanthate	contraceptive agent		endocrinology	contraceptive	AvaChem, AvaChem, AvaChem	96.7	CCCCCCC(=O)O[C@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3CC[C@]12C)C#C |t:16|, CCCCCCC(=O)O[C@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3CC[C@]12C)C#C |t:16|, CCCCCCC(=O)O[C@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3CC[C@]12C)C#C |t:16|	Launched
noretynodrel	progestogen hormone	PGR	endocrinology	contraceptive	MicroSource, MicroSource	81.73	C[C@]12CC[C@H]3[C@@H](CCC4=C3CCC(=O)C4)[C@@H]1CC[C@@]2(O)C#C |a:1,18,&1:4,&2:5,&3:15,c:8|, C[C@]12CC[C@H]3[C@@H](CCC4=C3CCC(=O)C4)[C@@H]1CC[C@@]2(O)C#C |a:1,18,&1:4,&2:5,&3:15,c:8|	Launched
norfloxacin	bacterial DNA gyrase inhibitor	TOP2A	infectious disease, urology	urinary tract infections, gonorrhea, prostatitis	MedChemEx, Selleck, Selleck, MicroSource	98.57	CCn1cc(C(O)=O)c(=O)c2cc(F)c(cc12)N1CCNCC1, CCn1cc(C(O)=O)c(=O)c2cc(F)c(cc12)N1CCNCC1, CCn1cc(C(O)=O)c(=O)c2cc(F)c(cc12)N1CCNCC1, CCn1cc(C(O)=O)c(=O)c2cc(F)c(cc12)N1CCNCC1	Launched
norfluoxetine	selective serotonin reuptake inhibitor (SSRI)	HTR2B			Cayman, Cayman	95.93	NCC[C@@H](Oc1ccc(cc1)C(F)(F)F)c1ccccc1 |&1:3,r|, NCC[C@@H](Oc1ccc(cc1)C(F)(F)F)c1ccccc1 |&1:3,r|	Phase 1
norgestimate	progesterone receptor agonist	ESR1, PGR	endocrinology	contraceptive	MicroSource, Sigma	61.05	CC[C@]12CC[C@H]3[C@@H](CCC4=C\C(CC[C@H]34)=N\O)[C@@H]1CC[C@@]2(OC(C)=O)C#C |t:9|, CC[C@]12CC[C@H]3[C@@H](CCC4=C\C(CC[C@H]34)=N\O)[C@@H]1CC[C@@]2(OC(C)=O)C#C |t:9|	Launched
norgestrel	progesterone receptor agonist	AR, ESR1, PGR, SRD5A1	endocrinology	contraceptive	MicroSource, MicroSource, MicroSource	98.29	CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C |a:2,6,15,16,19,&1:5,t:9|, CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C |a:2,6,15,16,19,&1:5,t:9|, CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C |a:2,6,15,16,19,&1:5,t:9|	Launched
nornicotine	acetylcholine receptor agonist				MedChemEx	82.9	C1CN[C@H](C1)c1cccnc1 |r|	Preclinical
nortriptyline	tricyclic antidepressant	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD2, HRH1, HTR1A, HTR2A, HTR2C, HTR6, KCNJ10, PGRMC1, SIGMAR1, SLC6A2, SLC6A4	neurology/psychiatry	depression	MedChemEx, MicroSource	98.98	CNCCC=C1c2ccccc2CCc2ccccc12, CNCCC=C1c2ccccc2CCc2ccccc12	Launched
norvancomycin					MedChemEx	87.55	[H][C@@]1(C[C@](C)(N)[C@H](O)[C@H](C)O1)O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1Oc1c2Oc3ccc(cc3Cl)[C@@H](O)[C@@H](NC(=O)[C@H](N)CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@]3([H])c(c2)cc1Oc1ccc(cc1Cl)[C@@H](O)[C@]1([H])NC(=O)[C@]([H])(NC3=O)c2ccc(O)c(c2)-c2c(O)cc(O)cc2[C@]([H])(NC1=O)C(O)=O	Preclinical
noscapine	bradykinin receptor antagonist, tubulin polymerization inhibitor	SIGMAR1	pulmonary	cough suppressant	Selleck, Pharmeks, Pharmeks, Tocris, Tocris	99.16	COc1ccc2[C@H](OC(=O)c2c1OC)[C@@H]1N(C)CCc2cc3OCOc3c(OC)c12, COc1ccc2[C@H](OC(=O)c2c1OC)[C@@H]1N(C)CCc2cc3OCOc3c(OC)c12, COc1ccc2[C@H](OC(=O)c2c1OC)[C@@H]1N(C)CCc2cc3OCOc3c(OC)c12, COc1ccc2[C@H](OC(=O)c2c1OC)[C@@H]1N(C)CCc2cc3OCOc3c(OC)c12, COc1ccc2[C@H](OC(=O)c2c1OC)[C@@H]1N(C)CCc2cc3OCOc3c(OC)c12	Launched
NOV-002		GSR			InterBioScreen, InterBioScreen	100	N[C@@H](CCC(=O)N[C@@H](CSSC[C@H](NC(=O)CC[C@@H](N)C(O)=O)C(=O)NCC(O)=O)C(=O)NCC(O)=O)C(O)=O, N[C@@H](CCC(=O)N[C@@H](CSSC[C@H](NC(=O)CC[C@@H](N)C(O)=O)C(=O)NCC(O)=O)C(=O)NCC(O)=O)C(O)=O	Phase 3
novobiocin	bacterial DNA gyrase inhibitor		obstetrics/gynecology	mastitis	MedChemEx, Selleck, Selleck, MicroSource, MicroSource, Selleck	89.03	CO[C@@H]1[C@@H](OC(N)=O)[C@@H](O)[C@H](Oc2ccc3c(O)c(NC(=O)c4ccc(O)c(CC=C(C)C)c4)c(=O)oc3c2C)OC1(C)C, CO[C@@H]1[C@@H](OC(N)=O)[C@@H](O)[C@H](Oc2ccc3c(O)c(NC(=O)c4ccc(O)c(CC=C(C)C)c4)c(=O)oc3c2C)OC1(C)C, CO[C@@H]1[C@@H](OC(N)=O)[C@@H](O)[C@H](Oc2ccc3c(O)c(NC(=O)c4ccc(O)c(CC=C(C)C)c4)c(=O)oc3c2C)OC1(C)C, CO[C@@H]1[C@@H](OC(N)=O)[C@@H](O)[C@H](Oc2ccc3c(O)c(NC(=O)c4ccc(O)c(CC=C(C)C)c4)c(=O)oc3c2C)OC1(C)C, CO[C@@H]1[C@@H](OC(N)=O)[C@@H](O)[C@H](Oc2ccc3c(O)c(NC(=O)c4ccc(O)c(CC=C(C)C)c4)c(=O)oc3c2C)OC1(C)C, CO[C@@H]1[C@@H](OC(N)=O)[C@@H](O)[C@H](Oc2ccc3c(O)c(NC(=O)c4ccc(O)c(CC=C(C)C)c4)c(=O)oc3c2C)OC1(C)C	Launched
NPC-01	steroid				Sigma, Sigma	93.36	C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CCC2=O |t:9|, C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CCC2=O |t:9|	Phase 3
NPC-15199	ICAM1 antagonist	PPARG			Tocris, Tocris	97.42	CC(C)C[C@@H](NC(=O)OCC1c2ccccc2-c2ccccc12)C(O)=O, CC(C)C[C@@H](NC(=O)OCC1c2ccccc2-c2ccccc12)C(O)=O	Phase 2
NPPB	chloride channel blocker	ANO1, CLCN2, CLCN7, TRPA1			Tocris, Tocris, Tocris, Tocris	98.44	OC(=O)c1cc(ccc1NCCCc1ccccc1)[N+]([O-])=O, OC(=O)c1cc(ccc1NCCCc1ccccc1)[N+]([O-])=O, OC(=O)c1cc(ccc1NCCCc1ccccc1)[N+]([O-])=O, OC(=O)c1cc(ccc1NCCCc1ccccc1)[N+]([O-])=O	Preclinical
NPS-2143	calcium receptor antagonist	CASR			Tocris, Tocris, Selleck, Selleck, Selleck, Tocris, Tocris	98.6	CC(C)(Cc1ccc2ccccc2c1)NC[C@@H](O)COc1cccc(Cl)c1C#N, CC(C)(Cc1ccc2ccccc2c1)NC[C@@H](O)COc1cccc(Cl)c1C#N, CC(C)(Cc1ccc2ccccc2c1)NC[C@@H](O)COc1cccc(Cl)c1C#N, CC(C)(Cc1ccc2ccccc2c1)NC[C@@H](O)COc1cccc(Cl)c1C#N, CC(C)(Cc1ccc2ccccc2c1)NC[C@@H](O)COc1cccc(Cl)c1C#N, CC(C)(Cc1ccc2ccccc2c1)NC[C@@H](O)COc1cccc(Cl)c1C#N, CC(C)(Cc1ccc2ccccc2c1)NC[C@@H](O)COc1cccc(Cl)c1C#N	Preclinical
NPS-2407	glutamate receptor antagonist				AMS	79.88	CC(C)(Cc1ccccc1)NC(=O)c1cnc2ccccc2n1	Preclinical
NPY-5RA972	neuropeptide receptor antagonist	NPY5R			Tocris, Tocris, Tocris	95.24	CC(C)n1c2ccccc2c2c(C)c(NC(=O)N3CCOCC3)ccc12, CC(C)n1c2ccccc2c2c(C)c(NC(=O)N3CCOCC3)ccc12, CC(C)n1c2ccccc2c2c(C)c(NC(=O)N3CCOCC3)ccc12	Preclinical
NQDI-1	caspase inhibitor	CASP3			MedChemEx, MedChemEx	96.79	CCOC(=O)c1c2-c3ccccc3C(=O)c3cccc([nH]c1=O)c23, CCOC(=O)c1c2-c3ccccc3C(=O)c3cccc([nH]c1=O)c23	Preclinical
NS-018	JAK inhibitor	JAK1, JAK2, JAK3, TYK2			MedChemEx, MedChemEx, MedChemEx	92.62	C[C@H](Nc1cc(cc(Nc2cnccn2)n1)-c1cnn(C)c1)c1ccc(F)cc1, C[C@H](Nc1cc(cc(Nc2cnccn2)n1)-c1cnn(C)c1)c1ccc(F)cc1, C[C@H](Nc1cc(cc(Nc2cnccn2)n1)-c1cnn(C)c1)c1ccc(F)cc1	Phase 1/Phase 2
NS-11021	calcium-activated potassium channel activator	KCNMA1			Tocris, Tocris	38.32	FC(F)(F)c1cc(NC(=S)Nc2ccc(Br)cc2-c2nn[nH]n2)cc(c1)C(F)(F)F, FC(F)(F)c1cc(NC(=S)Nc2ccc(Br)cc2-c2nn[nH]n2)cc(c1)C(F)(F)F	Preclinical
NS-11394	GABA receptor agonist				Sigma	98.14	CC(C)(O)c1ccc2n(cnc2c1)-c1cccc(c1)-c1ccccc1C#N	Preclinical
NS-1643	voltage-gated potassium channel activator	KCNH2, KCNH6, KCNMA1			Tocris, Stanley, Stanley, Stanley, Stanley	95.1	Oc1ccc(cc1NC(=O)Nc1cc(ccc1O)C(F)(F)F)C(F)(F)F, Oc1ccc(cc1NC(=O)Nc1cc(ccc1O)C(F)(F)F)C(F)(F)F, Oc1ccc(cc1NC(=O)Nc1cc(ccc1O)C(F)(F)F)C(F)(F)F, Oc1ccc(cc1NC(=O)Nc1cc(ccc1O)C(F)(F)F)C(F)(F)F, Oc1ccc(cc1NC(=O)Nc1cc(ccc1O)C(F)(F)F)C(F)(F)F	Preclinical
NS-19504	calcium-activated potassium channel activator	KCNMA1			Tocris, Tocris, Tocris	94.1	Nc1ncc(Cc2ccc(Br)cc2)s1, Nc1ncc(Cc2ccc(Br)cc2)s1, Nc1ncc(Cc2ccc(Br)cc2)s1	Preclinical
NS-309	calcium-activated potassium channel activator	KCNN1, KCNN2, KCNN3, KCNN4			Tocris	94.59	O\N=C1/C(=O)Nc2c1ccc(Cl)c2Cl	Preclinical
NS-3623	voltage-gated potassium channel activator	KCNH2			Tocris, Stanley, Stanley, Stanley, Stanley, Stanley	96.49	FC(F)(F)c1cccc(NC(=O)Nc2ccc(Br)cc2-c2nn[nH]n2)c1, FC(F)(F)c1cccc(NC(=O)Nc2ccc(Br)cc2-c2nn[nH]n2)c1, FC(F)(F)c1cccc(NC(=O)Nc2ccc(Br)cc2-c2nn[nH]n2)c1, FC(F)(F)c1cccc(NC(=O)Nc2ccc(Br)cc2-c2nn[nH]n2)c1, FC(F)(F)c1cccc(NC(=O)Nc2ccc(Br)cc2-c2nn[nH]n2)c1, FC(F)(F)c1cccc(NC(=O)Nc2ccc(Br)cc2-c2nn[nH]n2)c1	Preclinical
NS-3861	acetylcholine receptor agonist	CHRNA3, CHRNB4			Tocris	78.64	CN1[C@@H]2CC[C@H]1C=C(C2)c1sccc1Br |&1:2,5,c:7|	Preclinical
NS-5806	voltage-gated potassium channel activator	KCND3			Tocris, Tocris, Tocris	97	FC(F)(F)c1cc(NC(=O)Nc2c(Br)cc(Br)cc2-c2nn[nH]n2)cc(c1)C(F)(F)F, FC(F)(F)c1cc(NC(=O)Nc2c(Br)cc(Br)cc2-c2nn[nH]n2)cc(c1)C(F)(F)F, FC(F)(F)c1cc(NC(=O)Nc2c(Br)cc(Br)cc2-c2nn[nH]n2)cc(c1)C(F)(F)F	Preclinical
NS-8	potassium channel agonist	KCNMA1			Enamine	40.47	Cc1c([nH]c(N)c1C#N)-c1ccccc1F	Phase 2
NS-8593	calcium-activated potassium channel modulator	KCNN1, KCNN2, KCNN3			Tocris, Tocris	97.22	C1C[C@@H](Nc2nc3ccccc3[nH]2)c2ccccc2C1, C1C[C@@H](Nc2nc3ccccc3[nH]2)c2ccccc2C1	Preclinical
NS-9283	acetylcholine receptor allosteric modulator	CHRNA4			Tocris, Tocris, Tocris, Tocris	98	N#Cc1cccc(c1)-c1nc(no1)-c1cccnc1, N#Cc1cccc(c1)-c1nc(no1)-c1cccnc1, N#Cc1cccc(c1)-c1nc(no1)-c1cccnc1, N#Cc1cccc(c1)-c1nc(no1)-c1cccnc1	Preclinical
NSC-23766	Ras GTPase inhibitor				Tocris, Selleck, Tocris, Selleck	95.29	CCN(CC)CCC[C@@H](C)Nc1nc(C)cc(Nc2ccc3nc(C)cc(N)c3c2)n1 |&1:8|, CCN(CC)CCC[C@@H](C)Nc1nc(C)cc(Nc2ccc3nc(C)cc(N)c3c2)n1 |&1:8|, CCN(CC)CCC[C@@H](C)Nc1nc(C)cc(Nc2ccc3nc(C)cc(N)c3c2)n1 |&1:8|, CCN(CC)CCC[C@@H](C)Nc1nc(C)cc(Nc2ccc3nc(C)cc(N)c3c2)n1 |&1:8|	Preclinical
NSC-319726	p53 activator				Tocris, Selleck, Tocris, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck	95.41	C\C(=N/NC(=S)N1CCC1)c1ccccn1, C\C(=N/NC(=S)N1CCC1)c1ccccn1, C\C(=N/NC(=S)N1CCC1)c1ccccn1, C\C(=N/NC(=S)N1CCC1)c1ccccn1, C\C(=N/NC(=S)N1CCC1)c1ccccn1, C\C(=N/NC(=S)N1CCC1)c1ccccn1, C\C(=N/NC(=S)N1CCC1)c1ccccn1, C\C(=N/NC(=S)N1CCC1)c1ccccn1, C\C(=N/NC(=S)N1CCC1)c1ccccn1	Preclinical
NSC-3852	HDAC inhibitor	HDAC1			Tocris, Tocris, Tocris, Tocris	96.22	Oc1ccc(N=O)c2cccnc12, Oc1ccc(N=O)c2cccnc12, Oc1ccc(N=O)c2cccnc12, Oc1ccc(N=O)c2cccnc12	Preclinical
NSC-405020	matrix metalloprotease inhibitor	MMP1			Tocris, Tocris, Selleck, Selleck, Selleck, Selleck	97.07	CCC[C@@H](C)NC(=O)c1ccc(Cl)c(Cl)c1 |&1:3,r|, CCC[C@@H](C)NC(=O)c1ccc(Cl)c(Cl)c1 |&1:3,r|, CCC[C@@H](C)NC(=O)c1ccc(Cl)c(Cl)c1 |&1:3,r|, CCC[C@@H](C)NC(=O)c1ccc(Cl)c(Cl)c1 |&1:3,r|, CCC[C@@H](C)NC(=O)c1ccc(Cl)c(Cl)c1 |&1:3,r|, CCC[C@@H](C)NC(=O)c1ccc(Cl)c(Cl)c1 |&1:3,r|	Preclinical
NSC-4644	ACAT inhibitor, sterol regulatory element binding protein (SREBP) inhibitor	PYGM			MedChemEx, Enzo	100	CC(=C)[C@@H]1CC[C@]2(CO)CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12, CC(=C)[C@@H]1CC[C@]2(CO)CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12	Phase 2
NSC-5844	CC chemokine receptor agonist	CCR1			MedChemEx	96.41	Clc1ccc2c(NCCNc3ccnc4cc(Cl)ccc34)ccnc2c1	Preclinical
NSC-625987	CDK inhibitor	CDK2, CDK4			Tocris	0.34	COc1ccc(OC)c2c1[nH]c1ccccc1c2=S	Preclinical
NSC-632839	ubiquitin specific protease inhibitor	SENP2, USP1, USP2, USP7			Tocris, Tocris, Tocris, Tocris, Tocris	93.86	Cc1ccc(\C=C2/CNC\C(=C/c3ccc(C)cc3)C2=O)cc1, Cc1ccc(\C=C2/CNC\C(=C/c3ccc(C)cc3)C2=O)cc1, Cc1ccc(\C=C2/CNC\C(=C/c3ccc(C)cc3)C2=O)cc1, Cc1ccc(\C=C2/CNC\C(=C/c3ccc(C)cc3)C2=O)cc1, Cc1ccc(\C=C2/CNC\C(=C/c3ccc(C)cc3)C2=O)cc1	Preclinical
NSC-636819	histone demethylase inhibitor	KDM4A, KDM4B			Tocris	90.48	[O-][N+](=O)c1cc(c(\C=C\c2ccc(Cl)c(Cl)c2)cc1\C=C\c1ccc(Cl)c(Cl)c1)[N+]([O-])=O	Preclinical
NSC-663284	CDC inhibitor	CDC25A, CDC25B, CDC25C			Tocris, Tocris, Tocris, Tocris, Tocris, Tocris, Tocris	96.21	ClC1=C(NCCN2CCOCC2)C(=O)c2ncccc2C1=O |c:1|, ClC1=C(NCCN2CCOCC2)C(=O)c2ncccc2C1=O |c:1|, ClC1=C(NCCN2CCOCC2)C(=O)c2ncccc2C1=O |c:1|, ClC1=C(NCCN2CCOCC2)C(=O)c2ncccc2C1=O |c:1|, ClC1=C(NCCN2CCOCC2)C(=O)c2ncccc2C1=O |c:1|, ClC1=C(NCCN2CCOCC2)C(=O)c2ncccc2C1=O |c:1|, ClC1=C(NCCN2CCOCC2)C(=O)c2ncccc2C1=O |c:1|	Preclinical
NSC-697923	ubiquitin-conjugating enzyme inhibitor	UBE2N			Tocris, Selleck, Selleck, Tocris, Tocris	92.89	Cc1ccc(cc1)S(=O)(=O)c1ccc(o1)[N+]([O-])=O, Cc1ccc(cc1)S(=O)(=O)c1ccc(o1)[N+]([O-])=O, Cc1ccc(cc1)S(=O)(=O)c1ccc(o1)[N+]([O-])=O, Cc1ccc(cc1)S(=O)(=O)c1ccc(o1)[N+]([O-])=O, Cc1ccc(cc1)S(=O)(=O)c1ccc(o1)[N+]([O-])=O	Preclinical
NSC-95397	CDC inhibitor	CDC25A, CDC25B			Tocris	9.25	OCCSC1=C(SCCO)C(=O)c2ccccc2C1=O |c:4|	Preclinical
NSC-9965	acetylcholine receptor antagonist	CHRNA4, CHRNB2			Enzo, Enzo, Tocris	100	CO[C@H]1CC=C2CCN3CCC4=C(CC(=O)OC4)[C@]23C1 |t:4,11|, CO[C@H]1CC=C2CCN3CCC4=C(CC(=O)OC4)[C@]23C1 |t:4,11|, CO[C@H]1CC=C2CCN3CCC4=C(CC(=O)OC4)[C@]23C1 |t:4,11|	Preclinical
NSI-189	neurotrophic agent				MedChemEx, MedChemEx	99.38	CC(C)CCNc1ncccc1C(=O)N1CCN(Cc2ccccc2)CC1, CC(C)CCNc1ncccc1C(=O)N1CCN(Cc2ccccc2)CC1	Phase 2
NSP-805	phosphodiesterase inhibitor				MedChemEx	91.88	CC1=C(CCC1=O)Nc1ccc(cc1)C1=C(C)CC(=O)NN1 |c:16,t:1|	Preclinical
NTNCB	neuropeptide receptor antagonist	NPY5R			Tocris, Tocris, Tocris, Tocris, Tocris	97.68	[O-][N+](=O)c1ccccc1S(=O)(=O)NC[C@H]1CC[C@H](CNC[C@H]2CCc3ccccc3C2)CC1 |a:14,17,&1:21|, [O-][N+](=O)c1ccccc1S(=O)(=O)NC[C@H]1CC[C@H](CNC[C@H]2CCc3ccccc3C2)CC1 |a:14,17,&1:21|, [O-][N+](=O)c1ccccc1S(=O)(=O)NC[C@H]1CC[C@H](CNC[C@H]2CCc3ccccc3C2)CC1 |a:14,17,&1:21|, [O-][N+](=O)c1ccccc1S(=O)(=O)NC[C@H]1CC[C@H](CNC[C@H]2CCc3ccccc3C2)CC1 |a:14,17,&1:21|, [O-][N+](=O)c1ccccc1S(=O)(=O)NC[C@H]1CC[C@H](CNC[C@H]2CCc3ccccc3C2)CC1 |a:14,17,&1:21|	Preclinical
NTRC-824	neurotensin receptor antagonist	NTSR2			Tocris, Tocris	93.63	CC(C)C[C@H](NC(=O)Cn1cc(C(=O)C(F)(F)F)c2cc(NS(=O)(=O)c3ccc(C)cc3)ccc12)C(O)=O, CC(C)C[C@H](NC(=O)Cn1cc(C(=O)C(F)(F)F)c2cc(NS(=O)(=O)c3ccc(C)cc3)ccc12)C(O)=O	Preclinical
nTZDpa	PPAR receptor agonist	PPARG			Tocris, Tocris, Tocris	98	OC(=O)c1c(Sc2ccccc2)c2cc(Cl)ccc2n1Cc1ccc(Cl)cc1, OC(=O)c1c(Sc2ccccc2)c2cc(Cl)ccc2n1Cc1ccc(Cl)cc1, OC(=O)c1c(Sc2ccccc2)c2cc(Cl)ccc2n1Cc1ccc(Cl)cc1	Preclinical
NT157	IGF-1 inhibitor	IGF1R			MedChemEx, MedChemEx	66.42	Oc1cc(CNC(=S)\C=C\c2cc(O)c(O)c(Br)c2)cc(O)c1O, Oc1cc(CNC(=S)\C=C\c2cc(O)c(O)c(Br)c2)cc(O)c1O	Preclinical
NU-1025	PARP inhibitor	PARP1			Tocris, Tocris, Tocris	95.84	Cc1nc(=O)c2cccc(O)c2[nH]1, Cc1nc(=O)c2cccc(O)c2[nH]1, Cc1nc(=O)c2cccc(O)c2[nH]1	Preclinical
NU-2058	cyclin D inhibitor	CCNA2, CDK2			Tocris	91.61	Nc1nc(OCC2CCCCC2)c2[nH]cnc2n1	Preclinical
NU-6027	CDK inhibitor	CCNA2, CDK2			Selleck, Selleck, Selleck	95.4	Nc1nc(N)c(N=O)c(OCC2CCCCC2)n1, Nc1nc(N)c(N=O)c(OCC2CCCCC2)n1, Nc1nc(N)c(N=O)c(OCC2CCCCC2)n1	Preclinical
NU-7026	DNA dependent protein kinase inhibitor, mTOR inhibitor, PI3K inhibitor	PRKDC			MedChemEx, MedChemEx, Tocris, Selleck, Selleck	99.72	O=c1cc(oc2c3ccccc3ccc12)N1CCOCC1, O=c1cc(oc2c3ccccc3ccc12)N1CCOCC1, O=c1cc(oc2c3ccccc3ccc12)N1CCOCC1, O=c1cc(oc2c3ccccc3ccc12)N1CCOCC1, O=c1cc(oc2c3ccccc3ccc12)N1CCOCC1	Preclinical
NU-7441	DNA dependent protein kinase inhibitor	PRKDC			Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Focus	98.93	O=c1cc(oc2c(cccc12)-c1cccc2c3ccccc3sc12)N1CCOCC1, O=c1cc(oc2c(cccc12)-c1cccc2c3ccccc3sc12)N1CCOCC1, O=c1cc(oc2c(cccc12)-c1cccc2c3ccccc3sc12)N1CCOCC1, O=c1cc(oc2c(cccc12)-c1cccc2c3ccccc3sc12)N1CCOCC1, O=c1cc(oc2c(cccc12)-c1cccc2c3ccccc3sc12)N1CCOCC1, O=c1cc(oc2c(cccc12)-c1cccc2c3ccccc3sc12)N1CCOCC1, O=c1cc(oc2c(cccc12)-c1cccc2c3ccccc3sc12)N1CCOCC1, O=c1cc(oc2c(cccc12)-c1cccc2c3ccccc3sc12)N1CCOCC1	Preclinical
nuclomedone	immunosuppressant				InterBioScreen	93.86	Clc1ccc(C[C@H]2C(=O)N=C3SCCN3C2=O)cc1 |r,t:9|	Phase 3
nutlin-3	MDM inhibitor	MDM2, TP53			Tocris	95.27	COc1ccc(C2=N[C@H]([C@H](N2C(=O)N2CCNC(=O)C2)c2ccc(Cl)cc2)c2ccc(Cl)cc2)c(OC(C)C)c1 |&1:8,9,r,t:6|	Preclinical
nuvenzepine	acetylcholine receptor antagonist				MedChemEx	98.12	CN1CCC(CC1)C(=O)N1c2ccccc2NC(=O)c2cccnc12	Preclinical
NVP-ADW742	insulin growth factor receptor inhibitor	IGF1R			Tocris, Tocris, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck	96.14	Nc1ncnc2n(cc(-c3cccc(OCc4ccccc4)c3)c12)[C@H]1C[C@H](CN2CCCC2)C1 |r|, Nc1ncnc2n(cc(-c3cccc(OCc4ccccc4)c3)c12)[C@H]1C[C@H](CN2CCCC2)C1 |r|, Nc1ncnc2n(cc(-c3cccc(OCc4ccccc4)c3)c12)[C@H]1C[C@H](CN2CCCC2)C1 |r|, Nc1ncnc2n(cc(-c3cccc(OCc4ccccc4)c3)c12)[C@H]1C[C@H](CN2CCCC2)C1 |r|, Nc1ncnc2n(cc(-c3cccc(OCc4ccccc4)c3)c12)[C@H]1C[C@H](CN2CCCC2)C1 |r|, Nc1ncnc2n(cc(-c3cccc(OCc4ccccc4)c3)c12)[C@H]1C[C@H](CN2CCCC2)C1 |r|, Nc1ncnc2n(cc(-c3cccc(OCc4ccccc4)c3)c12)[C@H]1C[C@H](CN2CCCC2)C1 |r|, Nc1ncnc2n(cc(-c3cccc(OCc4ccccc4)c3)c12)[C@H]1C[C@H](CN2CCCC2)C1 |r|, Nc1ncnc2n(cc(-c3cccc(OCc4ccccc4)c3)c12)[C@H]1C[C@H](CN2CCCC2)C1 |r|	Preclinical
NVP-AEW541	IGF-1 inhibitor	IGF1R, INSR			MedChemEx, Selleck, Selleck, Selleck, Selleck	96.92	Nc1ncnc2n(cc(-c3cccc(OCc4ccccc4)c3)c12)[C@@H]1C[C@H](CN2CCC2)C1 |r|, Nc1ncnc2n(cc(-c3cccc(OCc4ccccc4)c3)c12)[C@@H]1C[C@H](CN2CCC2)C1 |r|, Nc1ncnc2n(cc(-c3cccc(OCc4ccccc4)c3)c12)[C@@H]1C[C@H](CN2CCC2)C1 |r|, Nc1ncnc2n(cc(-c3cccc(OCc4ccccc4)c3)c12)[C@@H]1C[C@H](CN2CCC2)C1 |r|, Nc1ncnc2n(cc(-c3cccc(OCc4ccccc4)c3)c12)[C@@H]1C[C@H](CN2CCC2)C1 |r|	Preclinical
NVP-AUY922	HSP inhibitor	HSP90AA1, HSP90AB1			MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx, Selleck, Selleck, Selleck, Selleck, Selleck	97.82	CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O, CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O, CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O, CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O, CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O, CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O, CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O, CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O, CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O, CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O, CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O	Phase 2
NVP-BEZ235	mTOR inhibitor, PI3K inhibitor	ATR, MTOR, PIK3CA, PIK3CD, PIK3CG			Selleck, Selleck, Selleck, Selleck	98.67	Cn1c2cnc3ccc(cc3c2n(-c2ccc(cc2)C(C)(C)C#N)c1=O)-c1cnc2ccccc2c1, Cn1c2cnc3ccc(cc3c2n(-c2ccc(cc2)C(C)(C)C#N)c1=O)-c1cnc2ccccc2c1, Cn1c2cnc3ccc(cc3c2n(-c2ccc(cc2)C(C)(C)C#N)c1=O)-c1cnc2ccccc2c1, Cn1c2cnc3ccc(cc3c2n(-c2ccc(cc2)C(C)(C)C#N)c1=O)-c1cnc2ccccc2c1	Phase 3
NVP-BGJ398	FGFR inhibitor	FGFR1, FGFR2, FGFR3, FGFR4, KDR			LCLabs, LCLabs, MedChemEx, Selleck, MedChemEx, Selleck	89.82	CCN1CCN(CC1)c1ccc(Nc2cc(ncn2)N(C)C(=O)Nc2c(Cl)c(OC)cc(OC)c2Cl)cc1, CCN1CCN(CC1)c1ccc(Nc2cc(ncn2)N(C)C(=O)Nc2c(Cl)c(OC)cc(OC)c2Cl)cc1, CCN1CCN(CC1)c1ccc(Nc2cc(ncn2)N(C)C(=O)Nc2c(Cl)c(OC)cc(OC)c2Cl)cc1, CCN1CCN(CC1)c1ccc(Nc2cc(ncn2)N(C)C(=O)Nc2c(Cl)c(OC)cc(OC)c2Cl)cc1, CCN1CCN(CC1)c1ccc(Nc2cc(ncn2)N(C)C(=O)Nc2c(Cl)c(OC)cc(OC)c2Cl)cc1, CCN1CCN(CC1)c1ccc(Nc2cc(ncn2)N(C)C(=O)Nc2c(Cl)c(OC)cc(OC)c2Cl)cc1	Phase 3
NVP-BHG712	ephrin inhibitor	EPHB4			MedChemEx, Selleck, Selleck, Selleck	98.2	Cc1ccc(cc1Nc1nc(nc2n(C)ncc12)-c1cccnc1)C(=O)Nc1cccc(c1)C(F)(F)F, Cc1ccc(cc1Nc1nc(nc2n(C)ncc12)-c1cccnc1)C(=O)Nc1cccc(c1)C(F)(F)F, Cc1ccc(cc1Nc1nc(nc2n(C)ncc12)-c1cccnc1)C(=O)Nc1cccc(c1)C(F)(F)F, Cc1ccc(cc1Nc1nc(nc2n(C)ncc12)-c1cccnc1)C(=O)Nc1cccc(c1)C(F)(F)F	Preclinical
NVP-BSK805	JAK inhibitor	JAK2			Selleck, Selleck, Selleck, Selleck, Selleck, Selleck	92.69	Fc1cc(cc(F)c1CN1CCOCC1)-c1cccc2ncc(nc12)-c1cnn(c1)C1CCNCC1, Fc1cc(cc(F)c1CN1CCOCC1)-c1cccc2ncc(nc12)-c1cnn(c1)C1CCNCC1, Fc1cc(cc(F)c1CN1CCOCC1)-c1cccc2ncc(nc12)-c1cnn(c1)C1CCNCC1, Fc1cc(cc(F)c1CN1CCOCC1)-c1cccc2ncc(nc12)-c1cnn(c1)C1CCNCC1, Fc1cc(cc(F)c1CN1CCOCC1)-c1cccc2ncc(nc12)-c1cnn(c1)C1CCNCC1, Fc1cc(cc(F)c1CN1CCOCC1)-c1cccc2ncc(nc12)-c1cnn(c1)C1CCNCC1	Preclinical
NVP-BVU972	MET inhibitor	MET			Selleck, MedChemEx	98.35	Cn1cc(cn1)-c1ccc2ncc(Cc3ccc4ncccc4c3)n2n1, Cn1cc(cn1)-c1ccc2ncc(Cc3ccc4ncccc4c3)n2n1	Preclinical
NVP-DPP728	dipeptidyl peptidase inhibitor	DPP4			Tocris, Tocris, Tocris, Tocris, Tocris, Tocris	92.57	O=C(CNCCNc1ccc(cn1)C#N)N1CCC[C@H]1C#N, O=C(CNCCNc1ccc(cn1)C#N)N1CCC[C@H]1C#N, O=C(CNCCNc1ccc(cn1)C#N)N1CCC[C@H]1C#N, O=C(CNCCNc1ccc(cn1)C#N)N1CCC[C@H]1C#N, O=C(CNCCNc1ccc(cn1)C#N)N1CCC[C@H]1C#N, O=C(CNCCNc1ccc(cn1)C#N)N1CCC[C@H]1C#N	Phase 2
NVP-HSP990	HSP inhibitor	HSP90AA1, HSP90AB1			MedChemEx, MedChemEx, MedChemEx, MedChemEx	95.72	COc1cccc(n1)-c1cc(F)ccc1[C@H]1Cc2nc(N)nc(C)c2C(=O)N1, COc1cccc(n1)-c1cc(F)ccc1[C@H]1Cc2nc(N)nc(C)c2C(=O)N1, COc1cccc(n1)-c1cc(F)ccc1[C@H]1Cc2nc(N)nc(C)c2C(=O)N1, COc1cccc(n1)-c1cc(F)ccc1[C@H]1Cc2nc(N)nc(C)c2C(=O)N1	Phase 1
NVP-TAE226	protein tyrosine kinase inhibitor	PTK2			Selleck, Selleck, Selleck, Selleck, Selleck, Selleck	95.2	CNC(=O)c1ccccc1Nc1nc(Nc2ccc(cc2OC)N2CCOCC2)ncc1Cl, CNC(=O)c1ccccc1Nc1nc(Nc2ccc(cc2OC)N2CCOCC2)ncc1Cl, CNC(=O)c1ccccc1Nc1nc(Nc2ccc(cc2OC)N2CCOCC2)ncc1Cl, CNC(=O)c1ccccc1Nc1nc(Nc2ccc(cc2OC)N2CCOCC2)ncc1Cl, CNC(=O)c1ccccc1Nc1nc(Nc2ccc(cc2OC)N2CCOCC2)ncc1Cl, CNC(=O)c1ccccc1Nc1nc(Nc2ccc(cc2OC)N2CCOCC2)ncc1Cl	Preclinical
NVP-TAE684	ALK tyrosine kinase receptor inhibitor	ALK, INSR			Selleck, Selleck, Selleck, Selleck	96.23	COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1)N1CCC(CC1)N1CCN(C)CC1, COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1)N1CCC(CC1)N1CCN(C)CC1, COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1)N1CCC(CC1)N1CCN(C)CC1, COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1)N1CCC(CC1)N1CCN(C)CC1	Preclinical
NVP-TNKS656	tankyrase inhibitor	TNKS2			MedChemEx	93.82	COc1ccc(cc1)C(=O)C1CCN(CC(=O)N(CC2CC2)Cc2nc(=O)c3COCCc3[nH]2)CC1	Preclinical
NVP-231	ceramidase inhibitor	CERK			Tocris, MedChemEx, MedChemEx, MedChemEx	97.09	O=C(Nc1nc2ccc(NC(=O)C34CC5CC(CC(C5)C3)C4)cc2s1)c1ccccc1, O=C(Nc1nc2ccc(NC(=O)C34CC5CC(CC(C5)C3)C4)cc2s1)c1ccccc1, O=C(Nc1nc2ccc(NC(=O)C34CC5CC(CC(C5)C3)C4)cc2s1)c1ccccc1, O=C(Nc1nc2ccc(NC(=O)C34CC5CC(CC(C5)C3)C4)cc2s1)c1ccccc1	Preclinical
NVS-PAK1-1	p21 activated kinase inhibitor	PAK1			MedChemEx, MedChemEx	99.3	CC(C)NC(=O)N1CC[C@@H](C1)NC1=Nc2cc(F)ccc2N(CC(F)F)c2ccc(Cl)cc12 |t:13|, CC(C)NC(=O)N1CC[C@@H](C1)NC1=Nc2cc(F)ccc2N(CC(F)F)c2ccc(Cl)cc12 |t:13|	Preclinical
NXY-059	free radical scavenger				MedChemEx, Selleck, Tocris	91.94	CC(C)(C)[N+](\[O-])=C\c1ccc(cc1S(O)(=O)=O)S(O)(=O)=O, CC(C)(C)[N+](\[O-])=C\c1ccc(cc1S(O)(=O)=O)S(O)(=O)=O, CC(C)(C)[N+](\[O-])=C\c1ccc(cc1S(O)(=O)=O)S(O)(=O)=O	Phase 3
nystatin	fungal ergosterol inhibitor		infectious disease	esophageal candidiasis, skin infections, yeast infection	Sigma, MedChemEx, MedChemEx	75.39	C[C@H]1O[C@@H](O[C@@H]2C[C@@H]3O[C@@](O)(C[C@H](O)[C@H]3C(O)=O)C[C@@H](O)[C@H](O)CC[C@@H](O)C[C@@H](O)C[C@@H](O)CC(=O)O[C@@H](C)[C@H](C)[C@H](O)[C@@H](C)\C=C\C=C\CC\C=C\C=C\C=C\C=C\2)[C@@H](O)[C@@H](N)[C@@H]1O |t:46,48,52,54,56,58|, C[C@H]1O[C@@H](O[C@@H]2C[C@@H]3O[C@@](O)(C[C@H](O)[C@H]3C(O)=O)C[C@@H](O)[C@H](O)CC[C@@H](O)C[C@@H](O)C[C@@H](O)CC(=O)O[C@@H](C)[C@H](C)[C@H](O)[C@@H](C)\C=C\C=C\CC\C=C\C=C\C=C\C=C\2)[C@@H](O)[C@@H](N)[C@@H]1O |t:46,48,52,54,56,58|, C[C@H]1O[C@@H](O[C@@H]2C[C@@H]3O[C@@](O)(C[C@H](O)[C@H]3C(O)=O)C[C@@H](O)[C@H](O)CC[C@@H](O)C[C@@H](O)C[C@@H](O)CC(=O)O[C@@H](C)[C@H](C)[C@H](O)[C@@H](C)\C=C\C=C\CC\C=C\C=C\C=C\C=C\2)[C@@H](O)[C@@H](N)[C@@H]1O |t:46,48,52,54,56,58|	Launched
N20C	glutamate receptor antagonist				Tocris, Tocris	95.35	NC(=O)CNCCC(c1ccccc1)c1ccccc1, NC(=O)CNCCC(c1ccccc1)c1ccccc1	Preclinical
N6-cyclopentyladenosine	adenosine receptor agonist	ADORA1, ADORA2A, ADORA2B, ADORA3, SLC29A1			Tocris, Tocris	97.75	OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(NC3CCCC3)ncnc12, OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(NC3CCCC3)ncnc12	Preclinical
N6-methyladenosine					MedChemEx, Selleck	97.73	CNc1ncnc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O, CNc1ncnc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O	Preclinical
N6022	alcohol dehydrogenase inhibitor	ADH5			MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx	98.67	Cc1cc(ccc1-n1c(CCC(O)=O)ccc1-c1ccc(cc1)-n1ccnc1)C(N)=O, Cc1cc(ccc1-n1c(CCC(O)=O)ccc1-c1ccc(cc1)-n1ccnc1)C(N)=O, Cc1cc(ccc1-n1c(CCC(O)=O)ccc1-c1ccc(cc1)-n1ccnc1)C(N)=O, Cc1cc(ccc1-n1c(CCC(O)=O)ccc1-c1ccc(cc1)-n1ccnc1)C(N)=O, Cc1cc(ccc1-n1c(CCC(O)=O)ccc1-c1ccc(cc1)-n1ccnc1)C(N)=O, Cc1cc(ccc1-n1c(CCC(O)=O)ccc1-c1ccc(cc1)-n1ccnc1)C(N)=O	Phase 1/Phase 2
O-acetyl-L-serine		PTGS1			Astatech	96.8	CC(=O)OC[C@H](N)C(O)=O	Preclinical
o-mercapto-benzoic-acid					Enamine	97.04	OC(=O)c1ccccc1S	Preclinical
O-1918	cannabinoid receptor antagonist				Tocris, Tocris, Tocris, Tocris, Tocris	97.55	COc1cc(C)cc(OC)c1[C@@H]1C=C(C)CC[C@H]1C(C)=C |t:13|, COc1cc(C)cc(OC)c1[C@@H]1C=C(C)CC[C@H]1C(C)=C |t:13|, COc1cc(C)cc(OC)c1[C@@H]1C=C(C)CC[C@H]1C(C)=C |t:13|, COc1cc(C)cc(OC)c1[C@@H]1C=C(C)CC[C@H]1C(C)=C |t:13|, COc1cc(C)cc(OC)c1[C@@H]1C=C(C)CC[C@H]1C(C)=C |t:13|	Preclinical
o-3M3FBS	phospholipase activator				Tocris, Tocris, Tocris	98.98	Cc1cc(C)c(c(C)c1)S(=O)(=O)Nc1ccccc1C(F)(F)F, Cc1cc(C)c(c(C)c1)S(=O)(=O)Nc1ccccc1C(F)(F)F, Cc1cc(C)c(c(C)c1)S(=O)(=O)Nc1ccccc1C(F)(F)F	Preclinical
O-304	AMPK activator				MedChemEx	95.47	Clc1ccc(Cn2sc(NC(=O)c3ccc(Cl)cc3)nc2=O)cc1	Preclinical
OAC1	Oct activator				Tocris, Tocris, Selleck	94.83	O=C(Nc1cc2cc[nH]c2cn1)c1ccccc1, O=C(Nc1cc2cc[nH]c2cn1)c1ccccc1, O=C(Nc1cc2cc[nH]c2cn1)c1ccccc1	Preclinical
OAC2	Oct activator	POU5F1			MedChemEx, MedChemEx	97.66	O=C(Nc1ccc2[nH]ccc2c1)c1ccccc1, O=C(Nc1ccc2[nH]ccc2c1)c1ccccc1	Preclinical
obatoclax	BCL inhibitor	BCL2			Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck	96.5	COC1=CC(=N\C1=C/c1[nH]c(C)cc1C)c1cc2ccccc2[nH]1 |c:4,t:2|, COC1=CC(=N\C1=C/c1[nH]c(C)cc1C)c1cc2ccccc2[nH]1 |c:4,t:2|, COC1=CC(=N\C1=C/c1[nH]c(C)cc1C)c1cc2ccccc2[nH]1 |c:4,t:2|, COC1=CC(=N\C1=C/c1[nH]c(C)cc1C)c1cc2ccccc2[nH]1 |c:4,t:2|, COC1=CC(=N\C1=C/c1[nH]c(C)cc1C)c1cc2ccccc2[nH]1 |c:4,t:2|, COC1=CC(=N\C1=C/c1[nH]c(C)cc1C)c1cc2ccccc2[nH]1 |c:4,t:2|, COC1=CC(=N\C1=C/c1[nH]c(C)cc1C)c1cc2ccccc2[nH]1 |c:4,t:2|, COC1=CC(=N\C1=C/c1[nH]c(C)cc1C)c1cc2ccccc2[nH]1 |c:4,t:2|, COC1=CC(=N\C1=C/c1[nH]c(C)cc1C)c1cc2ccccc2[nH]1 |c:4,t:2|, COC1=CC(=N\C1=C/c1[nH]c(C)cc1C)c1cc2ccccc2[nH]1 |c:4,t:2|, COC1=CC(=N\C1=C/c1[nH]c(C)cc1C)c1cc2ccccc2[nH]1 |c:4,t:2|	Phase 3
obeticholic-acid	FXR agonist	NR1H4	gastroenterology	primary biliary cholangitis	Selleck	67.62	CC[C@H]1[C@@H](O)[C@H]2[C@H]3CC[C@@H]([C@@H](C)CCC(O)=O)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12 |&1:2,&2:3,&3:5,&4:6,&5:9,&6:10,&7:17,&8:21,&9:22,&10:26,&11:29,r|	Launched
obidoxime	cholinesterase reactivator	ACHE	critical care, neurology/psychiatry	poison antidote, nerve gas poisoning	Vitas-M, Vitas-M	100	O\N=C\c1cc[n+](COC[n+]2ccc(\C=N\O)cc2)cc1, O\N=C\c1cc[n+](COC[n+]2ccc(\C=N\O)cc2)cc1	Launched
ocaperidone	serotonin receptor antagonist				MedChemEx	95.09	Cc1cccn2c1nc(C)c(CCN1CCC(CC1)c1noc3cc(F)ccc13)c2=O	Preclinical
ochromycinone	STAT inhibitor	STAT3			AnalytiCon	0	C[C@@H]1CC(=O)c2c(C1)ccc1C(=O)c3c(O)cccc3C(=O)c21	Phase 1
ocinaplon	GABA receptor modulator	GABRA1, GABRA2, GABRA3, GABRA5			Tocris	99.66	O=C(c1cnn2c(ccnc12)-c1ccncc1)c1ccccn1	Phase 3
OCO-1112	cholesterol inhibitor				Enamine, Enamine, Enamine, Enamine, Enamine	98.74	CC(C)c1ccc(cc1)C(=O)NCCOc1ccc(cc1)C(O)=O, CC(C)c1ccc(cc1)C(=O)NCCOc1ccc(cc1)C(O)=O, CC(C)c1ccc(cc1)C(=O)NCCOc1ccc(cc1)C(O)=O, CC(C)c1ccc(cc1)C(=O)NCCOc1ccc(cc1)C(O)=O, CC(C)c1ccc(cc1)C(=O)NCCOc1ccc(cc1)C(O)=O	Phase 2
octadecan-1-ol					Ark	0	CCCCCCCCCCCCCCCCCCO	Preclinical
octamethyltrisiloxane					Sigma	0	C[Si](C)(C)O[Si](C)(C)O[Si](C)(C)C	Preclinical
octenidine	membrane integrity inhibitor		infectious disease	gram-negative bacterial infections, gram-positive bacterial infections	TCI, TCI, TCI, TCI, TCI, TCI, TCI, TCI	99.2	CCCCCCCCN=c1ccn(CCCCCCCCCCn2ccc(cc2)=NCCCCCCCC)cc1, CCCCCCCCN=c1ccn(CCCCCCCCCCn2ccc(cc2)=NCCCCCCCC)cc1, CCCCCCCCN=c1ccn(CCCCCCCCCCn2ccc(cc2)=NCCCCCCCC)cc1, CCCCCCCCN=c1ccn(CCCCCCCCCCn2ccc(cc2)=NCCCCCCCC)cc1, CCCCCCCCN=c1ccn(CCCCCCCCCCn2ccc(cc2)=NCCCCCCCC)cc1, CCCCCCCCN=c1ccn(CCCCCCCCCCn2ccc(cc2)=NCCCCCCCC)cc1, CCCCCCCCN=c1ccn(CCCCCCCCCCn2ccc(cc2)=NCCCCCCCC)cc1, CCCCCCCCN=c1ccn(CCCCCCCCCCn2ccc(cc2)=NCCCCCCCC)cc1	Launched
octinoxate			dermatology	sunscreen lotion	MedChemEx	97.22	CCCC[C@@H](CC)COC(=O)\C=C\c1ccc(OC)cc1 |&1:4|	Launched
octisalate			dermatology	sunscreen lotion	MedChemEx	98.14	CCCC[C@@H](CC)COC(=O)c1ccccc1O |&1:4|	Launched
octocrylene			dermatology	sunscreen lotion	MedChemEx	96.3	CCCC[C@@H](CC)COC(=O)C(C#N)=C(c1ccccc1)c1ccccc1 |&1:4|	Launched
octodrine	antitumor agent				MicroSource, MedChemEx	100	CC(C)CCC[C@@H](C)N |&1:6,r|, CC(C)CCC[C@@H](C)N |&1:6,r|	Preclinical
octopamine	trace amine associated receptor agonist	F10, TAAR1			MicroSource, Tocris, Selleck, Selleck, Selleck	100	NCC(O)c1ccc(O)cc1, NCC(O)c1ccc(O)cc1, NCC(O)c1ccc(O)cc1, NCC(O)c1ccc(O)cc1, NCC(O)c1ccc(O)cc1	Preclinical
octreotide	somatostatin receptor agonist	SSTR2, SSTR3, SSTR5	gastroenterology, endocrinology, oncology	diarrhea, acromegaly, carcinoid tumors	MedChemEx, MedChemEx, MedChemEx	91	C[C@@H](O)[C@@H](CO)NC(=O)[C@H]1CSSC[C@@H](NC(=O)[C@@H](N)Cc2ccccc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](Cc2c[nH]c3ccccc23)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 |&1:1,&2:3,&3:9,&4:14,&5:18,&6:30,&7:41,&8:55,&9:64,&10:65|, C[C@@H](O)[C@@H](CO)NC(=O)[C@H]1CSSC[C@@H](NC(=O)[C@@H](N)Cc2ccccc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](Cc2c[nH]c3ccccc23)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 |&1:1,&2:3,&3:9,&4:14,&5:18,&6:30,&7:41,&8:55,&9:64,&10:65|, C[C@@H](O)[C@@H](CO)NC(=O)[C@H]1CSSC[C@@H](NC(=O)[C@@H](N)Cc2ccccc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](Cc2c[nH]c3ccccc23)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 |&1:1,&2:3,&3:9,&4:14,&5:18,&6:30,&7:41,&8:55,&9:64,&10:65|	Launched
OC000459	CRTH receptor antagonist	PTGDR2			MedChemEx, Selleck, Selleck	93.19	Cc1c(Cc2ccc3ccccc3n2)c2cc(F)ccc2n1CC(O)=O, Cc1c(Cc2ccc3ccccc3n2)c2cc(F)ccc2n1CC(O)=O, Cc1c(Cc2ccc3ccccc3n2)c2cc(F)ccc2n1CC(O)=O	Phase 2
odanacatib	cathepsin inhibitor	CTSK			MedChemEx, Selleck, Selleck, Selleck	98.17	CC(C)(F)C[C@H](N[C@@H](c1ccc(cc1)-c1ccc(cc1)S(C)(=O)=O)C(F)(F)F)C(=O)NC1(CC1)C#N, CC(C)(F)C[C@H](N[C@@H](c1ccc(cc1)-c1ccc(cc1)S(C)(=O)=O)C(F)(F)F)C(=O)NC1(CC1)C#N, CC(C)(F)C[C@H](N[C@@H](c1ccc(cc1)-c1ccc(cc1)S(C)(=O)=O)C(F)(F)F)C(=O)NC1(CC1)C#N, CC(C)(F)C[C@H](N[C@@H](c1ccc(cc1)-c1ccc(cc1)S(C)(=O)=O)C(F)(F)F)C(=O)NC1(CC1)C#N	Phase 3
ODQ	guanylyl cyclase inhibitor	GUCY1A2, GUCY1A3, GUCY1B3			Tocris, Tocris	70.01	O=c1onc2cnc3ccccc3n12, O=c1onc2cnc3ccccc3n12	Preclinical
OF-1	bromodomain inhibitor	BRD1			Tocris, Tocris	95.56	COc1cc2n(C)c(=O)n(C)c2cc1NS(=O)(=O)c1ccc(Br)cc1C, COc1cc2n(C)c(=O)n(C)c2cc1NS(=O)(=O)c1ccc(Br)cc1C	Preclinical
ofloxacin	bacterial DNA gyrase inhibitor		infectious disease, otolaryngology, gastroenterology, endocrinology	respiratory tract infections, sinusitis, skin infections, bone and joint infections, intra-abdominal infections, diarrhea, fever, urinary tract infections	MicroSource	98.67	C[C@H]1COc2c(N3CCN(C)CC3)c(F)cc3c2n1cc(C(O)=O)c3=O |&1:1|	Launched
OG-L002	histone lysine demethylase inhibitor	KDM1A			Selleck, Selleck, Selleck, Selleck, Selleck, Selleck	91.37	N[C@H]1C[C@@H]1c1ccc(cc1)-c1cccc(O)c1, N[C@H]1C[C@@H]1c1ccc(cc1)-c1cccc(O)c1, N[C@H]1C[C@@H]1c1ccc(cc1)-c1cccc(O)c1, N[C@H]1C[C@@H]1c1ccc(cc1)-c1cccc(O)c1, N[C@H]1C[C@@H]1c1ccc(cc1)-c1cccc(O)c1, N[C@H]1C[C@@H]1c1ccc(cc1)-c1cccc(O)c1	Preclinical
ogerin	G protein-coupled receptor modulator				MedChemEx	97.68	Nc1nc(NCc2ccccc2)nc(n1)-c1ccccc1CO	Preclinical
oglemilast	phosphodiesterase inhibitor				MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx	96.52	CS(=O)(=O)Nc1ccc2oc3c(OC(F)F)ccc(C(=O)Nc4c(Cl)cncc4Cl)c3c2c1, CS(=O)(=O)Nc1ccc2oc3c(OC(F)F)ccc(C(=O)Nc4c(Cl)cncc4Cl)c3c2c1, CS(=O)(=O)Nc1ccc2oc3c(OC(F)F)ccc(C(=O)Nc4c(Cl)cncc4Cl)c3c2c1, CS(=O)(=O)Nc1ccc2oc3c(OC(F)F)ccc(C(=O)Nc4c(Cl)cncc4Cl)c3c2c1, CS(=O)(=O)Nc1ccc2oc3c(OC(F)F)ccc(C(=O)Nc4c(Cl)cncc4Cl)c3c2c1, CS(=O)(=O)Nc1ccc2oc3c(OC(F)F)ccc(C(=O)Nc4c(Cl)cncc4Cl)c3c2c1	Phase 2
oglufanide	VEGF antagonist				MedChemEx	87.14	N[C@@H](CCC(O)=O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(O)=O	Phase 2
OICR-9429	WDR5/MLL interaction inhibitor	WDR5			Tocris, Tocris	95.2	CN1CCN(CC1)c1ccc(cc1NC(=O)c1c[nH]c(=O)cc1C(F)(F)F)-c1cccc(CN2CCOCC2)c1, CN1CCN(CC1)c1ccc(cc1NC(=O)c1c[nH]c(=O)cc1C(F)(F)F)-c1cccc(CN2CCOCC2)c1	Preclinical
olanzapine	dopamine receptor antagonist, serotonin receptor antagonist	ADRA1A, ADRA1B, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD1, DRD2, DRD3, DRD4, DRD5, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, HRH1, HRH2, HRH4, HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR3A, HTR5A, HTR6, HTR7	neurology/psychiatry	schizophrenia, bipolar disorder	MicroSource, MicroSource, Tocris, Selleck, Selleck	95.27	CN1CCN(CC1)C1=Nc2ccccc2Nc2sc(C)cc12 |t:8|, CN1CCN(CC1)C1=Nc2ccccc2Nc2sc(C)cc12 |t:8|, CN1CCN(CC1)C1=Nc2ccccc2Nc2sc(C)cc12 |t:8|, CN1CCN(CC1)C1=Nc2ccccc2Nc2sc(C)cc12 |t:8|, CN1CCN(CC1)C1=Nc2ccccc2Nc2sc(C)cc12 |t:8|	Launched
olaparib	PARP inhibitor	PARP1, PARP2	oncology	ovarian cancer	Selleck, Selleck, Selleck, Selleck, Selleck	98.64	Fc1ccc(Cc2n[nH]c(=O)c3ccccc23)cc1C(=O)N1CCN(CC1)C(=O)C1CC1, Fc1ccc(Cc2n[nH]c(=O)c3ccccc23)cc1C(=O)N1CCN(CC1)C(=O)C1CC1, Fc1ccc(Cc2n[nH]c(=O)c3ccccc23)cc1C(=O)N1CCN(CC1)C(=O)C1CC1, Fc1ccc(Cc2n[nH]c(=O)c3ccccc23)cc1C(=O)N1CCN(CC1)C(=O)C1CC1, Fc1ccc(Cc2n[nH]c(=O)c3ccccc23)cc1C(=O)N1CCN(CC1)C(=O)C1CC1	Launched
OLDA	TRPV agonist	GPR119			Tocris, Tocris, Tocris, Tocris, Tocris, Tocris	96.21	CCCCCCCC\C=C/CCCCCCCC(=O)NCCc1ccc(O)c(O)c1, CCCCCCCC\C=C/CCCCCCCC(=O)NCCc1ccc(O)c(O)c1, CCCCCCCC\C=C/CCCCCCCC(=O)NCCc1ccc(O)c(O)c1, CCCCCCCC\C=C/CCCCCCCC(=O)NCCc1ccc(O)c(O)c1, CCCCCCCC\C=C/CCCCCCCC(=O)NCCc1ccc(O)c(O)c1, CCCCCCCC\C=C/CCCCCCCC(=O)NCCc1ccc(O)c(O)c1	Preclinical
oleamide	cannabinoid receptor agonist	HTR7, PLA2G2A			Tocris, Tocris, Tocris	100	CCCCCCCC\C=C/CCCCCCCC(N)=O, CCCCCCCC\C=C/CCCCCCCC(N)=O, CCCCCCCC\C=C/CCCCCCCC(N)=O	Preclinical
oleandrin	Na/K-ATPase inhibitor				MedChemEx, MedChemEx, MedChemEx	94.85	CO[C@H]1C[C@H](O[C@H]2CC[C@@]3(C)[C@H](CC[C@@H]4[C@@H]3CC[C@]3(C)[C@H]([C@H](C[C@]43O)OC(C)=O)C3=CC(=O)OC3)C2)O[C@@H](C)[C@@H]1O |t:32|, CO[C@H]1C[C@H](O[C@H]2CC[C@@]3(C)[C@H](CC[C@@H]4[C@@H]3CC[C@]3(C)[C@H]([C@H](C[C@]43O)OC(C)=O)C3=CC(=O)OC3)C2)O[C@@H](C)[C@@H]1O |t:32|, CO[C@H]1C[C@H](O[C@H]2CC[C@@]3(C)[C@H](CC[C@@H]4[C@@H]3CC[C@]3(C)[C@H]([C@H](C[C@]43O)OC(C)=O)C3=CC(=O)OC3)C2)O[C@@H](C)[C@@H]1O |t:32|	Phase 1
oleanolic-acid	G protein-coupled receptor agonist	GPBAR1			Tocris, Selleck, Selleck	100	CC1(C)CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]2C1)C(O)=O |c:10|, CC1(C)CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]2C1)C(O)=O |c:10|, CC1(C)CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]2C1)C(O)=O |c:10|	Preclinical
oleoylethanolamide	cannabinoid receptor agonist, glucose dependent insulinotropic receptor agonist, potassium channel blocker, PPAR receptor agonist	CNR1, GPR119, GPR55, PPARA			Tocris, Tocris	99.32	CCCCCCCC\C=C/CCCCCCCC(=O)NCCO, CCCCCCCC\C=C/CCCCCCCC(=O)NCCO	Preclinical
olesoxime	apoptosis stimulant				MedChemEx, MedChemEx	69.73	CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CCC4=C\C(CC[C@]4(C)[C@H]3CC[C@]12C)=N\O |t:15|, CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CCC4=C\C(CC[C@]4(C)[C@H]3CC[C@]12C)=N\O |t:15|	Phase 2/Phase 3
oleuropein	estrogen receptor agonist	GPER1			Selleck	85.99	COC(=O)C1=CO[C@@H](O[C@H]2O[C@@H](CO)[C@@H](O)[C@@H](O)[C@@H]2O)\C(=C/C)[C@@H]1CC(=O)OCCc1ccc(O)c(O)c1 |&1:7,&2:9,&3:11,&4:14,&5:16,&6:18,&7:23,r,t:4|	Phase 2
oligomycin-A	ATP synthase inhibitor, ATPase inhibitor	ATP5A1			MedChemEx	93.31	[H][C@]12CC[C@@H](CC)\C=C\C=C\C[C@@H](C)[C@H](O)[C@@](C)(O)C(=O)[C@@H](C)[C@H](O)[C@@H](C)C(=O)[C@@H](C)[C@H](O)[C@@H](C)\C=C\C(=O)O[C@]([H])([C@@H]1C)[C@H](C)[C@@]1(CC[C@H](C)[C@H](C[C@@H](C)O)O1)O2 |t:7,9,35|	Preclinical
olmesartan	angiotensin receptor antagonist	AGTR1	cardiology	hypertension	Tocris, MedChemEx, MedChemEx, MicroSource, MedChemEx	95.2	CCCc1nc(c(C(O)=O)n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1)C(C)(C)O, CCCc1nc(c(C(O)=O)n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1)C(C)(C)O, CCCc1nc(c(C(O)=O)n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1)C(C)(C)O, CCCc1nc(c(C(O)=O)n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1)C(C)(C)O, CCCc1nc(c(C(O)=O)n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1)C(C)(C)O	Launched
olmesartan-medoxomil	angiotensin receptor antagonist	AGTR1	cardiology	hypertension	MicroSource, MicroSource, Tocris, Selleck, MedChemEx, MedChemEx	95.98	CCCc1nc(c(C(=O)OCc2oc(=O)oc2C)n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1)C(C)(C)O, CCCc1nc(c(C(=O)OCc2oc(=O)oc2C)n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1)C(C)(C)O, CCCc1nc(c(C(=O)OCc2oc(=O)oc2C)n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1)C(C)(C)O, CCCc1nc(c(C(=O)OCc2oc(=O)oc2C)n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1)C(C)(C)O, CCCc1nc(c(C(=O)OCc2oc(=O)oc2C)n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1)C(C)(C)O, CCCc1nc(c(C(=O)OCc2oc(=O)oc2C)n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1)C(C)(C)O	Launched
olmutinib	Bruton's tyrosine kinase (BTK) inhibitor, EGFR inhibitor	BTK, EGFR	oncology	non-small cell lung cancer (NSCLC)	MedChemEx, MedChemEx, MedChemEx, MedChemEx	91.76	CN1CCN(CC1)c1ccc(Nc2nc(Oc3cccc(NC(=O)C=C)c3)c3sccc3n2)cc1, CN1CCN(CC1)c1ccc(Nc2nc(Oc3cccc(NC(=O)C=C)c3)c3sccc3n2)cc1, CN1CCN(CC1)c1ccc(Nc2nc(Oc3cccc(NC(=O)C=C)c3)c3sccc3n2)cc1, CN1CCN(CC1)c1ccc(Nc2nc(Oc3cccc(NC(=O)C=C)c3)c3sccc3n2)cc1	Launched
olodanrigan	angiotensin antagonist				MedChemEx	97.15	COc1ccc2CN([C@@H](Cc2c1OCc1ccccc1)C(O)=O)C(=O)C(c1ccccc1)c1ccccc1	Phase 2
olomoucine	CDK inhibitor	CDK1, CDK2, CDK5, MAPK1			Tocris, Tocris	97.73	Cn1cnc2c(NCc3ccccc3)nc(NCCO)nc12, Cn1cnc2c(NCc3ccccc3)nc(NCCO)nc12	Preclinical
olopatadine	histamine receptor antagonist	HRH1, S100A1, S100A12, S100A13, S100A2, S100B	ophthalmology	conjunctivitis	Tocris, Selleck, Selleck	98.6	CN(C)CC\C=C1\c2ccccc2COc2ccc(CC(O)=O)cc12, CN(C)CC\C=C1\c2ccccc2COc2ccc(CC(O)=O)cc12, CN(C)CC\C=C1\c2ccccc2COc2ccc(CC(O)=O)cc12	Launched
olprinone	phosphodiesterase inhibitor	PDE3A	cardiology	congestive heart failure	MedChemEx, MedChemEx, MedChemEx	99.86	Cc1[nH]c(=O)c(cc1-c1ccc2nccn2c1)C#N, Cc1[nH]c(=O)c(cc1-c1ccc2nccn2c1)C#N, Cc1[nH]c(=O)c(cc1-c1ccc2nccn2c1)C#N	Launched
olsalazine	cyclooxygenase inhibitor	IFNG, TPMT	gastroenterology	ulcerative colitis	MedChemEx, MicroSource, Selleck	98.95	OC(=O)c1cc(ccc1O)\N=N\c1ccc(O)c(c1)C(O)=O, OC(=O)c1cc(ccc1O)\N=N\c1ccc(O)c(c1)C(O)=O, OC(=O)c1cc(ccc1O)\N=N\c1ccc(O)c(c1)C(O)=O	Launched
oltipraz	nuclear factor erythroid derived, like (NRF2) activator	ANG			MicroSource, MicroSource, MicroSource, MicroSource, MicroSource	97.51	Cc1c(ssc1=S)-c1cnccn1, Cc1c(ssc1=S)-c1cnccn1, Cc1c(ssc1=S)-c1cnccn1, Cc1c(ssc1=S)-c1cnccn1, Cc1c(ssc1=S)-c1cnccn1	Phase 3
olumacostat-glasaretil	acetyl-CoA carboxylase inhibitor				MedChemEx	85.94	CCCCCCCCCCCCCCOc1ccc(o1)C(=O)OCC(=O)N(C)CC(=O)OCC	Phase 3
olvanil	TRPV agonist	CNR1, GPR119, TRPV1			Tocris, Tocris, Tocris, Tocris, Tocris, Tocris	94.57	CCCCCCCC\C=C/CCCCCCCC(=O)NCc1ccc(O)c(OC)c1, CCCCCCCC\C=C/CCCCCCCC(=O)NCc1ccc(O)c(OC)c1, CCCCCCCC\C=C/CCCCCCCC(=O)NCc1ccc(O)c(OC)c1, CCCCCCCC\C=C/CCCCCCCC(=O)NCc1ccc(O)c(OC)c1, CCCCCCCC\C=C/CCCCCCCC(=O)NCc1ccc(O)c(OC)c1, CCCCCCCC\C=C/CCCCCCCC(=O)NCc1ccc(O)c(OC)c1	Preclinical
omadacycline	bacterial 30S ribosomal subunit inhibitor		infectious disease	pneumonia	MedChemEx	95.49	[H][C@@]12Cc3c(cc(CNCC(C)(C)C)c(O)c3C(=O)[C@H]1C(=O)[C@]1(O)C(=O)[C@@H](C(N)=O)C(=O)[C@@H](N(C)C)[C@]1([H])C2)N(C)C |&1:26,&2:19|	Launched
omapatrilat	metalloproteinase inhibitor	ACE, MME			MedChemEx	53.07	[H][C@]12CCC[C@H](N1C(=O)[C@H](CCS2)NC(=O)[C@@H](S)Cc1ccccc1)C(O)=O	Preclinical
omarigliptin	dipeptidyl peptidase inhibitor	DPP4	endocrinology	diabetes mellitus	MedChemEx, MedChemEx, MedChemEx, MedChemEx	94.52	CS(=O)(=O)n1cc2CN(Cc2n1)[C@H]1CO[C@@H]([C@@H](N)C1)c1cc(F)ccc1F, CS(=O)(=O)n1cc2CN(Cc2n1)[C@H]1CO[C@@H]([C@@H](N)C1)c1cc(F)ccc1F, CS(=O)(=O)n1cc2CN(Cc2n1)[C@H]1CO[C@@H]([C@@H](N)C1)c1cc(F)ccc1F, CS(=O)(=O)n1cc2CN(Cc2n1)[C@H]1CO[C@@H]([C@@H](N)C1)c1cc(F)ccc1F	Launched
ombitasvir	HCV inhibitor		infectious disease	hepatitis C	MedChemEx, MedChemEx	96.54	COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)Nc1ccc(cc1)[C@@H]1CC[C@H](N1c1ccc(cc1)C(C)(C)C)c1ccc(NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)OC)C(C)C)cc1, COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)Nc1ccc(cc1)[C@@H]1CC[C@H](N1c1ccc(cc1)C(C)(C)C)c1ccc(NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)OC)C(C)C)cc1	Launched
ombrabulin	tubulin polymerization inhibitor				MedChemEx	98.81	COc1ccc(\C=C/c2cc(OC)c(OC)c(OC)c2)cc1NC(=O)[C@@H](N)CO	Phase 3
OMDM-2	FAAH inhibitor	GPR119			Tocris, Tocris, Tocris	92.27	CCCCCCCC\C=C/CCCCCCCC(=O)N[C@@H](CO)Cc1ccc(O)cc1, CCCCCCCC\C=C/CCCCCCCC(=O)N[C@@H](CO)Cc1ccc(O)cc1, CCCCCCCC\C=C/CCCCCCCC(=O)N[C@@H](CO)Cc1ccc(O)cc1	Preclinical
omecamtiv-mecarbil	cardiac myosin activator	MYBPC3			Selleck, Selleck, MedChemEx	96.1	COC(=O)N1CCN(Cc2cccc(NC(=O)Nc3ccc(C)nc3)c2F)CC1, COC(=O)N1CCN(Cc2cccc(NC(=O)Nc3ccc(C)nc3)c2F)CC1, COC(=O)N1CCN(Cc2cccc(NC(=O)Nc3ccc(C)nc3)c2F)CC1	Phase 3
omega-(4-iodophenyl)pentadecanoic-acid					Sigma	13.69	OC(=O)CCCCCCCCCCCCCCc1ccc(I)cc1	Preclinical
omega-3-acid-esters	cholesterol inhibitor				MicroSource, MedChemEx, MedChemEx, MedChemEx	71.9	CCOC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC, CCOC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC, CCOC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC, CCOC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC	Launched
omeprazole	ATPase inhibitor	ATP4A, CLCN2	gastroenterology	heartburn	MicroSource, Selleck, Tocris, Selleck	99.07	COc1ccc2nc([nH]c2c1)[S@@](=O)Cc1ncc(C)c(OC)c1C |r|, COc1ccc2nc([nH]c2c1)[S@@](=O)Cc1ncc(C)c(OC)c1C |r|, COc1ccc2nc([nH]c2c1)[S@@](=O)Cc1ncc(C)c(OC)c1C |r|, COc1ccc2nc([nH]c2c1)[S@@](=O)Cc1ncc(C)c(OC)c1C |r|	Launched
omeprazole-magnesium	proton pump inhibitor	ATP4A, ATP4B	gastroenterology	gastroesophageal reflux disease (GERD), heartburn	Vitas-M	98.99	COc1ccc2n([Mg]n3c(nc4cc(OC)ccc34)[S@@](=O)Cc3ncc(C)c(OC)c3C)c(nc2c1)[S@@](=O)Cc1ncc(C)c(OC)c1C |r|	Launched
omeprazole-sulfide	ATPase inhibitor				AKSci	92.79	COc1ccc2nc(SCc3ncc(C)c(OC)c3C)[nH]c2c1	Phase 1
omtriptolide	ERK1 and ERK2 phosphorylation inhibitor				MedChemEx	93.75	[H][C@@]12C[C@@H]3O[C@@]33[C@H](OC(=O)CCC(O)=O)[C@]4(O[C@H]4[C@@H]4O[C@]34[C@@]1(C)CCC1=C2COC1=O)C(C)C |c:30|	Preclinical
ON-01500	apoptosis stimulant				MedChemEx, Enamine	93.86	COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(N)c2)c(OC)c1, COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(N)c2)c(OC)c1	Preclinical
oncrasin-1	apoptosis stimulant				Tocris, Tocris, Tocris, Tocris, Tocris, Tocris, EMDBio	99.67	Clc1ccc(Cn2cc(C=O)c3ccccc23)cc1, Clc1ccc(Cn2cc(C=O)c3ccccc23)cc1, Clc1ccc(Cn2cc(C=O)c3ccccc23)cc1, Clc1ccc(Cn2cc(C=O)c3ccccc23)cc1, Clc1ccc(Cn2cc(C=O)c3ccccc23)cc1, Clc1ccc(Cn2cc(C=O)c3ccccc23)cc1, Clc1ccc(Cn2cc(C=O)c3ccccc23)cc1	Preclinical
ONC201	AKT inhibitor, MAP kinase inhibitor	TNFSF10			Selleck, Cayman, Cayman, Cayman	98.82	Cc1ccccc1CN1C2=NCCN2C2=C(CN(Cc3ccccc3)CC2)C1=O |t:10,16|, Cc1ccccc1CN1C2=NCCN2C2=C(CN(Cc3ccccc3)CC2)C1=O |t:10,16|, Cc1ccccc1CN1C2=NCCN2C2=C(CN(Cc3ccccc3)CC2)C1=O |t:10,16|, Cc1ccccc1CN1C2=NCCN2C2=C(CN(Cc3ccccc3)CC2)C1=O |t:10,16|	Phase 2
ondansetron	serotonin receptor antagonist	HTR3A, HTR3B	gastroenterology	nausea, vomiting	MicroSource, Selleck	99.41	Cc1nccn1C[C@H]1CCc2c(C1=O)c1ccccc1n2C |r|, Cc1nccn1C[C@H]1CCc2c(C1=O)c1ccccc1n2C |r|	Launched
ONO-AE3-208	prostanoid receptor antagonist	PTGER4			Tocris, Tocris	96.7	C[C@@H](C(=O)Nc1cc(ccc1CCCC(O)=O)C#N)c1ccc(F)c2ccccc12 |&1:1,r|, C[C@@H](C(=O)Nc1cc(ccc1CCCC(O)=O)C#N)c1ccc(F)c2ccccc12 |&1:1,r|	Preclinical
ONO-4059	Bruton's tyrosine kinase (BTK) inhibitor	BTK			MedChemEx, MedChemEx	97.35	CC#CC(=O)N1CC[C@H](C1)n1c2ncnc(N)c2n(-c2ccc(Oc3ccccc3)cc2)c1=O, CC#CC(=O)N1CC[C@H](C1)n1c2ncnc(N)c2n(-c2ccc(Oc3ccccc3)cc2)c1=O	Phase 1
ONO-4817	matrix metalloprotease inhibitor	MMP8			Sigma, Sigma, Sigma	97.35	CCOCOC[C@H](C[C@H](C)C(=O)NO)NC(=O)c1ccc(Oc2ccccc2)cc1, CCOCOC[C@H](C[C@H](C)C(=O)NO)NC(=O)c1ccc(Oc2ccccc2)cc1, CCOCOC[C@H](C[C@H](C)C(=O)NO)NC(=O)c1ccc(Oc2ccccc2)cc1	Phase 1
ONO-8130	prostanoid receptor antagonist	PTGER1			Tocris, Tocris	97.38	CC(C)CN(c1cc2CCCc2cc1OCc1ccc(cc1)C(O)=O)S(=O)(=O)c1nc(C)cs1, CC(C)CN(c1cc2CCCc2cc1OCc1ccc(cc1)C(O)=O)S(=O)(=O)c1nc(C)cs1	Preclinical
ONX-0914	proteasome inhibitor				MedChemEx	95.31	COc1ccc(C[C@H](NC(=O)[C@H](C)NC(=O)CN2CCOCC2)C(=O)N[C@@H](Cc2ccccc2)C(=O)[C@@]2(C)CO2)cc1	Preclinical
ON123300	CDK inhibitor	CDK4, NUAK1, PDGFRB			MedChemEx, MedChemEx	91.24	CN1CCN(CC1)c1ccc(Nc2ncc3cc(C#N)c(=O)n(C4CCCC4)c3n2)cc1, CN1CCN(CC1)c1ccc(Nc2ncc3cc(C#N)c(=O)n(C4CCCC4)c3n2)cc1	Preclinical
OP-0595	beta lactamase inhibitor				AMS	77.8	NCCONC(=O)[C@@H]1CC[C@@H]2CN1C(=O)N2OS(O)(=O)=O	Preclinical
OPC-21268	vasopressin receptor antagonist	AVPR1A, AVPR2, OXTR			Tocris, Sigma, Sigma, Sigma	96.93	CC(=O)NCCCOc1ccc(cc1)C(=O)N1CCC(CC1)N1C(=O)CCc2ccccc12, CC(=O)NCCCOc1ccc(cc1)C(=O)N1CCC(CC1)N1C(=O)CCc2ccccc12, CC(=O)NCCCOc1ccc(cc1)C(=O)N1CCC(CC1)N1C(=O)CCc2ccccc12, CC(=O)NCCCOc1ccc(cc1)C(=O)N1CCC(CC1)N1C(=O)CCc2ccccc12	Phase 1
opicapone	catechol O methyltransferase inhibitor	COMT			MedChemEx, MedChemEx	94.71	Cc1c(Cl)c(C)[n+]([O-])c(Cl)c1-c1noc(n1)-c1cc(O)c(O)c(c1)[N+]([O-])=O, Cc1c(Cl)c(C)[n+]([O-])c(Cl)c1-c1noc(n1)-c1cc(O)c(O)c(c1)[N+]([O-])=O	Phase 3
opipramol	sigma receptor agonist		neurology/psychiatry	generalized anxiety disorder (GAD)	Prestwick, Prestwick, Prestwick	97.22	OCCN1CCN(CCCN2c3ccccc3C=Cc3ccccc23)CC1 |c:18|, OCCN1CCN(CCCN2c3ccccc3C=Cc3ccccc23)CC1 |c:18|, OCCN1CCN(CCCN2c3ccccc3C=Cc3ccccc23)CC1 |c:18|	Launched
oprozomib	proteasome inhibitor				MedChemEx	93.83	COC[C@H](NC(=O)[C@H](COC)NC(=O)c1cnc(C)s1)C(=O)N[C@@H](Cc1ccccc1)C(=O)[C@@]1(C)CO1	Phase 1/Phase 2
OR-486	catechol O methyltransferase inhibitor	COMT			Tocris, Tocris	95.46	Oc1cc(cc(c1O)[N+]([O-])=O)[N+]([O-])=O, Oc1cc(cc(c1O)[N+]([O-])=O)[N+]([O-])=O	Preclinical
orantinib	FGFR inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	AURKA, AURKB, EGFR, FGFR1, FGFR2, KDR, PDGFRA, PDGFRB			Tocris, Selleck, Tocris, Selleck	92.22	Cc1[nH]c(\C=C2/C(=O)Nc3ccccc23)c(C)c1CCC(O)=O, Cc1[nH]c(\C=C2/C(=O)Nc3ccccc23)c(C)c1CCC(O)=O, Cc1[nH]c(\C=C2/C(=O)Nc3ccccc23)c(C)c1CCC(O)=O, Cc1[nH]c(\C=C2/C(=O)Nc3ccccc23)c(C)c1CCC(O)=O	Phase 3
orbifloxacin	bacterial DNA gyrase inhibitor		infectious disease	urinary tract infections	MedChemEx, MedChemEx, MicroSource, Selleck, Selleck, Selleck	99.48	C[C@H]1CN(C[C@@H](C)N1)c1c(F)c(F)c2c(c1F)n(cc(C(O)=O)c2=O)C1CC1, C[C@H]1CN(C[C@@H](C)N1)c1c(F)c(F)c2c(c1F)n(cc(C(O)=O)c2=O)C1CC1, C[C@H]1CN(C[C@@H](C)N1)c1c(F)c(F)c2c(c1F)n(cc(C(O)=O)c2=O)C1CC1, C[C@H]1CN(C[C@@H](C)N1)c1c(F)c(F)c2c(c1F)n(cc(C(O)=O)c2=O)C1CC1, C[C@H]1CN(C[C@@H](C)N1)c1c(F)c(F)c2c(c1F)n(cc(C(O)=O)c2=O)C1CC1, C[C@H]1CN(C[C@@H](C)N1)c1c(F)c(F)c2c(c1F)n(cc(C(O)=O)c2=O)C1CC1	Launched
ORE1001	angiotensin converting enzyme inhibitor	ACE2			EMDBio, EMDBio	94.22	CC(C)C[C@H](N[C@@H](Cc1cncn1Cc1cc(Cl)cc(Cl)c1)C(O)=O)C(O)=O, CC(C)C[C@H](N[C@@H](Cc1cncn1Cc1cc(Cl)cc(Cl)c1)C(O)=O)C(O)=O	Phase 1/Phase 2
ORG-12962	serotonin receptor agonist	HTR2A, HTR2B, HTR2C			Key	91.07	FC(F)(F)c1ccc(nc1Cl)N1CCNCC1	Phase 2
ORG-25543	glycine transporter inhibitor	GLRB, SLC6A5			Tocris, Tocris	97.69	COc1cc(cc(OC)c1OCc1ccccc1)C(=O)NCC1(CCCC1)N(C)C, COc1cc(cc(OC)c1OCc1ccccc1)C(=O)NCC1(CCCC1)N(C)C	Preclinical
ORG-26576	glutamate receptor modulator				AMS	98.64	O=C1N2CCC[C@H]2COc2ncccc12	Phase 2
ORG-27569	cannabinoid receptor modulator	CNR1			Selleck, Selleck, Tocris, Tocris, Tocris	99.02	CCc1c([nH]c2ccc(Cl)cc12)C(=O)NCCc1ccc(cc1)N1CCCCC1, CCc1c([nH]c2ccc(Cl)cc12)C(=O)NCCc1ccc(cc1)N1CCCCC1, CCc1c([nH]c2ccc(Cl)cc12)C(=O)NCCc1ccc(cc1)N1CCCCC1, CCc1c([nH]c2ccc(Cl)cc12)C(=O)NCCc1ccc(cc1)N1CCCCC1, CCc1c([nH]c2ccc(Cl)cc12)C(=O)NCCc1ccc(cc1)N1CCCCC1	Preclinical
ORG-9768	adrenergic receptor antagonist	ADRA2A			Enamine, Enamine	93.42	CC1(CN)Cc2ccccc2C1, CC1(CN)Cc2ccccc2C1	Phase 1
oridonin	BCL inhibitor	BCL2			MedChemEx	84.29	[H][C@@]1(O)[C@@]2([H])CC[C@]3([H])[C@@]1(C(=O)C2=C)[C@]1(O)OC[C@]32[C@@H](O)CCC(C)(C)[C@@]2([H])[C@@H]1O	Preclinical
oritavancin	bacterial cell wall synthesis inhibitor		infectious disease	skin infections	MedChemEx	92.78	[H][C@@]1(C[C@](C)(NCc2ccc(cc2)-c2ccc(Cl)cc2)[C@@H](O)[C@H](C)O1)O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1Oc1c2Oc3ccc(cc3Cl)[C@@H](O)[C@@H](NC(=O)[C@@H](CC(C)C)NC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@]3([H])c(c2)cc1Oc1ccc(cc1Cl)[C@@H](O[C@@]1([H])C[C@](C)(N)[C@@H](O)[C@H](C)O1)[C@]1([H])NC(=O)[C@]([H])(NC3=O)c2ccc(O)c(c2)-c2c(O)cc(O)cc2[C@]([H])(NC1=O)C(O)=O	Launched
orlistat	lipase inhibitor	CNR1, DAGLA, DAGLB, FASN, LIPF, PNLIP	endocrinology	weight-loss aid	Tocris, Selleck, Tocris, Selleck, Selleck	100	CCCCCCCCCCC[C@@H](C[C@@H]1OC(=O)[C@H]1CCCCCC)OC(=O)[C@H](CC(C)C)NC=O, CCCCCCCCCCC[C@@H](C[C@@H]1OC(=O)[C@H]1CCCCCC)OC(=O)[C@H](CC(C)C)NC=O, CCCCCCCCCCC[C@@H](C[C@@H]1OC(=O)[C@H]1CCCCCC)OC(=O)[C@H](CC(C)C)NC=O, CCCCCCCCCCC[C@@H](C[C@@H]1OC(=O)[C@H]1CCCCCC)OC(=O)[C@H](CC(C)C)NC=O, CCCCCCCCCCC[C@@H](C[C@@H]1OC(=O)[C@H]1CCCCCC)OC(=O)[C@H](CC(C)C)NC=O	Launched
ormeloxifene	selective estrogen receptor modulator (SERM)		endocrinology	contraceptive	Sigma	81.67	COc1ccc2[C@H]([C@H](c3ccccc3)C(C)(C)Oc2c1)c1ccc(OCCN2CCCC2)cc1	Launched
ornidazole	antiprotozoal agent		infectious disease	protozoan infection	MicroSource, MedChemEx, Selleck, Selleck	92.96	Cc1ncc(n1C[C@@H](O)CCl)[N+]([O-])=O |&1:7,r|, Cc1ncc(n1C[C@@H](O)CCl)[N+]([O-])=O |&1:7,r|, Cc1ncc(n1C[C@@H](O)CCl)[N+]([O-])=O |&1:7,r|, Cc1ncc(n1C[C@@H](O)CCl)[N+]([O-])=O |&1:7,r|	Launched
ornipressin	vasoconstrictor				MedChemEx	77.29	[H][C@@]1(Cc2ccccc2)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H](N)CSSC[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC1=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCN)C(=O)NCC(N)=O	Preclinical
ornithine	NFkB pathway modulator	GPRC6A			MicroSource	0	Cl.NCCC[C@@H](N)C(O)=O |&1:5,r|	Launched
orotic-acid		DHODH			MicroSource, Selleck	100	OC(=O)c1cc(=O)[nH]c(=O)[nH]1, OC(=O)c1cc(=O)[nH]c(=O)[nH]1	Phase 2
orphanin-fq	opioid receptor agonist	OPRL1, OPRM1			MedChemEx, Enzo	63.03	CC(C)C[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)Cc1ccccc1)[C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O, CC(C)C[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)Cc1ccccc1)[C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O	Phase 1
orphenadrine	acetylcholine receptor antagonist		neurology/psychiatry	muscle pain	MicroSource, MicroSource, Selleck, Selleck, Selleck	98.55	CN(C)CCO[C@@H](c1ccccc1)c1ccccc1C |&1:6|, CN(C)CCO[C@@H](c1ccccc1)c1ccccc1C |&1:6|, CN(C)CCO[C@@H](c1ccccc1)c1ccccc1C |&1:6|, CN(C)CCO[C@@H](c1ccccc1)c1ccccc1C |&1:6|, CN(C)CCO[C@@H](c1ccccc1)c1ccccc1C |&1:6|	Launched
orteronel	androgen biosynthesis inhibitor, androgen receptor antagonist, cytochrome P450 inhibitor	CYP17A1			Selleck, Selleck, Selleck	98.05	CNC(=O)c1ccc2cc(ccc2c1)[C@]1(O)CCn2cncc12, CNC(=O)c1ccc2cc(ccc2c1)[C@]1(O)CCn2cncc12, CNC(=O)c1ccc2cc(ccc2c1)[C@]1(O)CCn2cncc12	Phase 3
ORY-1001	histone lysine demethylase inhibitor	KDM1A			MedChemEx, MedChemEx, Selleck	92.83	NC1CCC(CC1)N[C@@H]1C[C@H]1c1ccccc1, NC1CCC(CC1)N[C@@H]1C[C@H]1c1ccccc1, NC1CCC(CC1)N[C@@H]1C[C@H]1c1ccccc1	Phase 1/Phase 2
oseltamivir-carboxylate	neuraminidase inhibitor		infectious disease	influenza A virus infection	MedChemEx, MedChemEx	86.82	CCC(CC)O[C@@H]1C=C(C[C@H](N)[C@H]1NC(C)=O)C(O)=O |c:7|, CCC(CC)O[C@@H]1C=C(C[C@H](N)[C@H]1NC(C)=O)C(O)=O |c:7|	Launched
oseltamivir-phosphate	neuraminidase inhibitor	CES1, NEU1, NEU2	infectious disease	influenza A virus infection	MicroSource, MedChemEx, MedChemEx, Selleck, Selleck	94.24	CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1 |t:5|, CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1 |t:5|, CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1 |t:5|, CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1 |t:5|, CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1 |t:5|	Launched
osemozotan	serotonin receptor agonist	HTR1A			Sigma	98.16	C(CNC[C@H]1COc2ccccc2O1)COc1ccc2OCOc2c1	Phase 2/Phase 3
OSI-027	mTOR inhibitor	MTOR			MedChemEx, Selleck, Selleck	95.61	COc1cccc2cc([nH]c12)-c1nc([C@H]2CC[C@@H](CC2)C(O)=O)n2ncnc(N)c12 |r|, COc1cccc2cc([nH]c12)-c1nc([C@H]2CC[C@@H](CC2)C(O)=O)n2ncnc(N)c12 |r|, COc1cccc2cc([nH]c12)-c1nc([C@H]2CC[C@@H](CC2)C(O)=O)n2ncnc(N)c12 |r|	Phase 1
OSI-420	EGFR inhibitor	EGFR			MedChemEx, Selleck, Selleck	96.68	COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCO, COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCO, COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCO	Preclinical
OSI-930	KIT inhibitor, VEGFR inhibitor	FLT1, KDR, KIT			Selleck, Selleck, Selleck, Selleck	86.5	FC(F)(F)Oc1ccc(NC(=O)c2sccc2NCc2ccnc3ccccc23)cc1, FC(F)(F)Oc1ccc(NC(=O)c2sccc2NCc2ccnc3ccccc23)cc1, FC(F)(F)Oc1ccc(NC(=O)c2sccc2NCc2ccnc3ccccc23)cc1, FC(F)(F)Oc1ccc(NC(=O)c2sccc2NCc2ccnc3ccccc23)cc1	Phase 1
osilodrostat	cytochrome P450 inhibitor				MedChemEx	96.89	Fc1cc(ccc1[C@H]1CCc2cncn12)C#N	Launched
osimertinib	EGFR inhibitor	EGFR	oncology	non-small cell lung cancer (NSCLC)	MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx	97.69	COc1cc(N(C)CCN(C)C)c(NC(=O)C=C)cc1Nc1nccc(n1)-c1cn(C)c2ccccc12, COc1cc(N(C)CCN(C)C)c(NC(=O)C=C)cc1Nc1nccc(n1)-c1cn(C)c2ccccc12, COc1cc(N(C)CCN(C)C)c(NC(=O)C=C)cc1Nc1nccc(n1)-c1cn(C)c2ccccc12, COc1cc(N(C)CCN(C)C)c(NC(=O)C=C)cc1Nc1nccc(n1)-c1cn(C)c2ccccc12, COc1cc(N(C)CCN(C)C)c(NC(=O)C=C)cc1Nc1nccc(n1)-c1cn(C)c2ccccc12, COc1cc(N(C)CCN(C)C)c(NC(=O)C=C)cc1Nc1nccc(n1)-c1cn(C)c2ccccc12, COc1cc(N(C)CCN(C)C)c(NC(=O)C=C)cc1Nc1nccc(n1)-c1cn(C)c2ccccc12	Launched
ospemifene	selective estrogen receptor modulator (SERM)	ESR1, ESR2	obstetrics/gynecology, endocrinology	vaginal atrophy, dyspareunia, menopause	Selleck, Selleck	99.9	OCCOc1ccc(cc1)C(=C(\CCCl)c1ccccc1)\c1ccccc1, OCCOc1ccc(cc1)C(=C(\CCCl)c1ccccc1)\c1ccccc1	Launched
ostarine	androgen receptor modulator	AR			MedChemEx, Selleck	97.85	C[C@](O)(COc1ccc(cc1)C#N)C(=O)Nc1ccc(C#N)c(c1)C(F)(F)F, C[C@](O)(COc1ccc(cc1)C#N)C(=O)Nc1ccc(C#N)c(c1)C(F)(F)F	Phase 3
osthol	calcium channel blocker				MedChemEx, Selleck	98.35	COc1ccc2ccc(=O)oc2c1CC=C(C)C, COc1ccc2ccc(=O)oc2c1CC=C(C)C	Preclinical
OT-R-antagonist-1	oxytocin receptor antagonist	AVPR1A, OXTR			MedChemEx	98.05	CO\N=C1\C[C@H](N(C1)C(=O)c1ccc(cc1)-c1ccccc1C)C(=O)NC[C@@H](O)c1ccccc1	Preclinical
otamixaban	coagulation factor inhibitor	F10			MedChemEx, MedChemEx, MedChemEx, MedChemEx	96.17	COC(=O)[C@H](Cc1cccc(c1)C(N)=N)[C@@H](C)NC(=O)c1ccc(cc1)-c1cc[n+]([O-])cc1, COC(=O)[C@H](Cc1cccc(c1)C(N)=N)[C@@H](C)NC(=O)c1ccc(cc1)-c1cc[n+]([O-])cc1, COC(=O)[C@H](Cc1cccc(c1)C(N)=N)[C@@H](C)NC(=O)c1ccc(cc1)-c1cc[n+]([O-])cc1, COC(=O)[C@H](Cc1cccc(c1)C(N)=N)[C@@H](C)NC(=O)c1ccc(cc1)-c1cc[n+]([O-])cc1	Phase 3
otenzepad	acetylcholine receptor antagonist	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5			Tocris, Tocris, Tocris	96.5	CCN(CC)C[C@H]1CCCCN1CC(=O)N1c2ccccc2C(=O)Nc2cccnc12 |&1:6,r|, CCN(CC)C[C@H]1CCCCN1CC(=O)N1c2ccccc2C(=O)Nc2cccnc12 |&1:6,r|, CCN(CC)C[C@H]1CCCCN1CC(=O)N1c2ccccc2C(=O)Nc2cccnc12 |&1:6,r|	Phase 3
otilonium	acetylcholine receptor antagonist	CACNA1C	gastroenterology	irritable bowel syndrome	MedChemEx, MedChemEx, MedChemEx, Selleck, Selleck, Selleck	98.47	CCCCCCCCOc1ccccc1C(=O)Nc1ccc(cc1)C(=O)OCC[N+](C)(CC)CC, CCCCCCCCOc1ccccc1C(=O)Nc1ccc(cc1)C(=O)OCC[N+](C)(CC)CC, CCCCCCCCOc1ccccc1C(=O)Nc1ccc(cc1)C(=O)OCC[N+](C)(CC)CC, CCCCCCCCOc1ccccc1C(=O)Nc1ccc(cc1)C(=O)OCC[N+](C)(CC)CC, CCCCCCCCOc1ccccc1C(=O)Nc1ccc(cc1)C(=O)OCC[N+](C)(CC)CC, CCCCCCCCOc1ccccc1C(=O)Nc1ccc(cc1)C(=O)OCC[N+](C)(CC)CC	Launched
OTS167	maternal embryonic leucine zipper kinase inhibitor	MELK			MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx	97.89	CN(C)C[C@H]1CC[C@@H](CC1)Nc1c(cnc2ccc(nc12)-c1cc(Cl)c(O)c(Cl)c1)C(C)=O |r|, CN(C)C[C@H]1CC[C@@H](CC1)Nc1c(cnc2ccc(nc12)-c1cc(Cl)c(O)c(Cl)c1)C(C)=O |r|, CN(C)C[C@H]1CC[C@@H](CC1)Nc1c(cnc2ccc(nc12)-c1cc(Cl)c(O)c(Cl)c1)C(C)=O |r|, CN(C)C[C@H]1CC[C@@H](CC1)Nc1c(cnc2ccc(nc12)-c1cc(Cl)c(O)c(Cl)c1)C(C)=O |r|, CN(C)C[C@H]1CC[C@@H](CC1)Nc1c(cnc2ccc(nc12)-c1cc(Cl)c(O)c(Cl)c1)C(C)=O |r|, CN(C)C[C@H]1CC[C@@H](CC1)Nc1c(cnc2ccc(nc12)-c1cc(Cl)c(O)c(Cl)c1)C(C)=O |r|	Phase 1/Phase 2
OTS514	TOPK inhibitor				MedChemEx, MedChemEx, MedChemEx	93.47	C[C@@H](CN)c1ccc(cc1)-c1c(O)cc(C)c2[nH]c(=O)c3sccc3c12, C[C@@H](CN)c1ccc(cc1)-c1c(O)cc(C)c2[nH]c(=O)c3sccc3c12, C[C@@H](CN)c1ccc(cc1)-c1c(O)cc(C)c2[nH]c(=O)c3sccc3c12	Preclinical
OTX015	bromodomain inhibitor	BRD2, BRD3, BRD4			Selleck, Selleck, Selleck, Selleck, Selleck	98.65	Cc1sc-2c(c1C)C(=N[C@@H](CC(=O)Nc1ccc(O)cc1)c1nnc(C)n-21)c1ccc(Cl)cc1 |c:8|, Cc1sc-2c(c1C)C(=N[C@@H](CC(=O)Nc1ccc(O)cc1)c1nnc(C)n-21)c1ccc(Cl)cc1 |c:8|, Cc1sc-2c(c1C)C(=N[C@@H](CC(=O)Nc1ccc(O)cc1)c1nnc(C)n-21)c1ccc(Cl)cc1 |c:8|, Cc1sc-2c(c1C)C(=N[C@@H](CC(=O)Nc1ccc(O)cc1)c1nnc(C)n-21)c1ccc(Cl)cc1 |c:8|, Cc1sc-2c(c1C)C(=N[C@@H](CC(=O)Nc1ccc(O)cc1)c1nnc(C)n-21)c1ccc(Cl)cc1 |c:8|	Phase 1/Phase 2
ouabain	ATPase inhibitor	ATP1A1	cardiology	hypertension, cardiac arrythmia	MicroSource, MicroSource, MicroSource, Tocris, Tocris, Tocris, Tocris, Tocris, Tocris, Tocris, Selleck, Selleck	96.12	C[C@@H]1O[C@@H](O[C@@H]2C[C@@H](O)[C@]3(CO)[C@H]4[C@H](O)C[C@]5(C)[C@H](CC[C@]5(O)[C@@H]4CC[C@]3(O)C2)C2=CC(=O)OC2)[C@H](O)[C@H](O)[C@H]1O |t:33|, C[C@@H]1O[C@@H](O[C@@H]2C[C@@H](O)[C@]3(CO)[C@H]4[C@H](O)C[C@]5(C)[C@H](CC[C@]5(O)[C@@H]4CC[C@]3(O)C2)C2=CC(=O)OC2)[C@H](O)[C@H](O)[C@H]1O |t:33|, C[C@@H]1O[C@@H](O[C@@H]2C[C@@H](O)[C@]3(CO)[C@H]4[C@H](O)C[C@]5(C)[C@H](CC[C@]5(O)[C@@H]4CC[C@]3(O)C2)C2=CC(=O)OC2)[C@H](O)[C@H](O)[C@H]1O |t:33|, C[C@@H]1O[C@@H](O[C@@H]2C[C@@H](O)[C@]3(CO)[C@H]4[C@H](O)C[C@]5(C)[C@H](CC[C@]5(O)[C@@H]4CC[C@]3(O)C2)C2=CC(=O)OC2)[C@H](O)[C@H](O)[C@H]1O |t:33|, C[C@@H]1O[C@@H](O[C@@H]2C[C@@H](O)[C@]3(CO)[C@H]4[C@H](O)C[C@]5(C)[C@H](CC[C@]5(O)[C@@H]4CC[C@]3(O)C2)C2=CC(=O)OC2)[C@H](O)[C@H](O)[C@H]1O |t:33|, C[C@@H]1O[C@@H](O[C@@H]2C[C@@H](O)[C@]3(CO)[C@H]4[C@H](O)C[C@]5(C)[C@H](CC[C@]5(O)[C@@H]4CC[C@]3(O)C2)C2=CC(=O)OC2)[C@H](O)[C@H](O)[C@H]1O |t:33|, C[C@@H]1O[C@@H](O[C@@H]2C[C@@H](O)[C@]3(CO)[C@H]4[C@H](O)C[C@]5(C)[C@H](CC[C@]5(O)[C@@H]4CC[C@]3(O)C2)C2=CC(=O)OC2)[C@H](O)[C@H](O)[C@H]1O |t:33|, C[C@@H]1O[C@@H](O[C@@H]2C[C@@H](O)[C@]3(CO)[C@H]4[C@H](O)C[C@]5(C)[C@H](CC[C@]5(O)[C@@H]4CC[C@]3(O)C2)C2=CC(=O)OC2)[C@H](O)[C@H](O)[C@H]1O |t:33|, C[C@@H]1O[C@@H](O[C@@H]2C[C@@H](O)[C@]3(CO)[C@H]4[C@H](O)C[C@]5(C)[C@H](CC[C@]5(O)[C@@H]4CC[C@]3(O)C2)C2=CC(=O)OC2)[C@H](O)[C@H](O)[C@H]1O |t:33|, C[C@@H]1O[C@@H](O[C@@H]2C[C@@H](O)[C@]3(CO)[C@H]4[C@H](O)C[C@]5(C)[C@H](CC[C@]5(O)[C@@H]4CC[C@]3(O)C2)C2=CC(=O)OC2)[C@H](O)[C@H](O)[C@H]1O |t:33|, C[C@@H]1O[C@@H](O[C@@H]2C[C@@H](O)[C@]3(CO)[C@H]4[C@H](O)C[C@]5(C)[C@H](CC[C@]5(O)[C@@H]4CC[C@]3(O)C2)C2=CC(=O)OC2)[C@H](O)[C@H](O)[C@H]1O |t:33|, C[C@@H]1O[C@@H](O[C@@H]2C[C@@H](O)[C@]3(CO)[C@H]4[C@H](O)C[C@]5(C)[C@H](CC[C@]5(O)[C@@H]4CC[C@]3(O)C2)C2=CC(=O)OC2)[C@H](O)[C@H](O)[C@H]1O |t:33|	Launched
OXA-06	rho associated kinase inhibitor	ROCK1, ROCK2			Tocris, Tocris	97.04	Fc1ccccc1CNCc1ccc(cc1)-c1ccnc2[nH]ccc12, Fc1ccccc1CNCc1ccc(cc1)-c1ccnc2[nH]ccc12	Preclinical
oxaceprol	anti-inflammatory agent				MedChemEx	100	CC(=O)N1C[C@H](O)C[C@H]1C(O)=O	Preclinical
oxacillin	bacterial cell wall synthesis inhibitor		infectious disease	staphylococcal infections	MedChemEx, Selleck, Selleck, MicroSource, MicroSource, MicroSource	98.27	Cc1onc(c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O)-c1ccccc1, Cc1onc(c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O)-c1ccccc1, Cc1onc(c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O)-c1ccccc1, Cc1onc(c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O)-c1ccccc1, Cc1onc(c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O)-c1ccccc1, Cc1onc(c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O)-c1ccccc1	Launched
oxacyclohexadecan-2-one	protein kinase inhibitor				Sigma	0	O=C1CCCCCCCCCCCCCCO1	Preclinical
oxaliplatin	DNA inhibitor		oncology	colorectal cancer	MicroSource, MicroSource, Selleck, Selleck, Tocris, Tocris, Tocris, Selleck	98.79	O=C1O[Pt]2(N[C@@H]3CCCC[C@H]3N2)OC1=O, O=C1O[Pt]2(N[C@@H]3CCCC[C@H]3N2)OC1=O, O=C1O[Pt]2(N[C@@H]3CCCC[C@H]3N2)OC1=O, O=C1O[Pt]2(N[C@@H]3CCCC[C@H]3N2)OC1=O, O=C1O[Pt]2(N[C@@H]3CCCC[C@H]3N2)OC1=O, O=C1O[Pt]2(N[C@@H]3CCCC[C@H]3N2)OC1=O, O=C1O[Pt]2(N[C@@H]3CCCC[C@H]3N2)OC1=O, O=C1O[Pt]2(N[C@@H]3CCCC[C@H]3N2)OC1=O	Launched
oxaloacetate	glutamate release inhibitor				Sigma, Enamine	0	OC(=O)C=C(O)C(O)=O, OC(=O)C=C(O)C(O)=O	Phase 2/Phase 3
oxantel	anthelmintic agent		infectious disease	gastrointestinal parasites	MicroSource, MedChemEx	41.1	CN1CCCN=C1\C=C\c1cccc(O)c1 |c:5|, CN1CCCN=C1\C=C\c1cccc(O)c1 |c:5|	Launched
oxaprozin	cyclooxygenase inhibitor	PTGS1, PTGS2	rheumatology	osteoarthritis, rheumatoid arthritis	MicroSource, MedChemEx, Selleck	99.41	OC(=O)CCc1nc(c(o1)-c1ccccc1)-c1ccccc1, OC(=O)CCc1nc(c(o1)-c1ccccc1)-c1ccccc1, OC(=O)CCc1nc(c(o1)-c1ccccc1)-c1ccccc1	Launched
oxatomide	histamine receptor antagonist	HRH1	allergy	allergic rhinitis	Key, Vitas-M	97.1	O=c1[nH]c2ccccc2n1CCCN1CCN(CC1)C(c1ccccc1)c1ccccc1, O=c1[nH]c2ccccc2n1CCCN1CCN(CC1)C(c1ccccc1)c1ccccc1	Launched
oxcarbazepine	sodium channel blocker	SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A	neurology/psychiatry	seizures	MicroSource, Selleck, Selleck, Selleck, Selleck	95.44	NC(=O)N1c2ccccc2CC(=O)c2ccccc12, NC(=O)N1c2ccccc2CC(=O)c2ccccc12, NC(=O)N1c2ccccc2CC(=O)c2ccccc12, NC(=O)N1c2ccccc2CC(=O)c2ccccc12, NC(=O)N1c2ccccc2CC(=O)c2ccccc12	Launched
oxelaidin	antitussive		pulmonary	cough suppressant	Selleck, MicroSource, MedChemEx, Selleck	95.06	CCN(CC)CCOCCOC(=O)C(CC)(CC)c1ccccc1, CCN(CC)CCOCCOC(=O)C(CC)(CC)c1ccccc1, CCN(CC)CCOCCOC(=O)C(CC)(CC)c1ccccc1, CCN(CC)CCOCCOC(=O)C(CC)(CC)c1ccccc1	Launched
oxethazaine	local anesthetic		neurology/psychiatry	local anesthetic	MicroSource, MedChemEx, Selleck	98.08	CN(C(=O)CN(CCO)CC(=O)N(C)C(C)(C)Cc1ccccc1)C(C)(C)Cc1ccccc1, CN(C(=O)CN(CCO)CC(=O)N(C)C(C)(C)Cc1ccccc1)C(C)(C)Cc1ccccc1, CN(C(=O)CN(CCO)CC(=O)N(C)C(C)(C)Cc1ccccc1)C(C)(C)Cc1ccccc1	Launched
OXF-BD-02	bromodomain inhibitor	BRD4			Tocris, Tocris	96.76	Cc1noc(C)c1-c1cc(O)cc(c1)[C@@H](O)c1ccccc1 |&1:14,r|, Cc1noc(C)c1-c1cc(O)cc(c1)[C@@H](O)c1ccccc1 |&1:14,r|	Preclinical
oxfendazole	anthelmintic agent		infectious disease	lungworms, tapeworm, gastrointestinal roundworms	MicroSource, Selleck	97.28	COC(=O)Nc1nc2ccc(cc2[nH]1)[S@@](=O)c1ccccc1 |r|, COC(=O)Nc1nc2ccc(cc2[nH]1)[S@@](=O)c1ccccc1 |r|	Launched
oxfenicine	carnitine palmitoyltransferase inhibitor	CPT1A, CPT1B			MedChemEx, Enamine	100	N[C@@H](C(O)=O)c1ccc(O)cc1, N[C@@H](C(O)=O)c1ccc(O)cc1	Phase 1
oxibendazole	tubulin polymerization inhibitor	TUBB, TUBB4B	infectious disease	strongyles	MicroSource, Selleck, Selleck, Selleck	96.34	CCCOc1ccc2nc(NC(=O)OC)[nH]c2c1, CCCOc1ccc2nc(NC(=O)OC)[nH]c2c1, CCCOc1ccc2nc(NC(=O)OC)[nH]c2c1, CCCOc1ccc2nc(NC(=O)OC)[nH]c2c1	Launched
oxiconazole	bacterial cell wall synthesis inhibitor		infectious disease	tinea pedis, tinea cruris, tinea corporis	MicroSource, MedChemEx	98.63	Clc1ccc(CO\N=C(/Cn2ccnc2)c2ccc(Cl)cc2Cl)c(Cl)c1, Clc1ccc(CO\N=C(/Cn2ccnc2)c2ccc(Cl)cc2Cl)c(Cl)c1	Launched
oxidopamine	neurotoxin				Tocris, MicroSource	0	NCCc1cc(O)c(O)cc1O, NCCc1cc(O)c(O)cc1O	Preclinical
oxiniacic-acid					Vitas-M, Vitas-M, MedChemEx, MicroSource	100	OC(=O)c1ccc[n+]([O-])c1, OC(=O)c1ccc[n+]([O-])c1, OC(=O)c1ccc[n+]([O-])c1, OC(=O)c1ccc[n+]([O-])c1	Preclinical
oxiperomide	dopamine receptor antagonist				Enamine	86.05	O=c1[nH]c2ccccc2n1C1CCN(CCOc2ccccc2)CC1	Phase 2
oxiracetam	acetylcholine receptor agonist		neurology/psychiatry	senile dementia	MedChemEx, MedChemEx, MedChemEx	100	NC(=O)CN1C[C@H](O)CC1=O, NC(=O)CN1C[C@H](O)CC1=O, NC(=O)CN1C[C@H](O)CC1=O	Launched
oxolamine	antitussive		pulmonary	cough suppressant	MicroSource, MedChemEx	78.78	CCN(CC)CCc1nc(no1)-c1ccccc1, CCN(CC)CCc1nc(no1)-c1ccccc1	Launched
oxolinic-acid	bacterial DNA gyrase inhibitor				MicroSource, MedChemEx, MedChemEx	95.97	CCn1cc(C(O)=O)c(=O)c2cc3OCOc3cc12, CCn1cc(C(O)=O)c(=O)c2cc3OCOc3cc12, CCn1cc(C(O)=O)c(=O)c2cc3OCOc3cc12	Preclinical
oxonic-acid	uricase inhibitor				Sigma, AKSci	0	OC(=O)c1nc(=O)[nH]c(=O)[nH]1, OC(=O)c1nc(=O)[nH]c(=O)[nH]1	Preclinical
oxotremorine-M	acetylcholine receptor agonist	CHRM1, CHRM2, CHRM3, CHRM4			Tocris, Tocris, Tocris, Tocris	97.4	C[N+](C)(C)CC#CCN1CCCC1=O, C[N+](C)(C)CC#CCN1CCCC1=O, C[N+](C)(C)CC#CCN1CCCC1=O, C[N+](C)(C)CC#CCN1CCCC1=O	Preclinical
oxotremorine-sesquifumarate	cholinergic receptor agonist	CHRM1, CHRM2, CHRM3, CHRM4			Tocris, Tocris, Tocris	79.6	O=C1CCCN1CC#CCN1CCCC1, O=C1CCCN1CC#CCN1CCCC1, O=C1CCCN1CC#CCN1CCCC1	Preclinical
oxprenolol	adrenergic receptor antagonist	ADRB1	cardiology	angina pectoris, hypertension, cardiac arrythmia	Selleck, Selleck	95.83	CC(C)NC[C@@H](O)COc1ccccc1OCC=C |&1:5|, CC(C)NC[C@@H](O)COc1ccccc1OCC=C |&1:5|	Launched
oxybenzone	lipase inhibitor	LIPE	dermatology	sunscreen lotion	MedChemEx, MicroSource	98.47	COc1ccc(C(=O)c2ccccc2)c(O)c1, COc1ccc(C(=O)c2ccccc2)c(O)c1	Launched
oxybuprocaine	local anesthetic	SCN10A	neurology/psychiatry	local anesthetic	MicroSource, Selleck, Selleck, Selleck, Selleck	96.85	CCCCOc1cc(ccc1N)C(=O)OCCN(CC)CC, CCCCOc1cc(ccc1N)C(=O)OCCN(CC)CC, CCCCOc1cc(ccc1N)C(=O)OCCN(CC)CC, CCCCOc1cc(ccc1N)C(=O)OCCN(CC)CC, CCCCOc1cc(ccc1N)C(=O)OCCN(CC)CC	Launched
oxybutynin	acetylcholine receptor antagonist	CHRM1, CHRM2, CHRM3	urology	urinary incontinence	MedChemEx, Selleck	95.68	CCN(CC)CC#CCOC(=O)[C@@](O)(C1CCCCC1)c1ccccc1 |&1:12,r|, CCN(CC)CC#CCOC(=O)[C@@](O)(C1CCCCC1)c1ccccc1 |&1:12,r|	Launched
oxyclozanide			infectious disease	fascioliasis	MicroSource, MicroSource, MicroSource, MicroSource, MicroSource	95.9	Oc1c(Cl)cc(Cl)cc1NC(=O)c1c(O)c(Cl)cc(Cl)c1Cl, Oc1c(Cl)cc(Cl)cc1NC(=O)c1c(O)c(Cl)cc(Cl)c1Cl, Oc1c(Cl)cc(Cl)cc1NC(=O)c1c(O)c(Cl)cc(Cl)c1Cl, Oc1c(Cl)cc(Cl)cc1NC(=O)c1c(O)c(Cl)cc(Cl)c1Cl, Oc1c(Cl)cc(Cl)cc1NC(=O)c1c(O)c(Cl)cc(Cl)c1Cl	Launched
oxyfedrine	adrenergic receptor agonist		cardiology	angina pectoris	Kemprotec, Kemprotec	94.49	COc1cccc(c1)C(=O)CCN[C@@H](C)[C@H](O)c1ccccc1, COc1cccc(c1)C(=O)CCN[C@@H](C)[C@H](O)c1ccccc1	Launched
oxymatrine					MedChemEx	91.85	[H][C@]12CCC[N@@+]3([O-])CCC[C@]([H])([C@@]4([H])CCCC(=O)N4C1)[C@]23[H]	Launched
oxymetazoline	adrenergic receptor agonist	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, HTR1B, HTR1D, HTR2C	otolaryngology	nasal congestion	Tocris, MicroSource, Selleck	99.39	Cc1cc(c(O)c(C)c1CC1=NCCN1)C(C)(C)C |t:11|, Cc1cc(c(O)c(C)c1CC1=NCCN1)C(C)(C)C |t:11|, Cc1cc(c(O)c(C)c1CC1=NCCN1)C(C)(C)C |t:11|	Launched
oxyphenbutazone	cyclooxygenase inhibitor				MicroSource	69.64	CCCC[C@H]1C(=O)N(N(C1=O)c1ccc(O)cc1)c1ccccc1 |r|	Withdrawn
oxyphencyclimine	cholinergic receptor antagonist		gastroenterology	peptic ulcer disease (PUD)	MicroSource, MicroSource	97.02	CN1CCCN=C1COC(=O)[C@@](O)(C1CCCCC1)c1ccccc1 |&1:11,c:5|, CN1CCCN=C1COC(=O)[C@@](O)(C1CCCCC1)c1ccccc1 |&1:11,c:5|	Launched
oxyphenonium	cholinergic receptor antagonist	CHRM1, CHRM3	gastroenterology	peptic ulcer disease (PUD)	MicroSource	92.38	CC[N+](C)(CC)CCOC(=O)C(O)(C1CCCCC1)c1ccccc1	Launched
oxypurinol	xanthine oxidase inhibitor	XDH			AlfaAesar, AlfaAesar	95	O=c1nc2[nH][nH]cc2c(=O)[nH]1, O=c1nc2[nH][nH]cc2c(=O)[nH]1	Phase 2/Phase 3
oxyquinoline	chelating agent	METAP2	dermatology	cosmetic	MicroSource, MicroSource, MicroSource, MicroSource	97.72	Oc1cccc2cccnc12, Oc1cccc2cccnc12, Oc1cccc2cccnc12, Oc1cccc2cccnc12	Launched
oxytetracycline	bacterial 30S ribosomal subunit inhibitor		infectious disease, urology	chlamydia, urinary tract infections, skin infections, ear infections, gonorrhea, urethritis, Lyme disease	MedChemEx, Selleck, Selleck, Selleck	0	CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(=C(O)[C@]2(O)C(O)=C(C(N)=O)C1=O)C(=O)c1c(O)cccc1[C@@]3(C)O |a:3,4,5,7,11,30,&1:8,&2:15,t:8,15|, CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(=C(O)[C@]2(O)C(O)=C(C(N)=O)C1=O)C(=O)c1c(O)cccc1[C@@]3(C)O |a:3,4,5,7,11,30,&1:8,&2:15,t:8,15|, CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(=C(O)[C@]2(O)C(O)=C(C(N)=O)C1=O)C(=O)c1c(O)cccc1[C@@]3(C)O |a:3,4,5,7,11,30,&1:8,&2:15,t:8,15|, CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(=C(O)[C@]2(O)C(O)=C(C(N)=O)C1=O)C(=O)c1c(O)cccc1[C@@]3(C)O |a:3,4,5,7,11,30,&1:8,&2:15,t:8,15|	Launched
oxytocin	oxytocin receptor agonist	AVPR1A, AVPR1B, AVPR2, OXTR	obstetrics/gynecology	labor induction	Sigma, MedChemEx	84.04	CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H](N)CSSC[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC1=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O, CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H](N)CSSC[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC1=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O	Launched
ozagrel	thromboxane synthase inhibitor	TBXAS1	neurology/psychiatry	stroke	Tocris, Selleck, Selleck, Selleck, Tocris	97.74	OC(=O)\C=C\c1ccc(Cn2ccnc2)cc1, OC(=O)\C=C\c1ccc(Cn2ccnc2)cc1, OC(=O)\C=C\c1ccc(Cn2ccnc2)cc1, OC(=O)\C=C\c1ccc(Cn2ccnc2)cc1, OC(=O)\C=C\c1ccc(Cn2ccnc2)cc1	Launched
ozanimod	sphingosine 1-phosphate receptor agonist	S1PR1			MedChemEx	98.03	CC(C)Oc1ccc(cc1C#N)-c1nc(no1)-c1cccc2[C@H](CCc12)NCCO	Phase 3
ozenoxacin	antiinfective drug				MedChemEx	97.14	CNc1ncc(cc1C)-c1ccc2c(c1C)n(cc(C(O)=O)c2=O)C1CC1	Phase 3
ozolinone	diuretic				Sigma	78.8	CN1C(=O)[C@@H](S\C1=C/C(O)=O)N1CCCCC1 |&1:4,r|	Phase 3
O4I1	Oct inducer	POU5F1			Tocris, Tocris	0	COc1ccc(COc2ccc(CC#N)cc2)cc1, COc1ccc(COc2ccc(CC#N)cc2)cc1	Preclinical
O6-benzylguanine	O6-alkylguanine-DNA alkyltransferase inhibitor	MGMT			CombiBlocks, CombiBlocks, CombiBlocks	98.19	Nc1nc(OCc2ccccc2)c2[nH]cnc2n1, Nc1nc(OCc2ccccc2)c2[nH]cnc2n1, Nc1nc(OCc2ccccc2)c2[nH]cnc2n1	Phase 3
p-dimethylinamyl-benzoate					Enamine, Enamine	65.76	CCCCCOC(=O)c1ccc(cc1)N(C)C, CCCCCOC(=O)c1ccc(cc1)N(C)C	Preclinical
PA-452	retinoid receptor antagonist	RXRA			Tocris, Tocris, Tocris, Tocris	97.5	CCCCCCOc1cc2c(cc1N(C)c1ncc(cn1)C(O)=O)C(C)(C)CCC2(C)C, CCCCCCOc1cc2c(cc1N(C)c1ncc(cn1)C(O)=O)C(C)(C)CCC2(C)C, CCCCCCOc1cc2c(cc1N(C)c1ncc(cn1)C(O)=O)C(C)(C)CCC2(C)C, CCCCCCOc1cc2c(cc1N(C)c1ncc(cn1)C(O)=O)C(C)(C)CCC2(C)C	Preclinical
PAC-1	caspase activator	CASP3			Tocris, Tocris, Tocris, Tocris, Tocris, Tocris, Tocris, Tocris, Selleck, Selleck, Selleck	96.88	Oc1c(CC=C)cccc1\C=N\NC(=O)CN1CCN(Cc2ccccc2)CC1, Oc1c(CC=C)cccc1\C=N\NC(=O)CN1CCN(Cc2ccccc2)CC1, Oc1c(CC=C)cccc1\C=N\NC(=O)CN1CCN(Cc2ccccc2)CC1, Oc1c(CC=C)cccc1\C=N\NC(=O)CN1CCN(Cc2ccccc2)CC1, Oc1c(CC=C)cccc1\C=N\NC(=O)CN1CCN(Cc2ccccc2)CC1, Oc1c(CC=C)cccc1\C=N\NC(=O)CN1CCN(Cc2ccccc2)CC1, Oc1c(CC=C)cccc1\C=N\NC(=O)CN1CCN(Cc2ccccc2)CC1, Oc1c(CC=C)cccc1\C=N\NC(=O)CN1CCN(Cc2ccccc2)CC1, Oc1c(CC=C)cccc1\C=N\NC(=O)CN1CCN(Cc2ccccc2)CC1, Oc1c(CC=C)cccc1\C=N\NC(=O)CN1CCN(Cc2ccccc2)CC1, Oc1c(CC=C)cccc1\C=N\NC(=O)CN1CCN(Cc2ccccc2)CC1	Phase 1
paclitaxel	tubulin polymerization inhibitor	BCL2, MAP2, MAP4, MAPT, NR1I2, TLR4, TUBA1A, TUBA1B, TUBA1C, TUBA3C, TUBA3D, TUBA3E, TUBA4A, TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8	oncology	ovarian cancer, breast cancer, non-small cell lung cancer (NSCLC)	Tocris, MicroSource, MicroSource, Selleck, Selleck, Selleck, Selleck, Tocris, Tocris	98.1	CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1 |c:5|, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1 |c:5|, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1 |c:5|, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1 |c:5|, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1 |c:5|, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1 |c:5|, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1 |c:5|, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1 |c:5|, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1 |c:5|	Launched
PACOCF3	phospholipase inhibitor	PLA2G4A			Tocris, Tocris, Tocris	43.01	CCCCCCCCCCCCCCCC(=O)C(F)(F)F, CCCCCCCCCCCCCCCC(=O)C(F)(F)F, CCCCCCCCCCCCCCCC(=O)C(F)(F)F	Preclinical
pacritinib	FLT3 inhibitor, JAK inhibitor	FLT3, JAK1, JAK2, JAK3			MedChemEx, MedChemEx, MedChemEx, MedChemEx, Selleck, Selleck, Selleck	91.11	C(CN1CCCC1)Oc1ccc2Nc3nccc(n3)-c3cccc(COC\C=C\COCc1c2)c3 |t:29|, C(CN1CCCC1)Oc1ccc2Nc3nccc(n3)-c3cccc(COC\C=C\COCc1c2)c3 |t:29|, C(CN1CCCC1)Oc1ccc2Nc3nccc(n3)-c3cccc(COC\C=C\COCc1c2)c3 |t:29|, C(CN1CCCC1)Oc1ccc2Nc3nccc(n3)-c3cccc(COC\C=C\COCc1c2)c3 |t:29|, C(CN1CCCC1)Oc1ccc2Nc3nccc(n3)-c3cccc(COC\C=C\COCc1c2)c3 |t:29|, C(CN1CCCC1)Oc1ccc2Nc3nccc(n3)-c3cccc(COC\C=C\COCc1c2)c3 |t:29|, C(CN1CCCC1)Oc1ccc2Nc3nccc(n3)-c3cccc(COC\C=C\COCc1c2)c3 |t:29|	Phase 3
padsevonil	antiepileptic				MedChemEx	88.29	COCc1nn2c(CN3C[C@@H](CC(F)(F)Cl)CC3=O)c(nc2s1)C(F)(F)F	Phase 3
paeoniflorin	anticonvulsant				MedChemEx, Selleck, Selleck	92.42	C[C@@]12C[C@@]3(O)O[C@@H](O1)[C@]1(COC(=O)c4ccccc4)[C@H]3C[C@]21O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O, C[C@@]12C[C@@]3(O)O[C@@H](O1)[C@]1(COC(=O)c4ccccc4)[C@H]3C[C@]21O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O, C[C@@]12C[C@@]3(O)O[C@@H](O1)[C@]1(COC(=O)c4ccccc4)[C@H]3C[C@]21O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O	Preclinical
paeonol	anti-inflammatory agent				MedChemEx, Selleck	94.76	COc1ccc(C(C)=O)c(O)c1, COc1ccc(C(C)=O)c(O)c1	Preclinical
pafuramidine	DNA synthesis inhibitor				MedChemEx, MedChemEx	96.24	CON=C(N)c1ccc(cc1)-c1ccc(o1)-c1ccc(cc1)C(N)=NOC, CON=C(N)c1ccc(cc1)-c1ccc(o1)-c1ccc(cc1)C(N)=NOC	Phase 3
pagoclone	GABA receptor agonist				MedChemEx	89.95	CC(C)CCC(=O)C[C@@H]1N(C(=O)c2ccccc12)c1ccc2ccc(Cl)nc2n1 |&1:8,r|	Phase 2/Phase 3
palbociclib	CDK inhibitor	CDK4, CDK6	oncology	breast cancer	Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck	94.04	CC(=O)c1c(C)c2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n(C2CCCC2)c1=O, CC(=O)c1c(C)c2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n(C2CCCC2)c1=O, CC(=O)c1c(C)c2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n(C2CCCC2)c1=O, CC(=O)c1c(C)c2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n(C2CCCC2)c1=O, CC(=O)c1c(C)c2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n(C2CCCC2)c1=O, CC(=O)c1c(C)c2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n(C2CCCC2)c1=O, CC(=O)c1c(C)c2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n(C2CCCC2)c1=O, CC(=O)c1c(C)c2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n(C2CCCC2)c1=O, CC(=O)c1c(C)c2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n(C2CCCC2)c1=O	Launched
palifosfamide	DNA alkylating agent				MedChemEx, MedChemEx	0	OP(=O)(NCCCl)NCCCl, OP(=O)(NCCCl)NCCCl	Phase 3
paliperidone	dopamine receptor antagonist, serotonin receptor antagonist	DRD2, HTR2A	neurology/psychiatry	schizophrenia	Tocris, MicroSource, Selleck, Selleck	96.4	Cc1nc2[C@@H](O)CCCn2c(=O)c1CCN1CCC(CC1)c1noc2cc(F)ccc12 |&1:4,r|, Cc1nc2[C@@H](O)CCCn2c(=O)c1CCN1CCC(CC1)c1noc2cc(F)ccc12 |&1:4,r|, Cc1nc2[C@@H](O)CCCn2c(=O)c1CCN1CCC(CC1)c1noc2cc(F)ccc12 |&1:4,r|, Cc1nc2[C@@H](O)CCCn2c(=O)c1CCN1CCC(CC1)c1noc2cc(F)ccc12 |&1:4,r|	Launched
palmatine-chloride	dopamine synthesis inhibitor	CYP3A4			MedChemEx, Selleck, Selleck	95.74	COc1cc2CC[n+]3cc4c(OC)c(OC)ccc4cc3-c2cc1OC, COc1cc2CC[n+]3cc4c(OC)c(OC)ccc4cc3-c2cc1OC, COc1cc2CC[n+]3cc4c(OC)c(OC)ccc4cc3-c2cc1OC	Preclinical
palmitoleic-acid					Sigma, Sigma	100	CCCCCC\C=C/CCCCCCCC(O)=O, CCCCCC\C=C/CCCCCCCC(O)=O	Preclinical
palmitoylcarnitine	protein kinase inhibitor				Tocris, Tocris, Tocris	100	CCCCCCCCCCCCCCCC(=O)O[C@@H](CC(O)=O)C[N+](C)(C)C |&1:18|, CCCCCCCCCCCCCCCC(=O)O[C@@H](CC(O)=O)C[N+](C)(C)C |&1:18|, CCCCCCCCCCCCCCCC(=O)O[C@@H](CC(O)=O)C[N+](C)(C)C |&1:18|	Preclinical
palmitoylethanolamide	cannabinoid receptor agonist	CNR2, GPR119, GPR55			MicroSource, Tocris	96.53	CCCCCCCCCCCCCCCC(=O)NCCO, CCCCCCCCCCCCCCCC(=O)NCCO	Launched
palomid-529	AKT inhibitor, mTOR inhibitor	MTOR			MedChemEx, Selleck, Selleck	95.63	COc1ccc(COc2cc3oc(=O)c4cc(ccc4c3cc2OC)[C@@H](C)O)cc1 |&1:25,r|, COc1ccc(COc2cc3oc(=O)c4cc(ccc4c3cc2OC)[C@@H](C)O)cc1 |&1:25,r|, COc1ccc(COc2cc3oc(=O)c4cc(ccc4c3cc2OC)[C@@H](C)O)cc1 |&1:25,r|	Phase 1
palonosetron	serotonin receptor antagonist	HTR3A	gastroenterology	nausea, vomiting	MedChemEx, Selleck	97.7	O=C1N(C[C@H]2CCCc3cccc1c23)[C@@H]1CN2CCC1CC2, O=C1N(C[C@H]2CCCc3cccc1c23)[C@@H]1CN2CCC1CC2	Launched
palosuran	urotensin receptor antagonist	UTS2R			MedChemEx	98.46	Cc1cc(NC(=O)NCCN2CCC(O)(Cc3ccccc3)CC2)c2ccccc2n1	Phase 2
palovarotene	retinoid receptor agonist	RARG			MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx	93.11	CC1(C)CCC(C)(C)c2cc(\C=C\c3ccc(cc3)C(O)=O)c(Cn3cccn3)cc12, CC1(C)CCC(C)(C)c2cc(\C=C\c3ccc(cc3)C(O)=O)c(Cn3cccn3)cc12, CC1(C)CCC(C)(C)c2cc(\C=C\c3ccc(cc3)C(O)=O)c(Cn3cccn3)cc12, CC1(C)CCC(C)(C)c2cc(\C=C\c3ccc(cc3)C(O)=O)c(Cn3cccn3)cc12, CC1(C)CCC(C)(C)c2cc(\C=C\c3ccc(cc3)C(O)=O)c(Cn3cccn3)cc12	Phase 3
pamabrom	diuretic		gastroenterology	bloating	MicroSource, Sigma	0	CC(C)(N)CO.Cn1c2nc(Br)[nH]c2c(=O)n(C)c1=O, CC(C)(N)CO.Cn1c2nc(Br)[nH]c2c(=O)n(C)c1=O	Launched
pamidronate	bone resorption inhibitor	FDPS	endocrinology, oncology, hematologic malignancy	hypercalcemia, Paget's disease, breast cancer, multiple myeloma	Selleck, Selleck	0	NCCC(O)(P(O)(O)=O)P(O)(O)=O, NCCC(O)(P(O)(O)=O)P(O)(O)=O	Launched
pamiparib	PARP inhibitor				MedChemEx	97.75	C[C@]12CCCN1Cc1n[nH]c(=O)c3cc(F)cc4[nH]c2c1c34	Phase 3
pancuronium	acetylcholine receptor antagonist	CHRM2, CHRM3, CHRNA1, CHRNA2	critical care, neurology/psychiatry	endotracheal intubation, muscle relaxant	Tocris, Selleck, MedChemEx, Selleck	100	CC(=O)O[C@H]1[C@H](C[C@H]2[C@@H]3CC[C@H]4C[C@H](OC(C)=O)[C@H](C[C@]4(C)[C@H]3CC[C@]12C)[N+]1(C)CCCCC1)[N+]1(C)CCCCC1, CC(=O)O[C@H]1[C@H](C[C@H]2[C@@H]3CC[C@H]4C[C@H](OC(C)=O)[C@H](C[C@]4(C)[C@H]3CC[C@]12C)[N+]1(C)CCCCC1)[N+]1(C)CCCCC1, CC(=O)O[C@H]1[C@H](C[C@H]2[C@@H]3CC[C@H]4C[C@H](OC(C)=O)[C@H](C[C@]4(C)[C@H]3CC[C@]12C)[N+]1(C)CCCCC1)[N+]1(C)CCCCC1, CC(=O)O[C@H]1[C@H](C[C@H]2[C@@H]3CC[C@H]4C[C@H](OC(C)=O)[C@H](C[C@]4(C)[C@H]3CC[C@]12C)[N+]1(C)CCCCC1)[N+]1(C)CCCCC1	Launched
panipenem	antibacterial 				Adooq	17.51	C[C@@H](O)[C@@H]1[C@H]2CC(S[C@H]3CCN(C3)C(N)=C)=C(N2C1=O)C(O)=O |c:16|	Preclinical
panobinostat	HDAC inhibitor	HDAC1, HDAC2, HDAC3, HDAC4, HDAC6, HDAC7, HDAC8, HDAC9	hematologic malignancy	multiple myeloma	MedChemEx, MedChemEx, MedChemEx, MedChemEx, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck	91.31	Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1	Launched
pantethine	coenzyme A precursor				Sigma, MedChemEx, MedChemEx, MedChemEx, MedChemEx	97.01	CC(C)(CO)[C@@H](O)C(=O)NCCC(=O)NCCSSCCNC(=O)CCNC(=O)[C@H](O)C(C)(C)CO, CC(C)(CO)[C@@H](O)C(=O)NCCC(=O)NCCSSCCNC(=O)CCNC(=O)[C@H](O)C(C)(C)CO, CC(C)(CO)[C@@H](O)C(=O)NCCC(=O)NCCSSCCNC(=O)CCNC(=O)[C@H](O)C(C)(C)CO, CC(C)(CO)[C@@H](O)C(=O)NCCC(=O)NCCSSCCNC(=O)CCNC(=O)[C@H](O)C(C)(C)CO, CC(C)(CO)[C@@H](O)C(=O)NCCC(=O)NCCSSCCNC(=O)CCNC(=O)[C@H](O)C(C)(C)CO	Launched
pantoprazole	ATPase inhibitor	ATP4A	gastroenterology	gastroesophageal reflux disease (GERD), erosive esophagitis (EE), Zollinger-Ellison syndrome	MedChemEx	98.13	COc1ccnc(C[S@@](=O)c2nc3ccc(OC(F)F)cc3[nH]2)c1OC |&1:8|	Launched
pantothenic-acid	coenzyme A precursor				MedChemEx, MicroSource, Selleck, Selleck	100	CC(C)(CO)[C@@H](O)C(=O)NCCC(O)=O, CC(C)(CO)[C@@H](O)C(=O)NCCC(O)=O, CC(C)(CO)[C@@H](O)C(=O)NCCC(O)=O, CC(C)(CO)[C@@H](O)C(=O)NCCC(O)=O	Launched
PAOPA	dopamine receptor modulator	DRD2			Tocris, Tocris	82.29	NC(=O)CN1CC[C@@H](NC(=O)[C@@H]2CCCN2)C1=O, NC(=O)CN1CC[C@@H](NC(=O)[C@@H]2CCCN2)C1=O	Preclinical
papaverine	phosphodiesterase inhibitor	PDE10A, PDE4B, PDE5A	cardiology, hematology, gastroenterology	myocardial infarction, angina pectoris, pulmonary embolism (PE), colitis, vascular spasm	MicroSource, MicroSource, MicroSource	99.78	COc1ccc(Cc2nccc3cc(OC)c(OC)cc23)cc1OC, COc1ccc(Cc2nccc3cc(OC)c(OC)cc23)cc1OC, COc1ccc(Cc2nccc3cc(OC)c(OC)cc23)cc1OC	Launched
paquinimod	S100A9 inhibitor				MedChemEx	72.44	CCN(C(=O)c1c(O)c2c(CC)cccc2n(C)c1=O)c1ccccc1	Phase 2
para-toluenesulfonamide		CA12, CA2, CA6, CA9			MedChemEx, Enamine, Enamine	98.19	Cc1ccc(cc1)S(N)(=O)=O, Cc1ccc(cc1)S(N)(=O)=O, Cc1ccc(cc1)S(N)(=O)=O	Phase 3
paracetamol	cyclooxygenase inhibitor	FAAH, PTGS1, PTGS2, TRPV1	neurology/psychiatry, endocrinology	pain relief, fever	Tocris, MicroSource, Tocris, Prestwick, Prestwick, Prestwick, Prestwick	100	CC(=O)Nc1ccc(O)cc1, CC(=O)Nc1ccc(O)cc1, CC(=O)Nc1ccc(O)cc1, CC(=O)Nc1ccc(O)cc1, CC(=O)Nc1ccc(O)cc1, CC(=O)Nc1ccc(O)cc1, CC(=O)Nc1ccc(O)cc1	Launched
parachlorophenol	antiinfective drug		infectious disease	first-aid antiseptic	MedChemEx, MedChemEx, MicroSource, MicroSource	89.27	Oc1ccc(Cl)cc1, Oc1ccc(Cl)cc1, Oc1ccc(Cl)cc1, Oc1ccc(Cl)cc1	Launched
paramethadione	anticonvulsant	CACNA1G	neurology/psychiatry	seizures	MicroSource, Enamine	15	CC[C@@]1(C)OC(=O)N(C)C1=O |&1:2,r|, CC[C@@]1(C)OC(=O)N(C)C1=O |&1:2,r|	Launched
paraxanthine	adenosine receptor antagonist				Enzo, Enzo, Sigma	97.98	Cn1cnc2[nH]c(=O)n(C)c(=O)c12, Cn1cnc2[nH]c(=O)n(C)c(=O)c12, Cn1cnc2[nH]c(=O)n(C)c(=O)c12	Phase 1
parbendazole	tubulin polymerization inhibitor	TUBB			Prestwick, Prestwick, Prestwick	98.82	CCCCc1ccc2nc(NC(=O)OC)[nH]c2c1, CCCCc1ccc2nc(NC(=O)OC)[nH]c2c1, CCCCc1ccc2nc(NC(=O)OC)[nH]c2c1	Preclinical
parcetasal	anti-inflammatory agent				MedChemEx	95.17	CC(=O)Nc1ccc(O[C@]2(C)OC(=O)c3ccccc3O2)cc1 |&1:9,r|	Preclinical
pardoprunox	dopamine receptor agonist, serotonin receptor agonist	DRD2, DRD3, DRD4, HTR1A, HTR7			MedChemEx, MedChemEx, MedChemEx	96.94	CN1CCN(CC1)c1cccc2[nH]c(=O)oc12, CN1CCN(CC1)c1cccc2[nH]c(=O)oc12, CN1CCN(CC1)c1cccc2[nH]c(=O)oc12	Phase 3
parecoxib	cyclooxygenase inhibitor	LTF	neurology/psychiatry	pain relief	MedChemEx, MedChemEx, MedChemEx	99.02	CCC(=O)NS(=O)(=O)c1ccc(cc1)-c1c(C)onc1-c1ccccc1, CCC(=O)NS(=O)(=O)c1ccc(cc1)-c1c(C)onc1-c1ccccc1, CCC(=O)NS(=O)(=O)c1ccc(cc1)-c1c(C)onc1-c1ccccc1	Launched
parethoxycaine	local anesthetic				ChemBridge	91.8	CCOc1ccc(cc1)C(=O)OCCN(CC)CC	Preclinical
pargyline	monoamine oxidase inhibitor	MAOA, MAOB	cardiology	hypertension	MedChemEx, MicroSource	99.36	CN(CC#C)Cc1ccccc1, CN(CC#C)Cc1ccccc1	Launched
paricalcitol	vitamin D receptor agonist	VDR	nephrology, endocrinology	chronic kidney disease (CKD), hyperthyroidism	MedChemEx, MedChemEx, MedChemEx, MedChemEx	98.6	C[C@H](\C=C\[C@H](C)C(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1C[C@@H](O)C[C@H](O)C1, C[C@H](\C=C\[C@H](C)C(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1C[C@@H](O)C[C@H](O)C1, C[C@H](\C=C\[C@H](C)C(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1C[C@@H](O)C[C@H](O)C1, C[C@H](\C=C\[C@H](C)C(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1C[C@@H](O)C[C@H](O)C1	Launched
paritaprevir	HCV inhibitor		infectious disease	hepatitis C	MedChemEx, MedChemEx	97.16	Cc1cnc(cn1)C(=O)N[C@H]1CCCCC\C=C/[C@@H]2C[C@]2(NC(=O)[C@@H]2C[C@H](CN2C1=O)Oc1nc2ccccc2c2ccccc12)C(=O)NS(=O)(=O)C1CC1 |c:17|, Cc1cnc(cn1)C(=O)N[C@H]1CCCCC\C=C/[C@@H]2C[C@]2(NC(=O)[C@@H]2C[C@H](CN2C1=O)Oc1nc2ccccc2c2ccccc12)C(=O)NS(=O)(=O)C1CC1 |c:17|	Launched
paromomycin	bacterial 30S ribosomal subunit inhibitor		infectious disease	amebiasis	MicroSource, MedChemEx, Sigma, Selleck, Selleck	97.2	NC[C@@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@@H](O[C@@H]3[C@@H](O)[C@H](N)C[C@H](N)[C@H]3O[C@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3N)[C@@H]2O)[C@H](N)[C@@H](O)[C@@H]1O, NC[C@@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@@H](O[C@@H]3[C@@H](O)[C@H](N)C[C@H](N)[C@H]3O[C@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3N)[C@@H]2O)[C@H](N)[C@@H](O)[C@@H]1O, NC[C@@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@@H](O[C@@H]3[C@@H](O)[C@H](N)C[C@H](N)[C@H]3O[C@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3N)[C@@H]2O)[C@H](N)[C@@H](O)[C@@H]1O, NC[C@@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@@H](O[C@@H]3[C@@H](O)[C@H](N)C[C@H](N)[C@H]3O[C@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3N)[C@@H]2O)[C@H](N)[C@@H](O)[C@@H]1O, NC[C@@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@@H](O[C@@H]3[C@@H](O)[C@H](N)C[C@H](N)[C@H]3O[C@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3N)[C@@H]2O)[C@H](N)[C@@H](O)[C@@H]1O	Launched
paroxetine	selective serotonin reuptake inhibitor (SSRI)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, HTR2A, SLC6A2, SLC6A4	neurology/psychiatry	depression, obsessive compulsive disorder (OCD), generalized anxiety disorder (GAD), panic disorders, posttraumatic stress disorder, social anxiety disorder	MicroSource, Tocris, Selleck, Selleck, Selleck, Selleck	94.73	Fc1ccc(cc1)[C@@H]1CCNC[C@H]1COc1ccc2OCOc2c1, Fc1ccc(cc1)[C@@H]1CCNC[C@H]1COc1ccc2OCOc2c1, Fc1ccc(cc1)[C@@H]1CCNC[C@H]1COc1ccc2OCOc2c1, Fc1ccc(cc1)[C@@H]1CCNC[C@H]1COc1ccc2OCOc2c1, Fc1ccc(cc1)[C@@H]1CCNC[C@H]1COc1ccc2OCOc2c1, Fc1ccc(cc1)[C@@H]1CCNC[C@H]1COc1ccc2OCOc2c1	Launched
paroxypropione	gonadotropin inhibitor				MedChemEx, MicroSource	97.55	CCC(=O)c1ccc(O)cc1, CCC(=O)c1ccc(O)cc1	Launched
parsaclisib	PI3K inhibitor				MedChemEx	97.97	CCOc1c(cc(Cl)c(F)c1[C@@H]1CNC(=O)C1)[C@H](C)n1nc(C)c2c(N)ncnc12	Phase 2
parthenolide	NFkB pathway inhibitor				Tocris, Tocris, Tocris	96.19	C\C1=C/CC[C@@]2(C)O[C@H]2[C@H]2OC(=O)C(=C)[C@@H]2CC1 |c:1|, C\C1=C/CC[C@@]2(C)O[C@H]2[C@H]2OC(=O)C(=C)[C@@H]2CC1 |c:1|, C\C1=C/CC[C@@]2(C)O[C@H]2[C@H]2OC(=O)C(=C)[C@@H]2CC1 |c:1|	Phase 1
parthenolide-(-)	NFkB pathway inhibitor	HDAC1			Selleck, Selleck	96.2	C\C1=C\CC[C@@]2(C)O[C@H]2[C@H]2OC(=O)C(=C)[C@@H]2CC1 |t:1|, C\C1=C\CC[C@@]2(C)O[C@H]2[C@H]2OC(=O)C(=C)[C@@H]2CC1 |t:1|	Preclinical
parthenolide-(alternate-stereo)	NFkB pathway inhibitor	IKBKB, RELA			MedChemEx, MedChemEx, Prestwick, Prestwick, Prestwick	97.8	C\C1=C/CC[C@@]2(C)O[C@@H]2[C@H]2OC(=O)C(=C)[C@@H]2CC1 |c:1|, C\C1=C/CC[C@@]2(C)O[C@@H]2[C@H]2OC(=O)C(=C)[C@@H]2CC1 |c:1|, C\C1=C/CC[C@@]2(C)O[C@@H]2[C@H]2OC(=O)C(=C)[C@@H]2CC1 |c:1|, C\C1=C/CC[C@@]2(C)O[C@@H]2[C@H]2OC(=O)C(=C)[C@@H]2CC1 |c:1|, C\C1=C/CC[C@@]2(C)O[C@@H]2[C@H]2OC(=O)C(=C)[C@@H]2CC1 |c:1|	Preclinical
pasireotide	somatostatin receptor agonist	SSTR1, SSTR2, SSTR3, SSTR5	endocrinology	Cushing's syndrome, acromegaly	MedChemEx, MedChemEx	92.83	NCCCC[C@@H]1NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@@H](NC(=O)[C@@H]2C[C@H](CN2C(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2ccc(OCc3ccccc3)cc2)NC1=O)OC(=O)NCCN)c1ccccc1, NCCCC[C@@H]1NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@@H](NC(=O)[C@@H]2C[C@H](CN2C(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2ccc(OCc3ccccc3)cc2)NC1=O)OC(=O)NCCN)c1ccccc1	Launched
PAT-1251	lysyl oxidase inhibitor				MedChemEx	86.27	NCc1cc(Oc2cccc(c2)C(=O)N2C[C@@H](O)[C@H](F)C2)nc(c1)C(F)(F)F	Phase 1
pavinetant	neurokinin receptor antagonist				MedChemEx	97.33	CC[C@H](NC(=O)c1c(NS(C)(=O)=O)c(nc2ccccc12)-c1ccccc1)c1ccccc1	Phase 2
pazopanib	KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	CSF1R, FGF1, FGFR1, FGFR3, FLT1, FLT4, ITK, KDR, KIT, PDGFRA, PDGFRB, SH2B3	oncology	renal cell carcinoma (RCC), soft tissue sarcoma (STS)	Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck	98.32	CN(c1ccc2c(C)n(C)nc2c1)c1ccnc(Nc2ccc(C)c(c2)S(N)(=O)=O)n1, CN(c1ccc2c(C)n(C)nc2c1)c1ccnc(Nc2ccc(C)c(c2)S(N)(=O)=O)n1, CN(c1ccc2c(C)n(C)nc2c1)c1ccnc(Nc2ccc(C)c(c2)S(N)(=O)=O)n1, CN(c1ccc2c(C)n(C)nc2c1)c1ccnc(Nc2ccc(C)c(c2)S(N)(=O)=O)n1, CN(c1ccc2c(C)n(C)nc2c1)c1ccnc(Nc2ccc(C)c(c2)S(N)(=O)=O)n1, CN(c1ccc2c(C)n(C)nc2c1)c1ccnc(Nc2ccc(C)c(c2)S(N)(=O)=O)n1, CN(c1ccc2c(C)n(C)nc2c1)c1ccnc(Nc2ccc(C)c(c2)S(N)(=O)=O)n1	Launched
pazufloxacin	topoisomerase inhibitor		infectious disease	pneumonia, peritonitis, bacterial septicemia	MedChemEx, MicroSource	97.79	C[C@H]1COc2c(c(F)cc3c2n1cc(C(O)=O)c3=O)C1(N)CC1, C[C@H]1COc2c(c(F)cc3c2n1cc(C(O)=O)c3=O)C1(N)CC1	Launched
PBI-4050	free fatty acid receptor agonist				MedChemEx	91.94	CCCCCc1cccc(CC(O)=O)c1	Phase 2/Phase 3
PBT-1033	chelating agent				Astatech	83.21	CN(C)Cc1ccc2c(Cl)cc(Cl)c(O)c2n1	Preclinical
PCA-4248	platelet activating factor receptor antagonist	PTAFR			Tocris, Tocris, Tocris, Tocris	91.88	COC(=O)C1=C(C)NC(C)=C([C@@H]1C)C(=O)OCCSc1ccccc1 |&1:11,r,c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@@H]1C)C(=O)OCCSc1ccccc1 |&1:11,r,c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@@H]1C)C(=O)OCCSc1ccccc1 |&1:11,r,c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@@H]1C)C(=O)OCCSc1ccccc1 |&1:11,r,c:4,9|	Phase 1
PCI-24781	HDAC inhibitor	HDAC1, HDAC2, HDAC3, HDAC6			Selleck, Selleck, Selleck, Selleck	91.06	CN(C)Cc1c(oc2ccccc12)C(=O)NCCOc1ccc(cc1)C(=O)NO, CN(C)Cc1c(oc2ccccc12)C(=O)NCCOc1ccc(cc1)C(=O)NO, CN(C)Cc1c(oc2ccccc12)C(=O)NCCOc1ccc(cc1)C(=O)NO, CN(C)Cc1c(oc2ccccc12)C(=O)NCCOc1ccc(cc1)C(=O)NO	Phase 3
PCI-27483	ERK1 and ERK2 phosphorylation inhibitor				MedChemEx	93.54	NC(=N)c1ccc2nc([nH]c2c1)-c1cc(CC(=O)N[C@@H](CC(O)=O)C(O)=O)cc(c1O)-c1cc(ccc1O)S(N)(=O)=O	Phase 2
PCI-29732	Bruton's tyrosine kinase (BTK) inhibitor	BTK			Tocris, Tocris	97.95	Nc1ncnc2n(nc(-c3ccc(Oc4ccccc4)cc3)c12)C1CCCC1, Nc1ncnc2n(nc(-c3ccc(Oc4ccccc4)cc3)c12)C1CCCC1	Preclinical
PCI-34051	HDAC inhibitor	HDAC1, HDAC10, HDAC6, HDAC8			Tocris, Tocris, Tocris, Selleck, Selleck	97.28	COc1ccc(Cn2ccc3ccc(cc23)C(=O)NO)cc1, COc1ccc(Cn2ccc3ccc(cc23)C(=O)NO)cc1, COc1ccc(Cn2ccc3ccc(cc23)C(=O)NO)cc1, COc1ccc(Cn2ccc3ccc(cc23)C(=O)NO)cc1, COc1ccc(Cn2ccc3ccc(cc23)C(=O)NO)cc1	Preclinical
PCO-400	potassium channel activator	KCNJ8			Enzo, SantaCruz	90.29	CC1(C)Oc2ccc(cc2[C@@H](OC2=CC(=O)CC2)[C@@H]1O)C#N |t:13|, CC1(C)Oc2ccc(cc2[C@@H](OC2=CC(=O)CC2)[C@@H]1O)C#N |t:13|	Phase 1
PD-0325901	MEK inhibitor	MAP2K1			Selleck, Selleck	95.2	OC[C@@H](O)CONC(=O)c1ccc(F)c(F)c1Nc1ccc(I)cc1F, OC[C@@H](O)CONC(=O)c1ccc(F)c(F)c1Nc1ccc(I)cc1F	Phase 2
PD-102807	acetylcholine receptor antagonist	CHRM4			Tocris, Tocris, Tocris, Tocris	90.95	CCOC(=O)c1c(C)[nH]c2ccc3O[C@H]4N(CCc5cc(OC)ccc45)Cc3c12 |&1:14,r|, CCOC(=O)c1c(C)[nH]c2ccc3O[C@H]4N(CCc5cc(OC)ccc45)Cc3c12 |&1:14,r|, CCOC(=O)c1c(C)[nH]c2ccc3O[C@H]4N(CCc5cc(OC)ccc45)Cc3c12 |&1:14,r|, CCOC(=O)c1c(C)[nH]c2ccc3O[C@H]4N(CCc5cc(OC)ccc45)Cc3c12 |&1:14,r|	Preclinical
PD-118057	potassium channel activator	KCNH2			Sigma, Sigma, Sigma	94.44	OC(=O)c1ccccc1Nc1ccc(CCc2ccc(Cl)c(Cl)c2)cc1, OC(=O)c1ccccc1Nc1ccc(CCc2ccc(Cl)c(Cl)c2)cc1, OC(=O)c1ccccc1Nc1ccc(CCc2ccc(Cl)c(Cl)c2)cc1	Preclinical
PD-123319	angiotensin antagonist	AGTR2			Tocris, Selleck, Selleck, Tocris	96.91	CN(C)c1ccc(Cn2cnc3CN([C@@H](Cc23)C(O)=O)C(=O)C(c2ccccc2)c2ccccc2)cc1C, CN(C)c1ccc(Cn2cnc3CN([C@@H](Cc23)C(O)=O)C(=O)C(c2ccccc2)c2ccccc2)cc1C, CN(C)c1ccc(Cn2cnc3CN([C@@H](Cc23)C(O)=O)C(=O)C(c2ccccc2)c2ccccc2)cc1C, CN(C)c1ccc(Cn2cnc3CN([C@@H](Cc23)C(O)=O)C(=O)C(c2ccccc2)c2ccccc2)cc1C	Phase 1
PD-128907	dopamine receptor agonist	DRD2, DRD3			MedChemEx, Tocris, Tocris	93.45	CCCN1CCO[C@H]2[C@H]1COc1ccc(O)cc21, CCCN1CCO[C@H]2[C@H]1COc1ccc(O)cc21, CCCN1CCO[C@H]2[C@H]1COc1ccc(O)cc21	Preclinical
PD-153035	EGFR inhibitor	EGFR, KDR			MedChemEx, MedChemEx	98.35	COc1cc2ncnc(Nc3cccc(Br)c3)c2cc1OC, COc1cc2ncnc(Nc3cccc(Br)c3)c2cc1OC	Phase 1
PD-156707	endothelin receptor antagonist	EDNRA, EDNRB			Sigma	71.03	COc1ccc(cc1)C(=O)C(\Cc1cc(OC)c(OC)c(OC)c1)=C(/C(O)=O)c1ccc2OCOc2c1	Preclinical
PD-158780	EGFR inhibitor	EGFR			Tocris, Tocris, Tocris, Tocris, Tocris	98.94	CNc1cc2c(Nc3cccc(Br)c3)ncnc2cn1, CNc1cc2c(Nc3cccc(Br)c3)ncnc2cn1, CNc1cc2c(Nc3cccc(Br)c3)ncnc2cn1, CNc1cc2c(Nc3cccc(Br)c3)ncnc2cn1, CNc1cc2c(Nc3cccc(Br)c3)ncnc2cn1	Preclinical
PD-160170	neuropeptide receptor antagonist	NPY1R			Tocris, Tocris, Tocris	97.6	CC(C)c1ccccc1S(=O)(=O)c1cc(N)c2ncccc2c1[N+]([O-])=O, CC(C)c1ccccc1S(=O)(=O)c1cc(N)c2ncccc2c1[N+]([O-])=O, CC(C)c1ccccc1S(=O)(=O)c1cc(N)c2ncccc2c1[N+]([O-])=O	Preclinical
PD-161570	FGFR inhibitor	FGFR1			Tocris, Tocris, Tocris, Tocris	93.8	CCN(CC)CCCCNc1ncc2cc(c(NC(=O)NC(C)(C)C)nc2n1)-c1c(Cl)cccc1Cl, CCN(CC)CCCCNc1ncc2cc(c(NC(=O)NC(C)(C)C)nc2n1)-c1c(Cl)cccc1Cl, CCN(CC)CCCCNc1ncc2cc(c(NC(=O)NC(C)(C)C)nc2n1)-c1c(Cl)cccc1Cl, CCN(CC)CCCCNc1ncc2cc(c(NC(=O)NC(C)(C)C)nc2n1)-c1c(Cl)cccc1Cl	Preclinical
PD-166285	SRC inhibitor	EGFR, FGFR1, PDGFRB, PKMYT1, SRC, WEE1			Tocris, Tocris, Tocris, Tocris, Tocris, Tocris	98.74	CCN(CC)CCOc1ccc(Nc2ncc3cc(-c4c(Cl)cccc4Cl)c(=O)n(C)c3n2)cc1, CCN(CC)CCOc1ccc(Nc2ncc3cc(-c4c(Cl)cccc4Cl)c(=O)n(C)c3n2)cc1, CCN(CC)CCOc1ccc(Nc2ncc3cc(-c4c(Cl)cccc4Cl)c(=O)n(C)c3n2)cc1, CCN(CC)CCOc1ccc(Nc2ncc3cc(-c4c(Cl)cccc4Cl)c(=O)n(C)c3n2)cc1, CCN(CC)CCOc1ccc(Nc2ncc3cc(-c4c(Cl)cccc4Cl)c(=O)n(C)c3n2)cc1, CCN(CC)CCOc1ccc(Nc2ncc3cc(-c4c(Cl)cccc4Cl)c(=O)n(C)c3n2)cc1	Preclinical
PD-166793	collagenase inhibitor, metalloproteinase inhibitor	MMP13, MMP2, MMP3			Tocris, Tocris, Tocris, Tocris	98.52	CC(C)[C@H](NS(=O)(=O)c1ccc(cc1)-c1ccc(Br)cc1)C(O)=O, CC(C)[C@H](NS(=O)(=O)c1ccc(cc1)-c1ccc(Br)cc1)C(O)=O, CC(C)[C@H](NS(=O)(=O)c1ccc(cc1)-c1ccc(Br)cc1)C(O)=O, CC(C)[C@H](NS(=O)(=O)c1ccc(cc1)-c1ccc(Br)cc1)C(O)=O	Preclinical
PD-168077	dopamine receptor agonist	DRD2			Tocris	20.24	Cc1cccc(c1)C(=O)NCN1CCN(CC1)c1ccccc1C#N	Preclinical
PD-168393	EGFR inhibitor	EGFR, ERBB2, SRC			Selleck, Selleck, Selleck, Selleck	96.92	Brc1cccc(Nc2ncnc3ccc(NC(=O)C=C)cc23)c1, Brc1cccc(Nc2ncnc3ccc(NC(=O)C=C)cc23)c1, Brc1cccc(Nc2ncnc3ccc(NC(=O)C=C)cc23)c1, Brc1cccc(Nc2ncnc3ccc(NC(=O)C=C)cc23)c1	Preclinical
PD-168568	dopamine receptor antagonist	DRD2, DRD4			Tocris, Tocris, Tocris	96.65	Cc1ccc(cc1C)N1CCN(CC[C@H]2NC(=O)c3ccccc23)CC1 |&1:14|, Cc1ccc(cc1C)N1CCN(CC[C@H]2NC(=O)c3ccccc23)CC1 |&1:14|, Cc1ccc(cc1C)N1CCN(CC[C@H]2NC(=O)c3ccccc23)CC1 |&1:14|	Preclinical
PD-173074	FGFR inhibitor, VEGFR inhibitor	FGFR1, FGFR2, FGFR3, FGFR4, FLT1, FLT4, KDR, PDGFRA, PDGFRB			Tocris, Selleck, Selleck, Selleck, Selleck, Tocris	94.27	CCN(CC)CCCCNc1ncc2cc(c(NC(=O)NC(C)(C)C)nc2n1)-c1cc(OC)cc(OC)c1, CCN(CC)CCCCNc1ncc2cc(c(NC(=O)NC(C)(C)C)nc2n1)-c1cc(OC)cc(OC)c1, CCN(CC)CCCCNc1ncc2cc(c(NC(=O)NC(C)(C)C)nc2n1)-c1cc(OC)cc(OC)c1, CCN(CC)CCCCNc1ncc2cc(c(NC(=O)NC(C)(C)C)nc2n1)-c1cc(OC)cc(OC)c1, CCN(CC)CCCCNc1ncc2cc(c(NC(=O)NC(C)(C)C)nc2n1)-c1cc(OC)cc(OC)c1, CCN(CC)CCCCNc1ncc2cc(c(NC(=O)NC(C)(C)C)nc2n1)-c1cc(OC)cc(OC)c1	Preclinical
PD-173212	calcium channel blocker	CACNA1B			Tocris, Tocris, Tocris, Tocris	94.02	CC(C)C[C@H](N(C)Cc1ccc(cc1)C(C)(C)C)C(=O)N[C@@H](Cc1ccc(OCc2ccccc2)cc1)C(=O)NC(C)(C)C, CC(C)C[C@H](N(C)Cc1ccc(cc1)C(C)(C)C)C(=O)N[C@@H](Cc1ccc(OCc2ccccc2)cc1)C(=O)NC(C)(C)C, CC(C)C[C@H](N(C)Cc1ccc(cc1)C(C)(C)C)C(=O)N[C@@H](Cc1ccc(OCc2ccccc2)cc1)C(=O)NC(C)(C)C, CC(C)C[C@H](N(C)Cc1ccc(cc1)C(C)(C)C)C(=O)N[C@@H](Cc1ccc(OCc2ccccc2)cc1)C(=O)NC(C)(C)C	Preclinical
PD-184352	MEK inhibitor	MAP2K1, MAP3K1, MAP3K2			Selleck, Selleck, Selleck, Selleck, Selleck, Axon, Axon, Axon	100	Fc1ccc(C(=O)NOCC2CC2)c(Nc2ccc(I)cc2Cl)c1F, Fc1ccc(C(=O)NOCC2CC2)c(Nc2ccc(I)cc2Cl)c1F, Fc1ccc(C(=O)NOCC2CC2)c(Nc2ccc(I)cc2Cl)c1F, Fc1ccc(C(=O)NOCC2CC2)c(Nc2ccc(I)cc2Cl)c1F, Fc1ccc(C(=O)NOCC2CC2)c(Nc2ccc(I)cc2Cl)c1F, Fc1ccc(C(=O)NOCC2CC2)c(Nc2ccc(I)cc2Cl)c1F, Fc1ccc(C(=O)NOCC2CC2)c(Nc2ccc(I)cc2Cl)c1F, Fc1ccc(C(=O)NOCC2CC2)c(Nc2ccc(I)cc2Cl)c1F	Phase 2
PD-198306	MAP kinase inhibitor, MEK inhibitor	MAP2K1, MAP2K2			Tocris, Tocris, Tocris, Tocris, Tocris, Tocris, Tocris	97.2	Cc1cc(I)ccc1Nc1c(F)c(F)c(F)cc1C(=O)NOCC1CC1, Cc1cc(I)ccc1Nc1c(F)c(F)c(F)cc1C(=O)NOCC1CC1, Cc1cc(I)ccc1Nc1c(F)c(F)c(F)cc1C(=O)NOCC1CC1, Cc1cc(I)ccc1Nc1c(F)c(F)c(F)cc1C(=O)NOCC1CC1, Cc1cc(I)ccc1Nc1c(F)c(F)c(F)cc1C(=O)NOCC1CC1, Cc1cc(I)ccc1Nc1c(F)c(F)c(F)cc1C(=O)NOCC1CC1, Cc1cc(I)ccc1Nc1c(F)c(F)c(F)cc1C(=O)NOCC1CC1	Preclinical
PD-318088	MEK inhibitor				MedChemEx, Selleck, Selleck, Selleck	96.17	OC[C@@H](O)CONC(=O)c1cc(Br)c(F)c(F)c1Nc1ccc(I)cc1F |&1:2,r|, OC[C@@H](O)CONC(=O)c1cc(Br)c(F)c(F)c1Nc1ccc(I)cc1F |&1:2,r|, OC[C@@H](O)CONC(=O)c1cc(Br)c(F)c(F)c1Nc1ccc(I)cc1F |&1:2,r|, OC[C@@H](O)CONC(=O)c1cc(Br)c(F)c(F)c1Nc1ccc(I)cc1F |&1:2,r|	Preclinical
PD-407824	PKC inhibitor	WEE1			Tocris, Tocris, Tocris, Tocris, Tocris, Tocris	96.32	Oc1ccc2[nH]c3cc(c4C(=O)NC(=O)c4c3c2c1)-c1ccccc1, Oc1ccc2[nH]c3cc(c4C(=O)NC(=O)c4c3c2c1)-c1ccccc1, Oc1ccc2[nH]c3cc(c4C(=O)NC(=O)c4c3c2c1)-c1ccccc1, Oc1ccc2[nH]c3cc(c4C(=O)NC(=O)c4c3c2c1)-c1ccccc1, Oc1ccc2[nH]c3cc(c4C(=O)NC(=O)c4c3c2c1)-c1ccccc1, Oc1ccc2[nH]c3cc(c4C(=O)NC(=O)c4c3c2c1)-c1ccccc1	Preclinical
PD-81723	adenosine receptor agonist	ADORA1			Tocris, Tocris	86.53	Cc1sc(N)c(C(=O)c2cccc(c2)C(F)(F)F)c1C, Cc1sc(N)c(C(=O)c2cccc(c2)C(F)(F)F)c1C	Preclinical
PD-98059	MEK inhibitor	AKT1, CHEK1, GSK3B, LCK, MAP2K1, MAPK1, MAPK11, MAPK12, MAPK14, MAPK8, PRKCA, RAF1, ROCK1, RPS6KB1, SGK1			Selleck, Tocris, Tocris	94.02	COc1cccc(c1N)-c1cc(=O)c2ccccc2o1, COc1cccc(c1N)-c1cc(=O)c2ccccc2o1, COc1cccc(c1N)-c1cc(=O)c2ccccc2o1	Preclinical
PDD-00017273	PARG inhibitor				MedChemEx, MedChemEx	98.7	Cc1cc(Cn2c3ccc(cc3c(=O)n(Cc3cnc(C)s3)c2=O)S(=O)(=O)NC2(C)CC2)n(C)n1, Cc1cc(Cn2c3ccc(cc3c(=O)n(Cc3cnc(C)s3)c2=O)S(=O)(=O)NC2(C)CC2)n(C)n1	Preclinical
PDE10-IN-1	phosphodiesterase inhibitor	PDE10A			MedChemEx	96.99	Cc1c(nc2c3cccnc3ccn12)[C@@H]1C[C@H]1c1nc2c(C)ncc(C)n2n1	Preclinical
PDP-EA	FAAH activator	FAAH			Tocris, Tocris	96.07	CCCCCCCCCCCCCCCc1cccc(OCC(=O)NCCO)c1, CCCCCCCCCCCCCCCc1cccc(OCC(=O)NCCO)c1	Preclinical
PD1-PDL-inhibitor-1	programmed death ligand inhibitor	CD274			MedChemEx, MedChemEx	97.25	COc1cc(OCc2cccc(c2C)-c2ccccc2)cc(OC)c1CN1CCCC[C@H]1C(O)=O, COc1cc(OCc2cccc(c2C)-c2ccccc2)cc(OC)c1CN1CCCC[C@H]1C(O)=O	Preclinical
peficitinib	JAK inhibitor	JAK1, JAK2, JAK3	rheumatology	rheumatoid arthritis	Selleck	98.78	NC(=O)c1cnc2[nH]ccc2c1N[C@H]1[C@H]2C[C@H]3C[C@@H]1C[C@](O)(C3)C2 |&1:13,14,16,18,20,r|	Launched
pefloxacin	bacterial DNA gyrase inhibitor	TOP2A	infectious disease, urology	gastrointestinal infections, urethritis, gonorrhea, urinary tract infections	MedChemEx, MicroSource, Selleck	98.47	CCn1cc(C(O)=O)c(=O)c2cc(F)c(cc12)N1CCN(C)CC1, CCn1cc(C(O)=O)c(=O)c2cc(F)c(cc12)N1CCN(C)CC1, CCn1cc(C(O)=O)c(=O)c2cc(F)c(cc12)N1CCN(C)CC1	Launched
pelanserin	serotonin receptor antagonist	HTR2A			Enamine	91.31	O=c1[nH]c2ccccc2c(=O)n1CCCN1CCN(CC1)c1ccccc1	Phase 2
pelitinib	EGFR inhibitor	EGFR			MedChemEx, Selleck, Selleck, Selleck	96.63	CCOc1cc2ncc(C#N)c(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C, CCOc1cc2ncc(C#N)c(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C, CCOc1cc2ncc(C#N)c(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C, CCOc1cc2ncc(C#N)c(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C	Phase 2
pelrinone	phosphodiesterase inhibitor				AMS	95.85	Cc1nc(=O)c(C#N)c(NCc2cccnc2)[nH]1	Phase 2
pemafibrate	PPAR receptor agonist				MedChemEx	98.47	CC[C@@H](Oc1cccc(CN(CCCOc2ccc(OC)cc2)c2nc3ccccc3o2)c1)C(O)=O	Phase 3
pemetrexed	dihydrofolate reductase inhibitor, thymidylate synthase inhibitor	ATIC, DHFR, GART, TYMS	oncology	non-small cell lung cancer (NSCLC), mesothelioma	Key, Key, Key, Key, MedChemEx, MedChemEx, MedChemEx, MicroSource, Selleck, Selleck, Selleck	87.62	Nc1nc(=O)c2c(CCc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)c[nH]c2[nH]1, Nc1nc(=O)c2c(CCc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)c[nH]c2[nH]1, Nc1nc(=O)c2c(CCc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)c[nH]c2[nH]1, Nc1nc(=O)c2c(CCc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)c[nH]c2[nH]1, Nc1nc(=O)c2c(CCc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)c[nH]c2[nH]1, Nc1nc(=O)c2c(CCc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)c[nH]c2[nH]1, Nc1nc(=O)c2c(CCc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)c[nH]c2[nH]1, Nc1nc(=O)c2c(CCc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)c[nH]c2[nH]1, Nc1nc(=O)c2c(CCc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)c[nH]c2[nH]1, Nc1nc(=O)c2c(CCc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)c[nH]c2[nH]1, Nc1nc(=O)c2c(CCc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)c[nH]c2[nH]1	Launched
pemirolast	mediator release inhibitor	HRH1	pulmonary	asthma	MedChemEx, MedChemEx, Selleck	97.42	Cc1cccn2c1ncc(-c1nn[nH]n1)c2=O, Cc1cccn2c1ncc(-c1nn[nH]n1)c2=O, Cc1cccn2c1ncc(-c1nn[nH]n1)c2=O	Launched
pempidine	ganglionic blocker		cardiology	hypertension	MicroSource, MicroSource	52.72	CN1C(C)(C)CCCC1(C)C, CN1C(C)(C)CCCC1(C)C	Launched
penbutolol	adrenergic receptor antagonist	ADRB1, ADRB2, HTR1A, HTR1B	cardiology	hypertension	MicroSource, MicroSource, MicroSource, Toronto, Toronto, Toronto	95.02	CC(C)(C)NC[C@H](O)COc1ccccc1C1CCCC1, CC(C)(C)NC[C@H](O)COc1ccccc1C1CCCC1, CC(C)(C)NC[C@H](O)COc1ccccc1C1CCCC1, CC(C)(C)NC[C@H](O)COc1ccccc1C1CCCC1, CC(C)(C)NC[C@H](O)COc1ccccc1C1CCCC1, CC(C)(C)NC[C@H](O)COc1ccccc1C1CCCC1	Launched
penciclovir	DNA directed DNA polymerase inhibitor		dental	cold sore	MicroSource, Selleck, MedChemEx, Selleck	100	Nc1nc(=O)c2ncn(CCC(CO)CO)c2[nH]1, Nc1nc(=O)c2ncn(CCC(CO)CO)c2[nH]1, Nc1nc(=O)c2ncn(CCC(CO)CO)c2[nH]1, Nc1nc(=O)c2ncn(CCC(CO)CO)c2[nH]1	Launched
penfluridol	T-type calcium channel blocker	CACNA1G	neurology/psychiatry	schizophrenia	MicroSource, MicroSource, MicroSource, MicroSource, Selleck, Selleck	96.94	OC1(CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1)c1ccc(Cl)c(c1)C(F)(F)F, OC1(CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1)c1ccc(Cl)c(c1)C(F)(F)F, OC1(CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1)c1ccc(Cl)c(c1)C(F)(F)F, OC1(CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1)c1ccc(Cl)c(c1)C(F)(F)F, OC1(CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1)c1ccc(Cl)c(c1)C(F)(F)F, OC1(CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1)c1ccc(Cl)c(c1)C(F)(F)F	Launched
penicillamine-(D)	chelating agent		metabolism, rheumatology, nephrology	Wilson's disease, rheumatoid arthritis, cystinuria	Selleck, MedChemEx, Selleck	100	CC(C)(S)[C@@H](N)C(O)=O, CC(C)(S)[C@@H](N)C(O)=O, CC(C)(S)[C@@H](N)C(O)=O	Launched
penicillamine-(racemic)					MicroSource	0	CC(C)(S)[C@@H](N)C(O)=O |&1:4|	Launched
penicillin-v-potassium	bacterial cell wall synthesis inhibitor		infectious disease	pneumonia, ear infections, skin infections, throat infections, cholera, scarlet fever	MedChemEx, MicroSource	90.16	CC1(C)S[C@@H]2[C@H](NC(=O)COc3ccccc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)COc3ccccc3)C(=O)N2[C@H]1C(O)=O	Launched
pentacosanoic-acid					Cayman, Cayman	100	CCCCCCCCCCCCCCCCCCCCCCCCC(O)=O, CCCCCCCCCCCCCCCCCCCCCCCCC(O)=O	Preclinical
pentagastrin	CCK receptor agonist	CCKBR	gastroenterology	anacidity diagnostic, gastric hypersecretion diagnostic	MicroSource, Abblis	84.88	CSCC[C@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)CCNC(=O)OC(C)(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](Cc1ccccc1)C(N)=O, CSCC[C@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)CCNC(=O)OC(C)(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](Cc1ccccc1)C(N)=O	Launched
pentamidine	anti-pneumocystis agent	TRDMT1	infectious disease	pneumonia	MicroSource, Selleck	98.99	NC(=N)c1ccc(OCCCCCOc2ccc(cc2)C(N)=N)cc1, NC(=N)c1ccc(OCCCCCOc2ccc(cc2)C(N)=N)cc1	Launched
pentetic-acid	chelating agent				MedChemEx, MicroSource	100	OC(=O)CN(CCN(CC(O)=O)CC(O)=O)CCN(CC(O)=O)CC(O)=O, OC(=O)CN(CCN(CC(O)=O)CC(O)=O)CCN(CC(O)=O)CC(O)=O	Phase 2
pentolinium	cholinergic receptor antagonist	CHRNA10, CHRNA3, CHRNA4, CHRNB4	cardiology	hypertension	Prestwick, Acros, Acros	97.7	C[N+]1(CCCCC[N+]2(C)CCCC2)CCCC1, C[N+]1(CCCCC[N+]2(C)CCCC2)CCCC1, C[N+]1(CCCCC[N+]2(C)CCCC2)CCCC1	Launched
pentostatin	adenosine deaminase inhibitor, ribonucleotide reductase inhibitor	ADA	hematologic malignancy	hairy cell leukemia	MedChemEx, MedChemEx, Tocris	100	OC[C@H]1O[C@H](C[C@@H]1O)n1cnc2[C@H](O)CN=CNc12 |c:16|, OC[C@H]1O[C@H](C[C@@H]1O)n1cnc2[C@H](O)CN=CNc12 |c:16|, OC[C@H]1O[C@H](C[C@@H]1O)n1cnc2[C@H](O)CN=CNc12 |c:16|	Launched
pentoxifylline	phosphodiesterase inhibitor	ADORA1, ADORA2A, ADORA2B, ADRA2B, NT5E, PDE10A, PDE1A, PDE1B, PDE1C, PDE2A, PDE3A, PDE3B, PDE4A, PDE4B, PDE4C, PDE4D, PDE5A, PDE6A, PDE6B, PDE6C, PDE6D, PDE6G, PDE6H, PDE7A, PDE7B, PDE8A, PDE8B, PDE9A, TNF	cardiology	claudication	MicroSource, MicroSource, MicroSource, MicroSource, Selleck	99.53	CC(=O)CCCCn1c(=O)n(C)c2ncn(C)c2c1=O, CC(=O)CCCCn1c(=O)n(C)c2ncn(C)c2c1=O, CC(=O)CCCCn1c(=O)n(C)c2ncn(C)c2c1=O, CC(=O)CCCCn1c(=O)n(C)c2ncn(C)c2c1=O, CC(=O)CCCCn1c(=O)n(C)c2ncn(C)c2c1=O	Launched
pentylenetetrazol	GABA receptor antagonist				MedChemEx, MicroSource, MicroSource, Tocris	76.62	C1CCc2nnnn2CC1, C1CCc2nnnn2CC1, C1CCc2nnnn2CC1, C1CCc2nnnn2CC1	Withdrawn
peposertib	DNA dependent protein kinase inhibitor				MedChemEx	96.7	COc1ccc(nn1)[C@@H](O)c1cc(c(F)cc1Cl)-c1ncnc2cc(ccc12)N1CCOCC1	Phase 1/Phase 2
pepstatin	aspartic protease inhibitor	CTSB, CTSD, CTSL, REN			MedChemEx, Enzo	94.54	CC(C)C[C@H](NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CC(C)C)C(C)C)C(C)C)[C@@H](O)CC(O)=O, CC(C)C[C@H](NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CC(C)C)C(C)C)C(C)C)[C@@H](O)CC(O)=O	Preclinical
peramivir	neuraminidase inhibitor		infectious disease	influenza A virus infection	Selleck, Selleck, MedChemEx	100	CCC(CC)[C@H](NC(C)=O)[C@@H]1[C@H](O)[C@H](C[C@H]1NC(N)=N)C(O)=O, CCC(CC)[C@H](NC(C)=O)[C@@H]1[C@H](O)[C@H](C[C@H]1NC(N)=N)C(O)=O, CCC(CC)[C@H](NC(C)=O)[C@@H]1[C@H](O)[C@H](C[C@H]1NC(N)=N)C(O)=O	Launched
perchlozone			infectious disease	tuberculosis	Labotest	94.96	NC(=S)N\N=C\c1ccncc1	Launched
peretinoin	retinoid receptor agonist	RXRA			MedChemEx, MedChemEx, MedChemEx	85.75	CC(C)=CCC\C(C)=C\CC\C(C)=C\C=C\C(\C)=C\C(O)=O, CC(C)=CCC\C(C)=C\CC\C(C)=C\C=C\C(\C)=C\C(O)=O, CC(C)=CCC\C(C)=C\CC\C(C)=C\C=C\C(\C)=C\C(O)=O	Phase 3
perfluamine					Oakwood	0	FC(F)(F)C(F)(F)C(F)(F)N(C(F)(F)C(F)(F)C(F)(F)F)C(F)(F)C(F)(F)C(F)(F)F	Launched
perflubron	contrast agent		radiology	contrast agent	Sigma, Oakwood	0	FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)Br, FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)Br	Launched
perfluorodecalin			dermatology	cosmetic	Sigma	0	FC1(F)C(F)(F)C(F)(F)C2(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C2(F)C1(F)F	Launched
perfluorohexyloctane					Sigma	0	CCCCCCCCC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F	Launched
pergolide	dopamine receptor agonist	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C			MedChemEx, Selleck, Selleck, Selleck, Selleck	98.87	CCCN1C[C@H](CSC)C[C@H]2[C@H]1Cc1c[nH]c3cccc2c13, CCCN1C[C@H](CSC)C[C@H]2[C@H]1Cc1c[nH]c3cccc2c13, CCCN1C[C@H](CSC)C[C@H]2[C@H]1Cc1c[nH]c3cccc2c13, CCCN1C[C@H](CSC)C[C@H]2[C@H]1Cc1c[nH]c3cccc2c13, CCCN1C[C@H](CSC)C[C@H]2[C@H]1Cc1c[nH]c3cccc2c13	Withdrawn
perhexiline	carnitine palmitoyltransferase inhibitor	CPT1A	cardiology	angina pectoris	MicroSource, MicroSource, MicroSource, MicroSource, MicroSource, MicroSource, MicroSource, MicroSource, MicroSource	97.96	C(C(C1CCCCC1)C1CCCCC1)[C@H]1CCCCN1 |&1:14|, C(C(C1CCCCC1)C1CCCCC1)[C@H]1CCCCN1 |&1:14|, C(C(C1CCCCC1)C1CCCCC1)[C@H]1CCCCN1 |&1:14|, C(C(C1CCCCC1)C1CCCCC1)[C@H]1CCCCN1 |&1:14|, C(C(C1CCCCC1)C1CCCCC1)[C@H]1CCCCN1 |&1:14|, C(C(C1CCCCC1)C1CCCCC1)[C@H]1CCCCN1 |&1:14|, C(C(C1CCCCC1)C1CCCCC1)[C@H]1CCCCN1 |&1:14|, C(C(C1CCCCC1)C1CCCCC1)[C@H]1CCCCN1 |&1:14|, C(C(C1CCCCC1)C1CCCCC1)[C@H]1CCCCN1 |&1:14|	Launched
perifosine	AKT inhibitor	AKT1			MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx	100	CCCCCCCCCCCCCCCCCCOP(O)(=O)OC1CC[N+](C)(C)CC1 |&1:19|, CCCCCCCCCCCCCCCCCCOP(O)(=O)OC1CC[N+](C)(C)CC1 |&1:19|, CCCCCCCCCCCCCCCCCCOP(O)(=O)OC1CC[N+](C)(C)CC1 |&1:19|, CCCCCCCCCCCCCCCCCCOP(O)(=O)OC1CC[N+](C)(C)CC1 |&1:19|, CCCCCCCCCCCCCCCCCCOP(O)(=O)OC1CC[N+](C)(C)CC1 |&1:19|	Phase 3
perillyl-alcohol	apoptosis stimulant, farnesyltransferase inhibitor	FNTA			Enamine, Enamine, Enamine, Enamine	0	CC(=C)[C@H]1CCC(CO)=CC1 |&1:3,r,c:8|, CC(=C)[C@H]1CCC(CO)=CC1 |&1:3,r,c:8|, CC(=C)[C@H]1CCC(CO)=CC1 |&1:3,r,c:8|, CC(=C)[C@H]1CCC(CO)=CC1 |&1:3,r,c:8|	Phase 2
perindopril	angiotensin converting enzyme inhibitor	ACE	cardiology	hypertension, myocardial infarction, coronary artery disease (CAD)	MicroSource, Selleck, MedChemEx, Tocris, Tocris	95.89	CCC[C@H](N[C@@H](C)C(=O)N1[C@H]2CCCC[C@H]2C[C@H]1C(O)=O)C(=O)OCC, CCC[C@H](N[C@@H](C)C(=O)N1[C@H]2CCCC[C@H]2C[C@H]1C(O)=O)C(=O)OCC, CCC[C@H](N[C@@H](C)C(=O)N1[C@H]2CCCC[C@H]2C[C@H]1C(O)=O)C(=O)OCC, CCC[C@H](N[C@@H](C)C(=O)N1[C@H]2CCCC[C@H]2C[C@H]1C(O)=O)C(=O)OCC, CCC[C@H](N[C@@H](C)C(=O)N1[C@H]2CCCC[C@H]2C[C@H]1C(O)=O)C(=O)OCC	Launched
perindoprilat	angiotensin converting enzyme inhibitor	ACE			MicroSource	3.67	CCC[C@H](N[C@@H](C)C(=O)N1[C@H]2CCCC[C@H]2C[C@H]1C(O)=O)C(O)=O	Phase 2
permethrin			infectious disease	lice	MedChemEx, MicroSource, Sigma	0	CC1(C)[C@@H](C=C(Cl)Cl)[C@@H]1C(=O)OCc1cccc(Oc2ccccc2)c1 |&1:3,&2:8,r|, CC1(C)[C@@H](C=C(Cl)Cl)[C@@H]1C(=O)OCc1cccc(Oc2ccccc2)c1 |&1:3,&2:8,r|, CC1(C)[C@@H](C=C(Cl)Cl)[C@@H]1C(=O)OCc1cccc(Oc2ccccc2)c1 |&1:3,&2:8,r|	Launched
perospirone	dopamine receptor antagonist, serotonin receptor antagonist	DRD2, DRD3, DRD4	neurology/psychiatry	schizophrenia, bipolar disorder	Prestwick, AKSci, AKSci, AKSci, AKSci	99.7	O=C1[C@H]2CCCC[C@H]2C(=O)N1CCCCN1CCN(CC1)c1nsc2ccccc12, O=C1[C@H]2CCCC[C@H]2C(=O)N1CCCCN1CCN(CC1)c1nsc2ccccc12, O=C1[C@H]2CCCC[C@H]2C(=O)N1CCCCN1CCN(CC1)c1nsc2ccccc12, O=C1[C@H]2CCCC[C@H]2C(=O)N1CCCCN1CCN(CC1)c1nsc2ccccc12, O=C1[C@H]2CCCC[C@H]2C(=O)N1CCCCN1CCN(CC1)c1nsc2ccccc12	Launched
perphenazine	dopamine receptor antagonist	CALM1, DRD1, DRD2, HRH1, HTR2A, HTR2C, HTR6, HTR7	neurology/psychiatry, gastroenterology	schizophrenia, nausea, vomiting	MicroSource, MedChemEx, MedChemEx, Sigma	87.72	OCCN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc23)CC1, OCCN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc23)CC1, OCCN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc23)CC1, OCCN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc23)CC1	Launched
peruvoside	cardiac glycoside				Enzo	70.11	CO[C@H]1[C@@H](O)[C@@H](C)O[C@@H](O[C@H]2CC[C@@]3(C=O)[C@H](CC[C@@H]4[C@@H]3CC[C@]3(C)[C@H](CC[C@]43O)C3=CC(=O)OC3)C2)[C@@H]1O |a:2,3,8,10,13,16,19,20,23,25,28,&1:5,&2:37,t:33|	Phase 1
perzinfotel	glutamate receptor antagonist	GRIN1, GRIN2A, GRIN2B			Sigma, Sigma, Sigma	97	OP(O)(=O)CCN1CCCNc2c1c(=O)c2=O, OP(O)(=O)CCN1CCCNc2c1c(=O)c2=O, OP(O)(=O)CCN1CCCNc2c1c(=O)c2=O	Phase 2
PETCM	caspase activator	CASP3			Tocris, Tocris	93.77	O[C@@H](Cc1ccncc1)C(Cl)(Cl)Cl |&1:1,r|, O[C@@H](Cc1ccncc1)C(Cl)(Cl)Cl |&1:1,r|	Preclinical
pevonedistat	nedd activating enzyme inhibitor	NAE1, UBA3			MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx, Active, Active, Active	98.16	NS(=O)(=O)OC[C@@H]1C[C@H](C[C@@H]1O)n1ccc2c(N[C@H]3CCc4ccccc34)ncnc12, NS(=O)(=O)OC[C@@H]1C[C@H](C[C@@H]1O)n1ccc2c(N[C@H]3CCc4ccccc34)ncnc12, NS(=O)(=O)OC[C@@H]1C[C@H](C[C@@H]1O)n1ccc2c(N[C@H]3CCc4ccccc34)ncnc12, NS(=O)(=O)OC[C@@H]1C[C@H](C[C@@H]1O)n1ccc2c(N[C@H]3CCc4ccccc34)ncnc12, NS(=O)(=O)OC[C@@H]1C[C@H](C[C@@H]1O)n1ccc2c(N[C@H]3CCc4ccccc34)ncnc12, NS(=O)(=O)OC[C@@H]1C[C@H](C[C@@H]1O)n1ccc2c(N[C@H]3CCc4ccccc34)ncnc12, NS(=O)(=O)OC[C@@H]1C[C@H](C[C@@H]1O)n1ccc2c(N[C@H]3CCc4ccccc34)ncnc12, NS(=O)(=O)OC[C@@H]1C[C@H](C[C@@H]1O)n1ccc2c(N[C@H]3CCc4ccccc34)ncnc12	Phase 3
pexidartinib	tyrosine kinase inhibitor	CSF1R, FLT3, KIT			MedChemEx, MedChemEx, MedChemEx	94.9	FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1, FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1, FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1	Launched
pexmetinib	MAP kinase inhibitor, TIE tyrosine kinase inhibitor	MAPK14, TEK			Selleck, Selleck, Selleck, Selleck	99.4	Cc1ccc(cc1)-n1nc(cc1NC(=O)NCc1cc(F)ccc1Oc1ccc2n(CCO)ncc2c1)C(C)(C)C, Cc1ccc(cc1)-n1nc(cc1NC(=O)NCc1cc(F)ccc1Oc1ccc2n(CCO)ncc2c1)C(C)(C)C, Cc1ccc(cc1)-n1nc(cc1NC(=O)NCc1cc(F)ccc1Oc1ccc2n(CCO)ncc2c1)C(C)(C)C, Cc1ccc(cc1)-n1nc(cc1NC(=O)NCc1cc(F)ccc1Oc1ccc2n(CCO)ncc2c1)C(C)(C)C	Phase 1
PF-02413873	progesterone receptor antagonist				Sigma	96.06	Cc1c(Oc2cc(C)c(C#N)c(C)c2)c(nn1CS(C)(=O)=O)C1CC1	Phase 1
PF-02545920	phosphodiesterase inhibitor	PDE10A			Selleck, Selleck, Selleck	95.3	Cn1cc(c(n1)-c1ccc(OCc2ccc3ccccc3n2)cc1)-c1ccncc1, Cn1cc(c(n1)-c1ccc(OCc2ccc3ccccc3n2)cc1)-c1ccncc1, Cn1cc(c(n1)-c1ccc(OCc2ccc3ccccc3n2)cc1)-c1ccncc1	Phase 2
PF-03049423	phosphodiesterase inhibitor	PDE5A			Key, Key	97.3	CCCOCCn1c2cc(ncc2nc(N2CCN(CCO)CC2)c1=O)-c1ccc(OC)nc1, CCCOCCn1c2cc(ncc2nc(N2CCN(CCO)CC2)c1=O)-c1ccc(OC)nc1	Phase 2
PF-03084014	gamma secretase inhibitor				Tocris, MedChemEx, MedChemEx	91.79	CCC[C@H](N[C@H]1CCc2cc(F)cc(F)c2C1)C(=O)Nc1cn(cn1)C(C)(C)CNCC(C)(C)C, CCC[C@H](N[C@H]1CCc2cc(F)cc(F)c2C1)C(=O)Nc1cn(cn1)C(C)(C)CNCC(C)(C)C, CCC[C@H](N[C@H]1CCc2cc(F)cc(F)c2C1)C(=O)Nc1cn(cn1)C(C)(C)CNCC(C)(C)C	Phase 3
PF-03758309	p21 activated kinase inhibitor	PAK4			MedChemEx, MedChemEx, MedChemEx, MedChemEx, Broad Institute, Broad Institute, Broad Institute, Broad Institute, Broad Institute, Broad Institute, Broad Institute, Broad Institute	95.43	CN(C)C[C@@H](NC(=O)N1Cc2c(Nc3nc(C)nc4ccsc34)[nH]nc2C1(C)C)c1ccccc1, CN(C)C[C@@H](NC(=O)N1Cc2c(Nc3nc(C)nc4ccsc34)[nH]nc2C1(C)C)c1ccccc1, CN(C)C[C@@H](NC(=O)N1Cc2c(Nc3nc(C)nc4ccsc34)[nH]nc2C1(C)C)c1ccccc1, CN(C)C[C@@H](NC(=O)N1Cc2c(Nc3nc(C)nc4ccsc34)[nH]nc2C1(C)C)c1ccccc1, CN(C)C[C@@H](NC(=O)N1Cc2c(Nc3nc(C)nc4ccsc34)[nH]nc2C1(C)C)c1ccccc1, CN(C)C[C@@H](NC(=O)N1Cc2c(Nc3nc(C)nc4ccsc34)[nH]nc2C1(C)C)c1ccccc1, CN(C)C[C@@H](NC(=O)N1Cc2c(Nc3nc(C)nc4ccsc34)[nH]nc2C1(C)C)c1ccccc1, CN(C)C[C@@H](NC(=O)N1Cc2c(Nc3nc(C)nc4ccsc34)[nH]nc2C1(C)C)c1ccccc1, CN(C)C[C@@H](NC(=O)N1Cc2c(Nc3nc(C)nc4ccsc34)[nH]nc2C1(C)C)c1ccccc1, CN(C)C[C@@H](NC(=O)N1Cc2c(Nc3nc(C)nc4ccsc34)[nH]nc2C1(C)C)c1ccccc1, CN(C)C[C@@H](NC(=O)N1Cc2c(Nc3nc(C)nc4ccsc34)[nH]nc2C1(C)C)c1ccccc1, CN(C)C[C@@H](NC(=O)N1Cc2c(Nc3nc(C)nc4ccsc34)[nH]nc2C1(C)C)c1ccccc1	Phase 1
PF-03814735	Aurora kinase inhibitor	AURKA, AURKB			Tocris, Tocris, Tocris, MedChemEx	99.4	CC(=O)NCC(=O)N1[C@H]2CC[C@@H]1c1cc(Nc3ncc(c(NC4CCC4)n3)C(F)(F)F)ccc21, CC(=O)NCC(=O)N1[C@H]2CC[C@@H]1c1cc(Nc3ncc(c(NC4CCC4)n3)C(F)(F)F)ccc21, CC(=O)NCC(=O)N1[C@H]2CC[C@@H]1c1cc(Nc3ncc(c(NC4CCC4)n3)C(F)(F)F)ccc21, CC(=O)NCC(=O)N1[C@H]2CC[C@@H]1c1cc(Nc3ncc(c(NC4CCC4)n3)C(F)(F)F)ccc21	Phase 1
PF-03882845	mineralocorticoid receptor antagonist				Sigma, Sigma, Sigma, Sigma	91.12	OC(=O)c1ccc2C3=NN([C@@H](C4CCCC4)C3CCc2c1)c1ccc(C#N)c(Cl)c1 |t:7|, OC(=O)c1ccc2C3=NN([C@@H](C4CCCC4)C3CCc2c1)c1ccc(C#N)c(Cl)c1 |t:7|, OC(=O)c1ccc2C3=NN([C@@H](C4CCCC4)C3CCc2c1)c1ccc(C#N)c(Cl)c1 |t:7|, OC(=O)c1ccc2C3=NN([C@@H](C4CCCC4)C3CCc2c1)c1ccc(C#N)c(Cl)c1 |t:7|	Phase 1
PF-04136309	CC chemokine receptor antagonist				MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx	97.46	O[C@]1(CC[C@@H](CC1)N[C@H]1CCN(C1)C(=O)CNC(=O)c1cccc(c1)C(F)(F)F)c1ccc(cn1)-c1ncccn1, O[C@]1(CC[C@@H](CC1)N[C@H]1CCN(C1)C(=O)CNC(=O)c1cccc(c1)C(F)(F)F)c1ccc(cn1)-c1ncccn1, O[C@]1(CC[C@@H](CC1)N[C@H]1CCN(C1)C(=O)CNC(=O)c1cccc(c1)C(F)(F)F)c1ccc(cn1)-c1ncccn1, O[C@]1(CC[C@@H](CC1)N[C@H]1CCN(C1)C(=O)CNC(=O)c1cccc(c1)C(F)(F)F)c1ccc(cn1)-c1ncccn1, O[C@]1(CC[C@@H](CC1)N[C@H]1CCN(C1)C(=O)CNC(=O)c1cccc(c1)C(F)(F)F)c1ccc(cn1)-c1ncccn1	Phase 2
PF-04217903	c-Met inhibitor	MET			Selleck, Selleck, Selleck, Selleck	97.26	OCCn1cc(cn1)-c1cnc2nnn(Cc3ccc4ncccc4c3)c2n1, OCCn1cc(cn1)-c1cnc2nnn(Cc3ccc4ncccc4c3)c2n1, OCCn1cc(cn1)-c1cnc2nnn(Cc3ccc4ncccc4c3)c2n1, OCCn1cc(cn1)-c1cnc2nnn(Cc3ccc4ncccc4c3)c2n1	Phase 1
PF-04418948	prostaglandin inhibitor	PTGER2			Selleck, Tocris, Tocris	99.27	COc1ccc2cc(OCC3(CN(C3)C(=O)c3ccc(F)cc3)C(O)=O)ccc2c1, COc1ccc2cc(OCC3(CN(C3)C(=O)c3ccc(F)cc3)C(O)=O)ccc2c1, COc1ccc2cc(OCC3(CN(C3)C(=O)c3ccc(F)cc3)C(O)=O)ccc2c1	Phase 1
PF-04447943	phosphodiesterase inhibitor	PDE9A			MedChemEx, MedChemEx, MedChemEx	97.37	C[C@@H]1CN(Cc2ncccn2)C[C@H]1c1nc(=O)c2cnn(C3CCOCC3)c2[nH]1, C[C@@H]1CN(Cc2ncccn2)C[C@H]1c1nc(=O)c2cnn(C3CCOCC3)c2[nH]1, C[C@@H]1CN(Cc2ncccn2)C[C@H]1c1nc(=O)c2cnn(C3CCOCC3)c2[nH]1	Phase 2
PF-04457845	FAAH inhibitor	FAAH			Tocris, MedChemEx, MedChemEx	99.1	FC(F)(F)c1ccc(Oc2cccc(C=C3CCN(CC3)C(=O)Nc3cccnn3)c2)nc1, FC(F)(F)c1ccc(Oc2cccc(C=C3CCN(CC3)C(=O)Nc3cccnn3)c2)nc1, FC(F)(F)c1ccc(Oc2cccc(C=C3CCN(CC3)C(=O)Nc3cccnn3)c2)nc1	Phase 2
PF-04620110	diacylglycerol O acyltransferase inhibitor	DGAT1			Tocris, MedChemEx, MedChemEx	99.59	Nc1ncnc2OCCN(c3ccc(cc3)[C@H]3CC[C@H](CC(O)=O)CC3)C(=O)c12 |r|, Nc1ncnc2OCCN(c3ccc(cc3)[C@H]3CC[C@H](CC(O)=O)CC3)C(=O)c12 |r|, Nc1ncnc2OCCN(c3ccc(cc3)[C@H]3CC[C@H](CC(O)=O)CC3)C(=O)c12 |r|	Phase 1
PF-04691502	mTOR inhibitor, PI3K inhibitor	MTOR, PIK3CA			Selleck, Selleck, Selleck	96.68	COc1ccc(cn1)-c1cc2c(C)nc(N)nc2n([C@H]2CC[C@@H](CC2)OCCO)c1=O |r|, COc1ccc(cn1)-c1cc2c(C)nc(N)nc2n([C@H]2CC[C@@H](CC2)OCCO)c1=O |r|, COc1ccc(cn1)-c1cc2c(C)nc(N)nc2n([C@H]2CC[C@@H](CC2)OCCO)c1=O |r|	Phase 2
PF-04885614	voltage-gated sodium channel blocker	SCN10A			Tocris, Tocris	91.35	CC(C)(N)c1nc(c[nH]1)-c1ccc(OC(F)(F)F)cc1, CC(C)(N)c1nc(c[nH]1)-c1ccc(OC(F)(F)F)cc1	Preclinical
PF-04937319	glucokinase activator	GCK			Sigma	97.36	CN(C)C(=O)c1ncc(Oc2cc(cc3oc(C)cc23)C(=O)Nc2cnc(C)cn2)cn1	Phase 2
PF-04995274	serotonin receptor agonist				Sigma	95.7	OC1(CN2CCC(COc3noc4cccc(O[C@@H]5CCOC5)c34)CC2)CCOCC1	Phase 1
PF-05089771	sodium channel blocker				MedChemEx	92.1	Nc1[nH]ncc1-c1cc(Cl)ccc1Oc1cc(F)c(cc1Cl)S(=O)(=O)Nc1cscn1	Preclinical
PF-05175157	acetyl-CoA carboxylase inhibitor				MedChemEx	97.16	[H]n1c(C)nc2ccc(cc12)C(=O)N1CCC2(CC1)Cc1cnn(C(C)C)c1C(=O)C2	Phase 2
PF-05180999	phosphodiesterase inhibitor				MedChemEx	97.87	Cc1nc(-c2cnn(C)c2-c2ccc(cn2)C(F)(F)F)c2c(ncnn12)N1CCC1	Phase 1
PF-05190457	growth hormone secretagogue receptor inverse agonist	GHSR			Sigma	87.74	Cc1cn2cc(CC(=O)N3CCC4(CN(C4)[C@@H]4CCc5cc(ccc45)-c4cc(C)ncn4)CC3)nc2s1	Phase 2
PF-05212384	mTOR inhibitor, PI3K inhibitor	MTOR, PIK3CA			Key, Selleck, Selleck	97.48	CN(C)C1CCN(CC1)C(=O)c1ccc(NC(=O)Nc2ccc(cc2)-c2nc(nc(n2)N2CCOCC2)N2CCOCC2)cc1, CN(C)C1CCN(CC1)C(=O)c1ccc(NC(=O)Nc2ccc(cc2)-c2nc(nc(n2)N2CCOCC2)N2CCOCC2)cc1, CN(C)C1CCN(CC1)C(=O)c1ccc(NC(=O)Nc2ccc(cc2)-c2nc(nc(n2)N2CCOCC2)N2CCOCC2)cc1	Phase 2
PF-06260414	androgen receptor modulator				Sigma	17.39	C[C@@H]1CNS(=O)(=O)N(C1)c1ccc2c(nccc2c1)C#N	Phase 1
PF-06273340	tyrosine kinase receptor inhibitor				Sigma	96.55	CC(C)(CO)n1cc(C(=O)c2cncc(NC(=O)Cc3ccc(Cl)cn3)c2)c2cnc(N)nc12	Phase 1
PF-06282999	myeloperoxidase inhibitor				MedChemEx	97.4	COc1ccc(Cl)cc1-c1cc(=O)[nH]c(=S)n1CC(N)=O	Phase 1
PF-06305591	sodium channel blocker				Sigma	94.3	C[C@H]([C@H](N)c1nc2cc(ccc2[nH]1)C(C)(C)C)C(N)=O	Phase 1
PF-06409577	protein kinase activator				MedChemEx	96.7	OC(=O)c1c[nH]c2cc(Cl)c(cc12)-c1ccc(cc1)C1(O)CCC1	Phase 1
PF-06412562	dopamine receptor partial agonist				Sigma	97.43	Cc1cc(Oc2nccc3[nH]ncc23)ccc1-c1c(C)ncnc1C	Phase 1
PF-06447475	serine/threonine kinase inhibitor	LRRK2			Tocris, MedChemEx	99.15	N#Cc1cccc(c1)-c1c[nH]c2ncnc(N3CCOCC3)c12, N#Cc1cccc(c1)-c1c[nH]c2ncnc(N3CCOCC3)c12	Preclinical
PF-06459988	receptor tyrosine protein kinase inhibitor				MedChemEx	96.87	CO[C@H]1CN(C[C@@H]1COc1nc(Nc2cnn(C)c2)nc2[nH]cc(Cl)c12)C(=O)C=C	Phase 2
PF-06463922	ALK tyrosine kinase receptor inhibitor	ALK, FES, ROS1	oncology	non-small cell lung cancer (NSCLC)	Selleck	98.98	C[C@H]1Oc2cc(cnc2N)-c2c(CN(C)C(=O)c3ccc(F)cc13)nn(C)c2C#N |&1:1,r|	Launched
PF-06650833	kinase inhibitor				MedChemEx	95.84	CC[C@H]1[C@@H](COc2nccc3cc(C(N)=O)c(OC)cc23)NC(=O)[C@H]1F	Phase 1
PF-06651600	JAK inhibitor				MedChemEx	95.62	C[C@H]1CC[C@H](CN1C(=O)C=C)Nc1ncnc2[nH]ccc12	Phase 2/Phase 3
PF-06747775	EGFR inhibitor				Sigma	96.39	COc1nn(C)cc1Nc1nc(nc2n(C)cnc12)N1C[C@@H](F)[C@@H](C1)NC(=O)C=C	Phase 2
PF-06751979	beta secretase inhibitor				MedChemEx	95.8	C[C@H]1C[C@H]2CSC(N)=N[C@]2(CO1)c1nc(NC(=O)c2ccc(OC(F)F)cn2)cs1 |c:7|	Phase 1
PF-06840003	indoleamine 2,3-dioxygenase inhibitor				MedChemEx	96.34	Fc1ccc2[nH]cc([C@H]3CC(=O)NC3=O)c2c1 |&1:8,r|	Phase 1
PF-06873600	CDK inhibitor				MedChemEx	94.5	C[C@@]1(O)CCC[C@H]1n1c2nc(NC3CCN(CC3)S(C)(=O)=O)ncc2cc(C(F)F)c1=O	Phase 2
PF-06928215	cyclic GMP-AMP synthase inhibitor				MedChemEx	95.58	OC(=O)[C@@H]1CCCC[C@@H]1NC(=O)c1cnn2c(O)cc(nc12)-c1ccccc1	Preclinical
PF-3274167	oxytocin receptor antagonist	AVPR1A, OXTR			MedChemEx	96.73	COCc1nnc(N2CC(C2)Oc2ccc(F)cc2Cl)n1-c1ccc(OC)nc1	Phase 2
PF-3845	FAAH inhibitor	FAAH			Tocris, Selleck, Selleck	96.31	FC(F)(F)c1ccc(Oc2cccc(CC3CCN(CC3)C(=O)Nc3cccnc3)c2)nc1, FC(F)(F)c1ccc(Oc2cccc(CC3CCN(CC3)C(=O)Nc3cccnc3)c2)nc1, FC(F)(F)c1ccc(Oc2cccc(CC3CCN(CC3)C(=O)Nc3cccnc3)c2)nc1	Preclinical
PF-4191834	lipoxygenase inhibitor				Sigma	97.27	Cn1nccc1-c1ccc(Sc2cccc(c2)C2(CCOCC2)C(N)=O)cc1	Preclinical
PF-429242	SREBP inhibitor	MBTPS1			Tocris, Tocris	96.02	CCN(CC)Cc1ccc(cc1)C(=O)N(CCc1ccccc1OC)[C@@H]1CCNC1, CCN(CC)Cc1ccc(cc1)C(=O)N(CCc1ccccc1OC)[C@@H]1CCNC1	Preclinical
PF-431396	focal adhesion kinase inhibitor	PTK2, PTK2B			Tocris, Tocris, Tocris, Tocris	97.24	CN(c1ccccc1CNc1nc(Nc2ccc3NC(=O)Cc3c2)ncc1C(F)(F)F)S(C)(=O)=O, CN(c1ccccc1CNc1nc(Nc2ccc3NC(=O)Cc3c2)ncc1C(F)(F)F)S(C)(=O)=O, CN(c1ccccc1CNc1nc(Nc2ccc3NC(=O)Cc3c2)ncc1C(F)(F)F)S(C)(=O)=O, CN(c1ccccc1CNc1nc(Nc2ccc3NC(=O)Cc3c2)ncc1C(F)(F)F)S(C)(=O)=O	Preclinical
PF-4708671	ribosomal protein inhibitor	RPS6KB1			Selleck, Selleck, Tocris	98.79	CCc1cncnc1N1CCN(Cc2nc3ccc(cc3[nH]2)C(F)(F)F)CC1, CCc1cncnc1N1CCN(Cc2nc3ccc(cc3[nH]2)C(F)(F)F)CC1, CCc1cncnc1N1CCN(Cc2nc3ccc(cc3[nH]2)C(F)(F)F)CC1	Preclinical
PF-477736	CHK inhibitor	CHEK1, CHEK2			Selleck, Selleck, Selleck, Selleck, Tocris, Tocris, Selleck, Selleck	95	Cn1cc(cn1)-c1[nH]c2cc(NC(=O)[C@H](N)C3CCCCC3)cc3c2c1cn[nH]c3=O, Cn1cc(cn1)-c1[nH]c2cc(NC(=O)[C@H](N)C3CCCCC3)cc3c2c1cn[nH]c3=O, Cn1cc(cn1)-c1[nH]c2cc(NC(=O)[C@H](N)C3CCCCC3)cc3c2c1cn[nH]c3=O, Cn1cc(cn1)-c1[nH]c2cc(NC(=O)[C@H](N)C3CCCCC3)cc3c2c1cn[nH]c3=O, Cn1cc(cn1)-c1[nH]c2cc(NC(=O)[C@H](N)C3CCCCC3)cc3c2c1cn[nH]c3=O, Cn1cc(cn1)-c1[nH]c2cc(NC(=O)[C@H](N)C3CCCCC3)cc3c2c1cn[nH]c3=O, Cn1cc(cn1)-c1[nH]c2cc(NC(=O)[C@H](N)C3CCCCC3)cc3c2c1cn[nH]c3=O, Cn1cc(cn1)-c1[nH]c2cc(NC(=O)[C@H](N)C3CCCCC3)cc3c2c1cn[nH]c3=O	Phase 1
PF-4800567	casein kinase inhibitor	CSNK1D, CSNK1E			Tocris, Tocris, Tocris, Tocris, Tocris, Tocris, Tocris, Tocris, Tocris	99.49	Nc1ncnc2n(nc(COc3cccc(Cl)c3)c12)C1CCOCC1, Nc1ncnc2n(nc(COc3cccc(Cl)c3)c12)C1CCOCC1, Nc1ncnc2n(nc(COc3cccc(Cl)c3)c12)C1CCOCC1, Nc1ncnc2n(nc(COc3cccc(Cl)c3)c12)C1CCOCC1, Nc1ncnc2n(nc(COc3cccc(Cl)c3)c12)C1CCOCC1, Nc1ncnc2n(nc(COc3cccc(Cl)c3)c12)C1CCOCC1, Nc1ncnc2n(nc(COc3cccc(Cl)c3)c12)C1CCOCC1, Nc1ncnc2n(nc(COc3cccc(Cl)c3)c12)C1CCOCC1, Nc1ncnc2n(nc(COc3cccc(Cl)c3)c12)C1CCOCC1	Preclinical
PF-4981517	cytochrome P450 inhibitor	CYP3A4			Tocris, Selleck	96.16	Cc1ccc(cc1)-c1c(cnn1C)-c1nn(C)c2ncnc(N3CC[C@@H](C3)N3CCCCC3)c12, Cc1ccc(cc1)-c1c(cnn1C)-c1nn(C)c2ncnc(N3CC[C@@H](C3)N3CCCCC3)c12	Preclinical
PF-514273	cannabinoid receptor antagonist				Sigma	92.1	CC(F)(F)CN1CCOc2c(nn(c2-c2ccc(Cl)cc2)-c2ccccc2Cl)C1=O	Preclinical
PF-5274857	smoothened receptor antagonist	SMO			Tocris, Tocris, Tocris, Selleck, Selleck, Selleck	96.18	Cc1cnc(c(C)c1)-c1cc(ncc1Cl)N1CCN(CC1)C(=O)CCS(C)(=O)=O, Cc1cnc(c(C)c1)-c1cc(ncc1Cl)N1CCN(CC1)C(=O)CCS(C)(=O)=O, Cc1cnc(c(C)c1)-c1cc(ncc1Cl)N1CCN(CC1)C(=O)CCS(C)(=O)=O, Cc1cnc(c(C)c1)-c1cc(ncc1Cl)N1CCN(CC1)C(=O)CCS(C)(=O)=O, Cc1cnc(c(C)c1)-c1cc(ncc1Cl)N1CCN(CC1)C(=O)CCS(C)(=O)=O, Cc1cnc(c(C)c1)-c1cc(ncc1Cl)N1CCN(CC1)C(=O)CCS(C)(=O)=O	Preclinical
PF-562271	focal adhesion kinase inhibitor	PTK2, PTK2B			MedChemEx, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck	94.41	CN(c1ncccc1CNc1nc(Nc2ccc3NC(=O)Cc3c2)ncc1C(F)(F)F)S(C)(=O)=O, CN(c1ncccc1CNc1nc(Nc2ccc3NC(=O)Cc3c2)ncc1C(F)(F)F)S(C)(=O)=O, CN(c1ncccc1CNc1nc(Nc2ccc3NC(=O)Cc3c2)ncc1C(F)(F)F)S(C)(=O)=O, CN(c1ncccc1CNc1nc(Nc2ccc3NC(=O)Cc3c2)ncc1C(F)(F)F)S(C)(=O)=O, CN(c1ncccc1CNc1nc(Nc2ccc3NC(=O)Cc3c2)ncc1C(F)(F)F)S(C)(=O)=O, CN(c1ncccc1CNc1nc(Nc2ccc3NC(=O)Cc3c2)ncc1C(F)(F)F)S(C)(=O)=O, CN(c1ncccc1CNc1nc(Nc2ccc3NC(=O)Cc3c2)ncc1C(F)(F)F)S(C)(=O)=O, CN(c1ncccc1CNc1nc(Nc2ccc3NC(=O)Cc3c2)ncc1C(F)(F)F)S(C)(=O)=O, CN(c1ncccc1CNc1nc(Nc2ccc3NC(=O)Cc3c2)ncc1C(F)(F)F)S(C)(=O)=O, CN(c1ncccc1CNc1nc(Nc2ccc3NC(=O)Cc3c2)ncc1C(F)(F)F)S(C)(=O)=O	Phase 1
PF-573228	focal adhesion kinase inhibitor	CDK1, CDK2, CDK7, GSK3B, IKBKB			Selleck, Selleck, Selleck, Tocris, Tocris, Tocris	97.54	CS(=O)(=O)c1cccc(CNc2nc(Nc3ccc4NC(=O)CCc4c3)ncc2C(F)(F)F)c1, CS(=O)(=O)c1cccc(CNc2nc(Nc3ccc4NC(=O)CCc4c3)ncc2C(F)(F)F)c1, CS(=O)(=O)c1cccc(CNc2nc(Nc3ccc4NC(=O)CCc4c3)ncc2C(F)(F)F)c1, CS(=O)(=O)c1cccc(CNc2nc(Nc3ccc4NC(=O)CCc4c3)ncc2C(F)(F)F)c1, CS(=O)(=O)c1cccc(CNc2nc(Nc3ccc4NC(=O)CCc4c3)ncc2C(F)(F)F)c1, CS(=O)(=O)c1cccc(CNc2nc(Nc3ccc4NC(=O)CCc4c3)ncc2C(F)(F)F)c1	Preclinical
PF-670462	casein kinase inhibitor	CSNK1D, CSNK1E			MedChemEx, MedChemEx, Tocris, Tocris, Tocris	97.92	Nc1nccc(n1)-c1c(ncn1C1CCCCC1)-c1ccc(F)cc1, Nc1nccc(n1)-c1c(ncn1C1CCCCC1)-c1ccc(F)cc1, Nc1nccc(n1)-c1c(ncn1C1CCCCC1)-c1ccc(F)cc1, Nc1nccc(n1)-c1c(ncn1C1CCCCC1)-c1ccc(F)cc1, Nc1nccc(n1)-c1c(ncn1C1CCCCC1)-c1ccc(F)cc1	Preclinical
PF-750	FAAH inhibitor	FAAH			Tocris, Tocris	96.11	O=C(Nc1ccccc1)N1CCC(Cc2cnc3ccccc3c2)CC1, O=C(Nc1ccccc1)N1CCC(Cc2cnc3ccccc3c2)CC1	Preclinical
PF-8380	autotaxin inhibitor	ENPP2			MedChemEx, MedChemEx	87.86	Clc1cc(Cl)cc(COC(=O)N2CCN(CCC(=O)c3ccc4[nH]c(=O)oc4c3)CC2)c1, Clc1cc(Cl)cc(COC(=O)N2CCN(CCC(=O)c3ccc4[nH]c(=O)oc4c3)CC2)c1	Preclinical
PF-915275	11-beta hydroxysteroid dehydrogenase inhibitor	HSD11B1			Tocris, Tocris, MedChemEx, Tocris	98.29	Nc1cccc(NS(=O)(=O)c2ccc(cc2)-c2ccc(cc2)C#N)n1, Nc1cccc(NS(=O)(=O)c2ccc(cc2)-c2ccc(cc2)C#N)n1, Nc1cccc(NS(=O)(=O)c2ccc(cc2)-c2ccc(cc2)C#N)n1, Nc1cccc(NS(=O)(=O)c2ccc(cc2)-c2ccc(cc2)C#N)n1	Phase 1
PFI-1	bromodomain inhibitor	BRD4			Selleck, Selleck, Tocris, Tocris, Selleck, Selleck, Selleck	91.99	COc1ccccc1S(=O)(=O)Nc1ccc2NC(=O)N(C)Cc2c1, COc1ccccc1S(=O)(=O)Nc1ccc2NC(=O)N(C)Cc2c1, COc1ccccc1S(=O)(=O)Nc1ccc2NC(=O)N(C)Cc2c1, COc1ccccc1S(=O)(=O)Nc1ccc2NC(=O)N(C)Cc2c1, COc1ccccc1S(=O)(=O)Nc1ccc2NC(=O)N(C)Cc2c1, COc1ccccc1S(=O)(=O)Nc1ccc2NC(=O)N(C)Cc2c1, COc1ccccc1S(=O)(=O)Nc1ccc2NC(=O)N(C)Cc2c1	Preclinical
PFI-3	bromodomain inhibitor	PBRM1, SMARCA4			Tocris, Tocris, MedChemEx	94.54	Oc1ccccc1C(=O)\C=C\N1C[C@H]2C[C@@H]1CN2c1ccccn1, Oc1ccccc1C(=O)\C=C\N1C[C@H]2C[C@@H]1CN2c1ccccn1, Oc1ccccc1C(=O)\C=C\N1C[C@H]2C[C@@H]1CN2c1ccccn1	Preclinical
PFI-4	bromodomain inhibitor	BRPF1			Tocris, Tocris, Tocris	98.24	COc1ccccc1C(=O)Nc1cc2n(C)c(=O)n(C)c2cc1N1CCCC1, COc1ccccc1C(=O)Nc1cc2n(C)c(=O)n(C)c2cc1N1CCCC1, COc1ccccc1C(=O)Nc1cc2n(C)c(=O)n(C)c2cc1N1CCCC1	Preclinical
PFK-015	phosphofructokinase inhibitor	PFKFB3			MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx	94.52	O=C(\C=C\c1ccc2ccccc2n1)c1ccncc1, O=C(\C=C\c1ccc2ccccc2n1)c1ccncc1, O=C(\C=C\c1ccc2ccccc2n1)c1ccncc1, O=C(\C=C\c1ccc2ccccc2n1)c1ccncc1, O=C(\C=C\c1ccc2ccccc2n1)c1ccncc1	Phase 1
PFK-158	phosphofructokinase inhibitor	PFKFB3			MedChemEx, MedChemEx, MedChemEx	90.57	FC(F)(F)c1ccc2ccc(\C=C\C(=O)c3ccncc3)nc2c1, FC(F)(F)c1ccc2ccc(\C=C\C(=O)c3ccncc3)nc2c1, FC(F)(F)c1ccc2ccc(\C=C\C(=O)c3ccncc3)nc2c1	Phase 1
PG-9	acetylcholine receptor agonist				Tocris	87.9	C[C@@H](C(=O)O[C@@H]1C[C@@H]2CC[C@H](C1)N2C)c1ccc(Br)cc1 |&1:5,7,10,&2:1,r,TLB:13:12:8.9:5.6.11|	Preclinical
PGL5001	JNK inhibitor	MAPK10, MAPK8, MAPK9			MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx	97.5	N#C[C@@H](c1nc2ccccc2s1)c1ccnc(OCc2ccc(CN3CCOCC3)cc2)n1 |&1:2,r|, N#C[C@@H](c1nc2ccccc2s1)c1ccnc(OCc2ccc(CN3CCOCC3)cc2)n1 |&1:2,r|, N#C[C@@H](c1nc2ccccc2s1)c1ccnc(OCc2ccc(CN3CCOCC3)cc2)n1 |&1:2,r|, N#C[C@@H](c1nc2ccccc2s1)c1ccnc(OCc2ccc(CN3CCOCC3)cc2)n1 |&1:2,r|, N#C[C@@H](c1nc2ccccc2s1)c1ccnc(OCc2ccc(CN3CCOCC3)cc2)n1 |&1:2,r|, N#C[C@@H](c1nc2ccccc2s1)c1ccnc(OCc2ccc(CN3CCOCC3)cc2)n1 |&1:2,r|, N#C[C@@H](c1nc2ccccc2s1)c1ccnc(OCc2ccc(CN3CCOCC3)cc2)n1 |&1:2,r|, N#C[C@@H](c1nc2ccccc2s1)c1ccnc(OCc2ccc(CN3CCOCC3)cc2)n1 |&1:2,r|, N#C[C@@H](c1nc2ccccc2s1)c1ccnc(OCc2ccc(CN3CCOCC3)cc2)n1 |&1:2,r|, N#C[C@@H](c1nc2ccccc2s1)c1ccnc(OCc2ccc(CN3CCOCC3)cc2)n1 |&1:2,r|	Phase 2
PH-797804	p38 MAPK inhibitor	MAPK11, MAPK14			Tocris, Selleck, Selleck	97.66	CNC(=O)c1ccc(C)c(c1)-n1c(C)cc(OCc2ccc(F)cc2F)c(Br)c1=O, CNC(=O)c1ccc(C)c(c1)-n1c(C)cc(OCc2ccc(F)cc2F)c(Br)c1=O, CNC(=O)c1ccc(C)c(c1)-n1c(C)cc(OCc2ccc(F)cc2F)c(Br)c1=O	Phase 2
PHA-543613	nicotinic receptor agonist				Sigma	98.87	O=C(N[C@H]1CN2CCC1CC2)c1cc2ccoc2cn1	Preclinical
PHA-568487	nicotinic receptor agonist	CHRNA7			Tocris, Tocris	98.49	O=C(N[C@H]1CN2CCC1CC2)c1ccc2OCCOc2c1, O=C(N[C@H]1CN2CCC1CC2)c1ccc2OCCOc2c1	Preclinical
PHA-665752	c-Met inhibitor	MET			Tocris, Selleck, Selleck, Selleck, Tocris, Tocris	97.63	Cc1[nH]c(\C=C2/C(=O)Nc3ccc(cc23)S(=O)(=O)Cc2c(Cl)cccc2Cl)c(C)c1C(=O)N1CCC[C@@H]1CN1CCCC1, Cc1[nH]c(\C=C2/C(=O)Nc3ccc(cc23)S(=O)(=O)Cc2c(Cl)cccc2Cl)c(C)c1C(=O)N1CCC[C@@H]1CN1CCCC1, Cc1[nH]c(\C=C2/C(=O)Nc3ccc(cc23)S(=O)(=O)Cc2c(Cl)cccc2Cl)c(C)c1C(=O)N1CCC[C@@H]1CN1CCCC1, Cc1[nH]c(\C=C2/C(=O)Nc3ccc(cc23)S(=O)(=O)Cc2c(Cl)cccc2Cl)c(C)c1C(=O)N1CCC[C@@H]1CN1CCCC1, Cc1[nH]c(\C=C2/C(=O)Nc3ccc(cc23)S(=O)(=O)Cc2c(Cl)cccc2Cl)c(C)c1C(=O)N1CCC[C@@H]1CN1CCCC1, Cc1[nH]c(\C=C2/C(=O)Nc3ccc(cc23)S(=O)(=O)Cc2c(Cl)cccc2Cl)c(C)c1C(=O)N1CCC[C@@H]1CN1CCCC1	Preclinical
PHA-680632	Aurora kinase inhibitor	AURKA, AURKB, AURKC			MedChemEx, MedChemEx, Selleck, Selleck	94.34	CCc1cccc(CC)c1NC(=O)N1Cc2n[nH]c(NC(=O)c3ccc(cc3)N3CCN(C)CC3)c2C1, CCc1cccc(CC)c1NC(=O)N1Cc2n[nH]c(NC(=O)c3ccc(cc3)N3CCN(C)CC3)c2C1, CCc1cccc(CC)c1NC(=O)N1Cc2n[nH]c(NC(=O)c3ccc(cc3)N3CCN(C)CC3)c2C1, CCc1cccc(CC)c1NC(=O)N1Cc2n[nH]c(NC(=O)c3ccc(cc3)N3CCN(C)CC3)c2C1	Preclinical
PHA-767491	CDC inhibitor	CDK1, RPS6KB1			Selleck, Selleck, Tocris, Tocris, Tocris	98.06	O=C1NCCc2[nH]c(cc12)-c1ccncc1, O=C1NCCc2[nH]c(cc12)-c1ccncc1, O=C1NCCc2[nH]c(cc12)-c1ccncc1, O=C1NCCc2[nH]c(cc12)-c1ccncc1, O=C1NCCc2[nH]c(cc12)-c1ccncc1	Preclinical
PHA-793887	CDK inhibitor	CDK1, CDK2, CDK4, CDK5, CDK7, CDK9			MedChemEx, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck	91.57	CC(C)CC(=O)Nc1[nH]nc2c1CN(C(=O)C1CCN(C)CC1)C2(C)C, CC(C)CC(=O)Nc1[nH]nc2c1CN(C(=O)C1CCN(C)CC1)C2(C)C, CC(C)CC(=O)Nc1[nH]nc2c1CN(C(=O)C1CCN(C)CC1)C2(C)C, CC(C)CC(=O)Nc1[nH]nc2c1CN(C(=O)C1CCN(C)CC1)C2(C)C, CC(C)CC(=O)Nc1[nH]nc2c1CN(C(=O)C1CCN(C)CC1)C2(C)C, CC(C)CC(=O)Nc1[nH]nc2c1CN(C(=O)C1CCN(C)CC1)C2(C)C, CC(C)CC(=O)Nc1[nH]nc2c1CN(C(=O)C1CCN(C)CC1)C2(C)C, CC(C)CC(=O)Nc1[nH]nc2c1CN(C(=O)C1CCN(C)CC1)C2(C)C, CC(C)CC(=O)Nc1[nH]nc2c1CN(C(=O)C1CCN(C)CC1)C2(C)C, CC(C)CC(=O)Nc1[nH]nc2c1CN(C(=O)C1CCN(C)CC1)C2(C)C, CC(C)CC(=O)Nc1[nH]nc2c1CN(C(=O)C1CCN(C)CC1)C2(C)C, CC(C)CC(=O)Nc1[nH]nc2c1CN(C(=O)C1CCN(C)CC1)C2(C)C, CC(C)CC(=O)Nc1[nH]nc2c1CN(C(=O)C1CCN(C)CC1)C2(C)C	Phase 1
PHA-848125	CDK inhibitor, growth factor receptor inhibitor	CDK2, CDK4, CDK7, NTRK1			MedChemEx, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck	98.48	CNC(=O)c1nn(C)c-2c1C(C)(C)Cc1cnc(Nc3ccc(cc3)N3CCN(C)CC3)nc-21, CNC(=O)c1nn(C)c-2c1C(C)(C)Cc1cnc(Nc3ccc(cc3)N3CCN(C)CC3)nc-21, CNC(=O)c1nn(C)c-2c1C(C)(C)Cc1cnc(Nc3ccc(cc3)N3CCN(C)CC3)nc-21, CNC(=O)c1nn(C)c-2c1C(C)(C)Cc1cnc(Nc3ccc(cc3)N3CCN(C)CC3)nc-21, CNC(=O)c1nn(C)c-2c1C(C)(C)Cc1cnc(Nc3ccc(cc3)N3CCN(C)CC3)nc-21, CNC(=O)c1nn(C)c-2c1C(C)(C)Cc1cnc(Nc3ccc(cc3)N3CCN(C)CC3)nc-21, CNC(=O)c1nn(C)c-2c1C(C)(C)Cc1cnc(Nc3ccc(cc3)N3CCN(C)CC3)nc-21, CNC(=O)c1nn(C)c-2c1C(C)(C)Cc1cnc(Nc3ccc(cc3)N3CCN(C)CC3)nc-21, CNC(=O)c1nn(C)c-2c1C(C)(C)Cc1cnc(Nc3ccc(cc3)N3CCN(C)CC3)nc-21	Phase 2
PHCCC	glutamate receptor agonist	GRM1, GRM4			Tocris	91.91	O\N=C1/[C@@H]2C[C@@]2(Oc2ccccc12)C(=O)Nc1ccccc1 |&1:3,5|	Preclinical
phenacaine	local anesthetic		neurology/psychiatry	local anesthetic	MPBio, MPBio	99.16	CCOc1ccc(NC(C)=Nc2ccc(OCC)cc2)cc1, CCOc1ccc(NC(C)=Nc2ccc(OCC)cc2)cc1	Launched
phenacemide	sodium channel blocker	SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A	neurology/psychiatry	epilepsy, seizures	Sigma, MicroSource	99.38	NC(=O)NC(=O)Cc1ccccc1, NC(=O)NC(=O)Cc1ccccc1	Launched
phenacetin	cyclooxygenase inhibitor	PTGS1			MedChemEx, MicroSource, Selleck	99.33	CCOc1ccc(NC(C)=O)cc1, CCOc1ccc(NC(C)=O)cc1, CCOc1ccc(NC(C)=O)cc1	Withdrawn
phenazone	cyclooxygenase inhibitor	PTGS1, PTGS2	neurology/psychiatry	pain relief	MedChemEx, MicroSource, Selleck	99.14	Cc1cc(=O)n(-c2ccccc2)n1C, Cc1cc(=O)n(-c2ccccc2)n1C, Cc1cc(=O)n(-c2ccccc2)n1C	Launched
phenazopyridine	local anesthetic	SCN1A	infectious disease	urinary tract infections	MedChemEx, Selleck, MicroSource, Selleck, Selleck	96.12	Nc1ccc(\N=N\c2ccccc2)c(N)n1, Nc1ccc(\N=N\c2ccccc2)c(N)n1, Nc1ccc(\N=N\c2ccccc2)c(N)n1, Nc1ccc(\N=N\c2ccccc2)c(N)n1, Nc1ccc(\N=N\c2ccccc2)c(N)n1	Launched
phenelzine	monoamine oxidase inhibitor	ABAT, AOC3, GAD2, GPT, GPT2, MAOA, MAOB, SLC6A2, SLC6A3, SLC6A4	neurology/psychiatry	depression	Sigma, Sigma, MicroSource, Sigma, Sigma	80.24	NNCCc1ccccc1, NNCCc1ccccc1, NNCCc1ccccc1, NNCCc1ccccc1, NNCCc1ccccc1	Launched
phenethicillin	bacterial cell wall synthesis inhibitor				Prestwick	55.17	C[C@@H](Oc1ccccc1)C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O |a:12,13,18,&1:1|	Launched
phenethyl-isothiocyanate	anticancer agent	CYP2E1			Sigma	0	S=C=NCCc1ccccc1	Phase 2
phenformin	AMPK activator	KCNJ8, PRKAA1			MicroSource, MicroSource, MedChemEx, MedChemEx, Selleck	97.99	NC(N)=NC(=N)NCCc1ccccc1, NC(N)=NC(=N)NCCc1ccccc1, NC(N)=NC(=N)NCCc1ccccc1, NC(N)=NC(=N)NCCc1ccccc1, NC(N)=NC(=N)NCCc1ccccc1	Withdrawn
phenindamine	histamine receptor antagonist	HRH1	allergy, otolaryngology	allergic rhinitis, common cold	AMS, AMS	47.35	CN1CCC2=C(C1)[C@@H](c1ccccc21)c1ccccc1 |&1:7,r,c:4|, CN1CCC2=C(C1)[C@@H](c1ccccc21)c1ccccc1 |&1:7,r,c:4|	Launched
phenindione	vitamin K antagonist	VKORC1	hematology	deep vein thrombosis (DVT)	MedChemEx, MedChemEx, MedChemEx, Sigma, Selleck, Selleck, MedChemEx, MicroSource	95.63	O=C1C(C(=O)c2ccccc12)c1ccccc1, O=C1C(C(=O)c2ccccc12)c1ccccc1, O=C1C(C(=O)c2ccccc12)c1ccccc1, O=C1C(C(=O)c2ccccc12)c1ccccc1, O=C1C(C(=O)c2ccccc12)c1ccccc1, O=C1C(C(=O)c2ccccc12)c1ccccc1, O=C1C(C(=O)c2ccccc12)c1ccccc1, O=C1C(C(=O)c2ccccc12)c1ccccc1	Launched
pheniramine	histamine receptor antagonist	HRH1	allergy	allergic rhinitis, urticaria	Selleck, Selleck, MicroSource, MedChemEx	98.32	CN(C)CC[C@@H](c1ccccc1)c1ccccn1 |&1:5|, CN(C)CC[C@@H](c1ccccc1)c1ccccn1 |&1:5|, CN(C)CC[C@@H](c1ccccc1)c1ccccn1 |&1:5|, CN(C)CC[C@@H](c1ccccc1)c1ccccn1 |&1:5|	Launched
phenol		CA1, CA12, CA14, CA2, CA4, CA9	otolaryngology	pharyngitis	Sigma	0	Oc1ccccc1	Preclinical
phenolphthalein	indicator dye	UGT1A9			MedChemEx, MicroSource	98.24	Oc1ccc(cc1)C1(OC(=O)c2ccccc12)c1ccc(O)cc1, Oc1ccc(cc1)C1(OC(=O)c2ccccc12)c1ccc(O)cc1	Withdrawn
phenolsulfonphthalein					MedChemEx, MicroSource	94.8	Oc1ccc(cc1)C1(OS(=O)(=O)c2ccccc12)c1ccc(O)cc1, Oc1ccc(cc1)C1(OS(=O)(=O)c2ccccc12)c1ccc(O)cc1	Launched
phenothiazine	dopamine receptor antagonist				MicroSource, Selleck, Selleck, Selleck	96.7	N1c2ccccc2Sc2ccccc12, N1c2ccccc2Sc2ccccc12, N1c2ccccc2Sc2ccccc12, N1c2ccccc2Sc2ccccc12	Preclinical
phenothrin			infectious disease	lice	MicroSource, Selleck, Sigma	76.28	CC(C)=C[C@H]1[C@@H](C(=O)OCc2cccc(Oc3ccccc3)c2)C1(C)C |&1:4,&2:5,r|, CC(C)=C[C@H]1[C@@H](C(=O)OCc2cccc(Oc3ccccc3)c2)C1(C)C |&1:4,&2:5,r|, CC(C)=C[C@H]1[C@@H](C(=O)OCc2cccc(Oc3ccccc3)c2)C1(C)C |&1:4,&2:5,r|	Launched
phenoxybenzamine	adrenergic receptor antagonist	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C	cardiology, endocrinology	hypertension, pheochromocytoma	MedChemEx, Selleck, MedChemEx, MedChemEx, Selleck	90.78	CC(COc1ccccc1)N(CCCl)Cc1ccccc1, CC(COc1ccccc1)N(CCCl)Cc1ccccc1, CC(COc1ccccc1)N(CCCl)Cc1ccccc1, CC(COc1ccccc1)N(CCCl)Cc1ccccc1, CC(COc1ccccc1)N(CCCl)Cc1ccccc1	Launched
phenprobamate	muscle relaxant		neurology/psychiatry	anxiety, muscle relaxant	Prestwick	98.85	NC(=O)OCCCc1ccccc1	Launched
phenprocoumon	vitamin K antagonist	VKORC1	hematology	thrombosis, pulmonary embolism (PE)	Abblis	97.47	CC[C@@H](c1ccccc1)c1c(O)c2ccccc2oc1=O |&1:2,r|	Launched
phenserine	acetylcholinesterase inhibitor, beta amyloid synthesis inhibitor	ACHE, BCHE			Sigma, Sigma, Enzo	83.49	CN1CC[C@]2(C)[C@H]1N(C)c1ccc(OC(=O)Nc3ccccc3)cc21, CN1CC[C@]2(C)[C@H]1N(C)c1ccc(OC(=O)Nc3ccccc3)cc21, CN1CC[C@]2(C)[C@H]1N(C)c1ccc(OC(=O)Nc3ccccc3)cc21	Phase 3
phensuximide	succinimide antiepileptic		neurology/psychiatry	seizures	MicroSource, USP	98.87	CN1C(=O)C[C@@H](C1=O)c1ccccc1 |&1:5,r|, CN1C(=O)C[C@@H](C1=O)c1ccccc1 |&1:5,r|	Launched
phentolamine	adrenergic receptor antagonist	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C	endocrinology, cardiology	pheochromocytoma, hypertension	MedChemEx, MedChemEx, Enzo, Enzo, Selleck, MicroSource, Selleck	99.38	Cc1ccc(cc1)N(CC1=NCCN1)c1cccc(O)c1 |t:10|, Cc1ccc(cc1)N(CC1=NCCN1)c1cccc(O)c1 |t:10|, Cc1ccc(cc1)N(CC1=NCCN1)c1cccc(O)c1 |t:10|, Cc1ccc(cc1)N(CC1=NCCN1)c1cccc(O)c1 |t:10|, Cc1ccc(cc1)N(CC1=NCCN1)c1cccc(O)c1 |t:10|, Cc1ccc(cc1)N(CC1=NCCN1)c1cccc(O)c1 |t:10|, Cc1ccc(cc1)N(CC1=NCCN1)c1cccc(O)c1 |t:10|	Launched
phenyl-aminosalicylate			infectious disease	tuberculosis	MicroSource, FrontierSci	99.55	Nc1ccc(C(=O)Oc2ccccc2)c(O)c1, Nc1ccc(C(=O)Oc2ccccc2)c(O)c1	Launched
phenyl-salicylate	antiseptic		urology	interstitial cystitis (IC)	MedChemEx, Enamine	88.66	Oc1ccccc1C(=O)Oc1ccccc1, Oc1ccccc1C(=O)Oc1ccccc1	Launched
phenylacetylglutamine	DNA methylase inhibitor, protein synthesis inhibitor				Cayman	89.95	NC(=O)CC[C@H](NC(=O)Cc1ccccc1)C(O)=O	Phase 2
phenylbenzimidazole-sulfonic-acid			dermatology	sunscreen lotion	Vitas-M, Vitas-M	92.52	OS(=O)(=O)c1ccc2nc([nH]c2c1)-c1ccccc1, OS(=O)(=O)c1ccc2nc([nH]c2c1)-c1ccccc1	Launched
phenylbutazone	cyclooxygenase inhibitor, prostanoid receptor antagonist	PTGIS, PTGS1, PTGS2			MedChemEx, Selleck, Selleck, MicroSource	98.14	CCCCC1C(=O)N(N(C1=O)c1ccccc1)c1ccccc1, CCCCC1C(=O)N(N(C1=O)c1ccccc1)c1ccccc1, CCCCC1C(=O)N(N(C1=O)c1ccccc1)c1ccccc1, CCCCC1C(=O)N(N(C1=O)c1ccccc1)c1ccccc1	Withdrawn
phenylbutyrate	HDAC inhibitor	HDAC1	metabolism	urea cycle disorders	MicroSource, MicroSource, Tocris, Tocris, Tocris, Selleck	97.03	OC(=O)CCCc1ccccc1, OC(=O)CCCc1ccccc1, OC(=O)CCCc1ccccc1, OC(=O)CCCc1ccccc1, OC(=O)CCCc1ccccc1, OC(=O)CCCc1ccccc1	Launched
phenylephrine	adrenergic receptor agonist	ADRA1A, ADRA1B, ADRA1D	otolaryngology, gastroenterology, cardiology	nasal congestion, hemorrhoids, hypotension	Selleck, Selleck, Selleck, Selleck, MicroSource	93.38	CNC[C@H](O)c1cccc(O)c1, CNC[C@H](O)c1cccc(O)c1, CNC[C@H](O)c1cccc(O)c1, CNC[C@H](O)c1cccc(O)c1, CNC[C@H](O)c1cccc(O)c1	Launched
phenylethyl-alcohol					MicroSource, MedChemEx	0	OCCc1ccccc1, OCCc1ccccc1	Preclinical
phenylmercuric-acetate	other antifungal				MedChemEx, MicroSource, MicroSource, MicroSource	0	CC(=O)O[Hg]c1ccccc1, CC(=O)O[Hg]c1ccccc1, CC(=O)O[Hg]c1ccccc1, CC(=O)O[Hg]c1ccccc1	Preclinical
phenylmethylsulfonyl-fluoride	serine protease inhibitor				Selleck, Selleck, Selleck, Selleck	71.2	FS(=O)(=O)Cc1ccccc1, FS(=O)(=O)Cc1ccccc1, FS(=O)(=O)Cc1ccccc1, FS(=O)(=O)Cc1ccccc1	Preclinical
phenylpiracetam	noradrenaline uptake inhibitor		neurology/psychiatry	anxiety, fatigue, depression	MedChemEx	91.32	NC(=O)CN1C[C@@H](CC1=O)c1ccccc1 |&1:6,r|	Launched
phenytoin	hydantoin antiepileptic	SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A	neurology/psychiatry	seizures	Selleck, MicroSource, Selleck	99.77	O=C1NC(=O)C(N1)(c1ccccc1)c1ccccc1, O=C1NC(=O)C(N1)(c1ccccc1)c1ccccc1, O=C1NC(=O)C(N1)(c1ccccc1)c1ccccc1	Launched
PhiKan-083	p53 stabilizing agent	TP53			Tocris, Tocris	97.41	CCn1c2ccccc2c2cc(CNC)ccc12, CCn1c2ccccc2c2cc(CNC)ccc12	Preclinical
phloretin	sodium/glucose cotransporter inhibitor	AQP9, CLCN3, SLC23A1			Selleck, Selleck	95.59	Oc1ccc(CCC(=O)c2c(O)cc(O)cc2O)cc1, Oc1ccc(CCC(=O)c2c(O)cc(O)cc2O)cc1	Launched
phlorizin	sodium/glucose cotransporter inhibitor	SLC5A1, SLC5A11, SLC5A2, SLC5A3			Tocris	97.11	OC[C@H]1O[C@@H](Oc2cc(O)cc(O)c2C(=O)CCc2ccc(O)cc2)[C@H](O)[C@@H](O)[C@@H]1O	Preclinical
phloroglucin			neurology/psychiatry	spasms	Sigma, Vitas-M	100	Oc1cc(O)cc(O)c1, Oc1cc(O)cc(O)c1	Launched
phortress	aryl hydrocarbon receptor ligand	AHR			Key, Key, Key	92.95	Cc1cc(ccc1NC(=O)[C@@H](N)CCCCN)-c1nc2cc(F)ccc2s1, Cc1cc(ccc1NC(=O)[C@@H](N)CCCCN)-c1nc2cc(F)ccc2s1, Cc1cc(ccc1NC(=O)[C@@H](N)CCCCN)-c1nc2cc(F)ccc2s1	Phase 1
phosphatidylcholine			infectious disease, dermatology, gastroenterology, cardiology, obstetrics/gynecology	hepatitis B, hepatitis C, eczema, gallbladder disease, cholesterol, premenstrual syndrome	Selleck, Selleck, Selleck	0	CCCCCCCCCCCCCCCC(=O)OC[C@H](CO[P@](O)(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC |a:19,&1:22|, CCCCCCCCCCCCCCCC(=O)OC[C@H](CO[P@](O)(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC |a:19,&1:22|, CCCCCCCCCCCCCCCC(=O)OC[C@H](CO[P@](O)(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC |a:19,&1:22|	Launched
PHP-501	GABA receptor antagonist	GABRA1, GABRB2, GABRG2			Tocris, Tocris, Tocris	95.71	On1ncc(C2CCNCC2)c1-c1cccc(c1)-c1ccccc1, On1ncc(C2CCNCC2)c1-c1cccc(c1)-c1ccccc1, On1ncc(C2CCNCC2)c1-c1cccc(c1)-c1ccccc1	Preclinical
PHT-427	AKT inhibitor, pyruvate dehydrogenase inhibitor	AKT2, PDPK1			Tocris, Tocris, Tocris, Selleck, Selleck	96.76	CCCCCCCCCCCCc1ccc(cc1)S(=O)(=O)Nc1nncs1, CCCCCCCCCCCCc1ccc(cc1)S(=O)(=O)Nc1nncs1, CCCCCCCCCCCCc1ccc(cc1)S(=O)(=O)Nc1nncs1, CCCCCCCCCCCCc1ccc(cc1)S(=O)(=O)Nc1nncs1, CCCCCCCCCCCCc1ccc(cc1)S(=O)(=O)Nc1nncs1	Preclinical
phthalylsulfacetamide					Selleck, MicroSource, MedChemEx, Selleck	94.32	CC(=O)NS(=O)(=O)c1ccc(NC(=O)c2ccccc2C(O)=O)cc1, CC(=O)NS(=O)(=O)c1ccc(NC(=O)c2ccccc2C(O)=O)cc1, CC(=O)NS(=O)(=O)c1ccc(NC(=O)c2ccccc2C(O)=O)cc1, CC(=O)NS(=O)(=O)c1ccc(NC(=O)c2ccccc2C(O)=O)cc1	Preclinical
phthalylsulfathiazole	dihydropteroate synthetase inhibitor		infectious disease, gastroenterology	dysentry, colitis	MedChemEx, MicroSource	83.45	OC(=O)c1ccccc1C(=O)Nc1ccc(cc1)S(=O)(=O)Nc1nccs1, OC(=O)c1ccccc1C(=O)Nc1ccc(cc1)S(=O)(=O)Nc1nccs1	Launched
PHTPP	estrogen receptor antagonist	ESR2			Tocris, Tocris, Tocris	95.16	Oc1ccc(cc1)-c1c(nn2c(cc(nc12)C(F)(F)F)C(F)(F)F)-c1ccccc1, Oc1ccc(cc1)-c1c(nn2c(cc(nc12)C(F)(F)F)C(F)(F)F)-c1ccccc1, Oc1ccc(cc1)-c1c(nn2c(cc(nc12)C(F)(F)F)C(F)(F)F)-c1ccccc1	Preclinical
physostigmine	acetylcholinesterase inhibitor, cholinesterase inhibitor	ACHE, BCHE	cardiology, neurology/psychiatry, ophthalmology, gastroenterology	hypotension, Alzheimer's disease, glaucoma, gastroparesis	MicroSource, MicroSource, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck	93.77	CNC(=O)Oc1ccc2N(C)[C@H]3N(C)CC[C@@]3(C)c2c1, CNC(=O)Oc1ccc2N(C)[C@H]3N(C)CC[C@@]3(C)c2c1, CNC(=O)Oc1ccc2N(C)[C@H]3N(C)CC[C@@]3(C)c2c1, CNC(=O)Oc1ccc2N(C)[C@H]3N(C)CC[C@@]3(C)c2c1, CNC(=O)Oc1ccc2N(C)[C@H]3N(C)CC[C@@]3(C)c2c1, CNC(=O)Oc1ccc2N(C)[C@H]3N(C)CC[C@@]3(C)c2c1, CNC(=O)Oc1ccc2N(C)[C@H]3N(C)CC[C@@]3(C)c2c1, CNC(=O)Oc1ccc2N(C)[C@H]3N(C)CC[C@@]3(C)c2c1, CNC(=O)Oc1ccc2N(C)[C@H]3N(C)CC[C@@]3(C)c2c1, CNC(=O)Oc1ccc2N(C)[C@H]3N(C)CC[C@@]3(C)c2c1	Launched
phytonadione		BGLAP, GGCX	hematology	vitamin K deficiency, anticoagulation reversal	MicroSource, Sigma	2.14	CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC\C(C)=C\CC1=C(C)C(=O)c2ccccc2C1=O |c:20|, CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC\C(C)=C\CC1=C(C)C(=O)c2ccccc2C1=O |c:20|	Launched
phytosphingosine					Enzo, Avanti, Avanti, Avanti, Avanti, Avanti	100	CCCCCCCCCCCCCC[C@@H](O)[C@@H](O)[C@@H](N)CO, CCCCCCCCCCCCCC[C@@H](O)[C@@H](O)[C@@H](N)CO, CCCCCCCCCCCCCC[C@@H](O)[C@@H](O)[C@@H](N)CO, CCCCCCCCCCCCCC[C@@H](O)[C@@H](O)[C@@H](N)CO, CCCCCCCCCCCCCC[C@@H](O)[C@@H](O)[C@@H](N)CO, CCCCCCCCCCCCCC[C@@H](O)[C@@H](O)[C@@H](N)CO	Phase 1
PI-103	mTOR inhibitor, PI3K inhibitor	MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG, PRKDC			Tocris, Tocris, Selleck, Selleck, Selleck, Selleck, Selleck, Calbiochem, Calbiochem	97.96	Oc1cccc(c1)-c1nc(N2CCOCC2)c2oc3ncccc3c2n1, Oc1cccc(c1)-c1nc(N2CCOCC2)c2oc3ncccc3c2n1, Oc1cccc(c1)-c1nc(N2CCOCC2)c2oc3ncccc3c2n1, Oc1cccc(c1)-c1nc(N2CCOCC2)c2oc3ncccc3c2n1, Oc1cccc(c1)-c1nc(N2CCOCC2)c2oc3ncccc3c2n1, Oc1cccc(c1)-c1nc(N2CCOCC2)c2oc3ncccc3c2n1, Oc1cccc(c1)-c1nc(N2CCOCC2)c2oc3ncccc3c2n1, Oc1cccc(c1)-c1nc(N2CCOCC2)c2oc3ncccc3c2n1, Oc1cccc(c1)-c1nc(N2CCOCC2)c2oc3ncccc3c2n1	Preclinical
PI-828	PI3K inhibitor				Tocris, Tocris, Tocris, Tocris, Tocris, Tocris, Tocris, Tocris, Tocris, Tocris, Tocris	93.17	Nc1ccc(cc1)-c1cccc2c1oc(cc2=O)N1CCOCC1, Nc1ccc(cc1)-c1cccc2c1oc(cc2=O)N1CCOCC1, Nc1ccc(cc1)-c1cccc2c1oc(cc2=O)N1CCOCC1, Nc1ccc(cc1)-c1cccc2c1oc(cc2=O)N1CCOCC1, Nc1ccc(cc1)-c1cccc2c1oc(cc2=O)N1CCOCC1, Nc1ccc(cc1)-c1cccc2c1oc(cc2=O)N1CCOCC1, Nc1ccc(cc1)-c1cccc2c1oc(cc2=O)N1CCOCC1, Nc1ccc(cc1)-c1cccc2c1oc(cc2=O)N1CCOCC1, Nc1ccc(cc1)-c1cccc2c1oc(cc2=O)N1CCOCC1, Nc1ccc(cc1)-c1cccc2c1oc(cc2=O)N1CCOCC1, Nc1ccc(cc1)-c1cccc2c1oc(cc2=O)N1CCOCC1	Preclinical
pibenzimol	DNA inhibitor				Tocris, MedChemEx	94.39	CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1ccc2nc([nH]c2c1)-c1ccc(O)cc1, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1ccc2nc([nH]c2c1)-c1ccc(O)cc1	Phase 2
piboserod	serotonin receptor antagonist	HTR2B, HTR4			MedChemEx, MedChemEx	96.02	CCCCN1CCC(CNC(=O)c2c3OCCCn3c3ccccc23)CC1, CCCCN1CCC(CNC(=O)c2c3OCCCn3c3ccccc23)CC1	Phase 2
picartamide	H+/K+-ATPase inhibitor	ATP4A			Enamine	98.26	CNC(=S)[C@]1(CCCS1)c1ccccn1 |&1:4,r|	Phase 2
piceatannol	SYK inhibitor	ATP5A1, ATP5B, ATP5C1, IRF3			Tocris, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Tocris	97.51	Oc1cc(O)cc(\C=C\c2ccc(O)c(O)c2)c1, Oc1cc(O)cc(\C=C\c2ccc(O)c(O)c2)c1, Oc1cc(O)cc(\C=C\c2ccc(O)c(O)c2)c1, Oc1cc(O)cc(\C=C\c2ccc(O)c(O)c2)c1, Oc1cc(O)cc(\C=C\c2ccc(O)c(O)c2)c1, Oc1cc(O)cc(\C=C\c2ccc(O)c(O)c2)c1, Oc1cc(O)cc(\C=C\c2ccc(O)c(O)c2)c1, Oc1cc(O)cc(\C=C\c2ccc(O)c(O)c2)c1	Preclinical
piclamilast	phosphodiesterase inhibitor	PDE4A, PDE4B, PDE4C, PDE4D			Tocris, Tocris, Enamine, Enamine	99.07	COc1ccc(cc1OC1CCCC1)C(=O)Nc1c(Cl)cncc1Cl, COc1ccc(cc1OC1CCCC1)C(=O)Nc1c(Cl)cncc1Cl, COc1ccc(cc1OC1CCCC1)C(=O)Nc1c(Cl)cncc1Cl, COc1ccc(cc1OC1CCCC1)C(=O)Nc1c(Cl)cncc1Cl	Phase 2
picolamine					MedChemEx, MicroSource	98.78	NCc1cccnc1, NCc1cccnc1	Preclinical
picolinic-acid	chelating agent				Enamine, Enamine	0	OC(=O)c1ccccn1, OC(=O)c1ccccn1	Phase 2
piconol					MedChemEx, MicroSource	88.45	OCc1ccccn1, OCc1ccccn1	Preclinical
picotamide	thromboxane receptor antagonist, thromboxane synthase inhibitor	TBXA2R	hematology	thrombosis	Sigma, Prestwick, Prestwick, Prestwick, Prestwick, Prestwick	99.78	COc1ccc(cc1C(=O)NCc1cccnc1)C(=O)NCc1cccnc1, COc1ccc(cc1C(=O)NCc1cccnc1)C(=O)NCc1cccnc1, COc1ccc(cc1C(=O)NCc1cccnc1)C(=O)NCc1cccnc1, COc1ccc(cc1C(=O)NCc1cccnc1)C(=O)NCc1cccnc1, COc1ccc(cc1C(=O)NCc1cccnc1)C(=O)NCc1cccnc1, COc1ccc(cc1C(=O)NCc1cccnc1)C(=O)NCc1cccnc1	Launched
picrotin	GABA receptor antagonist	GLRA1, GLRA2, GLRA3, GLRB			SantaCruz, SantaCruz, SantaCruz, SantaCruz	100	CC(C)(O)[C@H]1[C@H]2OC(=O)[C@@H]1[C@@]1(O)C[C@H]3O[C@]33C(=O)O[C@@H]2[C@@]13C |&1:4,&2:5,&3:9,&4:10,&5:13,&6:15,&7:19,&8:20,r|, CC(C)(O)[C@H]1[C@H]2OC(=O)[C@@H]1[C@@]1(O)C[C@H]3O[C@]33C(=O)O[C@@H]2[C@@]13C |&1:4,&2:5,&3:9,&4:10,&5:13,&6:15,&7:19,&8:20,r|, CC(C)(O)[C@H]1[C@H]2OC(=O)[C@@H]1[C@@]1(O)C[C@H]3O[C@]33C(=O)O[C@@H]2[C@@]13C |&1:4,&2:5,&3:9,&4:10,&5:13,&6:15,&7:19,&8:20,r|, CC(C)(O)[C@H]1[C@H]2OC(=O)[C@@H]1[C@@]1(O)C[C@H]3O[C@]33C(=O)O[C@@H]2[C@@]13C |&1:4,&2:5,&3:9,&4:10,&5:13,&6:15,&7:19,&8:20,r|	Phase 2
picrotoxinin	GABA receptor antagonist	GLRA1, GLRA2, GLRA3, GLRB, HTR3A, HTR3B			Selleck, Selleck	100	CC(=C)[C@@H]1[C@H]2OC(=O)[C@H]1[C@]1(O)C[C@H]3O[C@]33C(=O)O[C@H]2[C@]13C, CC(=C)[C@@H]1[C@H]2OC(=O)[C@H]1[C@]1(O)C[C@H]3O[C@]33C(=O)O[C@H]2[C@]13C	Preclinical
pidolic-acid		ADAM28, AMY1A, AMY2A, AMY2B, ANG, CCL8, HCRT, IGLC1, KRTAP5-2, TFF2, VEGFA	dermatology	xerosis cutis	MicroSource	92.71	OC(=O)[C@@H]1CCC(=O)N1	Launched
pidotimod	interferon receptor agonist, interleukin receptor agonist		infectious disease	immune adjuvant	MedChemEx, MicroSource, Selleck, Selleck	94.03	OC(=O)[C@@H]1CSCN1C(=O)[C@@H]1CCC(=O)N1, OC(=O)[C@@H]1CSCN1C(=O)[C@@H]1CCC(=O)N1, OC(=O)[C@@H]1CSCN1C(=O)[C@@H]1CCC(=O)N1, OC(=O)[C@@H]1CSCN1C(=O)[C@@H]1CCC(=O)N1	Launched
pifithrin-alpha	TP53 inhibitor	TP53			Selleck, Selleck, Tocris	29.69	Cc1ccc(cc1)C(=O)Cn1c2CCCCc2sc1=N, Cc1ccc(cc1)C(=O)Cn1c2CCCCc2sc1=N, Cc1ccc(cc1)C(=O)Cn1c2CCCCc2sc1=N	Preclinical
pifithrin-cyclic	TP53 inhibitor	TP53			Tocris, Tocris, Tocris, Tocris	97.07	Cc1ccc(cc1)-c1cn2c3CCCCc3sc2n1, Cc1ccc(cc1)-c1cn2c3CCCCc3sc2n1, Cc1ccc(cc1)-c1cn2c3CCCCc3sc2n1, Cc1ccc(cc1)-c1cn2c3CCCCc3sc2n1	Preclinical
pifithrin-mu	HSP inhibitor	HSPA1A, TP53			Tocris, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck	95.11	NS(=O)(=O)C#Cc1ccccc1, NS(=O)(=O)C#Cc1ccccc1, NS(=O)(=O)C#Cc1ccccc1, NS(=O)(=O)C#Cc1ccccc1, NS(=O)(=O)C#Cc1ccccc1, NS(=O)(=O)C#Cc1ccccc1, NS(=O)(=O)C#Cc1ccccc1, NS(=O)(=O)C#Cc1ccccc1, NS(=O)(=O)C#Cc1ccccc1	Preclinical
PIK-293	PI3K inhibitor	PIK3CA, PIK3CB, PIK3CD, PIK3CG			Selleck, Selleck	96.72	Cc1ccccc1-n1c(Cn2ncc3c(N)ncnc23)nc2cccc(C)c2c1=O, Cc1ccccc1-n1c(Cn2ncc3c(N)ncnc23)nc2cccc(C)c2c1=O	Preclinical
PIK-294	PI3K inhibitor	PIK3CB, PIK3CD, PIK3CG			MedChemEx, Selleck	97.97	Cc1ccccc1-n1c(Cn2nc(-c3cccc(O)c3)c3c(N)ncnc23)nc2cccc(C)c2c1=O, Cc1ccccc1-n1c(Cn2nc(-c3cccc(O)c3)c3c(N)ncnc23)nc2cccc(C)c2c1=O	Preclinical
PIK-75	DNA protein kinase inhibitor, PI3K inhibitor	PIK3CA, PIK3CB, PIK3CD, PIK3CG, PRKDC			Selleck, Selleck, Selleck	98	CN(\N=C\c1cnc2ccc(Br)cn12)S(=O)(=O)c1cc(ccc1C)[N+]([O-])=O, CN(\N=C\c1cnc2ccc(Br)cn12)S(=O)(=O)c1cc(ccc1C)[N+]([O-])=O, CN(\N=C\c1cnc2ccc(Br)cn12)S(=O)(=O)c1cc(ccc1C)[N+]([O-])=O	Preclinical
PIK-93	PI3K inhibitor	PI4KB, PIK3C3, PIK3CG			Selleck, Selleck, Selleck, Selleck	92.8	CC(=O)Nc1nc(C)c(s1)-c1ccc(Cl)c(c1)S(=O)(=O)NCCO, CC(=O)Nc1nc(C)c(s1)-c1ccc(Cl)c(c1)S(=O)(=O)NCCO, CC(=O)Nc1nc(C)c(s1)-c1ccc(Cl)c(c1)S(=O)(=O)NCCO, CC(=O)Nc1nc(C)c(s1)-c1ccc(Cl)c(c1)S(=O)(=O)NCCO	Preclinical
pikamilone					Enamine	98.59	OC(=O)CCCNC(=O)c1cccnc1	Phase 1
piketoprofen	cyclooxygenase inhibitor		neurology/psychiatry	pain relief	Enamine, Enamine, Enamine, Enamine	93.58	C[C@@H](C(=O)Nc1cc(C)ccn1)c1cccc(c1)C(=O)c1ccccc1 |&1:1,r|, C[C@@H](C(=O)Nc1cc(C)ccn1)c1cccc(c1)C(=O)c1ccccc1 |&1:1,r|, C[C@@H](C(=O)Nc1cc(C)ccn1)c1cccc(c1)C(=O)c1ccccc1 |&1:1,r|, C[C@@H](C(=O)Nc1cc(C)ccn1)c1cccc(c1)C(=O)c1ccccc1 |&1:1,r|	Launched
pilaralisib	PI3K inhibitor				MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx	96.14	COc1ccc(Cl)c(Nc2nc3ccccc3nc2NS(=O)(=O)c2cccc(NC(=O)C(C)(C)N)c2)c1, COc1ccc(Cl)c(Nc2nc3ccccc3nc2NS(=O)(=O)c2cccc(NC(=O)C(C)(C)N)c2)c1, COc1ccc(Cl)c(Nc2nc3ccccc3nc2NS(=O)(=O)c2cccc(NC(=O)C(C)(C)N)c2)c1, COc1ccc(Cl)c(Nc2nc3ccccc3nc2NS(=O)(=O)c2cccc(NC(=O)C(C)(C)N)c2)c1, COc1ccc(Cl)c(Nc2nc3ccccc3nc2NS(=O)(=O)c2cccc(NC(=O)C(C)(C)N)c2)c1, COc1ccc(Cl)c(Nc2nc3ccccc3nc2NS(=O)(=O)c2cccc(NC(=O)C(C)(C)N)c2)c1	Phase 2
pilocarpine	acetylcholine receptor agonist	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5	ophthalmology, cardiology	glaucoma, hypertension	Tocris, Tocris, Tocris, Tocris, Tocris, Tocris, MicroSource, Tocris, Selleck	99.14	CC[C@H]1[C@@H](Cc2cncn2C)COC1=O, CC[C@H]1[C@@H](Cc2cncn2C)COC1=O, CC[C@H]1[C@@H](Cc2cncn2C)COC1=O, CC[C@H]1[C@@H](Cc2cncn2C)COC1=O, CC[C@H]1[C@@H](Cc2cncn2C)COC1=O, CC[C@H]1[C@@H](Cc2cncn2C)COC1=O, CC[C@H]1[C@@H](Cc2cncn2C)COC1=O, CC[C@H]1[C@@H](Cc2cncn2C)COC1=O, CC[C@H]1[C@@H](Cc2cncn2C)COC1=O	Launched
pilsicainide	sodium channel blocker	SCN5A	cardiology	cardiac arrythmia	AKSci, AKSci	99.35	Cc1cccc(C)c1NC(=O)CC12CCCN1CCC2, Cc1cccc(C)c1NC(=O)CC12CCCN1CCC2	Launched
PIM-1-Inhibitor-2	Pim kinase inhibitor	PIM1			Tocris, Tocris, Tocris	96.9	Nc1nccc(n1)-c1ccc2noc(-c3ccc(Cl)cc3)c2c1, Nc1nccc(n1)-c1ccc2noc(-c3ccc(Cl)cc3)c2c1, Nc1nccc(n1)-c1ccc2noc(-c3ccc(Cl)cc3)c2c1	Preclinical
PIM-447	Pim kinase inhibitor				MedChemEx	97.01	C[C@@H]1C[C@H](N)C[C@@H](C1)c1ccncc1NC(=O)c1ccc(F)c(n1)-c1c(F)cccc1F	Phase 1
pimavanserin	serotonin receptor inverse agonist	DRD2, HTR2A	neurology/psychiatry	Parkinson's Disease	MedChemEx, MedChemEx	98.11	CC(C)COc1ccc(CNC(=O)N(Cc2ccc(F)cc2)C2CCN(C)CC2)cc1, CC(C)COc1ccc(CNC(=O)N(Cc2ccc(F)cc2)C2CCN(C)CC2)cc1	Launched
pimecrolimus	calcineurin inhibitor		dermatology	eczema	MedChemEx, Selleck	95.57	CC[C@@H]1\C=C(C)\C[C@H](C)C[C@H](OC)[C@H]2O[C@](O)([C@H](C)C[C@@H]2OC)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@@H]([C@H](C)[C@@H](O)CC1=O)C(\C)=C\[C@@H]1CC[C@H](Cl)[C@@H](C1)OC |c:3|, CC[C@@H]1\C=C(C)\C[C@H](C)C[C@H](OC)[C@H]2O[C@](O)([C@H](C)C[C@@H]2OC)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@@H]([C@H](C)[C@@H](O)CC1=O)C(\C)=C\[C@@H]1CC[C@H](Cl)[C@@H](C1)OC |c:3|	Launched
pimethixene	antihistamine		neurology/psychiatry, allergy	attention-deficit/hyperactivity disorder (ADHD), anxiety, sleep cycle support, allergic rhinitis	MicroSource, Toronto	98.19	CN1CCC(CC1)=C1c2ccccc2Sc2ccccc12, CN1CCC(CC1)=C1c2ccccc2Sc2ccccc12	Launched
pimobendan	calcium sensitizer, phosphodiesterase inhibitor	PDE3A	cardiology	congestive heart failure	MedChemEx, MedChemEx	99.25	COc1ccc(cc1)-c1nc2ccc(cc2[nH]1)C1=NNC(=O)C[C@H]1C |&1:23,t:20|, COc1ccc(cc1)-c1nc2ccc(cc2[nH]1)C1=NNC(=O)C[C@H]1C |&1:23,t:20|	Launched
pimodivir	antiviral				MedChemEx	95.34	OC(=O)[C@H]1C2CCC(CC2)[C@@H]1Nc1nc(ncc1F)-c1c[nH]c2ncc(F)cc12	Phase 3
pimonidazole					Cayman, Cayman	94.99	O[C@@H](CN1CCCCC1)Cn1ccnc1[N+]([O-])=O |&1:1,r|, O[C@@H](CN1CCCCC1)Cn1ccnc1[N+]([O-])=O |&1:1,r|	Phase 3
pimozide	dopamine receptor antagonist	CACNA1I, CALM1, DRD1, DRD2, DRD3, DRD4, DRD5, HRH1, HTR1A, HTR2A, KCNA10, KCNH2	neurology/psychiatry	Tourette's disorder	Tocris, Selleck, MicroSource, Tocris	97.81	Fc1ccc(cc1)C(CCCN1CCC(CC1)n1c2ccccc2[nH]c1=O)c1ccc(F)cc1, Fc1ccc(cc1)C(CCCN1CCC(CC1)n1c2ccccc2[nH]c1=O)c1ccc(F)cc1, Fc1ccc(cc1)C(CCCN1CCC(CC1)n1c2ccccc2[nH]c1=O)c1ccc(F)cc1, Fc1ccc(cc1)C(CCCN1CCC(CC1)n1c2ccccc2[nH]c1=O)c1ccc(F)cc1	Launched
pinacidil	ATP channel activator, potassium channel activator	ABCC8, ABCC9	cardiology	hypertension	Selleck, MicroSource, MedChemEx, MedChemEx, MedChemEx	98.87	C[C@@H](NC(Nc1ccncc1)=NC#N)C(C)(C)C |&1:1,r|, C[C@@H](NC(Nc1ccncc1)=NC#N)C(C)(C)C |&1:1,r|, C[C@@H](NC(Nc1ccncc1)=NC#N)C(C)(C)C |&1:1,r|, C[C@@H](NC(Nc1ccncc1)=NC#N)C(C)(C)C |&1:1,r|, C[C@@H](NC(Nc1ccncc1)=NC#N)C(C)(C)C |&1:1,r|	Launched
pinanediol					Sigma	1.44	CC1(C)[C@H]2C[C@@H]1[C@](C)(O)[C@H](O)C2	Preclinical
pinaverium	T-type calcium channel blocker	CACNA1C	gastroenterology	irritable bowel syndrome	CombiBlocks	99.42	COc1cc(Br)c(C[N+]2(CCOCC[C@H]3CC[C@@H]4C[C@H]3C4(C)C)CCOCC2)cc1OC |&1:17,19,&2:14,r|	Launched
pincainide	antiarrhythmic				Enamine	96.6	Cc1cccc(C)c1NC(=O)CN1CCCCCC1	Phase 1
pindolol	adrenergic receptor antagonist	ADRB1, ADRB2, HTR1A, HTR2A, HTR2B	cardiology	hypertension	Selleck, Tocris, Tocris, Tocris, MicroSource	97.32	CC(C)NC[C@@H](O)COc1cccc2[nH]ccc12 |&1:5,r|, CC(C)NC[C@@H](O)COc1cccc2[nH]ccc12 |&1:5,r|, CC(C)NC[C@@H](O)COc1cccc2[nH]ccc12 |&1:5,r|, CC(C)NC[C@@H](O)COc1cccc2[nH]ccc12 |&1:5,r|, CC(C)NC[C@@H](O)COc1cccc2[nH]ccc12 |&1:5,r|	Launched
pindolol-(-)	adrenergic receptor antagonist, serotonin receptor antagonist	HTR1A			Tocris, Tocris	93.26	CC(C)NC[C@H](O)COc1cccc2[nH]ccc12, CC(C)NC[C@H](O)COc1cccc2[nH]ccc12	Phase 2
pinitol	gamma secretase inhibitor					0		Phase 2
pinocembrin	cytochrome P450 inhibitor	CYP1B1			Enzo, Sigma	97.52	Oc1cc(O)c2C(=O)C[C@H](Oc2c1)c1ccccc1, Oc1cc(O)c2C(=O)C[C@H](Oc2c1)c1ccccc1	Phase 2
pioglitazone	insulin sensitizer, PPAR receptor agonist	PPARG, TRPM3	endocrinology	diabetes mellitus	Selleck	97.91	CCc1ccc(CCOc2ccc(C[C@H]3SC(=O)NC3=O)cc2)nc1 |&1:14|	Launched
pipamperone	dopamine receptor antagonist	DRD2, HRH1, HTR1A, HTR1B, HTR1D, HTR2A	neurology/psychiatry	schizophrenia	MicroSource, MicroSource, Sigma	92.76	NC(=O)C1(CCN(CCCC(=O)c2ccc(F)cc2)CC1)N1CCCCC1, NC(=O)C1(CCN(CCCC(=O)c2ccc(F)cc2)CC1)N1CCCCC1, NC(=O)C1(CCN(CCCC(=O)c2ccc(F)cc2)CC1)N1CCCCC1	Launched
pipecuronium	neuromuscular blocker	CHRM2, CHRM3, CHRNA2	neurology/psychiatry	anesthetic		0		Launched
pipemidic-acid	topoisomerase inhibitor		infectious disease	gram-negative bacterial infections	MedChemEx, MicroSource	99.07	CCn1cc(C(O)=O)c(=O)c2cnc(nc12)N1CCNCC1, CCn1cc(C(O)=O)c(=O)c2cnc(nc12)N1CCNCC1	Launched
pipenzolate	cholinergic receptor antagonist	CHRM1	neurology/psychiatry	spasms	Selleck, MicroSource, Selleck	97.76	CC[N@@+]1(C)CCC[C@@H](C1)OC(=O)C(O)(c1ccccc1)c1ccccc1 |&1:2,&2:7|, CC[N@@+]1(C)CCC[C@@H](C1)OC(=O)C(O)(c1ccccc1)c1ccccc1 |&1:2,&2:7|, CC[N@@+]1(C)CCC[C@@H](C1)OC(=O)C(O)(c1ccccc1)c1ccccc1 |&1:2,&2:7|	Launched
piperacetazine	dopamine receptor antagonist		neurology/psychiatry	schizophrenia	MicroSource, MedChemEx	94.04	CC(=O)c1ccc2Sc3ccccc3N(CCCN3CCC(CCO)CC3)c2c1, CC(=O)c1ccc2Sc3ccccc3N(CCCN3CCC(CCO)CC3)c2c1	Launched
piperacillin	bacterial cell wall synthesis inhibitor		infectious disease	intra-abdominal infections, skin infections, pelvic inflammatory disease, pneumonia	MedChemEx, MedChemEx, Sigma, Selleck, Selleck, Selleck, Selleck	96.3	CCN1CCN(C(=O)N[C@@H](C(=O)N[C@H]2[C@H]3SC(C)(C)[C@@H](N3C2=O)C(O)=O)c2ccccc2)C(=O)C1=O, CCN1CCN(C(=O)N[C@@H](C(=O)N[C@H]2[C@H]3SC(C)(C)[C@@H](N3C2=O)C(O)=O)c2ccccc2)C(=O)C1=O, CCN1CCN(C(=O)N[C@@H](C(=O)N[C@H]2[C@H]3SC(C)(C)[C@@H](N3C2=O)C(O)=O)c2ccccc2)C(=O)C1=O, CCN1CCN(C(=O)N[C@@H](C(=O)N[C@H]2[C@H]3SC(C)(C)[C@@H](N3C2=O)C(O)=O)c2ccccc2)C(=O)C1=O, CCN1CCN(C(=O)N[C@@H](C(=O)N[C@H]2[C@H]3SC(C)(C)[C@@H](N3C2=O)C(O)=O)c2ccccc2)C(=O)C1=O, CCN1CCN(C(=O)N[C@@H](C(=O)N[C@H]2[C@H]3SC(C)(C)[C@@H](N3C2=O)C(O)=O)c2ccccc2)C(=O)C1=O, CCN1CCN(C(=O)N[C@@H](C(=O)N[C@H]2[C@H]3SC(C)(C)[C@@H](N3C2=O)C(O)=O)c2ccccc2)C(=O)C1=O	Launched
piperaquine-phosphate	antimalarial agent		infectious disease	malaria	AKSci, AKSci	96.15	Clc1ccc2c(ccnc2c1)N1CCN(CCCN2CCN(CC2)c2ccnc3cc(Cl)ccc23)CC1, Clc1ccc2c(ccnc2c1)N1CCN(CCCN2CCN(CC2)c2ccnc3cc(Cl)ccc23)CC1	Launched
piperazine	benzodiazepine receptor agonist	GABRB3	infectious disease	gastrointestinal roundworms	MedChemEx, MicroSource, MicroSource	100	C1CNCCN1, C1CNCCN1, C1CNCCN1	Launched
piperazinedione	DNA synthesis inhibitor				Enamine	97.3	O=C1CNC(=O)CN1	Phase 2
piperidolate	acetylcholine receptor antagonist	CHRM1	neurology/psychiatry	spasms	MicroSource, MedChemEx	98.09	CCN1CCC[C@@H](C1)OC(=O)C(c1ccccc1)c1ccccc1 |&1:6|, CCN1CCC[C@@H](C1)OC(=O)C(c1ccccc1)c1ccccc1 |&1:6|	Launched
piperine	monoamine oxidase inhibitor	MAOA, MAOB, TRPV1			Selleck, MedChemEx, MedChemEx, MicroSource, MicroSource, Selleck	97.26	O=C(\C=C\C=C\c1ccc2OCOc2c1)N1CCCCC1, O=C(\C=C\C=C\c1ccc2OCOc2c1)N1CCCCC1, O=C(\C=C\C=C\c1ccc2OCOc2c1)N1CCCCC1, O=C(\C=C\C=C\c1ccc2OCOc2c1)N1CCCCC1, O=C(\C=C\C=C\c1ccc2OCOc2c1)N1CCCCC1, O=C(\C=C\C=C\c1ccc2OCOc2c1)N1CCCCC1	Phase 1
piperonyl-butoxide	cytochrome P450 inhibitor		infectious disease	lice	MedChemEx, MicroSource, MicroSource	90.25	CCCCOCCOCCOCc1cc2OCOc2cc1CCC, CCCCOCCOCCOCc1cc2OCOc2cc1CCC, CCCCOCCOCCOCc1cc2OCOc2cc1CCC	Launched
pipobroman	DNA alkylating agent		hematology	polycythemia vera, thrombocythemia	MicroSource, MedChemEx, MedChemEx	81.16	BrCCC(=O)N1CCN(CC1)C(=O)CCBr, BrCCC(=O)N1CCN(CC1)C(=O)CCBr, BrCCC(=O)N1CCN(CC1)C(=O)CCBr	Launched
pipofezine	selective serotonin reuptake inhibitor (SSRI)				MedChemEx	97.43	CN1CCN(CC1)c1cc2N(C)c3ccccc3Oc2nn1	Preclinical
pipotiazine	dopamine receptor antagonist	DRD1, DRD2, HTR1A, HTR2A	neurology/psychiatry	schizophrenia	Sigma	0	CN(C)S(=O)(=O)c1ccc2Sc3ccccc3N(CCCN3CCC(CCO)CC3)c2c1	Launched
pipotiazine-palmitate	dopamine receptor antagonist, serotonin receptor antagonist	DRD1, DRD2, HTR1A, HTR2A	neurology/psychiatry	schizophrenia	Sigma	75.11	CCCCCCCCCCCCCCCC(=O)OCCC1CCN(CCCN2c3ccccc3Sc3ccc(cc23)S(=O)(=O)N(C)C)CC1	Launched
piracetam	acetylcholine receptor agonist	GRIA1, GRIA2, GRIA3, GRIA4	neurology/psychiatry	senile dementia	MicroSource, MicroSource, Selleck	100	NC(=O)CN1CCCC1=O, NC(=O)CN1CCCC1=O, NC(=O)CN1CCCC1=O	Launched
pirarubicin	topoisomerase inhibitor	TOP2A	oncology	breast cancer	MedChemEx, MedChemEx, Selleck, Selleck	71.82	COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O[C@@H]6CCCCO6)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O[C@@H]6CCCCO6)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O[C@@H]6CCCCO6)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O[C@@H]6CCCCO6)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO	Launched
pirenoxine	AGE inhibitor		ophthalmology	cataracts	AKSci	94.2	OC(=O)c1cc(=O)c2c3nc4ccccc4oc3cc(=O)c2[nH]1	Launched
pirenperone	serotonin receptor antagonist	HTR2A, HTR7			Sigma, Prestwick, Prestwick	98.26	Cc1nc2ccccn2c(=O)c1CCN1CCC(CC1)C(=O)c1ccc(F)cc1, Cc1nc2ccccn2c(=O)c1CCN1CCC(CC1)C(=O)c1ccc(F)cc1, Cc1nc2ccccn2c(=O)c1CCN1CCC(CC1)C(=O)c1ccc(F)cc1	Preclinical
pirenzepine	acetylcholine receptor antagonist	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5	gastroenterology	peptic ulcer disease (PUD)	MicroSource, MedChemEx, MedChemEx	98.33	CN1CCN(CC(=O)N2c3ccccc3C(=O)Nc3cccnc23)CC1, CN1CCN(CC(=O)N2c3ccccc3C(=O)Nc3cccnc23)CC1, CN1CCN(CC(=O)N2c3ccccc3C(=O)Nc3cccnc23)CC1	Launched
piretanide	glucocorticoid receptor agonist	SLC12A1, SLC12A2	cardiology	hypertension, edema	Prestwick, Prestwick	99.31	NS(=O)(=O)c1cc(cc(N2CCCC2)c1Oc1ccccc1)C(O)=O, NS(=O)(=O)c1cc(cc(N2CCCC2)c1Oc1ccccc1)C(O)=O	Launched
pirfenidone	TGF beta receptor inhibitor	FURIN, TNF	pulmonary	idiopathic pulmonary fibrosis (IPF)	MedChemEx, Selleck, Selleck, Tocris	97.6	Cc1ccc(=O)n(c1)-c1ccccc1, Cc1ccc(=O)n(c1)-c1ccccc1, Cc1ccc(=O)n(c1)-c1ccccc1, Cc1ccc(=O)n(c1)-c1ccccc1	Launched
piribedil	dopamine receptor agonist	ADRA1A, ADRA2A, ADRA2C, DRD2, DRD3, DRD4, HTR1A, HTR2B	neurology/psychiatry	Parkinson's Disease, dizziness	Tocris	87.35	C(N1CCN(CC1)c1ncccn1)c1ccc2OCOc2c1	Launched
piricapiron	dopamine receptor antagonist, serotonin receptor antagonist	HTR2A			Vitas-M	94.85	CC1(C)[C@@H]2CC[C@@]1(C)C(=O)N(CCCCN1CCN(CC1)c1ccccn1)C2=O |&1:3,6|	Phase 2
pirinixic-acid	PPAR receptor agonist	PPARA			Tocris, Tocris, Tocris, Selleck, Tocris	97.87	Cc1cccc(Nc2cc(Cl)nc(SCC(O)=O)n2)c1C, Cc1cccc(Nc2cc(Cl)nc(SCC(O)=O)n2)c1C, Cc1cccc(Nc2cc(Cl)nc(SCC(O)=O)n2)c1C, Cc1cccc(Nc2cc(Cl)nc(SCC(O)=O)n2)c1C, Cc1cccc(Nc2cc(Cl)nc(SCC(O)=O)n2)c1C	Preclinical
pirlindole	monoamine oxidase inhibitor	MAOA	neurology/psychiatry	depression	Tocris	90	Cc1ccc2n3CCN[C@H]4CCCc(c34)c2c1 |&1:9|	Launched
pirmenol	acetylcholine receptor inhibitor				MedChemEx	74.62	C[C@H]1CCC[C@@H](C)N1CCC[C@@](O)(c1ccccc1)c1ccccn1 |a:1,5,&1:11|	Preclinical
piroctone-olamine			infectious disease	fungal infection	MicroSource	0	C[C@@H](Cc1cc(C)cc(=O)n1O)CC(C)(C)C |&1:1|	Launched
pirodavir					MedChemEx, MedChemEx, MedChemEx	98.34	CCOC(=O)c1ccc(OCCC2CCN(CC2)c2ccc(C)nn2)cc1, CCOC(=O)c1ccc(OCCC2CCN(CC2)c2ccc(C)nn2)cc1, CCOC(=O)c1ccc(OCCC2CCN(CC2)c2ccc(C)nn2)cc1	Phase 2
piromidic-acid	bacterial DNA gyrase inhibitor				MedChemEx, MicroSource, Selleck, Selleck	100	CCn1cc(C(O)=O)c(=O)c2cnc(nc12)N1CCCC1, CCn1cc(C(O)=O)c(=O)c2cnc(nc12)N1CCCC1, CCn1cc(C(O)=O)c(=O)c2cnc(nc12)N1CCCC1, CCn1cc(C(O)=O)c(=O)c2cnc(nc12)N1CCCC1	Phase 2
piroxicam	cyclooxygenase inhibitor	PTGS1, PTGS2	rheumatology	osteoarthritis, rheumatoid arthritis	Tocris	93.49	CN1C(C(=O)Nc2ccccn2)=C(O)c2ccccc2S1(=O)=O |t:12|	Launched
piroximone	phosphodiesterase inhibitor	PDE3A			Enamine, Enamine	99.6	CCc1[nH]c(=O)[nH]c1C(=O)c1ccncc1, CCc1[nH]c(=O)[nH]c1C(=O)c1ccncc1	Phase 2
pirozadil	hypolipidemic				MedChemEx	97.32	COc1cc(cc(OC)c1OC)C(=O)OCc1cccc(COC(=O)c2cc(OC)c(OC)c(OC)c2)n1	Preclinical
pirquinozol	histamine release inhibitor				Enamine	98.69	OCc1cc2c3ccccc3[nH]c(=O)n2n1	Phase 1
PIT	purinergic receptor antagonist	P2RY1			Tocris, Tocris	41.7	[O-][N+]1=C(C(=O)c2ccccc12)c1ccccn1 |t:1|, [O-][N+]1=C(C(=O)c2ccccc12)c1ccccn1 |t:1|	Preclinical
pitavastatin	HMGCR inhibitor	HMGCR	endocrinology	hyperlipidemia	Tocris, Adooq, Adooq, Tocris, Tocris, Selleck, Selleck, Selleck, Selleck	97.39	O[C@H](C[C@H](O)\C=C\c1c(nc2ccccc2c1-c1ccc(F)cc1)C1CC1)CC(O)=O, O[C@H](C[C@H](O)\C=C\c1c(nc2ccccc2c1-c1ccc(F)cc1)C1CC1)CC(O)=O, O[C@H](C[C@H](O)\C=C\c1c(nc2ccccc2c1-c1ccc(F)cc1)C1CC1)CC(O)=O, O[C@H](C[C@H](O)\C=C\c1c(nc2ccccc2c1-c1ccc(F)cc1)C1CC1)CC(O)=O, O[C@H](C[C@H](O)\C=C\c1c(nc2ccccc2c1-c1ccc(F)cc1)C1CC1)CC(O)=O, O[C@H](C[C@H](O)\C=C\c1c(nc2ccccc2c1-c1ccc(F)cc1)C1CC1)CC(O)=O, O[C@H](C[C@H](O)\C=C\c1c(nc2ccccc2c1-c1ccc(F)cc1)C1CC1)CC(O)=O, O[C@H](C[C@H](O)\C=C\c1c(nc2ccccc2c1-c1ccc(F)cc1)C1CC1)CC(O)=O, O[C@H](C[C@H](O)\C=C\c1c(nc2ccccc2c1-c1ccc(F)cc1)C1CC1)CC(O)=O	Launched
pitolisant	histamine receptor antagonist	HRH3			Tocris, Tocris, Tocris, Tocris, Tocris	97	Clc1ccc(CCCOCCCN2CCCCC2)cc1, Clc1ccc(CCCOCCCN2CCCCC2)cc1, Clc1ccc(CCCOCCCN2CCCCC2)cc1, Clc1ccc(CCCOCCCN2CCCCC2)cc1, Clc1ccc(CCCOCCCN2CCCCC2)cc1	Launched
pivagabine	corticotropin releasing factor receptor antagonist	CRHR1, CRHR2	neurology/psychiatry	depression	Enamine, Enamine	53.16	CC(C)(C)C(=O)NCCCC(O)=O, CC(C)(C)C(=O)NCCCC(O)=O	Launched
pivampicillin	bacterial cell wall synthesis inhibitor		pulmonary, infectious disease	bronchitis, pneumonia, gynecologic infections	Prestwick	38.24	CC(C)(C)C(=O)OCOC(=O)[C@@H]1N2[C@H](SC1(C)C)[C@H](NC(=O)[C@H](N)c1ccccc1)C2=O	Launched
pivanex	HDAC inhibitor	HDAC1, HDAC2, HDAC3, HDAC8			Sigma, Sigma	0	CCCC(=O)OCOC(=O)C(C)(C)C, CCCC(=O)OCOC(=O)C(C)(C)C	Phase 2
pivmecillinam	bacterial cell wall synthesis inhibitor		infectious disease	urinary tract infections, gram-negative bacterial infections	Sigma, MedChemEx, Prestwick	95.37	CC(C)(C)C(=O)OCOC(=O)[C@@H]1N2[C@H](SC1(C)C)[C@H](\N=C\N1CCCCCC1)C2=O, CC(C)(C)C(=O)OCOC(=O)[C@@H]1N2[C@H](SC1(C)C)[C@H](\N=C\N1CCCCCC1)C2=O, CC(C)(C)C(=O)OCOC(=O)[C@@H]1N2[C@H](SC1(C)C)[C@H](\N=C\N1CCCCCC1)C2=O	Launched
pixantrone	topoisomerase inhibitor	TOP2A	hematologic malignancy	non-Hodgkin lymphoma (NHL)	MedChemEx, MedChemEx	53.02	NCCNc1ccc(NCCN)c2C(=O)c3cnccc3C(=O)c12, NCCNc1ccc(NCCN)c2C(=O)c3cnccc3C(=O)c12	Launched
pizotifen	serotonin receptor antagonist	HTR1A, HTR2A, HTR2C	neurology/psychiatry	migraine headache	MedChemEx, MicroSource, Selleck, Selleck	99.14	CN1CCC(CC1)=C1c2ccsc2CCc2ccccc12, CN1CCC(CC1)=C1c2ccsc2CCc2ccccc12, CN1CCC(CC1)=C1c2ccsc2CCc2ccccc12, CN1CCC(CC1)=C1c2ccsc2CCc2ccccc12	Launched
PI3K-IN-2	PI3K inhibitor				MedChemEx, MedChemEx, MedChemEx	94.14	Nc1cc(c(cn1)-c1nc(nc(n1)N1CCOCC1)N1CCOCC1)C(F)(F)F, Nc1cc(c(cn1)-c1nc(nc(n1)N1CCOCC1)N1CCOCC1)C(F)(F)F, Nc1cc(c(cn1)-c1nc(nc(n1)N1CCOCC1)N1CCOCC1)C(F)(F)F	Phase 2
PI3Kd-IN-2	PI3K inhibitor				MedChemEx	90.49	COc1ncc(cc1NS(C)(=O)=O)-c1nc(nc2c(CN3CCC(CC3)C(C)(C)O)cc(F)cc12)N1CCOCC1	Preclinical
PI4KIII-beta-inhibitor-1	PI4K inhibitor	PI4K2B			MedChemEx, MedChemEx	94.57	COc1ccc(cc1S(=O)(=O)Nc1ccc(O)cc1)-c1sc(NC(=O)C(C)(C)C)nc1C, COc1ccc(cc1S(=O)(=O)Nc1ccc(O)cc1)-c1sc(NC(=O)C(C)(C)C)nc1C	Preclinical
PJ-34	PARP inhibitor	EEF2, PARP1, PARP15, PARP3			Tocris, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck	95.18	CN(C)CC(=O)Nc1ccc2[nH]c(=O)c3ccccc3c2c1, CN(C)CC(=O)Nc1ccc2[nH]c(=O)c3ccccc3c2c1, CN(C)CC(=O)Nc1ccc2[nH]c(=O)c3ccccc3c2c1, CN(C)CC(=O)Nc1ccc2[nH]c(=O)c3ccccc3c2c1, CN(C)CC(=O)Nc1ccc2[nH]c(=O)c3ccccc3c2c1, CN(C)CC(=O)Nc1ccc2[nH]c(=O)c3ccccc3c2c1, CN(C)CC(=O)Nc1ccc2[nH]c(=O)c3ccccc3c2c1, CN(C)CC(=O)Nc1ccc2[nH]c(=O)c3ccccc3c2c1	Preclinical
PK-THPP	potassium channel blocker	KCNK9			Tocris, Tocris, Tocris	97.46	CCCC(=O)C1CCN(CC1)c1ncnc2CCN(Cc12)C(=O)c1ccc(cc1)-c1ccccc1, CCCC(=O)C1CCN(CC1)c1ncnc2CCN(Cc12)C(=O)c1ccc(cc1)-c1ccccc1, CCCC(=O)C1CCN(CC1)c1ncnc2CCN(Cc12)C(=O)c1ccc(cc1)-c1ccccc1	Preclinical
PK-11195	benzodiazepine receptor antagonist	TSPO			Tocris, Tocris	98.79	CC[C@@H](C)N(C)C(=O)c1cc2ccccc2c(n1)-c1ccccc1Cl |&1:2,r|, CC[C@@H](C)N(C)C(=O)c1cc2ccccc2c(n1)-c1ccccc1Cl |&1:2,r|	Phase 1
PK-44	dipeptidyl peptidase inhibitor	DPP4			Tocris, Tocris	91.71	N[C@@H](CC(=O)N1CCn2c(C1)nnc2C(F)(F)F)Cc1[nH]nc2c(F)c(F)ccc12, N[C@@H](CC(=O)N1CCn2c(C1)nnc2C(F)(F)F)Cc1[nH]nc2c(F)c(F)ccc12	Preclinical
PKI-166	EGFR inhibitor	EGFR			Sigma, Sigma	90.82	C[C@@H](Nc1ncnc2[nH]c(cc12)-c1ccc(O)cc1)c1ccccc1, C[C@@H](Nc1ncnc2[nH]c(cc12)-c1ccc(O)cc1)c1ccccc1	Phase 1
PKI-179	mTOR inhibitor, PI3K inhibitor	MTOR			EMDBio, EMDBio, EMDBio, EMDBio, EMDBio	97.35	O=C(Nc1ccncc1)Nc1ccc(cc1)-c1nc(nc(n1)N1CCOCC1)N1[C@H]2CC[C@@H]1COC2 |&1:29,&2:32|, O=C(Nc1ccncc1)Nc1ccc(cc1)-c1nc(nc(n1)N1CCOCC1)N1[C@H]2CC[C@@H]1COC2 |&1:29,&2:32|, O=C(Nc1ccncc1)Nc1ccc(cc1)-c1nc(nc(n1)N1CCOCC1)N1[C@H]2CC[C@@H]1COC2 |&1:29,&2:32|, O=C(Nc1ccncc1)Nc1ccc(cc1)-c1nc(nc(n1)N1CCOCC1)N1[C@H]2CC[C@@H]1COC2 |&1:29,&2:32|, O=C(Nc1ccncc1)Nc1ccc(cc1)-c1nc(nc(n1)N1CCOCC1)N1[C@H]2CC[C@@H]1COC2 |&1:29,&2:32|	Phase 1
pleconaril					MedChemEx, SantaCruz	91.31	Cc1cc(CCCOc2c(C)cc(cc2C)-c2noc(n2)C(F)(F)F)on1, Cc1cc(CCCOc2c(C)cc(cc2C)-c2noc(n2)C(F)(F)F)on1	Phase 3
plerixafor	CC chemokine receptor antagonist	ACKR3, CCR4, CXCR4	hematologic malignancy	non-Hodgkin lymphoma (NHL), multiple myeloma	MedChemEx, MedChemEx, Selleck, MedChemEx, MedChemEx, Selleck	97.85	C(N1CCCNCCNCCCNCC1)c1ccc(CN2CCCNCCNCCCNCC2)cc1, C(N1CCCNCCNCCCNCC1)c1ccc(CN2CCCNCCNCCCNCC2)cc1, C(N1CCCNCCNCCCNCC1)c1ccc(CN2CCCNCCNCCCNCC2)cc1, C(N1CCCNCCNCCCNCC1)c1ccc(CN2CCCNCCNCCCNCC2)cc1, C(N1CCCNCCNCCCNCC1)c1ccc(CN2CCCNCCNCCCNCC2)cc1, C(N1CCCNCCNCCCNCC1)c1ccc(CN2CCCNCCNCCCNCC2)cc1	Launched
plicamycin	alcohol dehydrogenase inhibitor		oncology, endocrinology	testicular carcinoma, Paget's disease, hypercalcemia	Enzo, Sigma	68.85	CO[C@@H]([C@@H]1Cc2cc3cc(O[C@H]4C[C@@H](O[C@H]5C[C@@H](O)[C@H](O)[C@@H](C)O5)[C@@H](O)[C@@H](C)O4)c(C)c(O)c3c(O)c2C(=O)[C@H]1O[C@H]1C[C@@H](O[C@H]2C[C@@H](O[C@H]3C[C@](C)(O)[C@H](O)[C@@H](C)O3)[C@H](O)[C@@H](C)O2)[C@H](O)[C@@H](C)O1)C(=O)[C@@H](O)[C@@H](C)O, CO[C@@H]([C@@H]1Cc2cc3cc(O[C@H]4C[C@@H](O[C@H]5C[C@@H](O)[C@H](O)[C@@H](C)O5)[C@@H](O)[C@@H](C)O4)c(C)c(O)c3c(O)c2C(=O)[C@H]1O[C@H]1C[C@@H](O[C@H]2C[C@@H](O[C@H]3C[C@](C)(O)[C@H](O)[C@@H](C)O3)[C@H](O)[C@@H](C)O2)[C@H](O)[C@@H](C)O1)C(=O)[C@@H](O)[C@@H](C)O	Launched
plinabulin	tubulin polymerization inhibitor				MedChemEx, MedChemEx, Adooq	78.21	CC(C)(C)c1nc[nH]c1\C=c1/[nH]c(=O)\c(=C\c2ccccc2)[nH]c1=O, CC(C)(C)c1nc[nH]c1\C=c1/[nH]c(=O)\c(=C\c2ccccc2)[nH]c1=O, CC(C)(C)c1nc[nH]c1\C=c1/[nH]c(=O)\c(=C\c2ccccc2)[nH]c1=O	Phase 3
plovamer-acetate		TAT, TH, YARS, YARS2			Sigma, EMDBio	98.02	N[C@@H](Cc1ccc(O)cc1)C(O)=O |&1:1,r|, N[C@@H](Cc1ccc(O)cc1)C(O)=O |&1:1,r|	Phase 2
plumbagin	anticancer agent				Sigma	89.25	CC1=CC(=O)c2c(O)cccc2C1=O |t:1|	Preclinical
plurisin-1	stearoyl-CoA desaturase inhibitor	SCD			Tocris, Tocris, Selleck, Selleck, Selleck, Selleck, Selleck	95.05	O=C(NNc1ccccc1)c1ccncc1, O=C(NNc1ccccc1)c1ccncc1, O=C(NNc1ccccc1)c1ccncc1, O=C(NNc1ccccc1)c1ccncc1, O=C(NNc1ccccc1)c1ccncc1, O=C(NNc1ccccc1)c1ccncc1, O=C(NNc1ccccc1)c1ccncc1	Preclinical
PLX4720	RAF inhibitor	BRAF, KDR			Selleck, Selleck	97.49	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(Cl)cc23)c1F, CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(Cl)cc23)c1F	Preclinical
PLX51107	bromodomain inhibitor				MedChemEx	97.86	C[C@@H](c1ccccn1)n1cc(-c2ccc(cc2)C(O)=O)c2ncc(cc12)-c1c(C)noc1C	Phase 1
PLX647	receptor tyrosine protein kinase inhibitor	CSF1R, KIT			Tocris, Tocris	94.1	FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncccc34)cn2)cc1, FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncccc34)cn2)cc1	Preclinical
PLX8394	serine/threonine kinase inhibitor	BRAF			MedChemEx, MedChemEx	96.23	F[C@@H]1CCN(C1)S(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2cnc(nc2)C2CC2)c1F, F[C@@H]1CCN(C1)S(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2cnc(nc2)C2CC2)c1F	Phase 1/Phase 2
PMPA	glutamate receptor antagonist	FOLH1			Tocris, Tocris, Tocris	86.5	OC(=O)CC[C@@H](CP(O)(O)=O)C(O)=O |&1:5,r|, OC(=O)CC[C@@H](CP(O)(O)=O)C(O)=O |&1:5,r|, OC(=O)CC[C@@H](CP(O)(O)=O)C(O)=O |&1:5,r|	Preclinical
PNU-120596	acetylcholine receptor agonist	CHRNA7			Tocris, Tocris, Tocris, Tocris, Tocris, Tocris, Selleck	98.45	COc1cc(OC)c(NC(=O)Nc2cc(C)on2)cc1Cl, COc1cc(OC)c(NC(=O)Nc2cc(C)on2)cc1Cl, COc1cc(OC)c(NC(=O)Nc2cc(C)on2)cc1Cl, COc1cc(OC)c(NC(=O)Nc2cc(C)on2)cc1Cl, COc1cc(OC)c(NC(=O)Nc2cc(C)on2)cc1Cl, COc1cc(OC)c(NC(=O)Nc2cc(C)on2)cc1Cl, COc1cc(OC)c(NC(=O)Nc2cc(C)on2)cc1Cl	Preclinical
PNU-142633	serotonin receptor agonist	HTR1D			Tocris	97.37	CNC(=O)c1ccc2[C@H](CCN3CCN(CC3)c3ccc(cc3)C(N)=O)OCCc2c1	Phase 2
PNU-177864	dopamine receptor antagonist	DRD3			Tocris, Tocris	96.5	CCCNCCc1ccc(NS(=O)(=O)c2ccc(OC(F)(F)F)cc2)cc1, CCCNCCc1ccc(NS(=O)(=O)c2ccc(OC(F)(F)F)cc2)cc1	Preclinical
PNU-22394	serotonin receptor agonist	HTR2A, HTR2B, HTR2C, MAOA, MAOB			Tocris, Tocris	87.68	Cn1c2CCNCCc2c2ccccc12, Cn1c2CCNCCc2c2ccccc12	Phase 2
PNU-282987	cholinergic receptor agonist	CHRNA7			Tocris, Tocris, Tocris, Tocris	95.1	Clc1ccc(cc1)C(=O)N[C@H]1CN2CCC1CC2, Clc1ccc(cc1)C(=O)N[C@H]1CN2CCC1CC2, Clc1ccc(cc1)C(=O)N[C@H]1CN2CCC1CC2, Clc1ccc(cc1)C(=O)N[C@H]1CN2CCC1CC2	Preclinical
PNU-37883	ATP-sensitive potassium channel antagonist				Tocris	96.83	C1CCC(CC1)N=C(NC12CC3CC(CC(C3)C1)C2)N1CCOCC1	Preclinical
PNU-74654	beta-catenin inhibitor	CTNNB1, TCF4			Tocris, Tocris, Tocris, Tocris, Tocris	96.85	Cc1ccc(\C=N\NC(=O)c2ccccc2Oc2ccccc2)o1, Cc1ccc(\C=N\NC(=O)c2ccccc2Oc2ccccc2)o1, Cc1ccc(\C=N\NC(=O)c2ccccc2Oc2ccccc2)o1, Cc1ccc(\C=N\NC(=O)c2ccccc2Oc2ccccc2)o1, Cc1ccc(\C=N\NC(=O)c2ccccc2Oc2ccccc2)o1	Preclinical
PNU-89843	benzodiazepine receptor agonist	GABBR1			Tocris	7.39	Cc1cc2c(nc(nc2n1C)N1CCCC1)N1CCCC1	Preclinical
pocapavir	Enterovirus capsid inhibitor				MedChemEx	0	COc1ccc(OCc2ccc(COc3c(Cl)cccc3Cl)cc2)c(Cl)c1	Preclinical
podophyllotoxin	microtubule inhibitor, tubulin polymerization inhibitor	IGF1R, TOP2A, TUBA4A, TUBB	infectious disease	genital warts	MicroSource, MicroSource, MicroSource, MicroSource, MedChemEx	95.6	COc1cc(cc(OC)c1OC)[C@H]1[C@@H]2[C@H](COC2=O)[C@@H](O)c2cc3OCOc3cc12, COc1cc(cc(OC)c1OC)[C@H]1[C@@H]2[C@H](COC2=O)[C@@H](O)c2cc3OCOc3cc12, COc1cc(cc(OC)c1OC)[C@H]1[C@@H]2[C@H](COC2=O)[C@@H](O)c2cc3OCOc3cc12, COc1cc(cc(OC)c1OC)[C@H]1[C@@H]2[C@H](COC2=O)[C@@H](O)c2cc3OCOc3cc12, COc1cc(cc(OC)c1OC)[C@H]1[C@@H]2[C@H](COC2=O)[C@@H](O)c2cc3OCOc3cc12	Launched
polaprezinc	chelating agent				MedChemEx	0	O=C1CCN[Zn]OC(=O)[C@H](Cc2cnc[nH]2)N1	Preclinical
polidocanol	local anesthetic		dermatology	varicose veins	Sigma	97.44	CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO	Launched
polydatin	ICAM1 expression inhibitor	ICAM1			Selleck, Selleck	93.06	OC[C@H]1O[C@@H](Oc2cc(O)cc(\C=C\c3ccc(O)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O, OC[C@H]1O[C@@H](Oc2cc(O)cc(\C=C\c3ccc(O)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O	Phase 2
polyinosine	immunostimulant	HPRT1, IMPDH2, PYGM			Sigma	98.8	O[C@H]1[C@@H](COP(O)(O)=O)O[C@@H]([C@@H]1O)n1cnc2c1[nH]cnc2=O |&1:1,&2:2,&3:10,&4:11,r|	Preclinical
polymyxin-B-sulfate	bacterial permeability inducer		ophthalmology	eye infection	Selleck, MicroSource	84.9	CC[C@@H](C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@@H](CCN)NC(=O)[C@@H](CCN)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H](CCN)NC1=O)[C@@H](C)O |&1:2,&2:11,&3:18,&4:19,&5:25,&6:32,&7:38,&8:42,&9:49,&10:56,&11:64,&12:75,&13:82|, CC[C@@H](C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@@H](CCN)NC(=O)[C@@H](CCN)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H](CCN)NC1=O)[C@@H](C)O |&1:2,&2:11,&3:18,&4:19,&5:25,&6:32,&7:38,&8:42,&9:49,&10:56,&11:64,&12:75,&13:82|	Launched
polythiazide	sodium/chloride cotransporter inhibitor	SLC12A3	cardiology, gastroenterology, rheumatology, nephrology	edema, congestive heart failure, hepatic cirrhosis, nephrotic syndrome, acute glomerulonephritis (AGN), chronic renal failure, hypertension	Kemprotec, Kemprotec	98.56	CN1[C@@H](CSCC(F)(F)F)Nc2cc(Cl)c(cc2S1(=O)=O)S(N)(=O)=O |&1:2,r|, CN1[C@@H](CSCC(F)(F)F)Nc2cc(Cl)c(cc2S1(=O)=O)S(N)(=O)=O |&1:2,r|	Launched
pomalidomide	angiogenesis inhibitor, tumor necrosis factor production inhibitor		hematologic malignancy	multiple myeloma	Selleck, Selleck, Selleck, MedChemEx	98.67	Nc1cccc2C(=O)N([C@H]3CCC(=O)NC3=O)C(=O)c12 |&1:9,r|, Nc1cccc2C(=O)N([C@H]3CCC(=O)NC3=O)C(=O)c12 |&1:9,r|, Nc1cccc2C(=O)N([C@H]3CCC(=O)NC3=O)C(=O)c12 |&1:9,r|, Nc1cccc2C(=O)N([C@H]3CCC(=O)NC3=O)C(=O)c12 |&1:9,r|	Launched
ponatinib	Bcr-Abl kinase inhibitor, FLT3 inhibitor, PDGFR tyrosine kinase receptor inhibitor	ABL1, BCR, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, KDR, KIT, LCK, LYN, PDGFRA, RET, SRC, TEK	hematologic malignancy	chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL)	Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck	96.33	CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4cccnn34)cc2C(F)(F)F)CC1, CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4cccnn34)cc2C(F)(F)F)CC1, CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4cccnn34)cc2C(F)(F)F)CC1, CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4cccnn34)cc2C(F)(F)F)CC1, CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4cccnn34)cc2C(F)(F)F)CC1, CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4cccnn34)cc2C(F)(F)F)CC1, CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4cccnn34)cc2C(F)(F)F)CC1, CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4cccnn34)cc2C(F)(F)F)CC1, CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4cccnn34)cc2C(F)(F)F)CC1	Launched
ponesimod	sphingosine 1-phosphate receptor agonist	S1PR1			MedChemEx, MedChemEx	95	CCC\N=C1/S\C(=C/c2ccc(OC[C@H](O)CO)c(Cl)c2)C(=O)N1c1ccccc1C, CCC\N=C1/S\C(=C/c2ccc(OC[C@H](O)CO)c(Cl)c2)C(=O)N1c1ccccc1C	Phase 3
posaconazole	sterol demethylase inhibitor	CYP3A4	infectious disease	oropharyngeal candidiasis	Selleck, Selleck, Selleck, Selleck, Selleck, Selleck	94.29	CC[C@@H]([C@H](C)O)n1ncn(-c2ccc(cc2)N2CCN(CC2)c2ccc(OC[C@@H]3CO[C@](Cn4cncn4)(C3)c3ccc(F)cc3F)cc2)c1=O, CC[C@@H]([C@H](C)O)n1ncn(-c2ccc(cc2)N2CCN(CC2)c2ccc(OC[C@@H]3CO[C@](Cn4cncn4)(C3)c3ccc(F)cc3F)cc2)c1=O, CC[C@@H]([C@H](C)O)n1ncn(-c2ccc(cc2)N2CCN(CC2)c2ccc(OC[C@@H]3CO[C@](Cn4cncn4)(C3)c3ccc(F)cc3F)cc2)c1=O, CC[C@@H]([C@H](C)O)n1ncn(-c2ccc(cc2)N2CCN(CC2)c2ccc(OC[C@@H]3CO[C@](Cn4cncn4)(C3)c3ccc(F)cc3F)cc2)c1=O, CC[C@@H]([C@H](C)O)n1ncn(-c2ccc(cc2)N2CCN(CC2)c2ccc(OC[C@@H]3CO[C@](Cn4cncn4)(C3)c3ccc(F)cc3F)cc2)c1=O, CC[C@@H]([C@H](C)O)n1ncn(-c2ccc(cc2)N2CCN(CC2)c2ccc(OC[C@@H]3CO[C@](Cn4cncn4)(C3)c3ccc(F)cc3F)cc2)c1=O	Launched
potassium-canrenoate	mineralocorticoid receptor antagonist	NR3C2	cardiology	edema	MicroSource, MicroSource, MicroSource, Selleck, Selleck, Selleck, Selleck	98.01	C[C@]12CC[C@H]3[C@@H](C=CC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@]2(O)CCC(O)=O |c:6,t:8|, C[C@]12CC[C@H]3[C@@H](C=CC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@]2(O)CCC(O)=O |c:6,t:8|, C[C@]12CC[C@H]3[C@@H](C=CC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@]2(O)CCC(O)=O |c:6,t:8|, C[C@]12CC[C@H]3[C@@H](C=CC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@]2(O)CCC(O)=O |c:6,t:8|, C[C@]12CC[C@H]3[C@@H](C=CC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@]2(O)CCC(O)=O |c:6,t:8|, C[C@]12CC[C@H]3[C@@H](C=CC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@]2(O)CCC(O)=O |c:6,t:8|, C[C@]12CC[C@H]3[C@@H](C=CC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@]2(O)CCC(O)=O |c:6,t:8|	Launched
potassium-iodide			pulmonary	asthma, bronchitis, emphysema	Selleck, Selleck	0	[K].I, [K].I	Launched
potassium-p-aminobenzoate			rheumatology, urology	scleroderma, dermatomyositis, Peyronie's disease	MedChemEx, MicroSource, MicroSource, MicroSource	100	Nc1ccc(cc1)C(O)=O, Nc1ccc(cc1)C(O)=O, Nc1ccc(cc1)C(O)=O, Nc1ccc(cc1)C(O)=O	Launched
pozanicline	acetylcholine receptor antagonist	CHRNA4, CHRNB2			Sigma	98.79	Cc1ncccc1OC[C@@H]1CCCN1	Phase 2
poziotinib	EGFR inhibitor	EGFR, ERBB2, ERBB4			Adooq, Adooq, Adooq, Selleck, Selleck	99.66	COc1cc2ncnc(Nc3ccc(Cl)c(Cl)c3F)c2cc1OC1CCN(CC1)C(=O)C=C, COc1cc2ncnc(Nc3ccc(Cl)c(Cl)c3F)c2cc1OC1CCN(CC1)C(=O)C=C, COc1cc2ncnc(Nc3ccc(Cl)c(Cl)c3F)c2cc1OC1CCN(CC1)C(=O)C=C, COc1cc2ncnc(Nc3ccc(Cl)c(Cl)c3F)c2cc1OC1CCN(CC1)C(=O)C=C, COc1cc2ncnc(Nc3ccc(Cl)c(Cl)c3F)c2cc1OC1CCN(CC1)C(=O)C=C	Phase 2
PP-1	SRC inhibitor	HCK, RET			Selleck, Tocris, Tocris, Tocris	99.39	Cc1ccc(cc1)-c1nn(c2ncnc(N)c12)C(C)(C)C, Cc1ccc(cc1)-c1nn(c2ncnc(N)c12)C(C)(C)C, Cc1ccc(cc1)-c1nn(c2ncnc(N)c12)C(C)(C)C, Cc1ccc(cc1)-c1nn(c2ncnc(N)c12)C(C)(C)C	Preclinical
PP-121	protein tyrosine kinase inhibitor	ABL1, EGFR, HCK, KDR, MTOR, PDGFRA, PIK3CA, PIK3CB, PIK3CD, PIK3CG, PRKDC, SRC			Selleck, Tocris, Tocris, Tocris	97.69	Nc1ncnc2n(nc(-c3cnc4[nH]ccc4c3)c12)C1CCCC1, Nc1ncnc2n(nc(-c3cnc4[nH]ccc4c3)c12)C1CCCC1, Nc1ncnc2n(nc(-c3cnc4[nH]ccc4c3)c12)C1CCCC1, Nc1ncnc2n(nc(-c3cnc4[nH]ccc4c3)c12)C1CCCC1	Preclinical
PP-2	SRC inhibitor	ABL1, LCK, RIPK2, SRC			Selleck, Tocris, Tocris, Tocris, Tocris	99.23	CC(C)(C)n1nc(-c2ccc(Cl)cc2)c2c(N)ncnc12, CC(C)(C)n1nc(-c2ccc(Cl)cc2)c2c(N)ncnc12, CC(C)(C)n1nc(-c2ccc(Cl)cc2)c2c(N)ncnc12, CC(C)(C)n1nc(-c2ccc(Cl)cc2)c2c(N)ncnc12, CC(C)(C)n1nc(-c2ccc(Cl)cc2)c2c(N)ncnc12	Preclinical
PPT	estrogen receptor agonist	ESR1			Tocris, Tocris, Tocris, Tocris	97.84	CCCc1c(nn(c1-c1ccc(O)cc1)-c1ccc(O)cc1)-c1ccc(O)cc1, CCCc1c(nn(c1-c1ccc(O)cc1)-c1ccc(O)cc1)-c1ccc(O)cc1, CCCc1c(nn(c1-c1ccc(O)cc1)-c1ccc(O)cc1)-c1ccc(O)cc1, CCCc1c(nn(c1-c1ccc(O)cc1)-c1ccc(O)cc1)-c1ccc(O)cc1	Preclinical
PPY-A	Abl kinase inhibitor	ABL1, BCR			Tocris, Tocris, Tocris, Tocris, Tocris	99.07	COc1ccccc1-c1c[nH]c2ncc(cc12)-c1cncc(c1)C(=O)N(C)C, COc1ccccc1-c1c[nH]c2ncc(cc12)-c1cncc(c1)C(=O)N(C)C, COc1ccccc1-c1c[nH]c2ncc(cc12)-c1cncc(c1)C(=O)N(C)C, COc1ccccc1-c1c[nH]c2ncc(cc12)-c1cncc(c1)C(=O)N(C)C, COc1ccccc1-c1c[nH]c2ncc(cc12)-c1cncc(c1)C(=O)N(C)C	Preclinical
PP242	mTOR inhibitor	MTOR, PASK			Selleck, Tocris, Tocris, Selleck	89.25	CC(C)n1nc(-c2cc3cc(O)ccc3[nH]2)c2c(N)ncnc12, CC(C)n1nc(-c2cc3cc(O)ccc3[nH]2)c2c(N)ncnc12, CC(C)n1nc(-c2cc3cc(O)ccc3[nH]2)c2c(N)ncnc12, CC(C)n1nc(-c2cc3cc(O)ccc3[nH]2)c2c(N)ncnc12	Preclinical
PQ-401	IGF-1 inhibitor	IGF1R			Selleck, Tocris, Tocris, Tocris, Tocris, Tocris, Tocris, Tocris, Tocris, Tocris	97.12	COc1ccc(Cl)cc1NC(=O)Nc1cc(C)nc2ccccc12, COc1ccc(Cl)cc1NC(=O)Nc1cc(C)nc2ccccc12, COc1ccc(Cl)cc1NC(=O)Nc1cc(C)nc2ccccc12, COc1ccc(Cl)cc1NC(=O)Nc1cc(C)nc2ccccc12, COc1ccc(Cl)cc1NC(=O)Nc1cc(C)nc2ccccc12, COc1ccc(Cl)cc1NC(=O)Nc1cc(C)nc2ccccc12, COc1ccc(Cl)cc1NC(=O)Nc1cc(C)nc2ccccc12, COc1ccc(Cl)cc1NC(=O)Nc1cc(C)nc2ccccc12, COc1ccc(Cl)cc1NC(=O)Nc1cc(C)nc2ccccc12, COc1ccc(Cl)cc1NC(=O)Nc1cc(C)nc2ccccc12	Preclinical
PR-619	DUB inhibitor				Tocris, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck	95.84	Nc1nc(N)c(SC#N)cc1SC#N, Nc1nc(N)c(SC#N)cc1SC#N, Nc1nc(N)c(SC#N)cc1SC#N, Nc1nc(N)c(SC#N)cc1SC#N, Nc1nc(N)c(SC#N)cc1SC#N, Nc1nc(N)c(SC#N)cc1SC#N, Nc1nc(N)c(SC#N)cc1SC#N	Preclinical
practolol	adrenergic receptor antagonist	ADRB1			Sigma, Prestwick	87.63	CC(C)NC[C@@H](O)COc1ccc(NC(C)=O)cc1 |&1:5,r|, CC(C)NC[C@@H](O)COc1ccc(NC(C)=O)cc1 |&1:5,r|	Withdrawn
pradefovir	cytochrome P450 activator				MedChemEx	97.65	Nc1ncnc2n(CCOC[P@@]3(=O)OCC[C@H](O3)c3cccc(Cl)c3)cnc12	Phase 2
pralatrexate	dihydrofolate reductase inhibitor	DHFR	hematologic malignancy	peripheral T-cell lymphoma (PTCL)	Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck	97.35	Nc1nc(N)c2nc(C[C@@H](CC#C)c3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)cnc2n1 |a:22,&1:9|, Nc1nc(N)c2nc(C[C@@H](CC#C)c3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)cnc2n1 |a:22,&1:9|, Nc1nc(N)c2nc(C[C@@H](CC#C)c3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)cnc2n1 |a:22,&1:9|, Nc1nc(N)c2nc(C[C@@H](CC#C)c3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)cnc2n1 |a:22,&1:9|, Nc1nc(N)c2nc(C[C@@H](CC#C)c3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)cnc2n1 |a:22,&1:9|, Nc1nc(N)c2nc(C[C@@H](CC#C)c3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)cnc2n1 |a:22,&1:9|, Nc1nc(N)c2nc(C[C@@H](CC#C)c3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)cnc2n1 |a:22,&1:9|	Launched
pralidoxime	acetylcholinesterase inhibitor	ACHE, BCHE	critical care	organophosphate poisoning	MicroSource, MicroSource, MedChemEx, MedChemEx	96.7	C[n+]1ccccc1\C=N\O, C[n+]1ccccc1\C=N\O, C[n+]1ccccc1\C=N\O, C[n+]1ccccc1\C=N\O	Launched
pralidoxime-chloride	acetylcholinesterase inhibitor	ACHE, BCHE	pulmonary	respiratory depression	Sigma, Sigma	97.1	C[n+]1ccccc1CN=O, C[n+]1ccccc1CN=O	Launched
pralmorelin	growth hormone releasing peptide ligand agonist				Sigma	91.62	C[C@@H](N)C(=O)N[C@H](Cc1ccc2ccccc2c1)C(=O)N[C@@H](C)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@H](Cc1ccccc1)C(=O)N[C@@H](CCCCN)C(N)=O	Launched
pramipexole	dopamine receptor agonist	ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C	neurology/psychiatry	Parkinson's Disease	Tocris, Tocris, Selleck, Selleck	100	CCCN[C@H]1CCc2nc(N)sc2C1, CCCN[C@H]1CCc2nc(N)sc2C1, CCCN[C@H]1CCc2nc(N)sc2C1, CCCN[C@H]1CCc2nc(N)sc2C1	Launched
pramiracetam	acetylcholine receptor agonist		neurology/psychiatry	senile dementia	Selleck, MedChemEx	93.06	CC(C)N(CCNC(=O)CN1CCCC1=O)C(C)C, CC(C)N(CCNC(=O)CN1CCCC1=O)C(C)C	Launched
pramoxine	topical anesthetic		dermatology	corticosteroid-responsive dermatoses	MedChemEx, Selleck, MicroSource	95.87	CCCCOc1ccc(OCCCN2CCOCC2)cc1, CCCCOc1ccc(OCCCN2CCOCC2)cc1, CCCCOc1ccc(OCCCN2CCOCC2)cc1	Launched
pranidipine	calcium channel blocker	CACNA1C			AKSci, AKSci, AKSci, AKSci, AKSci	98.76	COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC\C=C\c1ccccc1 |r,c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC\C=C\c1ccccc1 |r,c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC\C=C\c1ccccc1 |r,c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC\C=C\c1ccccc1 |r,c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC\C=C\c1ccccc1 |r,c:4,9|	Phase 2
pranlukast	leukotriene receptor antagonist	CYSLTR1, CYSLTR2, IL5, MUC2, NFKB1, RNASE3, TNF	pulmonary	bronchospasm, asthma	MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx, Tocris, Tocris, Selleck, Selleck, Selleck, Selleck	99.8	O=C(Nc1cccc2c1oc(cc2=O)-c1nn[nH]n1)c1ccc(OCCCCc2ccccc2)cc1, O=C(Nc1cccc2c1oc(cc2=O)-c1nn[nH]n1)c1ccc(OCCCCc2ccccc2)cc1, O=C(Nc1cccc2c1oc(cc2=O)-c1nn[nH]n1)c1ccc(OCCCCc2ccccc2)cc1, O=C(Nc1cccc2c1oc(cc2=O)-c1nn[nH]n1)c1ccc(OCCCCc2ccccc2)cc1, O=C(Nc1cccc2c1oc(cc2=O)-c1nn[nH]n1)c1ccc(OCCCCc2ccccc2)cc1, O=C(Nc1cccc2c1oc(cc2=O)-c1nn[nH]n1)c1ccc(OCCCCc2ccccc2)cc1, O=C(Nc1cccc2c1oc(cc2=O)-c1nn[nH]n1)c1ccc(OCCCCc2ccccc2)cc1, O=C(Nc1cccc2c1oc(cc2=O)-c1nn[nH]n1)c1ccc(OCCCCc2ccccc2)cc1, O=C(Nc1cccc2c1oc(cc2=O)-c1nn[nH]n1)c1ccc(OCCCCc2ccccc2)cc1, O=C(Nc1cccc2c1oc(cc2=O)-c1nn[nH]n1)c1ccc(OCCCCc2ccccc2)cc1, O=C(Nc1cccc2c1oc(cc2=O)-c1nn[nH]n1)c1ccc(OCCCCc2ccccc2)cc1, O=C(Nc1cccc2c1oc(cc2=O)-c1nn[nH]n1)c1ccc(OCCCCc2ccccc2)cc1	Launched
pranoprofen	cyclooxygenase inhibitor		neurology/psychiatry	pain relief	MicroSource, Selleck, MedChemEx, Selleck	98.99	C[C@@H](C(O)=O)c1ccc2Oc3ncccc3Cc2c1 |&1:1,r|, C[C@@H](C(O)=O)c1ccc2Oc3ncccc3Cc2c1 |&1:1,r|, C[C@@H](C(O)=O)c1ccc2Oc3ncccc3Cc2c1 |&1:1,r|, C[C@@H](C(O)=O)c1ccc2Oc3ncccc3Cc2c1 |&1:1,r|	Launched
prasterone-acetate					MedChemEx	80.86	CC(=O)O[C@H]1CC[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](CCC4=O)[C@@H]3CC=C2C1 |c:23|	Preclinical
prasugrel	purinergic receptor antagonist	P2RY12	cardiology	myocardial infarction, acute coronary syndrome (ACS)	MedChemEx, MedChemEx, MedChemEx, Selleck, Selleck, Selleck, MedChemEx	93.69	CC(=O)Oc1cc2CN(CCc2s1)[C@@H](C(=O)C1CC1)c1ccccc1F |&1:13,r|, CC(=O)Oc1cc2CN(CCc2s1)[C@@H](C(=O)C1CC1)c1ccccc1F |&1:13,r|, CC(=O)Oc1cc2CN(CCc2s1)[C@@H](C(=O)C1CC1)c1ccccc1F |&1:13,r|, CC(=O)Oc1cc2CN(CCc2s1)[C@@H](C(=O)C1CC1)c1ccccc1F |&1:13,r|, CC(=O)Oc1cc2CN(CCc2s1)[C@@H](C(=O)C1CC1)c1ccccc1F |&1:13,r|, CC(=O)Oc1cc2CN(CCc2s1)[C@@H](C(=O)C1CC1)c1ccccc1F |&1:13,r|, CC(=O)Oc1cc2CN(CCc2s1)[C@@H](C(=O)C1CC1)c1ccccc1F |&1:13,r|	Launched
pravadoline	cyclooxygenase inhibitor	CNR1, CNR2			Cayman	99.34	COc1ccc(cc1)C(=O)c1c(C)n(CCN2CCOCC2)c2ccccc12	Preclinical
pravastatin	HMGCR inhibitor	HMGCR, SLCO1B1	endocrinology, cardiology	hypercholesterolemia, myocardial infarction, hyperlipidemia	Tocris, Tocris, Tocris, Tocris, Selleck, Selleck	95.56	CC[C@H](C)C(=O)O[C@H]1C[C@H](O)C=C2C=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@@H]12 |c:13,t:11|, CC[C@H](C)C(=O)O[C@H]1C[C@H](O)C=C2C=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@@H]12 |c:13,t:11|, CC[C@H](C)C(=O)O[C@H]1C[C@H](O)C=C2C=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@@H]12 |c:13,t:11|, CC[C@H](C)C(=O)O[C@H]1C[C@H](O)C=C2C=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@@H]12 |c:13,t:11|, CC[C@H](C)C(=O)O[C@H]1C[C@H](O)C=C2C=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@@H]12 |c:13,t:11|, CC[C@H](C)C(=O)O[C@H]1C[C@H](O)C=C2C=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@@H]12 |c:13,t:11|	Launched
praziquantel	anthelmintic agent		infectious disease	gastrointestinal parasites, cystic hydatid disease, schistosomiasis	Selleck, MicroSource	99.62	O=C(C1CCCCC1)N1C[C@H]2N(CCc3ccccc23)C(=O)C1 |&1:10,r|, O=C(C1CCCCC1)N1C[C@H]2N(CCc3ccccc23)C(=O)C1 |&1:10,r|	Launched
prazosin	adrenergic receptor antagonist	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, KCNH2, KCNH6, KCNH7	cardiology	hypertension	Tocris, Tocris, MicroSource, Selleck, Selleck, Tocris	98.79	COc1cc2nc(nc(N)c2cc1OC)N1CCN(CC1)C(=O)c1ccco1, COc1cc2nc(nc(N)c2cc1OC)N1CCN(CC1)C(=O)c1ccco1, COc1cc2nc(nc(N)c2cc1OC)N1CCN(CC1)C(=O)c1ccco1, COc1cc2nc(nc(N)c2cc1OC)N1CCN(CC1)C(=O)c1ccco1, COc1cc2nc(nc(N)c2cc1OC)N1CCN(CC1)C(=O)c1ccco1, COc1cc2nc(nc(N)c2cc1OC)N1CCN(CC1)C(=O)c1ccco1	Launched
PRE-084	sigma receptor agonist	SIGMAR1			Tocris, Tocris, Tocris, Tocris	97.96	O=C(OCCN1CCOCC1)C1(CCCCC1)c1ccccc1, O=C(OCCN1CCOCC1)C1(CCCCC1)c1ccccc1, O=C(OCCN1CCOCC1)C1(CCCCC1)c1ccccc1, O=C(OCCN1CCOCC1)C1(CCCCC1)c1ccccc1	Preclinical
preclamol	dopamine receptor agonist	DRD2			SantaCruz, SantaCruz	91.07	CCCN1CCC[C@@H](C1)c1cccc(O)c1, CCCN1CCC[C@@H](C1)c1cccc(O)c1	Phase 2
prednicarbate	phospholipase activator	PLA2G1B	dermatology, ophthalmology, neurology/psychiatry	eczema, contact dermatitis, itching	MicroSource	0	CCOC(=O)O[C@@]1(CC[C@H]2[C@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@H]3[C@@H](O)C[C@]12C)C(=O)COC(=O)CC |a:6,19,22,25,&1:9,&2:10,&3:21,c:17,t:13|	Launched
prednisolone	glucocorticoid receptor agonist	NR3C1, NR3C2, SERPINA6	ophthalmology, dermatology, infectious disease	conjunctivitis, rosacea, punctate keratitis, shingles, iritis, cyclitis	MicroSource, MicroSource, MicroSource, Selleck, Selleck	96.97	C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO |a:1,3,15,20,&1:5,&2:6,&3:17,c:13,t:9|, C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO |a:1,3,15,20,&1:5,&2:6,&3:17,c:13,t:9|, C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO |a:1,3,15,20,&1:5,&2:6,&3:17,c:13,t:9|, C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO |a:1,3,15,20,&1:5,&2:6,&3:17,c:13,t:9|, C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO |a:1,3,15,20,&1:5,&2:6,&3:17,c:13,t:9|	Launched
prednisolone-acetate	glucocorticoid receptor agonist	NR3C1	ophthalmology, dermatology, infectious disease	conjunctivitis, rosacea, punctate keratitis, shingles, iritis, cyclitis	Selleck, MicroSource, Selleck, MedChemEx	97.37	CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C |c:19,t:15|, CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@H]3CCC4=CC(=O)C=C[C@@]4(C)[C@@H]3[C@@H](O)C[C@]12C |a:7,24,27,&1:11,&2:12,&3:21,&4:23,c:19,t:15|, CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C |c:19,t:15|, CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C |c:19,t:15|	Launched
prednisolone-hemisuccinate	glucocorticoid receptor agonist	NR3C1			MicroSource	95.56	C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1CC[C@]2(O)C(=O)COC(=O)CCC(O)=O |a:1,3,15,20,&1:5,&2:6,&3:17,c:13,t:9|	Preclinical
prednisolone-sodium-phosphate	glucocorticoid receptor agonist	NR3C1	allergy, pulmonary, ophthalmology, infectious disease, rheumatology, endocrinology, neurology/psychiatry, gastroenterology, hematology	allergic rhinitis, asthma, contact dermatitis, mycosis, lupus, hypercalcemia, thyroiditis, congenital adrenal hyperplasia, multiple sclerosis, ulcerative colitis, enteritis, thrombocythemia, pneumonia, meningitis, psoriatic arthritis, rheumatoid arthritis	MedChemEx	87.18	[H][C@@]12CC[C@](O)(C(=O)COP(O)(O)=O)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C |c:31,t:27|	Launched
prednisolone-tebutate	anti-inflammatory agent				MicroSource	96.64	CC(C)(C)CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@H]3[C@@H](O)C[C@]12C |a:11,25,28,31,&1:15,&2:16,&3:27,c:23,t:19|	Launched
prednisone	glucocorticoid receptor agonist	HSD11B1, NR3C1	endocrinology, rheumatology, infectious disease, dermatology, ophthalmology, hematology, gastroenterology, neurology/psychiatry	congenital adrenal hyperplasia, hypercalcemia, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, bursitis, osteoarthritis, epicondylitis, dermatomyositis, psoriasis, mycosis, conjunctivitis, anemia, ulcerative colitis, enteritis, multiple sclerosis, meningitis	MedChemEx, MedChemEx, Selleck, MicroSource, Selleck	95.73	C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO |c:13,t:9|, C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO |c:13,t:9|, C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO |c:13,t:9|, C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO |c:13,t:9|, C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO |c:13,t:9|	Launched
pregnenolone	glutamate receptor modulator	SULT2B1	rheumatology	rheumatoid arthritis	MedChemEx, MicroSource, Selleck, Selleck	98.34	CC(=O)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C |t:9|, CC(=O)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C |t:9|, CC(=O)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C |t:9|, CC(=O)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C |t:9|	Launched
pregnenolone-succinate	GABA receptor negative allosteric modulator	CYP17A1			MicroSource, MicroSource	99.33	CC(=O)[C@H]1CC[C@H]2[C@H]3CC=C4C[C@H](CC[C@]4(C)[C@@H]3CC[C@]12C)OC(=O)CCC(O)=O |a:3,12,15,20,&1:6,&2:7,&3:17,t:9|, CC(=O)[C@H]1CC[C@H]2[C@H]3CC=C4C[C@H](CC[C@]4(C)[C@@H]3CC[C@]12C)OC(=O)CCC(O)=O |a:3,12,15,20,&1:6,&2:7,&3:17,t:9|	Preclinical
preladenant	adenosine receptor antagonist	ADORA1, ADORA2A, ADORA2B, ADORA3			MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx	94.76	COCCOc1ccc(cc1)N1CCN(CCn2ncc3c2nc(N)n2nc(nc32)-c2ccco2)CC1, COCCOc1ccc(cc1)N1CCN(CCn2ncc3c2nc(N)n2nc(nc32)-c2ccco2)CC1, COCCOc1ccc(cc1)N1CCN(CCn2ncc3c2nc(N)n2nc(nc32)-c2ccco2)CC1, COCCOc1ccc(cc1)N1CCN(CCn2ncc3c2nc(N)n2nc(nc32)-c2ccco2)CC1, COCCOc1ccc(cc1)N1CCN(CCn2ncc3c2nc(N)n2nc(nc32)-c2ccco2)CC1	Phase 3
prenylamine	calcium channel blocker				Prestwick, Prestwick, Prestwick, Prestwick	98.2	C[C@@H](Cc1ccccc1)NCCC(c1ccccc1)c1ccccc1 |&2:1|, C[C@@H](Cc1ccccc1)NCCC(c1ccccc1)c1ccccc1 |&2:1|, C[C@@H](Cc1ccccc1)NCCC(c1ccccc1)c1ccccc1 |&2:1|, C[C@@H](Cc1ccccc1)NCCC(c1ccccc1)c1ccccc1 |&2:1|	Withdrawn
presatovir	RSV fusion inhibitor				MedChemEx, MedChemEx	95.26	Cc1cn2nc(cc2nc1N1CC[C@H](N)C1)[C@@H]1CCCCN1C(=O)c1cc(Cl)ccc1NS(C)(=O)=O, Cc1cn2nc(cc2nc1N1CC[C@H](N)C1)[C@@H]1CCCCN1C(=O)c1cc(Cl)ccc1NS(C)(=O)=O	Phase 2
pretomanid	nitric oxide donor	FASN			MedChemEx, Selleck	96.87	[O-][N+](=O)c1cn2C[C@@H](COc2n1)OCc1ccc(OC(F)(F)F)cc1, [O-][N+](=O)c1cn2C[C@@H](COc2n1)OCc1ccc(OC(F)(F)F)cc1	Launched
pridinol	muscle relaxant		neurology/psychiatry	muscle relaxant	Selleck, MicroSource, Selleck, Selleck	98.23	OC(CCN1CCCCC1)(c1ccccc1)c1ccccc1, OC(CCN1CCCCC1)(c1ccccc1)c1ccccc1, OC(CCN1CCCCC1)(c1ccccc1)c1ccccc1, OC(CCN1CCCCC1)(c1ccccc1)c1ccccc1	Launched
pridopidine	dopamine receptor antagonist				MedChemEx	94.48	CCCN1CCC(CC1)c1cccc(c1)S(C)(=O)=O	Phase 2
prilocaine	local anesthetic	SCN5A	neurology/psychiatry	anesthetic	MedChemEx, Selleck	91.74	CCCN[C@@H](C)C(=O)Nc1ccccc1C |&1:4,r|, CCCN[C@@H](C)C(=O)Nc1ccccc1C |&1:4,r|	Launched
primaquine	antimalarial agent, DNA inhibitor		infectious disease	malaria	MedChemEx	81.19	COc1cc(N[C@@H](C)CCCN)c2ncccc2c1 |r|	Launched
PRIMA1	TP53 inhibitor	ACHE			Tocris, Tocris, Tocris	100	OCC1(CO)N2CCC(CC2)C1=O, OCC1(CO)N2CCC(CC2)C1=O, OCC1(CO)N2CCC(CC2)C1=O	Preclinical
primidone	GABA receptor antagonist	CHRNA4, CHRNA7, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GRIA2, GRIK2, SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A	neurology/psychiatry	seizures	Selleck, Selleck, Tocris, Tocris, Tocris, MicroSource	99.02	CCC1(C(=O)NCNC1=O)c1ccccc1, CCC1(C(=O)NCNC1=O)c1ccccc1, CCC1(C(=O)NCNC1=O)c1ccccc1, CCC1(C(=O)NCNC1=O)c1ccccc1, CCC1(C(=O)NCNC1=O)c1ccccc1, CCC1(C(=O)NCNC1=O)c1ccccc1	Launched
prinaberel	estrogen receptor agonist	ESR2, NCOA1			MedChemEx	94.73	Oc1cc(C=C)c2oc(nc2c1)-c1ccc(O)c(F)c1	Phase 2
prinomastat	matrix metalloprotease inhibitor				MedChemEx	91.29	CC1(C)SCCN([C@H]1C(=O)NO)S(=O)(=O)c1ccc(Oc2ccncc2)cc1	Phase 3
priralfinamide	sodium channel blocker	CACNA1B			Tocris, AMS	98.67	C[C@H](NCc1ccc(OCc2ccccc2F)cc1)C(N)=O, C[C@H](NCc1ccc(OCc2ccccc2F)cc1)C(N)=O	Phase 3
prisotinol					Sigma	95.47	CC(C)N[C@H](C)Cc1ccc(O)cn1 |&1:4,r|	Phase 2
pritelivir	helicase primase inhibitor				MedChemEx, MedChemEx	98.06	CN(C(=O)Cc1ccc(cc1)-c1ccccn1)c1nc(C)c(s1)S(N)(=O)=O, CN(C(=O)Cc1ccc(cc1)-c1ccccn1)c1nc(C)c(s1)S(N)(=O)=O	Phase 2
PRLX-93936	voltage-dependent anion selective channel protein inhibitor				Key	92.91	CCOc1ccccc1-n1c(CN2CCNCC2)nc2ccccc2c1=O	Phase 1/Phase 2
PRN1008	Bruton's tyrosine kinase (BTK) inhibitor				MedChemEx	93.58	CC(C)(\C=C(/C#N)C(=O)N1CCC[C@H](C1)n1nc(-c2ccc(Oc3ccccc3)cc2F)c2c(N)ncnc12)N1CCN(CC1)C1COC1	Preclinical
PRN1371	protein tyrosine kinase inhibitor				MedChemEx	96.05	CNc1ncc2cc(-c3c(Cl)c(OC)cc(OC)c3Cl)c(=O)n(CCCN3CCN(CC3)C(=O)C=C)c2n1	Phase 1
proacipimox	cholesterol inhibitor				Enamine, Enamine	97.66	COCc1c[n+]([O-])c(C)cn1, COCc1c[n+]([O-])c(C)cn1	Phase 1
proadifen	nitric oxide synthase inhibitor	NOS1			Selleck, MicroSource, Selleck	93.97	CCCC(C(=O)OCCN(CC)CC)(c1ccccc1)c1ccccc1, CCCC(C(=O)OCCN(CC)CC)(c1ccccc1)c1ccccc1, CCCC(C(=O)OCCN(CC)CC)(c1ccccc1)c1ccccc1	Preclinical
probenecid	uricosuric blocker	PANX1, SLC22A11, SLC22A6, SLC22A8, SLCO1C1	nephrology, rheumatology	hyperuricemia, gout	Tocris, MicroSource, Tocris, Tocris, Selleck	98.66	CCCN(CCC)S(=O)(=O)c1ccc(cc1)C(O)=O, CCCN(CCC)S(=O)(=O)c1ccc(cc1)C(O)=O, CCCN(CCC)S(=O)(=O)c1ccc(cc1)C(O)=O, CCCN(CCC)S(=O)(=O)c1ccc(cc1)C(O)=O, CCCN(CCC)S(=O)(=O)c1ccc(cc1)C(O)=O	Launched
probucol	atherogenesis inhibitor	ABCA1, ABCB11, CES1	cardiology	coronary artery disease (CAD)	MicroSource, Tocris, Tocris, Selleck, Selleck	93.74	CC(C)(Sc1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C)Sc1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C, CC(C)(Sc1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C)Sc1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C, CC(C)(Sc1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C)Sc1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C, CC(C)(Sc1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C)Sc1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C, CC(C)(Sc1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C)Sc1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C	Launched
procainamide	sodium channel blocker	DNMT1, SCN5A	cardiology	ventricular arrhythmias, ventricular tachycardia (VT)	MedChemEx, MedChemEx, MicroSource, MicroSource	98.44	CCN(CC)CCNC(=O)c1ccc(N)cc1, CCN(CC)CCNC(=O)c1ccc(N)cc1, CCN(CC)CCNC(=O)c1ccc(N)cc1, CCN(CC)CCNC(=O)c1ccc(N)cc1	Launched
procaine	HMGCR inhibitor	CHRNA2, GRIN3A, HTR3A, KCNMA1, KCNMB1, KCNMB2, KCNMB3, KCNMB4, KCNN1, KCNN2, KCNN3, KCNN4, MAOA, MAOB, RYR1, RYR2, SCN10A, SLC6A3	neurology/psychiatry	anesthetic	MicroSource, Selleck	99.21	CCN(CC)CCOC(=O)c1ccc(N)cc1, CCN(CC)CCOC(=O)c1ccc(N)cc1	Launched
procarbazine	monoamine oxidase inhibitor		hematologic malignancy	Hodgkin's lymphoma	MicroSource, Selleck, Selleck, MedChemEx	47.77	CNNCc1ccc(cc1)C(=O)NC(C)C, CNNCc1ccc(cc1)C(=O)NC(C)C, CNNCc1ccc(cc1)C(=O)NC(C)C, CNNCc1ccc(cc1)C(=O)NC(C)C	Launched
procaterol	adrenergic receptor agonist	ADRB2	pulmonary	asthma	Tocris, Tocris, Tocris, Tocris	97.34	CC[C@H](NC(C)C)[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12, CC[C@H](NC(C)C)[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12, CC[C@H](NC(C)C)[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12, CC[C@H](NC(C)C)[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12	Launched
prochlorperazine	dopamine receptor antagonist	DRD1, DRD2, DRD3, DRD4	gastroenterology	nausea, vomiting	Tocris, Selleck, Selleck, MicroSource, MicroSource, Selleck	93.5	CN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc23)CC1, CN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc23)CC1, CN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc23)CC1, CN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc23)CC1, CN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc23)CC1, CN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc23)CC1	Launched
procodazole	immunostimulant				MicroSource, Selleck	98.53	OC(=O)CCc1nc2ccccc2[nH]1, OC(=O)CCc1nc2ccccc2[nH]1	Preclinical
procyanidin-B-2					MedChemEx, SantaCruz, SantaCruz	81.99	O[C@H]1Cc2c(O)cc(O)c([C@@H]3[C@@H](O)[C@H](Oc4cc(O)cc(O)c34)c3ccc(O)c(O)c3)c2O[C@@H]1c1ccc(O)c(O)c1, O[C@H]1Cc2c(O)cc(O)c([C@@H]3[C@@H](O)[C@H](Oc4cc(O)cc(O)c34)c3ccc(O)c(O)c3)c2O[C@@H]1c1ccc(O)c(O)c1, O[C@H]1Cc2c(O)cc(O)c([C@@H]3[C@@H](O)[C@H](Oc4cc(O)cc(O)c34)c3ccc(O)c(O)c3)c2O[C@@H]1c1ccc(O)c(O)c1	Phase 2
procyclidine	acetylcholine receptor antagonist		neurology/psychiatry	parkinsonism, Parkinson's Disease, akathisia, dystonia	MedChemEx	92.08	COc1cc(N[C@@H](C)CCCN)c2ncccc2c1 |&1:6|	Launched
procysteine	glutathione synthase stimulant				Sigma, Sigma	93.1	OC(=O)[C@@H]1CSC(=O)N1, OC(=O)[C@@H]1CSC(=O)N1	Phase 3
profenamine	butyrylcholinesterase inhibitor, cholinergic receptor antagonist	CHRM1	neurology/psychiatry	Parkinson's Disease	MicroSource, Sigma	45.81	CCN(CC)[C@@H](C)CN1c2ccccc2Sc2ccccc12 |&1:5|, CCN(CC)[C@@H](C)CN1c2ccccc2Sc2ccccc12 |&1:5|	Launched
proflavine-hemisulfate	topical anesthetic	F2			MicroSource, MicroSource, MicroSource, MedChemEx	87.04	Nc1ccc2cc3ccc(N)cc3nc2c1, Nc1ccc2cc3ccc(N)cc3nc2c1, Nc1ccc2cc3ccc(N)cc3nc2c1, Nc1ccc2cc3ccc(N)cc3nc2c1	Phase 2
progesterone	progesterone receptor agonist	CATSPER1, CATSPER2, CATSPER3, CATSPER4, CYP17A1, ESR1, NR3C2, OPRK1, PGR, TRPC5	obstetrics/gynecology, endocrinology	infertility, amenorrhea	MicroSource, Selleck	97.71	CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C |t:10|, CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C |t:10|	Launched
proglumetacin	cyclooxygenase inhibitor	PTGS1, PTGS2	neurology/psychiatry	pain relief	AKSci	0	CCCN(CCC)C(=O)[C@@H](CCC(=O)OCCCN1CCN(CCOC(=O)Cc2c(C)n(C(=O)c3ccc(Cl)cc3)c3ccc(OC)cc23)CC1)NC(=O)c1ccccc1 |&1:9,r|	Launched
proglumide	CCK receptor antagonist	CCKAR, CCKBR			Tocris	94.44	CCCN(CCC)C(=O)[C@@H](CCC(O)=O)NC(=O)c1ccccc1 |&1:9|	Withdrawn
proguanil	dihydrofolate reductase inhibitor	DHFR	infectious disease	malaria	MicroSource, MicroSource	92.08	CC(C)NC(=N)N=C(N)Nc1ccc(Cl)cc1, CC(C)NC(=N)N=C(N)Nc1ccc(Cl)cc1	Launched
prolylleucylglycinamide	melanocyte-stimulating hormone release inhibitor				Pharmeks	32.9	CC(C)C[C@@H](NC(=O)[C@H]1CCCN1)C(=O)NCC(N)=O |&1:4,&2:8,r|	Phase 2
promazine	dopamine receptor antagonist	ADRA1A, ADRA1B, ADRA1D, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD1, DRD2, DRD3, DRD4, HRH1, HTR2A, HTR2C	neurology/psychiatry	schizophrenia	MedChemEx, MicroSource	94.85	CN(C)CCCN1c2ccccc2Sc2ccccc12, CN(C)CCCN1c2ccccc2Sc2ccccc12	Launched
promestriene	estrogen receptor agonist	ESR1	endocrinology	androgenetic alopecia	Carbosynth	0	CCCOc1ccc2[C@H]3CC[C@]4(C)[C@H](CC[C@H]4[C@@H]3CCc2c1)OC	Launched
promethazine	histamine receptor antagonist	HRH1	neurology/psychiatry, allergy	sedative, allergic rhinitis	MedChemEx, MedChemEx, MedChemEx, MicroSource	88.98	CC(CN1c2ccccc2Sc2ccccc12)N(C)C, CC(CN1c2ccccc2Sc2ccccc12)N(C)C, CC(CN1c2ccccc2Sc2ccccc12)N(C)C, CC(CN1c2ccccc2Sc2ccccc12)N(C)C	Launched
pronethalol	adrenergic receptor antagonist				Tocris	97.29	CC(C)NC[C@@H](O)c1ccc2ccccc2c1 |&1:5,r|	Withdrawn
propacetamol	cyclooxygenase inhibitor	PTGS2	endocrinology, neurology/psychiatry	fever, pain relief	AKSci	94.37	CCN(CC)CC(=O)Oc1ccc(NC(C)=O)cc1	Launched
propafenone	antiarrhythmic	ADRB1, ADRB2, KCNA5, KCNH2	cardiology	atrial fibrillation (AF), ventricular tachycardia (VT), ventricular arrhythmias	MedChemEx, MedChemEx, Selleck	96.96	CCCNC[C@@H](O)COc1ccccc1C(=O)CCc1ccccc1 |&1:5,r|, CCCNC[C@@H](O)COc1ccccc1C(=O)CCc1ccccc1 |&1:5,r|, CCCNC[C@@H](O)COc1ccccc1C(=O)CCc1ccccc1 |&1:5,r|	Launched
propagermanium	CCR agonist, interferon receptor agonist	CCR2	infectious disease	hepatitis B	Sigma	0	OC(=O)CC[Ge](=O)O[Ge](=O)CCC(O)=O	Launched
propantheline	acetylcholine receptor antagonist	CHRM1, CHRM2, CHRM3, CHRM4	gastroenterology	peptic ulcer disease (PUD)	MedChemEx, MedChemEx, MicroSource	94.6	CC(C)[N+](C)(CCOC(=O)C1c2ccccc2Oc2ccccc12)C(C)C, CC(C)[N+](C)(CCOC(=O)C1c2ccccc2Oc2ccccc12)C(C)C, CC(C)[N+](C)(CCOC(=O)C1c2ccccc2Oc2ccccc12)C(C)C	Launched
propatylnitrate			cardiology	angina pectoris	Sigma, Sigma	94.44	CCC(CO[N+]([O-])=O)(CO[N+]([O-])=O)CO[N+]([O-])=O, CCC(CO[N+]([O-])=O)(CO[N+]([O-])=O)CO[N+]([O-])=O	Launched
propentofylline	adenosine reuptake inhibitor, phosphodiesterase inhibitor	PDE1A	neurology/psychiatry	stroke	Enzo, Sigma	95.57	CCCn1cnc2n(C)c(=O)n(CCCCC(C)=O)c(=O)c12, CCCn1cnc2n(C)c(=O)n(CCCCC(C)=O)c(=O)c12	Launched
propidium-iodide		ACHE			Tocris, Prestwick	94.88	CC[N+](C)(CC)CCC[n+]1c(-c2ccccc2)c2cc(N)ccc2c2ccc(N)cc12, CC[N+](C)(CC)CCC[n+]1c(-c2ccccc2)c2cc(N)ccc2c2ccc(N)cc12	Preclinical
propiolactone			infectious disease	antiseptic	MicroSource, Sigma	20	O=C1CCO1, O=C1CCO1	Launched
propiverine	acetylcholine receptor antagonist	CHRM1	urology	urinary incontinence	Sigma	97.84	CCCOC(C(=O)OC1CCN(C)CC1)(c1ccccc1)c1ccccc1	Launched
propofol	benzodiazepine receptor agonist	FAAH, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, SCN2A, SCN4A	neurology/psychiatry	anesthetic	MicroSource, Enamine	76.91	CC(C)c1cccc(C(C)C)c1O, CC(C)c1cccc(C(C)C)c1O	Launched
propoxur			infectious disease	flea control	MedChemEx, MicroSource	93.11	CNC(=O)Oc1ccccc1OC(C)C, CNC(=O)Oc1ccccc1OC(C)C	Launched
propoxycaine	local anesthetic		neurology/psychiatry	anesthetic	MedChemEx, MicroSource, MicroSource, MicroSource	98.96	CCCOc1cc(N)ccc1C(=O)OCCN(CC)CC, CCCOc1cc(N)ccc1C(=O)OCCN(CC)CC, CCCOc1cc(N)ccc1C(=O)OCCN(CC)CC, CCCOc1cc(N)ccc1C(=O)OCCN(CC)CC	Launched
propranolol	adrenergic receptor antagonist	ADRB1, ADRB2	cardiology, neurology/psychiatry	hypertension, angina pectoris, migraine headache	MicroSource, MicroSource, Selleck, Tocris	99.3	CC(C)NCC(O)COc1cccc2ccccc12, CC(C)NCC(O)COc1cccc2ccccc12, CC(C)NCC(O)COc1cccc2ccccc12, CC(C)NCC(O)COc1cccc2ccccc12	Launched
propranolol-(R)	adrenergic receptor antagonist	ADRB2, ADRB3			Tocris, Tocris, Tocris	98.07	CC(C)NC[C@@H](O)COc1cccc2ccccc12, CC(C)NC[C@@H](O)COc1cccc2ccccc12, CC(C)NC[C@@H](O)COc1cccc2ccccc12	Preclinical
propranolol-(S)	adrenergic receptor antagonist	ADRB1, HTR1A, HTR5A, SLC10A1			Tocris, Tocris, Tocris, MicroSource	97.96	CC(C)NC[C@H](O)COc1cccc2ccccc12, CC(C)NC[C@H](O)COc1cccc2ccccc12, CC(C)NC[C@H](O)COc1cccc2ccccc12, CC(C)NC[C@H](O)COc1cccc2ccccc12	Preclinical
propyl-benzoate					Enamine, Sigma	9.32	CCCOC(=O)c1ccccc1, CCCOC(=O)c1ccccc1	Launched
propylene-glycol					Sigma	0	C[C@@H](O)CO |&1:1,r|	Launched
propylhexedrine	adrenergic receptor agonist		otolaryngology, endocrinology, allergy	nasal congestion, fever, allergic rhinitis	PrincetonBio	76.33	CN[C@@H](C)CC1CCCCC1 |&1:2,r|	Launched
propylparaben					MedChemEx, ChemDiv	96.88	CCCOC(=O)c1ccc(O)cc1, CCCOC(=O)c1ccc(O)cc1	Launched
propylthiouracil	thyroid peroxidase inhibitor	DIO1, TPO	endocrinology	hyperthyroidism, Grave's disease, goiter	MicroSource, Selleck	97.48	CCCc1cc(=O)[nH]c(=S)[nH]1, CCCc1cc(=O)[nH]c(=S)[nH]1	Launched
propyphenazone	anti-inflammatory agent				MedChemEx	89.98	CC(C)c1c(C)n(C)n(-c2ccccc2)c1=O	Preclinical
proquazone	cyclooxygenase inhibitor	PTGS1, PTGS2	neurology/psychiatry	pain relief	AMS, AMS	97	CC(C)n1c2cc(C)ccc2c(nc1=O)-c1ccccc1, CC(C)n1c2cc(C)ccc2c(nc1=O)-c1ccccc1	Launched
proscillaridin-A			cardiology	congestive heart failure, cardiac arrythmia	Toronto, Toronto, Toronto	97.98	C[C@@H]1O[C@@H](O[C@H]2CC[C@]3(C)[C@H]4CC[C@]5(C)[C@H](CC[C@]5(O)[C@@H]4CCC3=C2)c2ccc(=O)oc2)[C@H](O)[C@H](O)[C@H]1O |c:26|, C[C@@H]1O[C@@H](O[C@H]2CC[C@]3(C)[C@H]4CC[C@]5(C)[C@H](CC[C@]5(O)[C@@H]4CCC3=C2)c2ccc(=O)oc2)[C@H](O)[C@H](O)[C@H]1O |c:26|, C[C@@H]1O[C@@H](O[C@H]2CC[C@]3(C)[C@H]4CC[C@]5(C)[C@H](CC[C@]5(O)[C@@H]4CCC3=C2)c2ccc(=O)oc2)[C@H](O)[C@H](O)[C@H]1O |c:26|	Launched
protionamide			infectious disease	tuberculosis	MicroSource, MedChemEx, Selleck	94.39	CCCc1cc(ccn1)C(N)=S, CCCc1cc(ccn1)C(N)=S, CCCc1cc(ccn1)C(N)=S	Launched
protirelin	thyrotropin releasing hormone receptor agonist	TRHR	radiology	thyroid function diagnostic	MedChemEx	92.56	NC(=O)[C@@H]1CCCN1C(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H]1CCC(=O)N1	Launched
protoporphyrin-IX	heme oxygenase inhibitor	HMOX1			MedChemEx, MicroSource	62.13	Cc1c(C=C)c2cc3[nH]c(cc4[nH]c(cc5nc(cc1n2)c(C=C)c5C)c(C)c4CCC(O)=O)c(CCC(O)=O)c3C, Cc1c(C=C)c2cc3[nH]c(cc4[nH]c(cc5nc(cc1n2)c(C=C)c5C)c(C)c4CCC(O)=O)c(CCC(O)=O)c3C	Preclinical
protriptyline	tricyclic antidepressant	SLC6A2, SLC6A4	neurology/psychiatry	depression	MedChemEx, MicroSource, MicroSource, MicroSource	98.39	CNCCCC1c2ccccc2C=Cc2ccccc12 |c:13|, CNCCCC1c2ccccc2C=Cc2ccccc12 |c:13|, CNCCCC1c2ccccc2C=Cc2ccccc12 |c:13|, CNCCCC1c2ccccc2C=Cc2ccccc12 |c:13|	Launched
proxodolol	adrenergic receptor antagonist				Vitas-M, InterBioScreen	97.24	Cc1noc(COc2ccccc2OC[C@@H](O)CNC(C)(C)C)n1 |&1:15|, Cc1noc(COc2ccccc2OC[C@@H](O)CNC(C)(C)C)n1 |&1:15|	Launched
proxyfan	histamine receptor modulator	HRH3			Tocris, Tocris, Tocris	97.13	C(COCc1ccccc1)Cc1cnc[nH]1, C(COCc1ccccc1)Cc1cnc[nH]1, C(COCc1ccccc1)Cc1cnc[nH]1	Preclinical
proxymetacaine	sodium channel blocker	SCN10A, SCN5A	neurology/psychiatry	anesthetic	MicroSource, MedChemEx, Selleck	97.7	CCCOc1ccc(cc1N)C(=O)OCCN(CC)CC, CCCOc1ccc(cc1N)C(=O)OCCN(CC)CC, CCCOc1ccc(cc1N)C(=O)OCCN(CC)CC	Launched
Proxyphylline			pulmonary	asthma	MicroSource, MedChemEx	97.97	C[C@@H](O)Cn1cnc2n(C)c(=O)n(C)c(=O)c12 |&1:1,r|, C[C@@H](O)Cn1cnc2n(C)c(=O)n(C)c(=O)c12 |&1:1,r|	Launched
PRT062070	JAK inhibitor, SYK inhibitor	SYK			MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx	92.76	CCS(=O)(=O)N1CCN(CC1)c1ccc(Nc2ncc(C(N)=O)c(NC3CC3)n2)cc1, CCS(=O)(=O)N1CCN(CC1)c1ccc(Nc2ncc(C(N)=O)c(NC3CC3)n2)cc1, CCS(=O)(=O)N1CCN(CC1)c1ccc(Nc2ncc(C(N)=O)c(NC3CC3)n2)cc1, CCS(=O)(=O)N1CCN(CC1)c1ccc(Nc2ncc(C(N)=O)c(NC3CC3)n2)cc1, CCS(=O)(=O)N1CCN(CC1)c1ccc(Nc2ncc(C(N)=O)c(NC3CC3)n2)cc1, CCS(=O)(=O)N1CCN(CC1)c1ccc(Nc2ncc(C(N)=O)c(NC3CC3)n2)cc1	Phase 2/Phase 3
PRT062607	SYK inhibitor	FGR, MAP3K9, SYK			Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck	95.12	N[C@H]1CCCC[C@H]1Nc1ncc(C(N)=O)c(Nc2cccc(c2)-n2nccn2)n1, N[C@H]1CCCC[C@H]1Nc1ncc(C(N)=O)c(Nc2cccc(c2)-n2nccn2)n1, N[C@H]1CCCC[C@H]1Nc1ncc(C(N)=O)c(Nc2cccc(c2)-n2nccn2)n1, N[C@H]1CCCC[C@H]1Nc1ncc(C(N)=O)c(Nc2cccc(c2)-n2nccn2)n1, N[C@H]1CCCC[C@H]1Nc1ncc(C(N)=O)c(Nc2cccc(c2)-n2nccn2)n1, N[C@H]1CCCC[C@H]1Nc1ncc(C(N)=O)c(Nc2cccc(c2)-n2nccn2)n1, N[C@H]1CCCC[C@H]1Nc1ncc(C(N)=O)c(Nc2cccc(c2)-n2nccn2)n1, N[C@H]1CCCC[C@H]1Nc1ncc(C(N)=O)c(Nc2cccc(c2)-n2nccn2)n1, N[C@H]1CCCC[C@H]1Nc1ncc(C(N)=O)c(Nc2cccc(c2)-n2nccn2)n1, N[C@H]1CCCC[C@H]1Nc1ncc(C(N)=O)c(Nc2cccc(c2)-n2nccn2)n1, N[C@H]1CCCC[C@H]1Nc1ncc(C(N)=O)c(Nc2cccc(c2)-n2nccn2)n1, N[C@H]1CCCC[C@H]1Nc1ncc(C(N)=O)c(Nc2cccc(c2)-n2nccn2)n1	Phase 2
PRT4165	polycomb repressive complex inhibitor	PRC1			MedChemEx, MedChemEx, Tocris	62.32	O=C1C(=Cc2cccnc2)C(=O)c2ccccc12, O=C1C(=Cc2cccnc2)C(=O)c2ccccc12, O=C1C(=Cc2cccnc2)C(=O)c2ccccc12	Preclinical
prucalopride	serotonin receptor agonist	HTR4	gastroenterology	constipation	MedChemEx, MedChemEx, Selleck, Selleck	98.37	COCCCN1CCC(CC1)NC(=O)c1cc(Cl)c(N)c2CCOc12, COCCCN1CCC(CC1)NC(=O)c1cc(Cl)c(N)c2CCOc12, COCCCN1CCC(CC1)NC(=O)c1cc(Cl)c(N)c2CCOc12, COCCCN1CCC(CC1)NC(=O)c1cc(Cl)c(N)c2CCOc12	Launched
prulifloxacin	bacterial DNA gyrase inhibitor		infectious disease, pulmonary, gastroenterology	urinary tract infections, bronchitis, diarrhea	MicroSource, MedChemEx	79.74	C[C@H]1Sc2c(C(O)=O)c(=O)c3cc(F)c(cc3n12)N1CCN(Cc2oc(=O)oc2C)CC1 |&1:1,r|, C[C@H]1Sc2c(C(O)=O)c(=O)c3cc(F)c(cc3n12)N1CCN(Cc2oc(=O)oc2C)CC1 |&1:1,r|	Launched
pruvanserin	serotonin receptor antagonist	HTR2A, HTR2C			Tocris, Tocris, Sigma	98.48	Fc1ccc(CCN2CCN(CC2)C(=O)c2cccc3c(c[nH]c23)C#N)cc1, Fc1ccc(CCN2CCN(CC2)C(=O)c2cccc3c(c[nH]c23)C#N)cc1, Fc1ccc(CCN2CCN(CC2)C(=O)c2cccc3c(c[nH]c23)C#N)cc1	Phase 2
PRX-07034	serotonin receptor antagonist				ChemDiv	86.32	COc1cc(Cl)cc([C@H](C)Nc2cc(ccc2S(C)(=O)=O)N2CCNCC2)c1OC |&1:8,r|	Phase 1
PRX-08066	serotonin receptor antagonist	HTR2B			Selleck, MedChemEx, MedChemEx	97.22	Fc1ccc(CN2CCC(CC2)Nc2ncnc3sc(Cl)cc23)cc1C#N, Fc1ccc(CN2CCC(CC2)Nc2ncnc3sc(Cl)cc23)cc1C#N, Fc1ccc(CN2CCC(CC2)Nc2ncnc3sc(Cl)cc23)cc1C#N	Phase 2
PSB-06126	NTPDase inhibitor	ENTPD3			Tocris, Tocris, Tocris, Tocris, Tocris, Tocris, Tocris, Tocris	99.7	Nc1c2C(=O)c3ccccc3C(=O)c2c(Nc2cccc3ccccc23)cc1S(O)(=O)=O, Nc1c2C(=O)c3ccccc3C(=O)c2c(Nc2cccc3ccccc23)cc1S(O)(=O)=O, Nc1c2C(=O)c3ccccc3C(=O)c2c(Nc2cccc3ccccc23)cc1S(O)(=O)=O, Nc1c2C(=O)c3ccccc3C(=O)c2c(Nc2cccc3ccccc23)cc1S(O)(=O)=O, Nc1c2C(=O)c3ccccc3C(=O)c2c(Nc2cccc3ccccc23)cc1S(O)(=O)=O, Nc1c2C(=O)c3ccccc3C(=O)c2c(Nc2cccc3ccccc23)cc1S(O)(=O)=O, Nc1c2C(=O)c3ccccc3C(=O)c2c(Nc2cccc3ccccc23)cc1S(O)(=O)=O, Nc1c2C(=O)c3ccccc3C(=O)c2c(Nc2cccc3ccccc23)cc1S(O)(=O)=O	Preclinical
PSB-11	adenosine receptor antagonist	ADORA1, ADORA2A, ADORA3			Tocris, Tocris, Tocris, Tocris, Tocris	97.61	CC[C@@H]1CN2C(=N1)c1nc([nH]c1N(C)C2=O)-c1ccccc1 |c:5|, CC[C@@H]1CN2C(=N1)c1nc([nH]c1N(C)C2=O)-c1ccccc1 |c:5|, CC[C@@H]1CN2C(=N1)c1nc([nH]c1N(C)C2=O)-c1ccccc1 |c:5|, CC[C@@H]1CN2C(=N1)c1nc([nH]c1N(C)C2=O)-c1ccccc1 |c:5|, CC[C@@H]1CN2C(=N1)c1nc([nH]c1N(C)C2=O)-c1ccccc1 |c:5|	Preclinical
PSB-1115	adenosine receptor antagonist	ADORA1, ADORA2B, ADORA3			Tocris, Tocris, Tocris, Tocris	97.08	CCCn1c(=O)[nH]c2nc([nH]c2c1=O)-c1ccc(cc1)S(O)(=O)=O, CCCn1c(=O)[nH]c2nc([nH]c2c1=O)-c1ccc(cc1)S(O)(=O)=O, CCCn1c(=O)[nH]c2nc([nH]c2c1=O)-c1ccc(cc1)S(O)(=O)=O, CCCn1c(=O)[nH]c2nc([nH]c2c1=O)-c1ccc(cc1)S(O)(=O)=O	Preclinical
PSB-36	adenosine receptor antagonist	ADORA1, ADORA2A, ADORA2B, ADORA3			Tocris	96.07	[H][C@]12C[C@H]3C[C@]([H])(C[C@]3(C1)c1nc3n(CCCO)c(=O)n(CCCC)c(=O)c3[nH]1)C2 |r,THB:9:1:4:7.8|	Preclinical
PSB-603	adenosine receptor antagonist	ADORA1, ADORA2A, ADORA2B, ADORA3			Tocris, Tocris, Tocris, Tocris	98.46	CCCn1c(=O)[nH]c2nc([nH]c2c1=O)-c1ccc(cc1)S(=O)(=O)N1CCN(CC1)c1ccc(Cl)cc1, CCCn1c(=O)[nH]c2nc([nH]c2c1=O)-c1ccc(cc1)S(=O)(=O)N1CCN(CC1)c1ccc(Cl)cc1, CCCn1c(=O)[nH]c2nc([nH]c2c1=O)-c1ccc(cc1)S(=O)(=O)N1CCN(CC1)c1ccc(Cl)cc1, CCCn1c(=O)[nH]c2nc([nH]c2c1=O)-c1ccc(cc1)S(=O)(=O)N1CCN(CC1)c1ccc(Cl)cc1	Preclinical
PSI-6130	RNA polymerase inhibitor				MedChemEx, MedChemEx	100	C[C@@]1(F)[C@H](O)[C@@H](CO)O[C@H]1n1ccc(N)nc1=O, C[C@@]1(F)[C@H](O)[C@@H](CO)O[C@H]1n1ccc(N)nc1=O	Phase 1
PSI-697	P selectin inhibitor				MedChemEx	92.55	OC(=O)c1c(O)c(Cc2ccc(Cl)cc2)nc2c3CCCCc3ccc12	Phase 1
PSI-7976	HCV inhibitor				MedChemEx, MedChemEx, MedChemEx	98.58	CC(C)OC(=O)[C@H](C)N[P@@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)Oc1ccccc1, CC(C)OC(=O)[C@H](C)N[P@@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)Oc1ccccc1, CC(C)OC(=O)[C@H](C)N[P@@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)Oc1ccccc1	Preclinical
PSN-375963	glucose dependent insulinotropic receptor agonist	GPR119			Tocris, Tocris, Tocris	66.55	CCCCC1CCC(CC1)c1nc(no1)-c1ccncc1, CCCCC1CCC(CC1)c1nc(no1)-c1ccncc1, CCCCC1CCC(CC1)c1nc(no1)-c1ccncc1	Preclinical
PSNCBAM-1	cannabinoid receptor modulator	CNR1			Tocris, Tocris	96.73	Clc1ccc(NC(=O)Nc2cccc(c2)-c2cccc(n2)N2CCCC2)cc1, Clc1ccc(NC(=O)Nc2cccc(c2)-c2cccc(n2)N2CCCC2)cc1	Preclinical
psoralen		MAOA, MAOB	dermatology	psoriasis, eczema, vitiligo	Specs	91.19	O=c1ccc2cc3ccoc3cc2o1	Launched
PS178990	androgen receptor modulator	AR			Tocris, MedChemEx, MedChemEx, MedChemEx, MedChemEx	98.09	Cc1c(Cl)c(ccc1N1C(=O)[C@@H]2[C@H](O)CCN2C1=O)C#N, Cc1c(Cl)c(ccc1N1C(=O)[C@@H]2[C@H](O)CCN2C1=O)C#N, Cc1c(Cl)c(ccc1N1C(=O)[C@@H]2[C@H](O)CCN2C1=O)C#N, Cc1c(Cl)c(ccc1N1C(=O)[C@@H]2[C@H](O)CCN2C1=O)C#N, Cc1c(Cl)c(ccc1N1C(=O)[C@@H]2[C@H](O)CCN2C1=O)C#N	Phase 1
PT-2385	hypoxia inducible factor inhibitor	EPAS1			MedChemEx, MedChemEx, MedChemEx	96.9	CS(=O)(=O)c1ccc(Oc2cc(F)cc(c2)C#N)c2CC(F)(F)[C@@H](O)c12, CS(=O)(=O)c1ccc(Oc2cc(F)cc(c2)C#N)c2CC(F)(F)[C@@H](O)c12, CS(=O)(=O)c1ccc(Oc2cc(F)cc(c2)C#N)c2CC(F)(F)[C@@H](O)c12	Phase 1
PTC-028	BMI-1 inhibitor				MedChemEx	93.71	Cc1nc2cc(F)c(F)cc2n1-c1cncc(Nc2ccc(cc2)C(F)(F)F)n1	Preclinical
PTC-209	BMI-1 inhibitor				Selleck, Selleck, MedChemEx, MedChemEx, MedChemEx, Selleck	85.87	COc1cc(Br)c(Nc2nc(cs2)-c2c(C)nc3ncccn23)c(Br)c1, COc1cc(Br)c(Nc2nc(cs2)-c2c(C)nc3ncccn23)c(Br)c1, COc1cc(Br)c(Nc2nc(cs2)-c2c(C)nc3ncccn23)c(Br)c1, COc1cc(Br)c(Nc2nc(cs2)-c2c(C)nc3ncccn23)c(Br)c1, COc1cc(Br)c(Nc2nc(cs2)-c2c(C)nc3ncccn23)c(Br)c1, COc1cc(Br)c(Nc2nc(cs2)-c2c(C)nc3ncccn23)c(Br)c1	Preclinical
pterostilbene	cyclooxygenase inhibitor, PPAR receptor agonist	PTGS2			MedChemEx	98.33	COc1cc(OC)cc(\C=C\c2ccc(O)cc2)c1	Phase 2/Phase 3
PU-H71	HSP inhibitor	HSP90AA1			MedChemEx, MedChemEx, MedChemEx	95.73	CC(C)NCCCn1c(Sc2cc3OCOc3cc2I)nc2c(N)ncnc12, CC(C)NCCCn1c(Sc2cc3OCOc3cc2I)nc2c(N)ncnc12, CC(C)NCCCn1c(Sc2cc3OCOc3cc2I)nc2c(N)ncnc12	Phase 1
puerarin	serotonin receptor antagonist				MedChemEx, Vitas-M, Selleck	97.51	OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)c1c(O)ccc2c1occ(-c1ccc(O)cc1)c2=O, OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)c1c(O)ccc2c1occ(-c1ccc(O)cc1)c2=O, OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)c1c(O)ccc2c1occ(-c1ccc(O)cc1)c2=O	Phase 2
pumosetrag	serotonin receptor agonist	HTR3A, HTR4			Sigma	98.08	O=C(N[C@H]1CN2CCC1CC2)c1c[nH]c2ccsc2c1=O	Phase 2
purmorphamine	smoothened receptor agonist	SMO			Tocris, Selleck, Selleck, Selleck, Selleck, Selleck	94.09	C1CCC(CC1)n1cnc2c(Nc3ccc(cc3)N3CCOCC3)nc(Oc3cccc4ccccc34)nc12, C1CCC(CC1)n1cnc2c(Nc3ccc(cc3)N3CCOCC3)nc(Oc3cccc4ccccc34)nc12, C1CCC(CC1)n1cnc2c(Nc3ccc(cc3)N3CCOCC3)nc(Oc3cccc4ccccc34)nc12, C1CCC(CC1)n1cnc2c(Nc3ccc(cc3)N3CCOCC3)nc(Oc3cccc4ccccc34)nc12, C1CCC(CC1)n1cnc2c(Nc3ccc(cc3)N3CCOCC3)nc(Oc3cccc4ccccc34)nc12, C1CCC(CC1)n1cnc2c(Nc3ccc(cc3)N3CCOCC3)nc(Oc3cccc4ccccc34)nc12	Preclinical
puromycin	protein synthesis inhibitor	NHP2L1, RPL10L, RPL11, RPL13A, RPL15, RPL19, RPL23, RPL23A, RPL26L1, RPL3, RPL37, RPL8, RSL24D1			Tocris	96.84	COc1ccc(C[C@H](N)C(=O)N[C@@H]2[C@@H](CO)O[C@H]([C@@H]2O)n2cnc3c(ncnc23)N(C)C)cc1	Preclinical
purvalanol-A	CDK inhibitor	CDK1, CDK2, CDK4, CDK5, CSNK1G3, RPS6KA1, SRC			Tocris, Tocris, Tocris, Tocris, Tocris	97.56	CC(C)[C@H](CO)Nc1nc(Nc2cccc(Cl)c2)c2ncn(C(C)C)c2n1, CC(C)[C@H](CO)Nc1nc(Nc2cccc(Cl)c2)c2ncn(C(C)C)c2n1, CC(C)[C@H](CO)Nc1nc(Nc2cccc(Cl)c2)c2ncn(C(C)C)c2n1, CC(C)[C@H](CO)Nc1nc(Nc2cccc(Cl)c2)c2ncn(C(C)C)c2n1, CC(C)[C@H](CO)Nc1nc(Nc2cccc(Cl)c2)c2ncn(C(C)C)c2n1	Preclinical
purvalanol-B	tyrosine kinase inhibitor	CDK2, CDK4, CDK5, MAPK1, MAPK3, SRPK2			Tocris, Tocris, Tocris, Tocris	97.82	CC(C)[C@H](CO)Nc1nc(Nc2ccc(C(O)=O)c(Cl)c2)c2ncn(C(C)C)c2n1, CC(C)[C@H](CO)Nc1nc(Nc2ccc(C(O)=O)c(Cl)c2)c2ncn(C(C)C)c2n1, CC(C)[C@H](CO)Nc1nc(Nc2ccc(C(O)=O)c(Cl)c2)c2ncn(C(C)C)c2n1, CC(C)[C@H](CO)Nc1nc(Nc2ccc(C(O)=O)c(Cl)c2)c2ncn(C(C)C)c2n1	Preclinical
putrescine	tissue transglutaminase inhibitor	AMD1, KCNJ4, ODC1			Sigma	0	NCCCCN	Phase 2
PX-12	thioredoxin inhibitor	CNR1, TXN			MedChemEx	95.68	CC[C@@H](C)SSc1ncc[nH]1 |&1:2,r|	Phase 2
PX-478	hypoxia inducible factor inhibitor				Selleck, Selleck, Selleck	88.15	N[C@@H](Cc1ccc(cc1)[N+]([O-])(CCCl)CCCl)C(O)=O |&1:1|, N[C@@H](Cc1ccc(cc1)[N+]([O-])(CCCl)CCCl)C(O)=O |&1:1|, N[C@@H](Cc1ccc(cc1)[N+]([O-])(CCCl)CCCl)C(O)=O |&1:1|	Phase 1
PYM50028	neurotrophic agent				MedChemEx, Enzo	100	C[C@H]1[C@H]2[C@H](C[C@H]3[C@@H]4CC[C@@H]5C[C@@H](O)CC[C@]5(C)[C@H]4CC[C@]23C)O[C@]11CC[C@H](C)CO1, C[C@H]1[C@H]2[C@H](C[C@H]3[C@@H]4CC[C@@H]5C[C@@H](O)CC[C@]5(C)[C@H]4CC[C@]23C)O[C@]11CC[C@H](C)CO1	Phase 2
PYR-41	ubiquitin activating enzyme inhibitor				Selleck, Selleck, Selleck	45.42	CCOC(=O)c1ccc(cc1)N1NC(=O)\C(=C\c2ccc(o2)[N+]([O-])=O)C1=O, CCOC(=O)c1ccc(cc1)N1NC(=O)\C(=C\c2ccc(o2)[N+]([O-])=O)C1=O, CCOC(=O)c1ccc(cc1)N1NC(=O)\C(=C\c2ccc(o2)[N+]([O-])=O)C1=O	Preclinical
pyrantel	acetylcholine receptor agonist, nicotinic receptor agonist		infectious disease	gastrointestinal roundworms	Sigma	97.74	OC(=O)c1cc2ccccc2c(Cc2c(O)c(cc3ccccc23)C(O)=O)c1O	Launched
pyrantel-pamoate	neuromuscular blocker		infectious disease	hookworm, tapeworm	MedChemEx, MedChemEx, MedChemEx, MedChemEx, Prestwick, MicroSource	94.32	CN1CCCN=C1\C=C\c1cccs1 |c:5|, CN1CCCN=C1\C=C\c1cccs1 |c:5|, CN1CCCN=C1\C=C\c1cccs1 |c:5|, CN1CCCN=C1\C=C\c1cccs1 |c:5|, CN1CCCN=C1\C=C\c1cccs1 |c:5|, CN1CCCN=C1\C=C\c1cccs1 |c:5|	Launched
pyrazinamide	fatty acid synthase inhibitor	FASN	infectious disease	tuberculosis	Selleck, MicroSource	98.54	NC(=O)c1cnccn1, NC(=O)c1cnccn1	Launched
pyrazinoylguanidine	diuretic				Enamine	95.97	NC(=N)NC(=O)c1cnccn1	Phase 1
pyrazolanthrone	JNK inhibitor	MAPK10, MAPK8, MAPK8IP1, MAPK9, TTK			Tocris, Selleck, Selleck, Selleck, Tocris	97.4	O=C1c2ccccc2-c2[nH]nc3cccc1c23, O=C1c2ccccc2-c2[nH]nc3cccc1c23, O=C1c2ccccc2-c2[nH]nc3cccc1c23, O=C1c2ccccc2-c2[nH]nc3cccc1c23, O=C1c2ccccc2-c2[nH]nc3cccc1c23	Preclinical
pyrazoloacridine	topoisomerase inhibitor	TOP1, TOP2A			Sigma	13.26	COc1ccc2nc3c(ccc4n(CCCN(C)C)[nH]c(c34)c2c1)[N+]([O-])=O	Phase 2
pyrethrins			infectious disease	flea control	TRC	96.88	CC(C)=C[C@@H]1[C@@H](C(=O)O[C@H]2CC(=O)C(C\C=C/C=C)=C2C)C1(C)C |c:18|	Launched
pyridoxal		PDXK	neurology/psychiatry	epilepsy	Vitas-M	92.3	Cc1ncc(CO)c(C=O)c1O	Launched
pyridoxal-isonicotinoyl-hydrazone	apoptosis stimulant				Cayman, Cayman	93.7	Cc1ncc(CO)c(\C=N\NC(=O)c2ccncc2)c1O, Cc1ncc(CO)c(\C=N\NC(=O)c2ccncc2)c1O	Phase 2
pyridoxamine	AGE inhibitor				Sigma	98.7	Cc1ncc(CO)c(CN)c1O	Phase 3
pyridoxine	vitamin B	DDC, PDXK	metabolism	vitamin B6 deficiency	MicroSource, Selleck	100	Cc1ncc(CO)c(CO)c1O, Cc1ncc(CO)c(CO)c1O	Launched
pyrimethamine	dihydrofolate reductase inhibitor	DHFR, SLC47A1	infectious disease	malaria	Tocris, Selleck, Selleck, Tocris, MicroSource, MicroSource, MicroSource, Tocris	99.69	CCc1nc(N)nc(N)c1-c1ccc(Cl)cc1, CCc1nc(N)nc(N)c1-c1ccc(Cl)cc1, CCc1nc(N)nc(N)c1-c1ccc(Cl)cc1, CCc1nc(N)nc(N)c1-c1ccc(Cl)cc1, CCc1nc(N)nc(N)c1-c1ccc(Cl)cc1, CCc1nc(N)nc(N)c1-c1ccc(Cl)cc1, CCc1nc(N)nc(N)c1-c1ccc(Cl)cc1, CCc1nc(N)nc(N)c1-c1ccc(Cl)cc1	Launched
pyrintegrin	integrin signaling activator				Tocris, Tocris	95.74	Oc1ccc2N(CCCc2c1)c1ccnc(Nc2ccc(cc2)S(=O)(=O)NCC2CC2)n1, Oc1ccc2N(CCCc2c1)c1ccnc(Nc2ccc(cc2)S(=O)(=O)NCC2CC2)n1	Preclinical
pyrithione-zinc	ATP synthase inhibitor	KCNQ1, KCNQ2, KCNQ4, KCNQ5	dermatology	dandruff, cosmetic	MicroSource, MicroSource, MicroSource, Selleck, Selleck, MedChemEx	99.05	O1[n+]2ccccc2S[Zn]11O[n+]2ccccc2S1, O1[n+]2ccccc2S[Zn]11O[n+]2ccccc2S1, O1[n+]2ccccc2S[Zn]11O[n+]2ccccc2S1, O1[n+]2ccccc2S[Zn]11O[n+]2ccccc2S1, O1[n+]2ccccc2S[Zn]11O[n+]2ccccc2S1, O1[n+]2ccccc2S[Zn]11O[n+]2ccccc2S1	Launched
pyrithyldione	psychoactive drug				MicroSource	97.73	CCC1(CC)C(=O)NC=CC1=O |c:8|	Withdrawn
pyritinol			rheumatology, neurology/psychiatry	rheumatoid arthritis, senile dementia	MedChemEx, MicroSource	97.57	Cc1ncc(CSSCc2cnc(C)c(O)c2CO)c(CO)c1O, Cc1ncc(CSSCc2cnc(C)c(O)c2CO)c(CO)c1O	Launched
pyronaridine	antimalarial agent				MicroSource, Vitas-M	86.56	COc1ccc2nc3cc(Cl)ccc3c(Nc3cc(CN4CCCC4)c(O)c(CN4CCCC4)c3)c2n1, COc1ccc2nc3cc(Cl)ccc3c(Nc3cc(CN4CCCC4)c(O)c(CN4CCCC4)c3)c2n1	Phase 3
pyrotinib	kinase inhibitor				MedChemEx	97.45	CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)\C=C\[C@H]1CCCN1C	Phase 3
pyroxamide	HDAC inhibitor	HDAC1			Cayman, Cayman, Tocris, Cayman, Cayman, Cayman, Cayman	97.08	ONC(=O)CCCCCCC(=O)Nc1cccnc1, ONC(=O)CCCCCCC(=O)Nc1cccnc1, ONC(=O)CCCCCCC(=O)Nc1cccnc1, ONC(=O)CCCCCCC(=O)Nc1cccnc1, ONC(=O)CCCCCCC(=O)Nc1cccnc1, ONC(=O)CCCCCCC(=O)Nc1cccnc1, ONC(=O)CCCCCCC(=O)Nc1cccnc1	Phase 1
pyrrolidine-dithiocarbamate	NFkB pathway inhibitor	HSD11B1, RELA			Tocris, Tocris	0	SC(=S)N1CCCC1, SC(=S)N1CCCC1	Preclinical
pyrvinium-pamoate	androgen receptor antagonist	AR	infectious disease	pinworm	Sigma, MicroSource	64.19	CN(C)c1ccc2[n+](C)c(\C=C\c3cc(C)n(c3C)-c3ccccc3)ccc2c1, CN(C)c1ccc2[n+](C)c(\C=C\c3cc(C)n(c3C)-c3ccccc3)ccc2c1	Launched
PZ-2891	pantothenate kinase activator				MedChemEx	96.3	CC(C)c1ccc(CC(=O)N2CCN(CC2)c2ccc(nn2)C#N)cc1	Preclinical
P22077	ubiquitin specific protease inhibitor	USP7			Tocris, Tocris, Tocris, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck	97.13	CC(=O)c1cc(c(Sc2ccc(F)cc2F)s1)[N+]([O-])=O, CC(=O)c1cc(c(Sc2ccc(F)cc2F)s1)[N+]([O-])=O, CC(=O)c1cc(c(Sc2ccc(F)cc2F)s1)[N+]([O-])=O, CC(=O)c1cc(c(Sc2ccc(F)cc2F)s1)[N+]([O-])=O, CC(=O)c1cc(c(Sc2ccc(F)cc2F)s1)[N+]([O-])=O, CC(=O)c1cc(c(Sc2ccc(F)cc2F)s1)[N+]([O-])=O, CC(=O)c1cc(c(Sc2ccc(F)cc2F)s1)[N+]([O-])=O, CC(=O)c1cc(c(Sc2ccc(F)cc2F)s1)[N+]([O-])=O, CC(=O)c1cc(c(Sc2ccc(F)cc2F)s1)[N+]([O-])=O, CC(=O)c1cc(c(Sc2ccc(F)cc2F)s1)[N+]([O-])=O	Preclinical
P276-00	CDK inhibitor	CDK1, CDK4, CDK9			Selleck, Selleck, Selleck, Selleck	97.85	CN1CC[C@H]([C@@H]1CO)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl, CN1CC[C@H]([C@@H]1CO)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl, CN1CC[C@H]([C@@H]1CO)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl, CN1CC[C@H]([C@@H]1CO)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl	Phase 2
P5091	ubiquitin specific protease inhibitor	USP7			MedChemEx, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck	97.85	CC(=O)c1cc(c(Sc2cccc(Cl)c2Cl)s1)[N+]([O-])=O, CC(=O)c1cc(c(Sc2cccc(Cl)c2Cl)s1)[N+]([O-])=O, CC(=O)c1cc(c(Sc2cccc(Cl)c2Cl)s1)[N+]([O-])=O, CC(=O)c1cc(c(Sc2cccc(Cl)c2Cl)s1)[N+]([O-])=O, CC(=O)c1cc(c(Sc2cccc(Cl)c2Cl)s1)[N+]([O-])=O, CC(=O)c1cc(c(Sc2cccc(Cl)c2Cl)s1)[N+]([O-])=O, CC(=O)c1cc(c(Sc2cccc(Cl)c2Cl)s1)[N+]([O-])=O, CC(=O)c1cc(c(Sc2cccc(Cl)c2Cl)s1)[N+]([O-])=O	Preclinical
P7C3	NAMPT inhibitor	NAMPT			Tocris, Tocris	95.81	O[C@@H](CNc1ccccc1)Cn1c2ccc(Br)cc2c2cc(Br)ccc12 |&1:1,r|, O[C@@H](CNc1ccccc1)Cn1c2ccc(Br)cc2c2cc(Br)ccc12 |&1:1,r|	Preclinical
Q-203	ATP synthase inhibitor				Enamine, Enamine	89.92	CCc1nc2ccc(Cl)cn2c1C(=O)NCc1ccc(cc1)N1CCC(CC1)c1ccc(OC(F)(F)F)cc1, CCc1nc2ccc(Cl)cn2c1C(=O)NCc1ccc(cc1)N1CCC(CC1)c1ccc(OC(F)(F)F)cc1	Phase 2
quazinone	phosphodiesterase inhibitor	PDE3A, PDE3B			AMS, AMS, AMS	97.92	CC1N2Cc3c(Cl)cccc3NC2=NC1=O |c:14|, CC1N2Cc3c(Cl)cccc3NC2=NC1=O |c:14|, CC1N2Cc3c(Cl)cccc3NC2=NC1=O |c:14|	Phase 2
quercetin	polar auxin transport inhibitor	ATP5A1, ATP5B, ATP5C1, HCK, HIBCH, PIK3CG, PIM1, STK17B, UGT3A1	neurology/psychiatry, allergy	fatigue, allergic rhinitis, drowsiness	Tocris, Tocris, Tocris, Selleck, Selleck, Selleck, Selleck	93.07	Oc1cc(O)c2c(c1)oc(-c1ccc(O)c(O)c1)c(O)c2=O, Oc1cc(O)c2c(c1)oc(-c1ccc(O)c(O)c1)c(O)c2=O, Oc1cc(O)c2c(c1)oc(-c1ccc(O)c(O)c1)c(O)c2=O, Oc1cc(O)c2c(c1)oc(-c1ccc(O)c(O)c1)c(O)c2=O, Oc1cc(O)c2c(c1)oc(-c1ccc(O)c(O)c1)c(O)c2=O, Oc1cc(O)c2c(c1)oc(-c1ccc(O)c(O)c1)c(O)c2=O, Oc1cc(O)c2c(c1)oc(-c1ccc(O)c(O)c1)c(O)c2=O	Launched
quetiapine	dopamine receptor antagonist, serotonin receptor antagonist	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD1, DRD2, DRD3, DRD4, DRD5, HRH1, HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2C, HTR3A, HTR6, HTR7, SLC6A2	neurology/psychiatry	schizophrenia, bipolar disorder	MicroSource, Tocris, Selleck, Selleck	98.67	OCCOCCN1CCN(CC1)C1=Nc2ccccc2Sc2ccccc12 |t:13|, OCCOCCN1CCN(CC1)C1=Nc2ccccc2Sc2ccccc12 |t:13|, OCCOCCN1CCN(CC1)C1=Nc2ccccc2Sc2ccccc12 |t:13|, OCCOCCN1CCN(CC1)C1=Nc2ccccc2Sc2ccccc12 |t:13|	Launched
quiflapon	leukotriene synthesis inhibitor	ALOX5, ALOX5AP			MedChemEx	97.94	CC(C)(C)Sc1c(CC(C)(C)C(O)=O)n(Cc2ccc(Cl)cc2)c2ccc(OCc3ccc4ccccc4n3)cc12	Phase 2
quinagolide	dopamine receptor agonist	DRD2	endocrinology	hyperprolactinemia	MedChemEx	90.35	CCCN1C[C@H](C[C@@H]2Cc3c(O)cccc3C[C@@H]12)NS(=O)(=O)N(CC)CC	Launched
quinapril	angiotensin converting enzyme inhibitor	ACE	cardiology	hypertension, congestive heart failure, angioedema	MicroSource, Selleck, Selleck, Selleck, Selleck	93.01	CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1Cc2ccccc2C[C@H]1C(O)=O, CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1Cc2ccccc2C[C@H]1C(O)=O, CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1Cc2ccccc2C[C@H]1C(O)=O, CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1Cc2ccccc2C[C@H]1C(O)=O, CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1Cc2ccccc2C[C@H]1C(O)=O	Launched
quinaprilat	angiotensin converting enzyme inhibitor	ACE	cardiology	hypertension, angioedema	MicroSource, MicroSource	24.38	C[C@H](N[C@@H](CCc1ccccc1)C(O)=O)C(=O)N1Cc2ccccc2C[C@H]1C(O)=O, C[C@H](N[C@@H](CCc1ccccc1)C(O)=O)C(=O)N1Cc2ccccc2C[C@H]1C(O)=O	Launched
quinelorane	dopamine receptor agonist	DRD2, DRD3			Enzo	97.42	CCCN1CCC[C@@H]2Cc3nc(N)ncc3C[C@@H]12	Phase 3
quinestrol	estrogen receptor agonist	ESR1, ESR2	endocrinology	menopause	MedChemEx	89.67	C[C@]12CC[C@H]3[C@@H](CCc4cc(OC5CCCC5)ccc34)[C@@H]1CC[C@@]2(O)C#C	Launched
quinethazone	thiazide diuretic		cardiology	hypertension	USP, USP, USP, MicroSource, MicroSource, MicroSource, MicroSource, MicroSource	98.85	CC[C@H]1NC(=O)c2cc(c(Cl)cc2N1)S(N)(=O)=O |&1:2,r|, CC[C@H]1NC(=O)c2cc(c(Cl)cc2N1)S(N)(=O)=O |&1:2,r|, CC[C@H]1NC(=O)c2cc(c(Cl)cc2N1)S(N)(=O)=O |&1:2,r|, CC[C@H]1NC(=O)c2cc(c(Cl)cc2N1)S(N)(=O)=O |&1:2,r|, CC[C@H]1NC(=O)c2cc(c(Cl)cc2N1)S(N)(=O)=O |&1:2,r|, CC[C@H]1NC(=O)c2cc(c(Cl)cc2N1)S(N)(=O)=O |&1:2,r|, CC[C@H]1NC(=O)c2cc(c(Cl)cc2N1)S(N)(=O)=O |&1:2,r|, CC[C@H]1NC(=O)c2cc(c(Cl)cc2N1)S(N)(=O)=O |&1:2,r|	Launched
quinidine	sodium channel blocker	KCNA5, KCNA7, KCNH1, KCNH2, KCNH5, KCNK1, KCNK6, SCN5A, SLC29A4	infectious disease, cardiology	malaria, atrial fibrillation (AF), ventricular arrhythmias	MedChemEx, MedChemEx, MicroSource, MicroSource	87.9	COc1ccc2nccc([C@H](O)[C@H]3C[C@@H]4CC[N@]3C[C@@H]4C=C)c2c1, COc1ccc2nccc([C@H](O)[C@H]3C[C@@H]4CC[N@]3C[C@@H]4C=C)c2c1, COc1ccc2nccc([C@H](O)[C@H]3C[C@@H]4CC[N@]3C[C@@H]4C=C)c2c1, COc1ccc2nccc([C@H](O)[C@H]3C[C@@H]4CC[N@]3C[C@@H]4C=C)c2c1	Launched
quinine	hemozoin biocrystallization inhibitor	GP9, KCNB2, KCNN4, SLC29A4	infectious disease	malaria	Selleck, CombiBlocks, Tocris	94.43	COc1ccc2nccc([C@@H](O)[C@@H]3C[C@@H]4CC[N@]3C[C@@H]4C=C)c2c1, COc1ccc2nccc([C@@H](O)[C@@H]3C[C@@H]4CC[N@]3C[C@@H]4C=C)c2c1, COc1ccc2nccc([C@@H](O)[C@@H]3C[C@@H]4CC[N@]3C[C@@H]4C=C)c2c1	Launched
quinine-ethyl-carbonate			infectious disease	malaria	MicroSource	92.37	CCOC(=O)O[C@H]([C@H]1C[C@@H]2CC[N@]1C[C@@H]2C=C)c1ccnc2ccc(OC)cc12	Launched
quinolinic-acid	glutamate receptor agonist				Tocris	94.44	OC(=O)c1cccnc1C(O)=O	Preclinical
quinpirol-(-)	dopamine receptor agonist	DRD1, DRD2, DRD3, DRD4, HTR1A, HTR2A, HTR2B, HTR2C			Tocris, Tocris, Tocris, Tocris, Tocris	100	CCCN1CCC[C@@H]2Cc3[nH]ncc3C[C@@H]12, CCCN1CCC[C@@H]2Cc3[nH]ncc3C[C@@H]12, CCCN1CCC[C@@H]2Cc3[nH]ncc3C[C@@H]12, CCCN1CCC[C@@H]2Cc3[nH]ncc3C[C@@H]12, CCCN1CCC[C@@H]2Cc3[nH]ncc3C[C@@H]12	Phase 2
quipazine	serotonin receptor agonist	HTR1A, HTR1D, HTR2A, HTR2B, HTR2C, HTR3A, HTR3B, HTR6, SLC6A4			MicroSource, Selleck, Tocris, Tocris	97.07	C1CN(CCN1)c1ccc2ccccc2n1, C1CN(CCN1)c1ccc2ccccc2n1, C1CN(CCN1)c1ccc2ccccc2n1, C1CN(CCN1)c1ccc2ccccc2n1	Preclinical
quizartinib	FLT3 inhibitor	CSF1R, FLT3, KIT, PDGFRA, PDGFRB, RET			MedChemEx, Selleck, Selleck, Selleck, Selleck	97.84	CC(C)(C)c1cc(NC(=O)Nc2ccc(cc2)-c2cn3c(n2)sc2cc(OCCN4CCOCC4)ccc32)no1, CC(C)(C)c1cc(NC(=O)Nc2ccc(cc2)-c2cn3c(n2)sc2cc(OCCN4CCOCC4)ccc32)no1, CC(C)(C)c1cc(NC(=O)Nc2ccc(cc2)-c2cn3c(n2)sc2cc(OCCN4CCOCC4)ccc32)no1, CC(C)(C)c1cc(NC(=O)Nc2ccc(cc2)-c2cn3c(n2)sc2cc(OCCN4CCOCC4)ccc32)no1, CC(C)(C)c1cc(NC(=O)Nc2ccc(cc2)-c2cn3c(n2)sc2cc(OCCN4CCOCC4)ccc32)no1	Phase 3
QX-222	sodium channel blocker				Tocris	98.05	Cc1cccc(C)c1NC(=O)C[N+](C)(C)C	Preclinical
QX-314	sodium channel blocker	MAPK14, TGFBR1			Tocris, Tocris, Tocris, Tocris	100	CC[N+](CC)(CC)CC(=O)Nc1c(C)cccc1C, CC[N+](CC)(CC)CC(=O)Nc1c(C)cccc1C, CC[N+](CC)(CC)CC(=O)Nc1c(C)cccc1C, CC[N+](CC)(CC)CC(=O)Nc1c(C)cccc1C	Preclinical
R-121919	CRF receptor antagonist				Adooq	97.86	CCCN(CCC)c1cc(C)nc2c(c(C)nn12)-c1cnc(cc1C)N(C)C	Preclinical
R-1479	HCV inhibitor				MedChemEx, MedChemEx	96.79	Nc1ccn([C@@H]2O[C@@](CO)(N=[N+]=[N-])[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@@](CO)(N=[N+]=[N-])[C@@H](O)[C@H]2O)c(=O)n1	Phase 1
R-1485	serotonin receptor antagonist	HTR6			Tocris, Tocris, Tocris	96.11	Fc1ccccc1S(=O)(=O)N1CCOc2c(cccc12)N1CCNCC1, Fc1ccccc1S(=O)(=O)N1CCOc2c(cccc12)N1CCNCC1, Fc1ccccc1S(=O)(=O)N1CCOc2c(cccc12)N1CCNCC1	Phase 1
R-1487	p38 MAPK inhibitor				AMS	95.05	Cn1c2nc(NC3CCOCC3)ncc2cc(Oc2ccc(F)cc2F)c1=O	Phase 1
R-268712	serine/threonine kinase inhibitor	TGFBR1			Tocris, Tocris, Tocris, Tocris	98.43	Cc1cccc(n1)-c1n[nH]cc1-c1ccc(F)c(c1)-c1cnn(CCO)c1, Cc1cccc(n1)-c1n[nH]cc1-c1ccc(F)c(c1)-c1cnn(CCO)c1, Cc1cccc(n1)-c1n[nH]cc1-c1ccc(F)c(c1)-c1cnn(CCO)c1, Cc1cccc(n1)-c1n[nH]cc1-c1ccc(F)c(c1)-c1cnn(CCO)c1	Preclinical
R-428	AXL kinase inhibitor	AXL			MedChemEx, MedChemEx, MedChemEx	88.26	Nc1nc(Nc2ccc3CC[C@@H](CCc3c2)N2CCCC2)nn1-c1cc2CCCc3ccccc3-c2nn1, Nc1nc(Nc2ccc3CC[C@@H](CCc3c2)N2CCCC2)nn1-c1cc2CCCc3ccccc3-c2nn1, Nc1nc(Nc2ccc3CC[C@@H](CCc3c2)N2CCCC2)nn1-c1cc2CCCc3ccccc3-c2nn1	Phase 2
R-59022	diacylglycerol kinase inhibitor, protein kinase inhibitor	DGKA			Tocris, Tocris	97.41	Cc1nc2sccn2c(=O)c1CCN1CCC(CC1)=C(c1ccccc1)c1ccc(F)cc1, Cc1nc2sccn2c(=O)c1CCN1CCC(CC1)=C(c1ccccc1)c1ccc(F)cc1	Preclinical
R-96544	serotonin receptor antagonist	HTR2A			Tocris, Tocris, Tocris	96.58	COc1cccc(CCc2ccccc2OCC[C@@H]2C[C@@H](O)CN2C)c1, COc1cccc(CCc2ccccc2OCC[C@@H]2C[C@@H](O)CN2C)c1, COc1cccc(CCc2ccccc2OCC[C@@H]2C[C@@H](O)CN2C)c1	Preclinical
rabeprazole	ATPase inhibitor, gastrin inhibitor	ATP4A	gastroenterology	gastroesophageal reflux disease (GERD), duodenal ulcer disease, Zollinger-Ellison syndrome	Sigma, MicroSource, MedChemEx, Sigma	98.9	COCCCOc1ccnc(C[S@@](=O)c2nc3ccccc3[nH]2)c1C |r|, COCCCOc1ccnc(C[S@@](=O)c2nc3ccccc3[nH]2)c1C |r|, COCCCOc1ccnc(C[S@@](=O)c2nc3ccccc3[nH]2)c1C |r|, COCCCOc1ccnc(C[S@@](=O)c2nc3ccccc3[nH]2)c1C |r|	Launched
rac-BHFF	GABA receptor positive allosteric modulator	GABBR1			Tocris, Tocris	42.99	CC(C)(C)c1cc2c(OC(=O)[C@@]2(O)C(F)(F)F)c(c1)C(C)(C)C |&1:11,r|, CC(C)(C)c1cc2c(OC(=O)[C@@]2(O)C(F)(F)F)c(c1)C(C)(C)C |&1:11,r|	Preclinical
racecadotril	enkephalinase inhibitor	MME	gastroenterology	diarrhea	MicroSource, MicroSource, MicroSource, MedChemEx, MedChemEx, Selleck, Selleck	99.4	CC(=O)SC[C@@H](Cc1ccccc1)C(=O)NCC(=O)OCc1ccccc1 |&1:5,r|, CC(=O)SC[C@@H](Cc1ccccc1)C(=O)NCC(=O)OCc1ccccc1 |&1:5,r|, CC(=O)SC[C@@H](Cc1ccccc1)C(=O)NCC(=O)OCc1ccccc1 |&1:5,r|, CC(=O)SC[C@@H](Cc1ccccc1)C(=O)NCC(=O)OCc1ccccc1 |&1:5,r|, CC(=O)SC[C@@H](Cc1ccccc1)C(=O)NCC(=O)OCc1ccccc1 |&1:5,r|, CC(=O)SC[C@@H](Cc1ccccc1)C(=O)NCC(=O)OCc1ccccc1 |&1:5,r|, CC(=O)SC[C@@H](Cc1ccccc1)C(=O)NCC(=O)OCc1ccccc1 |&1:5,r|	Launched
raclopride	dopamine receptor antagonist	DRD2, DRD3, HTR1A			Tocris, Tocris, Tocris	96.6	CCN1CCC[C@H]1CNC(=O)c1c(O)c(Cl)cc(Cl)c1OC, CCN1CCC[C@H]1CNC(=O)c1c(O)c(Cl)cc(Cl)c1OC, CCN1CCC[C@H]1CNC(=O)c1c(O)c(Cl)cc(Cl)c1OC	Launched
ractopamine	adrenergic receptor agonist		endocrinology	weight-gain aid	Tocris	93.86	C[C@@H](CCc1ccc(O)cc1)NC[C@@H](O)c1ccc(O)cc1 |&1:1,&2:13,r|	Launched
radafaxine	dopamine-norepinephrine reuptake inhibitor	SLC6A3			MedChemEx	92.33	C[C@@H]1NC(C)(C)CO[C@@]1(O)c1cccc(Cl)c1	Phase 2
radezolid	bacterial 30S ribosomal subunit inhibitor, bacterial 50S ribosomal subunit inhibitor				MedChemEx, MedChemEx, MedChemEx, MedChemEx	94.62	CC(=O)NC[C@H]1CN(C(=O)O1)c1ccc(c(F)c1)-c1ccc(CNCc2cn[nH]n2)cc1, CC(=O)NC[C@H]1CN(C(=O)O1)c1ccc(c(F)c1)-c1ccc(CNCc2cn[nH]n2)cc1, CC(=O)NC[C@H]1CN(C(=O)O1)c1ccc(c(F)c1)-c1ccc(CNCc2cn[nH]n2)cc1, CC(=O)NC[C@H]1CN(C(=O)O1)c1ccc(c(F)c1)-c1ccc(CNCc2cn[nH]n2)cc1	Phase 2
radiprodil	acetylcholine receptor antagonist				MedChemEx	97.93	Fc1ccc(CC2CCN(CC2)C(=O)C(=O)Nc2ccc3[nH]c(=O)oc3c2)cc1	Phase 2
radotinib	Bcr-Abl kinase inhibitor				Adooq	95.11	Cc1cn(cn1)-c1cc(NC(=O)c2ccc(C)c(Nc3nccc(n3)-c3cnccn3)c2)cc(c1)C(F)(F)F	Phase 3
RAD140	androgen receptor modulator				MedChemEx	96.01	[H][C@@](C)(O)[C@@]([H])(Nc1ccc(C#N)c(Cl)c1C)c1nnc(o1)-c1ccc(cc1)C#N	Phase 1
RAF265	RAF inhibitor, VEGFR inhibitor	BRAF			Tocris, Selleck, Selleck, Selleck	98.52	Cn1c(Nc2ccc(cc2)C(F)(F)F)nc2cc(Oc3ccnc(c3)-c3ncc([nH]3)C(F)(F)F)ccc12, Cn1c(Nc2ccc(cc2)C(F)(F)F)nc2cc(Oc3ccnc(c3)-c3ncc([nH]3)C(F)(F)F)ccc12, Cn1c(Nc2ccc(cc2)C(F)(F)F)nc2cc(Oc3ccnc(c3)-c3ncc([nH]3)C(F)(F)F)ccc12, Cn1c(Nc2ccc(cc2)C(F)(F)F)nc2cc(Oc3ccnc(c3)-c3ncc([nH]3)C(F)(F)F)ccc12	Phase 2
RAF709	RAF inhibitor				MedChemEx	96.68	Cc1ncc(NC(=O)c2cccc(c2)C(F)(F)F)cc1-c1cnc(OC2CCOCC2)c(c1)N1CCOCC1	Preclinical
ralinepag	IP1 prostacyclin receptor agonist				MedChemEx	91.2	OC(=O)COC[C@H]1CC[C@H](COC(=O)N(c2ccccc2)c2ccc(Cl)cc2)CC1 |r|	Phase 3
raloxifene	estrogen receptor antagonist, selective estrogen receptor modulator (SERM)	ESR1, ESR2	orthopedics, oncology	osteoporosis, breast cancer	MicroSource, MicroSource, Tocris, Tocris, Tocris, Selleck	98.21	Oc1ccc(cc1)-c1sc2cc(O)ccc2c1C(=O)c1ccc(OCCN2CCCCC2)cc1, Oc1ccc(cc1)-c1sc2cc(O)ccc2c1C(=O)c1ccc(OCCN2CCCCC2)cc1, Oc1ccc(cc1)-c1sc2cc(O)ccc2c1C(=O)c1ccc(OCCN2CCCCC2)cc1, Oc1ccc(cc1)-c1sc2cc(O)ccc2c1C(=O)c1ccc(OCCN2CCCCC2)cc1, Oc1ccc(cc1)-c1sc2cc(O)ccc2c1C(=O)c1ccc(OCCN2CCCCC2)cc1, Oc1ccc(cc1)-c1sc2cc(O)ccc2c1C(=O)c1ccc(OCCN2CCCCC2)cc1	Launched
raltegravir	HIV integrase inhibitor		infectious disease	human immunodeficiency virus (HIV-1)	Selleck, Selleck, Selleck	94.8	Cc1nnc(o1)C(=O)NC(C)(C)c1nc(C(=O)NCc2ccc(F)cc2)c(O)c(=O)n1C, Cc1nnc(o1)C(=O)NC(C)(C)c1nc(C(=O)NCc2ccc(F)cc2)c(O)c(=O)n1C, Cc1nnc(o1)C(=O)NC(C)(C)c1nc(C(=O)NCc2ccc(F)cc2)c(O)c(=O)n1C	Launched
raltitrexed	thymidylate synthase inhibitor	FPGS, TYMS	oncology	mesothelioma	MedChemEx, Selleck, Selleck, Selleck	93.68	CN(Cc1ccc2[nH]c(C)nc(=O)c2c1)c1ccc(s1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, CN(Cc1ccc2[nH]c(C)nc(=O)c2c1)c1ccc(s1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, CN(Cc1ccc2[nH]c(C)nc(=O)c2c1)c1ccc(s1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, CN(Cc1ccc2[nH]c(C)nc(=O)c2c1)c1ccc(s1)C(=O)N[C@@H](CCC(O)=O)C(O)=O	Launched
ramatroban	prostanoid receptor antagonist	PTGDR2, TBXA2R	cardiology, pulmonary	coronary artery disease (CAD), asthma	MedChemEx, MedChemEx, Tocris, Tocris	98.97	OC(=O)CCn1c2CC[C@H](Cc2c2ccccc12)NS(=O)(=O)c1ccc(F)cc1, OC(=O)CCn1c2CC[C@H](Cc2c2ccccc12)NS(=O)(=O)c1ccc(F)cc1, OC(=O)CCn1c2CC[C@H](Cc2c2ccccc12)NS(=O)(=O)c1ccc(F)cc1, OC(=O)CCn1c2CC[C@H](Cc2c2ccccc12)NS(=O)(=O)c1ccc(F)cc1	Launched
ramelteon	melatonin receptor agonist	MTNR1A, MTNR1B	neurology/psychiatry	insomnia	MicroSource, Selleck	98.49	CCC(=O)NCC[C@@H]1CCc2ccc3OCCc3c12, CCC(=O)NCC[C@@H]1CCc2ccc3OCCc3c12	Launched
ramifenazone	cyclooxygenase inhibitor		neurology/psychiatry, endocrinology	pain relief, fever	Key, Key, MicroSource	80.52	CC(C)Nc1c(C)n(C)n(-c2ccccc2)c1=O, CC(C)Nc1c(C)n(C)n(-c2ccccc2)c1=O, CC(C)Nc1c(C)n(C)n(-c2ccccc2)c1=O	Launched
ramipril	angiotensin converting enzyme inhibitor	ACE	cardiology	hypertension	MicroSource, Tocris, Tocris, Tocris, Selleck	98.06	CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1[C@H]2CCC[C@H]2C[C@H]1C(O)=O, CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1[C@H]2CCC[C@H]2C[C@H]1C(O)=O, CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1[C@H]2CCC[C@H]2C[C@H]1C(O)=O, CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1[C@H]2CCC[C@H]2C[C@H]1C(O)=O, CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1[C@H]2CCC[C@H]2C[C@H]1C(O)=O	Launched
ramosetron	serotonin receptor antagonist	HTR3A	gastroenterology	nausea, vomiting, irritable bowel syndrome	MedChemEx, MedChemEx	99.58	Cn1cc(C(=O)[C@@H]2CCc3nc[nH]c3C2)c2ccccc12, Cn1cc(C(=O)[C@@H]2CCc3nc[nH]c3C2)c2ccccc12	Launched
ranirestat	aldose reductase inhibitor	AKR1B1			MedChemEx, MedChemEx	96.29	Fc1cc(Br)ccc1CN1C(=O)c2cccn2[C@@]2(CC(=O)NC2=O)C1=O, Fc1cc(Br)ccc1CN1C(=O)c2cccn2[C@@]2(CC(=O)NC2=O)C1=O	Phase 3
ranitidine	histamine receptor antagonist	HRH2	gastroenterology	heartburn	Tocris	87.43	CN=C(C[N+]([O-])=O)NCCSCc1ccc(CN(C)C)o1	Launched
ranolazine	sodium channel blocker	SCN10A, SCN9A	cardiology	chronic stable angina	Tocris, Selleck, Selleck	98.13	COc1ccccc1OC[C@@H](O)CN1CCN(CC(=O)Nc2c(C)cccc2C)CC1 |&1:10|, COc1ccccc1OC[C@@H](O)CN1CCN(CC(=O)Nc2c(C)cccc2C)CC1 |&1:10|, COc1ccccc1OC[C@@H](O)CN1CCN(CC(=O)Nc2c(C)cccc2C)CC1 |&1:10|	Launched
rapastinel	glutamate receptor agonist				MedChemEx	0	C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(N)=O	Phase 2
rasagiline	monoamine oxidase inhibitor	BCL2, MAOB	neurology/psychiatry	Parkinson's Disease	Tocris, Selleck, MicroSource, MicroSource, Selleck, Selleck	98.6	C#CCN[C@@H]1CCc2ccccc12, C#CCN[C@@H]1CCc2ccccc12, C#CCN[C@@H]1CCc2ccccc12, C#CCN[C@@H]1CCc2ccccc12, C#CCN[C@@H]1CCc2ccccc12, C#CCN[C@@H]1CCc2ccccc12	Launched
rauwolscine	adrenergic receptor antagonist	ADRA2A, ADRA2B, ADRA2C, HTR1B, HTR1D, HTR1E, HTR2B			Tocris, Tocris, Tocris, Tocris	96.9	COC(=O)[C@@H]1[C@@H](O)CC[C@@H]2CN3CCc4c([nH]c5ccccc45)[C@@H]3C[C@H]12, COC(=O)[C@@H]1[C@@H](O)CC[C@@H]2CN3CCc4c([nH]c5ccccc45)[C@@H]3C[C@H]12, COC(=O)[C@@H]1[C@@H](O)CC[C@@H]2CN3CCc4c([nH]c5ccccc45)[C@@H]3C[C@H]12, COC(=O)[C@@H]1[C@@H](O)CC[C@@H]2CN3CCc4c([nH]c5ccccc45)[C@@H]3C[C@H]12	Preclinical
ravoxertinib	ERK1 and ERK2 phosphorylation inhibitor	MAPK1, MAPK3			MedChemEx, MedChemEx, Adooq, Adooq	98.38	Cn1nccc1Nc1nccc(n1)-c1ccn([C@H](CO)c2ccc(Cl)c(F)c2)c(=O)c1, Cn1nccc1Nc1nccc(n1)-c1ccn([C@H](CO)c2ccc(Cl)c(F)c2)c(=O)c1, Cn1nccc1Nc1nccc(n1)-c1ccn([C@H](CO)c2ccc(Cl)c(F)c2)c(=O)c1, Cn1nccc1Nc1nccc(n1)-c1ccn([C@H](CO)c2ccc(Cl)c(F)c2)c(=O)c1	Phase 1
ravuconazole	sterol demethylase inhibitor				Cayman, Cayman, Cayman	98.93	C[C@@H](c1nc(cs1)-c1ccc(cc1)C#N)[C@](O)(Cn1cncn1)c1ccc(F)cc1F, C[C@@H](c1nc(cs1)-c1ccc(cc1)C#N)[C@](O)(Cn1cncn1)c1ccc(F)cc1F, C[C@@H](c1nc(cs1)-c1ccc(cc1)C#N)[C@](O)(Cn1cncn1)c1ccc(F)cc1F	Phase 2
RBC8	Ral GTPase inhibitor	RALA, RALB			Tocris, MedChemEx, MedChemEx	84.72	COc1ccc(OC)c(c1)[C@@H]1C(C#N)C(=N)Oc2[nH]nc(c12)-c1ccc2ccccc2c1 |&1:10,r|, COc1ccc(OC)c(c1)[C@@H]1C(C#N)C(=N)Oc2[nH]nc(c12)-c1ccc2ccccc2c1 |&1:10,r|, COc1ccc(OC)c(c1)[C@@H]1C(C#N)C(=N)Oc2[nH]nc(c12)-c1ccc2ccccc2c1 |&1:10,r|	Preclinical
rebamipide	free radical scavenger	FPR1	gastroenterology	peptic ulcer disease (PUD), gastritis	MicroSource, MedChemEx, Selleck	98.72	OC(=O)[C@@H](Cc1cc(=O)[nH]c2ccccc12)NC(=O)c1ccc(Cl)cc1 |&1:3,r|, OC(=O)[C@@H](Cc1cc(=O)[nH]c2ccccc12)NC(=O)c1ccc(Cl)cc1 |&1:3,r|, OC(=O)[C@@H](Cc1cc(=O)[nH]c2ccccc12)NC(=O)c1ccc(Cl)cc1 |&1:3,r|	Launched
rebastinib	Bcr-Abl kinase inhibitor, TIE tyrosine kinase inhibitor, VEGFR inhibitor	ABL1, BCR, FGR, FLT3, HCK, LYN, SRC			MedChemEx, MedChemEx, MedChemEx, Selleck, Selleck, Selleck, Selleck	96.77	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3cc(nn3-c3ccc4ncccc4c3)C(C)(C)C)c(F)c2)ccn1, CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3cc(nn3-c3ccc4ncccc4c3)C(C)(C)C)c(F)c2)ccn1, CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3cc(nn3-c3ccc4ncccc4c3)C(C)(C)C)c(F)c2)ccn1, CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3cc(nn3-c3ccc4ncccc4c3)C(C)(C)C)c(F)c2)ccn1, CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3cc(nn3-c3ccc4ncccc4c3)C(C)(C)C)c(F)c2)ccn1, CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3cc(nn3-c3ccc4ncccc4c3)C(C)(C)C)c(F)c2)ccn1, CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3cc(nn3-c3ccc4ncccc4c3)C(C)(C)C)c(F)c2)ccn1	Phase 1/Phase 2
reboxetine	adrenergic receptor antagonist	SLC6A2	neurology/psychiatry	depression	Selleck, Tocris, MedChemEx	97.52	CCOc1ccccc1O[C@@H]([C@H]1CNCCO1)c1ccccc1 |&1:10,11|, CCOc1ccccc1O[C@@H]([C@H]1CNCCO1)c1ccccc1 |&1:10,11|, CCOc1ccccc1O[C@@H]([C@H]1CNCCO1)c1ccccc1 |&1:10,11|	Launched
Rec-15/2615	adrenergic receptor antagonist	ADRA1A			Tocris, Tocris	62.92	COc1cc2nc(nc(N)c2cc1OC)N1CCN(CC1)C(=O)COc1c(OC)cccc1C(C)C, COc1cc2nc(nc(N)c2cc1OC)N1CCN(CC1)C(=O)COc1c(OC)cccc1C(C)C	Phase 2
refametinib	MEK inhibitor	MAP2K1, MAP2K2			MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx	97.42	COc1cc(F)c(F)c(Nc2ccc(I)cc2F)c1NS(=O)(=O)C1(C[C@H](O)CO)CC1, COc1cc(F)c(F)c(Nc2ccc(I)cc2F)c1NS(=O)(=O)C1(C[C@H](O)CO)CC1, COc1cc(F)c(F)c(Nc2ccc(I)cc2F)c1NS(=O)(=O)C1(C[C@H](O)CO)CC1, COc1cc(F)c(F)c(Nc2ccc(I)cc2F)c1NS(=O)(=O)C1(C[C@H](O)CO)CC1, COc1cc(F)c(F)c(Nc2ccc(I)cc2F)c1NS(=O)(=O)C1(C[C@H](O)CO)CC1, COc1cc(F)c(F)c(Nc2ccc(I)cc2F)c1NS(=O)(=O)C1(C[C@H](O)CO)CC1	Phase 2
regadenoson	adenosine receptor agonist	ADORA1, ADORA2A, ADORA2B, ADORA3	radiology	myocardial perfusion imaging (MPI)	MedChemEx	95.62	CNC(=O)c1cnn(c1)-c1nc(N)c2ncn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c2n1	Launched
regorafenib	FGFR inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RAF inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor	ABL1, BRAF, DDR2, EPHA2, FGFR1, FGFR2, FLT1, FLT4, FRK, KDR, KIT, MAPK11, NTRK1, PDGFRA, PDGFRB, RAF1, RET, TEK	oncology	colorectal cancer, gastrointestinal stromal tumors (GIST)	Selleck, Selleck, Selleck, Selleck, Selleck, Selleck	97.87	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)c(F)c2)ccn1, CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)c(F)c2)ccn1, CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)c(F)c2)ccn1, CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)c(F)c2)ccn1, CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)c(F)c2)ccn1, CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)c(F)c2)ccn1	Launched
relcovaptan	vasopressin receptor antagonist	AVPR1A, AVPR1B, AVPR2, OXTR			Tocris, Tocris, Tocris	98.48	COc1ccc(cc1OC)S(=O)(=O)N1[C@@H](C(=O)N2CCC[C@H]2C(N)=O)[C@](O)(c2cc(Cl)ccc12)c1ccccc1Cl, COc1ccc(cc1OC)S(=O)(=O)N1[C@@H](C(=O)N2CCC[C@H]2C(N)=O)[C@](O)(c2cc(Cl)ccc12)c1ccccc1Cl, COc1ccc(cc1OC)S(=O)(=O)N1[C@@H](C(=O)N2CCC[C@H]2C(N)=O)[C@](O)(c2cc(Cl)ccc12)c1ccccc1Cl	Phase 2
relebactam	beta lactamase inhibitor				MedChemEx	86.36	OS(=O)(=O)ON1[C@H]2CN([C@@H](CC2)C(=O)NC2CCNCC2)C1=O	Launched
relugolix	gonadotropin releasing factor hormone receptor antagonist				MedChemEx	96.9	CONC(=O)Nc1ccc(cc1)-c1sc2n(Cc3c(F)cccc3F)c(=O)n(-c3ccc(OC)nn3)c(=O)c2c1CN(C)C	Phase 3
remacemide	glutamate receptor antagonist	GRIN1			Tocris, Tocris	97.95	C[C@@](Cc1ccccc1)(NC(=O)CN)c1ccccc1 |&1:1|, C[C@@](Cc1ccccc1)(NC(=O)CN)c1ccccc1 |&1:1|	Phase 3
remetinostat	HDAC inhibitor				MedChemEx	0	COC(=O)c1ccc(OC(=O)CCCCCCC(=O)NO)cc1	Phase 2
remimazolam	benzodiazepine receptor agonist	GABBR1			MedChemEx, MedChemEx	92.64	COC(=O)CC[C@@H]1N=C(c2ccccn2)c2cc(Br)ccc2-n2c(C)cnc12 |t:7|, COC(=O)CC[C@@H]1N=C(c2ccccn2)c2cc(Br)ccc2-n2c(C)cnc12 |t:7|	Phase 3
remodelin	transferase inhibitor	NAT10			Tocris, Tocris	82.53	N#Cc1ccc(cc1)-c1csc(NN=C2CCCC2)n1, N#Cc1ccc(cc1)-c1csc(NN=C2CCCC2)n1	Preclinical
remoxipride	dopamine receptor antagonist	DRD2, DRD3, DRD4, HTR2A, SIGMAR1			Tocris, Tocris, Tocris, Tocris, Tocris	98.5	CCN1CCC[C@H]1CNC(=O)c1c(OC)ccc(Br)c1OC, CCN1CCC[C@H]1CNC(=O)c1c(OC)ccc(Br)c1OC, CCN1CCC[C@H]1CNC(=O)c1c(OC)ccc(Br)c1OC, CCN1CCC[C@H]1CNC(=O)c1c(OC)ccc(Br)c1OC, CCN1CCC[C@H]1CNC(=O)c1c(OC)ccc(Br)c1OC	Withdrawn
repaglinide	insulin secretagogue	ABCC8, KCNJ11, PPARG	endocrinology	diabetes mellitus	Tocris, MicroSource, Tocris, Selleck, Tocris	99.06	CCOc1cc(CC(=O)N[C@@H](CC(C)C)c2ccccc2N2CCCCC2)ccc1C(O)=O, CCOc1cc(CC(=O)N[C@@H](CC(C)C)c2ccccc2N2CCCCC2)ccc1C(O)=O, CCOc1cc(CC(=O)N[C@@H](CC(C)C)c2ccccc2N2CCCCC2)ccc1C(O)=O, CCOc1cc(CC(=O)N[C@@H](CC(C)C)c2ccccc2N2CCCCC2)ccc1C(O)=O, CCOc1cc(CC(=O)N[C@@H](CC(C)C)c2ccccc2N2CCCCC2)ccc1C(O)=O	Launched
reparixin	CC chemokine receptor antagonist	CXCR1, CXCR2			MedChemEx, MedChemEx, MedChemEx, MedChemEx	99.13	CC(C)Cc1ccc(cc1)[C@@H](C)C(=O)NS(C)(=O)=O, CC(C)Cc1ccc(cc1)[C@@H](C)C(=O)NS(C)(=O)=O, CC(C)Cc1ccc(cc1)[C@@H](C)C(=O)NS(C)(=O)=O, CC(C)Cc1ccc(cc1)[C@@H](C)C(=O)NS(C)(=O)=O	Phase 3
repotrectinib	receptor tyrosine protein kinase inhibitor				MedChemEx	98.59	C[C@H]1CNC(=O)c2cnn3ccc(N[C@H](C)c4cc(F)ccc4O1)nc23	Phase 1/Phase 2
repsox	TGF beta receptor inhibitor	TGFBR1			Tocris, Tocris, Tocris, Selleck, Selleck, Selleck, Selleck, Tocris	98.05	Cc1cccc(n1)-c1n[nH]cc1-c1ccc2ncccc2n1, Cc1cccc(n1)-c1n[nH]cc1-c1ccc2ncccc2n1, Cc1cccc(n1)-c1n[nH]cc1-c1ccc2ncccc2n1, Cc1cccc(n1)-c1n[nH]cc1-c1ccc2ncccc2n1, Cc1cccc(n1)-c1n[nH]cc1-c1ccc2ncccc2n1, Cc1cccc(n1)-c1n[nH]cc1-c1ccc2ncccc2n1, Cc1cccc(n1)-c1n[nH]cc1-c1ccc2ncccc2n1, Cc1cccc(n1)-c1n[nH]cc1-c1ccc2ncccc2n1	Preclinical
resatorvid	toll-like receptor inhibitor	TLR4			MedChemEx, MedChemEx, MedChemEx	96.53	CCOC(=O)C1=CCCC[C@H]1S(=O)(=O)Nc1ccc(F)cc1Cl |t:5|, CCOC(=O)C1=CCCC[C@H]1S(=O)(=O)Nc1ccc(F)cc1Cl |t:5|, CCOC(=O)C1=CCCC[C@H]1S(=O)(=O)Nc1ccc(F)cc1Cl |t:5|	Phase 3
reserpine	vesicular monoamine transporter inhibitor	SLC18A1, SLC18A2	cardiology	hypertension	Selleck, Selleck, Tocris, Tocris, Tocris, Selleck, MicroSource	95.32	CO[C@H]1[C@@H](C[C@@H]2CN3CCc4c([nH]c5cc(OC)ccc45)[C@H]3C[C@@H]2[C@@H]1C(=O)OC)OC(=O)c1cc(OC)c(OC)c(OC)c1, CO[C@H]1[C@@H](C[C@@H]2CN3CCc4c([nH]c5cc(OC)ccc45)[C@H]3C[C@@H]2[C@@H]1C(=O)OC)OC(=O)c1cc(OC)c(OC)c(OC)c1, CO[C@H]1[C@@H](C[C@@H]2CN3CCc4c([nH]c5cc(OC)ccc45)[C@H]3C[C@@H]2[C@@H]1C(=O)OC)OC(=O)c1cc(OC)c(OC)c(OC)c1, CO[C@H]1[C@@H](C[C@@H]2CN3CCc4c([nH]c5cc(OC)ccc45)[C@H]3C[C@@H]2[C@@H]1C(=O)OC)OC(=O)c1cc(OC)c(OC)c(OC)c1, CO[C@H]1[C@@H](C[C@@H]2CN3CCc4c([nH]c5cc(OC)ccc45)[C@H]3C[C@@H]2[C@@H]1C(=O)OC)OC(=O)c1cc(OC)c(OC)c(OC)c1, CO[C@H]1[C@@H](C[C@@H]2CN3CCc4c([nH]c5cc(OC)ccc45)[C@H]3C[C@@H]2[C@@H]1C(=O)OC)OC(=O)c1cc(OC)c(OC)c(OC)c1, CO[C@H]1[C@@H](C[C@@H]2CN3CCc4c([nH]c5cc(OC)ccc45)[C@H]3C[C@@H]2[C@@H]1C(=O)OC)OC(=O)c1cc(OC)c(OC)c(OC)c1	Launched
resibufogenin	Na/K-ATPase inhibitor				MedChemEx	87.34	C[C@]12CC[C@H]3[C@@H](CC[C@@H]4C[C@@H](O)CC[C@]34C)[C@]11O[C@@H]1C[C@@H]2c1ccc(=O)oc1	Phase 2
resiquimod	toll-like receptor agonist	TLR7, TLR8			Tocris, Tocris, MedChemEx, MedChemEx	99.64	CCOCc1nc2c(N)nc3ccccc3c2n1CC(C)(C)O, CCOCc1nc2c(N)nc3ccccc3c2n1CC(C)(C)O, CCOCc1nc2c(N)nc3ccccc3c2n1CC(C)(C)O, CCOCc1nc2c(N)nc3ccccc3c2n1CC(C)(C)O	Phase 3
resmetirom	thyroid hormone receptor agonist				MedChemEx	96.94	CC(C)c1cc(Oc2c(Cl)cc(cc2Cl)-n2nc(C#N)c(=O)[nH]c2=O)nnc1O	Phase 3
resminostat	HDAC inhibitor	HDAC1, HDAC3, HDAC6, HDAC8			MedChemEx, MedChemEx, MedChemEx, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck	96.04	CN(C)Cc1ccc(cc1)S(=O)(=O)n1ccc(\C=C\C(=O)NO)c1, CN(C)Cc1ccc(cc1)S(=O)(=O)n1ccc(\C=C\C(=O)NO)c1, CN(C)Cc1ccc(cc1)S(=O)(=O)n1ccc(\C=C\C(=O)NO)c1, CN(C)Cc1ccc(cc1)S(=O)(=O)n1ccc(\C=C\C(=O)NO)c1, CN(C)Cc1ccc(cc1)S(=O)(=O)n1ccc(\C=C\C(=O)NO)c1, CN(C)Cc1ccc(cc1)S(=O)(=O)n1ccc(\C=C\C(=O)NO)c1, CN(C)Cc1ccc(cc1)S(=O)(=O)n1ccc(\C=C\C(=O)NO)c1, CN(C)Cc1ccc(cc1)S(=O)(=O)n1ccc(\C=C\C(=O)NO)c1, CN(C)Cc1ccc(cc1)S(=O)(=O)n1ccc(\C=C\C(=O)NO)c1, CN(C)Cc1ccc(cc1)S(=O)(=O)n1ccc(\C=C\C(=O)NO)c1, CN(C)Cc1ccc(cc1)S(=O)(=O)n1ccc(\C=C\C(=O)NO)c1	Phase 2
resorcinol	phosphodiesterase inhibitor	CA12, CA14, CA2, PTGS1	dermatology	acne vulgaris (AV), eczema, psoriasis, seborrheic dermatitis	MedChemEx, MicroSource, MicroSource	99.52	Oc1cccc(O)c1, Oc1cccc(O)c1, Oc1cccc(O)c1	Launched
resorcinol-monoacetate	antiseptic				MicroSource, MedChemEx	70.52	CC(=O)Oc1cccc(O)c1, CC(=O)Oc1cccc(O)c1	Launched
resveratrol	cytochrome P450 inhibitor, SIRT activator	CSNK2A1, NQO2, PTGS1, PTGS2			MedChemEx, Tocris, Selleck, Selleck, Tocris	95.03	Oc1ccc(\C=C\c2cc(O)cc(O)c2)cc1, Oc1ccc(\C=C\c2cc(O)cc(O)c2)cc1, Oc1ccc(\C=C\c2cc(O)cc(O)c2)cc1, Oc1ccc(\C=C\c2cc(O)cc(O)c2)cc1, Oc1ccc(\C=C\c2cc(O)cc(O)c2)cc1	Launched
retagliptin	dipeptidyl peptidase inhibitor				MedChemEx	90.32	COC(=O)c1nc(n2CCN(Cc12)C(=O)C[C@H](N)Cc1cc(F)c(F)cc1F)C(F)(F)F	Phase 1
retapamulin	protein synthesis inhibitor		infectious disease	impetigo	Selleck	100	C[C@@H]1CC[C@@]23CCC(=O)[C@H]2[C@]1(C)[C@@H](C[C@@](C)(C=C)[C@@H](O)[C@@H]3C)OC(=O)CS[C@H]1C[C@@H]2CC[C@H](C1)N2C	Launched
retaspimycin	HSP inhibitor	HSP90AA1			MedChemEx, MedChemEx	0	CO[C@H]1C[C@H](C)Cc2c(O)c(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)cc(O)c2NCC=C |c:17,t:15,28|, CO[C@H]1C[C@H](C)Cc2c(O)c(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)cc(O)c2NCC=C |c:17,t:15,28|	Phase 3
retinaldehyde			dermatology	cosmetic	SantaCruz	96.68	C\C(\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C)=C/C=O |c:9|	Launched
retinol	retinoid receptor ligand	ALDH1A1, ALDH1A2, ALDH1A3, DHRS3, DHRS4, LRAT, NR2C2, RBP1, RBP3, RDH11, RDH12, RDH13, RDH14, RDH5, RDH8, RETSAT, RHO, RLBP1, RXRA, RXRB, RXRG	dermatology	cosmetic, acne vulgaris (AV), keratosis	Sigma, MicroSource	0	C\C(=C/CO)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C |c:12|, C\C(=C/CO)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C |c:12|	Launched
retinyl-acetate					MicroSource, Sigma	0	CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C |c:15|, CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C |c:15|	Launched
retinyl-palmitate					MicroSource, Sigma	0	CCCCCCCCCCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C |c:29|, CCCCCCCCCCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C |c:29|	Launched
REV-5901	leukotriene receptor antagonist, lipoxygenase inhibitor	ALOX5			Sigma, Sigma, Enzo, Enzo	97.83	CCCCC[C@@H](O)c1cccc(OCc2ccc3ccccc3n2)c1 |&1:5,r|, CCCCC[C@@H](O)c1cccc(OCc2ccc3ccccc3n2)c1 |&1:5,r|, CCCCC[C@@H](O)c1cccc(OCc2ccc3ccccc3n2)c1 |&1:5,r|, CCCCC[C@@H](O)c1cccc(OCc2ccc3ccccc3n2)c1 |&1:5,r|	Phase 2
revaprazan	potassium-competitive acid antagonist	ATP4A	gastroenterology	gastritis	AvaChem	0	C[C@H]1N(CCc2ccccc12)c1nc(Nc2ccc(F)cc2)nc(C)c1C |&1:1,r|	Launched
revefenacin	cholinergic receptor antagonist				MedChemEx	97.72	CN(CCN1CCC(CC1)OC(=O)Nc1ccccc1-c1ccccc1)C(=O)c1ccc(CN2CCC(CC2)C(N)=O)cc1	Launched
reversan	MRP inhibitor	ABCC1			Tocris, Tocris, Tocris	96.72	O=C(NCCCN1CCOCC1)c1cnn2c(cc(nc12)-c1ccccc1)-c1ccccc1, O=C(NCCCN1CCOCC1)c1cnn2c(cc(nc12)-c1ccccc1)-c1ccccc1, O=C(NCCCN1CCOCC1)c1cnn2c(cc(nc12)-c1ccccc1)-c1ccccc1	Preclinical
reversine	Aurora kinase inhibitor	AURKB, INCENP, MAP2K1			MedChemEx, MedChemEx, MedChemEx	83.16	C1CCC(CC1)Nc1nc(Nc2ccc(cc2)N2CCOCC2)nc2nc[nH]c12, C1CCC(CC1)Nc1nc(Nc2ccc(cc2)N2CCOCC2)nc2nc[nH]c12, C1CCC(CC1)Nc1nc(Nc2ccc(cc2)N2CCOCC2)nc2nc[nH]c12	Preclinical
reynoutrin	antioxidant				MedChemEx, MedChemEx	100	O[C@@H]1CO[C@@H](Oc2c(oc3cc(O)cc(O)c3c2=O)-c2ccc(O)c(O)c2)[C@H](O)[C@H]1O, O[C@@H]1CO[C@@H](Oc2c(oc3cc(O)cc(O)c3c2=O)-c2ccc(O)c(O)c2)[C@H](O)[C@H]1O	Preclinical
RGB-286638	CDK inhibitor	CDK1, CDK2, CDK3, CDK4, CDK5, CDK6, CDK7, CDK9, FLT3, GSK3B, JAK2, MAP3K7, MAPK9			MedChemEx, MedChemEx, MedChemEx, MedChemEx	93.17	COCCN1CCN(Cc2ccc(cc2)-c2n[nH]c3-c4cccc(NC(=O)NN5CCOCC5)c4C(=O)c23)CC1, COCCN1CCN(Cc2ccc(cc2)-c2n[nH]c3-c4cccc(NC(=O)NN5CCOCC5)c4C(=O)c23)CC1, COCCN1CCN(Cc2ccc(cc2)-c2n[nH]c3-c4cccc(NC(=O)NN5CCOCC5)c4C(=O)c23)CC1, COCCN1CCN(Cc2ccc(cc2)-c2n[nH]c3-c4cccc(NC(=O)NN5CCOCC5)c4C(=O)c23)CC1	Phase 1
RGFP966	HDAC inhibitor	HDAC3			Selleck, Selleck, Selleck	93.69	Nc1cc(F)ccc1NC(=O)\C=C\c1cnn(C\C=C\c2ccccc2)c1, Nc1cc(F)ccc1NC(=O)\C=C\c1cnn(C\C=C\c2ccccc2)c1, Nc1cc(F)ccc1NC(=O)\C=C\c1cnn(C\C=C\c2ccccc2)c1	Preclinical
RGX-104	LXR agonist				MedChemEx	94.52	C[C@H](CCOc1cccc(CC(O)=O)c1)N(CC(c1ccccc1)c1ccccc1)Cc1cccc(c1Cl)C(F)(F)F	Phase 1
RG108	DNA methyltransferase inhibitor	DNMT1, DNMT3B			Tocris, Tocris, Tocris, Selleck	98.82	OC(=O)[C@H](Cc1c[nH]c2ccccc12)N1C(=O)c2ccccc2C1=O, OC(=O)[C@H](Cc1c[nH]c2ccccc12)N1C(=O)c2ccccc2C1=O, OC(=O)[C@H](Cc1c[nH]c2ccccc12)N1C(=O)c2ccccc2C1=O, OC(=O)[C@H](Cc1c[nH]c2ccccc12)N1C(=O)c2ccccc2C1=O	Preclinical
RG1530	FGFR inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	FGFR1, FGFR2			MedChemEx, MedChemEx, MedChemEx, Tocris	58.63	COc1cc2N=C3NN=C(C)C3N=C(c3ccccc3Cl)c2cc1F |t:5,8,13|, COc1cc2N=C3NN=C(C)C3N=C(c3ccccc3Cl)c2cc1F |t:5,8,13|, COc1cc2N=C3NN=C(C)C3N=C(c3ccccc3Cl)c2cc1F |t:5,8,13|, COc1cc2N=C3NN=C(C)C3N=C(c3ccccc3Cl)c2cc1F |t:5,8,13|	Phase 1
RG2833	HDAC inhibitor	HDAC1, HDAC3			MedChemEx, MedChemEx, MedChemEx, MedChemEx, Selleck	97.98	Cc1ccc(cc1)C(=O)NCCCCCC(=O)Nc1ccccc1N, Cc1ccc(cc1)C(=O)NCCCCCC(=O)Nc1ccccc1N, Cc1ccc(cc1)C(=O)NCCCCCC(=O)Nc1ccccc1N, Cc1ccc(cc1)C(=O)NCCCCCC(=O)Nc1ccccc1N, Cc1ccc(cc1)C(=O)NCCCCCC(=O)Nc1ccccc1N	Phase 1
RG4733	gamma secretase inhibitor	PSEN1			MedChemEx, MedChemEx, MedChemEx, MedChemEx	98.56	CC(C)(C(=O)NCC(F)(F)C(F)(F)F)C(=O)N[C@H]1c2ccccc2-c2ccccc2NC1=O, CC(C)(C(=O)NCC(F)(F)C(F)(F)F)C(=O)N[C@H]1c2ccccc2-c2ccccc2NC1=O, CC(C)(C(=O)NCC(F)(F)C(F)(F)F)C(=O)N[C@H]1c2ccccc2-c2ccccc2NC1=O, CC(C)(C(=O)NCC(F)(F)C(F)(F)F)C(=O)N[C@H]1c2ccccc2-c2ccccc2NC1=O	Phase 2
RG7112	MDM inhibitor	MDM2			Selleck	98.54	CCOc1cc(ccc1C1=N[C@@](C)(c2ccc(Cl)cc2)[C@](C)(N1C(=O)N1CCN(CCCS(C)(=O)=O)CC1)c1ccc(Cl)cc1)C(C)(C)C |t:10|	Phase 1
RG7800	RNA splicing modifier				MedChemEx	75.37	CCc1nc(C)cn2nc(cc12)-c1cc(=O)n2cc(cc(C)c2n1)C1CCN(C)CC1	Preclinical
RG7834	antiviral				Astatech	94.87	COCCCOc1cc2C[C@@H](C(C)C)n3cc(C(O)=O)c(=O)cc3-c2cc1OC	Preclinical
RHC-80267	triacylglycerol lipase inhibitor	DAGLA, DAGLB			Tocris, Tocris, Tocris	95.7	O=C(NCCCCCCNC(=O)ON=C1CCCCC1)ON=C1CCCCC1, O=C(NCCCCCCNC(=O)ON=C1CCCCC1)ON=C1CCCCC1, O=C(NCCCCCCNC(=O)ON=C1CCCCC1)ON=C1CCCCC1	Preclinical
rhein		HSP90AA1			MedChemEx, Selleck, Selleck	97.12	OC(=O)c1cc(O)c2C(=O)c3c(O)cccc3C(=O)c2c1, OC(=O)c1cc(O)c2C(=O)c3c(O)cccc3C(=O)c2c1, OC(=O)c1cc(O)c2C(=O)c3c(O)cccc3C(=O)c2c1	Phase 1
rheochrysidin	protein tyrosine kinase inhibitor	PTPN1			Selleck, Selleck, Selleck	86.96	COc1cc(O)c2C(=O)c3c(O)cc(C)cc3C(=O)c2c1, COc1cc(O)c2C(=O)c3c(O)cc(C)cc3C(=O)c2c1, COc1cc(O)c2C(=O)c3c(O)cc(C)cc3C(=O)c2c1	Preclinical
rhodamine-123					Cayman, Cayman, Cayman	95.8	COC(=O)c1ccccc1-c1c2ccc(N)cc2[o+]c2cc(N)ccc12, COC(=O)c1ccccc1-c1c2ccc(N)cc2[o+]c2cc(N)ccc12, COC(=O)c1ccccc1-c1c2ccc(N)cc2[o+]c2cc(N)ccc12	Phase 1
RI-1		RAD51			Tocris, Selleck	90.39	ClC1=C(N2CCOCC2)C(=O)N(C1=O)c1ccc(Cl)c(Cl)c1 |c:1|, ClC1=C(N2CCOCC2)C(=O)N(C1=O)c1ccc(Cl)c(Cl)c1 |c:1|	Preclinical
ribavirin	antiviral	ADK, ENPP1, IMPDH1, IMPDH2, NT5C2	infectious disease	hepatitis C	Tocris, Tocris, Tocris, MicroSource, Selleck	100	NC(=O)c1ncn(n1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O, NC(=O)c1ncn(n1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O, NC(=O)c1ncn(n1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O, NC(=O)c1ncn(n1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O, NC(=O)c1ncn(n1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O	Launched
ribitol					MedChemEx, Selleck	100	OC[C@H](O)[C@H](O)[C@H](O)CO, OC[C@H](O)[C@H](O)[C@H](O)CO	Preclinical
ribociclib	CDK inhibitor	CDK4, CDK6	oncology	breast cancer	MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx, Selleck, Selleck, Selleck	93.42	CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1, CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1, CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1, CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1, CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1, CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1, CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1, CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1	Launched
riboflavin	vitamin B	BLVRB, RFK	gastroenterology	jaundice	Selleck, Selleck, MedChemEx, Selleck	91.09	Cc1cc2nc3c(nc(=O)[nH]c3=O)n(C[C@H](O)[C@H](O)[C@H](O)CO)c2cc1C, Cc1cc2nc3c(nc(=O)[nH]c3=O)n(C[C@H](O)[C@H](O)[C@H](O)CO)c2cc1C, Cc1cc2nc3c(nc(=O)[nH]c3=O)n(C[C@H](O)[C@H](O)[C@H](O)CO)c2cc1C, Cc1cc2nc3c(nc(=O)[nH]c3=O)n(C[C@H](O)[C@H](O)[C@H](O)CO)c2cc1C	Launched
riboflavin-tetrabutyrate	antioxidant				MedChemEx	92.24	CCCC(=O)OC[C@@H](OC(=O)CCC)[C@@H](OC(=O)CCC)[C@H](Cn1c2cc(C)c(C)cc2nc2c1nc(=O)[nH]c2=O)OC(=O)CCC	Preclinical
riboflavin-5-phosphate-sodium		BLVRB, DHODH, DPYD, HAO1, HAO2, MT-ND1, NOS1, PNPO, POR, PPCDC, RFK, RPS6KA4, SGK1			MedChemEx, Sigma, Sigma	70.1	Cc1cc2nc3c(nc(=O)[nH]c3=O)n(C[C@H](O)[C@H](O)[C@H](O)COP(O)(O)=O)c2cc1C, Cc1cc2nc3c(nc(=O)[nH]c3=O)n(C[C@H](O)[C@H](O)[C@H](O)COP(O)(O)=O)c2cc1C, Cc1cc2nc3c(nc(=O)[nH]c3=O)n(C[C@H](O)[C@H](O)[C@H](O)COP(O)(O)=O)c2cc1C	Launched
ribostamycin	bacterial 30S ribosomal subunit inhibitor	P4HB	infectious disease	human immunodeficiency virus (HIV-1)	MedChemEx, MedChemEx, MedChemEx	73.8	NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O)[C@H]2O[C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)[C@H](N)[C@@H](O)[C@@H]1O, NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O)[C@H]2O[C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)[C@H](N)[C@@H](O)[C@@H]1O, NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O)[C@H]2O[C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)[C@H](N)[C@@H](O)[C@@H]1O	Launched
ribostamycin-sulfate	bacterial 30S ribosomal subunit inhibitor		infectious disease	gram-negative bacterial infections	MicroSource	0	NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O)[C@@H]2O[C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)[C@H](N)[C@@H](O)[C@@H]1O |a:2,4,6,7,10,12,16,18,21,23,25,27,29,&1:14|	Launched
ricinoleic-acid	prostanoid receptor agonist	PTGER3			TCI	51.56	CCCCCC[C@@H](O)C\C=C/CCCCCCCC(O)=O	Launched
ridinilazole	antibacterial				MedChemEx	97.14	c1cc(ccn1)-c1nc2ccc(cc2[nH]1)-c1ccc2nc([nH]c2c1)-c1ccncc1	Phase 3
rifabutin	protein synthesis inhibitor		infectious disease	human immunodeficiency virus (HIV-1)	MedChemEx	96.93	CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2C4=NC5(CCN(CC(C)C)CC5)NC4=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(=O)c2c(O)c3C |c:36,t:3,15,30,38|	Launched
rifampin	RNA polymerase inhibitor	NR1I2, SLCO1A2, SLCO1B1, SLCO1B3	infectious disease	tuberculosis, meningitis	Selleck, Selleck, Tocris, Selleck, Selleck	89.01	CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c(O)c(\C=N\N4CCN(C)CC4)c(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C |c:33,t:3,35|, CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c(O)c(\C=N\N4CCN(C)CC4)c(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C |c:33,t:3,35|, CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c(O)c(\C=N\N4CCN(C)CC4)c(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C |c:33,t:3,35|, CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c(O)c(\C=N\N4CCN(C)CC4)c(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C |c:33,t:3,35|, CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c(O)c(\C=N\N4CCN(C)CC4)c(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C |c:33,t:3,35|	Launched
rifamycin	DNA directed RNA polymerase inhibitor	SLCO1A2, SLCO1B1, SLCO1B3, SLCO2B1	infectious disease	tuberculosis, leprosy	AvaChem	2.86	CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c(O)cc(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C |c:23,t:3,25|	Launched
rifamycin-sv	RNA synthesis inhibitor				Selleck	96.94	CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c(O)cc(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C |c:23,t:3,25|	Phase 3
rifapentine	RNA polymerase inhibitor	CYP2C8, CYP2C9, CYP3A4	infectious disease	tuberculosis	Selleck, MedChemEx, MedChemEx, Selleck, Selleck	74.29	CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c(O)c(\C=N\N4CCN(CC4)C4CCCC4)c(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C |c:38,t:3,40|, CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c(O)c(\C=N\N4CCN(CC4)C4CCCC4)c(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C |c:38,t:3,40|, CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c(O)c(\C=N\N4CCN(CC4)C4CCCC4)c(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C |c:38,t:3,40|, CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c(O)c(\C=N\N4CCN(CC4)C4CCCC4)c(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C |c:38,t:3,40|, CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c(O)c(\C=N\N4CCN(CC4)C4CCCC4)c(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C |c:38,t:3,40|	Launched
rifaximin	RNA synthesis inhibitor		gastroenterology	diarrhea, irritable bowel syndrome, hepatic encephalopathy (HE)	Tocris, Tocris	98.57	CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c4nc5cc(C)ccn5c4c(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C |c:32,t:3,34|, CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c4nc5cc(C)ccn5c4c(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C |c:32,t:3,34|	Launched
rigosertib	cell cycle inhibitor, PLK inhibitor	PLK1			Selleck, MedChemEx, Selleck, Selleck, Selleck, Selleck, Selleck	94.32	COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1, COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1, COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1, COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1, COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1, COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1, COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1	Phase 3
rilapladib	phospholipase inhibitor				MedChemEx	96.22	COCCN1CCC(CC1)N(Cc1ccc(cc1)-c1ccc(cc1)C(F)(F)F)C(=O)Cn1c(SCc2cccc(F)c2F)cc(=O)c2ccccc12	Phase 2
rilmenidine	adrenergic receptor agonist, imidazoline receptor agonist	ADRA2A	cardiology	hypertension	Tocris, Selleck, Selleck	88.74	C1CC1C(NC1=NCCO1)C1CC1 |t:6|, C1CC1C(NC1=NCCO1)C1CC1 |t:6|, C1CC1C(NC1=NCCO1)C1CC1 |t:6|	Launched
rilpivirine	non-nucleoside reverse transcriptase inhibitor	NR1I2, SCN10A	infectious disease	human immunodeficiency virus (HIV-1)	MedChemEx, MedChemEx, Selleck	93.71	Cc1cc(\C=C\C#N)cc(C)c1Nc1ccnc(Nc2ccc(cc2)C#N)n1, Cc1cc(\C=C\C#N)cc(C)c1Nc1ccnc(Nc2ccc(cc2)C#N)n1, Cc1cc(\C=C\C#N)cc(C)c1Nc1ccnc(Nc2ccc(cc2)C#N)n1	Launched
riluzole	glutamate inhibitor	KCNK10, KCNK2, KCNK4, KCNN4, SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A, SLC7A11	neurology/psychiatry	amyotrophic lateral sclerosis (ALS)	Tocris, MicroSource, Selleck, Selleck	99.88	Nc1nc2ccc(OC(F)(F)F)cc2s1, Nc1nc2ccc(OC(F)(F)F)cc2s1, Nc1nc2ccc(OC(F)(F)F)cc2s1, Nc1nc2ccc(OC(F)(F)F)cc2s1	Launched
rimantadine	antiviral, RNA synthesis inhibitor		infectious disease	influenza A virus infection	Selleck, Selleck, Selleck	100	C[C@@H](N)C12CC3CC(CC(C3)C1)C2 |&1:1,r|, C[C@@H](N)C12CC3CC(CC(C3)C1)C2 |&1:1,r|, C[C@@H](N)C12CC3CC(CC(C3)C1)C2 |&1:1,r|	Launched
rimcazole	sigma receptor antagonist	SIGMAR1			Tocris, Tocris	96.68	C[C@H]1CN(CCCn2c3ccccc3c3ccccc23)C[C@@H](C)N1, C[C@H]1CN(CCCn2c3ccccc3c3ccccc23)C[C@@H](C)N1	Phase 1
rimegepant	calcitonin antagonist	CALCA			MedChemEx, MedChemEx, MedChemEx	95.12	N[C@H]1[C@@H](CC[C@@H](OC(=O)N2CCC(CC2)n2c3cccnc3[nH]c2=O)c2ncccc12)c1cccc(F)c1F, N[C@H]1[C@@H](CC[C@@H](OC(=O)N2CCC(CC2)n2c3cccnc3[nH]c2=O)c2ncccc12)c1cccc(F)c1F, N[C@H]1[C@@H](CC[C@@H](OC(=O)N2CCC(CC2)n2c3cccnc3[nH]c2=O)c2ncccc12)c1cccc(F)c1F	Launched
rimeporide	sodium/hydrogen exchanger inhibitor				Sigma	94.96	Cc1cc(c(cc1C(=O)NC(N)=N)S(C)(=O)=O)S(C)(=O)=O	Phase 1
rimexolone	glucocorticoid receptor agonist	NR3C1, SERPINA6	ophthalmology	anterior uveitis	Prestwick, Prestwick, USP	97.27	CCC(=O)[C@@]1(C)[C@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C |c:17,t:13|, CCC(=O)[C@@]1(C)[C@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C |c:17,t:13|, CCC(=O)[C@@]1(C)[C@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C |c:17,t:13|	Launched
rimonabant	cannabinoid receptor antagonist	CNR1, GPR55			Selleck, Selleck, MedChemEx	97.2	Cc1c(nn(c1-c1ccc(Cl)cc1)-c1ccc(Cl)cc1Cl)C(=O)NN1CCCCC1, Cc1c(nn(c1-c1ccc(Cl)cc1)-c1ccc(Cl)cc1Cl)C(=O)NN1CCCCC1, Cc1c(nn(c1-c1ccc(Cl)cc1)-c1ccc(Cl)cc1Cl)C(=O)NN1CCCCC1	Withdrawn
riociguat	guanylate cyclase stimulant	GUCY1A2, GUCY1A3, GUCY1B2, GUCY1B3	cardiology	hypertension	MedChemEx, MedChemEx, MedChemEx	99.03	COC(=O)N(C)c1c(N)nc(nc1N)-c1nn(Cc2ccccc2F)c2ncccc12, COC(=O)N(C)c1c(N)nc(nc1N)-c1nn(Cc2ccccc2F)c2ncccc12, COC(=O)N(C)c1c(N)nc(nc1N)-c1nn(Cc2ccccc2F)c2ncccc12	Launched
riodipine	calcium channel blocker				Sigma, Sigma	97.87	COC(=O)C1=C(C)NC(C)=C(C1c1ccccc1OC(F)F)C(=O)OC |c:4,9|, COC(=O)C1=C(C)NC(C)=C(C1c1ccccc1OC(F)F)C(=O)OC |c:4,9|	Phase 2
riodoxol	other antibiotic				Vitas-M, Vitas-M, Vitas-M	31.26	Oc1c(I)cc(I)c(O)c1I, Oc1c(I)cc(I)c(O)c1I, Oc1c(I)cc(I)c(O)c1I	Launched
ripasudil	rho associated kinase inhibitor	ROCK1, ROCK2	ophthalmology	glaucoma, ocular hypertension	MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx	98.73	C[C@H]1CNCCCN1S(=O)(=O)c1cccc2cncc(F)c12, C[C@H]1CNCCCN1S(=O)(=O)c1cccc2cncc(F)c12, C[C@H]1CNCCCN1S(=O)(=O)c1cccc2cncc(F)c12, C[C@H]1CNCCCN1S(=O)(=O)c1cccc2cncc(F)c12, C[C@H]1CNCCCN1S(=O)(=O)c1cccc2cncc(F)c12, C[C@H]1CNCCCN1S(=O)(=O)c1cccc2cncc(F)c12	Launched
ripazepam	benzodiazepine receptor agonist	GABRA1			Sigma, Sigma	99.45	CCn1nc(C)c2NC(=O)CN=C(c12)c1ccccc1 |c:11|, CCn1nc(C)c2NC(=O)CN=C(c12)c1ccccc1 |c:11|	Phase 2
ripretinib	receptor tyrosine protein kinase inhibitor				MedChemEx	95.43	CCn1c2cc(NC)ncc2cc(-c2cc(NC(=O)Nc3ccccc3)c(F)cc2Br)c1=O	Phase 3
risdiplam	RNA splicing inhibitor				MedChemEx	56.36	Cc1cn2nc(cc(C)c2n1)-c1cc(=O)n2cc(ccc2n1)N1CCNC2(CC2)C1	Phase 2/Phase 3
risedronate	osteoclast inhibitor	FDPS	orthopedics, endocrinology	osteoporosis, Paget's disease	MicroSource, Selleck, Selleck, Selleck, Selleck	0	OC(Cc1cccnc1)(P(O)(O)=O)P(O)(O)=O, OC(Cc1cccnc1)(P(O)(O)=O)P(O)(O)=O, OC(Cc1cccnc1)(P(O)(O)=O)P(O)(O)=O, OC(Cc1cccnc1)(P(O)(O)=O)P(O)(O)=O, OC(Cc1cccnc1)(P(O)(O)=O)P(O)(O)=O	Launched
rislenemdaz	ionotropic glutamate receptor antagonist				MedChemEx	94.73	Cc1ccc(COC(=O)N2CC[C@H](CNc3ncccn3)[C@H](F)C2)cc1	Preclinical
risperidone	dopamine receptor antagonist, serotonin receptor antagonist	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, HRH1, HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2C, HTR6, HTR7	neurology/psychiatry	schizophrenia, bipolar disorder, irritability	MicroSource, Selleck	98.34	Cc1nc2CCCCn2c(=O)c1CCN1CCC(CC1)c1noc2cc(F)ccc12, Cc1nc2CCCCn2c(=O)c1CCN1CCC(CC1)c1noc2cc(F)ccc12	Launched
RITA	MDM inhibitor	MDM2			Selleck, Selleck, Selleck	87.3	OCc1ccc(s1)-c1ccc(o1)-c1ccc(CO)s1, OCc1ccc(s1)-c1ccc(o1)-c1ccc(CO)s1, OCc1ccc(s1)-c1ccc(o1)-c1ccc(CO)s1	Preclinical
ritanserin	serotonin receptor antagonist	ADRA1A, ADRA1B, ADRA1D, HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C, HTR5A, HTR6, HTR7			Tocris, Tocris, MicroSource, Tocris, Tocris, Tocris	98.51	Cc1nc2sccn2c(=O)c1CCN1CCC(CC1)=C(c1ccc(F)cc1)c1ccc(F)cc1, Cc1nc2sccn2c(=O)c1CCN1CCC(CC1)=C(c1ccc(F)cc1)c1ccc(F)cc1, Cc1nc2sccn2c(=O)c1CCN1CCC(CC1)=C(c1ccc(F)cc1)c1ccc(F)cc1, Cc1nc2sccn2c(=O)c1CCN1CCC(CC1)=C(c1ccc(F)cc1)c1ccc(F)cc1, Cc1nc2sccn2c(=O)c1CCN1CCC(CC1)=C(c1ccc(F)cc1)c1ccc(F)cc1, Cc1nc2sccn2c(=O)c1CCN1CCC(CC1)=C(c1ccc(F)cc1)c1ccc(F)cc1	Phase 3
ritodrine	adrenergic receptor agonist		obstetrics/gynecology	premature labor	Selleck, Selleck, MedChemEx, MedChemEx	98.11	C[C@@H](NCCc1ccc(O)cc1)[C@@H](O)c1ccc(O)cc1 |&1:1,12|, C[C@@H](NCCc1ccc(O)cc1)[C@@H](O)c1ccc(O)cc1 |&1:1,12|, C[C@@H](NCCc1ccc(O)cc1)[C@@H](O)c1ccc(O)cc1 |&1:1,12|, C[C@@H](NCCc1ccc(O)cc1)[C@@H](O)c1ccc(O)cc1 |&1:1,12|	Withdrawn
ritonavir	HIV protease inhibitor	CYP1A2, CYP2B6, CYP2C19, CYP2C8, CYP2C9, CYP2D6, CYP2E1, CYP3A4, CYP3A5, CYP3A7	infectious disease	human immunodeficiency virus (HIV-1)	Selleck, Selleck, Selleck	98.16	CC(C)[C@H](NC(=O)N(C)Cc1csc(n1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)Cc1ccccc1, CC(C)[C@H](NC(=O)N(C)Cc1csc(n1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)Cc1ccccc1, CC(C)[C@H](NC(=O)N(C)Cc1csc(n1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)Cc1ccccc1	Launched
rivanicline	acetylcholine receptor agonist	CHRNA4, CHRNB2, CXCL8			MedChemEx, Enzo	97.21	CNCC\C=C\c1cccnc1, CNCC\C=C\c1cccnc1	Phase 2
rivaroxaban	coagulation factor inhibitor	F10	neurology/psychiatry, hematology, cardiology	stroke, systemic embolism, atrial fibrillation (AF), deep vein thrombosis (DVT), pulmonary embolism (PE)	MicroSource, Selleck, Selleck	97.02	Clc1ccc(s1)C(=O)NC[C@H]1CN(C(=O)O1)c1ccc(cc1)N1CCOCC1=O, Clc1ccc(s1)C(=O)NC[C@H]1CN(C(=O)O1)c1ccc(cc1)N1CCOCC1=O, Clc1ccc(s1)C(=O)NC[C@H]1CN(C(=O)O1)c1ccc(cc1)N1CCOCC1=O	Launched
rivastigmine	acetylcholinesterase inhibitor	ACHE, BCHE	neurology/psychiatry	Alzheimer's disease, Parkinson's Disease, senile dementia	Tocris, MicroSource, MicroSource, MicroSource, Tocris, Selleck, Tocris	97.89	CCN(C)C(=O)Oc1cccc(c1)[C@H](C)N(C)C, CCN(C)C(=O)Oc1cccc(c1)[C@H](C)N(C)C, CCN(C)C(=O)Oc1cccc(c1)[C@H](C)N(C)C, CCN(C)C(=O)Oc1cccc(c1)[C@H](C)N(C)C, CCN(C)C(=O)Oc1cccc(c1)[C@H](C)N(C)C, CCN(C)C(=O)Oc1cccc(c1)[C@H](C)N(C)C, CCN(C)C(=O)Oc1cccc(c1)[C@H](C)N(C)C	Launched
rizatriptan	serotonin receptor agonist	HTR1A, HTR1B, HTR1D, HTR1E, HTR1F	neurology/psychiatry	migraine headache	Tocris, MicroSource, Selleck, Selleck	93.99	CN(C)CCc1c[nH]c2ccc(Cn3cncn3)cc12, CN(C)CCc1c[nH]c2ccc(Cn3cncn3)cc12, CN(C)CCc1c[nH]c2ccc(Cn3cncn3)cc12, CN(C)CCc1c[nH]c2ccc(Cn3cncn3)cc12	Launched
RKI-1447	rho associated kinase inhibitor	CDC42BPA, DMPK, LIMK1, MYLK, PAK1, PKN1, ROCK1, ROCK2			Tocris, Tocris, Selleck, Selleck	98.46	Oc1cccc(CNC(=O)Nc2nc(cs2)-c2ccncc2)c1, Oc1cccc(CNC(=O)Nc2nc(cs2)-c2ccncc2)c1, Oc1cccc(CNC(=O)Nc2nc(cs2)-c2ccncc2)c1, Oc1cccc(CNC(=O)Nc2nc(cs2)-c2ccncc2)c1	Preclinical
RLX					Vitas-M, Vitas-M	95.72	O=c1n2CCCCCc2nc2ccccc12, O=c1n2CCCCCc2nc2ccccc12	Preclinical
RMC-4550	SHIP2 phosphatase inhibitor				MedChemEx, MedChemEx	96.25	C[C@@H]1OCC2(CCN(CC2)c2nc(C)c(nc2CO)-c2cccc(Cl)c2Cl)[C@@H]1N, C[C@@H]1OCC2(CCN(CC2)c2nc(C)c(nc2CO)-c2cccc(Cl)c2Cl)[C@@H]1N	Preclinical
RN-1	histone demethylase inhibitor	KDM1A			Tocris, Tocris	96.56	CN1CCN(CC1)C(=O)CN[C@@H]1C[C@H]1c1ccc(OCc2ccccc2)cc1, CN1CCN(CC1)C(=O)CN[C@@H]1C[C@H]1c1ccc(OCc2ccccc2)cc1	Preclinical
RN-1734	TRPV antagonist	TRPV4			Tocris, Tocris, Tocris, Tocris, Tocris, Tocris, Tocris	94.74	CC(C)NCCN(C(C)C)S(=O)(=O)c1ccc(Cl)cc1Cl, CC(C)NCCN(C(C)C)S(=O)(=O)c1ccc(Cl)cc1Cl, CC(C)NCCN(C(C)C)S(=O)(=O)c1ccc(Cl)cc1Cl, CC(C)NCCN(C(C)C)S(=O)(=O)c1ccc(Cl)cc1Cl, CC(C)NCCN(C(C)C)S(=O)(=O)c1ccc(Cl)cc1Cl, CC(C)NCCN(C(C)C)S(=O)(=O)c1ccc(Cl)cc1Cl, CC(C)NCCN(C(C)C)S(=O)(=O)c1ccc(Cl)cc1Cl	Preclinical
RN-1747	TRPV agonist	TRPV4			Tocris, Tocris, Tocris, Tocris	96.7	[O-][N+](=O)c1cc(Cl)ccc1S(=O)(=O)N1CCN(Cc2ccccc2)CC1, [O-][N+](=O)c1cc(Cl)ccc1S(=O)(=O)N1CCN(Cc2ccccc2)CC1, [O-][N+](=O)c1cc(Cl)ccc1S(=O)(=O)N1CCN(Cc2ccccc2)CC1, [O-][N+](=O)c1cc(Cl)ccc1S(=O)(=O)N1CCN(Cc2ccccc2)CC1	Preclinical
Ro-04-5595	glutamate receptor antagonist	GRIN2B			Tocris, Tocris, Tocris	94.07	COc1cc2CCN(C)[C@@H](CCc3ccc(Cl)cc3)c2cc1O |&1:9|, COc1cc2CCN(C)[C@@H](CCc3ccc(Cl)cc3)c2cc1O |&1:9|, COc1cc2CCN(C)[C@@H](CCc3ccc(Cl)cc3)c2cc1O |&1:9|	Preclinical
Ro-08-2750	NGF binding inhibitor	NGF, NGFR			Tocris, Tocris, Tocris	96.19	Cc1cc2nc3c(nc(=O)[nH]c3=O)n(C)c2cc1C=O, Cc1cc2nc3c(nc(=O)[nH]c3=O)n(C)c2cc1C=O, Cc1cc2nc3c(nc(=O)[nH]c3=O)n(C)c2cc1C=O	Preclinical
Ro-10-5824	dopamine receptor agonist	DRD4			Tocris, Tocris, Tocris, Tocris	93.04	Cc1ncc(CN2CCC(=CC2)c2ccccc2)c(N)n1 |c:9|, Cc1ncc(CN2CCC(=CC2)c2ccccc2)c(N)n1 |c:9|, Cc1ncc(CN2CCC(=CC2)c2ccccc2)c(N)n1 |c:9|, Cc1ncc(CN2CCC(=CC2)c2ccccc2)c(N)n1 |c:9|	Preclinical
Ro-106-9920	NFkB pathway inhibitor				Tocris, Tocris, Tocris, Tocris, Tocris, Tocris, Tocris, Tocris, Tocris	94.47	O=[S@@](c1ccccc1)c1ccc2nnnn2n1 |&1:1,r|, O=[S@@](c1ccccc1)c1ccc2nnnn2n1 |&1:1,r|, O=[S@@](c1ccccc1)c1ccc2nnnn2n1 |&1:1,r|, O=[S@@](c1ccccc1)c1ccc2nnnn2n1 |&1:1,r|, O=[S@@](c1ccccc1)c1ccc2nnnn2n1 |&1:1,r|, O=[S@@](c1ccccc1)c1ccc2nnnn2n1 |&1:1,r|, O=[S@@](c1ccccc1)c1ccc2nnnn2n1 |&1:1,r|, O=[S@@](c1ccccc1)c1ccc2nnnn2n1 |&1:1,r|, O=[S@@](c1ccccc1)c1ccc2nnnn2n1 |&1:1,r|	Preclinical
Ro-1138452	prostanoid receptor antagonist	PTGIR			Tocris, Tocris, Tocris, Tocris	96.69	CC(C)Oc1ccc(Cc2ccc(NC3=NCCN3)cc2)cc1 |t:14|, CC(C)Oc1ccc(Cc2ccc(NC3=NCCN3)cc2)cc1 |t:14|, CC(C)Oc1ccc(Cc2ccc(NC3=NCCN3)cc2)cc1 |t:14|, CC(C)Oc1ccc(Cc2ccc(NC3=NCCN3)cc2)cc1 |t:14|	Preclinical
Ro-15-4513	GABA benzodiazepine site receptor inverse agonist	GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB2, GABRG2			Tocris, Tocris	94.05	CCOC(=O)c1ncn-2c1CN(C)C(=O)c1cc(ccc-21)N=[N+]=[N-], CCOC(=O)c1ncn-2c1CN(C)C(=O)c1cc(ccc-21)N=[N+]=[N-]	Preclinical
Ro-19-4605	GABA benzodiazepine site receptor inverse agonist	GABRA1, GABRA2, GABRA3, GABRA5			Tocris, Tocris, Tocris, Tocris	98.3	CN1Cc2c(ncn2-c2ccsc2C1=O)C(=O)OC(C)(C)C, CN1Cc2c(ncn2-c2ccsc2C1=O)C(=O)OC(C)(C)C, CN1Cc2c(ncn2-c2ccsc2C1=O)C(=O)OC(C)(C)C, CN1Cc2c(ncn2-c2ccsc2C1=O)C(=O)OC(C)(C)C	Preclinical
Ro-20-1724	phosphodiesterase inhibitor	PDE3A, PDE4A, PDE4B, PDE4C, PDE4D			Tocris, Tocris, Tocris, Tocris, Tocris	98.13	CCCCOc1cc(C[C@H]2CNC(=O)N2)ccc1OC |&1:9,r|, CCCCOc1cc(C[C@H]2CNC(=O)N2)ccc1OC |&1:9,r|, CCCCOc1cc(C[C@H]2CNC(=O)N2)ccc1OC |&1:9,r|, CCCCOc1cc(C[C@H]2CNC(=O)N2)ccc1OC |&1:9,r|, CCCCOc1cc(C[C@H]2CNC(=O)N2)ccc1OC |&1:9,r|	Preclinical
Ro-25-6981	glutamate receptor antagonist, monamine transporter modulator	GRIN2B			Tocris, Tocris, Tocris, Tocris	97.03	C[C@@H](CN1CCC(Cc2ccccc2)CC1)[C@@H](O)c1ccc(O)cc1, C[C@@H](CN1CCC(Cc2ccccc2)CC1)[C@@H](O)c1ccc(O)cc1, C[C@@H](CN1CCC(Cc2ccccc2)CC1)[C@@H](O)c1ccc(O)cc1, C[C@@H](CN1CCC(Cc2ccccc2)CC1)[C@@H](O)c1ccc(O)cc1	Preclinical
Ro-28-1675	glucokinase activator	GCK			MedChemEx	99.65	CS(=O)(=O)c1ccc(cc1)[C@@H](CC1CCCC1)C(=O)Nc1nccs1	Preclinical
Ro-3	purinergic receptor antagonist	P2RX3			Tocris, Tocris, Tocris, Tocris	97.4	COc1cc(Cc2cnc(N)nc2N)c(cc1OC)C(C)C, COc1cc(Cc2cnc(N)nc2N)c(cc1OC)C(C)C, COc1cc(Cc2cnc(N)nc2N)c(cc1OC)C(C)C, COc1cc(Cc2cnc(N)nc2N)c(cc1OC)C(C)C	Preclinical
Ro-3306	CDK inhibitor	CDK1			Tocris, Tocris, Tocris	95.74	O=C1N=C(NCc2cccs2)S\C1=C/c1ccc2ncccc2c1 |t:2|, O=C1N=C(NCc2cccs2)S\C1=C/c1ccc2ncccc2c1 |t:2|, O=C1N=C(NCc2cccs2)S\C1=C/c1ccc2ncccc2c1 |t:2|	Preclinical
Ro-48-6791	GABA receptor modulator				Astatech	92.98	CCCN(CCC)Cc1nc(no1)-c1ncn-2c1CN(C)C(=O)c1cc(F)ccc-21	Preclinical
Ro-48-8071	oxidosqualene cyclase inhibitor	LSS			Tocris, Tocris, MedChemEx	96.64	CN(CCCCCCOc1ccc(C(=O)c2ccc(Br)cc2)c(F)c1)CC=C, CN(CCCCCCOc1ccc(C(=O)c2ccc(Br)cc2)c(F)c1)CC=C, CN(CCCCCCOc1ccc(C(=O)c2ccc(Br)cc2)c(F)c1)CC=C	Preclinical
Ro-4987655	MEK inhibitor	MAP2K1			MedChemEx, MedChemEx, MedChemEx	97.43	OCCONC(=O)c1cc(CN2OCCCC2=O)c(F)c(F)c1Nc1ccc(I)cc1F, OCCONC(=O)c1cc(CN2OCCCC2=O)c(F)c(F)c1Nc1ccc(I)cc1F, OCCONC(=O)c1cc(CN2OCCCC2=O)c(F)c(F)c1Nc1ccc(I)cc1F	Phase 1
Ro-5028442	vasopressin receptor antagonist				MedChemEx	99.2	CN(C)CCn1cc(C(=O)N2CCC3(CC2)OCc2ccccc32)c2ccc(Cl)cc12	Phase 1
Ro-5126766	MEK inhibitor, RAF inhibitor	BRAF, MAP2K1, MAP2K2, RAF1			MedChemEx, Selleck, MedChemEx	96.39	CNS(=O)(=O)Nc1nccc(Cc2c(C)c3ccc(Oc4ncccn4)cc3oc2=O)c1F, CNS(=O)(=O)Nc1nccc(Cc2c(C)c3ccc(Oc4ncccn4)cc3oc2=O)c1F, CNS(=O)(=O)Nc1nccc(Cc2c(C)c3ccc(Oc4ncccn4)cc3oc2=O)c1F	Phase 1
Ro-5263397	trace amine associated receptor agonist				Sigma	83.41	Cc1c(F)cccc1[C@H]1COC(N)=N1 |c:13|	Preclinical
Ro-60-0175	serotonin receptor agonist	HTR2A, HTR2B, HTR2C			Tocris, Tocris, Tocris, Tocris, Tocris	95.35	C[C@H](N)Cn1ccc2cc(F)c(Cl)cc12, C[C@H](N)Cn1ccc2cc(F)c(Cl)cc12, C[C@H](N)Cn1ccc2cc(F)c(Cl)cc12, C[C@H](N)Cn1ccc2cc(F)c(Cl)cc12, C[C@H](N)Cn1ccc2cc(F)c(Cl)cc12	Preclinical
Ro-61-8048	kynurenine 3-monooxygenase inhibitor	KMO			Tocris, MedChemEx, Tocris	98.09	COc1ccc(cc1OC)S(=O)(=O)Nc1nc(cs1)-c1cccc(c1)[N+]([O-])=O, COc1ccc(cc1OC)S(=O)(=O)Nc1nc(cs1)-c1cccc(c1)[N+]([O-])=O, COc1ccc(cc1OC)S(=O)(=O)Nc1nc(cs1)-c1cccc(c1)[N+]([O-])=O	Preclinical
Ro-67-7476	glutamate receptor positive allosteric modulator	GRM1			Tocris, Tocris	93.68	Cc1ccc(cc1)S(=O)(=O)N1CCC[C@H]1c1ccc(F)cc1, Cc1ccc(cc1)S(=O)(=O)N1CCC[C@H]1c1ccc(F)cc1	Preclinical
Ro-90-7501	beta amyloid protein neurotoxicity inhibitor	APP			Tocris, Tocris, Tocris, Tocris	90.66	Nc1ccc(cc1)-c1nc2ccc(cc2[nH]1)-c1nc2ccc(N)cc2[nH]1, Nc1ccc(cc1)-c1nc2ccc(cc2[nH]1)-c1nc2ccc(N)cc2[nH]1, Nc1ccc(cc1)-c1nc2ccc(cc2[nH]1)-c1nc2ccc(N)cc2[nH]1, Nc1ccc(cc1)-c1nc2ccc(cc2[nH]1)-c1nc2ccc(N)cc2[nH]1	Preclinical
Ro-9187	HCV inhibitor				MedChemEx, MedChemEx, MedChemEx	98.91	Nc1ccn([C@@H]2O[C@@](CO)(N=[N+]=[N-])[C@@H](O)[C@@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@@](CO)(N=[N+]=[N-])[C@@H](O)[C@@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@@](CO)(N=[N+]=[N-])[C@@H](O)[C@@H]2O)c(=O)n1	Preclinical
robalzotan	serotonin receptor antagonist	HTR1A			Tocris, Tocris, Tocris	95.29	NC(=O)c1ccc(F)c2OC[C@@H](Cc12)N(C1CCC1)C1CCC1, NC(=O)c1ccc(F)c2OC[C@@H](Cc12)N(C1CCC1)C1CCC1, NC(=O)c1ccc(F)c2OC[C@@H](Cc12)N(C1CCC1)C1CCC1	Phase 2
roblitinib	FGFR inhibitor				MedChemEx	94.87	COCCNc1cc(NC(=O)N2CCCc3cc(CN4CCN(C)CC4=O)c(C=O)nc23)ncc1C#N	Preclinical
rociletinib	EGFR inhibitor	EGFR			Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck	98.92	COc1cc(ccc1Nc1ncc(c(Nc2cccc(NC(=O)C=C)c2)n1)C(F)(F)F)N1CCN(CC1)C(C)=O, COc1cc(ccc1Nc1ncc(c(Nc2cccc(NC(=O)C=C)c2)n1)C(F)(F)F)N1CCN(CC1)C(C)=O, COc1cc(ccc1Nc1ncc(c(Nc2cccc(NC(=O)C=C)c2)n1)C(F)(F)F)N1CCN(CC1)C(C)=O, COc1cc(ccc1Nc1ncc(c(Nc2cccc(NC(=O)C=C)c2)n1)C(F)(F)F)N1CCN(CC1)C(C)=O, COc1cc(ccc1Nc1ncc(c(Nc2cccc(NC(=O)C=C)c2)n1)C(F)(F)F)N1CCN(CC1)C(C)=O, COc1cc(ccc1Nc1ncc(c(Nc2cccc(NC(=O)C=C)c2)n1)C(F)(F)F)N1CCN(CC1)C(C)=O, COc1cc(ccc1Nc1ncc(c(Nc2cccc(NC(=O)C=C)c2)n1)C(F)(F)F)N1CCN(CC1)C(C)=O, COc1cc(ccc1Nc1ncc(c(Nc2cccc(NC(=O)C=C)c2)n1)C(F)(F)F)N1CCN(CC1)C(C)=O, COc1cc(ccc1Nc1ncc(c(Nc2cccc(NC(=O)C=C)c2)n1)C(F)(F)F)N1CCN(CC1)C(C)=O, COc1cc(ccc1Nc1ncc(c(Nc2cccc(NC(=O)C=C)c2)n1)C(F)(F)F)N1CCN(CC1)C(C)=O, COc1cc(ccc1Nc1ncc(c(Nc2cccc(NC(=O)C=C)c2)n1)C(F)(F)F)N1CCN(CC1)C(C)=O, COc1cc(ccc1Nc1ncc(c(Nc2cccc(NC(=O)C=C)c2)n1)C(F)(F)F)N1CCN(CC1)C(C)=O	Phase 3
rocuronium	acetylcholine receptor antagonist	CHRM2, CHRNA2, HTR3A	neurology/psychiatry	anesthetic	MicroSource, MicroSource, Selleck	100	CC(=O)O[C@H]1[C@H](C[C@H]2[C@@H]3CC[C@H]4C[C@H](O)[C@H](C[C@]4(C)[C@H]3CC[C@]12C)N1CCOCC1)[N+]1(CC=C)CCCC1, CC(=O)O[C@H]1[C@H](C[C@H]2[C@@H]3CC[C@H]4C[C@H](O)[C@H](C[C@]4(C)[C@H]3CC[C@]12C)N1CCOCC1)[N+]1(CC=C)CCCC1, CC(=O)O[C@H]1[C@H](C[C@H]2[C@@H]3CC[C@H]4C[C@H](O)[C@H](C[C@]4(C)[C@H]3CC[C@]12C)N1CCOCC1)[N+]1(CC=C)CCCC1	Launched
rofecoxib	cyclooxygenase inhibitor	ELN, PTGS2			MicroSource, MedChemEx, MedChemEx, Sigma, Selleck, Selleck	98.36	CS(=O)(=O)c1ccc(cc1)C1=C(C(=O)OC1)c1ccccc1 |t:11|, CS(=O)(=O)c1ccc(cc1)C1=C(C(=O)OC1)c1ccccc1 |t:11|, CS(=O)(=O)c1ccc(cc1)C1=C(C(=O)OC1)c1ccccc1 |t:11|, CS(=O)(=O)c1ccc(cc1)C1=C(C(=O)OC1)c1ccccc1 |t:11|, CS(=O)(=O)c1ccc(cc1)C1=C(C(=O)OC1)c1ccccc1 |t:11|, CS(=O)(=O)c1ccc(cc1)C1=C(C(=O)OC1)c1ccccc1 |t:11|	Withdrawn
roflumilast	phosphodiesterase inhibitor	PDE4A, PDE4B, PDE4C, PDE4D	pulmonary	chronic obstructive pulmonary disease (COPD), bronchitis	Selleck, Selleck	99.14	FC(F)Oc1ccc(cc1OCC1CC1)C(=O)Nc1c(Cl)cncc1Cl, FC(F)Oc1ccc(cc1OCC1CC1)C(=O)Nc1c(Cl)cncc1Cl	Launched
rogaratinib	FGFR inhibitor				MedChemEx	96.76	COCc1c(CN2CCNC(=O)C2)n2ncnc(N)c2c1-c1cc2cc(C)cc(OC)c2s1	Phase 2/Phase 3
rolapitant	neurokinin receptor antagonist				MedChemEx	94.98	[H][C@](C)(OC[C@]1(CC[C@]2(CCC(=O)N2)CN1)c1ccccc1)c1cc(cc(c1)C(F)(F)F)C(F)(F)F	Phase 3
rolipram	phosphodiesterase inhibitor				Tocris, MicroSource, MicroSource, Tocris, Selleck	98.11	COc1ccc(cc1OC1CCCC1)[C@H]1CNC(=O)C1 |&1:14,r|, COc1ccc(cc1OC1CCCC1)[C@H]1CNC(=O)C1 |&1:14,r|, COc1ccc(cc1OC1CCCC1)[C@H]1CNC(=O)C1 |&1:14,r|, COc1ccc(cc1OC1CCCC1)[C@H]1CNC(=O)C1 |&1:14,r|, COc1ccc(cc1OC1CCCC1)[C@H]1CNC(=O)C1 |&1:14,r|	Phase 3
rolitetracycline	bacterial 30S ribosomal subunit inhibitor		infectious disease	gram-negative bacterial infections, gram-positive bacterial infections	MicroSource, Selleck, Selleck, Selleck	2.99	CN(C)[C@H]1[C@@H]2C[C@H]3C(=C(O)[C@]2(O)C(O)=C(C(=O)NCN2CCCC2)C1=O)C(=O)c1c(O)cccc1[C@@]3(C)O |a:3,4,6,10,35,&1:7,&2:14,t:7,14|, CN(C)[C@H]1[C@@H]2C[C@H]3C(=C(O)[C@]2(O)C(O)=C(C(=O)NCN2CCCC2)C1=O)C(=O)c1c(O)cccc1[C@@]3(C)O |a:3,4,6,10,35,&1:7,&2:14,t:7,14|, CN(C)[C@H]1[C@@H]2C[C@H]3C(=C(O)[C@]2(O)C(O)=C(C(=O)NCN2CCCC2)C1=O)C(=O)c1c(O)cccc1[C@@]3(C)O |a:3,4,6,10,35,&1:7,&2:14,t:7,14|, CN(C)[C@H]1[C@@H]2C[C@H]3C(=C(O)[C@]2(O)C(O)=C(C(=O)NCN2CCCC2)C1=O)C(=O)c1c(O)cccc1[C@@]3(C)O |a:3,4,6,10,35,&1:7,&2:14,t:7,14|	Launched
roluperidone					MedChemEx	100	Fc1ccc(cc1)C(=O)CN1CCC(CN2Cc3ccccc3C2=O)CC1	Phase 2
rolziracetam					Sigma	97.8	O=C1CCC2CCC(=O)N12	Phase 2
romidepsin	HDAC inhibitor	HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9	hematologic malignancy	cutaneous T-cell lymphoma (CTCL)	MedChemEx, MedChemEx, MedChemEx, MedChemEx, Selleck, Selleck, Selleck	98.84	C\C=C1/NC(=O)[C@H]2CSSCC\C=C\[C@H](CC(=O)N[C@H](C(C)C)C(=O)N2)OC(=O)[C@@H](NC1=O)C(C)C |t:12|, C\C=C1/NC(=O)[C@H]2CSSCC\C=C\[C@H](CC(=O)N[C@H](C(C)C)C(=O)N2)OC(=O)[C@@H](NC1=O)C(C)C |t:12|, C\C=C1/NC(=O)[C@H]2CSSCC\C=C\[C@H](CC(=O)N[C@H](C(C)C)C(=O)N2)OC(=O)[C@@H](NC1=O)C(C)C |t:12|, C\C=C1/NC(=O)[C@H]2CSSCC\C=C\[C@H](CC(=O)N[C@H](C(C)C)C(=O)N2)OC(=O)[C@@H](NC1=O)C(C)C |t:12|, C\C=C1/NC(=O)[C@H]2CSSCC\C=C\[C@H](CC(=O)N[C@H](C(C)C)C(=O)N2)OC(=O)[C@@H](NC1=O)C(C)C |t:12|, C\C=C1/NC(=O)[C@H]2CSSCC\C=C\[C@H](CC(=O)N[C@H](C(C)C)C(=O)N2)OC(=O)[C@@H](NC1=O)C(C)C |t:12|, C\C=C1/NC(=O)[C@H]2CSSCC\C=C\[C@H](CC(=O)N[C@H](C(C)C)C(=O)N2)OC(=O)[C@@H](NC1=O)C(C)C |t:12|	Launched
ronidazole	antiprotozoal agent		infectious disease	histomoniasis, dysentry	MedChemEx, MicroSource, Selleck	99.46	Cn1c(COC(N)=O)ncc1[N+]([O-])=O, Cn1c(COC(N)=O)ncc1[N+]([O-])=O, Cn1c(COC(N)=O)ncc1[N+]([O-])=O	Launched
ropinirole	dopamine receptor agonist	ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C	neurology/psychiatry	Parkinson's Disease, restless leg syndrome	MicroSource, Selleck, Selleck, Tocris	97.67	CCCN(CCC)CCc1cccc2NC(=O)Cc12, CCCN(CCC)CCc1cccc2NC(=O)Cc12, CCCN(CCC)CCc1cccc2NC(=O)Cc12, CCCN(CCC)CCc1cccc2NC(=O)Cc12	Launched
ropivacaine	sodium channel blocker	SCN10A	neurology/psychiatry	anesthetic	MedChemEx, MedChemEx, Selleck	97.16	CCCN1CCCC[C@H]1C(=O)Nc1c(C)cccc1C, CCCN1CCCC[C@H]1C(=O)Nc1c(C)cccc1C, CCCN1CCCC[C@H]1C(=O)Nc1c(C)cccc1C	Launched
roquinimex	angiogenesis inhibitor, tumor necrosis factor production inhibitor				Tocris, Tocris, Tocris	96.21	CN(C(=O)c1c(O)c2ccccc2n(C)c1=O)c1ccccc1, CN(C(=O)c1c(O)c2ccccc2n(C)c1=O)c1ccccc1, CN(C(=O)c1c(O)c2ccccc2n(C)c1=O)c1ccccc1	Phase 3
rosamicin	protein synthesis inhibitor				Vitas-M	95.1	CC[C@H]1OC(=O)C[C@@H](O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@H](CC=O)C[C@@H](C)C(=O)\C=C\[C@]2(C)O[C@H]2[C@@H]1C |t:34|	Phase 2
roscovitine	CDK inhibitor	CDK2, CDK9			Selleck, Selleck, Selleck, Selleck	97.94	CC[C@H](CO)Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1, CC[C@H](CO)Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1, CC[C@H](CO)Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1, CC[C@H](CO)Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1	Phase 2
rose-bengal	contrast agent, immunostimulant		radiology	diagnostic agent	Acros, SantaCruz, SantaCruz	77.2	OC(=O)c1c(Cl)c(Cl)c(Cl)c(Cl)c1-c1c2cc(I)c(O)c(I)c2oc2c(I)c(=O)c(I)cc12, OC(=O)c1c(Cl)c(Cl)c(Cl)c(Cl)c1-c1c2cc(I)c(O)c(I)c2oc2c(I)c(=O)c(I)cc12, OC(=O)c1c(Cl)c(Cl)c(Cl)c(Cl)c1-c1c2cc(I)c(O)c(I)c2oc2c(I)c(=O)c(I)cc12	Launched
rose-bengal-lactone	coloring agent		ophthalmology	staining agent	CombiBlocks, CombiBlocks	73.73	Oc1c(I)cc2c(Oc3c(I)c(O)c(I)cc3C22OC(=O)c3c2c(Cl)c(Cl)c(Cl)c3Cl)c1I, Oc1c(I)cc2c(Oc3c(I)c(O)c(I)cc3C22OC(=O)c3c2c(Cl)c(Cl)c(Cl)c3Cl)c1I	Launched
rosiglitazone	insulin sensitizer, PPAR receptor agonist	FFAR1, PPARG, TRPC5, TRPM3			Selleck, Selleck	98.53	CN(CCOc1ccc(C[C@H]2SC(=O)NC2=O)cc1)c1ccccn1 |&1:10|, CN(CCOc1ccc(C[C@H]2SC(=O)NC2=O)cc1)c1ccccn1 |&1:10|	Withdrawn
rosiptor	SHIP1 phosphatase activator				MedChemEx	100	[H][C@@]12CCC(=C)[C@@]1(C)CC[C@@]([H])([C@H]2CN)[C@@]1(C)CC[C@H](O)C[C@@H]1CO	Phase 2
rosmarinic-acid	GABA transaminase inhibitor	MCL1, TYR			Tocris, Tocris, Tocris, Tocris	94.4	OC(=O)[C@@H](Cc1ccc(O)c(O)c1)OC(=O)\C=C\c1ccc(O)c(O)c1, OC(=O)[C@@H](Cc1ccc(O)c(O)c1)OC(=O)\C=C\c1ccc(O)c(O)c1, OC(=O)[C@@H](Cc1ccc(O)c(O)c1)OC(=O)\C=C\c1ccc(O)c(O)c1, OC(=O)[C@@H](Cc1ccc(O)c(O)c1)OC(=O)\C=C\c1ccc(O)c(O)c1	Launched
rosoxacin	topoisomerase inhibitor		infectious disease	urinary tract infections	Accela	98.05	CCn1cc(C(O)=O)c(=O)c2ccc(cc12)-c1ccncc1	Launched
rostafuroxine	ATPase inhibitor	ATP1A1			Tocris, Tocris, MedChemEx	98.28	C[C@]12CC[C@H]3[C@@H](CC[C@@H]4C[C@@H](O)CC[C@]34C)[C@@]1(O)CC[C@]2(O)c1ccoc1, C[C@]12CC[C@H]3[C@@H](CC[C@@H]4C[C@@H](O)CC[C@]34C)[C@@]1(O)CC[C@]2(O)c1ccoc1, C[C@]12CC[C@H]3[C@@H](CC[C@@H]4C[C@@H](O)CC[C@]34C)[C@@]1(O)CC[C@]2(O)c1ccoc1	Phase 2
rosuvastatin	HMGCR inhibitor	HMGCR	endocrinology, cardiology	hyperlipidemia, dyslipidemia, hypertriglyceridemia, hypercholesterolemia, atherosclerosis	MicroSource, MicroSource, Pharmeks, Pharmeks, Tocris, Selleck, Selleck	95.27	CC(C)c1nc(nc(-c2ccc(F)cc2)c1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)N(C)S(C)(=O)=O, CC(C)c1nc(nc(-c2ccc(F)cc2)c1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)N(C)S(C)(=O)=O, CC(C)c1nc(nc(-c2ccc(F)cc2)c1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)N(C)S(C)(=O)=O, CC(C)c1nc(nc(-c2ccc(F)cc2)c1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)N(C)S(C)(=O)=O, CC(C)c1nc(nc(-c2ccc(F)cc2)c1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)N(C)S(C)(=O)=O, CC(C)c1nc(nc(-c2ccc(F)cc2)c1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)N(C)S(C)(=O)=O, CC(C)c1nc(nc(-c2ccc(F)cc2)c1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)N(C)S(C)(=O)=O	Launched
rotigotine	dopamine receptor agonist	ADRA2B, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A	neurology/psychiatry	Parkinson's Disease, restless leg syndrome	Tocris, MedChemEx, Tocris	98.62	CCCN(CCc1cccs1)[C@H]1CCc2c(O)cccc2C1, CCCN(CCc1cccs1)[C@H]1CCc2c(O)cccc2C1, CCCN(CCc1cccs1)[C@H]1CCc2c(O)cccc2C1	Launched
rotundine	serotonin receptor agonist	DRD1, DRD2, DRD3, HTR1A	neurology/psychiatry	anxiety, sedative	MedChemEx, Selleck	93.72	COc1cc2CCN3Cc4c(C[C@H]3c2cc1OC)ccc(OC)c4OC, COc1cc2CCN3Cc4c(C[C@H]3c2cc1OC)ccc(OC)c4OC	Launched
rovazolac	LXR agonist				MedChemEx	97.15	CCOC(=O)Cn1nc(cc1-c1ccc(cc1)-c1cccc(c1)S(C)(=O)=O)C(F)(F)F	Preclinical
roxarsone	antiprotozoal agent		endocrinology	weight-gain aid	MedChemEx, MedChemEx, MicroSource	98.02	Oc1ccc(cc1[N+]([O-])=O)[As](O)(O)=O, Oc1ccc(cc1[N+]([O-])=O)[As](O)(O)=O, Oc1ccc(cc1[N+]([O-])=O)[As](O)(O)=O	Launched
roxatidine-acetate	histamine receptor antagonist	HRH2	gastroenterology	Zollinger-Ellison syndrome, erosive esophagitis (EE), gastroesophageal reflux disease (GERD), gastritis	MedChemEx, MicroSource, Selleck	97.97	CC(=O)OCC(=O)NCCCOc1cccc(CN2CCCCC2)c1, CC(=O)OCC(=O)NCCCOc1cccc(CN2CCCCC2)c1, CC(=O)OCC(=O)NCCCOc1cccc(CN2CCCCC2)c1	Launched
roxithromycin	bacterial 50S ribosomal subunit inhibitor	MLNR	infectious disease	respiratory tract infections, urinary tract infections, skin infections	MedChemEx, MicroSource, Selleck	99.06	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)\C(=N/OCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)\C(=N/OCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)\C(=N/OCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O	Launched
RP-001	sphingosine 1-phosphate receptor agonist	S1PR1			Tocris, Tocris, Tocris	96.01	CC(C)Oc1ccc(cc1C#N)-c1nc(no1)-c1cccc2[C@@H](CCc12)NCCC(O)=O |&1:22|, CC(C)Oc1ccc(cc1C#N)-c1nc(no1)-c1cccc2[C@@H](CCc12)NCCC(O)=O |&1:22|, CC(C)Oc1ccc(cc1C#N)-c1nc(no1)-c1cccc2[C@@H](CCc12)NCCC(O)=O |&1:22|	Preclinical
RP67580					Tocris	44.82	COc1ccccc1CC(=N)N1C[C@H]2[C@@H](C1)C(CCC2=O)(c1ccccc1)c1ccccc1	Preclinical
RQ-00203078	transient receptor potential channel antagonist	TRPM8			Tocris, Tocris	95.32	OC(=O)c1ccc(cc1)S(=O)(=O)N(Cc1ccc(OC(F)(F)F)cc1)c1ncc(cc1Cl)C(F)(F)F, OC(=O)c1ccc(cc1)S(=O)(=O)N(Cc1ccc(OC(F)(F)F)cc1)c1ncc(cc1Cl)C(F)(F)F	Preclinical
RRx-001	glucose 6-phosphate dehydrogenase inhibitor	G6PD			MedChemEx, MedChemEx	0	[O-][N+](=O)C1(CN(C1)C(=O)CBr)[N+]([O-])=O, [O-][N+](=O)C1(CN(C1)C(=O)CBr)[N+]([O-])=O	Phase 3
RS-0481	immunostimulant					0		Phase 2
RS-100329	adrenergic receptor antagonist	ADRA1A, ADRA1D			Tocris, Tocris	97.46	Cc1c[nH]c(=O)n(CCCN2CCN(CC2)c2ccccc2OCC(F)(F)F)c1=O, Cc1c[nH]c(=O)n(CCCN2CCN(CC2)c2ccccc2OCC(F)(F)F)c1=O	Preclinical
RS-102221	serotonin receptor antagonist	HTR2A, HTR2B, HTR2C			Tocris, Tocris, Tocris, Tocris, Tocris	97.64	COc1cc(OC)c(cc1NS(=O)(=O)c1ccc(cc1)C(F)(F)F)C(=O)CCCCN1CCC2(CC1)NC(=O)NC2=O, COc1cc(OC)c(cc1NS(=O)(=O)c1ccc(cc1)C(F)(F)F)C(=O)CCCCN1CCC2(CC1)NC(=O)NC2=O, COc1cc(OC)c(cc1NS(=O)(=O)c1ccc(cc1)C(F)(F)F)C(=O)CCCCN1CCC2(CC1)NC(=O)NC2=O, COc1cc(OC)c(cc1NS(=O)(=O)c1ccc(cc1)C(F)(F)F)C(=O)CCCCN1CCC2(CC1)NC(=O)NC2=O, COc1cc(OC)c(cc1NS(=O)(=O)c1ccc(cc1)C(F)(F)F)C(=O)CCCCN1CCC2(CC1)NC(=O)NC2=O	Preclinical
RS-102895	CCR antagonist	CCR2			Tocris, Tocris, Tocris	97.44	FC(F)(F)c1ccc(CCN2CCC3(CC2)OC(=O)Nc2ccccc32)cc1, FC(F)(F)c1ccc(CCN2CCC3(CC2)OC(=O)Nc2ccccc32)cc1, FC(F)(F)c1ccc(CCN2CCC3(CC2)OC(=O)Nc2ccccc32)cc1	Preclinical
RS-127445	serotonin receptor antagonist	HTR2A, HTR2B, HTR2C			Selleck, Tocris, Tocris	98.5	CC(C)c1cc(nc(N)n1)-c1ccc(F)c2ccccc12, CC(C)c1cc(nc(N)n1)-c1ccc(F)c2ccccc12, CC(C)c1cc(nc(N)n1)-c1ccc(F)c2ccccc12	Phase 1
RS-16566	serotonin receptor antagonist				Tocris	97.92	CC(C)n1cnc2c(cc(Cl)cc12)C(=O)N[C@H]1C[N@@]2CC[C@H]1CC2	Preclinical
RS-17053	adrenergic receptor antagonist	ADRA1A, ADRA1D			Tocris, Tocris, Tocris, Tocris, Tocris, Tocris, Tocris, Tocris	97.61	CC(C)(Cc1c[nH]c2ccc(Cl)cc12)NCCOc1ccccc1OCC1CC1, CC(C)(Cc1c[nH]c2ccc(Cl)cc12)NCCOc1ccccc1OCC1CC1, CC(C)(Cc1c[nH]c2ccc(Cl)cc12)NCCOc1ccccc1OCC1CC1, CC(C)(Cc1c[nH]c2ccc(Cl)cc12)NCCOc1ccccc1OCC1CC1, CC(C)(Cc1c[nH]c2ccc(Cl)cc12)NCCOc1ccccc1OCC1CC1, CC(C)(Cc1c[nH]c2ccc(Cl)cc12)NCCOc1ccccc1OCC1CC1, CC(C)(Cc1c[nH]c2ccc(Cl)cc12)NCCOc1ccccc1OCC1CC1, CC(C)(Cc1c[nH]c2ccc(Cl)cc12)NCCOc1ccccc1OCC1CC1	Preclinical
RS-23597-190	serotonin receptor antagonist	HTR4			Tocris	98.28	COc1cc(N)c(Cl)cc1C(=O)OCCCN1CCCCC1	Preclinical
RS-39604	serotonin receptor antagonist	HTR4			Tocris, Tocris, Tocris, Tocris	98.29	COc1cc(COc2cc(N)c(Cl)cc2C(=O)CCC2CCN(CCNS(C)(=O)=O)CC2)cc(OC)c1, COc1cc(COc2cc(N)c(Cl)cc2C(=O)CCC2CCN(CCNS(C)(=O)=O)CC2)cc(OC)c1, COc1cc(COc2cc(N)c(Cl)cc2C(=O)CCC2CCN(CCNS(C)(=O)=O)CC2)cc(OC)c1, COc1cc(COc2cc(N)c(Cl)cc2C(=O)CCC2CCN(CCNS(C)(=O)=O)CC2)cc(OC)c1	Preclinical
RS-45041-190	imidazoline receptor agonist				Tocris, Tocris, Tocris	100	Clc1cccc2CN(Cc12)C1=NCCN1 |t:12|, Clc1cccc2CN(Cc12)C1=NCCN1 |t:12|, Clc1cccc2CN(Cc12)C1=NCCN1 |t:12|	Preclinical
RS-504393	CC chemokine receptor antagonist	CCL2, CCR2			Tocris, Tocris	97.31	Cc1oc(nc1CCN1CCC2(CC1)OC(=O)Nc1ccc(C)cc21)-c1ccccc1, Cc1oc(nc1CCN1CCC2(CC1)OC(=O)Nc1ccc(C)cc21)-c1ccccc1	Preclinical
RS-56812	serotonin receptor partial agonist	HTR3A			Tocris	98.24	Cn1cc(C(=O)C(=O)N[C@H]2C[N@@]3CC[C@H]2CC3)c2ccccc12	Preclinical
RS-67333	serotonin receptor partial agonist	HTR4			Tocris, Tocris, Tocris	97.37	CCCCN1CCC(CCC(=O)c2cc(Cl)c(N)cc2OC)CC1, CCCCN1CCC(CCC(=O)c2cc(Cl)c(N)cc2OC)CC1, CCCCN1CCC(CCC(=O)c2cc(Cl)c(N)cc2OC)CC1	Preclinical
RS-67506	serotonin receptor partial agonist	HTR4			Tocris, Tocris, Tocris, Tocris	96.93	COc1cc(N)c(Cl)cc1C(=O)CCC1CCN(CCNS(C)(=O)=O)CC1, COc1cc(N)c(Cl)cc1C(=O)CCC1CCN(CCNS(C)(=O)=O)CC1, COc1cc(N)c(Cl)cc1C(=O)CCC1CCN(CCNS(C)(=O)=O)CC1, COc1cc(N)c(Cl)cc1C(=O)CCC1CCN(CCNS(C)(=O)=O)CC1	Preclinical
RS-79948	adrenergic receptor antagonist	ADRA2A			Tocris, Tocris	97.72	CCS(=O)(=O)N1CCC[C@@H]2CN3CCc4cc(OC)ccc4[C@@H]3C[C@H]12, CCS(=O)(=O)N1CCC[C@@H]2CN3CCc4cc(OC)ccc4[C@@H]3C[C@H]12	Preclinical
RSV604	RSV replication inhibitor				MedChemEx	98.22	Fc1ccccc1NC(=O)N[C@H]1N=C(c2ccccc2)c2ccccc2NC1=O |t:13|	Phase 2
RTA-408	nitric oxide production inhibitor	NFE2L2			MedChemEx, MedChemEx, Selleck	90.95	CC(F)(F)C(=O)N[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@]4(C)C=C(C#N)C(=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2 |t:19,23|, CC(F)(F)C(=O)N[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@]4(C)C=C(C#N)C(=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2 |t:19,23|, CC(F)(F)C(=O)N[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@]4(C)C=C(C#N)C(=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2 |t:19,23|	Phase 2
RU-SKI-43	hedgehog pathway inhibitor	HHAT			Tocris, Tocris	93.99	CC[C@@H](C)CNCC(=O)N1CCc2sccc2[C@@H]1COc1cccc(C)c1 |&1:2,&2:17|, CC[C@@H](C)CNCC(=O)N1CCc2sccc2[C@@H]1COc1cccc(C)c1 |&1:2,&2:17|	Preclinical
RU-24969	serotonin receptor agonist	HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C, HTR5A, HTR6			MedChemEx, MedChemEx, Tocris	64.03	COc1ccc2[nH]cc(C3=CCNCC3)c2c1 |t:9|, COc1ccc2[nH]cc(C3=CCNCC3)c2c1 |t:9|, COc1ccc2[nH]cc(C3=CCNCC3)c2c1 |t:9|	Phase 1
RU-28318	cytochrome P450 inhibitor	NR3C2			Tocris, Tocris	96.9	CCC[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]3(O)CCC(O)=O)[C@H]12 |t:5|, CCC[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]3(O)CCC(O)=O)[C@H]12 |t:5|	Phase 2
RU-42173	adrenergic receptor agonist	ADRB2			Enzo	9.01	CC(C)N[C@@H]1CCn2c3c(cccc3[nH]c2=O)[C@H]1O	Phase 2
RU-58841	androgen receptor antagonist	AR			MedChemEx, MedChemEx	97.49	CC1(C)N(CCCCO)C(=O)N(C1=O)c1ccc(C#N)c(c1)C(F)(F)F, CC1(C)N(CCCCO)C(=O)N(C1=O)c1ccc(C#N)c(c1)C(F)(F)F	Phase 2
rubitecan	topoisomerase inhibitor	TOP1			Sigma, Sigma, Sigma	94.03	CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4cccc([N+]([O-])=O)c4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4cccc([N+]([O-])=O)c4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4cccc([N+]([O-])=O)c4cc3Cn1c2=O	Phase 3
ruboxistaurin	PKC inhibitor				MedChemEx	92.46	CN(C)C[C@@H]1CCn2cc(C3=C(C(=O)NC3=O)c3cn(CCO1)c1ccccc31)c1ccccc21 |t:10|	Phase 3
rucaparib	PARP inhibitor	PARP1, PARP2			Tocris, Tocris, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck	97.52	CNCc1ccc(cc1)-c1[nH]c2cc(F)cc3C(=O)NCCc1c23, CNCc1ccc(cc1)-c1[nH]c2cc(F)cc3C(=O)NCCc1c23, CNCc1ccc(cc1)-c1[nH]c2cc(F)cc3C(=O)NCCc1c23, CNCc1ccc(cc1)-c1[nH]c2cc(F)cc3C(=O)NCCc1c23, CNCc1ccc(cc1)-c1[nH]c2cc(F)cc3C(=O)NCCc1c23, CNCc1ccc(cc1)-c1[nH]c2cc(F)cc3C(=O)NCCc1c23, CNCc1ccc(cc1)-c1[nH]c2cc(F)cc3C(=O)NCCc1c23, CNCc1ccc(cc1)-c1[nH]c2cc(F)cc3C(=O)NCCc1c23, CNCc1ccc(cc1)-c1[nH]c2cc(F)cc3C(=O)NCCc1c23, CNCc1ccc(cc1)-c1[nH]c2cc(F)cc3C(=O)NCCc1c23, CNCc1ccc(cc1)-c1[nH]c2cc(F)cc3C(=O)NCCc1c23, CNCc1ccc(cc1)-c1[nH]c2cc(F)cc3C(=O)NCCc1c23	Phase 3
rucinol	tyrosinase inhibitor	TYR			TCI, TCI	98.99	CCCCc1ccc(O)cc1O, CCCCc1ccc(O)cc1O	Phase 1
rufinamide	voltage-gated sodium channel blocker	GRM5, SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A	neurology/psychiatry	seizures	Selleck	98.35	NC(=O)c1cn(Cc2c(F)cccc2F)nn1	Launched
rufloxacin	bacterial DNA gyrase inhibitor		infectious disease	gram-negative bacterial infections	MicroSource, MedChemEx, MedChemEx	97.36	CN1CCN(CC1)c1c(F)cc2c3c1SCCn3cc(C(O)=O)c2=O, CN1CCN(CC1)c1c(F)cc2c3c1SCCn3cc(C(O)=O)c2=O, CN1CCN(CC1)c1c(F)cc2c3c1SCCn3cc(C(O)=O)c2=O	Launched
rupatadine	histamine receptor antagonist, platelet activating factor receptor antagonist	HRH1, PTAFR	allergy	allergic rhinitis, urticaria	MedChemEx, Selleck	98.23	Cc1cncc(CN2CCC(CC2)=C2c3ccc(Cl)cc3CCc3cccnc23)c1, Cc1cncc(CN2CCC(CC2)=C2c3ccc(Cl)cc3CCc3cccnc23)c1	Launched
rutaecarpine	cyclooxygenase inhibitor	PTGS2			MedChemEx, Selleck, Selleck	97.45	O=c1n2CCc3c([nH]c4ccccc34)-c2nc2ccccc12, O=c1n2CCc3c([nH]c4ccccc34)-c2nc2ccccc12, O=c1n2CCc3c([nH]c4ccccc34)-c2nc2ccccc12	Preclinical
rutin	antioxidant, capillary stabilizing agent, nitric oxide scavenger	AKR1C3	rheumatology, otolaryngology, gastroenterology, neurology/psychiatry, allergy	joint pain, nasal congestion, constipation, irritability, allergic rhinitis	MicroSource, MedChemEx, Selleck, Selleck	91.2	C[C@@H]1O[C@@H](OC[C@H]2O[C@@H](Oc3c(oc4cc(O)cc(O)c4c3=O)-c3ccc(O)c(O)c3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O, C[C@@H]1O[C@@H](OC[C@H]2O[C@@H](Oc3c(oc4cc(O)cc(O)c4c3=O)-c3ccc(O)c(O)c3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O, C[C@@H]1O[C@@H](OC[C@H]2O[C@@H](Oc3c(oc4cc(O)cc(O)c4c3=O)-c3ccc(O)c(O)c3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O, C[C@@H]1O[C@@H](OC[C@H]2O[C@@H](Oc3c(oc4cc(O)cc(O)c4c3=O)-c3ccc(O)c(O)c3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O	Launched
ruxolitinib	JAK inhibitor	JAK1, JAK2, JAK3, TYK2	hematologic malignancy, hematology	myelofibrosis, polycythemia vera	Selleck, Selleck, Selleck, Selleck, Chemietek, Chemietek, Chemietek	99.11	N#CC[C@H](C1CCCC1)n1cc(cn1)-c1ncnc2[nH]ccc12, N#CC[C@H](C1CCCC1)n1cc(cn1)-c1ncnc2[nH]ccc12, N#CC[C@H](C1CCCC1)n1cc(cn1)-c1ncnc2[nH]ccc12, N#CC[C@H](C1CCCC1)n1cc(cn1)-c1ncnc2[nH]ccc12, N#CC[C@H](C1CCCC1)n1cc(cn1)-c1ncnc2[nH]ccc12, N#CC[C@H](C1CCCC1)n1cc(cn1)-c1ncnc2[nH]ccc12, N#CC[C@H](C1CCCC1)n1cc(cn1)-c1ncnc2[nH]ccc12	Launched
ruxolitinib-(S)	JAK inhibitor	JAK1, JAK2			MedChemEx, Selleck, Selleck	97.97	N#CC[C@@H](C1CCCC1)n1cc(cn1)-c1ncnc2[nH]ccc12, N#CC[C@@H](C1CCCC1)n1cc(cn1)-c1ncnc2[nH]ccc12, N#CC[C@@H](C1CCCC1)n1cc(cn1)-c1ncnc2[nH]ccc12	Preclinical
RV1729	PI3K inhibitor				Astatech	85.07	COCCN(CCOC)C(=O)CCCC#Cc1cccc2nc(Cn3nc(-c4cccc(O)c4)c4c(N)ncnc34)n(Cc3ccccc3Cl)c(=O)c12	Phase 1
RWJ-21757	toll-like receptor agonist	TLR7			Tocris, Sigma, Sigma, Tocris	85.47	Nc1nc(=O)c2n(CC=C)c(=O)n([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c2[nH]1, Nc1nc(=O)c2n(CC=C)c(=O)n([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c2[nH]1, Nc1nc(=O)c2n(CC=C)c(=O)n([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c2[nH]1, Nc1nc(=O)c2n(CC=C)c(=O)n([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c2[nH]1	Phase 2
RWJ-50271	integrin inhibitor	ICAM1			Tocris, Tocris, Tocris	97.8	Cc1c(cnn1-c1nc(cs1)-c1cccc(c1)C(F)(F)F)C(=O)NCCCO, Cc1c(cnn1-c1nc(cs1)-c1cccc(c1)C(F)(F)F)C(=O)NCCCO, Cc1c(cnn1-c1nc(cs1)-c1cccc(c1)C(F)(F)F)C(=O)NCCCO	Preclinical
RWJ-67657	MAP kinase inhibitor	MAPK14, PTGS2			Cayman, Cayman, Tocris, Tocris	93.32	OCCC#Cc1nc(c(-c2ccncc2)n1CCCc1ccccc1)-c1ccc(F)cc1, OCCC#Cc1nc(c(-c2ccncc2)n1CCCc1ccccc1)-c1ccc(F)cc1, OCCC#Cc1nc(c(-c2ccncc2)n1CCCc1ccccc1)-c1ccc(F)cc1, OCCC#Cc1nc(c(-c2ccncc2)n1CCCc1ccccc1)-c1ccc(F)cc1	Phase 1
RX-3117	CDK inhibitor, DNA synthesis inhibitor	CDK2, DNMT1			MedChemEx, MedChemEx, MedChemEx	83.1	Nc1ccn([C@H]2[C@H](O)[C@H](O)C(CO)=C2F)c(=O)n1 |c:12|, Nc1ccn([C@H]2[C@H](O)[C@H](O)C(CO)=C2F)c(=O)n1 |c:12|, Nc1ccn([C@H]2[C@H](O)[C@H](O)C(CO)=C2F)c(=O)n1 |c:12|	Phase 1/Phase 2
RX-821002	adrenergic receptor antagonist	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C			Tocris, Tocris, Tocris	97.1	CO[C@]1(COc2ccccc2O1)C1=NCCN1 |&1:2,t:14|, CO[C@]1(COc2ccccc2O1)C1=NCCN1 |&1:2,t:14|, CO[C@]1(COc2ccccc2O1)C1=NCCN1 |&1:2,t:14|	Preclinical
ryuvidine	histone lysine methyltransferase inhibitor	CDK2, CDK4			Tocris, Tocris, Tocris, Tocris, Tocris, Tocris, Tocris	95.15	Cc1nc2c(s1)C(=O)C=C(Nc1ccc(C)cc1)C2=O |t:9|, Cc1nc2c(s1)C(=O)C=C(Nc1ccc(C)cc1)C2=O |t:9|, Cc1nc2c(s1)C(=O)C=C(Nc1ccc(C)cc1)C2=O |t:9|, Cc1nc2c(s1)C(=O)C=C(Nc1ccc(C)cc1)C2=O |t:9|, Cc1nc2c(s1)C(=O)C=C(Nc1ccc(C)cc1)C2=O |t:9|, Cc1nc2c(s1)C(=O)C=C(Nc1ccc(C)cc1)C2=O |t:9|, Cc1nc2c(s1)C(=O)C=C(Nc1ccc(C)cc1)C2=O |t:9|	Preclinical
R112	SYK inhibitor	SYK			MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx	98	Oc1cccc(Nc2ncc(F)c(Nc3cccc(O)c3)n2)c1, Oc1cccc(Nc2ncc(F)c(Nc3cccc(O)c3)n2)c1, Oc1cccc(Nc2ncc(F)c(Nc3cccc(O)c3)n2)c1, Oc1cccc(Nc2ncc(F)c(Nc3cccc(O)c3)n2)c1, Oc1cccc(Nc2ncc(F)c(Nc3cccc(O)c3)n2)c1	Phase 1
R306465	HDAC inhibitor				AdvChemBlocks, AdvChemBlocks, AdvChemBlocks, AdvChemBlocks	82.42	ONC(=O)c1cnc(nc1)N1CCN(CC1)S(=O)(=O)c1ccc2ccccc2c1, ONC(=O)c1cnc(nc1)N1CCN(CC1)S(=O)(=O)c1ccc2ccccc2c1, ONC(=O)c1cnc(nc1)N1CCN(CC1)S(=O)(=O)c1ccc2ccccc2c1, ONC(=O)c1cnc(nc1)N1CCN(CC1)S(=O)(=O)c1ccc2ccccc2c1	Phase 1
R406	SYK inhibitor	RET, SYK			Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck	97.72	COc1cc(Nc2ncc(F)c(Nc3ccc4OC(C)(C)C(=O)Nc4n3)n2)cc(OC)c1OC, COc1cc(Nc2ncc(F)c(Nc3ccc4OC(C)(C)C(=O)Nc4n3)n2)cc(OC)c1OC, COc1cc(Nc2ncc(F)c(Nc3ccc4OC(C)(C)C(=O)Nc4n3)n2)cc(OC)c1OC, COc1cc(Nc2ncc(F)c(Nc3ccc4OC(C)(C)C(=O)Nc4n3)n2)cc(OC)c1OC, COc1cc(Nc2ncc(F)c(Nc3ccc4OC(C)(C)C(=O)Nc4n3)n2)cc(OC)c1OC, COc1cc(Nc2ncc(F)c(Nc3ccc4OC(C)(C)C(=O)Nc4n3)n2)cc(OC)c1OC, COc1cc(Nc2ncc(F)c(Nc3ccc4OC(C)(C)C(=O)Nc4n3)n2)cc(OC)c1OC, COc1cc(Nc2ncc(F)c(Nc3ccc4OC(C)(C)C(=O)Nc4n3)n2)cc(OC)c1OC, COc1cc(Nc2ncc(F)c(Nc3ccc4OC(C)(C)C(=O)Nc4n3)n2)cc(OC)c1OC, COc1cc(Nc2ncc(F)c(Nc3ccc4OC(C)(C)C(=O)Nc4n3)n2)cc(OC)c1OC, COc1cc(Nc2ncc(F)c(Nc3ccc4OC(C)(C)C(=O)Nc4n3)n2)cc(OC)c1OC, COc1cc(Nc2ncc(F)c(Nc3ccc4OC(C)(C)C(=O)Nc4n3)n2)cc(OC)c1OC, COc1cc(Nc2ncc(F)c(Nc3ccc4OC(C)(C)C(=O)Nc4n3)n2)cc(OC)c1OC, COc1cc(Nc2ncc(F)c(Nc3ccc4OC(C)(C)C(=O)Nc4n3)n2)cc(OC)c1OC	Phase 1
R547	CDK inhibitor	CDK1, CDK2, CDK4, CDK7			MedChemEx, Selleck, Selleck, Selleck	95.73	COc1ccc(F)c(F)c1C(=O)c1cnc(NC2CCN(CC2)S(C)(=O)=O)nc1N, COc1ccc(F)c(F)c1C(=O)c1cnc(NC2CCN(CC2)S(C)(=O)=O)nc1N, COc1ccc(F)c(F)c1C(=O)c1cnc(NC2CCN(CC2)S(C)(=O)=O)nc1N, COc1ccc(F)c(F)c1C(=O)c1cnc(NC2CCN(CC2)S(C)(=O)=O)nc1N	Phase 1
S-isopropylisothiourea	nitric oxide synthase inhibitor	NOS3			Tocris, Tocris	94.16	CC(C)SC(N)=N, CC(C)SC(N)=N	Preclinical
S-methylcysteine		CTSD, MGMT			Ark, Ark, Ark	100	CSC[C@H](N)C(O)=O, CSC[C@H](N)C(O)=O, CSC[C@H](N)C(O)=O	Phase 1
S-nitrosoglutathione	nitric oxide stimulant	PTPN1				0		Phase 1
S-sulfo-L-cysteine	glutamate receptor agonist				Tocris	90.28	N[C@@H](CSS(O)(=O)=O)C(O)=O	Preclinical
S-trityl-L-cysteine	mitotic kinesin inhibitor				Labotest, Tocris, Tocris	92.53	N[C@H](CSC(c1ccccc1)(c1ccccc1)c1ccccc1)C(O)=O, N[C@H](CSC(c1ccccc1)(c1ccccc1)c1ccccc1)C(O)=O, N[C@H](CSC(c1ccccc1)(c1ccccc1)c1ccccc1)C(O)=O	Preclinical
S-07662	CAR antagonist	NR1I3			Tocris, Tocris, Tocris, Tocris	98.5	Cc1oc2ccccc2c1CNC(=O)NCc1cccs1, Cc1oc2ccccc2c1CNC(=O)NCc1cccs1, Cc1oc2ccccc2c1CNC(=O)NCc1cccs1, Cc1oc2ccccc2c1CNC(=O)NCc1cccs1	Preclinical
S-111	PARP inhibitor	PARP1			MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx	100	CC(C)=CCC[C@](C)(O)[C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@@H]1[C@@]3(C)CC[C@H](O)C(C)(C)[C@@H]3CC[C@@]21C, CC(C)=CCC[C@](C)(O)[C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@@H]1[C@@]3(C)CC[C@H](O)C(C)(C)[C@@H]3CC[C@@]21C, CC(C)=CCC[C@](C)(O)[C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@@H]1[C@@]3(C)CC[C@H](O)C(C)(C)[C@@H]3CC[C@@]21C, CC(C)=CCC[C@](C)(O)[C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@@H]1[C@@]3(C)CC[C@H](O)C(C)(C)[C@@H]3CC[C@@]21C, CC(C)=CCC[C@](C)(O)[C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@@H]1[C@@]3(C)CC[C@H](O)C(C)(C)[C@@H]3CC[C@@]21C, CC(C)=CCC[C@](C)(O)[C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@@H]1[C@@]3(C)CC[C@H](O)C(C)(C)[C@@H]3CC[C@@]21C	Phase 2
S-14506	serotonin receptor agonist	HTR1A			Tocris, Tocris, Tocris, Tocris, Tocris, Tocris	99.32	COc1ccc2cccc(N3CCN(CCNC(=O)c4ccc(F)cc4)CC3)c2c1, COc1ccc2cccc(N3CCN(CCNC(=O)c4ccc(F)cc4)CC3)c2c1, COc1ccc2cccc(N3CCN(CCNC(=O)c4ccc(F)cc4)CC3)c2c1, COc1ccc2cccc(N3CCN(CCNC(=O)c4ccc(F)cc4)CC3)c2c1, COc1ccc2cccc(N3CCN(CCNC(=O)c4ccc(F)cc4)CC3)c2c1, COc1ccc2cccc(N3CCN(CCNC(=O)c4ccc(F)cc4)CC3)c2c1	Preclinical
S-17092	prolyl endopeptidase inhibitor				Sigma	86.56	O=C([C@@H]1C[C@H]1c1ccccc1)N1[C@H]2CCCC[C@H]2C[C@H]1C(=O)N1CCSC1	Preclinical
S-3304	matrix metalloprotease inhibitor				MedChemEx	95.77	Cc1ccc(cc1)C#Cc1ccc(s1)S(=O)(=O)N[C@H](Cc1c[nH]c2ccccc12)C(O)=O	Phase 1/Phase 2
S-38093	histamine receptor antagonist				MedChemEx	91.5	NC(=O)c1ccc(OCCCN2C[C@@H]3CCC[C@@H]3C2)cc1 |r|	Preclinical
SA-47	FAAH inhibitor	FAAH			Tocris, Tocris	93.41	CNC(=O)COC(=O)NCCC1CCN(CC1)c1cccc(C)n1, CNC(=O)COC(=O)NCCC1CCN(CC1)c1cccc(C)n1	Preclinical
saccharin	DNA polymerase inhibitor	CA1, CA12, CA2, CA9			MicroSource	98.63	O=C1NS(=O)(=O)c2ccccc12	Launched
saclofen	GABA receptor antagonist	GABBR1, GABBR2, KCTD12, KCTD16, KCTD8			Tocris, Tocris, Tocris	97.13	NC[C@@H](CS(O)(=O)=O)c1ccc(Cl)cc1 |&1:2,r|, NC[C@@H](CS(O)(=O)=O)c1ccc(Cl)cc1 |&1:2,r|, NC[C@@H](CS(O)(=O)=O)c1ccc(Cl)cc1 |&1:2,r|	Preclinical
sacubitril	neprilysin inhibitor	MME	cardiology	congestive heart failure	MedChemEx, MedChemEx, MedChemEx, MedChemEx	99.59	CCOC(=O)[C@H](C)C[C@@H](Cc1ccc(cc1)-c1ccccc1)NC(=O)CCC(O)=O, CCOC(=O)[C@H](C)C[C@@H](Cc1ccc(cc1)-c1ccccc1)NC(=O)CCC(O)=O, CCOC(=O)[C@H](C)C[C@@H](Cc1ccc(cc1)-c1ccccc1)NC(=O)CCC(O)=O, CCOC(=O)[C@H](C)C[C@@H](Cc1ccc(cc1)-c1ccccc1)NC(=O)CCC(O)=O	Launched
sacubitrilat	neprilysin inhibitor				MedChemEx	97.52	[H]N([C@@H](C[C@@H](C)C(O)=O)Cc1ccc(cc1)-c1ccccc1)C(=O)CCC(O)=O	Preclinical
safflower-yellow	anti-inflammatory agent				MedChemEx	0	OC[C@H]1O[C@@H]([C@H](O)[C@@H](O)[C@@H]1O)[C@]1(O)C(=O)[C@@H](\C=C2/C(=O)C(=C(O)\C=C\c3ccc(O)cc3)C(=O)[C@@](O)([C@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)C2=O)C(=O)C(=C(O)\C=C\c2ccc(O)cc2)C1=O |a:2,5,7,9,11,34,38,41,43,45,&1:4,&2:15,&3:20,&4:36,&5:51|	Preclinical
safinamide	dopamine reuptake inhibitor, glutamate inhibitor, monoamine oxidase inhibitor	MAOB	neurology/psychiatry	Parkinson's Disease	MedChemEx, Selleck	97.9	C[C@H](NCc1ccc(OCc2cccc(F)c2)cc1)C(N)=O, C[C@H](NCc1ccc(OCc2cccc(F)c2)cc1)C(N)=O	Launched
safingol	PKC inhibitor	TRPM3			Enzo, Tocris, Tocris	100	CCCCCCCCCCCCCCC[C@@H](O)[C@@H](N)CO, CCCCCCCCCCCCCCC[C@@H](O)[C@@H](N)CO, CCCCCCCCCCCCCCC[C@@H](O)[C@@H](N)CO	Phase 1
safranal	benzodiazepine receptor agonist	GABBR1			Sigma	0	CC1=C(C=O)C(C)(C)CC=C1 |c:1,9|	Phase 2
SAG	smoothened receptor agonist	SMO, TRPC6			Tocris, Tocris, Tocris, Tocris, Tocris	96.59	CN[C@H]1CC[C@@H](CC1)N(Cc1cccc(c1)-c1ccncc1)C(=O)c1sc2ccccc2c1Cl |r|, CN[C@H]1CC[C@@H](CC1)N(Cc1cccc(c1)-c1ccncc1)C(=O)c1sc2ccccc2c1Cl |r|, CN[C@H]1CC[C@@H](CC1)N(Cc1cccc(c1)-c1ccncc1)C(=O)c1sc2ccccc2c1Cl |r|, CN[C@H]1CC[C@@H](CC1)N(Cc1cccc(c1)-c1ccncc1)C(=O)c1sc2ccccc2c1Cl |r|, CN[C@H]1CC[C@@H](CC1)N(Cc1cccc(c1)-c1ccncc1)C(=O)c1sc2ccccc2c1Cl |r|	Preclinical
salazodine					Aronis	90.31	COc1ccc(NS(=O)(=O)c2ccc(cc2)N=Nc2ccc(O)c(c2)C(O)=O)nn1	Phase 2
salicin	anti-inflammatory agent				MedChemEx, MicroSource, Selleck	99.21	OC[C@H]1O[C@@H](Oc2ccccc2CO)[C@H](O)[C@@H](O)[C@@H]1O, OC[C@H]1O[C@@H](Oc2ccccc2CO)[C@H](O)[C@@H](O)[C@@H]1O, OC[C@H]1O[C@@H](Oc2ccccc2CO)[C@H](O)[C@@H](O)[C@@H]1O	Phase 1
salicyl-alcohol					MedChemEx, MicroSource, MicroSource	98.21	OCc1ccccc1O, OCc1ccccc1O, OCc1ccccc1O	Preclinical
salicylamide	analgesic agent		neurology/psychiatry, endocrinology	pain relief, fever	MedChemEx, MicroSource	98.74	NC(=O)c1ccccc1O, NC(=O)c1ccccc1O	Launched
salicylanilide	other antibiotic				MedChemEx, MicroSource, Selleck	99.27	Oc1ccccc1C(=O)Nc1ccccc1, Oc1ccccc1C(=O)Nc1ccccc1, Oc1ccccc1C(=O)Nc1ccccc1	Preclinical
salicylic-acid	cyclooxygenase inhibitor, prostanoid receptor antagonist	AKR1C1, ASIC3, PTGS1, PTGS2	dermatology, endocrinology, neurology/psychiatry	acne vulgaris (AV), fever, pain relief	MedChemEx, MedChemEx, Selleck, MicroSource, MicroSource	98.74	OC(=O)c1ccccc1O, OC(=O)c1ccccc1O, OC(=O)c1ccccc1O, OC(=O)c1ccccc1O, OC(=O)c1ccccc1O	Launched
salidroside	beta amyloid protein neurotoxicity inhibitor	APP			Selleck, Selleck	97.85	OC[C@H]1O[C@@H](OCCc2ccc(O)cc2)[C@H](O)[C@@H](O)[C@@H]1O, OC[C@H]1O[C@@H](OCCc2ccc(O)cc2)[C@H](O)[C@@H](O)[C@@H]1O	Preclinical
salinomycin			infectious disease	coccidiosis	Tocris	90.7	CC[C@H]([C@H]1CC[C@H](C)[C@@H](O1)[C@@H](C)[C@H](O)[C@H](C)C(=O)[C@H](CC)[C@H]1O[C@@]2(O[C@@]3(CC[C@](C)(O3)[C@H]3CC[C@](O)(CC)[C@H](C)O3)[C@H](O)C=C2)[C@H](C)C[C@@H]1C)C(O)=O |c:46|	Launched
salirasib	mTOR inhibitor	TRPA1			Tocris, Tocris, MedChemEx, MedChemEx	97.66	CC(C)=CCC\C(C)=C\CC\C(C)=C\CSc1ccccc1C(O)=O, CC(C)=CCC\C(C)=C\CC\C(C)=C\CSc1ccccc1C(O)=O, CC(C)=CCC\C(C)=C\CC\C(C)=C\CSc1ccccc1C(O)=O, CC(C)=CCC\C(C)=C\CC\C(C)=C\CSc1ccccc1C(O)=O	Phase 2
salmeterol	adrenergic receptor agonist	ADRB2	pulmonary	asthma, chronic obstructive pulmonary disease (COPD), bronchospasm	Sigma, MedChemEx, MedChemEx, Tocris, Tocris	67.68	OCc1cc(ccc1O)[C@@H](O)CNCCCCCCOCCCCc1ccccc1 |&1:9|, OCc1cc(ccc1O)[C@@H](O)CNCCCCCCOCCCCc1ccccc1 |&1:9|, OCc1cc(ccc1O)[C@@H](O)CNCCCCCCOCCCCc1ccccc1 |&1:9|, OCc1cc(ccc1O)[C@@H](O)CNCCCCCCOCCCCc1ccccc1 |&1:9|, OCc1cc(ccc1O)[C@@H](O)CNCCCCCCOCCCCc1ccccc1 |&1:9|	Launched
salsolinol-1-carboxylic-acid					Tocris, Tocris	24.5	C[C@]1(NCCc2cc(O)c(O)cc12)C(O)=O |&1:1,r|, C[C@]1(NCCc2cc(O)c(O)cc12)C(O)=O |&1:1,r|	Preclinical
salubrinal	eukaryotic translation initiation factor inhibitor	EIF2S1			Tocris, Tocris, Selleck, Selleck, Selleck, Selleck	97.81	ClC(Cl)(Cl)[C@H](NC(=S)Nc1cccc2cccnc12)NC(=O)\C=C\c1ccccc1 |&1:4,r|, ClC(Cl)(Cl)[C@H](NC(=S)Nc1cccc2cccnc12)NC(=O)\C=C\c1ccccc1 |&1:4,r|, ClC(Cl)(Cl)[C@H](NC(=S)Nc1cccc2cccnc12)NC(=O)\C=C\c1ccccc1 |&1:4,r|, ClC(Cl)(Cl)[C@H](NC(=S)Nc1cccc2cccnc12)NC(=O)\C=C\c1ccccc1 |&1:4,r|, ClC(Cl)(Cl)[C@H](NC(=S)Nc1cccc2cccnc12)NC(=O)\C=C\c1ccccc1 |&1:4,r|, ClC(Cl)(Cl)[C@H](NC(=S)Nc1cccc2cccnc12)NC(=O)\C=C\c1ccccc1 |&1:4,r|	Preclinical
salvianolic-acid-A	matrix metalloprotease inhibitor				MedChemEx	100	OC(=O)[C@@H](Cc1ccc(O)c(O)c1)OC(=O)\C=C\c1ccc(O)c(O)c1\C=C\c1ccc(O)c(O)c1	Phase 1
salvianolic-acid-B	EGFR inhibitor, metalloproteinase inhibitor	MMP9			AvaChem, AvaChem	95.4	OC(=O)[C@@H](Cc1ccc(O)c(O)c1)OC(=O)\C=C\c1ccc(O)c2O[C@H]([C@H](C(=O)O[C@H](Cc3ccc(O)c(O)c3)C(O)=O)c12)c1ccc(O)c(O)c1, OC(=O)[C@@H](Cc1ccc(O)c(O)c1)OC(=O)\C=C\c1ccc(O)c2O[C@H]([C@H](C(=O)O[C@H](Cc3ccc(O)c(O)c3)C(O)=O)c12)c1ccc(O)c(O)c1	Phase 2
salvinorin-A	opioid receptor agonist	OPRD1, OPRK1, OPRM1			Tocris, Enzo	96.14	COC(=O)[C@@H]1C[C@H](OC(C)=O)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@@H](C[C@]21C)c1ccoc1, COC(=O)[C@@H]1C[C@H](OC(C)=O)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@@H](C[C@]21C)c1ccoc1	Phase 1
sal003	eukaryotic translation initiation factor inhibitor	EIF2A			Tocris, Selleck, Selleck, Tocris, Tocris	96.4	Clc1ccc(NC(=S)N[C@H](NC(=O)\C=C\c2ccccc2)C(Cl)(Cl)Cl)cc1 |&1:9,r|, Clc1ccc(NC(=S)N[C@H](NC(=O)\C=C\c2ccccc2)C(Cl)(Cl)Cl)cc1 |&1:9,r|, Clc1ccc(NC(=S)N[C@H](NC(=O)\C=C\c2ccccc2)C(Cl)(Cl)Cl)cc1 |&1:9,r|, Clc1ccc(NC(=S)N[C@H](NC(=O)\C=C\c2ccccc2)C(Cl)(Cl)Cl)cc1 |&1:9,r|, Clc1ccc(NC(=S)N[C@H](NC(=O)\C=C\c2ccccc2)C(Cl)(Cl)Cl)cc1 |&1:9,r|	Preclinical
SAM-315	serotonin receptor antagonist				Sigma	92.25	O=S(=O)(c1n[nH]c2ccc(cc12)N1CCNCC1)c1cccc2ccccc12	Preclinical
sameridine	opioid receptor modulator				Sigma	91.84	CCCCCCN1CCC(CC1)(C(=O)N(C)CC)c1ccccc1	Preclinical
sanazole					Asinex	98.04	COCCNC(=O)Cn1cnc(n1)[N+]([O-])=O	Phase 1
sancycline	antitumor agent				MedChemEx	80.98	[H][C@@]12Cc3cccc(O)c3C(=O)[C@@H]1C(=O)[C@]1(O)C(=O)[C@H](C(N)=O)C(=O)[C@@H](N(C)C)[C@]1([H])C2 |&1:19,&2:12|	Preclinical
sangivamycin	DNA inhibitor				Toronto, Toronto	95.21	NC(=O)c1cn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c2ncnc(N)c12, NC(=O)c1cn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c2ncnc(N)c12	Phase 1
sanguinarium-chloride	apoptosis stimulant	CASP3			MicroSource, MicroSource, MicroSource, Sigma, Sigma, Sigma, Sigma, Sigma	92.68	C[n+]1cc2c3OCOc3ccc2c2ccc3cc4OCOc4cc3c12, C[n+]1cc2c3OCOc3ccc2c2ccc3cc4OCOc4cc3c12, C[n+]1cc2c3OCOc3ccc2c2ccc3cc4OCOc4cc3c12, C[n+]1cc2c3OCOc3ccc2c2ccc3cc4OCOc4cc3c12, C[n+]1cc2c3OCOc3ccc2c2ccc3cc4OCOc4cc3c12, C[n+]1cc2c3OCOc3ccc2c2ccc3cc4OCOc4cc3c12, C[n+]1cc2c3OCOc3ccc2c2ccc3cc4OCOc4cc3c12, C[n+]1cc2c3OCOc3ccc2c2ccc3cc4OCOc4cc3c12	Phase 1
SANT-1	smoothened receptor antagonist	SHH, SMO			Tocris, Tocris, Selleck, Selleck, Selleck, Tocris, Tocris	96.37	Cc1nn(c(C)c1\C=N\N1CCN(Cc2ccccc2)CC1)-c1ccccc1, Cc1nn(c(C)c1\C=N\N1CCN(Cc2ccccc2)CC1)-c1ccccc1, Cc1nn(c(C)c1\C=N\N1CCN(Cc2ccccc2)CC1)-c1ccccc1, Cc1nn(c(C)c1\C=N\N1CCN(Cc2ccccc2)CC1)-c1ccccc1, Cc1nn(c(C)c1\C=N\N1CCN(Cc2ccccc2)CC1)-c1ccccc1, Cc1nn(c(C)c1\C=N\N1CCN(Cc2ccccc2)CC1)-c1ccccc1, Cc1nn(c(C)c1\C=N\N1CCN(Cc2ccccc2)CC1)-c1ccccc1	Preclinical
SANT-2	smoothened receptor antagonist	SHH, SMO			Tocris, Tocris, Tocris, Tocris, Tocris, Tocris	98.44	CCOc1cc(cc(OCC)c1OCC)C(=O)Nc1ccc(Cl)c(c1)-c1nc2ccccc2[nH]1, CCOc1cc(cc(OCC)c1OCC)C(=O)Nc1ccc(Cl)c(c1)-c1nc2ccccc2[nH]1, CCOc1cc(cc(OCC)c1OCC)C(=O)Nc1ccc(Cl)c(c1)-c1nc2ccccc2[nH]1, CCOc1cc(cc(OCC)c1OCC)C(=O)Nc1ccc(Cl)c(c1)-c1nc2ccccc2[nH]1, CCOc1cc(cc(OCC)c1OCC)C(=O)Nc1ccc(Cl)c(c1)-c1nc2ccccc2[nH]1, CCOc1cc(cc(OCC)c1OCC)C(=O)Nc1ccc(Cl)c(c1)-c1nc2ccccc2[nH]1	Preclinical
sapacitabine	DNA synthesis inhibitor				MedChemEx	100	CCCCCCCCCCCCCCCC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2C#N)c(=O)n1	Phase 3
sapropterin	phenylalanine 4-hydroxylase stimulant	NOS3, PAH, TH, TPH1	metabolism	hyperphenylalaninemia (HPA)	Cayman, Cayman, Cayman	84.77	C[C@H](O)[C@H](O)[C@H]1CNc2[nH]c(N)nc(=O)c2N1, C[C@H](O)[C@H](O)[C@H]1CNc2[nH]c(N)nc(=O)c2N1, C[C@H](O)[C@H](O)[C@H]1CNc2[nH]c(N)nc(=O)c2N1	Launched
saquinavir	HIV protease inhibitor	CYP3A4	infectious disease	human immunodeficiency virus (HIV-1)	Tocris, Tocris, Tocris, Tocris, MedChemEx, MedChemEx	98.85	CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(N)=O)NC(=O)c1ccc2ccccc2n1, CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(N)=O)NC(=O)c1ccc2ccccc2n1, CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(N)=O)NC(=O)c1ccc2ccccc2n1, CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(N)=O)NC(=O)c1ccc2ccccc2n1, CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(N)=O)NC(=O)c1ccc2ccccc2n1, CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(N)=O)NC(=O)c1ccc2ccccc2n1	Launched
SAR-245409	PI3K inhibitor	MTOR, PIK3CG			Selleck	95.59	COc1cc(Nc2nc3ccccc3nc2NS(=O)(=O)c2ccc(NC(=O)c3ccc(C)c(OC)c3)cc2)cc(OC)c1	Phase 1/Phase 2
saracatinib	SRC inhibitor	ABL1, LCK, SRC, YES1			Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Stanley, Stanley, Stanley, Stanley, Stanley, Stanley, Stanley, Stanley, Stanley	98.23	CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c5OCOc5ccc4Cl)ncnc3c2)CC1, CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c5OCOc5ccc4Cl)ncnc3c2)CC1, CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c5OCOc5ccc4Cl)ncnc3c2)CC1, CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c5OCOc5ccc4Cl)ncnc3c2)CC1, CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c5OCOc5ccc4Cl)ncnc3c2)CC1, CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c5OCOc5ccc4Cl)ncnc3c2)CC1, CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c5OCOc5ccc4Cl)ncnc3c2)CC1, CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c5OCOc5ccc4Cl)ncnc3c2)CC1, CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c5OCOc5ccc4Cl)ncnc3c2)CC1, CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c5OCOc5ccc4Cl)ncnc3c2)CC1, CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c5OCOc5ccc4Cl)ncnc3c2)CC1, CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c5OCOc5ccc4Cl)ncnc3c2)CC1, CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c5OCOc5ccc4Cl)ncnc3c2)CC1, CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c5OCOc5ccc4Cl)ncnc3c2)CC1, CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c5OCOc5ccc4Cl)ncnc3c2)CC1, CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c5OCOc5ccc4Cl)ncnc3c2)CC1	Phase 2/Phase 3
sarafloxacin	bacterial DNA gyrase inhibitor		infectious disease	gram-negative bacterial infections, gram-positive bacterial infections	MicroSource, MedChemEx, Selleck	95.86	OC(=O)c1cn(-c2ccc(F)cc2)c2cc(N3CCNCC3)c(F)cc2c1=O, OC(=O)c1cn(-c2ccc(F)cc2)c2cc(N3CCNCC3)c(F)cc2c1=O, OC(=O)c1cn(-c2ccc(F)cc2)c2cc(N3CCNCC3)c(F)cc2c1=O	Launched
sarcosine	glycine transporter inhibitor	SLC6A9			Enamine	86.26	CNCC(O)=O	Phase 2
sardomozide	S-adenosylmethionine decarboxylase inhibitor				MedChemEx	89.7	NC(=N)N\N=C1/CCc2c1cccc2C(N)=N	Preclinical
sari-59-801					Sigma, Sigma	93.49	CCc1noc(C)c1-c1[nH]c2ccccc2c1[C@@H](O)CN(C)C |&1:17,r|, CCc1noc(C)c1-c1[nH]c2ccccc2c1[C@@H](O)CN(C)C |&1:17,r|	Phase 1
saroglitazar	PPAR receptor agonist	PPARA, PPARG	endocrinology, cardiology, gastroenterology	diabetes mellitus, dyslipidemia, non-alcoholic steatohepatitis (NASH)	MedChemEx, Synnovator	67.76	CCO[C@@H](Cc1ccc(OCCn2c(C)ccc2-c2ccc(SC)cc2)cc1)C(O)=O, CCO[C@@H](Cc1ccc(OCCn2c(C)ccc2-c2ccc(SC)cc2)cc1)C(O)=O	Launched
sarpogrelate	serotonin receptor antagonist	HTR2A, HTR2B, HTR2C	endocrinology, cardiology, rheumatology	diabetes mellitus, angina pectoris, Raynaud's disease, atherosclerosis, Buerger's disease	Tocris, MedChemEx, Tocris, Tocris	97.73	COc1cccc(CCc2ccccc2OC[C@@H](CN(C)C)OC(=O)CCC(O)=O)c1 |&1:17|, COc1cccc(CCc2ccccc2OC[C@@H](CN(C)C)OC(=O)CCC(O)=O)c1 |&1:17|, COc1cccc(CCc2ccccc2OC[C@@H](CN(C)C)OC(=O)CCC(O)=O)c1 |&1:17|, COc1cccc(CCc2ccccc2OC[C@@H](CN(C)C)OC(=O)CCC(O)=O)c1 |&1:17|	Launched
SAR131675	VEGFR inhibitor	FLT4			Selleck, MedChemEx	95.92	CCn1c(N)c(C(=O)NC)c(=O)c2ccc(nc12)C#C[C@@](C)(O)COC, CCn1c(N)c(C(=O)NC)c(=O)c2ccc(nc12)C#C[C@@](C)(O)COC	Preclinical
SAR405	PI3K inhibitor	PIK3C3			MedChemEx, MedChemEx, MedChemEx, MedChemEx	93.1	C[C@@H]1COCCN1c1cc(=O)n2CC[C@H](N(Cc3cncc(Cl)c3)c2n1)C(F)(F)F, C[C@@H]1COCCN1c1cc(=O)n2CC[C@H](N(Cc3cncc(Cl)c3)c2n1)C(F)(F)F, C[C@@H]1COCCN1c1cc(=O)n2CC[C@H](N(Cc3cncc(Cl)c3)c2n1)C(F)(F)F, C[C@@H]1COCCN1c1cc(=O)n2CC[C@H](N(Cc3cncc(Cl)c3)c2n1)C(F)(F)F	Preclinical
SAR405838	MDM inhibitor	MDM2			MedChemEx, MedChemEx, Selleck, Selleck, Selleck, Selleck, MedChemEx, MedChemEx	87.15	CC(C)(C)C[C@@H]1N[C@H]([C@H](c2cccc(Cl)c2F)[C@]11C(=O)Nc2cc(Cl)ccc12)C(=O)N[C@H]1CC[C@H](O)CC1, CC(C)(C)C[C@@H]1N[C@H]([C@H](c2cccc(Cl)c2F)[C@]11C(=O)Nc2cc(Cl)ccc12)C(=O)N[C@H]1CC[C@H](O)CC1, CC(C)(C)C[C@@H]1N[C@H]([C@H](c2cccc(Cl)c2F)[C@]11C(=O)Nc2cc(Cl)ccc12)C(=O)N[C@H]1CC[C@H](O)CC1, CC(C)(C)C[C@@H]1N[C@H]([C@H](c2cccc(Cl)c2F)[C@]11C(=O)Nc2cc(Cl)ccc12)C(=O)N[C@H]1CC[C@H](O)CC1, CC(C)(C)C[C@@H]1N[C@H]([C@H](c2cccc(Cl)c2F)[C@]11C(=O)Nc2cc(Cl)ccc12)C(=O)N[C@H]1CC[C@H](O)CC1, CC(C)(C)C[C@@H]1N[C@H]([C@H](c2cccc(Cl)c2F)[C@]11C(=O)Nc2cc(Cl)ccc12)C(=O)N[C@H]1CC[C@H](O)CC1, CC(C)(C)C[C@@H]1N[C@H]([C@H](c2cccc(Cl)c2F)[C@]11C(=O)Nc2cc(Cl)ccc12)C(=O)N[C@H]1CC[C@H](O)CC1, CC(C)(C)C[C@@H]1N[C@H]([C@H](c2cccc(Cl)c2F)[C@]11C(=O)Nc2cc(Cl)ccc12)C(=O)N[C@H]1CC[C@H](O)CC1	Phase 1
SAR407899	rho associated kinase inhibitor	ROCK1			MedChemEx, MedChemEx, MedChemEx	94.32	O=c1[nH]ccc2cc(OC3CCNCC3)ccc12, O=c1[nH]ccc2cc(OC3CCNCC3)ccc12, O=c1[nH]ccc2cc(OC3CCNCC3)ccc12	Phase 2
sasapyrine	NFkB pathway inhibitor	PTGS1, PTGS2	rheumatology	osteoarthritis, rheumatoid arthritis	MicroSource, MedChemEx, Selleck	97.73	OC(=O)c1ccccc1OC(=O)c1ccccc1O, OC(=O)c1ccccc1OC(=O)c1ccccc1O, OC(=O)c1ccccc1OC(=O)c1ccccc1O	Launched
satraplatin	DNA alkylating agent				MedChemEx, MedChemEx	96.09	CC(=O)O[Pt](N)(Cl)(Cl)(NC1CCCCC1)OC(C)=O, CC(=O)O[Pt](N)(Cl)(Cl)(NC1CCCCC1)OC(C)=O	Phase 3
savolitinib	c-Met inhibitor	MET			MedChemEx, MedChemEx, MedChemEx	97.52	C[C@@H](c1ccc2nccn2c1)n1nnc2ncc(nc12)-c1cnn(C)c1, C[C@@H](c1ccc2nccn2c1)n1nnc2ncc(nc12)-c1cnn(C)c1, C[C@@H](c1ccc2nccn2c1)n1nnc2ncc(nc12)-c1cnn(C)c1	Phase 3
saxagliptin	dipeptidyl peptidase inhibitor	DPP4	endocrinology	diabetes mellitus	MedChemEx	100	N[C@H](C(=O)N1[C@H]2C[C@H]2C[C@H]1C#N)[C@]12C[C@H]3C[C@H](C[C@](O)(C3)C1)C2	Launched
SB-200646	serotonin receptor antagonist	HTR2B, HTR2C			Tocris, Tocris, Tocris, Tocris, Tocris	95.8	Cn1ccc2cc(NC(=O)Nc3cccnc3)ccc12, Cn1ccc2cc(NC(=O)Nc3cccnc3)ccc12, Cn1ccc2cc(NC(=O)Nc3cccnc3)ccc12, Cn1ccc2cc(NC(=O)Nc3cccnc3)ccc12, Cn1ccc2cc(NC(=O)Nc3cccnc3)ccc12	Preclinical
SB-202190	p38 MAPK inhibitor	AKT1, ALOX5, CHEK1, GSK3B, LCK, MAPK1, MAPK11, MAPK12, MAPK14, MAPK8, PRKCA, ROCK1, RPS6KB1, SGK1			Tocris, Tocris, Selleck	94.52	Oc1ccc(cc1)-c1nc(c([nH]1)-c1ccc(F)cc1)-c1ccncc1, Oc1ccc(cc1)-c1nc(c([nH]1)-c1ccc(F)cc1)-c1ccncc1, Oc1ccc(cc1)-c1nc(c([nH]1)-c1ccc(F)cc1)-c1ccncc1	Preclinical
SB-203186	serotonin receptor antagonist	HTR4			Tocris, Tocris	98.69	O=C(OCCN1CCCCC1)c1c[nH]c2ccccc12, O=C(OCCN1CCCCC1)c1c[nH]c2ccccc12	Preclinical
SB-203580	p38 MAPK inhibitor	AKT1, ALOX5, CHEK1, CYP2D6, CYP3A4, GAK, GSK3B, LCK, MAPK1, MAPK10, MAPK11, MAPK12, MAPK14, MAPK8, MAPK9, PRKCA, RAF1, RIPK2, ROCK1, RPS6KB1, SGK1, SRC, TNF			Selleck, Tocris	98.22	C[S@@](=O)c1ccc(cc1)-c1nc(c([nH]1)-c1ccc(F)cc1)-c1ccncc1 |&1:1|, C[S@@](=O)c1ccc(cc1)-c1nc(c([nH]1)-c1ccc(F)cc1)-c1ccncc1 |&1:1|	Preclinical
SB-205384	GABA receptor modulator	GABRA3, GABRA5, GABRA6			Tocris, Tocris, Tocris, Tocris, Tocris, Tocris, Tocris	96.8	CC#CCOC(=O)c1c(C)nc2sc3C[C@@H](O)CCc3c2c1N |&1:15,r|, CC#CCOC(=O)c1c(C)nc2sc3C[C@@H](O)CCc3c2c1N |&1:15,r|, CC#CCOC(=O)c1c(C)nc2sc3C[C@@H](O)CCc3c2c1N |&1:15,r|, CC#CCOC(=O)c1c(C)nc2sc3C[C@@H](O)CCc3c2c1N |&1:15,r|, CC#CCOC(=O)c1c(C)nc2sc3C[C@@H](O)CCc3c2c1N |&1:15,r|, CC#CCOC(=O)c1c(C)nc2sc3C[C@@H](O)CCc3c2c1N |&1:15,r|, CC#CCOC(=O)c1c(C)nc2sc3C[C@@H](O)CCc3c2c1N |&1:15,r|	Preclinical
SB-206553	serotonin receptor antagonist	HTR2A, HTR2B, HTR2C			Tocris, Tocris, Tocris	95.94	Cn1ccc2cc3N(CCc3cc12)C(=O)Nc1cccnc1, Cn1ccc2cc3N(CCc3cc12)C(=O)Nc1cccnc1, Cn1ccc2cc3N(CCc3cc12)C(=O)Nc1cccnc1	Preclinical
SB-216641	serotonin receptor antagonist	HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C			Tocris, Tocris	92.59	COc1ccc(NC(=O)c2ccc(cc2)-c2ccc(cc2C)-c2noc(C)n2)cc1OCCN(C)C, COc1ccc(NC(=O)c2ccc(cc2)-c2ccc(cc2C)-c2noc(C)n2)cc1OCCN(C)C	Preclinical
SB-216763	glycogen synthase kinase inhibitor	CCNA2, CDK2, GSK3A, GSK3B			Selleck, Tocris	98.45	Cn1cc(C2=C(C(=O)NC2=O)c2ccc(Cl)cc2Cl)c2ccccc12 |t:4|, Cn1cc(C2=C(C(=O)NC2=O)c2ccc(Cl)cc2Cl)c2ccccc12 |t:4|	Preclinical
SB-218078	CHK inhibitor	CHEK1				0		Preclinical
SB-218795	tachykinin antagonist	TACR3			Tocris, Tocris, Tocris	97.4	COC(=O)[C@H](NC(=O)c1cc(nc2ccccc12)-c1ccccc1)c1ccccc1, COC(=O)[C@H](NC(=O)c1cc(nc2ccccc12)-c1ccccc1)c1ccccc1, COC(=O)[C@H](NC(=O)c1cc(nc2ccccc12)-c1ccccc1)c1ccccc1	Preclinical
SB-221284	serotonin receptor antagonist	HTR2A, HTR2B, HTR2C			Tocris, Tocris, Tocris	96.67	CSc1cc2CCN(C(=O)Nc3cccnc3)c2cc1C(F)(F)F, CSc1cc2CCN(C(=O)Nc3cccnc3)c2cc1C(F)(F)F, CSc1cc2CCN(C(=O)Nc3cccnc3)c2cc1C(F)(F)F	Preclinical
SB-222200	tachykinin antagonist	TACR3			Tocris, Tocris, Tocris, Tocris	99.49	CC[C@H](NC(=O)c1c(C)c(nc2ccccc12)-c1ccccc1)c1ccccc1, CC[C@H](NC(=O)c1c(C)c(nc2ccccc12)-c1ccccc1)c1ccccc1, CC[C@H](NC(=O)c1c(C)c(nc2ccccc12)-c1ccccc1)c1ccccc1, CC[C@H](NC(=O)c1c(C)c(nc2ccccc12)-c1ccccc1)c1ccccc1	Preclinical
SB-225002	CC chemokine receptor antagonist	CXCR2			Tocris, Tocris, Tocris, Tocris, Tocris, Tocris, Tocris	97.9	Oc1cc(ccc1NC(=O)Nc1ccccc1Br)[N+]([O-])=O, Oc1cc(ccc1NC(=O)Nc1ccccc1Br)[N+]([O-])=O, Oc1cc(ccc1NC(=O)Nc1ccccc1Br)[N+]([O-])=O, Oc1cc(ccc1NC(=O)Nc1ccccc1Br)[N+]([O-])=O, Oc1cc(ccc1NC(=O)Nc1ccccc1Br)[N+]([O-])=O, Oc1cc(ccc1NC(=O)Nc1ccccc1Br)[N+]([O-])=O, Oc1cc(ccc1NC(=O)Nc1ccccc1Br)[N+]([O-])=O	Preclinical
SB-228357	serotonin receptor antagonist	HTR2A, HTR2B, HTR2C			Tocris, Tocris, Tocris, Tocris	97.89	COc1cc2CCN(C(=O)Nc3cc(F)cc(c3)-c3cccnc3)c2cc1C(F)(F)F, COc1cc2CCN(C(=O)Nc3cc(F)cc(c3)-c3cccnc3)c2cc1C(F)(F)F, COc1cc2CCN(C(=O)Nc3cc(F)cc(c3)-c3cccnc3)c2cc1C(F)(F)F, COc1cc2CCN(C(=O)Nc3cc(F)cc(c3)-c3cccnc3)c2cc1C(F)(F)F	Preclinical
SB-2343	mTOR inhibitor, PI3K inhibitor	MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG			MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx	96.34	CC(C)n1c(C)nc2c(nc(nc12)N1CCOCC1)-c1cnc(N)nc1, CC(C)n1c(C)nc2c(nc(nc12)N1CCOCC1)-c1cnc(N)nc1, CC(C)n1c(C)nc2c(nc(nc12)N1CCOCC1)-c1cnc(N)nc1, CC(C)n1c(C)nc2c(nc(nc12)N1CCOCC1)-c1cnc(N)nc1, CC(C)n1c(C)nc2c(nc(nc12)N1CCOCC1)-c1cnc(N)nc1	Phase 1
SB-239063	p38 MAPK inhibitor	MAPK11, MAPK14, PTGS2			Tocris, Tocris, Tocris, Tocris, Tocris, Tocris, Tocris	96.09	COc1nccc(n1)-c1c(ncn1[C@H]1CC[C@H](O)CC1)-c1ccc(F)cc1 |r|, COc1nccc(n1)-c1c(ncn1[C@H]1CC[C@H](O)CC1)-c1ccc(F)cc1 |r|, COc1nccc(n1)-c1c(ncn1[C@H]1CC[C@H](O)CC1)-c1ccc(F)cc1 |r|, COc1nccc(n1)-c1c(ncn1[C@H]1CC[C@H](O)CC1)-c1ccc(F)cc1 |r|, COc1nccc(n1)-c1c(ncn1[C@H]1CC[C@H](O)CC1)-c1ccc(F)cc1 |r|, COc1nccc(n1)-c1c(ncn1[C@H]1CC[C@H](O)CC1)-c1ccc(F)cc1 |r|, COc1nccc(n1)-c1c(ncn1[C@H]1CC[C@H](O)CC1)-c1ccc(F)cc1 |r|	Preclinical
SB-242235	p38 MAPK inhibitor	HSPB1, MAPK14			MedChemEx, MedChemEx, MedChemEx, MedChemEx	91.5	COc1nccc(n1)-c1c(ncn1C1CCNCC1)-c1ccc(F)cc1, COc1nccc(n1)-c1c(ncn1C1CCNCC1)-c1ccc(F)cc1, COc1nccc(n1)-c1c(ncn1C1CCNCC1)-c1ccc(F)cc1, COc1nccc(n1)-c1c(ncn1C1CCNCC1)-c1ccc(F)cc1	Phase 1
SB-243213	serotonin receptor inverse agonist	HTR2A, HTR2B, HTR2C, HTR6			Tocris, Tocris, Tocris, Tocris	97.34	Cc1cc2CCN(C(=O)Nc3ccc(Oc4cccnc4C)nc3)c2cc1C(F)(F)F, Cc1cc2CCN(C(=O)Nc3ccc(Oc4cccnc4C)nc3)c2cc1C(F)(F)F, Cc1cc2CCN(C(=O)Nc3ccc(Oc4cccnc4C)nc3)c2cc1C(F)(F)F, Cc1cc2CCN(C(=O)Nc3ccc(Oc4cccnc4C)nc3)c2cc1C(F)(F)F	Phase 1
SB-258585	serotonin receptor antagonist	HTR6			Tocris, Tocris	94.76	COc1ccc(NS(=O)(=O)c2ccc(I)cc2)cc1N1CCN(C)CC1, COc1ccc(NS(=O)(=O)c2ccc(I)cc2)cc1N1CCN(C)CC1	Preclinical
SB-268262	calcitonin antagonist	CALCA			Tocris, Tocris, Tocris, Tocris, Tocris	97.6	CN(C(=O)c1ccc(c(c1)[N+]([O-])=O)[S@@](=O)c1nccs1)c1ccccc1C |&1:13,r|, CN(C(=O)c1ccc(c(c1)[N+]([O-])=O)[S@@](=O)c1nccs1)c1ccccc1C |&1:13,r|, CN(C(=O)c1ccc(c(c1)[N+]([O-])=O)[S@@](=O)c1nccs1)c1ccccc1C |&1:13,r|, CN(C(=O)c1ccc(c(c1)[N+]([O-])=O)[S@@](=O)c1nccs1)c1ccccc1C |&1:13,r|, CN(C(=O)c1ccc(c(c1)[N+]([O-])=O)[S@@](=O)c1nccs1)c1ccccc1C |&1:13,r|	Preclinical
SB-269970	serotonin receptor antagonist	HTR7			Tocris, Selleck, Tocris, Tocris, Tocris	97.96	CC1CCN(CC[C@H]2CCCN2S(=O)(=O)c2cccc(O)c2)CC1, CC1CCN(CC[C@H]2CCCN2S(=O)(=O)c2cccc(O)c2)CC1, CC1CCN(CC[C@H]2CCCN2S(=O)(=O)c2cccc(O)c2)CC1, CC1CCN(CC[C@H]2CCCN2S(=O)(=O)c2cccc(O)c2)CC1, CC1CCN(CC[C@H]2CCCN2S(=O)(=O)c2cccc(O)c2)CC1	Preclinical
SB-271046	serotonin receptor antagonist	HTR6			Tocris, Tocris, Tocris, Tocris, Tocris, Selleck, Selleck, Selleck	97.8	COc1ccc(NS(=O)(=O)c2sc3ccc(Cl)cc3c2C)cc1N1CCNCC1, COc1ccc(NS(=O)(=O)c2sc3ccc(Cl)cc3c2C)cc1N1CCNCC1, COc1ccc(NS(=O)(=O)c2sc3ccc(Cl)cc3c2C)cc1N1CCNCC1, COc1ccc(NS(=O)(=O)c2sc3ccc(Cl)cc3c2C)cc1N1CCNCC1, COc1ccc(NS(=O)(=O)c2sc3ccc(Cl)cc3c2C)cc1N1CCNCC1, COc1ccc(NS(=O)(=O)c2sc3ccc(Cl)cc3c2C)cc1N1CCNCC1, COc1ccc(NS(=O)(=O)c2sc3ccc(Cl)cc3c2C)cc1N1CCNCC1, COc1ccc(NS(=O)(=O)c2sc3ccc(Cl)cc3c2C)cc1N1CCNCC1	Phase 1
SB-297006	CC chemokine receptor antagonist	CCR3			Tocris, Tocris	95.38	CCOC(=O)[C@H](Cc1ccc(cc1)[N+]([O-])=O)NC(=O)c1ccccc1, CCOC(=O)[C@H](Cc1ccc(cc1)[N+]([O-])=O)NC(=O)c1ccccc1	Preclinical
SB-328437	CCR antagonist				Tocris, Tocris, Tocris	97.21	COC(=O)[C@H](Cc1ccc(cc1)[N+]([O-])=O)NC(=O)c1cccc2ccccc12, COC(=O)[C@H](Cc1ccc(cc1)[N+]([O-])=O)NC(=O)c1cccc2ccccc12, COC(=O)[C@H](Cc1ccc(cc1)[N+]([O-])=O)NC(=O)c1cccc2ccccc12	Preclinical
SB-334867	orexin receptor antagonist	HCRTR1, HCRTR2			Tocris, Tocris, Tocris, Tocris	99.08	Cc1nc2ccc(NC(=O)Nc3ccnc4cccnc34)cc2o1, Cc1nc2ccc(NC(=O)Nc3ccnc4cccnc34)cc2o1, Cc1nc2ccc(NC(=O)Nc3ccnc4cccnc34)cc2o1, Cc1nc2ccc(NC(=O)Nc3ccnc4cccnc34)cc2o1	Preclinical
SB-366791	TRPV antagonist	TRPV1			Tocris, Tocris, Tocris, Tocris, Tocris	99.59	COc1cccc(NC(=O)\C=C\c2ccc(Cl)cc2)c1, COc1cccc(NC(=O)\C=C\c2ccc(Cl)cc2)c1, COc1cccc(NC(=O)\C=C\c2ccc(Cl)cc2)c1, COc1cccc(NC(=O)\C=C\c2ccc(Cl)cc2)c1, COc1cccc(NC(=O)\C=C\c2ccc(Cl)cc2)c1	Preclinical
SB-399885	serotonin receptor antagonist	HTR6			Tocris, Tocris	97.19	COc1ccc(cc1N1CCNCC1)S(=O)(=O)Nc1cc(Cl)cc(Cl)c1OC, COc1ccc(cc1N1CCNCC1)S(=O)(=O)Nc1cc(Cl)cc(Cl)c1OC	Preclinical
SB-408124	orexin receptor antagonist	HCRTR1, HCRTR2			Tocris, Selleck, Selleck, Tocris, Selleck	95.35	CN(C)c1ccc(NC(=O)Nc2cc(C)nc3c(F)cc(F)cc23)cc1, CN(C)c1ccc(NC(=O)Nc2cc(C)nc3c(F)cc(F)cc23)cc1, CN(C)c1ccc(NC(=O)Nc2cc(C)nc3c(F)cc(F)cc23)cc1, CN(C)c1ccc(NC(=O)Nc2cc(C)nc3c(F)cc(F)cc23)cc1, CN(C)c1ccc(NC(=O)Nc2cc(C)nc3c(F)cc(F)cc23)cc1	Preclinical
SB-415286	glycogen synthase kinase inhibitor	GSK3A, GSK3B, RPS6KB1			Tocris, Selleck, Selleck, Selleck, Selleck, Tocris	91.95	Oc1ccc(NC2=C(C(=O)NC2=O)c2ccccc2[N+]([O-])=O)cc1Cl |t:6|, Oc1ccc(NC2=C(C(=O)NC2=O)c2ccccc2[N+]([O-])=O)cc1Cl |t:6|, Oc1ccc(NC2=C(C(=O)NC2=O)c2ccccc2[N+]([O-])=O)cc1Cl |t:6|, Oc1ccc(NC2=C(C(=O)NC2=O)c2ccccc2[N+]([O-])=O)cc1Cl |t:6|, Oc1ccc(NC2=C(C(=O)NC2=O)c2ccccc2[N+]([O-])=O)cc1Cl |t:6|, Oc1ccc(NC2=C(C(=O)NC2=O)c2ccccc2[N+]([O-])=O)cc1Cl |t:6|	Preclinical
SB-431542	TGF beta receptor inhibitor	ACVR1C, TGFBR1			Selleck, Selleck, Tocris, Tocris, Tocris, Tocris	98.92	NC(=O)c1ccc(cc1)-c1nc(c([nH]1)-c1ccc2OCOc2c1)-c1ccccn1, NC(=O)c1ccc(cc1)-c1nc(c([nH]1)-c1ccc2OCOc2c1)-c1ccccn1, NC(=O)c1ccc(cc1)-c1nc(c([nH]1)-c1ccc2OCOc2c1)-c1ccccn1, NC(=O)c1ccc(cc1)-c1nc(c([nH]1)-c1ccc2OCOc2c1)-c1ccccn1, NC(=O)c1ccc(cc1)-c1nc(c([nH]1)-c1ccc2OCOc2c1)-c1ccccn1, NC(=O)c1ccc(cc1)-c1nc(c([nH]1)-c1ccc2OCOc2c1)-c1ccccn1	Preclinical
SB-452533	TRPV antagonist	TRPV1			Tocris, Tocris	93.09	CCN(CCNC(=O)Nc1ccccc1Br)c1cccc(C)c1, CCN(CCNC(=O)Nc1ccccc1Br)c1cccc(C)c1	Preclinical
SB-505124	ALK tyrosine kinase receptor inhibitor	TGFBR1			Selleck, Selleck, Selleck	98.07	Cc1cccc(n1)-c1nc([nH]c1-c1ccc2OCOc2c1)C(C)(C)C, Cc1cccc(n1)-c1nc([nH]c1-c1ccc2OCOc2c1)C(C)(C)C, Cc1cccc(n1)-c1nc([nH]c1-c1ccc2OCOc2c1)C(C)(C)C	Preclinical
SB-525334	TGF beta receptor inhibitor	TGFBR1			Selleck, Selleck, Tocris, Tocris	95.92	Cc1cccc(n1)-c1nc([nH]c1-c1ccc2nccnc2c1)C(C)(C)C, Cc1cccc(n1)-c1nc([nH]c1-c1ccc2nccnc2c1)C(C)(C)C, Cc1cccc(n1)-c1nc([nH]c1-c1ccc2nccnc2c1)C(C)(C)C, Cc1cccc(n1)-c1nc([nH]c1-c1ccc2nccnc2c1)C(C)(C)C	Preclinical
SB-590885	RAF inhibitor	BRAF			Selleck, Selleck, Selleck, Selleck	87.33	CN(C)CCOc1ccc(cc1)-c1nc(c([nH]1)-c1ccc2\C(CCc2c1)=N\O)-c1ccncc1, CN(C)CCOc1ccc(cc1)-c1nc(c([nH]1)-c1ccc2\C(CCc2c1)=N\O)-c1ccncc1, CN(C)CCOc1ccc(cc1)-c1nc(c([nH]1)-c1ccc2\C(CCc2c1)=N\O)-c1ccncc1, CN(C)CCOc1ccc(cc1)-c1nc(c([nH]1)-c1ccc2\C(CCc2c1)=N\O)-c1ccncc1	Preclinical
SB-612111	nociceptin/orphanin FQ receptor antagonist	OPRL1			Tocris, Tocris, Tocris	98.74	Cc1cccc2[C@@H](O)C[C@@H](CN3CCC(CC3)c3c(Cl)cccc3Cl)CCc12, Cc1cccc2[C@@H](O)C[C@@H](CN3CCC(CC3)c3c(Cl)cccc3Cl)CCc12, Cc1cccc2[C@@H](O)C[C@@H](CN3CCC(CC3)c3c(Cl)cccc3Cl)CCc12	Preclinical
SB-649868	orexin receptor antagonist				MedChemEx	98.14	Cc1nc(C(=O)N2CCCC[C@H]2CNC(=O)c2cccc3occc23)c(s1)-c1ccc(F)cc1	Phase 2
SB-657510	urotensin receptor antagonist	UTS2R			Tocris, Tocris, Tocris, Tocris	98.3	COc1cc(Br)c(cc1OC)S(=O)(=O)Nc1ccc(Cl)c(O[C@@H]2CCN(C)C2)c1, COc1cc(Br)c(cc1OC)S(=O)(=O)Nc1ccc(Cl)c(O[C@@H]2CCN(C)C2)c1, COc1cc(Br)c(cc1OC)S(=O)(=O)Nc1ccc(Cl)c(O[C@@H]2CCN(C)C2)c1, COc1cc(Br)c(cc1OC)S(=O)(=O)Nc1ccc(Cl)c(O[C@@H]2CCN(C)C2)c1	Preclinical
SB-683698	integrin antagonist	ITGA4, ITGAV, ITGB1, ITGB7			MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx	95.84	COc1cccc(OC)c1-c1ccc(C[C@H](NC(=O)c2c(Cl)cccc2Cl)C(O)=O)cc1, COc1cccc(OC)c1-c1ccc(C[C@H](NC(=O)c2c(Cl)cccc2Cl)C(O)=O)cc1, COc1cccc(OC)c1-c1ccc(C[C@H](NC(=O)c2c(Cl)cccc2Cl)C(O)=O)cc1, COc1cccc(OC)c1-c1ccc(C[C@H](NC(=O)c2c(Cl)cccc2Cl)C(O)=O)cc1, COc1cccc(OC)c1-c1ccc(C[C@H](NC(=O)c2c(Cl)cccc2Cl)C(O)=O)cc1	Phase 1
SB-705498	TRPV antagonist	TRPV1			Selleck, Selleck, Selleck, Selleck, MedChemEx	98.38	FC(F)(F)c1ccc(nc1)N1CC[C@H](C1)NC(=O)Nc1ccccc1Br, FC(F)(F)c1ccc(nc1)N1CC[C@H](C1)NC(=O)Nc1ccccc1Br, FC(F)(F)c1ccc(nc1)N1CC[C@H](C1)NC(=O)Nc1ccccc1Br, FC(F)(F)c1ccc(nc1)N1CC[C@H](C1)NC(=O)Nc1ccccc1Br, FC(F)(F)c1ccc(nc1)N1CC[C@H](C1)NC(=O)Nc1ccccc1Br	Phase 2
SB-706375	urotensin receptor antagonist	UTS2R			Tocris, Tocris	98.2	COc1cc(Br)c(cc1OC)S(=O)(=O)Nc1ccc(c(O[C@@H]2CCN(C)C2)c1)C(F)(F)F, COc1cc(Br)c(cc1OC)S(=O)(=O)Nc1ccc(c(O[C@@H]2CCN(C)C2)c1)C(F)(F)F	Preclinical
SB-742457	serotonin receptor antagonist	HTR6			Selleck, MedChemEx, Selleck	89.14	O=S(=O)(c1ccccc1)c1cnc2c(cccc2c1)N1CCNCC1, O=S(=O)(c1ccccc1)c1cnc2c(cccc2c1)N1CCNCC1, O=S(=O)(c1ccccc1)c1cnc2c(cccc2c1)N1CCNCC1	Phase 3
SB-743921	kinesin-like spindle protein inhibitor	KIF11			Selleck, Selleck, Tocris	95.39	CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1oc2cc(Cl)ccc2c(=O)c1Cc1ccccc1, CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1oc2cc(Cl)ccc2c(=O)c1Cc1ccccc1, CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1oc2cc(Cl)ccc2c(=O)c1Cc1ccccc1	Phase 1/Phase 2
SB-747651A	kinase inhibitor	AKT1, AKT3, ROCK1, RPS6KA5, RPS6KB1			Tocris, Tocris, Tocris, Tocris	97.46	CCn1c(nc2cncc(CNC3CCNCC3)c12)-c1nonc1N, CCn1c(nc2cncc(CNC3CCNCC3)c12)-c1nonc1N, CCn1c(nc2cncc(CNC3CCNCC3)c12)-c1nonc1N, CCn1c(nc2cncc(CNC3CCNCC3)c12)-c1nonc1N	Preclinical
SB-756050	G protein-coupled receptor agonist	GPBAR1			MedChemEx, Enamine, Enamine	99.59	COc1ccc(cc1OC)S(=O)(=O)N1CCCN(CC1)S(=O)(=O)c1ccc(OC)c(OC)c1, COc1ccc(cc1OC)S(=O)(=O)N1CCCN(CC1)S(=O)(=O)c1ccc(OC)c(OC)c1, COc1ccc(cc1OC)S(=O)(=O)N1CCCN(CC1)S(=O)(=O)c1ccc(OC)c(OC)c1	Phase 1
SB-772077B	rho associated kinase inhibitor	ROCK1, ROCK2			Tocris, Tocris	97.75	CCn1c(nc2cncc(C(=O)N3CC[C@H](N)C3)c12)-c1nonc1N, CCn1c(nc2cncc(C(=O)N3CC[C@H](N)C3)c12)-c1nonc1N	Preclinical
SB-939	HDAC inhibitor	HDAC1, HDAC10, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC9			Selleck, Selleck, Selleck, Selleck, MedChemEx, MedChemEx, MedChemEx	96.42	CCCCc1nc2cc(\C=C\C(=O)NO)ccc2n1CCN(CC)CC, CCCCc1nc2cc(\C=C\C(=O)NO)ccc2n1CCN(CC)CC, CCCCc1nc2cc(\C=C\C(=O)NO)ccc2n1CCN(CC)CC, CCCCc1nc2cc(\C=C\C(=O)NO)ccc2n1CCN(CC)CC, CCCCc1nc2cc(\C=C\C(=O)NO)ccc2n1CCN(CC)CC, CCCCc1nc2cc(\C=C\C(=O)NO)ccc2n1CCN(CC)CC, CCCCc1nc2cc(\C=C\C(=O)NO)ccc2n1CCN(CC)CC	Phase 3
SBE-13	PLK inhibitor	PLK1			Tocris, Tocris	98.45	COc1ccc(CCNCc2ccc(OCc3ccc(Cl)nc3)c(OC)c2)cc1OC, COc1ccc(CCNCc2ccc(OCc3ccc(Cl)nc3)c(OC)c2)cc1OC	Preclinical
SBHA	HDAC inhibitor	HDAC1, HDAC3			Tocris, Tocris, Tocris	100	ONC(=O)CCCCCCC(=O)NO, ONC(=O)CCCCCCC(=O)NO, ONC(=O)CCCCCCC(=O)NO	Preclinical
SBI-115	G protein-coupled receptor antagonist				MedChemEx	48.8	CCS(=O)(=O)c1ncc(Cl)c(n1)C(=O)Oc1cccc(C)c1	Preclinical
SC-10	protein kinase activator	PRKCA			Tocris, Toronto	97.54	CCCCCCCNS(=O)(=O)c1cccc2c(Cl)cccc12, CCCCCCCNS(=O)(=O)c1cccc2c(Cl)cccc12	Preclinical
SC-12267	dihydroorotate dehydrogenase inhibitor	IL17A			MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx	98.78	COc1cccc(c1)-c1ccc(NC(=O)C2=C(CCC2)C(O)=O)c(F)c1 |t:16|, COc1cccc(c1)-c1ccc(NC(=O)C2=C(CCC2)C(O)=O)c(F)c1 |t:16|, COc1cccc(c1)-c1ccc(NC(=O)C2=C(CCC2)C(O)=O)c(F)c1 |t:16|, COc1cccc(c1)-c1ccc(NC(=O)C2=C(CCC2)C(O)=O)c(F)c1 |t:16|, COc1cccc(c1)-c1ccc(NC(=O)C2=C(CCC2)C(O)=O)c(F)c1 |t:16|, COc1cccc(c1)-c1ccc(NC(=O)C2=C(CCC2)C(O)=O)c(F)c1 |t:16|	Phase 2
SC-144	P glycoprotein inhibitor				Tocris, Selleck, Selleck, Selleck, Selleck, Tocris, Selleck	98.43	Fc1ccc2c(c1)nc(NNC(=O)c1cnccn1)c1cccn21, Fc1ccc2c(c1)nc(NNC(=O)c1cnccn1)c1cccn21, Fc1ccc2c(c1)nc(NNC(=O)c1cnccn1)c1cccn21, Fc1ccc2c(c1)nc(NNC(=O)c1cnccn1)c1cccn21, Fc1ccc2c(c1)nc(NNC(=O)c1cnccn1)c1cccn21, Fc1ccc2c(c1)nc(NNC(=O)c1cnccn1)c1cccn21, Fc1ccc2c(c1)nc(NNC(=O)c1cnccn1)c1cccn21	Preclinical
SC-19220	prostanoid receptor antagonist	PTGER1			Tocris, Tocris, Tocris, Tocris	96.83	CC(=O)NNC(=O)N1Cc2ccccc2Oc2ccc(Cl)cc12, CC(=O)NNC(=O)N1Cc2ccccc2Oc2ccc(Cl)cc12, CC(=O)NNC(=O)N1Cc2ccccc2Oc2ccc(Cl)cc12, CC(=O)NNC(=O)N1Cc2ccccc2Oc2ccc(Cl)cc12	Preclinical
SC-236	cyclooxygenase inhibitor	PTGS2			Tocris, Tocris, Tocris	98.26	NS(=O)(=O)c1ccc(cc1)-n1nc(cc1-c1ccc(Cl)cc1)C(F)(F)F, NS(=O)(=O)c1ccc(cc1)-n1nc(cc1-c1ccc(Cl)cc1)C(F)(F)F, NS(=O)(=O)c1ccc(cc1)-n1nc(cc1-c1ccc(Cl)cc1)C(F)(F)F	Preclinical
SC-51089	prostanoid receptor antagonist	PTGER1			Tocris, Tocris	96.02	Clc1ccc2Oc3ccccc3CN(C(=O)NNC(=O)CCc3ccncc3)c2c1, Clc1ccc2Oc3ccccc3CN(C(=O)NNC(=O)CCc3ccncc3)c2c1	Preclinical
SC-560	cyclooxygenase inhibitor	PTGS1			Tocris, Tocris, Tocris, Tocris	98.01	COc1ccc(cc1)-n1nc(cc1-c1ccc(Cl)cc1)C(F)(F)F, COc1ccc(cc1)-n1nc(cc1-c1ccc(Cl)cc1)C(F)(F)F, COc1ccc(cc1)-n1nc(cc1-c1ccc(Cl)cc1)C(F)(F)F, COc1ccc(cc1)-n1nc(cc1-c1ccc(Cl)cc1)C(F)(F)F	Preclinical
SC-9	protein tyrosine kinase activator	PRKCA			Tocris, Tocris, Tocris, Tocris, Tocris	98.46	Clc1cccc2c(cccc12)S(=O)(=O)NCCCCCCc1ccccc1, Clc1cccc2c(cccc12)S(=O)(=O)NCCCCCCc1ccccc1, Clc1cccc2c(cccc12)S(=O)(=O)NCCCCCCc1ccccc1, Clc1cccc2c(cccc12)S(=O)(=O)NCCCCCCc1ccccc1, Clc1cccc2c(cccc12)S(=O)(=O)NCCCCCCc1ccccc1	Preclinical
scabertopin	anticancer agent				MedChemEx	94.26	[H][C@]12C\C(C)=C/[C@@]3([H])OC(=O)C(=C)[C@]3([H])[C@H](CC(=C1)C(=O)O2)OC(=O)C(\C)=C/C |c:4,t:18|	Preclinical
SCH-202676	G protein-coupled receptor modulator	CHRM1, CHRM2, DRD1, DRD2			Tocris, Tocris, Tocris	80.2	CN=c1nc(-c2ccccc2)n(s1)-c1ccccc1, CN=c1nc(-c2ccccc2)n(s1)-c1ccccc1, CN=c1nc(-c2ccccc2)n(s1)-c1ccccc1	Preclinical
SCH-221510	nociceptin/orphanin FQ receptor agonist	OPRL1			Tocris	97.23	Cc1ccccc1C(N1[C@H]2CC[C@@H]1C[C@](O)(C2)c1ccccc1)c1ccccc1C |&1:9,12,14,r|	Preclinical
SCH-23390	dopamine receptor antagonist	DRD1, DRD5, HTR2C, KCNJ4, KCNJ6			Tocris, Tocris	96.81	CN1CCc2cc(Cl)c(O)cc2[C@H](C1)c1ccccc1, CN1CCc2cc(Cl)c(O)cc2[C@H](C1)c1ccccc1	Preclinical
SCH-28080	ATPase inhibitor	ATP4A			Tocris, Tocris	95.57	Cc1nc2c(OCc3ccccc3)cccn2c1CC#N, Cc1nc2c(OCc3ccccc3)cccn2c1CC#N	Phase 1
SCH-51344	MTH1 inhibitor	NUDT1			Tocris, Tocris	93.73	COc1ccc2nc3n[nH]c(C)c3c(NCCOCCO)c2c1, COc1ccc2nc3n[nH]c(C)c3c(NCCOCCO)c2c1	Preclinical
SCH-58261	adenosine receptor antagonist	ADORA1, ADORA2A, ADORA2B, ADORA3			Tocris, Tocris, Tocris, Tocris, Tocris, Tocris, Tocris	99.01	Nc1nc2n(CCc3ccccc3)ncc2c2nc(nn12)-c1ccco1, Nc1nc2n(CCc3ccccc3)ncc2c2nc(nn12)-c1ccco1, Nc1nc2n(CCc3ccccc3)ncc2c2nc(nn12)-c1ccco1, Nc1nc2n(CCc3ccccc3)ncc2c2nc(nn12)-c1ccco1, Nc1nc2n(CCc3ccccc3)ncc2c2nc(nn12)-c1ccco1, Nc1nc2n(CCc3ccccc3)ncc2c2nc(nn12)-c1ccco1, Nc1nc2n(CCc3ccccc3)ncc2c2nc(nn12)-c1ccco1	Preclinical
SCH-900776	CHK inhibitor	CDK2, CHEK1			Selleck, Selleck, Selleck, Selleck, Selleck	85.42	Cn1cc(cn1)-c1cnn2c(N)c(Br)c(nc12)[C@@H]1CCCNC1, Cn1cc(cn1)-c1cnn2c(N)c(Br)c(nc12)[C@@H]1CCCNC1, Cn1cc(cn1)-c1cnn2c(N)c(Br)c(nc12)[C@@H]1CCCNC1, Cn1cc(cn1)-c1cnn2c(N)c(Br)c(nc12)[C@@H]1CCCNC1, Cn1cc(cn1)-c1cnn2c(N)c(Br)c(nc12)[C@@H]1CCCNC1	Phase 2
schisandrin-B	antioxidant	ATR			MedChemEx	97.18	COc1cc2C[C@H](C)[C@H](C)Cc3cc4OCOc4c(OC)c3-c2c(OC)c1OC |r|	Preclinical
schisandrol-B	lipid peroxidase inhibitor				MedChemEx, MedChemEx	97.81	COc1cc2C[C@](C)(O)[C@@H](C)Cc3cc4OCOc4c(OC)c3-c2c(OC)c1OC, COc1cc2C[C@](C)(O)[C@@H](C)Cc3cc4OCOc4c(OC)c3-c2c(OC)c1OC	Phase 3
sclareol					Selleck, Selleck	100	CC(O)(CC[C@H]1[C@](C)(O)CC[C@H]2C(C)(C)CCC[C@]12C)C=C |a:5,6,18,&1:1,&2:11|, CC(O)(CC[C@H]1[C@](C)(O)CC[C@H]2C(C)(C)CCC[C@]12C)C=C |a:5,6,18,&1:1,&2:11|	Preclinical
sclareolide	other antifungal				Selleck, Selleck, Selleck	100	C[C@@]12CC[C@H]3C(C)(C)CCC[C@]3(C)[C@H]1CC(=O)O2, C[C@@]12CC[C@H]3C(C)(C)CCC[C@]3(C)[C@H]1CC(=O)O2, C[C@@]12CC[C@H]3C(C)(C)CCC[C@]3(C)[C@H]1CC(=O)O2	Launched
SCMC-Lys	mucolytic agent	GSTP1	pulmonary	chronic obstructive pulmonary disease (COPD)	ChemImpex, ChemImpex	83.3	N[C@@H](CSCC(O)=O)C(O)=O, N[C@@H](CSCC(O)=O)C(O)=O	Launched
scopine					MedChemEx, Selleck, Selleck, Selleck	100	CN1[C@H]2C[C@H](O)C[C@@H]1[C@H]1O[C@@H]21, CN1[C@H]2C[C@H](O)C[C@@H]1[C@H]1O[C@@H]21, CN1[C@H]2C[C@H](O)C[C@@H]1[C@H]1O[C@@H]21, CN1[C@H]2C[C@H](O)C[C@@H]1[C@H]1O[C@@H]21	Launched
scopolamine	acetylcholine receptor antagonist	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, SI	neurology/psychiatry, gastroenterology	motion sickness, vomiting, nausea	Selleck, Tocris, MedChemEx, Tocris	96.73	CN1[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)c1ccccc1, CN1[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)c1ccccc1, CN1[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)c1ccccc1, CN1[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)c1ccccc1	Launched
scopolamine-N-oxide	acetylcholine receptor antagonist	CHRM1, CHRM2, CHRM3, CHRM4			Prestwick, TCI	93.9	C[N@@+]1([O-])[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)c1ccccc1 |a:3,5,7,8,10,14,&1:1,TLB:0:1:4.5.6:8.10,THB:2:1:4.5.6:8.10,9:8:1:4.5.6,9:10:1:4.5.6,11:5:1:8.10|, C[N@@+]1([O-])[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)c1ccccc1 |a:3,5,7,8,10,14,&1:1,TLB:0:1:4.5.6:8.10,THB:2:1:4.5.6:8.10,9:8:1:4.5.6,9:10:1:4.5.6,11:5:1:8.10|	Preclinical
SCP-1	analgesic agent				SciExchange, Vitas-M	97.74	Oc1ccc(NC(=O)CN2C(=O)c3ccccc3S2(=O)=O)cc1, Oc1ccc(NC(=O)CN2C(=O)c3ccccc3S2(=O)=O)cc1	Phase 1
scriptaid	HDAC inhibitor	HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9			Tocris, Tocris, Selleck	96.95	ONC(=O)CCCCCN1C(=O)c2cccc3cccc(C1=O)c23, ONC(=O)CCCCCN1C(=O)c2cccc3cccc(C1=O)c23, ONC(=O)CCCCCN1C(=O)c2cccc3cccc(C1=O)c23	Preclinical
SCS					Tocris, Tocris, Tocris, Tocris	96.88	Oc1ccccc1\C=N\NC(=O)c1ccccc1O, Oc1ccccc1\C=N\NC(=O)c1ccccc1O, Oc1ccccc1\C=N\NC(=O)c1ccccc1O, Oc1ccccc1\C=N\NC(=O)c1ccccc1O	Preclinical
SD-0006	p38 MAPK inhibitor				MedChemEx	94.38	OCC(=O)N1CCC(CC1)c1[nH]nc(c1-c1ccncn1)-c1ccc(Cl)cc1	Phase 2
SD-169	p38 MAPK inhibitor	MAPK14			EMDBio	97.83	NC(=O)c1ccc2[nH]ccc2c1	Preclinical
SD-208	TGF beta receptor inhibitor	TGFBR1			Tocris, Tocris, Tocris	97.15	Fc1ccc(Cl)cc1-c1nc(Nc2ccncc2)c2nccnc2n1, Fc1ccc(Cl)cc1-c1nc(Nc2ccncc2)c2nccnc2n1, Fc1ccc(Cl)cc1-c1nc(Nc2ccncc2)c2nccnc2n1	Preclinical
SD-2590	matrix metalloprotease inhibitor	MMP1, MMP13, MMP2			Tocris, Tocris, Tocris	93.08	COCCN1CCC(CC1)(C(=O)NO)S(=O)(=O)c1ccc(Oc2ccc(OC(F)(F)F)cc2)cc1, COCCN1CCC(CC1)(C(=O)NO)S(=O)(=O)c1ccc(Oc2ccc(OC(F)(F)F)cc2)cc1, COCCN1CCC(CC1)(C(=O)NO)S(=O)(=O)c1ccc(Oc2ccc(OC(F)(F)F)cc2)cc1	Preclinical
SDM25N	opioid receptor antagonist	OPRD1			Tocris, Tocris, Tocris, Tocris, Tocris	93.48	CC(=C)CN1CC[C@@]23[C@H]4Oc5c2c(C[C@@H]1[C@]3(O)Cc1c4[nH]c2ccccc12)ccc5O |a:7,8,15,&1:14,TLB:17:15:4.5.6:11.12.13,THB:16:15:4.5.6:11.12.13|, CC(=C)CN1CC[C@@]23[C@H]4Oc5c2c(C[C@@H]1[C@]3(O)Cc1c4[nH]c2ccccc12)ccc5O |a:7,8,15,&1:14,TLB:17:15:4.5.6:11.12.13,THB:16:15:4.5.6:11.12.13|, CC(=C)CN1CC[C@@]23[C@H]4Oc5c2c(C[C@@H]1[C@]3(O)Cc1c4[nH]c2ccccc12)ccc5O |a:7,8,15,&1:14,TLB:17:15:4.5.6:11.12.13,THB:16:15:4.5.6:11.12.13|, CC(=C)CN1CC[C@@]23[C@H]4Oc5c2c(C[C@@H]1[C@]3(O)Cc1c4[nH]c2ccccc12)ccc5O |a:7,8,15,&1:14,TLB:17:15:4.5.6:11.12.13,THB:16:15:4.5.6:11.12.13|, CC(=C)CN1CC[C@@]23[C@H]4Oc5c2c(C[C@@H]1[C@]3(O)Cc1c4[nH]c2ccccc12)ccc5O |a:7,8,15,&1:14,TLB:17:15:4.5.6:11.12.13,THB:16:15:4.5.6:11.12.13|	Preclinical
SDZ-NKT-343	tachykinin antagonist	TACR1			Tocris, Tocris, Tocris, Tocris, Tocris	97.81	CN(Cc1ccccc1)C(=O)[C@H](Cc1ccc2ccccc2c1)NC(=O)[C@@H]1CCCN1C(=O)Nc1ccccc1[N+]([O-])=O, CN(Cc1ccccc1)C(=O)[C@H](Cc1ccc2ccccc2c1)NC(=O)[C@@H]1CCCN1C(=O)Nc1ccccc1[N+]([O-])=O, CN(Cc1ccccc1)C(=O)[C@H](Cc1ccc2ccccc2c1)NC(=O)[C@@H]1CCCN1C(=O)Nc1ccccc1[N+]([O-])=O, CN(Cc1ccccc1)C(=O)[C@H](Cc1ccc2ccccc2c1)NC(=O)[C@@H]1CCCN1C(=O)Nc1ccccc1[N+]([O-])=O, CN(Cc1ccccc1)C(=O)[C@H](Cc1ccc2ccccc2c1)NC(=O)[C@@H]1CCCN1C(=O)Nc1ccccc1[N+]([O-])=O	Phase 1
SDZ-SER-082	serotonin receptor antagonist	HTR2A, HTR2B, HTR2C			Tocris, Tocris	82.57	CN1CC[C@@H]2CN3CCc4cccc([C@@H]2C1)c34, CN1CC[C@@H]2CN3CCc4cccc([C@@H]2C1)c34	Preclinical
SDZ-WAG-994	adenosine receptor agonist	ADORA1			Tocris, Tocris, Tocris, Tocris	89.51	CO[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1n1cnc2c(NC3CCCCC3)ncnc12, CO[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1n1cnc2c(NC3CCCCC3)ncnc12, CO[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1n1cnc2c(NC3CCCCC3)ncnc12, CO[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1n1cnc2c(NC3CCCCC3)ncnc12	Phase 2
SDZ-205-557	serotonin receptor antagonist	HTR3A, HTR3B			Tocris, Tocris	97.71	CCN(CC)CCOC(=O)c1cc(Cl)c(N)cc1OC, CCN(CC)CCOC(=O)c1cc(Cl)c(N)cc1OC	Preclinical
SDZ-21009	adrenergic receptor antagonist, serotonin receptor antagonist	HTR1A, HTR1B			Tocris, Tocris, Tocris	93.11	CC(C)OC(=O)c1cc2c(OC[C@@H](O)CNC(C)(C)C)cccc2[nH]1 |&1:12,r|, CC(C)OC(=O)c1cc2c(OC[C@@H](O)CNC(C)(C)C)cccc2[nH]1 |&1:12,r|, CC(C)OC(=O)c1cc2c(OC[C@@H](O)CNC(C)(C)C)cccc2[nH]1 |&1:12,r|	Preclinical
SDZ-220-040	glutamate receptor antagonist	GRIN1			Tocris, Tocris	97.06	N[C@@H](Cc1cc(cc(CP(O)(O)=O)c1O)-c1ccc(Cl)cc1Cl)C(O)=O, N[C@@H](Cc1cc(cc(CP(O)(O)=O)c1O)-c1ccc(Cl)cc1Cl)C(O)=O	Preclinical
SDZ-220-581	glutamate receptor antagonist	GRIN1			Tocris, Tocris, Tocris, Tocris	98.62	N[C@@H](Cc1cc(CP(O)(O)=O)cc(c1)-c1ccccc1Cl)C(O)=O, N[C@@H](Cc1cc(CP(O)(O)=O)cc(c1)-c1ccccc1Cl)C(O)=O, N[C@@H](Cc1cc(CP(O)(O)=O)cc(c1)-c1ccccc1Cl)C(O)=O, N[C@@H](Cc1cc(CP(O)(O)=O)cc(c1)-c1ccccc1Cl)C(O)=O	Preclinical
Se-methylselenocysteine					Sigma, Acros	100	C[Se]C[C@H](N)C(O)=O, C[Se]C[C@H](N)C(O)=O	Phase 2
secalciferol	vitamin D receptor agonist	VDR	critical care	bone fracture	MedChemEx, MedChemEx, Enzo, Enzo	94.21	C[C@H](CC[C@@H](O)C(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C, C[C@H](CC[C@@H](O)C(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C, C[C@H](CC[C@@H](O)C(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C, C[C@H](CC[C@@H](O)C(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C	Launched
seclazone	anti-inflammatory agent				Enamine	99.72	Clc1ccc2O[C@H]3CCON3C(=O)c2c1 |&1:6,r|	Phase 1
seclidemstat	histone demethylase inhibitor				MedChemEx	93.58	CN1CCN(CC1)S(=O)(=O)c1cccc(c1)C(=O)N\N=C(/C)c1cc(Cl)ccc1O	Phase 1
secnidazole	acetylcholinesterase inhibitor, microtubule inhibitor		infectious disease	protozoan infection	MicroSource, Selleck, Selleck, Selleck, Selleck	99.58	C[C@@H](O)Cn1c(C)ncc1[N+]([O-])=O |&1:1,r|, C[C@@H](O)Cn1c(C)ncc1[N+]([O-])=O |&1:1,r|, C[C@@H](O)Cn1c(C)ncc1[N+]([O-])=O |&1:1,r|, C[C@@H](O)Cn1c(C)ncc1[N+]([O-])=O |&1:1,r|, C[C@@H](O)Cn1c(C)ncc1[N+]([O-])=O |&1:1,r|	Launched
secoisolariciresinol-(-)					Sigma, Sigma, Sigma	97.1	COc1cc(C[C@@H](CO)[C@H](CO)Cc2ccc(O)c(OC)c2)ccc1O, COc1cc(C[C@@H](CO)[C@H](CO)Cc2ccc(O)c(OC)c2)ccc1O, COc1cc(C[C@@H](CO)[C@H](CO)Cc2ccc(O)c(OC)c2)ccc1O	Phase 2
secoisolariciresinol-diglucoside	antioxidant				AvaChem	94.67	COc1cc(C[C@@H](CO[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@H](CO[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)Cc2ccc(O)c(OC)c2)ccc1O	Phase 2
securinine	GABA receptor antagonist, TP53 activator	GABRA1			MedChemEx, MedChemEx, MicroSource, MicroSource	94.32	O=C1O[C@@]23C[C@@H](C=CC2=C1)N1CCCC[C@H]31 |c:6,9|, O=C1O[C@@]23C[C@@H](C=CC2=C1)N1CCCC[C@H]31 |c:6,9|, O=C1O[C@@]23C[C@@H](C=CC2=C1)N1CCCC[C@H]31 |c:6,9|, O=C1O[C@@]23C[C@@H](C=CC2=C1)N1CCCC[C@H]31 |c:6,9|	Preclinical
segesterone-acetate	progesterone receptor agonist	PGR			MedChemEx	90.51	[H][C@@]12CC(=C)[C@](OC(C)=O)(C(C)=O)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H] |c:26|	Launched
seladelpar	PPAR receptor agonist				MedChemEx	94.96	CCO[C@H](COc1ccc(cc1)C(F)(F)F)CSc1ccc(OCC(O)=O)c(C)c1	Phase 3
selamectin	nematocide		infectious disease	flea control	MedChemEx	93.43	[H][C@@]12OC\C3=C/C=C/[C@H](C)[C@H](O[C@@]4([H])C[C@H](OC)[C@@H](O)[C@H](C)O4)\C(C)=C\C[C@]4([H])C[C@@]([H])(C[C@]5(CC[C@H](C)[C@H](O5)C5CCCCC5)O4)OC(=O)[C@]([H])(C=C(C)\C1=N\O)[C@@]23O |c:4,t:6,25,56|	Launched
selegiline	monoamine oxidase inhibitor	MAOA, MAOB	neurology/psychiatry	Parkinson's Disease	MedChemEx	87.55	C[C@H](Cc1ccccc1)N(C)CC#C	Launched
selenomethionine					Ark, MicroSource	100	C[Se]CC[C@H](N)C(O)=O, C[Se]CC[C@H](N)C(O)=O	Launched
seletalisib	PI3K inhibitor				MedChemEx	98.01	[O-][n+]1cccc(c1)-c1nc2c(Cl)cccc2cc1[C@@H](Nc1ncnc2cccnc12)C(F)(F)F	Preclinical
selexipag	IP1 prostacyclin receptor agonist, platelet aggregation inhibitor	PTGIR	pulmonary	pulmonary arterial hypertension (PAH)	Tocris, MedChemEx	95.84	CC(C)N(CCCCOCC(=O)NS(C)(=O)=O)c1cnc(-c2ccccc2)c(n1)-c1ccccc1, CC(C)N(CCCCOCC(=O)NS(C)(=O)=O)c1cnc(-c2ccccc2)c(n1)-c1ccccc1	Launched
selfotel	glutamate receptor antagonist	GRIN2A, GRIN2B, GRIN2C, GRIN2D			Enzo, Tocris, Tocris	56.69	OC(=O)[C@H]1C[C@@H](CP(O)(O)=O)CCN1, OC(=O)[C@H]1C[C@@H](CP(O)(O)=O)CCN1, OC(=O)[C@H]1C[C@@H](CP(O)(O)=O)CCN1	Phase 3
selinexor	exportin antagonist	XPO1	hematologic malignancy	multiple myeloma	MedChemEx, Selleck, Selleck, Selleck, Selleck	94.85	FC(F)(F)c1cc(cc(c1)C(F)(F)F)-c1ncn(\C=C/C(=O)NNc2cnccn2)n1, FC(F)(F)c1cc(cc(c1)C(F)(F)F)-c1ncn(\C=C/C(=O)NNc2cnccn2)n1, FC(F)(F)c1cc(cc(c1)C(F)(F)F)-c1ncn(\C=C/C(=O)NNc2cnccn2)n1, FC(F)(F)c1cc(cc(c1)C(F)(F)F)-c1ncn(\C=C/C(=O)NNc2cnccn2)n1, FC(F)(F)c1cc(cc(c1)C(F)(F)F)-c1ncn(\C=C/C(=O)NNc2cnccn2)n1	Launched
selitrectinib	protein tyrosine kinase inhibitor				MedChemEx	96.6	[H][C@]12CCCN1c1ccn3ncc(C(=O)N[C@H](C)CCc4ncc(F)cc24)c3n1	Phase 1/Phase 2
selonsertib	MAP kinase activator				MedChemEx	91.3	CC(C)n1cnnc1-c1cccc(NC(=O)c2cc(c(C)cc2F)-n2cnc(c2)C2CC2)n1	Phase 2
selumetinib	MEK inhibitor	MAP2K1			Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck	99.3	Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(cc12)C(=O)NOCCO, Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(cc12)C(=O)NOCCO, Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(cc12)C(=O)NOCCO, Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(cc12)C(=O)NOCCO, Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(cc12)C(=O)NOCCO, Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(cc12)C(=O)NOCCO, Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(cc12)C(=O)NOCCO, Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(cc12)C(=O)NOCCO	Phase 3
semagacestat	gamma secretase inhibitor	PSEN1			MedChemEx	93.94	CC(C)[C@H](O)C(=O)N[C@@H](C)C(=O)N[C@H]1c2ccccc2CCN(C)C1=O	Phase 3
semapimod	cytokine production inhibitor, p38 MAPK inhibitor	MAPK14			Enamine, Enamine, Enamine	86.13	CC(=NNC(N)=N)c1cc(NC(=O)CCCCCCCCC(=O)Nc2cc(cc(c2)C(C)=NNC(N)=N)C(C)=NNC(N)=N)cc(c1)C(C)=NNC(N)=N, CC(=NNC(N)=N)c1cc(NC(=O)CCCCCCCCC(=O)Nc2cc(cc(c2)C(C)=NNC(N)=N)C(C)=NNC(N)=N)cc(c1)C(C)=NNC(N)=N, CC(=NNC(N)=N)c1cc(NC(=O)CCCCCCCCC(=O)Nc2cc(cc(c2)C(C)=NNC(N)=N)C(C)=NNC(N)=N)cc(c1)C(C)=NNC(N)=N	Phase 2
semaxanib	VEGFR inhibitor	FGFR1, FLT1, KDR, KIT, PDGFRA, PDGFRB, RET			Tocris, Tocris, Selleck, Selleck, Selleck, Selleck, Tocris, Tocris, Tocris	96.75	Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1	Phase 3
semustine	DNA alkylating agent				MicroSource, Sigma	0	CC1CCC(CC1)NC(=O)N(CCCl)[NH2+][O-], CC1CCC(CC1)NC(=O)N(CCCl)[NH2+][O-]	Phase 3
SEN-1269	beta amyloid inhibitor	APP			Tocris, Tocris	97.39	CN(C)c1cccc(Oc2cnc(Nc3cccc(O)c3)nc2)c1, CN(C)c1cccc(Oc2cnc(Nc3cccc(O)c3)nc2)c1	Preclinical
senicapoc	intermediate conductance potassium channel blocker	KCNN4			MedChemEx, MedChemEx, MedChemEx	99.76	NC(=O)C(c1ccccc1)(c1ccc(F)cc1)c1ccc(F)cc1, NC(=O)C(c1ccccc1)(c1ccc(F)cc1)c1ccc(F)cc1, NC(=O)C(c1ccccc1)(c1ccc(F)cc1)c1ccc(F)cc1	Phase 3
sennoside-A	glycoside agonist		gastroenterology	constipation	MicroSource, MicroSource	98.1	OC[C@H]1O[C@H](Oc2cccc3c(-c4c5cccc(O[C@H]6O[C@H](CO)[C@@H](O)[C@H](O)[C@H]6O)c5c(O)c5c(O)cc(cc45)C(O)=O)c4cc(cc(O)c4c(O)c23)C(O)=O)[C@H](O)[C@@H](O)[C@@H]1O |a:2,4,12,19,21,24,26,28,56,58,60,&1:11|, OC[C@H]1O[C@H](Oc2cccc3c(-c4c5cccc(O[C@H]6O[C@H](CO)[C@@H](O)[C@H](O)[C@H]6O)c5c(O)c5c(O)cc(cc45)C(O)=O)c4cc(cc(O)c4c(O)c23)C(O)=O)[C@H](O)[C@@H](O)[C@@H]1O |a:2,4,12,19,21,24,26,28,56,58,60,&1:11|	Launched
sennoside-protonated					Vitas-M, Vitas-M	93.9	OC[C@H]1O[C@@H](Oc2cccc3c(-c4c5cccc(O[C@H]6O[C@@H](CO)[C@@H](O)[C@@H](O)[C@@H]6O)c5c(O)c5c(O)cc(cc45)C(O)=O)c4cc(cc(O)c4c(O)c23)C(O)=O)[C@@H](O)[C@@H](O)[C@@H]1O |&1:2,&2:4,&3:19,&4:21,&5:24,&6:26,&7:28,&8:56,&9:58,&10:60,r|, OC[C@H]1O[C@@H](Oc2cccc3c(-c4c5cccc(O[C@H]6O[C@@H](CO)[C@@H](O)[C@@H](O)[C@@H]6O)c5c(O)c5c(O)cc(cc45)C(O)=O)c4cc(cc(O)c4c(O)c23)C(O)=O)[C@@H](O)[C@@H](O)[C@@H]1O |&1:2,&2:4,&3:19,&4:21,&5:24,&6:26,&7:28,&8:56,&9:58,&10:60,r|	Preclinical
seocalcitol	vitamin D receptor agonist	VDR			MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx	92.75	CCC(O)(CC)\C=C\C=C\[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, CCC(O)(CC)\C=C\C=C\[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, CCC(O)(CC)\C=C\C=C\[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, CCC(O)(CC)\C=C\C=C\[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, CCC(O)(CC)\C=C\C=C\[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, CCC(O)(CC)\C=C\C=C\[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C	Phase 3
SEP-227900	D-amino acid oxidase Inhibitor	DAO			Vitas-M, Enamine	94.51	OC(=O)c1cc2occc2[nH]1, OC(=O)c1cc2occc2[nH]1	Phase 1
seratrodast	prostanoid receptor antagonist	TBXA2R	pulmonary	asthma	MedChemEx, MicroSource, MedChemEx	87.19	CC1=C(C)C(=O)C([C@@H](CCCCCC(O)=O)c2ccccc2)=C(C)C1=O |r,c:1,t:22|, CC1=C(C)C(=O)C([C@@H](CCCCCC(O)=O)c2ccccc2)=C(C)C1=O |r,c:1,t:22|, CC1=C(C)C(=O)C([C@@H](CCCCCC(O)=O)c2ccccc2)=C(C)C1=O |r,c:1,t:22|	Launched
serdemetan	MDM inhibitor	MDM2			Selleck, Selleck, Selleck, Selleck, Selleck, Selleck	94.54	C(Cc1c[nH]c2ccccc12)Nc1ccc(Nc2ccncc2)cc1, C(Cc1c[nH]c2ccccc12)Nc1ccc(Nc2ccncc2)cc1, C(Cc1c[nH]c2ccccc12)Nc1ccc(Nc2ccncc2)cc1, C(Cc1c[nH]c2ccccc12)Nc1ccc(Nc2ccncc2)cc1, C(Cc1c[nH]c2ccccc12)Nc1ccc(Nc2ccncc2)cc1, C(Cc1c[nH]c2ccccc12)Nc1ccc(Nc2ccncc2)cc1	Phase 1
serotonin	growth factor receptor activator	DRD1, DRD5, HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR3A, HTR3B, HTR4, HTR5A, HTR6, HTR7, SLC36A1	neurology/psychiatry	anxiety, depression, sleeplessness	Selleck, Tocris, Selleck	80.69	NCCc1c[nH]c2ccc(O)cc12, NCCc1c[nH]c2ccc(O)cc12, NCCc1c[nH]c2ccc(O)cc12	Launched
sertaconazole	sterol demethylase inhibitor		infectious disease	tinea pedis	MedChemEx, Selleck, Selleck, Selleck, Selleck	98.39	Clc1ccc([C@@H](Cn2ccnc2)OCc2csc3c(Cl)cccc23)c(Cl)c1 |&1:5,r|, Clc1ccc([C@@H](Cn2ccnc2)OCc2csc3c(Cl)cccc23)c(Cl)c1 |&1:5,r|, Clc1ccc([C@@H](Cn2ccnc2)OCc2csc3c(Cl)cccc23)c(Cl)c1 |&1:5,r|, Clc1ccc([C@@H](Cn2ccnc2)OCc2csc3c(Cl)cccc23)c(Cl)c1 |&1:5,r|, Clc1ccc([C@@H](Cn2ccnc2)OCc2csc3c(Cl)cccc23)c(Cl)c1 |&1:5,r|	Launched
sertindole	dopamine receptor antagonist, serotonin receptor antagonist	ADRA1A, ADRA1B, ADRA1D, DRD2, DRD3, DRD4, HRH1, HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2C, HTR6, KCNH2			Prestwick, Prestwick, Prestwick, Prestwick, MedChemEx	93.27	Fc1ccc(cc1)-n1cc(C2CCN(CCN3CCNC3=O)CC2)c2cc(Cl)ccc12, Fc1ccc(cc1)-n1cc(C2CCN(CCN3CCNC3=O)CC2)c2cc(Cl)ccc12, Fc1ccc(cc1)-n1cc(C2CCN(CCN3CCNC3=O)CC2)c2cc(Cl)ccc12, Fc1ccc(cc1)-n1cc(C2CCN(CCN3CCNC3=O)CC2)c2cc(Cl)ccc12, Fc1ccc(cc1)-n1cc(C2CCN(CCN3CCNC3=O)CC2)c2cc(Cl)ccc12	Withdrawn
sertraline	selective serotonin reuptake inhibitor (SSRI)	SLC6A3, SLC6A4	neurology/psychiatry, obstetrics/gynecology	depression, obsessive compulsive disorder (OCD), panic disorders, posttraumatic stress disorder, premenstrual syndrome, social anxiety disorder	MicroSource, Tocris, Tocris, Tocris, Selleck, Selleck, Selleck	98.35	CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc12, CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc12, CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc12, CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc12, CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc12, CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc12, CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc12	Launched
sesamin	NFkB pathway inhibitor				Selleck, Selleck, Selleck	99.85	C1Oc2ccc(cc2O1)[C@H]1OC[C@H]2[C@@H]1CO[C@@H]2c1ccc2OCOc2c1, C1Oc2ccc(cc2O1)[C@H]1OC[C@H]2[C@@H]1CO[C@@H]2c1ccc2OCOc2c1, C1Oc2ccc(cc2O1)[C@H]1OC[C@H]2[C@@H]1CO[C@@H]2c1ccc2OCOc2c1	Preclinical
setipiprant	prostaglandin inhibitor	PTGDR2			MedChemEx	96.5	OC(=O)Cn1c2CCN(Cc2c2cc(F)ccc12)C(=O)c1cccc2ccccc12	Phase 3
setiptiline	adrenergic receptor antagonist	HRH1, HTR2A, HTR2C	neurology/psychiatry	depression	MedChemEx, MedChemEx	96.01	CN1CCC2=C(C1)c1ccccc1Cc1ccccc21 |c:4|, CN1CCC2=C(C1)c1ccccc1Cc1ccccc21 |c:4|	Launched
setmelanotide	melanocortin receptor agonist				MedChemEx	83.94	[H][C@]1(Cc2ccccc2)NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)[C@@H](C)NC(=O)[C@]([H])(CSSC[C@H](NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](CCCNC(N)=N)NC1=O)C(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(C)=O	Phase 3
sevoflurane	membrane integrity inhibitor	ATP2C1, ATP5D, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GLRA1, GLRB, GRIA1, KCNA1, KCNK10, KCNK18, KCNK2, KCNK3, KCNK9, MT-ND1	neurology/psychiatry	anesthetic	Enamine, Enamine	0	FCOC(C(F)(F)F)C(F)(F)F, FCOC(C(F)(F)F)C(F)(F)F	Launched
SEW-2871	lysophospholipid receptor agonist	S1PR1			Tocris, Tocris	98.71	FC(F)(F)c1sc(cc1-c1ccccc1)-c1nc(no1)-c1cccc(c1)C(F)(F)F, FC(F)(F)c1sc(cc1-c1ccccc1)-c1nc(no1)-c1cccc(c1)C(F)(F)F	Preclinical
SF-11	neuropeptide receptor antagonist	MCOLN3, NPY2R			Tocris, Tocris	93.3	CCOc1ccc(NC(=S)N2CCC(CC2)C(O)(c2ccccc2)c2ccccc2)cc1, CCOc1ccc(NC(=S)N2CCC(CC2)C(O)(c2ccccc2)c2ccccc2)cc1	Preclinical
SGC-CBP30	bromodomain inhibitor	CREBBP, EP300			Tocris, Tocris, Selleck, Selleck, Selleck, Selleck	97.84	COc1ccc(CCc2nc3cc(ccc3n2C[C@H](C)N2CCOCC2)-c2c(C)noc2C)cc1Cl, COc1ccc(CCc2nc3cc(ccc3n2C[C@H](C)N2CCOCC2)-c2c(C)noc2C)cc1Cl, COc1ccc(CCc2nc3cc(ccc3n2C[C@H](C)N2CCOCC2)-c2c(C)noc2C)cc1Cl, COc1ccc(CCc2nc3cc(ccc3n2C[C@H](C)N2CCOCC2)-c2c(C)noc2C)cc1Cl, COc1ccc(CCc2nc3cc(ccc3n2C[C@H](C)N2CCOCC2)-c2c(C)noc2C)cc1Cl, COc1ccc(CCc2nc3cc(ccc3n2C[C@H](C)N2CCOCC2)-c2c(C)noc2C)cc1Cl	Preclinical
SGC-0946	histone lysine methyltransferase inhibitor				Tocris, Selleck, Selleck, Selleck, Selleck	95.72	CC(C)N(CCCNC(=O)Nc1ccc(cc1)C(C)(C)C)C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cc(Br)c2c(N)ncnc12, CC(C)N(CCCNC(=O)Nc1ccc(cc1)C(C)(C)C)C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cc(Br)c2c(N)ncnc12, CC(C)N(CCCNC(=O)Nc1ccc(cc1)C(C)(C)C)C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cc(Br)c2c(N)ncnc12, CC(C)N(CCCNC(=O)Nc1ccc(cc1)C(C)(C)C)C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cc(Br)c2c(N)ncnc12, CC(C)N(CCCNC(=O)Nc1ccc(cc1)C(C)(C)C)C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cc(Br)c2c(N)ncnc12	Preclinical
SGC-707	protein arginine N-methyltransferase inhibitor	PRMT3			Tocris, Tocris, Tocris	97.06	O=C(NCC(=O)N1CCCC1)Nc1ccc2cnccc2c1, O=C(NCC(=O)N1CCCC1)Nc1ccc2cnccc2c1, O=C(NCC(=O)N1CCCC1)Nc1ccc2cnccc2c1	Preclinical
SGI-1027	DNA methyltransferase inhibitor	DNMT1, DNMT3A, DNMT3B			Tocris, Selleck, Selleck, Selleck	91.55	Cc1cc(Nc2ccc(NC(=O)c3ccc(Nc4ccnc5ccccc45)cc3)cc2)nc(N)n1, Cc1cc(Nc2ccc(NC(=O)c3ccc(Nc4ccnc5ccccc45)cc3)cc2)nc(N)n1, Cc1cc(Nc2ccc(NC(=O)c3ccc(Nc4ccnc5ccccc45)cc3)cc2)nc(N)n1, Cc1cc(Nc2ccc(NC(=O)c3ccc(Nc4ccnc5ccccc45)cc3)cc2)nc(N)n1	Preclinical
SGI-1776	Pim kinase inhibitor	FLT3, PIM1, PIM2, PIM3			MedChemEx, MedChemEx, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck	96.84	CN1CCC(CNc2ccc3ncc(-c4cccc(OC(F)(F)F)c4)n3n2)CC1, CN1CCC(CNc2ccc3ncc(-c4cccc(OC(F)(F)F)c4)n3n2)CC1, CN1CCC(CNc2ccc3ncc(-c4cccc(OC(F)(F)F)c4)n3n2)CC1, CN1CCC(CNc2ccc3ncc(-c4cccc(OC(F)(F)F)c4)n3n2)CC1, CN1CCC(CNc2ccc3ncc(-c4cccc(OC(F)(F)F)c4)n3n2)CC1, CN1CCC(CNc2ccc3ncc(-c4cccc(OC(F)(F)F)c4)n3n2)CC1, CN1CCC(CNc2ccc3ncc(-c4cccc(OC(F)(F)F)c4)n3n2)CC1, CN1CCC(CNc2ccc3ncc(-c4cccc(OC(F)(F)F)c4)n3n2)CC1	Phase 1
SGS-742	GABA receptor antagonist	GABBR1, GABBR2			Sigma	0	CCCCP(O)(=O)CCCN	Preclinical
SGX523	hepatocyte growth factor receptor inhibitor	MET			Selleck, Selleck, Selleck	98.41	Cn1cc(cn1)-c1ccc2nnc(Sc3ccc4ncccc4c3)n2n1, Cn1cc(cn1)-c1ccc2nnc(Sc3ccc4ncccc4c3)n2n1, Cn1cc(cn1)-c1ccc2nnc(Sc3ccc4ncccc4c3)n2n1	Phase 1
SHA-68	neuropeptide receptor antagonist	NPSR1			Tocris, Tocris	97.57	Fc1ccc(CNC(=O)N2CCN3[C@@H](C2)C(OC3=O)(c2ccccc2)c2ccccc2)cc1 |&1:13,r|, Fc1ccc(CNC(=O)N2CCN3[C@@H](C2)C(OC3=O)(c2ccccc2)c2ccccc2)cc1 |&1:13,r|	Preclinical
shikimic-acid					Selleck, Selleck	94.86	O[C@@H]1CC(=C[C@@H](O)[C@@H]1O)C(O)=O |a:1,&1:5,&2:7,c:3|, O[C@@H]1CC(=C[C@@H](O)[C@@H]1O)C(O)=O |a:1,&1:5,&2:7,c:3|	Preclinical
SHP099	protein tyrosine kinase inhibitor	PTPN11			MedChemEx, MedChemEx, MedChemEx, MedChemEx	90.04	CC1(N)CCN(CC1)c1cnc(c(N)n1)-c1cccc(Cl)c1Cl, CC1(N)CCN(CC1)c1cnc(c(N)n1)-c1cccc(Cl)c1Cl, CC1(N)CCN(CC1)c1cnc(c(N)n1)-c1cccc(Cl)c1Cl, CC1(N)CCN(CC1)c1cnc(c(N)n1)-c1cccc(Cl)c1Cl	Preclinical
SIB-1553A	acetylcholine receptor agonist	CHRNB4			Tocris	94.8	CN1CCC[C@@H]1CCSc1ccc(O)cc1 |&1:5|	Phase 2
SIB-1757	glutamate receptor antagonist	GRM5			Tocris, Tocris, Tocris, Tocris, Tocris, Tocris	89.53	C=C1NC(=NNc2ccccc2)C(=O)C=C1 |c:15|, C=C1NC(=NNc2ccccc2)C(=O)C=C1 |c:15|, C=C1NC(=NNc2ccccc2)C(=O)C=C1 |c:15|, C=C1NC(=NNc2ccccc2)C(=O)C=C1 |c:15|, C=C1NC(=NNc2ccccc2)C(=O)C=C1 |c:15|, C=C1NC(=NNc2ccccc2)C(=O)C=C1 |c:15|	Preclinical
SIB-1893	glutamate receptor antagonist	GRM4, GRM5			Tocris, Tocris	87.81	Cc1cccc(\C=C\c2ccccc2)n1, Cc1cccc(\C=C\c2ccccc2)n1	Preclinical
SID-7969543	steroidogenic factor antagonist	NR5A1			Tocris, Tocris, Tocris	96.71	CCOC(=O)[C@@H](C)Oc1cccc2c1ccn(CC(=O)Nc1ccc3OCCOc3c1)c2=O |&1:5,r|, CCOC(=O)[C@@H](C)Oc1cccc2c1ccn(CC(=O)Nc1ccc3OCCOc3c1)c2=O |&1:5,r|, CCOC(=O)[C@@H](C)Oc1cccc2c1ccn(CC(=O)Nc1ccc3OCCOc3c1)c2=O |&1:5,r|	Preclinical
siguazodan	phosphodiesterase inhibitor	PDE3A			Tocris, Tocris, Tocris	97.8	CN\C(NC#N)=N/c1ccc(cc1)C1=NNC(=O)C[C@@H]1C |r,t:14|, CN\C(NC#N)=N/c1ccc(cc1)C1=NNC(=O)C[C@@H]1C |r,t:14|, CN\C(NC#N)=N/c1ccc(cc1)C1=NNC(=O)C[C@@H]1C |r,t:14|	Phase 1
sildenafil	phosphodiesterase inhibitor	PDE5A, PDE6G, PDE6H, SLCO1B1, SLCO1B3	urology	erectile dysfunction	Tocris, MicroSource, MicroSource, Selleck, Tocris, Tocris	99.19	CCCc1nn(C)c2c1nc([nH]c2=O)-c1cc(ccc1OCC)S(=O)(=O)N1CCN(C)CC1, CCCc1nn(C)c2c1nc([nH]c2=O)-c1cc(ccc1OCC)S(=O)(=O)N1CCN(C)CC1, CCCc1nn(C)c2c1nc([nH]c2=O)-c1cc(ccc1OCC)S(=O)(=O)N1CCN(C)CC1, CCCc1nn(C)c2c1nc([nH]c2=O)-c1cc(ccc1OCC)S(=O)(=O)N1CCN(C)CC1, CCCc1nn(C)c2c1nc([nH]c2=O)-c1cc(ccc1OCC)S(=O)(=O)N1CCN(C)CC1, CCCc1nn(C)c2c1nc([nH]c2=O)-c1cc(ccc1OCC)S(=O)(=O)N1CCN(C)CC1	Launched
silibinin	cytochrome P450 inhibitor	ALOX5	gastroenterology	hepatic cirrhosis	MicroSource, MedChemEx, Selleck, Selleck	98.02	COc1cc(ccc1O)[C@H]1Oc2cc(ccc2O[C@@H]1CO)[C@H]1Oc2cc(O)cc(O)c2C(=O)[C@@H]1O, COc1cc(ccc1O)[C@H]1Oc2cc(ccc2O[C@@H]1CO)[C@H]1Oc2cc(O)cc(O)c2C(=O)[C@@H]1O, COc1cc(ccc1O)[C@H]1Oc2cc(ccc2O[C@@H]1CO)[C@H]1Oc2cc(O)cc(O)c2C(=O)[C@@H]1O, COc1cc(ccc1O)[C@H]1Oc2cc(ccc2O[C@@H]1CO)[C@H]1Oc2cc(O)cc(O)c2C(=O)[C@@H]1O	Launched
silodosin	adrenergic receptor antagonist	ADRA1A, ADRA1B, ADRA1D	urology	benign prostatic hyperplasia (BPH)	MedChemEx, Selleck, Selleck	96.44	C[C@H](Cc1cc2CCN(CCCO)c2c(c1)C(N)=O)NCCOc1ccccc1OCC(F)(F)F, C[C@H](Cc1cc2CCN(CCCO)c2c(c1)C(N)=O)NCCOc1ccccc1OCC(F)(F)F, C[C@H](Cc1cc2CCN(CCCO)c2c(c1)C(N)=O)NCCOc1ccccc1OCC(F)(F)F	Launched
silver-sulfadiazine	PABA antagonist		critical care	sepsis	Sigma, Sigma, Enzo	99.7	Nc1ccc(cc1)S(=O)(=O)N([Ag])c1ncccn1, Nc1ccc(cc1)S(=O)(=O)N([Ag])c1ncccn1, Nc1ccc(cc1)S(=O)(=O)N([Ag])c1ncccn1	Launched
silymarin					Selleck, Selleck, Selleck	50.9	COc1cc(ccc1O)[C@H]1Oc2ccc(cc2O[C@@H]1CO)[C@H]1Oc2cc(O)cc(O)c2C(=O)[C@@H]1O |&1:9,&2:18,&3:21,&4:33,r|, COc1cc(ccc1O)[C@H]1Oc2ccc(cc2O[C@@H]1CO)[C@H]1Oc2cc(O)cc(O)c2C(=O)[C@@H]1O |&1:9,&2:18,&3:21,&4:33,r|, COc1cc(ccc1O)[C@H]1Oc2ccc(cc2O[C@@H]1CO)[C@H]1Oc2cc(O)cc(O)c2C(=O)[C@@H]1O |&1:9,&2:18,&3:21,&4:33,r|	Launched
simeprevir	HCV inhibitor	CYP1A2, CYP3A4	infectious disease	hepatitis C	MedChemEx, MedChemEx	92.2	COc1ccc2c(O[C@@H]3C[C@@H]4[C@@H](C3)C(=O)N(C)CCCC\C=C/[C@@H]3C[C@]3(NC4=O)C(=O)NS(=O)(=O)C3CC3)cc(nc2c1C)-c1nc(cs1)C(C)C |c:22|, COc1ccc2c(O[C@@H]3C[C@@H]4[C@@H](C3)C(=O)N(C)CCCC\C=C/[C@@H]3C[C@]3(NC4=O)C(=O)NS(=O)(=O)C3CC3)cc(nc2c1C)-c1nc(cs1)C(C)C |c:22|	Launched
simurosertib	kinase inhibitor				MedChemEx	91.08	Cc1n[nH]cc1-c1cc2[nH]c(nc(=O)c2s1)[C@H]1CC2CCN1CC2 |&1:16,r|	Preclinical
simvastatin	HMGCR inhibitor	HMGCR, ITGB2	endocrinology, cardiology, neurology/psychiatry	hypercholesterolemia, coronary heart disease, myocardial infarction, stroke, hyperlipidemia	Tocris, Tocris, MicroSource, MicroSource, MicroSource, MicroSource, Selleck, Tocris, Selleck	91.83	CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:14,t:12|, CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:14,t:12|, CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:14,t:12|, CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:14,t:12|, CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:14,t:12|, CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:14,t:12|, CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:14,t:12|, CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:14,t:12|, CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:14,t:12|	Launched
sincalide	cholecystokinin agonist				MedChemEx	80.31	CSCC[C@H](NC(=O)[C@H](Cc1ccc(OS(O)(=O)=O)cc1)NC(=O)[C@@H](N)CC(O)=O)C(=O)NCC(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](Cc1ccccc1)C(N)=O	Preclinical
sinefungin	DNA methyltransferase inhibitor, RNA synthesis inhibitor	CARM1			Sigma, Sigma	94.6	N[C@@H](CC[C@H](N)C(O)=O)C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)ncnc12, N[C@@H](CC[C@H](N)C(O)=O)C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)ncnc12	Preclinical
sinomenine	angiogenesis inhibitor				Selleck, Tocris	92.76	COC1=C[C@@H]2[C@@H]3Cc4ccc(OC)c(O)c4[C@]2(CCN3C)CC1=O |t:2|, COC1=C[C@@H]2[C@@H]3Cc4ccc(OC)c(O)c4[C@]2(CCN3C)CC1=O |t:2|	Preclinical
sipatrigine	voltage-gated sodium channel blocker	CACNA1D, SCN10A, SCN1A, SCN3A, SCN4A, SCN5A, SCN9A			Tocris, Tocris	98.09	CN1CCN(CC1)c1ncc(c(N)n1)-c1cc(Cl)cc(Cl)c1Cl, CN1CCN(CC1)c1ncc(c(N)n1)-c1cc(Cl)cc(Cl)c1Cl	Phase 2
siponimod	sphingosine 1-phosphate receptor modulator	S1PR1	neurology/psychiatry	multiple sclerosis	MedChemEx, MedChemEx, MedChemEx, MedChemEx, Selleck	95.58	CCc1cc(ccc1CN1CC(C1)C(O)=O)C(\C)=N\OCc1ccc(C2CCCCC2)c(c1)C(F)(F)F, CCc1cc(ccc1CN1CC(C1)C(O)=O)C(\C)=N\OCc1ccc(C2CCCCC2)c(c1)C(F)(F)F, CCc1cc(ccc1CN1CC(C1)C(O)=O)C(\C)=N\OCc1ccc(C2CCCCC2)c(c1)C(F)(F)F, CCc1cc(ccc1CN1CC(C1)C(O)=O)C(\C)=N\OCc1ccc(C2CCCCC2)c(c1)C(F)(F)F, CCc1cc(ccc1CN1CC(C1)C(O)=O)C(\C)=N\OCc1ccc(C2CCCCC2)c(c1)C(F)(F)F	Launched
siramesine	sigma receptor antagonist	ADRA1A, ADRA1B, ADRA1D			MedChemEx, MedChemEx, MedChemEx	98.3	Fc1ccc(cc1)-n1cc(CCCCN2CCC3(CC2)OCc2ccccc32)c2ccccc12, Fc1ccc(cc1)-n1cc(CCCCN2CCC3(CC2)OCc2ccccc32)c2ccccc12, Fc1ccc(cc1)-n1cc(CCCCN2CCC3(CC2)OCc2ccccc32)c2ccccc12	Phase 2
siremadlin	MDM inhibitor				MedChemEx	97.81	COc1ncc(-c2nc3C(=O)N([C@H](c3n2C(C)C)c2ccc(Cl)cc2)c2cc(Cl)cn(C)c2=O)c(OC)n1	Preclinical
sirolimus	mTOR inhibitor	FKBP1A, MTOR	transplant, pulmonary	organ rejection, lymphangioleiomyomatosis	MedChemEx, MedChemEx, MedChemEx, MedChemEx, Selleck, Selleck, Selleck, Selleck	95.67	CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1O |c:14,33,t:29,31|, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1O |c:14,33,t:29,31|, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1O |c:14,33,t:29,31|, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1O |c:14,33,t:29,31|, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1O |c:14,33,t:29,31|, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1O |c:14,33,t:29,31|, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1O |c:14,33,t:29,31|, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1O |c:14,33,t:29,31|	Launched
SirReal-2	SIRT inhibitor	SIRT2			Tocris, Tocris, Tocris	99.29	Cc1cc(C)nc(SCC(=O)Nc2ncc(Cc3cccc4ccccc34)s2)n1, Cc1cc(C)nc(SCC(=O)Nc2ncc(Cc3cccc4ccccc34)s2)n1, Cc1cc(C)nc(SCC(=O)Nc2ncc(Cc3cccc4ccccc34)s2)n1	Preclinical
sirtinol	SIRT inhibitor	SIRT1, SIRT2			Tocris, Selleck, Tocris, Selleck	11.06	C[C@@H](NC(=O)c1ccccc1\N=C\c1c(O)ccc2ccccc12)c1ccccc1 |&1:1,r|, C[C@@H](NC(=O)c1ccccc1\N=C\c1c(O)ccc2ccccc12)c1ccccc1 |&1:1,r|, C[C@@H](NC(=O)c1ccccc1\N=C\c1c(O)ccc2ccccc12)c1ccccc1 |&1:1,r|, C[C@@H](NC(=O)c1ccccc1\N=C\c1c(O)ccc2ccccc12)c1ccccc1 |&1:1,r|	Preclinical
sisomicin	protein synthesis inhibitor		ophthalmology	conjunctivitis, punctate keratitis	MedChemEx, MedChemEx, AvaChem, Selleck	11.93	CN[C@@H]1[C@@H](O)[C@@H](O[C@H]2[C@H](N)C[C@H](N)[C@@H](O[C@H]3OC(CN)=CC[C@H]3N)[C@@H]2O)OC[C@]1(C)O |c:19|, CN[C@@H]1[C@@H](O)[C@@H](O[C@H]2[C@H](N)C[C@H](N)[C@@H](O[C@H]3OC(CN)=CC[C@H]3N)[C@@H]2O)OC[C@]1(C)O |c:19|, CN[C@@H]1[C@@H](O)[C@@H](O[C@H]2[C@H](N)C[C@H](N)[C@@H](O[C@H]3OC(CN)=CC[C@H]3N)[C@@H]2O)OC[C@]1(C)O |c:19|, CN[C@@H]1[C@@H](O)[C@@H](O[C@H]2[C@H](N)C[C@H](N)[C@@H](O[C@H]3OC(CN)=CC[C@H]3N)[C@@H]2O)OC[C@]1(C)O |c:19|	Launched
sisomicin-sulfate	bacterial 30S ribosomal subunit inhibitor		infectious disease	gram-negative bacterial infections	MicroSource	0	CN[C@@H]1[C@@H](O)[C@@H](O[C@H]2[C@H](N)C[C@H](N)[C@@H](O[C@H]3OC(CN)=CC[C@H]3N)[C@@H]2O)OC[C@]1(C)O |a:2,5,7,8,11,13,15,22,24,28,&1:3,c:19|	Launched
SIS3	serine/threonine kinase inhibitor	SMAD3, TGFBR1			Tocris, Tocris	96.14	COc1cc2CCN(Cc2cc1OC)C(=O)\C=C\c1c(-c2ccccc2)n(C)c2ncccc12, COc1cc2CCN(Cc2cc1OC)C(=O)\C=C\c1c(-c2ccccc2)n(C)c2ncccc12	Preclinical
sitafloxacin	bacterial DNA gyrase inhibitor		infectious disease	buruli ulcer	MedChemEx, Selleck, Selleck, Selleck	98.54	N[C@@H]1CN(CC11CC1)c1c(F)cc2c(c1Cl)n(cc(C(O)=O)c2=O)[C@@H]1C[C@@H]1F, N[C@@H]1CN(CC11CC1)c1c(F)cc2c(c1Cl)n(cc(C(O)=O)c2=O)[C@@H]1C[C@@H]1F, N[C@@H]1CN(CC11CC1)c1c(F)cc2c(c1Cl)n(cc(C(O)=O)c2=O)[C@@H]1C[C@@H]1F, N[C@@H]1CN(CC11CC1)c1c(F)cc2c(c1Cl)n(cc(C(O)=O)c2=O)[C@@H]1C[C@@H]1F	Launched
sitagliptin	dipeptidyl peptidase inhibitor	DPP4	endocrinology	diabetes mellitus	MicroSource, Selleck, Selleck	92.63	N[C@@H](CC(=O)N1CCn2c(C1)nnc2C(F)(F)F)Cc1cc(F)c(F)cc1F, N[C@@H](CC(=O)N1CCn2c(C1)nnc2C(F)(F)F)Cc1cc(F)c(F)cc1F, N[C@@H](CC(=O)N1CCn2c(C1)nnc2C(F)(F)F)Cc1cc(F)c(F)cc1F	Launched
sitaxentan	endothelin receptor antagonist	EDNRA, EDNRB			MedChemEx, MedChemEx, MedChemEx, Selleck, Selleck	95.83	Cc1noc(NS(=O)(=O)c2ccsc2C(=O)Cc2cc3OCOc3cc2C)c1Cl, Cc1noc(NS(=O)(=O)c2ccsc2C(=O)Cc2cc3OCOc3cc2C)c1Cl, Cc1noc(NS(=O)(=O)c2ccsc2C(=O)Cc2cc3OCOc3cc2C)c1Cl, Cc1noc(NS(=O)(=O)c2ccsc2C(=O)Cc2cc3OCOc3cc2C)c1Cl, Cc1noc(NS(=O)(=O)c2ccsc2C(=O)Cc2cc3OCOc3cc2C)c1Cl	Withdrawn
sitosterol					MedChemEx, Selleck, Selleck	1.26	CC[C@H](CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C |t:13|, CC[C@H](CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C |t:13|, CC[C@H](CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C |t:13|	Preclinical
sitravatinib	receptor tyrosine protein kinase inhibitor				MedChemEx	94.75	COCCNCc1ccc(nc1)-c1cc2nccc(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3F)c2s1	Phase 3
sivelestat	elastase inhibitor	CELA1, ELANE	pulmonary	acute lung injury	Tocris, MedChemEx, MedChemEx, MedChemEx	97.49	CC(C)(C)C(=O)Oc1ccc(cc1)S(=O)(=O)Nc1ccccc1C(=O)NCC(O)=O, CC(C)(C)C(=O)Oc1ccc(cc1)S(=O)(=O)Nc1ccccc1C(=O)NCC(O)=O, CC(C)(C)C(=O)Oc1ccc(cc1)S(=O)(=O)Nc1ccccc1C(=O)NCC(O)=O, CC(C)(C)C(=O)Oc1ccc(cc1)S(=O)(=O)Nc1ccccc1C(=O)NCC(O)=O	Launched
SJ-172550	MDM inhibitor	MDM4			MedChemEx, Tocris, MedChemEx	6.12	CCOc1cc(\C=C2/C(C)=NN(C2=O)c2ccccc2)cc(Cl)c1OCC(=O)OC |c:9|, CCOc1cc(\C=C2/C(C)=NN(C2=O)c2ccccc2)cc(Cl)c1OCC(=O)OC |c:9|, CCOc1cc(\C=C2/C(C)=NN(C2=O)c2ccccc2)cc(Cl)c1OCC(=O)OC |c:9|	Preclinical
SJ-733	ATPase inhibitor				MedChemEx	97.78	Fc1ccc(NC(=O)[C@@H]2[C@H](N(CC(F)(F)F)C(=O)c3ccccc23)c2cccnc2)cc1C#N	Phase 1
SJG-136	DNA intercalating agent				MedChemEx	54.82	COc1cc2c(cc1OCCCOc1cc3N=C[C@@H]4CC(=C)CN4C(=O)c3cc1OC)N=C[C@@H]1CC(=C)CN1C2=O |c:17,35|	Phase 2
SK&F-10047-(+)	sigma receptor agonist	SIGMAR1			Tocris, Tocris	100	C[C@@H]1[C@@H]2Cc3ccc(O)cc3[C@@]1(C)CCN2CC=C, C[C@@H]1[C@@H]2Cc3ccc(O)cc3[C@@]1(C)CCN2CC=C	Phase 1
SKA-31	potassium channel activator	KCNN4			Tocris, Tocris, Tocris, Tocris	97.7	Nc1nc2c(ccc3ccccc23)s1, Nc1nc2c(ccc3ccccc23)s1, Nc1nc2c(ccc3ccccc23)s1, Nc1nc2c(ccc3ccccc23)s1	Preclinical
skepinone-L	p38 MAPK inhibitor	MAPK14			Selleck, Selleck, Selleck, MedChemEx	98.66	OC[C@@H](O)COc1ccc2CCc3cc(Nc4ccc(F)cc4F)ccc3C(=O)c2c1, OC[C@@H](O)COc1ccc2CCc3cc(Nc4ccc(F)cc4F)ccc3C(=O)c2c1, OC[C@@H](O)COc1ccc2CCc3cc(Nc4ccc(F)cc4F)ccc3C(=O)c2c1, OC[C@@H](O)COc1ccc2CCc3cc(Nc4ccc(F)cc4F)ccc3C(=O)c2c1	Preclinical
SKF-38393	dopamine receptor agonist	CALY, DRD1, DRD5			Tocris, Tocris, Tocris, Tocris	100	Oc1cc2CCNC[C@@H](c3ccccc3)c2cc1O |&1:8|, Oc1cc2CCNC[C@@H](c3ccccc3)c2cc1O |&1:8|, Oc1cc2CCNC[C@@H](c3ccccc3)c2cc1O |&1:8|, Oc1cc2CCNC[C@@H](c3ccccc3)c2cc1O |&1:8|	Preclinical
SKF-77434	dopamine receptor agonist	DRD1			Tocris, Tocris, Tocris	97.3	Oc1cc2CCN(CC=C)C[C@@H](c3ccccc3)c2cc1O |&1:11|, Oc1cc2CCN(CC=C)C[C@@H](c3ccccc3)c2cc1O |&1:11|, Oc1cc2CCN(CC=C)C[C@@H](c3ccccc3)c2cc1O |&1:11|	Preclinical
SKF-81297	dopamine receptor agonist	DRD1, DRD5			Tocris, Tocris, Tocris, Tocris, Tocris	97.4	Oc1cc2C(CNCCc2c(Cl)c1O)c1ccccc1, Oc1cc2C(CNCCc2c(Cl)c1O)c1ccccc1, Oc1cc2C(CNCCc2c(Cl)c1O)c1ccccc1, Oc1cc2C(CNCCc2c(Cl)c1O)c1ccccc1, Oc1cc2C(CNCCc2c(Cl)c1O)c1ccccc1	Preclinical
SKF-83566	dopamine receptor antagonist	DRD1, DRD5			Tocris, Tocris, Tocris	97.6	CN1CCc2cc(Br)c(O)cc2[C@@H](C1)c1ccccc1 |&1:12|, CN1CCc2cc(Br)c(O)cc2[C@@H](C1)c1ccccc1 |&1:12|, CN1CCc2cc(Br)c(O)cc2[C@@H](C1)c1ccccc1 |&1:12|	Preclinical
SKF-86002	p38 MAPK inhibitor	ALOX5, MAPK14			Tocris, Tocris, Tocris	94.86	Fc1ccc(cc1)-c1nc2SCCn2c1-c1ccncc1, Fc1ccc(cc1)-c1nc2SCCn2c1-c1ccncc1, Fc1ccc(cc1)-c1nc2SCCn2c1-c1ccncc1	Preclinical
SKF-89976A	GABA uptake inhibitor	SLC6A1			Tocris, Tocris, Tocris, Tocris	97.09	OC(=O)[C@H]1CCCN(CCC=C(c2ccccc2)c2ccccc2)C1 |&1:3|, OC(=O)[C@H]1CCCN(CCC=C(c2ccccc2)c2ccccc2)C1 |&1:3|, OC(=O)[C@H]1CCCN(CCC=C(c2ccccc2)c2ccccc2)C1 |&1:3|, OC(=O)[C@H]1CCCN(CCC=C(c2ccccc2)c2ccccc2)C1 |&1:3|	Preclinical
SKF-91488	histamine N-methyltransferase inhibitor	HNMT			Tocris, Tocris, Tocris	78.22	CN(C)CCCCSC(N)=N, CN(C)CCCCSC(N)=N, CN(C)CCCCSC(N)=N	Preclinical
SKF-96365	calcium channel blocker	CYP3A4, PKD2, TRPC1, TRPC3, TRPC4, TRPC5, TRPV2			Tocris, Tocris, Tocris, Tocris	98.58	COc1ccc(CCCO[C@@H](Cn2ccnc2)c2ccc(OC)cc2)cc1 |&1:10|, COc1ccc(CCCO[C@@H](Cn2ccnc2)c2ccc(OC)cc2)cc1 |&1:10|, COc1ccc(CCCO[C@@H](Cn2ccnc2)c2ccc(OC)cc2)cc1 |&1:10|, COc1ccc(CCCO[C@@H](Cn2ccnc2)c2ccc(OC)cc2)cc1 |&1:10|	Preclinical
SKI-II	sphingosine kinase inhibitor	SPHK1			Tocris, Tocris, Selleck, Selleck, Selleck, Selleck	94.83	Oc1ccc(Nc2nc(cs2)-c2ccc(Cl)cc2)cc1, Oc1ccc(Nc2nc(cs2)-c2ccc(Cl)cc2)cc1, Oc1ccc(Nc2nc(cs2)-c2ccc(Cl)cc2)cc1, Oc1ccc(Nc2nc(cs2)-c2ccc(Cl)cc2)cc1, Oc1ccc(Nc2nc(cs2)-c2ccc(Cl)cc2)cc1, Oc1ccc(Nc2nc(cs2)-c2ccc(Cl)cc2)cc1	Preclinical
SKLB-1028	Abl kinase inhibitor, EGFR inhibitor, FLT3 inhibitor				Astatech	86.39	CC(C)n1c(Nc2cccnc2)nc2cnc(Nc3ccc(cc3)N3CCN(C)CC3)nc12	Preclinical
SKLB1002	VEGFR inhibitor	KDR			Selleck, MedChemEx, MedChemEx	97.72	COc1cc2ncnc(Sc3nnc(C)s3)c2cc1OC, COc1cc2ncnc(Sc3nnc(C)s3)c2cc1OC, COc1cc2ncnc(Sc3nnc(C)s3)c2cc1OC	Preclinical
SLV-319-(+/-)	cannabinoid receptor antagonist	CNR1, DRD2, HTR1A			Tocris	97.15	C\N=C(\NS(=O)(=O)c1ccc(Cl)cc1)N1C[C@@H](C(=N1)c1ccc(Cl)cc1)c1ccccc1 |&1:16,r,c:18|	Phase 2
SLV-320	adenosine receptor antagonist	ADORA1, ADORA2A, ADORA2B, ADORA3			Tocris, Tocris, Tocris, Tocris	91.33	O[C@H]1CC[C@@H](CC1)Nc1nc(nc2[nH]ccc12)-c1ccccc1 |r|, O[C@H]1CC[C@@H](CC1)Nc1nc(nc2[nH]ccc12)-c1ccccc1 |r|, O[C@H]1CC[C@@H](CC1)Nc1nc(nc2[nH]ccc12)-c1ccccc1 |r|, O[C@H]1CC[C@@H](CC1)Nc1nc(nc2[nH]ccc12)-c1ccccc1 |r|	Phase 2
SM-108					Ark, Ark	100	NC(=O)C1N=CNC1=O |c:4|, NC(=O)C1N=CNC1=O |c:4|	Phase 2
SM-164	XIAP inhibitor	BIRC2, BIRC3, XIAP			MedChemEx, MedChemEx	85.5	CN[C@@H](C)C(=O)N[C@H]1CCCC[C@H]2CC[C@H](N2C1=O)C(=O)N[C@H](c1cn(CCCCc2ccc(CCCCn3cc(nn3)[C@@H](NC(=O)[C@@H]3CC[C@@H]4CCCC[C@H](NC(=O)[C@H](C)NC)C(=O)N34)c3ccccc3)cc2)nn1)c1ccccc1, CN[C@@H](C)C(=O)N[C@H]1CCCC[C@H]2CC[C@H](N2C1=O)C(=O)N[C@H](c1cn(CCCCc2ccc(CCCCn3cc(nn3)[C@@H](NC(=O)[C@@H]3CC[C@@H]4CCCC[C@H](NC(=O)[C@H](C)NC)C(=O)N34)c3ccccc3)cc2)nn1)c1ccccc1	Preclinical
SM-21	sigma receptor antagonist	PGRMC1			Tocris	85.27	CC[C@H](Oc1ccc(Cl)cc1)C(=O)O[C@@H]1C[C@@H]2CC[C@H](C1)N2C |&1:14,16,19,&2:2,r,TLB:22:21:17.18:14.15.20|	Preclinical
SMER-28	autophagy inducer	SNCA			Tocris, Tocris, Sigma, Sigma, Sigma	100	Brc1ccc2ncnc(NCC=C)c2c1, Brc1ccc2ncnc(NCC=C)c2c1, Brc1ccc2ncnc(NCC=C)c2c1, Brc1ccc2ncnc(NCC=C)c2c1, Brc1ccc2ncnc(NCC=C)c2c1	Preclinical
SMI-4a	Pim kinase inhibitor	PIM1			Tocris	91.18	FC(F)(F)c1cccc(\C=C2/SC(=O)NC2=O)c1	Preclinical
SN-2	transient receptor potential channel agonist	MCOLN3			Tocris	94.95	Cc1cc(C)c(C2=NO[C@@H]3[C@H]4CC[C@H](C4)[C@H]23)c(C)c1 |&1:9,10,13,15,t:6|	Preclinical
SN-38	topoisomerase inhibitor	TOP1	oncology	colorectal cancer	Tocris, Tocris, Tocris, Tocris, Selleck, Selleck, Selleck	98.53	CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(O)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(O)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(O)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(O)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(O)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(O)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(O)cc12	Launched
SN-6	sodium/calcium exchange inhibitor				Tocris, Tocris, Tocris	92.27	CCOC(=O)[C@H]1CS[C@H](Cc2ccc(OCc3ccc(cc3)[N+]([O-])=O)cc2)N1 |&1:5,&2:8,r|, CCOC(=O)[C@H]1CS[C@H](Cc2ccc(OCc3ccc(cc3)[N+]([O-])=O)cc2)N1 |&1:5,&2:8,r|, CCOC(=O)[C@H]1CS[C@H](Cc2ccc(OCc3ccc(cc3)[N+]([O-])=O)cc2)N1 |&1:5,&2:8,r|	Preclinical
SNAP	nitric oxide donor	PTPN1			Cayman, Cayman	40.86	CC(=O)N[C@@H](C(O)=O)C(C)(C)S[NH2+][O-] |&1:4,r|, CC(=O)N[C@@H](C(O)=O)C(C)(C)S[NH2+][O-] |&1:4,r|	Phase 2
SNAP-5089	adrenergic receptor antagonist	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, CACNA1C, CACNA1D			Tocris, Tocris	65.4	COC(=O)C1=C(C)NC(C)=C([C@@H]1c1ccc(cc1)[N+]([O-])=O)C(=O)NCCCN1CCC(CC1)(c1ccccc1)c1ccccc1 |&1:11,c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@@H]1c1ccc(cc1)[N+]([O-])=O)C(=O)NCCCN1CCC(CC1)(c1ccccc1)c1ccccc1 |&1:11,c:4,9|	Preclinical
SNAP-94847		ADRA1A, DRD2			Tocris, Tocris, Tocris, Tocris, Tocris	97.3	CC(C)C(=O)Nc1ccc(C)c(c1)C1CCN(Cc2ccc(Oc3ccc(F)c(F)c3)cc2)CC1, CC(C)C(=O)Nc1ccc(C)c(c1)C1CCN(Cc2ccc(Oc3ccc(F)c(F)c3)cc2)CC1, CC(C)C(=O)Nc1ccc(C)c(c1)C1CCN(Cc2ccc(Oc3ccc(F)c(F)c3)cc2)CC1, CC(C)C(=O)Nc1ccc(C)c(c1)C1CCN(Cc2ccc(Oc3ccc(F)c(F)c3)cc2)CC1, CC(C)C(=O)Nc1ccc(C)c(c1)C1CCN(Cc2ccc(Oc3ccc(F)c(F)c3)cc2)CC1	Preclinical
SNC-80		OPRD1			Tocris, Tocris, Tocris	98.29	CCN(CC)C(=O)c1ccc(cc1)[C@@H](N1C[C@@H](C)N(CC=C)C[C@@H]1C)c1cccc(OC)c1, CCN(CC)C(=O)c1ccc(cc1)[C@@H](N1C[C@@H](C)N(CC=C)C[C@@H]1C)c1cccc(OC)c1, CCN(CC)C(=O)c1ccc(cc1)[C@@H](N1C[C@@H](C)N(CC=C)C[C@@H]1C)c1cccc(OC)c1	Preclinical
SNG-1153	selective estrogen receptor modulator (SERM)	ESR1			MedChemEx, MedChemEx	97.18	CC(C)=CCc1c(O)cc(O)c2c1oc(c(O)c2=O)-c1ccc(cc1)C(F)(F)F, CC(C)=CCc1c(O)cc(O)c2c1oc(c(O)c2=O)-c1ccc(cc1)C(F)(F)F	Preclinical
SNS-314	Aurora kinase inhibitor	AURKA, AURKB, AURKC			Tocris, Tocris, Tocris, Selleck	96.75	Clc1cccc(NC(=O)Nc2ncc(CCNc3ncnc4ccsc34)s2)c1, Clc1cccc(NC(=O)Nc2ncc(CCNc3ncnc4ccsc34)s2)c1, Clc1cccc(NC(=O)Nc2ncc(CCNc3ncnc4ccsc34)s2)c1, Clc1cccc(NC(=O)Nc2ncc(CCNc3ncnc4ccsc34)s2)c1	Phase 1
SNX-2112	HSP inhibitor				Selleck, Selleck	97.02	CC1(C)Cc2c(c(nn2-c2ccc(C(N)=O)c(N[C@H]3CC[C@H](O)CC3)c2)C(F)(F)F)C(=O)C1 |r|, CC1(C)Cc2c(c(nn2-c2ccc(C(N)=O)c(N[C@H]3CC[C@H](O)CC3)c2)C(F)(F)F)C(=O)C1 |r|	Phase 1
SNX-5422	HSP inhibitor	HSP90AA1, HSP90AB1			MedChemEx, MedChemEx, Selleck, Selleck, Selleck	89.48	CC1(C)Cc2c(c(nn2-c2ccc(C(N)=O)c(N[C@H]3CC[C@@H](CC3)OC(=O)CN)c2)C(F)(F)F)C(=O)C1 |r|, CC1(C)Cc2c(c(nn2-c2ccc(C(N)=O)c(N[C@H]3CC[C@@H](CC3)OC(=O)CN)c2)C(F)(F)F)C(=O)C1 |r|, CC1(C)Cc2c(c(nn2-c2ccc(C(N)=O)c(N[C@H]3CC[C@@H](CC3)OC(=O)CN)c2)C(F)(F)F)C(=O)C1 |r|, CC1(C)Cc2c(c(nn2-c2ccc(C(N)=O)c(N[C@H]3CC[C@@H](CC3)OC(=O)CN)c2)C(F)(F)F)C(=O)C1 |r|, CC1(C)Cc2c(c(nn2-c2ccc(C(N)=O)c(N[C@H]3CC[C@@H](CC3)OC(=O)CN)c2)C(F)(F)F)C(=O)C1 |r|	Phase 1/Phase 2
sobetirome	thyroid hormone receptor agonist	THRA, THRB			Tocris, Tocris, Tocris, Tocris, MedChemEx, MedChemEx, MedChemEx	98.73	CC(C)c1cc(Cc2c(C)cc(OCC(O)=O)cc2C)ccc1O, CC(C)c1cc(Cc2c(C)cc(OCC(O)=O)cc2C)ccc1O, CC(C)c1cc(Cc2c(C)cc(OCC(O)=O)cc2C)ccc1O, CC(C)c1cc(Cc2c(C)cc(OCC(O)=O)cc2C)ccc1O, CC(C)c1cc(Cc2c(C)cc(OCC(O)=O)cc2C)ccc1O, CC(C)c1cc(Cc2c(C)cc(OCC(O)=O)cc2C)ccc1O, CC(C)c1cc(Cc2c(C)cc(OCC(O)=O)cc2C)ccc1O	Phase 1/Phase 2
soblidotin	microtubule inhibitor				MedChemEx	90.07	[H][C@]1(CCCN1C(=O)C[C@@H](OC)[C@H]([C@@H](C)CC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C)C(C)C)[C@H](OC)[C@@H](C)C(=O)NCCc1ccccc1	Phase 2
sobrepin	mucolytic agent		pulmonary	chest congestion	TCI	0	CC1=CC[C@H](C[C@@H]1O)C(C)(C)O |t:1|	Launched
sobuzoxane	topoisomerase inhibitor		hematologic malignancy	peripheral T-cell lymphoma (PTCL)	Astatech	100	CC(C)COC(=O)OCN1C(=O)CN(CCN2CC(=O)N(COC(=O)OCC(C)C)C(=O)C2)CC1=O	Launched
sodium-ascorbate					Selleck, Selleck	0	OC[C@H](O)[C@H]1OC(=O)[C@@H](O)[C@@H]1O |a:2,4,&1:8,&2:10|, OC[C@H](O)[C@H]1OC(=O)[C@@H](O)[C@@H]1O |a:2,4,&1:8,&2:10|	Launched
sodium-butyrate	HDAC inhibitor	BCHE, FFAR2, FFAR3, HDAC1, HDAC2, HDAC3, HDAC8			Selleck, Selleck, Selleck	25.75	CCCC(O)=O, CCCC(O)=O, CCCC(O)=O	Phase 2
sodium-danshensu					Selleck, Selleck, Selleck	100	O[C@@H](Cc1ccc(O)c(O)c1)C(O)=O |&1:1|, O[C@@H](Cc1ccc(O)c(O)c1)C(O)=O |&1:1|, O[C@@H](Cc1ccc(O)c(O)c1)C(O)=O |&1:1|	Preclinical
sodium-dodecyl-sulfate		ALB			Sigma, Enamine	98.3	[Na].CCCCCCCCCCCCOS(O)(=O)=O, [Na].CCCCCCCCCCCCOS(O)(=O)=O	Launched
sodium-gluconate					MedChemEx, MicroSource	0	OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O, OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O	Launched
sodium-gualenate	antacid		gastroenterology, otolaryngology	peptic ulcer disease (PUD), pharyngitis	AKSci	99.62	CC(C)c1ccc(C)c2c(cc(C)c2c1)S(O)(=O)=O	Launched
sodium-monofluorophosphate		PYGM	dental	cavities	MicroSource, Selleck, Selleck	0	OP(O)(F)=O, OP(O)(F)=O, OP(O)(F)=O	Launched
sodium-nitrite	nitric oxide donor		critical care	poison antidote, cyanide poisoning	Selleck, Selleck	0	[O-][NH2+][O-], [O-][NH2+][O-]	Launched
sodium-nitroprusside	nitric oxide donor		cardiology	hypertension, congestive heart failure	MedChemEx, MedChemEx	94.4	[O-][N+][Fe--](C#N)(C#N)(C#N)(C#N)C#N, [O-][N+][Fe--](C#N)(C#N)(C#N)(C#N)C#N	Launched
sodium-orthovanadate					Selleck, Selleck	5.51	O[V](O)(O)=O, O[V](O)(O)=O	Preclinical
sodium-picosulfate			gastroenterology	constipation	MedChemEx, Selleck	94.85	OS(=O)(=O)Oc1ccc(cc1)C(c1ccc(OS(O)(=O)=O)cc1)c1ccccn1, OS(=O)(=O)Oc1ccc(cc1)C(c1ccc(OS(O)(=O)=O)cc1)c1ccccn1	Launched
sodium-stibogluconate	tyrosine phosphatase inhibitor	PTPN6	infectious disease	leishmaniasis	MedChemEx	0	[H][C@@]1(O[Sb]2(O)(O[Sb]34(O)O[C@H]([C@@H](O3)[C@]([H])(O4)[C@H](O)CO)C(O)=O)O[C@H]([C@H]1O2)C(O)=O)[C@H](O)CO	Launched
sodium-tanshinone-II-A-sulfonate	potassium channel activator				Ark	93.63	Cc1c2c(oc1S(O)(=O)=O)-c1ccc3c(CCCC3(C)C)c1C(=O)C2=O	Phase 2
sodium-tetradecyl-sulfate		PROC	dermatology	varicose veins	MicroSource, MicroSource, MicroSource	98.56	CCCC[C@@H](CC)CC[C@@H](CC(C)C)OS(O)(=O)=O |&1:4,&2:9|, CCCC[C@@H](CC)CC[C@@H](CC(C)C)OS(O)(=O)=O |&1:4,&2:9|, CCCC[C@@H](CC)CC[C@@H](CC(C)C)OS(O)(=O)=O |&1:4,&2:9|	Launched
sofalcone	mucus protecting agent	CBR1	gastroenterology	peptic ulcer disease (PUD)	Cayman, Cayman	97.31	CC(C)=CCOc1ccc(\C=C\C(=O)c2ccc(OCC=C(C)C)cc2OCC(O)=O)cc1, CC(C)=CCOc1ccc(\C=C\C(=O)c2ccc(OCC=C(C)C)cc2OCC(O)=O)cc1	Launched
sofosbuvir	HCV inhibitor		infectious disease	hepatitis C, hepatitis C	MedChemEx, MedChemEx, MedChemEx	98.52	CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)Oc1ccccc1, CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)Oc1ccccc1, CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)Oc1ccccc1	Launched
sofosbuvir-impurity-m	antiviral				MedChemEx	95.1	CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@@](C)(O)[C@@H]1O)Oc1ccccc1	Preclinical
sograzepide	gastrin inhibitor				MedChemEx	63.93	CNc1cccc(NC(=O)N[C@@H]2N=C(c3ccccn3)c3ccccc3N(CC(=O)C(C)(C)C)C2=O)c1 |t:12|	Phase 2
solamargine	apoptosis inhibitor				MedChemEx, MedChemEx, MedChemEx, MedChemEx	100	C[C@H]1[C@H]2[C@@H](C[C@H]3[C@H]4CC=C5C[C@@H](CC[C@@]5(C)[C@@H]4CC[C@@]23C)O[C@H]2O[C@@H](CO)[C@@H](O[C@H]3O[C@@H](C)[C@@H](O)[C@@H](O)[C@@H]3O)[C@@H](O)[C@@H]2O[C@H]2O[C@@H](C)[C@@H](O)[C@@H](O)[C@@H]2O)O[C@]11CC[C@@H](C)CN1 |&1:1,&2:2,&3:3,&4:5,&5:6,&6:11,&7:14,&8:16,&9:19,&10:22,&11:24,&12:27,&13:29,&14:31,&15:33,&16:35,&17:37,&18:39,&19:41,&20:43,&21:45,&22:47,&23:49,&24:51,&25:54,&26:57,r,t:8|, C[C@H]1[C@H]2[C@@H](C[C@H]3[C@H]4CC=C5C[C@@H](CC[C@@]5(C)[C@@H]4CC[C@@]23C)O[C@H]2O[C@@H](CO)[C@@H](O[C@H]3O[C@@H](C)[C@@H](O)[C@@H](O)[C@@H]3O)[C@@H](O)[C@@H]2O[C@H]2O[C@@H](C)[C@@H](O)[C@@H](O)[C@@H]2O)O[C@]11CC[C@@H](C)CN1 |&1:1,&2:2,&3:3,&4:5,&5:6,&6:11,&7:14,&8:16,&9:19,&10:22,&11:24,&12:27,&13:29,&14:31,&15:33,&16:35,&17:37,&18:39,&19:41,&20:43,&21:45,&22:47,&23:49,&24:51,&25:54,&26:57,r,t:8|, C[C@H]1[C@H]2[C@@H](C[C@H]3[C@H]4CC=C5C[C@@H](CC[C@@]5(C)[C@@H]4CC[C@@]23C)O[C@H]2O[C@@H](CO)[C@@H](O[C@H]3O[C@@H](C)[C@@H](O)[C@@H](O)[C@@H]3O)[C@@H](O)[C@@H]2O[C@H]2O[C@@H](C)[C@@H](O)[C@@H](O)[C@@H]2O)O[C@]11CC[C@@H](C)CN1 |&1:1,&2:2,&3:3,&4:5,&5:6,&6:11,&7:14,&8:16,&9:19,&10:22,&11:24,&12:27,&13:29,&14:31,&15:33,&16:35,&17:37,&18:39,&19:41,&20:43,&21:45,&22:47,&23:49,&24:51,&25:54,&26:57,r,t:8|, C[C@H]1[C@H]2[C@@H](C[C@H]3[C@H]4CC=C5C[C@@H](CC[C@@]5(C)[C@@H]4CC[C@@]23C)O[C@H]2O[C@@H](CO)[C@@H](O[C@H]3O[C@@H](C)[C@@H](O)[C@@H](O)[C@@H]3O)[C@@H](O)[C@@H]2O[C@H]2O[C@@H](C)[C@@H](O)[C@@H](O)[C@@H]2O)O[C@]11CC[C@@H](C)CN1 |&1:1,&2:2,&3:3,&4:5,&5:6,&6:11,&7:14,&8:16,&9:19,&10:22,&11:24,&12:27,&13:29,&14:31,&15:33,&16:35,&17:37,&18:39,&19:41,&20:43,&21:45,&22:47,&23:49,&24:51,&25:54,&26:57,r,t:8|	Phase 3
solcitinib	JAK inhibitor	JAK1			MedChemEx, MedChemEx	97.64	CC1(C)CN(C1)C(=O)c1ccc(cc1)-c1cccc2nc(NC(=O)C3CC3)nn12, CC1(C)CN(C1)C(=O)c1ccc(cc1)-c1cccc2nc(NC(=O)C3CC3)nn12	Phase 1
solifenacin-succinate	acetylcholine receptor antagonist	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5	urology	urinary incontinence, urinary frequency	MedChemEx	97.25	[H][C@@]1(C[N@@]2CC[C@H]1CC2)OC(=O)N1CCc2ccccc2[C@@H]1c1ccccc1	Launched
solithromycin	protein synthesis inhibitor				MedChemEx	96.7	CC[C@H]1OC(=O)[C@@](C)(F)C(=O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@H]2N(CCCCn3cc(nn3)-c3cccc(N)c3)C(=O)O[C@]12C)OC	Phase 3
solriamfetol	dopamine reuptake inhibitor		neurology/psychiatry	narcolepsy	AMS	84.07	N[C@@H](COC(N)=O)Cc1ccccc1	Launched
somantadine	antiviral				ChemBridge	97.8	CC(C)(N)CC12CC3CC(CC(C3)C1)C2	Phase 1
somatostatin	somatostatin receptor agonist	OPRD1, OPRM1, SSTR1, SSTR2, SSTR3, SSTR4, SSTR5	hematology	hemorrhage	Key, Key	82.44	C[C@@H](O)[C@@H]1NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CO)NC1=O)C(O)=O)NC(=O)CNC(=O)[C@H](C)N)[C@@H](C)O, C[C@@H](O)[C@@H]1NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CO)NC1=O)C(O)=O)NC(=O)CNC(=O)[C@H](C)N)[C@@H](C)O	Launched
sonepiprazole	dopamine receptor antagonist				Sigma	92.91	NS(=O)(=O)c1ccc(cc1)N1CCN(CC[C@@H]2OCCc3ccccc23)CC1	Phase 2
sonidegib	smoothened receptor antagonist	SMO	oncology	basal cell carcinoma (BCC)	Selleck, Selleck, Selleck, Selleck	95.51	C[C@H]1CN(C[C@@H](C)O1)c1ccc(NC(=O)c2cccc(c2C)-c2ccc(OC(F)(F)F)cc2)cn1, C[C@H]1CN(C[C@@H](C)O1)c1ccc(NC(=O)c2cccc(c2C)-c2ccc(OC(F)(F)F)cc2)cn1, C[C@H]1CN(C[C@@H](C)O1)c1ccc(NC(=O)c2cccc(c2C)-c2ccc(OC(F)(F)F)cc2)cn1, C[C@H]1CN(C[C@@H](C)O1)c1ccc(NC(=O)c2cccc(c2C)-c2ccc(OC(F)(F)F)cc2)cn1	Launched
sophocarpine					Vitas-M, Selleck, Selleck	96.27	O=C1C=CC[C@@H]2[C@H]3CCCN4CCC[C@@H](CN12)[C@@H]34 |c:2|, O=C1C=CC[C@@H]2[C@H]3CCCN4CCC[C@@H](CN12)[C@@H]34 |c:2|, O=C1C=CC[C@@H]2[C@H]3CCCN4CCC[C@@H](CN12)[C@@H]34 |c:2|	Phase 3
sorafenib	FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RAF inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor	BRAF, DDR2, FGFR1, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RAF1, RET	oncology	renal cell carcinoma (RCC), thyroid cancer, hepatocellular carcinoma (HCC)	Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck	98.3	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1, CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1, CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1, CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1, CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1, CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1, CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1, CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1	Launched
soraprazan	proton pump inhibitor				MedChemEx	94.94	COCCO[C@H]1[C@H](O)[C@H](Nc2c1ccn1c(C)c(C)nc21)c1ccccc1	Preclinical
sorbic-acid					Sigma	0	C\C=C\C=C\C(O)=O	Launched
sorbinil	aldose reductase inhibitor	AKR1B1			Sigma, Key, Key, Key, Key	98.08	Fc1ccc2OCC[C@]3(NC(=O)NC3=O)c2c1 |&1:8,r|, Fc1ccc2OCC[C@]3(NC(=O)NC3=O)c2c1 |&1:8,r|, Fc1ccc2OCC[C@]3(NC(=O)NC3=O)c2c1 |&1:8,r|, Fc1ccc2OCC[C@]3(NC(=O)NC3=O)c2c1 |&1:8,r|, Fc1ccc2OCC[C@]3(NC(=O)NC3=O)c2c1 |&1:8,r|	Phase 3
sorbitan-monostearate					InterBioScreen, InterBioScreen	27.6	CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O |a:23,26,28,&1:21|, CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O |a:23,26,28,&1:21|	Preclinical
sorbitol	mucolytic agent		gastroenterology	constipation	MedChemEx, MicroSource, Selleck, Selleck	100	OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO, OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO, OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO, OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO	Launched
sotagliflozin	sodium/glucose cotransporter inhibitor	SLC5A1, SLC5A2			MedChemEx, MedChemEx, MedChemEx	95.58	CCOc1ccc(Cc2cc(ccc2Cl)[C@@H]2O[C@H](SC)[C@@H](O)[C@H](O)[C@H]2O)cc1, CCOc1ccc(Cc2cc(ccc2Cl)[C@@H]2O[C@H](SC)[C@@H](O)[C@H](O)[C@H]2O)cc1, CCOc1ccc(Cc2cc(ccc2Cl)[C@@H]2O[C@H](SC)[C@@H](O)[C@H](O)[C@H]2O)cc1	Phase 3
sotalol	adrenergic receptor antagonist	ADRB1, ADRB2, KCNH2	cardiology	atrial fibrillation (AF), ventricular arrhythmias	MicroSource, MicroSource, Selleck, Tocris	98.92	CC(C)NCC(O)c1ccc(NS(C)(=O)=O)cc1, CC(C)NCC(O)c1ccc(NS(C)(=O)=O)cc1, CC(C)NCC(O)c1ccc(NS(C)(=O)=O)cc1, CC(C)NCC(O)c1ccc(NS(C)(=O)=O)cc1	Launched
sotrastaurin	PKC inhibitor	PRKCA, PRKCB, PRKCD, PRKCE, PRKCH, PRKCQ			MedChemEx, MedChemEx, Selleck	98.9	CN1CCN(CC1)c1nc(C2=C(C(=O)NC2=O)c2c[nH]c3ccccc23)c2ccccc2n1 |t:11|, CN1CCN(CC1)c1nc(C2=C(C(=O)NC2=O)c2c[nH]c3ccccc23)c2ccccc2n1 |t:11|, CN1CCN(CC1)c1nc(C2=C(C(=O)NC2=O)c2c[nH]c3ccccc23)c2ccccc2n1 |t:11|	Phase 2
SP-100030	NFkB pathway inhibitor	JUN, NFKB1			Tocris, Tocris	83.3	FC(F)(F)c1cc(NC(=O)c2cnc(Cl)nc2C(F)(F)F)cc(c1)C(F)(F)F, FC(F)(F)c1cc(NC(=O)c2cnc(Cl)nc2C(F)(F)F)cc(c1)C(F)(F)F	Preclinical
SP-141	ubiquitin ligase inhibitor	MDM2			Tocris, Tocris, Tocris, Tocris, Tocris	97.08	COc1ccc2[nH]c3c(nccc3c2c1)-c1cccc2ccccc12, COc1ccc2[nH]c3c(nccc3c2c1)-c1cccc2ccccc12, COc1ccc2[nH]c3c(nccc3c2c1)-c1cccc2ccccc12, COc1ccc2[nH]c3c(nccc3c2c1)-c1cccc2ccccc12, COc1ccc2[nH]c3c(nccc3c2c1)-c1cccc2ccccc12	Preclinical
SP-420					MedChemEx, MedChemEx	85.18	COCCOCCOc1ccc(C2=N[C@](C)(CS2)C(O)=O)c(O)c1 |t:12|, COCCOCCOc1ccc(C2=N[C@](C)(CS2)C(O)=O)c(O)c1 |t:12|	Phase 1
spaglumic-acid	glutamate receptor antagonist	GRM3	allergy	allergic conjunctivitis, allergic rhinitis	Prestwick, Enzo, Enzo, Tocris	98.11	CC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O, CC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O, CC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O, CC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O	Launched
sparfloxacin	bacterial DNA gyrase inhibitor	TOP2A			MedChemEx, MicroSource, MicroSource, Selleck, Selleck, Selleck	96.86	C[C@H]1CN(C[C@@H](C)N1)c1c(F)c(N)c2c(c1F)n(cc(C(O)=O)c2=O)C1CC1, C[C@H]1CN(C[C@@H](C)N1)c1c(F)c(N)c2c(c1F)n(cc(C(O)=O)c2=O)C1CC1, C[C@H]1CN(C[C@@H](C)N1)c1c(F)c(N)c2c(c1F)n(cc(C(O)=O)c2=O)C1CC1, C[C@H]1CN(C[C@@H](C)N1)c1c(F)c(N)c2c(c1F)n(cc(C(O)=O)c2=O)C1CC1, C[C@H]1CN(C[C@@H](C)N1)c1c(F)c(N)c2c(c1F)n(cc(C(O)=O)c2=O)C1CC1, C[C@H]1CN(C[C@@H](C)N1)c1c(F)c(N)c2c(c1F)n(cc(C(O)=O)c2=O)C1CC1	Withdrawn
sparfosate	aspartate carbamoyltransferase inhibitor	CA2, CA4			AMS	0	OC(=O)C[C@@H](NC(=O)CP(O)(O)=O)C(O)=O |&1:4|	Phase 3
sparsentan	angiotensin receptor antagonist				MedChemEx	96.98	CCCCC1=NC2(CCCC2)C(=O)N1Cc1ccc(c(COCC)c1)-c1ccccc1S(=O)(=O)Nc1noc(C)c1C |t:4|	Phase 3
sparteine-(+)					Oakwood	93.7	C1CCN2C[C@H]3C[C@H](CN4CCCC[C@H]34)[C@@H]2C1	Launched
sparteine-(-)					Oakwood	100	C1CCN2C[C@@H]3C[C@@H](CN4CCCC[C@H]34)[C@@H]2C1	Launched
sparteine-sulfate					MicroSource	100	C1CCN2C[C@H]3C[C@@H](CN4CCCC[C@H]34)[C@@H]2C1	Launched
spautin-1	deubiquitinase inhibitor	USP10, USP13			Tocris, Tocris, Tocris	98	Fc1ccc(CNc2ncnc3ccc(F)cc23)cc1, Fc1ccc(CNc2ncnc3ccc(F)cc23)cc1, Fc1ccc(CNc2ncnc3ccc(F)cc23)cc1	Preclinical
spectinomycin	bacterial 30S ribosomal subunit inhibitor		pulmonary	airsacculitis, chronic respiratory disease	MedChemEx, MedChemEx, Selleck, MicroSource, Selleck	68.33	CN[C@@H]1[C@H](O)[C@H](NC)[C@H]2O[C@]3(O)[C@@H](O[C@H](C)CC3=O)O[C@@H]2[C@H]1O, CN[C@@H]1[C@H](O)[C@H](NC)[C@H]2O[C@]3(O)[C@@H](O[C@H](C)CC3=O)O[C@@H]2[C@H]1O, CN[C@@H]1[C@H](O)[C@H](NC)[C@H]2O[C@]3(O)[C@@H](O[C@H](C)CC3=O)O[C@@H]2[C@H]1O, CN[C@@H]1[C@H](O)[C@H](NC)[C@H]2O[C@]3(O)[C@@H](O[C@H](C)CC3=O)O[C@@H]2[C@H]1O, CN[C@@H]1[C@H](O)[C@H](NC)[C@H]2O[C@]3(O)[C@@H](O[C@H](C)CC3=O)O[C@@H]2[C@H]1O	Launched
spermidine	glutamate receptor modulator	KCNJ4, TXNRD1			Tocris, Tocris	100	NCCCCNCCCN, NCCCCNCCCN	Preclinical
spermine		CA14, CA4, CA6, CA9, CASR, GRIN1, GRIN2A, KCNJ4, ODC1, SMOX, SMS, TRPM4, TRPM5			Enzo	100	NCCCNCCCCNCCCN	Preclinical
sphingosylphosphorylcholine	gene expression stimulant	GPR12			EMDBio	100	CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)COP(O)(=O)OCC[N+](C)(C)C |a:15,17,&1:21|	Preclinical
spiperone	dopamine receptor antagonist	ADRA1A, ADRA1B, ADRA1D, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR1D, HTR2A, HTR2B, HTR2C, HTR6, HTR7	neurology/psychiatry	schizophrenia	MicroSource, Tocris	96.07	Fc1ccc(cc1)C(=O)CCCN1CCC2(CC1)N(CNC2=O)c1ccccc1, Fc1ccc(cc1)C(=O)CCCN1CCC2(CC1)N(CNC2=O)c1ccccc1	Launched
spiradoline	opioid receptor agonist	OPRK1			Enzo, Enzo, Enzo, Enzo, Sigma	98.15	CN([C@H]1CC[C@@]2(CCCO2)C[C@@H]1N1CCCC1)C(=O)Cc1ccc(Cl)c(Cl)c1, CN([C@H]1CC[C@@]2(CCCO2)C[C@@H]1N1CCCC1)C(=O)Cc1ccc(Cl)c(Cl)c1, CN([C@H]1CC[C@@]2(CCCO2)C[C@@H]1N1CCCC1)C(=O)Cc1ccc(Cl)c(Cl)c1, CN([C@H]1CC[C@@]2(CCCO2)C[C@@H]1N1CCCC1)C(=O)Cc1ccc(Cl)c(Cl)c1, CN([C@H]1CC[C@@]2(CCCO2)C[C@@H]1N1CCCC1)C(=O)Cc1ccc(Cl)c(Cl)c1	Phase 2
spiramycin	bacterial 50S ribosomal subunit inhibitor		infectious disease	toxoplasmosis, soft tissue infection	MedChemEx	87.58	CO[C@H]1[C@H](O)CC(=O)O[C@H](C)C\C=C\C=C\[C@H](O[C@H]2CC[C@@H]([C@@H](C)O2)N(C)C)[C@H](C)C[C@H](CC=O)[C@@H]1O[C@@H]1O[C@H](C)[C@@H](O[C@H]2C[C@@](C)(O)[C@@H](O)[C@H](C)O2)[C@@H]([C@H]1O)N(C)C |t:12,14|	Launched
spirobromin					MatrixSci	0	BrCCC(=O)N1CC[N+]2(CC1)CC[N+]1(CCN(CC1)C(=O)CCBr)CC2	Phase 1
spironolactone	mineralocorticoid receptor antagonist	AR, CACNA1A, CACNA1B, CACNA1C, CACNA1D, CACNA1F, CACNA1G, CACNA1H, CACNA1I, CACNA1S, CACNA2D1, CACNA2D2, CACNA2D3, CACNB1, CACNB2, CACNB3, CACNB4, CACNG1, CYP11B2, NR3C1, NR3C2, PGR, SHBG	endocrinology, cardiology, gastroenterology, rheumatology	hyperaldosteronism, congestive heart failure, hepatic cirrhosis, nephrotic syndrome, hypertension, hypokalemia	Tocris, Tocris, Tocris, MicroSource, Selleck, Selleck, Selleck	98.19	CC(=O)S[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]33CCC(=O)O3)[C@H]12 |t:6|, CC(=O)S[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]33CCC(=O)O3)[C@H]12 |t:6|, CC(=O)S[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]33CCC(=O)O3)[C@H]12 |t:6|, CC(=O)S[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]33CCC(=O)O3)[C@H]12 |t:6|, CC(=O)S[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]33CCC(=O)O3)[C@H]12 |t:6|, CC(=O)S[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]33CCC(=O)O3)[C@H]12 |t:6|, CC(=O)S[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]33CCC(=O)O3)[C@H]12 |t:6|	Launched
spiroxatrine	serotonin receptor antagonist	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, HTR1A, HTR2B			Tocris, Tocris	91.09	O=C1NCN(c2ccccc2)C11CCN(C[C@H]2COc3ccccc3O2)CC1 |&1:16,r|, O=C1NCN(c2ccccc2)C11CCN(C[C@H]2COc3ccccc3O2)CC1 |&1:16,r|	Preclinical
spizofurone					Sigma	97.9	CC(=O)c1ccc2OC3(CC3)C(=O)c2c1	Withdrawn
splitomycin	SIRT inhibitor	SIRT1			Tocris	38.94	O=C1CCc2c(O1)ccc1ccccc21	Preclinical
SPP301	endothelin receptor antagonist	EDNRA			MedChemEx, MedChemEx	99.69	COc1ccccc1Oc1c(NS(=O)(=O)c2ccc(C)cn2)nc(nc1OC)-c1ccncc1, COc1ccccc1Oc1c(NS(=O)(=O)c2ccc(C)cn2)nc(nc1OC)-c1ccncc1	Phase 3
SPP86	receptor tyrosine protein kinase inhibitor	RET			Tocris, Tocris	98.51	CC(C)n1nc(C#Cc2ccccc2)c2c(N)ncnc12, CC(C)n1nc(C#Cc2ccccc2)c2c(N)ncnc12	Preclinical
SQ-109	bacterial cell wall synthesis inhibitor	FDFT1			MedChemEx, MedChemEx	97.97	CC(C)=CCC\C(C)=C\CNCCNC1[C@H]2C[C@@H]3C[C@@H](C[C@H]1C3)C2 |r|, CC(C)=CCC\C(C)=C\CNCCNC1[C@H]2C[C@@H]3C[C@@H](C[C@H]1C3)C2 |r|	Phase 3
SQ-22536	adenylyl cyclase inhibitor	ADCY1			Tocris, Tocris	98.05	Nc1ncnc2n(cnc12)[C@H]1CCCO1 |&1:10,r|, Nc1ncnc2n(cnc12)[C@H]1CCCO1 |&1:10,r|	Preclinical
squalamine	antiviral				MedChemEx	94.7	[H][C@@]1(CC[C@@]2([H])[C@]3([H])[C@H](O)C[C@@]4([H])C[C@H](CC[C@]4(C)[C@@]3([H])CC[C@]12C)NCCCNCCCCN)[C@H](C)CC[C@@H](OS(O)(=O)=O)C(C)C	Phase 3
squaric-acid-dibutyl-ester	oxidative stress inducer				AMS	0	CCCCOc1c(OCCCC)c(=O)c1=O	Preclinical
SR-1078	retinoid receptor agonist	RORA, RORC			Tocris, Tocris	93.79	OC(c1ccc(NC(=O)c2ccc(cc2)C(F)(F)F)cc1)(C(F)(F)F)C(F)(F)F, OC(c1ccc(NC(=O)c2ccc(cc2)C(F)(F)F)cc1)(C(F)(F)F)C(F)(F)F	Preclinical
SR-11302					Tocris, Tocris	64.05	C\C(\C=C\C=C(\C=C\C1=C(C)CCCC1(C)C)/c1ccc(C)cc1)=C/C(O)=O |c:8|, C\C(\C=C\C=C(\C=C\C1=C(C)CCCC1(C)C)/c1ccc(C)cc1)=C/C(O)=O |c:8|	Preclinical
SR-140333	neurokinin receptor antagonist	TACR1			Tocris, Tocris, Tocris	94.45	CC(C)Oc1cccc(CC(=O)N2CCC[C@@](CC[N+]34CCC(CC3)(CC4)c3ccccc3)(C2)c2ccc(Cl)c(Cl)c2)c1, CC(C)Oc1cccc(CC(=O)N2CCC[C@@](CC[N+]34CCC(CC3)(CC4)c3ccccc3)(C2)c2ccc(Cl)c(Cl)c2)c1, CC(C)Oc1cccc(CC(=O)N2CCC[C@@](CC[N+]34CCC(CC3)(CC4)c3ccccc3)(C2)c2ccc(Cl)c(Cl)c2)c1	Phase 2
SR-1664	PPAR receptor ligand	PPARG			Tocris, Sigma	94.36	C[C@H](NC(=O)c1ccc2n(Cc3ccc(cc3)-c3ccccc3C(O)=O)c(C)c(C)c2c1)c1ccc(cc1)[N+]([O-])=O, C[C@H](NC(=O)c1ccc2n(Cc3ccc(cc3)-c3ccccc3C(O)=O)c(C)c(C)c2c1)c1ccc(cc1)[N+]([O-])=O	Preclinical
SR-2211	retinoid receptor inverse agonist	RORC			Tocris, Tocris, Tocris	95.83	OC(c1ccc(c(F)c1)-c1ccc(CN2CCN(Cc3ccncc3)CC2)cc1)(C(F)(F)F)C(F)(F)F, OC(c1ccc(c(F)c1)-c1ccc(CN2CCN(Cc3ccncc3)CC2)cc1)(C(F)(F)F)C(F)(F)F, OC(c1ccc(c(F)c1)-c1ccc(CN2CCN(Cc3ccncc3)CC2)cc1)(C(F)(F)F)C(F)(F)F	Preclinical
SR-2640	leukotriene receptor antagonist	CYSLTR1			Tocris, Tocris, Tocris	95.08	OC(=O)c1ccccc1Nc1cccc(OCc2ccc3ccccc3n2)c1, OC(=O)c1ccccc1Nc1cccc(OCc2ccc3ccccc3n2)c1, OC(=O)c1ccccc1Nc1cccc(OCc2ccc3ccccc3n2)c1	Phase 2
SR-27897	CCK receptor antagonist	CCKAR			Tocris, Tocris, Tocris, Tocris	99.12	OC(=O)Cn1c(cc2ccccc12)C(=O)Nc1nc(cs1)-c1ccccc1Cl, OC(=O)Cn1c(cc2ccccc12)C(=O)Nc1nc(cs1)-c1ccccc1Cl, OC(=O)Cn1c(cc2ccccc12)C(=O)Nc1nc(cs1)-c1ccccc1Cl, OC(=O)Cn1c(cc2ccccc12)C(=O)Nc1nc(cs1)-c1ccccc1Cl	Phase 2
SR-3306	JNK inhibitor	MAPK10, MAPK8, MAPK9			MedChemEx, MedChemEx, MedChemEx, MedChemEx	95.09	Cc1ccc(cn1)-c1ncn(n1)-c1ccc(Nc2nccc(n2)-c2cccc(c2)N2CCOCC2)cc1, Cc1ccc(cn1)-c1ncn(n1)-c1ccc(Nc2nccc(n2)-c2cccc(c2)N2CCOCC2)cc1, Cc1ccc(cn1)-c1ncn(n1)-c1ccc(Nc2nccc(n2)-c2cccc(c2)N2CCOCC2)cc1, Cc1ccc(cn1)-c1ncn(n1)-c1ccc(Nc2nccc(n2)-c2cccc(c2)N2CCOCC2)cc1	Preclinical
SR-33805	calcium channel blocker				Tocris, Tocris, Tocris, Tocris, Tocris	97.8	COc1ccc(CCN(C)CCCOc2ccc(cc2)S(=O)(=O)c2c(C(C)C)c3ccccc3n2C)cc1OC, COc1ccc(CCN(C)CCCOc2ccc(cc2)S(=O)(=O)c2c(C(C)C)c3ccccc3n2C)cc1OC, COc1ccc(CCN(C)CCCOc2ccc(cc2)S(=O)(=O)c2c(C(C)C)c3ccccc3n2C)cc1OC, COc1ccc(CCN(C)CCCOc2ccc(cc2)S(=O)(=O)c2c(C(C)C)c3ccccc3n2C)cc1OC, COc1ccc(CCN(C)CCCOc2ccc(cc2)S(=O)(=O)c2c(C(C)C)c3ccccc3n2C)cc1OC	Phase 1
SR-3576	JNK inhibitor	MAPK10			Tocris, Tocris, Tocris	99.49	COc1cc(NC(=O)c2cccc(c2)-n2cc(NC(=O)Nc3cccc(C)c3)cn2)cc(OC)c1OC, COc1cc(NC(=O)c2cccc(c2)-n2cc(NC(=O)Nc3cccc(C)c3)cn2)cc(OC)c1OC, COc1cc(NC(=O)c2cccc(c2)-n2cc(NC(=O)Nc3cccc(C)c3)cn2)cc(OC)c1OC	Preclinical
SR-3677	rho associated kinase inhibitor	ROCK2			Tocris, Tocris	90.89	CN(C)CCOc1cc(ccc1NC(=O)[C@H]1COc2ccccc2O1)-c1cn[nH]c1 |&1:15|, CN(C)CCOc1cc(ccc1NC(=O)[C@H]1COc2ccccc2O1)-c1cn[nH]c1 |&1:15|	Preclinical
SR-57227A	serotonin receptor agonist	HTR3A			Tocris, Tocris	95.89	NC1CCN(CC1)c1cccc(Cl)n1, NC1CCN(CC1)c1cccc(Cl)n1	Phase 2
SR-59230A	adrenergic receptor antagonist	ADRB1, ADRB2, ADRB3			Tocris, Tocris, Tocris, Tocris	95.68	CCc1ccccc1OC[C@@H](O)CN[C@H]1CCCc2ccccc12, CCc1ccccc1OC[C@@H](O)CN[C@H]1CCCc2ccccc12, CCc1ccccc1OC[C@@H](O)CN[C@H]1CCCc2ccccc12, CCc1ccccc1OC[C@@H](O)CN[C@H]1CCCc2ccccc12	Preclinical
SR-95639A	acetylcholine receptor agonist	CHRM1			Prestwick, Prestwick	98.78	C(CN1CCOCC1)Nc1cc2CCCc3ccccc3-c2nn1, C(CN1CCOCC1)Nc1cc2CCCc3ccccc3-c2nn1	Preclinical
SRC-kinase-inhibitor-I	SRC inhibitor	CSK, LCK, RIPK2			Tocris, Tocris, Tocris	98.18	COc1cc2ncnc(Nc3ccc(Oc4ccccc4)cc3)c2cc1OC, COc1cc2ncnc(Nc3ccc(Oc4ccccc4)cc3)c2cc1OC, COc1cc2ncnc(Nc3ccc(Oc4ccccc4)cc3)c2cc1OC	Preclinical
SRPIN340	serine arginine protein kinase inhibitor	SRPK1, SRPK2			Tocris, Tocris, Selleck, Selleck	98.5	FC(F)(F)c1ccc(N2CCCCC2)c(NC(=O)c2ccncc2)c1, FC(F)(F)c1ccc(N2CCCCC2)c(NC(=O)c2ccncc2)c1, FC(F)(F)c1ccc(N2CCCCC2)c(NC(=O)c2ccncc2)c1, FC(F)(F)c1ccc(N2CCCCC2)c(NC(=O)c2ccncc2)c1	Preclinical
SRT1720	SIRT activator	SIRT1			Selleck, Selleck, Selleck, Selleck, MedChemEx, MedChemEx	93.47	O=C(Nc1ccccc1-c1cn2c(CN3CCNCC3)csc2n1)c1cnc2ccccc2n1, O=C(Nc1ccccc1-c1cn2c(CN3CCNCC3)csc2n1)c1cnc2ccccc2n1, O=C(Nc1ccccc1-c1cn2c(CN3CCNCC3)csc2n1)c1cnc2ccccc2n1, O=C(Nc1ccccc1-c1cn2c(CN3CCNCC3)csc2n1)c1cnc2ccccc2n1, O=C(Nc1ccccc1-c1cn2c(CN3CCNCC3)csc2n1)c1cnc2ccccc2n1, O=C(Nc1ccccc1-c1cn2c(CN3CCNCC3)csc2n1)c1cnc2ccccc2n1	Preclinical
SRT2104	SIRT activator	SIRT1			Selleck, MedChemEx	99.71	Cc1nc(sc1C(=O)Nc1ccccc1-c1cn2c(CN3CCOCC3)csc2n1)-c1cccnc1, Cc1nc(sc1C(=O)Nc1ccccc1-c1cn2c(CN3CCOCC3)csc2n1)-c1cccnc1	Phase 2
SRT3190	CC chemokine receptor antagonist				MedChemEx, MedChemEx, MedChemEx	98.58	C[C@H](Nc1cc(NS(=O)(=O)N2CCC2)nc(SCc2cccc(F)c2F)n1)[C@@H](O)CO, C[C@H](Nc1cc(NS(=O)(=O)N2CCC2)nc(SCc2cccc(F)c2F)n1)[C@@H](O)CO, C[C@H](Nc1cc(NS(=O)(=O)N2CCC2)nc(SCc2cccc(F)c2F)n1)[C@@H](O)CO	Preclinical
SSR128129E					Selleck, MedChemEx	96.61	COc1c(C)c(C(=O)c2ccc(N)c(c2)C(O)=O)n2ccccc12, COc1c(C)c(C(=O)c2ccc(N)c(c2)C(O)=O)n2ccccc12	Preclinical
SSR180711	acetylcholine receptor agonist	CHRNA7			Tocris	90.15	Brc1ccc(OC(=O)N2CC[N@@]3CC[C@H]2CC3)cc1 |r|	Phase 2
SSR240612	bradykinin receptor antagonist				MedChemEx	96.86	COc1ccc2cc(ccc2c1)S(=O)(=O)N[C@H](CC(=O)N[C@H](Cc1ccc(CN2[C@@H](C)CCC[C@H]2C)cc1)C(=O)N(C)C(C)C)c1ccc2OCOc2c1	Preclinical
ST-1535	adenosine receptor antagonist				AMS	89.18	CCCCc1nc(N)c2nc(-n3nccn3)n(C)c2n1	Preclinical
ST-1859	antiamyloidogenic agent				Sigma, Enamine, Enamine, Enamine	96.67	Oc1ccc2ccccc2c1Cc1c(O)ccc2ccccc12, Oc1ccc2ccccc2c1Cc1c(O)ccc2ccccc12, Oc1ccc2ccccc2c1Cc1c(O)ccc2ccccc12, Oc1ccc2ccccc2c1Cc1c(O)ccc2ccccc12	Phase 1
ST-2825	myeloid differentiation primary response inhibitor	MYD88			MedChemEx	97.03	NC(=O)[C@H]1CCS[C@@H]2C[C@]3(CCCN3C(=O)Cc3ccc(NC(=O)COc4ccc(Cl)cc4Cl)cc3)C(=O)N12	Preclinical
ST-91	adrenergic receptor agonist				Tocris, Tocris, Tocris, Tocris	96.08	CCc1cccc(CC)c1NC1=NCCN1 |t:12|, CCc1cccc(CC)c1NC1=NCCN1 |t:12|, CCc1cccc(CC)c1NC1=NCCN1 |t:12|, CCc1cccc(CC)c1NC1=NCCN1 |t:12|	Preclinical
STA-5326	interleukin synthesis inhibitor	IL12A			MedChemEx, MedChemEx, MedChemEx, MedChemEx, ApexBio, ApexBio, ApexBio	99.19	Cc1cccc(\C=N\Nc2cc(nc(OCCc3ccccn3)n2)N2CCOCC2)c1, Cc1cccc(\C=N\Nc2cc(nc(OCCc3ccccn3)n2)N2CCOCC2)c1, Cc1cccc(\C=N\Nc2cc(nc(OCCc3ccccn3)n2)N2CCOCC2)c1, Cc1cccc(\C=N\Nc2cc(nc(OCCc3ccccn3)n2)N2CCOCC2)c1, Cc1cccc(\C=N\Nc2cc(nc(OCCc3ccccn3)n2)N2CCOCC2)c1, Cc1cccc(\C=N\Nc2cc(nc(OCCc3ccccn3)n2)N2CCOCC2)c1, Cc1cccc(\C=N\Nc2cc(nc(OCCc3ccccn3)n2)N2CCOCC2)c1	Phase 2
statil	aldose reductase inhibitor				CombiBlocks	95.19	OC(=O)Cc1nn(Cc2ccc(Br)cc2F)c(=O)c2ccccc12	Preclinical
stattic					Selleck	95.9	[O-][N+](=O)c1ccc2C=CS(=O)(=O)c2c1 |c:7|	Preclinical
STAT3-inhibitor-VI	STAT inhibitor	STAT3			MedChemEx, MedChemEx, Tocris, Selleck, Selleck, MedChemEx	96.39	Cc1ccc(cc1)S(=O)(=O)OCC(=O)Nc1ccc(C(O)=O)c(O)c1, Cc1ccc(cc1)S(=O)(=O)OCC(=O)Nc1ccc(C(O)=O)c(O)c1, Cc1ccc(cc1)S(=O)(=O)OCC(=O)Nc1ccc(C(O)=O)c(O)c1, Cc1ccc(cc1)S(=O)(=O)OCC(=O)Nc1ccc(C(O)=O)c(O)c1, Cc1ccc(cc1)S(=O)(=O)OCC(=O)Nc1ccc(C(O)=O)c(O)c1, Cc1ccc(cc1)S(=O)(=O)OCC(=O)Nc1ccc(C(O)=O)c(O)c1	Preclinical
stavudine	DNA directed DNA polymerase inhibitor, nucleoside reverse transcriptase inhibitor		infectious disease	human immunodeficiency virus (HIV-1)	Tocris, Tocris, MicroSource, MicroSource, MicroSource, Selleck	98.62	Cc1cn([C@@H]2O[C@H](CO)C=C2)c(=O)[nH]c1=O |c:9|, Cc1cn([C@@H]2O[C@H](CO)C=C2)c(=O)[nH]c1=O |c:9|, Cc1cn([C@@H]2O[C@H](CO)C=C2)c(=O)[nH]c1=O |c:9|, Cc1cn([C@@H]2O[C@H](CO)C=C2)c(=O)[nH]c1=O |c:9|, Cc1cn([C@@H]2O[C@H](CO)C=C2)c(=O)[nH]c1=O |c:9|, Cc1cn([C@@H]2O[C@H](CO)C=C2)c(=O)[nH]c1=O |c:9|	Launched
stemregenin-1	aryl hydrocarbon receptor antagonist	AHR			Selleck, Selleck, Selleck	95.36	CC(C)n1cnc2c(NCCc3ccc(O)cc3)nc(nc12)-c1csc2ccccc12, CC(C)n1cnc2c(NCCc3ccc(O)cc3)nc(nc12)-c1csc2ccccc12, CC(C)n1cnc2c(NCCc3ccc(O)cc3)nc(nc12)-c1csc2ccccc12	Preclinical
stepronin	mucolytic agent				AKSci	98.87	C[C@@H](SC(=O)c1cccs1)C(=O)NCC(O)=O |&1:1,r|	Launched
stetaderm					Sigma, Sigma	96.74	CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@H](O)C[C@]12C |t:10|, CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@H](O)C[C@]12C |t:10|	Launched
STF-083010	serine/threonine kinase inhibitor	ERN1			MedChemEx, MedChemEx	1.02	Oc1ccc2ccccc2c1\C=N\S(=O)(=O)c1cccs1, Oc1ccc2ccccc2c1\C=N\S(=O)(=O)c1cccs1	Preclinical
STF-118804	NAMPT inhibitor	NAMPT			Tocris, Tocris, Tocris, Tocris, Selleck, Selleck	96.03	Cc1oc(nc1CS(=O)(=O)c1ccc(C)cc1)-c1ccc(cc1)C(=O)NCc1cccnc1, Cc1oc(nc1CS(=O)(=O)c1ccc(C)cc1)-c1ccc(cc1)C(=O)NCc1cccnc1, Cc1oc(nc1CS(=O)(=O)c1ccc(C)cc1)-c1ccc(cc1)C(=O)NCc1cccnc1, Cc1oc(nc1CS(=O)(=O)c1ccc(C)cc1)-c1ccc(cc1)C(=O)NCc1cccnc1, Cc1oc(nc1CS(=O)(=O)c1ccc(C)cc1)-c1ccc(cc1)C(=O)NCc1cccnc1, Cc1oc(nc1CS(=O)(=O)c1ccc(C)cc1)-c1ccc(cc1)C(=O)NCc1cccnc1	Preclinical
STF-31	NAMPT inhibitor	NAMPT, SLC2A1			Tocris, Tocris, Broad Institute, Broad Institute, Broad Institute, Broad Institute, Broad Institute, Broad Institute, Broad Institute, Broad Institute, Broad Institute, Broad Institute	100	CC(C)(C)c1ccc(cc1)S(=O)(=O)NCc1ccc(cc1)C(=O)Nc1cccnc1, CC(C)(C)c1ccc(cc1)S(=O)(=O)NCc1ccc(cc1)C(=O)Nc1cccnc1, CC(C)(C)c1ccc(cc1)S(=O)(=O)NCc1ccc(cc1)C(=O)Nc1cccnc1, CC(C)(C)c1ccc(cc1)S(=O)(=O)NCc1ccc(cc1)C(=O)Nc1cccnc1, CC(C)(C)c1ccc(cc1)S(=O)(=O)NCc1ccc(cc1)C(=O)Nc1cccnc1, CC(C)(C)c1ccc(cc1)S(=O)(=O)NCc1ccc(cc1)C(=O)Nc1cccnc1, CC(C)(C)c1ccc(cc1)S(=O)(=O)NCc1ccc(cc1)C(=O)Nc1cccnc1, CC(C)(C)c1ccc(cc1)S(=O)(=O)NCc1ccc(cc1)C(=O)Nc1cccnc1, CC(C)(C)c1ccc(cc1)S(=O)(=O)NCc1ccc(cc1)C(=O)Nc1cccnc1, CC(C)(C)c1ccc(cc1)S(=O)(=O)NCc1ccc(cc1)C(=O)Nc1cccnc1, CC(C)(C)c1ccc(cc1)S(=O)(=O)NCc1ccc(cc1)C(=O)Nc1cccnc1, CC(C)(C)c1ccc(cc1)S(=O)(=O)NCc1ccc(cc1)C(=O)Nc1cccnc1	Preclinical
STF-62247	autophagy inducer				Selleck, Selleck	89.5	Cc1cccc(Nc2nc(cs2)-c2ccncc2)c1, Cc1cccc(Nc2nc(cs2)-c2ccncc2)c1	Preclinical
stigmasterol					Selleck, Selleck	0	CC[C@H](\C=C\[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C |t:13|, CC[C@H](\C=C\[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C |t:13|	Preclinical
stiripentol	GABA uptake inhibitor	GABRA3	neurology/psychiatry	epilepsy	Sigma, Sigma	0	CC(C)(C)[C@@H](O)\C=C\c1ccc2OCOc2c1 |&1:4,r|, CC(C)(C)[C@@H](O)\C=C\c1ccc2OCOc2c1 |&1:4,r|	Launched
stobadine	adrenergic receptor antagonist	ADRA1A			Enamine	67.37	CN1CC[C@H]2Nc3ccc(C)cc3[C@H]2C1	Phase 2
streptomycin	bacterial 30S ribosomal subunit inhibitor		infectious disease	tuberculosis	Selleck, Selleck, MedChemEx	94.3	CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](NC(N)=N)[C@@H](O)[C@@H]2NC(N)=N)O[C@@H](C)[C@]1(O)C=O, CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](NC(N)=N)[C@@H](O)[C@@H]2NC(N)=N)O[C@@H](C)[C@]1(O)C=O, CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](NC(N)=N)[C@@H](O)[C@@H]2NC(N)=N)O[C@@H](C)[C@]1(O)C=O	Launched
streptozotocin	DNA alkylating agent		oncology	pancreatic cancer	Sigma, MedChemEx, Selleck, MicroSource, Selleck, Tocris	83.34	CN([NH2+][O-])C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O, CN([NH2+][O-])C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O, CN([NH2+][O-])C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O, CN([NH2+][O-])C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O, CN([NH2+][O-])C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O, CN([NH2+][O-])C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O	Launched
strontium-ranelate	bone formation stimulant, bone resorption inhibitor	CASR	orthopedics, rheumatology	osteoporosis, osteoarthritis	LKT, MedChemEx, Selleck, Selleck	0	OC1=CN(C=C(O)O[Sr]O1)c1sc2c(CC(=O)O[Sr]OC2=O)c1C#N, OC1=CN(C=C(O)O[Sr]O1)c1sc2c(CC(=O)O[Sr]OC2=O)c1C#N, OC1=CN(C=C(O)O[Sr]O1)c1sc2c(CC(=O)O[Sr]OC2=O)c1C#N, OC1=CN(C=C(O)O[Sr]O1)c1sc2c(CC(=O)O[Sr]OC2=O)c1C#N	Launched
strychnine	acetylcholine receptor antagonist	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, CHRNA10, CHRNA9, GLRA1, GLRA2, GLRA3, GLRB			Sigma	92.76	O=C1C[C@@H]2OCC=C3CN4CC[C@@]56[C@@H]4C[C@@H]3[C@@H]2[C@@H]5N1c1ccccc61 |t:6|	Preclinical
substance-P	neurokinin receptor antagonist	TACR1, TACR2, TACR3			Tocris, Tocris, Tocris, Tocris	92.33	CSCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CCCNC(N)=N)C(N)=O, CSCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CCCNC(N)=N)C(N)=O, CSCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CCCNC(N)=N)C(N)=O, CSCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CCCNC(N)=N)C(N)=O	Phase 1
succinic-acid		ALDH5A1, ASPH, BBOX1, HSD17B6, OXCT1, OXCT2, P3H1, P3H2, P3H3, P4HA1, P4HA2, PLOD1, PLOD3, SDHA, SDHB, SDHC, SDHD, SLC13A1, SLC13A2, SLC13A3, SLC25A10, SUCLA2, SUCLG1, SUCLG2, SUCNR1, TMLHE			Enamine	100	OC(=O)CCC(O)=O	Launched
succinobucol	antioxidant	VCAM1			MedChemEx	99.04	CC(C)(C)c1cc(SC(C)(C)Sc2cc(c(OC(=O)CCC(O)=O)c(c2)C(C)(C)C)C(C)(C)C)cc(c1O)C(C)(C)C	Phase 2/Phase 3
succinylcholine-chloride		CHRFAM7A, CHRM1, CHRM2, CHRM3, CHRNA1, CHRNA10	neurology/psychiatry	muscle relaxant	Sigma, DuPont, Selleck, Selleck	66.78	C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C, C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C, C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C, C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C	Launched
succinylsulfathiazole	dihydrofolate reductase inhibitor	DHFR			MedChemEx, MicroSource	96.18	OC(=O)CCC(=O)Nc1ccc(cc1)S(=O)(=O)Nc1nccs1, OC(=O)CCC(=O)Nc1ccc(cc1)S(=O)(=O)Nc1nccs1	Phase 2
sucralfate	antacid		gastroenterology	duodenal ulcer disease	MicroSource, Selleck	0	O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)OS(=O)(=O)OC[C@H]1O[C@@](COS(=O)(=O)O[Al](O)O)(O[C@H]2O[C@H](COS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@H]2OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@@H]1OS(=O)(=O)O[Al](O)O, O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)OS(=O)(=O)OC[C@H]1O[C@@](COS(=O)(=O)O[Al](O)O)(O[C@H]2O[C@H](COS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@H]2OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@@H]1OS(=O)(=O)O[Al](O)O	Launched
sucralose					MedChemEx, MicroSource, Selleck, Selleck, Selleck	100	OC[C@H]1O[C@H](O[C@]2(CCl)O[C@H](CCl)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@H]1Cl, OC[C@H]1O[C@H](O[C@]2(CCl)O[C@H](CCl)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@H]1Cl, OC[C@H]1O[C@H](O[C@]2(CCl)O[C@H](CCl)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@H]1Cl, OC[C@H]1O[C@H](O[C@]2(CCl)O[C@H](CCl)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@H]1Cl, OC[C@H]1O[C@H](O[C@]2(CCl)O[C@H](CCl)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@H]1Cl	Launched
sucrose		ACTA1, ATOX1, C22orf28, LYZ			Sigma	99.8	OC[C@H]1O[C@@](CO)(O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@@H]1O	Launched
sucrose-octaacetate					Acros	100	CC(=O)OC[C@H]1O[C@@](COC(C)=O)(O[C@H]2O[C@H](COC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]2OC(C)=O)[C@@H](OC(C)=O)[C@@H]1OC(C)=O	Preclinical
sudan-IV					Sigma	62.07	Cc1ccccc1\N=N\c1ccc(\N=N\c2c(O)ccc3ccccc23)c(C)c1	Preclinical
sufugolix	gonadotropin releasing factor hormone receptor antagonist				MedChemEx	93.8	CONC(=O)Nc1ccc(cc1)-c1sc2n(Cc3c(F)cccc3F)c(=O)n(-c3ccccc3)c(=O)c2c1CN(C)Cc1ccccc1	Preclinical
sugammadex	neuromuscular blockade reversal agent				MedChemEx	0	O[C@H]1[C@H](O)[C@H]2O[C@@H]3O[C@@H](CSCCC(O)=O)[C@H](O[C@@H]4O[C@@H](CSCCC(O)=O)[C@H](O[C@@H]5O[C@@H](CSCCC(O)=O)[C@H](O[C@@H]6O[C@@H](CSCCC(O)=O)[C@H](O[C@@H]7O[C@@H](CSCCC(O)=O)[C@H](O[C@@H]8O[C@@H](CSCCC(O)=O)[C@H](O[C@@H]9O[C@@H](CSCCC(O)=O)[C@H](O[C@@H]1O[C@H]2CSCCC(O)=O)[C@@H](O)[C@@H]9O)[C@@H](O)[C@@H]8O)[C@@H](O)[C@@H]7O)[C@@H](O)[C@@H]6O)[C@@H](O)[C@@H]5O)[C@@H](O)[C@@H]4O)[C@@H](O)[C@@H]3O	Launched
sulbactam	beta lactamase inhibitor		infectious disease	skin infections, intra-abdominal infections, gynecologic infections	MedChemEx, MedChemEx, Selleck, Selleck, Selleck, Selleck, Selleck	100	CC1(C)[C@@H](N2[C@@H](CC2=O)S1(=O)=O)C(O)=O, CC1(C)[C@@H](N2[C@@H](CC2=O)S1(=O)=O)C(O)=O, CC1(C)[C@@H](N2[C@@H](CC2=O)S1(=O)=O)C(O)=O, CC1(C)[C@@H](N2[C@@H](CC2=O)S1(=O)=O)C(O)=O, CC1(C)[C@@H](N2[C@@H](CC2=O)S1(=O)=O)C(O)=O, CC1(C)[C@@H](N2[C@@H](CC2=O)S1(=O)=O)C(O)=O, CC1(C)[C@@H](N2[C@@H](CC2=O)S1(=O)=O)C(O)=O	Launched
sulbactam-pivoxil	beta lactamase inhibitor		infectious disease	skin infections	AvaChem	85.23	CC(C)(C)C(=O)OCOC(=O)[C@H]1N2[C@@H](CC2=O)S(=O)(=O)C1(C)C |&1:11,&2:13,r|	Launched
sulbentine	other antifungal				MedChemEx, MicroSource	94.5	S=C1SCN(Cc2ccccc2)CN1Cc1ccccc1, S=C1SCN(Cc2ccccc2)CN1Cc1ccccc1	Preclinical
sulbutiamine	acetylcholine receptor antagonist		neurology/psychiatry	asthenia	AKSci	97.93	CC(C)C(=O)OCC\C(SS\C(CCOC(=O)C(C)C)=C(/C)N(Cc1cnc(C)nc1N)C=O)=C(\C)N(Cc1cnc(C)nc1N)C=O	Launched
sulconazole	sterol demethylase inhibitor		infectious disease	tinea pedis, tinea cruris, tinea corporis	MicroSource, MicroSource, MicroSource, MicroSource, MicroSource, MedChemEx, Selleck	99.7	Clc1ccc(CS[C@@H](Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1 |&1:7|, Clc1ccc(CS[C@@H](Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1 |&1:7|, Clc1ccc(CS[C@@H](Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1 |&1:7|, Clc1ccc(CS[C@@H](Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1 |&1:7|, Clc1ccc(CS[C@@H](Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1 |&1:7|, Clc1ccc(CS[C@@H](Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1 |&1:7|, Clc1ccc(CS[C@@H](Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1 |&1:7|	Launched
sulfabenzamide	bacterial antifolate		infectious disease	gram-negative bacterial infections, gram-positive bacterial infections	MicroSource, MicroSource, MicroSource	98.4	Nc1ccc(cc1)S(=O)(=O)NC(=O)c1ccccc1, Nc1ccc(cc1)S(=O)(=O)NC(=O)c1ccccc1, Nc1ccc(cc1)S(=O)(=O)NC(=O)c1ccccc1	Launched
sulfacarbamide					MedChemEx, MicroSource	100	NC(=O)NS(=O)(=O)c1ccc(N)cc1, NC(=O)NS(=O)(=O)c1ccc(N)cc1	Withdrawn
sulfacetamide	PABA antagonist		ophthalmology	conjunctivitis	Selleck, MicroSource, Selleck	97.83	CC(=O)NS(=O)(=O)c1ccc(N)cc1, CC(=O)NS(=O)(=O)c1ccc(N)cc1, CC(=O)NS(=O)(=O)c1ccc(N)cc1	Launched
sulfachlorpyridazine	bacterial antifolate		infectious disease	urinary tract infections	MedChemEx, MicroSource	98.26	Nc1ccc(cc1)S(=O)(=O)Nc1ccc(Cl)nn1, Nc1ccc(cc1)S(=O)(=O)Nc1ccc(Cl)nn1	Launched
sulfadiazine	bacterial antifolate		infectious disease, ophthalmology	malaria, meningitis, urinary tract infections, conjunctivitis, trachoma, chancroid	MedChemEx, Enamine, Selleck, MicroSource	99.24	Nc1ccc(cc1)S(=O)(=O)Nc1ncccn1, Nc1ccc(cc1)S(=O)(=O)Nc1ncccn1, Nc1ccc(cc1)S(=O)(=O)Nc1ncccn1, Nc1ccc(cc1)S(=O)(=O)Nc1ncccn1	Launched
sulfadoxine	dihydropteroate synthase inhibitor		infectious disease	malaria	MedChemEx, MicroSource, MicroSource, Selleck	96.8	COc1ncnc(NS(=O)(=O)c2ccc(N)cc2)c1OC, COc1ncnc(NS(=O)(=O)c2ccc(N)cc2)c1OC, COc1ncnc(NS(=O)(=O)c2ccc(N)cc2)c1OC, COc1ncnc(NS(=O)(=O)c2ccc(N)cc2)c1OC	Launched
sulfafurazole	bacterial antifolate		infectious disease	urinary tract infections	Tocris, Tocris, Tocris, MicroSource, Selleck, Selleck	97.76	Cc1noc(NS(=O)(=O)c2ccc(N)cc2)c1C, Cc1noc(NS(=O)(=O)c2ccc(N)cc2)c1C, Cc1noc(NS(=O)(=O)c2ccc(N)cc2)c1C, Cc1noc(NS(=O)(=O)c2ccc(N)cc2)c1C, Cc1noc(NS(=O)(=O)c2ccc(N)cc2)c1C, Cc1noc(NS(=O)(=O)c2ccc(N)cc2)c1C	Launched
sulfaguanidine	bacterial antifolate		infectious disease	urinary tract infections	MedChemEx, MicroSource, Selleck, Selleck	100	NC(=N)NS(=O)(=O)c1ccc(N)cc1, NC(=N)NS(=O)(=O)c1ccc(N)cc1, NC(=N)NS(=O)(=O)c1ccc(N)cc1, NC(=N)NS(=O)(=O)c1ccc(N)cc1	Launched
sulfamerazine	bacterial antifolate		infectious disease	coccidiosis, cholera	MedChemEx, MicroSource, Selleck, Selleck	98.63	Cc1ccnc(NS(=O)(=O)c2ccc(N)cc2)n1, Cc1ccnc(NS(=O)(=O)c2ccc(N)cc2)n1, Cc1ccnc(NS(=O)(=O)c2ccc(N)cc2)n1, Cc1ccnc(NS(=O)(=O)c2ccc(N)cc2)n1	Launched
sulfameter	dihydrofolate reductase inhibitor	DHFR	infectious disease	urinary tract infections	MedChemEx, Selleck, MicroSource	99.1	COc1cnc(NS(=O)(=O)c2ccc(N)cc2)nc1, COc1cnc(NS(=O)(=O)c2ccc(N)cc2)nc1, COc1cnc(NS(=O)(=O)c2ccc(N)cc2)nc1	Launched
sulfamethazine	PABA antagonist		gastroenterology	enteritis	MedChemEx, Prestwick, MicroSource, Selleck	99.35	Cc1cc(C)nc(NS(=O)(=O)c2ccc(N)cc2)n1, Cc1cc(C)nc(NS(=O)(=O)c2ccc(N)cc2)n1, Cc1cc(C)nc(NS(=O)(=O)c2ccc(N)cc2)n1, Cc1cc(C)nc(NS(=O)(=O)c2ccc(N)cc2)n1	Launched
sulfamethizole	bacterial antifolate		infectious disease	urinary tract infections	MedChemEx, MicroSource, Selleck	97.3	Cc1nnc(NS(=O)(=O)c2ccc(N)cc2)s1, Cc1nnc(NS(=O)(=O)c2ccc(N)cc2)s1, Cc1nnc(NS(=O)(=O)c2ccc(N)cc2)s1	Launched
sulfamethoxazole	PABA antagonist		infectious disease, gastroenterology	pneumonia, enteritis, urinary tract infections	MedChemEx, MicroSource, Selleck	98.94	Cc1cc(NS(=O)(=O)c2ccc(N)cc2)no1, Cc1cc(NS(=O)(=O)c2ccc(N)cc2)no1, Cc1cc(NS(=O)(=O)c2ccc(N)cc2)no1	Launched
sulfamethoxypyridazine	bacterial antifolate				MedChemEx, MicroSource, Selleck	98.28	COc1ccc(NS(=O)(=O)c2ccc(N)cc2)nn1, COc1ccc(NS(=O)(=O)c2ccc(N)cc2)nn1, COc1ccc(NS(=O)(=O)c2ccc(N)cc2)nn1	Withdrawn
sulfametopyrazine	PABA antagonist		infectious disease	malaria, urinary tract infections, respiratory tract infections	MedChemEx, Enamine, Enamine, Enamine, Enamine	98.18	COc1nccnc1NS(=O)(=O)c1ccc(N)cc1, COc1nccnc1NS(=O)(=O)c1ccc(N)cc1, COc1nccnc1NS(=O)(=O)c1ccc(N)cc1, COc1nccnc1NS(=O)(=O)c1ccc(N)cc1, COc1nccnc1NS(=O)(=O)c1ccc(N)cc1	Launched
sulfamonomethoxine	bacterial antifolate		infectious disease	urinary tract infections	MedChemEx, MicroSource	97.68	COc1cc(NS(=O)(=O)c2ccc(N)cc2)ncn1, COc1cc(NS(=O)(=O)c2ccc(N)cc2)ncn1	Launched
sulfamoxole	PABA antagonist		infectious disease	urinary tract infections	Sigma, Sigma, SantaCruz	70.9	Cc1nc(NS(=O)(=O)c2ccc(N)cc2)oc1C, Cc1nc(NS(=O)(=O)c2ccc(N)cc2)oc1C, Cc1nc(NS(=O)(=O)c2ccc(N)cc2)oc1C	Launched
sulfanilamide	carbonic anhydrase inhibitor	CYP2C19, CYP2C9, CYP2D6, CYP2E1, CYP3A4	infectious disease	vulvovaginal candidiasis	MicroSource, Selleck	100	Nc1ccc(cc1)S(N)(=O)=O, Nc1ccc(cc1)S(N)(=O)=O	Launched
sulfanilate-zinc					MicroSource	0	Nc1ccc(cc1)S(=O)(=O)O[Zn]OS(=O)(=O)c1ccc(N)cc1	Preclinical
sulfanitran			infectious disease	coccidiosis	MicroSource, MedChemEx	93.2	CC(=O)Nc1ccc(cc1)S(=O)(=O)Nc1ccc(cc1)[N+]([O-])=O, CC(=O)Nc1ccc(cc1)S(=O)(=O)Nc1ccc(cc1)[N+]([O-])=O	Launched
sulfaphenazole	dihydropteroate synthetase inhibitor	DHPS	infectious disease	urinary tract infections	MedChemEx, MicroSource, MicroSource	95.81	Nc1ccc(cc1)S(=O)(=O)Nc1ccnn1-c1ccccc1, Nc1ccc(cc1)S(=O)(=O)Nc1ccnn1-c1ccccc1, Nc1ccc(cc1)S(=O)(=O)Nc1ccnn1-c1ccccc1	Launched
sulfapyridine	PABA antagonist		infectious disease	gram-negative bacterial infections, gram-positive bacterial infections	MedChemEx, Selleck, MicroSource, MicroSource, MicroSource, MicroSource	98.64	Nc1ccc(cc1)S(=O)(=O)Nc1ccccn1, Nc1ccc(cc1)S(=O)(=O)Nc1ccccn1, Nc1ccc(cc1)S(=O)(=O)Nc1ccccn1, Nc1ccc(cc1)S(=O)(=O)Nc1ccccn1, Nc1ccc(cc1)S(=O)(=O)Nc1ccccn1, Nc1ccc(cc1)S(=O)(=O)Nc1ccccn1	Launched
sulfaquinoxaline	vitamin K antagonist		infectious disease	coccidiosis	MicroSource, MicroSource	92.12	Nc1ccc(cc1)S(=O)(=O)Nc1cnc2ccccc2n1, Nc1ccc(cc1)S(=O)(=O)Nc1cnc2ccccc2n1	Launched
sulfasalazine	cyclooxygenase inhibitor	ACAT1, ALOX5, CHUK, IKBKB, PLA2G1B, PPARG, PTGS1, PTGS2, SLC46A1, SLC7A11, TBXAS1	gastroenterology	ulcerative colitis	Tocris, MicroSource, Selleck, Selleck	97.78	OC(=O)c1cc(ccc1O)\N=N\c1ccc(cc1)S(=O)(=O)Nc1ccccn1, OC(=O)c1cc(ccc1O)\N=N\c1ccc(cc1)S(=O)(=O)Nc1ccccn1, OC(=O)c1cc(ccc1O)\N=N\c1ccc(cc1)S(=O)(=O)Nc1ccccn1, OC(=O)c1cc(ccc1O)\N=N\c1ccc(cc1)S(=O)(=O)Nc1ccccn1	Launched
sulfathiazole	dihydropteroate synthase inhibitor		infectious disease	gram-negative bacterial infections, gram-positive bacterial infections	MedChemEx, MicroSource, Selleck	98.28	Nc1ccc(cc1)S(=O)(=O)Nc1nccs1, Nc1ccc(cc1)S(=O)(=O)Nc1nccs1, Nc1ccc(cc1)S(=O)(=O)Nc1nccs1	Launched
sulfatinib	tyrosine kinase inhibitor				MedChemEx	95.61	CN(C)CCNS(=O)(=O)Cc1cccc(Nc2nccc(Oc3ccc4[nH]c(C)cc4c3)n2)c1	Phase 1
sulfinpyrazone	uricosuric blocker	ABCC1, FPR1, SLC22A12	rheumatology	gout	Sigma	96.76	O=C1C(CC[S@](=O)c2ccccc2)C(=O)N(N1c1ccccc1)c1ccccc1 |&1:5,r|	Launched
sulfisomidin	antibacterial				MedChemEx	89.68	Cc1cc(NS(=O)(=O)c2ccc(N)cc2)nc(C)n1	Preclinical
sulfisoxazole-acetyl	folic acid antagonist		infectious disease, otolaryngology	meningitis, urinary tract infections, otitis, trachoma	MicroSource	56.69	CC(=O)N(c1onc(C)c1C)S(=O)(=O)c1ccc(N)cc1	Launched
sulforaphane	anticancer agent, aryl hydrocarbon receptor antagonist	NFE2L2			EMDBio, EMDBio, EMDBio	95.09	C[S@@](=O)CCCCN=C=S |r|, C[S@@](=O)CCCCN=C=S |r|, C[S@@](=O)CCCCN=C=S |r|	Phase 2
sulindac	cyclooxygenase inhibitor	AKR1B1	rheumatology	osteoarthritis, rheumatoid arthritis, ankylosing spondylitis	MedChemEx, Tocris, Selleck, Selleck, MicroSource	96.44	CC1=C(CC(O)=O)c2cc(F)ccc2\C1=C/c1ccc(cc1)[S@@](C)=O |r,c:1|, CC1=C(CC(O)=O)c2cc(F)ccc2\C1=C/c1ccc(cc1)[S@@](C)=O |r,c:1|, CC1=C(CC(O)=O)c2cc(F)ccc2\C1=C/c1ccc(cc1)[S@@](C)=O |r,c:1|, CC1=C(CC(O)=O)c2cc(F)ccc2\C1=C/c1ccc(cc1)[S@@](C)=O |r,c:1|, CC1=C(CC(O)=O)c2cc(F)ccc2\C1=C/c1ccc(cc1)[S@@](C)=O |r,c:1|	Launched
sulisobenzone			dermatology	sunscreen lotion	MicroSource, MicroSource, ChemBridge	98.83	COc1cc(O)c(cc1S(O)(=O)=O)C(=O)c1ccccc1, COc1cc(O)c(cc1S(O)(=O)=O)C(=O)c1ccccc1, COc1cc(O)c(cc1S(O)(=O)=O)C(=O)c1ccccc1	Launched
sulmazole	adenosine receptor antagonist				SantaCruz, Prestwick, Prestwick	98.4	COc1cc(ccc1-c1nc2ncccc2[nH]1)[S@@](C)=O |r|, COc1cc(ccc1-c1nc2ncccc2[nH]1)[S@@](C)=O |r|, COc1cc(ccc1-c1nc2ncccc2[nH]1)[S@@](C)=O |r|	Phase 1
sulmetozine	gastrin inhibitor	GAST	gastroenterology	peptic ulcer disease (PUD)	Vitas-M, Vitas-M	97.21	COc1cc(cc(OC)c1OC)C(=S)N1CCOCC1, COc1cc(cc(OC)c1OC)C(=S)N1CCOCC1	Launched
suloctidil	adrenergic receptor antagonist				MedChemEx	79.62	CCCCCCCCN[C@H](C)[C@@H](O)c1ccc(SC(C)C)cc1 |&1:9,11|	Withdrawn
sulopenem	antibacterial				Sigma	87.61	C[C@@H](O)[C@@H]1[C@H]2SC(S[C@H]3CC[S@@](=O)C3)=C(N2C1=O)C(O)=O |&1:11,c:14|	Phase 3
sulphadimethoxine	dihydropteroate synthetase inhibitor		infectious disease	gram-negative bacterial infections, gram-positive bacterial infections	MedChemEx, MedChemEx, Selleck, MicroSource	99.08	COc1cc(NS(=O)(=O)c2ccc(N)cc2)nc(OC)n1, COc1cc(NS(=O)(=O)c2ccc(N)cc2)nc(OC)n1, COc1cc(NS(=O)(=O)c2ccc(N)cc2)nc(OC)n1, COc1cc(NS(=O)(=O)c2ccc(N)cc2)nc(OC)n1	Launched
sulpiride	dopamine receptor antagonist		neurology/psychiatry	schizophrenia	Tocris, Tocris, MicroSource, Tocris, Tocris	98.91	CCN1CCC[C@@H]1CNC(=O)c1cc(ccc1OC)S(N)(=O)=O |&1:6,r|, CCN1CCC[C@@H]1CNC(=O)c1cc(ccc1OC)S(N)(=O)=O |&1:6,r|, CCN1CCC[C@@H]1CNC(=O)c1cc(ccc1OC)S(N)(=O)=O |&1:6,r|, CCN1CCC[C@@H]1CNC(=O)c1cc(ccc1OC)S(N)(=O)=O |&1:6,r|, CCN1CCC[C@@H]1CNC(=O)c1cc(ccc1OC)S(N)(=O)=O |&1:6,r|	Launched
sultamicillin	antibacterial 		infectious disease	gram-negative bacterial infections, gram-positive bacterial infections	Bosche	81.3	CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccccc3)C(=O)N2[C@H]1C(=O)OCOC(=O)[C@@H]1N2[C@@H](CC2=O)S(=O)(=O)C1(C)C	Launched
sultiame	carbonic anhydrase inhibitor	CA2			MedChemEx	92.35	NS(=O)(=O)c1ccc(cc1)N1CCCCS1(=O)=O	Phase 3
sultopride	dopamine receptor antagonist				MedChemEx	89.99	CCN1CCC[C@H]1CNC(=O)c1cc(ccc1OC)S(=O)(=O)CC |&1:6,r|	Preclinical
sumanirole	dopamine receptor agonist	DRD2			Sigma	82.4	CN[C@@H]1Cc2cccc3[nH]c(=O)n(C1)c23	Phase 3
sumatriptan	serotonin receptor agonist	HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR5A, HTR6, HTR7	neurology/psychiatry	migraine headache	MicroSource, Tocris, Selleck, Tocris	95.83	CNS(=O)(=O)Cc1ccc2[nH]cc(CCN(C)C)c2c1, CNS(=O)(=O)Cc1ccc2[nH]cc(CCN(C)C)c2c1, CNS(=O)(=O)Cc1ccc2[nH]cc(CCN(C)C)c2c1, CNS(=O)(=O)Cc1ccc2[nH]cc(CCN(C)C)c2c1	Launched
SUN-B-8155	calcitonin agonist	CALCR			Tocris, Tocris, Tocris	70.44	C\C(=N/c1ccccc1N)c1c(C)cc(=O)n(O)c1O, C\C(=N/c1ccccc1N)c1c(C)cc(=O)n(O)c1O, C\C(=N/c1ccccc1N)c1c(C)cc(=O)n(O)c1O	Preclinical
SUN-11602	fibroblast growth factor mimetic	FGFR1			Tocris, Tocris, Tocris	90.13	CN(C1CCN(Cc2ccc(cc2)C(N)=O)CC1)C(=O)CNc1c(C)c(C)c(N)c(C)c1C, CN(C1CCN(Cc2ccc(cc2)C(N)=O)CC1)C(=O)CNc1c(C)c(C)c(N)c(C)c1C, CN(C1CCN(Cc2ccc(cc2)C(N)=O)CC1)C(=O)CNc1c(C)c(C)c(N)c(C)c1C	Preclinical
sunitinib	FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor	CSF1R, FGFR1, FLT1, FLT3, FLT4, KDR, KIT, PDGFRA, PDGFRB, RET	oncology	gastrointestinal stromal tumors (GIST), renal cell carcinoma (RCC), neuroendocrine tumors of pancreatic origin (PNET)	MedChemEx, MedChemEx, MedChemEx, MedChemEx, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Tocris	94.01	CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C	Launched
suplatast	histamine release inhibitor, immunoglobulin inhibitor		rheumatology	Kimura's disease	MedChemEx, Tocris, Selleck, MedChemEx, Selleck	36.74	CCOC[C@@H](O)COc1ccc(NC(=O)CC[S+](C)C)cc1 |&1:4|, CCOC[C@@H](O)COc1ccc(NC(=O)CC[S+](C)C)cc1 |&1:4|, CCOC[C@@H](O)COc1ccc(NC(=O)CC[S+](C)C)cc1 |&1:4|, CCOC[C@@H](O)COc1ccc(NC(=O)CC[S+](C)C)cc1 |&1:4|, CCOC[C@@H](O)COc1ccc(NC(=O)CC[S+](C)C)cc1 |&1:4|	Launched
suprofen	cyclooxygenase inhibitor	PTGS1, PTGS2			MicroSource, Selleck, MedChemEx	97.91	C[C@@H](C(O)=O)c1ccc(cc1)C(=O)c1cccs1 |&1:1,r|, C[C@@H](C(O)=O)c1ccc(cc1)C(=O)c1cccs1 |&1:1,r|, C[C@@H](C(O)=O)c1ccc(cc1)C(=O)c1cccs1 |&1:1,r|	Withdrawn
suramin	DNA synthesis inhibitor	F2, FSHR, P2RY1, P2RY11, P2RY13, P2RY2, PLA2G2A, RYR1, RYR2, SIRT5	infectious disease	African trypanosomiasis, onchocerciasis	MicroSource, Tocris	96.4	Cc1ccc(cc1NC(=O)c1cccc(NC(=O)Nc2cccc(c2)C(=O)Nc2cc(ccc2C)C(=O)Nc2ccc(c3cc(cc(c23)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O)c1)C(=O)Nc1ccc(c2cc(cc(c12)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O, Cc1ccc(cc1NC(=O)c1cccc(NC(=O)Nc2cccc(c2)C(=O)Nc2cc(ccc2C)C(=O)Nc2ccc(c3cc(cc(c23)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O)c1)C(=O)Nc1ccc(c2cc(cc(c12)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O	Launched
suritozole	GABA receptor inverse agonist	GABBR1			Enamine, Enamine	94.9	Cn1nc(-c2cccc(F)c2)n(C)c1=S, Cn1nc(-c2cccc(F)c2)n(C)c1=S	Phase 2
sutezolid	protein synthesis inhibitor				MedChemEx	91.81	CC(=O)NC[C@H]1CN(C(=O)O1)c1ccc(N2CCSCC2)c(F)c1	Phase 2
suxibuzone	cyclooxygenase inhibitor		rheumatology, neurology/psychiatry	joint pain, muscle pain	MedChemEx, Selleck, Selleck, MicroSource	97.83	CCCCC1(COC(=O)CCC(O)=O)C(=O)N(N(C1=O)c1ccccc1)c1ccccc1, CCCCC1(COC(=O)CCC(O)=O)C(=O)N(N(C1=O)c1ccccc1)c1ccccc1, CCCCC1(COC(=O)CCC(O)=O)C(=O)N(N(C1=O)c1ccccc1)c1ccccc1, CCCCC1(COC(=O)CCC(O)=O)C(=O)N(N(C1=O)c1ccccc1)c1ccccc1	Launched
SU014813	PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	KDR			MedChemEx	67.11	Cc1[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1	Phase 2
SU11274	hepatocyte growth factor receptor inhibitor, tyrosine kinase inhibitor	MET			Selleck, Selleck, Selleck, Tocris	96.9	CN(c1cccc(Cl)c1)S(=O)(=O)c1ccc2NC(=O)\C(=C/c3[nH]c(C)c(C(=O)N4CCN(C)CC4)c3C)c2c1, CN(c1cccc(Cl)c1)S(=O)(=O)c1ccc2NC(=O)\C(=C/c3[nH]c(C)c(C(=O)N4CCN(C)CC4)c3C)c2c1, CN(c1cccc(Cl)c1)S(=O)(=O)c1ccc2NC(=O)\C(=C/c3[nH]c(C)c(C(=O)N4CCN(C)CC4)c3C)c2c1, CN(c1cccc(Cl)c1)S(=O)(=O)c1ccc2NC(=O)\C(=C/c3[nH]c(C)c(C(=O)N4CCN(C)CC4)c3C)c2c1	Preclinical
SU16f	PDGFR tyrosine kinase receptor inhibitor	PDGFRB			Tocris, Tocris, Tocris	93.54	Cc1[nH]c(\C=C2/C(=O)Nc3cc(ccc23)-c2ccccc2)c(C)c1CCC(O)=O, Cc1[nH]c(\C=C2/C(=O)Nc3cc(ccc23)-c2ccccc2)c(C)c1CCC(O)=O, Cc1[nH]c(\C=C2/C(=O)Nc3cc(ccc23)-c2ccccc2)c(C)c1CCC(O)=O	Preclinical
SU3327	JNK inhibitor	MAPK8			Tocris, Tocris, Tocris, Tocris, Tocris, Tocris	94.69	Nc1nnc(Sc2ncc(s2)[N+]([O-])=O)s1, Nc1nnc(Sc2ncc(s2)[N+]([O-])=O)s1, Nc1nnc(Sc2ncc(s2)[N+]([O-])=O)s1, Nc1nnc(Sc2ncc(s2)[N+]([O-])=O)s1, Nc1nnc(Sc2ncc(s2)[N+]([O-])=O)s1, Nc1nnc(Sc2ncc(s2)[N+]([O-])=O)s1	Preclinical
SU4312	PDGFR tyrosine kinase receptor inhibitor, tyrosine kinase inhibitor, VEGFR inhibitor	KDR, PDGFRB			Tocris, Tocris	67.6	CN(C)c1ccc(\C=C2/C(=O)Nc3ccccc23)cc1, CN(C)c1ccc(\C=C2/C(=O)Nc3ccccc23)cc1	Preclinical
SU9516	CDK inhibitor	CDK1, CDK2, CDK4, CDK5			Tocris, MedChemEx, MedChemEx	87.43	COc1ccc2NC(=O)\C(=C/c3cnc[nH]3)c2c1, COc1ccc2NC(=O)\C(=C/c3cnc[nH]3)c2c1, COc1ccc2NC(=O)\C(=C/c3cnc[nH]3)c2c1	Preclinical
swainsonine	alpha mannosidase inhibitor	MAN2A1			Enzo	97.53	O[C@@H]1CN2CCC[C@@H](O)[C@@H]2[C@@H]1O	Phase 2
SX-011	MAP kinase inhibitor	MAPK14			Tocris, Tocris, Tocris	97.88	CN(C)C(=O)C(=O)c1cn(C)c2cc(Cl)c(cc12)C(=O)N1CCC(Cc2ccc(F)cc2)CC1, CN(C)C(=O)C(=O)c1cn(C)c2cc(Cl)c(cc12)C(=O)N1CCC(Cc2ccc(F)cc2)CC1, CN(C)C(=O)C(=O)c1cn(C)c2cc(Cl)c(cc12)C(=O)N1CCC(Cc2ccc(F)cc2)CC1	Preclinical
SY-640					Enamine	94.75	CN(Cc1ccc2OCOc2c1)C(C)=O	Phase 2
SYM-2081	kainate receptor antagonist	GRIK1, GRIK2, GRIK3, GRIK4, GRIK5, SLC1A2			Enzo, Tocris	70.5	C[C@H](C[C@H](N)C(O)=O)C(O)=O, C[C@H](C[C@H](N)C(O)=O)C(O)=O	Preclinical
SYM-2206	glutamate receptor antagonist	GRIA1, GRIA2, GRIA3, GRIA4			Tocris, Tocris, Tocris	95.25	CCCNC(=O)N1N=C(c2ccc(N)cc2)c2cc3OCOc3cc2[C@@H]1C |r,t:7|, CCCNC(=O)N1N=C(c2ccc(N)cc2)c2cc3OCOc3cc2[C@@H]1C |r,t:7|, CCCNC(=O)N1N=C(c2ccc(N)cc2)c2cc3OCOc3cc2[C@@H]1C |r,t:7|	Preclinical
symclosene					MicroSource, Sigma	0	Cln1c(=O)n(Cl)c(=O)n(Cl)c1=O, Cln1c(=O)n(Cl)c(=O)n(Cl)c1=O	Preclinical
synephrine	adrenergic receptor agonist	ADRA1A	otolaryngology	sinusitis	Selleck, Selleck	100	CNC[C@@H](O)c1ccc(O)cc1 |&1:3|, CNC[C@@H](O)c1ccc(O)cc1 |&1:3|	Launched
S1P1-agonist-III	sphingosine kinase inhibitor	S1PR1			Tocris, MedChemEx, MedChemEx, MedChemEx	94.83	COc1ccncc1C(=O)NC(=O)Nc1ccc(-c2ccccc2)c(c1)C(F)(F)F, COc1ccncc1C(=O)NC(=O)Nc1ccc(-c2ccccc2)c(c1)C(F)(F)F, COc1ccncc1C(=O)NC(=O)Nc1ccc(-c2ccccc2)c(c1)C(F)(F)F, COc1ccncc1C(=O)NC(=O)Nc1ccc(-c2ccccc2)c(c1)C(F)(F)F	Preclinical
S15535	serotonin receptor agonist				Sigma	96.36	C1C(Cc2ccccc12)N1CCN(CC1)c1cccc2OCCOc12	Preclinical
S18986	glutamate receptor modulator	GRIA1, GRIA2, GRIA3, GRIA4			EMDBio, EMDBio	95.87	O=S1(=O)N[C@H]2CCCN2c2ccccc12, O=S1(=O)N[C@H]2CCCN2c2ccccc12	Phase 2
S26948	PPAR receptor agonist	PPARG			Tocris, Tocris, Tocris	98.35	COC(=O)C(Cc1ccc(OCCn2c3ccc(cc3sc2=O)C(=O)c2ccccc2)cc1)C(=O)OC, COC(=O)C(Cc1ccc(OCCn2c3ccc(cc3sc2=O)C(=O)c2ccccc2)cc1)C(=O)OC, COC(=O)C(Cc1ccc(OCCn2c3ccc(cc3sc2=O)C(=O)c2ccccc2)cc1)C(=O)OC	Preclinical
S4	carbonic anhydrase inhibitor	CA12, CA9			Tocris, Tocris	91.97	Cc1cc(C)cc(NC(=O)Nc2ccc(OS(N)(=O)=O)cc2)c1, Cc1cc(C)cc(NC(=O)Nc2ccc(OS(N)(=O)=O)cc2)c1	Preclinical
S49076	tyrosine kinase inhibitor				MedChemEx	74.75	O=C1CSC(=O)N1Cc1ccc2NC(=O)\C(=C/c3cc(CN4CCOCC4)c[nH]3)c2c1	Preclinical
S63845	MCL1 inhibitor				MedChemEx, MedChemEx	96.1	CN1CCN(CCOc2ccc(-c3c(sc4ncnc(O[C@H](Cc5ccccc5OCc5ccnn5CC(F)(F)F)C(O)=O)c34)-c3ccc(F)o3)c(C)c2Cl)CC1, CN1CCN(CCOc2ccc(-c3c(sc4ncnc(O[C@H](Cc5ccccc5OCc5ccnn5CC(F)(F)F)C(O)=O)c34)-c3ccc(F)o3)c(C)c2Cl)CC1	Preclinical
T-0070907	PPAR receptor antagonist	PPARG			Tocris, Tocris, Tocris, Tocris, Selleck	98.04	[O-][N+](=O)c1ccc(Cl)c(c1)C(=O)Nc1ccncc1, [O-][N+](=O)c1ccc(Cl)c(c1)C(=O)Nc1ccncc1, [O-][N+](=O)c1ccc(Cl)c(c1)C(=O)Nc1ccncc1, [O-][N+](=O)c1ccc(Cl)c(c1)C(=O)Nc1ccncc1, [O-][N+](=O)c1ccc(Cl)c(c1)C(=O)Nc1ccncc1	Preclinical
T-0156	phosphodiesterase inhibitor	PDE5A			Tocris, Tocris, Tocris, Tocris, Tocris	98.39	COC(=O)c1c(-c2cc(OC)c(OC)c(OC)c2)c2ccnc(OCc3ncccn3)c2c(=O)n1Cc1ccnc(C)c1, COC(=O)c1c(-c2cc(OC)c(OC)c(OC)c2)c2ccnc(OCc3ncccn3)c2c(=O)n1Cc1ccnc(C)c1, COC(=O)c1c(-c2cc(OC)c(OC)c(OC)c2)c2ccnc(OCc3ncccn3)c2c(=O)n1Cc1ccnc(C)c1, COC(=O)c1c(-c2cc(OC)c(OC)c(OC)c2)c2ccnc(OCc3ncccn3)c2c(=O)n1Cc1ccnc(C)c1, COC(=O)c1c(-c2cc(OC)c(OC)c(OC)c2)c2ccnc(OCc3ncccn3)c2c(=O)n1Cc1ccnc(C)c1	Preclinical
T-025	CLK inhibitor					0		Preclinical
T-0901317	LXR agonist	NCOA1, NCOA2, NR1H2, NR1H3, NR1I2, RXRB			Tocris, Tocris, Tocris, Tocris, Tocris, Tocris, Selleck, Tocris	96.75	OC(c1ccc(cc1)N(CC(F)(F)F)S(=O)(=O)c1ccccc1)(C(F)(F)F)C(F)(F)F, OC(c1ccc(cc1)N(CC(F)(F)F)S(=O)(=O)c1ccccc1)(C(F)(F)F)C(F)(F)F, OC(c1ccc(cc1)N(CC(F)(F)F)S(=O)(=O)c1ccccc1)(C(F)(F)F)C(F)(F)F, OC(c1ccc(cc1)N(CC(F)(F)F)S(=O)(=O)c1ccccc1)(C(F)(F)F)C(F)(F)F, OC(c1ccc(cc1)N(CC(F)(F)F)S(=O)(=O)c1ccccc1)(C(F)(F)F)C(F)(F)F, OC(c1ccc(cc1)N(CC(F)(F)F)S(=O)(=O)c1ccccc1)(C(F)(F)F)C(F)(F)F, OC(c1ccc(cc1)N(CC(F)(F)F)S(=O)(=O)c1ccccc1)(C(F)(F)F)C(F)(F)F, OC(c1ccc(cc1)N(CC(F)(F)F)S(=O)(=O)c1ccccc1)(C(F)(F)F)C(F)(F)F	Preclinical
T-1095	sodium/glucose cotransporter inhibitor				AMS	89.4	COC(=O)OC[C@H]1O[C@@H](Oc2cc(C)cc(O)c2C(=O)CCc2ccc3occc3c2)[C@H](O)[C@@H](O)[C@@H]1O	Preclinical
T-5224	AP inhibitor	JUN			MedChemEx, MedChemEx, MedChemEx	95.74	OC(=O)CCc1cc(ccc1OCc1ccc2c(c1)o[nH]c2=O)C(=O)c1ccc(OC2CCCC2)cc1O, OC(=O)CCc1cc(ccc1OCc1ccc2c(c1)o[nH]c2=O)C(=O)c1ccc(OC2CCCC2)cc1O, OC(=O)CCc1cc(ccc1OCc1ccc2c(c1)o[nH]c2=O)C(=O)c1ccc(OC2CCCC2)cc1O	Phase 2
T-5601640	LIM kinase inhibitor	LIMK2			Tocris, Tocris	99.12	Cc1cc(on1)C(=O)Nc1cccc(c1)C(=O)Nc1cccc(c1)C(F)(F)F, Cc1cc(on1)C(=O)Nc1cccc(c1)C(=O)Nc1cccc(c1)C(F)(F)F	Preclinical
T-62	adenosine receptor modulator	ADORA2A			Enamine, Enamine	63.41	Nc1sc2CCCCc2c1C(=O)c1ccc(Cl)cc1, Nc1sc2CCCCc2c1C(=O)c1ccc(Cl)cc1	Phase 2
T-807	PET radiotracer				MedChemEx	85.96	Fc1ccc(cn1)-c1ccc2c(c1)[nH]c1ccncc21	Phase 2
TA-01	casein kinase inhibitor, MAP kinase inhibitor	CSNK1D, CSNK1E, MAPK14			MedChemEx, MedChemEx, MedChemEx, MedChemEx	98.14	Fc1ccc(cc1)-c1[nH]c(nc1-c1ccncc1)-c1c(F)cccc1F, Fc1ccc(cc1)-c1[nH]c(nc1-c1ccncc1)-c1c(F)cccc1F, Fc1ccc(cc1)-c1[nH]c(nc1-c1ccncc1)-c1c(F)cccc1F, Fc1ccc(cc1)-c1[nH]c(nc1-c1ccncc1)-c1c(F)cccc1F	Preclinical
tabimorelin	growth hormone secretagogue receptor agonist	GHSR			Tocris, Tocris, Tocris	96.19	CNC(=O)[C@@H](Cc1ccccc1)N(C)C(=O)[C@@H](Cc1ccc2ccccc2c1)N(C)C(=O)\C=C\CC(C)(C)N, CNC(=O)[C@@H](Cc1ccccc1)N(C)C(=O)[C@@H](Cc1ccc2ccccc2c1)N(C)C(=O)\C=C\CC(C)(C)N, CNC(=O)[C@@H](Cc1ccccc1)N(C)C(=O)[C@@H](Cc1ccc2ccccc2c1)N(C)C(=O)\C=C\CC(C)(C)N	Phase 2
tacalcitol	vitamin D receptor agonist	VDR	dermatology	psoriasis, chapped lips	MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx	93.65	CC(C)[C@H](O)CC[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, CC(C)[C@H](O)CC[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, CC(C)[C@H](O)CC[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, CC(C)[C@H](O)CC[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, CC(C)[C@H](O)CC[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, CC(C)[C@H](O)CC[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, CC(C)[C@H](O)CC[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C	Launched
tacedinaline	HDAC inhibitor	HDAC1			Tocris, Tocris, Selleck, Selleck, Selleck, Selleck, Selleck	97.49	CC(=O)Nc1ccc(cc1)C(=O)Nc1ccccc1N, CC(=O)Nc1ccc(cc1)C(=O)Nc1ccccc1N, CC(=O)Nc1ccc(cc1)C(=O)Nc1ccccc1N, CC(=O)Nc1ccc(cc1)C(=O)Nc1ccccc1N, CC(=O)Nc1ccc(cc1)C(=O)Nc1ccccc1N, CC(=O)Nc1ccc(cc1)C(=O)Nc1ccccc1N, CC(=O)Nc1ccc(cc1)C(=O)Nc1ccccc1N	Phase 3
tacrine	acetylcholinesterase inhibitor	ACHE, BCHE	neurology/psychiatry	Alzheimer's disease	Selleck, Selleck, Selleck, MicroSource, Tocris, Tocris	99.35	Nc1c2CCCCc2nc2ccccc12, Nc1c2CCCCc2nc2ccccc12, Nc1c2CCCCc2nc2ccccc12, Nc1c2CCCCc2nc2ccccc12, Nc1c2CCCCc2nc2ccccc12, Nc1c2CCCCc2nc2ccccc12	Launched
tacrolimus	calcineurin inhibitor	FKBP1A	transplant	organ rejection	MedChemEx, MicroSource, MicroSource, Selleck, Selleck, Selleck	97.24	CO[C@@H]1C[C@@H](CC[C@H]1O)\C=C(/C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@H](C[C@@H](C)C\C(C)=C\[C@@H](CC=C)C(=O)C[C@H](O)[C@H]1C)OC |t:45|, CO[C@@H]1C[C@@H](CC[C@H]1O)\C=C(/C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@H](C[C@@H](C)C\C(C)=C\[C@@H](CC=C)C(=O)C[C@H](O)[C@H]1C)OC |t:45|, CO[C@@H]1C[C@@H](CC[C@H]1O)\C=C(/C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@H](C[C@@H](C)C\C(C)=C\[C@@H](CC=C)C(=O)C[C@H](O)[C@H]1C)OC |t:45|, CO[C@@H]1C[C@@H](CC[C@H]1O)\C=C(/C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@H](C[C@@H](C)C\C(C)=C\[C@@H](CC=C)C(=O)C[C@H](O)[C@H]1C)OC |t:45|, CO[C@@H]1C[C@@H](CC[C@H]1O)\C=C(/C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@H](C[C@@H](C)C\C(C)=C\[C@@H](CC=C)C(=O)C[C@H](O)[C@H]1C)OC |t:45|, CO[C@@H]1C[C@@H](CC[C@H]1O)\C=C(/C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@H](C[C@@H](C)C\C(C)=C\[C@@H](CC=C)C(=O)C[C@H](O)[C@H]1C)OC |t:45|	Launched
tadalafil	phosphodiesterase inhibitor	PDE11A, PDE5A	urology	erectile dysfunction	MicroSource, MicroSource, MicroSource, Tocris, Tocris, Selleck	99.23	CN1CC(=O)N2[C@H](Cc3c([nH]c4ccccc34)[C@H]2c2ccc3OCOc3c2)C1=O, CN1CC(=O)N2[C@H](Cc3c([nH]c4ccccc34)[C@H]2c2ccc3OCOc3c2)C1=O, CN1CC(=O)N2[C@H](Cc3c([nH]c4ccccc34)[C@H]2c2ccc3OCOc3c2)C1=O, CN1CC(=O)N2[C@H](Cc3c([nH]c4ccccc34)[C@H]2c2ccc3OCOc3c2)C1=O, CN1CC(=O)N2[C@H](Cc3c([nH]c4ccccc34)[C@H]2c2ccc3OCOc3c2)C1=O, CN1CC(=O)N2[C@H](Cc3c([nH]c4ccccc34)[C@H]2c2ccc3OCOc3c2)C1=O	Launched
tafamidis-meglumine	transthyretin amyloid inhibitor	TTR	neurology/psychiatry	familial amyloid polyneuropathy (FAP)	MedChemEx, MedChemEx	99.69	OC(=O)c1ccc2nc(oc2c1)-c1cc(Cl)cc(Cl)c1, OC(=O)c1ccc2nc(oc2c1)-c1cc(Cl)cc(Cl)c1	Launched
tafenoquine	antimalarial agent		infectious disease	malaria	Sigma	82.25	COc1cc(C)c2c(Oc3cccc(c3)C(F)(F)F)c(OC)cc(N[C@@H](C)CCCN)c2n1 |&1:25|	Launched
tafluprost	prostaglandin inhibitor	PTGFR	ophthalmology	glaucoma, ocular hypertension	MedChemEx	95.14	CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\C(F)(F)COc1ccccc1	Launched
tagatose	phosphorylase inhibitor	PYGL			Sigma	0	OC[C@@H](O)[C@H](O)[C@H](O)C(=O)CO	Launched
TAK-063	phosphodiesterase inhibitor	PDE10A			MedChemEx	96.14	COc1cn(nc(-c2ccnn2-c2ccccc2)c1=O)-c1ccc(cc1F)-n1cccn1	Phase 2
TAK-220	CC chemokine receptor antagonist	CCR5			MedChemEx, MedChemEx, MedChemEx	97.73	CC(=O)N1CCC(CC1)C(=O)N(CCCN1CCC(Cc2ccc(cc2)C(N)=O)CC1)c1ccc(C)c(Cl)c1, CC(=O)N1CCC(CC1)C(=O)N(CCCN1CCC(Cc2ccc(cc2)C(N)=O)CC1)c1ccc(C)c(Cl)c1, CC(=O)N1CCC(CC1)C(=O)N(CCCN1CCC(Cc2ccc(cc2)C(N)=O)CC1)c1ccc(C)c(Cl)c1	Phase 1
TAK-243	ubiquitin activating enzyme inhibitor				MedChemEx	95.52	NS(=O)(=O)OC[C@H]1C[C@@H](Nc2ccnc3cc(nn23)-c2cccc(SC(F)(F)F)c2)[C@H](O)[C@@H]1O	Phase 1
TAK-285	EGFR inhibitor	ERBB2			MedChemEx, Selleck, Selleck, Selleck	95.38	CC(C)(O)CC(=O)NCCn1ccc2ncnc(Nc3ccc(Oc4cccc(c4)C(F)(F)F)c(Cl)c3)c12, CC(C)(O)CC(=O)NCCn1ccc2ncnc(Nc3ccc(Oc4cccc(c4)C(F)(F)F)c(Cl)c3)c12, CC(C)(O)CC(=O)NCCn1ccc2ncnc(Nc3ccc(Oc4cccc(c4)C(F)(F)F)c(Cl)c3)c12, CC(C)(O)CC(=O)NCCn1ccc2ncnc(Nc3ccc(Oc4cccc(c4)C(F)(F)F)c(Cl)c3)c12	Phase 1
TAK-593	VEGFR inhibitor	PDGFRA			MedChemEx, MedChemEx	94.1	Cc1cc(C(=O)Nc2cc(Oc3ccc4nc(NC(=O)C5CC5)cn4n3)ccc2C)n(C)n1, Cc1cc(C(=O)Nc2cc(Oc3ccc4nc(NC(=O)C5CC5)cn4n3)ccc2C)n(C)n1	Phase 1
TAK-632	RAF inhibitor	BRAF			Selleck, Selleck, Selleck, Selleck	97.83	Fc1ccc(Oc2ccc3nc(NC(=O)C4CC4)sc3c2C#N)cc1NC(=O)Cc1cccc(c1)C(F)(F)F, Fc1ccc(Oc2ccc3nc(NC(=O)C4CC4)sc3c2C#N)cc1NC(=O)Cc1cccc(c1)C(F)(F)F, Fc1ccc(Oc2ccc3nc(NC(=O)C4CC4)sc3c2C#N)cc1NC(=O)Cc1cccc(c1)C(F)(F)F, Fc1ccc(Oc2ccc3nc(NC(=O)C4CC4)sc3c2C#N)cc1NC(=O)Cc1cccc(c1)C(F)(F)F	Preclinical
TAK-659	spleen associated tyrosine kinase inhibitor				MedChemEx, MedChemEx	96.64	Cn1cc(cn1)-c1nc(N[C@@H]2CCCC[C@@H]2N)c(F)c2CNC(=O)c12, Cn1cc(cn1)-c1nc(N[C@@H]2CCCC[C@@H]2N)c(F)c2CNC(=O)c12	Phase 2
TAK-715	p38 MAPK inhibitor	MAPK14			Tocris, Tocris, Selleck, Selleck, Tocris	98.88	CCc1nc(c(s1)-c1ccnc(NC(=O)c2ccccc2)c1)-c1cccc(C)c1, CCc1nc(c(s1)-c1ccnc(NC(=O)c2ccccc2)c1)-c1cccc(C)c1, CCc1nc(c(s1)-c1ccnc(NC(=O)c2ccccc2)c1)-c1cccc(C)c1, CCc1nc(c(s1)-c1ccnc(NC(=O)c2ccccc2)c1)-c1cccc(C)c1, CCc1nc(c(s1)-c1ccnc(NC(=O)c2ccccc2)c1)-c1cccc(C)c1	Phase 2
TAK-733	MEK inhibitor	MAP2K1			Selleck, MedChemEx, Selleck, Selleck	98.86	Cn1c2ncn(C[C@@H](O)CO)c(=O)c2c(Nc2ccc(I)cc2F)c(F)c1=O, Cn1c2ncn(C[C@@H](O)CO)c(=O)c2c(Nc2ccc(I)cc2F)c(F)c1=O, Cn1c2ncn(C[C@@H](O)CO)c(=O)c2c(Nc2ccc(I)cc2F)c(F)c1=O, Cn1c2ncn(C[C@@H](O)CO)c(=O)c2c(Nc2ccc(I)cc2F)c(F)c1=O	Phase 1
TAK-779	CC chemokine receptor antagonist				MedChemEx	98.08	Cc1ccc(cc1)-c1ccc2CCCC(=Cc2c1)C(=O)Nc1ccc(C[N+](C)(C)C2CCOCC2)cc1 |c:15|	Preclinical
TAK-875	insulin secretagogue	FFAR1			MedChemEx, Selleck, Selleck, Selleck, Selleck, Selleck	97.03	Cc1cc(OCCCS(C)(=O)=O)cc(C)c1-c1cccc(COc2ccc3[C@H](CC(O)=O)COc3c2)c1, Cc1cc(OCCCS(C)(=O)=O)cc(C)c1-c1cccc(COc2ccc3[C@H](CC(O)=O)COc3c2)c1, Cc1cc(OCCCS(C)(=O)=O)cc(C)c1-c1cccc(COc2ccc3[C@H](CC(O)=O)COc3c2)c1, Cc1cc(OCCCS(C)(=O)=O)cc(C)c1-c1cccc(COc2ccc3[C@H](CC(O)=O)COc3c2)c1, Cc1cc(OCCCS(C)(=O)=O)cc(C)c1-c1cccc(COc2ccc3[C@H](CC(O)=O)COc3c2)c1, Cc1cc(OCCCS(C)(=O)=O)cc(C)c1-c1cccc(COc2ccc3[C@H](CC(O)=O)COc3c2)c1	Phase 3
TAK-901	Aurora kinase inhibitor	AURKB			Selleck, Selleck, MedChemEx	97.57	CCS(=O)(=O)c1cccc(c1)-c1cc(C(=O)NC2CCN(C)CC2)c(C)c2[nH]c3ncc(C)cc3c12, CCS(=O)(=O)c1cccc(c1)-c1cc(C(=O)NC2CCN(C)CC2)c(C)c2[nH]c3ncc(C)cc3c12, CCS(=O)(=O)c1cccc(c1)-c1cc(C(=O)NC2CCN(C)CC2)c(C)c2[nH]c3ncc(C)cc3c12	Phase 1
TAK-960	PLK inhibitor	PLK1			Tocris, MedChemEx, MedChemEx, MedChemEx	98.58	COc1cc(C(=O)NC2CCN(C)CC2)c(F)cc1Nc1ncc2N(C)C(=O)C(F)(F)CN(C3CCCC3)c2n1, COc1cc(C(=O)NC2CCN(C)CC2)c(F)cc1Nc1ncc2N(C)C(=O)C(F)(F)CN(C3CCCC3)c2n1, COc1cc(C(=O)NC2CCN(C)CC2)c(F)cc1Nc1ncc2N(C)C(=O)C(F)(F)CN(C3CCCC3)c2n1, COc1cc(C(=O)NC2CCN(C)CC2)c(F)cc1Nc1ncc2N(C)C(=O)C(F)(F)CN(C3CCCC3)c2n1	Phase 1
talabostat	dipeptidyl peptidase inhibitor, fibroblast activation protein inhibitor	DPP4			MedChemEx, MedChemEx, MedChemEx	67.55	CC(C)[C@H](N)C(=O)N1CCC[C@H]1B(O)O, CC(C)[C@H](N)C(=O)N1CCC[C@H]1B(O)O, CC(C)[C@H](N)C(=O)N1CCC[C@H]1B(O)O	Phase 3
taladegib	smoothened receptor antagonist	DHH, IHH, SMO			MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx	99.58	CN(C1CCN(CC1)c1nnc(-c2ccnn2C)c2ccccc12)C(=O)c1ccc(F)cc1C(F)(F)F, CN(C1CCN(CC1)c1nnc(-c2ccnn2C)c2ccccc12)C(=O)c1ccc(F)cc1C(F)(F)F, CN(C1CCN(CC1)c1nnc(-c2ccnn2C)c2ccccc12)C(=O)c1ccc(F)cc1C(F)(F)F, CN(C1CCN(CC1)c1nnc(-c2ccnn2C)c2ccccc12)C(=O)c1ccc(F)cc1C(F)(F)F, CN(C1CCN(CC1)c1nnc(-c2ccnn2C)c2ccccc12)C(=O)c1ccc(F)cc1C(F)(F)F, CN(C1CCN(CC1)c1nnc(-c2ccnn2C)c2ccccc12)C(=O)c1ccc(F)cc1C(F)(F)F	Phase 2
talampanel	glutamate receptor antagonist	GRIA1, GRIA2, GRIA3, GRIA4			MedChemEx, MedChemEx, Tocris	93	C[C@@H]1Cc2cc3OCOc3cc2C(=NN1C(C)=O)c1ccc(N)cc1 |c:14|, C[C@@H]1Cc2cc3OCOc3cc2C(=NN1C(C)=O)c1ccc(N)cc1 |c:14|, C[C@@H]1Cc2cc3OCOc3cc2C(=NN1C(C)=O)c1ccc(N)cc1 |c:14|	Phase 2
talaporfin	photosensitizing agent				MedChemEx	83.11	CCc1c(C)c2cc3[nH]c(cc4nc([C@@H](CCC(O)=O)[C@@H]4C)c(CC(=O)N[C@@H](CC(O)=O)C(O)=O)c4nc(cc1[nH]2)c(C)c4C(O)=O)c(C)c3C=C	Phase 3
talarozole	cytochrome P450 inhibitor	CYP26A1			MedChemEx, MedChemEx, MedChemEx	96.25	CCC(CC)[C@@H](c1ccc(Nc2nc3ccccc3s2)cc1)n1cncn1 |&1:5,r|, CCC(CC)[C@@H](c1ccc(Nc2nc3ccccc3s2)cc1)n1cncn1 |&1:5,r|, CCC(CC)[C@@H](c1ccc(Nc2nc3ccccc3s2)cc1)n1cncn1 |&1:5,r|	Phase 2
talazoparib	PARP inhibitor	PARP2	oncology	breast cancer	Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, MedChemEx	97.61	Cn1ncnc1[C@@H]1[C@H](Nc2cc(F)cc3c2c1n[nH]c3=O)c1ccc(F)cc1, Cn1ncnc1[C@@H]1[C@H](Nc2cc(F)cc3c2c1n[nH]c3=O)c1ccc(F)cc1, Cn1ncnc1[C@@H]1[C@H](Nc2cc(F)cc3c2c1n[nH]c3=O)c1ccc(F)cc1, Cn1ncnc1[C@@H]1[C@H](Nc2cc(F)cc3c2c1n[nH]c3=O)c1ccc(F)cc1, Cn1ncnc1[C@@H]1[C@H](Nc2cc(F)cc3c2c1n[nH]c3=O)c1ccc(F)cc1, Cn1ncnc1[C@@H]1[C@H](Nc2cc(F)cc3c2c1n[nH]c3=O)c1ccc(F)cc1, Cn1ncnc1[C@@H]1[C@H](Nc2cc(F)cc3c2c1n[nH]c3=O)c1ccc(F)cc1	Launched
talinolol	adrenergic receptor antagonist	ADRB1	cardiology	hypertension	Cayman, Cayman, Cayman	100	CC(C)(C)NC[C@@H](O)COc1ccc(NC(=O)NC2CCCCC2)cc1 |&1:6,r|, CC(C)(C)NC[C@@H](O)COc1ccc(NC(=O)NC2CCCCC2)cc1 |&1:6,r|, CC(C)(C)NC[C@@H](O)COc1ccc(NC(=O)NC2CCCCC2)cc1 |&1:6,r|	Launched
talipexole	adrenergic receptor agonist, dopamine receptor agonist	ADRA2A, DRD2, HTR3A	infectious disease	genitial herpes	MedChemEx, MedChemEx, MedChemEx, Enzo	84.52	Nc1nc2CCN(CC=C)CCc2s1, Nc1nc2CCN(CC=C)CCc2s1, Nc1nc2CCN(CC=C)CCc2s1, Nc1nc2CCN(CC=C)CCc2s1	Launched
talmapimod	p38 MAPK inhibitor	IL1B, MAPK11, MAPK14, MT-CO2, TNF			Tocris, Tocris, Tocris, Tocris, Tocris, Tocris, MedChemEx, MedChemEx, MedChemEx	98.07	C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C, C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C, C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C, C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C, C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C, C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C, C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C, C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C, C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C	Phase 2
talnetant	tachykinin antagonist	TACR2, TACR3			Tocris, MedChemEx	98.57	CC[C@H](NC(=O)c1c(O)c(nc2ccccc12)-c1ccccc1)c1ccccc1, CC[C@H](NC(=O)c1c(O)c(nc2ccccc12)-c1ccccc1)c1ccccc1	Phase 2
talniflumate	cyclooxygenase inhibitor	CLCA1	neurology/psychiatry	pain relief	Tocris, Tocris, Tocris, Tocris, Tocris	97.87	FC(F)(F)c1cccc(Nc2ncccc2C(=O)O[C@H]2OC(=O)c3ccccc23)c1 |&1:19,r|, FC(F)(F)c1cccc(Nc2ncccc2C(=O)O[C@H]2OC(=O)c3ccccc23)c1 |&1:19,r|, FC(F)(F)c1cccc(Nc2ncccc2C(=O)O[C@H]2OC(=O)c3ccccc23)c1 |&1:19,r|, FC(F)(F)c1cccc(Nc2ncccc2C(=O)O[C@H]2OC(=O)c3ccccc23)c1 |&1:19,r|, FC(F)(F)c1cccc(Nc2ncccc2C(=O)O[C@H]2OC(=O)c3ccccc23)c1 |&1:19,r|	Launched
talopram	adrenergic inhibitor	SLC6A2			Tocris, Tocris, Tocris	96.24	CNCCC[C@]1(OC(C)(C)c2ccccc12)c1ccccc1 |&1:5|, CNCCC[C@]1(OC(C)(C)c2ccccc12)c1ccccc1 |&1:5|, CNCCC[C@]1(OC(C)(C)c2ccccc12)c1ccccc1 |&1:5|	Phase 2
talsaclidine	acetylcholine receptor agonist				Sigma	0	C#CCO[C@H]1CN2CCC1CC2	Phase 2/Phase 3
taltirelin	thyrotropin releasing hormone receptor agonist	TRHR	neurology/psychiatry	spinocerebellar ataxia	MedChemEx, MedChemEx	95.09	CN1C(=O)C[C@H](NC1=O)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@H]1C(N)=O, CN1C(=O)C[C@H](NC1=O)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@H]1C(N)=O	Launched
taltobulin	tubulin polymerization inhibitor				MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx	96.83	CN[C@H](C(=O)N[C@H](C(=O)N(C)[C@H](\C=C(/C)C(O)=O)C(C)C)C(C)(C)C)C(C)(C)c1ccccc1, CN[C@H](C(=O)N[C@H](C(=O)N(C)[C@H](\C=C(/C)C(O)=O)C(C)C)C(C)(C)C)C(C)(C)c1ccccc1, CN[C@H](C(=O)N[C@H](C(=O)N(C)[C@H](\C=C(/C)C(O)=O)C(C)C)C(C)(C)C)C(C)(C)c1ccccc1, CN[C@H](C(=O)N[C@H](C(=O)N(C)[C@H](\C=C(/C)C(O)=O)C(C)C)C(C)(C)C)C(C)(C)c1ccccc1, CN[C@H](C(=O)N[C@H](C(=O)N(C)[C@H](\C=C(/C)C(O)=O)C(C)C)C(C)(C)C)C(C)(C)c1ccccc1, CN[C@H](C(=O)N[C@H](C(=O)N(C)[C@H](\C=C(/C)C(O)=O)C(C)C)C(C)(C)C)C(C)(C)c1ccccc1	Phase 1
TAME					MedChemEx, Selleck	94.63	COC(=O)[C@H](CCCNC(N)=N)NS(=O)(=O)c1ccc(C)cc1, COC(=O)[C@H](CCCNC(N)=N)NS(=O)(=O)c1ccc(C)cc1	Preclinical
tamibarotene	retinoid receptor agonist	RARA, RARB	hematologic malignancy	acute promyelocytic leukemia (APL)	Selleck, Selleck, Selleck, MedChemEx	99.43	CC1(C)CCC(C)(C)c2cc(NC(=O)c3ccc(cc3)C(O)=O)ccc12, CC1(C)CCC(C)(C)c2cc(NC(=O)c3ccc(cc3)C(O)=O)ccc12, CC1(C)CCC(C)(C)c2cc(NC(=O)c3ccc(cc3)C(O)=O)ccc12, CC1(C)CCC(C)(C)c2cc(NC(=O)c3ccc(cc3)C(O)=O)ccc12	Launched
taminadenant	adenosine receptor antagonist				AMS	89.55	Nc1nc(nc(c1Br)-n1cccn1)-n1cccn1	Phase 1/Phase 2
tamoxifen	estrogen receptor antagonist, selective estrogen receptor modulator (SERM)	EBP, ESR1, ESR2, GPER1, PRKCA, PRKCB, PRKCD, PRKCE, PRKCG, PRKCI, PRKCQ, PRKCZ	oncology	breast cancer	Tocris, Tocris, Tocris, Selleck, Tocris, MicroSource, Selleck	97.31	CC\C(=C(/c1ccccc1)c1ccc(OCCN(C)C)cc1)c1ccccc1, CC\C(=C(/c1ccccc1)c1ccc(OCCN(C)C)cc1)c1ccccc1, CC\C(=C(/c1ccccc1)c1ccc(OCCN(C)C)cc1)c1ccccc1, CC\C(=C(/c1ccccc1)c1ccc(OCCN(C)C)cc1)c1ccccc1, CC\C(=C(/c1ccccc1)c1ccc(OCCN(C)C)cc1)c1ccccc1, CC\C(=C(/c1ccccc1)c1ccc(OCCN(C)C)cc1)c1ccccc1, CC\C(=C(/c1ccccc1)c1ccc(OCCN(C)C)cc1)c1ccccc1	Launched
tamsulosin	adrenergic receptor antagonist	ADRA1A, ADRA1B, ADRA1D	urology	benign prostatic hyperplasia (BPH)	Tocris, Enzo	99.03	CCOc1ccccc1OCCN[C@H](C)Cc1ccc(OC)c(c1)S(N)(=O)=O, CCOc1ccccc1OCCN[C@H](C)Cc1ccc(OC)c(c1)S(N)(=O)=O	Launched
tanaproget	progesterone receptor agonist	PGR			MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx	98.3	Cn1c(ccc1-c1ccc2NC(=S)OC(C)(C)c2c1)C#N, Cn1c(ccc1-c1ccc2NC(=S)OC(C)(C)c2c1)C#N, Cn1c(ccc1-c1ccc2NC(=S)OC(C)(C)c2c1)C#N, Cn1c(ccc1-c1ccc2NC(=S)OC(C)(C)c2c1)C#N, Cn1c(ccc1-c1ccc2NC(=S)OC(C)(C)c2c1)C#N	Phase 2
tandospirone	serotonin receptor agonist	HTR1A	neurology/psychiatry	generalized anxiety disorder (GAD), dysthymic disorder	Tocris, Tocris, MedChemEx, Tocris	98.71	O=C1[C@H]2[C@@H]3CC[C@@H](C3)[C@H]2C(=O)N1CCCCN1CCN(CC1)c1ncccn1, O=C1[C@H]2[C@@H]3CC[C@@H](C3)[C@H]2C(=O)N1CCCCN1CCN(CC1)c1ncccn1, O=C1[C@H]2[C@@H]3CC[C@@H](C3)[C@H]2C(=O)N1CCCCN1CCN(CC1)c1ncccn1, O=C1[C@H]2[C@@H]3CC[C@@H](C3)[C@H]2C(=O)N1CCCCN1CCN(CC1)c1ncccn1	Launched
tandutinib	FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor	CSF1R, FLT3, KIT, PDGFD, PDGFRB			MedChemEx, MicroSource, MicroSource, MicroSource, Selleck, Selleck	97.46	COc1cc2c(ncnc2cc1OCCCN1CCCCC1)N1CCN(CC1)C(=O)Nc1ccc(OC(C)C)cc1, COc1cc2c(ncnc2cc1OCCCN1CCCCC1)N1CCN(CC1)C(=O)Nc1ccc(OC(C)C)cc1, COc1cc2c(ncnc2cc1OCCCN1CCCCC1)N1CCN(CC1)C(=O)Nc1ccc(OC(C)C)cc1, COc1cc2c(ncnc2cc1OCCCN1CCCCC1)N1CCN(CC1)C(=O)Nc1ccc(OC(C)C)cc1, COc1cc2c(ncnc2cc1OCCCN1CCCCC1)N1CCN(CC1)C(=O)Nc1ccc(OC(C)C)cc1, COc1cc2c(ncnc2cc1OCCCN1CCCCC1)N1CCN(CC1)C(=O)Nc1ccc(OC(C)C)cc1	Phase 2
tanespimycin	HSP inhibitor	HSP90AA1			MedChemEx, Selleck, Selleck, Selleck, Tocris, Tocris, Selleck, Selleck, Selleck	97.71	CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O |c:7,23,t:15,21,34|, CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O |c:7,23,t:15,21,34|, CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O |c:7,23,t:15,21,34|, CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O |c:7,23,t:15,21,34|, CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O |c:7,23,t:15,21,34|, CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O |c:7,23,t:15,21,34|, CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O |c:7,23,t:15,21,34|, CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O |c:7,23,t:15,21,34|, CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O |c:7,23,t:15,21,34|	Phase 3
tangeritin	cell cycle inhibitor				MedChemEx, Selleck	97.77	COc1ccc(cc1)-c1cc(=O)c2c(OC)c(OC)c(OC)c(OC)c2o1, COc1ccc(cc1)-c1cc(=O)c2c(OC)c(OC)c(OC)c(OC)c2o1	Preclinical
tannic-acid	PARG inhibitor	ANO1	gastroenterology	constipation	MedChemEx	100	Oc1cc(cc(O)c1O)C(=O)Oc1cc(cc(O)c1O)C(=O)OC[C@H]1O[C@@H](OC(=O)c2cc(O)c(O)c(OC(=O)c3cc(O)c(O)c(O)c3)c2)[C@H](OC(=O)c2cc(O)c(O)c(OC(=O)c3cc(O)c(O)c(O)c3)c2)[C@@H](OC(=O)c2cc(O)c(O)c(OC(=O)c3cc(O)c(O)c(O)c3)c2)[C@@H]1OC(=O)c1cc(O)c(O)c(OC(=O)c2cc(O)c(O)c(O)c2)c1	Launched
tanshinone-I	AP inhibitor	IFNG			MedChemEx, Selleck, Selleck, Selleck	87.49	Cc1coc-2c1C(=O)C(=O)c1c-2ccc2c(C)cccc12, Cc1coc-2c1C(=O)C(=O)c1c-2ccc2c(C)cccc12, Cc1coc-2c1C(=O)C(=O)c1c-2ccc2c(C)cccc12, Cc1coc-2c1C(=O)C(=O)c1c-2ccc2c(C)cccc12	Phase 2
tanshinone-IIA	anti-inflammatory agent, interleukin inhibitor	IL1B, NR1I2, TNF			Tocris, Selleck, Selleck, Selleck	90.3	Cc1coc-2c1C(=O)C(=O)c1c3CCCC(C)(C)c3ccc-21, Cc1coc-2c1C(=O)C(=O)c1c3CCCC(C)(C)c3ccc-21, Cc1coc-2c1C(=O)C(=O)c1c3CCCC(C)(C)c3ccc-21, Cc1coc-2c1C(=O)C(=O)c1c3CCCC(C)(C)c3ccc-21	Phase 2/Phase 3
tapinarof	aryl hydrocarbon receptor agonist				MedChemEx	97.56	CC(C)c1c(O)cc(\C=C\c2ccccc2)cc1O	Phase 3
taprenepag	prostaglandin receptor agonist	PTGER2			MedChemEx	96.08	OC(=O)COc1cccc(CN(Cc2ccc(cc2)-n2cccn2)S(=O)(=O)c2cccnc2)c1	Phase 2
tarafenacin	acetylcholine receptor antagonist	CHRM3			MedChemEx	96.05	Fc1cccc(c1)N(Cc1cc(F)c(F)c(F)c1)C(=O)O[C@H]1C[N@@]2CC[C@H]1CC2	Phase 2
taranabant	cannabinoid receptor inverse agonist	CNR1			MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx	98.67	C[C@H](NC(=O)C(C)(C)Oc1ccc(cn1)C(F)(F)F)[C@@H](Cc1ccc(Cl)cc1)c1cccc(c1)C#N, C[C@H](NC(=O)C(C)(C)Oc1ccc(cn1)C(F)(F)F)[C@@H](Cc1ccc(Cl)cc1)c1cccc(c1)C#N, C[C@H](NC(=O)C(C)(C)Oc1ccc(cn1)C(F)(F)F)[C@@H](Cc1ccc(Cl)cc1)c1cccc(c1)C#N, C[C@H](NC(=O)C(C)(C)Oc1ccc(cn1)C(F)(F)F)[C@@H](Cc1ccc(Cl)cc1)c1cccc(c1)C#N, C[C@H](NC(=O)C(C)(C)Oc1ccc(cn1)C(F)(F)F)[C@@H](Cc1ccc(Cl)cc1)c1cccc(c1)C#N	Phase 3
targinine	nitric oxide synthase inhibitor	NOS3			Cayman	100	CNC(=N)NCCC[C@H](N)C(O)=O	Phase 3
tariquidar	P glycoprotein inhibitor	ABCB1			Selleck, Selleck, Selleck, Selleck, MedChemEx, MedChemEx, MedChemEx	95.08	COc1cc2CCN(CCc3ccc(NC(=O)c4cc(OC)c(OC)cc4NC(=O)c4cnc5ccccc5c4)cc3)Cc2cc1OC, COc1cc2CCN(CCc3ccc(NC(=O)c4cc(OC)c(OC)cc4NC(=O)c4cnc5ccccc5c4)cc3)Cc2cc1OC, COc1cc2CCN(CCc3ccc(NC(=O)c4cc(OC)c(OC)cc4NC(=O)c4cnc5ccccc5c4)cc3)Cc2cc1OC, COc1cc2CCN(CCc3ccc(NC(=O)c4cc(OC)c(OC)cc4NC(=O)c4cnc5ccccc5c4)cc3)Cc2cc1OC, COc1cc2CCN(CCc3ccc(NC(=O)c4cc(OC)c(OC)cc4NC(=O)c4cnc5ccccc5c4)cc3)Cc2cc1OC, COc1cc2CCN(CCc3ccc(NC(=O)c4cc(OC)c(OC)cc4NC(=O)c4cnc5ccccc5c4)cc3)Cc2cc1OC, COc1cc2CCN(CCc3ccc(NC(=O)c4cc(OC)c(OC)cc4NC(=O)c4cnc5ccccc5c4)cc3)Cc2cc1OC	Phase 3
tartaric-acid	antioxidant				MedChemEx, MicroSource	100	O[C@H]([C@@H](O)C(O)=O)C(O)=O, O[C@H]([C@@H](O)C(O)=O)C(O)=O	Launched
TAS-103	topoisomerase inhibitor	TOP1			MedChemEx, MedChemEx, MedChemEx	91.54	CN(C)CCNc1nc2cc(O)ccc2c2-c3ccccc3C(=O)c12, CN(C)CCNc1nc2cc(O)ccc2c2-c3ccccc3C(=O)c12, CN(C)CCNc1nc2cc(O)ccc2c2-c3ccccc3C(=O)c12	Phase 1
taselisib	PI3K inhibitor	PIK3CA			MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx	99.17	CC(C)n1nc(C)nc1-c1cn2CCOc3cc(ccc3-c2n1)-c1cnn(c1)C(C)(C)C(N)=O, CC(C)n1nc(C)nc1-c1cn2CCOc3cc(ccc3-c2n1)-c1cnn(c1)C(C)(C)C(N)=O, CC(C)n1nc(C)nc1-c1cn2CCOc3cc(ccc3-c2n1)-c1cnn(c1)C(C)(C)C(N)=O, CC(C)n1nc(C)nc1-c1cn2CCOc3cc(ccc3-c2n1)-c1cnn(c1)C(C)(C)C(N)=O, CC(C)n1nc(C)nc1-c1cn2CCOc3cc(ccc3-c2n1)-c1cnn(c1)C(C)(C)C(N)=O, CC(C)n1nc(C)nc1-c1cn2CCOc3cc(ccc3-c2n1)-c1cnn(c1)C(C)(C)C(N)=O, CC(C)n1nc(C)nc1-c1cn2CCOc3cc(ccc3-c2n1)-c1cnn(c1)C(C)(C)C(N)=O, CC(C)n1nc(C)nc1-c1cn2CCOc3cc(ccc3-c2n1)-c1cnn(c1)C(C)(C)C(N)=O, CC(C)n1nc(C)nc1-c1cn2CCOc3cc(ccc3-c2n1)-c1cnn(c1)C(C)(C)C(N)=O, CC(C)n1nc(C)nc1-c1cn2CCOc3cc(ccc3-c2n1)-c1cnn(c1)C(C)(C)C(N)=O, CC(C)n1nc(C)nc1-c1cn2CCOc3cc(ccc3-c2n1)-c1cnn(c1)C(C)(C)C(N)=O	Phase 3
tasimelteon	melatonin receptor agonist	MTNR1A, MTNR1B	neurology/psychiatry	Non-24-Hour Sleep-Wake Disorder	Synnovator	98.42	CCC(=O)NC[C@@H]1C[C@H]1c1cccc2OCCc12	Launched
tasisulam	apoptosis stimulant				Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck	98.7	Clc1ccc(C(=O)NS(=O)(=O)c2ccc(Br)s2)c(Cl)c1, Clc1ccc(C(=O)NS(=O)(=O)c2ccc(Br)s2)c(Cl)c1, Clc1ccc(C(=O)NS(=O)(=O)c2ccc(Br)s2)c(Cl)c1, Clc1ccc(C(=O)NS(=O)(=O)c2ccc(Br)s2)c(Cl)c1, Clc1ccc(C(=O)NS(=O)(=O)c2ccc(Br)s2)c(Cl)c1, Clc1ccc(C(=O)NS(=O)(=O)c2ccc(Br)s2)c(Cl)c1, Clc1ccc(C(=O)NS(=O)(=O)c2ccc(Br)s2)c(Cl)c1	Phase 3
tasquinimod	angiogenesis inhibitor, S100A9 inhibitor	HDAC4			MedChemEx, MedChemEx, MedChemEx, MedChemEx	99.3	COc1cccc2n(C)c(=O)c(C(=O)N(C)c3ccc(cc3)C(F)(F)F)c(O)c12, COc1cccc2n(C)c(=O)c(C(=O)N(C)c3ccc(cc3)C(F)(F)F)c(O)c12, COc1cccc2n(C)c(=O)c(C(=O)N(C)c3ccc(cc3)C(F)(F)F)c(O)c12, COc1cccc2n(C)c(=O)c(C(=O)N(C)c3ccc(cc3)C(F)(F)F)c(O)c12	Phase 3
tasuldine	mucolytic agent				Labotest, Vitas-M	98.77	C(Sc1ncccn1)c1cccnc1, C(Sc1ncccn1)c1cccnc1	Phase 3
taurine	antioxidant		neurology/psychiatry	anxiety, irritability, sleeplessness	MicroSource, Selleck	100	NCCS(O)(=O)=O, NCCS(O)(=O)=O	Launched
taurocholate	G protein-coupled receptor agonist	CEL, FABP6, SLCO1C1			Enzo, Selleck	100	C[C@H](CCC(=O)NCCS(O)(=O)=O)[C@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3C[C@H](O)[C@]12C, C[C@H](CCC(=O)NCCS(O)(=O)=O)[C@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3C[C@H](O)[C@]12C	Phase 1
tauroglycocholate	membrane permeability enhancer				MedChemEx	100	[H][C@@]1(CC[C@@]2([H])[C@]3([H])[C@H](O)C[C@]4([H])C[C@H](O)CC[C@]4(C)[C@@]3([H])C[C@H](O)[C@]12C)[C@H](C)CCC(=O)NCC(=O)NCCS(O)(=O)=O	Preclinical
taurolidine	apoptosis stimulant		infectious disease	catheter-related bloodstream infection	Sigma	0	O=S1(=O)CCN(CN2CCS(=O)(=O)NC2)CN1	Launched
tavaborole	leucyl-tRNA synthetase inhibitor		infectious disease	onychomycosis	MedChemEx, MedChemEx, MedChemEx	91.53	OB1OCc2cc(F)ccc12, OB1OCc2cc(F)ccc12, OB1OCc2cc(F)ccc12	Launched
tavilermide	tyrosine kinase partial agonist				MedChemEx	85.65	NCCCC[C@@H]1NC(=O)[C@H](CCC(O)=O)NC(=O)c2cc(ccc2OCC[C@H](NC1=O)C(=O)NCC(O)=O)[N+]([O-])=O	Phase 3
taxifolin	opioid receptor antagonist	ADIPOR2			MedChemEx, MedChemEx, Selleck, Selleck, Selleck, Selleck	97.48	O[C@@H]1[C@H](Oc2cc(O)cc(O)c2C1=O)c1ccc(O)c(O)c1, O[C@@H]1[C@H](Oc2cc(O)cc(O)c2C1=O)c1ccc(O)c(O)c1, O[C@@H]1[C@H](Oc2cc(O)cc(O)c2C1=O)c1ccc(O)c(O)c1, O[C@@H]1[C@H](Oc2cc(O)cc(O)c2C1=O)c1ccc(O)c(O)c1, O[C@@H]1[C@H](Oc2cc(O)cc(O)c2C1=O)c1ccc(O)c(O)c1, O[C@@H]1[C@H](Oc2cc(O)cc(O)c2C1=O)c1ccc(O)c(O)c1	Phase 2
tazarotene	retinoid receptor agonist	RARA, RARB, RARG, RXRB	dermatology	cosmetic, sunscreen lotion	Selleck, Selleck, Tocris	97.09	CCOC(=O)c1ccc(nc1)C#Cc1ccc2SCCC(C)(C)c2c1, CCOC(=O)c1ccc(nc1)C#Cc1ccc2SCCC(C)(C)c2c1, CCOC(=O)c1ccc(nc1)C#Cc1ccc2SCCC(C)(C)c2c1	Launched
tazemetostat	histone lysine methyltransferase inhibitor	EZH2			Selleck, Selleck, Selleck, Selleck	93.46	CCN(C1CCOCC1)c1cc(cc(C(=O)NCc2c(C)cc(C)[nH]c2=O)c1C)-c1ccc(CN2CCOCC2)cc1, CCN(C1CCOCC1)c1cc(cc(C(=O)NCc2c(C)cc(C)[nH]c2=O)c1C)-c1ccc(CN2CCOCC2)cc1, CCN(C1CCOCC1)c1cc(cc(C(=O)NCc2c(C)cc(C)[nH]c2=O)c1C)-c1ccc(CN2CCOCC2)cc1, CCN(C1CCOCC1)c1cc(cc(C(=O)NCc2c(C)cc(C)[nH]c2=O)c1C)-c1ccc(CN2CCOCC2)cc1	Launched
tazobactam	beta lactamase inhibitor		infectious disease	pneumonia	MedChemEx	96.16	C[C@]1(Cn2ccnn2)[C@@H](N2[C@@H](CC2=O)S1(=O)=O)C(O)=O	Launched
TBA-354					MedChemEx, MedChemEx	96.43	[O-][N+](=O)c1cn2C[C@@H](COc2n1)OCc1ccc(nc1)-c1ccc(OC(F)(F)F)cc1, [O-][N+](=O)c1cn2C[C@@H](COc2n1)OCc1ccc(nc1)-c1ccc(OC(F)(F)F)cc1	Phase 1
TBOA-(DL)	excitatory amino acid transporter inhibitor	SLC1A1, SLC1A2, SLC1A3, SLC1A6, SLC1A7			Tocris, Tocris, Tocris, Tocris, Tocris	91	N[C@@H]([C@H](OCc1ccccc1)C(O)=O)C(O)=O.N[C@H]([C@@H](OCc1ccccc1)C(O)=O)C(O)=O, N[C@@H]([C@H](OCc1ccccc1)C(O)=O)C(O)=O.N[C@H]([C@@H](OCc1ccccc1)C(O)=O)C(O)=O, N[C@@H]([C@H](OCc1ccccc1)C(O)=O)C(O)=O.N[C@H]([C@@H](OCc1ccccc1)C(O)=O)C(O)=O, N[C@@H]([C@H](OCc1ccccc1)C(O)=O)C(O)=O.N[C@H]([C@@H](OCc1ccccc1)C(O)=O)C(O)=O, N[C@@H]([C@H](OCc1ccccc1)C(O)=O)C(O)=O.N[C@H]([C@@H](OCc1ccccc1)C(O)=O)C(O)=O	Preclinical
TC-A-2317	Aurora kinase inhibitor	AURKA			Tocris, Tocris, Tocris, Tocris	92.69	C[C@@H](CCCC(C)(C)O)Nc1nc(Nc2cc(C)n[nH]2)cc(C)c1C#N |&1:1|, C[C@@H](CCCC(C)(C)O)Nc1nc(Nc2cc(C)n[nH]2)cc(C)c1C#N |&1:1|, C[C@@H](CCCC(C)(C)O)Nc1nc(Nc2cc(C)n[nH]2)cc(C)c1C#N |&1:1|, C[C@@H](CCCC(C)(C)O)Nc1nc(Nc2cc(C)n[nH]2)cc(C)c1C#N |&1:1|	Preclinical
TC-ASK-10	MAP kinase inhibitor	MAP3K5, MAP3K6			Tocris, Tocris, Tocris, Focus	97.32	CC(C)(C)c1ccc(cc1)C(=O)Nc1cn2cc(ccc2n1)-n1ccnc1, CC(C)(C)c1ccc(cc1)C(=O)Nc1cn2cc(ccc2n1)-n1ccnc1, CC(C)(C)c1ccc(cc1)C(=O)Nc1cn2cc(ccc2n1)-n1ccnc1, CC(C)(C)c1ccc(cc1)C(=O)Nc1cn2cc(ccc2n1)-n1ccnc1	Preclinical
TC-E-5002	histone demethylase inhibitor	KDM2A, KDM4A, KDM4C, KDM5A, KDM6A, KDM7A, PHF8			Tocris, Tocris, Tocris	96.52	ON(CCC(O)=O)C(=O)CCCCCCCCC1CC1, ON(CCC(O)=O)C(=O)CCCCCCCCC1CC1, ON(CCC(O)=O)C(=O)CCCCCCCCC1CC1	Preclinical
TC-E-5006	gamma secretase modulator	APP			Tocris, Tocris, Tocris, Tocris	97.9	C[C@@H](C(O)=O)c1ccc([C@@H](N2CCC(C)CC2)c2ccc(F)cc2)c(c1)-c1ccc(cc1)C(F)(F)F |&1:1,&2:9,r|, C[C@@H](C(O)=O)c1ccc([C@@H](N2CCC(C)CC2)c2ccc(F)cc2)c(c1)-c1ccc(cc1)C(F)(F)F |&1:1,&2:9,r|, C[C@@H](C(O)=O)c1ccc([C@@H](N2CCC(C)CC2)c2ccc(F)cc2)c(c1)-c1ccc(cc1)C(F)(F)F |&1:1,&2:9,r|, C[C@@H](C(O)=O)c1ccc([C@@H](N2CCC(C)CC2)c2ccc(F)cc2)c(c1)-c1ccc(cc1)C(F)(F)F |&1:1,&2:9,r|	Preclinical
TC-F-2	FAAH inhibitor	FAAH			Tocris, Tocris	98.4	CCn1c2ccccc2n([C@H]2CCCN(C2)c2nccc(n2)-c2cc3ccccc3o2)c1=O, CCn1c2ccccc2n([C@H]2CCCN(C2)c2nccc(n2)-c2cc3ccccc3o2)c1=O	Preclinical
TC-FPR-43	formyl peptide receptor agonist	FPR2			Tocris, Tocris	97.83	CC(C)c1c(NC(=O)Nc2ccc(Cl)cc2)c(=O)n(-c2ccccc2)n1C, CC(C)c1c(NC(=O)Nc2ccc(Cl)cc2)c(=O)n(-c2ccccc2)n1C	Preclinical
TC-G-1000	adrenergic receptor agonist	ADRA2A, ADRA2B, ADRA2C			Tocris, Tocris	93.6	Cc1sc(C)c2c1CCC=C2c1cnc[nH]1 |c:10|, Cc1sc(C)c2c1CCC=C2c1cnc[nH]1 |c:10|	Preclinical
TC-G-1004	adenosine receptor antagonist	ADORA2A			Tocris, Tocris, Tocris	95.87	COC1CCN(CC1)c1cccc(n1)-c1cc(NC(C)=O)nc(n1)-n1nc(C)cc1C, COC1CCN(CC1)c1cccc(n1)-c1cc(NC(C)=O)nc(n1)-n1nc(C)cc1C, COC1CCN(CC1)c1cccc(n1)-c1cc(NC(C)=O)nc(n1)-n1nc(C)cc1C	Preclinical
TC-G-1005	G protein-coupled receptor agonist	GPBAR1			Tocris, Tocris	94.65	Cc1ccc(C)c(Oc2ccncc2C(=O)N2CCN(C3CC3)c3ccccc23)c1, Cc1ccc(C)c(Oc2ccncc2C(=O)N2CCN(C3CC3)c3ccccc23)c1	Preclinical
TC-G-1008	G protein-coupled receptor agonist	GPR39			Tocris, Tocris	98.28	CNc1nc(NCc2ccc(NS(C)(=O)=O)cc2Cl)cc(n1)-c1ccccn1, CNc1nc(NCc2ccc(NS(C)(=O)=O)cc2Cl)cc(n1)-c1ccccn1	Preclinical
TC-H-106	HDAC inhibitor	HDAC1, HDAC2, HDAC3, HDAC8			Tocris, Tocris, Stanley, Stanley, Stanley, Stanley	100	Cc1ccc(NC(=O)CCCCCC(=O)Nc2ccccc2N)cc1, Cc1ccc(NC(=O)CCCCCC(=O)Nc2ccccc2N)cc1, Cc1ccc(NC(=O)CCCCCC(=O)Nc2ccccc2N)cc1, Cc1ccc(NC(=O)CCCCCC(=O)Nc2ccccc2N)cc1, Cc1ccc(NC(=O)CCCCCC(=O)Nc2ccccc2N)cc1, Cc1ccc(NC(=O)CCCCCC(=O)Nc2ccccc2N)cc1	Preclinical
TC-I-15	integrin inhibitor	ITGA2, ITGB1			Tocris, Tocris, Tocris	96.07	CC1(C)SCN([C@@H]1C(=O)N[C@@H](CNC(=O)NCc1ccccc1)C(O)=O)S(=O)(=O)c1ccccc1, CC1(C)SCN([C@@H]1C(=O)N[C@@H](CNC(=O)NCc1ccccc1)C(O)=O)S(=O)(=O)c1ccccc1, CC1(C)SCN([C@@H]1C(=O)N[C@@H](CNC(=O)NCc1ccccc1)C(O)=O)S(=O)(=O)c1ccccc1	Preclinical
TC-I-2000	transient receptor potential channel antagonist	TRPM8			Tocris, Tocris, Tocris, Tocris	96.77	Fc1ccc(NC(=O)N2CCc3ccccc3[C@@H]2c2ccc(cc2)C(F)(F)F)cc1 |&1:17,r|, Fc1ccc(NC(=O)N2CCc3ccccc3[C@@H]2c2ccc(cc2)C(F)(F)F)cc1 |&1:17,r|, Fc1ccc(NC(=O)N2CCc3ccccc3[C@@H]2c2ccc(cc2)C(F)(F)F)cc1 |&1:17,r|, Fc1ccc(NC(=O)N2CCc3ccccc3[C@@H]2c2ccc(cc2)C(F)(F)F)cc1 |&1:17,r|	Preclinical
TC-I-2014	transient receptor potential channel antagonist	TRPM8			Tocris, Tocris, Tocris	95.86	FC(F)(F)c1ccccc1-c1cc(c2[nH]c(nc2c1)C1=NOC2(C1)CCCCC2)C(F)(F)F |t:22|, FC(F)(F)c1ccccc1-c1cc(c2[nH]c(nc2c1)C1=NOC2(C1)CCCCC2)C(F)(F)F |t:22|, FC(F)(F)c1ccccc1-c1cc(c2[nH]c(nc2c1)C1=NOC2(C1)CCCCC2)C(F)(F)F |t:22|	Preclinical
TC-LPA5-4	lysophosphatidic acid receptor antagonist	LPAR5			Tocris, Tocris, Tocris, Tocris, Tocris	97.3	COc1cccc(c1)-n1nc(cc1-c1ccc(C2CCCCC2)c(Cl)c1)C(O)=O, COc1cccc(c1)-n1nc(cc1-c1ccc(C2CCCCC2)c(Cl)c1)C(O)=O, COc1cccc(c1)-n1nc(cc1-c1ccc(C2CCCCC2)c(Cl)c1)C(O)=O, COc1cccc(c1)-n1nc(cc1-c1ccc(C2CCCCC2)c(Cl)c1)C(O)=O, COc1cccc(c1)-n1nc(cc1-c1ccc(C2CCCCC2)c(Cl)c1)C(O)=O	Preclinical
TC-Mps1-12	monopolar spindle 1 kinase inhibitor	TTK			Tocris, Tocris	98.5	CC(C)(C)Nc1nc(Nc2ccc(cc2)C(N)=O)cc(N)c1C#N, CC(C)(C)Nc1nc(Nc2ccc(cc2)C(N)=O)cc(N)c1C#N	Preclinical
TC-N-1752	sodium channel blocker	SCN9A			Tocris, Tocris, Tocris	98.27	CC(=O)Nc1cccc(Nc2ncnc(n2)N2CCC(CC2)OCc2ccc(OC(F)(F)F)cc2)c1C, CC(=O)Nc1cccc(Nc2ncnc(n2)N2CCC(CC2)OCc2ccc(OC(F)(F)F)cc2)c1C, CC(=O)Nc1cccc(Nc2ncnc(n2)N2CCC(CC2)OCc2ccc(OC(F)(F)F)cc2)c1C	Preclinical
TC-NTR1-17	neurotensin agonist	NTSR1			Tocris, Tocris	98.19	COc1cccc(OC)c1-c1cc(nn1-c1ccnc2cc(Cl)ccc12)C(=O)N[C@@H](CC(C)C)C(O)=O, COc1cccc(OC)c1-c1cc(nn1-c1ccnc2cc(Cl)ccc12)C(=O)N[C@@H](CC(C)C)C(O)=O	Preclinical
TC-O-9311	G protein-coupled receptor agonist	GPR139			Tocris, Tocris, Tocris	95.92	COc1cc(OC)cc(c1)C(=O)NNC(=O)Nc1cccc2ccccc12, COc1cc(OC)cc(c1)C(=O)NNC(=O)Nc1cccc2ccccc12, COc1cc(OC)cc(c1)C(=O)NNC(=O)Nc1cccc2ccccc12	Preclinical
TC-OT-39	oxytocin receptor agonist, vasopressin receptor agonist	AVPR1A, OXT			Tocris, Tocris, Tocris	96.28	CN1CCCN(CC1)C(=S)[C@@H]1CCCN1C(=O)NCc1ccc(cc1C)C(=O)N1Cc2cnn(C)c2Nc2ccccc12, CN1CCCN(CC1)C(=S)[C@@H]1CCCN1C(=O)NCc1ccc(cc1C)C(=O)N1Cc2cnn(C)c2Nc2ccccc12, CN1CCCN(CC1)C(=S)[C@@H]1CCCN1C(=O)NCc1ccc(cc1C)C(=O)N1Cc2cnn(C)c2Nc2ccccc12	Preclinical
TC-S-7003	SRC inhibitor	LCK			Tocris, Tocris	94.27	CN1CCN(CC1)c1ccc(Nc2ncc3c(n2)n2c(nc4ccccc24)n(-c2c(C)cccc2C)c3=O)cc1, CN1CCN(CC1)c1ccc(Nc2ncc3c(n2)n2c(nc4ccccc24)n(-c2c(C)cccc2C)c3=O)cc1	Preclinical
TC-S-7004	DYRK inhibitor	DYRK1A, DYRK1B			Tocris, Tocris, Tocris, Tocris	95.75	COc1ncc2cc(C(=O)Nc3cc(ccc3Cl)C(=O)NCc3cccc(Cl)c3)c(=O)[nH]c2n1, COc1ncc2cc(C(=O)Nc3cc(ccc3Cl)C(=O)NCc3cccc(Cl)c3)c(=O)[nH]c2n1, COc1ncc2cc(C(=O)Nc3cc(ccc3Cl)C(=O)NCc3cccc(Cl)c3)c(=O)[nH]c2n1, COc1ncc2cc(C(=O)Nc3cc(ccc3Cl)C(=O)NCc3cccc(Cl)c3)c(=O)[nH]c2n1	Preclinical
TC-S-7005	PLK inhibitor	PLK2			Tocris, Tocris	99.07	C[C@H](Nc1cc2c(noc2cn1)-c1ccc2OCOc2c1)c1ccccc1, C[C@H](Nc1cc2c(noc2cn1)-c1ccc2OCOc2c1)c1ccccc1	Preclinical
TC-S-7006	MAP kinase inhibitor	MAP3K8			Tocris, Tocris	94.67	Fc1ccc(Nc2c(cnc3cnc(NCc4cccnc4)cc23)C#N)cc1Cl, Fc1ccc(Nc2c(cnc3cnc(NCc4cccnc4)cc23)C#N)cc1Cl	Preclinical
TC-S-7009	hypoxia inducible factor inhibitor	EPAS1			Tocris, Tocris	97.41	[O-][N+](=O)c1c(Nc2cc(F)cc(Cl)c2)ccc2nonc12, [O-][N+](=O)c1c(Nc2cc(F)cc(Cl)c2)ccc2nonc12	Preclinical
TC-SP-14	sphingosine 1-phosphate receptor agonist	S1PR1			Tocris, Tocris	96.27	OC(=O)C1CN(Cc2ccc(-c3nc4cc(Cc5ccccc5F)ccc4s3)c(F)c2)C1, OC(=O)C1CN(Cc2ccc(-c3nc4cc(Cc5ccccc5F)ccc4s3)c(F)c2)C1	Preclinical
TCID					Tocris, Tocris, Selleck, Selleck, Selleck	80.05	Clc1c2C(=O)CC(=O)c2c(Cl)c(Cl)c1Cl, Clc1c2C(=O)CC(=O)c2c(Cl)c(Cl)c1Cl, Clc1c2C(=O)CC(=O)c2c(Cl)c(Cl)c1Cl, Clc1c2C(=O)CC(=O)c2c(Cl)c(Cl)c1Cl, Clc1c2C(=O)CC(=O)c2c(Cl)c(Cl)c1Cl	Preclinical
TCN201	glutamate receptor antagonist	GRIN2A			Tocris, Tocris, Tocris, Tocris	97.03	Fc1ccc(cc1Cl)S(=O)(=O)NCc1ccc(cc1)C(=O)NNC(=O)c1ccccc1, Fc1ccc(cc1Cl)S(=O)(=O)NCc1ccc(cc1)C(=O)NNC(=O)c1ccccc1, Fc1ccc(cc1Cl)S(=O)(=O)NCc1ccc(cc1)C(=O)NNC(=O)c1ccccc1, Fc1ccc(cc1Cl)S(=O)(=O)NCc1ccc(cc1)C(=O)NNC(=O)c1ccccc1	Preclinical
TCN238	glutamate receptor positive allosteric modulator	GRM4			Tocris, Tocris	90.73	Nc1nccc(\C=C\c2ccccc2)n1, Nc1nccc(\C=C\c2ccccc2)n1	Preclinical
TCS-HDAC6-20b	HDAC inhibitor	HDAC6			Tocris, Tocris, Tocris	100	CC(C)C(=O)SCCCCC[C@H](NC(=O)OC(C)(C)C)C(=O)NC12CC3CC(CC(C3)C1)C2, CC(C)C(=O)SCCCCC[C@H](NC(=O)OC(C)(C)C)C(=O)NC12CC3CC(CC(C3)C1)C2, CC(C)C(=O)SCCCCC[C@H](NC(=O)OC(C)(C)C)C(=O)NC12CC3CC(CC(C3)C1)C2	Preclinical
TCS-OX2-29	orexin receptor antagonist	HCRTR2			Tocris, Tocris	98.33	COc1cc2CCN(Cc2cc1OC)C(=O)[C@@H](NCc1ccncc1)C(C)(C)C, COc1cc2CCN(Cc2cc1OC)C(=O)[C@@H](NCc1ccncc1)C(C)(C)C	Preclinical
TCS-PIM-1-1	Pim kinase inhibitor	PIM1			Tocris, Tocris	97.43	Oc1ccc(Br)cc1-c1cc(-c2ccccc2)c(C#N)c(=O)[nH]1, Oc1ccc(Br)cc1-c1cc(-c2ccccc2)c(C#N)c(=O)[nH]1	Preclinical
TCS-2002	glycogen synthase kinase inhibitor	GSK3B			Tocris	94.75	Cc1nnc(o1)-c1ccc2occ(-c3ccc(cc3)[S@](C)=O)c2c1 |&1:19,r|	Preclinical
TCS-21311	JAK inhibitor	JAK3			Tocris, Tocris, Tocris, AcmeBio, AcmeBio	96.69	CC(C)(O)C(=O)N1CCN(CC1)c1ccc(c(c1)C1=C(C(=O)NC1=O)c1c[nH]c2ccccc12)C(F)(F)F |t:20|, CC(C)(O)C(=O)N1CCN(CC1)c1ccc(c(c1)C1=C(C(=O)NC1=O)c1c[nH]c2ccccc12)C(F)(F)F |t:20|, CC(C)(O)C(=O)N1CCN(CC1)c1ccc(c(c1)C1=C(C(=O)NC1=O)c1c[nH]c2ccccc12)C(F)(F)F |t:20|, CC(C)(O)C(=O)N1CCN(CC1)c1ccc(c(c1)C1=C(C(=O)NC1=O)c1c[nH]c2ccccc12)C(F)(F)F |t:20|, CC(C)(O)C(=O)N1CCN(CC1)c1ccc(c(c1)C1=C(C(=O)NC1=O)c1c[nH]c2ccccc12)C(F)(F)F |t:20|	Preclinical
TCS-2210	neural stem cell inducer				Tocris, Tocris	94.21	ONC(=O)c1ccc2[nH]c(=O)c(CCCc3ccccc3)nc2c1, ONC(=O)c1ccc2[nH]c(=O)c(CCCc3ccccc3)nc2c1	Preclinical
TCS-2314	integrin inhibitor	ITGA4, ITGB1			Tocris, Tocris, Tocris	97.08	Cc1ccccc1NC(=O)Nc1ccc(CC(=O)N2CCOC[C@H]2C(=O)N2CCC(CC(O)=O)CC2)cc1, Cc1ccccc1NC(=O)Nc1ccc(CC(=O)N2CCOC[C@H]2C(=O)N2CCC(CC(O)=O)CC2)cc1, Cc1ccccc1NC(=O)Nc1ccc(CC(=O)N2CCOC[C@H]2C(=O)N2CCC(CC(O)=O)CC2)cc1	Preclinical
TCS-3035	G protein-coupled receptor agonist	GPR35			Tocris, Tocris	93.12	OC(=O)COc1ccc(\C=C2/SC(=O)NC2=O)cc1, OC(=O)COc1ccc(\C=C2/SC(=O)NC2=O)cc1	Preclinical
TCS-359	FLT3 inhibitor	FLT3			Tocris, Tocris, Tocris, Selleck, Selleck, Tocris, Selleck	95.75	COc1ccc(cc1OC)C(=O)Nc1sc2CCCCc2c1C(N)=O, COc1ccc(cc1OC)C(=O)Nc1sc2CCCCc2c1C(N)=O, COc1ccc(cc1OC)C(=O)Nc1sc2CCCCc2c1C(N)=O, COc1ccc(cc1OC)C(=O)Nc1sc2CCCCc2c1C(N)=O, COc1ccc(cc1OC)C(=O)Nc1sc2CCCCc2c1C(N)=O, COc1ccc(cc1OC)C(=O)Nc1sc2CCCCc2c1C(N)=O, COc1ccc(cc1OC)C(=O)Nc1sc2CCCCc2c1C(N)=O	Preclinical
TCS-5861528	transient receptor potential channel antagonist	TRPA1			Tocris, Tocris, Tocris, Tocris	97.49	CC[C@@H](C)c1ccc(NC(=O)Cn2cnc3n(C)c(=O)n(C)c(=O)c23)cc1 |&1:2,r|, CC[C@@H](C)c1ccc(NC(=O)Cn2cnc3n(C)c(=O)n(C)c(=O)c23)cc1 |&1:2,r|, CC[C@@H](C)c1ccc(NC(=O)Cn2cnc3n(C)c(=O)n(C)c(=O)c23)cc1 |&1:2,r|, CC[C@@H](C)c1ccc(NC(=O)Cn2cnc3n(C)c(=O)n(C)c(=O)c23)cc1 |&1:2,r|	Preclinical
TCV-309	platelet activating factor receptor antagonist				MedChemEx	70.33	CCC[n+]1cc(Br)cc(c1)C(=O)N(CCC(=O)NCCOC(=O)N1CCc2ccccc2C1)c1ccccc1	Preclinical
TC1	beta-secretase inhibitor	BACE1			Tocris, Tocris, Tocris, Tocris, Tocris, Tocris	96.9	O[C@@]12[C@H]3[C@H]4[C@H]5[C@@H]3[C@@H]([C@H]3[C@@H]5C[C@@H]4[C@@H]13)N2CCc1cccc(F)c1 |&1:1,&2:2,&3:3,&4:4,&5:5,&6:6,&7:7,&8:8,&9:10,&10:11,r,TLB:13:12:2.5:7.11|, O[C@@]12[C@H]3[C@H]4[C@H]5[C@@H]3[C@@H]([C@H]3[C@@H]5C[C@@H]4[C@@H]13)N2CCc1cccc(F)c1 |&1:1,&2:2,&3:3,&4:4,&5:5,&6:6,&7:7,&8:8,&9:10,&10:11,r,TLB:13:12:2.5:7.11|, O[C@@]12[C@H]3[C@H]4[C@H]5[C@@H]3[C@@H]([C@H]3[C@@H]5C[C@@H]4[C@@H]13)N2CCc1cccc(F)c1 |&1:1,&2:2,&3:3,&4:4,&5:5,&6:6,&7:7,&8:8,&9:10,&10:11,r,TLB:13:12:2.5:7.11|, O[C@@]12[C@H]3[C@H]4[C@H]5[C@@H]3[C@@H]([C@H]3[C@@H]5C[C@@H]4[C@@H]13)N2CCc1cccc(F)c1 |&1:1,&2:2,&3:3,&4:4,&5:5,&6:6,&7:7,&8:8,&9:10,&10:11,r,TLB:13:12:2.5:7.11|, O[C@@]12[C@H]3[C@H]4[C@H]5[C@@H]3[C@@H]([C@H]3[C@@H]5C[C@@H]4[C@@H]13)N2CCc1cccc(F)c1 |&1:1,&2:2,&3:3,&4:4,&5:5,&6:6,&7:7,&8:8,&9:10,&10:11,r,TLB:13:12:2.5:7.11|, O[C@@]12[C@H]3[C@H]4[C@H]5[C@@H]3[C@@H]([C@H]3[C@@H]5C[C@@H]4[C@@H]13)N2CCc1cccc(F)c1 |&1:1,&2:2,&3:3,&4:4,&5:5,&6:6,&7:7,&8:8,&9:10,&10:11,r,TLB:13:12:2.5:7.11|	Preclinical
TC2559	acetylcholine receptor agonist	CHRNA4			Tocris, Tocris	75.02	CCOc1cncc(\C=C\CCNC)c1, CCOc1cncc(\C=C\CCNC)c1	Preclinical
TD139	anti-inflammatory agent				MedChemEx	97.78	OC[C@H]1O[C@@H](S[C@@H]2O[C@H](CO)[C@H](O)[C@@H]([C@H]2O)n2cc(nn2)-c2cccc(F)c2)[C@H](O)[C@H]([C@H]1O)n1cc(nn1)-c1cccc(F)c1	Phase 2
tebipenem	bacterial cell wall synthesis inhibitor	CNR1	infectious disease, otolaryngology	pneumonia, otitis	MedChemEx	99.48	C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(SC3CN(C3)C3=NCCS3)=C(N2C1=O)C(=O)OCOC(=O)C(C)(C)C |c:19,t:14|	Launched
tecadenoson	adenosine receptor agonist	ADORA1			MedChemEx	97.17	OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N[C@@H]3CCOC3)ncnc12	Phase 2
tecalcet	calcium-sensing receptor agonist	CASR			Tocris, Cayman	96	COc1cccc(c1)[C@@H](C)NCCCc1ccccc1Cl, COc1cccc(c1)[C@@H](C)NCCCc1ccccc1Cl	Phase 2
tecastemizole	histamine receptor antagonist	KCNH2			ChemPacific, ChemPacific, ChemPacific, ChemPacific	91.7	Fc1ccc(Cn2c(NC3CCNCC3)nc3ccccc23)cc1, Fc1ccc(Cn2c(NC3CCNCC3)nc3ccccc23)cc1, Fc1ccc(Cn2c(NC3CCNCC3)nc3ccccc23)cc1, Fc1ccc(Cn2c(NC3CCNCC3)nc3ccccc23)cc1	Phase 3
tecovirimat	orthopoxvirus egress inhibitor		infectious disease	smallpox	MedChemEx, MedChemEx	98.79	FC(F)(F)c1ccc(cc1)C(=O)NN1C(=O)[C@H]2[C@H]([C@H]3C=C[C@@H]2[C@@H]2C[C@H]32)C1=O |c:20|, FC(F)(F)c1ccc(cc1)C(=O)NN1C(=O)[C@H]2[C@H]([C@H]3C=C[C@@H]2[C@@H]2C[C@H]32)C1=O |c:20|	Launched
tedizolid	bacterial 50S ribosomal subunit inhibitor		infectious disease	skin infections	MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx	98.73	Cn1nnc(n1)-c1ccc(cn1)-c1ccc(cc1F)N1C[C@H](CO)OC1=O, Cn1nnc(n1)-c1ccc(cn1)-c1ccc(cc1F)N1C[C@H](CO)OC1=O, Cn1nnc(n1)-c1ccc(cn1)-c1ccc(cc1F)N1C[C@H](CO)OC1=O, Cn1nnc(n1)-c1ccc(cn1)-c1ccc(cc1F)N1C[C@H](CO)OC1=O, Cn1nnc(n1)-c1ccc(cn1)-c1ccc(cc1F)N1C[C@H](CO)OC1=O	Launched
tedizolid-phosphate	protein synthesis inhibitor		infectious disease	skin infections	MedChemEx, Annova, MedChemEx, MedChemEx	94.69	Cn1nnc(n1)-c1ccc(cn1)-c1ccc(cc1F)N1C[C@H](COP(O)(O)=O)OC1=O, Cn1nnc(n1)-c1ccc(cn1)-c1ccc(cc1F)N1C[C@H](COP(O)(O)=O)OC1=O, Cn1nnc(n1)-c1ccc(cn1)-c1ccc(cc1F)N1C[C@H](COP(O)(O)=O)OC1=O, Cn1nnc(n1)-c1ccc(cn1)-c1ccc(cc1F)N1C[C@H](COP(O)(O)=O)OC1=O	Launched
tegaserod	serotonin receptor partial agonist	HTR2A, HTR2B, HTR2C, HTR4			MicroSource, MedChemEx, MedChemEx, Tocris	95.01	CCCCCNC(=N)N\N=C\c1c[nH]c2ccc(OC)cc12, CCCCCNC(=N)N\N=C\c1c[nH]c2ccc(OC)cc12, CCCCCNC(=N)N\N=C\c1c[nH]c2ccc(OC)cc12, CCCCCNC(=N)N\N=C\c1c[nH]c2ccc(OC)cc12	Withdrawn
tegobuvir	HCV inhibitor, protease inhibitor				MedChemEx, MedChemEx	96.11	Fc1ccccc1-c1nc2ccn(Cc3ccc(nn3)-c3ccc(cc3C(F)(F)F)C(F)(F)F)cc2n1, Fc1ccccc1-c1nc2ccn(Cc3ccc(nn3)-c3ccc(cc3C(F)(F)F)C(F)(F)F)cc2n1	Phase 3
teicoplanin	bacterial cell wall synthesis inhibitor		infectious disease	gram-positive bacterial infections	MedChemEx, MedChemEx	56.59	CCCCCCCCCC(=O)N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1Oc1c2Oc3ccc(C[C@H]4NC(=O)[C@@H](N)c5ccc(O)c(Oc6cc(O)cc(c6)[C@H](NC4=O)C(=O)N[C@@H]4c(c2)cc1Oc1ccc(cc1Cl)[C@@H](O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1NC(C)=O)[C@@H]1NC(=O)[C@H](NC4=O)c2ccc(O)c(c2)-c2c(O[C@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]4O)cc(O)cc2[C@@H](NC1=O)C(O)=O)c5)cc3Cl, CCCCCCCCCC(=O)N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1Oc1c2Oc3ccc(C[C@H]4NC(=O)[C@@H](N)c5ccc(O)c(Oc6cc(O)cc(c6)[C@H](NC4=O)C(=O)N[C@@H]4c(c2)cc1Oc1ccc(cc1Cl)[C@@H](O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1NC(C)=O)[C@@H]1NC(=O)[C@H](NC4=O)c2ccc(O)c(c2)-c2c(O[C@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]4O)cc(O)cc2[C@@H](NC1=O)C(O)=O)c5)cc3Cl	Launched
teicoplanin-A2-1	bacterial cell wall synthesis inhibitor		infectious disease	gram-positive bacterial infections	MicroSource, Selleck	46.55	CCCCC\C=C\CCC(=O)N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1Oc1c2Oc3ccc(C[C@H]4NC(=O)[C@H](N)c5ccc(O)c(Oc6cc(O)cc(c6)[C@H](NC4=O)C(=O)N[C@@H]4c(c2)cc1Oc1ccc(cc1Cl)[C@@H](O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1NC(C)=O)[C@@H]1NC(=O)[C@H](NC4=O)c2ccc(O)c(c2)-c2c(O[C@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]4O)cc(O)cc2[C@H](NC1=O)C(O)=O)c5)cc3Cl |a:12,13,15,17,21,35,51,58,71,73,75,78,80,82,87,91,107,110,112,114,121,&1:31,&2:105|, CCCCC\C=C\CCC(=O)N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1Oc1c2Oc3ccc(C[C@H]4NC(=O)[C@H](N)c5ccc(O)c(Oc6cc(O)cc(c6)[C@H](NC4=O)C(=O)N[C@@H]4c(c2)cc1Oc1ccc(cc1Cl)[C@@H](O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1NC(C)=O)[C@@H]1NC(=O)[C@H](NC4=O)c2ccc(O)c(c2)-c2c(O[C@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]4O)cc(O)cc2[C@H](NC1=O)C(O)=O)c5)cc3Cl |a:12,13,15,17,21,35,51,58,71,73,75,78,80,82,87,91,107,110,112,114,121,&1:31,&2:105|	Launched
teicoplanin-A2-3	bacterial cell wall synthesis inhibitor		infectious disease	gram-positive bacterial infections	Selleck	9.36	CC(C)CCCCCCCC(=O)N[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1Oc1c2Oc3ccc(C[C@H]4NC(=O)[C@H](N)c5ccc(O)c(Oc6cc(O)cc(c6)[C@H](NC4=O)C(=O)N[C@H]4c(c2)cc1Oc1ccc(cc1Cl)[C@@H](O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]1NC(C)=O)[C@@H]1NC(=O)[C@@H](NC4=O)c2ccc(O)c(c2)-c2c(O[C@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]4O)cc(O)cc2[C@@H](NC1=O)C(O)=O)c5)cc3Cl	Launched
teijin-compound-1	CC chemokine receptor antagonist	CCR2			Tocris, Tocris	98.07	FC(F)(F)c1cccc(c1)C(=O)NCC(=O)N[C@@H]1CCN(Cc2ccc(Cl)cc2)C1, FC(F)(F)c1cccc(c1)C(=O)NCC(=O)N[C@@H]1CCN(Cc2ccc(Cl)cc2)C1	Preclinical
telaprevir	HCV inhibitor	CTSA, PGR	infectious disease	hepatitis C	MedChemEx, MedChemEx, Selleck, Selleck, Selleck, Selleck, Selleck	97.83	CCC[C@H](NC(=O)[C@@H]1[C@H]2CCC[C@H]2CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)c1cnccn1)C1CCCCC1)C(C)(C)C)C(=O)C(=O)NC1CC1, CCC[C@H](NC(=O)[C@@H]1[C@H]2CCC[C@H]2CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)c1cnccn1)C1CCCCC1)C(C)(C)C)C(=O)C(=O)NC1CC1, CCC[C@H](NC(=O)[C@@H]1[C@H]2CCC[C@H]2CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)c1cnccn1)C1CCCCC1)C(C)(C)C)C(=O)C(=O)NC1CC1, CCC[C@H](NC(=O)[C@@H]1[C@H]2CCC[C@H]2CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)c1cnccn1)C1CCCCC1)C(C)(C)C)C(=O)C(=O)NC1CC1, CCC[C@H](NC(=O)[C@@H]1[C@H]2CCC[C@H]2CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)c1cnccn1)C1CCCCC1)C(C)(C)C)C(=O)C(=O)NC1CC1, CCC[C@H](NC(=O)[C@@H]1[C@H]2CCC[C@H]2CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)c1cnccn1)C1CCCCC1)C(C)(C)C)C(=O)C(=O)NC1CC1, CCC[C@H](NC(=O)[C@@H]1[C@H]2CCC[C@H]2CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)c1cnccn1)C1CCCCC1)C(C)(C)C)C(=O)C(=O)NC1CC1	Launched
telatinib	KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	KDR			MedChemEx, Selleck, Selleck	97.97	CNC(=O)c1cc(COc2nnc(Nc3ccc(Cl)cc3)c3ccoc23)ccn1, CNC(=O)c1cc(COc2nnc(Nc3ccc(Cl)cc3)c3ccoc23)ccn1, CNC(=O)c1cc(COc2nnc(Nc3ccc(Cl)cc3)c3ccoc23)ccn1	Phase 2
telbivudine	DNA polymerase inhibitor		infectious disease	hepatitis B	Selleck, Selleck	97.7	Cc1cn([C@@H]2C[C@@H](O)[C@H](CO)O2)c(=O)[nH]c1=O, Cc1cn([C@@H]2C[C@@H](O)[C@H](CO)O2)c(=O)[nH]c1=O	Launched
telcagepant	calcitonin antagonist	CALCRL, RAMP1			MedChemEx, MedChemEx, MedChemEx, MedChemEx	97.22	Fc1cccc([C@@H]2CC[C@@H](NC(=O)N3CCC(CC3)n3c4cccnc4[nH]c3=O)C(=O)N(CC(F)(F)F)C2)c1F, Fc1cccc([C@@H]2CC[C@@H](NC(=O)N3CCC(CC3)n3c4cccnc4[nH]c3=O)C(=O)N(CC(F)(F)F)C2)c1F, Fc1cccc([C@@H]2CC[C@@H](NC(=O)N3CCC(CC3)n3c4cccnc4[nH]c3=O)C(=O)N(CC(F)(F)F)C2)c1F, Fc1cccc([C@@H]2CC[C@@H](NC(=O)N3CCC(CC3)n3c4cccnc4[nH]c3=O)C(=O)N(CC(F)(F)F)C2)c1F	Phase 3
telenzepine	acetylcholine receptor antagonist	CHRM1			MicroSource, Tocris	98.14	CN1CCN(CC(=O)N2c3c(C)scc3C(=O)Nc3ccccc23)CC1, CN1CCN(CC(=O)N2c3c(C)scc3C(=O)Nc3ccccc23)CC1	Phase 3
telithromycin	bacterial 30S ribosomal subunit inhibitor, bacterial 50S ribosomal subunit inhibitor	CYP1A2, CYP2D6, CYP3A4, CYP3A5, CYP3A7	infectious disease	pneumonia	MedChemEx, Cayman	89.32	CC[C@H]1OC(=O)[C@H](C)C(=O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@H]2N(CCCCn3cnc(c3)-c3cccnc3)C(=O)O[C@]12C)OC, CC[C@H]1OC(=O)[C@H](C)C(=O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@H]2N(CCCCn3cnc(c3)-c3cccnc3)C(=O)O[C@]12C)OC	Launched
telmesteine	mucolytic agent		pulmonary	cough suppressant	TCI	96.9	CCOC(=O)N1CSC[C@@H]1C(O)=O |&1:9,r|	Launched
telmisartan	angiotensin receptor antagonist	AGTR1, PPARG	cardiology	hypertension	MicroSource, MicroSource, Tocris, Tocris, Tocris, Selleck, Selleck, Selleck, Selleck	99.08	CCCc1nc2c(C)cc(cc2n1Cc1ccc(cc1)-c1ccccc1C(O)=O)-c1nc2ccccc2n1C, CCCc1nc2c(C)cc(cc2n1Cc1ccc(cc1)-c1ccccc1C(O)=O)-c1nc2ccccc2n1C, CCCc1nc2c(C)cc(cc2n1Cc1ccc(cc1)-c1ccccc1C(O)=O)-c1nc2ccccc2n1C, CCCc1nc2c(C)cc(cc2n1Cc1ccc(cc1)-c1ccccc1C(O)=O)-c1nc2ccccc2n1C, CCCc1nc2c(C)cc(cc2n1Cc1ccc(cc1)-c1ccccc1C(O)=O)-c1nc2ccccc2n1C, CCCc1nc2c(C)cc(cc2n1Cc1ccc(cc1)-c1ccccc1C(O)=O)-c1nc2ccccc2n1C, CCCc1nc2c(C)cc(cc2n1Cc1ccc(cc1)-c1ccccc1C(O)=O)-c1nc2ccccc2n1C, CCCc1nc2c(C)cc(cc2n1Cc1ccc(cc1)-c1ccccc1C(O)=O)-c1nc2ccccc2n1C, CCCc1nc2c(C)cc(cc2n1Cc1ccc(cc1)-c1ccccc1C(O)=O)-c1nc2ccccc2n1C	Launched
telotristat	tryptophan hydroxylase inhibitor	TPH1	gastroenterology	diarrhea	MedChemEx, MedChemEx	94.93	Cc1ccn(n1)-c1cc(Cl)ccc1[C@@H](Oc1cc(nc(N)n1)-c1ccc(C[C@H](N)C(O)=O)cc1)C(F)(F)F, Cc1ccn(n1)-c1cc(Cl)ccc1[C@@H](Oc1cc(nc(N)n1)-c1ccc(C[C@H](N)C(O)=O)cc1)C(F)(F)F	Launched
telotristat-ethyl	tryptophan hydroxylase inhibitor	TPH1	gastroenterology	diarrhea	MedChemEx, MedChemEx, Selleck, MedChemEx	99.27	CCOC(=O)[C@@H](N)Cc1ccc(cc1)-c1cc(O[C@H](c2ccc(Cl)cc2-n2ccc(C)n2)C(F)(F)F)nc(N)n1, CCOC(=O)[C@@H](N)Cc1ccc(cc1)-c1cc(O[C@H](c2ccc(Cl)cc2-n2ccc(C)n2)C(F)(F)F)nc(N)n1, CCOC(=O)[C@@H](N)Cc1ccc(cc1)-c1cc(O[C@H](c2ccc(Cl)cc2-n2ccc(C)n2)C(F)(F)F)nc(N)n1, CCOC(=O)[C@@H](N)Cc1ccc(cc1)-c1cc(O[C@H](c2ccc(Cl)cc2-n2ccc(C)n2)C(F)(F)F)nc(N)n1	Launched
telratolimod	toll-like receptor agonist				MedChemEx	12.91	CCCCCCCCCCCCCCCCCC(=O)NCCCCOn1c(CCCC)nc2c(N)nc3ccccc3c12	Preclinical
temanogrel	serotonin receptor antagonist				MedChemEx	95.3	COc1cccc(c1)C(=O)Nc1ccc(OCCN2CCOCC2)c(c1)-c1ccnn1C	Preclinical
temefos	cholinesterase inhibitor				MicroSource, MedChemEx	83.67	COP(=S)(OC)Oc1ccc(Sc2ccc(OP(=S)(OC)OC)cc2)cc1, COP(=S)(OC)Oc1ccc(Sc2ccc(OP(=S)(OC)OC)cc2)cc1	Launched
temocapril	angiotensin converting enzyme inhibitor	ACE	cardiology, nephrology	hypertension, congestive heart failure, diabetic nephropathy, coronary artery disease (CAD)	Selleck, MedChemEx, MedChemEx, MedChemEx	98.28	CCOC(=O)[C@H](CCc1ccccc1)N[C@H]1CS[C@@H](CN(CC(O)=O)C1=O)c1cccs1, CCOC(=O)[C@H](CCc1ccccc1)N[C@H]1CS[C@@H](CN(CC(O)=O)C1=O)c1cccs1, CCOC(=O)[C@H](CCc1ccccc1)N[C@H]1CS[C@@H](CN(CC(O)=O)C1=O)c1cccs1, CCOC(=O)[C@H](CCc1ccccc1)N[C@H]1CS[C@@H](CN(CC(O)=O)C1=O)c1cccs1	Launched
temoporfin	radical formation stimulant		oncology	head and neck squamous cell carcinoma (HNSCC)	MedChemEx, MedChemEx, MedChemEx	85.6	Oc1cccc(c1)-c1c2CCc([nH]2)c(-c2cccc(O)c2)c2ccc([nH]2)c(-c2cccc(O)c2)c2ccc(n2)c(-c2cccc(O)c2)c2ccc1n2, Oc1cccc(c1)-c1c2CCc([nH]2)c(-c2cccc(O)c2)c2ccc([nH]2)c(-c2cccc(O)c2)c2ccc(n2)c(-c2cccc(O)c2)c2ccc1n2, Oc1cccc(c1)-c1c2CCc([nH]2)c(-c2cccc(O)c2)c2ccc([nH]2)c(-c2cccc(O)c2)c2ccc(n2)c(-c2cccc(O)c2)c2ccc1n2	Launched
temozolomide	DNA alkylating agent	MGMT	oncology	glioblastoma, astrocytoma	Tocris, MicroSource, Tocris, Selleck	97.56	Cn1nnc2c(ncn2c1=O)C(N)=O, Cn1nnc2c(ncn2c1=O)C(N)=O, Cn1nnc2c(ncn2c1=O)C(N)=O, Cn1nnc2c(ncn2c1=O)C(N)=O	Launched
tempol	free radical scavenger				Selleck, Acros, Selleck	100	CC1(C)CC(O)CC(C)(C)N1O, CC1(C)CC(O)CC(C)(C)N1O, CC1(C)CC(O)CC(C)(C)N1O	Phase 2
temsirolimus	mTOR inhibitor	MTOR	oncology	renal cell carcinoma (RCC)	Tocris, Tocris	96.7	CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OC(=O)C(C)(CO)CO |c:14,33,t:29,31|, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OC(=O)C(C)(CO)CO |c:14,33,t:29,31|	Launched
TEN-010	bromodomain inhibitor				MedChemEx	94.38	CN1CCN(CCCNC(=O)C[C@@H]2N=C(c3c(C)c(C)sc3-n3c(C)nnc23)c2ccc(Cl)cc2)CC1 |c:13|	Preclinical
tenalisib	PI3K inhibitor				MedChemEx	97.79	CC[C@H](Nc1ncnc2nc[nH]c12)c1oc2ccccc2c(=O)c1-c1cccc(F)c1	Phase 2
tenapanor	sodium/hydrogen exchanger inhibitor				MedChemEx	82.6	CN1C[C@@H](c2cccc(c2)S(=O)(=O)NCCOCCOCCNC(=O)NCCCCNC(=O)NCCOCCOCCNS(=O)(=O)c2cccc(c2)[C@@H]2CN(C)Cc3c(Cl)cc(Cl)cc23)c2cc(Cl)cc(Cl)c2C1	Launched
tenatoprazole	ATPase inhibitor	IDO1			MicroSource	95.62	COc1ccc2[nH]c(nc2n1)[S@@](=O)Cc1ncc(C)c(OC)c1C |r|	Phase 2
teneligliptin	dipeptidyl peptidase inhibitor	DPP4	endocrinology	diabetes mellitus	MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx	96.62	Cc1cc(N2CCN(CC2)[C@@H]2CN[C@@H](C2)C(=O)N2CCSC2)n(n1)-c1ccccc1, Cc1cc(N2CCN(CC2)[C@@H]2CN[C@@H](C2)C(=O)N2CCSC2)n(n1)-c1ccccc1, Cc1cc(N2CCN(CC2)[C@@H]2CN[C@@H](C2)C(=O)N2CCSC2)n(n1)-c1ccccc1, Cc1cc(N2CCN(CC2)[C@@H]2CN[C@@H](C2)C(=O)N2CCSC2)n(n1)-c1ccccc1, Cc1cc(N2CCN(CC2)[C@@H]2CN[C@@H](C2)C(=O)N2CCSC2)n(n1)-c1ccccc1, Cc1cc(N2CCN(CC2)[C@@H]2CN[C@@H](C2)C(=O)N2CCSC2)n(n1)-c1ccccc1	Launched
tenidap	cyclooxygenase inhibitor	KCNJ4, PTGS1			Tocris	93.72	NC(=O)N1C(=O)[C@@H](C(=O)c2cccs2)c2cc(Cl)ccc12 |&1:6,r|	Phase 3
tenilsetam	AGE inhibitor				Enamine, LifeChem	59.54	O=C1NCCN[C@@H]1c1cccs1 |&1:6,r|, O=C1NCCN[C@@H]1c1cccs1 |&1:6,r|	Phase 3
teniposide	topoisomerase inhibitor	TOP2A, TOP2B	hematologic malignancy	acute lymphoblastic leukemia (ALL)	Selleck, Selleck, Selleck, Selleck	96.09	COc1cc(cc(OC)c1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@H](O[C@H]3[C@H](O)[C@H]2O)c2cccs2)c2cc3OCOc3cc12, COc1cc(cc(OC)c1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@H](O[C@H]3[C@H](O)[C@H]2O)c2cccs2)c2cc3OCOc3cc12, COc1cc(cc(OC)c1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@H](O[C@H]3[C@H](O)[C@H]2O)c2cccs2)c2cc3OCOc3cc12, COc1cc(cc(OC)c1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@H](O[C@H]3[C@H](O)[C@H]2O)c2cccs2)c2cc3OCOc3cc12	Launched
tenofovir	HIV integrase inhibitor, nucleoside reverse transcriptase inhibitor		infectious disease	human immunodeficiency virus (HIV-1), hepatitis B	MicroSource, Selleck, Selleck	100	C[C@H](Cn1cnc2c(N)ncnc12)OCP(O)(O)=O, C[C@H](Cn1cnc2c(N)ncnc12)OCP(O)(O)=O, C[C@H](Cn1cnc2c(N)ncnc12)OCP(O)(O)=O	Launched
tenofovir-alafenamide	nucleoside reverse transcriptase inhibitor		infectious disease	hepatitis B	Selleck	93.68	CC(C)OC(=O)[C@@H](C)NP(=O)(CO[C@@H](C)Cn1cnc2c(N)ncnc12)Oc1ccccc1 |&1:6,&2:9,&3:13,r|	Launched
tenofovir-disoproxil	nucleoside reverse transcriptase inhibitor	CYP1A2	infectious disease	human immunodeficiency virus (HIV-1), hepatitis B	Selleck, Selleck, Selleck, Selleck	95.24	CC(C)OC(=O)OCOP(=O)(CO[C@H](C)Cn1cnc2c(N)ncnc12)OCOC(=O)OC(C)C, CC(C)OC(=O)OCOP(=O)(CO[C@H](C)Cn1cnc2c(N)ncnc12)OCOC(=O)OC(C)C, CC(C)OC(=O)OCOP(=O)(CO[C@H](C)Cn1cnc2c(N)ncnc12)OCOC(=O)OC(C)C, CC(C)OC(=O)OCOP(=O)(CO[C@H](C)Cn1cnc2c(N)ncnc12)OCOC(=O)OC(C)C	Launched
tenovin-1	SIRT inhibitor, TP53 activator	SIRT1			Tocris, Tocris, Tocris, Tocris, Tocris, Selleck, Selleck	97.6	CC(=O)Nc1ccc(NC(=S)NC(=O)c2ccc(cc2)C(C)(C)C)cc1, CC(=O)Nc1ccc(NC(=S)NC(=O)c2ccc(cc2)C(C)(C)C)cc1, CC(=O)Nc1ccc(NC(=S)NC(=O)c2ccc(cc2)C(C)(C)C)cc1, CC(=O)Nc1ccc(NC(=S)NC(=O)c2ccc(cc2)C(C)(C)C)cc1, CC(=O)Nc1ccc(NC(=S)NC(=O)c2ccc(cc2)C(C)(C)C)cc1, CC(=O)Nc1ccc(NC(=S)NC(=O)c2ccc(cc2)C(C)(C)C)cc1, CC(=O)Nc1ccc(NC(=S)NC(=O)c2ccc(cc2)C(C)(C)C)cc1	Preclinical
tenovin-6	SIRT inhibitor	SIRT1, SIRT2, SIRT3			Selleck, Selleck, Selleck, Selleck, MedChemEx	96.44	CN(C)CCCCC(=O)Nc1ccc(NC(=S)NC(=O)c2ccc(cc2)C(C)(C)C)cc1, CN(C)CCCCC(=O)Nc1ccc(NC(=S)NC(=O)c2ccc(cc2)C(C)(C)C)cc1, CN(C)CCCCC(=O)Nc1ccc(NC(=S)NC(=O)c2ccc(cc2)C(C)(C)C)cc1, CN(C)CCCCC(=O)Nc1ccc(NC(=S)NC(=O)c2ccc(cc2)C(C)(C)C)cc1, CN(C)CCCCC(=O)Nc1ccc(NC(=S)NC(=O)c2ccc(cc2)C(C)(C)C)cc1	Preclinical
tenoxicam	cyclooxygenase inhibitor	PTGS1, PTGS2	rheumatology, orthopedics	rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, tendinitis, bursitis, periarthritis	MedChemEx, MicroSource, Selleck	98.19	CN1C(C(=O)Nc2ccccn2)=C(O)c2sccc2S1(=O)=O |t:12|, CN1C(C(=O)Nc2ccccn2)=C(O)c2sccc2S1(=O)=O |t:12|, CN1C(C(=O)Nc2ccccn2)=C(O)c2sccc2S1(=O)=O |t:12|	Launched
tenylidone					MicroSource, ChemDiv	71.2	O=C1\C(CCC\C1=C/c1cccs1)=C\c1cccs1, O=C1\C(CCC\C1=C/c1cccs1)=C\c1cccs1	Preclinical
tepoxalin	cyclooxygenase inhibitor, lipoxygenase inhibitor	ALOX5	rheumatology, orthopedics	rheumatoid arthritis, hip dysplasia	MicroSource, MicroSource, MicroSource, Toronto, Toronto	98.03	COc1ccc(cc1)-n1nc(CCC(=O)N(C)O)cc1-c1ccc(Cl)cc1, COc1ccc(cc1)-n1nc(CCC(=O)N(C)O)cc1-c1ccc(Cl)cc1, COc1ccc(cc1)-n1nc(CCC(=O)N(C)O)cc1-c1ccc(Cl)cc1, COc1ccc(cc1)-n1nc(CCC(=O)N(C)O)cc1-c1ccc(Cl)cc1, COc1ccc(cc1)-n1nc(CCC(=O)N(C)O)cc1-c1ccc(Cl)cc1	Launched
TEPP-46	pyruvate kinase isozyme activator	PKM			MedChemEx, MedChemEx, MedChemEx	97.55	Cn1c2cc(sc2c2cnn(Cc3cccc(N)c3)c(=O)c12)[S@@](C)=O |r|, Cn1c2cc(sc2c2cnn(Cc3cccc(N)c3)c(=O)c12)[S@@](C)=O |r|, Cn1c2cc(sc2c2cnn(Cc3cccc(N)c3)c(=O)c12)[S@@](C)=O |r|	Preclinical
teprenone	mucus protecting agent		dermatology	cosmetic	MedChemEx, MedChemEx, SantaCruz, SantaCruz	82.34	CC(C)=CCC\C(C)=C\CC\C(C)=C\CC\C(C)=C\CCC(C)=O, CC(C)=CCC\C(C)=C\CC\C(C)=C\CC\C(C)=C\CCC(C)=O, CC(C)=CCC\C(C)=C\CC\C(C)=C\CC\C(C)=C\CCC(C)=O, CC(C)=CCC\C(C)=C\CC\C(C)=C\CC\C(C)=C\CCC(C)=O	Launched
terameprocol	lipoxygenase inhibitor	BIRC5, CDK1			Sigma	99.1	COc1ccc(C[C@H](C)[C@H](C)Cc2ccc(OC)c(OC)c2)cc1OC	Phase 1/Phase 2
terazosin	adrenergic receptor antagonist	ADRA1A, ADRA1B, ADRA1D	urology, cardiology	benign prostatic hyperplasia (BPH), hypertension	Tocris, Tocris	98.27	COc1cc2nc(nc(N)c2cc1OC)N1CCN(CC1)C(=O)[C@H]1CCCO1 |&1:23,r|, COc1cc2nc(nc(N)c2cc1OC)N1CCN(CC1)C(=O)[C@H]1CCCO1 |&1:23,r|	Launched
terbinafine	fungal squalene epoxidase inhibitor	SQLE	infectious disease	tinea pedis, tinea cruris, tinea corporis	MicroSource, Selleck, Selleck, Selleck, Selleck	98.76	CN(C\C=C\C#CC(C)(C)C)Cc1cccc2ccccc12, CN(C\C=C\C#CC(C)(C)C)Cc1cccc2ccccc12, CN(C\C=C\C#CC(C)(C)C)Cc1cccc2ccccc12, CN(C\C=C\C#CC(C)(C)C)Cc1cccc2ccccc12, CN(C\C=C\C#CC(C)(C)C)Cc1cccc2ccccc12	Launched
terbutaline	adrenergic receptor agonist	ADRB2	pulmonary	bronchospasm, bronchitis, emphysema	MedChemEx, MedChemEx, MicroSource	96.73	CC(C)(C)NC[C@@H](O)c1cc(O)cc(O)c1 |&1:6|, CC(C)(C)NC[C@@H](O)c1cc(O)cc(O)c1 |&1:6|, CC(C)(C)NC[C@@H](O)c1cc(O)cc(O)c1 |&1:6|	Launched
terciprazine					PrincetonBio, PrincetonBio	94.14	O[C@@H](COC1(CCCCC1)C#C)CN1CCN(CC1)c1cccc(c1)C(F)(F)F |&1:1,r|, O[C@@H](COC1(CCCCC1)C#C)CN1CCN(CC1)c1cccc(c1)C(F)(F)F |&1:1,r|	Phase 1
terconazole	sterol demethylase inhibitor		infectious disease	vulvovaginal candidiasis	MedChemEx, MicroSource	95.98	CC(C)N1CCN(CC1)c1ccc(OC[C@H]2CO[C@@](Cn3cncn3)(O2)c2ccc(Cl)cc2Cl)cc1, CC(C)N1CCN(CC1)c1ccc(OC[C@H]2CO[C@@](Cn3cncn3)(O2)c2ccc(Cl)cc2Cl)cc1	Launched
terfenadine	histamine receptor antagonist	HRH1, KCNH1, KCNH2			MicroSource, MicroSource, Tocris, Tocris, Selleck, Tocris	97.86	CC(C)(C)c1ccc(cc1)[C@@H](O)CCCN1CCC(CC1)C(O)(c1ccccc1)c1ccccc1 |&1:10,r|, CC(C)(C)c1ccc(cc1)[C@@H](O)CCCN1CCC(CC1)C(O)(c1ccccc1)c1ccccc1 |&1:10,r|, CC(C)(C)c1ccc(cc1)[C@@H](O)CCCN1CCC(CC1)C(O)(c1ccccc1)c1ccccc1 |&1:10,r|, CC(C)(C)c1ccc(cc1)[C@@H](O)CCCN1CCC(CC1)C(O)(c1ccccc1)c1ccccc1 |&1:10,r|, CC(C)(C)c1ccc(cc1)[C@@H](O)CCCN1CCC(CC1)C(O)(c1ccccc1)c1ccccc1 |&1:10,r|, CC(C)(C)c1ccc(cc1)[C@@H](O)CCCN1CCC(CC1)C(O)(c1ccccc1)c1ccccc1 |&1:10,r|	Withdrawn
terguride	dopamine receptor agonist, serotonin receptor antagonist	ADRA1A, ADRA2A, ADRA2B, ADRA2C, DRD2, DRD3, DRD4, HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C	neurology/psychiatry	Parkinson's Disease	Kemprotec	94.68	CCN(CC)C(=O)N[C@H]1C[C@H]2[C@@H](Cc3c[nH]c4cccc2c34)N(C)C1 |a:8,&1:10,&2:11|	Launched
teriflunomide	dihydroorotate dehydrogenase inhibitor	DHODH	neurology/psychiatry	multiple sclerosis	Selleck, Tocris, Selleck	99.84	CC(=O)[C@@H](C#N)C(=O)Nc1ccc(cc1)C(F)(F)F |&1:3,r|, CC(=O)[C@@H](C#N)C(=O)Nc1ccc(cc1)C(F)(F)F |&1:3,r|, CC(=O)[C@@H](C#N)C(=O)Nc1ccc(cc1)C(F)(F)F |&1:3,r|	Launched
terlipressin	vasopressin receptor agonist	AVPR1A	cardiology	hypotension	Key, Key	96.16	NCCCC[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CSSC[C@H](NC(=O)CNC(=O)CNC(=O)CN)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N1)C(=O)NCC(N)=O, NCCCC[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CSSC[C@H](NC(=O)CNC(=O)CNC(=O)CN)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N1)C(=O)NCC(N)=O	Launched
terodiline	cholinergic receptor antagonist				Sigma	97.58	C[C@@H](CC(c1ccccc1)c1ccccc1)NC(C)(C)C |&1:1|	Withdrawn
teroxirone	DNA inhibitor				Sigma, ChemDiv, ChemDiv	100	O=c1n(C[C@H]2CO2)c(=O)n(C[C@H]2CO2)c(=O)n1C[C@H]1CO1 |&1:4,&2:11,&3:18,r|, O=c1n(C[C@H]2CO2)c(=O)n(C[C@H]2CO2)c(=O)n1C[C@H]1CO1 |&1:4,&2:11,&3:18,r|, O=c1n(C[C@H]2CO2)c(=O)n(C[C@H]2CO2)c(=O)n1C[C@H]1CO1 |&1:4,&2:11,&3:18,r|	Phase 1
terpene					MedChemEx	0	CC(C)(O)[C@H]1CC[C@](C)(O)CC1 |&1:7,&2:4|	Preclinical
terreic-acid-(-)	Bruton's tyrosine kinase (BTK) inhibitor	BTK				0		Preclinical
terutroban	prostanoid receptor antagonist	TBXA2R			MedChemEx, MedChemEx	95.89	Cc1ccc2C[C@@H](CCc2c1CCC(O)=O)NS(=O)(=O)c1ccc(Cl)cc1, Cc1ccc2C[C@@H](CCc2c1CCC(O)=O)NS(=O)(=O)c1ccc(Cl)cc1	Phase 3
tesaglitazar	insulin sensitizer, PPAR receptor agonist	PPARA, PPARG			Tocris, Cayman	96.97	CCO[C@@H](Cc1ccc(OCCc2ccc(OS(C)(=O)=O)cc2)cc1)C(O)=O, CCO[C@@H](Cc1ccc(OCCc2ccc(OS(C)(=O)=O)cc2)cc1)C(O)=O	Phase 3
tetomilast	phosphodiesterase inhibitor	PDE4D			Sigma	93.74	CCOc1ccc(cc1OCC)-c1nc(cs1)-c1cccc(n1)C(O)=O	Phase 2
tetrabenazine	vesicular monoamine transporter inhibitor	SLC18A1, SLC18A2	infectious disease, neurology/psychiatry	cholera, Huntington's disease	Tocris, Tocris, Tocris, Tocris, Tocris	93.02	COc1cc2CCN3C[C@H](CC(C)C)C(=O)C[C@H]3c2cc1OC, COc1cc2CCN3C[C@H](CC(C)C)C(=O)C[C@H]3c2cc1OC, COc1cc2CCN3C[C@H](CC(C)C)C(=O)C[C@H]3c2cc1OC, COc1cc2CCN3C[C@H](CC(C)C)C(=O)C[C@H]3c2cc1OC, COc1cc2CCN3C[C@H](CC(C)C)C(=O)C[C@H]3c2cc1OC	Launched
tetracaine	membrane integrity inhibitor	SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A	neurology/psychiatry	anesthetic	Selleck, MicroSource	98.82	CCCCNc1ccc(cc1)C(=O)OCCN(C)C, CCCCNc1ccc(cc1)C(=O)OCCN(C)C	Launched
tetracycline	bacterial 30S ribosomal subunit inhibitor		infectious disease, dermatology	respiratory tract infections, pneumonia, skin infections, urinary tract infections, acne vulgaris (AV), plague, psittacosis	MedChemEx	52.63	[H][C@@]12C[C@@]3([H])[C@@H](C(=O)c4c(O)cccc4[C@@]3(C)O)C(=O)[C@]1(O)C(=O)[C@@H](C(N)=O)C(=O)[C@H]2N(C)C |&1:24,&2:5|	Launched
tetradecylthioacetic-acid	lipid peroxidase inhibitor				Enzo, Enzo, Sigma	100	CCCCCCCCCCCCCCSCC(O)=O, CCCCCCCCCCCCCCSCC(O)=O, CCCCCCCCCCCCCCSCC(O)=O	Phase 2
tetraethylenepentamine	superoxide dismutase inhibitor	SOD1, SOD2			Selleck, Selleck, Selleck, Selleck, Selleck	99.86	NCCNCCNCCNCCN, NCCNCCNCCNCCN, NCCNCCNCCNCCN, NCCNCCNCCNCCN, NCCNCCNCCNCCN	Phase 2/Phase 3
tetrahydrofolic-acid		FOLR2			Sigma	0	Nc1nc(=O)c2N[C@@H](CNc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)CNc2[nH]1 |a:19,&1:7|	Launched
tetrahydropapaverine					Selleck, Selleck	97.58	COc1ccc(C[C@H]2NCCc3cc(OC)c(OC)cc23)cc1OC |&1:7|, COc1ccc(C[C@H]2NCCc3cc(OC)c(OC)cc23)cc1OC |&1:7|	Preclinical
tetrahydrouridine	cytidine deaminase inhibitor	CDA			EMDBio	100	OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)N1CC[C@@H](O)NC1=O |a:2,4,5,7,&1:12|	Phase 2
tetrahydrozoline	adrenergic receptor agonist		ophthalmology	eye irritation	Selleck, MicroSource, MicroSource, MedChemEx	97.41	C1CN=C(N1)[C@H]1CCCc2ccccc12 |&1:5,c:2|, C1CN=C(N1)[C@H]1CCCc2ccccc12 |&1:5,c:2|, C1CN=C(N1)[C@H]1CCCc2ccccc12 |&1:5,c:2|, C1CN=C(N1)[C@H]1CCCc2ccccc12 |&1:5,c:2|	Launched
tetramethylthiuram-monosulfide					AKSci	94.7	CN(C)C(=S)SC(=S)N(C)C	Preclinical
tetramisole	immunostimulant	ALPPL2, CHRNA3	infectious disease	gastrointestinal parasites	MicroSource, MicroSource, MicroSource, Selleck	99.58	C1CN2C[C@@H](N=C2S1)c1ccccc1 |&1:4,c:5|, C1CN2C[C@@H](N=C2S1)c1ccccc1 |&1:4,c:5|, C1CN2C[C@@H](N=C2S1)c1ccccc1 |&1:4,c:5|, C1CN2C[C@@H](N=C2S1)c1ccccc1 |&1:4,c:5|	Launched
tetrandrine	calcium channel blocker	SLC6A3			Selleck, Selleck, Selleck, Selleck	97.19	COc1ccc2C[C@@H]3N(C)CCc4cc(OC)c(OC)c(Oc5cc6[C@H](Cc7ccc(Oc1c2)cc7)N(C)CCc6cc5OC)c34, COc1ccc2C[C@@H]3N(C)CCc4cc(OC)c(OC)c(Oc5cc6[C@H](Cc7ccc(Oc1c2)cc7)N(C)CCc6cc5OC)c34, COc1ccc2C[C@@H]3N(C)CCc4cc(OC)c(OC)c(Oc5cc6[C@H](Cc7ccc(Oc1c2)cc7)N(C)CCc6cc5OC)c34, COc1ccc2C[C@@H]3N(C)CCc4cc(OC)c(OC)c(Oc5cc6[C@H](Cc7ccc(Oc1c2)cc7)N(C)CCc6cc5OC)c34	Preclinical
tetrazol-5-yl-glycine-(RS)	glutamate receptor agonist	GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D			Tocris, Tocris	100	N[C@@H](C(O)=O)c1nn[nH]n1 |&1:1,r|, N[C@@H](C(O)=O)c1nn[nH]n1 |&1:1,r|	Preclinical
tetrindole	monoamine oxidase inhibitor	MAOA			Tocris, Tocris, Tocris, Tocris, Tocris, Tocris, Tocris	93.92	C1CCC(CC1)c1ccc2n3CCNC4CCCc(c34)c2c1, C1CCC(CC1)c1ccc2n3CCNC4CCCc(c34)c2c1, C1CCC(CC1)c1ccc2n3CCNC4CCCc(c34)c2c1, C1CCC(CC1)c1ccc2n3CCNC4CCCc(c34)c2c1, C1CCC(CC1)c1ccc2n3CCNC4CCCc(c34)c2c1, C1CCC(CC1)c1ccc2n3CCNC4CCCc(c34)c2c1, C1CCC(CC1)c1ccc2n3CCNC4CCCc(c34)c2c1	Phase 3
tetroquinone					MicroSource, MicroSource, CombiBlocks	0	OC1C(=O)C(=O)C(O)C(=O)C1=O, OC1C(=O)C(=O)C(O)C(=O)C1=O, OC1C(=O)C(=O)C(O)C(=O)C1=O	Preclinical
tezacaftor	CFTR channel agonist		pulmonary	cystic fibrosis	Selleck, MedChemEx	96.52	CC(C)(CO)c1cc2cc(NC(=O)C3(CC3)c3ccc4OC(F)(F)Oc4c3)c(F)cc2n1C[C@@H](O)CO, CC(C)(CO)c1cc2cc(NC(=O)C3(CC3)c3ccc4OC(F)(F)Oc4c3)c(F)cc2n1C[C@@H](O)CO	Launched
TFC-007	prostaglandin inhibitor	HPGDS			Tocris, Tocris, Tocris	95.55	O=C(Nc1ccc(cc1)N1CCC(CC1)C(=O)N1CCOCC1)c1cnc(Oc2ccccc2)nc1, O=C(Nc1ccc(cc1)N1CCC(CC1)C(=O)N1CCOCC1)c1cnc(Oc2ccccc2)nc1, O=C(Nc1ccc(cc1)N1CCC(CC1)C(=O)N1CCOCC1)c1cnc(Oc2ccccc2)nc1	Preclinical
TG-003	CLK inhibitor	CLK1, CLK4, DYRK1A, DYRK1B			Selleck, Selleck, Tocris	96.57	CCN1\C(Sc2ccc(OC)cc12)=C\C(C)=O, CCN1\C(Sc2ccc(OC)cc12)=C\C(C)=O, CCN1\C(Sc2ccc(OC)cc12)=C\C(C)=O	Preclinical
TG-02	CDK inhibitor, FLT3 inhibitor, JAK inhibitor	CDK1, CDK2, CDK7, CDK9, FLT3, JAK2			MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx	96.86	CN1C\C=C\CCOc2cccc(c2)-c2ccnc(Nc3cccc(C1)c3)n2 |t:3|, CN1C\C=C\CCOc2cccc(c2)-c2ccnc(Nc3cccc(C1)c3)n2 |t:3|, CN1C\C=C\CCOc2cccc(c2)-c2ccnc(Nc3cccc(C1)c3)n2 |t:3|, CN1C\C=C\CCOc2cccc(c2)-c2ccnc(Nc3cccc(C1)c3)n2 |t:3|, CN1C\C=C\CCOc2cccc(c2)-c2ccnc(Nc3cccc(C1)c3)n2 |t:3|, CN1C\C=C\CCOc2cccc(c2)-c2ccnc(Nc3cccc(C1)c3)n2 |t:3|, CN1C\C=C\CCOc2cccc(c2)-c2ccnc(Nc3cccc(C1)c3)n2 |t:3|, CN1C\C=C\CCOc2cccc(c2)-c2ccnc(Nc3cccc(C1)c3)n2 |t:3|	Phase 1/Phase 2
TG-100572	SRC inhibitor, VEGFR inhibitor	KDR, SRC			MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx	96.3	Cc1cc(cc2nnc(Nc3ccc(OCCN4CCCC4)cc3)nc12)-c1cc(O)ccc1Cl, Cc1cc(cc2nnc(Nc3ccc(OCCN4CCCC4)cc3)nc12)-c1cc(O)ccc1Cl, Cc1cc(cc2nnc(Nc3ccc(OCCN4CCCC4)cc3)nc12)-c1cc(O)ccc1Cl, Cc1cc(cc2nnc(Nc3ccc(OCCN4CCCC4)cc3)nc12)-c1cc(O)ccc1Cl, Cc1cc(cc2nnc(Nc3ccc(OCCN4CCCC4)cc3)nc12)-c1cc(O)ccc1Cl	Preclinical
TG-100713	PI3K inhibitor				Tocris, Selleck	96.93	Nc1nc(N)c2nc(cnc2n1)-c1cccc(O)c1, Nc1nc(N)c2nc(cnc2n1)-c1cccc(O)c1	Preclinical
TG-100801	SRC inhibitor, VEGFR inhibitor	CSK, FGFR1, FLT1, FLT4, KDR, SRC			MedChemEx, MedChemEx, MedChemEx	89.33	Cc1cc(cc2nnc(Nc3ccc(OCCN4CCCC4)cc3)nc12)-c1cc(OC(=O)c2ccccc2)ccc1Cl, Cc1cc(cc2nnc(Nc3ccc(OCCN4CCCC4)cc3)nc12)-c1cc(OC(=O)c2ccccc2)ccc1Cl, Cc1cc(cc2nnc(Nc3ccc(OCCN4CCCC4)cc3)nc12)-c1cc(OC(=O)c2ccccc2)ccc1Cl	Phase 2
TG-101209	JAK inhibitor	JAK2, JAK3			MedChemEx, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck	95.64	CN1CCN(CC1)c1ccc(Nc2ncc(C)c(Nc3cccc(c3)S(=O)(=O)NC(C)(C)C)n2)cc1, CN1CCN(CC1)c1ccc(Nc2ncc(C)c(Nc3cccc(c3)S(=O)(=O)NC(C)(C)C)n2)cc1, CN1CCN(CC1)c1ccc(Nc2ncc(C)c(Nc3cccc(c3)S(=O)(=O)NC(C)(C)C)n2)cc1, CN1CCN(CC1)c1ccc(Nc2ncc(C)c(Nc3cccc(c3)S(=O)(=O)NC(C)(C)C)n2)cc1, CN1CCN(CC1)c1ccc(Nc2ncc(C)c(Nc3cccc(c3)S(=O)(=O)NC(C)(C)C)n2)cc1, CN1CCN(CC1)c1ccc(Nc2ncc(C)c(Nc3cccc(c3)S(=O)(=O)NC(C)(C)C)n2)cc1, CN1CCN(CC1)c1ccc(Nc2ncc(C)c(Nc3cccc(c3)S(=O)(=O)NC(C)(C)C)n2)cc1	Preclinical
TGR-1202	PI3K inhibitor				MedChemEx, MedChemEx	94.1	CC(C)Oc1ccc(cc1F)-c1nn([C@@H](C)c2oc3ccc(F)cc3c(=O)c2-c2cccc(F)c2)c2ncnc(N)c12, CC(C)Oc1ccc(cc1F)-c1nn([C@@H](C)c2oc3ccc(F)cc3c(=O)c2-c2cccc(F)c2)c2ncnc(N)c12	Phase 3
TGX-221	PI3K inhibitor	PIK3CB, PIK3CD			Selleck, Selleck, Selleck	91.18	C[C@@H](Nc1ccccc1)c1cc(C)cn2c1nc(cc2=O)N1CCOCC1 |&1:1,r|, C[C@@H](Nc1ccccc1)c1cc(C)cn2c1nc(cc2=O)N1CCOCC1 |&1:1,r|, C[C@@H](Nc1ccccc1)c1cc(C)cn2c1nc(cc2=O)N1CCOCC1 |&1:1,r|	Preclinical
TG100-115	PI3K inhibitor	PIK3CA, PIK3CB, PIK3CD, PIK3CG			Selleck	94.74	Nc1nc(N)c2nc(-c3cccc(O)c3)c(nc2n1)-c1cccc(O)c1	Phase 1/Phase 2
TH-302	DNA alkylating agent				MedChemEx, MedChemEx, MedChemEx	88.37	Cn1c(COP(=O)(NCCBr)NCCBr)cnc1[N+]([O-])=O, Cn1c(COP(=O)(NCCBr)NCCBr)cnc1[N+]([O-])=O, Cn1c(COP(=O)(NCCBr)NCCBr)cnc1[N+]([O-])=O	Phase 3
TH-588	MTH1 inhibitor	NUDT1			MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx	98.29	Nc1nc(NC2CC2)cc(n1)-c1cccc(Cl)c1Cl, Nc1nc(NC2CC2)cc(n1)-c1cccc(Cl)c1Cl, Nc1nc(NC2CC2)cc(n1)-c1cccc(Cl)c1Cl, Nc1nc(NC2CC2)cc(n1)-c1cccc(Cl)c1Cl, Nc1nc(NC2CC2)cc(n1)-c1cccc(Cl)c1Cl, Nc1nc(NC2CC2)cc(n1)-c1cccc(Cl)c1Cl	Preclinical
thaliblastine	DNA inhibitor				InterBioScreen	0	COc1cc(C[C@@H]2N(C)CCc3cc(OC)c(OC)cc23)c(Oc2cc3C[C@@H]4N(C)CCc5cc(OC)c(OC)c(-c3cc2OC)c45)cc1OC	Phase 2
thalidomide	tumor necrosis factor production inhibitor	TNF	oncology	myeloma	Tocris, Tocris, Selleck	99	O=C1N([C@H]2CCC(=O)NC2=O)C(=O)c2ccccc12 |&1:3,r|, O=C1N([C@H]2CCC(=O)NC2=O)C(=O)c2ccccc12 |&1:3,r|, O=C1N([C@H]2CCC(=O)NC2=O)C(=O)c2ccccc12 |&1:3,r|	Launched
theaflavin	antiviral				MedChemEx	78.41	O[C@@H]1Cc2c(O)cc(O)cc2O[C@@H]1c1cc(O)c(=O)c2c(O)c(O)cc(cc12)[C@H]1Oc2cc(O)cc(O)c2C[C@H]1O	Preclinical
theobromine	phosphodiesterase inhibitor	ADORA1, ADORA2A, PDE4B			MicroSource, MedChemEx, Selleck, Selleck, Selleck	98.78	Cn1cnc2n(C)c(=O)[nH]c(=O)c12, Cn1cnc2n(C)c(=O)[nH]c(=O)c12, Cn1cnc2n(C)c(=O)[nH]c(=O)c12, Cn1cnc2n(C)c(=O)[nH]c(=O)c12, Cn1cnc2n(C)c(=O)[nH]c(=O)c12	Launched
thiamet-g	GLCNAC phosphotransferase inhibitor	MGEA5			Tocris, Tocris, Selleck	95.3	CCNC1=N[C@H]2[C@H](O[C@H](CO)[C@@H](O)[C@@H]2O)S1 |t:3|, CCNC1=N[C@H]2[C@H](O[C@H](CO)[C@@H](O)[C@@H]2O)S1 |t:3|, CCNC1=N[C@H]2[C@H](O[C@H](CO)[C@@H](O)[C@@H]2O)S1 |t:3|	Preclinical
thiamine	vitamin B	SLC19A2, SLC19A3, TPK1	metabolism	thiamine deficiency	MedChemEx, MicroSource, Selleck	96.41	Cc1c(CCO)sc[n+]1Cc1cnc(C)nc1N, Cc1c(CCO)sc[n+]1Cc1cnc(C)nc1N, Cc1c(CCO)sc[n+]1Cc1cnc(C)nc1N	Launched
thiamine-pyrophosphate			hematology	anemia	ChemImpex	0	Cc1c(CCOP(O)(=O)OP(O)(O)=O)sc[n+]1Cc1cnc(C)nc1N |&1:6|	Launched
thiamphenicol	bacterial 50S ribosomal subunit inhibitor		infectious disease	pelvic inflammatory disease	MicroSource, MedChemEx, Selleck	98.69	CS(=O)(=O)c1ccc(cc1)[C@@H](O)[C@@H](CO)NC(=O)C(Cl)Cl, CS(=O)(=O)c1ccc(cc1)[C@@H](O)[C@@H](CO)NC(=O)C(Cl)Cl, CS(=O)(=O)c1ccc(cc1)[C@@H](O)[C@@H](CO)NC(=O)C(Cl)Cl	Launched
thiamylal	glutamate receptor antagonist	GABRA1	neurology/psychiatry	sedative	MicroSource	52.77	CCC[C@@H](C)C1(CC=C)C(=O)NC(=S)NC1=O |&1:3,&2:5|	Launched
thiazovivin	rho associated kinase inhibitor				Tocris, Tocris, Selleck, Selleck	96.94	O=C(NCc1ccccc1)c1csc(Nc2ccncn2)n1, O=C(NCc1ccccc1)c1csc(Nc2ccncn2)n1, O=C(NCc1ccccc1)c1csc(Nc2ccncn2)n1, O=C(NCc1ccccc1)c1csc(Nc2ccncn2)n1	Preclinical
thiethylperazine	dopamine receptor antagonist	DRD1, DRD2, DRD4	gastroenterology	nausea	AMS, Prestwick, Prestwick, Toronto, Toronto	93.9	CCSc1ccc2Sc3ccccc3N(CCCN3CCN(C)CC3)c2c1, CCSc1ccc2Sc3ccccc3N(CCCN3CCN(C)CC3)c2c1, CCSc1ccc2Sc3ccccc3N(CCCN3CCN(C)CC3)c2c1, CCSc1ccc2Sc3ccccc3N(CCCN3CCN(C)CC3)c2c1, CCSc1ccc2Sc3ccccc3N(CCCN3CCN(C)CC3)c2c1	Launched
thiocolchicoside	GABA receptor antagonist	GABRA1, GABRB2, GABRG2, GLRA1, GLRB	neurology/psychiatry	muscle relaxant	Prestwick, Prestwick, Prestwick, Sigma, Sigma	96.58	COc1c(O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc2CC[C@H](NC(C)=O)c3cc(=O)c(SC)ccc3-c2c1OC, COc1c(O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc2CC[C@H](NC(C)=O)c3cc(=O)c(SC)ccc3-c2c1OC, COc1c(O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc2CC[C@H](NC(C)=O)c3cc(=O)c(SC)ccc3-c2c1OC, COc1c(O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc2CC[C@H](NC(C)=O)c3cc(=O)c(SC)ccc3-c2c1OC, COc1c(O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc2CC[C@H](NC(C)=O)c3cc(=O)c(SC)ccc3-c2c1OC	Launched
thioctic-acid	reducing agent	ACHE, PTGS2	nephrology	diabetic nephropathy	MicroSource	94.83	OC(=O)CCCC[C@H]1CCSS1 |&1:7,r|	Launched
thiodiglycol					MicroSource, Oakwood	95.75	OCCSCCO, OCCSCCO	Preclinical
thioguanine	purine antagonist	IMPDH1, IMPDH2	hematologic malignancy	acute myeloid leukemia (AML)	MicroSource, Selleck, MicroSource, MicroSource	100	Nc1nc2nc[nH]c2c(=S)[nH]1, Nc1nc2nc[nH]c2c(=S)[nH]1, Nc1nc2nc[nH]c2c(=S)[nH]1, Nc1nc2nc[nH]c2c(=S)[nH]1	Launched
thiomersal	other antibiotic	OXCT1	infectious disease	preservative	MedChemEx, MedChemEx, MedChemEx, MicroSource, MicroSource, MicroSource, MicroSource, MicroSource	98.29	CC[Hg]Sc1ccccc1C(O)=O, CC[Hg]Sc1ccccc1C(O)=O, CC[Hg]Sc1ccccc1C(O)=O, CC[Hg]Sc1ccccc1C(O)=O, CC[Hg]Sc1ccccc1C(O)=O, CC[Hg]Sc1ccccc1C(O)=O, CC[Hg]Sc1ccccc1C(O)=O, CC[Hg]Sc1ccccc1C(O)=O	Launched
thiopental	GABA receptor antagonist	FAAH	neurology/psychiatry	anesthetic	Key, MicroSource	63.17	CCC[C@@H](C)C1(CC)C(=O)NC(=S)NC1=O |&1:3,&2:5|, CCC[C@@H](C)C1(CC)C(=O)NC(=S)NC1=O |&1:3,&2:5|	Launched
thioperamide	histamine receptor antagonist	HRH3, HRH4			Tocris	95.41	S=C(NC1CCCCC1)N1CCC(CC1)[C@H]1C=NC=N1 |r,c:18,20|	Preclinical
thiophanate					Sigma, Sigma, Sigma, MicroSource	94.28	COC(=O)NC(=S)Nc1ccccc1NC(=S)NC(=O)OC, COC(=O)NC(=S)Nc1ccccc1NC(=S)NC(=O)OC, COC(=O)NC(=S)Nc1ccccc1NC(=S)NC(=O)OC, COC(=O)NC(=S)Nc1ccccc1NC(=S)NC(=O)OC	Preclinical
thioproperazine	dopamine receptor antagonist	ADRA1A, ADRA1B, DRD1, DRD2, HTR1A, HTR2A	neurology/psychiatry	schizophrenia	Sigma, Prestwick	97.81	CN(C)S(=O)(=O)c1ccc2Sc3ccccc3N(CCCN3CCN(C)CC3)c2c1, CN(C)S(=O)(=O)c1ccc2Sc3ccccc3N(CCCN3CCN(C)CC3)c2c1	Launched
thioridazine	dopamine receptor antagonist	DRD1, DRD2, DRD3, DRD4, DRD5, HRH1, HTR1A, HTR2A, HTR2C, HTR6, HTR7			Selleck, Selleck, Selleck, MicroSource	94.6	CSc1ccc2Sc3ccccc3N(CCC3CCCCN3C)c2c1, CSc1ccc2Sc3ccccc3N(CCC3CCCCN3C)c2c1, CSc1ccc2Sc3ccccc3N(CCC3CCCCN3C)c2c1, CSc1ccc2Sc3ccccc3N(CCC3CCCCN3C)c2c1	Withdrawn
thiorphan	membrane metalloendopeptidase inhibitor	MME			Enzo, Sigma	38.61	OC(=O)CNC(=O)[C@@H](CS)Cc1ccccc1 |&1:7,r|, OC(=O)CNC(=O)[C@@H](CS)Cc1ccccc1 |&1:7,r|	Phase 1
thiostrepton	FOXM1 inhibitor, protein synthesis inhibitor	FOXM1	obstetrics/gynecology	mastitis	MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx, Selleck, Selleck	96.6	CC[C@H](C)[C@@H]1N[C@@H]2C=Cc3c(cc(nc3[C@H]2O)C(=O)O[C@H](C)[C@@H]2NC(=O)c3csc(n3)[C@@H](NC(=O)[C@H]3CSC(=N3)\C(NC(=O)[C@@H](NC(=O)c3csc(n3)[C@]3(CCC(=N[C@@H]3c3csc2n3)c2nc(cs2)C(=O)NC(=C)C(=O)NC(=C)C(N)=O)NC(=O)[C@H](C)NC(=O)C(=C)NC(=O)[C@H](C)NC1=O)[C@@H](C)O)=C\C)[C@](C)(O)[C@@H](C)O)[C@H](C)O |c:7,41,61|, CC[C@H](C)[C@@H]1N[C@@H]2C=Cc3c(cc(nc3[C@H]2O)C(=O)O[C@H](C)[C@@H]2NC(=O)c3csc(n3)[C@@H](NC(=O)[C@H]3CSC(=N3)\C(NC(=O)[C@@H](NC(=O)c3csc(n3)[C@]3(CCC(=N[C@@H]3c3csc2n3)c2nc(cs2)C(=O)NC(=C)C(=O)NC(=C)C(N)=O)NC(=O)[C@H](C)NC(=O)C(=C)NC(=O)[C@H](C)NC1=O)[C@@H](C)O)=C\C)[C@](C)(O)[C@@H](C)O)[C@H](C)O |c:7,41,61|, CC[C@H](C)[C@@H]1N[C@@H]2C=Cc3c(cc(nc3[C@H]2O)C(=O)O[C@H](C)[C@@H]2NC(=O)c3csc(n3)[C@@H](NC(=O)[C@H]3CSC(=N3)\C(NC(=O)[C@@H](NC(=O)c3csc(n3)[C@]3(CCC(=N[C@@H]3c3csc2n3)c2nc(cs2)C(=O)NC(=C)C(=O)NC(=C)C(N)=O)NC(=O)[C@H](C)NC(=O)C(=C)NC(=O)[C@H](C)NC1=O)[C@@H](C)O)=C\C)[C@](C)(O)[C@@H](C)O)[C@H](C)O |c:7,41,61|, CC[C@H](C)[C@@H]1N[C@@H]2C=Cc3c(cc(nc3[C@H]2O)C(=O)O[C@H](C)[C@@H]2NC(=O)c3csc(n3)[C@@H](NC(=O)[C@H]3CSC(=N3)\C(NC(=O)[C@@H](NC(=O)c3csc(n3)[C@]3(CCC(=N[C@@H]3c3csc2n3)c2nc(cs2)C(=O)NC(=C)C(=O)NC(=C)C(N)=O)NC(=O)[C@H](C)NC(=O)C(=C)NC(=O)[C@H](C)NC1=O)[C@@H](C)O)=C\C)[C@](C)(O)[C@@H](C)O)[C@H](C)O |c:7,41,61|, CC[C@H](C)[C@@H]1N[C@@H]2C=Cc3c(cc(nc3[C@H]2O)C(=O)O[C@H](C)[C@@H]2NC(=O)c3csc(n3)[C@@H](NC(=O)[C@H]3CSC(=N3)\C(NC(=O)[C@@H](NC(=O)c3csc(n3)[C@]3(CCC(=N[C@@H]3c3csc2n3)c2nc(cs2)C(=O)NC(=C)C(=O)NC(=C)C(N)=O)NC(=O)[C@H](C)NC(=O)C(=C)NC(=O)[C@H](C)NC1=O)[C@@H](C)O)=C\C)[C@](C)(O)[C@@H](C)O)[C@H](C)O |c:7,41,61|, CC[C@H](C)[C@@H]1N[C@@H]2C=Cc3c(cc(nc3[C@H]2O)C(=O)O[C@H](C)[C@@H]2NC(=O)c3csc(n3)[C@@H](NC(=O)[C@H]3CSC(=N3)\C(NC(=O)[C@@H](NC(=O)c3csc(n3)[C@]3(CCC(=N[C@@H]3c3csc2n3)c2nc(cs2)C(=O)NC(=C)C(=O)NC(=C)C(N)=O)NC(=O)[C@H](C)NC(=O)C(=C)NC(=O)[C@H](C)NC1=O)[C@@H](C)O)=C\C)[C@](C)(O)[C@@H](C)O)[C@H](C)O |c:7,41,61|, CC[C@H](C)[C@@H]1N[C@@H]2C=Cc3c(cc(nc3[C@H]2O)C(=O)O[C@H](C)[C@@H]2NC(=O)c3csc(n3)[C@@H](NC(=O)[C@H]3CSC(=N3)\C(NC(=O)[C@@H](NC(=O)c3csc(n3)[C@]3(CCC(=N[C@@H]3c3csc2n3)c2nc(cs2)C(=O)NC(=C)C(=O)NC(=C)C(N)=O)NC(=O)[C@H](C)NC(=O)C(=C)NC(=O)[C@H](C)NC1=O)[C@@H](C)O)=C\C)[C@](C)(O)[C@@H](C)O)[C@H](C)O |c:7,41,61|	Launched
thiotepa	cytochrome P450 inhibitor	CYP2B6, CYP3A4	oncology	breast cancer, ovarian cancer, bladder cancer	MedChemEx, MedChemEx, MicroSource, MedChemEx	83.39	S=P(N1CC1)(N1CC1)N1CC1, S=P(N1CC1)(N1CC1)N1CC1, S=P(N1CC1)(N1CC1)N1CC1, S=P(N1CC1)(N1CC1)N1CC1	Launched
thiothixene	dopamine receptor antagonist	DRD1, DRD2, HRH1, HTR2A	neurology/psychiatry	schizophrenia	MedChemEx	96.15	CN(C)S(=O)(=O)c1ccc2Sc3ccccc3\C(=C\CCN3CCN(C)CC3)c2c1	Launched
thiram		JAK2	ophthalmology	contact dermatitis	MicroSource, MicroSource	97.98	CN(C)C(=S)SSC(=S)N(C)C, CN(C)C(=S)SSC(=S)N(C)C	Launched
THK5351	PET radiotracer 				MedChemEx	96.78	CNc1ccc(cn1)-c1ccc2cc(OC[C@H](O)CF)ccc2n1	Phase 2
thonzonium	ATPase inhibitor		infectious disease	ear infections	MedChemEx, MicroSource, Selleck, Selleck, Selleck, Selleck, Selleck	94.95	CCCCCCCCCCCCCCCC[N+](C)(C)CCN(Cc1ccc(OC)cc1)c1ncccn1, CCCCCCCCCCCCCCCC[N+](C)(C)CCN(Cc1ccc(OC)cc1)c1ncccn1, CCCCCCCCCCCCCCCC[N+](C)(C)CCN(Cc1ccc(OC)cc1)c1ncccn1, CCCCCCCCCCCCCCCC[N+](C)(C)CCN(Cc1ccc(OC)cc1)c1ncccn1, CCCCCCCCCCCCCCCC[N+](C)(C)CCN(Cc1ccc(OC)cc1)c1ncccn1, CCCCCCCCCCCCCCCC[N+](C)(C)CCN(Cc1ccc(OC)cc1)c1ncccn1, CCCCCCCCCCCCCCCC[N+](C)(C)CCN(Cc1ccc(OC)cc1)c1ncccn1	Launched
thonzylamine	antihistamine		neurology/psychiatry	itching	MicroSource	91.69	COc1ccc(CN(CCN(C)C)c2ncccn2)cc1	Launched
threo-2-methylisocitrate-(DL)	isocitrate lyase substrate				MedChemEx, MedChemEx	93.35	[NaH].[NaH].[NaH].[NaH].[NaH].[NaH].CC(O)([C@@H](CC(O)=O)C(O)=O)C(O)=O.CC(O)([C@H](CC(O)=O)C(O)=O)C(O)=O |a:9,23,&1:7,&2:21|, [NaH].[NaH].[NaH].[NaH].[NaH].[NaH].CC(O)([C@@H](CC(O)=O)C(O)=O)C(O)=O.CC(O)([C@H](CC(O)=O)C(O)=O)C(O)=O |a:9,23,&1:7,&2:21|	Preclinical
thymalfasin	immune response modulator		infectious disease	hepatitis B, hepatitis C	Key	100	CC[C@H](C)[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(C)=O)C(C)C)[C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O	Launched
thymol	GABA receptor positive allosteric modulator	TRPA1	infectious disease	ringworm, antiseptic	Enamine, Sigma	0	CC(C)c1ccc(C)cc1O, CC(C)c1ccc(C)cc1O	Launched
thymol-iodide					SantaCruz	50.02	CC(C)c1cc(c(C)cc1OI)-c1cc(C(C)C)c(OI)cc1C	Preclinical
thymopentin	immune response stimulator				Key	94.22	CC(C)[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(O)=O	Launched
THZ1	CDK inhibitor	CDK7			MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx	92.24	CN(C)C\C=C\C(=O)Nc1ccc(cc1)C(=O)Nc1cccc(Nc2ncc(Cl)c(n2)-c2c[nH]c3ccccc23)c1, CN(C)C\C=C\C(=O)Nc1ccc(cc1)C(=O)Nc1cccc(Nc2ncc(Cl)c(n2)-c2c[nH]c3ccccc23)c1, CN(C)C\C=C\C(=O)Nc1ccc(cc1)C(=O)Nc1cccc(Nc2ncc(Cl)c(n2)-c2c[nH]c3ccccc23)c1, CN(C)C\C=C\C(=O)Nc1ccc(cc1)C(=O)Nc1cccc(Nc2ncc(Cl)c(n2)-c2c[nH]c3ccccc23)c1, CN(C)C\C=C\C(=O)Nc1ccc(cc1)C(=O)Nc1cccc(Nc2ncc(Cl)c(n2)-c2c[nH]c3ccccc23)c1, CN(C)C\C=C\C(=O)Nc1ccc(cc1)C(=O)Nc1cccc(Nc2ncc(Cl)c(n2)-c2c[nH]c3ccccc23)c1, CN(C)C\C=C\C(=O)Nc1ccc(cc1)C(=O)Nc1cccc(Nc2ncc(Cl)c(n2)-c2c[nH]c3ccccc23)c1, CN(C)C\C=C\C(=O)Nc1ccc(cc1)C(=O)Nc1cccc(Nc2ncc(Cl)c(n2)-c2c[nH]c3ccccc23)c1	Preclinical
THZ1-R	CDK inhibitor	CDK7			MedChemEx, MedChemEx	90.43	CN(C)CCCC(=O)Nc1ccc(cc1)C(=O)Nc1cccc(Nc2ncc(Cl)c(n2)-c2c[nH]c3ccccc23)c1, CN(C)CCCC(=O)Nc1ccc(cc1)C(=O)Nc1cccc(Nc2ncc(Cl)c(n2)-c2c[nH]c3ccccc23)c1	Preclinical
THZ2	CDK inhibitor	CDK7			MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx	91.43	CN(C)C\C=C\C(=O)Nc1cccc(c1)C(=O)Nc1cccc(Nc2ncc(Cl)c(n2)-c2c[nH]c3ccccc23)c1, CN(C)C\C=C\C(=O)Nc1cccc(c1)C(=O)Nc1cccc(Nc2ncc(Cl)c(n2)-c2c[nH]c3ccccc23)c1, CN(C)C\C=C\C(=O)Nc1cccc(c1)C(=O)Nc1cccc(Nc2ncc(Cl)c(n2)-c2c[nH]c3ccccc23)c1, CN(C)C\C=C\C(=O)Nc1cccc(c1)C(=O)Nc1cccc(Nc2ncc(Cl)c(n2)-c2c[nH]c3ccccc23)c1, CN(C)C\C=C\C(=O)Nc1cccc(c1)C(=O)Nc1cccc(Nc2ncc(Cl)c(n2)-c2c[nH]c3ccccc23)c1	Preclinical
tiabendazole	angiogenesis inhibitor		infectious disease	gastrointestinal roundworms, hookworm	MedChemEx, MedChemEx, Selleck, MicroSource	99.12	c1nc(cs1)-c1nc2ccccc2[nH]1, c1nc(cs1)-c1nc2ccccc2[nH]1, c1nc(cs1)-c1nc2ccccc2[nH]1, c1nc(cs1)-c1nc2ccccc2[nH]1	Launched
tiagabine	GABA uptake inhibitor	SLC6A1	neurology/psychiatry	seizures	Tocris, Enzo, Enzo	95.06	Cc1ccsc1C(=CCCN1CCC[C@H](C1)C(O)=O)c1sccc1C, Cc1ccsc1C(=CCCN1CCC[C@H](C1)C(O)=O)c1sccc1C, Cc1ccsc1C(=CCCN1CCC[C@H](C1)C(O)=O)c1sccc1C	Launched
tianeptine	selective serotonin reuptake enhancer (SSRE)	OPRD1, OPRK1, OPRM1	neurology/psychiatry, pulmonary, gastroenterology	depression, asthma, irritable bowel syndrome	MedChemEx, MedChemEx	98.15	CN1c2ccccc2[C@@H](NCCCCCCC(O)=O)c2ccc(Cl)cc2S1(=O)=O |&1:8,r|, CN1c2ccccc2[C@@H](NCCCCCCC(O)=O)c2ccc(Cl)cc2S1(=O)=O |&1:8,r|	Launched
tiapride	dopamine receptor antagonist	DRD2, DRD3	neurology/psychiatry	dyskinesia, abstinence from alcohol, psychosis	MicroSource, MedChemEx, MedChemEx	98.27	CCN(CC)CCNC(=O)c1cc(ccc1OC)S(C)(=O)=O, CCN(CC)CCNC(=O)c1cc(ccc1OC)S(C)(=O)=O, CCN(CC)CCNC(=O)c1cc(ccc1OC)S(C)(=O)=O	Launched
tiaprofenic-acid	cyclooxygenase inhibitor	PTGS2	rheumatology	rheumatoid arthritis	Sigma, Sigma, Prestwick	94.01	C[C@@H](C(O)=O)c1ccc(s1)C(=O)c1ccccc1 |&1:1,r|, C[C@@H](C(O)=O)c1ccc(s1)C(=O)c1ccccc1 |&1:1,r|, C[C@@H](C(O)=O)c1ccc(s1)C(=O)c1ccccc1 |&1:1,r|	Launched
tiaramide	anti-inflammatory agent		pulmonary	asthma	Sigma	99.54	OCCN1CCN(CC1)C(=O)Cn1c2cc(Cl)ccc2sc1=O	Launched
tibolone	androgen receptor agonist, estrogen receptor agonist, progesterone receptor agonist	ESR1	obstetrics/gynecology	endometriosis	MicroSource, MicroSource, MicroSource	93.9	C[C@@H]1CC2=C(CCC(=O)C2)[C@H]2CC[C@@]3(C)[C@H](CC[C@@]3(O)C#C)[C@@H]12 |a:1,10,13,15,18,&1:22,t:3|, C[C@@H]1CC2=C(CCC(=O)C2)[C@H]2CC[C@@]3(C)[C@H](CC[C@@]3(O)C#C)[C@@H]12 |a:1,10,13,15,18,&1:22,t:3|, C[C@@H]1CC2=C(CCC(=O)C2)[C@H]2CC[C@@]3(C)[C@H](CC[C@@]3(O)C#C)[C@@H]12 |a:1,10,13,15,18,&1:22,t:3|	Launched
ticagrelor	purinergic receptor antagonist	P2RY12	cardiology	acute coronary syndrome (ACS), myocardial infarction	MedChemEx, MedChemEx	97.4	CCCSc1nc(N[C@@H]2C[C@H]2c2ccc(F)c(F)c2)c2nnn([C@@H]3C[C@H](OCCO)[C@@H](O)[C@H]3O)c2n1, CCCSc1nc(N[C@@H]2C[C@H]2c2ccc(F)c(F)c2)c2nnn([C@@H]3C[C@H](OCCO)[C@@H](O)[C@H]3O)c2n1	Launched
ticarcillin	lactamase inhibitor		infectious disease	gram-negative bacterial infections	MicroSource, MicroSource, Selleck, Selleck, MedChemEx	0	CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](C(O)=O)c3ccsc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](C(O)=O)c3ccsc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](C(O)=O)c3ccsc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](C(O)=O)c3ccsc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](C(O)=O)c3ccsc3)C(=O)N2[C@H]1C(O)=O	Launched
ticlopidine	purinergic receptor antagonist	P2RY12	hematology, neurology/psychiatry	thrombosis, stroke	MicroSource, MicroSource, MicroSource, Selleck, Tocris	98.54	Clc1ccccc1CN1CCc2sccc2C1, Clc1ccccc1CN1CCc2sccc2C1, Clc1ccccc1CN1CCc2sccc2C1, Clc1ccccc1CN1CCc2sccc2C1, Clc1ccccc1CN1CCc2sccc2C1	Launched
TIC10	AKT inhibitor, TRAIL modulator	AKT1, MAPK1			Selleck, MedChemEx	95.04	Cc1ccccc1CN1C2=NCCN2C(=O)C2=C1CCN(Cc1ccccc1)C2 |c:18,t:10|, Cc1ccccc1CN1C2=NCCN2C(=O)C2=C1CCN(Cc1ccccc1)C2 |c:18,t:10|	Phase 2
tideglusib	glycogen synthase kinase inhibitor	GSK3B			Selleck, Selleck, Selleck, Selleck, MedChemEx, MedChemEx	96.84	O=c1sn(-c2cccc3ccccc23)c(=O)n1Cc1ccccc1, O=c1sn(-c2cccc3ccccc23)c(=O)n1Cc1ccccc1, O=c1sn(-c2cccc3ccccc23)c(=O)n1Cc1ccccc1, O=c1sn(-c2cccc3ccccc23)c(=O)n1Cc1ccccc1, O=c1sn(-c2cccc3ccccc23)c(=O)n1Cc1ccccc1, O=c1sn(-c2cccc3ccccc23)c(=O)n1Cc1ccccc1	Phase 2
tienilic-acid	cytochrome P450 inhibitor, sodium/potassium/chloride transporter inhibitor	CYP2C9, SLC12A1			Sigma, Sigma	99.37	OC(=O)COc1ccc(C(=O)c2cccs2)c(Cl)c1Cl, OC(=O)COc1ccc(C(=O)c2cccs2)c(Cl)c1Cl	Withdrawn
tie2-kinase-inhibitor	TIE tyrosine kinase inhibitor	KDR, MAPK14			Selleck, Selleck, Selleck	93.92	COc1ccc2cc(ccc2c1)-c1[nH]c(nc1-c1ccncc1)-c1ccc(cc1)[S@@](C)=O |r|, COc1ccc2cc(ccc2c1)-c1[nH]c(nc1-c1ccncc1)-c1ccc(cc1)[S@@](C)=O |r|, COc1ccc2cc(ccc2c1)-c1[nH]c(nc1-c1ccncc1)-c1ccc(cc1)[S@@](C)=O |r|	Preclinical
tifenazoxide	ATP-sensitive potassium channel agonist	ABCC8, KCNJ11			Sigma, Sigma, Sigma	95	CC1(CC1)NC1=NS(=O)(=O)c2sc(Cl)cc2N1 |t:6|, CC1(CC1)NC1=NS(=O)(=O)c2sc(Cl)cc2N1 |t:6|, CC1(CC1)NC1=NS(=O)(=O)c2sc(Cl)cc2N1 |t:6|	Phase 1
tigecycline	bacterial 30S ribosomal subunit inhibitor		infectious disease	skin infections, pneumonia, intra-abdominal infections	MedChemEx	0	[H][C@@]12Cc3c(cc(NC(=O)CNC(C)(C)C)c(O)c3C(=O)[C@@H]1C(=O)[C@]1(O)C(=O)[C@H](C(N)=O)C(=O)[C@@H](N(C)C)[C@]1([H])C2)N(C)C |&1:28,&2:21|	Launched
tilmicosin	bacterial 50S ribosomal subunit inhibitor		pulmonary	bovine respiratory disease (BRD)	MedChemEx	67.94	CC[C@H]1OC(=O)C[C@@H](O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)[C@@H](O)[C@@H]([C@H]2O)N(C)C)[C@@H](CCN2C[C@@H](C)C[C@@H](C)C2)C[C@@H](C)C(=O)\C=C\C(\C)=C\[C@@H]1CO[C@@H]1O[C@H](C)[C@@H](O)[C@@H](OC)[C@H]1OC |t:43,46|	Launched
tilorone	interferon inducer		infectious disease, gastroenterology, neurology/psychiatry	influenza A virus infection, diarrhea, hepatitis B, multiple sclerosis, urinary tract infections, virus herpes simplex (HSV), hepatitis C	MedChemEx, MedChemEx, MicroSource	95.68	CCN(CC)CCOc1ccc2-c3ccc(OCCN(CC)CC)cc3C(=O)c2c1, CCN(CC)CCOc1ccc2-c3ccc(OCCN(CC)CC)cc3C(=O)c2c1, CCN(CC)CCOc1ccc2-c3ccc(OCCN(CC)CC)cc3C(=O)c2c1	Launched
tiludronate	bone resorption inhibitor, osteoclast inhibitor	ATP6V1A, MMP2, PTPN1	orthopedics	navicular syndrome	Enzo, Enzo	100	OP(O)(=O)C(Sc1ccc(Cl)cc1)P(O)(O)=O, OP(O)(=O)C(Sc1ccc(Cl)cc1)P(O)(O)=O	Launched
timofibrate	cholesterol inhibitor, lipase clearing factor inhibitor	LPL			Enamine, Enamine, Enamine, Enamine, Enamine	98.06	CC(C)(Oc1ccc(Cl)cc1)C(=O)N1CSC[C@@H]1C(O)=O |&1:17,r|, CC(C)(Oc1ccc(Cl)cc1)C(=O)N1CSC[C@@H]1C(O)=O |&1:17,r|, CC(C)(Oc1ccc(Cl)cc1)C(=O)N1CSC[C@@H]1C(O)=O |&1:17,r|, CC(C)(Oc1ccc(Cl)cc1)C(=O)N1CSC[C@@H]1C(O)=O |&1:17,r|, CC(C)(Oc1ccc(Cl)cc1)C(=O)N1CSC[C@@H]1C(O)=O |&1:17,r|	Phase 2
timolol	adrenergic receptor antagonist	ADRB1, ADRB2	ophthalmology	ocular hypertension, glaucoma	Tocris, Tocris, Selleck	94.28	CC(C)(C)NC[C@H](O)COc1nsnc1N1CCOCC1, CC(C)(C)NC[C@H](O)COc1nsnc1N1CCOCC1, CC(C)(C)NC[C@H](O)COc1nsnc1N1CCOCC1	Launched
timonacic	antioxidant				MedChemEx	100	OC(=O)[C@H]1CSCN1 |&1:3|	Launched
tinazoline	adrenergic receptor agonist				Enamine	44.23	C1CN=C(N1)Sc1c[nH]c2ccccc12 |c:2|	Launched
tinidazole	antiprotozoal agent		infectious disease, obstetrics/gynecology	giardiasis, amebiasis, bacterial vaginosis, trichomoniasis	MedChemEx, Selleck, MicroSource, Selleck, Selleck	98.57	CCS(=O)(=O)CCn1c(C)ncc1[N+]([O-])=O, CCS(=O)(=O)CCn1c(C)ncc1[N+]([O-])=O, CCS(=O)(=O)CCn1c(C)ncc1[N+]([O-])=O, CCS(=O)(=O)CCn1c(C)ncc1[N+]([O-])=O, CCS(=O)(=O)CCn1c(C)ncc1[N+]([O-])=O	Launched
tinoridine	anti-inflammatory agent		neurology/psychiatry	pain relief	MedChemEx	94.02	CCOC(=O)c1c(N)sc2CN(Cc3ccccc3)CCc12	Launched
tioconazole	sterol demethylase inhibitor		infectious disease	yeast infection	MedChemEx	98.21	Clc1sccc1CO[C@@H](Cn1ccnc1)c1ccc(Cl)cc1Cl |&1:8|	Launched
tioguanine	purine antagonist		hematologic malignancy	acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myeloid leukemia (CML)	Prestwick, Prestwick, Prestwick, Toronto, Toronto	100	Nc1nc(=S)c2ncn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c2[nH]1, Nc1nc(=S)c2ncn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c2[nH]1, Nc1nc(=S)c2ncn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c2[nH]1, Nc1nc(=S)c2ncn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c2[nH]1, Nc1nc(=S)c2ncn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c2[nH]1	Launched
tiopronin	chelating agent, reducing agent		urology	kidney stones	MedChemEx, Sigma, MicroSource, Selleck, Selleck	91.45	C[C@@H](S)C(=O)NCC(O)=O |&1:1,r|, C[C@@H](S)C(=O)NCC(O)=O |&1:1,r|, C[C@@H](S)C(=O)NCC(O)=O |&1:1,r|, C[C@@H](S)C(=O)NCC(O)=O |&1:1,r|, C[C@@H](S)C(=O)NCC(O)=O |&1:1,r|	Launched
tiotidine	histamine receptor antagonist	HRH2			Tocris	96.18	CN=C(NCCSCc1csc(NC(N)=N)n1)NC#N	Phase 2
tiotropium	acetylcholine receptor antagonist	CHRM1, CHRM2, CHRM3	pulmonary	chronic obstructive pulmonary disease (COPD), bronchitis, emphysema	Selleck, Selleck	93.69	C[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1, C[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1	Launched
tioxolone	carbonic anhydrase inhibitor	CA2			MedChemEx, MicroSource, Selleck	93.15	Oc1ccc2sc(=O)oc2c1, Oc1ccc2sc(=O)oc2c1, Oc1ccc2sc(=O)oc2c1	Preclinical
tipelukast	leukotriene receptor antagonist				Sigma	97.11	CCCc1c(O)c(ccc1SCCCOc1ccc(C(C)=O)c(OCCCC(O)=O)c1CCC)C(C)=O	Phase 2
tipifarnib	farnesyltransferase inhibitor	FNTA, FNTB			Selleck, Selleck, Selleck, Selleck, Selleck, Selleck	99.07	Cn1cncc1[C@@](N)(c1ccc(Cl)cc1)c1ccc2n(C)c(=O)cc(-c3cccc(Cl)c3)c2c1, Cn1cncc1[C@@](N)(c1ccc(Cl)cc1)c1ccc2n(C)c(=O)cc(-c3cccc(Cl)c3)c2c1, Cn1cncc1[C@@](N)(c1ccc(Cl)cc1)c1ccc2n(C)c(=O)cc(-c3cccc(Cl)c3)c2c1, Cn1cncc1[C@@](N)(c1ccc(Cl)cc1)c1ccc2n(C)c(=O)cc(-c3cccc(Cl)c3)c2c1, Cn1cncc1[C@@](N)(c1ccc(Cl)cc1)c1ccc2n(C)c(=O)cc(-c3cccc(Cl)c3)c2c1, Cn1cncc1[C@@](N)(c1ccc(Cl)cc1)c1ccc2n(C)c(=O)cc(-c3cccc(Cl)c3)c2c1	Phase 3
tipiracil	thymidine phosphorylase inhibitor		oncology	colorectal cancer	MedChemEx, MedChemEx, MedChemEx	100	Clc1c(CN2CCCC2=N)[nH]c(=O)[nH]c1=O, Clc1c(CN2CCCC2=N)[nH]c(=O)[nH]c1=O, Clc1c(CN2CCCC2=N)[nH]c(=O)[nH]c1=O	Launched
tiplaxtinin	plasminogen activator inhibitor	SERPINE1			Tocris, MedChemEx, MedChemEx, MedChemEx	92.85	OC(=O)C(=O)c1cn(Cc2ccccc2)c2ccc(cc12)-c1ccc(OC(F)(F)F)cc1, OC(=O)C(=O)c1cn(Cc2ccccc2)c2ccc(cc12)-c1ccc(OC(F)(F)F)cc1, OC(=O)C(=O)c1cn(Cc2ccccc2)c2ccc(cc12)-c1ccc(OC(F)(F)F)cc1, OC(=O)C(=O)c1cn(Cc2ccccc2)c2ccc(cc12)-c1ccc(OC(F)(F)F)cc1	Phase 1
tipranavir	HIV protease inhibitor		infectious disease	human immunodeficiency virus (HIV-1)	MedChemEx, MedChemEx, MedChemEx, MedChemEx	88.06	CCC[C@@]1(CCc2ccccc2)CC(=O)[C@@H]([C@H](CC)c2cccc(NS(=O)(=O)c3ccc(cn3)C(F)(F)F)c2)C(=O)O1 |a:3,16,&1:15|, CCC[C@@]1(CCc2ccccc2)CC(=O)[C@@H]([C@H](CC)c2cccc(NS(=O)(=O)c3ccc(cn3)C(F)(F)F)c2)C(=O)O1 |a:3,16,&1:15|, CCC[C@@]1(CCc2ccccc2)CC(=O)[C@@H]([C@H](CC)c2cccc(NS(=O)(=O)c3ccc(cn3)C(F)(F)F)c2)C(=O)O1 |a:3,16,&1:15|, CCC[C@@]1(CCc2ccccc2)CC(=O)[C@@H]([C@H](CC)c2cccc(NS(=O)(=O)c3ccc(cn3)C(F)(F)F)c2)C(=O)O1 |a:3,16,&1:15|	Launched
tiprenolol	adrenergic receptor antagonist	ADRB1, ADRB2, ADRB3			Enamine	96.46	CSc1ccccc1OC[C@@H](O)CNC(C)C |&1:10,r|	Phase 2
tiquizium	acetylcholine receptor antagonist		neurology/psychiatry	spasms	AKSci	97.14	C[N@+]12CCCC[C@@H]1CCC(C2)=C(c1cccs1)c1cccs1	Launched
tiracizine	sodium channel blocker	SCN5A			ChemDiv	98.01	CCOC(=O)Nc1ccc2CCc3ccccc3N(C(=O)CN(C)C)c2c1	Withdrawn
tirapazamine	DNA inhibitor				Adooq, Adooq, Adooq, Adooq, MedChemEx	98.06	Nc1n[n+]([O-])c2ccccc2[n+]1[O-], Nc1n[n+]([O-])c2ccccc2[n+]1[O-], Nc1n[n+]([O-])c2ccccc2[n+]1[O-], Nc1n[n+]([O-])c2ccccc2[n+]1[O-], Nc1n[n+]([O-])c2ccccc2[n+]1[O-]	Phase 3
tirasemtiv	troponin activator				MedChemEx, MedChemEx	99.62	CCC(CC)n1c2nc(cnc2[nH]c1=O)C#C, CCC(CC)n1c2nc(cnc2[nH]c1=O)C#C	Phase 2
tiratricol	thyroid hormone stimulant	THRA, THRB	endocrinology	Refetoff syndrome	Selleck, MicroSource, Selleck	92.5	OC(=O)Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1, OC(=O)Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1, OC(=O)Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1	Launched
tirofiban	platelet aggregation inhibitor, structural glycoprotein antagonist	ITGA2B, ITGB3	cardiology	myocardial infarction, refactory angina	Enzo, Enzo	97.97	CCCCS(=O)(=O)N[C@@H](Cc1ccc(OCCCCC2CCNCC2)cc1)C(O)=O, CCCCS(=O)(=O)N[C@@H](Cc1ccc(OCCCCC2CCNCC2)cc1)C(O)=O	Launched
titanocene-dichloride	apoptosis stimulant				Sigma, Oakwood	98.9	Cl[Ti](Cl)(C1C=CC=C1)C1C=CC=C1 |c:4,6,10,12|, Cl[Ti](Cl)(C1C=CC=C1)C1C=CC=C1 |c:4,6,10,12|	Phase 2
tivantinib	tyrosine kinase inhibitor	MET			MedChemEx, MedChemEx, MedChemEx, MedChemEx	98.79	O=C1NC(=O)[C@H]([C@@H]1c1c[nH]c2ccccc12)c1cn2CCCc3cccc1c23, O=C1NC(=O)[C@H]([C@@H]1c1c[nH]c2ccccc12)c1cn2CCCc3cccc1c23, O=C1NC(=O)[C@H]([C@@H]1c1c[nH]c2ccccc12)c1cn2CCCc3cccc1c23, O=C1NC(=O)[C@H]([C@@H]1c1c[nH]c2ccccc12)c1cn2CCCc3cccc1c23	Phase 3
tivozanib	VEGFR inhibitor	FLT1, FLT4, KDR, KIT, PDGFRA, PDGFRB	oncology	renal cell carcinoma (RCC)	Selleck, Selleck, Selleck, Selleck, Selleck, Selleck	97.41	COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC, COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC, COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC, COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC, COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC, COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC	Launched
tizanidine	adrenergic receptor agonist	ADRA2A, ADRA2B, ADRA2C, NISCH	neurology/psychiatry	spasms	Tocris, Tocris, Selleck, Selleck, Selleck	98.81	Clc1ccc2nsnc2c1NC1=NCCN1 |t:13|, Clc1ccc2nsnc2c1NC1=NCCN1 |t:13|, Clc1ccc2nsnc2c1NC1=NCCN1 |t:13|, Clc1ccc2nsnc2c1NC1=NCCN1 |t:13|, Clc1ccc2nsnc2c1NC1=NCCN1 |t:13|	Launched
TMC-353121	RSV fusion inhibitor				MedChemEx, MedChemEx	96.14	Cc1ccc(CCCO)c(NCc2ccc3nc(NCCCN4CCOCC4)n(Cc4nc(C)ccc4O)c3c2)c1, Cc1ccc(CCCO)c(NCc2ccc3nc(NCCCN4CCOCC4)n(Cc4nc(C)ccc4O)c3c2)c1	Phase 2
TMC647055	RNA polymerase inhibitor				MedChemEx	97.37	COc1ccc2-c3c(C4CCCCC4)c4ccc5cc4n3CC(=Cc2c1)C(=O)N(C)CCOCCN(C)S(=O)(=O)NC5=O |c:25|	Phase 2
TMN-355	cyclophilin inhibitor	PPIA			Tocris, Tocris	96.06	Fc1cccc(Cl)c1C(=O)NC(=O)NC1c2ccccc2-c2ccccc12, Fc1cccc(Cl)c1C(=O)NC(=O)NC1c2ccccc2-c2ccccc12	Preclinical
TMPH					Tocris, Tocris, Tocris	100	CCCCCCC(=O)OC1CC(C)(C)NC(C)(C)C1, CCCCCCC(=O)OC1CC(C)(C)NC(C)(C)C1, CCCCCCC(=O)OC1CC(C)(C)NC(C)(C)C1	Preclinical
TMS					Tocris, Tocris, Tocris, Tocris, Tocris	96.72	COc1ccc(\C=C\c2cc(OC)cc(OC)c2)c(OC)c1, COc1ccc(\C=C\c2cc(OC)cc(OC)c2)c(OC)c1, COc1ccc(\C=C\c2cc(OC)cc(OC)c2)c(OC)c1, COc1ccc(\C=C\c2cc(OC)cc(OC)c2)c(OC)c1, COc1ccc(\C=C\c2cc(OC)cc(OC)c2)c(OC)c1	Preclinical
TNP-470	methionine aminopeptidase inhibitor	METAP2			Sigma, Sigma, Sigma	80.16	CO[C@@H]1[C@@H](CC[C@]2(CO2)[C@H]1[C@@]1(C)O[C@@H]1CC=C(C)C)OC(=O)NC(=O)CCl, CO[C@@H]1[C@@H](CC[C@]2(CO2)[C@H]1[C@@]1(C)O[C@@H]1CC=C(C)C)OC(=O)NC(=O)CCl, CO[C@@H]1[C@@H](CC[C@]2(CO2)[C@H]1[C@@]1(C)O[C@@H]1CC=C(C)C)OC(=O)NC(=O)CCl	Phase 2
tobramycin	bacterial 30S ribosomal subunit inhibitor		infectious disease	bacterial septicemia, respiratory tract infections, meningitis, skin infections, urinary tract infections	MicroSource, Selleck, Selleck	100	NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](N)C[C@@H]1O, NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](N)C[C@@H]1O, NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](N)C[C@@H]1O	Launched
tocainide	sodium channel blocker	SCN5A	cardiology	cardiac arrythmia	Sigma, Sigma	98.08	C[C@@H](N)C(=O)Nc1c(C)cccc1C |&1:1,r|, C[C@@H](N)C(=O)Nc1c(C)cccc1C |&1:1,r|	Launched
toceranib	protein tyrosine kinase inhibitor	FLT1, FLT3, KDR, PDGFRA, PDGFRB	oncology	cutaneous mast cell tumors	MedChemEx, MedChemEx, MedChemEx, MedChemEx	92.31	Cc1[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c(C)c1C(=O)NCCN1CCCC1, Cc1[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c(C)c1C(=O)NCCN1CCCC1, Cc1[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c(C)c1C(=O)NCCN1CCCC1, Cc1[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c(C)c1C(=O)NCCN1CCCC1	Launched
tocofersolan	antioxidant		cardiology	cerebral cholesterosis	MedChemEx, MedChemEx	0	CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC[C@]1(C)CCc2c(C)c(OC(=O)CCC(=O)OCCO)c(C)c(C)c2O1, CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC[C@]1(C)CCc2c(C)c(OC(=O)CCC(=O)OCCO)c(C)c(C)c2O1	Launched
todralazine	antihypertensive agent		cardiology	hypertension	MicroSource	89.59	CCOC(=O)NNc1nncc2ccccc12	Launched
tofacitinib	JAK inhibitor	JAK1, JAK2, JAK3	rheumatology	rheumatoid arthritis	Tocris, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck	98.2	C[C@@H]1CCN(C[C@@H]1N(C)c1ncnc2[nH]ccc12)C(=O)CC#N, C[C@@H]1CCN(C[C@@H]1N(C)c1ncnc2[nH]ccc12)C(=O)CC#N, C[C@@H]1CCN(C[C@@H]1N(C)c1ncnc2[nH]ccc12)C(=O)CC#N, C[C@@H]1CCN(C[C@@H]1N(C)c1ncnc2[nH]ccc12)C(=O)CC#N, C[C@@H]1CCN(C[C@@H]1N(C)c1ncnc2[nH]ccc12)C(=O)CC#N, C[C@@H]1CCN(C[C@@H]1N(C)c1ncnc2[nH]ccc12)C(=O)CC#N, C[C@@H]1CCN(C[C@@H]1N(C)c1ncnc2[nH]ccc12)C(=O)CC#N, C[C@@H]1CCN(C[C@@H]1N(C)c1ncnc2[nH]ccc12)C(=O)CC#N	Launched
tofisopam	cytochrome P450 inhibitor, phosphodiesterase inhibitor	CYP3A4	neurology/psychiatry	anxiety, abstinence from alcohol	Sigma, Sigma	80.14	CCC1=C(C)NN=C(c2ccc(OC)c(OC)c2)c2cc(OC)c(OC)cc12 |c:2,t:6|, CCC1=C(C)NN=C(c2ccc(OC)c(OC)c2)c2cc(OC)c(OC)cc12 |c:2,t:6|	Launched
tofogliflozin	sodium/glucose cotransporter inhibitor	GCK	endocrinology	diabetes mellitus	MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx	95.64	CCc1ccc(Cc2ccc3CO[C@]4(O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)c3c2)cc1, CCc1ccc(Cc2ccc3CO[C@]4(O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)c3c2)cc1, CCc1ccc(Cc2ccc3CO[C@]4(O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)c3c2)cc1, CCc1ccc(Cc2ccc3CO[C@]4(O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)c3c2)cc1, CCc1ccc(Cc2ccc3CO[C@]4(O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)c3c2)cc1	Launched
tolamolol	adrenergic receptor antagonist	ADRB1, ADRB2, ADRB3			Sigma	94.9	Cc1ccccc1OC[C@@H](O)CNCCOc1ccc(cc1)C(N)=O |&1:9,r|	Phase 3
tolazamide	ATP channel blocker	ABCC8, KCNJ1, KCNJ10, KCNJ11	endocrinology	diabetes mellitus	Selleck, MicroSource, Selleck	97.65	Cc1ccc(cc1)S(=O)(=O)NC(=O)NN1CCCCCC1, Cc1ccc(cc1)S(=O)(=O)NC(=O)NN1CCCCCC1, Cc1ccc(cc1)S(=O)(=O)NC(=O)NN1CCCCCC1	Launched
tolazoline	adrenergic receptor antagonist	ADRA1A, ADRA2A, ADRA2B, ADRA2C, HRH1, HRH2	neurology/psychiatry	reverse sedative	MedChemEx, MicroSource, Selleck	98.11	C(C1=NCCN1)c1ccccc1 |t:1|, C(C1=NCCN1)c1ccccc1 |t:1|, C(C1=NCCN1)c1ccccc1 |t:1|	Launched
tolbutamide	ATP channel blocker	ABCC8, KCNJ1, KCNJ11, KCNJ8	endocrinology	diabetes mellitus	MedChemEx, MicroSource, Selleck	98.93	CCCCNC(=O)NS(=O)(=O)c1ccc(C)cc1, CCCCNC(=O)NS(=O)(=O)c1ccc(C)cc1, CCCCNC(=O)NS(=O)(=O)c1ccc(C)cc1	Launched
tolcapone	catechol O methyltransferase inhibitor	COMT			Tocris, Tocris, Selleck, Selleck, Selleck, Selleck, Selleck	100	Cc1ccc(cc1)C(=O)c1cc(O)c(O)c(c1)[N+]([O-])=O, Cc1ccc(cc1)C(=O)c1cc(O)c(O)c(c1)[N+]([O-])=O, Cc1ccc(cc1)C(=O)c1cc(O)c(O)c(c1)[N+]([O-])=O, Cc1ccc(cc1)C(=O)c1cc(O)c(O)c(c1)[N+]([O-])=O, Cc1ccc(cc1)C(=O)c1cc(O)c(O)c(c1)[N+]([O-])=O, Cc1ccc(cc1)C(=O)c1cc(O)c(O)c(c1)[N+]([O-])=O, Cc1ccc(cc1)C(=O)c1cc(O)c(O)c(c1)[N+]([O-])=O	Withdrawn
tolfenamic-acid	cyclooxygenase inhibitor, prostanoid receptor antagonist		neurology/psychiatry	migraine headache	MedChemEx, MicroSource, Selleck	99.01	Cc1c(Cl)cccc1Nc1ccccc1C(O)=O, Cc1c(Cl)cccc1Nc1ccccc1C(O)=O, Cc1c(Cl)cccc1Nc1ccccc1C(O)=O	Launched
tolimidone	SRC activator	LYN, SRC			Tocris, Tocris, Axon	99.28	Cc1cccc(Oc2cnc(=O)[nH]c2)c1, Cc1cccc(Oc2cnc(=O)[nH]c2)c1, Cc1cccc(Oc2cnc(=O)[nH]c2)c1	Phase 2
tolmetin	cyclooxygenase inhibitor	PTGS1, PTGS2	rheumatology	rheumatoid arthritis, osteoarthritis	MedChemEx, Selleck, MicroSource	98.68	Cc1ccc(cc1)C(=O)c1ccc(CC(O)=O)n1C, Cc1ccc(cc1)C(=O)c1ccc(CC(O)=O)n1C, Cc1ccc(cc1)C(=O)c1ccc(CC(O)=O)n1C	Launched
tolnaftate	fungal squalene epoxidase inhibitor		infectious disease	tinea pedis, tinea corporis	MedChemEx, MicroSource, Selleck	99.91	CN(C(=S)Oc1ccc2ccccc2c1)c1cccc(C)c1, CN(C(=S)Oc1ccc2ccccc2c1)c1cccc(C)c1, CN(C(=S)Oc1ccc2ccccc2c1)c1cccc(C)c1	Launched
tolonidine	adrenergic receptor antagonist	ADRA2A			Enamine	98.87	Cc1ccc(NC2=NCCN2)c(Cl)c1 |t:6|	Launched
tolonium			hematology	methemoglobinemia	MicroSource, Sigma	90.9	Cc1cc2nc3ccc(cc3sc2cc1N)=[N+](C)C, Cc1cc2nc3ccc(cc3sc2cc1N)=[N+](C)C	Launched
toloxatone	monoamine oxidase inhibitor	MAOA, MAOB	neurology/psychiatry	depression	Sigma, Sigma	99.02	Cc1cccc(c1)N1C[C@@H](CO)OC1=O |&1:9,r|, Cc1cccc(c1)N1C[C@@H](CO)OC1=O |&1:9,r|	Launched
tolperisone	voltage-gated sodium channel blocker	CYP2C19, CYP2D6	neurology/psychiatry, infectious disease, rheumatology, cardiology	muscle relaxant, multiple sclerosis, encephalomyelitis, ankylosing spondylitis, atherosclerosis, Raynaud's disease	MicroSource, MicroSource, MicroSource, Selleck	97.96	C[C@@H](CN1CCCCC1)C(=O)c1ccc(C)cc1 |r|, C[C@@H](CN1CCCCC1)C(=O)c1ccc(C)cc1 |r|, C[C@@H](CN1CCCCC1)C(=O)c1ccc(C)cc1 |r|, C[C@@H](CN1CCCCC1)C(=O)c1ccc(C)cc1 |r|	Launched
tolrestat	aldose reductase inhibitor	AKR1A1, AKR1B1, AKR1B10			MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx	89.37	COc1ccc2c(cccc2c1C(F)(F)F)C(=S)N(C)CC(O)=O, COc1ccc2c(cccc2c1C(F)(F)F)C(=S)N(C)CC(O)=O, COc1ccc2c(cccc2c1C(F)(F)F)C(=S)N(C)CC(O)=O, COc1ccc2c(cccc2c1C(F)(F)F)C(=S)N(C)CC(O)=O, COc1ccc2c(cccc2c1C(F)(F)F)C(=S)N(C)CC(O)=O	Withdrawn
tolterodine	acetylcholine receptor antagonist	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5	urology	urinary incontinence, urinary frequency	Tocris, Selleck, Tocris, Selleck	90.63	CC(C)N(CC[C@H](c1ccccc1)c1cc(C)ccc1O)C(C)C, CC(C)N(CC[C@H](c1ccccc1)c1cc(C)ccc1O)C(C)C, CC(C)N(CC[C@H](c1ccccc1)c1cc(C)ccc1O)C(C)C, CC(C)N(CC[C@H](c1ccccc1)c1cc(C)ccc1O)C(C)C	Launched
toltrazuril	antiprotozoal agent		infectious disease	coccidiosis	MedChemEx, MedChemEx, MicroSource, Selleck	99.46	Cc1cc(ccc1Oc1ccc(SC(F)(F)F)cc1)-n1c(=O)[nH]c(=O)n(C)c1=O, Cc1cc(ccc1Oc1ccc(SC(F)(F)F)cc1)-n1c(=O)[nH]c(=O)n(C)c1=O, Cc1cc(ccc1Oc1ccc(SC(F)(F)F)cc1)-n1c(=O)[nH]c(=O)n(C)c1=O, Cc1cc(ccc1Oc1ccc(SC(F)(F)F)cc1)-n1c(=O)[nH]c(=O)n(C)c1=O	Launched
tolvaptan	vasopressin receptor antagonist	AVPR1A, AVPR2	endocrinology, cardiology, gastroenterology	hyponatremia, congestive heart failure, hepatic cirrhosis	Tocris, Tocris, Tocris, Selleck	99.2	Cc1ccccc1C(=O)Nc1ccc(C(=O)N2CCC[C@@H](O)c3cc(Cl)ccc23)c(C)c1 |&1:20,r|, Cc1ccccc1C(=O)Nc1ccc(C(=O)N2CCC[C@@H](O)c3cc(Cl)ccc23)c(C)c1 |&1:20,r|, Cc1ccccc1C(=O)Nc1ccc(C(=O)N2CCC[C@@H](O)c3cc(Cl)ccc23)c(C)c1 |&1:20,r|, Cc1ccccc1C(=O)Nc1ccc(C(=O)N2CCC[C@@H](O)c3cc(Cl)ccc23)c(C)c1 |&1:20,r|	Launched
tomeglovir	antiviral				MedChemEx	97.71	CN(C)c1cccc2c(cccc12)S(=O)(=O)Nc1ccc(NC(=O)C(C)(C)CO)cc1	Preclinical
tomelukast	leukotriene receptor antagonist	CYSLTR1			Enzo	94.74	CCCc1c(OCCCCc2nn[nH]n2)ccc(C(C)=O)c1O	Phase 3
tomivosertib	MAPK-interacting kinase inhibitor				MedChemEx	96.64	Cc1cc(Nc2cc(N)ncn2)c(=O)n2c1C(=O)NC21CCCCC1	Phase 2
tonabersat	gap junction modulator, nitric oxide production inhibitor				MedChemEx, MedChemEx	99.82	CC(=O)c1ccc2OC(C)(C)[C@@H](O)[C@@H](NC(=O)c3ccc(F)c(Cl)c3)c2c1, CC(=O)c1ccc2OC(C)(C)[C@@H](O)[C@@H](NC(=O)c3ccc(F)c(Cl)c3)c2c1	Phase 2
topilutamide	androgen receptor antagonist				MedChemEx	95.48	C[C@](O)(CNC(=O)C(F)(F)F)C(=O)Nc1ccc(c(c1)C(F)(F)F)[N+]([O-])=O |&1:1,r|	Preclinical
topiramate	carbonic anhydrase inhibitor, glutamate receptor antagonist, kainate receptor antagonist	CA1, CA12, CA2, CA4, CA7, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GRIA1, GRIA2, GRIA3, GRIA4, GRIK1, GRIK2, GRIK3, GRIK4, GRIK5, SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A	neurology/psychiatry	epilepsy, migraine headache	Tocris, MicroSource, Tocris, Selleck, Selleck, Selleck	100	CC1(C)O[C@@H]2CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@H]3[C@@H]2O1, CC1(C)O[C@@H]2CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@H]3[C@@H]2O1, CC1(C)O[C@@H]2CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@H]3[C@@H]2O1, CC1(C)O[C@@H]2CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@H]3[C@@H]2O1, CC1(C)O[C@@H]2CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@H]3[C@@H]2O1, CC1(C)O[C@@H]2CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@H]3[C@@H]2O1	Launched
topiroxostat	xanthine oxidase inhibitor	XDH	rheumatology, nephrology	gout, hyperuricemia	MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx	99.78	N#Cc1cc(ccn1)-c1nnc([nH]1)-c1ccncc1, N#Cc1cc(ccn1)-c1nnc([nH]1)-c1ccncc1, N#Cc1cc(ccn1)-c1nnc([nH]1)-c1ccncc1, N#Cc1cc(ccn1)-c1nnc([nH]1)-c1ccncc1, N#Cc1cc(ccn1)-c1nnc([nH]1)-c1ccncc1	Launched
topotecan	topoisomerase inhibitor	TOP1, TOP1MT	oncology	small cell lung cancer, cervical cancer	MedChemEx, MicroSource, Key, Selleck, MedChemEx, MedChemEx, Selleck	76.92	CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)c(CN(C)C)c4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)c(CN(C)C)c4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)c(CN(C)C)c4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)c(CN(C)C)c4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)c(CN(C)C)c4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)c(CN(C)C)c4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)c(CN(C)C)c4cc3Cn1c2=O	Launched
torasemide	electrolyte reabsorption inhibitor, thromboxane receptor antagonist	SLC12A1	cardiology	edema, congestive heart failure, hypertension	MicroSource, MedChemEx, MedChemEx, Selleck	99.36	CC(C)NC(=O)NS(=O)(=O)c1cnccc1Nc1cccc(C)c1, CC(C)NC(=O)NS(=O)(=O)c1cnccc1Nc1cccc(C)c1, CC(C)NC(=O)NS(=O)(=O)c1cnccc1Nc1cccc(C)c1, CC(C)NC(=O)NS(=O)(=O)c1cnccc1Nc1cccc(C)c1	Launched
torcetrapib	cholesteryl ester transfer protein inhibitor	CETP			Tocris, Selleck, Selleck, Tocris	96.58	CCOC(=O)N1[C@H](CC)C[C@H](N(Cc2cc(cc(c2)C(F)(F)F)C(F)(F)F)C(=O)OC)c2cc(ccc12)C(F)(F)F, CCOC(=O)N1[C@H](CC)C[C@H](N(Cc2cc(cc(c2)C(F)(F)F)C(F)(F)F)C(=O)OC)c2cc(ccc12)C(F)(F)F, CCOC(=O)N1[C@H](CC)C[C@H](N(Cc2cc(cc(c2)C(F)(F)F)C(F)(F)F)C(=O)OC)c2cc(ccc12)C(F)(F)F, CCOC(=O)N1[C@H](CC)C[C@H](N(Cc2cc(cc(c2)C(F)(F)F)C(F)(F)F)C(=O)OC)c2cc(ccc12)C(F)(F)F	Phase 3
torcitabine	DNA polymerase inhibitor	DCK, TK2			MedChemEx, MedChemEx	100	Nc1ccn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1, Nc1ccn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1	Phase 2
toremifene	estrogen receptor antagonist, selective estrogen receptor modulator (SERM)	ESR1	oncology	breast cancer	MicroSource, MedChemEx, MedChemEx, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck	97.25	CN(C)CCOc1ccc(cc1)C(=C(\CCCl)c1ccccc1)\c1ccccc1, CN(C)CCOc1ccc(cc1)C(=C(\CCCl)c1ccccc1)\c1ccccc1, CN(C)CCOc1ccc(cc1)C(=C(\CCCl)c1ccccc1)\c1ccccc1, CN(C)CCOc1ccc(cc1)C(=C(\CCCl)c1ccccc1)\c1ccccc1, CN(C)CCOc1ccc(cc1)C(=C(\CCCl)c1ccccc1)\c1ccccc1, CN(C)CCOc1ccc(cc1)C(=C(\CCCl)c1ccccc1)\c1ccccc1, CN(C)CCOc1ccc(cc1)C(=C(\CCCl)c1ccccc1)\c1ccccc1, CN(C)CCOc1ccc(cc1)C(=C(\CCCl)c1ccccc1)\c1ccccc1, CN(C)CCOc1ccc(cc1)C(=C(\CCCl)c1ccccc1)\c1ccccc1, CN(C)CCOc1ccc(cc1)C(=C(\CCCl)c1ccccc1)\c1ccccc1	Launched
torin-1	mTOR inhibitor	MTOR			Selleck, Selleck, Selleck, Selleck, Tocris	95.98	CCC(=O)N1CCN(CC1)c1ccc(cc1C(F)(F)F)-n1c2c(ccc1=O)cnc1ccc(cc21)-c1cnc2ccccc2c1, CCC(=O)N1CCN(CC1)c1ccc(cc1C(F)(F)F)-n1c2c(ccc1=O)cnc1ccc(cc21)-c1cnc2ccccc2c1, CCC(=O)N1CCN(CC1)c1ccc(cc1C(F)(F)F)-n1c2c(ccc1=O)cnc1ccc(cc21)-c1cnc2ccccc2c1, CCC(=O)N1CCN(CC1)c1ccc(cc1C(F)(F)F)-n1c2c(ccc1=O)cnc1ccc(cc21)-c1cnc2ccccc2c1, CCC(=O)N1CCN(CC1)c1ccc(cc1C(F)(F)F)-n1c2c(ccc1=O)cnc1ccc(cc21)-c1cnc2ccccc2c1	Preclinical
torin-2	mTOR inhibitor	MTOR			Selleck, Selleck, Tocris, Tocris, Tocris, Tocris	97.57	Nc1ccc(cn1)-c1ccc2ncc3ccc(=O)n(-c4cccc(c4)C(F)(F)F)c3c2c1, Nc1ccc(cn1)-c1ccc2ncc3ccc(=O)n(-c4cccc(c4)C(F)(F)F)c3c2c1, Nc1ccc(cn1)-c1ccc2ncc3ccc(=O)n(-c4cccc(c4)C(F)(F)F)c3c2c1, Nc1ccc(cn1)-c1ccc2ncc3ccc(=O)n(-c4cccc(c4)C(F)(F)F)c3c2c1, Nc1ccc(cn1)-c1ccc2ncc3ccc(=O)n(-c4cccc(c4)C(F)(F)F)c3c2c1, Nc1ccc(cn1)-c1ccc2ncc3ccc(=O)n(-c4cccc(c4)C(F)(F)F)c3c2c1	Preclinical
tosedostat	peptidase inhibitor	ANPEP, LAP3, NPEPPS			Tocris, Selleck, Tocris, Tocris, Tocris, Tocris, Tocris, Selleck	93.96	CC(C)C[C@H]([C@H](O)C(=O)NO)C(=O)N[C@H](C(=O)OC1CCCC1)c1ccccc1, CC(C)C[C@H]([C@H](O)C(=O)NO)C(=O)N[C@H](C(=O)OC1CCCC1)c1ccccc1, CC(C)C[C@H]([C@H](O)C(=O)NO)C(=O)N[C@H](C(=O)OC1CCCC1)c1ccccc1, CC(C)C[C@H]([C@H](O)C(=O)NO)C(=O)N[C@H](C(=O)OC1CCCC1)c1ccccc1, CC(C)C[C@H]([C@H](O)C(=O)NO)C(=O)N[C@H](C(=O)OC1CCCC1)c1ccccc1, CC(C)C[C@H]([C@H](O)C(=O)NO)C(=O)N[C@H](C(=O)OC1CCCC1)c1ccccc1, CC(C)C[C@H]([C@H](O)C(=O)NO)C(=O)N[C@H](C(=O)OC1CCCC1)c1ccccc1, CC(C)C[C@H]([C@H](O)C(=O)NO)C(=O)N[C@H](C(=O)OC1CCCC1)c1ccccc1	Phase 2
tosufloxacin	bacterial DNA gyrase inhibitor		infectious disease	gram-negative bacterial infections	Prestwick	97.24	N[C@H]1CCN(C1)c1nc2n(cc(C(O)=O)c(=O)c2cc1F)-c1ccc(F)cc1F |&1:1|	Launched
toyocamycin	serine/threonine kinase inhibitor	ERN1			Sigma, Sigma, Sigma	99.13	Nc1ncnc2n(cc(C#N)c12)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O, Nc1ncnc2n(cc(C#N)c12)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O, Nc1ncnc2n(cc(C#N)c12)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O	Phase 1
tozadenant	adenosine receptor antagonist	ADORA2A			MedChemEx, MedChemEx, MedChemEx, MedChemEx	96.14	COc1ccc(N2CCOCC2)c2sc(NC(=O)N3CCC(C)(O)CC3)nc12, COc1ccc(N2CCOCC2)c2sc(NC(=O)N3CCC(C)(O)CC3)nc12, COc1ccc(N2CCOCC2)c2sc(NC(=O)N3CCC(C)(O)CC3)nc12, COc1ccc(N2CCOCC2)c2sc(NC(=O)N3CCC(C)(O)CC3)nc12	Phase 3
tozasertib	Aurora kinase inhibitor, Bcr-Abl kinase inhibitor, FLT3 inhibitor, JAK inhibitor	AURKA, AURKB, AURKC, LCK			Selleck, Selleck, Selleck, Selleck, Selleck	97.69	CN1CCN(CC1)c1cc(Nc2cc(C)n[nH]2)nc(Sc2ccc(NC(=O)C3CC3)cc2)n1, CN1CCN(CC1)c1cc(Nc2cc(C)n[nH]2)nc(Sc2ccc(NC(=O)C3CC3)cc2)n1, CN1CCN(CC1)c1cc(Nc2cc(C)n[nH]2)nc(Sc2ccc(NC(=O)C3CC3)cc2)n1, CN1CCN(CC1)c1cc(Nc2cc(C)n[nH]2)nc(Sc2ccc(NC(=O)C3CC3)cc2)n1, CN1CCN(CC1)c1cc(Nc2cc(C)n[nH]2)nc(Sc2ccc(NC(=O)C3CC3)cc2)n1	Phase 2
TP-003	GABA receptor inverse agonist	GABRA1, GABRA2, GABRA3, GABRA5			Tocris, Tocris	95.5	CC(C)(O)c1ccn2c(cnc2c1F)-c1ccc(F)c(c1)-c1ccc(F)cc1C#N, CC(C)(O)c1ccn2c(cnc2c1F)-c1ccc(F)c(c1)-c1ccc(F)cc1C#N	Preclinical
TP-0903	AXL kinase inhibitor	AXL			MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx	98.07	CN(C)S(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(CN3CCN(C)CC3)cc2)ncc1Cl, CN(C)S(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(CN3CCN(C)CC3)cc2)ncc1Cl, CN(C)S(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(CN3CCN(C)CC3)cc2)ncc1Cl, CN(C)S(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(CN3CCN(C)CC3)cc2)ncc1Cl, CN(C)S(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(CN3CCN(C)CC3)cc2)ncc1Cl	Phase 1/Phase 2
TP-3654	1,4,5-trisphosphate inhibitor				MedChemEx	96.51	CC(C)(O)[C@H]1CC[C@@H](CC1)Nc1ccc2ncc(-c3cccc(c3)C(F)(F)F)n2n1 |r|	Phase 1
TPCA-1	IKK inhibitor	IKBKB			Tocris, Tocris, Tocris, Tocris, Tocris, Selleck	98.3	NC(=O)Nc1sc(cc1C(N)=O)-c1ccc(F)cc1, NC(=O)Nc1sc(cc1C(N)=O)-c1ccc(F)cc1, NC(=O)Nc1sc(cc1C(N)=O)-c1ccc(F)cc1, NC(=O)Nc1sc(cc1C(N)=O)-c1ccc(F)cc1, NC(=O)Nc1sc(cc1C(N)=O)-c1ccc(F)cc1, NC(=O)Nc1sc(cc1C(N)=O)-c1ccc(F)cc1	Preclinical
TPPS4					Vitas-M	40.2	OS(=O)(=O)c1ccc(cc1)-c1c2ccc(n2)c(-c2ccc(cc2)S(O)(=O)=O)c2ccc([nH]2)c(-c2ccc(cc2)S(O)(=O)=O)c2ccc(n2)c(-c2ccc(cc2)S(O)(=O)=O)c2ccc1[nH]2	Phase 1
trabectedin	antitumor agent				MedChemEx	85.45	[H][C@@]12Cc3cc(C)c(OC)c(O)c3[C@@]([H])(N1C)[C@@]1([H])N([C@H]2O)[C@@]2([H])COC(=O)[C@]3(CS[C@]1([H])c1c(OC(C)=O)c(C)c4OCOc4c21)NCCc1cc(O)c(OC)cc31 |THB:16:15:2.3.12:17.19.20|	Phase 3
trabodenoson	adenosine receptor agonist				AMS	81.93	O[C@@H]1[C@@H](CO[N+]([O-])=O)O[C@H]([C@@H]1O)n1cnc2c(NC3CCCC3)ncnc12	Phase 3
tracazolate	GABA receptor modulator	GABRA1			Tocris, Tocris, Tocris, Tocris	98.96	CCCCNc1c(C(=O)OCC)c(C)nc2n(CC)ncc12, CCCCNc1c(C(=O)OCC)c(C)nc2n(CC)ncc12, CCCCNc1c(C(=O)OCC)c(C)nc2n(CC)ncc12, CCCCNc1c(C(=O)OCC)c(C)nc2n(CC)ncc12	Phase 2
tradipitant	neurokinin receptor antagonist				MedChemEx	97.43	FC(F)(F)c1cc(Cn2nnc(c2-c2ccncc2)-c2ncccc2C(=O)c2ccccc2Cl)cc(c1)C(F)(F)F	Phase 3
TRAM-34	potassium channel antagonist	KCNN4			MedChemEx, MedChemEx	0	Clc1ccccc1C(c1ccccc1)(c1ccccc1)n1cccn1, Clc1ccccc1C(c1ccccc1)(c1ccccc1)n1cccn1	Preclinical
TRAM-39	calcium-activated potassium channel activator	KCNN4			Tocris, Tocris, Tocris	98.14	Clc1ccccc1C(C#N)(c1ccccc1)c1ccccc1, Clc1ccccc1C(C#N)(c1ccccc1)c1ccccc1, Clc1ccccc1C(C#N)(c1ccccc1)c1ccccc1	Preclinical
trametinib	MEK inhibitor	MAP2K1, MAP2K2	oncology	melanoma	Selleck, Selleck, Selleck, Selleck, MedChemEx, MedChemEx, MedChemEx, Selleck, Selleck, Selleck, Selleck	94.67	CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O	Launched
tramiprosate	beta amyloid protein neurotoxicity inhibitor	APP			MicroSource, Tocris	100	NCCCS(O)(=O)=O, NCCCS(O)(=O)=O	Phase 3
trandolapril	angiotensin converting enzyme inhibitor	ACE	cardiology	hypertension, myocardial infarction	MedChemEx, MedChemEx	92.63	CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1[C@H]2CCCC[C@@H]2C[C@H]1C(O)=O, CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1[C@H]2CCCC[C@@H]2C[C@H]1C(O)=O	Launched
tranexamic-acid	antifibrinolytic, plasminogen activator inhibitor	PLG	hematology	hemophilia	MedChemEx, MedChemEx, MicroSource, Selleck, Selleck	97	NC[C@H]1CC[C@@H](CC1)C(O)=O |r|, NC[C@H]1CC[C@@H](CC1)C(O)=O |r|, NC[C@H]1CC[C@@H](CC1)C(O)=O |r|, NC[C@H]1CC[C@@H](CC1)C(O)=O |r|, NC[C@H]1CC[C@@H](CC1)C(O)=O |r|	Launched
tranilast	angiogenesis inhibitor	HPGDS, HRH1	pulmonary	asthma	Tocris, Tocris, MicroSource, Selleck, Selleck, Tocris	99.75	COc1ccc(\C=C\C(=O)Nc2ccccc2C(O)=O)cc1OC, COc1ccc(\C=C\C(=O)Nc2ccccc2C(O)=O)cc1OC, COc1ccc(\C=C\C(=O)Nc2ccccc2C(O)=O)cc1OC, COc1ccc(\C=C\C(=O)Nc2ccccc2C(O)=O)cc1OC, COc1ccc(\C=C\C(=O)Nc2ccccc2C(O)=O)cc1OC, COc1ccc(\C=C\C(=O)Nc2ccccc2C(O)=O)cc1OC	Launched
trans-10,cis-12-conjugated-linoleic-acid					Cayman, Cayman	95.61	CCCCC\C=C/C=C/CCCCCCCCC(O)=O, CCCCC\C=C/C=C/CCCCCCCCC(O)=O	Launched
trans-2-undecenoic-acid					AlfaAesar	90.54	CCCCCCCC\C=C\C(O)=O	Preclinical
trans-4-[8-(3-fluorophenyl)-1,7-naphthyridin-6-yl]cyclohexanecarboxylic-acid					Key, Key	95.64	OC(=O)C1CCC(CC1)c1cc2cccnc2c(n1)-c1cccc(F)c1, OC(=O)C1CCC(CC1)c1cc2cccnc2c(n1)-c1cccc(F)c1	Preclinical
trans-4-hydroxycrotonic-acid	gamma hydroxybutyric acid ligand				Tocris, Tocris	0	OC\C=C\C(O)=O, OC\C=C\C(O)=O	Preclinical
trans-4-methoxycinnamic-acid					Sigma, Vitas-M, Vitas-M	96.49	COc1ccc(\C=C\C(O)=O)cc1, COc1ccc(\C=C\C(O)=O)cc1, COc1ccc(\C=C\C(O)=O)cc1	Preclinical
transcrocetinate	glutamate receptor antagonist				MedChemEx	0	C\C(\C=C\C=C(/C)C(O)=O)=C/C=C/C=C(\C)/C=C/C=C(\C)C(O)=O	Preclinical
tranylcypromine	monoamine oxidase inhibitor	KDM1A, MAOA, MAOB	neurology/psychiatry	depression	MedChemEx	77.31	N[C@H]1C[C@@H]1c1ccccc1 |&1:1,3|	Launched
trap-101	nociceptin/orphanin FQ receptor antagonist, opioid receptor antagonist	OPRL1			Tocris, Tocris, Tocris, Tocris	97.83	CCn1c2ccccc2n(C2=C(CO)CN(CC3CCCCCCC3)CC2)c1=O |c:11|, CCn1c2ccccc2n(C2=C(CO)CN(CC3CCCCCCC3)CC2)c1=O |c:11|, CCn1c2ccccc2n(C2=C(CO)CN(CC3CCCCCCC3)CC2)c1=O |c:11|, CCn1c2ccccc2n(C2=C(CO)CN(CC3CCCCCCC3)CC2)c1=O |c:11|	Preclinical
trapidil	PDGFR tyrosine kinase receptor inhibitor	PDGFRA	cardiology	coronary artery disease (CAD)	MedChemEx, MedChemEx, Prestwick	99.14	CCN(CC)c1cc(C)nc2ncnn12, CCN(CC)c1cc(C)nc2ncnn12, CCN(CC)c1cc(C)nc2ncnn12	Launched
travoprost	prostanoid receptor agonist	PTGFR	ophthalmology	ocular hypertension, glaucoma	MedChemEx, Enzo	95.41	CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)COc1cccc(c1)C(F)(F)F, CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)COc1cccc(c1)C(F)(F)F	Launched
traxoprodil	glutamate receptor antagonist	GRIN2B			EMDBio, EMDBio	93.36	C[C@@H]([C@@H](O)c1ccc(O)cc1)N1CCC(O)(CC1)c1ccccc1, C[C@@H]([C@@H](O)c1ccc(O)cc1)N1CCC(O)(CC1)c1ccccc1	Phase 2
trazodone	adrenergic receptor antagonist, serotonin receptor antagonist, serotonin reuptake inhibitor	ADRA1A, ADRA2A, HRH1, HTR1A, HTR2A, HTR2B, HTR2C, SLC6A4	neurology/psychiatry	depression	MicroSource, Selleck	97.98	Clc1cccc(c1)N1CCN(CCCn2nc3ccccn3c2=O)CC1, Clc1cccc(c1)N1CCN(CCCn2nc3ccccn3c2=O)CC1	Launched
trebenzomine					Sigma	53.54	C[C@H]1Oc2ccccc2C[C@@H]1N(C)C |&1:1,&2:10,r|	Phase 2
trelagliptin	dipeptidyl peptidase inhibitor	DPP4	endocrinology	diabetes mellitus	MedChemEx	78.61	Cn1c(=O)cc(N2CCC[C@@H](N)C2)n(Cc2cc(F)ccc2C#N)c1=O	Launched
tremorine	acetylcholine receptor agonist				Vitas-M, Prestwick, Prestwick	100	C(C#CCN1CCCC1)N1CCCC1, C(C#CCN1CCCC1)N1CCCC1, C(C#CCN1CCCC1)N1CCCC1	Preclinical
treosulfan	DNA synthesis inhibitor		oncology	ovarian cancer	MedChemEx, MedChemEx	0	CS(=O)(=O)OC[C@H](O)[C@@H](O)COS(C)(=O)=O, CS(=O)(=O)OC[C@H](O)[C@@H](O)COS(C)(=O)=O	Launched
trepibutone	cholinergic receptor antagonist	CHRM1, CHRM2, CHRM3, CHRM4	gastroenterology	irritable bowel syndrome	AvaChem	97.79	CCOc1cc(OCC)c(cc1OCC)C(=O)CCC(O)=O	Launched
treprostinil	prostanoid receptor agonist	P2RY12, PPARD, PTGIR	pulmonary	pulmonary arterial hypertension (PAH)	MedChemEx	97.03	CCCCC[C@H](O)CC[C@H]1[C@H](O)C[C@@H]2Cc3c(C[C@H]12)cccc3OCC(O)=O	Launched
trequinsin	phosphodiesterase inhibitor	PDE5A			Tocris, Tocris, Tocris, Tocris	96.03	COc1cc2CCn3c(c\c(=N/c4c(C)cc(C)cc4C)n(C)c3=O)-c2cc1OC, COc1cc2CCn3c(c\c(=N/c4c(C)cc(C)cc4C)n(C)c3=O)-c2cc1OC, COc1cc2CCn3c(c\c(=N/c4c(C)cc(C)cc4C)n(C)c3=O)-c2cc1OC, COc1cc2CCn3c(c\c(=N/c4c(C)cc(C)cc4C)n(C)c3=O)-c2cc1OC	Phase 1
tretazicar	DNA replication inhibitor	NQO2			Sigma, Sigma, Sigma	92.47	NC(=O)c1cc(N2CC2)c(cc1[N+]([O-])=O)[N+]([O-])=O, NC(=O)c1cc(N2CC2)c(cc1[N+]([O-])=O)[N+]([O-])=O, NC(=O)c1cc(N2CC2)c(cc1[N+]([O-])=O)[N+]([O-])=O	Phase 2
tretinoin	retinoid receptor agonist, retinoid receptor ligand	ALDH1A1, ALDH1A2, GPRC5A, NR0B1, NR2C2, PPARD, RARA, RARB, RARG, RARRES1, RORB, RORC, RXRB, RXRG	hematologic malignancy	acute promyelocytic leukemia (APL)	MedChemEx, MedChemEx, MedChemEx, Sigma, MicroSource, Selleck, MedChemEx, Tocris, Selleck	84.83	C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C/C(O)=O |c:4|, C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C/C(O)=O |c:4|, C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C/C(O)=O |c:4|, C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C/C(O)=O |c:4|, C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C/C(O)=O |c:4|, C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C/C(O)=O |c:4|, C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C/C(O)=O |c:4|, C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C/C(O)=O |c:4|, C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C/C(O)=O |c:4|	Launched
triacetin					MedChemEx, MicroSource	85.32	CC(=O)OCC(COC(C)=O)OC(C)=O, CC(=O)OCC(COC(C)=O)OC(C)=O	Launched
triamcinolone	glucocorticoid receptor agonist	NR3C1	dermatology	corticosteroid-responsive dermatoses	MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx, Selleck, Selleck, Selleck, MicroSource, MicroSource, Selleck	97	C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO |c:14,t:10|, C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO |c:14,t:10|, C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO |c:14,t:10|, C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO |c:14,t:10|, C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO |c:14,t:10|, C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO |c:14,t:10|, C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO |c:14,t:10|, C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO |c:14,t:10|, C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO |c:14,t:10|, C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO |c:14,t:10|, C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO |c:14,t:10|	Launched
triamcinolone-acetonide	glucocorticoid receptor agonist, immunosuppressant	NR3C1, SERPINA6	dermatology	corticosteroid-responsive dermatoses	MedChemEx	91.09	CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO |c:14,t:10|	Launched
triamcinolone-hexacetonide	anti-inflammatory agent				MedChemEx	80.82	[H][C@@]12C[C@@]3([H])[C@]4([H])CCC5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]1(OC(C)(C)O2)C(=O)COC(=O)CC(C)(C)C |c:13,t:9|	Launched
triamterene	sodium channel blocker	SCNN1A, SCNN1B, SCNN1D, SCNN1G	endocrinology, cardiology	hypokalemia, hypertension, edema	MedChemEx, MedChemEx, MicroSource, MicroSource, MicroSource, MicroSource, Selleck	99.47	Nc1nc(N)c2nc(c(N)nc2n1)-c1ccccc1, Nc1nc(N)c2nc(c(N)nc2n1)-c1ccccc1, Nc1nc(N)c2nc(c(N)nc2n1)-c1ccccc1, Nc1nc(N)c2nc(c(N)nc2n1)-c1ccccc1, Nc1nc(N)c2nc(c(N)nc2n1)-c1ccccc1, Nc1nc(N)c2nc(c(N)nc2n1)-c1ccccc1, Nc1nc(N)c2nc(c(N)nc2n1)-c1ccccc1	Launched
triapine	ribonucleotide reductase inhibitor	RRM1, RRM2			MedChemEx, Selleck, Selleck	99.17	NC(=S)N\N=C\c1ncccc1N, NC(=S)N\N=C\c1ncccc1N, NC(=S)N\N=C\c1ncccc1N	Phase 2
tribenoside	anti-inflammatory agent, capillary stabilizing agent				ChemImpex, Prestwick	63.93	CCO[C@H]1O[C@H]([C@@H](COCc2ccccc2)OCc2ccccc2)[C@H](OCc2ccccc2)[C@H]1O |a:5,6,24,33,&1:3|, CCO[C@H]1O[C@H]([C@@H](COCc2ccccc2)OCc2ccccc2)[C@H](OCc2ccccc2)[C@H]1O |a:5,6,24,33,&1:3|	Launched
tribomsalan					Sigma, Vitas-M, Vitas-M, Vitas-M	97.22	Oc1c(Br)cc(Br)cc1C(=O)Nc1ccc(Br)cc1, Oc1c(Br)cc(Br)cc1C(=O)Nc1ccc(Br)cc1, Oc1c(Br)cc(Br)cc1C(=O)Nc1ccc(Br)cc1, Oc1c(Br)cc(Br)cc1C(=O)Nc1ccc(Br)cc1	Preclinical
tribromoethanol	analgesic agent				MedChemEx, MicroSource	0	OCC(Br)(Br)Br, OCC(Br)(Br)Br	Preclinical
tributyrin	HDAC inhibitor				Sigma, Sigma	73.5	CCCC(=O)OCC(COC(=O)CCC)OC(=O)CCC, CCCC(=O)OCC(COC(=O)CCC)OC(=O)CCC	Phase 1
tricaprylin			dermatology	cosmetic	MicroSource, Sigma	85.71	CCCCCCCC(=O)OCC(COC(=O)CCCCCCC)OC(=O)CCCCCCC, CCCCCCCC(=O)OCC(COC(=O)CCCCCCC)OC(=O)CCCCCCC	Launched
trichlormethiazide	chloride channel blocker	PTGS1, PTGS2, SLC12A1	cardiology	hypertension, edema	Selleck, MicroSource, Selleck, Selleck, Selleck	100	NS(=O)(=O)c1cc2c(N[C@@H](NS2(=O)=O)C(Cl)Cl)cc1Cl |&1:9,r|, NS(=O)(=O)c1cc2c(N[C@@H](NS2(=O)=O)C(Cl)Cl)cc1Cl |&1:9,r|, NS(=O)(=O)c1cc2c(N[C@@H](NS2(=O)=O)C(Cl)Cl)cc1Cl |&1:9,r|, NS(=O)(=O)c1cc2c(N[C@@H](NS2(=O)=O)C(Cl)Cl)cc1Cl |&1:9,r|, NS(=O)(=O)c1cc2c(N[C@@H](NS2(=O)=O)C(Cl)Cl)cc1Cl |&1:9,r|	Launched
trichloroacetic-acid			dermatology	warts	Enamine, Enamine, Enamine	0	OC(=O)C(Cl)(Cl)Cl, OC(=O)C(Cl)(Cl)Cl, OC(=O)C(Cl)(Cl)Cl	Launched
trichloroethylene					Sigma, MicroSource	0	ClC=C(Cl)Cl, ClC=C(Cl)Cl	Preclinical
trichostatin-a	HDAC inhibitor	HDAC1, HDAC10, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9			Selleck, Selleck, Selleck, Selleck, Selleck, Selleck	98.67	C[C@H](\C=C(/C)\C=C\C(=O)NO)C(=O)c1ccc(cc1)N(C)C, C[C@H](\C=C(/C)\C=C\C(=O)NO)C(=O)c1ccc(cc1)N(C)C, C[C@H](\C=C(/C)\C=C\C(=O)NO)C(=O)c1ccc(cc1)N(C)C, C[C@H](\C=C(/C)\C=C\C(=O)NO)C(=O)c1ccc(cc1)N(C)C, C[C@H](\C=C(/C)\C=C\C(=O)NO)C(=O)c1ccc(cc1)N(C)C, C[C@H](\C=C(/C)\C=C\C(=O)NO)C(=O)c1ccc(cc1)N(C)C	Phase 1
triciribine	AKT inhibitor	AKT1, AKT2, AKT3			Tocris, Tocris, Tocris, Tocris, Selleck, Selleck, Selleck, Selleck, Selleck	95.13	Cn1nc(N)c2cn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c3ncnc1c23, Cn1nc(N)c2cn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c3ncnc1c23, Cn1nc(N)c2cn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c3ncnc1c23, Cn1nc(N)c2cn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c3ncnc1c23, Cn1nc(N)c2cn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c3ncnc1c23, Cn1nc(N)c2cn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c3ncnc1c23, Cn1nc(N)c2cn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c3ncnc1c23, Cn1nc(N)c2cn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c3ncnc1c23, Cn1nc(N)c2cn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c3ncnc1c23	Phase 1/Phase 2
triciribine-phosphate	AKT inhibitor				Adooq	95.69	Cn1nc(N)c2cn([C@@H]3O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]3O)c3ncnc1c23	Phase 1/Phase 2
triclabendazole	microtubule inhibitor	DNMT1	infectious disease	tapeworm	MedChemEx, MicroSource, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck	98.03	CSc1nc2cc(Cl)c(Oc3cccc(Cl)c3Cl)cc2[nH]1, CSc1nc2cc(Cl)c(Oc3cccc(Cl)c3Cl)cc2[nH]1, CSc1nc2cc(Cl)c(Oc3cccc(Cl)c3Cl)cc2[nH]1, CSc1nc2cc(Cl)c(Oc3cccc(Cl)c3Cl)cc2[nH]1, CSc1nc2cc(Cl)c(Oc3cccc(Cl)c3Cl)cc2[nH]1, CSc1nc2cc(Cl)c(Oc3cccc(Cl)c3Cl)cc2[nH]1, CSc1nc2cc(Cl)c(Oc3cccc(Cl)c3Cl)cc2[nH]1, CSc1nc2cc(Cl)c(Oc3cccc(Cl)c3Cl)cc2[nH]1, CSc1nc2cc(Cl)c(Oc3cccc(Cl)c3Cl)cc2[nH]1	Launched
triclocarban	other antibiotic		infectious disease	first-aid antiseptic	MedChemEx, ChemDiv, ChemDiv, ChemDiv, ChemDiv, ChemDiv	97.9	Clc1ccc(NC(=O)Nc2ccc(Cl)c(Cl)c2)cc1, Clc1ccc(NC(=O)Nc2ccc(Cl)c(Cl)c2)cc1, Clc1ccc(NC(=O)Nc2ccc(Cl)c(Cl)c2)cc1, Clc1ccc(NC(=O)Nc2ccc(Cl)c(Cl)c2)cc1, Clc1ccc(NC(=O)Nc2ccc(Cl)c(Cl)c2)cc1, Clc1ccc(NC(=O)Nc2ccc(Cl)c(Cl)c2)cc1	Launched
triclosan	antibacterial agent	DNMT1	infectious disease	first-aid antiseptic	MicroSource, MicroSource, MicroSource, MicroSource	99.42	Oc1cc(Cl)ccc1Oc1ccc(Cl)cc1Cl, Oc1cc(Cl)ccc1Oc1ccc(Cl)cc1Cl, Oc1cc(Cl)ccc1Oc1ccc(Cl)cc1Cl, Oc1cc(Cl)ccc1Oc1ccc(Cl)cc1Cl	Launched
tridihexethyl	acetylcholine receptor antagonist		gastroenterology, ophthalmology	peptic ulcer disease (PUD), nystagmus	Prestwick	94	CC[N+](CC)(CC)CC[C@@](O)(C1CCCCC1)c1ccccc1 |&1:9|	Launched
trientine	chelating agent	CA14	metabolism	Wilson's disease	MicroSource, Sigma	100	NCCNCCNCCN, NCCNCCNCCN	Launched
trifloxystrobin	mitochondrial electron transport inhibitor				MedChemEx	97.32	CO\N=C(\C(=O)OC)c1ccccc1CO\N=C(/C)c1cccc(c1)C(F)(F)F	Preclinical
trifluoperazine	dopamine receptor antagonist	ADRA1A, CALM1, CALY, DRD2, DRD4, HRH1, HTR2A, HTR2C, S100A4, TNNC1	neurology/psychiatry	schizophrenia	MedChemEx, Selleck, Selleck, Selleck, MicroSource, MicroSource, Selleck	96.64	CN1CCN(CCCN2c3ccccc3Sc3ccc(cc23)C(F)(F)F)CC1, CN1CCN(CCCN2c3ccccc3Sc3ccc(cc23)C(F)(F)F)CC1, CN1CCN(CCCN2c3ccccc3Sc3ccc(cc23)C(F)(F)F)CC1, CN1CCN(CCCN2c3ccccc3Sc3ccc(cc23)C(F)(F)F)CC1, CN1CCN(CCCN2c3ccccc3Sc3ccc(cc23)C(F)(F)F)CC1, CN1CCN(CCCN2c3ccccc3Sc3ccc(cc23)C(F)(F)F)CC1, CN1CCN(CCCN2c3ccccc3Sc3ccc(cc23)C(F)(F)F)CC1	Launched
triflupromazine	dopamine receptor antagonist	CHRM1, CHRM2, DRD1, DRD2, HTR2B	neurology/psychiatry, gastroenterology	psychosis, nausea, vomiting	MedChemEx, MedChemEx, MicroSource, MicroSource, Selleck, Selleck, Selleck	97.93	CN(C)CCCN1c2ccccc2Sc2ccc(cc12)C(F)(F)F, CN(C)CCCN1c2ccccc2Sc2ccc(cc12)C(F)(F)F, CN(C)CCCN1c2ccccc2Sc2ccc(cc12)C(F)(F)F, CN(C)CCCN1c2ccccc2Sc2ccc(cc12)C(F)(F)F, CN(C)CCCN1c2ccccc2Sc2ccc(cc12)C(F)(F)F, CN(C)CCCN1c2ccccc2Sc2ccc(cc12)C(F)(F)F, CN(C)CCCN1c2ccccc2Sc2ccc(cc12)C(F)(F)F	Launched
trifluridine	DNA directed DNA polymerase inhibitor, thymidylate synthase inhibitor	TYMS	infectious disease	virus herpes simplex (HSV)	Tocris, MicroSource, MicroSource, MicroSource, MicroSource, Selleck, Selleck, Selleck, Selleck	96.52	OC[C@H]1O[C@H](C[C@@H]1O)n1cc(c(=O)[nH]c1=O)C(F)(F)F, OC[C@H]1O[C@H](C[C@@H]1O)n1cc(c(=O)[nH]c1=O)C(F)(F)F, OC[C@H]1O[C@H](C[C@@H]1O)n1cc(c(=O)[nH]c1=O)C(F)(F)F, OC[C@H]1O[C@H](C[C@@H]1O)n1cc(c(=O)[nH]c1=O)C(F)(F)F, OC[C@H]1O[C@H](C[C@@H]1O)n1cc(c(=O)[nH]c1=O)C(F)(F)F, OC[C@H]1O[C@H](C[C@@H]1O)n1cc(c(=O)[nH]c1=O)C(F)(F)F, OC[C@H]1O[C@H](C[C@@H]1O)n1cc(c(=O)[nH]c1=O)C(F)(F)F, OC[C@H]1O[C@H](C[C@@H]1O)n1cc(c(=O)[nH]c1=O)C(F)(F)F, OC[C@H]1O[C@H](C[C@@H]1O)n1cc(c(=O)[nH]c1=O)C(F)(F)F	Launched
triflusal	cyclooxygenase inhibitor, platelet aggregation inhibitor, thromboxane synthase inhibitor	NFKB1, NOS2, PDE10A, PTGS1	neurology/psychiatry, cardiology	stroke, myocardial infarction, atrial fibrillation (AF)	MedChemEx, MedChemEx, MedChemEx, Selleck, Selleck, MedChemEx, Selleck	94.75	CC(=O)Oc1cc(ccc1C(O)=O)C(F)(F)F, CC(=O)Oc1cc(ccc1C(O)=O)C(F)(F)F, CC(=O)Oc1cc(ccc1C(O)=O)C(F)(F)F, CC(=O)Oc1cc(ccc1C(O)=O)C(F)(F)F, CC(=O)Oc1cc(ccc1C(O)=O)C(F)(F)F, CC(=O)Oc1cc(ccc1C(O)=O)C(F)(F)F, CC(=O)Oc1cc(ccc1C(O)=O)C(F)(F)F	Launched
trigonelline					Enzo, Enzo	100	C[n+]1cccc(c1)C(O)=O, C[n+]1cccc(c1)C(O)=O	Phase 1
trihexyphenidyl	acetylcholine receptor antagonist	CHRM1	neurology/psychiatry	parkinsonism	MedChemEx	93.48	O[C@@](CCN1CCCCC1)(C1CCCCC1)c1ccccc1 |&1:1|	Launched
trilaciclib	CDK inhibitor				MedChemEx	86.11	CN1CCN(CC1)c1ccc(Nc2ncc3cc4C(=O)NCC5(CCCCC5)n4c3n2)nc1	Phase 2
trilostane	3beta-hydroxy-delta5-steroid dehydrogenase inhibitor		endocrinology	Cushing's syndrome	MicroSource, MedChemEx, Selleck	99.44	C[C@]12CC[C@H]3[C@@H](CC[C@@]45O[C@@H]4C(=O)[C@@H](C[C@]35C)C#N)[C@@H]1CC[C@@H]2O |a:1,4,5,8,10,15,19,22,&1:13|, C[C@]12CC[C@H]3[C@@H](CC[C@@]45O[C@@H]4C(=O)[C@@H](C[C@]35C)C#N)[C@@H]1CC[C@@H]2O |a:1,4,5,8,10,15,19,22,&1:13|, C[C@]12CC[C@H]3[C@@H](CC[C@@]45O[C@@H]4C(=O)[C@@H](C[C@]35C)C#N)[C@@H]1CC[C@@H]2O |a:1,4,5,8,10,15,19,22,&1:13|	Launched
TRIM					Tocris	0	FC(F)(F)c1ccccc1-n1ccnc1	Preclinical
trimebutine	opioid receptor agonist	OPRD1, OPRK1, OPRM1	gastroenterology	irritable bowel syndrome	MedChemEx	96.27	CC[C@](COC(=O)c1cc(OC)c(OC)c(OC)c1)(N(C)C)c1ccccc1 |&1:2|	Launched
trimetazidine	3-ketoacyl CoA thiolase inhibitor	ACAA2	cardiology	angina pectoris	MedChemEx, MedChemEx, MicroSource	98.64	COc1ccc(CN2CCNCC2)c(OC)c1OC, COc1ccc(CN2CCNCC2)c(OC)c1OC, COc1ccc(CN2CCNCC2)c(OC)c1OC	Launched
trimethadione	oxazolidine antiepileptic	CACNA1G, CACNA1H, CACNA1I	neurology/psychiatry	seizures	MicroSource, MedChemEx, Sigma, MedChemEx	12.34	CN1C(=O)OC(C)(C)C1=O, CN1C(=O)OC(C)(C)C1=O, CN1C(=O)OC(C)(C)C1=O, CN1C(=O)OC(C)(C)C1=O	Launched
trimethobenzamide	histamine receptor antagonist	DRD2	gastroenterology	vomiting, nausea, gastroenteritis	MicroSource, MicroSource, CombiBlocks, CombiBlocks	99.34	COc1cc(cc(OC)c1OC)C(=O)NCc1ccc(OCCN(C)C)cc1, COc1cc(cc(OC)c1OC)C(=O)NCc1ccc(OCCN(C)C)cc1, COc1cc(cc(OC)c1OC)C(=O)NCc1ccc(OCCN(C)C)cc1, COc1cc(cc(OC)c1OC)C(=O)NCc1ccc(OCCN(C)C)cc1	Launched
trimethoprim	dihydrofolate reductase inhibitor	DHFR, TYMS	infectious disease, gastroenterology	urinary tract infections, ear infections, diarrhea	MicroSource, Selleck	98.69	COc1cc(Cc2cnc(N)nc2N)cc(OC)c1OC, COc1cc(Cc2cnc(N)nc2N)cc(OC)c1OC	Launched
trimethoquinol	adrenergic receptor antagonist	ADRB2, ADRB3	pulmonary	asthma	Sigma	85.22	COc1cc(C[C@H]2NCCc3cc(O)c(O)cc23)cc(OC)c1OC |&1:6|	Launched
trimethylolpropane-triacrylate					Sigma	75.72	CCC(COC(=O)C=C)(COC(=O)C=C)COC(=O)C=C	Preclinical
trimetozine	sedative		neurology/psychiatry	sedative	MicroSource, Sigma	99.51	COc1cc(cc(OC)c1OC)C(=O)N1CCOCC1, COc1cc(cc(OC)c1OC)C(=O)N1CCOCC1	Launched
trimetrexate	dihydrofolate reductase inhibitor	DHFR			MedChemEx	97.2	COc1cc(NCc2ccc3nc(N)nc(N)c3c2C)cc(OC)c1OC	Phase 3
trimipramine	norepinephrine reputake inhibitor, tricyclic antidepressant	SLC6A2, SLC6A3, SLC6A4	neurology/psychiatry	depression	MedChemEx	95.57	C[C@@H](CN(C)C)CN1c2ccccc2CCc2ccccc12 |&1:1|	Launched
trioxsalen	DNA synthesis inhibitor		dermatology	vitiligo, eczema	MedChemEx, MicroSource	97.99	Cc1cc2cc3c(C)cc(=O)oc3c(C)c2o1, Cc1cc2cc3c(C)cc(=O)oc3c(C)c2o1	Launched
tripelennamine	histamine receptor antagonist	HRH1	pulmonary, allergy	asthma, allergic rhinitis, urticaria	MicroSource, Selleck, MedChemEx	96.93	CN(C)CCN(Cc1ccccc1)c1ccccn1, CN(C)CCN(Cc1ccccc1)c1ccccn1, CN(C)CCN(Cc1ccccc1)c1ccccn1	Launched
triprolidine	histamine receptor antagonist	HRH1	allergy	allergic rhinitis	MicroSource, Tocris	98.84	Cc1ccc(cc1)C(=C/CN1CCCC1)\c1ccccn1, Cc1ccc(cc1)C(=C/CN1CCCC1)\c1ccccn1	Launched
triptan	serotonin receptor agonist	HTR1B, HTR1D			Sigma	0	CC(C)C(C)(C)C	Phase 1
triptolide	RNA polymerase inhibitor	RELA			Tocris, Tocris, Selleck, Selleck, Selleck, Selleck, Selleck	98.14	CC(C)[C@]12O[C@H]1[C@@H]1O[C@]11[C@]3(O[C@H]3C[C@H]3C4=C(CC[C@]13C)C(=O)OC4)[C@@H]2O |c:17|, CC(C)[C@]12O[C@H]1[C@@H]1O[C@]11[C@]3(O[C@H]3C[C@H]3C4=C(CC[C@]13C)C(=O)OC4)[C@@H]2O |c:17|, CC(C)[C@]12O[C@H]1[C@@H]1O[C@]11[C@]3(O[C@H]3C[C@H]3C4=C(CC[C@]13C)C(=O)OC4)[C@@H]2O |c:17|, CC(C)[C@]12O[C@H]1[C@@H]1O[C@]11[C@]3(O[C@H]3C[C@H]3C4=C(CC[C@]13C)C(=O)OC4)[C@@H]2O |c:17|, CC(C)[C@]12O[C@H]1[C@@H]1O[C@]11[C@]3(O[C@H]3C[C@H]3C4=C(CC[C@]13C)C(=O)OC4)[C@@H]2O |c:17|, CC(C)[C@]12O[C@H]1[C@@H]1O[C@]11[C@]3(O[C@H]3C[C@H]3C4=C(CC[C@]13C)C(=O)OC4)[C@@H]2O |c:17|, CC(C)[C@]12O[C@H]1[C@@H]1O[C@]11[C@]3(O[C@H]3C[C@H]3C4=C(CC[C@]13C)C(=O)OC4)[C@@H]2O |c:17|	Phase 3
triptorelin	gonadotropin releasing factor hormone receptor agonist	GNRHR	oncology, endocrinology, obstetrics/gynecology	prostate cancer, breast cancer, precocious puberty, endometriosis, myoma, gender dysphoria	Enzo, MedChemEx	96.28	CC(C)C[C@H](NC(=O)[C@@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)NCC(N)=O, CC(C)C[C@H](NC(=O)[C@@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)NCC(N)=O	Launched
troclosene					MicroSource, Sigma	0	Cln1c(=O)[nH]c(=O)n(Cl)c1=O, Cln1c(=O)[nH]c(=O)n(Cl)c1=O	Launched
trodusquemine	tyrosine phosphatase inhibitor				MedChemEx	95.5	[H][C@@]1(CC[C@@]2([H])[C@]3([H])[C@H](O)C[C@@]4([H])C[C@H](CC[C@]4(C)[C@@]3([H])CC[C@]12C)NCCCNCCCCNCCCN)[C@H](C)CC[C@@H](OS(O)(=O)=O)C(C)C	Phase 1
trofinetide	cytokine production inhibitor	IFNG, IL6, TNF			Sigma	44.1	NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(O)=O	Phase 2
trofosfamide	DNA alkylating agent		oncology	medulloblastoma	Sigma	0	ClCCN(CCCl)[P@@]1(=O)OCCCN1CCCl |&1:7,r|	Launched
troglitazone	insulin sensitizer, PPAR receptor agonist	CYP2C8, PPARG, TRPM3			Tocris, Tocris, Enzo	93.99	Cc1c(C)c2O[C@@](C)(COc3ccc(C[C@H]4SC(=O)NC4=O)cc3)CCc2c(C)c1O |&1:6,r|, Cc1c(C)c2O[C@@](C)(COc3ccc(C[C@H]4SC(=O)NC4=O)cc3)CCc2c(C)c1O |&1:6,r|, Cc1c(C)c2O[C@@](C)(COc3ccc(C[C@H]4SC(=O)NC4=O)cc3)CCc2c(C)c1O |&1:6,r|	Withdrawn
troleandomycin	protein synthesis inhibitor		infectious disease, pulmonary, otolaryngology	pneumonia, bronchitis, tonsillitis, sinusitis	Enzo	92.6	CO[C@H]1C[C@H](O[C@H]2[C@H](C)[C@@H](O[C@@H]3O[C@H](C)C[C@@H]([C@H]3OC(C)=O)N(C)C)[C@@H](C)C[C@@]3(CO3)C(=O)[C@H](C)[C@@H](OC(C)=O)[C@@H](C)[C@@H](C)OC(=O)[C@@H]2C)O[C@@H](C)[C@@H]1OC(C)=O	Launched
trolox	antioxidant				Tocris, Tocris, Enzo	100	Cc1c(C)c2O[C@@](C)(CCc2c(C)c1O)C(O)=O |&1:6,r|, Cc1c(C)c2O[C@@](C)(CCc2c(C)c1O)C(O)=O |&1:6,r|, Cc1c(C)c2O[C@@](C)(CCc2c(C)c1O)C(O)=O |&1:6,r|	Launched
tromaril	prostanoid receptor antagonist		ophthalmology	eye inflammation	Enamine, Enamine, Enamine, Enamine	99.33	OC(=O)c1ccccc1NCCc1ccccc1, OC(=O)c1ccccc1NCCc1ccccc1, OC(=O)c1ccccc1NCCc1ccccc1, OC(=O)c1ccccc1NCCc1ccccc1	Launched
trometamol		AMD1, CANT1, DCN, NEIL1, VEGFA			MedChemEx, MedChemEx, MicroSource, Selleck	100	NC(CO)(CO)CO, NC(CO)(CO)CO, NC(CO)(CO)CO, NC(CO)(CO)CO	Launched
tropanyl-3,5-dimethylbenzoate	serotonin receptor antagonist	HTR3A, HTR3B			Tocris	94.98	CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)c1cc(C)cc(C)c1 |&1:2,&2:5,&3:7,r,TLB:0:1:3.4:6.7.8|	Preclinical
tropesin	cyclooxygenase inhibitor	PTGS1, PTGS2			Sigma	99.27	COc1ccc2n(C(=O)c3ccc(Cl)cc3)c(C)c(CC(=O)OC[C@@H](C(O)=O)c3ccccc3)c2c1 |&1:24,r|	Launched
tropicamide	acetylcholine receptor antagonist	CHRM3, CHRM4	ophthalmology	mydriasis diagnostic, cycloplegia diagnostic	Tocris, Tocris, Tocris, MicroSource, Selleck, Selleck	99.63	CCN(Cc1ccncc1)C(=O)[C@@H](CO)c1ccccc1 |&1:12,r|, CCN(Cc1ccncc1)C(=O)[C@@H](CO)c1ccccc1 |&1:12,r|, CCN(Cc1ccncc1)C(=O)[C@@H](CO)c1ccccc1 |&1:12,r|, CCN(Cc1ccncc1)C(=O)[C@@H](CO)c1ccccc1 |&1:12,r|, CCN(Cc1ccncc1)C(=O)[C@@H](CO)c1ccccc1 |&1:12,r|, CCN(Cc1ccncc1)C(=O)[C@@H](CO)c1ccccc1 |&1:12,r|	Launched
tropifexor	FXR agonist				MedChemEx	98.24	OC(=O)c1cc(F)c2nc(sc2c1)N1[C@H]2CC[C@@H]1C[C@@H](C2)OCc1c(onc1-c1ccccc1OC(F)(F)F)C1CC1 |TLB:9:13:16.15:19.20.18|	Phase 2
tropisetron	serotonin receptor antagonist	GLRA1, GLRA2, GLRB, HTR3A, HTR4	gastroenterology	nausea, vomiting	Selleck, Tocris, Tocris, Tocris	98.6	CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)c1c[nH]c2ccccc12, CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)c1c[nH]c2ccccc12, CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)c1c[nH]c2ccccc12, CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)c1c[nH]c2ccccc12	Launched
trospium	acetylcholine receptor antagonist	CHRM1	urology	urinary incontinence, urinary frequency	MedChemEx	89.72	[H][C@]12CC[C@]([H])(C[C@@H](C1)OC(=O)C(O)(c1ccccc1)c1ccccc1)[N+]21CCCC1 |&1:1,4,7|	Launched
trovafloxacin	bacterial DNA gyrase inhibitor	TOP2A			Tocris, Tocris, Tocris, Enzo, Tocris	97.94	N[C@H]1[C@@H]2CN(C[C@H]12)c1nc2n(cc(C(O)=O)c(=O)c2cc1F)-c1ccc(F)cc1F, N[C@H]1[C@@H]2CN(C[C@H]12)c1nc2n(cc(C(O)=O)c(=O)c2cc1F)-c1ccc(F)cc1F, N[C@H]1[C@@H]2CN(C[C@H]12)c1nc2n(cc(C(O)=O)c(=O)c2cc1F)-c1ccc(F)cc1F, N[C@H]1[C@@H]2CN(C[C@H]12)c1nc2n(cc(C(O)=O)c(=O)c2cc1F)-c1ccc(F)cc1F, N[C@H]1[C@@H]2CN(C[C@H]12)c1nc2n(cc(C(O)=O)c(=O)c2cc1F)-c1ccc(F)cc1F	Withdrawn
troventol					MatrixSci	95.22	CCC(CO)(C(=O)OC1C[C@@H]2CC[C@H](C1)[N+]2(C)C)c1ccccc1 |&1:2,&2:13,&3:10,TLB:7:8:11.12:15|	Phase 1
trovirdine	non-nucleoside reverse transcriptase inhibitor				MedChemEx, MedChemEx, MedChemEx	96.32	Brc1ccc(NC(=S)NCCc2ccccn2)nc1, Brc1ccc(NC(=S)NCCc2ccccn2)nc1, Brc1ccc(NC(=S)NCCc2ccccn2)nc1	Phase 1
troxerutin	antioxidant				MedChemEx, MicroSource, Selleck, Selleck	90.3	C[C@@H]1O[C@@H](OC[C@H]2O[C@@H](Oc3c(oc4cc(OCCO)cc(O)c4c3=O)-c3ccc(OCCO)c(OCCO)c3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O, C[C@@H]1O[C@@H](OC[C@H]2O[C@@H](Oc3c(oc4cc(OCCO)cc(O)c4c3=O)-c3ccc(OCCO)c(OCCO)c3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O, C[C@@H]1O[C@@H](OC[C@H]2O[C@@H](Oc3c(oc4cc(OCCO)cc(O)c4c3=O)-c3ccc(OCCO)c(OCCO)c3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O, C[C@@H]1O[C@@H](OC[C@H]2O[C@@H](Oc3c(oc4cc(OCCO)cc(O)c4c3=O)-c3ccc(OCCO)c(OCCO)c3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O	Launched
troxipide	glucosamine synthetase stimulant		gastroenterology	gastroesophageal reflux disease (GERD)	Selleck, Selleck, MedChemEx, Selleck	91.95	COc1cc(cc(OC)c1OC)C(=O)N[C@H]1CCCNC1 |&1:15,r|, COc1cc(cc(OC)c1OC)C(=O)N[C@H]1CCCNC1 |&1:15,r|, COc1cc(cc(OC)c1OC)C(=O)N[C@H]1CCCNC1 |&1:15,r|, COc1cc(cc(OC)c1OC)C(=O)N[C@H]1CCCNC1 |&1:15,r|	Launched
TRV130	opioid receptor agonist	OPRM1			MedChemEx	90.27	COc1ccsc1CNCC[C@]1(CCOC2(CCCC2)C1)c1ccccn1	Phase 3
tryptanthrin	cyclooxygenase inhibitor	IDO1			Enzo, Selleck	99.15	O=C1c2ccccc2-n2c1nc1ccccc1c2=O, O=C1c2ccccc2-n2c1nc1ccccc1c2=O	Preclinical
tryptophan	serotonin receptor partial agonist	CASR, IDO1, SLC36A1, WARS, WARS2	neurology/psychiatry, gastroenterology	anxiety, bloating, constipation, fatigue, sleeplessness	Sigma, Sigma, MicroSource	98.59	N[C@@H](Cc1c[nH]c2ccccc12)C(O)=O, N[C@@H](Cc1c[nH]c2ccccc12)C(O)=O, N[C@@H](Cc1c[nH]c2ccccc12)C(O)=O	Launched
TS-011	delayed vasospasm antagonist				AMS	85.42	[O-][N+]CNc1ccc(N2CCOCC2)c(Cl)c1	Preclinical
TTNPB	retinoid receptor agonist	RARA, RARB, RARG			Tocris, Selleck, Selleck	91.34	C\C(=C/c1ccc(cc1)C(O)=O)c1ccc2c(c1)C(C)(C)CCC2(C)C, C\C(=C/c1ccc(cc1)C(O)=O)c1ccc2c(c1)C(C)(C)CCC2(C)C, C\C(=C/c1ccc(cc1)C(O)=O)c1ccc2c(c1)C(C)(C)CCC2(C)C	Phase 1
TTP-22	casein kinase inhibitor	CSNK2A1			Tocris, Tocris	98.64	Cc1ccc(cc1)-c1csc2ncnc(SCCC(O)=O)c12, Cc1ccc(cc1)-c1csc2ncnc(SCCC(O)=O)c12	Preclinical
TU-2100					Vitas-M, Vitas-M	98.81	CCOC(=O)c1ccccc1OC(=O)CCCCCCCC(=O)Oc1ccccc1C(=O)OCC, CCOC(=O)c1ccccc1OC(=O)CCCCCCCC(=O)Oc1ccccc1C(=O)OCC	Phase 2
tuaminoheptane			otolaryngology	nasal congestion	MicroSource, MedChemEx	100	CCCCC[C@@H](C)N |&1:5|, CCCCC[C@@H](C)N |&1:5|	Launched
tubastatin-A	HDAC inhibitor	HDAC6			Selleck, Selleck, Selleck, Selleck, Selleck, Selleck	92.88	CN1CCc2c(C1)c1ccccc1n2Cc1ccc(cc1)C(=O)NO, CN1CCc2c(C1)c1ccccc1n2Cc1ccc(cc1)C(=O)NO, CN1CCc2c(C1)c1ccccc1n2Cc1ccc(cc1)C(=O)NO, CN1CCc2c(C1)c1ccccc1n2Cc1ccc(cc1)C(=O)NO, CN1CCc2c(C1)c1ccccc1n2Cc1ccc(cc1)C(=O)NO, CN1CCc2c(C1)c1ccccc1n2Cc1ccc(cc1)C(=O)NO	Preclinical
tubocurarine	acetylcholine receptor antagonist	ACHE, CHRNA2, HTR3A, HTR3B, KCNN1, KCNN2, KCNN3, ZACN	neurology/psychiatry	anesthetic	MicroSource, Tocris, Tocris	97.35	COc1cc2CC[N+](C)(C)[C@@H]3Cc4ccc(O)c(Oc5cc6[C@H](Cc7ccc(Oc(c1O)c23)cc7)N(C)CCc6cc5OC)c4, COc1cc2CC[N+](C)(C)[C@@H]3Cc4ccc(O)c(Oc5cc6[C@H](Cc7ccc(Oc(c1O)c23)cc7)N(C)CCc6cc5OC)c4, COc1cc2CC[N+](C)(C)[C@@H]3Cc4ccc(O)c(Oc5cc6[C@H](Cc7ccc(Oc(c1O)c23)cc7)N(C)CCc6cc5OC)c4	Launched
tucatinib	EGFR inhibitor	ERBB2			MedChemEx, MedChemEx, MedChemEx, MedChemEx	94.53	Cc1cc(Nc2ncnc3ccc(NC4=NC(C)(C)CO4)cc23)ccc1Oc1ccn2ncnc2c1 |t:14|, Cc1cc(Nc2ncnc3ccc(NC4=NC(C)(C)CO4)cc23)ccc1Oc1ccn2ncnc2c1 |t:14|, Cc1cc(Nc2ncnc3ccc(NC4=NC(C)(C)CO4)cc23)ccc1Oc1ccn2ncnc2c1 |t:14|, Cc1cc(Nc2ncnc3ccc(NC4=NC(C)(C)CO4)cc23)ccc1Oc1ccn2ncnc2c1 |t:14|	Phase 3
tucidinostat	HDAC inhibitor				MedChemEx	88.6	Nc1cc(F)ccc1NC(=O)c1ccc(CNC(=O)\C=C\c2cccnc2)cc1	Phase 3
tuftsin	macrophage activator				MedChemEx	95.02	C[C@@H](O)[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(O)=O	Preclinical
TUG-770	free fatty acid receptor agonist	FFAR1			MedChemEx	96.74	OC(=O)CCc1ccc(cc1F)C#Cc1ccccc1CC#N	Preclinical
TUG-891	free fatty acid receptor agonist	FFAR4			Tocris, Tocris, Tocris, Tocris	97.9	Cc1ccc(cc1)-c1ccc(F)cc1COc1ccc(CCC(O)=O)cc1, Cc1ccc(cc1)-c1ccc(F)cc1COc1ccc(CCC(O)=O)cc1, Cc1ccc(cc1)-c1ccc(F)cc1COc1ccc(CCC(O)=O)cc1, Cc1ccc(cc1)-c1ccc(F)cc1COc1ccc(CCC(O)=O)cc1	Preclinical
tulobuterol	adrenergic receptor agonist	ADRB2	pulmonary	asthma	MedChemEx	91.87	CC(C)(C)NC[C@H](O)c1ccccc1Cl |&1:6|	Launched
tulrampator	antidepressant 				MedChemEx	96.55	Fc1cccc(CCn2nnc3cc4C(=O)N(COc4cc3c2=O)C2CC2)c1	Phase 2
TW-37	BCL inhibitor	BCL2, BCL2L1, MCL1			Selleck, Selleck, Selleck, Selleck	91.58	CC(C)c1ccccc1Cc1cc(C(=O)Nc2ccc(cc2)S(=O)(=O)c2ccccc2C(C)(C)C)c(O)c(O)c1O, CC(C)c1ccccc1Cc1cc(C(=O)Nc2ccc(cc2)S(=O)(=O)c2ccccc2C(C)(C)C)c(O)c(O)c1O, CC(C)c1ccccc1Cc1cc(C(=O)Nc2ccc(cc2)S(=O)(=O)c2ccccc2C(C)(C)C)c(O)c(O)c1O, CC(C)c1ccccc1Cc1cc(C(=O)Nc2ccc(cc2)S(=O)(=O)c2ccccc2C(C)(C)C)c(O)c(O)c1O	Preclinical
TWS-119	glycogen synthase kinase inhibitor	GSK3B, JUN, MYC			Selleck, Selleck, Selleck, Tocris, Tocris	96.85	Nc1cccc(c1)-c1cc2c(Oc3cccc(O)c3)ncnc2[nH]1, Nc1cccc(c1)-c1cc2c(Oc3cccc(O)c3)ncnc2[nH]1, Nc1cccc(c1)-c1cc2c(Oc3cccc(O)c3)ncnc2[nH]1, Nc1cccc(c1)-c1cc2c(Oc3cccc(O)c3)ncnc2[nH]1, Nc1cccc(c1)-c1cc2c(Oc3cccc(O)c3)ncnc2[nH]1	Preclinical
TXA127	angiotensin receptor agonist				MedChemEx, MedChemEx, MedChemEx	96.53	CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@H]1C(O)=O, CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@H]1C(O)=O, CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@H]1C(O)=O	Phase 2
TY-52156	sphingosine 1-phosphate receptor antagonist	S1PR3			Tocris, MedChemEx, MedChemEx	88.43	CC(C)(C)C(=O)C(Nc1ccc(Cl)cc1)=NNc1ccc(Cl)cc1, CC(C)(C)C(=O)C(Nc1ccc(Cl)cc1)=NNc1ccc(Cl)cc1, CC(C)(C)C(=O)C(Nc1ccc(Cl)cc1)=NNc1ccc(Cl)cc1	Preclinical
tylosin	protein synthesis inhibitor		infectious disease, gastroenterology	gram-positive bacterial infections, colitis	MicroSource, MedChemEx, Selleck	100	CC[C@H]1OC(=O)C[C@@H](O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)[C@@H](O[C@H]3C[C@@](C)(O)[C@@H](O)[C@H](C)O3)[C@@H]([C@H]2O)N(C)C)[C@@H](CC=O)C[C@@H](C)C(=O)\C=C\C(\C)=C\[C@@H]1CO[C@@H]1O[C@H](C)[C@@H](O)[C@@H](OC)[C@H]1OC |t:46,49|, CC[C@H]1OC(=O)C[C@@H](O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)[C@@H](O[C@H]3C[C@@](C)(O)[C@@H](O)[C@H](C)O3)[C@@H]([C@H]2O)N(C)C)[C@@H](CC=O)C[C@@H](C)C(=O)\C=C\C(\C)=C\[C@@H]1CO[C@@H]1O[C@H](C)[C@@H](O)[C@@H](OC)[C@H]1OC |t:46,49|, CC[C@H]1OC(=O)C[C@@H](O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)[C@@H](O[C@H]3C[C@@](C)(O)[C@@H](O)[C@H](C)O3)[C@@H]([C@H]2O)N(C)C)[C@@H](CC=O)C[C@@H](C)C(=O)\C=C\C(\C)=C\[C@@H]1CO[C@@H]1O[C@H](C)[C@@H](O)[C@@H](OC)[C@H]1OC |t:46,49|	Launched
tymazoline			allergy	allergic rhinitis	Sigma	53.77	CC(C)c1ccc(C)cc1OCC1=NCCN1 |t:13|	Launched
tyrphostin-AG-1296	FLT3 inhibitor	FLT3			Selleck, Selleck, Selleck, Selleck, Selleck, Selleck	99.91	COc1cc2ncc(nc2cc1OC)-c1ccccc1, COc1cc2ncc(nc2cc1OC)-c1ccccc1, COc1cc2ncc(nc2cc1OC)-c1ccccc1, COc1cc2ncc(nc2cc1OC)-c1ccccc1, COc1cc2ncc(nc2cc1OC)-c1ccccc1, COc1cc2ncc(nc2cc1OC)-c1ccccc1	Preclinical
tyrphostin-AG-1478	EGFR inhibitor	EGFR, MAPK14			Selleck, Selleck	98.06	COc1cc2ncnc(Nc3cccc(Cl)c3)c2cc1OC, COc1cc2ncnc(Nc3cccc(Cl)c3)c2cc1OC	Preclinical
tyrphostin-AG-18	EGFR inhibitor, tyrosine kinase inhibitor	EGFR			Tocris, Tocris, Selleck, Selleck	87.88	Oc1ccc(C=C(C#N)C#N)cc1O, Oc1ccc(C=C(C#N)C#N)cc1O, Oc1ccc(C=C(C#N)C#N)cc1O, Oc1ccc(C=C(C#N)C#N)cc1O	Preclinical
tyrphostin-AG-494	EGFR inhibitor	EGFR			Tocris, Tocris, Tocris, Tocris	93.17	Oc1ccc(\C=C(/C#N)C(=O)Nc2ccccc2)cc1O, Oc1ccc(\C=C(/C#N)C(=O)Nc2ccccc2)cc1O, Oc1ccc(\C=C(/C#N)C(=O)Nc2ccccc2)cc1O, Oc1ccc(\C=C(/C#N)C(=O)Nc2ccccc2)cc1O	Preclinical
tyrphostin-AG-825	protein tyrosine kinase inhibitor	ERBB2			Tocris, Tocris	87.11	COc1cc(\C=C(/C#N)C(N)=O)cc(CSc2nc3ccccc3s2)c1O, COc1cc(\C=C(/C#N)C(N)=O)cc(CSc2nc3ccccc3s2)c1O	Preclinical
tyrphostin-AG-835	protein tyrosine kinase inhibitor	EGFR			Tocris, Tocris	93.78	C[C@H](NC(=O)C(=C\c1ccc(O)c(O)c1)\C#N)c1ccccc1, C[C@H](NC(=O)C(=C\c1ccc(O)c(O)c1)\C#N)c1ccccc1	Preclinical
tyrphostin-AG-879	tyrosine kinase inhibitor	ERBB2, KDR, NTRK1			Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck	96.11	CC(C)(C)c1cc(\C=C(/C#N)C(N)=S)cc(c1O)C(C)(C)C, CC(C)(C)c1cc(\C=C(/C#N)C(N)=S)cc(c1O)C(C)(C)C, CC(C)(C)c1cc(\C=C(/C#N)C(N)=S)cc(c1O)C(C)(C)C, CC(C)(C)c1cc(\C=C(/C#N)C(N)=S)cc(c1O)C(C)(C)C, CC(C)(C)c1cc(\C=C(/C#N)C(N)=S)cc(c1O)C(C)(C)C, CC(C)(C)c1cc(\C=C(/C#N)C(N)=S)cc(c1O)C(C)(C)C, CC(C)(C)c1cc(\C=C(/C#N)C(N)=S)cc(c1O)C(C)(C)C, CC(C)(C)c1cc(\C=C(/C#N)C(N)=S)cc(c1O)C(C)(C)C, CC(C)(C)c1cc(\C=C(/C#N)C(N)=S)cc(c1O)C(C)(C)C, CC(C)(C)c1cc(\C=C(/C#N)C(N)=S)cc(c1O)C(C)(C)C	Preclinical
tyrphostin-AG-99	tyrosine kinase inhibitor	EGFR			Tocris, Tocris, Tocris	96.88	NC(=O)C(=C\c1ccc(O)c(O)c1)\C#N, NC(=O)C(=C\c1ccc(O)c(O)c1)\C#N, NC(=O)C(=C\c1ccc(O)c(O)c1)\C#N	Preclinical
tyrphostin-A9	protein tyrosine kinase inhibitor, tyrosine kinase inhibitor				Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Enzo	95.09	CC(C)(C)c1cc(C=C(C#N)C#N)cc(c1O)C(C)(C)C, CC(C)(C)c1cc(C=C(C#N)C#N)cc(c1O)C(C)(C)C, CC(C)(C)c1cc(C=C(C#N)C#N)cc(c1O)C(C)(C)C, CC(C)(C)c1cc(C=C(C#N)C#N)cc(c1O)C(C)(C)C, CC(C)(C)c1cc(C=C(C#N)C#N)cc(c1O)C(C)(C)C, CC(C)(C)c1cc(C=C(C#N)C#N)cc(c1O)C(C)(C)C, CC(C)(C)c1cc(C=C(C#N)C#N)cc(c1O)C(C)(C)C, CC(C)(C)c1cc(C=C(C#N)C#N)cc(c1O)C(C)(C)C, CC(C)(C)c1cc(C=C(C#N)C#N)cc(c1O)C(C)(C)C	Preclinical
U-0124	MEK inhibitor				Tocris, Tocris	94.09	CSC(=N)C(C#N)C(C#N)C(=N)SC, CSC(=N)C(C#N)C(C#N)C(=N)SC	Preclinical
U-0126	MEK inhibitor	AKT1, CHEK1, GSK3B, LCK, MAP2K1, MAP2K2, MAP2K7, MAPK1, MAPK11, MAPK12, MAPK14, MAPK8, PRKCA, RAF1, ROCK1, RPS6KB1, SGK1			Selleck, Selleck, Tocris, Tocris, Tocris, Selleck	93.15	Nc1ccccc1SC(=N)C(C#N)C(C#N)C(=N)Sc1ccccc1N, Nc1ccccc1SC(=N)C(C#N)C(C#N)C(=N)Sc1ccccc1N, Nc1ccccc1SC(=N)C(C#N)C(C#N)C(=N)Sc1ccccc1N, Nc1ccccc1SC(=N)C(C#N)C(C#N)C(=N)Sc1ccccc1N, Nc1ccccc1SC(=N)C(C#N)C(C#N)C(=N)Sc1ccccc1N, Nc1ccccc1SC(=N)C(C#N)C(C#N)C(=N)Sc1ccccc1N	Preclinical
U-0521	catechol O methyltransferase inhibitor	COMT			SantaCruz	98.18	CC(C)C(=O)c1ccc(O)c(O)c1	Preclinical
U-104	carbonic anhydrase inhibitor	CA1, CA12, CA2, CA9			Tocris, Selleck, Tocris, Tocris, Tocris	96.75	NS(=O)(=O)c1ccc(NC(=O)Nc2ccc(F)cc2)cc1, NS(=O)(=O)c1ccc(NC(=O)Nc2ccc(F)cc2)cc1, NS(=O)(=O)c1ccc(NC(=O)Nc2ccc(F)cc2)cc1, NS(=O)(=O)c1ccc(NC(=O)Nc2ccc(F)cc2)cc1, NS(=O)(=O)c1ccc(NC(=O)Nc2ccc(F)cc2)cc1	Phase 1/Phase 2
U-18666A	oxidosqualene cyclase inhibitor				Tocris, Tocris, Tocris, Tocris, Tocris	99.54	CCN(CC)CCO[C@H]1CC[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](CCC4=O)[C@@H]3CC=C2C1 |c:27|, CCN(CC)CCO[C@H]1CC[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](CCC4=O)[C@@H]3CC=C2C1 |c:27|, CCN(CC)CCO[C@H]1CC[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](CCC4=O)[C@@H]3CC=C2C1 |c:27|, CCN(CC)CCO[C@H]1CC[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](CCC4=O)[C@@H]3CC=C2C1 |c:27|, CCN(CC)CCO[C@H]1CC[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](CCC4=O)[C@@H]3CC=C2C1 |c:27|	Preclinical
U-50488-(-)	opioid receptor agonist	OPRK1			Tocris, Tocris, Tocris, Tocris, Tocris, Tocris	97.11	CN([C@H]1CCCC[C@@H]1N1CCCC1)C(=O)Cc1ccc(Cl)c(Cl)c1, CN([C@H]1CCCC[C@@H]1N1CCCC1)C(=O)Cc1ccc(Cl)c(Cl)c1, CN([C@H]1CCCC[C@@H]1N1CCCC1)C(=O)Cc1ccc(Cl)c(Cl)c1, CN([C@H]1CCCC[C@@H]1N1CCCC1)C(=O)Cc1ccc(Cl)c(Cl)c1, CN([C@H]1CCCC[C@@H]1N1CCCC1)C(=O)Cc1ccc(Cl)c(Cl)c1, CN([C@H]1CCCC[C@@H]1N1CCCC1)C(=O)Cc1ccc(Cl)c(Cl)c1	Preclinical
U-54494A	opioid receptor agonist	OPRK1			Tocris, Tocris	96.38	CN([C@@H]1CCCC[C@@H]1N1CCCC1)C(=O)c1ccc(Cl)c(Cl)c1, CN([C@@H]1CCCC[C@@H]1N1CCCC1)C(=O)c1ccc(Cl)c(Cl)c1	Preclinical
U-75799E	growth hormone releasing factor agonist	GHSR			Adooq, Adooq, Adooq	96.47	C[C@H](NC(=O)[C@@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H](N)Cc1cnc[nH]1)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@H](Cc1ccccc1)C(=O)N[C@@H](CCCCN)C(N)=O, C[C@H](NC(=O)[C@@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H](N)Cc1cnc[nH]1)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@H](Cc1ccccc1)C(=O)N[C@@H](CCCCN)C(N)=O, C[C@H](NC(=O)[C@@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H](N)Cc1cnc[nH]1)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@H](Cc1ccccc1)C(=O)N[C@@H](CCCCN)C(N)=O	Phase 1
U-99194	dopamine receptor antagonist	DRD3			Tocris	94.8	CCCN(CCC)C1Cc2cc(OC)c(OC)cc2C1	Preclinical
UAMC-00039	dipeptidyl peptidase inhibitor	DPP4, DPP7			Tocris, Tocris	95.29	N[C@@H](CCNCc1ccc(Cl)cc1)C(=O)N1CCCCC1, N[C@@H](CCNCc1ccc(Cl)cc1)C(=O)N1CCCCC1	Preclinical
UB-165	acetylcholine receptor agonist	CHRNA3, CHRNA4, CHRNB2			Tocris, Tocris, Tocris	90.79	Clc1ccc(cn1)C1=CCC[C@H]2CC[C@@H]1N2 |&1:11,&2:14,t:8,THB:4:7:12.13:15|, Clc1ccc(cn1)C1=CCC[C@H]2CC[C@@H]1N2 |&1:11,&2:14,t:8,THB:4:7:12.13:15|, Clc1ccc(cn1)C1=CCC[C@H]2CC[C@@H]1N2 |&1:11,&2:14,t:8,THB:4:7:12.13:15|	Preclinical
ubenimex	leukotriene synthesis inhibitor	LTA4H, RNPEP	hematologic malignancy	acute myeloid leukemia (AML)	Tocris, Selleck, Selleck, Tocris	92.27	CC(C)C[C@H](NC(=O)[C@@H](O)[C@H](N)Cc1ccccc1)C(O)=O, CC(C)C[C@H](NC(=O)[C@@H](O)[C@H](N)Cc1ccccc1)C(O)=O, CC(C)C[C@H](NC(=O)[C@@H](O)[C@H](N)Cc1ccccc1)C(O)=O, CC(C)C[C@H](NC(=O)[C@@H](O)[C@H](N)Cc1ccccc1)C(O)=O	Launched
UBP-296	glutamate receptor antagonist	GRIK1			Tocris, Tocris, Tocris	95.4	N[C@@H](Cn1ccc(=O)n(Cc2ccccc2C(O)=O)c1=O)C(O)=O |&1:1,r|, N[C@@H](Cn1ccc(=O)n(Cc2ccccc2C(O)=O)c1=O)C(O)=O |&1:1,r|, N[C@@H](Cn1ccc(=O)n(Cc2ccccc2C(O)=O)c1=O)C(O)=O |&1:1,r|	Preclinical
UBP-302	glutamate receptor antagonist	GRIK1			Tocris, Tocris, Tocris, Tocris	96.2	N[C@@H](Cn1ccc(=O)n(Cc2ccccc2C(O)=O)c1=O)C(O)=O, N[C@@H](Cn1ccc(=O)n(Cc2ccccc2C(O)=O)c1=O)C(O)=O, N[C@@H](Cn1ccc(=O)n(Cc2ccccc2C(O)=O)c1=O)C(O)=O, N[C@@H](Cn1ccc(=O)n(Cc2ccccc2C(O)=O)c1=O)C(O)=O	Preclinical
UBP-310	glutamate receptor antagonist	GRIK1, GRIK5			Tocris, Tocris	92.8	Cc1cn(C[C@H](N)C(O)=O)c(=O)n(Cc2ccsc2C(O)=O)c1=O, Cc1cn(C[C@H](N)C(O)=O)c(=O)n(Cc2ccsc2C(O)=O)c1=O	Preclinical
UC-112	XIAP inhibitor	XIAP			Tocris, Tocris, Tocris	85.21	Oc1c(CN2CCCC2)cc(COCc2ccccc2)c2cccnc12, Oc1c(CN2CCCC2)cc(COCc2ccccc2)c2cccnc12, Oc1c(CN2CCCC2)cc(COCc2ccccc2)c2cccnc12	Preclinical
UCL-2077	slow afterhyperpolarization channel blocker				Tocris, Tocris, Tocris	99.33	C(NC(c1ccccc1)(c1ccccc1)c1ccccc1)c1cccnc1, C(NC(c1ccccc1)(c1ccccc1)c1ccccc1)c1cccnc1, C(NC(c1ccccc1)(c1ccccc1)c1ccccc1)c1cccnc1	Preclinical
udenafil	phosphodiesterase inhibitor		urology	erectile dysfunction	MedChemEx	98.08	CCCOc1ccc(cc1-c1nc2c(CCC)nn(C)c2c(=O)[nH]1)S(=O)(=O)NCC[C@@H]1CCCN1C |&1:30,r|	Launched
UF-010	HDAC inhibitor	HDAC1, HDAC2, HDAC3, HDAC8			Tocris, Tocris, Tocris	96.15	CCCCNNC(=O)c1ccc(Br)cc1, CCCCNNC(=O)c1ccc(Br)cc1, CCCCNNC(=O)c1ccc(Br)cc1	Preclinical
ufenamate	cyclooxygenase inhibitor	PTGS1, PTGS2	dermatology	eczema, dermatitis	AvaChem, AvaChem	98.96	CCCCOC(=O)c1ccccc1Nc1cccc(c1)C(F)(F)F, CCCCOC(=O)c1ccccc1Nc1cccc(c1)C(F)(F)F	Launched
UH-232-(+)	dopamine receptor antagonist	DRD2, DRD3, DRD4, HTR1A			Tocris, Tocris	90.44	CCCN(CCC)[C@@H]1CCc2c(OC)cccc2[C@@H]1C, CCCN(CCC)[C@@H]1CCc2c(OC)cccc2[C@@H]1C	Preclinical
UK-356618	metalloproteinase inhibitor	MMP13, MMP14, MMP2, MMP3, MMP9			Tocris, Tocris, Tocris, Tocris, Tocris	100	C[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CCCc1ccc(c(C)c1)-c1ccccc1)CC(=O)NO)C(C)(C)C)c1ccccc1, C[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CCCc1ccc(c(C)c1)-c1ccccc1)CC(=O)NO)C(C)(C)C)c1ccccc1, C[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CCCc1ccc(c(C)c1)-c1ccccc1)CC(=O)NO)C(C)(C)C)c1ccccc1, C[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CCCc1ccc(c(C)c1)-c1ccccc1)CC(=O)NO)C(C)(C)C)c1ccccc1, C[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CCCc1ccc(c(C)c1)-c1ccccc1)CC(=O)NO)C(C)(C)C)c1ccccc1	Preclinical
UK-383367	procollagen C-endopeptidase inhibitor	BMP1			Tocris, Selleck, Selleck, Tocris, Tocris, Selleck	95.33	NC(=O)c1noc(n1)[C@H](CCCC1CCCCC1)CC(=O)NO, NC(=O)c1noc(n1)[C@H](CCCC1CCCCC1)CC(=O)NO, NC(=O)c1noc(n1)[C@H](CCCC1CCCCC1)CC(=O)NO, NC(=O)c1noc(n1)[C@H](CCCC1CCCCC1)CC(=O)NO, NC(=O)c1noc(n1)[C@H](CCCC1CCCCC1)CC(=O)NO, NC(=O)c1noc(n1)[C@H](CCCC1CCCCC1)CC(=O)NO	Phase 1
UK-5099	monocarboxylate transporter inhibitor	SLC16A1			Tocris, Tocris, Tocris	95.88	OC(=O)C(=C\c1cn(-c2ccccc2)c2ccccc12)\C#N, OC(=O)C(=C\c1cn(-c2ccccc2)c2ccccc12)\C#N, OC(=O)C(=C\c1cn(-c2ccccc2)c2ccccc12)\C#N	Preclinical
uki-1	urokinase inhibitor				MedChemEx	100	CCOC(=O)N1CCN(CC1)C(=O)[C@H](Cc1cccc(c1)C(N)=N)NS(=O)(=O)c1c(cc(cc1C(C)C)C(C)C)C(C)C	Preclinical
ulifloxacin			infectious disease	gram-negative bacterial infections, gram-positive bacterial infections	Ark, AKSci	79.96	C[C@H]1Sc2c(C(O)=O)c(=O)c3cc(F)c(cc3n12)N1CCNCC1 |&1:1,r|, C[C@H]1Sc2c(C(O)=O)c(=O)c3cc(F)c(cc3n12)N1CCNCC1 |&1:1,r|	Launched
ulipristal	progesterone receptor antagonist	PGR	endocrinology	contraceptive	Selleck, Selleck, Selleck, Selleck, MedChemEx	95.69	CN(C)c1ccc(cc1)[C@H]1C[C@@]2(C)[C@@H](CC[C@]2(OC(C)=O)C(C)=O)[C@@H]2CCC3=CC(=O)CCC3=C12 |t:29,36|, CN(C)c1ccc(cc1)[C@H]1C[C@@]2(C)[C@@H](CC[C@]2(OC(C)=O)C(C)=O)[C@@H]2CCC3=CC(=O)CCC3=C12 |t:29,36|, CN(C)c1ccc(cc1)[C@H]1C[C@@]2(C)[C@@H](CC[C@]2(OC(C)=O)C(C)=O)[C@@H]2CCC3=CC(=O)CCC3=C12 |t:29,36|, CN(C)c1ccc(cc1)[C@H]1C[C@@]2(C)[C@@H](CC[C@]2(OC(C)=O)C(C)=O)[C@@H]2CCC3=CC(=O)CCC3=C12 |t:29,36|, CN(C)c1ccc(cc1)[C@H]1C[C@@]2(C)[C@@H](CC[C@]2(OC(C)=O)C(C)=O)[C@@H]2CCC3=CC(=O)CCC3=C12 |t:29,36|	Launched
umeclidinium	acetylcholine receptor antagonist	CHRM1, CHRM2, CHRM3	pulmonary	chronic obstructive pulmonary disease (COPD), bronchitis, emphysema	MedChemEx, MedChemEx, MedChemEx, MedChemEx	98.3	OC(c1ccccc1)(c1ccccc1)C12CC[N+](CCOCc3ccccc3)(CC1)CC2, OC(c1ccccc1)(c1ccccc1)C12CC[N+](CCOCc3ccccc3)(CC1)CC2, OC(c1ccccc1)(c1ccccc1)C12CC[N+](CCOCc3ccccc3)(CC1)CC2, OC(c1ccccc1)(c1ccccc1)C12CC[N+](CCOCc3ccccc3)(CC1)CC2	Launched
unbs-5162	CC chemokine receptor antagonist				MedChemEx, MedChemEx, MedChemEx	97.44	CN(C)CCN1C(=O)c2cccc3cc(NC(N)=O)cc(C1=O)c23, CN(C)CCN1C(=O)c2cccc3cc(NC(N)=O)cc(C1=O)c23, CN(C)CCN1C(=O)c2cccc3cc(NC(N)=O)cc(C1=O)c23	Phase 1
UNC0224	histone lysine methyltransferase inhibitor	EHMT1, EHMT2			Tocris, Tocris, Tocris, Tocris	93.47	COc1cc2c(NC3CCN(C)CC3)nc(nc2cc1OCCCN(C)C)N1CCCN(C)CC1, COc1cc2c(NC3CCN(C)CC3)nc(nc2cc1OCCCN(C)C)N1CCCN(C)CC1, COc1cc2c(NC3CCN(C)CC3)nc(nc2cc1OCCCN(C)C)N1CCCN(C)CC1, COc1cc2c(NC3CCN(C)CC3)nc(nc2cc1OCCCN(C)C)N1CCCN(C)CC1	Preclinical
UNC0321	histone lysine methyltransferase inhibitor	EHMT2			MedChemEx, MedChemEx, MedChemEx	91.24	COc1cc2c(NC3CCN(C)CC3)nc(nc2cc1OCCOCCN(C)C)N1CCCN(C)CC1, COc1cc2c(NC3CCN(C)CC3)nc(nc2cc1OCCOCCN(C)C)N1CCCN(C)CC1, COc1cc2c(NC3CCN(C)CC3)nc(nc2cc1OCCOCCN(C)C)N1CCCN(C)CC1	Preclinical
UNC0631	histone lysine methyltransferase inhibitor	EHMT2			MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx	96.26	COc1cc2c(NC3CCN(CC4CCCCC4)CC3)nc(nc2cc1OCCCN1CCCCC1)N1CCCN(CC1)C(C)C, COc1cc2c(NC3CCN(CC4CCCCC4)CC3)nc(nc2cc1OCCCN1CCCCC1)N1CCCN(CC1)C(C)C, COc1cc2c(NC3CCN(CC4CCCCC4)CC3)nc(nc2cc1OCCCN1CCCCC1)N1CCCN(CC1)C(C)C, COc1cc2c(NC3CCN(CC4CCCCC4)CC3)nc(nc2cc1OCCCN1CCCCC1)N1CCCN(CC1)C(C)C, COc1cc2c(NC3CCN(CC4CCCCC4)CC3)nc(nc2cc1OCCCN1CCCCC1)N1CCCN(CC1)C(C)C, COc1cc2c(NC3CCN(CC4CCCCC4)CC3)nc(nc2cc1OCCCN1CCCCC1)N1CCCN(CC1)C(C)C, COc1cc2c(NC3CCN(CC4CCCCC4)CC3)nc(nc2cc1OCCCN1CCCCC1)N1CCCN(CC1)C(C)C	Preclinical
UNC0638	histone lysine methyltransferase inhibitor	EHMT1, EHMT2			MedChemEx, MedChemEx, Tocris, Tocris	94.36	COc1cc2c(NC3CCN(CC3)C(C)C)nc(nc2cc1OCCCN1CCCC1)C1CCCCC1, COc1cc2c(NC3CCN(CC3)C(C)C)nc(nc2cc1OCCCN1CCCC1)C1CCCCC1, COc1cc2c(NC3CCN(CC3)C(C)C)nc(nc2cc1OCCCN1CCCC1)C1CCCCC1, COc1cc2c(NC3CCN(CC3)C(C)C)nc(nc2cc1OCCCN1CCCC1)C1CCCCC1	Preclinical
UNC0642	histone lysine methyltransferase inhibitor	EHMT1, EHMT2			MedChemEx, MedChemEx, Tocris, MedChemEx	97.06	COc1cc2c(NC3CCN(CC3)C(C)C)nc(nc2cc1OCCCN1CCCC1)N1CCC(F)(F)CC1, COc1cc2c(NC3CCN(CC3)C(C)C)nc(nc2cc1OCCCN1CCCC1)N1CCC(F)(F)CC1, COc1cc2c(NC3CCN(CC3)C(C)C)nc(nc2cc1OCCCN1CCCC1)N1CCC(F)(F)CC1, COc1cc2c(NC3CCN(CC3)C(C)C)nc(nc2cc1OCCCN1CCCC1)N1CCC(F)(F)CC1	Preclinical
UNC0646	histone lysine methyltransferase inhibitor	EHMT2			MedChemEx, Tocris, MedChemEx	90.65	COc1cc2c(NC3CCN(CC3)C3CCCCC3)nc(nc2cc1OCCCN1CCCCC1)N1CCCN(CC1)C(C)C, COc1cc2c(NC3CCN(CC3)C3CCCCC3)nc(nc2cc1OCCCN1CCCCC1)N1CCCN(CC1)C(C)C, COc1cc2c(NC3CCN(CC3)C3CCCCC3)nc(nc2cc1OCCCN1CCCCC1)N1CCCN(CC1)C(C)C	Preclinical
UNC0737	histone lysine methyltransferase inhibitor	EHMT1, EHMT2			SGC	82.62	COc1cc2c(nc(nc2cc1OCCCN1CCCC1)C1CCCCC1)N(C)C1CCN(CC1)C(C)C	Preclinical
UNC1215	L3MBTL antagonist	L3MBTL3			Tocris, Selleck, Selleck	96.21	O=C(N1CCC(CC1)N1CCCC1)c1ccc(C(=O)N2CCC(CC2)N2CCCC2)c(Nc2ccccc2)c1, O=C(N1CCC(CC1)N1CCCC1)c1ccc(C(=O)N2CCC(CC2)N2CCCC2)c(Nc2ccccc2)c1, O=C(N1CCC(CC1)N1CCCC1)c1ccc(C(=O)N2CCC(CC2)N2CCCC2)c(Nc2ccccc2)c1	Preclinical
UNC1999	histone lysine methyltransferase inhibitor	EZH2			Tocris, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck	96.39	CCCc1cc(C)[nH]c(=O)c1CNC(=O)c1cc(cc2n(ncc12)C(C)C)-c1ccc(nc1)N1CCN(CC1)C(C)C, CCCc1cc(C)[nH]c(=O)c1CNC(=O)c1cc(cc2n(ncc12)C(C)C)-c1ccc(nc1)N1CCN(CC1)C(C)C, CCCc1cc(C)[nH]c(=O)c1CNC(=O)c1cc(cc2n(ncc12)C(C)C)-c1ccc(nc1)N1CCN(CC1)C(C)C, CCCc1cc(C)[nH]c(=O)c1CNC(=O)c1cc(cc2n(ncc12)C(C)C)-c1ccc(nc1)N1CCN(CC1)C(C)C, CCCc1cc(C)[nH]c(=O)c1CNC(=O)c1cc(cc2n(ncc12)C(C)C)-c1ccc(nc1)N1CCN(CC1)C(C)C, CCCc1cc(C)[nH]c(=O)c1CNC(=O)c1cc(cc2n(ncc12)C(C)C)-c1ccc(nc1)N1CCN(CC1)C(C)C, CCCc1cc(C)[nH]c(=O)c1CNC(=O)c1cc(cc2n(ncc12)C(C)C)-c1ccc(nc1)N1CCN(CC1)C(C)C	Preclinical
UNC2025	FLT3 inhibitor, MER tyrosine kinase inhibitor	FLT3, MERTK			MedChemEx, MedChemEx	96.41	CCCCNc1ncc2c(cn([C@H]3CC[C@H](O)CC3)c2n1)-c1ccc(CN2CCN(C)CC2)cc1 |r|, CCCCNc1ncc2c(cn([C@H]3CC[C@H](O)CC3)c2n1)-c1ccc(CN2CCN(C)CC2)cc1 |r|	Preclinical
UNC2250	MER tyrosine kinase inhibitor	MERTK			Selleck, Selleck, Selleck, MedChemEx	95.44	CCCCNc1ncc(c(N[C@H]2CC[C@H](O)CC2)n1)-c1ccc(CN2CCOCC2)cn1 |r|, CCCCNc1ncc(c(N[C@H]2CC[C@H](O)CC2)n1)-c1ccc(CN2CCOCC2)cn1 |r|, CCCCNc1ncc(c(N[C@H]2CC[C@H](O)CC2)n1)-c1ccc(CN2CCOCC2)cn1 |r|, CCCCNc1ncc(c(N[C@H]2CC[C@H](O)CC2)n1)-c1ccc(CN2CCOCC2)cn1 |r|	Preclinical
UNC2327	protein arginine N-methyltransferase inhibitor	PRMT3			Tocris, Tocris, Tocris	97.06	O=C(NCC(=O)N1CCCCC1)Nc1ccc2nnsc2c1, O=C(NCC(=O)N1CCCCC1)Nc1ccc2nnsc2c1, O=C(NCC(=O)N1CCCCC1)Nc1ccc2nnsc2c1	Preclinical
UNC3230	phosphatidyl-inositol activator	PIP5K1C			Tocris, Tocris	96.42	NC(=O)c1nc(Nc2ccccc2)sc1NC(=O)C1CCCCC1, NC(=O)c1nc(Nc2ccccc2)sc1NC(=O)C1CCCCC1	Preclinical
UNC669	L3MBTL antagonist	L3MBTL1			Selleck, Selleck, MedChemEx	95.32	Brc1cncc(c1)C(=O)N1CCC(CC1)N1CCCC1, Brc1cncc(c1)C(=O)N1CCC(CC1)N1CCCC1, Brc1cncc(c1)C(=O)N1CCC(CC1)N1CCCC1	Preclinical
UNC926	MBT inhibitor	L3MBTL1			Tocris, Tocris, Tocris	96.06	Brc1cccc(c1)C(=O)N1CCC(CC1)N1CCCC1, Brc1cccc(c1)C(=O)N1CCC(CC1)N1CCCC1, Brc1cccc(c1)C(=O)N1CCC(CC1)N1CCCC1	Preclinical
undecylenic-acid	other antifungal		infectious disease	tinea pedis, tinea corporis	MicroSource, MedChemEx	25.82	OC(=O)CCCCCCCCC=C, OC(=O)CCCCCCCCC=C	Launched
upadacitinib	JAK inhibitor				MedChemEx	91.62	CC[C@@H]1CN(C[C@@H]1c1cnc2cnc3[nH]ccc3n12)C(=O)NCC(F)(F)F	Launched
upamostat	serine protease inhibitor				MedChemEx	42.18	CCOC(=O)N1CCN(CC1)C(=O)[C@H](Cc1cccc(c1)C(=N)NO)NS(=O)(=O)c1c(cc(cc1C(C)C)C(C)C)C(C)C	Phase 2
UPF-1069	PARP inhibitor	PARP2			Tocris, Tocris, Selleck, Selleck, Tocris	97.99	O=C(COc1cccc2c1cc[nH]c2=O)c1ccccc1, O=C(COc1cccc2c1cc[nH]c2=O)c1ccccc1, O=C(COc1cccc2c1cc[nH]c2=O)c1ccccc1, O=C(COc1cccc2c1cc[nH]c2=O)c1ccccc1, O=C(COc1cccc2c1cc[nH]c2=O)c1ccccc1	Preclinical
uprifosbuvir	antiviral				MedChemEx	87.25	CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(Cl)[C@@H]1O)Oc1ccccc1	Preclinical
uprosertib	AKT inhibitor	AKT1, AKT2, AKT3			MedChemEx, MedChemEx, MedChemEx, MedChemEx	87.27	Cn1ncc(Cl)c1-c1cc(oc1Cl)C(=O)N[C@H](CN)Cc1ccc(F)c(F)c1, Cn1ncc(Cl)c1-c1cc(oc1Cl)C(=O)N[C@H](CN)Cc1ccc(F)c(F)c1, Cn1ncc(Cl)c1-c1cc(oc1Cl)C(=O)N[C@H](CN)Cc1ccc(F)c(F)c1, Cn1ncc(Cl)c1-c1cc(oc1Cl)C(=O)N[C@H](CN)Cc1ccc(F)c(F)c1	Phase 2
uracil		DPYD, UCKL1			MedChemEx, MicroSource, Selleck, Selleck	100	O=c1cc[nH]c(=O)[nH]1, O=c1cc[nH]c(=O)[nH]1, O=c1cc[nH]c(=O)[nH]1, O=c1cc[nH]c(=O)[nH]1	Launched
uracil-mustard	DNA synthesis inhibitor		hematologic malignancy	non-Hodgkin lymphoma (NHL)	MedChemEx, Sigma, MedChemEx	69.59	ClCCN(CCCl)c1c[nH]c(=O)[nH]c1=O, ClCCN(CCCl)c1c[nH]c(=O)[nH]c1=O, ClCCN(CCCl)c1c[nH]c(=O)[nH]c1=O	Launched
urapidil	adrenergic receptor antagonist	HTR1A	cardiology	hypertension	MicroSource, Tocris, Tocris, Tocris, Selleck, Tocris	99.06	COc1ccccc1N1CCN(CCCNc2cc(=O)n(C)c(=O)n2C)CC1, COc1ccccc1N1CCN(CCCNc2cc(=O)n(C)c(=O)n2C)CC1, COc1ccccc1N1CCN(CCCNc2cc(=O)n(C)c(=O)n2C)CC1, COc1ccccc1N1CCN(CCCNc2cc(=O)n(C)c(=O)n2C)CC1, COc1ccccc1N1CCN(CCCNc2cc(=O)n(C)c(=O)n2C)CC1, COc1ccccc1N1CCN(CCCNc2cc(=O)n(C)c(=O)n2C)CC1	Launched
URB597	FAAH inhibitor	FAAH, FAAH2, TRPA1			Tocris, Tocris, Tocris, Selleck, Selleck, Selleck, Selleck	98.1	NC(=O)c1cccc(c1)-c1cccc(OC(=O)NC2CCCCC2)c1, NC(=O)c1cccc(c1)-c1cccc(OC(=O)NC2CCCCC2)c1, NC(=O)c1cccc(c1)-c1cccc(OC(=O)NC2CCCCC2)c1, NC(=O)c1cccc(c1)-c1cccc(OC(=O)NC2CCCCC2)c1, NC(=O)c1cccc(c1)-c1cccc(OC(=O)NC2CCCCC2)c1, NC(=O)c1cccc(c1)-c1cccc(OC(=O)NC2CCCCC2)c1, NC(=O)c1cccc(c1)-c1cccc(OC(=O)NC2CCCCC2)c1	Phase 1
urea	hydroxy radical formation stimulant	ARG1, CA2, CTNNB1	dermatology	psoriasis, xerosis cutis, ichthyosis vulgaris, eczema, keratosis, dermatitis	MedChemEx, MicroSource, MicroSource	100	NC(N)=O, NC(N)=O, NC(N)=O	Launched
urethane	local anesthetic				MicroSource, MedChemEx	0	CCOC(N)=O, CCOC(N)=O	Preclinical
uric-acid		PYGL			Enamine	100	O=c1[nH]c2[nH]c(=O)[nH]c(=O)c2[nH]1	Phase 3
uridine	dopamine receptor agonist	LSM6, TYMP			Selleck, Selleck, Selleck	97.91	OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1ccc(=O)[nH]c1=O, OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1ccc(=O)[nH]c1=O, OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1ccc(=O)[nH]c1=O	Phase 2
uridine-triacetate			nephrology	orotic aciduria	Bepharm	96.02	CC(=O)OC[C@H]1O[C@H]([C@H](OC(C)=O)[C@@H]1OC(C)=O)n1ccc(=O)[nH]c1=O	Launched
uridine-5'-triphosphate	purinergic receptor activator	P2RY11, P2RY2, P2RY4, P2RY6, UCK2			CombiBlocks	0	O[C@@H]1[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]([C@@H]1O)n1ccc(=O)[nH]c1=O |a:1,2,18,19,&1:5,&2:9|	Launched
URMC-099	mixed lineage kinase inhibitor	CDKL2, DAPK3, FLT3, LRRK2, MAP3K10, MAP3K11, MAP3K2, MAP3K9, SRPK2			MedChemEx, MedChemEx	91.98	CN1CCN(Cc2ccc(cc2)-c2cnc3[nH]cc(-c4ccc5[nH]ccc5c4)c3c2)CC1, CN1CCN(Cc2ccc(cc2)-c2cnc3[nH]cc(-c4ccc5[nH]ccc5c4)c3c2)CC1	Preclinical
urolithin-A	antioxidant				MedChemEx	94.6	Oc1ccc2c(c1)oc(=O)c1cc(O)ccc21	Phase 3
ursodeoxycholyltaurine	cholesterol inhibitor				MedChemEx, MedChemEx, Enzo	100	C[C@H](CCC(=O)NCCS(O)(=O)=O)[C@H]1CC[C@H]2[C@@H]3[C@@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C, C[C@H](CCC(=O)NCCS(O)(=O)=O)[C@H]1CC[C@H]2[C@@H]3[C@@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C, C[C@H](CCC(=O)NCCS(O)(=O)=O)[C@H]1CC[C@H]2[C@@H]3[C@@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C	Phase 3
ursodiol	nuclear factor erythroid derived, like (NRF2) activator	AKR1C2, NR1H4	gastroenterology	gallstones	MicroSource, Selleck	100	C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3[C@@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C, C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3[C@@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C	Launched
ursolic-acid	ATPase inhibitor, NFkB pathway inhibitor, STAT inhibitor	HSD11B1, PLA2G1B, PTPN1, PYGM			Sigma, Selleck, Selleck, Selleck, Selleck	90.07	C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]2[C@H]1C)C(O)=O |c:9|, C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]2[C@H]1C)C(O)=O |c:9|, C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]2[C@H]1C)C(O)=O |c:9|, C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]2[C@H]1C)C(O)=O |c:9|, C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]2[C@H]1C)C(O)=O |c:9|	Phase 2/Phase 3
usniacin-(+)	MAP kinase activator	PTPN1			Selleck, Selleck, Selleck	92.95	CC(O)=C1C(=O)C=C2Oc3c(c(O)c(C)c(O)c3C(C)=O)[C@]2(C)C1=O |a:21,&1:3,t:6|, CC(O)=C1C(=O)C=C2Oc3c(c(O)c(C)c(O)c3C(C)=O)[C@@]2(C)C1=O |a:21,&1:3,t:6|, CC(O)=C1C(=O)C=C2Oc3c(c(O)c(C)c(O)c3C(C)=O)[C@@]2(C)C1=O |a:21,&1:3,t:6|	Preclinical
V-51	adrenergic receptor antagonist				ChemBridge, ChemBridge	98.78	COc1cc(CN2CCN(CC2)c2ccc(F)cc2)cc(OC)c1OC, COc1cc(CN2CCN(CC2)c2ccc(F)cc2)cc(OC)c1OC	Phase 1
vaborbactam	beta lactamase inhibitor				MedChemEx	95.26	OB1O[C@H](CC(O)=O)CC[C@@H]1NC(=O)Cc1cccs1	Launched
vadadustat	hypoxia inducible factor prolyl hydroxylase inhibitor				MedChemEx	98.2	OC(=O)CNC(=O)c1ncc(cc1O)-c1cccc(Cl)c1	Phase 3
val-tyr	angiotensin converting enzyme inhibitor				Sigma	100	CC(C)[C@H](N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(O)=O	Preclinical
valaciclovir	DNA polymerase inhibitor		infectious disease	shingles, virus herpes simplex (HSV)	MicroSource, Selleck, Selleck	97.83	CC(C)[C@H](N)C(=O)OCCOCn1cnc2c1[nH]c(N)nc2=O, CC(C)[C@H](N)C(=O)OCCOCn1cnc2c1[nH]c(N)nc2=O, CC(C)[C@H](N)C(=O)OCCOCn1cnc2c1[nH]c(N)nc2=O	Launched
valbenazine	vesicular monoamine transporter inhibitor		neurology/psychiatry	dyskinesia	MedChemEx	88.74	[H][C@]12C[C@@H](OC(=O)[C@@H](N)C(C)C)[C@H](CC(C)C)CN1CCc1cc(OC)c(OC)cc21	Launched
valdecoxib	cyclooxygenase inhibitor	CA12, PTGS2			Tocris, Selleck, Selleck	98.16	Cc1onc(c1-c1ccc(cc1)S(N)(=O)=O)-c1ccccc1, Cc1onc(c1-c1ccc(cc1)S(N)(=O)=O)-c1ccccc1, Cc1onc(c1-c1ccc(cc1)S(N)(=O)=O)-c1ccccc1	Withdrawn
valethamate	acetylcholine receptor antagonist	CHRM1, CHRM4, CHRM5	obstetrics/gynecology	labor induction	Sigma	90.39	CC[C@@H](C)[C@@H](C(=O)OCC[N+](C)(CC)CC)c1ccccc1 |&1:2,&2:4|	Launched
valganciclovir	DNA synthesis inhibitor		infectious disease	cytomegalovirus (CMV)	Selleck	100	CC(C)[C@H](N)C(=O)OC[C@@H](CO)OCn1cnc2c1[nH]c(N)nc2=O |a:3,&1:9|	Launched
valnemulin	bacterial 50S ribosomal subunit inhibitor		infectious disease, gastroenterology	dysentry, colitis, pneumonia	MedChemEx	93.2	CC(C)[C@@H](N)C(=O)NCC(C)(C)SCC(=O)O[C@@H]1C[C@@](C)(C=C)[C@@H](O)[C@H](C)[C@]23CCC(=O)[C@H]2[C@@]1(C)[C@H](C)CC3	Launched
valnoctamide	arachidonic acid acylation inhibitor, benzodiazepine receptor agonist		neurology/psychiatry	sleeplessness	Sigma	61.43	CC[C@@H](C)[C@@H](CC)C(N)=O |&1:2,&2:4,r|	Launched
valproic-acid	benzodiazepine receptor agonist, HDAC inhibitor	ABAT, ACADSB, ALDH5A1, HDAC1, HDAC2, HDAC9, OGDH, SCN10A, SCN11A, SCN1A, SCN1B, SCN2A, SCN2B, SCN3A, SCN3B, SCN4A, SCN4B, SCN5A, SCN7A, SCN8A, SCN9A	neurology/psychiatry	epilepsy, seizures, seizures	Selleck, Selleck, Selleck, EMDBio, Enzo, Sigma, Tocris, Selleck, MicroSource, Selleck	100	CCCC(CCC)C(O)=O, CCCC(CCC)C(O)=O, CCCC(CCC)C(O)=O, CCCC(CCC)C(O)=O, CCCC(CCC)C(O)=O, CCCC(CCC)C(O)=O, CCCC(CCC)C(O)=O, CCCC(CCC)C(O)=O, CCCC(CCC)C(O)=O, CCCC(CCC)C(O)=O	Launched
valpromide	epoxide hydolase inhibitor		neurology/psychiatry	epilepsy	Sigma	60.96	CCCC(CCC)C(N)=O	Launched
valrocemide					Enamine	99	CCCC(CCC)C(=O)NCC(N)=O	Phase 2
valrubicin	DNA inhibitor, topoisomerase inhibitor	TOP2A	oncology	bladder cancer	MedChemEx, MedChemEx, MedChemEx, MedChemEx	97.11	CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1, CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1, CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1, CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1	Launched
valsartan	angiotensin receptor antagonist	AGTR1	cardiology	hypertension, congestive heart failure, congestive heart failure	MicroSource, MicroSource, MicroSource, Tocris, Tocris, Selleck, Tocris, Tocris	99.42	CCCCC(=O)N(Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1)[C@@H](C(C)C)C(O)=O, CCCCC(=O)N(Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1)[C@@H](C(C)C)C(O)=O, CCCCC(=O)N(Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1)[C@@H](C(C)C)C(O)=O, CCCCC(=O)N(Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1)[C@@H](C(C)C)C(O)=O, CCCCC(=O)N(Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1)[C@@H](C(C)C)C(O)=O, CCCCC(=O)N(Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1)[C@@H](C(C)C)C(O)=O, CCCCC(=O)N(Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1)[C@@H](C(C)C)C(O)=O, CCCCC(=O)N(Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1)[C@@H](C(C)C)C(O)=O	Launched
valspodar	P glycoprotein inhibitor	ABCB1			MedChemEx, MedChemEx, MedChemEx	43.76	C\C=C\C[C@@H](C)C(=O)[C@@H]1N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C(=O)[C@@H](NC1=O)C(C)C)C(C)C, C\C=C\C[C@@H](C)C(=O)[C@@H]1N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C(=O)[C@@H](NC1=O)C(C)C)C(C)C, C\C=C\C[C@@H](C)C(=O)[C@@H]1N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C(=O)[C@@H](NC1=O)C(C)C)C(C)C	Phase 3
vancomycin	bacterial cell wall synthesis inhibitor		infectious disease	endocarditis	Tocris, Tocris, MedChemEx, MicroSource, Selleck, Selleck	88.61	CN[C@H](CC(C)C)C(=O)N[C@@H]1[C@H](O)c2ccc(Oc3cc4cc(Oc5ccc(cc5Cl)[C@@H](O)[C@@H]5NC(=O)[C@H](NC(=O)[C@@H]4NC(=O)[C@H](CC(N)=O)NC1=O)c1ccc(O)c(c1)-c1c(O)cc(O)cc1[C@H](NC5=O)C(O)=O)c3O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1)c(Cl)c2, CN[C@H](CC(C)C)C(=O)N[C@@H]1[C@H](O)c2ccc(Oc3cc4cc(Oc5ccc(cc5Cl)[C@@H](O)[C@@H]5NC(=O)[C@H](NC(=O)[C@@H]4NC(=O)[C@H](CC(N)=O)NC1=O)c1ccc(O)c(c1)-c1c(O)cc(O)cc1[C@H](NC5=O)C(O)=O)c3O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1)c(Cl)c2, CN[C@H](CC(C)C)C(=O)N[C@@H]1[C@H](O)c2ccc(Oc3cc4cc(Oc5ccc(cc5Cl)[C@@H](O)[C@@H]5NC(=O)[C@H](NC(=O)[C@@H]4NC(=O)[C@H](CC(N)=O)NC1=O)c1ccc(O)c(c1)-c1c(O)cc(O)cc1[C@H](NC5=O)C(O)=O)c3O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1)c(Cl)c2, CN[C@H](CC(C)C)C(=O)N[C@@H]1[C@H](O)c2ccc(Oc3cc4cc(Oc5ccc(cc5Cl)[C@@H](O)[C@@H]5NC(=O)[C@H](NC(=O)[C@@H]4NC(=O)[C@H](CC(N)=O)NC1=O)c1ccc(O)c(c1)-c1c(O)cc(O)cc1[C@H](NC5=O)C(O)=O)c3O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1)c(Cl)c2, CN[C@H](CC(C)C)C(=O)N[C@@H]1[C@H](O)c2ccc(Oc3cc4cc(Oc5ccc(cc5Cl)[C@@H](O)[C@@H]5NC(=O)[C@H](NC(=O)[C@@H]4NC(=O)[C@H](CC(N)=O)NC1=O)c1ccc(O)c(c1)-c1c(O)cc(O)cc1[C@H](NC5=O)C(O)=O)c3O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1)c(Cl)c2, CN[C@H](CC(C)C)C(=O)N[C@@H]1[C@H](O)c2ccc(Oc3cc4cc(Oc5ccc(cc5Cl)[C@@H](O)[C@@H]5NC(=O)[C@H](NC(=O)[C@@H]4NC(=O)[C@H](CC(N)=O)NC1=O)c1ccc(O)c(c1)-c1c(O)cc(O)cc1[C@H](NC5=O)C(O)=O)c3O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1)c(Cl)c2	Launched
vandetanib	EGFR inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor	EGFR, EPHA1, EPHA10, EPHA2, EPHA3, EPHA4, EPHA5, EPHA6, EPHA7, EPHA8, EPHB1, EPHB2, EPHB3, EPHB4, EPHB6, ERBB2, ERBB3, ERBB4, FLT1, FLT4, KDR, PTK6, RET, SRC, TEK, VEGFA	oncology	medullary thyroid cancer (MTC)	MedChemEx, MedChemEx, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck	99.2	COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1, COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1, COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1, COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1, COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1, COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1, COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1, COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1	Launched
vanillin		ABAT, ALDH5A1			MedChemEx, Selleck, Selleck	98.63	COc1cc(C=O)ccc1O, COc1cc(C=O)ccc1O, COc1cc(C=O)ccc1O	Preclinical
vanillylacetone					Selleck, Selleck	98.97	COc1cc(CCC(C)=O)ccc1O, COc1cc(CCC(C)=O)ccc1O	Preclinical
vaniprevir	serine protease inhibitor				MedChemEx, MedChemEx	94.28	CC[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H]2CN1C(=O)[C@@H](NC(=O)OCC(C)(C)CCCCc1cccc3CN(Cc13)C(=O)O2)C(C)(C)C)C(=O)NS(=O)(=O)C1CC1, CC[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H]2CN1C(=O)[C@@H](NC(=O)OCC(C)(C)CCCCc1cccc3CN(Cc13)C(=O)O2)C(C)(C)C)C(=O)NS(=O)(=O)C1CC1	Phase 3
vanitiolide					MicroSource, Sigma	95.56	COc1cc(ccc1O)C(=S)N1CCOCC1, COc1cc(ccc1O)C(=S)N1CCOCC1	Preclinical
vanoxerine	dopamine reuptake inhibitor	SLC6A3			Tocris, Tocris, Tocris, Tocris, Tocris, Tocris	96.73	Fc1ccc(cc1)C(OCCN1CCN(CCCc2ccccc2)CC1)c1ccc(F)cc1, Fc1ccc(cc1)C(OCCN1CCN(CCCc2ccccc2)CC1)c1ccc(F)cc1, Fc1ccc(cc1)C(OCCN1CCN(CCCc2ccccc2)CC1)c1ccc(F)cc1, Fc1ccc(cc1)C(OCCN1CCN(CCCc2ccccc2)CC1)c1ccc(F)cc1, Fc1ccc(cc1)C(OCCN1CCN(CCCc2ccccc2)CC1)c1ccc(F)cc1, Fc1ccc(cc1)C(OCCN1CCN(CCCc2ccccc2)CC1)c1ccc(F)cc1	Phase 3
vapendavir	antiviral				Astatech	97.98	CCOc1noc2cc(OCCC3CCN(CC3)c3ccc(C)nn3)ccc12	Phase 2
vardenafil	phosphodiesterase inhibitor	PDE5A, PDE6G, PDE6H	urology	erectile dysfunction	MicroSource, MicroSource, MedChemEx, Selleck	99.24	CCCc1nc(C)c2n1[nH]c(nc2=O)-c1cc(ccc1OCC)S(=O)(=O)N1CCN(CC)CC1, CCCc1nc(C)c2n1[nH]c(nc2=O)-c1cc(ccc1OCC)S(=O)(=O)N1CCN(CC)CC1, CCCc1nc(C)c2n1[nH]c(nc2=O)-c1cc(ccc1OCC)S(=O)(=O)N1CCN(CC)CC1, CCCc1nc(C)c2n1[nH]c(nc2=O)-c1cc(ccc1OCC)S(=O)(=O)N1CCN(CC)CC1	Launched
varenicline	acetylcholine receptor agonist	CHRNA3, CHRNA4, CHRNA6, CHRNA7	neurology/psychiatry	smoking cessation	Tocris	97.1	C1[C@H]2CNC[C@@H]1c1cc3nccnc3cc21 |&1:1,5|	Launched
varespladib	secretory phospholipase inhibitor	PLA2G2A			Selleck	98.89	CCc1c(C(=O)C(N)=O)c2c(OCC(O)=O)cccc2n1Cc1ccccc1	Phase 3
vasopressin	vasopressin receptor agonist	AVPR1A, AVPR1B, AVPR2, OXTR	gastroenterology	abdominal distension	Sigma	85.73	N[C@H]1CSSC[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2ccc(O)cc2)NC1=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(N)=O	Launched
vatalanib	KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	EGFR, FLT1, FLT4, KDR, PDGFRB			Selleck, Tocris, Selleck	99.48	Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1, Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1, Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1	Phase 3
vatinoxan	adrenergic receptor antagonist				MedChemEx	95.42	[H][C@@]12C[C@@]3(CNC(=O)N3CCNS(C)(=O)=O)CCN1CCc1c2oc2ccccc12	Preclinical
VBY-825	cathepsin inhibitor	CTSB, CTSL, CTSS			MedChemEx, MedChemEx, MedChemEx, MedChemEx	100	CC[C@H](NC(=O)[C@H](CS(=O)(=O)CC1CC1)N[C@@H](c1ccc(F)cc1)C(F)(F)F)C(=O)C(=O)NC1CC1, CC[C@H](NC(=O)[C@H](CS(=O)(=O)CC1CC1)N[C@@H](c1ccc(F)cc1)C(F)(F)F)C(=O)C(=O)NC1CC1, CC[C@H](NC(=O)[C@H](CS(=O)(=O)CC1CC1)N[C@@H](c1ccc(F)cc1)C(F)(F)F)C(=O)C(=O)NC1CC1, CC[C@H](NC(=O)[C@H](CS(=O)(=O)CC1CC1)N[C@@H](c1ccc(F)cc1)C(F)(F)F)C(=O)C(=O)NC1CC1	Preclinical
VCH-916	HCV inhibitor				MedChemEx, MedChemEx, MedChemEx	98.31	CO[C@H]1CC[C@@H](CC1)N(C(=O)[C@H]1CC[C@H](C)CC1)c1cc(sc1C(O)=O)C1=CCCCC1 |r,t:29|, CO[C@H]1CC[C@@H](CC1)N(C(=O)[C@H]1CC[C@H](C)CC1)c1cc(sc1C(O)=O)C1=CCCCC1 |r,t:29|, CO[C@H]1CC[C@@H](CC1)N(C(=O)[C@H]1CC[C@H](C)CC1)c1cc(sc1C(O)=O)C1=CCCCC1 |r,t:29|	Phase 1
VE-821	ATR kinase inhibitor	ATR			MedChemEx, Selleck, Selleck, Selleck	97.3	CS(=O)(=O)c1ccc(cc1)-c1cnc(N)c(n1)C(=O)Nc1ccccc1, CS(=O)(=O)c1ccc(cc1)-c1cnc(N)c(n1)C(=O)Nc1ccccc1, CS(=O)(=O)c1ccc(cc1)-c1cnc(N)c(n1)C(=O)Nc1ccccc1, CS(=O)(=O)c1ccc(cc1)-c1cnc(N)c(n1)C(=O)Nc1ccccc1	Preclinical
VE-822	ATR kinase inhibitor	ATM, ATR, MTOR, PIK3CG			MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx, Selleck, Selleck, Selleck	95.02	CNCc1ccc(cc1)-c1cc(on1)-c1nc(cnc1N)-c1ccc(cc1)S(=O)(=O)C(C)C, CNCc1ccc(cc1)-c1cc(on1)-c1nc(cnc1N)-c1ccc(cc1)S(=O)(=O)C(C)C, CNCc1ccc(cc1)-c1cc(on1)-c1nc(cnc1N)-c1ccc(cc1)S(=O)(=O)C(C)C, CNCc1ccc(cc1)-c1cc(on1)-c1nc(cnc1N)-c1ccc(cc1)S(=O)(=O)C(C)C, CNCc1ccc(cc1)-c1cc(on1)-c1nc(cnc1N)-c1ccc(cc1)S(=O)(=O)C(C)C, CNCc1ccc(cc1)-c1cc(on1)-c1nc(cnc1N)-c1ccc(cc1)S(=O)(=O)C(C)C, CNCc1ccc(cc1)-c1cc(on1)-c1nc(cnc1N)-c1ccc(cc1)S(=O)(=O)C(C)C, CNCc1ccc(cc1)-c1cc(on1)-c1nc(cnc1N)-c1ccc(cc1)S(=O)(=O)C(C)C	Phase 2
vecabrutinib	Bruton's tyrosine kinase (BTK) inhibitor				MedChemEx	97.63	NC(=O)[C@H]1CCN(C[C@@H]1N1CCC[C@@H](Nc2cc(Cl)cc(c2)C(F)(F)F)C1=O)c1ncnc(N)c1F	Phase 1/Phase 2
vecuronium	acetylcholine receptor antagonist	CHRNA2	neurology/psychiatry	muscle relaxant	MedChemEx, MicroSource, Selleck	100	CC(=O)O[C@H]1[C@H](C[C@H]2[C@@H]3CC[C@H]4C[C@H](OC(C)=O)[C@H](C[C@]4(C)[C@H]3CC[C@]12C)N1CCCCC1)[N+]1(C)CCCCC1, CC(=O)O[C@H]1[C@H](C[C@H]2[C@@H]3CC[C@H]4C[C@H](OC(C)=O)[C@H](C[C@]4(C)[C@H]3CC[C@]12C)N1CCCCC1)[N+]1(C)CCCCC1, CC(=O)O[C@H]1[C@H](C[C@H]2[C@@H]3CC[C@H]4C[C@H](OC(C)=O)[C@H](C[C@]4(C)[C@H]3CC[C@]12C)N1CCCCC1)[N+]1(C)CCCCC1	Launched
vedaprofen	anti-inflammatory agent	PTGS2	neurology/psychiatry, endocrinology	pain relief, fever	Sigma	98.74	C[C@H](C(O)=O)c1ccc(C2CCCCC2)c2ccccc12 |&1:1,r|	Launched
velaresol					AMS	0	OC(=O)CCCCOc1cccc(O)c1C=O	Preclinical
veledimex	cytochrome P450 inhibitor				MedChemEx	97.45	CCC[C@@H](N(NC(=O)c1cccc(OC)c1CC)C(=O)c1cc(C)cc(C)c1)C(C)(C)C	Phase 2
veliflapon	leukotriene synthesis inhibitor	ALOX5AP			Sigma	99.55	OC(=O)[C@H](C1CCCC1)c1ccc(OCc2ccc3ccccc3n2)cc1	Phase 3
veliparib	PARP inhibitor	PARP1, PARP2			MedChemEx	98.6	C[C@@]1(CCCN1)c1nc2cccc(C(N)=O)c2[nH]1	Phase 3
velneperit	neuropeptide receptor antagonist	NPY5R			MedChemEx, MedChemEx	84.28	CC(C)(C)S(=O)(=O)N[C@H]1CC[C@@H](CC1)C(=O)Nc1ccc(cn1)C(F)(F)F |r|, CC(C)(C)S(=O)(=O)N[C@H]1CC[C@@H](CC1)C(=O)Nc1ccc(cn1)C(F)(F)F |r|	Phase 2
velpatasvir	antiviral		infectious disease	hepatitis C	MedChemEx	98.09	COC[C@H]1C[C@H](N(C1)C(=O)[C@H](NC(=O)OC)c1ccccc1)c1nc(c[nH]1)-c1ccc-2c(COc3cc4c5nc([nH]c5ccc4cc-23)[C@@H]2CC[C@H](C)N2C(=O)[C@@H](NC(=O)OC)C(C)C)c1	Launched
vemurafenib	RAF inhibitor	BRAF, RAF1	oncology	melanoma	Selleck, Selleck, Selleck, Selleck, Selleck, MedChemEx, MedChemEx, MedChemEx, Selleck, Selleck, Selleck	98.74	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F, CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F, CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F, CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F, CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F, CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F, CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F, CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F, CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F, CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F, CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F	Launched
venetoclax	BCL inhibitor	BCL2	hematologic malignancy	chronic lymphocytic leukemia (CLL)	Selleck, Selleck, Selleck, Selleck, Adooq, Adooq, Adooq, Adooq, Adooq, Selleck, Selleck, Selleck	97.4	CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1 |c:57|, CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1 |c:57|, CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1 |c:57|, CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1 |c:57|, CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1 |c:57|, CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1 |c:57|, CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1 |c:57|, CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1 |c:57|, CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1 |c:57|, CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1 |c:57|, CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1 |c:57|, CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1 |c:57|	Launched
venlafaxine	adrenergic inhibitor, norepinephrine reuptake inhibitor, serotoninnorepinephrine reuptake inhibitor (SNRI)	SLC6A2, SLC6A4	neurology/psychiatry	depression, generalized anxiety disorder (GAD), panic disorders, social anxiety disorder	Tocris, Selleck, MicroSource, MicroSource	96.92	COc1ccc(cc1)[C@@H](CN(C)C)C1(O)CCCCC1 |&1:8|, COc1ccc(cc1)[C@@H](CN(C)C)C1(O)CCCCC1 |&1:8|, COc1ccc(cc1)[C@@H](CN(C)C)C1(O)CCCCC1 |&1:8|, COc1ccc(cc1)[C@@H](CN(C)C)C1(O)CCCCC1 |&1:8|	Launched
VER-155008	HSP inhibitor	HSPA1A			Tocris, WuXi, WuXi, WuXi, WuXi, WuXi, WuXi, WuXi, WuXi, WuXi, WuXi, WuXi	99.77	Nc1ncnc2n([C@@H]3O[C@H](COCc4ccc(cc4)C#N)[C@@H](O)[C@H]3O)c(NCc3ccc(Cl)c(Cl)c3)nc12, Nc1ncnc2n([C@@H]3O[C@H](COCc4ccc(cc4)C#N)[C@@H](O)[C@H]3O)c(NCc3ccc(Cl)c(Cl)c3)nc12, Nc1ncnc2n([C@@H]3O[C@H](COCc4ccc(cc4)C#N)[C@@H](O)[C@H]3O)c(NCc3ccc(Cl)c(Cl)c3)nc12, Nc1ncnc2n([C@@H]3O[C@H](COCc4ccc(cc4)C#N)[C@@H](O)[C@H]3O)c(NCc3ccc(Cl)c(Cl)c3)nc12, Nc1ncnc2n([C@@H]3O[C@H](COCc4ccc(cc4)C#N)[C@@H](O)[C@H]3O)c(NCc3ccc(Cl)c(Cl)c3)nc12, Nc1ncnc2n([C@@H]3O[C@H](COCc4ccc(cc4)C#N)[C@@H](O)[C@H]3O)c(NCc3ccc(Cl)c(Cl)c3)nc12, Nc1ncnc2n([C@@H]3O[C@H](COCc4ccc(cc4)C#N)[C@@H](O)[C@H]3O)c(NCc3ccc(Cl)c(Cl)c3)nc12, Nc1ncnc2n([C@@H]3O[C@H](COCc4ccc(cc4)C#N)[C@@H](O)[C@H]3O)c(NCc3ccc(Cl)c(Cl)c3)nc12, Nc1ncnc2n([C@@H]3O[C@H](COCc4ccc(cc4)C#N)[C@@H](O)[C@H]3O)c(NCc3ccc(Cl)c(Cl)c3)nc12, Nc1ncnc2n([C@@H]3O[C@H](COCc4ccc(cc4)C#N)[C@@H](O)[C@H]3O)c(NCc3ccc(Cl)c(Cl)c3)nc12, Nc1ncnc2n([C@@H]3O[C@H](COCc4ccc(cc4)C#N)[C@@H](O)[C@H]3O)c(NCc3ccc(Cl)c(Cl)c3)nc12, Nc1ncnc2n([C@@H]3O[C@H](COCc4ccc(cc4)C#N)[C@@H](O)[C@H]3O)c(NCc3ccc(Cl)c(Cl)c3)nc12	Preclinical
VER-49009	HSP inhibitor	HSP90AA1			Selleck, Selleck, Selleck, Selleck, MedChemEx	98.19	CCNC(=O)c1[nH]nc(c1-c1ccc(OC)cc1)-c1cc(Cl)c(O)cc1O, CCNC(=O)c1[nH]nc(c1-c1ccc(OC)cc1)-c1cc(Cl)c(O)cc1O, CCNC(=O)c1[nH]nc(c1-c1ccc(OC)cc1)-c1cc(Cl)c(O)cc1O, CCNC(=O)c1[nH]nc(c1-c1ccc(OC)cc1)-c1cc(Cl)c(O)cc1O, CCNC(=O)c1[nH]nc(c1-c1ccc(OC)cc1)-c1cc(Cl)c(O)cc1O	Preclinical
veralipride	dopamine receptor antagonist				MedChemEx	97.67	COc1cc(cc(C(=O)NC[C@@H]2CCCN2CC=C)c1OC)S(N)(=O)=O |&1:11,r|	Preclinical
verapamil	calcium channel blocker	CACNA1A, CACNA1B, CACNA1C, CACNA1D, CACNA1F, CACNA1G, CACNA1I, CACNA1S, CACNB1, CACNB2, CACNB3, CACNB4, CYP3A4, KCNA10, KCNA7, KCNH2, KCNJ11, NALCN, SCN5A, SLC29A4, SLC6A4	cardiology	hypertension	Selleck, MicroSource, MicroSource, MicroSource	97.04	COc1ccc(CCN(C)CCCC(C#N)(C(C)C)c2ccc(OC)c(OC)c2)cc1OC |&1:13|, COc1ccc(CCN(C)CCCC(C#N)(C(C)C)c2ccc(OC)c(OC)c2)cc1OC |&1:13|, COc1ccc(CCN(C)CCCC(C#N)(C(C)C)c2ccc(OC)c(OC)c2)cc1OC |&1:13|, COc1ccc(CCN(C)CCCC(C#N)(C(C)C)c2ccc(OC)c(OC)c2)cc1OC |&1:13|	Launched
verbascoside	NFkB pathway inhibitor, PKC inhibitor				MedChemEx, MedChemEx	79.95	C[C@@H]1O[C@@H](O[C@@H]2[C@@H](O)[C@H](OCCc3ccc(O)c(O)c3)O[C@H](CO)[C@H]2OC(=O)\C=C\c2ccc(O)c(O)c2)[C@H](O)[C@H](O)[C@H]1O, C[C@@H]1O[C@@H](O[C@@H]2[C@@H](O)[C@H](OCCc3ccc(O)c(O)c3)O[C@H](CO)[C@H]2OC(=O)\C=C\c2ccc(O)c(O)c2)[C@H](O)[C@H](O)[C@H]1O	Phase 2/Phase 3
vercirnon	CC chemokine receptor antagonist	CCR9			MedChemEx, MedChemEx	95.9	CC(C)(C)c1ccc(cc1)S(=O)(=O)Nc1ccc(Cl)cc1C(=O)c1cc[n+]([O-])cc1, CC(C)(C)c1ccc(cc1)S(=O)(=O)Nc1ccc(Cl)cc1C(=O)c1cc[n+]([O-])cc1	Phase 3
verdinexor	exportin antagonist				Adooq	95.01	FC(F)(F)c1cc(cc(c1)C(F)(F)F)-c1ncn(\C=C/C(=O)NNc2ccccn2)n1	Preclinical
verdiperstat	myeloperoxidase inhibitor				MedChemEx	91.59	CC(C)OCCn1c2cc[nH]c2c(=O)[nH]c1=S	Phase 3
vericiguat	guanylate cyclase stimulant				MedChemEx	96.29	COC(=O)Nc1c(N)nc(nc1N)-c1nn(Cc2ccccc2F)c2ncc(F)cc12	Phase 3
verinurad	urate transporter inhibitor	SLC22A12			MedChemEx	98.04	CC(C)(Sc1ccncc1-c1ccc(C#N)c2ccccc12)C(O)=O	Phase 2
vernakalant	potassium channel blocker	KCNA5	cardiology	atrial fibrillation (AF)	MedChemEx, MedChemEx, MedChemEx, MedChemEx	97.82	COc1ccc(CCO[C@@H]2CCCC[C@H]2N2CC[C@@H](O)C2)cc1OC, COc1ccc(CCO[C@@H]2CCCC[C@H]2N2CC[C@@H](O)C2)cc1OC, COc1ccc(CCO[C@@H]2CCCC[C@H]2N2CC[C@@H](O)C2)cc1OC, COc1ccc(CCO[C@@H]2CCCC[C@H]2N2CC[C@@H](O)C2)cc1OC	Launched
verteporfin	photosensitizing agent		ophthalmology	macular degeneration	Tocris, Tocris, MedChemEx, Tocris, Selleck, Cayman, Selleck	69.27	COC(=O)CCc1c(C)c2cc3[nH]c(cc4nc(cc5nc(cc1[nH]2)c(CCC(O)=O)c5C)c(C=C)c4C)C1=CC=C([C@@H](C(=O)OC)[C@@]31C)C(=O)OC |c:44,t:42|, COC(=O)CCc1c(C)c2cc3[nH]c(cc4nc(cc5nc(cc1[nH]2)c(CCC(O)=O)c5C)c(C=C)c4C)C1=CC=C([C@@H](C(=O)OC)[C@@]31C)C(=O)OC |c:44,t:42|, COC(=O)CCc1c(C)c2cc3[nH]c(cc4nc(cc5nc(cc1[nH]2)c(CCC(O)=O)c5C)c(C=C)c4C)C1=CC=C([C@@H](C(=O)OC)[C@@]31C)C(=O)OC |c:44,t:42|, COC(=O)CCc1c(C)c2cc3[nH]c(cc4nc(cc5nc(cc1[nH]2)c(CCC(O)=O)c5C)c(C=C)c4C)C1=CC=C([C@@H](C(=O)OC)[C@@]31C)C(=O)OC |c:44,t:42|, COC(=O)CCc1c(C)c2cc3[nH]c(cc4nc(cc5nc(cc1[nH]2)c(CCC(O)=O)c5C)c(C=C)c4C)C1=CC=C([C@@H](C(=O)OC)[C@@]31C)C(=O)OC |c:44,t:42|, COC(=O)CCc1c(C)c2cc3[nH]c(cc4nc(cc5nc(cc1[nH]2)c(CCC(O)=O)c5C)c(C=C)c4C)C1=CC=C([C@@H](C(=O)OC)[C@@]31C)C(=O)OC |c:44,t:42|, COC(=O)CCc1c(C)c2cc3[nH]c(cc4nc(cc5nc(cc1[nH]2)c(CCC(O)=O)c5C)c(C=C)c4C)C1=CC=C([C@@H](C(=O)OC)[C@@]31C)C(=O)OC |c:44,t:42|	Launched
verubecestat	beta secretase inhibitor				MedChemEx	97.57	CN1C(N)=N[C@@](C)(CS1(=O)=O)c1cc(NC(=O)c2ccc(F)cn2)ccc1F |c:3|	Phase 3
verubulin	tubulin polymerization inhibitor	TUBB			Key, Key, Key, Tocris	99.3	COc1ccc(cc1)N(C)c1nc(C)nc2ccccc12, COc1ccc(cc1)N(C)c1nc(C)nc2ccccc12, COc1ccc(cc1)N(C)c1nc(C)nc2ccccc12, COc1ccc(cc1)N(C)c1nc(C)nc2ccccc12	Phase 2
verucerfont	corticotropin releasing factor receptor antagonist				MedChemEx	99.36	CC[C@H](Nc1cc(C)nc2c(c(C)nn12)-c1ccc(OC)cc1C)c1nc(C)no1	Phase 2
vesamicol	acetylcholinesterase inhibitor	SLC18A3			Tocris, Tocris, Tocris, Tocris, Tocris	97.14	O[C@@H]1CCCC[C@H]1N1CCC(CC1)c1ccccc1, O[C@@H]1CCCC[C@H]1N1CCC(CC1)c1ccccc1, O[C@@H]1CCCC[C@H]1N1CCC(CC1)c1ccccc1, O[C@@H]1CCCC[C@H]1N1CCC(CC1)c1ccccc1, O[C@@H]1CCCC[C@H]1N1CCC(CC1)c1ccccc1	Preclinical
vesnarinone	phosphodiesterase inhibitor	KCNH2, PDE3A	cardiology	congestive heart failure	MedChemEx, MedChemEx, MedChemEx	89.35	COc1ccc(cc1OC)C(=O)N1CCN(CC1)c1ccc2NC(=O)CCc2c1, COc1ccc(cc1OC)C(=O)N1CCN(CC1)c1ccc2NC(=O)CCc2c1, COc1ccc(cc1OC)C(=O)N1CCN(CC1)c1ccc2NC(=O)CCc2c1	Launched
VGX-1027	tumor necrosis factor receptor antagonist	TLR4			MedChemEx, Selleck, Selleck	97.76	OC(=O)C[C@H]1CC(=NO1)c1ccccc1 |&1:4,r,c:6|, OC(=O)C[C@H]1CC(=NO1)c1ccccc1 |&1:4,r,c:6|, OC(=O)C[C@H]1CC(=NO1)c1ccccc1 |&1:4,r,c:6|	Phase 1
vicriviroc	CC chemokine receptor antagonist	CCR5			MedChemEx, MedChemEx, MedChemEx	98.7	COC[C@H](N1CCN(C[C@@H]1C)C1(C)CCN(CC1)C(=O)c1c(C)ncnc1C)c1ccc(cc1)C(F)(F)F, COC[C@H](N1CCN(C[C@@H]1C)C1(C)CCN(CC1)C(=O)c1c(C)ncnc1C)c1ccc(cc1)C(F)(F)F, COC[C@H](N1CCN(C[C@@H]1C)C1(C)CCN(CC1)C(=O)c1c(C)ncnc1C)c1ccc(cc1)C(F)(F)F	Phase 3
vidarabine	antiviral	ADA	infectious disease	virus herpes simplex (HSV), varicella-zoster virus (VZV)	MicroSource, Selleck	98.16	Nc1ncnc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O, Nc1ncnc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O	Launched
vigabatrin	GABA aminotransferase inhibitor	ABAT, SLC32A1	neurology/psychiatry	seizures, spasms	MicroSource, Tocris	0	N[C@@H](CCC(O)=O)C=C |&1:1|, N[C@@H](CCC(O)=O)C=C |&1:1|	Launched
vilanterol	adrenergic receptor agonist	ADRB2	pulmonary	chronic obstructive pulmonary disease (COPD)		0		Launched
vilazodone	serotonin reuptake inhibitor	DRD2, DRD3, HRH1, HTR1A, HTR4, SLC6A4	neurology/psychiatry	depression	MicroSource, Tocris, Tocris, Selleck, Selleck	98.4	NC(=O)c1cc2cc(ccc2o1)N1CCN(CCCCc2c[nH]c3ccc(cc23)C#N)CC1, NC(=O)c1cc2cc(ccc2o1)N1CCN(CCCCc2c[nH]c3ccc(cc23)C#N)CC1, NC(=O)c1cc2cc(ccc2o1)N1CCN(CCCCc2c[nH]c3ccc(cc23)C#N)CC1, NC(=O)c1cc2cc(ccc2o1)N1CCN(CCCCc2c[nH]c3ccc(cc23)C#N)CC1, NC(=O)c1cc2cc(ccc2o1)N1CCN(CCCCc2c[nH]c3ccc(cc23)C#N)CC1	Launched
vildagliptin	dipeptidyl peptidase inhibitor	DPP4	endocrinology	diabetes mellitus	MedChemEx	85.64	O[C@]12C[C@@H]3C[C@H](C1)C[C@@](C3)(C2)NCC(=O)N1CCC[C@H]1C#N	Launched
viloxazine	norepinephrine reuptake inhibitor	SLC6A2	neurology/psychiatry	depression	ChemDiv, ChemDiv, Prestwick	98.75	CCOc1ccccc1OC[C@H]1CNCCO1 |&1:11|, CCOc1ccccc1OC[C@H]1CNCCO1 |&1:11|, CCOc1ccccc1OC[C@H]1CNCCO1 |&1:11|	Launched
vinblastine	microtubule inhibitor, tubulin polymerization inhibitor	JUN, TUBA1A, TUBB, TUBD1, TUBE1, TUBG1	hematologic malignancy, infectious disease, oncology	Hodgkin's lymphoma, true histiocytic lymphoma (THL), mycosis, small lymphocytic lymphoma (SLL), testicular carcinoma, Kaposi sarcoma	MedChemEx, MedChemEx, MedChemEx, MedChemEx, MicroSource, MicroSource, Selleck, Selleck, Selleck, Selleck, Tocris	96.33	CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC |c:48|, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC |c:48|, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC |c:48|, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC |c:48|, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC |c:48|, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC |c:48|, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC |c:48|, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC |c:48|, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC |c:48|, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC |c:48|, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC |c:48|	Launched
vinburnine	adrenergic receptor antagonist	CHRM1, CHRM2, CHRM3, CHRM4	neurology/psychiatry	stroke	Enzo, MedChemEx	98.61	CC[C@@]12CCCN3CCc4c([C@H]13)n(C(=O)C2)c1ccccc41, CC[C@@]12CCCN3CCc4c([C@H]13)n(C(=O)C2)c1ccccc41	Launched
vincamine	adrenergic receptor antagonist	CHRM1, CHRM2, CHRM3, CHRM4			MedChemEx	99.37	CC[C@@]12CCCN3CCc4c([C@H]13)n(c1ccccc41)[C@](O)(C2)C(=O)OC	Withdrawn
vincristine	tubulin polymerization inhibitor	TUBA4A, TUBB	hematologic malignancy	acute lymphoblastic leukemia (ALL)	MicroSource, MedChemEx, Selleck, MedChemEx, MedChemEx, Tocris, Selleck	90.52	CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C=O)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC |c:49|, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C=O)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC |c:49|, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C=O)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC |c:49|, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C=O)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC |c:49|, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C=O)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC |c:49|, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C=O)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC |c:49|, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C=O)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC |c:49|	Launched
vindesine	tubulin polymerization inhibitor	TUBB, TUBB1	oncology	breast cancer, non-small cell lung cancer (NSCLC), melanoma	AvaChem, AvaChem, AvaChem, AvaChem	78.54	CC[C@]1(O)C[C@H]2CN(C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](O)[C@]1(O)C(N)=O |c:48|, CC[C@]1(O)C[C@H]2CN(C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](O)[C@]1(O)C(N)=O |c:48|, CC[C@]1(O)C[C@H]2CN(C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](O)[C@]1(O)C(N)=O |c:48|, CC[C@]1(O)C[C@H]2CN(C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](O)[C@]1(O)C(N)=O |c:48|	Launched
vinflunine	microtubule inhibitor		oncology	bladder cancer	Selleck, Selleck, AvaChem, AvaChem	95.66	CC[C@@]12C=CCN3CC[C@@]4([C@H]13)[C@@H](N(C)c1cc(OC)c(cc41)[C@]1(C[C@@H]3C[C@H](C[N@@](C3)CCc3c1[nH]c1ccccc31)C(C)(F)F)C(=O)OC)[C@](O)([C@@H]2OC(C)=O)C(=O)OC |c:3|, CC[C@@]12C=CCN3CC[C@@]4([C@H]13)[C@@H](N(C)c1cc(OC)c(cc41)[C@]1(C[C@@H]3C[C@H](C[N@@](C3)CCc3c1[nH]c1ccccc31)C(C)(F)F)C(=O)OC)[C@](O)([C@@H]2OC(C)=O)C(=O)OC |c:3|, CC[C@@]12C=CCN3CC[C@@]4([C@H]13)[C@@H](N(C)c1cc(OC)c(cc41)[C@]1(C[C@@H]3C[C@H](C[N@@](C3)CCc3c1[nH]c1ccccc31)C(C)(F)F)C(=O)OC)[C@](O)([C@@H]2OC(C)=O)C(=O)OC |c:3|, CC[C@@]12C=CCN3CC[C@@]4([C@H]13)[C@@H](N(C)c1cc(OC)c(cc41)[C@]1(C[C@@H]3C[C@H](C[N@@](C3)CCc3c1[nH]c1ccccc31)C(C)(F)F)C(=O)OC)[C@](O)([C@@H]2OC(C)=O)C(=O)OC |c:3|	Launched
vinorelbine	tubulin polymerization inhibitor	TUBA1A, TUBA1B, TUBA1C, TUBA3C, TUBA3D, TUBA3E, TUBA4A, TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8	oncology	non-small cell lung cancer (NSCLC)	MedChemEx, MedChemEx	27.23	CCC1=C[C@@H]2C[N@](C1)Cc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC |c:46,t:2|, CCC1=C[C@@H]2C[N@](C1)Cc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC |c:46,t:2|	Launched
vinpocetine	phosphodiesterase inhibitor, sodium channel blocker	PDE1A, PDE1C	neurology/psychiatry	stroke, senile dementia	MicroSource, Tocris, Tocris, Tocris, Selleck	98.68	CCOC(=O)C1=C[C@]2(CC)CCCN3CCc4c([C@H]23)n1c1ccccc41 |t:5|, CCOC(=O)C1=C[C@]2(CC)CCCN3CCc4c([C@H]23)n1c1ccccc41 |t:5|, CCOC(=O)C1=C[C@]2(CC)CCCN3CCc4c([C@H]23)n1c1ccccc41 |t:5|, CCOC(=O)C1=C[C@]2(CC)CCCN3CCc4c([C@H]23)n1c1ccccc41 |t:5|, CCOC(=O)C1=C[C@]2(CC)CCCN3CCc4c([C@H]23)n1c1ccccc41 |t:5|	Launched
viomycin	protein synthesis inhibitor		infectious disease	tuberculosis	Prestwick	39.8	NCCC[C@H](N)CC(=O)N[C@H]1CNC(=O)[C@@H](NC(=O)C(NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC1=O)C=NC(N)=O)[C@H]1C[C@H](O)N=C(N)N1 |a:4,10,15,23,29,42,&1:40,&2:35,w:35.35,t:45|	Launched
vipadenant	adenosine receptor antagonist	ADORA1, ADORA2A, ADORA2B, ADORA3			MedChemEx, MedChemEx, MedChemEx, MedChemEx	94.33	Cc1cc(Cn2nnc3c(nc(N)nc23)-c2ccco2)ccc1N, Cc1cc(Cn2nnc3c(nc(N)nc23)-c2ccco2)ccc1N, Cc1cc(Cn2nnc3c(nc(N)nc23)-c2ccco2)ccc1N, Cc1cc(Cn2nnc3c(nc(N)nc23)-c2ccco2)ccc1N	Phase 1
vismodegib	hedgehog pathway inhibitor, smoothened receptor antagonist	SMO	oncology	basal cell carcinoma (BCC)	Selleck, Selleck, Selleck, Broad Institute	98.12	CS(=O)(=O)c1ccc(C(=O)Nc2ccc(Cl)c(c2)-c2ccccn2)c(Cl)c1, CS(=O)(=O)c1ccc(C(=O)Nc2ccc(Cl)c(c2)-c2ccccn2)c(Cl)c1, CS(=O)(=O)c1ccc(C(=O)Nc2ccc(Cl)c(c2)-c2ccccn2)c(Cl)c1, CS(=O)(=O)c1ccc(C(=O)Nc2ccc(Cl)c(c2)-c2ccccn2)c(Cl)c1	Launched
visomitin	antioxidant				MedChemEx, MedChemEx	71.8	CC1=C(C)C(=O)C(CCCCCCCCCC[P+](c2ccccc2)(c2ccccc2)c2ccccc2)=CC1=O |c:1,38|, CC1=C(C)C(=O)C(CCCCCCCCCC[P+](c2ccccc2)(c2ccccc2)c2ccccc2)=CC1=O |c:1,38|	Preclinical
vitamin-B12			hematology	megaloblastic anemia	MedChemEx	95.98	C[C@H](CNC(=O)CC[C@]1(C)[C@@H](CC(N)=O)[C@H]2N=C1\C(C)=C1/N=C(/C=C3\N=C(\C(\C)=C4\[C@@H](CCC(N)=O)[C@](C)(CC(N)=O)[C@@]2(C)N4[Co+]C#N)[C@@](C)(CC(N)=O)[C@@H]3CCC(N)=O)C(C)(C)[C@@H]1CCC(N)=O)OP(O)(=O)O[C@@H]1[C@@H](CO)O[C@@H]([C@@H]1O)n1cnc2cc(C)c(C)cc12 |c:16,20,24,t:22,26,29|	Launched
vitamin-E	LDL oxidation inhibitor, PKC inhibitor	ALOX5, DGKA, NR1I2, PPP2CA, PPP2CB, PRKCA, PRKCB, SEC14L2, SEC14L3, SEC14L4			CombiBlocks	0	CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC[C@]1(C)CCc2c(C)c(O)c(C)c(C)c2O1	Launched
vixotrigine	sodium channel blocker				MedChemEx	86.82	NC(=O)[C@@H]1CC[C@@H](N1)c1ccc(OCc2ccccc2F)cc1	Phase 2
VLX1570	deubiquitinase inhibitor				MedChemEx	93.32	[O-][N+](=O)c1cc(\C=C2/CCN(C\C(=C/c3ccc(F)c(c3)[N+]([O-])=O)C2=O)C(=O)C=C)ccc1F	Phase 1/Phase 2
VLX600	antitumor agent, ubiquitin C-terminal hydrolase inhibitor	TP53, USP14			Enamine, Enamine, ChemDiv, ChemDiv, ChemDiv, ChemDiv	87.51	CC(=NNc1nnc2c(n1)[nH]c1c(C)cccc21)c1ccccn1, CC(=NNc1nnc2c(n1)[nH]c1c(C)cccc21)c1ccccn1, C\C(=N\Nc1nnc2c(n1)[nH]c1c(C)cccc21)c1ccccn1, C\C(=N\Nc1nnc2c(n1)[nH]c1c(C)cccc21)c1ccccn1, C\C(=N\Nc1nnc2c(n1)[nH]c1c(C)cccc21)c1ccccn1, C\C(=N\Nc1nnc2c(n1)[nH]c1c(C)cccc21)c1ccccn1	Phase 1
VL285	PROTAC				MedChemEx	95.21	CC(C)[C@H](N1Cc2ccccc2C1=O)C(=O)N1C[C@H](O)C[C@H]1C(=O)NCc1ccc(cc1)-c1scnc1C	Preclinical
voclosporin	calcineurin inhibitor				MedChemEx	92.03	[H][C@@]1(CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@]([H])(NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C(=O)[C@H](CC)NC(=O)[C@]([H])([C@H](O)[C@H](C)C\C=C\C=C)N(C)C(=O)[C@]([H])(C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C1=O)C(C)C	Phase 3
voglibose	glucosidase inhibitor	MGAM	endocrinology	diabetes mellitus, hyperglycemia	Tocris, Tocris, Selleck	100	OCC(CO)N[C@H]1C[C@](O)(CO)[C@@H](O)[C@H](O)[C@H]1O, OCC(CO)N[C@H]1C[C@](O)(CO)[C@@H](O)[C@H](O)[C@H]1O, OCC(CO)N[C@H]1C[C@](O)(CO)[C@@H](O)[C@H](O)[C@H]1O	Launched
volasertib	PLK inhibitor	PLK1			MedChemEx, Selleck, Selleck, Selleck, Selleck, Focus, Focus, Focus	96.17	CC[C@H]1N(C(C)C)c2nc(Nc3ccc(cc3OC)C(=O)N[C@H]3CC[C@@H](CC3)N3CCN(CC4CC4)CC3)ncc2N(C)C1=O, CC[C@H]1N(C(C)C)c2nc(Nc3ccc(cc3OC)C(=O)N[C@H]3CC[C@@H](CC3)N3CCN(CC4CC4)CC3)ncc2N(C)C1=O, CC[C@H]1N(C(C)C)c2nc(Nc3ccc(cc3OC)C(=O)N[C@H]3CC[C@@H](CC3)N3CCN(CC4CC4)CC3)ncc2N(C)C1=O, CC[C@H]1N(C(C)C)c2nc(Nc3ccc(cc3OC)C(=O)N[C@H]3CC[C@@H](CC3)N3CCN(CC4CC4)CC3)ncc2N(C)C1=O, CC[C@H]1N(C(C)C)c2nc(Nc3ccc(cc3OC)C(=O)N[C@H]3CC[C@@H](CC3)N3CCN(CC4CC4)CC3)ncc2N(C)C1=O, CC[C@H]1N(C(C)C)c2nc(Nc3ccc(cc3OC)C(=O)N[C@H]3CC[C@@H](CC3)N3CCN(CC4CC4)CC3)ncc2N(C)C1=O, CC[C@H]1N(C(C)C)c2nc(Nc3ccc(cc3OC)C(=O)N[C@H]3CC[C@@H](CC3)N3CCN(CC4CC4)CC3)ncc2N(C)C1=O, CC[C@H]1N(C(C)C)c2nc(Nc3ccc(cc3OC)C(=O)N[C@H]3CC[C@@H](CC3)N3CCN(CC4CC4)CC3)ncc2N(C)C1=O	Phase 3
volinanserin	serotonin receptor antagonist	HTR2A, HTR2B, HTR2C, KCNH2			Tocris, Cayman	98.59	COc1cccc([C@H](O)C2CCN(CCc3ccc(F)cc3)CC2)c1OC, COc1cccc([C@H](O)C2CCN(CCc3ccc(F)cc3)CC2)c1OC	Phase 3
vonoprazan	potassium-competitive acid antagonist	ATP4A	gastroenterology	peptic ulcer disease (PUD)	MedChemEx, Selleck, Selleck, Selleck, Selleck	88.52	CNCc1cc(-c2ccccc2F)n(c1)S(=O)(=O)c1cccnc1, CNCc1cc(-c2ccccc2F)n(c1)S(=O)(=O)c1cccnc1, CNCc1cc(-c2ccccc2F)n(c1)S(=O)(=O)c1cccnc1, CNCc1cc(-c2ccccc2F)n(c1)S(=O)(=O)c1cccnc1, CNCc1cc(-c2ccccc2F)n(c1)S(=O)(=O)c1cccnc1	Launched
vorapaxar	thrombin inhibitor	F2R	cardiology	myocardial infarction, peripheral artery disease (PAD)	Adooq, Adooq, Adooq, Adooq	98.32	CCOC(=O)N[C@@H]1CC[C@@H]2[C@H](C[C@@H]3[C@@H]([C@@H](C)OC3=O)[C@H]2\C=C\c2ccc(cn2)-c2cccc(F)c2)C1, CCOC(=O)N[C@@H]1CC[C@@H]2[C@H](C[C@@H]3[C@@H]([C@@H](C)OC3=O)[C@H]2\C=C\c2ccc(cn2)-c2cccc(F)c2)C1, CCOC(=O)N[C@@H]1CC[C@@H]2[C@H](C[C@@H]3[C@@H]([C@@H](C)OC3=O)[C@H]2\C=C\c2ccc(cn2)-c2cccc(F)c2)C1, CCOC(=O)N[C@@H]1CC[C@@H]2[C@H](C[C@@H]3[C@@H]([C@@H](C)OC3=O)[C@H]2\C=C\c2ccc(cn2)-c2cccc(F)c2)C1	Launched
vorasidenib	isocitrate dehydrogenase inhibitor				MedChemEx	97.5	C[C@@H](Nc1nc(N[C@H](C)C(F)(F)F)nc(n1)-c1cccc(Cl)n1)C(F)(F)F	Preclinical
voreloxin	topoisomerase inhibitor	TOP2A			MedChemEx, MedChemEx, MedChemEx	97.57	CN[C@H]1CN(C[C@@H]1OC)c1ccc2c(n1)n(cc(C(O)=O)c2=O)-c1nccs1, CN[C@H]1CN(C[C@@H]1OC)c1ccc2c(n1)n(cc(C(O)=O)c2=O)-c1nccs1, CN[C@H]1CN(C[C@@H]1OC)c1ccc2c(n1)n(cc(C(O)=O)c2=O)-c1nccs1	Phase 3
voriconazole	cytochrome P450 inhibitor	CYP2C19, CYP2C9, CYP3A4, CYP3A5, PTGS1	infectious disease	esophageal candidiasis, aspergillosis, skin infections	MicroSource, MicroSource, Selleck, Tocris, Selleck	99.42	C[C@@H](c1ncncc1F)[C@](O)(Cn1cncn1)c1ccc(F)cc1F, C[C@@H](c1ncncc1F)[C@](O)(Cn1cncn1)c1ccc(F)cc1F, C[C@@H](c1ncncc1F)[C@](O)(Cn1cncn1)c1ccc(F)cc1F, C[C@@H](c1ncncc1F)[C@](O)(Cn1cncn1)c1ccc(F)cc1F, C[C@@H](c1ncncc1F)[C@](O)(Cn1cncn1)c1ccc(F)cc1F	Launched
vorinostat	HDAC inhibitor	HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC5, HDAC6, HDAC8, HDAC9	hematologic malignancy	cutaneous T-cell lymphoma (CTCL)	Tocris, Tocris, Tocris, Tocris, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck	99.7	ONC(=O)CCCCCCC(=O)Nc1ccccc1, ONC(=O)CCCCCCC(=O)Nc1ccccc1, ONC(=O)CCCCCCC(=O)Nc1ccccc1, ONC(=O)CCCCCCC(=O)Nc1ccccc1, ONC(=O)CCCCCCC(=O)Nc1ccccc1, ONC(=O)CCCCCCC(=O)Nc1ccccc1, ONC(=O)CCCCCCC(=O)Nc1ccccc1, ONC(=O)CCCCCCC(=O)Nc1ccccc1, ONC(=O)CCCCCCC(=O)Nc1ccccc1, ONC(=O)CCCCCCC(=O)Nc1ccccc1, ONC(=O)CCCCCCC(=O)Nc1ccccc1, ONC(=O)CCCCCCC(=O)Nc1ccccc1, ONC(=O)CCCCCCC(=O)Nc1ccccc1, ONC(=O)CCCCCCC(=O)Nc1ccccc1, ONC(=O)CCCCCCC(=O)Nc1ccccc1	Launched
vortioxetine	serotonin receptor agonist, serotonin receptor antagonist	HTR1A, HTR1B, HTR2A, HTR2C, HTR3A, HTR5A, HTR6, HTR7, SLC6A4	neurology/psychiatry	depression	MicroSource, Selleck, Selleck, Selleck, MedChemEx	95.12	Cc1ccc(Sc2ccccc2N2CCNCC2)c(C)c1, Cc1ccc(Sc2ccccc2N2CCNCC2)c(C)c1, Cc1ccc(Sc2ccccc2N2CCNCC2)c(C)c1, Cc1ccc(Sc2ccccc2N2CCNCC2)c(C)c1, Cc1ccc(Sc2ccccc2N2CCNCC2)c(C)c1	Launched
voruciclib	CDK9 inhibitor				Astatech	97.7	CN1CC[C@H]([C@@H]1CO)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccc(cc1Cl)C(F)(F)F	Phase 1
voxelotor	hemoglobin modulator				MedChemEx, MedChemEx	96.07	CC(C)n1nccc1-c1ncccc1COc1cccc(O)c1C=O, CC(C)n1nccc1-c1ncccc1COc1cccc(O)c1C=O	Launched
voxtalisib	mTOR inhibitor, PI3K inhibitor	MTOR, PIK3CA			MedChemEx, MedChemEx, MedChemEx	99.19	CCn1c2nc(N)nc(C)c2cc(-c2cc[nH]n2)c1=O, CCn1c2nc(N)nc(C)c2cc(-c2cc[nH]n2)c1=O, CCn1c2nc(N)nc(C)c2cc(-c2cc[nH]n2)c1=O	Phase 2
VP-20629	beta amyloid antagonist	PLA2G2E, SLC36A1			ChemDiv	99.13	OC(=O)CCc1c[nH]c2ccccc12	Phase 1
VS-4718	focal adhesion kinase inhibitor				MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx	98.41	CNC(=O)c1ccccc1Nc1cc(Nc2ccc(cc2OC)N2CCOCC2)ncc1C(F)(F)F, CNC(=O)c1ccccc1Nc1cc(Nc2ccc(cc2OC)N2CCOCC2)ncc1C(F)(F)F, CNC(=O)c1ccccc1Nc1cc(Nc2ccc(cc2OC)N2CCOCC2)ncc1C(F)(F)F, CNC(=O)c1ccccc1Nc1cc(Nc2ccc(cc2OC)N2CCOCC2)ncc1C(F)(F)F, CNC(=O)c1ccccc1Nc1cc(Nc2ccc(cc2OC)N2CCOCC2)ncc1C(F)(F)F, CNC(=O)c1ccccc1Nc1cc(Nc2ccc(cc2OC)N2CCOCC2)ncc1C(F)(F)F, CNC(=O)c1ccccc1Nc1cc(Nc2ccc(cc2OC)N2CCOCC2)ncc1C(F)(F)F, CNC(=O)c1ccccc1Nc1cc(Nc2ccc(cc2OC)N2CCOCC2)ncc1C(F)(F)F	Phase 1
VT-464	cytochrome P450 inhibitor	CYP17A1			MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx	98.44	CC(C)[C@@](O)(c1cn[nH]n1)c1ccc2cc(OC(F)F)c(OC(F)F)cc2c1, CC(C)[C@@](O)(c1cn[nH]n1)c1ccc2cc(OC(F)F)c(OC(F)F)cc2c1, CC(C)[C@@](O)(c1cn[nH]n1)c1ccc2cc(OC(F)F)c(OC(F)F)cc2c1, CC(C)[C@@](O)(c1cn[nH]n1)c1ccc2cc(OC(F)F)c(OC(F)F)cc2c1, CC(C)[C@@](O)(c1cn[nH]n1)c1ccc2cc(OC(F)F)c(OC(F)F)cc2c1	Phase 2
VTP-27999	renin inhibitor	REN			MedChemEx, MedChemEx	92.33	CN[C@H](CNC(=O)N1CCC[C@H](C1)[C@@H](OCCNC(=O)OC)c1cccc(Cl)c1)C[C@H]1CCCOC1, CN[C@H](CNC(=O)N1CCC[C@H](C1)[C@@H](OCCNC(=O)OC)c1cccc(Cl)c1)C[C@H]1CCCOC1	Phase 1
VUF10166	serotonin receptor antagonist	HTR3A, HTR3B			Tocris, Selleck	97.1	CN1CCN(CC1)c1nc2ccccc2nc1Cl, CN1CCN(CC1)c1nc2ccccc2nc1Cl	Preclinical
VUF10460	histamine receptor agonist	HRH4			Tocris, Tocris, Tocris	96.93	CN1CCN(CC1)c1cc(nc(N)n1)-c1ccccc1, CN1CCN(CC1)c1cc(nc(N)n1)-c1ccccc1, CN1CCN(CC1)c1cc(nc(N)n1)-c1ccccc1	Preclinical
VUF11207	CC chemokine receptor agonist	ACKR3			Tocris, Tocris	97.54	COc1cc(cc(OC)c1OC)C(=O)N(CC[C@H]1CCCN1C)C\C(C)=C\c1ccccc1F |&1:17|, COc1cc(cc(OC)c1OC)C(=O)N(CC[C@H]1CCCN1C)C\C(C)=C\c1ccccc1F |&1:17|	Preclinical
VU0155069	phospholipase inhibitor	PLD1			Tocris, Tocris, Tocris, Tocris	97.48	C[C@@H](CN1CCC(CC1)n1c2ccc(Cl)cc2[nH]c1=O)NC(=O)c1ccc2ccccc2c1, C[C@@H](CN1CCC(CC1)n1c2ccc(Cl)cc2[nH]c1=O)NC(=O)c1ccc2ccccc2c1, C[C@@H](CN1CCC(CC1)n1c2ccc(Cl)cc2[nH]c1=O)NC(=O)c1ccc2ccccc2c1, C[C@@H](CN1CCC(CC1)n1c2ccc(Cl)cc2[nH]c1=O)NC(=O)c1ccc2ccccc2c1	Preclinical
VU0238429	acetylcholine receptor allosteric modulator	CHRM5			Tocris, Tocris, Tocris, Tocris, Tocris, Tocris	97.9	COc1ccc(CN2C(=O)C(=O)c3cc(OC(F)(F)F)ccc23)cc1, COc1ccc(CN2C(=O)C(=O)c3cc(OC(F)(F)F)ccc23)cc1, COc1ccc(CN2C(=O)C(=O)c3cc(OC(F)(F)F)ccc23)cc1, COc1ccc(CN2C(=O)C(=O)c3cc(OC(F)(F)F)ccc23)cc1, COc1ccc(CN2C(=O)C(=O)c3cc(OC(F)(F)F)ccc23)cc1, COc1ccc(CN2C(=O)C(=O)c3cc(OC(F)(F)F)ccc23)cc1	Preclinical
VU0240551	potassium/chloride cotransporter inhibitor	SLC12A5			MedChemEx	97.16	Cc1csc(NC(=O)CSc2ccc(nn2)-c2ccccc2)n1	Preclinical
VU0357121	glutamate receptor positive allosteric modulator	GRM5			Tocris, Tocris, Tocris, Selleck, Selleck, Selleck, Selleck	99	CCCCOc1ccc(cc1)C(=O)Nc1ccc(F)cc1F, CCCCOc1ccc(cc1)C(=O)Nc1ccc(F)cc1F, CCCCOc1ccc(cc1)C(=O)Nc1ccc(F)cc1F, CCCCOc1ccc(cc1)C(=O)Nc1ccc(F)cc1F, CCCCOc1ccc(cc1)C(=O)Nc1ccc(F)cc1F, CCCCOc1ccc(cc1)C(=O)Nc1ccc(F)cc1F, CCCCOc1ccc(cc1)C(=O)Nc1ccc(F)cc1F	Preclinical
VU0360172	glutamate receptor positive allosteric modulator	GRM5			Tocris, Tocris	94.7	Fc1cccc(c1)C#Cc1ccc(cn1)C(=O)NC1CCC1, Fc1cccc(c1)C#Cc1ccc(cn1)C(=O)NC1CCC1	Preclinical
VU0361737	glutamate receptor positive allosteric modulator	GRM4			Tocris, Tocris, Tocris, Tocris, Selleck	98.82	COc1cc(NC(=O)c2ccccn2)ccc1Cl, COc1cc(NC(=O)c2ccccn2)ccc1Cl, COc1cc(NC(=O)c2ccccn2)ccc1Cl, COc1cc(NC(=O)c2ccccn2)ccc1Cl, COc1cc(NC(=O)c2ccccn2)ccc1Cl	Preclinical
VU0364439	glutamate receptor positive allosteric modulator	GRM4			Tocris, Tocris, Selleck	98.19	Clc1ccccc1NS(=O)(=O)c1ccc(NC(=O)c2ccccn2)cc1Cl, Clc1ccccc1NS(=O)(=O)c1ccc(NC(=O)c2ccccn2)cc1Cl, Clc1ccccc1NS(=O)(=O)c1ccc(NC(=O)c2ccccn2)cc1Cl	Preclinical
VU0364739	phospholipase inhibitor	PLD2			Tocris, Tocris, Tocris	95.98	Fc1cccc(c1)N1CNC(=O)C11CCN(CCNC(=O)c2ccc3ccccc3c2)CC1, Fc1cccc(c1)N1CNC(=O)C11CCN(CCNC(=O)c2ccc3ccccc3c2)CC1, Fc1cccc(c1)N1CNC(=O)C11CCN(CCNC(=O)c2ccc3ccccc3c2)CC1	Preclinical
VU0364770	glutamate receptor positive allosteric modulator	GRM4			Tocris, Tocris, Selleck	96.96	Clc1cccc(NC(=O)c2ccccn2)c1, Clc1cccc(NC(=O)c2ccccn2)c1, Clc1cccc(NC(=O)c2ccccn2)c1	Preclinical
VU0422288	glutamate receptor positive allosteric modulator	GRM3			Tocris, Tocris, Tocris	98.8	Clc1ccc(Oc2ccc(NC(=O)c3ccccn3)cc2Cl)nc1, Clc1ccc(Oc2ccc(NC(=O)c3ccccn3)cc2Cl)nc1, Clc1ccc(Oc2ccc(NC(=O)c3ccccn3)cc2Cl)nc1	Preclinical
VU10010	acetylcholine receptor allosteric modulator	CHRM4			Tocris, Tocris, Tocris, Tocris	96.9	Cc1cc(C)c2c(N)c(sc2n1)C(=O)NCc1ccc(Cl)cc1, Cc1cc(C)c2c(N)c(sc2n1)C(=O)NCc1ccc(Cl)cc1, Cc1cc(C)c2c(N)c(sc2n1)C(=O)NCc1ccc(Cl)cc1, Cc1cc(C)c2c(N)c(sc2n1)C(=O)NCc1ccc(Cl)cc1	Preclinical
VU152100	acetylcholine receptor allosteric modulator	CHRM4			Tocris, Tocris, Tocris	95.97	COc1ccc(CNC(=O)c2sc3nc(C)cc(C)c3c2N)cc1, COc1ccc(CNC(=O)c2sc3nc(C)cc(C)c3c2N)cc1, COc1ccc(CNC(=O)c2sc3nc(C)cc(C)c3c2N)cc1	Preclinical
VU1545	glutamate receptor positive allosteric modulator	GRM5			Tocris, Tocris, Tocris	96.37	[O-][N+](=O)c1ccc(cc1)C(=O)Nc1cc(nn1-c1ccccc1F)-c1ccccc1, [O-][N+](=O)c1ccc(cc1)C(=O)Nc1cc(nn1-c1ccccc1F)-c1ccccc1, [O-][N+](=O)c1ccc(cc1)C(=O)Nc1cc(nn1-c1ccccc1F)-c1ccccc1	Preclinical
VU29	glutamate receptor potentiator	GRM5			Tocris, Tocris, Tocris	98.04	[O-][N+](=O)c1ccc(cc1)C(=O)Nc1cc(nn1-c1ccccc1)-c1ccccc1, [O-][N+](=O)c1ccc(cc1)C(=O)Nc1cc(nn1-c1ccccc1)-c1ccccc1, [O-][N+](=O)c1ccc(cc1)C(=O)Nc1cc(nn1-c1ccccc1)-c1ccccc1	Preclinical
VU591	potassium channel blocker	KCNJ1			Tocris, Tocris, Tocris, Tocris	98.13	[O-][N+](=O)c1ccc2nc(COCc3nc4ccc(cc4[nH]3)[N+]([O-])=O)[nH]c2c1, [O-][N+](=O)c1ccc2nc(COCc3nc4ccc(cc4[nH]3)[N+]([O-])=O)[nH]c2c1, [O-][N+](=O)c1ccc2nc(COCc3nc4ccc(cc4[nH]3)[N+]([O-])=O)[nH]c2c1, [O-][N+](=O)c1ccc2nc(COCc3nc4ccc(cc4[nH]3)[N+]([O-])=O)[nH]c2c1	Preclinical
VX-11e	MAP kinase inhibitor	MAPK1			MedChemEx, MedChemEx, MedChemEx	97.32	Cc1cnc(Nc2ccc(F)cc2Cl)nc1-c1c[nH]c(c1)C(=O)N[C@H](CO)c1cccc(Cl)c1, Cc1cnc(Nc2ccc(F)cc2Cl)nc1-c1c[nH]c(c1)C(=O)N[C@H](CO)c1cccc(Cl)c1, Cc1cnc(Nc2ccc(F)cc2Cl)nc1-c1c[nH]c(c1)C(=O)N[C@H](CO)c1cccc(Cl)c1	Preclinical
VX-222	HCV inhibitor				MedChemEx, Selleck	97.92	C[C@H]1CC[C@@H](CC1)C(=O)N([C@@H]1CC[C@H](O)CC1)c1cc(sc1C(O)=O)C#CC(C)(C)C |r|, C[C@H]1CC[C@@H](CC1)C(=O)N([C@@H]1CC[C@H](O)CC1)c1cc(sc1C(O)=O)C#CC(C)(C)C |r|	Phase 2
VX-702	p38 MAPK inhibitor	IL1B, IL6, MAPK11, MAPK12, MAPK14, TNF			Selleck, Selleck, Selleck, Tocris, Selleck, Selleck	93.86	NC(=O)N(c1ccc(C(N)=O)c(n1)-c1ccc(F)cc1F)c1c(F)cccc1F, NC(=O)N(c1ccc(C(N)=O)c(n1)-c1ccc(F)cc1F)c1c(F)cccc1F, NC(=O)N(c1ccc(C(N)=O)c(n1)-c1ccc(F)cc1F)c1c(F)cccc1F, NC(=O)N(c1ccc(C(N)=O)c(n1)-c1ccc(F)cc1F)c1c(F)cccc1F, NC(=O)N(c1ccc(C(N)=O)c(n1)-c1ccc(F)cc1F)c1c(F)cccc1F, NC(=O)N(c1ccc(C(N)=O)c(n1)-c1ccc(F)cc1F)c1c(F)cccc1F	Phase 2
VX-745	p38 MAPK inhibitor	MAPK11, MAPK12, MAPK14			MedChemEx, MedChemEx, MedChemEx, MedChemEx, Selleck, Selleck	78.69	Fc1ccc(Sc2ccc3c(-c4c(Cl)cccc4Cl)c(=O)ncn3n2)c(F)c1, Fc1ccc(Sc2ccc3c(-c4c(Cl)cccc4Cl)c(=O)ncn3n2)c(F)c1, Fc1ccc(Sc2ccc3c(-c4c(Cl)cccc4Cl)c(=O)ncn3n2)c(F)c1, Fc1ccc(Sc2ccc3c(-c4c(Cl)cccc4Cl)c(=O)ncn3n2)c(F)c1, Fc1ccc(Sc2ccc3c(-c4c(Cl)cccc4Cl)c(=O)ncn3n2)c(F)c1, Fc1ccc(Sc2ccc3c(-c4c(Cl)cccc4Cl)c(=O)ncn3n2)c(F)c1	Phase 2
VX-765	caspase inhibitor	CASP1			Selleck	97.92	CCO[C@@H]1OC(=O)C[C@@H]1NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)c1ccc(N)c(Cl)c1)C(C)(C)C	Phase 2
W-54011	anaphylatoxin chemotactic receptor antagonist	C5AR1			Tocris, MedChemEx	89.3	COc1ccc2CCC[C@@H](C(=O)N(Cc3ccc(cc3)N(C)C)c3ccc(cc3)C(C)C)c2c1 |&1:9|, COc1ccc2CCC[C@@H](C(=O)N(Cc3ccc(cc3)N(C)C)c3ccc(cc3)C(C)C)c2c1 |&1:9|	Preclinical
walrycin-B	transcriptional regulatory protein WalR				MedChemEx, MedChemEx, MedChemEx, MedChemEx	88.74	Cn1nc(nc2c1nc(=O)n(C)c2=O)-c1ccc(cc1)C(F)(F)F, Cn1nc(nc2c1nc(=O)n(C)c2=O)-c1ccc(cc1)C(F)(F)F, Cn1nc(nc2c1nc(=O)n(C)c2=O)-c1ccc(cc1)C(F)(F)F, Cn1nc(nc2c1nc(=O)n(C)c2=O)-c1ccc(cc1)C(F)(F)F	Preclinical
warfarin	vitamin K antagonist	VKORC1	hematology, cardiology	deep vein thrombosis (DVT), pulmonary embolism (PE), atrial fibrillation (AF), myocardial infarction	MedChemEx, MedChemEx	99.3	CC(=O)C[C@@H](c1ccccc1)c1c(O)c2ccccc2oc1=O |&1:4|, CC(=O)C[C@@H](c1ccccc1)c1c(O)c2ccccc2oc1=O |&1:4|	Launched
WAY-100635	serotonin receptor antagonist	HTR1A			MedChemEx, MedChemEx, Selleck	97.88	COc1ccccc1N1CCN(CCN(C(=O)C2CCCCC2)c2ccccn2)CC1, COc1ccccc1N1CCN(CCN(C(=O)C2CCCCC2)c2ccccn2)CC1, COc1ccccc1N1CCN(CCN(C(=O)C2CCCCC2)c2ccccn2)CC1	Phase 1
WAY-161503	serotonin receptor agonist	HTR2C			Tocris, Tocris, Tocris, Tocris	96.6	Clc1cc2NC(=O)[C@H]3CNCCN3c2cc1Cl |&1:7|, Clc1cc2NC(=O)[C@H]3CNCCN3c2cc1Cl |&1:7|, Clc1cc2NC(=O)[C@H]3CNCCN3c2cc1Cl |&1:7|, Clc1cc2NC(=O)[C@H]3CNCCN3c2cc1Cl |&1:7|	Preclinical
WAY-170523	metalloproteinase inhibitor	MMP13			Tocris, Tocris, Tocris, Tocris, Tocris	97.03	Cc1cc(C)c(N(Cc2ccccc2)S(=O)(=O)c2ccc(OCCNC(=O)c3cc4ccccc4o3)cc2)c(c1)C(=O)NO, Cc1cc(C)c(N(Cc2ccccc2)S(=O)(=O)c2ccc(OCCNC(=O)c3cc4ccccc4o3)cc2)c(c1)C(=O)NO, Cc1cc(C)c(N(Cc2ccccc2)S(=O)(=O)c2ccc(OCCNC(=O)c3cc4ccccc4o3)cc2)c(c1)C(=O)NO, Cc1cc(C)c(N(Cc2ccccc2)S(=O)(=O)c2ccc(OCCNC(=O)c3cc4ccccc4o3)cc2)c(c1)C(=O)NO, Cc1cc(C)c(N(Cc2ccccc2)S(=O)(=O)c2ccc(OCCNC(=O)c3cc4ccccc4o3)cc2)c(c1)C(=O)NO	Preclinical
WAY-200070	estrogen receptor agonist	ERBB2, ERBB3, ERBB4, ESR2			Tocris, Tocris, Tocris	96.79	Oc1ccc(cc1)-c1nc2cc(O)cc(Br)c2o1, Oc1ccc(cc1)-c1nc2cc(O)cc(Br)c2o1, Oc1ccc(cc1)-c1nc2cc(O)cc(Br)c2o1	Preclinical
WAY-207024	gonadotropin releasing factor hormone receptor antagonist	GNRHR, HRH2, TACR2			Tocris, Tocris, Tocris, Tocris, Tocris	98.9	CC(C)(C)c1ccc(cc1)-c1nc2c(cccc2[nH]1)N1CCN(Cc2ccc3nccnc3c2)CC1, CC(C)(C)c1ccc(cc1)-c1nc2c(cccc2[nH]1)N1CCN(Cc2ccc3nccnc3c2)CC1, CC(C)(C)c1ccc(cc1)-c1nc2c(cccc2[nH]1)N1CCN(Cc2ccc3nccnc3c2)CC1, CC(C)(C)c1ccc(cc1)-c1nc2c(cccc2[nH]1)N1CCN(Cc2ccc3nccnc3c2)CC1, CC(C)(C)c1ccc(cc1)-c1nc2c(cccc2[nH]1)N1CCN(Cc2ccc3nccnc3c2)CC1	Preclinical
WAY-208466	serotonin receptor agonist	DRD2, HTR2A, HTR2C, HTR6, HTR7			Tocris, Tocris, Tocris	97.67	CN(C)CCn1cc(c2cccnc12)S(=O)(=O)c1cccc(F)c1, CN(C)CCn1cc(c2cccnc12)S(=O)(=O)c1cccc(F)c1, CN(C)CCn1cc(c2cccnc12)S(=O)(=O)c1cccc(F)c1	Preclinical
WAY-213613	glutamate inhibitor	SLC1A2			Tocris, Tocris, Tocris, Tocris	97.19	N[C@@H](CC(=O)Nc1ccc(Oc2cc(F)c(F)cc2Br)cc1)C(O)=O, N[C@@H](CC(=O)Nc1ccc(Oc2cc(F)c(F)cc2Br)cc1)C(O)=O, N[C@@H](CC(=O)Nc1ccc(Oc2cc(F)c(F)cc2Br)cc1)C(O)=O, N[C@@H](CC(=O)Nc1ccc(Oc2cc(F)c(F)cc2Br)cc1)C(O)=O	Preclinical
WAY-255348	progesterone receptor antagonist				Sigma	92.87	Cn1c(ccc1-c1cc2c(NC(=O)C2(C)C)c(F)c1)C#N	Preclinical
WAY-316606	secreted frizzled related protein inhibitor	SFRP1			MedChemEx, MedChemEx, Tocris	94.21	FC(F)(F)c1ccc(cc1S(=O)(=O)NC1CCNCC1)S(=O)(=O)c1ccccc1, FC(F)(F)c1ccc(cc1S(=O)(=O)NC1CCNCC1)S(=O)(=O)c1ccccc1, FC(F)(F)c1ccc(cc1S(=O)(=O)NC1CCNCC1)S(=O)(=O)c1ccccc1	Preclinical
WAY-362450	FXR agonist	NR1H4			MedChemEx, Selleck	94.08	CC(C)OC(=O)C1=CN(CC(C)(C)c2c1[nH]c1ccccc21)C(=O)c1ccc(F)c(F)c1 |t:6|, CC(C)OC(=O)C1=CN(CC(C)(C)c2c1[nH]c1ccccc21)C(=O)c1ccc(F)c(F)c1 |t:6|	Phase 1
WAY-600	mTOR inhibitor	MTOR			Selleck, Selleck, MedChemEx	93.96	C(N1CCC(CC1)n1ncc2c(nc(nc12)-c1ccc2[nH]ccc2c1)N1CCOCC1)c1cccnc1, C(N1CCC(CC1)n1ncc2c(nc(nc12)-c1ccc2[nH]ccc2c1)N1CCOCC1)c1cccnc1, C(N1CCC(CC1)n1ncc2c(nc(nc12)-c1ccc2[nH]ccc2c1)N1CCOCC1)c1cccnc1	Preclinical
WAY-629	serotonin receptor agonist	HTR2C			Tocris, Tocris	81.9	C1CCc2c(C1)n1CCNCc3cccc2c13, C1CCc2c(C1)n1CCNCc3cccc2c13	Preclinical
WB-4101	adrenergic receptor antagonist	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, HTR1A			Tocris, Tocris, Tocris	96.8	COc1cccc(OC)c1OCCNC[C@H]1COc2ccccc2O1 |&1:15|, COc1cccc(OC)c1OCCNC[C@H]1COc2ccccc2O1 |&1:15|, COc1cccc(OC)c1OCCNC[C@H]1COc2ccccc2O1 |&1:15|	Preclinical
WDR5-0103	histone lysine methyltransferase inhibitor	WDR5			Tocris, Tocris, Vitas-M	99.17	COC(=O)c1ccc(N2CCN(C)CC2)c(NC(=O)c2cccc(OC)c2)c1, COC(=O)c1ccc(N2CCN(C)CC2)c(NC(=O)c2cccc(OC)c2)c1, COC(=O)c1ccc(N2CCN(C)CC2)c(NC(=O)c2cccc(OC)c2)c1	Preclinical
WEHI-345-analog	SRC inhibitor				MedChemEx, MedChemEx	95.92	Cc1ccc(cc1)-c1nn(c2ncnc(N)c12)C(C)(C)CNC(=O)c1ncccc1C, Cc1ccc(cc1)-c1nn(c2ncnc(N)c12)C(C)(C)CNC(=O)c1ncccc1C	Preclinical
WH-4-023	SRC inhibitor	LCK, SRC			Tocris, Tocris, Tocris	97.53	COc1ccc(N(C(=O)Oc2c(C)cccc2C)c2ccnc(Nc3ccc(cc3)N3CCN(C)CC3)n2)c(OC)c1, COc1ccc(N(C(=O)Oc2c(C)cccc2C)c2ccnc(Nc3ccc(cc3)N3CCN(C)CC3)n2)c(OC)c1, COc1ccc(N(C(=O)Oc2c(C)cccc2C)c2ccnc(Nc3ccc(cc3)N3CCN(C)CC3)n2)c(OC)c1	Preclinical
WHI-P154	JAK inhibitor	EGFR, JAK1, JAK2, JAK3			Tocris, Selleck, Selleck, Selleck, Tocris	90.22	COc1cc2ncnc(Nc3ccc(O)c(Br)c3)c2cc1OC, COc1cc2ncnc(Nc3ccc(O)c(Br)c3)c2cc1OC, COc1cc2ncnc(Nc3ccc(O)c(Br)c3)c2cc1OC, COc1cc2ncnc(Nc3ccc(O)c(Br)c3)c2cc1OC, COc1cc2ncnc(Nc3ccc(O)c(Br)c3)c2cc1OC	Preclinical
WIKI4	tankyrase inhibitor, WNT pathway inhibitor	TNKS2			MedChemEx	98.16	COc1ccc(cc1)-n1c(SCCCN2C(=O)c3cccc4cccc(C2=O)c34)nnc1-c1ccncc1	Preclinical
WIN-18446	aldehyde dehydrogenase inhibitor	ALDH1A2			DuPont	97.79	ClC(Cl)C(=O)NCCCCCCCCNC(=O)C(Cl)Cl	Preclinical
WIN-64338	bradykinin receptor antagonist	BDKRB2			Tocris, Tocris, Tocris, Tocris, Tocris	95.81	CCCC[P+](CCCC)(CCCC)Cc1ccc(NC(=O)[C@H](Cc2ccc3ccccc3c2)N\C(NC2CCCCC2)=N\C2CCCCC2)cc1, CCCC[P+](CCCC)(CCCC)Cc1ccc(NC(=O)[C@H](Cc2ccc3ccccc3c2)N\C(NC2CCCCC2)=N\C2CCCCC2)cc1, CCCC[P+](CCCC)(CCCC)Cc1ccc(NC(=O)[C@H](Cc2ccc3ccccc3c2)N\C(NC2CCCCC2)=N\C2CCCCC2)cc1, CCCC[P+](CCCC)(CCCC)Cc1ccc(NC(=O)[C@H](Cc2ccc3ccccc3c2)N\C(NC2CCCCC2)=N\C2CCCCC2)cc1, CCCC[P+](CCCC)(CCCC)Cc1ccc(NC(=O)[C@H](Cc2ccc3ccccc3c2)N\C(NC2CCCCC2)=N\C2CCCCC2)cc1	Preclinical
wiskostatin	actin related protein inhibitor, neural Wiskott-Aldrich syndrome protein inhibitor	WASL			Tocris, Tocris, Tocris	97.05	CN(C)C[C@@H](O)Cn1c2ccc(Br)cc2c2cc(Br)ccc12 |&1:4,r|, CN(C)C[C@@H](O)Cn1c2ccc(Br)cc2c2cc(Br)ccc12 |&1:4,r|, CN(C)C[C@@H](O)Cn1c2ccc(Br)cc2c2cc(Br)ccc12 |&1:4,r|	Preclinical
wnt-c59	porcupine inhibitor	PORCN			Tocris, Tocris, Tocris, Tocris, Tocris, Selleck, Selleck, Selleck	98.11	Cc1cc(ccn1)-c1ccc(CC(=O)Nc2ccc(cc2)-c2cccnc2)cc1, Cc1cc(ccn1)-c1ccc(CC(=O)Nc2ccc(cc2)-c2cccnc2)cc1, Cc1cc(ccn1)-c1ccc(CC(=O)Nc2ccc(cc2)-c2cccnc2)cc1, Cc1cc(ccn1)-c1ccc(CC(=O)Nc2ccc(cc2)-c2cccnc2)cc1, Cc1cc(ccn1)-c1ccc(CC(=O)Nc2ccc(cc2)-c2cccnc2)cc1, Cc1cc(ccn1)-c1ccc(CC(=O)Nc2ccc(cc2)-c2cccnc2)cc1, Cc1cc(ccn1)-c1ccc(CC(=O)Nc2ccc(cc2)-c2cccnc2)cc1, Cc1cc(ccn1)-c1ccc(CC(=O)Nc2ccc(cc2)-c2cccnc2)cc1	Preclinical
wortmannin	PI3K inhibitor	PI4KA, PI4KB, PIK3CA, PIK3CD, PIK3CG, PIK3R1, PLK1, PRKDC			MedChemEx, Selleck, Selleck	93.41	COC[C@H]1OC(=O)c2coc3c2[C@@]1(C)C1=C([C@@H]2CCC(=O)[C@@]2(C)C[C@H]1OC(C)=O)C3=O |t:16|, COC[C@H]1OC(=O)c2coc3c2[C@@]1(C)C1=C([C@@H]2CCC(=O)[C@@]2(C)C[C@H]1OC(C)=O)C3=O |t:16|, COC[C@H]1OC(=O)c2coc3c2[C@@]1(C)C1=C([C@@H]2CCC(=O)[C@@]2(C)C[C@H]1OC(C)=O)C3=O |t:16|	Preclinical
WP1066	STAT inhibitor	STAT3			Selleck, Selleck, Selleck, Selleck, MedChemEx	90.12	C[C@H](NC(=O)C(=C\c1cccc(Br)n1)\C#N)c1ccccc1, C[C@H](NC(=O)C(=C\c1cccc(Br)n1)\C#N)c1ccccc1, C[C@H](NC(=O)C(=C\c1cccc(Br)n1)\C#N)c1ccccc1, C[C@H](NC(=O)C(=C\c1cccc(Br)n1)\C#N)c1ccccc1, C[C@H](NC(=O)C(=C\c1cccc(Br)n1)\C#N)c1ccccc1	Phase 1
WP1130	deubiquitinase inhibitor	JAK2, UCHL5, USP14, USP9X			Selleck, Selleck, Selleck, Selleck, Selleck, Selleck, Selleck	88.88	CCC[C@H](NC(=O)C(=C\c1cccc(Br)n1)\C#N)c1ccccc1, CCC[C@H](NC(=O)C(=C\c1cccc(Br)n1)\C#N)c1ccccc1, CCC[C@H](NC(=O)C(=C\c1cccc(Br)n1)\C#N)c1ccccc1, CCC[C@H](NC(=O)C(=C\c1cccc(Br)n1)\C#N)c1ccccc1, CCC[C@H](NC(=O)C(=C\c1cccc(Br)n1)\C#N)c1ccccc1, CCC[C@H](NC(=O)C(=C\c1cccc(Br)n1)\C#N)c1ccccc1, CCC[C@H](NC(=O)C(=C\c1cccc(Br)n1)\C#N)c1ccccc1	Preclinical
WP921					Enamine	93.05	OC(=O)Cn1nnnc1-c1ccsc1	Preclinical
WR99210	dihydrofolate reductase inhibitor	TYMS	infectious disease	malaria	Sigma	98.92	CC1(C)N=C(N)N=C(N)N1OCCCOc1cc(Cl)c(Cl)cc1Cl |t:3,6|	Preclinical
WWL-113	carboxylesterase inhibitor	CES3			Tocris, Tocris	98.37	CCOC(=O)c1ccc(cc1)-c1ccc(OC(=O)N(C)Cc2cccc(c2)-c2ccncc2)cc1, CCOC(=O)c1ccc(cc1)-c1ccc(OC(=O)N(C)Cc2cccc(c2)-c2ccncc2)cc1	Preclinical
WWL-123	monoacylglycerol lipase inhibitor	ABHD6			Tocris, Tocris, Tocris, Tocris	96.84	CN(Cc1cccc(c1)-c1ccccc1)C(=O)Oc1ccc(cc1)-c1ccc(cc1)C(N)=O, CN(Cc1cccc(c1)-c1ccccc1)C(=O)Oc1ccc(cc1)-c1ccc(cc1)C(N)=O, CN(Cc1cccc(c1)-c1ccccc1)C(=O)Oc1ccc(cc1)-c1ccc(cc1)C(N)=O, CN(Cc1cccc(c1)-c1ccccc1)C(=O)Oc1ccc(cc1)-c1ccc(cc1)C(N)=O	Preclinical
WY-16922	histamine release inhibitor				Sigma	96.26	CCOC(=O)C(=O)Nc1cccc(OC)c1C(N)=O	Phase 1
WYE-125132	mTOR inhibitor	MTOR			MedChemEx	96.04	CNC(=O)Nc1ccc(cc1)-c1nc(N2C[C@@H]3CC[C@H](C2)O3)c2cnn(C3CCC4(CC3)OCCO4)c2n1 |&1:16,19|	Preclinical
WYE-354	mTOR inhibitor	MTOR			MedChemEx, Selleck	95.6	COC(=O)Nc1ccc(cc1)-c1nc(N2CCOCC2)c2cnn(C3CCN(CC3)C(=O)OC)c2n1, COC(=O)Nc1ccc(cc1)-c1nc(N2CCOCC2)c2cnn(C3CCN(CC3)C(=O)OC)c2n1	Preclinical
WYE-687	mTOR inhibitor	MTOR			Tocris, Tocris	94.1	COC(=O)Nc1ccc(cc1)-c1nc(N2CCOCC2)c2cnn(C3CCN(Cc4cccnc4)CC3)c2n1, COC(=O)Nc1ccc(cc1)-c1nc(N2CCOCC2)c2cnn(C3CCN(Cc4cccnc4)CC3)c2n1	Preclinical
WZ-3146	EGFR inhibitor	EGFR			Selleck, Selleck	95.83	CN1CCN(CC1)c1ccc(Nc2ncc(Cl)c(Oc3cccc(NC(=O)C=C)c3)n2)cc1, CN1CCN(CC1)c1ccc(Nc2ncc(Cl)c(Oc3cccc(NC(=O)C=C)c3)n2)cc1	Preclinical
WZ-4002	EGFR inhibitor	EGFR, ERBB2			Selleck, Selleck, Selleck	92.97	COc1cc(ccc1Nc1ncc(Cl)c(Oc2cccc(NC(=O)C=C)c2)n1)N1CCN(C)CC1, COc1cc(ccc1Nc1ncc(Cl)c(Oc2cccc(NC(=O)C=C)c2)n1)N1CCN(C)CC1, COc1cc(ccc1Nc1ncc(Cl)c(Oc2cccc(NC(=O)C=C)c2)n1)N1CCN(C)CC1	Preclinical
WZ4003	AMPK inhibitor	NUAK1, NUAK2			Selleck, Selleck, Selleck, Selleck	95.12	CCC(=O)Nc1cccc(Oc2nc(Nc3ccc(cc3OC)N3CCN(C)CC3)ncc2Cl)c1, CCC(=O)Nc1cccc(Oc2nc(Nc3ccc(cc3OC)N3CCN(C)CC3)ncc2Cl)c1, CCC(=O)Nc1cccc(Oc2nc(Nc3ccc(cc3OC)N3CCN(C)CC3)ncc2Cl)c1, CCC(=O)Nc1cccc(Oc2nc(Nc3ccc(cc3OC)N3CCN(C)CC3)ncc2Cl)c1	Preclinical
WZ8040	EGFR inhibitor	EGFR			Selleck, Selleck, Selleck	94.06	CN1CCN(CC1)c1ccc(Nc2ncc(Cl)c(Sc3cccc(NC(=O)C=C)c3)n2)cc1, CN1CCN(CC1)c1ccc(Nc2ncc(Cl)c(Sc3cccc(NC(=O)C=C)c3)n2)cc1, CN1CCN(CC1)c1ccc(Nc2ncc(Cl)c(Sc3cccc(NC(=O)C=C)c3)n2)cc1	Preclinical
WZ811	CC chemokine receptor antagonist	CXCR4			Tocris, Selleck, Selleck, Selleck, Selleck	95.7	C(Nc1ccccn1)c1ccc(CNc2ccccn2)cc1, C(Nc1ccccn1)c1ccc(CNc2ccccn2)cc1, C(Nc1ccccn1)c1ccc(CNc2ccccn2)cc1, C(Nc1ccccn1)c1ccc(CNc2ccccn2)cc1, C(Nc1ccccn1)c1ccc(CNc2ccccn2)cc1	Preclinical
xaliproden	serotonin receptor agonist	HTR1A			Tocris, Tocris, Tocris, Tocris	99.44	FC(F)(F)c1cccc(c1)C1=CCN(CCc2ccc3ccccc3c2)CC1 |t:11|, FC(F)(F)c1cccc(c1)C1=CCN(CCc2ccc3ccccc3c2)CC1 |t:11|, FC(F)(F)c1cccc(c1)C1=CCN(CCc2ccc3ccccc3c2)CC1 |t:11|, FC(F)(F)c1cccc(c1)C1=CCN(CCc2ccc3ccccc3c2)CC1 |t:11|	Phase 3
xamoterol	adrenergic receptor agonist	ADRB1			Tocris, Tocris, Tocris, Tocris	87.58	OC(CNCCNC(=O)N1CCOCC1)COc1ccc(O)cc1, OC(CNCCNC(=O)N1CCOCC1)COc1ccc(O)cc1, OC(CNCCNC(=O)N1CCOCC1)COc1ccc(O)cc1, OC(CNCCNC(=O)N1CCOCC1)COc1ccc(O)cc1	Phase 3
xanomeline	acetylcholine receptor agonist	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR6, HTR7			Tocris, MedChemEx	97.8	CCCCCCOc1nsnc1C1=CCCN(C)C1 |t:13|, CCCCCCOc1nsnc1C1=CCCN(C)C1 |t:13|	Phase 3
xanthone	antimalarial agent				Selleck, Selleck	97.2	O=c1c2ccccc2oc2ccccc12, O=c1c2ccccc2oc2ccccc12	Preclinical
XAV-939	tankyrase inhibitor	TNKS, TNKS2			Tocris, Tocris, Tocris, Selleck	96.8	FC(F)(F)c1ccc(cc1)-c1nc(=O)c2CSCCc2[nH]1, FC(F)(F)c1ccc(cc1)-c1nc(=O)c2CSCCc2[nH]1, FC(F)(F)c1ccc(cc1)-c1nc(=O)c2CSCCc2[nH]1, FC(F)(F)c1ccc(cc1)-c1nc(=O)c2CSCCc2[nH]1	Preclinical
XBD173	benzodiazepine receptor ligand	TSPO			Tocris, Tocris, MedChemEx	99.75	CCN(Cc1ccccc1)C(=O)Cn1c2nc(ncc2n(C)c1=O)-c1ccccc1, CCN(Cc1ccccc1)C(=O)Cn1c2nc(ncc2n(C)c1=O)-c1ccccc1, CCN(Cc1ccccc1)C(=O)Cn1c2nc(ncc2n(C)c1=O)-c1ccccc1	Phase 2
XD-14	bromodomain inhibitor	BRD2, BRD3, BRD4, BRDT			Tocris, Tocris	87.21	CCN(CC)S(=O)(=O)c1ccc(O)c(NC(=O)c2[nH]c(C)c(C(C)=O)c2CC)c1, CCN(CC)S(=O)(=O)c1ccc(O)c(NC(=O)c2[nH]c(C)c(C(C)=O)c2CC)c1	Preclinical
XE-991	potassium channel blocker	KCNQ1, KCNQ2, KCNQ3, KCNQ4, KCNQ5			Tocris, Tocris	98.74	O=C1c2ccccc2C(Cc2ccncc2)(Cc2ccncc2)c2ccccc12, O=C1c2ccccc2C(Cc2ccncc2)(Cc2ccncc2)c2ccccc12	Preclinical
xenalipin					Enamine	98.55	OC(=O)c1ccccc1-c1ccc(cc1)C(F)(F)F	Phase 2
xibenolol	adrenergic receptor antagonist				PrincetonBio	98.27	Cc1cccc(OC[C@@H](O)CNC(C)(C)C)c1C |&1:8,r|	Phase 3
xilobam					Enamine	88.42	CN1CCC\C1=N\C(=O)Nc1c(C)cccc1C	Phase 1
xipamide	carbonic anhydrase inhibitor	SLC12A3	cardiology	edema, hypertension	OxChem, OxChem	99.61	Cc1cccc(C)c1NC(=O)c1cc(c(Cl)cc1O)S(N)(=O)=O, Cc1cccc(C)c1NC(=O)c1cc(c(Cl)cc1O)S(N)(=O)=O	Launched
XL019	JAK inhibitor	JAK1, JAK2, JAK3			MedChemEx, MedChemEx, Selleck, Selleck, Selleck	85.4	O=C(Nc1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1)[C@@H]1CCCN1, O=C(Nc1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1)[C@@H]1CCCN1, O=C(Nc1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1)[C@@H]1CCCN1, O=C(Nc1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1)[C@@H]1CCCN1, O=C(Nc1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1)[C@@H]1CCCN1	Phase 1
XL041	LXR agonist				MedChemEx	98.23	CC(C)(O)c1cn(c(n1)C(C)(C)c1c(Cl)cccc1Cl)-c1ccc(cc1F)-c1cc(F)c(CO)c(c1)S(C)(=O)=O	Preclinical
XL147	PI3K inhibitor	PIK3CA, PIK3CD, PIK3CG			Selleck, MedChemEx	96.66	Cc1ccc(cc1)S(=O)(=O)Nc1nc2ccccc2nc1Nc1ccc2nsnc2c1, Cc1ccc(cc1)S(=O)(=O)Nc1nc2ccccc2nc1Nc1ccc2nsnc2c1	Phase 2
XL228	Abl kinase inhibitor, insulin growth factor receptor inhibitor, SRC inhibitor	IGF1R, SRC			MedChemEx, MedChemEx, MedChemEx, MedChemEx	96.72	CC(C)c1cc(CNc2nc(Nc3cc(n[nH]3)C3CC3)cc(n2)N2CCN(C)CC2)on1, CC(C)c1cc(CNc2nc(Nc3cc(n[nH]3)C3CC3)cc(n2)N2CCN(C)CC2)on1, CC(C)c1cc(CNc2nc(Nc3cc(n[nH]3)C3CC3)cc(n2)N2CCN(C)CC2)on1, CC(C)c1cc(CNc2nc(Nc3cc(n[nH]3)C3CC3)cc(n2)N2CCN(C)CC2)on1	Phase 1
XL388	mTOR inhibitor	MTOR			Tocris, Selleck	97.77	Cc1c(F)c(ccc1C(=O)N1CCOc2ccc(cc2C1)-c1ccc(N)nc1)S(C)(=O)=O, Cc1c(F)c(ccc1C(=O)N1CCOc2ccc(cc2C1)-c1ccc(N)nc1)S(C)(=O)=O	Preclinical
XL647	EGFR inhibitor, VEGFR inhibitor	EGFR, EPHB4, ERBB2, FLT4, KDR			MedChemEx, MedChemEx, MedChemEx, MedChemEx	95.23	COc1cc2c(Nc3ccc(Cl)c(Cl)c3F)ncnc2cc1OC[C@H]1C[C@H]2CN(C)C[C@H]2C1, COc1cc2c(Nc3ccc(Cl)c(Cl)c3F)ncnc2cc1OC[C@H]1C[C@H]2CN(C)C[C@H]2C1, COc1cc2c(Nc3ccc(Cl)c(Cl)c3F)ncnc2cc1OC[C@H]1C[C@H]2CN(C)C[C@H]2C1, COc1cc2c(Nc3ccc(Cl)c(Cl)c3F)ncnc2cc1OC[C@H]1C[C@H]2CN(C)C[C@H]2C1	Phase 3
XL888	HSP inhibitor				MedChemEx	97.08	[H][C@]1(C[C@@H]2CC[C@H](C1)N2c1ccc(cn1)C(=O)C1CC1)NC(=O)c1cc(N[C@H](C)CC)c(cc1C)C(N)=O |TLB:9:8:4.5:1.2.7|	Phase 1
XMD17-109	MAP kinase inhibitor	MAPK7			Tocris, Tocris, MedChemEx, MedChemEx, MedChemEx	98.26	CCOc1cc(ccc1Nc1ncc2N(C)C(=O)c3ccccc3N(C3CCCC3)c2n1)C(=O)N1CCC(CC1)N1CCN(C)CC1, CCOc1cc(ccc1Nc1ncc2N(C)C(=O)c3ccccc3N(C3CCCC3)c2n1)C(=O)N1CCC(CC1)N1CCN(C)CC1, CCOc1cc(ccc1Nc1ncc2N(C)C(=O)c3ccccc3N(C3CCCC3)c2n1)C(=O)N1CCC(CC1)N1CCN(C)CC1, CCOc1cc(ccc1Nc1ncc2N(C)C(=O)c3ccccc3N(C3CCCC3)c2n1)C(=O)N1CCC(CC1)N1CCN(C)CC1, CCOc1cc(ccc1Nc1ncc2N(C)C(=O)c3ccccc3N(C3CCCC3)c2n1)C(=O)N1CCC(CC1)N1CCN(C)CC1	Preclinical
XMD8-92	MAP kinase inhibitor	DCLK2, MAPK7, PLK4, TNK1			MedChemEx, MedChemEx, Tocris	88.71	CCOc1cc(ccc1Nc1ncc2N(C)C(=O)c3ccccc3N(C)c2n1)N1CCC(O)CC1, CCOc1cc(ccc1Nc1ncc2N(C)C(=O)c3ccccc3N(C)c2n1)N1CCC(O)CC1, CCOc1cc(ccc1Nc1ncc2N(C)C(=O)c3ccccc3N(C)c2n1)N1CCC(O)CC1	Preclinical
xylazine	adrenergic receptor agonist	ADRA2A, ADRA2B, ADRA2C	neurology/psychiatry	anesthetic	MedChemEx, MicroSource, Selleck	99.59	Cc1cccc(C)c1NC1=NCCCS1 |t:10|, Cc1cccc(C)c1NC1=NCCCS1 |t:10|, Cc1cccc(C)c1NC1=NCCCS1 |t:10|	Launched
xylometazoline	adrenergic receptor agonist	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C	otolaryngology, allergy	nasal congestion, allergic rhinitis	MedChemEx, MicroSource, Selleck	98.38	Cc1cc(cc(C)c1CC1=NCCN1)C(C)(C)C |t:10|, Cc1cc(cc(C)c1CC1=NCCN1)C(C)(C)C |t:10|, Cc1cc(cc(C)c1CC1=NCCN1)C(C)(C)C |t:10|	Launched
xylose					Selleck, Selleck	100	OC[C@@H](O)[C@H](O)[C@@H](O)C=O, OC[C@@H](O)[C@H](O)[C@@H](O)C=O	Launched
Y-11	focal adhesion kinase inhibitor	PTK2			Tocris, Tocris	100	OCC[N+]12CN3CN(CN(C3)C1)C2, OCC[N+]12CN3CN(CN(C3)C1)C2	Preclinical
Y-134	estrogen receptor antagonist	ESR1, ESR2			Tocris, Tocris, Tocris, Tocris, Tocris	93.94	CC(C)N1CCN(CC1)c1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1, CC(C)N1CCN(CC1)c1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1, CC(C)N1CCN(CC1)c1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1, CC(C)N1CCN(CC1)c1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1, CC(C)N1CCN(CC1)c1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1	Preclinical
Y-26763	potassium channel activator	KCNJ8			Tocris, Tocris, Tocris	96.19	CC(=O)N(O)[C@H]1[C@H](O)C(C)(C)Oc2ccc(cc12)C#N, CC(=O)N(O)[C@H]1[C@H](O)C(C)(C)Oc2ccc(cc12)C#N, CC(=O)N(O)[C@H]1[C@H](O)C(C)(C)Oc2ccc(cc12)C#N	Phase 1
Y-27152	potassium channel activator	KCNJ8			Tocris, Tocris	99.08	CC(=O)N(OCc1ccccc1)[C@H]1[C@H](O)C(C)(C)Oc2ccc(cc12)C#N, CC(=O)N(OCc1ccccc1)[C@H]1[C@H](O)C(C)(C)Oc2ccc(cc12)C#N	Phase 1
Y-27632	rho associated kinase inhibitor	PKIA, PKN2, PRKACA, PRKCE, ROCK1, ROCK2			Selleck, Selleck, Selleck, Tocris, Selleck	99.62	C[C@@H](N)[C@H]1CC[C@@H](CC1)C(=O)Nc1ccncc1, C[C@@H](N)[C@H]1CC[C@@H](CC1)C(=O)Nc1ccncc1, C[C@@H](N)[C@H]1CC[C@@H](CC1)C(=O)Nc1ccncc1, C[C@@H](N)[C@H]1CC[C@@H](CC1)C(=O)Nc1ccncc1, C[C@@H](N)[C@H]1CC[C@@H](CC1)C(=O)Nc1ccncc1	Preclinical
Y-29794	prolyl endopeptidase inhibitor	PREP			Tocris, Tocris	89.89	CC(C)c1ccc(C(=O)c2cccs2)c(SCCCCCCCCN(C)C)n1, CC(C)c1ccc(C(=O)c2cccs2)c(SCCCCCCCCN(C)C)n1	Preclinical
Y-320	interleukin inhibitor	IL17A			Selleck, MedChemEx	96.38	Cc1c(cnn1-c1ccc(Cl)cc1)C(=O)Nc1ccc(N2CCC(CC2)N2CCOCC2)c(c1)C#N, Cc1c(cnn1-c1ccc(Cl)cc1)C(=O)Nc1ccc(N2CCC(CC2)N2CCOCC2)c(c1)C#N	Preclinical
Y-39983	rho associated kinase inhibitor	ROCK1, ROCK2			MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx	97.51	C[C@@H](N)c1ccc(cc1)C(=O)Nc1ccnc2[nH]ccc12, C[C@@H](N)c1ccc(cc1)C(=O)Nc1ccnc2[nH]ccc12, C[C@@H](N)c1ccc(cc1)C(=O)Nc1ccnc2[nH]ccc12, C[C@@H](N)c1ccc(cc1)C(=O)Nc1ccnc2[nH]ccc12, C[C@@H](N)c1ccc(cc1)C(=O)Nc1ccnc2[nH]ccc12, C[C@@H](N)c1ccc(cc1)C(=O)Nc1ccnc2[nH]ccc12, C[C@@H](N)c1ccc(cc1)C(=O)Nc1ccnc2[nH]ccc12	Phase 2
YC-1	guanylyl cyclase activator	GUCY1A2, GUCY1A3, GUCY1B3, HIF1A			Tocris, Tocris	95.49	OCc1ccc(o1)-c1nn(Cc2ccccc2)c2ccccc12, OCc1ccc(o1)-c1nn(Cc2ccccc2)c2ccccc12	Preclinical
YIL-781	ghrelin receptor antagonist	GHSR			Tocris, Tocris	95.61	CC(C)N1CCC[C@H](Cn2c(C)nc3ccc(Oc4ccc(F)cc4)cc3c2=O)C1, CC(C)N1CCC[C@H](Cn2c(C)nc3ccc(Oc4ccc(F)cc4)cc3c2=O)C1	Preclinical
YK-4-279	apoptosis inhibitor	EWSR1, FLI1			Tocris, MedChemEx	98.2	COc1ccc(cc1)C(=O)C[C@@]1(O)C(=O)Nc2c1c(Cl)ccc2Cl |&1:11,r|, COc1ccc(cc1)C(=O)C[C@@]1(O)C(=O)Nc2c1c(Cl)ccc2Cl |&1:11,r|	Preclinical
YL0919	selective serotonin reuptake inhibitor (SSRI)				MedChemEx	96.45	OC1(Cn2ccccc2=O)CCN(Cc2ccccc2)CC1	Preclinical
YM-022	CCK receptor antagonist	CCKBR			Sigma	99.62	Cc1cccc(NC(=O)N[C@@H]2N=C(c3ccccc3)c3ccccc3N(CC(=O)c3ccccc3C)C2=O)c1 |t:11|	Phase 2
YM-155	survivin inhibitor	BIRC5			MedChemEx, MedChemEx, Selleck, Selleck, MedChemEx	93.58	COCCn1c(C)[n+](Cc2cnccn2)c2c1C(=O)c1ccccc1C2=O, COCCn1c(C)[n+](Cc2cnccn2)c2c1C(=O)c1ccccc1C2=O, COCCn1c(C)[n+](Cc2cnccn2)c2c1C(=O)c1ccccc1C2=O, COCCn1c(C)[n+](Cc2cnccn2)c2c1C(=O)c1ccccc1C2=O, COCCn1c(C)[n+](Cc2cnccn2)c2c1C(=O)c1ccccc1C2=O	Phase 2
YM-201636	PI3K inhibitor				Selleck, Selleck, Selleck	95.9	Nc1ccc(cn1)C(=O)Nc1cccc(c1)-c1nc(N2CCOCC2)c2oc3ncccc3c2n1, Nc1ccc(cn1)C(=O)Nc1cccc(c1)-c1nc(N2CCOCC2)c2oc3ncccc3c2n1, Nc1ccc(cn1)C(=O)Nc1cccc(c1)-c1nc(N2CCOCC2)c2oc3ncccc3c2n1	Preclinical
YM-244769	sodium/calcium exchange inhibitor				Tocris, Tocris	94.4	Nc1cccc(CNC(=O)c2ccc(Oc3ccc(OCc4cccc(F)c4)cc3)nc2)c1, Nc1cccc(CNC(=O)c2ccc(Oc3ccc(OCc4cccc(F)c4)cc3)nc2)c1	Preclinical
YM-298198	glutamate receptor antagonist	GRM1			Tocris, Tocris, Tocris	97.2	CN(C1CCCCC1)C(=O)c1sc2nc3ccc(N)cc3n2c1C, CN(C1CCCCC1)C(=O)c1sc2nc3ccc(N)cc3n2c1C, CN(C1CCCCC1)C(=O)c1sc2nc3ccc(N)cc3n2c1C	Preclinical
YM-298198-desmethyl	glutamate receptor antagonist	GRM1			Tocris, Tocris	87.86	Cc1c(sc2nc3ccc(N)cc3n12)C(=O)NC1CCCCC1, Cc1c(sc2nc3ccc(N)cc3n12)C(=O)NC1CCCCC1	Preclinical
YM-511	aromatase inhibitor	CYP19A1			Tocris	98.92	Brc1ccc(CN(c2ccc(cc2)C#N)n2cnnc2)cc1	Phase 2
YM-58483	calcium channel blocker	TRPC3, TRPC5, TRPM4			Tocris, EMDBio, EMDBio, EMDBio, EMDBio, EMDBio, EMDBio, EMDBio, EMDBio	99.86	Cc1nnsc1C(=O)Nc1ccc(cc1)-n1nc(cc1C(F)(F)F)C(F)(F)F, Cc1nnsc1C(=O)Nc1ccc(cc1)-n1nc(cc1C(F)(F)F)C(F)(F)F, Cc1nnsc1C(=O)Nc1ccc(cc1)-n1nc(cc1C(F)(F)F)C(F)(F)F, Cc1nnsc1C(=O)Nc1ccc(cc1)-n1nc(cc1C(F)(F)F)C(F)(F)F, Cc1nnsc1C(=O)Nc1ccc(cc1)-n1nc(cc1C(F)(F)F)C(F)(F)F, Cc1nnsc1C(=O)Nc1ccc(cc1)-n1nc(cc1C(F)(F)F)C(F)(F)F, Cc1nnsc1C(=O)Nc1ccc(cc1)-n1nc(cc1C(F)(F)F)C(F)(F)F, Cc1nnsc1C(=O)Nc1ccc(cc1)-n1nc(cc1C(F)(F)F)C(F)(F)F, Cc1nnsc1C(=O)Nc1ccc(cc1)-n1nc(cc1C(F)(F)F)C(F)(F)F	Preclinical
YM-750	ACAT inhibitor	SOAT1			Tocris, Tocris	98.4	Cc1cc(C)c(NC(=O)N(Cc2ccc-3c(Cc4ccccc-34)c2)C2CCCCCC2)c(C)c1, Cc1cc(C)c(NC(=O)N(Cc2ccc-3c(Cc4ccccc-34)c2)C2CCCCCC2)c(C)c1	Phase 1
YM-90709	IL5 inhibitor	CSF2RB, IL5RA			MedChemEx, Tocris, Tocris	95.6	COc1cc2CC(C)(C)n3c(cc4nc5ccccc5nc34)-c2cc1OC, COc1cc2CC(C)(C)n3c(cc4nc5ccccc5nc34)-c2cc1OC, COc1cc2CC(C)(C)n3c(cc4nc5ccccc5nc34)-c2cc1OC	Preclinical
YM-976	phosphodiesterase inhibitor	PDE4A			Tocris, Tocris, Tocris, Tocris	98.61	CCc1ccc2c(nc(=O)n(CC)c2n1)-c1cccc(Cl)c1, CCc1ccc2c(nc(=O)n(CC)c2n1)-c1cccc(Cl)c1, CCc1ccc2c(nc(=O)n(CC)c2n1)-c1cccc(Cl)c1, CCc1ccc2c(nc(=O)n(CC)c2n1)-c1cccc(Cl)c1	Phase 1
YO-01027	gamma secretase inhibitor				Tocris, Tocris, Selleck	97.84	C[C@H](NC(=O)Cc1cc(F)cc(F)c1)C(=O)N[C@H]1c2ccccc2-c2ccccc2N(C)C1=O, C[C@H](NC(=O)Cc1cc(F)cc(F)c1)C(=O)N[C@H]1c2ccccc2-c2ccccc2N(C)C1=O, C[C@H](NC(=O)Cc1cc(F)cc(F)c1)C(=O)N[C@H]1c2ccccc2-c2ccccc2N(C)C1=O	Preclinical
yoda-1	piezo channel activator	PIEZO1			Tocris, Tocris, Tocris	96.08	Clc1cccc(Cl)c1CSc1nnc(s1)-c1cnccn1, Clc1cccc(Cl)c1CSc1nnc(s1)-c1cnccn1, Clc1cccc(Cl)c1CSc1nnc(s1)-c1cnccn1	Preclinical
yohimbine	adrenergic receptor antagonist	ADRA2A, ADRA2B, ADRA2C, DRD2, DRD3, HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR5A, HTR7, KCNJ1, KCNJ10, KCNJ11, KCNJ12, KCNJ14, KCNJ15, KCNJ8	cardiology	cardiac arrythmia, bradycardia	Tocris, Selleck, MicroSource, MicroSource	97.72	COC(=O)[C@H]1[C@@H](O)CC[C@H]2CN3CCc4c([nH]c5ccccc45)[C@@H]3C[C@H]12, COC(=O)[C@H]1[C@@H](O)CC[C@H]2CN3CCc4c([nH]c5ccccc45)[C@@H]3C[C@H]12, COC(=O)[C@H]1[C@@H](O)CC[C@H]2CN3CCc4c([nH]c5ccccc45)[C@@H]3C[C@H]12, COC(=O)[C@H]1[C@@H](O)CC[C@H]2CN3CCc4c([nH]c5ccccc45)[C@@H]3C[C@H]12	Launched
YS-035	calcium channel blocker				Tocris, Tocris	96.03	COc1ccc(CCN(C)CCc2ccc(OC)c(OC)c2)cc1OC, COc1ccc(CCN(C)CCc2ccc(OC)c(OC)c2)cc1OC	Preclinical
YS-201	calcium receptor antagonist				MedChemEx	93.12	CCOC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OCCN1CCCCC1 |&1:12,r,c:5,10|	Preclinical
YZ9	phosphofructokinase inhibitor	MIF, PFKFB3			Tocris, Tocris, Tocris	97.18	CCOC(=O)c1cc2ccc(O)cc2oc1=O, CCOC(=O)c1cc2ccc(O)cc2oc1=O, CCOC(=O)c1cc2ccc(O)cc2oc1=O	Preclinical
Y16	rho associated kinase inhibitor	RHOA			MedChemEx, MedChemEx	63.43	Cc1cccc(COc2cccc(\C=C3/C(=O)NN(C3=O)c3ccccc3)c2)c1, Cc1cccc(COc2cccc(\C=C3/C(=O)NN(C3=O)c3ccccc3)c2)c1	Preclinical
zacopride	serotonin receptor antagonist	HTR3A, HTR3B, HTR4, HTR5A			Tocris, Tocris	97.84	COc1cc(N)c(Cl)cc1C(=O)N[C@H]1CN2CCC1CC2 |&1:13,THB:12:13:16.17:19.20|, COc1cc(N)c(Cl)cc1C(=O)N[C@H]1CN2CCC1CC2 |&1:13,THB:12:13:16.17:19.20|	Phase 2
zafirlukast	leukotriene receptor antagonist	CYSLTR1, CYSLTR2	pulmonary	asthma	Selleck, Selleck, Selleck	95.1	COc1cc(ccc1Cc1cn(C)c2ccc(NC(=O)OC3CCCC3)cc12)C(=O)NS(=O)(=O)c1ccccc1C, COc1cc(ccc1Cc1cn(C)c2ccc(NC(=O)OC3CCCC3)cc12)C(=O)NS(=O)(=O)c1ccccc1C, COc1cc(ccc1Cc1cn(C)c2ccc(NC(=O)OC3CCCC3)cc12)C(=O)NS(=O)(=O)c1ccccc1C	Launched
zalcitabine	nucleoside reverse transcriptase inhibitor		infectious disease	human immunodeficiency virus (HIV-1)	MicroSource, MicroSource, Selleck, MedChemEx, MedChemEx	100	Nc1ccn([C@H]2CC[C@@H](CO)O2)c(=O)n1, Nc1ccn([C@H]2CC[C@@H](CO)O2)c(=O)n1, Nc1ccn([C@H]2CC[C@@H](CO)O2)c(=O)n1, Nc1ccn([C@H]2CC[C@@H](CO)O2)c(=O)n1, Nc1ccn([C@H]2CC[C@@H](CO)O2)c(=O)n1	Launched
zaldaride	calmodulin antagonist	CALM1			Tocris, Tocris, Tocris, Tocris	96.11	C[C@@]1(CN2CCC(CC2)n2c3ccccc3[nH]c2=O)OCc2ccccc2-n2cccc12 |&1:1|, C[C@@]1(CN2CCC(CC2)n2c3ccccc3[nH]c2=O)OCc2ccccc2-n2cccc12 |&1:1|, C[C@@]1(CN2CCC(CC2)n2c3ccccc3[nH]c2=O)OCc2ccccc2-n2cccc12 |&1:1|, C[C@@]1(CN2CCC(CC2)n2c3ccccc3[nH]c2=O)OCc2ccccc2-n2cccc12 |&1:1|	Phase 3
zaltidine	histamine receptor antagonist	HRH2			MedChemEx, MedChemEx	88.8	Cc1nc(c[nH]1)-c1csc(NC(N)=N)n1, Cc1nc(c[nH]1)-c1csc(NC(N)=N)n1	Phase 3
zaltoprofen	cyclooxygenase inhibitor		endocrinology, neurology/psychiatry	fever, pain relief	Selleck, MedChemEx	97.2	C[C@@H](C(O)=O)c1ccc2Sc3ccccc3C(=O)Cc2c1 |&1:1,r|, C[C@@H](C(O)=O)c1ccc2Sc3ccccc3C(=O)Cc2c1 |&1:1,r|	Launched
ZAMI-633	urease inhibitor				PrincetonBio	0	CCC(=O)NO	Phase 3
zamifenacin	acetylcholine receptor antagonist	CHRM3			Tocris, Tocris, Tocris	97.71	C(Cc1ccc2OCOc2c1)N1CCC[C@H](C1)OC(c1ccccc1)c1ccccc1, C(Cc1ccc2OCOc2c1)N1CCC[C@H](C1)OC(c1ccccc1)c1ccccc1, C(Cc1ccc2OCOc2c1)N1CCC[C@H](C1)OC(c1ccccc1)c1ccccc1	Phase 3
zanamivir	neuraminidase inhibitor	NEU2	infectious disease	influenza A virus infection	MedChemEx, Selleck, Selleck	100	CC(=O)N[C@@H]1[C@@H](NC(N)=N)C=C(O[C@H]1[C@H](O)[C@H](O)CO)C(O)=O |c:10|, CC(=O)N[C@@H]1[C@@H](NC(N)=N)C=C(O[C@H]1[C@H](O)[C@H](O)CO)C(O)=O |c:10|, CC(=O)N[C@@H]1[C@@H](NC(N)=N)C=C(O[C@H]1[C@H](O)[C@H](O)CO)C(O)=O |c:10|	Launched
zanubrutinib	Bruton's tyrosine kinase (BTK) inhibitor				MedChemEx	92.97	NC(=O)c1c2NCC[C@@H](C3CCN(CC3)C(=O)C=C)n2nc1-c1ccc(Oc2ccccc2)cc1	Launched
ZAPA					Tocris, Tocris	100	NC(=N)S\C=C/C(O)=O, NC(=N)S\C=C/C(O)=O	Preclinical
zaprinast	phosphodiesterase inhibitor	GPR35, PDE1A, PDE4D, PDE5A, PDE9A			Tocris, Tocris, MicroSource, Tocris, Tocris	99.3	CCCOc1ccccc1-c1nc(=O)c2n[nH]nc2[nH]1, CCCOc1ccccc1-c1nc(=O)c2n[nH]nc2[nH]1, CCCOc1ccccc1-c1nc(=O)c2n[nH]nc2[nH]1, CCCOc1ccccc1-c1nc(=O)c2n[nH]nc2[nH]1, CCCOc1ccccc1-c1nc(=O)c2n[nH]nc2[nH]1	Phase 2
zardaverine	phosphodiesterase inhibitor	PDE4D			Tocris, Tocris, Tocris, Tocris, Tocris, Tocris, Tocris, Tocris	99.64	COc1cc(ccc1OC(F)F)-c1ccc(=O)[nH]n1, COc1cc(ccc1OC(F)F)-c1ccc(=O)[nH]n1, COc1cc(ccc1OC(F)F)-c1ccc(=O)[nH]n1, COc1cc(ccc1OC(F)F)-c1ccc(=O)[nH]n1, COc1cc(ccc1OC(F)F)-c1ccc(=O)[nH]n1, COc1cc(ccc1OC(F)F)-c1ccc(=O)[nH]n1, COc1cc(ccc1OC(F)F)-c1ccc(=O)[nH]n1, COc1cc(ccc1OC(F)F)-c1ccc(=O)[nH]n1	Phase 2
zatebradine	HCN channel blocker	HCN1, HCN2, HCN3, HCN4			MedChemEx, MedChemEx, Tocris	94.13	COc1ccc(CCN(C)CCCN2CCc3cc(OC)c(OC)cc3CC2=O)cc1OC, COc1ccc(CCN(C)CCCN2CCc3cc(OC)c(OC)cc3CC2=O)cc1OC, COc1ccc(CCN(C)CCCN2CCc3cc(OC)c(OC)cc3CC2=O)cc1OC	Phase 3
ZCL-278	CDC inhibitor	CDC42			Tocris, Tocris, Selleck, Selleck	91.54	Cc1cc(C)nc(NS(=O)(=O)c2ccc(NC(=S)NC(=O)COc3ccc(Br)cc3Cl)cc2)n1, Cc1cc(C)nc(NS(=O)(=O)c2ccc(NC(=S)NC(=O)COc3ccc(Br)cc3Cl)cc2)n1, Cc1cc(C)nc(NS(=O)(=O)c2ccc(NC(=S)NC(=O)COc3ccc(Br)cc3Cl)cc2)n1, Cc1cc(C)nc(NS(=O)(=O)c2ccc(NC(=S)NC(=O)COc3ccc(Br)cc3Cl)cc2)n1	Preclinical
ZD-0947	potassium channel activator				Sigma	90.69	FC(F)(F)C1=C[C@H](C2=C(CCCC2=O)N1)c1cccc(c1)C#N |t:4,7|	Preclinical
ZD-2079	adrenergic receptor agonist	ADRB3			Tocris, Tocris	96.4	O[C@@H](CNCCOc1ccc(CC(O)=O)cc1)c1ccccc1, O[C@@H](CNCCOc1ccc(CC(O)=O)cc1)c1ccccc1	Phase 2
ZD-7114	adrenergic receptor agonist	ADRB3			Tocris, Tocris, Tocris, Tocris	97.54	COCCNC(=O)COc1ccc(OCCNC[C@H](O)COc2ccccc2)cc1, COCCNC(=O)COc1ccc(OCCNC[C@H](O)COc2ccccc2)cc1, COCCNC(=O)COc1ccc(OCCNC[C@H](O)COc2ccccc2)cc1, COCCNC(=O)COc1ccc(OCCNC[C@H](O)COc2ccccc2)cc1	Phase 1
ZD-7155	angiotensin receptor antagonist	AGTR1			Tocris, Tocris, Tocris, Tocris, Tocris	97.94	CCc1cc2N(Cc3ccc(cc3)-c3ccccc3-c3nn[nH]n3)C(=O)CCc2c(CC)n1, CCc1cc2N(Cc3ccc(cc3)-c3ccccc3-c3nn[nH]n3)C(=O)CCc2c(CC)n1, CCc1cc2N(Cc3ccc(cc3)-c3ccccc3-c3nn[nH]n3)C(=O)CCc2c(CC)n1, CCc1cc2N(Cc3ccc(cc3)-c3ccccc3-c3nn[nH]n3)C(=O)CCc2c(CC)n1, CCc1cc2N(Cc3ccc(cc3)-c3ccccc3-c3nn[nH]n3)C(=O)CCc2c(CC)n1	Preclinical
ZD-7288	HCN channel blocker	HCN1, HCN2, HCN3, HCN4			Tocris, Tocris, Tocris, Tocris, Tocris, Tocris	100	CCN(c1ccccc1)c1cc(=NC)n(C)c(C)n1, CCN(c1ccccc1)c1cc(=NC)n(C)c(C)n1, CCN(c1ccccc1)c1cc(=NC)n(C)c(C)n1, CCN(c1ccccc1)c1cc(=NC)n(C)c(C)n1, CCN(c1ccccc1)c1cc(=NC)n(C)c(C)n1, CCN(c1ccccc1)c1cc(=NC)n(C)c(C)n1	Phase 2
zeatin					TimTec	96.05	C\C(CO)=C/CNc1ncnc2nc[nH]c12	Phase 1
zebularine	DNA methyltransferase inhibitor	CDA, DNMT1			Tocris, Tocris, Tocris, Selleck, Selleck	100	OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cccnc1=O, OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cccnc1=O, OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cccnc1=O, OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cccnc1=O, OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cccnc1=O	Preclinical
zibotentan	endothelin receptor antagonist	EDNRA			Selleck, Selleck, Selleck	95.3	COc1nc(C)cnc1NS(=O)(=O)c1cccnc1-c1ccc(cc1)-c1nnco1, COc1nc(C)cnc1NS(=O)(=O)c1cccnc1-c1ccc(cc1)-c1nnco1, COc1nc(C)cnc1NS(=O)(=O)c1cccnc1-c1ccc(cc1)-c1nnco1	Phase 3
zidovudine	nucleoside reverse transcriptase inhibitor	TERT	infectious disease	human immunodeficiency virus (HIV-1), acquired immunodeficiency syndrome (AIDS)	Selleck, MedChemEx, Selleck	96.81	Cc1cn([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)c(=O)[nH]c1=O, Cc1cn([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)c(=O)[nH]c1=O, Cc1cn([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)c(=O)[nH]c1=O	Launched
zileuton	leukotriene synthesis inhibitor, lipoxygenase inhibitor	ALOX5	pulmonary	asthma	Tocris, MicroSource, Selleck, Selleck, MedChemEx	92.71	C[C@@H](N(O)C(N)=O)c1cc2ccccc2s1 |&1:1,r|, C[C@@H](N(O)C(N)=O)c1cc2ccccc2s1 |&1:1,r|, C[C@@H](N(O)C(N)=O)c1cc2ccccc2s1 |&1:1,r|, C[C@@H](N(O)C(N)=O)c1cc2ccccc2s1 |&1:1,r|, C[C@@H](N(O)C(N)=O)c1cc2ccccc2s1 |&1:1,r|	Launched
zilpaterol	adrenergic receptor agonist	ADRB2	endocrinology	weight-gain aid	Cayman	97.26	CC(C)N[C@H]1CCn2c3c(cccc3[nH]c2=O)[C@@H]1O	Launched
zimelidine	selective serotonin reuptake inhibitor (SSRI)	MAOA, MAOB, SLC6A4			Tocris, Tocris	95.65	CN(C)C\C=C(\c1ccc(Br)cc1)c1cccnc1, CN(C)C\C=C(\c1ccc(Br)cc1)c1cccnc1	Withdrawn
zinc-undecylenate	other antifungal		infectious disease	tinea pedis	MicroSource, MedChemEx	0	C=CCCCCCCCCC(=O)O[Zn]OC(=O)CCCCCCCCC=C, C=CCCCCCCCCC(=O)O[Zn]OC(=O)CCCCCCCCC=C	Launched
zindotrine	phosphodiesterase inhibitor				Labotest	0	Cc1cc(nn2cnnc12)N1CCCCC1	Phase 2
ziprasidone	dopamine receptor antagonist, serotonin receptor antagonist	ADRA1A, ADRA1B, ADRA2A, ADRA2B, ADRA2C, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD1, DRD2, DRD3, DRD4, DRD5, HRH1, HTR1A, HTR1B, HTR1D, HTR1E, HTR2A, HTR2C, HTR3A, HTR6, HTR7, SLC6A4	neurology/psychiatry	schizophrenia, bipolar disorder	MicroSource, Selleck	94.98	Clc1cc2NC(=O)Cc2cc1CCN1CCN(CC1)c1nsc2ccccc12, Clc1cc2NC(=O)Cc2cc1CCN1CCN(CC1)c1nsc2ccccc12	Launched
ziritaxestat	autotaxin inhibitor				MedChemEx	94.19	CCc1nc2c(C)cc(cn2c1N(C)c1nc(c(s1)C#N)-c1ccc(F)cc1)N1CCN(CC(=O)N2CC(O)C2)CC1	Phase 3
ZK-164015	estrogen receptor antagonist	ESR1, ESR2			Tocris, Tocris, Tocris	94.03	CCCCCS(=O)(=O)CCCCCCCCCCn1c(c(C)c2cc(O)ccc12)-c1ccc(O)cc1, CCCCCS(=O)(=O)CCCCCCCCCCn1c(c(C)c2cc(O)ccc12)-c1ccc(O)cc1, CCCCCS(=O)(=O)CCCCCCCCCCn1c(c(C)c2cc(O)ccc12)-c1ccc(O)cc1	Preclinical
ZK-200775	kainate receptor antagonist				Tocris, Tocris, Tocris, Tocris	98.5	OP(O)(=O)Cn1c2cc(N3CCOCC3)c(cc2[nH]c(=O)c1=O)C(F)(F)F, OP(O)(=O)Cn1c2cc(N3CCOCC3)c(cc2[nH]c(=O)c1=O)C(F)(F)F, OP(O)(=O)Cn1c2cc(N3CCOCC3)c(cc2[nH]c(=O)c1=O)C(F)(F)F, OP(O)(=O)Cn1c2cc(N3CCOCC3)c(cc2[nH]c(=O)c1=O)C(F)(F)F	Phase 2
ZK-811752	CC chemokine receptor antagonist	CCR1			Tocris, MedChemEx, MedChemEx, MedChemEx, MedChemEx, Tocris, Tocris	100	C[C@@H]1CN(Cc2ccc(F)cc2)CCN1C(=O)COc1ccc(Cl)cc1NC(N)=O, C[C@@H]1CN(Cc2ccc(F)cc2)CCN1C(=O)COc1ccc(Cl)cc1NC(N)=O, C[C@@H]1CN(Cc2ccc(F)cc2)CCN1C(=O)COc1ccc(Cl)cc1NC(N)=O, C[C@@H]1CN(Cc2ccc(F)cc2)CCN1C(=O)COc1ccc(Cl)cc1NC(N)=O, C[C@@H]1CN(Cc2ccc(F)cc2)CCN1C(=O)COc1ccc(Cl)cc1NC(N)=O, C[C@@H]1CN(Cc2ccc(F)cc2)CCN1C(=O)COc1ccc(Cl)cc1NC(N)=O, C[C@@H]1CN(Cc2ccc(F)cc2)CCN1C(=O)COc1ccc(Cl)cc1NC(N)=O	Phase 2
ZK-93423	benzodiazepine receptor agonist	GABRA1, GABRA2, GABRA3, GABRA5, GABRB2, GABRG2			Tocris, Tocris, Tocris, Tocris, Tocris, Tocris, Tocris	96.03	CCOC(=O)c1ncc2[nH]c3ccc(OCc4ccccc4)cc3c2c1COC, CCOC(=O)c1ncc2[nH]c3ccc(OCc4ccccc4)cc3c2c1COC, CCOC(=O)c1ncc2[nH]c3ccc(OCc4ccccc4)cc3c2c1COC, CCOC(=O)c1ncc2[nH]c3ccc(OCc4ccccc4)cc3c2c1COC, CCOC(=O)c1ncc2[nH]c3ccc(OCc4ccccc4)cc3c2c1COC, CCOC(=O)c1ncc2[nH]c3ccc(OCc4ccccc4)cc3c2c1COC, CCOC(=O)c1ncc2[nH]c3ccc(OCc4ccccc4)cc3c2c1COC	Phase 3
ZK-93426	benzodiazepine receptor antagonist	GABRA1, GABRA2, GABRA3, GABRA5			Tocris, Tocris, Tocris, Tocris	98.03	CCOC(=O)c1ncc2[nH]c3cccc(OC(C)C)c3c2c1C, CCOC(=O)c1ncc2[nH]c3cccc(OC(C)C)c3c2c1C, CCOC(=O)c1ncc2[nH]c3cccc(OC(C)C)c3c2c1C, CCOC(=O)c1ncc2[nH]c3cccc(OC(C)C)c3c2c1C	Phase 1
ZLN005					MedChemEx, Selleck, Selleck, Selleck, Selleck	98.14	CC(C)(C)c1ccc(cc1)-c1nc2ccccc2[nH]1, CC(C)(C)c1ccc(cc1)-c1nc2ccccc2[nH]1, CC(C)(C)c1ccc(cc1)-c1nc2ccccc2[nH]1, CC(C)(C)c1ccc(cc1)-c1nc2ccccc2[nH]1, CC(C)(C)c1ccc(cc1)-c1nc2ccccc2[nH]1	Preclinical
ZLN024	AMPK activator	PRKAA1, PRKAB1, PRKAG1			Tocris, Tocris, Tocris	95.4	Cc1ccc(OCCSc2ncccn2)c(Br)c1, Cc1ccc(OCCSc2ncccn2)c(Br)c1, Cc1ccc(OCCSc2ncccn2)c(Br)c1	Preclinical
ZM-226600	Kir6 channel (KATP) activator				Tocris, Tocris	95.64	C[C@@](O)(C(=O)Nc1ccc(cc1)S(=O)(=O)c1ccccc1)C(F)(F)F |&1:1|, C[C@@](O)(C(=O)Nc1ccc(cc1)S(=O)(=O)c1ccccc1)C(F)(F)F |&1:1|	Preclinical
ZM-241385	adenosine receptor antagonist	ADORA1, ADORA2A, ADORA2B, ADORA3			Tocris, Tocris, Tocris, Tocris, Tocris, Tocris	99.1	Nc1nc(NCCc2ccc(O)cc2)nc2nc(nn12)-c1ccco1, Nc1nc(NCCc2ccc(O)cc2)nc2nc(nn12)-c1ccco1, Nc1nc(NCCc2ccc(O)cc2)nc2nc(nn12)-c1ccco1, Nc1nc(NCCc2ccc(O)cc2)nc2nc(nn12)-c1ccco1, Nc1nc(NCCc2ccc(O)cc2)nc2nc(nn12)-c1ccco1, Nc1nc(NCCc2ccc(O)cc2)nc2nc(nn12)-c1ccco1	Preclinical
ZM-306416	Abl kinase inhibitor, SRC inhibitor, VEGFR inhibitor	EGFR, FLT1, FLT4, KDR			Tocris, Tocris, Tocris, Selleck, Selleck, Selleck	97.56	COc1cc2ncnc(Nc3ccc(Cl)cc3F)c2cc1OC, COc1cc2ncnc(Nc3ccc(Cl)cc3F)c2cc1OC, COc1cc2ncnc(Nc3ccc(Cl)cc3F)c2cc1OC, COc1cc2ncnc(Nc3ccc(Cl)cc3F)c2cc1OC, COc1cc2ncnc(Nc3ccc(Cl)cc3F)c2cc1OC, COc1cc2ncnc(Nc3ccc(Cl)cc3F)c2cc1OC	Preclinical
ZM-323881	VEGFR inhibitor	KDR			Tocris, Tocris, Tocris, Tocris, Selleck	95.74	Cc1cc(F)c(Nc2ncnc3cc(OCc4ccccc4)ccc23)cc1O, Cc1cc(F)c(Nc2ncnc3cc(OCc4ccccc4)ccc23)cc1O, Cc1cc(F)c(Nc2ncnc3cc(OCc4ccccc4)ccc23)cc1O, Cc1cc(F)c(Nc2ncnc3cc(OCc4ccccc4)ccc23)cc1O, Cc1cc(F)c(Nc2ncnc3cc(OCc4ccccc4)ccc23)cc1O	Preclinical
ZM-336372	RAF inhibitor	BRAF, LCK, MAPK14, RAF1			Selleck, Selleck, Tocris, Tocris	92.91	CN(C)c1cccc(c1)C(=O)Nc1ccc(C)c(NC(=O)c2ccc(O)cc2)c1, CN(C)c1cccc(c1)C(=O)Nc1ccc(C)c(NC(=O)c2ccc(O)cc2)c1, CN(C)c1cccc(c1)C(=O)Nc1ccc(C)c(NC(=O)c2ccc(O)cc2)c1, CN(C)c1cccc(c1)C(=O)Nc1ccc(C)c(NC(=O)c2ccc(O)cc2)c1	Preclinical
ZM-39923	JAK inhibitor	JAK1, JAK3			Tocris, Tocris, Selleck, Tocris, Selleck	93.58	CC(C)N(CCC(=O)c1ccc2ccccc2c1)Cc1ccccc1, CC(C)N(CCC(=O)c1ccc2ccccc2c1)Cc1ccccc1, CC(C)N(CCC(=O)c1ccc2ccccc2c1)Cc1ccccc1, CC(C)N(CCC(=O)c1ccc2ccccc2c1)Cc1ccccc1, CC(C)N(CCC(=O)c1ccc2ccccc2c1)Cc1ccccc1	Preclinical
ZM-447439	Aurora kinase inhibitor	AURKA, AURKB			Tocris, Selleck, Tocris, Tocris	96.51	COc1cc2c(Nc3ccc(NC(=O)c4ccccc4)cc3)ncnc2cc1OCCCN1CCOCC1, COc1cc2c(Nc3ccc(NC(=O)c4ccccc4)cc3)ncnc2cc1OCCCN1CCOCC1, COc1cc2c(Nc3ccc(NC(=O)c4ccccc4)cc3)ncnc2cc1OCCCN1CCOCC1, COc1cc2c(Nc3ccc(NC(=O)c4ccccc4)cc3)ncnc2cc1OCCCN1CCOCC1	Preclinical
zofenopril-calcium	angiotensin converting enzyme inhibitor	ACE	cardiology	hypertension	MedChemEx, MedChemEx, MedChemEx, MedChemEx, MedChemEx	99.29	C[C@H](CSC(=O)c1ccccc1)C(=O)N1C[C@H](C[C@H]1C(O)=O)Sc1ccccc1, C[C@H](CSC(=O)c1ccccc1)C(=O)N1C[C@H](C[C@H]1C(O)=O)Sc1ccccc1, C[C@H](CSC(=O)c1ccccc1)C(=O)N1C[C@H](C[C@H]1C(O)=O)Sc1ccccc1, C[C@H](CSC(=O)c1ccccc1)C(=O)N1C[C@H](C[C@H]1C(O)=O)Sc1ccccc1, C[C@H](CSC(=O)c1ccccc1)C(=O)N1C[C@H](C[C@H]1C(O)=O)Sc1ccccc1	Launched
zolantidine	histamine receptor antagonist				Tocris, Tocris	98.14	C(CNc1nc2ccccc2s1)COc1cccc(CN2CCCCC2)c1, C(CNc1nc2ccccc2s1)COc1cccc(CN2CCCCC2)c1	Preclinical
zoledronic-acid	bone resorption inhibitor	FDPS, GGPS1	endocrinology	Paget's disease	Tocris, Selleck, Selleck	0	OC(Cn1ccnc1)(P(O)(O)=O)P(O)(O)=O, OC(Cn1ccnc1)(P(O)(O)=O)P(O)(O)=O, OC(Cn1ccnc1)(P(O)(O)=O)P(O)(O)=O	Launched
zoliflodacin	antibacterial 				MedChemEx	99.28	[H][C@]12[C@H](C)O[C@H](C)CN1c1c(CC22C(=O)NC(=O)NC2=O)cc2c(noc2c1F)N1[C@@H](C)COC1=O	Phase 3
zolimidine	mucus protecting agent		gastroenterology	peptic ulcer disease (PUD), gastroesophageal reflux disease (GERD)	Enamine	89.09	CS(=O)(=O)c1ccc(cc1)-c1cn2ccccc2n1	Launched
zolmitriptan	serotonin receptor agonist	HTR1A, HTR1B, HTR1D, HTR1E, HTR1F	neurology/psychiatry	migraine headache	Tocris, Tocris, MicroSource, Selleck	95.65	CN(C)CCc1c[nH]c2ccc(C[C@H]3COC(=O)N3)cc12, CN(C)CCc1c[nH]c2ccc(C[C@H]3COC(=O)N3)cc12, CN(C)CCc1c[nH]c2ccc(C[C@H]3COC(=O)N3)cc12, CN(C)CCc1c[nH]c2ccc(C[C@H]3COC(=O)N3)cc12	Launched
zomepirac	prostaglandin synthesis inhibitor	PTGDR2			MedChemEx, Sigma, MicroSource	95.49	Cc1cc(CC(O)=O)n(C)c1C(=O)c1ccc(Cl)cc1, Cc1cc(CC(O)=O)n(C)c1C(=O)c1ccc(Cl)cc1, Cc1cc(CC(O)=O)n(C)c1C(=O)c1ccc(Cl)cc1	Withdrawn
zometapine					Sigma	99.02	Cc1nn(C)c2NCCN=C(c12)c1cccc(Cl)c1 |c:9|	Phase 2
zoniporide	sodium/hydrogen exchanger inhibitor	SLC9A1			Tocris, Tocris	97.75	NC(N)=NC(=O)c1cnn(c1C1CC1)-c1cccc2ncccc12, NC(N)=NC(=O)c1cnn(c1C1CC1)-c1cccc2ncccc12	Phase 3
zonisamide	sodium channel blocker, T-type calcium channel blocker	CA1, CA10, CA11, CA12, CA13, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA8, CA9, CACNA1G, CACNA1H, CACNA1I, MAOA, MAOB, SCN10A, SCN11A, SCN1A, SCN1B, SCN2A, SCN2B, SCN3A, SCN3B, SCN4A, SCN4B, SCN5A, SCN7A, SCN8A, SCN9A	neurology/psychiatry	seizures, epilepsy	Tocris, Tocris, Selleck, Selleck	98.12	NS(=O)(=O)Cc1noc2ccccc12, NS(=O)(=O)Cc1noc2ccccc12, NS(=O)(=O)Cc1noc2ccccc12, NS(=O)(=O)Cc1noc2ccccc12	Launched
zopolrestat		AKR1B1, AKR1B10			Sigma, Sigma	99.72	OC(=O)Cc1nn(Cc2nc3cc(ccc3s2)C(F)(F)F)c(=O)c2ccccc12, OC(=O)Cc1nn(Cc2nc3cc(ccc3s2)C(F)(F)F)c(=O)c2ccccc12	Phase 2
zosuquidar	P glycoprotein inhibitor	ABCB1, ABCB4			Tocris, Selleck	96.07	O[C@@H](COc1cccc2ncccc12)CN1CCN(CC1)[C@@H]1c2ccccc2[C@@H]2[C@H](c3ccccc13)C2(F)F, O[C@@H](COc1cccc2ncccc12)CN1CCN(CC1)[C@@H]1c2ccccc2[C@@H]2[C@H](c3ccccc13)C2(F)F	Phase 3
zotarolimus	mTOR inhibitor	FKBP1A	cardiology	coronary artery restenosis	Adooq, Adooq, Adooq	97.3	CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@@H]1n1cnnn1 |c:14,33,t:29,31|, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@@H]1n1cnnn1 |c:14,33,t:29,31|, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@@H]1n1cnnn1 |c:14,33,t:29,31|	Launched
zotepine	dopamine receptor antagonist, serotonin receptor antagonist	ADRA2B, DRD2, DRD3, DRD4, HRH1, HTR1A, HTR1B, HTR1D, HTR1E, HTR2A, HTR2C, HTR6, HTR7, SLC6A2, SLC6A4	neurology/psychiatry	schizophrenia	Prestwick, Prestwick, Prestwick, Tocris	97.88	CN(C)CCOC1=Cc2ccccc2Sc2ccc(Cl)cc12 |t:6|, CN(C)CCOC1=Cc2ccccc2Sc2ccc(Cl)cc12 |t:6|, CN(C)CCOC1=Cc2ccccc2Sc2ccc(Cl)cc12 |t:6|, CN(C)CCOC1=Cc2ccccc2Sc2ccc(Cl)cc12 |t:6|	Launched
zoxazolamine	myorelaxant				MedChemEx, MicroSource, Selleck	98.37	Nc1nc2cc(Cl)ccc2o1, Nc1nc2cc(Cl)ccc2o1, Nc1nc2cc(Cl)ccc2o1	Phase 2
ZSET1446	nicotinic receptor agonist				MedChemEx	95.54	O=C1N=C2C=CC=CN2C11Cc2ccccc2C1 |c:4,6,t:2|	Preclinical
ZSTK-474	PI3K inhibitor	PIK3CB, PIK3CD, PIK3CG			MedChemEx, Selleck	98.66	FC(F)c1nc2ccccc2n1-c1nc(nc(n1)N1CCOCC1)N1CCOCC1, FC(F)c1nc2ccccc2n1-c1nc(nc(n1)N1CCOCC1)N1CCOCC1	Phase 1/Phase 2
zuclopenthixol	dopamine receptor antagonist	ADRA1A, ADRA2A, DRD1, DRD2, DRD5, HRH1, HTR2A	neurology/psychiatry	schizophrenia, bipolar disorder	MedChemEx, Prestwick, Prestwick	97.19	OCCN1CCN(CC\C=C2\c3ccccc3Sc3ccc(Cl)cc23)CC1, OCCN1CCN(CC\C=C2\c3ccccc3Sc3ccc(Cl)cc23)CC1, OCCN1CCN(CC\C=C2\c3ccccc3Sc3ccc(Cl)cc23)CC1	Launched
zuranolone	GABA receptor agonist				MedChemEx	92.59	[H][C@@]12CC[C@H](C(=O)Cn3cc(cn3)C#N)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@]2([H])C[C@](C)(O)CC[C@]12[H]	Phase 3
Z160	N-type calcium channel blocker	CACNA2D1			MedChemEx, MedChemEx, MedChemEx	97.39	O=C(CC(c1ccccc1)c1ccccc1)N1CCN(CC1)C(c1ccccc1)c1ccccc1, O=C(CC(c1ccccc1)c1ccccc1)N1CCN(CC1)C(c1ccccc1)c1ccccc1, O=C(CC(c1ccccc1)c1ccccc1)N1CCN(CC1)C(c1ccccc1)c1ccccc1	Phase 2
1,12-Besm	polyamine biosynthesis inhibitor				Tocris	96.1	CCNCCCNCCCCNCCCNCC	Phase 2
1,2,3,4,5,6-hexabromocyclohexane	JAK inhibitor	JAK2			Tocris, Tocris, Tocris	38.29	BrC1C(Br)C(Br)C(Br)C(Br)C1Br, BrC1C(Br)C(Br)C(Br)C(Br)C1Br, BrC1C(Br)C(Br)C(Br)C(Br)C1Br	Preclinical
1,3-dipropyl-8-phenylxanthine	adenosine receptor antagonist				Tocris, Tocris	97.89	CCCn1c2nc([nH]c2c(=O)n(CCC)c1=O)-c1ccccc1, CCCn1c2nc([nH]c2c(=O)n(CCC)c1=O)-c1ccccc1	Preclinical
1,4-butanediol	benzodiazepine receptor agonist, gamma hydroxybutyric acid agonist	MAN1B1, PLA2G2A, PLA2G2E			Sigma	0	OCCCCO	Phase 1
1,5-dicaffeoylquinic-acid					AnalytiCon, MedChemEx	95.94	O[C@@H]1C[C@@](C[C@@H](OC(=O)\C=C\c2ccc(O)c(O)c2)[C@@H]1O)(OC(=O)\C=C\c1ccc(O)c(O)c1)C(O)=O, O[C@@H]1C[C@@](C[C@@H](OC(=O)\C=C\c2ccc(O)c(O)c2)[C@@H]1O)(OC(=O)\C=C\c1ccc(O)c(O)c1)C(O)=O	Phase 1
1-((Z)-3-chloroallyl)-1,3,5,7-tetraazaadamantan-1-ium					BidePharm	94.41	Cl\C=C/C[N+]12CN3CN(CN(C3)C1)C2	Preclinical
1-(1,2-diphenylethyl)piperidine-(+/-)	glutamate receptor antagonist				Tocris, Tocris	98.04	C([C@@H](N1CCCCC1)c1ccccc1)c1ccccc1 |&1:1|, C([C@@H](N1CCCCC1)c1ccccc1)c1ccccc1 |&1:1|	Preclinical
1-(2-chloro-5-methylphenoxy)-3-(isopropylamino)-2-propanol					Enamine	92.38	CC(C)NC[C@@H](O)COc1cc(C)ccc1Cl |&1:5,r|	Preclinical
1-acetyl-4-methylpiperazine	acetylcholine receptor agonist				Tocris, Tocris	90.28	CN1CCN(CC1)C(C)=O, CN1CCN(CC1)C(C)=O	Preclinical
1-azakenpaullone	glycogen synthase kinase inhibitor	CCNB1, CDK1, CDK5, GSK3B			Selleck, Selleck, Selleck, Selleck, Selleck, Selleck	95.26	Brc1ccc2[nH]c-3c(CC(=O)Nc4cccnc-34)c2c1, Brc1ccc2[nH]c-3c(CC(=O)Nc4cccnc-34)c2c1, Brc1ccc2[nH]c-3c(CC(=O)Nc4cccnc-34)c2c1, Brc1ccc2[nH]c-3c(CC(=O)Nc4cccnc-34)c2c1, Brc1ccc2[nH]c-3c(CC(=O)Nc4cccnc-34)c2c1, Brc1ccc2[nH]c-3c(CC(=O)Nc4cccnc-34)c2c1	Preclinical
1-deoxymannojirimycin	alpha mannosidase inhibitor	MAN2A1			Tocris, Tocris	100	OC[C@H]1NC[C@@H](O)[C@@H](O)[C@@H]1O, OC[C@H]1NC[C@@H](O)[C@@H](O)[C@@H]1O	Preclinical
1-EBIO	potassium channel activator	KCNN1, KCNN2, KCNN3, KCNN4			Tocris, Tocris, Tocris, Tocris	96.95	CCn1c2ccccc2[nH]c1=O, CCn1c2ccccc2[nH]c1=O, CCn1c2ccccc2[nH]c1=O, CCn1c2ccccc2[nH]c1=O	Preclinical
1-ethyl-2-pyrrolidone	transdermal absorption-enhancing compound				CombiBlocks	98.42	CCN1CCCC1=O	Preclinical
1-hexadecanal	sphingosine 1-phosphate receptor substrate	DBI, RHO			DuPont	0	CCCCCCCCCCCCCCCC=O	Preclinical
1-hexadecanol			dermatology	cosmetic	Selleck, Selleck, Selleck	0	CCCCCCCCCCCCCCCCO, CCCCCCCCCCCCCCCCO, CCCCCCCCCCCCCCCCO	Launched
1-naphthyl-PP1	SRC inhibitor	SRC			Tocris, Tocris, Tocris, Tocris, Tocris, Tocris	98.62	CC(C)(C)n1nc(-c2cccc3ccccc23)c2c(N)ncnc12, CC(C)(C)n1nc(-c2cccc3ccccc23)c2c(N)ncnc12, CC(C)(C)n1nc(-c2cccc3ccccc23)c2c(N)ncnc12, CC(C)(C)n1nc(-c2cccc3ccccc23)c2c(N)ncnc12, CC(C)(C)n1nc(-c2cccc3ccccc23)c2c(N)ncnc12, CC(C)(C)n1nc(-c2cccc3ccccc23)c2c(N)ncnc12	Preclinical
1-octacosanol					Acros	1.71	CCCCCCCCCCCCCCCCCCCCCCCCCCCCO	Phase 2
1-octanol		GJA1, GJA10, GJA3, GJA4, GJA5, GJA8, GJA9, GJB1, GJB2, GJB3, GJB4, GJB5, GJB6, GJB7, GJC1, GJC2, GJC3, GJD2, GJD3, GJD4, GJE1			Enamine, Enamine	0	CCCCCCCCO, CCCCCCCCO	Phase 2
1-phenylbiguanide	serotonin receptor agonist	HTR3A, HTR3B			Tocris, Tocris	96.75	NC(N)=NC(=N)Nc1ccccc1, NC(N)=NC(=N)Nc1ccccc1	Preclinical
1E-1-(2-hydroxy-5-methylphenyl)-1-dodecanone-oxime					Sigma, Sigma, Sigma, Sigma	98.81	CCCCCCCCCCC[C@@H](N=O)c1cc(C)ccc1O |r|, CCCCCCCCCCC[C@@H](N=O)c1cc(C)ccc1O |r|, CCCCCCCCCCC[C@@H](N=O)c1cc(C)ccc1O |r|, CCCCCCCCCCC[C@@H](N=O)c1cc(C)ccc1O |r|	Preclinical
1S,2R-phenylpropanolamine	adrenergic receptor agonist				MicroSource	98.2	C[C@@H](N)[C@@H](O)c1ccccc1	Withdrawn
10-deacetylbaccatin	antitumor agent				MedChemEx, Selleck, Selleck, Selleck	95.89	CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](O)C(C)=C([C@@H](O)C1=O)C2(C)C |t:33|, CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](O)C(C)=C([C@@H](O)C1=O)C2(C)C |t:33|, CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](O)C(C)=C([C@@H](O)C1=O)C2(C)C |t:33|, CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](O)C(C)=C([C@@H](O)C1=O)C2(C)C |t:33|	Preclinical
10-DEBC	AKT inhibitor	PIM1			Tocris, Tocris, Tocris, Tocris	97.32	CCN(CC)CCCCN1c2ccccc2Oc2ccc(Cl)cc12, CCN(CC)CCCCN1c2ccccc2Oc2ccc(Cl)cc12, CCN(CC)CCCCN1c2ccccc2Oc2ccc(Cl)cc12, CCN(CC)CCCCN1c2ccccc2Oc2ccc(Cl)cc12	Preclinical
10-hydroxycamptothecin	topoisomerase inhibitor	TOP1			MedChemEx, MedChemEx, Selleck, Selleck, Selleck	97.94	CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)cc4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)cc4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)cc4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)cc4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)cc4cc3Cn1c2=O	Preclinical
10058-F4	c-Myc inhibitor				Tocris, Selleck, Selleck, Selleck, Selleck	95.9	CCc1ccc(\C=C2\SC(=S)NC2=O)cc1, CCc1ccc(\C=C2\SC(=S)NC2=O)cc1, CCc1ccc(\C=C2\SC(=S)NC2=O)cc1, CCc1ccc(\C=C2\SC(=S)NC2=O)cc1, CCc1ccc(\C=C2\SC(=S)NC2=O)cc1	Preclinical
12-O-tetradecanoylphorbol-13-acetate	PKC activator	KCNT2, TRPV4			Enzo, Enzo, Enzo, Enzo, Sigma, Sigma	97.9	CCCCCCCCCCCCCC(=O)O[C@@H]1[C@@H](C)[C@]2(O)[C@@H]3C=C(C)C(=O)[C@@]3(O)CC(CO)=C[C@H]2[C@@H]2C(C)(C)[C@]12OC(C)=O |c:33,t:22|, CCCCCCCCCCCCCC(=O)O[C@@H]1[C@@H](C)[C@]2(O)[C@@H]3C=C(C)C(=O)[C@@]3(O)CC(CO)=C[C@H]2[C@@H]2C(C)(C)[C@]12OC(C)=O |c:33,t:22|, CCCCCCCCCCCCCC(=O)O[C@@H]1[C@@H](C)[C@]2(O)[C@@H]3C=C(C)C(=O)[C@@]3(O)CC(CO)=C[C@H]2[C@@H]2C(C)(C)[C@]12OC(C)=O |c:33,t:22|, CCCCCCCCCCCCCC(=O)O[C@@H]1[C@@H](C)[C@]2(O)[C@@H]3C=C(C)C(=O)[C@@]3(O)CC(CO)=C[C@H]2[C@@H]2C(C)(C)[C@]12OC(C)=O |c:33,t:22|, CCCCCCCCCCCCCC(=O)O[C@@H]1[C@@H](C)[C@]2(O)[C@@H]3C=C(C)C(=O)[C@@]3(O)CC(CO)=C[C@H]2[C@@H]2C(C)(C)[C@]12OC(C)=O |c:33,t:22|, CCCCCCCCCCCCCC(=O)O[C@@H]1[C@@H](C)[C@]2(O)[C@@H]3C=C(C)C(=O)[C@@]3(O)CC(CO)=C[C@H]2[C@@H]2C(C)(C)[C@]12OC(C)=O |c:33,t:22|	Phase 2
1400W	nitric oxide synthase inhibitor	NOS1, NOS2, NOS3			Tocris, Tocris	89.27	CC(=N)NCc1cccc(CN)c1, CC(=N)NCc1cccc(CN)c1	Preclinical
16,16-dimethylprostaglandin-e2	prostanoid receptor agonist	HPGD			Enzo, Sigma, Sigma	100	CCCCC(C)(C)[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O, CCCCC(C)(C)[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O, CCCCC(C)(C)[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O	Phase 2
17-hydroxyprogesterone-caproate	progesterone receptor agonist	AR, ESR1, ESR2, NR1H4, NR1I2, NR3C1, PGR	obstetrics/gynecology	spontaneous preterm birth	MedChemEx	89.88	CCCCCC(=O)O[C@@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)=O |t:15|	Launched
17-PA	glucocorticoid receptor agonist				Tocris, Tocris	94.15	C[C@]12CC[C@H]3[C@@H](CC[C@H]4C[C@H](O)CC[C@]34C)[C@@H]1CC=C2c1ccccc1 |c:21|, C[C@]12CC[C@H]3[C@@H](CC[C@H]4C[C@H](O)CC[C@]34C)[C@@H]1CC=C2c1ccccc1 |c:21|	Preclinical
2'-C-methylguanosine	HCV inhibitor				Sigma	99.3	C[C@@]1(O)[C@H](O)[C@@H](CO)O[C@H]1n1cnc2c1[nH]c(N)nc2=O	Preclinical
2'-MeCCPA	adenosine receptor agonist	ADORA1			Tocris, Tocris, Tocris, Tocris, Tocris	95.81	C[C@@]1(O)[C@H](O)[C@@H](CO)O[C@H]1n1cnc2c(NC3CCCC3)nc(Cl)nc12, C[C@@]1(O)[C@H](O)[C@@H](CO)O[C@H]1n1cnc2c(NC3CCCC3)nc(Cl)nc12, C[C@@]1(O)[C@H](O)[C@@H](CO)O[C@H]1n1cnc2c(NC3CCCC3)nc(Cl)nc12, C[C@@]1(O)[C@H](O)[C@@H](CO)O[C@H]1n1cnc2c(NC3CCCC3)nc(Cl)nc12, C[C@@]1(O)[C@H](O)[C@@H](CO)O[C@H]1n1cnc2c(NC3CCCC3)nc(Cl)nc12	Preclinical
2,3-cis/exo-camphanediol					BroadPharm	0	CC1(C)[C@@H]2CC[C@@]1(C)[C@H](O)[C@@H]2O	Phase 1
2,3-cis/exo-pinanediol					Maybridge	0	CC1(C)C2CC1[C@](C)(O)[C@H](O)C2	Phase 1
2,3-DCPE	BCL-XL downregulator	BCL2L1			Tocris, Tocris, Tocris, Tocris	100	OCCNCCCOc1cccc(Cl)c1Cl, OCCNCCCOc1cccc(Cl)c1Cl, OCCNCCCOc1cccc(Cl)c1Cl, OCCNCCCOc1cccc(Cl)c1Cl	Preclinical
2,4-dinitrochlorobenzene	thioredoxin inhibitor	TXN			Sigma	0	[O-][N+](=O)c1ccc(Cl)c(c1)[N+]([O-])=O	Phase 2
2,4-dinitrophenol	ATP synthase inhibitor	APP			MicroSource	98.95	Oc1ccc(cc1[N+]([O-])=O)[N+]([O-])=O	Preclinical
2,5-furandimethanol	hemoglobin modulator	HBB			Key	0	OCc1ccc(CO)o1	Phase 2
2,6-dimethylpiperidine					MicroSource, MedChemEx	0	C[C@H]1CCC[C@@H](C)N1 |&1:1,&2:5,r|, C[C@H]1CCC[C@@H](C)N1 |&1:1,&2:5,r|	Preclinical
2-(chloromethyl)-5,6,7,8-tetrahydro[1]benzothieno[2,3-d]pyrimidin-4(3H)-one					Enamine	80.5	ClC=C1Nc2sc3CCCCc3c2C(=O)N1	Preclinical
2-(1-adamantylamino)benzoic-acid					Enamine	97.76	OC(=O)c1ccccc1NC(=O)C12CC3CC(CC(C3)C1)C2	Preclinical
2-(3-mercaptopropyl)pentanedioic-acid	glutamate carboxypeptidase inhibitor	FOLH1			Tocris, Tocris	84.2	OC(=O)CC[C@@H](CCCS)C(O)=O |&1:5,r|, OC(=O)CC[C@@H](CCCS)C(O)=O |&1:5,r|	Phase 1
2-[1-(4-piperonyl)piperazinyl]benzothiazole	serotonin receptor agonist	HTR4			Tocris, Tocris	99.23	C(N1CCN(CC1)c1nc2ccccc2s1)c1ccc2OCOc2c1, C(N1CCN(CC1)c1nc2ccccc2s1)c1ccc2OCOc2c1	Preclinical
2-aminobenzenesulfonamide	carbonic anhydrase inhibitor	CA12, CA14, CA2, CA6, CA9			Prestwick	99.54	Nc1ccccc1S(N)(=O)=O	Preclinical
2-APB	1,4,5-trisphosphate inhibitor	TRPC1, TRPC3, TRPC4, TRPC5, TRPC6, TRPC7, TRPM2, TRPM3, TRPM6, TRPV1, TRPV6			Tocris, Tocris	0	NCCOB(c1ccccc1)c1ccccc1, NCCOB(c1ccccc1)c1ccccc1	Preclinical
2-BFI	imidazoline receptor ligand	ADRA2A, ADRA2B, ADRA2C, MAOA, MAOB			Tocris	97.63	C1CN=C(N1)c1cc2ccccc2o1 |c:2|	Preclinical
2-chloro-N6-cyclopentyladenosine	adenosine receptor agonist	ADORA1, ADORA2A, ADORA2B, ADORA3			Tocris, Tocris, Tocris, Tocris	98.41	OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(NC3CCCC3)nc(Cl)nc12, OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(NC3CCCC3)nc(Cl)nc12, OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(NC3CCCC3)nc(Cl)nc12, OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(NC3CCCC3)nc(Cl)nc12	Preclinical
2-chloroadenosine	adenosine receptor agonist	ADORA1, ADORA2A, ADORA2B			Tocris, Tocris, Tocris	98.42	Nc1nc(Cl)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O, Nc1nc(Cl)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O, Nc1nc(Cl)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O	Preclinical
2-chloropyrazine					MedChemEx, Prestwick	94.15	Clc1cnccn1, Clc1cnccn1	Preclinical
2-CMDO	dopamine receptor antagonist	DRD2, DRD4			Tocris, Tocris, Tocris, Tocris	95.69	CN1CCN(CC1)C1=Cc2ccccc2Oc2ccc(Cl)cc12 |t:8|, CN1CCN(CC1)C1=Cc2ccccc2Oc2ccc(Cl)cc12 |t:8|, CN1CCN(CC1)C1=Cc2ccccc2Oc2ccc(Cl)cc12 |t:8|, CN1CCN(CC1)C1=Cc2ccccc2Oc2ccc(Cl)cc12 |t:8|	Preclinical
2-deoxy-2-([methyl(nitroso)carbamoyl]amino)hexose			oncology, endocrinology	pancreatic cancer, hypoglycemia	Labotest	0	CN([NH2+][O-])C(=O)N[C@@H](C=O)[C@@H](O)[C@@H](O)[C@@H](O)CO |&1:7,&2:10,&3:12,&4:14,r|	Preclinical
2-deoxyglucose	glycolysis inhibitor	SLC2A1, SLC2A2, SLC2A3, SLC2A4			Enzo, Enzo, MedChemEx	100	OC[C@H]1O[C@H](O)C[C@@H](O)[C@@H]1O, OC[C@H]1O[C@H](O)C[C@@H](O)[C@@H]1O, OC[C@H]1O[C@H](O)C[C@@H](O)[C@@H]1O	Phase 2
2-ethoxybenzoic-acid	analgesic agent				Enamine	97.32	CCOc1ccccc1C(O)=O	Phase 1
2-ethyl-1,3-hexanediol					Sigma, Sigma, TCI	0	CCC[C@@H](O)[C@@H](CC)CO |&1:3,&2:5,r|, CCC[C@@H](O)[C@@H](CC)CO |&1:3,&2:5,r|, CCC[C@@H](O)[C@@H](CC)CO |&1:3,&2:5,r|	Preclinical
2-fluoro-2-deoxy-D-galactose		LCT			SantaCruz	100	OC[C@H]1O[C@@H](O)[C@@H](F)[C@@H](O)[C@@H]1O |&1:2,&2:4,&3:6,&4:8,&5:10,r|	Phase 1
2-fluorofucose					Apollo	0	C[C@@H]1O[C@H](O)[C@@H](F)[C@H](O)[C@@H]1O |&1:3|	Phase 1
2-hydroxy-4-((E)-3-(4-hydroxyphenyl)acryloyl)-2-((2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)-6-((2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)cyclohexane-1,3,5-trione					MedChemEx, MedChemEx	76.37	OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)[C@H]1C(=O)C(=C(O)\C=C\c2ccc(O)cc2)C(=O)[C@@](O)([C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)C1=O |a:2,4,5,7,9,30,32,35,37,39,&1:11,&2:14,&3:28|, OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)[C@H]1C(=O)C(=C(O)\C=C\c2ccc(O)cc2)C(=O)[C@@](O)([C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)C1=O |a:2,4,5,7,9,30,32,35,37,39,&1:11,&2:14,&3:28|	Preclinical
2-hydroxyethyl-salicylate			neurology/psychiatry	pain relief	Acros	97.62	OCCOC(=O)c1ccccc1O	Launched
2-hydroxyflutamide	androgen receptor antagonist	AR			Sigma, Enamine	99.33	CC(C)(O)C(=O)Nc1ccc(c(c1)C(F)(F)F)[N+]([O-])=O, CC(C)(O)C(=O)Nc1ccc(c(c1)C(F)(F)F)[N+]([O-])=O	Phase 2
2-hydroxysaclofen	GABA receptor antagonist	GABBR1, GABBR2			Tocris, Tocris, Tocris, Tocris, Tocris, Tocris, Tocris	96.08	NC[C@@](O)(CS(O)(=O)=O)c1ccc(Cl)cc1 |&1:2,r|, NC[C@@](O)(CS(O)(=O)=O)c1ccc(Cl)cc1 |&1:2,r|, NC[C@@](O)(CS(O)(=O)=O)c1ccc(Cl)cc1 |&1:2,r|, NC[C@@](O)(CS(O)(=O)=O)c1ccc(Cl)cc1 |&1:2,r|, NC[C@@](O)(CS(O)(=O)=O)c1ccc(Cl)cc1 |&1:2,r|, NC[C@@](O)(CS(O)(=O)=O)c1ccc(Cl)cc1 |&1:2,r|, NC[C@@](O)(CS(O)(=O)=O)c1ccc(Cl)cc1 |&1:2,r|	Preclinical
2-iminobiotin	nitric oxide synthase inhibitor	NOS1, NOS2			Sigma, BroadPharm	90.08	NC1=N[C@H]2CS[C@@H](CCCCC(O)=O)[C@H]2N1 |t:1|, NC1=N[C@H]2CS[C@@H](CCCCC(O)=O)[C@H]2N1 |t:1|	Phase 2
2-iodohippuric-acid					Enamine, Sigma	98.84	OC(=O)CNC(=O)c1ccccc1I, OC(=O)CNC(=O)c1ccccc1I	Preclinical
2-iodomelatonin	melatonin receptor agonist	MTNR1A, MTNR1B, NQO2			Tocris, Tocris	96.09	COc1ccc2[nH]c(I)c(CCNC(C)=O)c2c1, COc1ccc2[nH]c(I)c(CCNC(C)=O)c2c1	Preclinical
2-methoxyestradiol	hypoxia inducible factor inhibitor	COMT, CYP19A1, CYP1A1, CYP1B1, HIF1A, TUBB			Tocris, Selleck, Selleck, Selleck, Selleck, Tocris, Tocris, Tocris	97.09	COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O, COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O, COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O, COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O, COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O, COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O, COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O, COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O	Phase 2
2-methyl-5-hydroxytryptamine	serotonin receptor agonist	HTR1B, HTR1D, HTR1E, HTR1F, HTR3A, HTR3B, HTR6			Tocris, Tocris, Tocris	97.17	Cc1[nH]c2ccc(O)cc2c1CCN, Cc1[nH]c2ccc(O)cc2c1CCN, Cc1[nH]c2ccc(O)cc2c1CCN	Preclinical
2-methyl-5-nitrophenol					MedChemEx, Enamine	86.08	Cc1ccc(cc1O)[N+]([O-])=O, Cc1ccc(cc1O)[N+]([O-])=O	Preclinical
2-methylimidazole	cholesterol inhibitor				Sigma	93.95	Cc1ncc[nH]1	Preclinical
2-octyldodecan-1-ol					Sigma, Bepharm, Bepharm	0	CCCCCCCCCC[C@@H](CO)CCCCCCCC |&1:10,r|, CCCCCCCCCC[C@@H](CO)CCCCCCCC |&1:10,r|, CCCCCCCCCC[C@@H](CO)CCCCCCCC |&1:10,r|	Preclinical
2-oleoylglycerol	glucose dependent insulinotropic receptor ligand	GPR119			Cayman, Cayman	94.8	CCCCCCCC\C=C/CCCCCCCC(=O)OC(CO)CO, CCCCCCCC\C=C/CCCCCCCC(=O)OC(CO)CO	Phase 1
2-oxoglutaric-acid		OXGR1			MedChemEx, Enamine	100	OC(=O)CCC(=O)C(O)=O, OC(=O)CCC(=O)C(O)=O	Preclinical
2-oxopropanoate	pyruvate dehydrogenase kinase inhibitor	ABAT			Sigma	76.6	OC(=C)C(O)=O	Preclinical
2-phenylmelatonin	melatonin receptor agonist	MTNR1A, MTNR1B			Tocris, Tocris, Tocris, Tocris, Tocris	97.9	COc1ccc2[nH]c(c(CCNC(C)=O)c2c1)-c1ccccc1, COc1ccc2[nH]c(c(CCNC(C)=O)c2c1)-c1ccccc1, COc1ccc2[nH]c(c(CCNC(C)=O)c2c1)-c1ccccc1, COc1ccc2[nH]c(c(CCNC(C)=O)c2c1)-c1ccccc1, COc1ccc2[nH]c(c(CCNC(C)=O)c2c1)-c1ccccc1	Preclinical
2-PMDQ	adrenergic receptor antagonist	ADRA1A			Tocris, Tocris	97.31	O=C1Nc2ccccc2C2=N[C@@H](CN3CCN(CC3)c3ccccc3)CN12 |&1:11,r,t:10|, O=C1Nc2ccccc2C2=N[C@@H](CN3CCN(CC3)c3ccccc3)CN12 |&1:11,r,t:10|	Preclinical
2-pyridylethylamine	histamine receptor agonist	HRH1			Tocris, Tocris, Tocris	97.88	NCCc1ccccn1, NCCc1ccccn1, NCCc1ccccn1	Preclinical
2-TEDC	lipoxygenase inhibitor	ALOX12			Tocris, Tocris	94.84	Oc1ccc(\C=C(/C#N)C(=O)OCCc2cccs2)cc1O, Oc1ccc(\C=C(/C#N)C(=O)OCCc2cccs2)cc1O	Preclinical
2-thiouracil					MedChemEx, MicroSource, Selleck	100	O=c1cc[nH]c(=S)[nH]1, O=c1cc[nH]c(=S)[nH]1, O=c1cc[nH]c(=S)[nH]1	Preclinical
20-HETE	ion channel antagonist				MedChemEx	0	OCCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O	Preclinical
20-hydroxyecdysone	ecdysone receptor modulator				Selleck	92.15	CC(C)(O)CC[C@@H](O)[C@](C)(O)[C@@H]1CC[C@@]2(O)C3=CC(=O)[C@@H]4C[C@@H](O)[C@@H](O)C[C@]4(C)[C@@H]3CC[C@]12C |t:16|	Phase 2
3'-fluorobenzylspiperone	dopamine receptor ligand	DRD2			Tocris, Tocris, Tocris, Tocris	93.86	Fc1ccc(cc1)C(=O)CCCN1CCC2(CC1)N(CN(Cc1cccc(F)c1)C2=O)c1ccccc1, Fc1ccc(cc1)C(=O)CCCN1CCC2(CC1)N(CN(Cc1cccc(F)c1)C2=O)c1ccccc1, Fc1ccc(cc1)C(=O)CCCN1CCC2(CC1)N(CN(Cc1cccc(F)c1)C2=O)c1ccccc1, Fc1ccc(cc1)C(=O)CCCN1CCC2(CC1)N(CN(Cc1cccc(F)c1)C2=O)c1ccccc1	Preclinical
3,3'-dichlorobenzaldazine	glutamate receptor modulator	GRM5			Tocris, Tocris	96.54	Clc1cccc(\C=N\N=C\c2cccc(Cl)c2)c1, Clc1cccc(\C=N\N=C\c2cccc(Cl)c2)c1	Preclinical
3,3'-diindolylmethane	CHK inhibitor, cytochrome P450 activator, indoleamine 2,3-dioxygenase inhibitor	AR, HIF1A, IFNG, PI3			Enzo, Sigma, Sigma	93.17	C(c1c[nH]c2ccccc12)c1c[nH]c2ccccc12, C(c1c[nH]c2ccccc12)c1c[nH]c2ccccc12, C(c1c[nH]c2ccccc12)c1c[nH]c2ccccc12	Phase 3
3,4-DCPG-(+/-)	glutamate receptor agonist	GRM8			Tocris, Tocris	0	N[C@@H](C(O)=O)c1ccc(C(O)=O)c(c1)C(O)=O |&1:1,r|, N[C@@H](C(O)=O)c1ccc(C(O)=O)c(c1)C(O)=O |&1:1,r|	Preclinical
3,4-DCPG-(R)	glutamate receptor antagonist				Tocris, Tocris	100	N[C@@H](C(O)=O)c1ccc(C(O)=O)c(c1)C(O)=O, N[C@@H](C(O)=O)c1ccc(C(O)=O)c(c1)C(O)=O	Preclinical
3,4-DCPG-(S)	glutamate receptor agonist	GRM8			Tocris, Tocris, Tocris	90.3	N[C@H](C(O)=O)c1ccc(C(O)=O)c(c1)C(O)=O, N[C@H](C(O)=O)c1ccc(C(O)=O)c(c1)C(O)=O, N[C@H](C(O)=O)c1ccc(C(O)=O)c(c1)C(O)=O	Preclinical
3,4-methylenedioxy-beta-nitrostyrene	SRC inhibitor, SYK inhibitor	SRC, SYK			Selleck, Selleck, Selleck, Selleck, Selleck, Selleck	96.95	[O-][N+](=O)\C=C\c1ccc2OCOc2c1, [O-][N+](=O)\C=C\c1ccc2OCOc2c1, [O-][N+](=O)\C=C\c1ccc2OCOc2c1, [O-][N+](=O)\C=C\c1ccc2OCOc2c1, [O-][N+](=O)\C=C\c1ccc2OCOc2c1, [O-][N+](=O)\C=C\c1ccc2OCOc2c1	Preclinical
3,5-DHPG-(S)	glutamate receptor agonist	GRM1			Tocris, Tocris, Tocris	100	N[C@H](C(O)=O)c1cc(O)cc(O)c1, N[C@H](C(O)=O)c1cc(O)cc(O)c1, N[C@H](C(O)=O)c1cc(O)cc(O)c1	Preclinical
3-(4-methylbenzylidene)camphor	endocrine disruptor		dermatology	sunscreen lotion	AlfaAesar, Selleck	98.91	Cc1ccc(\C=C2\[C@H]3CC[C@@](C)(C2=O)C3(C)C)cc1 |&1:7,&2:10,r|, Cc1ccc(\C=C2\[C@H]3CC[C@@](C)(C2=O)C3(C)C)cc1 |&1:7,&2:10,r|	Launched
3-alpha-bis-(4-fluorophenyl)-methoxytropane	dopamine uptake inhibitor	CHRM1, SLC6A2, SLC6A3, SLC6A4			Tocris	95.34	CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(c1ccc(F)cc1)c1ccc(F)cc1 |&1:2,5,7|	Preclinical
3-alpha-hydroxy-5-beta-androstan-17-one		HSD17B11, IGHG2, SULT2A1			Prestwick	100	C[C@]12CC[C@H]3[C@@H](CC[C@@H]4C[C@H](O)CC[C@]34C)[C@@H]1CCC2=O |a:1,5,8,10,14,16,&1:4|	Preclinical
3-amino-benzamide	PARP inhibitor	PARP1			Selleck, Tocris, Tocris	97.46	NC(=O)c1cccc(N)c1, NC(=O)c1cccc(N)c1, NC(=O)c1cccc(N)c1	Phase 2
3-anilinopropan-1-ol					Enamine, Enamine	29.93	OCCCNc1ccccc1, OCCCNc1ccccc1	Preclinical
3-AQC	serotonin receptor agonist	HTR3A			Tocris, Tocris, Tocris	91.1	C=CCN1CCN(CC1)c1nc2ccccc2nc1C#N, C=CCN1CCN(CC1)c1nc2ccccc2nc1C#N, C=CCN1CCN(CC1)c1nc2ccccc2nc1C#N	Preclinical
3-bromo-7-nitroindazole	nitric oxide synthase inhibitor	NOS1, NOS2, NOS3			Tocris, Tocris, Tocris, Tocris	97.63	[O-][N+](=O)c1cccc2c(Br)[nH]nc12, [O-][N+](=O)c1cccc2c(Br)[nH]nc12, [O-][N+](=O)c1cccc2c(Br)[nH]nc12, [O-][N+](=O)c1cccc2c(Br)[nH]nc12	Preclinical
3-bromocamphor					Pharmeks	3.7	[H][C@]1(Br)[C@@H]2CC[C@@](C)(C1=O)C2(C)C |&1:1,3,6|	Launched
3-bromopyruvate	hexokinase inhibitor	HK2			MedChemEx, MedChemEx, Enamine	0	OC(=O)C(O)=CBr, OC(=O)C(O)=CBr, OC(=O)C(O)=CBr	Preclinical
3-carboxy-4-hydroxyphenylglycine-(R)	glutamate receptor antagonist	GRIN1, GRIN2A, GRIN2B, GRIN2C			Tocris, Tocris	100	N[C@@H](C(O)=O)c1ccc(O)c(c1)C(O)=O, N[C@@H](C(O)=O)c1ccc(O)c(c1)C(O)=O	Preclinical
3-carboxy-4-hydroxyphenylglycine-(S)	glutamate receptor antagonist	GRM1, GRM5			Tocris, Tocris	100	N[C@H](C(O)=O)c1ccc(O)c(c1)C(O)=O, N[C@H](C(O)=O)c1ccc(O)c(c1)C(O)=O	Preclinical
3-CPMT	dopamine reuptake inhibitor				Tocris	94.3	CN1[C@H]2CC[C@@H]1C[C@@H](C2)O[C@H](c1ccccc1)c1ccc(Cl)cc1 |&1:2,5,7,&2:10,r,THB:0:1:3.4:6.7.8|	Preclinical
3-deazaadenosine	adenosylhomocysteinase inhibitor	AHCY			Enzo	100	Nc1nccc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O |a:10,12,&1:15,&2:17|	Phase 2
3-deazaneplanocin-A	histone lysine methyltransferase inhibitor	EZH2			Selleck, MedChemEx, Selleck, Selleck	97.43	Nc1nccc2n(cnc12)[C@@H]1C=C(CO)[C@@H](O)[C@H]1O |t:13|, Nc1nccc2n(cnc12)[C@@H]1C=C(CO)[C@@H](O)[C@H]1O |t:13|, Nc1nccc2n(cnc12)[C@@H]1C=C(CO)[C@@H](O)[C@H]1O |t:13|, Nc1nccc2n(cnc12)[C@@H]1C=C(CO)[C@@H](O)[C@H]1O |t:13|	Preclinical
3-deazauridine	cytidine deaminase inhibitor				AMS	99.3	OC[C@H]1O[C@@H]([C@@H](O)[C@@H]1O)n1ccc(O)cc1=O |&1:2,&2:4,&3:5,&4:7,r|	Preclinical
3-hydroxy-3-phenylpentanamide	GABA receptor modulator				Enamine, Enamine	96.14	CC[C@@](O)(CC(N)=O)c1ccccc1 |&1:2,r|, CC[C@@](O)(CC(N)=O)c1ccccc1 |&1:2,r|	Phase 1
3-indolebutyric-acid		B2M, HLA-A, TRAC, TRBC1			Selleck	97.58	OC(=O)CCCc1c[nH]c2ccccc12	Preclinical
3-MATIDA	glutamate receptor antagonist	GRM1			Tocris, Tocris	80	Cc1cc(sc1[C@@H](N)C(O)=O)C(O)=O |&1:6,r|, Cc1cc(sc1[C@@H](N)C(O)=O)C(O)=O |&1:6,r|	Preclinical
3-methyl-GABA	GABA aminotransferase activator	ABAT			Tocris, Tocris	100	C[C@@H](CN)CC(O)=O |&1:1|, C[C@@H](CN)CC(O)=O |&1:1|	Preclinical
3-methyladenine	PI3K inhibitor	PI3			Selleck, Selleck, Selleck	100	Cn1cnc(=N)c2[nH]cnc12, Cn1cnc(=N)c2[nH]cnc12, Cn1cnc(=N)c2[nH]cnc12	Preclinical
3-MPPI	adrenergic receptor ligand	ADRA1A			Tocris, Tocris, Tocris	98	COc1ccccc1N1CCN(CCn2c(=O)[nH]c3c4ccccc4[nH]c3c2=O)CC1, COc1ccccc1N1CCN(CCn2c(=O)[nH]c3c4ccccc4[nH]c3c2=O)CC1, COc1ccccc1N1CCN(CCn2c(=O)[nH]c3c4ccccc4[nH]c3c2=O)CC1	Preclinical
3PO	phosphofructokinase inhibitor	PFKFB3			MedChemEx, MedChemEx	92.61	O=C(\C=C\c1cccnc1)c1ccncc1, O=C(\C=C\c1cccnc1)c1ccncc1	Preclinical
4,4'-DDT					SantaCruz	0	Clc1ccc(cc1)C(c1ccc(Cl)cc1)C(Cl)(Cl)Cl	Preclinical
4,4-pentamethylenepiperidine	M2 channel blocker				Tocris, Tocris	100	C1CCC2(CC1)CCNCC2, C1CCC2(CC1)CCNCC2	Preclinical
4,5,6,7-tetrabromobenzotriazole	casein kinase inhibitor	AKT1, CHEK1, CSNK2A1, GSK3B, LCK, MAP2K1, MAPK1, MAPK11, MAPK12, MAPK14, MAPK8, PRKCA, ROCK1, RPS6KB1, SGK1			Tocris, Tocris, Tocris, Tocris	98.03	Brc1c(Br)c(Br)c2n[nH]nc2c1Br, Brc1c(Br)c(Br)c2n[nH]nc2c1Br, Brc1c(Br)c(Br)c2n[nH]nc2c1Br, Brc1c(Br)c(Br)c2n[nH]nc2c1Br	Preclinical
4-(aminomethyl)benzoic-acid	hemostatic agent				MedChemEx	0	NCc1ccc(cc1)C(O)=O	Preclinical
4-(4-fluorobenzoyl)-1-(4-phenylbutyl)-piperidine	serotonin receptor antagonist	HTR2A			Tocris, Tocris, Tocris, Tocris	97.38	Fc1ccc(cc1)C(=O)C1CCN(CCCCc2ccccc2)CC1, Fc1ccc(cc1)C(=O)C1CCN(CCCCc2ccccc2)CC1, Fc1ccc(cc1)C(=O)C1CCN(CCCCc2ccccc2)CC1, Fc1ccc(cc1)C(=O)C1CCN(CCCCc2ccccc2)CC1	Preclinical
4-acetyl-1,1-dimethylpiperazinium	acetylcholine receptor agonist				Tocris, Tocris	100	CC(=O)N1CC[N+](C)(C)CC1, CC(=O)N1CC[N+](C)(C)CC1	Preclinical
4-aminohippuric-acid		SLC22A6	nephrology	renal diagnostic agent	MicroSource, Selleck, MedChemEx, Selleck, Selleck	100	Nc1ccc(cc1)C(=O)NCC(O)=O, Nc1ccc(cc1)C(=O)NCC(O)=O, Nc1ccc(cc1)C(=O)NCC(O)=O, Nc1ccc(cc1)C(=O)NCC(O)=O, Nc1ccc(cc1)C(=O)NCC(O)=O	Launched
4-carboxy-3-hydroxyphenylglycine-(RS)	glutamate receptor agonist, glutamate receptor antagonist	GRM1			Tocris, Tocris	0	N[C@@H](C(O)=O)c1ccc(C(O)=O)c(O)c1 |&1:1,r|, N[C@@H](C(O)=O)c1ccc(C(O)=O)c(O)c1 |&1:1,r|	Preclinical
4-carboxy-3-hydroxyphenylglycine-(S)	glutamate receptor agonist, glutamate receptor antagonist	GRM1, GRM2			Tocris, Tocris	0	N[C@H](C(O)=O)c1ccc(C(O)=O)c(O)c1, N[C@H](C(O)=O)c1ccc(C(O)=O)c(O)c1	Preclinical
4-chlorophenylguanidine	urokinase inhibitor	PLAUR			Tocris, Tocris	94.15	NC(=N)Nc1ccc(Cl)cc1, NC(=N)Nc1ccc(Cl)cc1	Preclinical
4-CMTB	free fatty acid receptor agonist	FFAR2			Tocris, Tocris, Tocris	95.73	CC(C)[C@@H](C(=O)Nc1nccs1)c1ccc(Cl)cc1 |&1:3,r|, CC(C)[C@@H](C(=O)Nc1nccs1)c1ccc(Cl)cc1 |&1:3,r|, CC(C)[C@@H](C(=O)Nc1nccs1)c1ccc(Cl)cc1 |&1:3,r|	Preclinical
4-DAMP	cholinergic receptor antagonist	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5			Tocris, Tocris	95.95	C[N+]1(C)CCC(CC1)OC(=O)C(c1ccccc1)c1ccccc1, C[N+]1(C)CCC(CC1)OC(=O)C(c1ccccc1)c1ccccc1	Preclinical
4-galactosyllactose					Key	96.9	OC[C@H]1O[C@@H](O[C@@H]2[C@H](O)[C@@H](O)[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)O[C@@H]3CO)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O |a:2,4,6,7,9,11,13,14,16,21,25,28,30,32,&1:18|	Preclinical
4-HQN	PARP inhibitor	PARP1			Tocris, Tocris	96.43	O=c1nc[nH]c2ccccc12, O=c1nc[nH]c2ccccc12	Preclinical
4-hydroxy-phenazone					MedChemEx, Prestwick, Prestwick	92.54	Cc1c(O)c(=O)n(-c2ccccc2)n1C, Cc1c(O)c(=O)n(-c2ccccc2)n1C, Cc1c(O)c(=O)n(-c2ccccc2)n1C	Preclinical
4-IBP	sigma receptor agonist	SIGMAR1			Tocris	98.48	Ic1ccc(cc1)C(=O)NC1CCN(Cc2ccccc2)CC1	Preclinical
4-iodo-L-phenylalanine		DPP4			MedChemEx, Key	87.58	N[C@H](Cc1ccc(I)cc1)C(O)=O, N[C@H](Cc1ccc(I)cc1)C(O)=O	Preclinical
4-iodo-6-phenylpyrimidine	macrophage migration inhibiting factor inhibitor	MIF			Tocris	98.51	Ic1cc(ncn1)-c1ccccc1	Preclinical
4-methylgenistein	protein tyrosine kinase inhibitor	CYP19A1, ESRRA, ESRRB, ESRRG, FASN			Selleck	95.83	COc1ccc(cc1)-c1coc2cc(O)cc(O)c2c1=O	Preclinical
4-methylhistamine	histamine receptor agonist	HRH4			Tocris	90.32	Cc1nc[nH]c1CCN	Preclinical
4-mu-8C	IRE1 inhibitor	ERN1			Tocris, Tocris, Selleck, Selleck, Selleck	95.59	Cc1cc(=O)oc2c(C=O)c(O)ccc12, Cc1cc(=O)oc2c(C=O)c(O)ccc12, Cc1cc(=O)oc2c(C=O)c(O)ccc12, Cc1cc(=O)oc2c(C=O)c(O)ccc12, Cc1cc(=O)oc2c(C=O)c(O)ccc12	Preclinical
4-P-PDOT	melatonin receptor antagonist	MTNR1A, MTNR1B			Tocris	95.99	CCC(=O)N[C@H]1C[C@@H](c2ccccc2)c2ccccc2C1 |&1:5,7|	Preclinical
4-phenolsulfonic-acid					Acros	92.14	Oc1ccc(cc1)S(O)(=O)=O	Preclinical
4-phenyl-1,2,3,4-tetrahydroisoquinoline	dopamine release inhibitor				Tocris, Tocris	94.82	C1NCc2ccccc2[C@@H]1c1ccccc1 |&1:9,r|, C1NCc2ccccc2[C@@H]1c1ccccc1 |&1:9,r|	Preclinical
4-PPBP	sigma receptor ligand	SIGMAR1			Tocris, Tocris, Tocris	96.19	C(CCc1ccccc1)CN1CCC(CC1)c1ccccc1, C(CCc1ccccc1)CN1CCC(CC1)c1ccccc1, C(CCc1ccccc1)CN1CCC(CC1)c1ccccc1	Preclinical
4-propylbenzoic-acid					Maybridge	0	CCCc1ccc(cc1)C(O)=O	Preclinical
4-pyrimidinecarbonitrile					Enamine	0	N#Cc1ccncn1	Preclinical
4-tert-butylphenol					Enamine, Sigma	80.77	CC(C)(C)c1ccc(O)cc1, CC(C)(C)c1ccc(O)cc1	Preclinical
4BP-TQS	nicotinic receptor agonist	CHRNA7			Tocris, Tocris	90.97	NS(=O)(=O)c1ccc2N[C@@H]([C@H]3CC=C[C@@H]3c2c1)c1ccc(Br)cc1 |&1:9,&2:10,&3:14,r,c:12|, NS(=O)(=O)c1ccc2N[C@@H]([C@H]3CC=C[C@@H]3c2c1)c1ccc(Br)cc1 |&1:9,&2:10,&3:14,r,c:12|	Preclinical
4EGI-1	protein synthesis inhibitor	EIF4E			Tocris	74.01	OC(=O)C(Cc1ccccc1[N+]([O-])=O)=NNc1nc(cs1)-c1ccc(Cl)c(Cl)c1	Preclinical
4E1RCat	protein synthesis inhibitor	EIF4E, EIF4G1			Tocris, Selleck, Tocris, Selleck, Selleck	93.94	OC(=O)c1ccc(cc1)N1C(=O)\C(=C\c2ccc(o2)-c2ccc(cc2)[N+]([O-])=O)C=C1c1ccccc1 |c:31|, OC(=O)c1ccc(cc1)N1C(=O)\C(=C\c2ccc(o2)-c2ccc(cc2)[N+]([O-])=O)C=C1c1ccccc1 |c:31|, OC(=O)c1ccc(cc1)N1C(=O)\C(=C\c2ccc(o2)-c2ccc(cc2)[N+]([O-])=O)C=C1c1ccccc1 |c:31|, OC(=O)c1ccc(cc1)N1C(=O)\C(=C\c2ccc(o2)-c2ccc(cc2)[N+]([O-])=O)C=C1c1ccccc1 |c:31|, OC(=O)c1ccc(cc1)N1C(=O)\C(=C\c2ccc(o2)-c2ccc(cc2)[N+]([O-])=O)C=C1c1ccccc1 |c:31|	Preclinical
4SC-202	HDAC inhibitor	HDAC1			MedChemEx, MedChemEx, MedChemEx, Selleck, Selleck, Selleck, Selleck, MedChemEx	96.41	Cn1cc(cn1)-c1ccc(cc1)S(=O)(=O)n1ccc(\C=C\C(=O)Nc2ccccc2N)c1, Cn1cc(cn1)-c1ccc(cc1)S(=O)(=O)n1ccc(\C=C\C(=O)Nc2ccccc2N)c1, Cn1cc(cn1)-c1ccc(cc1)S(=O)(=O)n1ccc(\C=C\C(=O)Nc2ccccc2N)c1, Cn1cc(cn1)-c1ccc(cc1)S(=O)(=O)n1ccc(\C=C\C(=O)Nc2ccccc2N)c1, Cn1cc(cn1)-c1ccc(cc1)S(=O)(=O)n1ccc(\C=C\C(=O)Nc2ccccc2N)c1, Cn1cc(cn1)-c1ccc(cc1)S(=O)(=O)n1ccc(\C=C\C(=O)Nc2ccccc2N)c1, Cn1cc(cn1)-c1ccc(cc1)S(=O)(=O)n1ccc(\C=C\C(=O)Nc2ccccc2N)c1, Cn1cc(cn1)-c1ccc(cc1)S(=O)(=O)n1ccc(\C=C\C(=O)Nc2ccccc2N)c1	Phase 1
5'-chloro-5'-deoxy-ENBA-(+/-)	adenosine receptor agonist	ADORA1			Tocris	92.56	O[C@@H]1[C@@H](CCl)O[C@H]([C@@H]1O)n1cnc2c(N[C@H]3C[C@@H]4CC[C@H]3C4)ncnc12 |a:1,2,6,7,&1:17,20,&2:15|	Preclinical
5,7-dichlorokynurenic-acid	glutamate receptor antagonist	GLRA2, GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D			Tocris, Tocris, Tocris	98.43	OC(=O)c1cc(=O)c2c(Cl)cc(Cl)cc2[nH]1, OC(=O)c1cc(=O)c2c(Cl)cc(Cl)cc2[nH]1, OC(=O)c1cc(=O)c2c(Cl)cc(Cl)cc2[nH]1	Preclinical
5-(4chlorophenyl)-4-ethyl-2,4-dihydro-3H-1,2,4-triazol-3-one					AMS	0	CCn1c(n[nH]c1=O)-c1ccc(Cl)cc1	Preclinical
5-amino-3-D-ribofuranosylthiazolo[4,5-d]pyrimidin-2,7(3H,6H)-dione		TLR7			Berry	98.58	Nc1nc(=O)c2sc(=O)n([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c2[nH]1	Preclinical
5-aminolevulinic-acid	oxidizing agent	ALAD	oncology, dermatology	glioma, actinic keratosis (AK)	MicroSource, Selleck	100	NCC(=O)CCC(O)=O, NCC(=O)CCC(O)=O	Launched
5-BDBD	purinergic receptor antagonist	P2RX4			Tocris, Tocris, Tocris, Tocris, Tocris, Tocris	98.81	Brc1cccc(c1)C1=NCC(=O)Nc2c1oc1ccccc21 |t:8|, Brc1cccc(c1)C1=NCC(=O)Nc2c1oc1ccccc21 |t:8|, Brc1cccc(c1)C1=NCC(=O)Nc2c1oc1ccccc21 |t:8|, Brc1cccc(c1)C1=NCC(=O)Nc2c1oc1ccccc21 |t:8|, Brc1cccc(c1)C1=NCC(=O)Nc2c1oc1ccccc21 |t:8|, Brc1cccc(c1)C1=NCC(=O)Nc2c1oc1ccccc21 |t:8|	Preclinical
5-carboxamidotryptamine	serotonin receptor agonist	HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR5A, HTR6, HTR7			Tocris, Tocris	94.32	NCCc1c[nH]c2ccc(cc12)C(N)=O, NCCc1c[nH]c2ccc(cc12)C(N)=O	Preclinical
5-fluoro-3-pyridyl-methanol					Manchester	96.92	OCc1cncc(F)c1	Preclinical
5-fluoropyrimidine	kinase inhibitor				AMS	0	Fc1cncnc1	Phase 3
5-fluorouracil	thymidylate synthase inhibitor	DPYD, TYMS	oncology	colorectal cancer, breast cancer, pancreatic cancer, gastric adenocarcinoma	MicroSource, MicroSource, MicroSource, Selleck, Selleck	100	Fc1c[nH]c(=O)[nH]c1=O, Fc1c[nH]c(=O)[nH]c1=O, Fc1c[nH]c(=O)[nH]c1=O, Fc1c[nH]c(=O)[nH]c1=O, Fc1c[nH]c(=O)[nH]c1=O	Launched
5-FP	thymidylate synthase inhibitor	TYMS			Sigma, Maybridge	0	Fc1cnc(=O)[nH]c1, Fc1cnc(=O)[nH]c1	Phase 1
5-HMF					Sigma, OxChem, Sigma	84.12	OCc1ccc(C=O)o1, OCc1ccc(C=O)o1, OCc1ccc(C=O)o1	Phase 2
5-hydroxydecanoic-acid					Enzo	64	CCCCC[C@@H](O)CCCC(O)=O |&1:5|	Preclinical
5-hydroxyectoine					Sigma, Sigma, Sigma	100	CC1=NC[C@H](O)[C@H](N1)C(O)=O |t:1|, CC1=NC[C@H](O)[C@H](N1)C(O)=O |t:1|, CC1=NC[C@H](O)[C@H](N1)C(O)=O |t:1|	Preclinical
5-hydroxymethyl-tolterodine	acetylcholine receptor antagonist	CHRM3			MedChemEx, Selleck, Selleck, Selleck	96.55	CC(C)N(CC[C@H](c1ccccc1)c1cc(CO)ccc1O)C(C)C, CC(C)N(CC[C@H](c1ccccc1)c1cc(CO)ccc1O)C(C)C, CC(C)N(CC[C@H](c1ccccc1)c1cc(CO)ccc1O)C(C)C, CC(C)N(CC[C@H](c1ccccc1)c1cc(CO)ccc1O)C(C)C	Phase 1
5-hydroxytryptophan	neurotransmitter	SLC36A1, SLC36A2	neurology/psychiatry	insomnia	Selleck, Selleck, Selleck	97.09	N[C@@H](Cc1c[nH]c2ccc(O)cc12)C(O)=O |&1:1,r|, N[C@@H](Cc1c[nH]c2ccc(O)cc12)C(O)=O |&1:1,r|, N[C@@H](Cc1c[nH]c2ccc(O)cc12)C(O)=O |&1:1,r|	Launched
5-iodo-A-85380	acetylcholine receptor agonist				Tocris, Tocris	93.6	Ic1cncc(OC[C@@H]2CCN2)c1, Ic1cncc(OC[C@@H]2CCN2)c1	Phase 2
5-methylfurmethiodide	acetylcholine receptor agonist	CHRM1, CHRM2, CHRM3, CHRM4			Tocris, Tocris	95.87	Cc1ccc(C[N+](C)(C)C)o1, Cc1ccc(C[N+](C)(C)C)o1	Preclinical
5-methylhydantoin-(D)					Selleck, Selleck	0	C[C@H]1NC(=O)NC1=O, C[C@H]1NC(=O)NC1=O	Preclinical
5-methylhydantoin-(L)					Prestwick	89.08	C[C@@H]1NC(=O)NC1=O	Preclinical
5-octanoylsalicylic-acid	protein kinase activator				AMS	94.63	CCCCCCCC(=O)c1ccc(O)c(c1)C(O)=O	Preclinical
6,7-dehydro-17-acetoxy-progesterone	steroidal progestin				InterBioScreen, InterBioScreen, InterBioScreen	100	CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=CC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)=O |c:9,t:11|, CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=CC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)=O |c:9,t:11|, CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=CC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)=O |c:9,t:11|	Preclinical
6-aminochrysene	transferase inhibitor				Sigma	30.33	Nc1cc2c3ccccc3ccc2c2ccccc12	Phase 2
6-aminopenicillanic-acid					Enamine, Sigma	100	CC1(C)S[C@@H]2[C@H](N)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](N)C(=O)N2[C@H]1C(O)=O	Preclinical
6-benzylaminopurine	purinergic receptor activator				Sigma, Prestwick, Prestwick	99.22	C(Nc1ncnc2nc[nH]c12)c1ccccc1, C(Nc1ncnc2nc[nH]c12)c1ccccc1, C(Nc1ncnc2nc[nH]c12)c1ccccc1	Preclinical
6-chloromelatonin	melatonin receptor agonist	MTNR1A, MTNR1B			Tocris, Tocris, Tocris, Tocris	97.22	COc1cc2c(CCNC(C)=O)c[nH]c2cc1Cl, COc1cc2c(CCNC(C)=O)c[nH]c2cc1Cl, COc1cc2c(CCNC(C)=O)c[nH]c2cc1Cl, COc1cc2c(CCNC(C)=O)c[nH]c2cc1Cl	Preclinical
6-diazo-5-oxo-L-norleucine	glutamate receptor antagonist, glutaminase inhibitor				Sigma, ChemImpex	0	N[C@@H](CCC(=O)C[N+]#N)C(O)=O, N[C@@H](CCC(=O)C[N+]#N)C(O)=O	Preclinical
6-iodo-nordihydrocapsaicin	TRPV antagonist	TRPV1			Tocris, Tocris	92.2	CCCCCCCCC(=O)NCc1cc(OC)c(O)cc1I, CCCCCCCCC(=O)NCc1cc(OC)c(O)cc1I	Preclinical
7,8,9,10-tetrahydroazepino[2,1-b]quinazolin-12(6H)-one					Vitas-M	99.06	O=C1N2CCCCC=C2Nc2ccccc12 |c:7|	Preclinical
7-aminocephalosporanic-acid	beta lactamase inhibitor				Selleck, Selleck	100	CC(=O)OCC1=C(N2[C@H](SC1)[C@H](N)C2=O)C(O)=O |t:5|, CC(=O)OCC1=C(N2[C@H](SC1)[C@H](N)C2=O)C(O)=O |t:5|	Preclinical
7-chlorokynurenic-acid	glutamate receptor antagonist	GRIN1, GRIN2A, GRIN2B, GRIN2C			Tocris, Tocris, Tocris, Tocris	99.07	OC(=O)c1cc(=O)c2ccc(Cl)cc2[nH]1, OC(=O)c1cc(=O)c2ccc(Cl)cc2[nH]1, OC(=O)c1cc(=O)c2ccc(Cl)cc2[nH]1, OC(=O)c1cc(=O)c2ccc(Cl)cc2[nH]1	Preclinical
7-hydroxy-DPAT	dopamine receptor agonist	DRD2, DRD3			Tocris, Tocris, Tocris, Tocris	89.47	CCCN(CCC)[C@H]1CCc2ccc(O)cc2C1 |&1:7|, CCCN(CCC)[C@H]1CCc2ccc(O)cc2C1 |&1:7|, CCCN(CCC)[C@H]1CCc2ccc(O)cc2C1 |&1:7|, CCCN(CCC)[C@H]1CCc2ccc(O)cc2C1 |&1:7|	Preclinical
7-hydroxy-PIPAT	dopamine receptor ligand	DRD3			Tocris	54.71	CCCN(C\C=C\I)[C@H]1CCc2ccc(O)cc2C1 |&1:8|	Preclinical
7-hydroxystaurosporine	CDK inhibitor, CHK inhibitor, PKC inhibitor	CDK1, CHEK1, CHEK2, GSK3B, LCK, MAPK14, MARK1, MARK3, PDPK1, PRKCA, PRKCB, PRKCD, PRKCE, PRKCG			EMDBio, EMDBio, EMDBio	80.79	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4[C@H](O)NC(=O)c4c4c5ccccc5n2c4c13, CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4[C@H](O)NC(=O)c4c4c5ccccc5n2c4c13, CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4[C@H](O)NC(=O)c4c4c5ccccc5n2c4c13	Phase 2
7-keto-DHEA	steroid				ChemImpex	98.83	CC(=O)O[C@H]1CC[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](CCC4=O)[C@@H]3C(=O)C=C2C1 |c:24|	Launched
7-methoxytacrine	acetylcholinesterase inhibitor	ACHE			Enamine, Enamine	98.23	COc1ccc2nc3CCCCc3c(N)c2c1, COc1ccc2nc3CCCCc3c(N)c2c1	Phase 2
7-methylxanthine	adenosine receptor antagonist				Sigma, Sigma, Sigma	100	Cn1cnc2[nH]c(=O)[nH]c(=O)c12, Cn1cnc2[nH]c(=O)[nH]c(=O)c12, Cn1cnc2[nH]c(=O)[nH]c(=O)c12	Phase 2
7-nitroindazole	nitric oxide synthase inhibitor	NOS1, NOS2, NOS3			Tocris, Tocris, Tocris	96.6	[O-][N+](=O)c1cccc2c[nH]nc12, [O-][N+](=O)c1cccc2c[nH]nc12, [O-][N+](=O)c1cccc2c[nH]nc12	Preclinical
8-bromo-cAMP	PKA activator				Tocris, Tocris, Tocris, Tocris, Tocris	96.24	Nc1ncnc2n([C@@H]3O[C@@H]4CO[P@](O)(=O)O[C@H]4[C@H]3O)c(Br)nc12 |a:7,9,16,17,&1:12|, Nc1ncnc2n([C@@H]3O[C@@H]4CO[P@](O)(=O)O[C@H]4[C@H]3O)c(Br)nc12 |a:7,9,16,17,&1:12|, Nc1ncnc2n([C@@H]3O[C@@H]4CO[P@](O)(=O)O[C@H]4[C@H]3O)c(Br)nc12 |a:7,9,16,17,&1:12|, Nc1ncnc2n([C@@H]3O[C@@H]4CO[P@](O)(=O)O[C@H]4[C@H]3O)c(Br)nc12 |a:7,9,16,17,&1:12|, Nc1ncnc2n([C@@H]3O[C@@H]4CO[P@](O)(=O)O[C@H]4[C@H]3O)c(Br)nc12 |a:7,9,16,17,&1:12|	Preclinical
8-bromo-cGMP	PKA activator	PRKG1			Tocris, Tocris, Tocris, Tocris	90.87	Nc1nc(=O)c2nc(Br)n([C@@H]3O[C@@H]4CO[P@](O)(=O)O[C@H]4[C@H]3O)c2[nH]1 |a:10,12,19,20,&1:15|, Nc1nc(=O)c2nc(Br)n([C@@H]3O[C@@H]4CO[P@](O)(=O)O[C@H]4[C@H]3O)c2[nH]1 |a:10,12,19,20,&1:15|, Nc1nc(=O)c2nc(Br)n([C@@H]3O[C@@H]4CO[P@](O)(=O)O[C@H]4[C@H]3O)c2[nH]1 |a:10,12,19,20,&1:15|, Nc1nc(=O)c2nc(Br)n([C@@H]3O[C@@H]4CO[P@](O)(=O)O[C@H]4[C@H]3O)c2[nH]1 |a:10,12,19,20,&1:15|	Preclinical
8-hydroxy-DPAT	serotonin receptor agonist	HTR5A, HTR7			Tocris, Tocris	93.13	CCCN(CCC)[C@H]1CCc2cccc(O)c2C1 |&1:7|, CCCN(CCC)[C@H]1CCc2cccc(O)c2C1 |&1:7|	Preclinical
8-hydroxy-PIPAT	dopamine receptor ligand	DRD2, DRD3			Tocris, Tocris	97.35	CCCN(C\C=C\I)[C@H]1CCc2cccc(O)c2C1 |&1:8|, CCCN(C\C=C\I)[C@H]1CCc2cccc(O)c2C1 |&1:8|	Preclinical
8-M-PDOT	melatonin receptor agonist	MTNR1A, MTNR1B			Tocris, Tocris	97.76	CCC(=O)N[C@H]1CCc2cccc(OC)c2C1 |&1:5,r|, CCC(=O)N[C@H]1CCc2cccc(OC)c2C1 |&1:5,r|	Preclinical
80841-78-7					Sigma	0	Cc1oc(=O)oc1CCl	Preclinical
9-aminoacridine					Selleck, MicroSource, Selleck, Selleck, Selleck	96	Nc1c2ccccc2nc2ccccc12, Nc1c2ccccc2nc2ccccc12, Nc1c2ccccc2nc2ccccc12, Nc1c2ccccc2nc2ccccc12, Nc1c2ccccc2nc2ccccc12	Preclinical
9-aminocamptothecin	topoisomerase inhibitor	TOP1			Sigma, Sigma	91.91	CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4cccc(N)c4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4cccc(N)c4cc3Cn1c2=O	Phase 2
9-anthracenecarboxylic-acid		ANO1, CLCN1			Tocris, Tocris	88.03	OC(=O)c1c2ccccc2cc2ccccc12, OC(=O)c1c2ccccc2cc2ccccc12	Preclinical
